<SEC-DOCUMENT>0000950170-25-030849.txt : 20250303
<SEC-HEADER>0000950170-25-030849.hdr.sgml : 20250303
<ACCEPTANCE-DATETIME>20250303161024
ACCESSION NUMBER:		0000950170-25-030849
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250303
DATE AS OF CHANGE:		20250303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annexon, Inc.
		CENTRAL INDEX KEY:			0001528115
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				275414423
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39402
		FILM NUMBER:		25697978

	BUSINESS ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(650)-822-5500

	MAIL ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>annx-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-03T13:13:34.1877+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:annx="http://annexonbio.com/20241231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4daf25ad-1482-4cce-bd6a-2c1b69969a92" name="dei:EntityCentralIndexKey" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e">0001528115</ix:nonNumeric><ix:nonNumeric id="F_372bda1d-91a3-4095-a2b2-64e8ebd59d19" name="dei:DocumentFiscalPeriodFocus" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e">FY</ix:nonNumeric><ix:nonNumeric id="F_242fa94f-8172-496a-ba18-273e2b04187c" name="dei:AmendmentFlag" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e">false</ix:nonNumeric><ix:nonFraction id="F_420f1a7b-75ca-4c11-8930-c039b5bd7f95" name="us-gaap:CommitmentsAndContingencies" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c0349d88-3f94-454f-954e-b3a1d9c41c2e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_8f39b772-731f-41b9-9d02-0d66e7276fae" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_1cc25f78-dbe3-41a1-b7d8-90bfc1df6bd1">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric id="F_a1b6e2c0-03d3-4a20-b626-abcffa81b2cd" name="us-gaap:OpenTaxYear" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e">2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="annx-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_816a75eb-eeac-444c-b1ad-06f15723b3de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_818dd59d-4920-4aa4-ac11-e7a600a5d4b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">annx:PersonnelExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83482f61-92c5-4f8a-a1dd-156bef5f21aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_843798ed-5a68-4641-8a36-ece949ec58c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8472ac84-55e5-434a-90d4-c7f9d7aa4437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_855b89a1-84bd-4934-adb2-47fa9352df11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">annx:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8835a1b4-527a-43d8-b69a-a0eca9a1005c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_887b31a4-95c1-40be-a759-5e56b5fa7540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e8bc1e1-c0eb-4e34-a2ff-e496756a8fca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:CommonWarrantAndPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_948f2da9-09b8-4835-b79f-9b108878b9f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94c78139-5590-4748-8160-840a5d169474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95063796-51a0-4a4f-80df-7a8de33bf4a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95335bc0-36c3-45f2-998d-639cb78b1f47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95493879-152b-4afb-9460-55860ac0385d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_988ddfc5-9dce-4f27-b086-5099244cdafc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ae8f66d-5240-4728-81a8-25950cb83964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b5d4612-62c8-4e9e-9732-fb24b3fc9113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0b71661-aa15-48ab-9fd1-0c1f5bd8eb06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2a16639-89ee-4f7b-8678-74e032c6acd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2b98230-0f7a-4d29-8918-901b611f045a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4b8204b-10aa-4078-99c0-be6c2915b494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">annx:ProgramExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a59b470f-7ad8-4b6e-a84a-dddba145a948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:UnvestedRestrictedStockUnitsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6321396-4c80-49a4-a286-91e5bcfaf1eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">annx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a89b88c0-ec52-4b3d-8aa8-2fcdcacd2667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8a555d1-c90f-4f9c-959d-6220a378be31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a909da49-1edd-4a9f-a0aa-5b1551fca7c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">annx:CommonStockAndPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab735fa4-b8ce-4204-bd13-e3e5137bced9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abbf44cf-6ebe-4194-9a41-e2cb42bf1eb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac099453-0c31-4ead-a71c-3537f6410632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae76d731-12db-4f4c-9bcd-ade6fdbeaa43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b058d9ba-58ce-4e56-a243-4df02901e4e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1f5099c-e23a-49a6-8643-c8f3e583dd88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">annx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b56b58f7-0eb2-431c-93e8-e770362d3636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b57972b4-cb2c-4aba-9af4-d01913068013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b64c79b4-fe65-47cc-bb5d-7ddb0490610e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7464154-5bfb-48e8-b9ee-4421be6a566c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b856724b-67a4-4bba-a3f2-933d6bdcf267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbc49f27-1c6e-406e-a095-7623fd68f696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc70ca19-dd4e-484a-9840-e8e349d6ed16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd2c86aa-468c-41c3-bcc5-d4bb6af8a626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf13cefb-5813-466c-a528-52377f64fc89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c060d1ca-b9cb-4849-9fbb-3cadae61b6dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1fa55bb-8cda-41f2-be10-9c4b61733d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c86633a7-f190-4e56-90c2-b45ffb2a2fec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c91f5f8f-b8d5-4019-a7fb-1c7e1652024e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9766150-3460-412e-b465-7535db7a6402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc036091-0094-4f93-92df-aa8d88aeaf09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdc4c27d-b376-4374-8ee1-613abe059850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce377faf-e56d-4d57-9149-325ff3298695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1fd9ac5-bc60-4fb7-9382-fc0aedcbb6f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d22db712-c793-4143-97f9-0b1afeba048b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d35db099-094f-4b2e-a082-7d4a3c739571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">annx:DouglasLoveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">annx:DouglasLoveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d39e2be4-3f00-449f-bea4-e4669b559cd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3a9e2dc-37bc-4427-af29-49d412bd1d30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d579d761-816c-4e55-92d6-ce372f29566a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db3563d3-30d0-495f-ae87-183cd7735dd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc545e9b-21db-4b67-ad10-065bcc3c2d12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dddec901-694e-4786-914e-180bcc77bb3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de537ec6-325e-4910-8f4c-21e257afbcae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df95e66b-dc80-4420-b35b-25735aaee5e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e30eb803-2850-45ea-964d-0c167ebab98b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e330e31d-eab9-4389-8fa9-bef76e997d23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">annx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e35f510e-8466-4a7b-bbdd-fbb00d74b1e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4222e01-171b-4f31-917f-bc3457cfb96a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5457637-3c61-492e-b073-b90232effb2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e671e012-c921-435e-938c-d68a826109d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e84f496a-0f64-496c-8511-31490901d115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">annx:PersonnelExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9fbcf92-912d-427d-ae6e-83428851302a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eaec4616-b419-452f-afec-7269fe2849b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb44a589-ed4e-4789-9745-4e687e913dc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb92638f-ef52-4c87-b5ac-58d1b991d572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec22ff7d-ccec-45fd-a10c-766baaf42b25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed0ef5bd-d7b5-41fd-bc14-c386fcc1efd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed76a48d-5680-4d30-a58e-a560abef9d60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed7afca9-65c9-4663-b96f-deb75482c773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef904358-5a05-4938-94ed-ed05188133ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f125691b-d9b3-4307-871d-e301d62747a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4174d5a-db4b-4a44-b7ea-89d6395031d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5167882-1b9d-47e5-a675-47eb50fb2f3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9d86972-6bef-4c53-8764-f295400423e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc111147-f3e4-414e-8968-b78d5df90526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0428a48b-fcf2-4525-9a5d-beb6a7560084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06a73ed8-fa35-4a8b-9584-91fdd26d518e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06de6640-01c9-4281-bfc6-944a3b827353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_072050e6-df46-49a7-bd7c-e1422281108a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07dde65d-d011-4647-84a8-b3adc4b0a081"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07f46682-ea8e-47fe-a18f-70b0bb1a100b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08392b92-b47a-463c-9c19-05c9de02b962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_099f9f27-8db7-4796-925e-5a5030924004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b957594-7615-4933-9789-94cb54dc8638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f36b114-1cd5-47b2-9612-e2686951639e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">annx:ProgramExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_138cc2dd-081f-4945-96e9-e817d5140d0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14a08883-0225-4ca1-b9a6-4b86b0937620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_165aca0e-bcd9-4004-974b-91e78177d7c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17ade79a-934b-4095-8b9f-770d560529d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_181b327c-8c4d-49cd-992f-be0a8cabfe0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a083296-3cca-4c7e-aef5-14001cb6517c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cc25f78-dbe3-41a1-b7d8-90bfc1df6bd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22fb27c8-c805-4aa1-944d-38a2963e3541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2321ba61-567c-412f-bf92-06d0f3f4b95c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_262315fc-5a70-4273-9329-a8573c6e8ac6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27512148-cc01-4328-b869-9d09fda6ba2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29782950-7a96-4afe-b123-68b6a1a44a9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ba532e7-e440-42d5-911c-cf6ce266687f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c4873ea-60ed-4c68-a1a0-60c57456e3bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2cebc1d1-94ac-454e-86c1-67082e75afe2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e220b19-1558-4357-a8ce-4bbf8e24c875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">annx:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fd32b35-c1b6-48a1-aae6-77286e901eaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_301be3cb-1afb-480f-886a-93603e1ae4a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">annx:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32785c93-aaca-43fa-a248-cb24bd9882bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:CommonWarrantAndPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3465210b-00bd-416d-9ded-e8a899b86e31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_347d207b-e303-43ed-928d-7392f73d169f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_369ed887-7421-4d9b-9304-a1aaa66c59c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3869c6ca-09db-441d-8246-9d11c931b28c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a117edd-79b6-42cf-bde0-58487b0502bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d6b212d-b7a8-4e3f-bfeb-dc2b3be0b024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e3b68fc-a6f3-457c-8152-64fa99e75d60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43b053ed-5a1a-4d6e-8884-dff3a7269d3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_443c81d2-cb73-4f5e-bd81-93e201b4f7af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4595fc5f-0546-4bdf-8e9d-71d2422bc886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45af3c57-9293-4248-ba7b-bfd6daa609f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47d568cb-1d08-4229-bd46-d15c10848115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47ff50b0-e58b-40e4-8ff0-c5bad7aafd91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48cf44ed-6e91-4e9a-ac99-23eaa9cb9ebc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4972a734-b0dc-409d-bf12-d162a67e116d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">annx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49a7915e-73e3-40e2-8989-6689fbe67430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ac38cec-c321-4987-9f13-09b843771ddb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4aeda5c6-0f0c-4565-a458-c8ad2779242a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b7bb28a-5cbc-497a-b670-2377da981ce9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b7c8434-c7e2-4ff2-b583-26501f87a512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d34fdbe-9026-4710-920e-640cc4668c81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_547ea12c-5672-44e1-81bd-5c04ecd20f79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5525b019-e48a-443f-8f6c-bc589e834f80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55a285e5-5315-412c-bf43-8041cddc34bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_571d253c-4271-4944-954f-09fa5121f2db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59694837-0d85-444e-93f3-2dab4c74940e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b853485-b4de-4aef-8684-04438a8b004d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c8914a1-6122-42c7-8190-e7a265b496b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f614136-7067-4542-9d0b-a420c024f04d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:IncentiveStockOptionsAndNonstatutoryStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_634f5a22-da7a-4c41-b9ae-27784aa5495b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_650433ef-c0b4-4034-b841-f9093d2a4e91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">annx:CommonStockAndPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66179d4e-f740-4656-9e26-82ac3de679ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:UnvestedRestrictedStockUnitsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bb50bac-b7de-4de8-a130-52d5e9a81ba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c830638-e7f6-4b1b-b448-37326bf9c73c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f21bd05-943f-438a-9b7b-5906dcadd8cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f5f0013-61b6-4736-b7e9-a7f934312508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_766389fd-d63f-45a1-a7be-f2588e021646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7968ae91-6275-4ca5-8e22-5c0bb5f5da6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b518a40-52a6-4973-869c-448436c41106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d9aed7f-6bbe-4caa-a2eb-d48056481199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Claim"><xbrli:measure>annx:Claim</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>annx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_917ca3f1-fc87-4b2a-b400-173d2c524312" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_278ba818-58da-4408-bcd0-6e2a1d847704" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf2f3818-8608-4d2b-a7dc-997b0d21c642" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8411b044-b058-4aee-a019-0faba19356a9" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9aba9214-1c8e-400a-9ea1-26665d1d3536" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_d14eed5b-9f0a-4a2e-82bb-175715ba57db" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM     TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cee2b430-7b9f-426b-930e-a003b2ebfc14" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39402</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecbd7dd6-c2dc-4b5a-8dcf-6719622a4252" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_21b06ec9-39d2-4175-b254-811db042f404" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_967ea4e8-28c4-489f-bbd0-1c4977a9d436" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">27-5414423</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2130fac6-a73f-4c9d-9bbc-0b2675287a37" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1400 Sierra Point Parkway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49f82bef-582a-4d64-bb9e-e1ea5755dbc9" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bldg C</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65f57819-23de-4775-92f1-2f06dff7ffd7" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityAddressAddressLine3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 200</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41e2594d-4926-4cda-9ddd-1235040a957c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Brisbane</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_489e615e-2d0c-47d8-a58c-25a1f3edc663" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4344c36f-8ed1-4013-a541-db4364979b21" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94005</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices including zip code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5def167-2cbd-418e-9ead-ba62f6db567f" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a721a85b-18e5-488d-aec6-fe05756a6e6c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">822-5500</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:27%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:38.68%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_8c28782f-34e5-45d2-b84c-825ffa3b386c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_f5aa4cea-ac27-4e7f-a6fc-3a3dc3a36d8a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ANNX</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">The </span><span style="font-size:8.5pt;"><ix:nonNumeric id="F_3540313f-f3ae-44bc-9931-ccd88c0b4cbe" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">&#160;Stock Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab0f3258-50db-4959-bd40-4ee11cf838a9" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_368308c3-cc2e-421e-9fc4-dc570f1f410a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2cdefe3-6c07-44e1-9926-af48c8b7c8ce" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04ed347d-c308-463e-bdf1-ae9b91d70f12" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.364%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:56.131%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:20.404%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:2.04%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10.8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_be3a8370-e7a9-48a3-aa9d-f78cb548c3e7" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_1606879d-3bab-4322-b7bf-d7e26140501b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntitySmallBusiness" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0ac83d6f-2e8c-4ef9-a4c2-49d2498057b5" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_2caf5330-b99f-411e-bd81-698710ee9ff6" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_974df037-12ee-4eb7-93db-c2acc00bad89" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_36015465-aee2-4ea3-b6f8-9693d3fbcda8" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 28, 2024, the aggregate market value of the Registrant&#8217;s Common Stock held by non-affil</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iates of the Registrant (based on the closing sales price of such shares on the Nasdaq Global Select Market on June 28, 2024) was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0653baf-8a43-4165-84c8-0547f01d8814" contextRef="C_a2a16639-89ee-4f7b-8678-74e032c6acd2" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">477.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. F</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or purposes of calculating the aggregate market value of shares held by non-affiliates, we have assumed that all outstanding shares are held by non-affiliates, except for shares held by each of our executive officers, directors and 10% or greater stockholders. This calculation does not reflect a determination that such parties are affiliates for any other purpose.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of the Registrant&#8217;s Common Stock outstanding as of February 28, 2025 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de820295-daeb-4e6b-8a9d-75faf81fe7e2" contextRef="C_d3a9e2dc-37bc-4427-af29-49d412bd1d30" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">109,709,826</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This number does not include </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_142deaa3-6f96-472b-a170-226ca96eca6c" contextRef="C_f125691b-d9b3-4307-871d-e301d62747a4" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,543,577</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock issuable upon the exercise of pre-funded warrants (which are immediately exercisable at an exercise</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price of $0.001 per share of Common Stock, subject to beneficial ownership limitations). See Note 6&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the Registrant&#8217;s audited consolidated financial statements.</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;box-sizing:content-box;"/>
    <td style="width:82.82%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	our clinical and regulatory development plans;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	our expectations with regard to the initiation, scope, rate of progress, enrollment, dosing and results of our clinical studies, preclinical studies and research and development programs, including the timing and availability of data from such studies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	the timing of commencement of future nonclinical studies, preclinical studies and clinical trials and research and development programs;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	our ability to acquire, discover, develop and advance product candidates into, and successfully complete, clinical trials;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	our intentions and our ability to establish collaborations and/or partnerships;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	the timing or likelihood of regulatory filings and approvals for our product candidates;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	our commercialization, marketing and manufacturing capabilities and expectations;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	our intentions with respect to the commercialization of our product candidates;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	the pricing and reimbursement of our product candidates, if approved;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	the implementation of our business model and strategic plans for our business and product candidates, including additional indications for which we may pursue;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	estimates regarding the sufficiency of our cash resources and our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	the potential future sales of our common stock under our at-the-market offering program;</span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	our future financial or operating performance;</span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	developments and projections relating to our competitors and our industry, including competing products; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans, objectives, expectations and initiations and any other statements that are not historical facts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations, estimates, forecasts and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the sections titled &#8220;Summary Risk Factor,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Annual Report on Form 10-K for a discussion of important factors that may cause our actual results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed as exhibits completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this Annual Report on Form 10-K by these cautionary statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the most material risks that make an investment in our securities risky or speculative. If any of the following risks occur or persist, our business, financial condition and results of operations could be materially harmed and the price of our common stock could significantly decline.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of our product candidates, some of which are in early stages of clinical development.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory authorities may not accept data from such trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse events or undesirable side effects caused by, or other unexpected properties of, any of our product candidates could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain and enforce intellectual property protection directed to our current and any future technologies that we develop, others may be able to make, use or sell products substantially the same as ours, which could adversely affect our ability to compete in the market.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price has been volatile, and could in the future be volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual or perceived failure to comply with applicable data protection laws, regulations, standards, contractual obligations and other requirements related to data privacy and security could lead to government enforcement actions and civil or criminal penalties, private litigation (including class actions) or adverse publicity and otherwise could negatively affect our results of operations and business.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Bu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">siness.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In this Annual Report on Form 10-K, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Annexon&#8221; and the &#8220;Company&#8221; refer to Annexon, Inc. and its consolidated subsidiary. Annexon, Annexon, Inc., the Annexon logo and other trade names, trademarks or service marks of Annexon are the property of Annexon, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for people living with devastating inflammatory-related diseases. The classical complement pathway is a core component to the body&#8217;s immune system that activates a powerful inflammatory cascade. We believe that by stopping the classical complement pathway at its start by targeting C1q, the initiating molecule of the classical complement pathway, our approach may have the potential to provide more complete protection against complement-mediated disorders of the body, brain and eye.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Using our proprietary platform, we are identifying and characterizing the role of the classical complement pathway in three therapeutic areas&#8212;autoimmune, neurodegeneration and ophthalmology. In so doing, we are advancing a pipeline of product candidates designed to block the early classical cascade and all downstream pathway components and their tissue-damaging functions. Our goal is to suppress excessive or aberrant classical complement activity that contributes to chronic inflammation and tissue damage to slow or even halt disease progression, while preserving the beneficial immune functions of the lectin and alternative complement pathways involved in the clearance of pathogens and damaged cells. We have demonstrated robust target engagement in the body, brain and eye, and clinical proof of concept in multiple diseases, and have focused our resources on development of three priority programs:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guillain-Barr&#233; Syndrome, or GBS: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing our lead candidate, ANX005, an investigational, full-length monoclonal antibody, or mAb, formulated for intravenous administration as the potential first targeted treatment for patients with GBS. GBS is a rare antibody-mediated autoimmune disease that is the most common cause of acute neuromuscular paralysis, with no therapies in the United States approved by the FDA. We believe maximum suppression of C1q and the classical complement cascade early in the disease process may act to rapidly prevent complement-mediated nerve damage and irreversible neurological disability. In a prior Phase 1b placebo-controlled proof-of-concept trial, a single dose of ANX005 showed rapid and consistent improvement in muscle strength that translated into observable gains in health status, including a reduction in the need of mechanical ventilation, as well as a reduction in nerve damage and clinical function. In 2024, we completed a Phase 3 trial in 241 patients, which showed ANX005 helped patients improve sooner with rapid increase in muscle strength and more complete functional recovery than placebo through six months, and provided an important benefit in the burden of care by enabling patients to walk or be off ventilation earlier. In addition, we completed a Real World Evidence, or RWE, study that matched ANX005-treated patients from the Phase 3 study with a western world patient population from the International Guillain-Barr&#233; Syndrome Outcomes Study, or IGOS, predominantly from Europe and North America treated with current standards of care (intravenous immunoglobulin, or IVIg, or plasma exchange, or PE). Consistent with the Phase 3 trial, ANX005 showed a rapid increase in muscle strength with more complete recovery over IVIg or PE. We anticipate the Phase 3 and RWE results to support a comprehensive dataset for our Biologics License Application, or BLA, and are targeting the first half of 2025 for our pre-BLA meeting with the FDA ahead of our planned BLA submission. ANX005 has been granted Fast Track and orphan drug designation for the treatment of GBS from the FDA. ANX005 has also been granted orphan designation from the European Medicines Agency, or EMA.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geographic Atrophy, or GA: </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing ANX007, an antigen-binding fragment, or Fab, formulated for intravitreal administration, as the first potential program with a global registration path to </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval in Europe and the United States for the treatment of dry AMD with GA. Dry AMD with GA is a leading cause of vision loss in the elderly, that affects more than an estimated eight million people globally, and there are no approved therapies targeting the preservation of vision in this disease. ANX007 is designed to block C1q locally in the eye, to provide more complete protection against excess classical complement activity and the loss of photoreceptor neurons. It is the only investigational therapy in GA to show significant vision preservation on assessments of best corrected visual acuity, or BCVA, and low luminance visual acuity, or LLVA, demonstrating significant protection from vision loss in both normal and low light conditions, as well as significant preservation of central retinal photoreceptors necessary for visual acuity as demonstrated in the Phase 2 ARCHER trial. In 2024, we initiated our Phase 3 ARCHER II trial, a global, sham-controlled, double-masked trial expected to enroll ~630 patients who have dry AMD with GA. The primary endpoint of ARCHER II is prevention of &#8805;15-letter loss of BCVA, and a secondary objective structural measure is prevention of ellipsoid zone (EZ) loss. The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA&#8217;s two-trial recommendation. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial. We expect to complete enrollment of ARCHER II in the second half of 2025 and report topline data in the second half of 2026. ANX007 is the first and only therapeutic candidate for the treatment of GA to receive Priority Medicine, or PRIME, designation by the EMA, which provides early and proactive support to developers of promising medicines that may offer a major therapeutic advantage over existing treatments or benefit to patients without treatment options.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX1502 for Autoimmune Indications: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing ANX1502, a novel oral small molecule inhibitor of classical complement which we believe is first-in-kind. In a Phase 1 single-ascending dose, or SAD, and multiple-ascending dose, or MAD, clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, ANX1502 was generally well tolerated across cohorts with no serious adverse events, achieved target levels of active drug and showed supportive impact on a PD biomarker of complement activity that support its advancement. We are evaluating a tablet formulation of ANX1502 in an ongoing proof-of-concept study in patients with cold agglutinin disease, or CAD, to assess PK, PD and clinical efficacy endpoints (e.g., hemolysis as measured by reduction of elevated bilirubin) and data are expected in mid-2025. Following the successful completion of the proof-of-concept study, we intend to evaluate ANX1502 in serious complement-mediated diseases, with the aim of providing enhanced efficacy and offering convenient dosing administration for long-term treatment of chronic autoimmune conditions.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annexon was co-founded by the late Dr. Ben Barres, former member of the National Academy of Sciences, Chair of Neurobiology at Stanford University and a pioneer in complement-mediated neurodegeneration, and Dr. Arnon Rosenthal, a world-renowned scientist and industry executive. We have assembled a seasoned and accomplished management team that has been involved in the discovery, development, approval and commercialization of numerous marketed drugs, and has been studying the complement pathway and autoimmune and neurodegenerative disorders for decades. Our team is further supported by an experienced scientific advisory board, board of directors and leading healthcare investors that share our commitment to advancing transformative medicines for patients suffering from debilitating autoimmune and neurodegenerative diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We hold worldwide development and commercialization rights, including through exclusive licenses, to all of our product candidates, which allows us to strategically maximize value from our product portfolio over time. Our patent portfolio includes patent protection for our upstream complement platform and each of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our pipeline is led by three flagship programs focused on complement-mediated diseases of the body, brain and eye for which there is significant unmet medical need and where we have the potential to provide a first-in-class treatment opportunity. Beyond our flagship programs, our &#8220;next wave&#8221; programs are supported by a strong scientific</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and clinical rationale and poised for advancement following availability of resources and ongoing evaluation of further development options. Our clinical-stage pipeline is summarized below:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img136305557_0.jpg" alt="img136305557_0.jpg" style="width:578px;height:271px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our flagship programs in GBS, dry AMD with GA and ANX1502 for autoimmune indications, we continue to be encouraged by multiple &#8220;next wave&#8221; programs, which provide additional potential portfolio growth and diversification.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have evaluated ANX005 in patients with Huntington&#8217;s Disease, or HD, and amyotrophic lateral sclerosis, or ALS, chronic neurodegenerative disorders in which aberrant classical complement activation drives neuroinflammation and has been shown to be associated with disease progression. In a completed Phase 2 clinical trial in patients with manifest HD, chronic dosing of ANX005 was generally well-tolerated, demonstrated rapid and sustained target engagement of C1q in both blood and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cerebrospinal fluid, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSF, reduced downstream complement markers in CSF, and showed promising efficacy signals on standard measures of disease progression in patients with higher levels of classical complement activity at baseline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a completed signal-finding open-label Phase 2a trial in patients with ALS, chronic dosing of ANX005 was generally well-tolerated, showed rapid and sustained target engagement of C1q in blood, and reduced downstream pharmacodynamic complement markers in blood. Consistent with what has been shown in other neurodegenerative diseases, including HD, exploratory analyses indicated that patients with higher baseline classical complement activation who enrolled within 12 months of diagnosis achieved better outcomes, including less functional decline on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and stabilization of neurofilament light chain (NfL). These analyses support a precision medicine approach to identify patients most likely to respond to anti-C1q therapy in clinical trials with recently diagnosed ALS patients who have elevated baseline levels of classical complement activity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we have developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis, or LN, who have high baseline complement activity. LN is an autoimmune disease for which pathogenic anti-C1q antibodies, or PACAs, enhance activity and uniquely amplify kidney inflammation and damage. In a completed Phase 1b signal-finding trial, ANX009 was well tolerated, demonstrated plasma C1q target engagement and complement inhibition, and rapidly increased free/circulating PACA levels (consistent with decreased deposition in the kidney) and improved all downstream markers of complement consumption and activation (C4, as well as C3 and C5b-9).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are evaluating options for future development of ANX005 in chronic neurodegenerative indications and ANX009 in LN.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to develop disease-modifying medicines for patients suffering from classical complement-mediated diseases of the body, brain and eye. Key elements of our strategy include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leveraging our distinct approach of inhibiting C1q and aberrant classical complement activity to address a broad range of well-characterized classical complement-mediated diseases of the body, brain and eye.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> By inhibiting C1q and the early classical cascade, we believe our product candidates are uniquely designed to address a wide range of antibody-mediated autoimmune diseases and complement-mediated neurodegenerative disorders. We believe full classical complement inhibition may result in clinical benefits by blocking aberrant upstream and downstream immune cell activation in our targeted indications, as well as potentially provide safety advantages by leaving the lectin and alternative pathways intact to perform their normal immune functions.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prioritizing resources and execution of mid- to late-stage development of three flagship programs. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By focusing our resources on our three flagship programs in GBS, GA and ANX1502, our novel oral small molecule complement inhibitor, our goal is to create near-term value for patients, physicians and stakeholders.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANX005 for dry AMD with GBS: Prepare for BLA Submission and Commercialization, if approved. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ANX005 as the potential first targeted therapy for GBS, an acute neurological emergency for which there is no FDA approved treatment. ANX005 is being developed as a first-line monotherapy treatment option to address the global unmet needs of 150,000 patients annually diagnosed with GBS, in support of our goal of obtaining the first FDA-approval for the treatment of GBS. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX005&#8217;s well-tolerated, differentiated profile showing rapid and durable improvement in muscle strength, has received both Fast Track and orphan drug designations from the FDA, as well as orphan drug designation by the EMA.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANX007 for GA: Execute Global Registration Program. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing ANX007 as the potential first program with a global registration path to approval for the treatment of dry AMD with GA in Europe and the United States to address the unmet needs of more than 8 million patients worldwide. ANX007&#8217;s well-tolerated, differentiated profile is the only program to show significant protection against vision loss as well as significant protection of c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entral retinal photoreceptors necessary</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for visual acuity. ANX007 is the first and only therapeutic candidate for the treatment of GA to receive PRIME designation in the EU, which provides early and proactive support to developers of promising medicines that may offer a major therapeutic advantage over existing treatments or benefit to patients without treatment options.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANX1502 for Autoimmune Disease: Advance First-in-Kind Oral Small Molecule Program. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing an enhanced tablet formulation of ANX1502 designed to disrupt the complement-mediated autoimmune space as the potentially first orally available treatment. Following successful completion of the proof-of-concept study in patients with CAD, we intend to evaluate ANX1502 in serious complement-mediated diseases, with the aim of providing efficacy with enhanced dosing flexibility and convenience for long-term treatment of chronic autoimmune conditions.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expanding our portfolio across three therapeutics franchises informed by data from our flagship programs. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to leverage learnings and proof-of-concept data from our flagship programs to inform selection of additional patient populations involving classical complement-mediated diseases of the body, brain and eye. As we enhance our resources, we plan to efficiently prosecute opportunities across our three therapeutic franchises utilizing our disciplined, data-driven development strategy.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Maximizing the value of our product candidates</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently hold worldwide development and commercialization rights, including through exclusive licenses, to all of our product candidates. We have secured broad intellectual property protection for our upstream complement platform and intend to leverage our intellectual property and know-how to protect and enhance our leading position in developing novel therapeutics that target the classical complement cascade. We intend to pursue independent development and commercialization in indications and markets we can address with a focused sales and marketing organization. We plan to explore licensing agreements, collaborations or partnerships to advance our product candidates in indications and markets where we could accelerate and expand development and commercialization leveraging the resources of larger biopharmaceutical companies.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview of the Complement System and C1q Biology</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Complement System&#8212;three main complement pathways</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The complement system is an integral component of the immune system that consists of many circulating and locally-produced molecules. This system evolved to enhance, or complement, other components of the adaptive and innate immune systems. The complement system, also known as the complement cascade, rapidly responds to pathogens, damaged cells and unwanted tissue components to facilitate their removal by the immune system.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are three main complement pathways (also called cascades)&#8212;the classical, lectin and alternative pathways. Each pathway is initiated by different molecules that respond to distinct triggers. When activated, the initiating molecules set in motion a cascade of enzymatic reactions that greatly amplify, or complement, an inflammatory response. The classical pathway is initiated by C1q, which recognizes antibody complexes, specific pathogens, damaged cells or unwanted cellular components. The lectin pathway is triggered by carbohydrates on the surface of pathogens or cells. The alternative pathway amplifies the action of the other two pathways and also self-activates to eliminate pathogens or cells that are not specifically shielded by the body&#8217;s built-in self-protective systems. While these three pathways are initiated by distinct molecules, they converge downstream on common pathway components known as C3 and C5.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aberrant activation of the complement system can result in a range of diseases characterized by an attack on healthy tissue, such as red blood cells, nerve cells or kidney components. A broad range of diseases are known to be associated with pathological activation of the complement cascade, including antibody-mediated autoimmune disorders such as GBS, CAD and lupus nephritis, and complement-mediated neurodegeneration disorders in the eye, such as glaucoma and GA, and complement-mediated neurodegeneration disorders in the brain, such as HD, ALS, frontotemporal dementia and Alzheimer&#8217;s disease. We believe intervening in the activation of the complement cascade offers a potent and selective mechanism for specifically slowing or reversing these disease processes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific activated components of the complement cascade have important immune functions that contribute to three key outcomes:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Immune cell recruitment and inflammation</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific activated molecules from the cascade serve as soluble signals to make blood vessels leaky and attract immune cells into tissues.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Directed immune cell attack</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Several complement components, including C1q, bind directly to the pathogen and serve as receptors that direct immune cell attack and pathogen engulfment.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Membrane damage</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Downstream components of the cascade directly puncture the pathogen or cell surface, causing membrane damage and lysis.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Broad potential for classical complement pathway targeted therapeutics in autoimmune and neurodegenerative diseases</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The classical complement cascade has a well-established role in augmenting antibody function within the immune system. C1q recognizes antibodies bound to pathogens or cells and activates the classical pathway to trigger their removal and clearance by the immune system. C1q can also directly recognize pathogens, damaged cells or unwanted cellular components leading to similar downstream clearance. A more recent finding made by the laboratory of Dr. Ben Barres, our scientific founder, is that C1q also directly interacts with neuronal connections, or synapses, during early development. Recognition of weaker synapses by C1q </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">triggers the classical complement cascade and directs immune cells to &#8220;prune&#8221; the synapses away from neurons, thereby reinforcing stronger synapses to establish appropriate neuronal connections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its central role in immune function, aberrant activation of C1q can lead to damage of healthy tissue and destruction of functioning synapses. We are focused on two distinct disease processes involving C1q as a key mediator of tissue damage: antibody-mediated autoimmune disease and complement-mediated neurodegeneration.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">antibody-mediated autoimmune disease, self-reactive antibodies bind to cells or tissues, activating C1q and leading to damaging inflammatory responses. In GBS, pathogenic antibodies react with components of the peripheral nerve system, or PNS, to cause widespread peripheral nerve damage and paralysis. This disease process is also evident</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in antibody-mediated autoimmune disease involving blood components, such as CAD, characterized by auto-reactive antibodies that trigger destruction of red blood cells, and in a subset of patients with systemic lupus erythematosus, or SLE, where endogenous pathogenic antibodies against C1q itself drive aberrant C1q activation and are highly associated with kidney damage, or lupus nephritis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In complement-mediated neurodegeneration, aberrant activation of C1q at synapses in aging and disease can lead to excessive synapse loss and neuronal damage, driving disease progression in multiple neurodegenerative disorders regardless of the initiating factor. In animal models, C1q accumulated on synapses with age, building up to 300-fold higher levels than in younger animals. It did not activate with normal aging, but other inflammatory stimuli, including misfolded proteins, metabolic dysfunction or increases in intraocular pressure, appeared to aberrantly reactivate C1q&#8217;s developmental role in synapse elimination. Complement activation and aberrant synapse pruning in disease may lead to neuroinflammation, loss of synaptic neuronal connections and neurodegeneration. In support of this hypothesis, we and other investigators have observed that C1q inhibition was protective in numerous models of neurodegenerative disease, including diseases of the eye, such as glaucoma and age-related macular degeneration, chronic diseases of the CNS, such as frontotemporal dementia, Alzheimer&#8217;s, HD and Spinal Muscular Atrophy, or SMA, and acute injury, such as traumatic brain injury and stroke.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our differentiated approach to treating complement-mediated autoimmune and neurodegenerative disease through inhibition of C1q</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that in order to selectively inhibit aberrant activation of the classical complement pathway implicated in driving certain complement-mediated autoimmune and neurodegenerative diseases, it is important to target the early components of the classical cascade, particularly C1q, C4 and C3. Activated fragments of C4 and C3 induce vascular leakiness and immune cell recruitment into the tissue, while other fragments of C4 and C3, as well as C1q, work together to direct immune cell attack to the cell or synapse surface. Furthermore, C1q inhibition blocks downstream classical pathway activation of C5 and its membrane damaging effects. We believe that inhibition of C1q does not block the activity of these components in the lectin or alternative complement pathways, and both of these pathways will continue to perform their normal immune functions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Platform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our novel upstream complement platform is designed to completely inhibit classical complement activity for the treatment of antibody-mediated autoimmune diseases and complement-mediated neurodegenerative diseases in the body, brain and eye. We believe there are potential advantages to our approach of upstream inhibition of the classical complement cascade, which include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Full inhibition of the classical cascade while preserving healthy immune function of the other complement pathways</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inhibition of C1q fully inhibits the classical cascade, including components downstream of C1q such as C4, C3, C5 and the downstream membrane attack complex. As a result, we believe our approach is designed to block all classical complement activity that can contribute to disease pathology, including immune cell recruitment, directed immune cell attack and membrane damage. By targeting upstream tissue-damaging components of the classical complement pathway, our approach leaves the lectin and alternative pathways to perform their normal immune function, which may aid both clinical improvement and safety. Our approach is also distinct from inhibiting C3 or C5. Inhibition of C5 will not affect the upstream components of the classical pathway involved in pathology (C1q, C4 and C3), while inhibition of C3 will block downstream components in all three complement pathways.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Broad applicability across many indications</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our approach has broad utility for the treatment of diseases in which full inhibition of the entire classical complement cascade may be beneficial. We believe our approach is distinguishable from those that target only downstream complement components. Our initial indications represent our beachhead within antibody-mediated autoimmune and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complement-mediated neurodegenerative diseases, and we will selectively pursue both orphan and larger patient population diseases with clear biological evidence of classical complement activation.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Flagship Programs</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guillain-Barr&#233; Syndrome</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Guillain-Barr&#233; Syndrome</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guillain-Barr&#233;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">syndrome (GBS)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a serious and life-threatening condition that continues to be associated with significant long-term morbidity and mortality in patients despite use of IVIg treatment as standard of care. GBS is a rare disease, but is also the most common, most severe, and well understood acute paralytic inflammatory disease of the peripheral nervous system. GBS generally occurs post-infection in otherwise healthy persons. Antibodies generated against an infectious agent cross-react with components of peripheral nerves, leading to a complement mediated attack on nerve components, including myelin sheath and axonal tissue. The ensuing peripheral nerve damage is acute and rapidly progressive, leading to acute severe paralysis, significant morbidity, disability and mortality. The neuronal destruction progresses until titers of the cross-reactive, complement-activating antibodies have diminished (van den Berg et al., 2014). </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GBS impacts approximately 150,000 people annually worldwide, 22,000 in the United States and EU, and 7,000 are hospitalized each year in the United States. The prevalence of GBS continues to increase with advancing age. In 2004, the annual economic cost of GBS in the United States was $2 billion, largely due to the permanent disability and mortality it can cause.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are currently no FDA-approved or targeted therapies for the treatment of GBS. Treatment guidelines published by the American Academy of Neurology recommend early initiation of IVIg or plasma exchange in patients diagnosed with GBS. Although IVIg and plasma exchange are the established standards of care in the western world and parts of Asia, significant unmet need still exists, and many patients, despite receiving the standard of care, are left with residual neurological disability, accompanied by chronic pain and fatigue.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical course of GBS usually involves rapidly progressive weakness in the limbs culminating in neuromuscular paralysis within two to four weeks of onset. According to 2011 estimates, 20 to 30% of patients require mechanical ventilation, over 20% have permanent motor or sensory disability and 2 to 20% of cases result in death globally. Many patients with GBS require extensive monitoring and supportive care and will seek treatment in a hospital within a few days of onset of the disease. Because approximately a quarter of patients need artificial ventilation due to respiratory muscle weakness, and many develop autonomic disturbances, admission in an intensive care unit is frequently necessary. Symptoms peak within four weeks as the auto-antibody response declines, followed by a recovery period that can last months or years, as the nervous system repairs itself. The development of targeted treatments for GBS is crucial to improve outcomes and quality of life for those affected by this debilitating condition.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C1q is a key driver of pathogenesis in GBS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GBS is an acute, autoimmune disease driven by antibodies that lead to activation of the classical complement cascade. Pathological nerve-targeting auto-antibodies, which may be triggered by an infection, lead to the activation of C1q and the classical complement cascade. Studies have shown that pathogenic auto-antibodies are present in the serum and CSF, and that activated components of the complement cascade are deposited on peripheral nerve tissue from GBS patients. Peripheral nerve roots are immersed in CSF as they emerge from the spinal cord and are prominent sites of damage in GBS. The figure below illustrates the activation of the classical complement pathway within peripheral nerves in GBS patient samples from autopsy. The left image shows a low magnification view of a peripheral nerve with numerous individual nerve fibers coated with membrane-damaging complement activation products (C5b-9; dark staining). The middle image shows a high magnification view of an individual nerve fiber with deposition of C3d (dark staining), a complement activation product that directs immune cell attack. The right image shows a highpower image of an individual nerve fiber being probed by an infiltrating immune cell (macrophage).</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img136305557_1.jpg" alt="img136305557_1.jpg" style="width:468px;height:176px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that by blocking the activity of C1q early in the onset of the disease, we can minimize the neuronal damage caused by these pathogenic auto-antibodies, in turn reducing the patients&#8217; symptoms and accelerating their neurological recovery.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANX005 Development Background in GBS</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since 2015, we have developed ANX005 as the potential first targeted therapy for patients with GBS, an acute neurological emergency for which there is no FDA approved treatment. ANX005 is being developed as a first-line monotherapy treatment option to address the unmet needs of GBS patients and healthcare providers, leveraging our expertise and leadership in classical complement-mediated diseases. A robust data package has been generated over the nine year development path that includes a placebo-controlled Phase 1b trial that established POC for ANX005 as a first-line treatment for GBS, a successful Phase 3 trial showing that ANX005 was generally well-tolerated and resulted in faster and more complete functional recovery versus placebo, a RWE study that showed improved outcomes against current standards of care in matched patient populations, and a drug-drug interaction study with ANX005 and IVIg strengthening the safety profile for ANX005 in GBS. Importantly, to ethically provide a placebo-controlled dataset, Annexon conducted ANX005&#8217;s clinical development for GBS outside of the U.S. in jurisdictions where IVIg treatment is not readily available. In addition, Annexon has generated real-world evidence to support the generalizability of ANX005 to a matched Western patient population and compared ANX005 treatment outcomes from a single infusion of ANX005 versus standard of care IVIg given as a 5-day infusion or PE.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have closely coordinated our clinical efforts with leading researchers of the International GBS Outcome Study, or IGOS, in pursuing a novel therapy for GBS. With the goal of aiding the development of effective treatments for GBS, practitioners established IGOS in May 2012, and have collected natural history data from 2,000 GBS patients worldwide. IGOS is a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset as well as the subtype, course and outcome of GBS. IGOS was established to help develop a better understanding of the mechanism of disease progression and recovery and to conduct selective therapeutic trials to improve patient outcomes. This natural history database is an invaluable resource to clinical development, facilitating the design of clinical trials, optimal selection of endpoints, and patient follow-up for one to three years. We initiated our GBS clinical development in Bangladesh, a country where the incidence of GBS is several times higher than in North America and Europe and where 17% of patients die from the disease and 20% suffer permanent disability and are unable to walk. Additionally, our site in Bangladesh is well situated to conduct clinical research in GBS in a manner compliant with good clinical practice, or GCP, requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1b Trial of ANX005 in GBS</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted a Phase 1b placebo-controlled, dose escalation trial (n=50) of ANX005 in GBS patients at a tertiary care hospital in Bangladesh, in compliance with GCP as described above. The trial objectives included safety and tolerability, dosing levels and target engagement, and included a follow up of eight weeks. The dosing levels of ANX005 delivered in this trial ranged from 3 mg/kg to 75 mg/kg. ANX005 was well tolerated, and no drug-related serious adverse events or drug-related discontinuations occurred. The most common adverse events were acute infusion-related reactions, or IRRs, which occurred in the majority of patients and presented as low grade, non-serious, transient skin rash. These acute IRRs were mitigated by standard anti-inflammatory pre-medications.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results from the Phase 1b trial showed increasing serum levels of ANX005 and its duration in the circulation at increasing dose levels, and that the drug was present in the serum for up to three weeks at a dose of 75 mg/kg. When ANX005 was present in the circulation C1q function was fully inhibited, and rapidly returned to normal levels as ANX005 serum levels declined.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Much of the proximal weakness in GBS patients is due to involvement of peripheral nerve roots that are immersed in CSF as they exit the spinal cord. Hence, we believe product candidate levels and target inhibition in CSF may be an important contributor to efficacy. We observed that ANX005 entered the CSF of GBS patients treated with doses of 18-75 mg/kg of ANX005, resulting in full engagement of C1q inhibition in the CSF.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the Phase 1b trial in GBS patients, ANX005 treatment at doses that engaged C1q in both serum and CSF (i.e., 18-75 mg/kg dose) resulted in a statistically significant early decline in serum NfL levels compared to placebo (two to four-week post treatment p-value &lt;0.05). In this Phase 1b trial, we also explored the administration of ANX005 on multiple validated clinical disability measures including GBS-Disability Score, or GBS-DS, Medical Research Council Muscle Strength Scale, or MRC, and Inflammatory Rasch-built Overall Disability Scale, or I-RODS, over an eight-week period. We observed that early decline in NfL correlated with improvement in the GBS-DS at the end of the study (two to eight-week post treatment p-value &lt;0.05). We believe these results suggest that ANX005 had a rapid impact on the disease process by ameliorating antibody-induced nerve damage, likely within the first two weeks of dosing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Though the trial was not powered for statistical significance, treatment with ANX005 resulted in consistent, positive numerical trends, including an improvement in MRC score and the number of days of ventilation. We observed a dose-dependent trend for improvement in MRC within the first week of treatment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early improvement in MRC is known to have strong prognostic implications on long-term functional recovery (modified Erasmus GBS Outcome Score). In line with this published data, we found that early improvement in MRC correlated with patients&#8217; disability scores at the end of the Phase 1b trial (GBS-DS at week eight). This result is important because GBS-DS is typically used as the primary endpoint in GBS registrational studies. In addition, using a responder analysis, 28% of patients treated with high dose ANX005 (18-75 mg/kg) improved by at least three points on GBS-DS by week eight compared to 0% of placebo-treated patients.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the completion of the Phase 1b treatment cohorts (through 75 mg/kg), two unblinded exploratory cohorts were enrolled to establish higher dose and multiple dose safety and PK/PD to inform subsequent chronic dosing trials. These two exploratory cohorts were a single dose of 100 mg/kg, and two doses of 75 mg/kg separated by one week (150 mg/kg total). At these higher dose levels, ANX005 was well-tolerated, and no drug-related serious adverse events or drug-related discontinuations occurred; moreover, we did not reach a maximum tolerated dose. Similarly, we observed full inhibition of C1q in serum and CSF, a reduction in NfL and trends of improvement in clinical measures when compared to placebo; however, there was no additional impact on these clinical measures beyond that seen at 75 mg/kg.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of the Phase 1b dose-ranging trial in GBS showed that ANX005 was well-tolerated, fully inhibited C1q in the blood and CSF at target doses, and demonstrated an early reduction in NfL levels. Drug treatment was associated with a trend for early improvement in MRC, and early changes in MRC significantly correlated with improved clinical measures in GBS patients. An additional key learning from the study is the importance of using baseline MRC for patient stratification at the time of hospitalization and study entry. Accounting for baseline MRC strengthened the impact of ANX005 treatment in the biomarker and clinical measures, demonstrating that MRC will be an important stratification tool in future GBS trials.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 Trial of ANX005 in GBS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the positive findings from our Phase 1b trial, we conducted a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ANX005 administered by a single intravenous, or IV, infusion. The Phase 3 trial enrolled 241 patients in Bangladesh and the Philippines diagnosed with GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for Guillain-Barr&#233; Syndrome at the onset of GBS-related weakness &#8804;10 days prior to the start of</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">treatment. Patients were stratified for leading prognostic factors including muscle strength and time from symptom onset.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we presented topline results from the Phase 3 trial demonstrating that a single infusion of ANX005 at 30 mg/met the trial&#8217;s primary endpoint of a meaningful improvement in GBS-disability scale at week 8. Specifically, ANX005 30 mg/kg achieved a highly statistically significant 2.4-fold improvement on the GBS-DS (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 0.0058), utilizing a proportional odds methodology to assess the proportion of patients who shift to better outcomes on the GBS-DS with ANX005 treatment compared to placebo at week 8. ANX005 30 mg/kg treatment also demonstrated improvements versus placebo on key secondary endpoints, including early gains in muscle strength by Medical Research Council (MRC) sum score at day 8 (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &lt;0.0001*) and at week 8 (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 0.0351*), and a median of 28 fewer days on artificial ventilation through week 26 (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 0.0356*). Additionally, ANX005 30 mg/kg demonstrated a 31-day reduction in the median time to walk independently versus placebo (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 0.0211*) in a prespecified analysis. ANX005 30 mg/kg treated patients got better sooner on each of these assessments, presenting important clinical care outcomes for patients and the healthcare community.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* nominal p-values</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 3 trial evaluated two doses of ANX005, 30 mg/kg and 75 mg/kg, both of which delivered rapid and complete suppression of complement activity but differed in duration of C1q inhibition. The 30 mg/kg dose suppression lasted one week and the 75 mg/kg dose suppression lasted two to three weeks. ANX005 75 mg/kg outperformed placebo on multiple endpoints; however, it was not statistically significant on the primary endpoint of GBS-DS at week 8 (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 0.5548). The two dose levels were evaluated based on findings in the earlier Phase 1b proof-of-concept study, which showed efficacy in pooled analysis of both shorter and longer duration of ANX005 C1q inhibition. Because classical complement drives tissue damage in the early phase of disease, while facilitating nerve repair after acute nerve injury, the strong positive Phase 3 results with the 30 mg/kg dose resulting in one week of C1q inhibition appeared to define the optimal treatment window.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical safety and tolerability findings of ANX005 at both doses in the Phase 3 study support a generally well-tolerated profile with no new safety signals. The majority of adverse events were mild Grade 1 to moderate Grade 2 events. The most common treatment-related adverse events were infusion related reactions (30.4%) that were mostly mild transient rashes. There were no autoimmune related adverse events, and no drug-related deaths or serious infections were observed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Real World Evidence Study of ANX005 in GBS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our studies to date for ANX005 in GBS have been conducted at sites outside the United States. To support these clinical trials and based on feedback from the FDA, we conducted a RWE study in collaboration with IGOS investigators to establish comparability between Phase 3 participants and western patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IGOS investigators and we established a cohort of 79 real-world patients from the IGOS global patient registry that was matched based on key prespecified prognostic factors to the cohort of 79 patients treated with ANX005 30 mg/kg from our completed Phase 3 study. Patients in the ANX005 Phase 3 population had moderate to severe disease, and the matching level demonstrates that the Phase 3 population is represented within the global GBS patient spectrum captured in IGOS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This RWE study also provided the first insights comparing ANX005 with the standard of care IVIg or PE. Patients treated with ANX005 showed faster and greater improvement in muscle strength and disability compared to patients in the matched IGOS cohort treated with IVIg or PE. The comparison also showed that fewer patients treated with ANX005 required mechanical ventilation. Further, ANX005-treated patients were observed to spend less time on ventilation and less time in the intensive care unit, or ICU. These findings indicate that ANX005 may decrease the overall burden of GBS care.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some key findings comparing ANX005 30 mg/kg to IVIg or PE included:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By week 1, patients treated with ANX005 showed more than 10-point improvement in muscle strength over patients treated with IVIg or PE, a clinically meaningful benefit as measured by MRC sumscore and an indicator for future recovery potential (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &lt; 0.0001).</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients treated with ANX005 were approximately twice as likely to be in a better state of health than patients on IVIg or PE on the GBS-DS at multiple timepoints throughout the study, including at week 8, the primary endpoint for the Phase 3 trial (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 0.0459).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approximately half the number of patients treated with ANX005 (n=15 of 79) required mechanical ventilation compared with patients treated with IVIg or PE (n=32 of 79) (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> = 0.022).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX005-treated patients were observed to spend fewer days on mechanical ventilation and fewer days in the ICU (median of 12 fewer days for each measure, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">= n.s.).</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Together, we believe the Phase 3 trial and RWE study demonstrate consistent, robust effects of ANX005 treatment in support of a potential U.S. BLA. ANX005 has received both Fast Track and orphan drug designations from the FDA as well as orphan designation by the EMA for the treatment of GBS. The EMA orphan designation was based on an indirect comparison between ANX005 and IVIg that demonstrated a notable and early improvement in muscle strength with ANX005 versus patients treated with IVIg, which translated into observable gains in health status, including a reduction in the need of mechanical ventilation.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Geographic Atrophy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Geographic Atrophy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GA is an advanced form of dry age-related macular degeneration (AMD), an eye disease that is the leading cause of blindness in the elderly. GA is a chronic progressive neurodegenerative disorder of the retina involving the loss of photoreceptor synapses and cells in the outer retina. GA affects an estimated one million people in the United States and eight million people globally, severely limiting their independence and causing frustration, anxiety and emotional hardship. Effective treatments that preserve vision are still needed, as no currently approved therapies have been shown in clinical trials to significantly prevent vision loss.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Role of C1q and Complement in Geographic Atrophy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Genome-wide association studies have strongly implicated multiple components of the complement cascade in AMD and geographic atrophy. For example, specific alleles of the gene for C3 can increase the likelihood of developing AMD by 50%. Histopathological investigations have also observed the presence of complement components in geographic atrophy. These studies largely point to a role of excessive C3 activity in disease, but do not indicate how C3 is being activated (classical, lectin or alternative pathways). We have identified a potential dual role of C1q and the classical cascade as an important complement-activating system in geographic atrophy. First, we found that C1q strongly accumulated on photoreceptor cell synapses with normal age or disease, as shown below (left panel), implicating C1q&#8217;s role in excessive synapse pruning and complement-mediated neurodegeneration. Second, C1q and C1q ligands, such as C-reactive protein, also accumulated in the retina below photoreceptor cells in association with drusen (extracellular membrane and protein debris associated with geographic atrophy; right panel). These results suggest that the photoreceptor neurons and pigmented retinal epithelial cells &#8211; cell types that are both lost in GA &#8211; are sandwiched between deposits of C1q and that the classical complement cascade may have an ongoing and pathogenic role in GA by activating C3.</span></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img136305557_2.jpg" alt="img136305557_2.jpg" style="width:239px;height:182px;"/><img src="img136305557_3.jpg" alt="img136305557_3.jpg" style="width:267px;height:181px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In support of this hypothesis, we found that either deletion or pharmacologic inhibition of C1q was protective in an animal model of photoreceptor neuron loss induced by photo-oxidation, as shown below. Further, components of the classical complement cascade have been associated with photoreceptor cells in human GA tissue (C4 and C3) and implicated in photoreceptor cell targeting with an in vitro assay. Finally, C1q is locally produced within the retina during disease by infiltrating immune cells, indicating that its pathogenic role may be amenable to local inhibition of C1q. As described above, we believe inhibition of C1q would block all key components of the classical cascade, including C1q, C4, and C3 involved in immune cell attack and synapse pruning, as well as C5 involved in direct membrane damage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C1q inhibition was shown to be protective of photoreceptor cells and retinal function in a model of photoreceptor cell damage induced by light.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1b Trial of ANX007 in Glaucoma to Support Development in GA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed single-ascending dose (n=9) and sham-controlled multiple dose (n=17) studies of intravitreal ANX007 in patients with glaucoma to evaluate safety, tolerability, pharmacokinetics and target engagement. These patients had aqueous humor taps so that ocular fluid could be analyzed for levels of ANX007 and free C1q immediately prior to first dose (day 1) and prior to second dose (day 29). The studies showed that ANX007 was well-tolerated at all doses (1 mg, 2.5 mg and 5 mg) and achieved complete suppression of C1q at 2.5 mg and 5 mg.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 ARCHER Trial of ANX007 in GA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted the randomized, multi-center, double-masked, sham-controlled Phase 2 ARCHER trial to compare the safety and efficacy of ANX007 in patients with GA secondary to AMD. The study enrolled a total of 270 patients, stratified by GA lesion size, location and choroidal neovascularization, or CNV, in the fellow eye at the time of enrollment. Patients were nearly equally split between foveal (49.4% to 57.3%) and non-foveal groups, had an average age of 80 years and were balanced between female and male. Ninety-six percent of patients enrolled were from the United States. Patients were randomized to receive an intravitreal dose of 5mg ANX007 monthly (n=89), 5mg ANX007 every other month (n=92) or sham monthly or every other month (pooled n=89) for a treatment period of 12 months, followed by a six-month off-treatment period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary outcome measure of the study was the rate of change in GA lesion growth (slope) from baseline as measured by fundus autofluorescence through 12 months for the study eye. The study included multiple pre-specified visual function measures to assess the effects of ANX007 on vision: change from baseline in BCVA; change from baseline in low-luminance best corrected visual acuity; and change in baseline from low-luminance visual acuity deficit, or LLVD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the Phase 2 ARCHER trial, ANX007 demonstrated consistent protection against vision loss in a broad population of patients with GA. Specifically, topline data from the Phase 2 ARCHER trial reported in May 2023 and presented at the American Society of Retina Specialists Annual Meeting in July 2023 showed that ANX007 provided significant, time and dose-dependent protection from vision loss in patients with GA, measured by BCVA &#8805; 15-letter loss, the widely accepted and clinically meaningful functional endpoint assessing visual acuity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Monthly treatment with ANX007 demonstrated nominally statistically significant reduction in BCVA &#8805;15-letter loss (p=0.0021) compared to sham. The persistent &#8805;15-letter BCVA loss through month 12 hazard was reduced 72% in the monthly arm (p=0.006) and 48% in the every other month arm (p=0.064). Protection from vision loss was also shown in multiple additional prespecified measures of BCVA and visual function, including in standard and low light conditions. Protection from vision loss was enhanced in a subpopulation of patients with less advanced disease defined by LLVD &lt; 30 at baseline and in patients with more intact vision as defined by &lt;80% ellipsoid zone, or EZ, loss. ANX007&#8217;s treatment effect increased over the course of the on-treatment portion of the study, suggesting that ANX007 may provide a growing and durable treatment effect over time. While benefit gained against vision lost was maintained during the subsequent six-month off-treatment period, the rate of decline for BCVA &#8805; 15-letter vision began to parallel that of sham, providing additional support for the observed on-treatment protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance, greater impact on retinal pigment epithelium loss was observed in the second six months of treatment versus the first. Consistent with its proposed mechanism, ANX007 reduced photoreceptor EZ loss and showed more pronounced effect in reducing total EZ loss and protection of photoreceptors in the central fovea that are associated with visual acuity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX007 treatment was generally well-tolerated, with no increase in CNV rates between the treated and sham arms and no events of retinal vasculitis reported.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 Program of ANX007 in dry AMD with GA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, we initiated the Phase 3 ARCHER II trial, a global, sham-controlled, double-masked trial enrolling approximately 630 patients who have dry AMD with GA. The single-study program will be analyzed as two sub-studies in the U.S. in accordance with the FDA&#8217;s two-trial recommendation. The primary endpoint of ARCHER II is prevention of &#8805;15-letter loss of BCVA, and an objective secondary objective structural measure is prevention of EZ loss. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX007 is the first therapeutic candidate for the treatment of GA to receive PRIME designation by the EMA, which provides early and proactive support to developers of promising medicines that may offer a major therapeutic advantage over existing treatments or benefit to patients without treatment options.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX1502</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of ANX1502</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX1502 is a novel small molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. ANX1502 converts to the active compound, ANX1439, on administration and delivers a highly potent and selective inhibitor of the activated form of C1s&#8212;part of the C1 complex that initiates the classical pathway. The active compound has been shown to have a high affinity to C1s and demonstrate a robust functional inhibition of the classical pathway.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Role of C1s in Complement-Mediated Autoimmune Diseases</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The C1 complex is responsible for the activation of the classical pathway and is comprised of C1r, C1s and C1q. As part of the disease process, once activated, C1s is responsible for cleaving C4 and C2, key amplification components of the classical cascade. We believe that by stopping C1s from cleaving C4 and C2 with ANX1502, we will be able to block the classical cascade to reduce levels of inflammation, slow disease progression and potentially impact disease outcomes for patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img136305557_4.jpg" alt="img136305557_4.jpg" style="width:487px;height:221px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 SAD/MAD Trial of ANX1502</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed the randomized, double-blind, placebo-controlled Phase 1 SAD/MAD trial of ANX1502 to assess the safety, tolerability, PK and PD of ANX1502 liquid suspension formulation in healthy adults. The study evaluated single ascending doses of ANX1502 ranging from 25 mg to 1050 mg (6 patients treated with ANX1502 plus 2 placebo subjects per cohort) and multiple ascending doses of ANX1502 ranging from 200 mg twice-daily to 525 mg twice-daily (9 patients treated with ANX1502 plus 3 placebo subjects per cohort).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the SAD/MAD study, dose-proportional PK and targeted levels of active drug were observed across both cohorts, and single doses of 525-1025 mg ANX1502 suppressed C4d serum levels in healthy volunteers with higher than median baseline C4d. Across all doses evaluated, ANX1502 was generally well tolerated with mild to moderate treatment-emergent adverse events (TEAEs), which included gastro-intestinal events such as nausea, emesis and diarrhea. No serious adverse events were reported, and there were no significant clinical or lab findings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ongoing Development of ANX1502 in Autoimmune Diseases</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are evaluating a tablet formation of ANX1502 in an ongoing open-label, single arm POC study in patients with CAD for up to four weeks to assess tolerability, pharmacokinetics, pharmacodynamic and clinical efficacy endpoints (e.g., hemolysis as measured by reduction of elevated bilirubin). Enteric coated tablets allow flexible dosing 4-5-times above target concentrations of 100nM for rigorous testing in CAD, a classical complement-mediated disease. Three patients have been enrolled to date with observed reduction in key clinical and biomarker outcomes consistent with complement inhibition. Data in up to seven patients are expected in mid-2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the successful completion of the proof-of-concept study, we intend to evaluate ANX1502 in serious complement-mediated diseases, with the aim of providing enhanced efficacy and offering convenient dosing administration for long-term treatment of chronic autoimmune conditions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Next Wave Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANX005 for Huntington&#8217;s Disease</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed a Phase 2 trial of ANX005 in patients with HD (28 patients were enrolled with safety data measured from all 28 patients and efficacy data measured from 23 patients that completed both six-months of treatment and subsequent three-month follow-up period), which showed that treatment with ANX005 was generally well-tolerated, with full target engagement of C1q in both serum and CSF observed throughout the six-month treatment period and well into the three-month follow-up period. Disease progression stabilized for the entire nine months of the study, as assessed by both Composite Unified Huntington's Disease Rating Scale, or cUHDRS, and Total Functional Capacity, or TFC, the two primary clinical measurement scales for HD. Additionally, HD patients with higher baseline complement activity, as measured by elevated levels of C4a/C4 in CSF, demonstrated a rapid clinical benefit as early as week 6, as assessed by both cUHDRS and TFC, that was sustained over the entire nine months of the study. Plasma and CSF NfL levels remained generally consistent through the nine-month study and were comparable to NfL levels described in published natural history data for HD patients. Based on these findings and productive engagement with the FDA, we are assessing opportunities for late-stage development of ANX005 in HD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANX005 for ALS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed a Phase 2a signal-finding trial evaluating ANX005 in patients with ALS, designed to assess safety, tolerability, and target engagement (13 patients were enrolled and treated for 12 weeks, of which 7 patients continued on treatment for 24 weeks). Chronic dosing of ANX005 was generally well-tolerated, showed rapid and sustained target engagement of C1q in blood, and reduced downstream pharmacodynamic complement markers in blood. Consistent with what has been shown in other neurodegenerative diseases, including HD, exploratory analyses indicated that patients with higher baseline classical complement activation who enrolled within 12 months of diagnosis achieved better outcomes, including less functional decline on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and stabilization of neurofilament light chain (NfL). These analyses support a precision medicine approach to identify patients most likely to respond to anti-C1q therapy in clinical trials with recently diagnosed ALS patients who have elevated baseline levels of classical complement activity.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANX009 for Lupus Nephritis</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX009, an investigational C1q Fab formulated for subcutaneous delivery, which was most recently evaluated in a Phase 1b signal-finding trial using a precision medicine approach for patients with lupus nephritis (LN) who have high baseline complement activity. LN is an autoimmune disease for which pathogenic anti-C1q antibodies (PACAs) enhance activity and uniquely amplify kidney inflammation and damage. We designed ANX009 with a goal of enabling chronic dosing for patients with antibody-mediated autoimmune disorders where anti-C1q may have a disease-modifying effect and where we can utilize our targeted biomarker-driven approach. In a first-in-human clinical trial, ANX009 was well-tolerated (7 patients were enrolled, of which 6 patients completed treatment) at all dose levels tested and no drug-related safety signals were observed. The trial showed that ANX009 led to sustained C1q inhibition at multiple doses, supporting the potential for twice-weekly subcutaneous administration with the current formulation, and advancement into the Phase 1b signal-finding trial for patients with LN.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial results from the Phase 1b trial were presented at the American Society of Nephrology&#8217;s Kidney Week 2023 conference, which showed subcutaneous ANX009 was well tolerated and demonstrated plasma C1q target engagement and complement inhibition. Importantly, inhibition of C1q rapidly increased free/circulating PACA levels (consistent with decreased deposition in the kidney) and improved all downstream markers of complement consumption and activation (C4, as well as C3 and C5b-9). These results indicate that C1q and the classical pathway are key drivers of complement activation in LN, independent of the alternative and lectin pathways, and that PACAs are a component of the classical complement activation pathway. Consistent with the short duration of this signal-finding study (3 weeks), changes in urinary protein excretion were not observed as anticipated. We are evaluating options for future development of ANX009 in LN.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important for the development and implementation of our business. We also rely on the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how that is not patentable, we rely on confidentiality agreements to protect our interests. We generally require our employees, consultants, scientific advisors and contractors to enter into confidentiality agreements prohibiting the disclosure of confidential information and requiring disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio includes patents and patent applications that are licensed to us in whole or in part from a number of partners, including Stanford University and the University of California, and patents and patent applications that are owned by us. Our proprietary technology has been primarily developed by in-house research and development programs, and to a lesser extent through acquisitions, relationships with academic research centers and contract research organizations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our product candidates, we will, in general, initially pursue patent protection covering compositions of matter and methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including by protecting inventions related to additional methods of use, processes of making, formulation and dosing regimens.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We hold worldwide development and commercialization rights, including through exclusive licenses, to all of our product candidates, which allows us to strategically maximize value from our product portfolio over time. Our patent portfolio includes patent protection for our upstream complement platform and each of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 10, 2025, our patent portfolio, including patents licensed from our partners, comprised 18 different patent families filed in various jurisdictions worldwide. Our patent portfolio includes issued patents and patent applications in the United States and in other jurisdictions.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One patent family, which we exclusively license from Stanford University, includes nine granted U.S. patents covering various methods of treating neurodegeneration and related medical conditions by inhibiting the C1 complex or its components, such as by using an anti-C1q antibody. The U.S. patents in this family include claims covering uses of ANX005, ANX007 and ANX009. These U.S. patents will expire between 2026 and 2030, absent any additional disclaimers, extensions or adjustments of patent term. There are no pending applications or foreign patents in this family.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Two other patent families, which we own, are directed to anti-C1q antibodies and methods of using them. These families include six granted U.S. patents, two pending U.S. patent applications, 30 granted foreign patents and eight pending foreign patent applications. The patents in these families cover ANX005, ANX007 and ANX009. These patents will expire between 2034 and 2037, absent any additional disclaimers, extensions or adjustments of patent term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other patent families that we own include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two granted U.S. patents, one pending U.S. patent application, eight granted foreign patents, and nine pending foreign patent applications. The patents in this family include claims directed to ANX007 and will expire between 2036 and 2038, absent any additional disclaimers, extensions or adjustments of patent term;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one pending PCT application. The pending PCT application in this family includes claims covering a pharmaceutical formulation comprising anti-C1q antibodies, including ANX005, ANX007 and ANX009. Patents that may be issued from this family would expire in 2043, absent any disclaimers, extensions or adjustments of patent term;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one granted U.S. patent, one pending U.S. patent application, and 37 pending foreign patent applications. The granted U.S. patent in this family includes claims covering certain small molecule modulators of the classical pathway, including ANX1502. This patent will expire in 2041, absent any additional disclaimers, extensions or adjustments of patent term. Patents that may be issued from these applications would expire in 2041, absent any disclaimers, extensions or adjustments of patent term; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one pending U.S. patent application and 16 pending foreign applications</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The pending U.S. patent application in this family includes claims covering certain small molecule modulators of the classical pathway. Patents that may be issued from this family would expire in 2043, absent any disclaimers, extensions or adjustments of patent term. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio also includes ten patent families, owned by us solely or jointly with the University of California or The J. David Gladstone Institutes or Fondazione Telethon and Universita&#8217; degli Studi di Trento, directed to the treatment of certain medical conditions using anti-C1q antibodies, including ANX005, ANX007 and ANX009. These families include nine pending U.S. patent applications, three granted foreign patents, and 84 pending foreign patent applications. Patents that may be issued from these applications would expire between 2034 and 2043, absent any disclaimers, extensions or adjustments of patent term.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2011, we and The Board of Trustees of the Leland Stanford Junior University, or Stanford, entered into an exclusive licensing agreement, or the Stanford Agreement. Under the Stanford Agreement, Stanford granted to us an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patent rights, or the Licensed Patents, to make, use, offer for sale, sell, import and otherwise commercialize products covered by the Licensed Patents for human or animal diseases, disorders or conditions. We are required to meet certain development and funding milestones for the licensed products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Stanford Agreement, we are obligated to pay Stanford an upfront payment, license maintenance fees ranging from the single digit to tens of thousands of dollars per year, and milestone payments totaling up to $675,000. We also agreed to make royalty payments at a rate equal to a low single-digit percentage of worldwide net sales of licensed products and a portion of certain sublicensing income we receive from sublicensees at a rate in the low double digit percentages, subject to a specified maximum total payment.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in accordance with the terms of the Stanford Agreement, upon closing our first financing event that raised at least $2.0 million, we granted Stanford $150,000 in shares of our redeemable convertible preferred stock, which were automatically converted into shares of our common stock prior to the completion of the initial public offering, or IPO, in July 2020. We may also have to pay a fee to Stanford if we assign our rights under the Stanford Agreement to a third party.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate the Stanford Agreement in its entirety, or as to a particular Licensed Patent or licensed product, for convenience on thirty days&#8217; prior written notice. Stanford may terminate the Stanford Agreement for our breach that remains uncured for forty-five days or if we provide any false report, are delinquent on any report or payment, fail to achieve a milestone or fail to diligently develop and commercialize a licensed product.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term and Term Extensions</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the filing date of the earliest non-provisional patent application to which a claim of priority is made. In addition, in certain instances, the term of a U.S. patent can be extended to recapture a portion of any delay caused by the United States Patent and Trademark Office, or USPTO, in issuing the patent, as well as a portion of the term of a granted patent that is effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend the patent term beyond 14 years from FDA approval for the product covered by that patent. In addition, only one patent applicable to an approved drug may receive the extension, and the extension applies only to coverage for the approved drug, methods for using it and methods of manufacturing it, even if the claims cover other products or product candidates. Where one patent covers multiple products or product candidates, it may only receive an extension for one of the covered products; any extension related to a second product or product candidate must be applied to a different patent. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from filing date of the earliest non-provisional patent application to which a claim of priority is made, such as a PCT application. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign jurisdictions, must be timely paid in order for the patent to remain in force during this period of time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The actual protection afforded by a patent may vary on a product by product basis, from country to country, and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more information, see the section titled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trademarks and Know-How</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the ongoing development and advancement of our products and services in the United States and various international jurisdictions, we seek to create protection for our marks and enhance their value by pursuing trademarks and service marks where available and when appropriate.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent and trademark protection, we rely upon know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our commercial partners, collaborators, employees and consultants, and invention assignment agreements with our employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed by our employees and through relationships with third parties. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our contractors, commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights in related or resulting know-how and inventions. For more information, see the section titled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and Marketing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We hold worldwide commercialization rights, including through exclusive licenses, to our product candidates. Given our stage of development, we have established a small commercial organization and have not established distribution capabilities. Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success as a company will depend on our ability to deliver reliable, high-quality drug supply. We do not currently own or operate facilities for product manufacturing, storage and distribution, or testing. We contract with third parties for the manufacture of our product candidates. Because we rely on contract manufacturers, we employ personnel with extensive technical, manufacturing, analytical and quality experience. Our staff has strong project management discipline to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing is subject to extensive regulation that imposes various procedural and documentation requirements and that governs record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, and more. Our systems and our contractors are required to be in compliance with these regulations, and compliance is assessed regularly through monitoring of performance and a formal audit program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current supply chains for our lead drug candidates involve several manufacturers that specialize in specific operations of the manufacturing process, specifically, raw materials procuring, drug substance manufacturing and drug product manufacturing. We currently operate under work order programs for our drug candidates with Master Services and Quality agreements in place that include specific supply timelines, volume and quality specifications. We are in discussions with our current manufacturers regarding preparation of Biologics License Applications (BLA) and Marketing Authorization Application (MAA) in the near future. This involves technology transfers, process characterization, and process validation to establish commercial manufacturing capabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to establish long-term supply agreements in the future. We believe our current manufacturers have the scale, the system, and the experience to supply our currently planned clinical trials and commercial launch. To ensure continuity in our supply chain, we plan to establish supply arrangements with alternative larger scale suppliers for certain portions of our supply chain, as appropriate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical, biopharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our executive and scientific team, research, clinical capabilities, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical, biopharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, and experience in obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guillain-Barr&#233; Syndrome</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are currently no approved therapies for GBS in the United States. IVIg and PE are the most commonly used therapies in the Western world and parts of Asia. Currently, two investigational products are in development. Hansa Biopharma AB is conducting an open label Phase 2 trial of imlifidase in GBS patients in Europe and the United Kingdom for which it released topline results in December 2023 and real-world comparison data in December 2024. AstraZeneca/Alexion completed a Phase 3 trial of SOLIRIS (eculizumab) in Japan that did not meet its primary endpoint. Additionally, a primary investigator sponsored Phase 2 trial with argenx&#8217;s efgartigimod is listed as an active trial.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Geographic Atrophy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Two treatments are currently FDA-approved for GA, both receiving approval in 2023: Apellis&#8217;s Syfovre, a C3 inhibitor as well as Astellas&#8217;s avacincaptad pegol, a C5 inhibitor. There are currently no approved therapies for GA in the EU. There is currently one combination complement cascade-targeted therapy in Phase 3 development for GA: Regeneron&#8217;s pozelimab, a C5 inhibiting monoclonal antibody combined with cemdisiran, a C5-targeted siRNA molecule. In Phase 2, there are currently four complement-targeting agents: Aviceda Therapeutics&#8217;s AVD-104, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a nanoparticle molecule that inhibits complement cascade amplification and inflammation pathways, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AstraZeneca&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">danicopan, an oral, complement factor D inhibitor, Janssen&#8217;s JNJ 1887, a gene therapy candidate which expresses soluble CD59, a complement protein, and Novartis&#8217;s iptacopan, an oral factor B inhibitor. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other products that do not target the complement cascade currently in Phase 2 or 3 clinical trials are being developed by Roche, Alkeus, Belite Bio, Stealth BioTherapeutics, Boehringer Ingelheim, Galimedix Therapeutics, Cognition Therapeutics and ONL Therapeutics. Perceive Bio, Ocugen, and Astellas each have an asset in Phase 1 of development.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cold Agglutinin Disease, a type of autoimmune hemolytic anemia</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanofi&#8217;s Enjaymo was approved by the FDA for CAD in February 2022, and in October 2024, Sanofi sold global rights to Enjaymo to Italy-based Recordati. There are currently two investigational agents in clinical trials for CAD: Alpine Immune Sciences, Inc. is developing povetacicept, a fusion protein that blocks the function of two cytokines and Sanofi completed a phase I trial of BIVV020 in November 2023 with positive results with a single dose delivery in CAD patients.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Multifocal Motor Neuropathy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently, Gammagard Liquid (10% Immune Globulin Infusion (Human)) is the only therapy approved by the FDA for MMN. There are currently two agents in Phase 3 of development: Argenx&#8217;s empasiprubart (ARGX-117), an IV-delivered C2 inhibitor and Takeda&#8217;s TAK-771, which is being studied in a Japan-based Phase 3 trial. TAK-771 is a 10% Immune Globulin and Recombinant Human Hyaluronidase (rHuPH20) delivered as a subcutaneous infusion. There is also a complement-targeted agent, in Phase 2 development, Dianthus Therapeutics&#8217; DNTH103, a monoclonal antibody inhibitor of C1s.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lupus Nephritis</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are currently two approved medicines specifically for LN: GSK&#8217;s Benlysta and Aurinia&#8217;s Lupkynis. One agent, Roche&#8217;s obinutuzumab (Gazyva), has been filed with the FDA and EMA with approvals expected in 2025. There are four agents in development targeting the complement pathway, three in Phase 2 development and one in Phase 1 development: AstraZeneca&#8217;s ravulizumab, a C5 inhibitor, vemircopan</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALXN2050), an oral Factor D inhibitor, and Novartis&#8217;s iptacopan, an oral factor B inhibitor, are in Phase 2. AstraZeneca has a 3</span><span style="color:#231f20;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> generation, subcutaneously administered C5 inhibitor, gefurulimab, which is being studied in a Phase 1, specifically for proteinuria. Outside of the complement pathway</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there are currently four agents in Phase 3 development for adults with lupus: Novartis&#8217;s ianalumab, AstraZeneca&#8217;s anifrolumab, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vera Therapeutics&#8217;s atacicept and Aurinia&#8217;s voclosporin in adolescents with lupus nephritis. There are twelve cellular therapies in Phase 1 and Phase 1/2 of development as well as oral agents and monoclonal antibodies from BMS, Boehringer Engelheim, argenx, Janssen, Novartis and others in Phase 1 and Phase 2 development.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Huntington&#8217;s Disease</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no approved disease-modifying therapies for HD, and no potentially disease modifying agents in Phase 3 development. Multiple companies are developing potentially disease-modifying therapies in earlier stages of development, including, PTC Therapeutics&#8217;s oral PTC518 in Phase 2, uniQure&#8217;s gene t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">herapy candidate, AMT-130 in Phase 1/2, Roche&#8217;s tominersen in prodromal or early manifest HD patients aged 25-50 in Phase 2 and Vaccinex&#8217;s pepinemab in Phase 2. Addit</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ional early-stage products in development are Wave Life Sciences&#8217;s WVE-003 in Phase 1/2, Vico Therapeutics&#8217;s V0659 in Phase 1/2 and Alnylam&#8217;s ALN-HTT02 in Phase 1.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amyotrophic Lateral Sclerosis</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are currently no additional complement-targeted therapies in clinical development. The drugs riluzole, Radicava and Radicava ORS (edaravone) are currently approved for the treatment of ALS and have shown modest effects in slowing the progression of the disease. Biogen&#8217;s Qalsody, an antisense oligonucleotide that binds to SOD1 mRNA, for those ALS patients with SOD1-ALS, received accelerated approval from the FDA in April 2023. Amylyx&#8217;s Relyvrio (AMX0035) was approved by the FDA in September 2022 for people living with ALS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> but was voluntarily pulled from the market by Amylyx after their Phase 3 confirmatory failed to show a benefit for ALS patients.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Seven investigational agents are currently in Phase 3 development. There are a significant number of companies conducting earlier-stage clinical trials in ALS patients, including Ionis, argenx, Novartis, uniQure, NeuroSense, and others, testing oral agents, cellular therapies, gene therapies and other modalities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of product candidates such as those we are developing. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A new drug must be approved by the FDA through the approval process and a new biologic must be approved by the FDA through the biologics license application, or BLA, process before it may be legally marketed in the United States. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, along with third-party contractors, will be required to navigate the various preclinical, clinical manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Biologics Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and in the case of biologics, also under the Public Health Service Act, or PHSA, and their implementing regulations. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s Good Laboratory Practice requirements, or GLP requirements and other applicable regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an Investigational New Drug application, or IND, which must become effective before clinical trials may begin;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an institutional review board, or IRB, or ethics committee, or EC, at each clinical site before the trial is commenced at such site;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in accordance with Good Clinical Practice, or GCP, requirements to establish the safety and efficacy of the proposed drug, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or the safety, purity and potency of the proposed biologic for its intended purpose;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of and submission to the FDA of an NDA or BLA after completion of all required clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA or BLA whether to file the application for review;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed drug or biologic is produced to assess compliance with current Good Manufacturing Practices, or cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCP; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the BLA or NDA to permit commercial marketing of the product for specific indication(s) for use in the United States.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. Prior to beginning the first clinical trial with a product candidate in the United States, a sponsor must submit an IND to the FDA, which </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for the proposed clinical trial(s). The IND also includes results of animal and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product; chemistry, manufacturing and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically goes into effect 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, an independent IRB or EC for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the trial until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a Data Safety Monitoring Board, which provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Regulatory authorities, the IRB/ethics committee or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objective(s). There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of BLA or NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1&#8212;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 trials may also be made a condition to approval of the BLA or NDA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMPs. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Review and Approval Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA or NDA requesting approval to market the product candidate for one or more indications. The BLA or NDA must include all relevant data available from preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of the product candidate or from a number of alternative sources, including studies and trials initiated by investigators. The submission of a BLA or NDA requires payment of a substantial user fee to the FDA, and the sponsor of an approved BLA or NDA is also subject to an annual program fee. A waiver of user fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on BLAs or NDAs for products designated as Orphan Drugs, unless the application also seeks a non-orphan-designated indication.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews a BLA or NDA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA or NDA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the Sponsor may meet with the FDA to confirm the additional information required to resubmit the BLA or NDA. Once a BLA or NDA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after it accepts the application for filing. Priority review designation will direct overall attention and resources to the evaluation of applications for products that, if approved, would represent significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP&#8209;compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facilities in which it is manufactured, processed, packed or held meet standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may also convene a public Advisory Committee to provide additional expert insight on application review questions. The FDA is not bound by recommendations of an Advisory Committee, but it considers such recommendations when making decisions regarding approval.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA or NDA, the FDA will typically inspect the facility or facilities where the product candidate is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product candidate within required specifications. Additionally, before approving a BLA or NDA, the FDA will typically inspect one or more clinical sites and/or the sponsor to assure compliance with GCP.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates a BLA or NDA and conducts inspections of clinical trial sites and manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an Approval Letter or a Complete Response Letter. An Approval Letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the BLA or NDA is not ready for approval in its present form and ends the current review cycle, and will describe all of the deficiencies that the FDA has identified in the BLA or NDA. The FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA or NDA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA or NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. Additionally, the FDA may approve a BLA or NDA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. Once approved, the FDA may withdraw the product approval if compliance with pre- and post- marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-marketing studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#8217;s review and approval of product candidates that meet certain criteria. Specifically, drugs and biologics s are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. For a Fast Track product candidate, the FDA may consider sections of the BLA or NDA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. A BLA or NDA for a Fast Track-designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA or NDA at six months after the FDA accepts the application for filing. Priority review is granted when there is evidence that the product candidate, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious disease or condition. If criteria are not met for priority review, the application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior reviewers at FDA.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a product candidate may be eligible for accelerated approval. Drugs and biologics intended to treat serious or life threatening diseases or conditions may be eligible for accelerated approval upon a determination that the drug or biologic has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires sponsors of products receiving accelerated approval to conduct well-controlled confirmatory required to verify or characterize the drug or biologic&#8217;s predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. The FDA may withdraw approval of a product or indication approved under accelerated approval if, for example, the sponsor fails to conduct any required confirmatory studies in a timely manner, or if such studies fail to verify the predicted clinical benefit of the product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant Orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan Drug designation must be requested before submitting a BLA or NDA. After the FDA grants Orphan Drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval requirements or process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product candidate that has Orphan Drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA or NDA, to market the same biologic or chemical entity for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with Orphan Drug exclusivity or if the FDA finds that the holder of the Orphan Drug exclusivity has not shown that it can assure the availability of sufficient quantities of the Orphan Drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan Drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of Orphan Drug designation are tax credits for certain research and development activities and a waiver of the BLA or NDA application user fee.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A designated Orphan Drug may not receive Orphan Drug exclusivity if it is approved for a use that is broader than the indication for which it received Orphan designation. In addition, Orphan Drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with Orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any drugs or biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug and biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, Warning Letters, or untitled enforcement letters;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical holds on clinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of drugs and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of so-called &#8220;off-label&#8221; uses. Failure to comply with these requirements can result in, among other things, adverse publicity, Warning Letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biosimilars and Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, signed into law in 2010, includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to, or interchangeable with, an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Product Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. For example, the FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state fraud and abuse laws, including false claims, civil monetary penalties, consumer protection and transparency laws regarding drug pricing and payments or other transfers of value made to physicians and other licensed healthcare professionals, as well as similar foreign laws in the jurisdictions outside the United States. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines, disgorgement, additional reporting obligations, contractual damages, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and imprisonment.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Privacy and Security Laws</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous state, federal and foreign laws, regulations, and standards govern the collection, use, access to, confidentiality and security of health-related and other personal data, including clinical trial data, and apply now or could apply in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal data. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. For example, the European Union General Data Protection Regulation, or the EU GDPR, imposes strict requirements for processing the personal data of individuals within the European Economic Area, or the EEA. Companies that must comply with the EU GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Further, from January 1, 2021, certain companies that have had to comply with the EU GDPR also have to comply with the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. Privacy and security laws, regulations, and other obligations globally are evolving, may conflict with each other (which complicate compliance efforts and increases compliance cost), and can result in investigations, proceedings, and other actions that can lead to significant civil and/or criminal penalties and fines.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. No uniform policy exists for coverage and reimbursement for products exists among U.S. third-party payors. Therefore, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. The process for determining whether a third-party payor will provide coverage for a product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication, or place products at certain formulary levels that result in lower reimbursement levels and higher cost-sharing obligation imposed on patients. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service. As a result, the coverage determination process will often require us to provide scientific and clinical support for the use of our product candidates to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. Furthermore, there can be no assurance that a product will be considered medically reasonable and necessary for a specific indication, that a product will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payor&#8217;s reimbursement policies will not adversely affect the ability to sell a product profitably.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States and significantly affected the pharmaceutical industry. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70.0% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> enactment, there have been amendments to and judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted, including aggregate reductions of Medicare payments to providers, which will remain in effect through 2032, absent additional Congressional action. In addition, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100.0% of a drug&#8217;s average manufacturer price, effective January 1, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. Most recently</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the IRA, among other things, (1) directs the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain single-source drugs and biologics that have been on the market for at least 7 years covered under Medicare, or Medicare Drug Price Negotiation Program, and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect beginning fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon price of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. The IRA permits the Secretary of the Department of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare product candidates and services, which could result in reduced demand for our product candidates once approved or additional pricing pressures.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 100 full-time employees, 80 of whom were primarily engaged in research and development activities. A total of 38 employees have an M.D., Ph.D. or Pharm.D. degree. Most of our employees are based in our Brisbane, California facility, subject to hybrid and remote work arrangements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our future success will depend, in part, on our ability to continue to attract, hire, and retain qualified personnel. We continue to seek additions to our science and technical staff. Through our experience with technological innovation, we appreciate the importance of retention, growth and development of our employees. We believe we offer competitive compensation (including salary, incentive bonus, and equity) and benefits packages. None of our employees is represented by a labor union, and we consider our employee relations to be good.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the State of Delaware on March 3, 2011. Our principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005, and our telephone number is (650) 822-5500. Our corporate website address is www.annexonbio.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, and related amendments, exhibits and other information with the Securities and Exchange Commission, or the SEC. You may access and read our filings without charge through the SEC&#8217;s website at www.sec.gov or through our website at https://ir.annexonbio.com/financial-information/sec-filings, as soon as reasonably practicable after such materials are electronically filed with or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves significant risks, some of which are described below. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report on Form 10-K, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the financial statements and the related notes. If any of the following risks actually occur, it could harm our business, prospects, results of operations and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company, and we have only a limited operating history upon which you can evaluate our business and prospects. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have no products approved for commercial sale and have not generated any revenue from sales of our product candidates and have incurred losses in each year since our inception in March 2011. We have only a limited operating history upon which you can evaluate our business and prospects. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical, biopharmaceutical and biotechnology industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have had significant operating losses since our inception. Our net loss for the years ended December 31, 2024 and 2023 was approximately $138.2 million and $134.2 million, respectively. As of December 31, 2024, we had an accumulated deficit of $710.7 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will continue as we develop our product candidates, conduct clinical trials and pursue research and development activities. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities. Our product candidates will require additional clinical development, and we intend to conduct additional research and development activities to discover and develop new product candidates, including conducting preclinical studies and clinical trials, all of which will require substantial additional funds. We will continue to expend significant resources for the foreseeable future in connection with these activities. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had capital resources consisting of cash and cash equivalents and short-term investments of approximately $312.0 million. We expect our existing capital resources to fund our planned operating expenses into the second half of 2026. However, our operating plans may change as a result of many factors currently</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unknown to us, and we may need to seek additional funds sooner than planned through public or private equity offerings or debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to our stockholders, imposition of burdensome debt covenants and repayment obligations, or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching and developing our current product candidates or any other future product candidates we choose to pursue, conducting preclinical studies and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining feedback from regulators on our clinical trials and regulatory approvals for our product candidates or any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to our current or any future license or collaboration agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our product candidates or any future product candidates and any products we successfully commercialize; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of building a sales force in anticipation of product commercialization; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of commercialization activities of our product candidates, if approved for sale, including marketing, sales and distribution costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product liability or other lawsuits related to our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with being a public company; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt and amount of sales of any future approved products.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> macroeconomic factors, including recent and potential bank failures, increasing inflation and interest rates, exchange rate fluctuations and supply chain disruptions, geopolitical conflicts, such as the war in Ukraine and hostilities in the Middle East, and disruptions to and volatility in the credit and financial markets in the United States and worldwide. If adequate funds are not available to us on a timely basis, we may be required to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product candidates or any future product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay, limit, reduce or terminate our research and development activities; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates or any future product candidate or reduce our flexibility in developing or maintaining our sales and marketing strategy. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and until our product candidates are clinically tested, approved for commercialization and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully marketed. To date, we have primarily financed our operations through the sale of equity securities and warrants to purchase our equity securities. We will be required to seek additional funding in the future and currently intend to do so through public or private equity offerings or debt financings, credit or loan facilities, collaborations or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently focused on developing product candidates to address classical complement-mediated autoimmune and neurodegenerative diseases. We seek to maintain a process of prioritization and resource allocation among our programs to balance time, risk and cost, due to the significant resources required for the development of our product candidates. Our resources are currently focused on advancing ANX005 in GBS, ANX007 in GA and ANX1502 in autoimmune diseases. If sufficient funding is not available, we may not be able to complete our planned clinical trials, or on the timelines we currently anticipate, and we may need to redesign, reduce the scope of or terminate some of our programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, any decision to delay, terminate or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the autoimmune or neurodegenerative or pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conducting a global Phase 3 program for ANX007 in patients with dry AMD with GA will be expensive and time consuming, and we may need additional capital to complete the Phase 3 clinical program and even if favorable, the FDA and comparable foreign regulatory authorities may not accept data from our Phase 3 program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent regulatory engagement regarding the Phase 3 ARCHER II trial design has established a global registration path for ANX007 in the U.S. and Europe. As a result, we are conducting ARCHER II, a global sham-controlled double-masked, Phase 3 trial. The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA&#8217;s two-trial recommendation. The primary endpoint of ARCHER II is prevention of &#8805;15-letter loss of BCVA, and an objective secondary structural measure is prevention of EZ loss. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial. There can be no assurance that the FDA and comparable regulatory authorities will accept the data from our Phase 3 program or determine that it is sufficient to support approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conducting large Phase 3 trials in multiple jurisdictions is expensive and can take many years to complete, and we cannot guarantee that clinical trials will be conducted as planned or completed timely, if at all. In addition, there are two FDA-approved therapies for GA in the United States, which may adversely impact our ability to recruit patients into our clinical trials. Our timeline and costs for ARCHER II could be substantially longer and larger than</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we initially planned. We may need additional capital to complete the Phase 3 clinical program for ANX007 and may not be able to raise sufficient capital in a timely manner. The occurrence of any such events could delay either trial, prevent us from completing our clinical trials, prevent us from seeking FDA approval of ANX007, if ever, and could delay or prevent commercialization of ANX007.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our results of operations may fluctuate significantly, which makes our future results of operations difficult to predict and could cause our results of operations to fall below expectations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our quarterly and annual results of operations may fluctuate significantly, which makes it difficult for us to predict our future results of operations. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to our product candidates, which may change from time to time; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and status of enrollment for our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States and internationally; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of demand for our product candidates, if approved, which may vary significantly over time. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual results of operations. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or results of operations fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of our product candidates, some of which are in early stages of clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no products approved for sale, and several of our product candidates are in early stages of clinical development. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates and, in particular, the advancement of our current clinical-stage product candidates. However,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">given the stage of development of our product candidates, it may be many years, if we succeed at all, before we have demonstrated the safety, purity, potency and/or efficacy of a product candidate sufficient to warrant approval for commercialization. We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While inhibition of the complement pathway has been validated as a therapeutic approach, C1q inhibition is a novel therapeutic approach, which exposes us to certain risks. For example, we may discover that our product candidates do not possess certain properties required for therapeutic effectiveness, or even if found to be effective in one type of disease, they are not effective in other types of disease. In addition, given the novel nature of this therapeutic approach, designing preclinical studies and clinical trials to demonstrate the effect of the product candidates is complex and exposes us to risks, including that our biomarker-driven approach may not translate into therapeutic effectiveness.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we may also become dependent on other product candidates that we may develop or acquire. The clinical and commercial success of our product candidates and future product candidates will depend on a number of factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to raise any additional required capital on acceptable terms, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to complete an investigational new drug application, or IND, enable studies and successfully submit INDs or comparable applications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we are required by the U.S. Food and Drug Administration, or the FDA, or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the convenience of our treatment or dosing regimen; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or any future product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient demand for our product candidates, if approved, including the willingness of patients to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public health crises such as pandemics or similar outbreaks have, and could in the future, materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of public health crises, including the COVID-19 pandemic, we have experienced, and may in the future experience, disruptions that could materially and adversely impact our clinical trials, business, financial condition and results of operations. These disruptions include but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or difficulties in enrolling patients in our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of health conditions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations, or CROs, and vendors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and pre-clinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulations as part of a response to pandemics or similar outbreaks, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The extent to which any future outbreak may affect our clinical trials, business, financial condition, results of operations and clinical development timelines and plans will depend on factors including the duration of the outbreak, rates of infection in the locations in which we and our CROs, third-party manufacturers, regulatory authorities and other third parties with whom we do business operate, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are at an early stage of clinical development of our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our product candidates may not successfully complete preclinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may be shown to have harmful side effects or other characteristics that indicate it does not meet applicable regulatory criteria; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these events occur, we may be forced to abandon our development efforts for a product candidate or candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and we may never succeed in developing marketable products or generating product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to further develop our current and future product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates will require significant additional clinical development, management of preclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA or other regulatory agencies may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions. Regulatory agencies, including the FDA may require that we conduct more than one pivotal trial in order to gain approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, clinical trials must be conducted in accordance with the laws, rules and regulations, guidelines and other requirements of the FDA, the European Medicines Agency, or the EMA, and other applicable regulatory authorities outside of those jurisdictions and are subject to oversight by these regulatory authorities and institutional review boards, or IRBs, or ethics committees at the medical institutions where such clinical trials are conducted. Further, conducting global clinical trials, as we do for GBS and GA, may require that we coordinate among the legal requirements and guidelines of regulatory authorities across a number of jurisdictions, including the United States, the European Union, or the EU, and countries outside of those jurisdictions, which could require that we amend clinical trial protocols or determine not to conduct a trial in one or more jurisdictions or to run separate trials in various jurisdictions due to the inability, cost or delay in harmonizing divergent requests from such regulatory authorities, all of which could increase costs. In addition, clinical trials that are conducted in countries outside the United States and the EU may subject us to risks associated with the engagement of non-United States and non-EU CROs who are unknown to the FDA or the EMA, or the EU member states&#8217; regulatory authorities and may have different standards of diagnosis, screening and medical care, as well as risks associated with further delays and expenses as a result of increased shipment costs (including as a result of local quality release or in-country testing of a product candidate supply produced in a different jurisdiction for our clinical trials) and political and economic risks relevant to such countries outside the United States and the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates successfully completes clinical trials, we plan to seek regulatory approval to market our product candidates in the United States, the European Union, or the EU, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on collaborators or partners to conduct the required activities to support an application for regulatory approval and to seek approval for one or more of our product candidates. We cannot be sure that any such collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. Even if we or any future collaborators or partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a Risk Evaluation and Mitigation Strategy, or REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an IND or a clinical trial application, or CTA, will result in the FDA or other regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">generating sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining regulatory authorization to commence a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreements on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, recruiting and training suitable clinical investigators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining IRB approval at each trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, or equivalent foreign application or amendment; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new safety findings that present unreasonable risk to clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a negative finding from an inspection of our clinical trial operations or study sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruiting an adequate number of suitable patients to participate in a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">having subjects complete a trial or return for post-treatment follow-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing subject safety concerns that arise during the course of a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adding a sufficient number of clinical trial sites; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining sufficient product supply of product candidates for use in preclinical studies or clinical trials from third-party suppliers. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials or require that we submit additional data or information before allowing a clinical trial to be initiated; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical studies of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators may revise the requirements and add new requirements for approving our product candidates, or such requirements may not be as we anticipate; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur unplanned costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval in some countries and not in others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we intend to seek FDA approval of ANX005 for the treatment of patients with GBS. We are preparing for a pre-BLA meeting with FDA, targeted for the first half of 2025. Our data package is based on clinical trials conducted outside the United States and includes a placebo-controlled Phase 1b trial that established POC for ANX005 as a first-line treatment for GBS, a successful Phase 3 trial showing that ANX005 was generally well tolerated and resulted in faster and more complete functional recovery versus placebo, a RWE study that showed improved outcomes against current standards of care in matched patient populations, and a drug-drug interaction study with ANX005 and IVIg strengthening the safety profile for ANX005 in GBS. The FDA may not agree that this RWE data is sufficient to support generalizability of the Phase 3 results to a U.S. population. The FDA ordinarily requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy of a biologic for approval, and our single Phase 3 trial may be inadequate. The FDA may not agree that the data package is sufficient to accept for filing a BLA, and we may receive a refusal to file letter and be required to conduct additional clinical trials of ANX005 for GBS prior to resubmission of a BLA, which would result in delays in our application process and increase our expenses, and delay or prevent commercialization of ANX005 in GBS. Even if accepted for filing by the FDA, any such BLA could be the subject of a complete response letter rather than approval, which would increase our expenses and delay or prevent commercialization of ANX005 in GBS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we plan to do for certain of our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">customs and managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in the completion, or termination, of any preclinical study or clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. If one or more of our product candidates proves to be ineffective, unsafe or commercially unviable, our business, financial condition, results of operations and prospects may be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity and difficulty of diagnosing the disease under investigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility and exclusion criteria defined in the protocol; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the existing body of safety and efficacy data with respect to the study drug and safety concerns; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk that enrolled subjects will drop out before completion of the trial, including as a result of health conditions or being forced to quarantine; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to monitor patients adequately during and after treatment; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability and efficacy of approved medications or therapies, or other clinical trials, for the disease or condition under investigation; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. In addition, patients may not opt to enroll in our trials because of the availability of approved therapeutics for their disease. Because the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse events or undesirable side effects caused by, or other unexpected properties of, any of our product candidates could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. We have experienced adverse events during clinical trials, and may in the future experience, adverse or unforeseen events during, or as a result of, clinical trials. If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, early clinical trials may only include a limited number of subjects and limited duration of exposure to our product candidates. In particular, we are pursuing a novel approach to inhibiting upstream molecules of the classical complement pathway, primarily C1q, and as a result, our product candidates may cause unforeseen safety events when evaluated in larger patient populations. Further, clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates receives marketing approval, and we or others later identify undesirable and unforeseen side effects caused by such product, a number of potentially significant negative consequences could result, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to conduct additional clinical trials or post-approval studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to implement a REMS or create a Medication Guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of criminal penalties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates prove to be unsafe, our business, financial condition, results of operations and prospects may be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, &#8220;top-line&#8221; and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we publicly disclose interim, &#8220;top-line&#8221; or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish such data. As a result, the &#8220;top-line&#8221; results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. &#8220;Top-line&#8221; or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, &#8220;top-line&#8221; and preliminary data should be viewed with caution until the final data are available. From time to time, we also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, &#8220;top-line&#8221; or preliminary data and final data could significantly harm our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the &#8220;top-line,&#8221; preliminary or interim data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if one or more of our product candidates receive FDA or other regulatory approvals, the commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. Our product candidates may not be commercially successful. For a variety of reasons, including, among other things, competitive factors, pricing or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">physician preference, reimbursement by insurers, the degree and rate of physician and patient adoption of our current or future product candidates, if approved, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety and efficacy of our product as compared to other available therapies; for example, with respect to ANX007, physicians may prescribe or patients may prefer recently approved therapies for the treatment of GA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement from managed care plans, insurers and other healthcare payors for any of our product candidates that may be approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proper training and administration of our product candidates by physicians and medical staff; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public misperception regarding the use of our therapies, if approved for commercial sale; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue and profitability that our products may offer a physician as compared to alternative therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of side effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the FDA-approved labeling for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of physicians, operators of clinics and patients to utilize or adopt our products as a solution; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any FDA requirement to undertake a REMS; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our sales, marketing and distribution efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity about our products or favorable publicity about competitive products; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product liability claims. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians and patients. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have received Orphan Drug designation for ANX005 for the treatment of GBS and HD in the United States and for GBS in Europe, and we may seek Orphan Drug designation for certain future product candidates. We may be unable to obtain such designations or to maintain the benefits associated with Orphan Drug designation, including market exclusivity, which may cause any revenue from product sales to be reduced.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received Orphan Drug designation in the United States for ANX005 for the treatment of GBS and HD and for the treatment of GBS in Europe from the European Medicines Agency, or EMA. Although we may seek Orphan product designation for some or all of our other product candidates, we may never receive such designations. Under the Orphan Drug Act, the FDA may designate a drug or biologic product as an Orphan Drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing the drug will be recovered from sales in the United States. Orphan Drug designation must be requested before submitting a biologics license application, or BLA, or new drug application, or NDA. In the EU, the EMA&#8217;s Committee for Orphan Medicinal Products, or COMP, grants Orphan Drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and application fee waivers. After the FDA grants Orphan Drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to Orphan Drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same disease or condition for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with Orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity to the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. In the EU, Orphan Drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the Orphan Drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable to not justify maintenance of market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain Orphan Drug designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain Orphan Drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an Orphan Drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective or makes a major contribution to patient care. Orphan Drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek a Breakthrough Therapy designation for our product candidates if the clinical data support such a designation for one or more product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs and biologics designated as breakthrough therapies by the FDA may also be eligible for priority review and rolling review of BLA or NDA submissions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A Fast Track designation by the FDA or PRIME designation by the EMA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has granted Fast Track designation for ANX005 in GBS and for ANX007 in GA, and the EMA has granted PRIME designation for ANX007 in GA, and, in the future, we may seek Fast Track designation or PRIME designation for our product candidates. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the drug or biologic demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for Fast Track designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA or NDA is submitted, the application may be eligible for priority review. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA or NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA or NDA, the FDA agrees to accept sections of the BLA or NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA or NDA. The FDA has broad discretion whether or not to grant this designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRIME is a program launched by the EMA to enhance support for research on and development of medicines that have demonstrated preliminary safety and efficacy and thus the potential to target a significant unmet medical need and bring a major therapeutic advantage to patients. This regulatory program offers developers of promising medicines enhanced interaction and early dialogue with the EMA and is designed to optimize development plans and speed evaluation ensuring these medicines reach patients as early as possible. The EMA has broad discretion whether or not to grant this designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we believe a particular product candidate is eligible for these designations, we cannot assure you that the FDA, EMA or similar regulatory agency would decide to grant them. Fast Track and PRIME designations may not result in a faster development process, review or approval compared to conventional FDA or EMA procedures, respectively. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. The Fast Track and PRIME designations do not assure ultimate regulatory approval by the FDA or the EMA. Many drugs and biologics that have received Fast Track or PRIME designation have failed to obtain approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies or foreign regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies or comparable foreign regulatory authorities may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Similar considerations are applicable to foreign regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a prolonged government shutdown occurs, or if new or existing global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We conduct, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct clinical trials of our product candidates outside the United States, and plan to continue to do so. For example, we conducted our Phase 1b GBS clinical trial of ANX005 in Bangladesh, and have completed our Phase 3 clinical trial of ANX005 in patients with GBS at sites in Bangladesh and the Philippines. We are also conducting a global Phase 3 program for ANX007 in dry AMD with GA. The acceptance of study data from clinical trials conducted outside the United States or the applicable jurisdiction by the FDA and comparable foreign regulatory authorities may be subject to certain conditions, or may not be accepted at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, regardless of whether such trials were conducted under an IND, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the United States population and United States medical practice, the trials were performed by clinical investigators of recognized competence and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. For trials that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with good clinical practice, or GCP, requirements, and the FDA must be able to validate the data from the clinical trial through an on-site inspection if it deems such inspection necessary. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To support data from clinical trials conducted in foreign jurisdictions, applicants may submit clinical evidence, clinical trials, patient registries or other sources of RWE, such as electronic health records or the collection of larger confirmatory data sets. In particular, because all of our studies to date for ANX005 in GBS have been conducted at sites outside the United States, we have conducted a RWE study to assess comparability of disease populations in the US and ex-US using a large natural history database from IGOS. Published data from IGOS presents baseline characteristics of GBS patients in various jurisdictions and patient outcomes at certain timepoints over the course of their disease. We intend to use the results of the RWE study along with any other requested information for generalizability of Southeast Asian patients to a Western population as part of our data package in support of the ANX005 BLA. However, the FDA may not agree that the current data package is sufficient to accept for filing a BLA and we may receive a refusal to file letter and be required to conduct additional clinical trials of ANX005 for GBS prior to resubmission of a BLA, which would result in delays in our application process and increase our expenses, and delay or prevent commercialization of ANX005 in GBS. Even if accepted for filing by the FDA, any such BLA could be the subject of a complete response letter rather than approval, which would increase our expenses and delay or prevent commercialization of ANX005 in GBS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we are conducting a global registrational program of ANX007 for the treatment of dry AMD with GA. To accomplish this objective, we must obtain and maintain regulatory approvals and comply with regulatory requirements in each jurisdiction. We are in ongoing discussions with the relevant regulatory authorities. While we believe we have designed a global clinical development program that could satisfy the regulators in all of our target markets, there is no assurance that our efforts will be successful or that the various regulators will be aligned or accept the data from the Phase 3 program are sufficient to warrant approval of ANX007.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the product candidates that we develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for our product candidates and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or any future collaborators&#8217; ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the EU, and many other jurisdictions, we and any future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or any future collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have the ability, and we do not plan to build or acquire the infrastructure or capability internally, to manufacture supplies of our product candidates or the materials necessary to produce our product candidates for use in the conduct of our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a preclinical, clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing processes of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements, known as cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of our product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently intend to supply our product candidates in all territories for our clinical development programs, and rely on third parties at key stages in our supply chain. For instance, the supply chains for our product candidates involve several manufacturers that specialize in specific operations of the manufacturing process, specifically, raw materials manufacturing, drug substance manufacturing and drug product manufacturing. As a result, the supply chain for the manufacturing of our product candidates is complicated, and we expect the logistical challenges associated with our supply chain to grow more complex as our product candidates are further developed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any control over the process or timing of the acquisition or manufacture of materials by our manufacturers. We generally do not begin preclinical or clinical trials unless we believe we have access to a sufficient supply of a product candidate to complete such study. In addition, any significant delay in, or quality control problems with respect to, the supply of a product candidate, or the raw material components thereof, for an ongoing study could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not yet engaged any manufacturers for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business. Moreover, if there is a disruption to one or more of our third-party manufacturers&#8217; or suppliers&#8217; relevant operations, or if we are unable to enter into arrangements for the commercial supply of our product candidates, we will have no other means of producing our product candidates until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or destruction of our third-party manufacturers&#8217; or suppliers&#8217; facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, to manufacture our product candidates in the quantities we believe would be required to meet anticipated market demand, our third-party manufacturers would likely need to increase manufacturing capacity and we may need to secure alternative sources of commercial supply, which could involve significant challenges and may require additional regulatory approvals. In addition, the development of commercial-scale manufacturing capabilities may require us and our third-party manufacturers to invest substantial additional funds and hire and retain the technical personnel who have the necessary manufacturing experience. Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers or we are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels or in adequate quantities, if at all, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties in the conduct of all of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently do not have the ability to independently conduct preclinical studies or clinical trials that comply with the regulatory requirements known as good laboratory practice, or GLP, requirements or GCP requirements,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respectively. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLPs or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our business, financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not successful in identifying, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although a substantial amount of our effort will focus on the continued development and potential approval of our current product candidates, a key element of our strategy is to identify, develop and commercialize a portfolio of products that address classical complement-mediated autoimmune and neurodegenerative diseases. A component of our strategy is to evaluate our product candidates in multiple indications based, in part, on our evaluation of certain biomarkers in a disease area. For example, we intend to evaluate ANX005 in neurodegenerative diseases, including amyotrophic lateral sclerosis, or ALS, and Huntington&#8217;s disease, or HD; however, we are continuing to evaluate ANX005 in these patient populations, and even if we believe we have obtained positive clinical results in patients with one of these neurodegenerative diseases, such results may not be replicated in later studies evaluating ANX005 in patients with the same disease or across other neurodegenerative or autoimmune diseases. Even though we are currently developing a pipeline of product candidates, our development efforts may still fail to yield product candidates potentially suitable for commercialization for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competitors may develop alternatives that render our product candidates obsolete; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be accepted as safe and effective by physicians and patients. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We therefore cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire, develop or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunities may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological and scientific change, and our product candidates, if approved, will face significant competition, which may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical, biopharmaceutical and biotechnology industries in particular are characterized by rapidly advancing technologies, intense competition and a strong emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing and marketing of healthcare products competitive with those that we are developing. We face competition from a number of sources, such as pharmaceutical, biopharmaceutical and biotechnology companies, generic drug companies and academic and research institutions, many of which have greater financial resources, marketing capabilities, sales forces, manufacturing capabilities, research and development capabilities, clinical trial expertise, intellectual property portfolios, experience in obtaining patents and regulatory approvals for product candidates and other resources than we do. Some of the companies also have a broad range of other product offerings, large direct sales forces and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts. Mergers and acquisitions in the pharmaceutical, biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain alternative treatments offered by competitors may be available at lower prices and may offer greater efficacy or better safety profiles. Furthermore, currently approved products could be discovered to have application for the intended indication of our product candidates, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. For example, with respect to ANX007, there are two approved products for GA which may pose competition for ANX007, if approved. For additional information regarding our competition, see the section titled &#8220;Business&#8212;Competition&#8221; in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Even if we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for our product candidates or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical, biopharmaceutical and biotechnology products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our investment in the development of product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently do not have a marketing or sales organization. In order to commercialize our product candidates in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical, biopharmaceutical and biotechnology products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our product candidates or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 100 full-time employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize our product candidates or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this or any future growth. Our need to effectively execute our growth strategy requires that we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manage our clinical trials effectively; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully commercialize ANX005 and any of our other product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify, recruit, retain, incentivize and integrate additional employees, including sales personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to improve our operational, financial and management controls, reports systems and procedures. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If management is unable to effectively manage our growth, our expenses may increase more than expected. Our future financial performance and our ability to compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, as well as our senior scientists. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that we will not face turnover in the future. Our ability to execute our business strategies may be adversely affected by the uncertainty associated with any transition and the time and management attention needed to fill any vacant role could disrupt our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our current or future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management&#8217;s time and our resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize our current or any future product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have not entered into any collaboration agreements to date, we may seek collaboration arrangements for the commercialization, or potentially for the development, of certain of our product candidates depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration arrangements. For example, certain of the disease areas that we believe our product candidates address, including, among others,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ophthalmic indications, require large, costly and later-stage clinical trials, which a collaboration partner may be better positioned to finance and/or conduct. In addition, a component of our strategy is to maximize the commercial value of our current and future product candidates, which may also strategically align with partnering commercial rights with partners that have larger and established sales organizations. To the extent that we decide to enter into collaboration agreements, we may face significant competition for appropriate collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain and challenging to manage. We may not be successful in our efforts to enter into collaboration agreements. The terms of collaborations or other arrangements that we may establish may not be favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include risks that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise between us and collaborators that cause the delay or termination of the research, development or commercialization of our current or future product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated, and, if terminated, this may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may own or co-own intellectual property covering products that result from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators&#8217; sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global and macroeconomic or political conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is susceptible to general conditions in the global economy and in the global financial markets. Global financial crises and global or regional political disruptions have caused, and could in the future cause, extreme volatility in the capital and credit markets. A severe or prolonged economic downturn, including a recession or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">depression, recent and potential bank failures, the current inflationary economic environment, rising interest rates, debt and equity market fluctuations, diminished liquidity and credit availability, increased unemployment rates, decreased investor and consumer confidence, supply chain challenges, natural catastrophes, the effects of climate change, regional and global conflicts and terrorist attacks or political disruption or turmoil could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend on may be adversely affected by earthquakes or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which has experienced both severe earthquakes and the effects of wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could severely disrupt our operations, and could materially and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">programs, other sanctions, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including the components of our product candidates and other hazardous compounds. We and any third-party manufacturers and suppliers are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, nor can we eliminate the risk of accidental contamination or injury from these materials. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from hazardous materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and any future product candidates or products could be alleged to infringe patent rights and other proprietary rights of third parties, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and/or limit our ability to commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends on our ability to develop, manufacture and market our current and any future product candidates that may be approved for sale, and to use our proprietary technology without infringing the patents and other proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, results of operations and financial condition to suffer. We operate in an industry with extensive intellectual property litigation. As the pharmaceutical, biopharmaceutical and biotechnology industries expand and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our products and technology of which we are not aware or that we may need to challenge to continue our operations as currently contemplated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether merited or not, we may face allegations that we have infringed the trademarks, copyrights, patents and other intellectual property rights of third parties, including patents held by our competitors or by non-practicing entities. We may also face allegations that our employees have misappropriated the intellectual property rights of their former employers or other third parties. Litigation may make it necessary to defend ourselves by determining the scope, enforceability and validity of third-party proprietary rights, or to establish our proprietary rights. Regardless of whether claims that we are infringing patents or other intellectual property rights have merit, such litigation can be time consuming, divert management attention and financial resources and are costly to evaluate and defend. There can be no assurance with respect to the outcome of any current or future litigation brought by or against us, and the outcome of any such litigation could have a material adverse impact on our business, results of operations and financial condition. Litigation is inherently unpredictable, and outcomes are uncertain. Further, as the costs and outcome of such litigation can vary significantly, it is difficult to estimate potential losses that may occur. As a result of such litigation, we may be required to stop treating certain conditions, obtain licenses or modify our products and features while we develop non-infringing substitutes, or may result in significant settlement costs or royalty obligations. For example, litigation can involve substantial damages for infringement, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees. We may also be prohibited from selling or licensing our products unless the third-party licenses rights to us, which it is not required to do at a commercially reasonable price or at all. If a license is available from a third party, we may have to pay substantial royalties or upfront fees or grant cross-licenses to intellectual property rights for our products. We may also have to redesign our products so they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our products may not be available for manufacture, use or sale. Accordingly, we are unable at this time to estimate the effects of these potential future lawsuits on our financial condition, operations or cash flows.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have reviewed certain third-party patents and patent filings that we believe may be relevant to our product candidates, we have not conducted a comprehensive freedom-to-operate search or analysis for any of our product candidates, and we may not be aware of patents or pending or future patent applications that, if issued, would block us from commercializing our product candidates. Additionally, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to commercialize our product candidates. Thus, we cannot guarantee that our activities related to their product candidates, or our commercialization, do not and will not infringe any third party&#8217;s intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, patent applications in the United States and many other jurisdictions are typically not published until 18 months after the filing of certain priority documents (or, in some cases, are not published until they issue as patents), and publications in the scientific literature often lag behind actual discoveries. Therefore, we cannot be certain that others have not filed patent applications or made public disclosures relating to our technology or our contemplated technology. A third party may have already filed, and may in the future file, patent applications covering our product candidates or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, depending on whether the timing of the filing date falls under certain patent laws, we may have to participate in a priority contest (such as an interference proceeding) declared by the United States Patent and Trademark Office, or the USPTO, to determine priority of invention in the United States. The costs of patent litigation and other proceedings related to the protection of our global patent position could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our patent position with respect to such invention.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain and enforce intellectual property protection directed to our current and any future technologies that we develop, others may be able to make, use or sell products substantially the same as ours, which could adversely affect our ability to compete in the market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market for pharmaceuticals and biopharmaceuticals is highly competitive and subject to rapid technological change. Our success depends, in part, upon our ability to maintain a competitive position in the development and protection of technologies and any future products for use in these fields and upon our ability to obtain, maintain and enforce our intellectual property rights. We seek to obtain and maintain patents and other intellectual property rights to restrict the ability of others to market products that misappropriate our technology and/or infringe our intellectual property to unfairly and illegally compete with any future products. If we are unable to protect our intellectual property and proprietary rights, our competitive position and our business could be harmed, as third parties may be able to make, use or sell products that are substantially the same as any future products we may sell without incurring the sizeable development and licensing costs that we have incurred, which would adversely affect our ability to compete in the market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use a combination of patents, trademarks, know-how, confidentiality procedures and contractual provisions to protect our proprietary technology. However, these protections may not be adequate and may not provide us with any competitive advantage. For example, patents may not issue from any of our currently pending or any future patent applications, and our issued patents and any future patents that may issue may not survive legal challenges to their scope, validity or enforceability, or provide significant protection for us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products. In addition, we cannot be sure that any of our pending patent applications or pending trademark applications will issue or that, if issued, they will issue in a form that will provide adequate protection for our products. The USPTO, patent offices in other jurisdictions, or judicial or other bodies in any jurisdiction may deny or significantly narrow claims made under our patent applications, and claims in our issued patents may be invalidated, may be designed around or may otherwise be unable to provide us with protection for our products. Further, the USPTO, trademark offices in other jurisdictions, or judicial or other bodies in any jurisdiction may deny our trademark applications and, even if published or registered, these trademarks may not effectively protect our brand and goodwill. Like patents, trademarks also may be successfully opposed or challenged.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that the steps we have taken will prevent unauthorized use or unauthorized reverse engineering of our technology that is material to our business. Moreover, third parties may independently develop technologies that are competitive with ours and such competitive technologies may or may not infringe our intellectual property. The enforcement of our intellectual property rights also depends on the success of any legal actions we may take against these third parties in the respective country or forum, but these actions may not be successful. As with all granted intellectual property, such intellectual property may be challenged, invalidated or circumvented, may not provide protection and/or may not prove to be enforceable in actions against specific alleged infringers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or any future collaborators we may have were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or future product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including obviousness or lack of novelty, enablement or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before the USPTO even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution, or that a defendant would not prevail on an assertion of invalidity based on prior art that we were aware of during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if claims in our patents survive assertions of invalidity and unenforceability, they may not be broad enough to prevent others from marketing products similar to ours or designing around our patents. For example, third parties may be able to make products that are similar to ours but that are not covered by the claims of our patents. The claims of our issued patents or patent applications when issued may not cover our product candidates or any future products that we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent law can be highly uncertain and involve complex legal and factual questions for which important principles remain unresolved. In the United States and in many other jurisdictions, policies regarding the breadth of claims allowed in patents can be inconsistent. The U.S. Supreme Court and the Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, courts in other jurisdictions have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and international legislative bodies. Those changes may materially affect the patents and patent applications of our licensors, our existing or future patents and patent applications and our ability to obtain additional patents in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent reform legislation in the United States could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-to-file provisions, only became effective on March 16, 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, which could have a material adverse effect on our business and financial condition. Any future changes in the patent laws of the United States, or even the possibility of such changes, may further increase these uncertainties and costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO and various patent agencies in other jurisdictions require compliance with a number of procedural, documentary, fee, annuity payment and other provisions to maintain patent applications and issued patents. Although an inadvertent lapse, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we have a number of patents and patent applications outside of the United States and expect to continue to pursue patent protection in many of the significant markets in which we intend to do business. The laws of some international jurisdictions do not protect intellectual property rights to the same extent as laws in the United States, and many companies have encountered significant difficulties in obtaining, protecting and defending such rights in certain jurisdictions outside of the United States. If we encounter such difficulties or we are otherwise precluded from effectively protecting our intellectual property rights in international jurisdictions, our business, financial condition, results of operations and prospects could be materially and adversely affected. Earlier patent filings in certain international countries may also permit third parties to allege priority to certain technology in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent terms may be shortened or lengthened in certain jurisdictions by, for example, terminal disclaimers, patent term adjustments, supplemental protection certificates and patent term extensions. Patent term extensions and supplemental protection certificates, and the like, may be impacted by the regulatory process and may not significantly lengthen patent term. Non-payment or delay in payment of patent extension filing (including any patent term extension or adjustment filing) fees, whether intentional or unintentional, may also result in the loss of patent rights important to our business. Certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. In addition, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we review our competitors&#8217; products, and may in the future seek to enforce our patents or other rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Our competitors may also independently develop similar technology. Any inability to meaningfully protect our intellectual property could result in competitors offering products competitive to our products. In addition, we may need to defend our patents from third-party challenges, such as interferences, derivation proceedings, re-examination proceedings, post-grant review, inter partes review, third-party submissions, oppositions, nullity actions or other patent proceedings. We may need to initiate infringement claims or litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse proceedings such as litigation can be expensive, time consuming and may divert the efforts of our technical and managerial personnel, which could in turn materially and adversely affect our business, financial condition, results of operations and prospects, whether or not we receive a determination favorable to us. In addition, in an infringement proceeding, a court or other judicial body may decide that the patent we seek to enforce is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that the patent in question does not cover the technology in question or that stopping the other party would harm the public interest. An adverse result in any litigation could put one or more of our patents at risk of being invalidated or interpreted narrowly. Some of our competitors may be able to devote significantly more resources to intellectual property litigation, and may have significantly broader patent portfolios to assert against us if we assert our rights against them. Further, because of the substantial discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be disclosed or otherwise compromised during litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to correctly estimate or control our future operating expenses in relation to obtaining intellectual property, enforcing intellectual property and/or defending intellectual property, which could affect operating expenses. Our operating expenses may fluctuate significantly in the future as a result of a variety of factors, including the costs of preparing, filing, prosecuting, defending and enforcing patent and trademark claims and other intellectual property-related costs, including adverse proceedings and litigation costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to prevent disclosure of our trade secrets or other confidential information to third parties, our competitive position may be impaired.</span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on confidentiality agreements to protect confidential information and proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. Agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Furthermore, the laws of some other jurisdictions do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and in other jurisdictions. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. The failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We license patent rights from third-party owners. Such licenses may be subject to early termination if we fail to comply with our obligations in our licenses with third parties, which could result in the loss of rights or technology that are material to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are or may become a party to licenses that give us rights to third-party intellectual property that are necessary or useful for our business, and we may enter into additional licenses in the future. Under these license agreements, we are or may become obligated to pay the licensor fees, which may include annual license fees, milestone payments, royalties, a percentage of revenues associated with the licensed technology and a percentage of sublicensing revenue. These fees may be significant, which could make it difficult for us to achieve or maintain profitability. In addition, under certain of such agreements, we are or may become required to diligently pursue the development of products using the licensed technology. If we fail to comply with these obligations and fail to cure our breach within a specified period of time, the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology that are material to our business, harming our ability to develop, manufacture and/or commercialize our platform or product candidates. If the licensor retains control of prosecution of the patents and patent applications licensed to us, we may have limited or no control over the manner in which the licensor chooses to prosecute or maintain its patents and patent applications and have limited or no right to continue to prosecute any patents or patent applications that the licensor elects to abandon.</span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the licensor retains control of prosecution of the patents and patent applications licensed to us, we may have limited or no control over the manner in which the licensor chooses to prosecute or maintain its patents and patent applications and have limited or no right to continue to prosecute any patents or patent applications that the licensor elects to abandon.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may also require specific components to work effectively and efficiently, and rights to those components may be held by others. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies, which could harm our business prospects, financial condition and results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We jointly own certain patent rights with third parties. Our ability to out-license these patent rights, or to prevent the third party from out-licensing these patent rights, may be limited in certain countries.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We jointly own certain patents and patent applications with third parties, and may jointly own patents and patent applications with third parties in the future. Unless we enter into an agreement with the joint owner, we will be subject to certain default rules pertaining to joint ownership. Certain countries require the consent of all joint owners to license jointly owned patents, and if we are unable to obtain such consent from the joint owner, we may not be able to license our rights under these patents and patent applications. In certain other countries, including the United States, the joint owner could license its rights under these patents and patent applications to another party without our consent and without any duty of accounting to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to claims that former employees, any future collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and could even face litigation for infringing patents that we had regarded as ours. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as national governments, such that we or our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our patents, including in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or conflict with third-party rights. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition with potential partners, physicians or patients in our markets of interest. During trademark registration proceedings, our trademark applications may be rejected. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties can oppose pending trademark applications and seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Furthermore, third parties may file first for our trademarks in certain countries. If they succeeded in registering such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our future products in those countries. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. In such cases, over the long term, if we are unable to establish and maintain name recognition based on our trademarks and trade names, then our commercial success abilities may be impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any name we propose to use with our product candidates in the United States or any other country must be approved by the FDA, EMA or any other relevant health authority regardless of whether we have registered it, or applied to register it, as a trademark. The FDA as well as EMA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA, EMA or any other relevant approval authority objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA, EMA or any other relevant approval authority.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing and prosecuting patent applications, and defending patents, related to our product candidates in all countries throughout the world would be prohibitively expensive, and the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with any future products we may sell, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals and biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will have to comply with requirements concerning advertising and promotion for any future products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. We may not promote products for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety, purity, potency and/or efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue warning letters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impose civil or criminal penalties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend or withdraw regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend any of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seize or detain products, or require a product recall. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from any future products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our results of operations will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. The ACA, among other things: (i) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (ii) established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; (iii) expanded the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; (iv) increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; (v) expanded the eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; (vi) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (vii) established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been amendments and judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is unclear how other healthcare reform measures will impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s AMP, effective January 1, 2024. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. Most recently, the IRA, among other things, (1) directs the U.S. Department of Health and Human Services, or HHS to negotiate the price of certain single-source drugs and biologics that have been on the market for at least 7 years covered under Medicare, or the Medicare Drug Price Negotiation Program, and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect beginning fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon reimbursement price of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, particularly in light of the recent change in administration, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could materially and adversely affect our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or judicial action in the United States, the EU or any other jurisdiction. If we or any third</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may submit an abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#8217;s prior findings of safety and effectiveness of the small molecule innovator product. For example, a 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the Orange Book. If there are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in their applications what is known as a &#8220;Paragraph IV&#8221; certification, challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, if our small molecule program results in a product that is approved, competitors could submit ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products. If there are patents listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include, without limitation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal civil and criminal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal false claims laws, including the False Claims Act, which can be enforced through whistleblower actions, and civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Health Insurance Portability and Accountability Act of 1996, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians, as defined by such law, certain non-physician providers such as physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state and local laws that require the registration of pharmaceutical sales representatives; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, such as the provision of stock options to physicians who may influence the ordering, prescribing or use of our product candidates, if approved, as compensation for consulting services, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, disgorgement, imprisonment,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our stock price has been volatile, and could in the future be volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock price of our common stock has been, and could in the future be, subject to substantial volatility and wide fluctuations in response to various factors, some of which are beyond our control. In particular, the stock prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of extreme volatility and disruptions in the global economy, including rising inflation and interest rates, declines in economic growth, the war between Russia and Ukraine and uncertainty about economic stability, including a potential recession. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results from, and delays in, our clinical trials for our product candidates or any other future clinical development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of regulatory approval or disapproval of our current or any future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure or discontinuation of any of our research and development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the termination of any of our existing license agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements relating to any future licensing, collaboration or development agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in the commercialization of our current or any future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public misperception regarding the use of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquisitions and sales of new products or product candidates, technologies or businesses;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing and supply issues related to our product candidates for clinical trials or future product candidates for commercialization;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quarterly variations in our results of operations or those of our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in earnings estimates or recommendations by securities analysts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of new products or product candidates, significant contracts, commercial relationships, acquisitions or capital commitments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments with respect to intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commencement of, or involvement in, litigation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in financial estimates or guidance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any major changes in our board of directors or management;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new legislation or regulation in the United States relating to the sale or pricing of pharmaceuticals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA or other U.S. or foreign regulatory actions affecting us or our industry;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product liability claims or other litigation or public concern about the safety of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical, biopharmaceutical and biotechnology sectors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic conditions in the United States and abroad, the current inflationary economic environment, rising interest rates and global health concerns;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock, including sales by our officers, directors and specific existing stockholders; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of shares of our common stock pursuant to the exercise of outstanding warrants.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the stock price or liquidity of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; and as a result of the reduced disclosure and governance requirements applicable to smaller reporting companies, our common stock may be less attractive to investors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company and are therefore entitled to take advantage of many of the same exemptions from disclosure requirements as an emerging growth company, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. In addition, as a smaller reporting company with less than $100 million in annual revenue, we are exempt from the requirement to obtain an auditor attestation on the effectiveness of our internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management needs to devote substantial time to compliance initiatives. We may fail to comply with the rules that apply to public companies, which could result in sanctions or other penalties that could materially and adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Stock Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel needs to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, these reporting requirements, rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to Section 404 of the Sarbanes-Oxley Act, or Section 404, and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Pursuant to Section 404(a), we are required to file with the SEC an annual management assessment of the effectiveness of our internal control over financial reporting. Because we re-qualified as a smaller reporting company and we have less than $100 million in annual revenue, as of December 31, 2024, we are a non-accelerated filer and are not required to comply with the auditor attestation requirements regarding the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act until we become an accelerated filer or large accelerated filer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual and interim financial statements will not be detected or prevented on a timely basis. If we identify one or more material weaknesses in our internal control over financial reporting, we will be unable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">faulty human judgment and simple errors, omissions or mistakes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fraudulent action of an individual or collusion of two or more people;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inappropriate management override of procedures; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and accurate financial control.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we believe our internal control over financial reporting is currently effective, the effectiveness of our internal controls in future periods is subject to the risk that our controls may become inadequate because of changes in conditions. Establishing, testing and maintaining an effective system of internal control over financial reporting requires significant resources and time commitments on the part of our management and our finance staff, may require additional staffing and infrastructure investments and would increase our costs of doing business. We can give no assurance that material weaknesses in our internal control over financial reporting will not be identified in the future. Our failure to implement and maintain effective internal control over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations. Effective internal control over financial reporting is necessary for us to provide reliable and timely financial reports and, together with adequate disclosure controls and procedures, are designed to reasonably detect and prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences that would materially and adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned a majority of our outstanding voting stock. In addition, in our 2023 and 2024 financings, certain of the holders of 5% or more of our capital stock acquired pre-funded warrants to purchase shares of our common stock (which are immediately exercisable and have an exercise price of $0.001 per share) or common warrants to purchase shares of our common stock. Until exercised, the shares issuable upon the exercise of the pre-funded warrants and the common warrants are not included in the number of our outstanding shares of common stock. If such holders exercise their warrants, then the shares of our capital stock beneficially owned by our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates would increase significantly. Therefore, these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current shares outstanding and resulting market valuation do not reflect shares of our common stock issuable upon the exercise of pre-funded warrants and common warrants that are exercisable at the discretion of the holders of such warrants. If we sell shares of our common stock in the future, stockholders may experience immediate dilution. Stockholders may be unable to compute the dilutive impact of future financings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may from time to time issue additional shares of common stock, and as a result, our stockholders would experience immediate dilution. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. For example, in March 2024, we entered into a sales agreement with Cowen and Company LLC, or TD Cowen, as sales agent,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to which we may issue and sell shares of our common stock for an aggregate maximum offering price of $100.0 million under an at-the-market offering program under which we have sold approximately $4.5 million of shares of our common stock as of the date of this Annual Report on Form 10-K. In addition, in July 2022, December 2023, and June 2024, we closed financings which included the sale of pre-funded warrants or common warrants to purchase shares of our common stock. Until exercised, the shares issuable upon the exercise of the pre-funded warrants or the common warrants are not included in the number of our outstanding shares of common stock. If we issue common stock or securities convertible into common stock in the future, our stockholders would experience additional dilution and such dilutive impact may be difficult to compute.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the stock price of our common stock could decline. As of December 31, 2024, the number of shares of our common stock outstanding was 109,381,556. This number does not include 38,543,577 shares of common stock issuable upon the exercise of pre-funded warrants or 8,104,615 shares of common stock issuable upon the exercise of common warrants. On August 12, 2024, we filed a resale registration statement on Form S-3, pursuant to which, entities and trusts affiliated with Muneer Satter, a member of our board of directors, can sell up to 3,000,000 shares of common stock. Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, may reduce the stock price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOLs or credits if we undergo a future ownership change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed a study through December 31, 2024, to determine whether an ownership change had occurred under Section 382 or 383 of the Code, and we determined that ownership changes occurred in 2011, 2014, 2020 and 2023. We have identified $0.1 million and $34.7 million of federal and state NOLs, respectively, that will expire unused due to ownership changes, and federal credits of $4.3 million that will not be able to be utilized due to ownership change limitation and excluded these amounts from deferred tax asset balances as of December 31, 2024. Federal NOLs of $367.6 million and state and local NOLs of $189.2 million are not expected to expire unutilized as a result of ownership changes identified through December 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to use NOLs, research and development credit carryforwards and other tax attributes to reduce future taxable income and tax liabilities may be further limited as a result of shifts in our stock ownership subsequent to December 31, 2024. As a result, even if we attain profitability, our ability to use our pre-change NOLs or other pre-change tax attributes to offset United States federal and state taxable income may be subject to further limitations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exclusive right of our board of directors to elect a director to fill a vacancy, however occurring, including by an expansion of the board of directors, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including voting or other rights or preferences, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we maintain a directors&#8217; and officers&#8217; insurance policy, such insurance may not be adequate to cover all liabilities that we may incur, which may reduce our available funds to satisfy third-party claims and may adversely impact our cash position.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with any future products we may sell, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals and biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. Generally, future changes in applicable U.S. and non-U.S. tax laws and regulations, or their interpretation and application, could have an adverse effect on our business, financial conditions and results of operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity risks and the failure to maintain the security, confidentiality, integrity, or availability of our information technology systems or data, and those maintained on our behalf, could lead to adverse consequences that materially adversely affect our business, including, without limitation, regulatory investigations or actions, a material interruption to our operations, including clinical trials, damage to our reputation and/or subject us to costs, loss of customers or sales, fines and penalties or lawsuits.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We collect and maintain information in digital and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we and the third parties with whom we work process sensitive data. We have established physical, electronic and organizational measures designed to safeguard and secure our systems in an effort to prevent a data compromise; there can, however, be no assurance that these measures will be or have been effective. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors have access to our sensitive data. Our information technology systems and infrastructure, and those of any future collaborators and our contractors, consultants, vendors and other third parties with whom we work, are vulnerable to and have experienced attacks, damage and interruption from cyber-attacks, malicious internet-based activity, online and offline fraud, computer viruses, malware (e.g., ransomware), credential stuffing, credential harvesting, supply-chain attacks, natural disasters, fire, terrorism, war, telecommunication and electrical failures, attacks enhanced or facilitated by AI, denial or degradation of service attacks, hacking, sophisticated nation-state and nation-state supported actors, phishing and other social engineering attacks (including through deep fakes, which are increasingly more difficult to identify), attachments to emails, fraud, personnel misconduct or error, server malfunctions, software or hardware failures, loss or theft of data or information technology assets, unauthorized access or use, and other similar threats. In particular, ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of a security breach or disruption, particularly through cyber-attacks, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The prevalent use of mobile devices that access sensitive data also increases the risk of lost or stolen devices, security incidents and data security breaches, which could lead to the loss or other compromise of sensitive data. In a hybrid working environment, we also face risks of a security breach or disruption due to our reliance on internet technology and the number of our personnel who are working remotely, which creates additional opportunities for cyber criminals to exploit vulnerabilities or other weaknesses. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. We may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. Security breaches may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties with whom we work). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we have and may in the future experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon third-party service providers and technologies to operate critical business systems and process sensitive data in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, encryption and authentication technology, employee email, and other functions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to monitor these third parties&#8217; security practices is limited, and these third parties may not have adequate security measures in place. Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">service providers have experienced and may experience in the future a security incident or other interruption. For example, one of our third-party drug component suppliers experienced a cyber-attack, which did not materially impact our operations. In addition, in 2024, one of our vendors experienced a cyber-attack which resulted in our access to the third-party system being unavailable to us for a brief period of time before being restored, which we concluded did not</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2f15383-b56d-412e-870f-a423b5450549" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> materially impact</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> our operations or clinical data. These and similar incidents have and could lead to business interruptions and additional costs. Any significant system failure, accident or security breach and resulting interruptions in our operations or our critical third parties&#8217; operations could result in a material disruption of our product development programs, and ultimately, our financial results. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. The costs to us to prevent, investigate, mitigate and remediate security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures designed to protect our data security and information technology systems and sensitive data, our efforts to address these problems may not be successful, and these problems have and may in the future result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. Any security compromise affecting us or the third parties with whom we work, or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny. Moreover, if a security breach affects our systems or results in the unauthorized access to or unauthorized use, disclosure, release or other processing of sensitive data, we may be required, or we may voluntarily choose, to notify individuals, governmental authorities, supervisory bodies, the media and other parties, or to take other actions, such as providing credit monitoring and identity theft protection services pursuant to privacy and security laws or other obligations, and our reputation could be materially damaged. We would also be exposed to a risk of loss, governmental investigations or enforcement, or litigation (including class action claims) and other potential liability, which could materially adversely affect our business, results of operations and financial condition. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Actual or perceived failure to comply with applicable data protection laws, regulations, standards, contractual obligations and other requirements related to data privacy and security could lead to government enforcement actions and civil or criminal penalties, private litigation (including class actions) or adverse publicity and otherwise could negatively affect our results of operations and business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive and confidential information, including proprietary and confidential business data, trade secrets, intellectual property, data we may collect about trial participants in connection with clinical trials, sensitive third-party data, and employee data (collectively, sensitive data). Our data processing activities actually or may subject us to numerous privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. Data privacy and security obligations are stringent and changing, with new data privacy and security laws being proposed or enacted. Preparing for and complying with these obligations requires significant resources and has in the past necessitated and may in the future necessitate changes to our information technologies, systems, and practices and to those of any third parties with whom we work. The laws and regulations that affect our ability to operate include, but may not be limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, or HIPAA, </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. Depending on the facts and circumstances, however, we could be subject to significant administrative, civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the California Consumer Privacy Act of 2018, or CCPA, which requires covered businesses to provide certain disclosures in privacy notices to California residents, including consumers, business representatives, and employees, and requires businesses honor certain requests of California residents to exercise certain privacy rights. The CCPA provides for administrative fines, as well as a private right of action for data breaches that has increased the likelihood of, and risks associated with data breach litigation. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws may impact our business activities depending on how it is interpreted. Further, the amendments to the CCPA expanded the CCPA&#8217;s requirements, including by adding a right for individuals to correct their personal data and establishing a regulatory agency to implement and enforce the law. Additional compliance investment and business process changes may be required in an effort to address data protection laws. Similar laws have been passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that make compliance challenging; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign data protection laws, including the European Union&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom GDPR, or UK GDPR, which contain provisions specifically directed at the processing of health data and, more broadly, impose significant and complex compliance burdens on processing personal data. Under the EU and UK GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines for noncompliance of up to &#8364;20 million under the EU GDPR (&#163;17.5 million under the UK GDPR) or 4% of annual global revenue of the noncompliance company, whichever is greater. Noncompliance with the EU and UK GDPR could also result in private litigation related to the processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. These laws such as the EU and UK GDPR impose numerous requirements for the collection, use, storage and disclosure of personal data of data subjects, including requirements relating to providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border transfers of personal data, and honoring and providing for the rights of individuals in relation to their personal data, including the right to access, correct and delete their data. Among other requirements, the EU and UK GDPR regulate transfers of personal data subject to the EU and UK GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we transfer personal data from Europe and other jurisdictions to the United States and other countries. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States or other relevant countries. If there were no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations. Other jurisdictions (including the US) have adopted or may adopt stringent data localization and cross-border data transfer laws. For example, regulators in the United States have enacted certain restrictions on cross-border personal data transfers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to data privacy and security laws, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, have and may in the future limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results of operations and prospects. We also publish policies, marketing materials, and other statements regarding data privacy and security. Regulators are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we work to comply with applicable privacy and data security laws, regulations and standards, contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Compliance with these data protection obligations has in the past and may in the future require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use, disclose and otherwise process personal data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Any actual or perceived failure to comply by us or our personnel, representatives, contractors, consultants, collaborators, or other third parties could result in government investigations and/or enforcement actions, fines, civil or criminal penalties, additional reporting requirements and/or oversight, bans on processing personal data (including clinical trial data), orders to destroy or not use personal data, private litigation (including class action claims) and mass arbitration demands, adverse publicity and could otherwise negatively affect our results of operations and business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and results of operations fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_63c98ab4-c41f-4491-9390-b498a19ca29d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented a risk-based approach designed to identify, assess and manage cybersecurity threats that could materially affect our business and information systems. We attempt to identify and assess risks from cybersecurity threats by evaluating our threat environment using various methods including, for example: maintaining manual and automated tools, subscribing to reports and services that identify cybersecurity threats, evaluating threats reported to us, and completing third-party cybersecurity threat assessments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use cybersecurity consultants and penetration testing firms in an effort to identify, assess, and manage material risks from cybersecurity threats. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c186012-1d5c-4bf5-9dfc-68f5950f50e8" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers in various elements to our business operations such as data hosting providers. To help manage cybersecurity risks associated with our use of third-party service providers, we primarily </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f3562d6-fcd2-4e20-b734-1c9b0d15f87d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with industry-preferred service providers, and we also contractually require service providers with access to personal, confidential, or proprietary information to maintain data security controls and practices.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity risks and the failure to maintain the security, confidentiality, integrity, or availability of our information technology systems or data, and those maintained on our behalf, could lead to adverse consequences that materially adversely affect our business, including, without limitation, regulatory investigations or actions, a material interruption to our operations, including clinical trials, damage to our reputation and/or subject us to costs, loss of customers or sales, fines and penalties or lawsuits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><ix:nonNumeric id="F_0efb0959-a49c-4d93-a6a1-39fc7bec3193" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0cab033e-5333-417b-8ff1-5a65d953878e" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses our cybersecurity risk management as part of its general oversight function.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7659ed20-33fb-4e4d-bf8a-1c231e89f59f" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for advising on our cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span></ix:nonNumeric></span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_3b27e004-fe63-4fb2-bd07-c1ebfe0302bd" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d17ab1c-35f5-4e7d-b5e0-57364333bd40" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c88f3c1-c3fc-442e-b5d1-960416c5a9f6" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5bff5fd-a211-4242-a63b-5b9da4eb4e10" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4df89c7b-5e53-4503-9503-a9a276f5117d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true" continuedAt="F_4df89c7b-5e53-4503-9503-a9a276f5117d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CFO has supervisory responsibility over IT and cybersecurity functions.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4df89c7b-5e53-4503-9503-a9a276f5117d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our management is responsible for helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1da43bd4-7749-4566-ae65-190ef65c8ffd" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dfe614b4-8da5-4997-afc9-2faf26ec966e" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security-related reports</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9474f6a-b3b5-4fc2-8ade-2b0b8bd8246a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.</span></ix:nonNumeric></span></ix:continuation></span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a cybersecurity policy, reviewed with our audit committee, which is designed to address cybersecurity risks to us (including by escalating certain cybersecurity incidents to members of management and the board of the audit committee, in each case depending on the circumstances). We also maintain incident response procedures designed to assist us in responding to cybersecurity incidents.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters are located in Brisbane, California, where we lease approximately 65,818 square feet of office and laboratory space. The contractual term of the Brisbane lease commenced in November 2021 and will end in October 2031, with an option to extend for an additional ten years.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are not currently a party to any material legal proceedings. We may, however, in the ordinary course of business face various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these claims could subject us to costly litigation, and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our business, results of operations and financial condition. Additionally, any such claims, whether or not successful, could damage our reputation and business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock has been traded on the Nasdaq Global Select Market under the symbol &#8220;ANNX&#8221; since July 24, 2020. Prior to that, there was no public market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of this Annual Report on Form 10-K, there were 28 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid, and do not anticipate declaring or paying in the foreseeable future, any cash dividends on our capital stock. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws and will depend on then existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for information regarding securities authorized for issuance.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Parties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. [R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eserved]</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs, and expectations, and involve risks and uncertainties. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 10-K, particularly in the sections titled &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for people living with devastating inflammatory-related diseases. The classical complement pathway is a core component to the body&#8217;s immune system that activates a powerful inflammatory cascade. We believe that by stopping the classical complement pathway at its start by targeting C1q, the initiating molecule of the classical complement pathway, our approach may have the potential to provide more complete protection against complement-mediated disorders of the body, brain and eye.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Using our proprietary platform, we are identifying and characterizing the role of the classical complement pathway in three therapeutic areas&#8212;autoimmune, neurodegeneration and ophthalmology. In so doing, we are advancing a pipeline of product candidates designed to block the early classical cascade and all downstream pathway components and their tissue-damaging functions. Our goal is to suppress excessive or aberrant classical complement activity that contributes to chronic inflammation and tissue damage to slow or even halt disease progression, while preserving the beneficial immune functions of the lectin and alternative complement pathways involved in the clearance of pathogens and damaged cells. We have demonstrated robust target engagement in the body, brain and eye, and clinical proof of concept in multiple diseases, and have focused our resources on development of three priority programs:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guillain-Barr&#233; Syndrome, or GBS: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing our lead candidate, ANX005, an investigational, full-length monoclonal antibody, or mAb, formulated for intravenous administration as the potential first targeted treatment for patients with GBS. GBS is a rare antibody-mediated autoimmune disease that is the most common cause of acute neuromuscular paralysis, with no therapies in the United States approved by the FDA. We believe maximum suppression of C1q and the classical complement cascade early in the disease process may act to rapidly prevent complement-mediated nerve damage and irreversible neurological disability. In a prior Phase 1b placebo-controlled proof-of-concept trial, a single dose of ANX005 showed rapid and consistent improvement in muscle strength that translated into observable gains in health status, including a reduction in the need of mechanical ventilation, as well as a reduction in nerve damage and clinical function. In 2024, we completed a Phase 3 trial in 241 patients, which showed ANX005 helped patients improve sooner with rapid increase in muscle strength and more complete functional recovery than placebo through six months, and provided an important benefit in the burden of care by enabling patients to walk or be off ventilation earlier. In addition, we completed a Real World Evidence, or RWE, study that matched ANX005-treated patients from the Phase 3 study with a western world patient population from the International Guillain-Barr&#233; Syndrome Outcomes Study, or IGOS, predominantly from Europe and North America treated with current standards of care (intravenous immunoglobulin, or IVIg, or plasma exchange, or PE). Consistent with the Phase 3 trial, ANX005 showed a rapid increase in muscle strength with more complete recovery over IVIg or PE. We anticipate the Phase 3 and RWE results to support a comprehensive dataset for our Biologics License Application, or BLA, and are targeting the first half of 2025 for our pre-BLA meeting with the FDA ahead of our planned BLA submission. ANX005 has been granted Fast Track and orphan drug designation for the treatment of GBS from the FDA. ANX005 has also been granted orphan designation from the European Medicines Agency, or EMA.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geographic Atrophy, or GA: </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing ANX007, an antigen-binding fragment, or Fab, formulated for intravitreal administration, as the first potential program with a global registration path to approval in Europe and the United States for the treatment of dry AMD with GA. Dry AMD with GA is </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a leading cause of vision loss in the elderly, that affects more than an estimated eight million people globally, and there are no approved therapies targeting the preservation of vision in this disease. ANX007 is designed to block C1q locally in the eye, to provide more complete protection against excess classical complement activity and the loss of photoreceptor neurons. It is the only investigational therapy in GA to show significant vision preservation on assessments of best corrected visual acuity, or BCVA, and low luminance visual acuity, or LLVA, demonstrating significant protection from vision loss in both normal and low light conditions, as well as significant preservation of central retinal photoreceptors necessary for visual acuity as demonstrated in the Phase 2 ARCHER trial. In 2024, we initiated our Phase 3 ARCHER II trial, a global, sham-controlled, double-masked trial expected to enroll ~630 patients who have dry AMD with GA. The primary endpoint of ARCHER II is prevention of &#8805;15-letter loss of BCVA, and a secondary objective structural measure is prevention of ellipsoid zone (EZ) loss. The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA&#8217;s two-trial recommendation. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial. We expect to complete enrollment of ARCHER II in the second half of 2025 and report topline data in the second half of 2026. ANX007 is the first and only therapeutic candidate for the treatment of GA to receive Priority Medicine, or PRIME, designation by the EMA, which provides early and proactive support to developers of promising medicines that may offer a major therapeutic advantage over existing treatments or benefit to patients without treatment options.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANX1502 for Autoimmune Indications: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing ANX1502, a novel oral small molecule inhibitor of classical complement which we believe is first-in-kind. In a Phase 1 single-ascending dose, or SAD, and multiple-ascending dose, or MAD, clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, ANX1502 was generally well tolerated across cohorts with no serious adverse events, achieved target levels of active drug and showed supportive impact on a PD biomarker of complement activity that support its advancement. We are evaluating a tablet formulation of ANX1502 in an ongoing proof-of-concept study in patients with cold agglutinin disease, or CAD, to assess PK, PD and clinical efficacy endpoints (e.g., hemolysis as measured by reduction of elevated bilirubin) and data are expected in mid-2025. Following the successful completion of the proof-of-concept study, we intend to evaluate ANX1502 in a host of diseases, including serious complement-mediated autoimmune diseases, with the aim of providing enhanced efficacy and offering convenient dosing administration for long-term treatment of chronic conditions.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in March 2011 and commenced operations later that year. To date, we have focused primarily on performing research and development activities, hiring personnel and raising capital to support and expand these activities. We do not have any products approved for sale, and we have not generated any revenue from product sales. We have incurred net losses each year since our inception. Our net losses were $138.2 million and $134.2 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $710.7 million and cash and cash equivalents and short-term investments of $312.0 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are not approved for commercial sale. We have not generated any revenue from sales of our product candidates and do not expect to do so in the foreseeable future and until we complete clinical development, submit regulatory filings and receive approvals from applicable regulatory bodies for such product candidates, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses account for a significant portion of our operating expenses. Research and development expenses consist primarily of direct and indirect costs incurred for the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">professional services agreements with third party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on our behalf; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contract manufacturing costs to produce clinical trial materials and commercial materials to support any BLA to the FDA; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory supplies and materials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indirect expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compensation and personnel-related expenses (including stock-based compensation); </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocated expenses for facilities and depreciation; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other indirect costs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record research and development expenses as incurred. Payments made to other entities are under agreements that are generally cancelable by us. Advance payments for goods or services to be received in future periods for use in research and development activities are deferred as prepaid expenses. The prepaid amounts are then expensed as the related services are performed. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our future research and development expenses to increase as we pursue regulatory approval of our product candidates, continue to advance our product candidates through late-stage clinical trials, invest in capabilities to prepare for commercialization including manufacturing, and hire additional personnel to support our organization. The process of conducting the necessary clinical research, development and manufacturing to obtain regulatory approval is costly and time-consuming, and the successful development and approval of our product candidates is highly uncertain.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of compensation and personnel-related expenses (including stock-based compensation) for our personnel in executive, finance and other administrative functions. General and administrative expenses also include professional fees paid for accounting, legal and tax services, allocated expenses for facilities and depreciation and other general and administrative costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our general and administrative expenses to increase as we continue to support our research and development activities, grow our business, advance our product candidates in late-stage clinical trials and toward regulatory approval and commercialization activities, and operate as a public company.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest and Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and other income, net, primarily consists of interest income earned on our cash equivalents and short-term investments.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize our results of operations for the periods presented:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.32%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.700000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.700000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.539999999999999%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dollar<br/>Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%<br/>Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,448</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,756</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,692</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,625</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,967</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,658</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,073</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,723</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,350</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(154,073</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(143,723</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,350</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,873</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,486</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,387</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(138,200</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(134,237</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,963</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.33%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.602%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.521%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dollar<br/>Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%<br/>Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct costs:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical and nonclinical outside services</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,901</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,456</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,555</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,328</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,598</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,270</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consulting and professional services</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,083</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,347</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,736</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory supplies and materials</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">848</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,453</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(605</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indirect costs:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation and personnel-related <br/>(including stock-based compensation)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,492</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,868</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,624</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities and depreciation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,875</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,009</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,866</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">921</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,025</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(104</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,448</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,756</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,692</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $5.7 million, or 5%, for the year ended December 31, 2024 compared to the year ended December 31, 2023. The increase was primarily due to an increase of $8.7 million in consulting and professional services in support of our development organization driving the advancement of our flagship programs, an increase of $1.9 million in facilities related costs due to the expiration of a sublease agreement, and an increase of $1.6 million in compensation and personnel-related expenses due to an increase in headcount, partially offset by a decrease of $3.6 million in direct clinical and nonclinical outside services costs due to completion of the Phase 2 ARCHER trial in GA in 2023, a decrease of $2.3 million due to timing of contract manufacturing expenses for ANX005, and a decrease of $0.6 million in laboratory supplies and materials.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.33%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.602%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.521%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dollar<br/>Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%<br/>Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation and personnel-related <br/>(including stock-based compensation)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,858</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,404</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">454</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consulting and professional services</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,161</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,738</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,423</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities and depreciation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,598</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">652</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,008</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,879</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,625</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,967</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,658</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $4.7 million, or 16%, for the year ended December 31, 2024 compared to the year ended December 31, 2023. The increase was primarily due to an increase of $3.4 million in consulting and professional services costs for business development, market research, and recruitment costs, an increase of $0.7 million in facilities related costs due to the expiration of a sublease agreement, and an increase in compensation and personnel-related expenses of $0.5 million due to an increase in headcount.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and other income increased by $6.4 million for the year ended December 31, 2024 compared to the year ended December 31, 2023. The increase was primarily due to higher average cash and investment balances and favorable interest rates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to our significant research and development expenditures, we have generated operating losses since our inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have funded our operations primarily through the sale of equity securities. As of December 31, 2024, we had available cash and cash equivalents and short-term investments of $312.0 million and an accumulated deficit of $710.7 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Historical Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.547%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.498%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.517999999999999%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(118,006</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(121,142</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(218,797</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,703</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,206</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,524</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(175,597</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,085</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flow from Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities for the year ended December 31, 2024 was $118.0 million, which consisted of a net loss of $138.2 million, partially offset by $13.8 million in non-cash charges and a net change of $6.4 million in our operating assets and liabilities. The non-cash charges consisted of stock-based compensation of $19.4 million,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">depreciation and amortization of $2.2 million, and reduction in the carrying amount of right-of-use assets of $1.3 million, partially offset by accretion of discount on available-for-sale securities of $9.1 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities for the year ended December 31, 2023 was $121.1 million, which consisted of a net loss of $134.2 million and a net change of $5.8 million in our operating assets and liabilities, partially offset by $18.9 million in non-cash charges. The non-cash charges consisted of stock-based compensation of $18.2 million, depreciation and amortization of $2.1 million, and reduction in the carrying amount of right-of-use assets of $1.1 million, partially offset by accretion of discount on available-for-sale securities of $2.6 million.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flow from Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in investing activities for the year ended December 31, 2024 was $218.8 million, which consisted of $583.9 million of purchases of available-for-sale securities, partially offset by $365.1 million of proceeds from maturities of available-for-sale securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by investing activities for the year ended December 31, 2023 was $70.7 million, which consisted of $179.0 million of proceeds from maturities of available-for-sale securities, partially offset by $108.1 million of purchases of available-for-sale securities and $0.2 million of equipment purchases.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flow from Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2024 was $161.2 million, which consisted of $116.8 million of net proceeds from the issuance of common stock and pre-funded warrants under our 2024 financing, $42.8 million of net proceeds from the issuance of common stock under our 2021 and 2024 ATM programs and $1.6 million of proceeds from the exercise of common stock options and employee stock purchase plan purchases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2023 was $135.5 million, which consisted of $117.5 million of net proceeds from the issuance of common stock and pre-funded warrants, $17.5 million of net proceeds from the issuance of common stock to a related party under our at-the-market offering program and $0.6 million of proceeds from the exercise of common stock options and employee stock purchase plan purchases.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use our cash to fund operations, primarily to fund our clinical trials, research and development expenditures and related personnel costs. We expect our future research and development expenses to increase as we pursue regulatory approval of our product candidates, continue to advance our product candidates through late-stage clinical trials, invest in capabilities to prepare for commercialization including manufacturing, and hire additional personnel to support our organization. In addition, we expect our general and administrative expenses to increase as we continue to support our research and development activities, grow our business, advance our product candidates in late-stage clinical trials and toward regulatory approval and commercialization activities, and operate as a public company. The timing and amount of our operating expenditures will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching and developing our current product candidates or any other future product candidates we choose to pursue, and conducting preclinical studies and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining feedback from regulators on our clinical trials and regulatory approvals for our lead product candidates or any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to our current or any future license or collaboration agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our lead product candidates or any future product candidates and any products we successfully commercialize; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of building a sales force in anticipation of product commercialization; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of commercialization activities of our product candidates, if approved for sale, including marketing, sales and distribution costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product liability or other lawsuits related to our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with operating as a public company; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt and amount of sales of any future approved products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash and cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2026. We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Until such time, if ever, as we can generate substantial product revenue, we will be required to seek additional funding in the future and currently intend to do so through public or private equity offerings or debt financings, credit or loan facilities, collaborations or a combination of one or more of these funding sources. Additional funds may not be available to us on acceptable terms or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, we could be forced to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Financing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we raised net proceeds of approximately $116.8 million after deducting underwriting discounts and offering expenses through the sale of 13,001,120 shares of our common stock, par value $0.001 per share at a price of $6.25 per share and pre-funded warrants to purchase an aggregate of 7,000,000 shares of common stock at a price of $6.249 per share, which equals the per share offering price for the shares of common stock less the $0.001 exercise price for each pre-funded warrant.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Financing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, we raised net proceeds of approximately $117.0 million after deducting underwriting discounts and offering expenses through the sale of 25,035,000 shares of our common stock, par value $0.001 per share at a price of $2.880 per share and pre-funded warrants to purchase an aggregate of 18,379,861 shares of common stock at a price of $2.879 per share, which equals the per share offering price for the shares of common stock less the $0.001 exercise price for each pre-funded warrant. We issued an aggregate of 5,243,400 and 965,427 shares of common stock upon cashless and cash exercise of these pre-funded warrants in February 2024 and April 2024, respectively.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Financing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, we raised net proceeds of approximately $122.5 million after deducting fees and expenses through the sale of an aggregate of 9,013,834 shares of common stock, pre-funded warrants to purchase up to 24,696,206 shares of our common stock and accompanying common warrants to purchase up to 8,427,508 shares of our common</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock. The offering price per share and accompanying common warrant was $3.87125 per share and the offering price per pre-funded warrant and accompanying common warrant was $3.87025 per share, which equals the per share offering price for the shares of common stock less the $0.001 exercise price for each such pre-funded warrant. The pre-funded warrants remain exercisable until exercised in full. The common warrants have an exercise price of $5.806875 per share and expire on June 30, 2025. Both the pre-funded and common warrants are immediately exercisable, subject to beneficial ownership limitations. We issued an aggregate of 2,582,557 shares of common stock upon the cashless exercise of the pre-funded warrants in March 2023. We issued an aggregate of 19,901 and 2,739,096 shares of common stock upon the cashless exercise of the common warrants and pre-funded warrants in June 2024 and November 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Funded and Common Warrants</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes warrant activity during the years ended December 31, 2024 and 2023:</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.9%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20.7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:16.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.82%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:16.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Common Warrants</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded Warrants</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,696,206</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,379,861</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,583,144</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,492,923</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(322,893</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,949,346</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.216</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,104,615</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,543,577</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 At-the-Market (ATM) Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we entered into a sales agreement with Cowen and Company LLC, or TD Cowen, as sales agent, or 2024 ATM program, pursuant to which we may issue and sell shares of our common stock for an aggregate maximum offering of $100.0 million. TD Cowen is entitled to compensation up to 3% of the aggregate gross proceeds for the common stock sold through the 2024 ATM program. During the year ended December 31, 2024, we sold 750,000 shares of common stock for net proceeds of approximately $4.5 million, after deducting commissions paid to TD Cowen. As of December 31, 2024, approximately $95.4 million remained available for the offer and sale of shares of common stock under the 2024 ATM program.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 ATM Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2021, we entered into a sales agreement with TD Cowen, as sales agent, pursuant to which we may issue and sell shares of our common stock for an aggregate maximum offering of $100.0 million under an at-the-market offering program, or 2021 ATM program. TD Cowen is entitled to compensation up to 3% of the aggregate gross proceeds for the common stock sold through the 2021 ATM program. During the years ended December 31, 2024 and 2023, we sold 7,576,067 shares and 2,646,458 shares of common stock, respectively, under the 2021 ATM program for net proceeds of approximately $38.4 million and $17.5 million, respectively, after deducting commissions paid to TD Cowen and other financing costs. The Form S-3 registration statement, which registered the 2021 ATM Program, expired on August 15, 2024. As a result, no shares of common stock may be sold under the 2021 ATM Program.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">liabilities, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued and Prepaid Research and Development Costs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record accrued expenses for estimated costs of our research and development activities conducted by third-party service providers, which include the conduct of clinical trials and nonclinical studies. We estimate preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions, clinical research organizations, and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on our behalf. In recording service fees as either prepaid or accrued costs, we estimate the period over which services will be performed and the level of effort to be expended in each period. The level of judgment required to estimate research and development expenses varies based on the nature of the services being performed and the underlying support obtained. Accordingly, research and development expenses supported by invoices or reports of costs from third-party providers for the services performed do not require us to make significant estimates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services provided and efforts expended pursuant to contracts with contract research organizations that may be used to conduct and manage our clinical trials. We recognize costs for contract manufacturing based on evaluation of the progress to completion of specific tasks. These estimates of the expense are based on communications with and information provided by the third-party service providers at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the amounts recorded accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. We have not experienced any material differences between accrued or prepaid costs and actual costs incurred since inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We defer and capitalize non-refundable advance payments for goods or services that will be used or rendered for future research and development activities as prepaid expenses until the related goods are delivered or services are performed. We evaluate such payments for current or long-term classification based on when such services are expected to be received.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess the initial classification of our warrants as either liability or equity, we apply judgment when evaluating the potential settlement options. We first assess whether the warrants are within the scope of ASC 480-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 480. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate us to settle the warrants or the underlying shares by paying cash or other assets, or require settlement by issuing variable number of shares.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If the warrants are not within the scope of ASC 480, they are subsequently assessed under ASC 815-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock , or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 815-40. We review the terms of the warrants to determine whether they require or may require us to settle or net settle the contract for cash which would result in classification of the warrants as liabilities recorded at fair value. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, we also assess whether the warrants are indexed to our common stock and meet equity classification criteria under ASC 815-40. Liability-classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity-classified warrants only require fair value accounting at issuance and are not subsequently remeasured.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. We periodically evaluate changes in facts and circumstances that could impact the classification of warrants.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2&#8212;Basis of Presentation and Significant Accounting Policies to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not required for the Company as a smaller reporting company.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Supplementary Data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span><ix:nonNumeric id="F_dfe4a65f-8a7d-42b8-85c2-967afb64f6b2" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_fcba404b-cd4d-415e-ab79-d3d66dabb3f2" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">San Francisco, CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, Auditor Firm ID: </span><span><ix:nonNumeric id="F_9c1ad972-277a-48b0-bbf8-64c023fc44df" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_comprehensive_lo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_redeemable_conv"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors<br/>Annexon, Inc.:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Annexon, Inc. and subsidiary (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-funded warrants</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in Note 6 to the consolidated financial statements, in June 2024 the Company closed a financing transaction which included the issuance of common stock and pre-funded warrants to purchase its common stock. Upon issuance, the pre-funded warrants were recorded at fair value as of the grant date as a component of stockholders' equity within additional paid-in capital.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified the balance sheet classification of the pre-funded warrants as part of the June 2024 financing transaction as either liabilities or equity as a critical audit matter. Subjective auditor judgment was required in the evaluation of the balance sheet classification of the pre-funded warrants due to certain provisions included within the warrant agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are the primary procedures we performed to address this critical audit matter. We obtained and inspected the pre-funded warrant agreement to identify key terms and conditions within the agreement that were relevant to the balance sheet classification determination. We obtained and assessed the Company's technical accounting analysis to evaluate whether the Company had considered those key terms and conditions of the pre-funded warrant agreement. We evaluated the Company's interpretation and application of the relevant accounting literature, including considerations of the settlement provisions unique to the pre-funded warrants.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2016.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Francisco, California<br/>March 3, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.613%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.263%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.683%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4518111f-f8f4-4913-8b59-8c9d7f1b0ea9" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,498</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e6e48da-feaa-47b0-84d2-d9b86c40469e" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225,110</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c355ef8-f9aa-4206-a817-40929e3060ea" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,519</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_916bbca5-4892-451e-9791-b406248c171d" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,606</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc85cebd-e80a-44d5-bb3c-72be16fd7cba" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,444</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85da647f-5d56-419f-9987-5166082aea96" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,144</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90cef349-b80f-4eb3-bd16-4a0fb5bca08b" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316,461</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_348d7833-db54-49d2-8005-8d29d256a711" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,860</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e415913-413e-4676-95c4-673e2f704e57" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1f5986c-cebe-4696-9f27-8697c50eae93" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70f8e4f0-4140-4d65-9a32-401744f6edab" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,638</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b393b43d-9102-4420-94f5-34ecb97a1f38" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec430792-9758-401c-8b7a-f2ea9dcbd245" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,705</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34fbccc1-e60f-407c-8f14-2d95d2aeabd6" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,009</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a95dfe3-148b-40bf-b209-46d50190aa45" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,235</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8e4b440-196f-4ac6-9350-60f95e4f8cc6" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,071</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66a929ab-10e8-483a-ab96-e5e287c4c23b" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">297,674</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4069588d-ee9d-48ce-97de-6f2a8c83681b" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,426</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b18b60d4-4367-4af6-9a07-a65b8c5cc0fb" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,487</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bfa1453-2b8f-4a84-8108-c3e5be617ba3" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:AccruedAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,568</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a495236-87e7-4f6a-8871-b4890bdb485c" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:AccruedAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,276</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe8f0a69-40ec-4975-8eeb-8c88a5aaaac5" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,518</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a12d50f-4eb6-42c3-b7e2-3d2b91acc935" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,165</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bf73d62-4f0b-48e9-b271-8800e37b3032" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,512</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20151d98-5838-49d1-b168-e2e35c871e34" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,928</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90c92b75-65b9-402a-9659-b470fbfcd3c5" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,454</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a701e07e-2728-4ba0-bc40-e4929dd242a0" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,190</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a091a83-c75d-4aa9-b203-65db3827a936" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,966</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_447172d8-d192-4a89-9176-0f9d9a848917" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,118</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_420f1a7b-75ca-4c11-8930-c039b5bd7f95;"><span style="-sec-ix-hidden:F_c0349d88-3f94-454f-954e-b3a1d9c41c2e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 5)</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b20f260d-29ba-49d4-8dfc-9bc10920a56f" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_29f8024b-a838-4dab-8e8a-eccee524a6b0" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf84dd05-91c3-4c66-858c-87b3ce00ec70" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_de12b456-aee4-400f-a0fc-328dc4ff5265" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized <br/>&#160;&#160;&#160;&#160;as of December 31, 2024 and 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d263248b-5817-4e96-90cf-c9e07326efc2" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3f53f4c4-21b9-4dab-8131-9a5fd0afaca5" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">109,381,556</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;<br/>&#160;&#160;&#160;&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d277fdee-58bf-4f4f-871d-87789645cd21" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b41e11cc-7ea9-45b5-ac37-ea0b2f5ddfe1" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">78,369,099</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of<br/>&#160;&#160;&#160;&#160;December 31, 2024 and 2023, respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e3c71f7-36d9-4720-9e4a-41075e7cff0e" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_724f6880-3376-4737-a1df-c61ec87195cd" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7805a9b-bf2c-436d-8e2f-6d6fc7d7f03d" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,003,685</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7145b1f3-1aa8-4467-bbd2-93baa348c4b5" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">823,029</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab658e93-f8a7-4ee8-aa7a-593cad757060" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88ddf383-640e-4fb2-9afb-3fdb9cced6f2" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f37e577-f4a8-4f82-bea6-59ddd2fce775" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">710,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f785006-7ce8-4c4b-873e-e7b832b6dcc5" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">572,499</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae6e805f-bcc5-410f-90bb-8d5ad575d28c" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,105</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54287b31-9618-422d-95b5-a083bcb34571" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,556</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b265ceb-8b49-4251-b779-fc274bc920c5" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,071</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e6b7cb6-7a98-4b9d-9249-8b8707c76bf3" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">297,674</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ents of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands,</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.673%;box-sizing:content-box;"/>
    <td style="width:1.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.923%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.923%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58b01161-448e-42c1-815a-c189b8ae42ce" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97e0ed74-82fc-4006-ad4e-cdd101e92315" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,756</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bbb14d9-f10c-40dd-b570-f61837208b5a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,625</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80954cca-e2df-49bc-96a7-430f0fd32870" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,967</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa841351-6b7c-40ee-8d64-fb32752a8924" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,073</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f11c52f-7ca8-4de5-9de4-b00eb1a1b47d" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,723</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85828081-24ba-4302-b720-8ee6ff0ebe3a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">154,073</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44791ccb-1e3e-4a52-af32-c641c0ea8786" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">143,723</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe5c2b1d-ce75-4e44-8535-d697e98ae197" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:InterestAndOtherNonOperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,873</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81bb42c3-761c-44cb-8a5e-7d16772bf48f" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="annx:InterestAndOtherNonOperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,486</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb19144c-1331-454c-81f8-0da2e497492d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4df6c280-c61e-46f1-9834-9f3d640c6bf2" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,237</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c682e7f-0718-40ed-ab8c-fe430ddc515b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4dae8709-2629-4e36-98e6-d7f554e4f22f" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.01</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a235edc-e255-47fb-ba91-1fc9685bc24e" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_04ce5345-5701-49c2-b3d6-b4162a731840" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.77</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share,<br/>&#160;&#160;&#160;basic and diluted</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbff9d8c-fb3c-4c37-aba6-6a14e8491934" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_88ed794c-9e78-4973-a06f-b8ea1e055f66" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">137,404,145</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97a6b197-cfbc-406e-a4d1-32e7ba1d6552" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1a863d14-e9d4-4f84-9b13-db9ba6eab9ad" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">75,673,081</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_comprehensive_lo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fedd00d9-0f4a-4643-b401-e8f0bfaa075b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28295577-a46b-4b58-b4c0-4768b753b6e5" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,237</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca7c3ec3-94e7-4332-9fd5-c721f45fc833" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">15</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1e3fc18-f245-4757-897e-4962c76e3ab3" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on available-for-sale securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8168b5a5-81d4-456d-980b-dba3c0061399" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3">77</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_671a2327-c74b-4ca6-ba42-4da949cc3918" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3">315</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dde563aa-a670-423e-9e3b-942c071b35c1" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,138</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0172b03-68c7-4e93-87bb-2dc78719a22d" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">133,917</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_redeemable_conv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.168%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.577%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.539%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.158%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.539%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.097%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.539%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.196%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.539%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.097%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.539%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.956%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other<br/>Comprehensive</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84047048-1844-40ca-b274-68097ee11bb0" contextRef="C_eb92638f-ef52-4c87-b5ac-58d1b991d572" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,722,995</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a7625ce-0d6c-4e11-b09e-17060086e542" contextRef="C_eb92638f-ef52-4c87-b5ac-58d1b991d572" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51a42454-26b8-4170-9922-303923424fb0" contextRef="C_b56b58f7-0eb2-431c-93e8-e770362d3636" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">669,780</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceddc67d-36b4-401f-a06f-90466eca3e43" contextRef="C_ed7afca9-65c9-4663-b96f-deb75482c773" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">372</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06b5cfb1-3392-4de8-a964-246d3e6cce3c" contextRef="C_443c81d2-cb73-4f5e-bd81-93e201b4f7af" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">438,262</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_082e2eaf-ff31-4e91-a5eb-c25aa497a97b" contextRef="C_a2b98230-0f7a-4d29-8918-901b611f045a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">231,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd9b692e-a18f-4f5a-b1ad-408d2a36f0ad" contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,888</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d490fc17-ae24-4fb6-9df9-68aab2e3f855" contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1f224fa-459c-4e56-97fd-f4005bb5c4fd" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of pre-funded warrants</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d53b310-d65f-4245-927b-9e3dd396a96d" contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2" name="annx:ExerciseOfPreFundedWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,582,557</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6191669-909c-4b57-b8ae-f4a730dc5edd" contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2" name="annx:ExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fa4d670-b80c-45ee-adba-623a4ade529a" contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115" name="annx:ExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock to a related <br/>&#160;&#160;party, net of issuance costs of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd9cb68f-8e67-440c-baa6-7cdb59e0adf0" contextRef="C_45af3c57-9293-4248-ba7b-bfd6daa609f3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7130fd2-d01f-4108-9320-71364fcd223d" contextRef="C_0428a48b-fcf2-4525-9a5d-beb6a7560084" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,646,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0967a7e8-0191-463a-a3b3-87fc33022ddc" contextRef="C_0428a48b-fcf2-4525-9a5d-beb6a7560084" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad3c35e4-0d46-4e41-bdc9-61b7b02bff66" contextRef="C_6bb50bac-b7de-4de8-a130-52d5e9a81ba7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,468</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_316b95c0-f776-4431-be1a-7174e42390f0" contextRef="C_45af3c57-9293-4248-ba7b-bfd6daa609f3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,470</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and pre-<br/>&#160;&#160;funded warrants, net of issuance cost <br/>&#160;&#160;of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0afb424-020b-46eb-b81a-816f3b3a31b0" contextRef="C_a909da49-1edd-4a9f-a0aa-5b1551fca7c2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,014</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7155fa5c-e8a7-4b49-ab06-55f846cf828b" contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2" name="annx:IssuanceOfStockAndPrefundedWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,035,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91cf04a7-1181-480b-8dcd-6a406f87101a" contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2" name="annx:IssuanceOfStockAndPrefundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_548d87c2-e704-4f2b-ac0e-a748e98aeb88" contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115" name="annx:IssuanceOfStockAndPrefundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,977</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0edbcede-1b1f-40b9-9952-1571eb206ca0" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="annx:IssuanceOfStockAndPrefundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,002</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock per Employee <br/>&#160;&#160;Stock Purchase Plan purchase</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaca0568-0fbb-4cbc-8e6d-48bd393e98f0" contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">133,105</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7d9beb0-abda-4d77-acd7-f12bb3cbbfd5" contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_826f47ce-bbff-4e17-a400-07940d40acdf" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock vested in the period</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be3cd6ef-6026-4ab2-872e-eb81264bfd10" contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2" name="annx:RestrictedStockVestedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">172,096</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94fd3cf6-23d5-4adc-8c24-925e4baa511f" contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,183</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca07eb93-0531-4dd8-9eaa-688cd087fbd2" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,183</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e966acc-7bac-4403-b7f9-b3eabd6c97ff" contextRef="C_df95e66b-dc80-4420-b35b-25735aaee5e0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a791cd42-344a-4f4b-a4c1-2ca97cfc3390" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34f2c8a7-aa57-447c-ba90-fba8d20e294f" contextRef="C_8835a1b4-527a-43d8-b69a-a0eca9a1005c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,237</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35f9a26e-2dff-4c18-87fe-a91f4ae1cf49" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,237</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61226bf8-7617-436a-a4f0-d3c706dc9426" contextRef="C_db3563d3-30d0-495f-ae87-183cd7735dd2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">78,369,099</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66553fba-5dcf-4e08-a72b-82f827322073" contextRef="C_db3563d3-30d0-495f-ae87-183cd7735dd2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7f86980-9e5d-4dcc-bfee-f6a428fd43ce" contextRef="C_1a083296-3cca-4c7e-aef5-14001cb6517c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">823,029</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_537eab8c-ba94-4788-8472-0b152e4a4a30" contextRef="C_06de6640-01c9-4281-bfc6-944a3b827353" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b48b874-8a02-4c10-9bc4-71d89d47c84a" contextRef="C_766389fd-d63f-45a1-a7be-f2588e021646" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">572,499</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4d74882-cd10-4986-8331-5e169f018bfe" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,556</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3d08362-0731-43c9-a4e4-6ac156a30149" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">382,122</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c45025fb-d14f-44fd-82e5-12ed163f5785" contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,232</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec1d9b0b-f67d-4267-82c3-c6ec0513da40" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,232</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of pre-funded warrants</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddc58398-eb91-48e6-b36a-fe93bcf9fb48" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="annx:ExerciseOfPreFundedWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,947,923</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0418d6c9-79de-4d11-aca6-7f5bf49c8fc6" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="annx:ExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_337106e0-2f77-48c7-9977-27731b4042cb" contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60" name="annx:ExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common warrants</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20a49e5b-c627-4903-85f9-b864cbb7c1f3" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="annx:ExerciseOfCommonWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,901</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance<br/>&#160;&#160;costs of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc82fac-a97e-4345-af65-9584f239b523" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,528</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f006f12-05ba-474d-be40-99b77a3182f8" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,326,067</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c178df7-6f68-4b6f-89c1-5e4a059f7f72" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fde75d6-b2dc-44af-93a2-96b2babc462f" contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,835</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_354e14df-f953-417c-864b-88a8208483c9" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,843</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and pre-funded <br/>&#160;&#160;warrants, net of issuance costs $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6443b832-16eb-470b-801e-707b46d206c6" contextRef="C_650433ef-c0b4-4034-b841-f9093d2a4e91" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,183</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e6e2969-aedb-41ef-ae1a-07cefb2b99e1" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="annx:IssuanceOfStockAndPrefundedWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,001,120</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1580dea9-2464-4d2f-95e2-ee9bb8f5ad3e" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="annx:IssuanceOfStockAndPrefundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de53360f-bae7-45ff-aaac-3fc58ab803c3" contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60" name="annx:IssuanceOfStockAndPrefundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,804</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd063fb5-cfba-4b65-9e79-0c08f6f1d779" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:IssuanceOfStockAndPrefundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,817</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock per Employee    <br/>&#160;&#160;Stock Purchase Plan purchase</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_535919ca-8928-41ec-ae32-d5d794e24163" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">138,147</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adb10432-5424-4974-8170-c5e5ccd7634a" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec9646b-919d-4ba8-bec1-719232ad6712" contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">361</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f5eace6-e33e-4188-9666-73b774d5e239" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock vested in the period</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43457a62-2f88-46b8-96ce-7eabf3f560f9" contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513" name="annx:RestrictedStockVestedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">197,177</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aef650d-c5ce-4d63-89ee-a31a87800848" contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,433</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e5cdfe2-1d71-49ae-a5ed-9dfa1b94e5ca" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,433</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_905fdf24-e0a3-4fdf-8cec-bb93ed473ee6" contextRef="C_138cc2dd-081f-4945-96e9-e817d5140d0d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e02211c-93ba-47c2-9dc5-622c9831f4f4" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2da1fb8c-9e52-45d5-91d3-63060952258b" contextRef="C_4ac38cec-c321-4987-9f13-09b843771ddb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bba45185-87a8-4344-ad41-72f4b0b22c1b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ac949bc-b1f5-4826-9d10-1ebbe0687e4d" contextRef="C_dc545e9b-21db-4b67-ad10-065bcc3c2d12" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">109,381,556</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c13337e6-ad37-44a9-af62-2f72b7271caf" contextRef="C_dc545e9b-21db-4b67-ad10-065bcc3c2d12" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb1b6031-1581-48ec-81d7-3469cb71dbc7" contextRef="C_4b7bb28a-5cbc-497a-b670-2377da981ce9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,003,685</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e972a03-c4d8-43d9-a7f7-eb8c135fa5e9" contextRef="C_2cebc1d1-94ac-454e-86c1-67082e75afe2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e42f340c-7cde-456e-907d-bb404fcc7fc3" contextRef="C_3465210b-00bd-416d-9ded-e8a899b86e31" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">710,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1051a4b8-8c16-4664-880b-a63f24c422a4" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,105</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nts of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:71.946%;box-sizing:content-box;"/>
    <td style="width:1.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.858%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.318%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e14311b-82e5-4c37-ad37-59710fa4a55e" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_807d77da-0315-4a68-acb0-681d6c5a3982" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,237</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0db5f48-bfac-4495-9dfe-0679882d5be6" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,150</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cae93b2-1303-46e6-b949-0ec2e2a698ff" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,148</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount on available-for-sale securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_389b0fc5-c6c9-40de-9820-867b70c7882c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,054</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e25a8598-9708-4049-a510-10f26e791639" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,550</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8b64731-0f32-4b2e-8cf9-c6f62aa10a3a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,433</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0e95d94-d5b2-47d6-9a17-d9c1c71f2f25" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,183</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of right-of-use assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a02ee992-0f96-4222-a565-4c9e88af468b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,304</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aba9a59a-8a9e-4266-b603-7b0dffadbd0d" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,119</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:20pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db6b26b7-7b60-4eaf-8265-ac2672b47340" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eeaa69b-cb91-44ed-a66b-e0f3ce210497" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,352</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cceb94b8-7e42-4fc4-8173-41da5cccc54e" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,184</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca082264-ab55-469a-bd3f-87ded9787604" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,936</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baced14b-6874-497a-88cd-3badea799190" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,077</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91419271-d8f0-4156-8868-03ca631b7fdc" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,292</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9337f4d-72d7-4704-bb5c-32775fc7057f" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,577</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d165b461-0686-4833-8d6e-872ed622e098" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,383</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a8a6d3-a679-4fa6-8714-c3b285a94018" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="annx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,503</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:40pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:40pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_664d879b-9e00-456e-8ed5-80a4757a0ad2" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,006</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d044746b-7e00-427e-b7d3-e34ece58b7c2" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,142</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5caccc5c-46ae-45e3-8217-324727de4abb" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73329250-9766-455a-b1cc-aebcc684aca0" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of available-for-sale securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee873427-eada-4977-b7ac-77c60109f613" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">583,932</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4582aa62-5358-47df-8c43-52f9384c511c" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of available-for-sale securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec9423c6-e1d8-447d-a083-f8ab5af3796d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">365,150</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94b98171-9525-4b3f-832b-9ec6ac9f1a1e" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,984</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9547e1e4-9375-4a4f-b30d-15b47f742c0c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">218,797</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3961dc7-11a2-45ad-9589-8fe879dc8ebf" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,703</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the exercise of common stock options</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9376254-f286-413d-bcb0-44ea8058d66a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,232</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac1be757-2659-4c78-ab79-4a54b7b7cf3d" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from Employee Stock Purchase Plan purchases</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc17797-ff69-4b64-86a7-a85e9053856d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ce4c2f7-2620-4d09-ae46-91de476c1fe7" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock, including to related parties, of </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44a3e1da-a4ba-4101-87ec-0e342c455978" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;and <br/>&#160;&#160;&#160;&#160;&#160;$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ce2a340-4838-41b2-b3d5-db4c1199e711" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="annx:ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,995</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;for the years ended December 31, 2024 and 2023, respectively</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef80834f-fb0d-4326-b77f-f229b852bc89" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,371</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_442dc7fa-c3ec-4bf0-be1b-92397c8183c2" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,995</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock and pre-funded warrants, net of commissions</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01310d58-9f46-4c38-ab8a-d1cf1f6105ff" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6f23df4-cd68-4375-8d0b-80a09b209c9d" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="annx:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,515</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of financing costs</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e253398f-fa68-4043-ab3e-6b70c053ae87" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,259</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75c39459-72e0-4890-b264-42d453a85c5a" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">555</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_847bde6b-6813-4318-abe4-5340d3960581" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,206</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec3aa151-1dca-4c64-b3c2-297f2b98e8df" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,524</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_531d6b59-25cf-45b9-b782-03ae50293e3c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">175,597</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff84cf55-8cd5-4676-8785-6715fe2d04c9" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,085</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52e7388b-cbc2-4a03-bf72-5c14eb9a2c4d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caf14948-80ac-4c70-92a0-778f0f6c4fc0" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning of period</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b70f1cd3-04d4-443d-8b44-badaec88c40c" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,142</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33a121e8-fea1-44f3-a846-793222f71912" contextRef="C_a2b98230-0f7a-4d29-8918-901b611f045a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,052</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">End of period</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18e29ff1-e7a1-4d55-b9fe-d4a3c0c7f97f" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,530</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b6d05ab-1261-43fb-afb0-099651ea81df" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,142</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8336b2cf-bce5-4ea6-ab7e-638fd41694d3" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,893</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c4dbc07-38a1-4aa3-a467-46a60ceb17a5" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="annx:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,728</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred offering costs included in accounts payable and accrued liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b155cdba-0e26-4443-ba6a-5d7278ccaba6" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5c7698e-d4ef-455b-a033-c32822993844" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred offering costs included in other non-current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6c9c730-e6c2-42b9-8fe9-1acd50728aa2" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:DeferredOfferingCostsIncludedInOtherNonCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment included in accounts payable and accrued liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_856703f5-8725-436b-915c-ddd763f4c335" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annexon, Inc., or the Company, is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for people living with devasting inflammatory-related diseases. The Company is located in Brisbane, California and was incorporated in Delaware in March 2011.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s wholly-owned subsidiary, Annexon Biosciences Australia Pty Ltd, or the Subsidiary, is a proprietary limited company incorporated in 2016 and domiciled in Australia.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, the Company has been involved primarily in performing research and development activities, conducting clinical trials, hiring personnel, and raising capital to support and expand these activities. The Company has experienced losses and negative cash flows from operations since its inception and, as of December 31, 2024, had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4455e1be-45d3-4e3f-8d28-55da51b89325" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">710.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash and cash equivalents and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1abe14d3-350d-4f82-a9a8-d67d1bd4bded" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">312.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically funded its operations through the issuance of shares of its common stock and warrants. Based on projected activities, management projects that existing cash and cash equivalents and short-term investments will enable the Company to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements. The Company&#8217;s future viability beyond that point is dependent on its ability to achieve development milestones and obtain additional funding. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years. There are uncertainties associated with the Company&#8217;s ability to (1) obtain additional equity or debt financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs and its business could be materially harmed.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a764e5bc-5ca5-46ca-b7e2-57f870702cd4" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. Management evaluates its estimates, including but not limited to the fair value of investments, operating lease right-of-use assets and liabilities, valuation of deferred tax assets and uncertain tax positions (including valuation allowance), clinical trial accruals and stock-based compensation. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f4fbd6b-ee69-4251-afa5-57108980c7d6" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the operations of Annexon, Inc. and its wholly owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6adeb2ae-7c35-4d2a-bcd5-38065b3ec71e" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s chief operating decision maker ("CODM") is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40714774-becc-4926-babb-4bc354af7e2d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d_1" continuedAt="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11a12486-a283-4423-837d-cde06b52eb85" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">considers</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds and short-term government bonds, are stated at fair value.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash as of December 31, 2024 relates to the letters of credit established for the Company&#8217;s office lease.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_caef5fbe-ac32-4ee2-961a-deddad2eb899" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bad1f977-62c4-4c0c-ba76-0cf77eb18063" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,651</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_457ddef2-6b85-42b1-a69b-5ffc5b4051c5" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,488</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e1d0fea-154f-4db7-93cd-3c29f5a90eef" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,847</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13d57518-8a1c-41df-8acd-2cb13e5582a3" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,622</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_008efe2c-d085-4222-912b-4e012b8c535d" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,498</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c754fd13-1dbe-47a0-a77a-53d8d1b6d8a1" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225,110</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce5b6f1f-dde2-4a11-99a4-d44b97e3c165" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,032</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4d0a5ac-f8f5-49f7-bb46-089e502c1714" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,032</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d3bf3af-7edf-4652-8c96-ae99e68e1696" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,530</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd75b62d-875f-4269-a46b-01a61a2a7bad" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,142</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b9351a0-4e2b-41da-a0c3-e3d89b6e6cef" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:ShortTermInvestmentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short-Term Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security&#8217;s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of investments sold is based on the specific-identification method. Interest on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available-for-sale debt</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities is included in interest and other income (expense), net.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_d99428cd-0ae7-4c29-a905-57626bcd195c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_d99428cd-0ae7-4c29-a905-57626bcd195c_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation begins at the time the asset is placed in service. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d_2" continuedAt="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d_3"><div><ix:continuation id="F_d99428cd-0ae7-4c29-a905-57626bcd195c_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b848835-c3c5-4d46-8ab5-a5138a807d84" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" escape="true" continuedAt="F_1b848835-c3c5-4d46-8ab5-a5138a807d84_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The useful lives of the property and equipment are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:39.588%;box-sizing:content-box;"/>
          <td style="width:2.06%;box-sizing:content-box;"/>
          <td style="width:58.352%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_d0ffe231-adca-44b9-b502-b2db4c2c4c68" contextRef="C_c060d1ca-b9cb-4849-9fbb-3cadae61b6dd" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment and furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_2b099106-31f6-4c17-ad8f-cd63068f5d37" contextRef="C_4972a734-b0dc-409d-bf12-d162a67e116d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8f39b772-731f-41b9-9d02-0d66e7276fae;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Shorter of remaining lease term or estimated useful life</span></span></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_1b848835-c3c5-4d46-8ab5-a5138a807d84_1"></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19509c4d-2f7b-450f-a995-c16c4a346e99" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. When indications of impairment are present and the estimated undiscounted future cash flows from the use of these assets is less than the assets&#8217; carrying value, the related assets will be written down to fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd43d0b3-e931-4c1c-b938-d1ff65659eff" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairments of the Company&#8217;s long-lived assets for the periods presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7dfc5ebe-adc4-45fa-8e51-bb9cd393bf73" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. The Company includes operating leases in operating lease right of use, or ROU, assets, current and noncurrent operating lease liabilities in the Company&#8217;s consolidated balance sheets. The ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company measures the ROU assets based on the associated lease liabilities adjusted for any lease incentives such as tenant improvement allowances. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the commencement date. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Lease expense for lease payments is recognized on a straight-line basis, net of sublease income, over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a practical expedient, the Company elected, for all facility leases, not to separate non-lease components from lease components and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1cf399b9-63d9-46a2-823f-c9fecaa8c8ba" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred taxes to the amounts expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merit, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d_3" continuedAt="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd36dbd7-95e4-493a-9898-2dcffe907de2" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liabilities</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e67a10aa-1e0b-4c85-abb7-c40d3b74c950" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:WarrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company&#8217;s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba1106f0-839f-456f-b6ba-a3f72d8f7a4f" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company&#8217;s product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company&#8217;s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company&#8217;s behalf; (iii) contract manufacturing costs to produce clinical trial materials </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and commercial materials to support future biologics license applications ("BLA") to the FDA,</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation), (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf. The Company also estimates manufacturing costs based on services performed pursuant to contracts with contract manufacturing organizations that develop and manufacture product on the Company&#8217;s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company&#8217;s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_5216a2dd-5141-4cb8-a286-62c55e76c9ad" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_5216a2dd-5141-4cb8-a286-62c55e76c9ad_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employees on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation costs are based on the fair value of the underlying RSUs and options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d_4"><div><ix:continuation id="F_5216a2dd-5141-4cb8-a286-62c55e76c9ad_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Determining the appropriate fair value model and related assumptions requires judgment, including estimating expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_236bf767-f884-4426-adeb-1db72c1ec220" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share because the effects of potentially dilutive securities are antidilutive.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_278caac8-5e5e-4bd8-9a13-70bc7aa48f07" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company&#8217;s cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Management </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5f7d80b-71ae-4fd5-8d0d-681e0d937573" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting: Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e708c463-a6f5-4070-995f-8212ad363af7" contextRef="C_099f9f27-8db7-4796-925e-5a5030924004" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annual and interim requirements under ASU 2023-07 on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60a9d72b-2d7b-42b4-a665-3b62d3a8d6e5" contextRef="C_099f9f27-8db7-4796-925e-5a5030924004" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2025, respectively. The adoption of ASU 2023-07 did </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12ab1f43-a8b9-4717-8b6c-a73dcd74ff26" contextRef="C_099f9f27-8db7-4796-925e-5a5030924004" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company's consolidated financial statements. See Note 10</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes: Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_96820730-adfa-4be2-8877-58be150769d7" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_96820730-adfa-4be2-8877-58be150769d7_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1 Inputs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2 Inputs: </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than quoted prices included in Level 1 inputs that are observable for the asset or </span></div></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_96820730-adfa-4be2-8877-58be150769d7_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3 Inputs: </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On a recurring basis, the Company measures certain financial assets and liabilities at fair value. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9979e7c2-98f4-42af-be2a-fa21839f6c39" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_9979e7c2-98f4-42af-be2a-fa21839f6c39_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_9979e7c2-98f4-42af-be2a-fa21839f6c39_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.467%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:9.946%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.946999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.946999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.946999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.946999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42c83ace-e63f-443b-bf1a-510865a9a35d" contextRef="C_3869c6ca-09db-441d-8246-9d11c931b28c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,680</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34450094-d0d5-45e4-962f-4ba2f1f1c62f" contextRef="C_3869c6ca-09db-441d-8246-9d11c931b28c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,680</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c23c83d3-20fa-4e77-8062-ebdc3cefa83f" contextRef="C_a0b71661-aa15-48ab-9fd1-0c1f5bd8eb06" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9b8a003-06e9-473b-b2e2-d554ef324a83" contextRef="C_a0b71661-aa15-48ab-9fd1-0c1f5bd8eb06" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_755a1718-5a9e-497f-b134-17f2e3e14bcc" contextRef="C_7968ae91-6275-4ca5-8e22-5c0bb5f5da6b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88203657-07cb-4fef-bae5-5d99d36f1bac" contextRef="C_7968ae91-6275-4ca5-8e22-5c0bb5f5da6b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b01bebda-2b23-4951-a063-c53b85b258b7" contextRef="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,424</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71d8fb6c-411b-4e15-8783-6b75e8799412" contextRef="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc889726-87d9-4a1c-917b-7669e9825415" contextRef="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76392b20-5402-4086-90d6-21dba554e443" contextRef="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,519</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f400186-931c-4652-ad83-2ec1e4b40e14" contextRef="C_5525b019-e48a-443f-8f6c-bc589e834f80" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,424</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b570f87c-26c6-4a14-913d-1b1211eebb35" contextRef="C_5525b019-e48a-443f-8f6c-bc589e834f80" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abd226a1-0909-42ad-a2b6-6a905079de7e" contextRef="C_5525b019-e48a-443f-8f6c-bc589e834f80" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1179b7e-140b-4a2d-aaaf-772a0e8d4205" contextRef="C_5525b019-e48a-443f-8f6c-bc589e834f80" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,519</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9046cd6f-b77a-4417-8c3b-32532b32d67f" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">309,271</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b130c13f-765c-4d1e-9749-9f85d01e8120" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30b63b7b-9277-4459-8be7-99dae275cf9f" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab8c764c-daad-4283-a17a-755b40de7d22" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">309,366</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.467%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:9.946%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.946999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.946999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.946999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.946999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f8cb448-4ea6-4fec-8311-9bba12bb2ea5" contextRef="C_9b5d4612-62c8-4e9e-9732-fb24b3fc9113" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,933</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90aaed36-f359-440c-82d8-1dcbbd51dec6" contextRef="C_9b5d4612-62c8-4e9e-9732-fb24b3fc9113" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,933</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc73e361-f6b2-4c76-a2bf-eb9ac45bd1a8" contextRef="C_bbc49f27-1c6e-406e-a095-7623fd68f696" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e867adf4-485b-419a-b1ba-0272a48a14be" contextRef="C_bbc49f27-1c6e-406e-a095-7623fd68f696" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88fb2c23-1417-462a-8e96-5ceafde703d6" contextRef="C_ac099453-0c31-4ead-a71c-3537f6410632" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,622</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6830948-abea-4460-b795-2f773f86518e" contextRef="C_ac099453-0c31-4ead-a71c-3537f6410632" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,622</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f910a9d-541e-4cc4-89b4-4c7ddd047bd5" contextRef="C_49a7915e-73e3-40e2-8989-6689fbe67430" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,596</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92705a4a-bff4-4ae6-ae88-36cc89674f6a" contextRef="C_49a7915e-73e3-40e2-8989-6689fbe67430" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbec40c1-1597-472d-ab8e-f4d60657729e" contextRef="C_49a7915e-73e3-40e2-8989-6689fbe67430" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,606</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_642a1dd4-0574-4b33-9307-c0adb2c5acfe" contextRef="C_dddec901-694e-4786-914e-180bcc77bb3d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,596</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84490b32-0f95-4cc2-a619-76e2db939a5d" contextRef="C_dddec901-694e-4786-914e-180bcc77bb3d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e4e80bd-7ca7-4fc4-b8ef-07bf776c3e03" contextRef="C_dddec901-694e-4786-914e-180bcc77bb3d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,606</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f98e7b2-0e47-4eed-b99e-902af6736f01" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,218</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fe6858c-4f21-460b-b0c8-e932d696d6c8" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_893d7274-9688-4ce3-bb88-a699d174a7cf" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,228</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the investments held as of December 31, 2024 had original maturities of less than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcded90e-f255-4b5a-8e84-124079da140b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:InvestmentMaturityPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, all of the investments are scheduled to mature in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28b74be2-1201-415a-810c-033a93a858ca" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:InvestmentExpectedMaturityPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af02f18a-220e-4c29-9661-3955cd0a4257" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any credit losses. The Company determined that the decline in fair value of debt securities was not due to credit-related factors, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12f6b07b-6f2e-4dbe-a523-d63f330cb4c9" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for expected credit losses was recorded as of December 31, 2024. There were nominal unrealized losses as of December 31, 2024, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f49c1dbd-2f16-4c34-b8f7-851794a612ca" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrealized losses have been in the loss position for more than 12 months. However, the Company is planning to hold these securities until maturity and expects to recover the amortized cost basis.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the Company recognized no material realized gains or losses on financial instruments.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a5d719a-931b-4a12-a36d-645da70201d9" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:BalanceSheetComponentsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheet Components</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_669d19e4-d08e-4127-849a-0afeb41bb1fb" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8d1de93-c956-457a-b49e-68d80c320981" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:PrepaidResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,640</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14fd8f5d-d586-4c28-aa40-7dc076064cb6" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:PrepaidResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,617</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e7a0e2b-cb98-4d8a-bffa-160b56f3da39" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">700</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceff6129-72f7-42b2-9415-913d79168df9" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid and other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f2a9b60-ce7a-40b0-a9e8-f03a42184e3c" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:PrepaidAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,104</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bab88fc3-7453-43fe-b2eb-8a2987f745e5" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:PrepaidAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">823</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f6fb076-e9ba-47de-90f5-6fee1602a367" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,444</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c171fcab-f698-453c-8aa4-8a42125b41bd" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3401bfe2-abd4-49e9-b6cb-7ca20541395a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50ea9219-e324-4ae9-8a09-43ff05177f65" contextRef="C_1cc25f78-dbe3-41a1-b7d8-90bfc1df6bd1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,254</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9289f343-a986-4def-9f84-c8fa6c9b6483" contextRef="C_17ade79a-934b-4095-8b9f-770d560529d3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,245</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b49c089-18e8-4d46-a2fb-75f58f4e4b61" contextRef="C_4972a734-b0dc-409d-bf12-d162a67e116d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,838</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0991565d-8a00-4c07-bebc-cccd73829f6f" contextRef="C_a6321396-4c80-49a4-a286-91e5bcfaf1eb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,832</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c8ddd7f-6d22-4dea-a671-0598fb81ff22" contextRef="C_547ea12c-5672-44e1-81bd-5c04ecd20f79" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2793356f-3e1a-4818-b40d-b84bbd866cff" contextRef="C_95063796-51a0-4a4f-80df-7a8de33bf4a0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56fb0ac8-93db-46f7-8920-0202171e8a12" contextRef="C_e330e31d-eab9-4389-8fa9-bef76e997d23" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d86b57b3-b653-4d92-8739-129c8a7af50f" contextRef="C_b1f5099c-e23a-49a6-8643-c8f3e583dd88" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8d8a669-3b85-4148-818a-05283536b6d0" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,817</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_402af775-ed30-41ec-b12e-1f20cf823917" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,802</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a098861f-9aa5-4916-9a83-73a8687e4009" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,179</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fa44d05-5413-4477-a820-d571e69d29ae" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,029</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50b35936-4f04-4b0e-a5e6-a1d1a3bd645c" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,638</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b65982c-8ecd-434c-93bf-52f3390470f8" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,773</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total depreciation expense recognized for the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_1fe8fe9d-575a-458b-9bd9-f30950571440" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8baefc43-4053-4d2d-9899-378226fbade8" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued and Other Current Liabilities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20cfeb8f-1517-43df-aa1b-a2f0543f309a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da2d7534-3df0-4be1-8104-65ed86c73e0c" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,992</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_666265a5-205b-4195-ba64-f881a416d797" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,027</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fc2871e-2ef0-4612-8540-1cf8c9b33966" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:AccruedCompensationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,833</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_066cd703-d962-49d9-97b9-b99152b5e2a4" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:AccruedCompensationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,607</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50a4be4e-d322-42e9-92d1-67cec7dd34f2" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">602</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f233509a-5d6a-462e-9ebd-7dde2d54579c" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued and current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2deb1cbc-dc51-4703-bf8b-a613b59c9a9b" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf7c3cd0-b689-449e-af1c-b67c21524f5c" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33d4a004-3ca1-4072-8555-17cadee2aae4" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:AccruedAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,568</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f24ecf8-59b6-410c-92f6-3f50f382fb6c" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:AccruedAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,276</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_b9f504da-e84b-4b78-a868-5480fd8d5da2" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_b9f504da-e84b-4b78-a868-5480fd8d5da2_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases its offices and laboratory in Brisbane, California, or the Brisbane Lease, under a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c8eda20-4b15-4ce7-b31a-d07f18ac46b0" contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">noncancelable lease agreement that ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cf3aff0-152e-471b-9049-198750f34bee" contextRef="C_855b89a1-84bd-4934-adb2-47fa9352df11" name="annx:LesseeOperatingLeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4e5b14c-d9e5-4fe0-aa88-a65ee0b45fd9" contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> renewable option. In November 2021, the Company subleased unoccupied space for two years from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f7db2ed-f4c9-4afb-9a25-86f54b4e6f30" contextRef="C_301be3cb-1afb-480f-886a-93603e1ae4a3" name="annx:LesseeOperatingSubleaseCommencementYearAndMonth" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abd40b88-829a-4af5-ac75-1f3fcaaab710" contextRef="C_301be3cb-1afb-480f-886a-93603e1ae4a3" name="annx:LesseeOperatingSubleaseExpirationYearAndMonth" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for aggregate sublease payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f884ac61-bedd-4d02-9bf5-050b0cd4fd2f" contextRef="C_e30eb803-2850-45ea-964d-0c167ebab98b" name="annx:AggregateSubleasePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The sublease income, while it reduces the rent expense, is not considered in the value of the right-of-use assets or lease liabilities. The Company&#8217;s sublease income was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_724e5d3a-8cd0-4344-9cfc-ce14a9644e4f" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a19dac1-3aed-4ade-b184-59dad418bd17" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the operating lease right-of-use assets were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_35491445-dc71-453c-82a5-7be13ebee216" contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and lease liabilities were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_258bed3f-f088-4bcb-a000-8c1d398fc27d" contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the consolidated balance sheet. The weighted average remaining lease term is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa27df6c-1f0d-4700-b804-2ac3d4485715" contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b9f504da-e84b-4b78-a868-5480fd8d5da2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average incremental borrowing rate used to measure the operating lease liability is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fd627d1-acf5-472b-b6f3-c76cc59ac40a" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease cost for the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f7ac965a-45a9-4266-9f0f-dca757cfa96b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94edd66a-bb7e-4179-9c87-fbd291924ea5" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Variable lease payments for the years ended December 31, 2024 and 2023 were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_a2bbaf05-8c53-463a-bbee-10b88089dde7" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:VariableLeasePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ec128c6-0ed4-4529-bba2-e7a85c981609" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:VariableLeasePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bd54cfe-1b5e-475f-9a04-556ca729ed41" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments and related lease liabilities as of December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;box-sizing:content-box;"/>
        <td style="width:2.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c82f908-5810-440b-a9ab-f381575f4022" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,065</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eec894d0-c842-4501-9dcf-e6bf6afc801d" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,242</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85cfbf50-1f60-4465-a974-646264838f07" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,425</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3edeaaa-02d2-4326-9f1b-534c9f839cd6" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,615</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43fbf499-f4c1-4f9a-90d9-f924724f08f8" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,985</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba2af39d-255c-40b3-b8a1-3334c64a2e5e" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,332</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49a01ec8-87d2-4cf0-b975-0836379719ac" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,360</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3876341-3f9e-4602-b840-db23458b8e45" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,972</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantees and Indemnifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b9e3a29-d057-4f47-831e-82327f8fe72e" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t paid any claims or been required to defend any action related to its indemnification obligations. As of December 31, 2024, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77cfbaf5-5bd9-4385-bf77-14c0e36fab4c" contextRef="C_072050e6-df46-49a7-bd7c-e1422281108a" name="us-gaap:LossContingencyPendingClaimsNumber" unitRef="U_Claim" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_f7838c5f-dd9b-4b79-998c-d867ec1687c5" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_f7838c5f-dd9b-4b79-998c-d867ec1687c5_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders' Equity </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Financing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 2024, the Company raised net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8778f2e0-8f8d-4041-b46a-8582dbf158ad" contextRef="C_5b853485-b4de-4aef-8684-04438a8b004d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">116.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting underwriting discounts and offering expenses through the sale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ede82fb0-f560-4c66-86de-721ab7db21b6" contextRef="C_5b853485-b4de-4aef-8684-04438a8b004d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,001,120</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0781ff8d-8091-4954-9d22-55a4ea89227c" contextRef="C_3e3b68fc-a6f3-457c-8152-64fa99e75d60" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d7100d3-222e-4659-b4fe-8c9c1b442cde" contextRef="C_3e3b68fc-a6f3-457c-8152-64fa99e75d60" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and pre-funded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af251dc5-3622-4ba1-b418-645f60685d65" contextRef="C_8472ac84-55e5-434a-90d4-c7f9d7aa4437" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08f17ee0-29b6-4c9f-8fad-c20cd199ac75" contextRef="C_3d6b212d-b7a8-4e3f-bfeb-dc2b3be0b024" name="annx:OfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">6.249</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which equals the per share offering price for the shares of common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08f5a8c3-3861-4f9f-b6f9-cbe4673abb9f" contextRef="C_27512148-cc01-4328-b869-9d09fda6ba2d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each pre-funded warrant. The pre-funded warrants are immediately exercisable, subject to certain beneficial ownership limitations. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#8217; equity within additional paid-in capital.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Financing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Company raised net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b03fa6c0-e7cb-4b11-874b-312acbe577f2" contextRef="C_9ae8f66d-5240-4728-81a8-25950cb83964" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">117.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting underwriting discounts and offering expenses through the sale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e30662e8-d606-4331-97e8-dd29770c6ec4" contextRef="C_9ae8f66d-5240-4728-81a8-25950cb83964" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,035,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dddfe3c-c9ee-4cf9-90bf-55e982833470" contextRef="C_4d34fdbe-9026-4710-920e-640cc4668c81" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7988add-1c84-4e80-bbe1-b42f8d5e0235" contextRef="C_4d34fdbe-9026-4710-920e-640cc4668c81" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.880</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and pre-funded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f106f6e3-23ac-49da-bcf6-bb6366a04f70" contextRef="C_ab735fa4-b8ce-4204-bd13-e3e5137bced9" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,379,861</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15cb8cb4-0d0a-41da-b56f-59e0225a2e34" contextRef="C_571d253c-4271-4944-954f-09fa5121f2db" name="annx:OfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.879</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which equals the per share offering price for the shares of common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c6292bb-15cf-453f-a823-64caa984a672" contextRef="C_55a285e5-5315-412c-bf43-8041cddc34bc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each pre-funded warrant. An entity related to one of the Company&#8217;s directors participated in the public offering and purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1b5a06d-c99c-4909-a175-2bc2c2ff8885" contextRef="C_a89b88c0-ec52-4b3d-8aa8-2fcdcacd2667" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for an aggregate price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5598ac35-ddbb-47b4-9e37-b258a539cdb3" contextRef="C_9ae8f66d-5240-4728-81a8-25950cb83964" name="annx:CommonSharesExchangeValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#8217; equity within additional paid-in capital. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2af01a1-2480-43cd-afe0-5ad3debd9f12" contextRef="C_08392b92-b47a-463c-9c19-05c9de02b962" name="annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,243,400</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee576a69-1dae-46a2-a724-59b8a50d1363" contextRef="C_c1fa55bb-8cda-41f2-be10-9c4b61733d56" name="annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">965,427</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the cashless and cash exercise of these pre-funded warrants in February 2024 and April 2024, respectively.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f7838c5f-dd9b-4b79-998c-d867ec1687c5_1" continuedAt="F_f7838c5f-dd9b-4b79-998c-d867ec1687c5_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Financing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, the Company raised net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c59b2e01-741b-4218-b56b-e67e76318ebd" contextRef="C_262315fc-5a70-4273-9329-a8573c6e8ac6" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">122.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting fees and expenses through the sale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69bc3e36-3f93-417f-8308-2aafa259e885" contextRef="C_7d9aed7f-6bbe-4caa-a2eb-d48056481199" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,013,834</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, pre-funded warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a5fb63b-f71d-4051-bdc9-3dbe1ccbe9c8" contextRef="C_de537ec6-325e-4910-8f4c-21e257afbcae" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,696,206</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock and accompanying common warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0e4c1a3-8b1c-4dc3-ac17-caf193820d84" contextRef="C_d579d761-816c-4e55-92d6-ce372f29566a" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,427,508</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock. The offering price per share and accompanying common warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07139a8a-633c-411c-b396-6faaf4bfbbb1" contextRef="C_c86633a7-f190-4e56-90c2-b45ffb2a2fec" name="annx:OfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:num-dot-decimal">3.87125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the offering price per pre-funded warrant and accompanying common warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cb9dbc8-7f3f-4154-a2e8-b399f7be0dbe" contextRef="C_14a08883-0225-4ca1-b9a6-4b86b0937620" name="annx:OfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:num-dot-decimal">3.87025</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which equals the per share offering price for the shares of common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca69e110-15f7-47ee-8297-d9549a6c35bb" contextRef="C_de537ec6-325e-4910-8f4c-21e257afbcae" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each such pre-funded warrant. The pre-funded warrants remain exercisable until exercised in full. The common warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f70ce75b-dbc5-4018-8d9e-269ddda41a88" contextRef="C_4b7c8434-c7e2-4ff2-b583-26501f87a512" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="6" format="ixt:num-dot-decimal">5.806875</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1eaea120-5511-4744-9ee1-3eb47b30f8cd" contextRef="C_4b7c8434-c7e2-4ff2-b583-26501f87a512" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Both the pre-funded and common warrants are immediately exercisable, subject to beneficial ownership limitations. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#8217; equity within additional paid-in capital. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_271e8ebd-f596-4992-8ab8-cb33950fad0d" contextRef="C_f9d86972-6bef-4c53-8764-f295400423e9" name="annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,582,557</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the cashless exercise of the pre-funded warrants in March 2023. The Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84d16830-04c4-4fe5-8b29-4fbb1e8a931f" contextRef="C_cdc4c27d-b376-4374-8ee1-613abe059850" name="annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,901</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eba047f-2f27-4a7a-a426-edd2b226847e" contextRef="C_95335bc0-36c3-45f2-998d-639cb78b1f47" name="annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,739,096</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the cashless exercise of the common warrants and pre-funded warrants in June 2024 and November 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Funded and Common Warrants</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d50ea72f-39a7-4652-a5ae-e8056662fdde" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes warrant activity during the years ended December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.9%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:20.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Common Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f4047f7-b579-4b19-a151-32825834483c" contextRef="C_ec22ff7d-ccec-45fd-a10c-766baaf42b25" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,427,508</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35a5cdcd-8eef-47e9-b1f2-05c81b8518ba" contextRef="C_b058d9ba-58ce-4e56-a243-4df02901e4e2" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">24,696,206</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e8db9ee-476d-4111-b2b3-ff7a04f8e4fb" contextRef="C_0b957594-7615-4933-9789-94cb54dc8638" name="annx:ClassOfWarrantOrRightIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,379,861</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69152487-6cd2-4315-8d70-9b370620d22f" contextRef="C_32785c93-aaca-43fa-a248-cb24bd9882bf" name="annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8172069-daef-44af-81a0-1ee6b1e06dc5" contextRef="C_0b957594-7615-4933-9789-94cb54dc8638" name="annx:ClassOfWarrantOrRightExcercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,583,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1618251-33c8-4aed-ba07-f6fdd61f71b4" contextRef="C_32785c93-aaca-43fa-a248-cb24bd9882bf" name="annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83625211-1ff4-47aa-a272-5041c7de599e" contextRef="C_ae76d731-12db-4f4c-9bcd-ade6fdbeaa43" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,427,508</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7f524e5-1050-48ee-a924-d18284119416" contextRef="C_ab735fa4-b8ce-4204-bd13-e3e5137bced9" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,492,923</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbf33fa1-182a-44c8-9181-569f942b2614" contextRef="C_d39e2be4-3f00-449f-bea4-e4669b559cd6" name="annx:ClassOfWarrantOrRightIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,000,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaa8c140-eaff-4b37-a21b-89ab330e2967" contextRef="C_8e8bc1e1-c0eb-4e34-a2ff-e496756a8fca" name="annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c94859f-cbd3-43de-8f12-1632833f91ce" contextRef="C_2ba532e7-e440-42d5-911c-cf6ce266687f" name="annx:ClassOfWarrantOrRightExcercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">322,893</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bf0637f-528e-4f5d-805b-b7727c4d717c" contextRef="C_d39e2be4-3f00-449f-bea4-e4669b559cd6" name="annx:ClassOfWarrantOrRightExcercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,949,346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08afd25d-e697-487e-b5d2-348cdac66424" contextRef="C_8e8bc1e1-c0eb-4e34-a2ff-e496756a8fca" name="annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.216</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46f8bcd8-5780-4812-a59b-e7e8ccb576b9" contextRef="C_b64c79b4-fe65-47cc-bb5d-7ddb0490610e" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,104,615</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_403399be-b664-4ef7-8f1a-310390095a9a" contextRef="C_816a75eb-eeac-444c-b1ad-06f15723b3de" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">38,543,577</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 At-the-Market ("ATM") Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into a sales agreement with TD Cowen, as sales agent, or 2024 ATM program, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43617fae-24fe-4bed-a40a-92393d890b9b" contextRef="C_e671e012-c921-435e-938c-d68a826109d9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. TD Cowen </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is entitled to compensation up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9464273-3b5e-4cef-bb50-7620a417421e" contextRef="C_bc70ca19-dd4e-484a-9840-e8e349d6ed16" name="annx:PercentageOfGrossProceedsOfCommonStockToBePaid" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross proceeds for the common stock sold through the 2024 ATM program. During the year ended December 31, 2024, t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8e9d654-6f9e-4649-9b29-b79322e8c211" contextRef="C_b7464154-5bfb-48e8-b9ee-4421be6a566c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_321d5b4b-397e-4143-9e5f-8e3e72ebd86f" contextRef="C_b7464154-5bfb-48e8-b9ee-4421be6a566c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting commissions paid to TD Cowen. As of December 31, 2024, approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d3071fc-ea1f-45ec-ad8c-4f0a9f1522b4" contextRef="C_06a73ed8-fa35-4a8b-9584-91fdd26d518e" name="annx:RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">95.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million remained available for the offer and sales of shares of common stock under the 2024 ATM program.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 ATM Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2021, the Company entered into a sales agreement with TD Cowen as sales agent, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b5d93f9-38da-4a99-bc51-b06f2fa28ab4" contextRef="C_7b518a40-52a6-4973-869c-448436c41106" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under an at-the-market offering program, or 2021 ATM program. TD Cowen is entitled to compensation up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fba75845-16e7-4167-8d6d-a12a56644905" contextRef="C_ed0ef5bd-d7b5-41fd-bc14-c386fcc1efd8" name="annx:PercentageOfGrossProceedsOfCommonStockToBePaid" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross proceeds for the common stock sold through the 2021 ATM program. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db2b8737-f9b8-433d-b000-eaf171ddafd4" contextRef="C_d22db712-c793-4143-97f9-0b1afeba048b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,576,067</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_700e2606-dbba-44e5-ab6f-98acbc0b7a78" contextRef="C_6f5f0013-61b6-4736-b7e9-a7f934312508" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,646,458</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, respectively, under the 2021 ATM program for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a639960-226a-487e-9381-ad7664e92620" contextRef="C_c9766150-3460-412e-b465-7535db7a6402" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26216e7f-0d31-41f0-bf5a-90c672747337" contextRef="C_948f2da9-09b8-4835-b79f-9b108878b9f6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting commissions paid to TD Cowen and other financing costs. The Form S-3 registration statement, which registered the 2021 ATM Program, expired on August 15, 2024. As a result, no further shares of common stock may be sold under the 2021 ATM Program.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f7838c5f-dd9b-4b79-998c-d867ec1687c5_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ed4fe06-ebc0-4195-b39a-ac0ab3a27d1b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the Company&#8217;s common stock have one vote for each share of common stock.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common stockholders are entitled to dividends when, as, and if declared by the board of directors. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd7558dc-90c4-422e-9cfe-de8b70f77dc3" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:CommonStockDividendsPerShareDeclared" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends had been declared by the board of directors.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_707dcfe7-db2a-4746-8d97-3a93194a0962" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" escape="true" continuedAt="F_707dcfe7-db2a-4746-8d97-3a93194a0962_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock for issuance as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.089%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.676%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.676%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3d4a1f6-6526-451b-abda-2d1b0c1d3f42" contextRef="C_29782950-7a96-4afe-b123-68b6a1a44a9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,594,720</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_541ad21a-c4ef-4ffd-abcf-73d584c9d8a3" contextRef="C_3a117edd-79b6-42cf-bde0-58487b0502bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,208,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options reserved for 2020 Incentive Award Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4e67c84-c864-48e1-90a1-4eba671b49ca" contextRef="C_e5457637-3c61-492e-b073-b90232effb2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,109,758</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f67bc5a8-0f89-432e-8231-0857cd1a626a" contextRef="C_2c4873ea-60ed-4c68-a1a0-60c57456e3bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,988,340</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_374bc597-4ee5-4e56-bb5d-e2497cbba19d" contextRef="C_66179d4e-f740-4656-9e26-82ac3de679ad" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">770,028</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_876b7c79-4615-4340-b887-c01cd9a0d9da" contextRef="C_a59b470f-7ad8-4b6e-a84a-dddba145a948" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">495,579</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2021 ATM program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_165995a6-bfb1-4969-a62f-f0a077df835f" contextRef="C_ce377faf-e56d-4d57-9149-325ff3298695" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,619,471</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2024 ATM program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca09e562-3663-4f5f-abe3-e0f8a1ca2a3e" contextRef="C_07f46682-ea8e-47fe-a18f-70b0bb1a100b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,250,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d8e1c1f-e617-4e0e-ad30-8e041a73b880" contextRef="C_95493879-152b-4afb-9460-55860ac0385d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,983,924</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d382441-3ddd-402d-86e8-58ee22a2ba6a" contextRef="C_e9fbcf92-912d-427d-ae6e-83428851302a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,338,381</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2022 Employment Inducement <br/>&#160;&#160;&#160;&#160;Award Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dabd0d83-c474-4843-8875-2631dd78aa4f" contextRef="C_a8a555d1-c90f-4f9c-959d-6220a378be31" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,359,230</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecdad73d-722c-4b81-9a39-ee4cca56f06d" contextRef="C_bf13cefb-5813-466c-a528-52377f64fc89" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">758,084</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for pre-funded warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ad2bade-9bcc-4d5d-9533-c24cd66f302e" contextRef="C_b856724b-67a4-4bba-a3f2-933d6bdcf267" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,543,577</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d69f4b98-c3fb-4fd9-91e2-ac7b926157e9" contextRef="C_181b327c-8c4d-49cd-992f-be0a8cabfe0b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,493,510</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for common warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_915627f1-d9bb-429c-8ecd-f84b5c954409" contextRef="C_d1fd9ac5-bc60-4fb7-9382-fc0aedcbb6f9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,104,615</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4700f3ed-4b4d-4f88-b543-33a9fe08c7f5" contextRef="C_47ff50b0-e58b-40e4-8ff0-c5bad7aafd91" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,427,508</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd5916c6-5bb3-4109-a594-9479003949b6" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">93,715,852</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62f6c680-a2d8-47db-bc2e-24e49648566d" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,329,843</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_707dcfe7-db2a-4746-8d97-3a93194a0962_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_2eb7e6cb-f1bc-4a0b-bedf-c452e86e0005" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_2eb7e6cb-f1bc-4a0b-bedf-c452e86e0005_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Incentive Plan</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2020, the Company&#8217;s board of directors and stockholders adopted and approved the 2020 Incentive Award Plan, or the 2020 Plan, and the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may not grant any additional awards under the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of common stock reserved for issuance under the 2020 Plan automatically increase on the first day of January, in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed5a5f17-0c97-4f5a-9b60-ca019a3ff9a8" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" unitRef="U_pure" scale="-2" decimals="2">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of the Company&#8217;s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company&#8217;s board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62afd9af-8d8b-4e4b-b211-51173df8e30c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards granted under the 2020 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9975677e-7e6d-4756-9df9-482c883c5ac8" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. For the Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99b42bd2-e9e2-4b7f-af11-543a7dee1a14" contextRef="C_5f614136-7067-4542-9d0b-a420c024f04d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62429d6b-626c-4e84-a0f3-c35df3f252f6" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period but may be granted with different vesting terms.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2024 and 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0f3b5f7-e1d9-4268-9fe1-7bbc706a980e" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,109,758</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40f5b56c-1f0a-4460-b5b0-cc60f9cbebd6" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,988,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the 2020 Plan, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Employment Inducement Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, the Company&#8217;s board of directors adopted the Annexon, Inc. 2022 Employment Inducement Award Plan, or the Inducement Plan, and together with the 2011 Plan and the 2020 Plan, the Plans. The Inducement Plan was adopted by the Company&#8217;s board of directors without stockholder approval pursuant to Nasdaq Marketplace Rule 5635(c)(4), or Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan may only be granted to newly hired employees as an inducement material to the employees entering into employment with the Company. Awards granted under the Inducement Plan expire no later than ten years from the date of grant. An aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fc4b36f-2830-45fe-b372-840007070727" contextRef="C_369ed887-7421-4d9b-9304-a1aaa66c59c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,850,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved for issuance under the Inducement Plan. As of December 31, 2024 and 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb3bc31a-c105-478c-aed4-282165de0d47" contextRef="C_f4174d5a-db4b-4a44-b7ea-89d6395031d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,359,230</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6231e5ce-303a-442b-b650-1f081715bb57" contextRef="C_43b053ed-5a1a-4d6e-8884-dff3a7269d3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">758,084</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the Inducement Plan, respectively.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_2eb7e6cb-f1bc-4a0b-bedf-c452e86e0005_1" continuedAt="F_2eb7e6cb-f1bc-4a0b-bedf-c452e86e0005_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46a7a782-571e-48c7-ad25-6d3313745d19" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents stock option activity under the Plans for the period:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.420000000000002%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57c16293-9509-44d4-ae70-c15646cf0453" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,208,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5516a35f-710f-4d9e-9a87-6190fa9abae4" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.31</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9eae3b20-4e1c-4d6c-8388-42d63d3186e3" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.53</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2bf9bc6-383a-4344-88f2-1e370b71f520" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b75a7c72-8845-44e7-adbc-d820ebc04a59" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,749,824</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b63e2d9-d4b6-46c7-a819-d9c1716a0a29" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.73</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63f5e3cd-e8ec-47af-a96d-2b41503ac5b0" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">382,122</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fb2dbba-8397-47e3-907f-0f09010a129a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.22</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aba2dfdf-f28c-45ce-829e-f66144115671" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">981,952</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_815677d4-2619-4564-97f2-e740eb2a9106" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.55</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_972ec9f6-4cf3-4164-9211-59053e6a0391" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,594,720</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c25fdce-2587-4e45-981e-a1ae31e8fd24" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.29</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ee7e4d93-d3a0-40d6-ac38-40017b868ebe" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.94</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbe07b1c-09ff-466d-955b-609c0da2b626" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,059</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5a3b86e-1e40-4fa6-bd5d-3f5ec73f6cae" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,813,637</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cae4e647-530c-4258-8d39-de2172ab9f31" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.06</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_afd92498-919a-4dff-ac10-116488449467" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.58</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_361f464b-85ec-4c0b-8468-a6534488c7b1" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,194</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28c7900e-ac53-4c03-873a-79446402d590" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_903bcaa6-46e6-475f-87fb-0b3da63cfdef" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The intrinsic value is the difference between the fair value of the Company&#8217;s common stock at the time of exercise and the exercise price of the stock option.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted to employees during the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e855fed-6081-4481-bcb8-2acedee0c218" contextRef="C_eaec4616-b419-452f-afec-7269fe2849b9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.56</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcfeee88-8068-4939-bec5-b001e7681cca" contextRef="C_c91f5f8f-b8d5-4019-a7fb-1c7e1652024e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the total unrecognized stock-based compensation cost related to outstanding unvested stock options was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_520bc201-65d5-4131-bab8-0a0781676de8" contextRef="C_48cf44ed-6e91-4e9a-ac99-23eaa9cb9ebc" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which the Company expects to recognize over an estimated weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e68d556-c613-496d-8b12-a19ccabf129f" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are share awards that entitle the holder to receive freely tradeable shares of the Company&#8217;s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder&#8217;s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a three-year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company&#8217;s common stock on the grant date.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24ad6736-aec7-4411-80fc-ae4b0b7b776c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of RSU activity under the equity incentive plan and related information is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.383%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.923%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84e71b0b-326e-445d-9092-101922afe3de" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">495,579</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec20e8fd-e892-4d85-9c3c-d985e9119520" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.69</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbeb7518-c250-4399-b15a-e1623533a249" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">602,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f317410d-eb18-48ff-b362-d49e02e9f0f0" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.13</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb6cd726-088d-488c-b129-7d542ed35539" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">197,177</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42845484-4d24-4193-92cf-3fa8f90da856" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.85</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7c48261-0ce2-429a-8c7b-852f5d560eec" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">130,974</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adf07d84-6fec-4526-8a6e-52194b2c976f" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.29</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9b370f9-c85d-4eea-8a0f-16e4c5c66690" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">770,028</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_836c252b-99a8-44d2-8243-d4cc63b16223" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.28</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, unrecognized stock-based compensation expense related to outstanding unvested RSUs was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed7dc860-25fa-4e3d-b761-05b439950883" contextRef="C_bd2c86aa-468c-41c3-bcc5-d4bb6af8a626" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f179a85f-b638-4dcb-ad6e-83907e4449ec" contextRef="C_eb44a589-ed4e-4789-9745-4e687e913dc7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ESPP enables eligible employees to purchase shares of the Company&#8217;s common stock at the end of each offering period at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd446571-47ee-482a-b30e-3b164b568b6b" contextRef="C_b57972b4-cb2c-4aba-9af4-d01913068013" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Share purchases are funded through payroll deductions of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e32261bf-1281-4fa9-8f64-be4faad24ada" contextRef="C_95493879-152b-4afb-9460-55860ac0385d" name="annx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_037b90cd-46d0-40dd-9c43-b967fe9f1415" contextRef="C_95493879-152b-4afb-9460-55860ac0385d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of an employee&#8217;s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP increase automatically on the first</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_2eb7e6cb-f1bc-4a0b-bedf-c452e86e0005_2" continuedAt="F_2eb7e6cb-f1bc-4a0b-bedf-c452e86e0005_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">day </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of each fiscal year, by a number equal to, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e09f56c-7df3-4d36-855e-9684ce9dd8a0" contextRef="C_b57972b4-cb2c-4aba-9af4-d01913068013" name="annx:PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" unitRef="U_pure" scale="-2" decimals="2">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or such number of shares determined by the Company&#8217;s board of directors. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cfdb768-fe6c-444d-a683-038b0dba22be" contextRef="C_95493879-152b-4afb-9460-55860ac0385d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,983,924</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future purchase. The ESPP generally provides for six-month consecutive offering periods beginning on May 15</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and November 15</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of each year. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. As such, stock-based compensation expense has been recorded for the years ended December 31, 2024 and 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock-based compensation expense related to the ESPP for the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53a33aba-efd8-4177-8dc7-2218a757b2de" contextRef="C_b57972b4-cb2c-4aba-9af4-d01913068013" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1586d179-c958-41da-b672-fc054dd7c57f" contextRef="C_94c78139-5590-4748-8160-840a5d169474" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60ba1df5-df2e-4aa5-a434-47b807da894d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total stock-based compensation expense recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.6%;box-sizing:content-box;"/>
        <td style="width:2.52%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.52%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1a71fce-7093-4de5-bc39-eb8d8fc57855" contextRef="C_07dde65d-d011-4647-84a8-b3adc4b0a081" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99da1d17-1e83-4a6f-a15e-b43e077a8266" contextRef="C_887b31a4-95c1-40be-a759-5e56b5fa7540" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,878</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5db77ec-765d-4969-b9ec-39dfe43598c0" contextRef="C_e35f510e-8466-4a7b-bbdd-fbb00d74b1e0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,763</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60b1f1e5-5ad6-42ed-881e-ffbb23e3ef28" contextRef="C_988ddfc5-9dce-4f27-b086-5099244cdafc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,305</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1d9c964-7aa9-4590-b394-793b65cded93" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,433</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6729ce74-5768-4777-8ac3-2317e4ebb331" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,183</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the value of stock option awards for stock-based compensation purposes, the Company uses the Black-Scholes option pricing model and the assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The fair value of each share of underlying common stock is based on the closing price of the Company&#8217;s common stock as reported on the date of grant on the Nasdaq Global Select Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company continues using the simplified method as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Beginning in 2024, the expected volatility was estimated based on a weighted volatility using both the Company&#8217;s trading history for its common stock and the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. Prior to 2024, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_2eb7e6cb-f1bc-4a0b-bedf-c452e86e0005_3"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b545907-4847-421c-9282-99d49471a3bf" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.16%;box-sizing:content-box;"/>
        <td style="width:3.24%;box-sizing:content-box;"/>
        <td style="width:27.68%;box-sizing:content-box;"/>
        <td style="width:3.24%;box-sizing:content-box;"/>
        <td style="width:27.68%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f5a0fd79-4a5f-4259-a835-f21d7351df9e" contextRef="C_4595fc5f-0546-4bdf-8e9d-71d2422bc886" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_e07240a9-652d-46c9-8ff8-d2efca4d1a2a" contextRef="C_347d207b-e303-43ed-928d-7392f73d169f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1fc66583-2a6d-458d-924a-119e0dd1b225" contextRef="C_fc111147-f3e4-414e-8968-b78d5df90526" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_0b82bf72-4f55-42b8-b286-89fe938ec982" contextRef="C_6c830638-e7f6-4b1b-b448-37326bf9c73c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e96a3ca-f84c-43f6-adf8-3c4fe128ed1a" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">95.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_223d43f7-7aac-4833-90b6-1d8878932d3d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">99.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66f1457a-d741-4cf2-ad68-a10172747ccc" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">81.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26e6da34-3141-44d1-ba5f-37fd63d0e6f6" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">82.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df183bd1-2886-4cdb-b689-69fe16124da8" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92198baf-fb62-4e0a-966c-54c0bc3912b3" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e11b79d-15f6-426b-bdb9-951cbe69c1e4" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51430ced-b9f0-465e-9b6e-65847ee4b701" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_eefc453e-a2a5-4d3e-bb38-8b6e8d61718b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_eefc453e-a2a5-4d3e-bb38-8b6e8d61718b_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8ce3e1d-23b1-4110-ab58-d50264f8e031" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For financial reporting purposes, loss before provision for income taxes, includes the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.74%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_184d5697-65af-44cd-81a0-d7b5fa16218b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,193</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd70300e-63b0-47b4-9964-3be9adecd925" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,233</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98e3d094-e825-4132-b209-5a9e30d32388" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c1edfcb-1d33-48a2-9f4e-97a7f6796be9" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db3107b9-df54-40ff-ad57-6d1997c20962" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58490425-9eaf-4e41-bdf4-48835cad26cc" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,237</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each of the years ended December 31, 2024 and 2023, the Company incurred insignificant amounts for an income tax provision. The U.S. federal and California deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba6b5d90-7740-4e49-b11f-310ef7aa086c" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax provision at U.S. statutory rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e60b1d6d-3942-4d01-8437-d28b0eadcb80" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,022</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eb93fdf-2b48-48af-b962-91eef7416551" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,190</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc5d929c-a828-4074-bcbc-430978d58fa1" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,548</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1359661f-bc45-458e-9674-63fdd7773554" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,343</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c251414-9ff1-47ff-8649-3704d2dfb1dc" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,526</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3cc960c-417b-486e-8c6e-26a52eedbee0" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,883</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47beeb48-fe48-4369-a1cb-718fea1eb344" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,184</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87febd31-3e2a-4ee8-8f1a-adb4a666a044" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,066</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a75bdc29-9d28-49fa-869d-1bd800eb7afb" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:IncomeTaxRateReconciliationSection162MCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,773</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4760e463-aab2-4aba-bace-21dda558b5b2" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="annx:IncomeTaxRateReconciliationSection162MCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,594</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0de0b042-99f4-4978-8e30-f0654843d74e" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2afb1629-0528-43ff-9d4f-0a44a5fb98ab" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9e2c45c-89df-4343-8030-be829b203cb3" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5f01c76-1c0d-4c1c-8512-68c80ef04eb4" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_eefc453e-a2a5-4d3e-bb38-8b6e8d61718b_1" continuedAt="F_eefc453e-a2a5-4d3e-bb38-8b6e8d61718b_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Tax Assets and Liabilities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_33552ab4-8e22-46ea-adb3-71e18fa2c840" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6507b4b5-17ae-4792-b36b-d5b7e9bfe5c4" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,198</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64af6d9a-d86a-4ba7-8521-f9dd4a33d418" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,996</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5852b74b-c223-487f-90a4-b41e36c277fe" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,095</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13673311-89b1-4b6e-a915-a64259378b93" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,070</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other intangibles</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4ec61f7-94ff-4f0e-a494-afa272aa819b" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:DeferredTaxAssetsOtherIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa318126-a467-4134-b171-b89fb1228196" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:DeferredTaxAssetsOtherIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f53ccc89-bd0f-46f0-af0f-f00fe9f7815c" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7698d990-4fc1-461c-a4b2-db9444ccd06c" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,074</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20e10cef-7a74-4521-ae9a-ded0442168f4" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,599</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd146a7a-94aa-47b9-b44a-5d92c460884c" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,185</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c57c63d8-8800-4fda-8f34-dc71d2f50928" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,837</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58a5d8d6-5230-4d7f-b1cc-5d2d86ae4d4c" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,568</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e9b79c4-a0f4-4417-ab47-23b46a07c38f" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,087</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cee7199-e2ab-4976-ad0a-7a944e17a9be" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,610</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1b392f9-cd16-4391-8a5f-0ff945747735" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,937</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e85c47cf-495b-43d0-9cd7-3cd3d3acd6dc" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,506</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53b79aa0-8e8e-4784-a220-1533915aec9d" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,958</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da7fa040-cf99-49e2-9655-70a1127c7abe" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,939</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b2c7e47-5133-44ac-848b-717017ba6364" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,979</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c1d060f-5476-47d3-87c9-2464919be6dd" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,567</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab706a1d-d558-4f69-b083-2bed452a4e47" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,469</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8da547c-eb50-4e94-b0f3-2705d958f92b" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,771</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_871f6a01-cf6e-4bf6-b97d-f2a2c6fd3422" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="annx:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,510</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d79fc671-061f-4a78-8097-6e6b8ca03b1d" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="annx:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,796</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44930757-2664-431c-ade7-7b67a78dd797" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,979</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5019f6ef-77a3-4f21-b1b0-64e759fa9cd8" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,567</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a0c781b-2b96-474f-8937-a356d4062e45" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8abfbe0-7887-40e4-b485-00f1f03dcf33" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2024, the Company completed a research credit study for the years ended December 31, 2020 through 2023. This resulted in true ups to the credit carryovers, which also impacted the Section 174 capitalized research expenses and net operating losses deferred tax assets disclosed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e31f2703-775c-4adb-9c50-3b54ea2dee90" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">367.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ea872be-cdbd-4292-8f99-3ecaf127ce56" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">223.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state net operating loss, or NOL, carryforwards available to offset future taxable income. Under the Tax Cuts and Jobs Act of 2017, or the Tax Act, federal NOLs generated after December 31, 2017 will be carried forward indefinitely with the yearly NOL utilization limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c032fb2d-1857-47bd-9979-ee3a95e53100" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" unitRef="U_pure" scale="-2" decimals="2">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of taxable income. The Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b64f64b3-8f53-43d8-8c63-559c6fa309d9" contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2" name="annx:DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">324.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of such federal NOLs that do not expire. If not utilized, the federal carryforward losses generated prior to 2018 and the state carryforward losses will expire in various amounts beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a50e3032-53b3-43ad-b979-4980c233f303" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="annx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_054eb9d7-91e7-4af7-8459-d9dc25cf1b35" contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cf85d0b-8bbe-4cc3-9271-e3f9a43db51f" contextRef="C_6f21bd05-943f-438a-9b7b-5906dcadd8cc" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state credit carryforwards available to offset future taxable income. If not utilized, these credit carryforwards will expire in various amounts for federal purposes beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0db9ebf-a622-4745-8689-1c72299ab13d" contextRef="C_ef904358-5a05-4938-94ed-ed05188133ac" name="annx:DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The state credits do not expire.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not some portion or all of the deferred tax assets will not be realized. Management believes that, based on available evidence, both positive and negative, it is more likely than not that the deferred tax assets will not be utilized; therefore, a full valuation allowance has been recorded. The Company&#8217;s valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32d86d8c-61cb-425c-82ab-01c27857aaa2" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca88f2a1-ed4f-49ab-803c-0b17bbbaae12" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively. The changes in the 2024 valuation allowance were primarily due to the addition of capitalized research and development costs, current year loss carryforwards and research and development credits. The changes in the 2023 valuation allowance were primarily due to the addition of capitalized research and development costs, current year loss carryforwards and research and development credits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of the net operating loss carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2024. Federal net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0d44401-c7a4-4334-9746-8ae4f97c21c8" contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">367.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and state and local net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d36c17c1-9035-48f2-b05f-f6462b1fdbb6" contextRef="C_6f21bd05-943f-438a-9b7b-5906dcadd8cc" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">189.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are not expected to expire unutilized as a result of ownership changes identified through December 31, 2024. The Company has identified $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08bebdf3-3612-4c63-8f8c-236212486318" contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dbf7ca2-5451-48e6-9cd0-7b3d00883ece" contextRef="C_6f21bd05-943f-438a-9b7b-5906dcadd8cc" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of federal and state net operating losses, respectively, that will expire unused due to ownership changes,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_eefc453e-a2a5-4d3e-bb38-8b6e8d61718b_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27b93636-62fb-4cab-a669-49bbc8e510c2" contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that will not be able to be utilized due to ownership change limitation; these amounts have been excluded from the deferred tax assets table above. Further ownership changes subsequent to December 31, 2024 may be identified which could result in limitations to the amount of net operating losses and credits which may be utilized prior to expiration.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Uncertain Tax Benefits</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bfc808c5-4a06-4dca-8c22-64d2873a80eb" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the following activity relating to the gross amount of unrecognized tax benefits (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.248%;box-sizing:content-box;"/>
        <td style="width:1.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.917%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.917%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c45386fb-2adc-40c4-bf22-78a1f24ec182" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ff89cfa-f6cd-4a95-bde0-671d2ddbb189" contextRef="C_a2b98230-0f7a-4d29-8918-901b611f045a" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,726</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9fc5409-601a-4f47-bdcf-a255ac47b4f4" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,388</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_416911e3-0f90-4c83-9280-02eddcd3c43b" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reductions based on tax positions related to prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1838ece2-c016-4f20-8139-f61df4d4911b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,726</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e55e480-7e17-4302-9a48-d763f9a22101" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d2c8613-3829-4630-b675-a3295723c58d" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,787</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9911901-e233-4ea6-bc01-0170f6b251c7" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,055</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec5a238e-16fc-46b0-95aa-d99b3351f96c" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,419</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26ce22e4-01d0-40ca-9c38-e23f075f00b4" contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3946e32-8082-47f1-9a50-3777caefd67b" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">None</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of these uncertain tax positions will impact the Company&#8217;s effective tax rate if assessed. The Company&#8217;s policy is to classify interest and penalties associated with unrecognized tax benefits as income tax expense. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7e38585-dda8-487c-b3c0-f298683d7a3f" contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest or penalty accruals associated with uncertain tax benefits in its consolidated balance sheet and consolidated statement of operations for the years ended December 31, 2024 and 2023. The Company files income tax returns in the United States, various states, and Australia. The Company is not currently under examination by any major tax jurisdictions nor has it been in the past. The tax years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a1b6e2c0-03d3-4a20-b626-abcffa81b2cd;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2011 through 2024</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remain effectively open for examination by the Internal Revenue Service and most state tax authorities because of net operating losses and credit carryovers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next twelve months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_b059d745-ac6e-4d3e-97a3-064071ce97fc" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding. The weighted-average number of shares of common stock used in the basic and diluted net loss per share calculation include pre-funded warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e752d4b7-3952-4201-abce-b760131d3fba" contextRef="C_634f5a22-da7a-4c41-b9ae-27784aa5495b" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,543,577</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2770691-fbdf-4c39-8d3c-0450b9c18066" contextRef="C_2fd32b35-c1b6-48a1-aae6-77286e901eaa" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,492,923</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for the years ended December 31, 2024 and 2023, respectively, as the pre-funded warrants are exercisable at any time for nominal cash consideration. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f977a5ed-c8e9-48a6-87dc-0a47e6fe9ed3" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_f977a5ed-c8e9-48a6-87dc-0a47e6fe9ed3_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.383%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.383%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a9e081c-e082-450b-80f1-544a334ec356" contextRef="C_abbf44cf-6ebe-4194-9a41-e2cb42bf1eb6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,594,720</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87058036-c9c9-49d2-9d0d-5f0836396752" contextRef="C_e4222e01-171b-4f31-917f-bc3457cfb96a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,208,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares subject to Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4497a16-d182-4cfa-affd-4eb460785893" contextRef="C_eaec4616-b419-452f-afec-7269fe2849b9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,922</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eeadc5d-e085-4cd4-8fd3-3bd9ad13b2d3" contextRef="C_c91f5f8f-b8d5-4019-a7fb-1c7e1652024e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f9b7dc-6063-4703-8c3c-2d667c213c36" contextRef="C_22fb27c8-c805-4aa1-944d-38a2963e3541" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">770,028</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a1bf3c-7c3d-431f-9dd0-c5e09cf7bce6" contextRef="C_83482f61-92c5-4f8a-a1dd-156bef5f21aa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">495,579</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c56da0e-8ae7-4d7d-b54e-56e7d9abd92a" contextRef="C_4aeda5c6-0f0c-4565-a458-c8ad2779242a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,104,615</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37b7b8a1-23d8-4ba8-b83e-133390198523" contextRef="C_2321ba61-567c-412f-bf92-06d0f3f4b95c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,427,508</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ed55de9-4172-4f76-9c44-2f97a989092b" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,485,285</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_099ced65-fa87-457e-bbf9-45ac54df834a" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,149,257</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_f977a5ed-c8e9-48a6-87dc-0a47e6fe9ed3_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c33c0341-0fc4-4155-a252-adec786baba9" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Segment </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f55a3ced-44aa-4317-8e29-a4686abb93ff" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is related to the research and development of its product candidates focused on complement-mediated diseases of the body, brain and eye for which there is significant unmet medical need. The accounting policies of the one reportable segment are the same as those described in the summary of significant accounting policies. See Note 2&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b240e588-dda8-4aa1-a285-a3d6c41ddb14" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The segment is managed on a consolidated basis and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results and allocate resources. In assessing the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. This includes a review of budget versus actual expenses and direct program spend, which includes clinical costs, consultant fees, manufacturing expenses, and other direct external costs.</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_7b0630e8-2cdc-478f-aeb1-1aef19d21081" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the operations for the reportable segment during the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.02%;box-sizing:content-box;"/>
        <td style="width:2.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:22.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:22.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - program expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d8dc279-f592-47a7-9d3f-3471b24e94b3" contextRef="C_a4b8204b-10aa-4078-99c0-be6c2915b494" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,548</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06baf220-5d86-438a-842b-67519b942cb2" contextRef="C_0f36b114-1cd5-47b2-9612-e2686951639e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,008</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - personnel</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e353c3c-0aac-4e98-b4e2-5f2496ca1d11" contextRef="C_e84f496a-0f64-496c-8511-31490901d115" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,291</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_368cf87d-e789-43fb-b0c2-4fcb6ddb9e5d" contextRef="C_818dd59d-4920-4aa4-ac11-e7a600a5d4b6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,893</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative - personnel</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0d4eb41-a228-441f-a76a-da76250cd59e" contextRef="C_e84f496a-0f64-496c-8511-31490901d115" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,578</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fd28006-7d67-4835-af69-6e2f5942714d" contextRef="C_818dd59d-4920-4aa4-ac11-e7a600a5d4b6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,896</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9f1cc64-e0f8-414e-aa87-16937aa72784" contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,073</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08d24199-1a0e-40eb-8c25-2d52b469f6c6" contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,595</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a01170ab-a885-4d29-ae7d-a2a723499b07" contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,150</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70ad18eb-394f-4e94-893c-61c6734bfcb6" contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,148</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a03c8a0-8598-4d6e-ae23-c6775a5fe382" contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,433</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9688f377-de64-4c34-bc95-12cb4d97d537" contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,183</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c97a8bf-6fa3-4c43-b7b7-a79ec02a24c6" contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,073</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b3a26b1-5ae0-41bc-8bdd-fb8e9db92fad" contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,723</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92089de2-014e-40f9-94a1-8d6ced78bcba" contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">154,073</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60b4fdce-1db2-4fb1-bf97-5aaa9480c3b0" contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">143,723</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfd19e20-9efa-4921-ac8b-33ff96e6ff50" contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c" name="annx:InterestAndOtherNonOperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,873</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78cfe5a0-2ada-4929-b7bb-29290a86e060" contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3" name="annx:InterestAndOtherNonOperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,486</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated segment net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4238a7fe-3b49-4085-abcb-67dfa42b37dd" contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bdf7525-4d2f-4c94-ad96-71c8aa5241d6" contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,237</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">__________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Research and development - program expenses include other non-program specific expenses and other research expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Other general and administrative expenses include consulting and professional services fees for legal, accounting, tax, and facilities costs.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act). Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the December 31, 2024, our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management has evaluated the effectiveness of our internal control over financial reporting as of December 31, 2024 using the criteria set forth in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8212; Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of the Company&#8217;s independent registered public accounting firm regarding internal control over financial reporting. Pursuant to rules of the SEC, such attestation is not required for smaller reporting companies, which permit the Company to provide only management&#8217;s report in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2024 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inherent Limitation on the Effectiveness of Internal Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_a853ef61-32f0-436b-8cf5-cd0c40235922" contextRef="C_f5167882-1b9d-47e5-a675-47eb50fb2f3b" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Arrangements of Section 16 Reporting Persons.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Company&#8217;s last fiscal quarter, the Company&#8217;s directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company&#8217;s securities set forth in the table below.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:28%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:11%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:11%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:8%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:10%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Types of Trading Arrangement</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Position</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Termination Date</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule <br/>10b5-1*</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Rule 10b5-1**</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shares of Common Stock to be Sold</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shares of Common Stock to be Purchased</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_864ad0af-0930-487c-98d1-606fc05b21f3" contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Douglas Love</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_6c78a090-3bc6-4662-9cc9-b1e8d1119e7d" contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_45bfa6a5-a7d3-41bd-8d47-655a8f51d13d" contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/16/2024</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5935eb1e-e453-45e6-bdc4-46ae1bca54df" contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50977837-0d6b-429f-b126-3791826b8fa1" contextRef="C_d35db099-094f-4b2e-a082-7d4a3c739571" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,994</ix:nonFraction></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bee34d8b-10cb-4dbe-9528-a1668f83c020" contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/22/2025</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">__________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#242424;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#242424;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** &#8220;Non-Rule 10b5-1 trading arrangement&#8221; as defined in Item 408(a) of Regulation S-K under the Exchange Act.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign J</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">urisdictions That Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2025 Annual Meeting of Stockholders, or the Proxy Statement, which will be filed no later than 120 days after the end of our fiscal year ended December 31, 2024 and is incorporated herein by reference.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees which is available on our website at ir.annexonbio.com. The Code of Business Conduct and Ethics is intended to qualify as a &#8220;code of ethics&#8221; within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (1) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our directors or our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to a director one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The remaining information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2025 Annual Meeting of Stockholders, or the Proxy Statement, which will be filed no later than 120 days after the end of our fiscal year ended December 31, 2024 and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item regarding executive compensation will be incorporated by reference to the information set forth in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item regarding security ownership of certain beneficial owners and management and our equity compensation plans will be incorporated by reference to the information set forth in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item regarding certain relationships and related transactions and director independence will be incorporated by reference to the information set forth in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tant Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item regarding principal accountant fees and services will be incorporated by reference to the information set forth in our Proxy Statement.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">al Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.173%;text-indent:-9.291%;padding-left:8.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) The following documents are filed as part of this report:</span></p>
  <p style="margin-left:6.16%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Financial Statements</span></p>
  <p style="margin-left:12.293%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information in response to this Item is included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="margin-left:6.16%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Financial Statement Schedules</span></p>
  <p style="margin-left:12.293%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></p>
  <p style="margin-left:6.16%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.242%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:39.748%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:6.261%;box-sizing:content-box;"/>
    <td style="width:1.44%;box-sizing:content-box;"/>
    <td style="width:11.002%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:10.262%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:7.662%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520201003/d75304dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/28/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520201003/d75304dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/28/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reference is made to </span><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520201003/d75304dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits 3.1</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;through </span><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520201003/d75304dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.2</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000156459022008044/annx-ex43_9.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/01/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312522190590/d342746dex41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/08/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312522190590/d342746dex42.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/08/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312523302246/d719794dex41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/22/23</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312524157454/d841004dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">06/07/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement, dated June 30, 2020, by and among the Registrant and the investors listed therein</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.2&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive (Equity) Agreement, dated November 21, 2011, by and between the Registrant and The Board of Trustees of the Leland Stanford Junior University</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520324523/d73975dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease, dated December 18, 2020, by and between the Registrant and HCP LS Brisbane, LLC.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/22/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.4(a)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520195043/d773514dex104a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2011 Incentive Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/20/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.4(b)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520186799/d773514dex104b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Agreement under 2011 Equity Incentive Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.242%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:39.748%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:6.261%;box-sizing:content-box;"/>
    <td style="width:1.44%;box-sizing:content-box;"/>
    <td style="width:11.002%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:10.262%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:7.662%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.5(a)+</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520198653/d944841dex992a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2020 Incentive Award Plan</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-240101</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.2(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/24/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.5(b)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex105b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.5(c)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex105c.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2020 Incentive Award Plan</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.5(d)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex105d.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2020 Incentive Award Plan</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5(d)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.6+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520198653/d944841dex993.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-240101</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/24/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.7+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520186799/d773514dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Douglas Love, Esq.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.8+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Jennifer Lew.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.9+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Michael Overdorf.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/20/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.10+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="annx-ex10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Program.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.11+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312520186799/d773514dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification and Advancement Agreement for directors and officers.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.12+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017023006232/annx-ex10_12.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Dean Richard Artis, Ph.D.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/06/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.13</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312524077697/d763284dex12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sales Agreement, dated as of March 26, 2024, by and between Annexon Inc. and Cowen and Company, LLC.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-278246</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/26/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312522190590/d342746dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, dated July 7,</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312522190590/d342746dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2022, by and among the Registrant and the</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000119312522190590/d342746dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Purchasers named within.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/08/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.15+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017022015560/annx-ex10_2a.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Annexon, Inc. 2022 Employment Inducement</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017022015560/annx-ex10_2a.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">08/08/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.16+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017022015560/annx-ex10_2b.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2022</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017022015560/annx-ex10_2b.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Inducement Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">08/08/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.17+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017022015560/annx-ex10_2c.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Award Grant</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017022015560/annx-ex10_2c.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notice and Restricted Stock Unit Award</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017022015560/annx-ex10_2c.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement under the 2022 Employment</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017022015560/annx-ex10_2c.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Inducement Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">08/08/22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.18+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017023039054/annx-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017023039054/annx-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registrant and Jamie Dananberg, M.D.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">08/07/23</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.242%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:39.748%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:6.261%;box-sizing:content-box;"/>
    <td style="width:1.44%;box-sizing:content-box;"/>
    <td style="width:11.002%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:10.262%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:7.662%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;19.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="annx-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of subsidiaries.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239647</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/02/20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;23.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="annx-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;24.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included in the signature page hereto).</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;31.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="annx-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;31.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="annx-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;32.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="annx-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1528115/000095017024036408/annx-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Policy for Recovery of Erroneously Awarded Compensation.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/26/24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Certain portions of this document that constitute confidential information have been redacted in accordance with Regulation S-K, Item 601(b)(10).</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, is not deemed &#8220;filed&#8221; by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60%;box-sizing:content-box;"/>
    <td style="width:3.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:35.52%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annexon, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Douglas Love, Esq.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Douglas Love, Esq.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jennifer Lew</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jennifer Lew</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President and Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Douglas Love and Jennifer Lew his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.293%;box-sizing:content-box;"/>
    <td style="width:1.004%;box-sizing:content-box;"/>
    <td style="width:46.955%;box-sizing:content-box;"/>
    <td style="width:1.004%;box-sizing:content-box;"/>
    <td style="width:19.744%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Douglas Love, Esq.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;President, Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Douglas Love, Esq.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jennifer Lew</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Executive Vice President and Chief Financial Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jennifer Lew</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Principal Financial and Accounting Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Thomas G. Wiggans</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Chairperson &amp; Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Thomas G. Wiggans</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ William H. Carson, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">William H. Carson, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jung E. Choi</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jung E. Choi</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Bettina M. Cockroft, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Bettina M. Cockroft, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ William Jones</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">William Jones</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Muneer A. Satter</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:11.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Muneer A. Satter</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ William D. Waddill</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 3, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">William D. Waddill</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>2
<FILENAME>annx-ex10_10.htm
<DESCRIPTION>EX-10.10
<TEXT>
<html>
 <head>
  <title>EX-10.10</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.10</font></p></div>
  <p style="margin-left:0.027%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.12%;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.12%;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annexon, Inc. (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) Non-Employee Director Compensation Program (this &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Program</font><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has been adopted under the Company&#x2019;s 2020 Incentive Award Plan (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and shall be effective as of April 1, 2024. Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan.</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Compensation</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual retainers will be paid in the following amounts to Non-Employee Directors:</font></p>
  <table style="margin-left:2.333%;border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:79.44%;box-sizing:content-box;"></td>
    <td style="width:20.56%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #231f20;padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-Employee Director:</font></p></td>
    <td style="border-top:0.5pt solid #231f20;padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$40,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-Executive Chair:</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$35,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Committee Chair:</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$20,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation Committee Chair:</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$12,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee Chair:</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$10,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Science and Technology Committee Chair:</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$12,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Committee Member (non-Chair):</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$10,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation Committee Member (non-Chair):</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$6,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee Member (non-Chair):</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$5,000</font></p></td>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;text-indent:5.75pt;border-left:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;"><p style="margin-left:1.067%;text-indent:0;font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Science and Technology Committee Member (non-Chair):</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #231f20;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #231f20;text-align:center;"><p style="font-size:10pt;margin-top:1.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.926%;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$6,000</font></p></td>
   </tr>
  </table>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All annual retainers will be paid in cash quarterly in arrears promptly following the end of the applicable calendar quarter, but in no event more than 30 days after the end of such quarter. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described above, for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non- Employee Director, or in such position, as applicable.</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Compensation</font></p>
  <p style="margin-left:0.92%;text-indent:-37.684%;padding-left:26.573%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Stock Option Grant:	Each Non-Employee Director who is initially elected or appointed to serve on the Board shall be granted an Option under the Plan or any other applicable Company equity incentive plan then-maintained by the Company to purchase 88,000 shares of Common Stock.</font></p>
  <p style="margin-left:27.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.037%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Initial Option will be automatically granted on the date on which such Non-Employee Director commences service on the Board, and will vest as to 1/36</font><font style="color:#231f20;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the shares subject thereto on each monthly anniversary of the applicable date of grant such that the shares subject to the Initial Option are fully vested on the third anniversary of the grant, subject to the Non-Employee Director continuing in service on the Board through each vesting date.</font></p>
  <p style="margin-left:0.92%;text-indent:-37.684%;padding-left:26.573%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Stock Option Grant:	Each Non-Employee Director who is serving on the Board as of the date of each annual stockholder meeting of the Company (each, an &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual Meeting</font><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be granted an Option under the Plan or any other applicable Company equity incentive plan then-maintained by the Company to purchase 44,000 shares of Common Stock.</font></p>
  <p style="margin-left:27.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.037%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Annual Option will be automatically granted on the date of the applicable</font><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.10</font></p></div>
  <p style="margin-left:27.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.037%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Meeting and will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Non-Employee Director continuing in service on the Board through such vesting date.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The per share exercise price of each Option granted to a Non-Employee Director shall equal the Fair Market Value of a share of common stock on the date the Option is granted.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of each Option granted to a Non-Employee Director shall be ten years from the date the Option is granted.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No portion of an Initial Option or Annual Option which is unvested or unexercisable at the time of a Non-Employee Director&#x2019;s termination of service on the Board shall become vested and exercisable thereafter.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their service with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Option, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from service with the Company and any parent or subsidiary of the Company, Annual Options as described above.</font></p>
  <p style="margin-left:0.8%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon a Change in Control of the Company, all outstanding equity awards granted under the Plan and any other equity incentive plan maintained by the Company that are held by a Non-Employee Director shall become fully vested and/or exercisable, irrespective of any other provisions of the Non-Employee Director&#x2019;s Award Agreement.</font></p>
  <p style="margin-left:0.8%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reimbursements</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall reimburse each Non-Employee Director for all reasonable, documented, out- of-pocket travel and other business expenses incurred by such Non-Employee Director in the performance of his or her duties to the Company in accordance with the Company&#x2019;s applicable expense reimbursement policies and procedures as in effect from time to time.</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Miscellaneous</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.991%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The other provisions of the Plan shall apply to the Options granted automatically pursuant to this Program, except to the extent such other provisions are inconsistent with this Program. All applicable terms of the Plan apply to this Program as if fully set forth herein, and all grants of Options hereby are subject in all respects to the terms of the Plan. The grant of any Option under</font><font style="color:#231f20;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this Program shall be made solely by and subject to the terms set forth in a written agreement in a form to be approved by the Board and duly executed by an executive officer of the Company.</font></p>
  <p style="margin-left:0.053%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.12%;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* * * * *</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.868%;font-size:10pt;margin-top:6.5pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:2.009%;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I hereby certify that the foregoing Program was adopted by the Board of Directors of Annexon, Inc. on July 14, 2020 and was amended on April 25, 2022, March 16, 2023, June 8, 2023 and June 5, 2024.</font></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.12%;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* * * * *</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executed on June 5, 2024.</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.941%;box-sizing:content-box;"></td>
    <td style="width:47.059%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;/s/ Jennifer Lew</font></p></td>
   </tr>
  </table>
  <p style="margin-left:40.933%;text-indent:11.287%;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jennifer Lew, Corporate Secretary</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>annx-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNEXON, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INSIDER TRADING compliance POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective as of July 27</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2020, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as amended on </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">M</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arch 16</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023)<br></font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Compliance Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) consists of seven sections:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section I provides an overview; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section II sets forth policies of Annexon, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) prohibiting insider trading; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section III explains insider trading; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section IV consists of procedures that have been put in place by the Company to prevent insider trading; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section V sets forth additional transactions that are prohibited by this Policy; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section VI explains Rule 10b5-1 trading plans and provides information about Section 16 and Rule 144; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section VII refers to the execution and return of a compliance certificate.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OVERVIEW</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of the Company as well as that of all persons affiliated with the Company. &#x201c;Insider trading&#x201d; occurs when any person purchases or sells a security (e.g., common stock) while in possession of &#x201c;inside information&#x201d; relating to the security. As explained in Section III below, &#x201c;inside information&#x201d; is information that is both &#x201c;material&#x201d; and &#x201c;non-public.&#x201d; Insider trading violates several laws, including civil and criminal laws. The penalties for violating insider trading laws include imprisonment, disgorgement of profits, civil fines and criminal fines of up to $5 million for individuals and $25 million for entities. Insider trading is also prohibited by this Policy, and violation of this Policy may result in Company-imposed sanctions, including removal or dismissal for cause.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to all officers, directors, employees and certain consultants of the Company and extends to all activities within and outside an individual&#x2019;s duties at the Company. Individuals subject to this Policy are responsible for ensuring that their immediate family members and members of their households also comply with this Policy. This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#x2019;s own account. Notwithstanding the foregoing, this Policy, including without limitation, the pre-clearance policy, blackout periods and prohibited transactions, does not apply to venture capital entities or other institutional investors, and the related transactions in the Company&#x2019;s equity securities by such entities, that may be affiliated with a director of the Company or for Company equity securities that a director may be deemed to have beneficial ownership of by virtue of such affiliation.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy extends to all activities within and outside an individual&#x2019;s Company duties. Every officer, director and employee (and if designated by management, applicable consultants) must review this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions regarding the Policy should be directed to the Company&#x2019;s General Counsel (or the Chief Financial Officer in the absence of a General Counsel, or, in his or her absence from the office, the Chief Executive Officer), or such other person as the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) may designate from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENT OF POLICIES PROHIBITING INSIDER TRADING</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No officer, director, employee or consultant, or any immediate family member or any member of the household of any such person, shall purchase or sell any type of security while in possession of material, non-public information relating to the security, whether the issuer of such security is the Company or any other company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, no officer, director, employee or certain consultants designated by management, or any immediate family member or any member of the household of any such person, shall purchase or sell any security of the Company during the period beginning  on the fifteenth day following the last day of any fiscal quarter of the Company and ending at market close on the first full trading day after the public release of financial results for such fiscal quarter whether or not the Company or any of its officers, directors, employees or consultants is in possession of material, non-public information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, from time to time, the Company, through the Board of Directors, the Company&#x2019;s disclosure committee or the Compliance Officer, may recommend that some or all officers, directors, employees, consultants or others suspend trading in the Company&#x2019;s securities because of developments that have not yet been disclosed to the public. Individuals affected by such an event-specific blackout may be notified by the Company that they are subject to the blackout (or the Compliance Officer may determine in his or her discretion to rely instead on the pre-clearance requirement provided for in Section IV.B of this policy). Subject to the exceptions noted below, persons notified should not trade in our securities while the event-specific blackout is in effect, and in the event that a press release is issued by the Company in connection with the event that resulted in the event-specific blackout (or the event or circumstances go away), such suspension shall continue for one full trading day after the public release (or the event or circumstances go away).  Additionally, those subject to the event-specific blackout should not disclose to others that we have suspended trading, as the event-specific blackout itself is material non-public information. Events that may give rise to event-specific blackouts may include consideration of major strategic transactions (e.g., acquisitions, dispositions, joint ventures), product developments, interim earnings or sales releases, significant legal proceedings and other circumstances that potentially implicate material non-public information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These prohibitions do not apply to:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases of the Company&#x2019;s securities from the Company (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., Employee Stock Purchase Plan), sales of the Company&#x2019;s securities to the Company, or the surrender to or withholding by the Company of the Company&#x2019;s securities (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to cover withholding obligations upon the vesting or settlement of equity-based awards);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercises of stock options or other equity awards or vesting of equity-based awards that do not involve a market sale of the Company&#x2019;s securities (note that the &#x201c;cashless exercise&#x201d; of a Company stock option </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> involve a market sale of the Company&#x2019;s securities, and therefore would not qualify under this exception);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gifts of the Company&#x2019;s securities, unless the individual making the gift knows, or is reckless in not knowing, the recipient intends to sell the securities; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases or sales of the Company&#x2019;s securities made pursuant to any pre-existing binding contract, specific instruction or written plan entered into while the purchaser or seller, as applicable, was unaware of any material, non-public information and which contract, instruction or plan (i) meets all requirements of the affirmative defense provided by Rule 10b5-1 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) promulgated under the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1934 Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy. For more information about Rule 10b5-1 trading plans, see Section VI below.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this Policy, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is a day on which the Nasdaq Stock Market is open for trading.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No officer, director, employee or consultant shall directly or indirectly communicate (or &#x201c;tip&#x201d;) material, non-public information to anyone outside the Company (except in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">III.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXPLANATION OF INSIDER TRADING</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider trading</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; refers to the purchase or sale of a security by someone who is in possession of &#x201c;material,&#x201d; &#x201c;non-public&#x201d; information relating to the security.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; refers to employees, officers, directors and certain consultants of the Company and anyone else within the Company who has material, non-public information about the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; includes stocks, bonds, notes, debentures, options, warrants and other convertible securities, as well as derivative instruments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sale</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; are defined broadly under the federal securities law. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of warrants or puts, calls or other derivative securities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is generally understood that insider trading includes the following:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading by insiders while in possession of material, non-public information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading by persons other than insiders while in possession of material, non-public information, if the information either was given in breach of an insider&#x2019;s duty to keep it confidential or was misappropriated; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communicating or tipping material, non-public information to others, including recommending the purchase or sale of a security while in possession of such information.</font></div></div>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What Facts are Material?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The materiality of a fact depends upon the circumstances. A fact is considered &#x201c;material&#x201d; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold a security, or if the fact is likely to have a significant effect on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of a company&#x2019;s business or to any type of security, debt or equity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Examples of material information include (but are not limited to) information about the results of clinical trials; communications sent to or received from the U.S. Food and Drug Administration; dividends; corporate earnings or earnings forecasts; mergers, acquisitions, tender offers or dispositions; major new products or product developments; important business developments such as major contract awards or cancellations; management or control changes; significant borrowing or financing developments including pending public sales or offerings of debt or equity securities; defaults on borrowings; bankruptcies; and significant litigation or regulatory actions. Moreover, material information does not have to be related to a company&#x2019;s business. For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A good general rule of thumb: </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When in doubt, do not trade.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What is Non-public?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information is &#x201c;non-public&#x201d; if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dow Jones</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Wire</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reuters</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Associated Press</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Press International</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (all of which generally are accessible via a nationally recognized service such as Global News Wire, Business Wire or PR Newswire), a broadcast on widely available radio or television programs, publication in a widely available newspaper, magazine or news web site, a Regulation FD-compliant conference call, or public disclosure documents filed with the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that are available on the SEC&#x2019;s web site.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination. In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information. Generally, one should allow one full trading day following publication as a reasonable waiting period before such information is deemed to be public.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Who is an Insider?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; include officers, directors, employees and certain consultants of a company and anyone else within the Company who has material, non-public information about a company. Insiders have independent fiduciary duties to their company and its stockholders not to trade on material, non-public information relating to the company&#x2019;s securities. All officers, directors, employees and consultants of the Company should consider themselves insiders with respect to material, non-public information about the Company&#x2019;s business, activities and securities. Officers, directors, employees and consultants may not trade in the Company&#x2019;s securities while in possession of material, non-public information relating to the Company, nor may they tip such information to anyone outside the Company (except in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals subject to this Policy are responsible for ensuring that their immediate family members and members of their households also comply with this Policy. This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#x2019;s own account.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Persons Other than Insiders</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders may be liable for communicating or tipping material, non-public information to a third party (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tippee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and insider trading violations are not limited to trading or tipping by insiders. Persons other than insiders also can be liable for insider trading, including tippees who trade on material, non-public information tipped to them or individuals who trade on material, non-public information that has been misappropriated.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tippees inherit an insider&#x2019;s duties and are liable for trading on material, non-public information illegally tipped to them by an insider. Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade. In other words, a tippee&#x2019;s liability for insider trading is no different from that of an insider. Tippees can obtain material, non-public information by receiving overt tips from others or through, among other things, conversations at social, business, or other gatherings.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties for Engaging in Insider Trading</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties for trading on or tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct and their employers. The SEC and Department of Justice have made the civil and criminal prosecution of insider trading violations a top priority.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforcement remedies available to the government or private plaintiffs (e.g., the Company&#x2019;s stockholders) under the federal securities laws include:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC administrative sanctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities industry self-regulatory organization sanctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil injunctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage awards to private plaintiffs;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disgorgement of all profits;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil fines for the violator of up to three times the amount of profit gained or loss avoided;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil fines for the employer or other controlling person of a violator (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, where the violator is an employee or other controlled person) of up to the greater of $1,425,000 or three times the amount of profit gained or loss avoided by the violator;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an entity); and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jail sentences of up to 20 years.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, insider trading could result in serious sanctions by the Company, including dismissal. Insider trading violations are not limited to violations of the federal securities laws. Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer Influenced and Corrupt Organizations Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RICO</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), also may be violated in connection with insider trading.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Size of Transaction and Reason for Transaction Do Not Matter</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The size of the transaction or the amount of profit received does not have to be significant to result in prosecution. The SEC has the ability to monitor even the smallest trades, and the SEC performs routine market surveillance. Brokers and dealers are required by law to inform the SEC of any possible violations by people who may have material, non-public information. The SEC aggressively investigates and refers for prosecution even small insider trading violations.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Examples of Insider Trading</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Examples of insider trading cases include actions brought against corporate officers, directors, employees and consultants who traded in a company&#x2019;s securities after learning of significant confidential corporate developments; friends, business associates, family members and other tippees of such officers, directors, employees and consultants who traded in the securities after receiving such information; government employees who learned of such information in the course of their employment; and other persons who misappropriated, and took advantage of, confidential information from their employers.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are illustrations of insider trading violations. These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities or business of the Company or any other entity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Insider</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An officer of X Corporation learns that earnings to be reported by X Corporation will increase dramatically. Prior to the public announcement of such earnings, the officer purchases X Corporation&#x2019;s stock. The officer,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an insider, is liable for all profits as well as penalties of up to three times the amount of all profits. The officer also is subject to, among other things, criminal prosecution, including up to $5,000,000 in additional fines and 20 years in jail. Depending upon the circumstances, X Corporation and the individual to whom the officer reports also could be liable as controlling persons.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Tippee</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An officer of X Corporation tells a friend that X Corporation is about to publicly announce that it has concluded an agreement for a major acquisition. This tip causes the friend to purchase X Corporation&#x2019;s stock in advance of the announcement. The officer is jointly liable with his friend for all of the friend&#x2019;s profits, and each is liable for all civil penalties of up to three times the amount of the friend&#x2019;s profits. The officer and his friend are also subject to criminal prosecution and other remedies and sanctions, as described above.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">H.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition of Records Falsification and False Statements</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13(b)(2) of the 1934 Act requires companies subject to the 1934 Act (such as the Company) to maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls. The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading, or incomplete statement to any accountant in connection with any audit or filing with the SEC. These provisions reflect the SEC&#x2019;s intent to discourage officers, directors and other persons with access to the Company&#x2019;s books and records from taking action that might result in the communication of materially misleading financial information to the investing public.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IV.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading. Each of the officers, directors, employees and certain consultants designated by management are required to follow these procedures.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blackout Periods</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No officer, director, employee or consultant designated by management, or any immediate family member or any member of the household of any such person, shall purchase or sell any security of the Company during the period beginning on the fifteenth day following the last day of any fiscal quarter of the Company and ending at market close on the first full trading day after the public release of financial results for such fiscal quarter of the Company or during any other trading suspension period declared by the Company,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> except for:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases of the Company&#x2019;s securities from the Company or sales of the Company&#x2019;s securities to the Company;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercises of stock options or other equity awards or vesting of equity-based awards that do not involve a market sale of the Company&#x2019;s securities (the &#x201c;cashless exercise&#x201d; of a Company stock option </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> involve a market sale of the Company&#x2019;s securities, and therefore would not qualify under this exception);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gifts of the Company&#x2019;s securities, unless the individual making the gift knows, or is reckless in not knowing, the recipient intends to sell the securities; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases or sales of the Company&#x2019;s securities made pursuant to any binding contract, specific instruction or written plan entered into while the purchaser or seller, as applicable, was unaware of any material, non-public information and which contract, instruction or plan (i) meets all </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements of the affirmative defense provided by Rule 10b5-1, (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions to the blackout period policy may be approved only by the Compliance Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company, through the Board of Directors, the Company&#x2019;s disclosure committee or the Compliance Officer, may recommend that some or all officers, directors, employees, consultants or others suspend trading in the Company&#x2019;s securities because of developments that have not yet been disclosed to the public. Individuals affected by such an event-specific blackout will be notified by the Company that they are subject to the blackout. Subject to the exceptions noted above, all those affected should not trade in our securities while the suspension is in effect, and in the event that a press release is issued by the Company in connection with the event that resulted in the event-specific blackout (or the event or circumstances go away), such suspension shall continue for one full trading day after the public release. Additionally, individuals affected by such an event-specific blackout should not disclose to others that we have suspended trading, because the event-specific blackout itself is material non-public information.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance of All Transactions by All Officers, Directors, Employees and Certain Consultants</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To provide assistance in preventing inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale of the Company&#x2019;s securities, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all transactions in the Company&#x2019;s securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (including without limitation, acquisitions and dispositions (including gifts) of Company stock, the &#x201c;net&#x201d; or &#x201c;cashless&#x2019; exercise of stock options and the sale of Company stock issued upon exercise of stock options) by all officers, directors, employees and certain consultants designated by management, other than exercises of stock options with cash or other equity awards or vesting of equity-based awards that do not involve a market sale of the Company&#x2019;s securities </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">must be pre-cleared</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Compliance Officer</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the pre-clearance process, the individual requesting pre-clearance must confirm that he or she is not in possession of material, non-public information. Pre-clearance does not relieve anyone of his or her responsibility under SEC rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, transactions in the Company&#x2019;s securities pursuant to a Rule 10b5-1 plan, which was approved in advance of entering into the plan, are considered pre-cleared.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Transactions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The insider trading laws continue to apply to transactions in the Company&#x2019;s securities even after termination of service to the Company. If an individual is in possession of material, non-public information when his or her service terminates, that individual may not trade in the Company&#x2019;s securities until that information has become public or is no longer material.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Relating to the Company</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Access to Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Access to material, non-public information about the Company, including the Company&#x2019;s business, earnings or prospects, should be limited to officers, directors, employees and consultants of the Company on a need-to-know basis. In addition, such information should not be communicated to anyone outside the Company under any circumstances (except in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company on an other than need-to-know basis.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In communicating material, non-public information to employees of the Company, all officers, directors, employees and consultants must take care to emphasize the need for confidential treatment of such information and adherence to the Company&#x2019;s policies with regard to confidential information.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inquiries From Third Parties</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inquiries from third parties, such as industry analysts or members of the media, about the Company should be directed to the Compliance Officer, Chief Financial Officer or head of Investor relations.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Access to Company Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following procedures are designed to maintain confidentiality with respect to the Company&#x2019;s business operations and activities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All officers, directors, employees and consultants should take all steps and precautions necessary to restrict access to, and secure, material, non-public information by, among other things:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining the confidentiality of Company-related transactions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting their business and social activities so as not to risk inadvertent disclosure of confidential information. Review of confidential documents in public places should be conducted so as to prevent access by unauthorized persons;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restricting access to documents and files (including computer files) containing material, non-public information to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">promptly removing and cleaning up all confidential documents and other materials from conference rooms following the conclusion of any meetings (including erasing any whiteboards or other viewable information);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disposing of all confidential documents and other papers, after there is no longer any business or other legally required need, through shredders when appropriate;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restricting access to areas likely to contain confidential documents or material, non-public information, including individual offices that may contain such information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safeguarding laptop computers, mobile devices, tablets, memory sticks, CDs and other items that contain confidential information, including complying with Company IT policies to prevent unauthorized access to your devices and/or electronic information to which you have access; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">avoiding the discussion of material, non-public information in places where the information could be overheard by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel involved with material, non-public information, to the extent feasible, should conduct their business and activities in areas separate from other Company activities.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">V.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADDITIONAL PROHIBITED TRANSACTIONS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy engage in certain types of transactions. Therefore, officers, directors, employees and the specified consultants shall comply with the following policies with respect to certain transactions in the Company securities:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short sales of the Company&#x2019;s securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller&#x2019;s incentive to improve the Company&#x2019;s performance. For these reasons, short sales of the Company&#x2019;s securities are prohibited by this Policy. In addition, as noted below, Section 16(c) of the 1934 Act absolutely prohibits Section 16 reporting persons from making short sales of the Company&#x2019;s equity securities, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, sales of shares that the insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publicly Traded Options</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A transaction in options is, in effect, a bet on the short-term movement of the Company&#x2019;s stock and therefore creates the appearance that an officer, director, employee or consultant is trading based on inside information. Transactions in options also may focus an officer&#x2019;s, director&#x2019;s, employee&#x2019;s or consultant&#x2019;s attention on short-term performance at the expense of the Company&#x2019;s long-term objectives. Accordingly, transactions in puts, calls or other derivative securities involving the Company&#x2019;s equity securities, on an exchange or in any other organized market, are prohibited by this Policy.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging Transactions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow an insider to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. These transactions allow the insider to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, the insider may no longer have the same objectives as the Company&#x2019;s other stockholders. Therefore, hedging transactions involving the Company&#x2019;s equity securities, including but not limited to zero-cost collars and forward sale contracts, are prohibited by this Policy.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of the Company&#x2019;s Securities on Margin; Pledging the Company&#x2019;s Securities to Secure Margin or Other Loans</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchasing on margin means borrowing from a brokerage firm, bank or other entity in order to purchase the Company&#x2019;s securities (other than in connection with a cashless exercise of stock options under the Company&#x2019;s equity plans). Margin purchases of the Company&#x2019;s securities are prohibited by this Policy. Pledging the Company&#x2019;s securities as collateral to secure loans is prohibited. This prohibition means, among other things, that you cannot hold the Company&#x2019;s securities in a &#x201c;margin account&#x201d; (which would allow you to borrow against your holdings to buy securities).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VI.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULE 10b5-1 TRADING PLANS, SECTION 16 AND RULE 144</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 will protect directors, officers, employees and consultants from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade in the Company&#x2019;s stock (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) entered into in good faith at a time when he or she is not in possession of material, non-public</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information, and where he or she acted in good faith with respect to the Trading Plan, and in accordance with the terms of Rule 10b5-1 and all applicable state laws, and such transactions will be exempt from the trading restrictions set forth in this Policy. The initiation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company&#x2019;s securities, and such initiation or modification is subject to all limitations and prohibitions relating to transactions in the Company&#x2019;s securities. You may not adopt more than one Trading Plan at a time except under the limited circumstances permitted by Rule 10b5-1 (i.e., all transactions under the later adopted Trading Plan may only begin after all transactions under the earlier adopted Trading Plan have been completed or expired and after the observance of the applicable cooling-off period) and subject to preapproval by the Compliance Officer. Plans that authorize sell-to-cover transactions to satisfy tax withholding obligations incident to the vesting of equity awards are permitted even if you have another Trading Plan in place, as long as the sell-to-cover plan authorizes an agent to sell only the securities necessary to satisfy the tax withholding obligations, and you do not otherwise control the timing of the sales.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each such Trading Plan, and any modification or revocation thereof, must be submitted to and pre-approved by the Compliance Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who may impose such conditions on the implementation and operation of the Trading Plan as the Compliance Officer deems necessary or advisable. The Compliance Officer may prescribe certain forms of Trading Plans to which employees&#x2019; Trading Plans must conform. The Compliance Officer may also require that Trading Plans be arranged with a specified broker. However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or the Compliance Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Plans do not exempt individuals from complying with Section 16 short-swing profit rules or liability.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of trading windows and blackout periods, even when there is undisclosed material information. A Trading Plan may also help reduce negative publicity that may result when key executives sell the Company&#x2019;s stock. Rule 10b5-1 only provides an &#x201c;affirmative defense&#x201d; in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A director, officer, employee or consultant may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during a trading window period outside of the trading blackout period. Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&#x2019;s filing coordinator to assist in the preparation and filing of a required Form 4.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the Company&#x2019;s securities, even pursuant to a previously approved Trading Plan, if the Compliance Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation or other prohibition is in the best interests of the Company. Any Trading Plan submitted for approval hereunder should explicitly acknowledge the Company&#x2019;s right to prohibit transactions in the Company&#x2019;s securities. Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this Policy and result in a loss of the exemption set forth herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers, directors, employees and consultants may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company&#x2019;s stock, including the exercise of options. Trades pursuant to a Trading Plan generally may occur at any time. However, the Company requires a cooling-off period under which no purchases or sales may occur for:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16 reporting persons that extends to the later of 90 days after adoption or modification of a Trading Plan or two business days after filing of the Form 10-K or Form 10-Q covering the fiscal quarter in which the Trading Plan was adopted, up to a maximum of 120 days; and </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employees and any other persons, other than the Company, that extends 30 days after adoption or modification of a Trading Plan.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Please review the following description of how a Trading Plan works.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Rule 10b5-1, an individual&#x2019;s purchase or sale of securities will not be &#x201c;on the basis of&#x201d; material, non-public information if:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).	</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second, the Trading Plan must either (i) specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold or (ii) include a written formula or computer algorithm for determining the amount, price and date of the transactions, and prohibit the individual from exercising any subsequent influence over the purchase or sale of the Company&#x2019;s stock under the Trading Plan in question.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third, for Section 16 reporting persons, the Trading Plan must include a representation that the Section 16 reporting person is (i) not aware of any material non-public information about the Company or its securities and (ii) adopting the Trading Plan in good faith and not as part of a plan or scheme to evade Rule 10b-5.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fourth, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revocation of and Amendments to Trading Plans</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revocation of Trading Plans should occur only in unusual circumstances. Effectiveness of any revocation, modification or amendment of a Trading Plan will be subject to the prior review and approval of the Compliance Officer. Revocation is effected upon written notice to the broker. You should note that revocation of a Trading Plan can result in the loss of an affirmative defense for past or future transactions under a Trading Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A person acting in good faith may modify a prior Trading Plan so long as such modifications are made outside of a blackout period and at a time when the Trading Plan participant does not possess material, non-public information. Modifications of a Trading Plan that change the amount, price or timing of the purchase or sale of the securities underlying a Trading Plan will trigger a new cooling-off period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Trading Plan shall include provision for suspension or revocation in certain circumstances, such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or be expected to have an adverse effect on the Company. The Compliance Officer or administrator of the Company&#x2019;s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of suspension or revocation.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discretionary Plans</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred to a broker, are permitted if pre-approved by the Compliance Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases of the Company&#x2019;s stock or option exercises, including but not limited to, blind trusts, discretionary accounts with banks or brokers, or limit orders. The actual transactions effected</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to a pre-approved Trading Plan will not be subject to further pre-clearance for transactions in the Company&#x2019;s stock once the Trading Plan or other arrangement has been pre-approved by the Compliance Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reporting (if Required)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If required, an SEC Form 144 will be completed and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings. A footnote at the bottom of the Form 144 should indicate that the trades &#x201c;are in accordance with a Trading Plan adopted under Rule 10b5-1.&#x201d; For Section 16 reporting persons, Forms 4 are required to be filed before the end of the second business day following the date that the broker, dealer or plan administrator informs the individual that a transaction was executed, provided that the date of such notification is not later than the third business day following the trade date. A similar footnote should be placed at the bottom of the Form 4 as outlined above.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercises of options for cash may be executed at any time. &#x201c;Cashless exercise&#x201d; option exercises are subject to trading windows. However, the Company will permit same day sales under Trading Plans. If a broker is required to execute a cashless exercise in accordance with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are signed, undated and with the number of shares to be exercised left blank. Once a broker determines that the time is right to exercise the option and dispose of the shares in accordance with the Trading Plan, the broker will notify the Company in writing and the administrator of the Company&#x2019;s stock plans will fill in the number of shares and the date of exercise on the previously signed exercise form. The insider should not be involved with this part of the exercise.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trades Outside of a Trading Plan</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During an open trading window, trading in Company securities not pursuant to an approved Trading Plan is allowed as long as the trading instructions in the approved Trading Plan continue to be followed.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public Announcements</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may make a public disclosure or announcement that Trading Plans and non-Rule 10b5-1 trading arrangements are being adopted, modified or terminated as required by SEC rules or otherwise in the Company&#x2019;s discretion. It will consider in each case whether a public disclosure or announcement should be made. It may also make public disclosures, announcements or respond to inquiries from the media as transactions are made under a Trading Plan.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibited Transactions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transactions prohibited under Section V of this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company&#x2019;s securities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	9.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation on Liability</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of the Company, the Compliance Officer or the Company&#x2019;s other employees will have any liability for any delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this Policy. Notwithstanding any review of a Trading Plan pursuant to this Policy, none of the Company, the Compliance Officer or the Company&#x2019;s other employees assumes any liability for the legality or consequences relating to such Trading Plan to the person adopting such Trading Plan.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16: Insider Reporting Requirements, Short-Swing Profits and Short Sales (Applicable to Officers, Directors and 10% Stockholders)</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reporting Obligations Under Section 16(a): SEC Forms 3, 4 and 5</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) of the 1934 Act generally requires all officers, directors and beneficial owners of more than ten percent of our outstanding stock (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10% stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16 insider</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), within 10 days after the Section 16 insider becomes an officer, director, or 10% stockholder, to file with the SEC an &#x201c;Initial Statement of Beneficial Ownership of Securities&#x201d; on Form 3 listing the amount of the Company&#x2019;s stock, options and warrants which the Section 16 insider beneficially owns. Following the initial filing on Form 3, changes in beneficial ownership of the Company&#x2019;s stock, options and warrants, including as a result of a disposition of equity securities by gift, must be reported on Form 4, generally within two business days after the date on which such change occurs, or in certain cases on Form 5, within 45 days after fiscal year end. The two-day Form 4 deadline begins to run from the trade date rather than the settlement date (or for gifts, the date of the gift). A Form 4 must be filed even if, as a result of balancing transactions, there has been no net change in holdings. In certain situations, purchases or sales of Company stock made within six months </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">prior</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the filing of a Form 3 must be reported on Form 4. Similarly, certain purchases or sales of Company stock made within six months </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">after</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an officer or director ceases to be an insider must be reported on Form 4.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recovery of Profits Under Section 16(b)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of preventing the unfair use of information which may have been obtained by a Section 16 insider, any profits realized by any officer, director or 10% stockholder from any &#x201c;purchase&#x201d; and &#x201c;sale&#x201d; of Company stock during a six-month period (so called &#x201c;short-swing profits&#x201d;) are subject to recovery by the Company. When such a purchase and sale occurs, good faith is no defense. The Section 16 insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without the use of any inside information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liability of an insider under Section 16(b) of the 1934 Act is only to the Company itself. The Company, however, cannot waive its right to short swing profits, and any Company stockholder can bring suit in the name of the Company. Reports of ownership filed with the SEC on Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations. In addition, liabilities under Section 16(b) may require separate disclosure in the Company&#x2019;s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders. No suit may be brought more than two years after the date the profit was realized. However, if the Section 16 insider fails to file a report of the transaction under Section 16(a), as required, the two-year limitation period does not begin to run until after the transactions giving rise to the profit have been disclosed. Failure to report transactions and late filing of reports require separate disclosure in the Company&#x2019;s proxy statement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers and directors should consult the attached &#x201c;Short-Swing Profit Rule Section 16(b) Checklist&#x201d; attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in addition to consulting the Compliance Officer prior to engaging in any transactions involving the Company&#x2019;s securities, including without limitation, the Company&#x2019;s stock, options or warrants.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales Prohibited Under Section 16(c)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(c) of the 1934 Act prohibits insiders absolutely from making short sales of the Company&#x2019;s equity securities. Short sales include sales of stock which the insider does not own at the time of sale, or sales of stock against which the insider does not deliver the shares within 20 days after the sale. Under certain circumstances, the purchase or sale of put or call options, or the writing of such options, can result in a violation of Section 16(c). Insiders violating Section 16(c) face criminal liability.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer should be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales under Section 16.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144 (Applicable to Officers, Directors and 10% Stockholders)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144 provides a safe harbor exemption to the registration requirements of the Securities Act of 1933, as amended, for certain resales of &#x201c;restricted securities&#x201d; and &#x201c;control securities.&#x201d; &#x201c;Restricted securities&#x201d; are securities acquired from an issuer, or an affiliate of an issuer, in a transaction, or chain of transactions, not involving a public offering. &#x201c;Control securities&#x201d; are </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">any</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities owned by directors, executive officers or other &#x201c;affiliates&#x201d; of the issuer, including stock purchased in the open market and stock received upon exercise of stock options. Sales of Company securities by affiliates (generally, directors, officers and 10% stockholders of the Company) must comply with the requirements of Rule 144, which are summarized below:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current Public Information.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company must have filed all SEC-required reports during the last 12 months.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Volume Limitations.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Total sales of Company common stock by a covered individual for any three-month period may not exceed the </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">greater</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of: (i) 1% of the total number of outstanding shares of Company common stock, as reflected in the most recent report or statement published by the Company, or (ii) the average weekly reported volume of such shares traded during the four calendar weeks preceding the filing of the requisite Form 144.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Method of Sale.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The shares must be sold either in a &#x201c;broker&#x2019;s transaction&#x201d; or in a transaction directly with a &#x201c;market maker.&#x201d; A &#x201c;broker&#x2019;s transaction&#x201d; is one in which the broker does no more than execute the sale order and receive the usual and customary commission. Neither the broker nor the selling person can solicit or arrange for the sale order. In addition, the selling person or Board member must not pay any fee or commission other than to the broker. A &#x201c;market maker&#x201d; includes a specialist permitted to act as a dealer, a dealer acting in the position of a block positioner, and a dealer who holds himself out as being willing to buy and sell Company common stock for his own account on a regular and continuous basis. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice of Proposed Sale.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> A notice of the sale (a Form 144) must be filed with the SEC at the time of the sale. Brokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing the Form 144 and in complying with the other requirements of Rule 144.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are subject to Rule 144, you must instruct your broker who handles trades in Company securities to follow the brokerage firm&#x2019;s Rule 144 compliance procedures in connection with all trades.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VII.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	After reading this Policy, all officers, directors and employees and any consultant identified by management should execute and return to the Compliance Officer the Certification of Compliance form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment B</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.94in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1 Attachment A</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-Swing Profit Rule Section 16(b) Checklist</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note: ANY combination of PURCHASE AND SALE or SALE AND PURCHASE within six months of each other by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities) results in a violation of Section 16(b), and the &#x201c;profit&#x201d; must be recovered by Annexon, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). It makes no difference how long the shares being sold have been held or, for officers and directors, that you were an insider for only one of the two matching transactions. The highest priced sale will be matched with the lowest priced purchase within the six-month period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If a sale is to be made by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities):</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	1.	Have there been any purchases by the insider (or family members living in the same household or certain affiliated entities) within the past six months?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	2.	Have there been any option grants or exercises not exempt under Rule 16b-3 within the past six months?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	3.	Are any purchases (or non-exempt option exercises) anticipated or required within the next six months?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	4.	Has a Form 4 been prepared?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Note: If a sale is to be made by an affiliate of the Company, has a Form 144 been prepared and has the broker been reminded to sell pursuant to Rule 144 under the <br>Securities Act of 1933, as amended?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases And Option Exercises</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If a purchase or option exercise for Company stock is to be made:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	1.	Have there been any sales by the insider (or family members living in the same household or certain affiliated entities) within the past six months?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	2.	Are any sales anticipated or required within the next six months (such as tax-related or year-end transactions)?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	3.	Has a Form 4 been prepared?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Before proceeding with a purchase or sale, consider whether you are aware of material inside information which could affect the price of the Company stock. All transactions in the Company&#x2019;s securities by officers and directors must be </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-cleared</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by contacting the Compliance Officer.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\109333072.8||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>annx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1.13in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:20pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (Nos.333-258863, 333-268181, 333-278246, and 333-281493) on Form S-3 and in the registration statements (Nos. 333-240101, 333-254707, 333-263193, 333-266671, 333-270307, 333-278244, 333-282360, and 333-283944) on Form S-8 of our report dated March 3, 2025, with respect to the consolidated financial statements of Annexon, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Francisco, California<br>March 3, 2025</font></p>
  <p style="text-indent:-5.337%;padding-left:5.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>annx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1.13in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Douglas Love, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Annexon, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:49%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Douglas Love</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Douglas Love, Esq.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>annx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1.13in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Jennifer Lew, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Annexon, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:49%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jennifer Lew</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jennifer Lew</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Executive Vice President and Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>annx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1.13in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002, AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Annexon, Inc. (&#x201c;Company&#x201d;) for the year ended December 31, 2024 (&#x201c;Report&#x201d;) filed with the Securities and Exchange Commission on the date hereof, Douglas Love, President and Chief Executive Officer of the Company, and Jennifer Lew, Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended, that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:2%;box-sizing:content-box;"></td>
    <td style="width:48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Douglas Love</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Douglas Love, Esq.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jennifer Lew</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jennifer Lew</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President and Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img136305557_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img136305557_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /)" \# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_ '_ )_U9^5_[FJ*_AE_XB<?VHO^B:>"?_!9!_\ )E'_ !$X_M1?]$T\$_\
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M>"?_  60?_)E'_$3C^U%_P!$T\$_^"R#_P"3*/[#S#_GW#_P8@_M7"?S5/\
MP!_Y_P!6?E?^YJBOX9?^(G']J+_HFG@G_P %D'_R91_Q$X_M1?\ 1-/!/_@L
M@_\ DRC^P\P_Y]P_\&(/[5PG\U3_ , ?^?\ 5GY7_N:HK^&7_B)Q_:B_Z)IX
M)_\ !9!_\F4?\1./[47_ $33P3_X+(/_ ),H_L/,/^?</_!B#^U<)_-4_P#
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M_P!6?E?^YJBOX9?^(G']J+_HFG@G_P %D'_R91_Q$X_M1?\ 1-/!/_@L@_\
MDRC^P\P_Y]P_\&(/[5PG\U3_ , ?^?\ 5GY7_N:HK^&7_B)Q_:B_Z)IX)_\
M!9!_\F4?\1./[47_ $33P3_X+(/_ ),H_L/,/^?</_!B#^U<)_-4_P# '_G_
M %9^5_[FJ*_AE_XB<?VHO^B:>"?_  60?_)E'_$3C^U%_P!$T\$_^"R#_P"3
M*/[#S#_GW#_P8@_M7"?S5/\ P!_Y_P!6?E?^YJBOX9?^(G']J+_HFG@G_P %
MD'_R92'_ (.<OVH@"1\-/!)P"<?V9#V'_7Y1_8>8?\^X?^#$']JX3^:I_P"
M/_/^K/RO_<W17\>'BC_@X3_:*T3]G7P=\7H/A_X1?6/$/BJWT*YM'T^+[/'!
M-9W%PSJANL!PT2X.[H>^:^=/^(G']J+_ *)IX)_\%D'_ ,F5,<FQTKN,(.S<
M7[ZW6_0J69X6-KRGJE)>X]G9KKV>W_ O_<U17\,O_$3C^U%_T33P3_X+(/\
MY,H_XB<?VHO^B:>"?_!9!_\ )E5_8>8?\^X?^#$3_:N$_FJ?^ /_ #_JS\K_
M -S5%?PR_P#$3C^U%_T33P3_ ."R#_Y,H_XB<?VHO^B:>"?_  60?_)E']AY
MA_S[A_X,0?VKA/YJG_@#_P _ZL_*_P#<U17\,O\ Q$X_M1?]$T\$_P#@L@_^
M3*/^(G']J+_HFG@G_P %D'_R91_8>8?\^X?^#$']JX3^:I_X _\ /^K/RO\
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MRC^P\P_Y]P_\&(7]JX3^:I_X _\ /^K/RO\ W-45_#+_ ,1./[47_1-/!/\
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M3*/^(G']J+_HFG@G_P %D'_R91_8>8?\^X?^#$']JX3^:I_X _\ /^K/RO\
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MJR3[._X)_P#_ "<YH?\ V3WXJ_\ J%ZC7R3XB_Y&#7/^PI=_^C#7UM_P3_\
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M:U.$:BO"4I*TE:]X]U9H(4:U1RC3ISG*&DE&+;CK;7MJG]S/PVHK]'_V;_\
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MN[&RDOM6\3:ZUQ8^#M%"(DD=IJVLP0SK9WMU$_FVL+Q_O8T=@W&*^IOVN_\
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M12?LDY5+27N13LV_)-I-]V7]7KKDO1J+VC2A>+]YM727G;IN?G/17[S^*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCZMX0\#>'M UC4-'T86&C2K):SZ_I5C=VUIK4C&XD65M0A=I,*7)(!K]FO\
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M-"N-7N(KR2VC6%&@>\S/+#&T9!,BK\U</_P3@_X)(_!C]E7]N/3_ -H;P?\
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M** "BBB@ HHHH *^A_V1/^3K?V;_ /LLO@G_ -.2U\\5]#_LB?\ )UO[-_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5_ER_\%*_^3X?V@?\ L=M7_P#3I?U_J-5_ER_\%*_^3X?V@?\ L=M7_P#3
MI?U]%PY_O&(_Z\Q_]+1X^<?PJ7^*7_MI\,T445]<?/A@>E%%% !@=<<^M%%%
M "8'H/R%+110 F!Z#\J" >H!^M+10 F .@ _"C QC QZ=J6B@ I, = !2T4
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M[]7^844458@HHHH **** "BBB@ P.N.?6BBB@ P/2BBB@ P!T&*,#THHH 3
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MU_I:\/\ 8]+_ )_5/NC_ )'^8K_PZ:_;_P#^B":M_P"!B_\ R/1_PZ:_;_\
M^B":M_X&+_\ (]?Z=5%'^L6)_P"?-'[Y?Y^O]+4_L>E_S^J?='_(_P Q7_AT
MU^W_ /\ 1!-6_P# Q?\ Y'H_X=-?M_\ _1!-6_\  Q?_ )'K_3JHH_UBQ/\
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MR_S]?Z6I_8]+_G]4^Z/^1_F*_P##IK]O_P#Z()JW_@8O_P CT?\ #IK]O_\
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MY32Y%#VM324I7M'[2BFK6_NK\3_,5_X=-?M__P#1!-6_\#%_^1Z/^'37[?\
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M^W__ -$$U;_P,7_Y'K_3JHH_UBQ/_/FC]\O\_7^EJ?V/2_Y_5/NC_D?YBO\
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M'[Y?Y^O]+4_L>E_S^J?='_(_S%?^'37[?_\ T035O_ Q?_D>C_ATU^W_ /\
M1!-6_P# Q?\ Y'K_ $ZJ*/\ 6+$_\^:/WR_S]?Z6I_8]+_G]4^Z/^1_F*_\
M#IK]O_\ Z()JW_@8O_R/1_PZ:_;_ /\ H@FK?^!B_P#R/7^G511_K%B?^?-'
M[Y?Y^O\ 2U/['I?\_JGW1_R/\Q7_ (=-?M__ /1!-6_\#%_^1Z/^'37[?_\
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MY\T?OE_GZ_TM3^QZ7_/ZI]T?\C_,5_X=-?M__P#1!-6_\#%_^1Z/^'37[?\
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M6I_8]+_G]4^Z/^1_F*_\.FOV_P#_ *()JW_@8O\ \CT?\.FOV_\ _H@FK?\
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M+_\ (]?Z=5%'^L6)_P"?-'[Y?Y^O]+4_L>E_S^J?='_(_P Q7_ATU^W_ /\
M1!-6_P# Q?\ Y'H_X=-?M_\ _1!-6_\  Q?_ )'K_3JHH_UBQ/\ SYH_?+_/
MU_I:G]CTO^?U3[H_Y'^8K_PZ:_;_ /\ H@FK?^!B_P#R/1_PZ:_;_P#^B":M
M_P"!B_\ R/7^G511_K%B?^?-'[Y?Y^O]+4_L>E_S^J?='_(_S%?^'37[?_\
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M"=.G&,W%MQYK^ZU+2[MNON-L/EM/#U8U8U)R<4TDTDM5;6P4445XYZ04444
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MNL>!O#\NKV&DZL]S'IU[.DD<:173V;QW*Q$OEC$ZM@<&ORB_X(R?\%9/B_\
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M7_A'?M5S<W\[V,<$LUXMR4\N(J1D@@^!?\$W?V[?V.O@3_P2Q^%-M\6?C?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#^<G_@YN_Y,*\._]E6T[_TP:S7YM?\
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MC*^'E#,<-B7Q%G$94,WP7UOZHXX6I2HTG[7$4I*G"./J2P\YRIJWY*?MJ?\
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MI<L,Q1Z):ND&8]J/M4*BC%>!?LAY/_!RI\?>I/\ PTS\5/?IIU__ "%?U/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_\ +>C_ (A^O^"5_P#T;Q+_ .%UXQ_^6]'-G_\ SZRKI_R]Q/E?_EWZ_?\
M<?4_HP_]#OQM_P##)P7_ //3^KORM].?\/6/^"=7_1WOP8_\*9/_ (S1_P /
M6/\ @G5_T=[\&/\ PID_^,U\Q?\ $/S_ ,$L/^C>9O\ PN?&'_RVH_XA^?\
M@EA_T;S-_P"%SXP_^6U'-G__ #ZRKI_R]Q/E?_EWZ_?]Q]3^C#_T._&W_P ,
MG!?_ ,]/ZN_*WT[_ ,/6/^"=7_1WOP8_\*9/_C-'_#UC_@G5_P!'>_!C_P *
M9/\ XS7S%_Q#\_\ !+#_ *-YF_\ "Y\8?_+:C_B'Y_X)8?\ 1O,W_A<^,/\
MY;4<V?\ _/K*NG_+W$^5_P#EWZ_?]Q]3^C#_ -#OQM_\,G!?_P ]/ZN_*WT[
M_P /6/\ @G5_T=[\&/\ PID_^,T?\/6/^"=7_1WOP8_\*9/_ (S7S%_Q#\_\
M$L/^C>9O_"Y\8?\ RVH_XA^?^"6'_1O,W_A<^,/_ );4<V?_ //K*NG_ "]Q
M/E?_ )=^OW_<?4_HP_\ 0[\;?_#)P7_\]/ZN_*WT[_P]8_X)U?\ 1WOP8_\
M"F3_ .,T?\/6/^"=7_1WOP8_\*9/_C-?,7_$/S_P2P_Z-YF_\+GQA_\ +:C_
M (A^?^"6'_1O,W_A<^,/_EM1S9__ ,^LJZ?\O<3Y7_Y=^OW_ ''U/Z,/_0[\
M;?\ PR<%_P#ST_J[\K?3O_#UC_@G5_T=[\&/_"F3_P",T?\ #UC_ ()U?]'>
M_!C_ ,*9/_C-?,7_ !#\_P#!+#_HWF;_ ,+GQA_\MJ/^(?G_ ()8?]&\S?\
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M;S-_X7/C#_Y;4<V?_P#/K*NG_+W$^5_^7?K]_P!Q]3^C#_T._&W_ ,,G!?\
M\]/ZN_*WT[_P]8_X)U?]'>_!C_PID_\ C-'_  ]8_P""=7_1WOP8_P#"F3_X
MS7S%_P 0_/\ P2P_Z-YF_P#"Y\8?_+:C_B'Y_P""6'_1O,W_ (7/C#_Y;4<V
M?_\ /K*NG_+W$^5_^7?K]_W'U/Z,/_0[\;?_  R<%_\ ST_J[\K?3O\ P]8_
MX)U?]'>_!C_PID_^,T?\/6/^"=7_ $=[\&/_  ID_P#C-?,7_$/S_P $L/\
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M7?K]_P!Q]3^C#_T._&W_ ,,G!?\ \]/ZN_*WT[_P]8_X)U?]'>_!C_PID_\
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MPS!>6^CQS>+?%3R6T5_<&ZN5:7^U0\OF3$MF0L1T&*SO^'"__!+K_HW"T_\
M"L\5_P#RUKUJ3JNE!UU!5N5>T5)RE34[>\H.24G&^S:3/Q3.HY/#-LQCP]4S
M&MD<<76655<WIX>CF=3!*3]A+'4L).IAJ>)<+>UC0J3IJ7PNVWT9_P /3O\
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M]._X)T_]'D_ ;_PN-/H_X>G?\$Z?^CR?@-_X7&GU\Y_\.%_^"77_ $;A:?\
MA6>*_P#Y:T?\.%_^"77_ $;A:?\ A6>*_P#Y:T ?1G_#T[_@G3_T>3\!O_"X
MT^C_ (>G?\$Z?^CR?@-_X7&GU\Z?\.&/^"7/_1M]G_X5GBS_ .6U'_#AC_@E
MS_T;?9_^%9XL_P#EM0!]%_\ #T[_ ()T_P#1Y/P&_P#"XT^C_AZ=_P $Z?\
MH\GX#?\ A<:?7SI_PX8_X)<_]&WV?_A6>+/_ );4?\.&/^"7/_1M]G_X5GBS
M_P"6U 'T7_P]._X)T_\ 1Y/P&_\ "XT^C_AZ=_P3I_Z/)^ W_A<:?7SI_P .
M&/\ @ES_ -&WV?\ X5GBS_Y;4?\ #AC_ ()<_P#1M]G_ .%9XL_^6U 'T7_P
M]._X)T_]'D_ ;_PN-/H_X>G?\$Z?^CR?@-_X7&GU\Z?\.&/^"7/_ $;?9_\
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M^ W_ (7&GU\Z?\.&/^"7/_1M]G_X5GBS_P"6U'_#AC_@ES_T;?9_^%9XL_\
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M 'T9_P /3O\ @G3_ -'D_ ;_ ,+C3Z/^'IW_  3I_P"CR?@-_P"%QI]?.?\
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M (_3U_X(6?\ !+DC/_#-J]>_C;Q+_2Y%3R/^OE_7R]+USK^OEY>;^[S/K_\
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MX)T_]'D_ ;_PN-/KYN_X<-?\$N?^C;[7_P *[Q9_\M:/^'#7_!+G_HV^U_\
M"N\6?_+6@H^D?^'IW_!.G_H\GX#?^%QI]'_#T[_@G3_T>3\!O_"XT^OF[_AP
MU_P2Y_Z-OM?_  KO%G_RUJ4?\$&/^"7) /\ PSA:<_\ 4V>*_P#Y:T";2:3Z
M['T9_P /3O\ @G3_ -'D_ ;_ ,+C3Z/^'IW_  3I_P"CR?@-_P"%QI]?.?\
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M_A3)_P#&:^8O^(?G_@EA_P!&\S?^%SXP_P#EM1_Q#\_\$L/^C>9O_"Y\8?\
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MB_XA^?\ @EA_T;S-_P"%SXP_^6U'_$/S_P $L/\ HWF;_P +GQA_\MJ.;/\
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MS?\ A<^,/_EM1_Q#\_\ !+#_ *-YF_\ "Y\8?_+:CFS_ /Y]95T_Y>XGRO\
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M_+OU^_[CZG]&'_H=^-O_ (9."_\ YZ?U=^5OIW_AZQ_P3J_Z.]^#'_A3)_\
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M'?C;_P"&3@O_ .>G]7?E;Z=_X>L?\$ZO^CO?@Q_X4R?_ !FC_AZQ_P $ZO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFTO]:N(-[_P<M\F_^8;R_J^G^L.O_!4O_@FP#G_AN7]FWC_JH>G_ -4%2?\
M#TW_ ()L=_VY?V;?_#B:=_\ $BO\G7[/;_\ /"'_ +])_P#$T?9[?_GA#_WZ
M3_XFH_UIQE[_ %3#=OXE7;3^[Y/[_(U_XE*X6=[\5<0:VO\ N<M\O^H?R_+S
M/]9#_AZ?_P $V/\ H^/]F_\ \.'IW_Q-2I_P50_X)K@<_MR?LW=?^BB:=_\
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M5_E(_8K/_GTMO^_$7_Q%'V*S_P"?2V_[\1?_ !%'^M6+6^$PW1:3J];+_/\
M T7T'^"G9_ZZ<4V>O^[93Y?]0_J?ZMW_  ]0_P""<G_1Z?[/'_AQ]"_^2*7_
M (>G_P#!.7_H]+]GG_PXVA__ !^O\I)+*SW#_1+;O_RPB]#_ +%3?8K/_GTM
MO^_$7_Q%'^M6+_Z!,-_X,J^7EZ_@:1^@YP2U?_73BG>W^[93Y?\ 4/Z_@?ZL
M_P#P]/\ ^"<O_1Z7[//_ (<;0_\ X_2_\/3O^"<W_1Z/[/7_ (<;0_\ X_7^
M4XMC9;1_H=KW_P"7>+U/^Q3OL-E_SYVO_@/%_P#$5F^+<8FU]4PVG]^J5_Q(
MWP1_T6O%7_A-E'_S.?ZL/_#TW_@G-_T>C^SU_P"'&T/_ ./T?\/3?^"<W_1Z
M/[/7_AQM#_\ C]?Y3WV*S'2TM1_V[Q?_ !%/6RL]P_T2V[_\L(O0_P"Q0^+<
M8O\ F$PVR?QU>JN6OH,<$-)_Z[<5:_\ 4+E'_P H/]5[_AZ;_P $YO\ H]']
MGK_PXVA__'Z4?\%3/^"<YZ?MH?L]?^'&T/\ ^2*_RI?L-E_SYVO_ (#Q?_$4
M?8;+_GSM?_ >+_XBC_6W&?\ 0)AO_ ZI<?H+<#MI?Z[<5_\ A+E';_L']?Z6
MO^JW_P /2_\ @G1_T>A^SU_X<;0__DBC_AZ7_P $Z/\ H]#]GK_PXVA__)%?
MY4GV&R_Y\[7_ ,!XO_B*7[%9_P#/I;?]^(O_ (BC_6W&?] F&_\  ZI?_$BG
M W7C;BO_ ,)<H_\ F<_U6O\ AZ7_ ,$Z/^CT/V>O_#C:'_\ )%'_  ]+_P""
M='_1Z'[/7_AQM#_^2*_RI?L5G_SZ6W_?B+_XBGI969SFTM3TZV\7O_L4?ZVX
MS_H$PW_@=4I?03X&;2_UWXLU_P"H7)^R_P"H?U_ _P!5?_AZ7_P3H_Z/0_9Z
M_P##C:'_ /)%'_#TK_@G1_T>?^SU_P"'&T/_ .2*_P JS[#9?\^=K_X#Q?\
MQ%.2QLMP_P!#M>__ "[Q>G^Y1_K;C/\ H$PW_@=4O_B1#@;_ *+?BS_PER?R
M_P"H?U_#MK_JI?\ #TG_ ()T_P#1Y_[/?_AQM#_^/T?\/2?^"=/_ $>=^SW_
M .'%T/\ ^/U_E9_8;+_GSM?_  'B_P#B*/L-E_SYVO\ X#Q?_$4O];<;_P!
MF%_\#J^7_!_#S#_B1#@7KQQQ9_X2Y/Y?]./7\#_5,_X>D_\ !.G_ *//_9[_
M /#C:'_\?I?^'I/_  3J/3]L[]GL_P#=1=#_ /C]?Y67V&R_Y\[7_P !XO\
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M_P!RH?&&-3M]3PO3[=7R_P"#^'S?_$@W ?\ T77%W_A)DWE_U#^OX>9_J?\
M_#T3_@G=_P!'E_L^_P#AQ=#_ /C]'_#T3_@G=_T>7^S[_P"'%T/_ ./U_EC?
M8+'_ )\K3_P&A_\ B*/L%C_SY6G_ (#0_P#Q%+_7'&?] >%_\#J_UW_I:G_$
M@W ?_1=<7?\ A)DWE_U#^OX>9_J=?\/0_P#@G?\ ]'E?L_?^'$T3_P"/T?\
M#T/_ ()W_P#1Y7[/W_AQ-$_^/U_EC?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/
M%_\ $4?ZXXS_ * \+_X'5_KO_2UU_P") N O^B[XO_\ "3)O_F?U_IZ?ZG/_
M  ]#_P""=_\ T>5^S]_X<31/_C]'_#T+_@G?_P!'E?L_?^'$T3_X_7^6-]AL
MO^?.U_\  >+_ .(H^PV7_/G:_P#@/%_\11_KCC/^@/"_^!U?Z[_TM3_B0+@+
M_HN^+_\ PDR;_P"9_7^GI_J=?\/0?^"=_P#T>5^S[_X<70__ )(H_P"'H/\
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M_B*A\:8Q-KZGA=';XZO^?K_3T?\ Q3T\/O\ HON,O_"/)/\ YG]?Z6O^H_\
M\///^">AZ?MC?  _]U"T7_X_1_P\\_X)Z_\ 1XWP!_\ #A:+_P#'Z_RX?L-B
M.EG:C_MWA_\ B*/L-E_SYVO_ (#Q?_$54>,L8U?ZGAO_  .KY>?]?F/]GIX?
M+_FON,ME_P P>2=4G_T#G^H__P /._\ @GJ?^;QO@!^/Q#T0?SGH_P"'G?\
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M)UH*M&@[\\HN:T=K)I.[[Z['ZY4445@:A117\Y'_  6 _P""P/[07[!7QO\
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M2#DE=QYH-JZ3V\GV9%'$TJ\I1@Y*<4G*$X2A))[.TDG;5'KE%%%<IT!1110
M445^./\ P4__ ."D/Q(_9-U_X4_ []F;X;6?Q>_:9^+FIP#0/!^L:;K%UHEG
MH,[7$*ZM?3Z7<63*@GM;E64W<;*(ON-O!&M&C4Q%14J:3D[O5J,4DKN4I/2,
M4M6WHC.K4A2@YS=HJRT5VVW91BEJVV[)+4_8ZBO*O@???%C4OA/X%U#XYV'A
MC2_BS>Z'!<^-]-\&K?IX:L=7FDED-KI::I-<7ZQ0VS6\<PN9G<7*S8.S:!R7
M[47[1G@?]E+X(^-_CA\09)?[ \'Z;+.EI;E!<ZKJCPS-INDVID(C%SJ%Q$+>
M$N0N]AD@<B5"3J>SC:<G/DCRNZE*_*N5]4WL^JU*<TH<\O=BH\SYM'%6N^9=
M&ENCZ"HK^1?PK_P6M_X*L_'/2=;^-?[-_P"PAX:\;?LU:/>WJ7/B>ZM-;DU^
MQ@TUO,O[:[,'B6"UEO;6 J)?LMM)&)6XRN,_T;?L3?M'ZC^U7^SQX%^,FL^$
M[OP3K/B73HYM6\.7D,MO+IM]M!F@$4S/(JHQP-SL?4FNG$8&OAH\]7V=N;DD
MH5(3E"35^6<8MN+MT9A1Q5*O+EI\^W,G*$HQE'36$FK26JU1]94445QG2%%%
M% !117\HW_!/G]L?]J;XE?\ !8?XS?!+Q_\ '+QYXK^$>CZA\4X-'^'FKZE'
M-X;TN/0XM6.F"SM%MT>/[(88C$#(=IC7GBNFAAIUX8BI&48K#TO:R4KWDKVM
M&R:OZV1A5KQI3HP<6W6G[.+5K)Z:N[VUZ7/ZN:***YC<**** "BBB@ HHHH
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MZW3W32VN??=%%%<QN%%%% !1110 4444 %%%% !1110 5_E__P#!RS_REO\
MC)_V3WX3?^HO'7^H!7^7_P#\'+/_ "EO^,G_ &3WX3?^HO'7B9__ +C3_P"P
MNC_Z;KG]"?1G_P"3CXC_ +)?-?\ U.R@_!>ID^Z/Q_F:AJ9/NC\?YFODC^_X
M;OT_5#JDC[_A_6HZDC[_ (?UI2V?H_R-22BBBL#2GU^7ZDR?='X_S-.IJ?='
MX_S-.K:?POY?FC:'Q+Y_DPHHHK$V+%%%%/HO5_E$Z"Q1112''=>J_,*G7H/H
M/Y5!4Z]!]!_*@W%HHHH-X[+T7Y!3D^\/Q_D:;3D^\/Q_D:#:&S]?T1-4R?='
MX_S-0U,GW1^/\S43V7K^C+'4445D;0^%?/\ -A5BJ]6*N6T/3]$;4^OR_4**
M**@UCNO5?F*O4?4?SJ>H%ZCZC^=3T&Y.O0?0?RI:1>@^@_E2T%PW?I^J"E7J
M/J/YTE*O4?4?SH-2>BBB@N&[]/U05,GW1^/\S4-3)]T?C_,U,OL_XE^IM'=>
MJ_,=5BJ]6*FIT^?Z%T^OR_4****S-H?$OG^3')]X?C_(U-4*?>'X_P C4U!L
M%.3[P_'^1IM.3[P_'^1H.@FHHHH''=>J_,5>H^H_G4]0+U'U'\ZGH-PHHHI/
M;YQ_-&\=EZ+\AR?>'X_R-35"GWA^/\C4U,VAL_7]$3)]T?C_ #-.IJ?='X_S
M-.K"6[]7^984Y/O#\?Y&FTY/O#\?Y&A[_*/Y(VA\*^?YLFHHHI&D/B7S_)A1
M110;!4D??\/ZU'4D??\ #^M!4/B7S_)DE.3[P_'^1IM.3[P_'^1H-B:BBB@
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MXKU?#^G'_5?#RP,>'G4HR:K824Y4L?F3P[^KQS',5BL1%IXB-JLG?HOV#O\
M@HE\6OVJ?^"<?[0'Q2\17%OHWQI^!_@_Q+IUWXKLHX)9;OQ'!H&K:OI^L36$
MMNME%=6K6\:&W6#[.WE@-'G<6P_^"#?[8'[2'[6/A+X]7?[0_P 2[OXD7W@[
MQ'H=GX>N[S2='TI["UO3J_GPA-(L[1)0PMH1NE#L G!&37Y\?\$(-$UCQO\
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M#7K2WO;'P#\0O@KI^C1W)-W&5N? _A:_>62"X$D*_OI7_=*IC8DLPW5]L_\
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M-S! LIMG$V&BV;5'U=_P;+R12_L8_$9X9(Y(V^+4S;HG5T9CHUN"VY"5)(4
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M#\/?L\S0_P#$1IX]B$L?GK\2/B*3&)$\U4?3]:4DH&WA7!VDXPP.#Z5]A?\
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MOA8J?OJ-#D7-[UKZGSEX0_9!_98^'^KQ>(/ _P"SU\'_  GKD#^;#JWA_P
M^'-+U"*0'(>.ZM+"*96!.00P-?1O3I111"G"FK4X0@M[0BHJ_>T4D+'9EF.9
MU(ULRQ^-S"M&/)&KCL57Q=2,/Y8SQ%2I)1_NII>044459Q!1110 4444 %%%
M% !1110 4444 >+^._V<O@)\4?$^C>-?B/\ !WX<>./%WAV>VN="\2^*?".B
MZWK>CW%DT;VD^G:C?VD]U:2VSQ1M"\,B-&T:%2"HQ[. % 50 J@  #   P !
MV ' %+13<I-).3:CI%-MJ*>Z2>BOY"48IMI).6K:23;[M]?F>(ZC^S5^S[J_
MQ*TSXR:I\%_AIJ'Q7T:_35=)^(UYX.T2?QEIVI1*4COK+Q#)9MJ5O=(C,JSQ
M7"R!20&P:N>'OV>O@7X2^(>I?%OPQ\(OAYX?^*&LV]Q::M\0-(\)Z-8>+M2M
M;O9]JM[W7K>T34;B&XV)YT<L[+)M7<#@5[%15>TG:W/.W+RVYG;E_EM>W+Y;
M>0N2"=U&*=[WY5>_?;?SW.#^(GPN^''Q=\.S>$?BCX&\+?$'PO<R137'A_Q?
MHEAK^D32PN)(I)+#48+BW=XW571FC)5@",$5P^G?LP_LZZ3\--9^#.E_!'X8
M:?\ ";Q%=S7^O?#BS\&:%;^"]8O9VMVFN]2\/1V2Z9=W$K6ML9)9K=W<P1%B
M3&N/=**2G-))3DDI*22DTE);223LI+H]P<8MMN,6VK-M*[3W3=KV?;8\_P#A
MQ\*/AG\'M 'A7X5> O"?P[\-++YXT+P=H6G^']*$VT)YHLM-@MX/,V +NV9Q
MQ7$>,?V7OV<OB%XXL/B9XZ^!_P +O%WQ#TJZTV^TWQKXA\%:#JOB>QO='$8T
MJZM=9O+*6^@GT\11"SECF5X/+3RRNT5[O1352:DY*<U)WO)2:D[[W=[N_6[#
MEC91Y8V6J5E9-;-*UE8\R^)?P7^$GQETVUT;XL?#;P5\1])LG=[33O&?AW3/
M$-G;/(%#M!;ZG;W$<;.$4,549"@'I65\,/V>O@7\$WO)/A#\(OAW\-)-0C\J
M^?P1X3T;PXUW%N#^7<-I=I;&5-ZAMKDC(!KV*BESSY>3GER?R\SY>_PWMOKL
M'+'FYN6/-_-9<W;>U]CB/'WPU^'WQ4T)_"_Q*\%^&?'?AR259Y-#\5Z-8ZYI
M;S*K(LK66H0SP%PK,H8ID!B,X)KS_P"&O[+O[./P;U9]>^%'P.^%OPYUJ2*2
M%]5\&>"M!\/7[Q2KLDC:ZTVRMY2DB_*Z[L,.#D5[O10IS47%2DHO>*DU%^JO
M9[+[@<8MJ3C%R6TFE=>CM<X+X@_"SX;?%C28M!^)O@7PKX^T6&22:+2O%NB:
M?KMA'+*@CDD2UU"">%7= $=@H+* #D 5Y[\._P!E/]FCX1:NFO\ PN^ WPH^
M'VMQLS1ZKX0\#>']!OT9P5=ENM.L8)5+!B"0P)!->_T4*<TG%3DHO>*DTGZI
M.P.,6^9QBY+:32O]]KA1114E!1110 4444 %>+?$;]G'X!?%^X-W\4_@W\-O
MB%=%0IN/&'A#1-?F*J J@R:C9SL0  !D].*]IHIQE*+O&3B^\6T_O5F)I25I
M)-=FDU]S/GOP1^R9^S%\-+^UU3X?? 'X2>"]2LIX[FTOO#7@3P]H]U;7$3AX
MIX)[&PADBEC<!D=&#*PR#FO1_B'\+?AO\6]";PQ\4/ WA7X@>'7?S&T3Q=HE
MAKVF-)E3O-EJ,$\!;**<[,Y53V%=[15.I-R4G.;DMI.3<EZ.]U]XE""3BHQ2
M>Z44D_56L?.NG_LB?LMZ3X4U?P+IG[/GP@L/!FOQI%K?A>T\ ^'(-"U6..6.
M=$O],CL%M;I$FBCE598F >-&'*C'2^)_V=O@/XU^'^B_"GQ?\(/AUXE^&?AR
M>VNM!\!ZWX2T;4O">CW-GY_V6?3=#NK233[26W^U7'DO# C1^?+M(WMGV6BC
MVE2]^>=T^9/FE=2M;FO?>VE]["]G!*RA"S5FN56:WMMM?IL>1^(/@'\$_%GP
M[@^$?B;X4^ ->^%UK):2VWP^U;PMI%]X0@EL':2RDBT&XM9-.1[61F>!E@!B
M9B4P3FEN_@)\$[_X:2_!J]^%/@&Z^$T\<,,WPXG\+Z1+X,EBMY89X(Y/#SVI
MTUEAFMX)8U-N0LD4; 952/6Z*7//^>6DN=>\])_S;_%_>W\Q\L?Y8[<NR^'M
MMMY;'G7A;X1?"WP/X-?X=^#OA]X/\,> Y89+>3P?H>@:;IOAR2"5522%](M;
M>.R:-T159#%M*J 1P*\ETS]B?]D+1;^_U32/V:/@EINHZI#/!J-]9?#CPO;7
M5]#<MNN(KJ:+3E>>.9OFD60L'/)!KZ?HIJI45[5)KF^*TI+F]==?F#A!V3A%
MI:).*=EV6FAX[X7_ &>_@7X)\(:Y\/\ P?\ "+X>>&? _B87"^(O"6B>%-'T
MWP_K:W7F?:1J>E6MI'9WHG\Z7S?/B??YC[L[C4O@3X _!'X7^$=3\ ?#GX3_
M  _\#^"-:-RVK^$_"WA71]%T#4FO%VW1O=+L+6"TN3<+\LQEB;S!PV17KM%+
MGF[WG)W:;]YZM;-ZZM=&]5T#EBK6C%632T6B>Z6FB?5'D_PM^!'P7^!]AJ.E
M_!WX6> _AAINKW;W^J6/@;PQI/AJUU"]D $EU>0:5:VT=Q<2!0'ED5G8 9;B
ML_PK^SE\ _ WC_4_BMX-^#GPX\+_ !+UFTN+#5O'FA>$=%TWQ9J5E=O')=6E
M[KEK:1ZA<V]P\4;2Q2SLCLBE@2HQ[111SSO)\\KS5I/F=Y+M)WU7K<.2'NKE
MC:.L5RKW7WCII\@KQ/XH_LV?L_\ QNO+'4/C!\&/AK\3;[3$\O3[OQQX/T3Q
M)<64?S#9;2ZI9W+PKAV&$(&&/J:]LHI1E*+O&3B^\6T_O5F-QC)6DE)=FDU]
MST/F#PM^Q1^R'X'U>'7_  =^S1\$O#&MV^WR-6T/X<>%]-OX=K!U\NZM=-CE
M3:X####!Y%?1NJZ-I.N:3>Z%K.FV6J:+J5G+I^H:5?6T5S87EC-&8I;2YM95
M:&:WDC)1XG0HR_*1BM*BG*<Y-.4Y2:V<I-M>C;T$HQC\,8Q]$E^2/F#1/V)_
MV0O#=[?:EX?_ &:/@EHNH:E#=6^H7NF?#CPO9W-[!?1O#>0W4T&G(\T=U%))
M'.DC,)$=E<$$UW7AK]G;X#^#?A[J_P )O"?P@^'7ASX8Z_<7-WK?@#1O"6C:
M?X2U:YO#;M=7&H:%;6D>GW4MPUK;&9YH&:0P1%B2BX]EHINK4>]2;U3UG)ZK
M9ZO==.W0%""VA%:-:12T>ZVV=E?O8\Z^&GPA^%OP:T2;PW\)OA[X/^''A^XN
MC>W&C>#- TWP]ILUXRA#<RV>F6]O"\Y0;3(R%MO&<5S^N_L[? ?Q/X_L?BMX
MC^#_ ,.=<^)>F26LNG^/-4\):+>^++*2R$:VDEMKD]H^H0O;"*(0M'.IC\M-
MF-HQ[+12YYW<N:7,[IOF=VGNF[W=^MPY8V4>6-E9I65DULTK65NEMACQI*CQ
M2*LD<B-'(C@,KHX*LK*1@JRDA@1@@D8Q7S)KO[%'[(?BC79?$_B/]FCX):YX
MBFE,TVMZI\./"][JDDI;>9'O)]->=G+?,6+Y)Y)KZ>HHC.<+\LI1OH^63C==
MG9JX2C&7Q1C*VW,D[?><_P"&/"?ACP3HUIX=\(:!I'AG0;!/*LM'T.PMM-TZ
MTCR3LM[2UCBAB7))PB 9)IWB7POX<\9:/=>'_%FAZ5XCT.] 6\TC6K&WU'3[
ME1D 3VETDD,H&3@.AQDUO44KN][N][WOK?>]][WUN.RM:RMM:VENUCY6TS]A
MO]C?1=7CU_2/V7_@7INMQ7'VN/5K+X:>%;?4$NMXD^T+=1::LPEW@/O#;MP!
MSFOHO6+[3/"WAO4=0F1;/2=$TJXG:.VMGE6"UM+=F$<%I;1O(X"J$CAAC);A
M56MZ@@$8(!!Z@\@_A3E.<VN>4IVT7-)MI=DW>W]:"48QORQC&_9)??:Q_$__
M ,$FOA=XL_:Q_P""LWQI_:K\6?#_ %KPGX)\,W6O:A8'5/"^IZ!:KXKT?4K6
MST)M.AU2TM WVBU@>Z>>WWK\S-NWD _V3_$7X8_#OXO>%KOP1\4O!/ACXA>#
MK^:VN+[PQXOT6PU_0[NXLY1-:37&FZC#<6LLEM*!)"[QDQO\RD'FNU2**//E
MQQIGKL15S]=H&:DKJQ>+EBJL*BC[%4Z<*=.$9-\B@K)J5HN]];V5C##X=4*<
MH.7M'.<ISDXJ/,Y.]N6[5EZG!>'OA9\-_"7@P?#KPQX%\*Z!X"%M+9?\(=I.
MB6%CX<^R3QK%-;?V1;P)9>1+$JQO%Y6QD 5@0!6#\+/@)\%/@?;:C9_!SX4^
M ?AA::O<M>ZI;>!O"^D>&H=0NW(+W%Y'I5K;+<3/M&Z20,QP.>*];HKEYYM2
M3E*TG>2YG:36SDKZM=V;\L;I\L;Q5HNRO%=EV7H?.>L_LA?LL^(O%LGCS7OV
M>O@_K'C66X6[D\5:CX!\.7>O/<H04G;4YK![LRJ0"',NX$#FNST7X#?!7PYX
MZD^)^@?"OP%HWQ%ETV+1Y/&^F^%](L_%#Z5!;&SATYM:@M4OFLXK5FMTMS,8
MEA)C"[217K-%-U)O1SFU;ELY-^[VWVT6FV@<D$[J$;WO?E5[K9WMNN^YXUI_
M[.WP'TGXBW/Q=TSX/_#K3_BE>33W%U\0;3PEHL'B^XGN0XN)IM?CM%U&2282
M2"5WG)<.P8G<<^JZKI.F:[IM]HVM:?::KI.IVTMGJ.G7]O'=65[:3J4FMKJW
MF5XIH94)5XY%96!(((K0HJ7*3:;DVTDDVVVDMDK[)=$MAI)7LDKN[LDKM[M]
MVSY7B_8;_8W@UE?$4/[+_P "XM>6=;E=73X:>%5U%;A&W+,+L:;YPE5AN#[]
MP/(.:^B;[PIX9U/P[-X1U'0=)O?"UQIYTJ?P]=6-O-H\NF-$8&L)+!XVMFM#
M"3$8#&8S&2NW'%;]%5*I.5N:<Y6VYI-V]+MV^0E"$;VC%7WM%*_K9:_,\K^%
M_P #?@W\$M'O?#_P?^&'@;X9Z'J5S+>ZAI/@CPUI7AO3[V[G"B:YN;32[:VA
MFFE"J))'0LP !/ K/\&?L[_ CX=>--:^(_@+X0?#KP=X^\1VTEGK_C+PWX2T
M;2/$FLVDTT4\MMJ6KV5I#>WD,DT,4KQSS.K/&C$94$>R44N>;YKSD^?X_>?O
M?XM?>^=PY8^[[L?=^'1>[_ATT^1XOKO[.7P$\4?$"S^*_B/X._#C7/B;I[VD
MECX]U3PCHM[XLM)+!8TLGM]=GM'U")K58HU@*3J8A&@3&T8W_B1\'/A1\8=/
MM=*^*OPZ\&_$33;)I'M+'QCX?TWQ!:VSS*JRM#!J5O<1QM(JJ'**-P !Z5Z3
M11SSO%\\KQ5HOF=XKM%WT7I8.6-FN6-I.[5E9O>[TU=^K/!_AQ^RY^SC\']1
M_M?X5_ WX6?#S5-S-_:'@[P3H.@7FYU*NWVC3;*WDW,I*L=V2"037O%%%*4I
M2=Y2<GWDVW][NQJ,8JT4HKLDDON1_*S_ ,'&W[._B2"\_9R_;&^'_AO6M9U+
MX.^,+:7Q3!X>TV^U;4[R5=1TJ;P[-#::=;W%WOM6LYU,JQ.D:A"2A!)_HC_9
M3^)J?&+]G3X._$4_V@M[XF\ >&-0U>#5K*]T_4K36IM'LY-4M+VUU""WN4N+
M>[>2.0O& Y&X'D@?0+QI(-LB(Z_W74,/R8$4JJJ@*JA5' 50  /0 8 KIJXI
MU<-0P\H:X=SY*G-O";3Y'&W1W=^;K:VAA"@J=>K6C+2LH\T+:<\5;F3OU22:
MMOK<^=?&_P"R%^RS\2]4FUOX@_L]_!_QIJ]Q,;B?4O$W@'PYK%[+.W6:2XOK
M":5I#W<L2?6NI^'7[/?P+^$4QN/A;\(OAY\/IS$T!F\(>$]&T&0PM@M%OTZT
M@;8Q ++G!(&17L5%8>TJ<O+[2?+_ "\TN7[KV_ V4()\RA%2[J*O]]K]6?/_
M ,2?V4?V9_C'X@/BSXK_  &^$_Q&\3&W@M#K_C/P-X?\0ZL;:VB$-O ;[4K&
MXN/*AB CB3?M1 %4 #%5/ O[(?[+7PPU>/Q!\.OV>_@_X(UR(@Q:MX7\ ^'-
M&U",@D@I=6-A#,I!)QAQC-?1=%/VM7EY?:5.6UN7GERV[6O:WE87LX7YN2'-
M>]^57OWO:]]%]QP'C_X5?#3XK:8FC?$OP'X4\>:3&V]-.\6:'I^N62,0066W
MU"">)6(9AD+G!(KS'P-^R!^RO\,M;MO$OP\_9Y^#W@KQ!9W$=W:ZUX9\ >'-
M'U*WNHF#QW$-Y8V$,\<R. RR*X96 (.:^C:*2J347%3FHO>*DU%^J3LQN$&^
M9QBY=W%-_?:Y^#G_  <(?%_Q-X,_8BO_ (4^ M%\3ZMX\^-/B#2=$T%O#FC:
MMJ[16^DZGI]QJD5X=*M+C[*EY;W*0K+<-%$1Y@RP!Q]1_P#!'S]FRY_9A_84
M^$WA#4K,Z=KWBVQ3XC>)-,DA:"?3]>\3Z?IYOK6Z1E4_:(Q9Q&1L9R0#R"!^
MGKQ1R8\R-'P<C>JM@^VX''X4X      <  8 'H .E;O%-X2.$C#E2JRK3GS7
M<Y-*,5;E7*HI=W=]C)4/]HEB'*[=-4X1M905[R=[N[D_)66FMD+1117*;A11
M10 4444 %%%% !1110 4444 %?Y?_P#P<L_\I;_C)_V3WX3?^HO'7^H!7^7]
M_P '+)'_  ]O^,G(_P"2>_";_P!1>.O$S_\ W&G_ -A='_TW7/Z$^C/_ ,G'
MQ'_9+YK_ .IV4'X,5,GW1^/\S4-2J1M'([]_<U\D?W_#?Y?Y#ZDC[_A_6HLC
MU'YBI(R.>1V[CWI2V?HS6S[?U_31+129'J/S%+6!I#K\OU)D^Z/Q_F:=3%(V
MCD=^_N:=D>H_,5M/X7_75&T/B7S_ "%HI,CU'YBEK$V+%%)D>H_,49'J/S%/
MHO5_E$Z"S129'J/S%&1ZC\Q2'%.ZTZK\T+4Z]!]!_*J^1ZC\Q4X(P.1T'<4&
MXZBDR/4?F*,CU'YB@WCLO1"TY/O#\?Y&F9'J/SIZ_>'X_P C0;0V?K^B)JF3
M[H_'^9J'(/0YJ52-HY'?O[FHGM\_T_X*+'T4F1ZC\Q1D>H_,5D;1^%?UU%JQ
M5>I\CU'YBKEM'T_1&T.OR_46BDR/4?F*,@]"#^-0:Q3NM.J_-#EZCZC^=3U
MO4?4?SJ>@W)UZ#Z#^5+301@<CH.XI<CU'YB@N&_R_P A:5>H^H_G3<CU'YTX
M=1]1_.@U)Z*3(]1^8HR/4?F*"X;_ "_R%J9/NC\?YFH,@]"#4RD8 R,^F?>I
MDU[NOVD;1W7JOS0^K%5ZGR/4?F*F?3Y_H7#K\OU%HI,CU'YBC(]1^8K,VA\2
M^?Y#T^\/Q_D:FJ!"-PY'Y^QJ;(]1^8H-A:<GWA^/\C3,CU'YBG(1N'([]QZ&
M@Z">BDR/4?F*,CU'YT#BG=:=5^:'+U'U'\ZGJ =1]1_.ILCU'YB@W%HI,CU'
MYBC(/0@TG^J_-&\=EZ(>GWA^/\C4U0K]X?C_ "-2Y'J/S%,VAL_7]$3I]T?C
M_,TZF*1M'(_,>M.R/4?F*P>[]7^98M.3[P_'^1IF0>A!_&GK]X?C_(T/?Y1_
M)&T?A7]=2:BDR/4?F*,CU'YBD:13YEIW_+_@K[Q:*3(]1^8I<@]#F@V"I(^_
MX?UJ.GH0,Y('3K^-!44^9:=_R_X*^\EIR?>'X_R-,R/4?F*<A&X<COW'H:#8
MGHI,CU'YBC(]1^8H 6BDR/4?F*,@]"#^-%UW_K^FBHIW6CW7Z"TY/O#\?Y&F
MTY?O#\?Y&@V)J*3(]1^8HR/4?F*"HIW6CW7Z"T4F1ZC\Q1D>H_,5+:L]5L_R
M_P""OO-A:5>H^H_G3<CU'YBG#J/J/YU-/K\OU&D[K3JOS7^:^\GHI,CU'YBC
M(]1^8K0W%I5ZCZC^=-R#T(-.'4?4?SK&7Q/Y?D@)Z*3(]1^8HR/4?F*D=GV?
M]?\ #K[Q:*3(]1^8HR/4?F*#<6BBB@=GV?\ 7_#K[RQ129'J/S%&1ZC\Q0;B
MT4F1ZC\Q1D>H_,4#L^S_ *_X=?>+1110;DZ]!]!_*EIH(P.1T'<4[(/0YH F
M3[H_'^9IU,4C:.1W[^YIV1ZC\Q1==_Z_IK[QV?9_U_PZ^\6BDR/4?F*,CU'Y
MBLH;OT_5&RV7HA:***U*L^S_ *_X=?>2IT/U_H*?4:$ ') Y]?I3\CU'YBBZ
M[_U_37WFT=EZ+\A:*3(]1^8HR/4?F*P>[]7^95GV?]?\.OO%HHR#T.:*TAM\
M_P#(;3TT>R_)$D??\/ZU)42$#.2!TZ_C4F1ZC\Q5W7?^OZ:^\TC\*_KJ3)T/
MU_H*?4:$8ZCKZ^PI^1ZC\Q7.59]OZ_IH6BDR/4?F*0L.V6)X"J"S,2<!5506
M9B2   22>!0;1^%?UU'=2  26(55 )+,Q"JJ@9)+,0H !)) ')K^G_\ X(N_
M\$7[_P",M_X=_:F_:C\/3V'PNT^Y@U7X=_#O58#%<>.;JWFWV^LZU:3HX'AV
M*:&XM+K2+^VAEO28Y(W$8+%O_!%[_@B[>_&>\\._M3?M2^'9K/X5VDUOJOP[
M^'6K6[Q2>/7C:.:VUK6;>5"K^%Y8W+6PBEM[UKZV&Y1$":_MHL+"RTNRM--T
MVU@LK"QMX;2SM+:-8H+:VMXUB@AAC0!4CBC1450.%4"OM^'>'74<,?CX6IJT
M\/AY+6H]XU:J>T%O"#^)ZR7+92_S=^EA]+&.30S'PP\,<Q4LWDJN"XJXIP=5
M2CE<6G3KY/DU>F[2S!KFI8_'0DXX)<^'P[EBG.IAFZ=IUAI&GV.DZ79V^GZ9
MIEI;V&GV%G$D%K965I$D%K:VT$86.*""&-(HHT4*B*J@ "KM%%?H.VQ_E9*4
MI2E*4G*4FY2E)MRE)N[E)N[;;;;;=V]6%%%% @HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@K]@4^\/Q_D:FH_LW+O^@'"?^$]+_P"0\E]P_P#B(?'W_1;<6?\ B0YMY?\
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MYY+^FP_XB7XBJ=O]>^,+=O\ 63..R_ZC/(_&[_AP#_P24_Z-(\/?^%E\0_\
MYJJ/^' /_!)3_HTCP]_X67Q#_P#FJK]D:*/[-R[_ * ,'_X34?+^YY(T_P"(
ME^(O_1><8_\ B29Q_P#-GDON/QN_X< _\$E!_P VD>'O_"R^(9_GXJJ8?\$
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MXG_]'%XX_P#$JSS_ .;C\>_^'"/_  2@'_-IOAO\?%OQ /\ /Q31_P .$O\
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M&_\ PK/'W_S44O\ PX5_X)1CI^R=X;'_ '-GC_\ ^:BOV!HH_LS+?^A?@O\
MPEH>7]SR0+Q:\4UMXD<=+_N[,]\O^H[R1^/W_#A;_@E)_P!&G>'/_"M\?_\
MS44?\.%O^"4G_1IWAS_PK?'_ /\ -17[ T4?V9EO_0OP7_A+0\O[GDA_\1;\
M5%_S<GCO_P 2S/?+_J/\D?C]_P .%O\ @E)_T:=X<_\ "M\?_P#S44?\.%O^
M"4G_ $:?X<_\*WQ__P#-17[ T4?V9EO_ $+\%_X2T/+^YY(/^(M^*B_YN3QW
M_P")9GOE_P!1_DC\?_\ APO_ ,$I?^C4/#O_ (5OC_\ ^:FC_APO_P $I?\
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M .;_ "_/NS\@?^'#7_!*?_HU'P[_ .%;X_\ _FHH_P"'#7_!*?\ Z-1\._\
MA6^/_P#YJ*_7ZBC^S,N_Z ,%_P"$M'_Y#R_/NP_XB_XK_P#1S./O_$NS_P O
M^H_R_J[/R"_X<-?\$IQ_S:AX<_'Q9X^/\_%%'_#AO_@E/_T:AX<_\*OQ]_\
M-17Z^T4O[+RS_H7X+_PEH>7]SR_J[#_B+_BQ_P!',X^_\2_/_+_J/\D?D)_P
MX=_X)4?]&H>'/_"L\?\ _P U-'_#AW_@E1_T:AX<_P#"L\?_ /S4U^O=%']E
M99_T+\%_X2T?_D _XB_XL?\ 1S./O_$OS_R_ZC_)'Y"_\.'O^"5/_1J'AO\
M\*OQ]_\ -11_PX>_X)4_]&H>&_\ PJ_'W_S45^O5%']EY9_T+\%_X34?_D!_
M\1@\6/\ HYO'_P#XE^?]+?\ 4P\OZNS\AO\ AQ!_P2J_Z-1\.?\ A6>/O_FH
MH_X<0?\ !*K_ *-1\.?^%9X^_P#FHK]>:*/[*RS_ *%^"_\ "6C_ /(!_P 1
M@\6?^CF\?_\ B7Y_Y?\ 4P\D?D-_PX@_X)5?]&H^'/\ PK/'W_S44?\ #B#_
M ()5?]&H^'/_  K/'W_S45^O-%']E99_T+\%_P"$M'_Y /\ B,/BS_T<WC__
M ,3#B#R_ZF'DC\AO^'$'_!*K_HU'PY_X5GC[_P":BC_AQ!_P2J_Z-1\.?^%9
MX^_^:BOUYHH_LO+/^A?@O_"6C_\ (#_XC%XM?]'.\0/_ !,.(/+_ *F'DC\B
M/^'$7_!*S_HU+PY_X5?C[_YJ*/\ AQ%_P2L_Z-2\.?\ A5^/O_FHK]=Z*/[*
MRS_H7X+_ ,):/_R ?\1B\6O^CG>('_B8<0>7_4P\D?D1_P .(O\ @E9_T:EX
M<_\ "K\??_-12_\ #B/_ ()6#_FU+PW_ .%5X]/\_$]?KM11_966?]"_!?\
MA+1_^0'_ ,1B\6_^CG^(/_B8\0?_ #P\OS[L_(G_ (<1_P#!*S_HU+PW_P"%
M5X\_^:>C_AQ'_P $K/\ HU+PW_X57CS_ .:>OUVHH_LK+/\ H7X+_P ):/\
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MRS_H7X+_ ,):/_R _P#B,WB]_P!'2\0O_$RXA\O^IAY+[D?D9_PXG_X)7_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7S???\A+4O^OZY_\ 1SU](5\WWW_(2U+_ *_KG_T<
M]=6%WG_VY_Z4<]?['_;W_MHQ.A^O]!5A.A^O]!5=.A^O]!5A.A^O]!79]O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%4O_ )#R_/NPY%WG_P"!R_S_ *N_*W'?V%XD_P"AON?_  66/_Q-']A>)/\
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M'_XFC^PO$G_0WW/_ (++'_XFNQHH]I+M3_\ !5+_ .0\OS[L.1=Y_P#@<O\
M/^KORMQW]A>)/^AON?\ P66/_P 31_87B3_H;[G_ ,%EC_\ $UV-%'M)=J?_
M (*I?_(>7Y]V'(N\_P#P.7^?]7?E;CO["\2?]#?<_P#@LL?_ (FC^PO$G_0W
MW/\ X++'_P")KL:*/:2[4_\ P52_^0\OS[L.1=Y_^!R_S_J[\K<=_87B3_H;
M[G_P66/_ ,31_87B3_H;[G_P66/_ ,378T4>TEVI_P#@JE_\AY?GW8<B[S_\
M#E_G_5WY6X[^PO$G_0WW/_@LL?\ XFC^PO$G_0WW/_@LL?\ XFNQHH]I+M3_
M /!5+_Y#R_/NPY%WG_X'+_/^KORMQW]A>)/^AON?_!98_P#Q-']A>)/^AON?
M_!98_P#Q-=C11[27:G_X*I?_ "'E^?=AR+O/_P #E_G_ %=^5N._L+Q)_P!#
M?<_^"RQ_^)H_L+Q)_P!#?<_^"RQ_^)KL:*/:2[4__!5+_P"0\OS[L.1=Y_\
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M (FNQHH]I+M3_P#!5+_Y#R_/NPY%WG_X'+_/^KORMQW]A>)/^AON?_!98_\
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M ,%EC_\ $T?V%XD_Z&^Y_P#!98__ !-=C11[27:G_P""J7_R'E^?=AR+O/\
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M^"J7_P AY?GW8<B[S_\  Y?Y_P!7?E;CO["\2?\ 0WW/_@LL?_B:/["\2?\
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M ,378T4>TEVI_P#@JE_\AY?GW8<B[S_\#E_G_5WY6X[^PO$G_0WW/_@LL?\
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M .)KL:*/:2[4_P#P52_^0\OS[L.1=Y_^!R_S_J[\K<=_87B3_H;[G_P66/\
M\31_87B3_H;[G_P66/\ \378T4>TEVI_^"J7_P AY?GW8<B[S_\  Y?Y_P!7
M?E;CO["\2?\ 0WW/_@LL?_B:/["\2?\ 0WW/_@LL?_B:[&BCVDNU/_P52_\
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M_ *V_P *E32M?QQXEFZ_\^5N?\/T_GFN@J5.A^O]!67M)=H?^"X=+?W?)?\
M#6+Y?.7WO^OZ['/+I6O[A_Q4TP_[<;;T]ZE_LG7_ /H9Y_\ P!M?\*Z%/O#\
M?Y&IJ7M)?W>GV(=+6^SY(.1::RT_O2U]=?ZZG.KI/B#G'BF<_6PMO_K4_P#L
MGQ!W\3S_ /@!:C_&NCC[_A_6I*7/+^[T^Q#IM]D?*N\O_ I?Y^7]79SJZ1XA
MP"/%-P/3_0;4XIW]D^(_^AJN/_ "UKIUZ#Z#^5+1SN][1NO[D/\ Y$.5+O\
M^!2].YS:Z1XDP,>*[@#T_L^T_P *=_9'B7_H;+C_ ,%]I74)]T?C_,TZCF?:
M'_@NGY?W?)!9>?WO_,YM=(\2[1_Q5EQ_X+[3_#]*=_9'B7_H;+C_ ,%]I74)
M]T?C_,TZCF\H?^ 0_P#D?)?<'*O/_P "E_GY?U=G,+I'B7G'BRXSW_T"T_\
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MNZ?2W]SR1*BE.UY_^!R[+S\EYG(?V)XE_P"AON?_  6V?^%']B>)?^AON?\
MP6V?^%=?11[6?]S_ ,%4_+^YY(OD7>?_ ('+_/\ J[\K<A_8GB7_ *&^Y_\
M!;9_X5(-"\3=_%\^/;3;+_XFNKJ=>@^@_E1[67:'_@JGY?W?)$RBDXZRU?64
MO+S^?K\CC_["\2?]#?<_^"RQ_P#B:/["\2?]#?<_^"RQ_P#B:[&BCVDNU/\
M\%4O_D/+\^[*Y%WG_P"!R_S_ *N_*W'?V%XD_P"AON?_  66/_Q-']A>)/\
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M'_XFC^PO$G_0WW/_ (++'_XFNQHH]I+M3_\ !5+_ .0\OS[L.1=Y_P#@<O\
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M?<_^"RQ_^)H_L+Q)_P!#?<_^"RQ_^)KL:*/:2[4__!5+_P"0\OS[L.1=Y_\
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M (FNQHH]I+M3_P#!5+_Y#R_/NPY%WG_X'+_/^KORMQW]A>)/^AON?_!98_\
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M ,%EC_\ $T?V%XD_Z&^Y_P#!98__ !-=C11[27:G_P""J7_R'E^?=AR+O/\
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M^"J7_P AY?GW8<B[S_\  Y?Y_P!7?E;CO["\2?\ 0WW/_@LL?_B:/["\2?\
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M ,378T4>TEVI_P#@JE_\AY?GW8<B[S_\#E_G_5WY6X[^PO$G_0WW/_@LL?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^;[[_D):E_U_7/\
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M(_:O_B(;_P""M_\ T<Y;?^&S\ __ "EIZ_\ !PU_P5P.<?M.VHQ_U3'P!_\
M*7BOQ1J2/O\ A_6H^NXW_H-QG_A7B/+_ *>>2_ILZ8^&7AU=+_47A.W_ &(,
ML[?]@Q^UP_X.&_\ @KB/^;GK8_\ =,?A_P#_ "E-2K_P<-?\%<",_P##3MKS
M_P!4P^'Y[^^BU^*%3)]T?C_,U3QF-7+;&XSX4_\ >L1_\L\E]QLO#+PZ6W O
M"7_A@RO_ .9C]J_^(AK_ (*X?]'.VG_AK_A]_P#*6GI_P<-?\%<,X/[3EF<]
M_P#A5_P^]/\ L"5^*=.3[P_'^1J?KF,_Z#,9\\5B.EO^GGDC6'AEX=6O_J+P
ME>__ $(,K\O^H;R/VN'_  <,_P#!7 =/VG+/_P -?\/O_E)3A_P<-_\ !7#_
M *.<LS_W2[X>_P!-$K\5:*7US&?]!F+_ /"JOY?]//)&\/#'PYM?_43A+1_]
M$_E?9?\ 4+Y(_:P?\'#G_!6_O^TU9'_NE_P^'_N%J1?^#AO_ (*WD9_X::LN
MIZ_"[X?'T_Z@E?B?4J=#]?Z"A8O&+;&8O_PJQ'E_T\\D=$?##PX:3? G"/7_
M )I_*^__ &"G[8K_ ,'#/_!6XC/_  TS8=?^B6_#[]?^)+S3O^(AG_@K=W_:
M9T__ ,-9\/1_[A37XJ)T/U_H*?64L;C5)VQN,Z?\Q5?LO^GGD7'PP\.+K_C!
M.$=U_P T]E??_L%/VJ_XB&O^"MP_YN9T_P#\-9\/#_/1*>O_  <,_P#!6TG!
M_:7T[I_T2SX>^W_4%K\4J>G4_3^HIK&8WED_KN,O=;XJN_Y?^GGI]QO'PO\
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M?C_,TOK^._Z#<9_X55_+_IYY(W7A1X863_XAYP4]%OPSD[\^N#/VA_XB#?\
M@K-_T<GI7_AI_AU_\I*<O_!P9_P5E)Q_PTGI/K_R2?X=^WIHHK\7J>G4_3^H
MI?7\=_T&XS_PJK__ "SR_J[-X^$_A?9/_B'?!6J7_-,9,_\ W3/VB_XB"O\
M@K+_ -'):0?^Z3_#S^FC4O\ Q$%_\%9/^CD=)_\ #4?#S_Y35^,-%'U_'?\
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M\Z?]H9A_T'8S_P *J_\ \L-8>#WA/;_DVG >C_Z)/(_+_J!\D?LI_P /^/\
M@JW_ -''Z1_X:CX??_*BC_A_Q_P5;_Z./TC_ ,-1\/O_ )45^.5%+^T,?_T'
M8W_PJK__ "SR_J[+7@]X377_ !K/@+=?\TED7=?]0/DON/V-_P"'_'_!5O\
MZ./TC_PU'P^_^5%+_P /^/\ @JU_T<=I/_AJ?A]_\IZ_'&BIGF&8):8_&[_]
M!>(\_P#IX;?\0<\)?^C9<!?^(ED7E_U ^2/V._X?\_\ !5G_ *..TG_PU/P^
M_P#E/4O_  _V_P""K/\ T<=I'_AJ/A__ /*FOQLJQ5+,,PLO]NQNR_YBJ_E_
MT\_K7NS2'@YX2.]_#+@'2W_-)9%_\P^2^X_8O_A_M_P59_Z..TC_ ,-1\/\
M_P"5-+_P_P!O^"K'_1QFC_\ AJ? '_RJK\<Z*B>8Y@K6Q^-7_<W7Z6_Z>?\
M#]2_^(-^$G_1L> ?_$1R'R_Z@?)?<?L@/^"^?_!5<@'_ (:-TCD#_FE/@#_Y
M54O_  _S_P""J_\ T<;I'_AJ? '_ ,J:_'5>@^@_E2UG_:68_P#0?CO_  KQ
M'_RSR_/NQKP;\)+K_C6/ &Z_YI'(>Z_Z@/)?<?L3_P /\_\ @JO_ -'&Z1_X
M:GP!_P#*FE_X?Y_\%5O^CC-)_P##5?#_ /\ E17XZT4_[2S'_H/QO_A57_\
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M_P""^'_!50G'_#1>D]/^B5^ ?;TTD5^.M/3J?I_44?VEF/\ T'XW_P *J_\
M\L-H^"_A!9/_ (A=X?[+_FD<A?1?]0']?-G[%?\ #^[_ (*J?]'%Z1_X:KP#
M_P#*JI!_P7L_X*J$ _\ #1FC\C/_ "2CP!_\JJ_':IUZ#Z#^5+^TLQ_Z#\=_
MX5XC_P"6>7Y]V/\ X@OX0?\ 1KO#[_Q#\@\O^H#R1^P?_#^S_@JI_P!'&:/_
M .&H\ ?_ "JI?^']G_!5/_HXO2/_  U/@#_Y4U^/E%+^TLQYK?VACK<M_P#>
MZ_>W6I_7S=](>"W@^UKX6^'VCM_R1^0>7_4 ?L'_ ,/[/^"J?_1Q>D?^&I\
M?_*FC_A_9_P53_Z.+TC_ ,-3X _^5-?CY15?VEF/_0?C?_"JO_\ +"_^(+>#
MZ_YM9X>_^(=P_P#_ #O\E]R/V(_X?T_\%4O^CB]'_P##4^ ?_E71_P /Z?\
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MO;36SXYT&PT:*9[&]6QF?3VM-7U%KA#.Z@%EC903O565E'\_/_!735]9MO\
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M?6.AZG"DB/'-<V-Z$N;:&1&B>:-/-5HPRG^8_P#X)D?\%.OV\-#_ &U_@_\
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M%% !1110 4444 %%%% !1110 4444 %%%% '\E?_  <_:OK9\.?L_:!_I/\
MPCA\3V.IM^\D^Q_VO]JOK7!B_P!5YYM./,QYGEDK]T5_1)^PUHVA:!^R=\#]
M)\-6]M:Z-;>!]-:TM[1E:WC:X#75SY>T!1ONIIY'"@ 2.Y/)-?'G_!8_]@S7
M/VZ/V9HM#\"+&WQ,^&NN#QQX.LBR0/X@O;2TGMET)[J1XXHHY3<?:%\YQ$'B
M/!9A7XG?LQ?\%<OVM_V!OA?I'[.'[07[&'Q5^*5_X%LKW2?#&M>#M/OHC!#'
M=W$P75;^+1]3AU.*.:<A&C>*4P!8TEVHN/FYUHY;G&+Q&+52.'Q="DJ5>-.=
M2$94[*5.3A&3BW9NUM;)O=,_L' Y%C/%SZ/O!'"? ];+<5Q3P1Q/GE;.N&J^
M:8#+,;B<+FB<\-FN'CF.)PM#$0IQ]V<U4]WVE:$9<\)0E!_P<>6UK%^U)^R=
M>6<,*ZK-K-FLTT")]MD-O+I1LE=E E;RV)^SAF(5B=F#DU!_P6+^,WQ;^%.L
M?L":QX$\:^+/#VL?\*Y\!P)86'B#5=+L;O6-<LI=*BEUBQM[F.VO1'<7,4KK
M>1RJ"@9N0"*OPM_9J_:\_P""P_[9WA3]IC]H+P/J/P=^!7@#4= UG3;#4[=K
M"YB3P](E[H^C1:/</:WD]SJGV-;74KI8MDGS2W 6,58_X.38CI7QG_9M@T6U
MAC?21X970[&-%2!;C3]1DDTJR2/A5A:YBMX O"A&P>,UY.+]I+#YOF4(U:5'
M$XC"+#N47"I-4Y1O44':25[.+:UUM>S/V_@IY3@>+/ ;PFQN*RG/,^X1X5XR
MGQ70PU:CF678#$9QA*E2CE57$P]IAZU:E2J5(XB$)/V4:=.32C5A?F/VZO\
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M#GQ'XJTSPSIU[K]^'U#6M=U%4CL-(CO9EBTVQFM8;DI&1'.)#*REE55)0?\
M:OU#ZP\&\JJ?6/;>V=\5I:_MES>ULY.5M+<]M+"P,\PI1\$WXF/A&CQ['QJR
MB?#,L@?#].5/@BT_:R4LD:PRR7VKPOU.51^U:^INM)U%6/E;X9_\$\_VL/BU
M^P ?VH=5_:U\:^ +3P%HL^I_#_X4>"KNXTS1=0T31TAW2:KJVE:K8M;W;621
MS".2UF::1)(Y'5BI?[+_ ."><GQB_P""H_\ P37^('P6^(7QT\;?#CQ!\.?&
M'B)=(^*_AJ2XN?$MSX>T_2[6*S\/WZQZCI\]Q;K(DC7-[)>2W,L=Q*/+D8!3
M][?LX>&/$T'_  1CN]"N/#NN6VO-\-/$K+H5UI5];ZRQ;249(QIDT"7OG. 0
ML7D>8S?*%)KY._X-N_"'B[1_V8?CMIGB#PIXF\-7^H>)O%$-G:>)=!U70+BX
M:YMH(X6AAU6UM9)$9F WJI7.1G(..G#X2G3Q>748JJZ>-RVI];C*I5?M)*$&
MF_>7(TW:/)RV25N[^2XHXZS#-N!?%?/,3/(J>;^'OB]E$>"L3A<HR6A5R?#5
M,9BZ5;V$(X5K'4JT:<IUYX^.,5:<YRJRFO9J'XQ?\$A/V"=;_;)^)WCR/2/V
MCOB!\"S\+M;U":X;P1#<R2^,?[)UC[$T>I^3J^E(B7S'S[GS7FP-XVROM5OJ
M?_@MOX<\6W'_  4=_9D\%^!-7,/C]KGX8>%/!?B*^**R>+HK70=-T77+XRL\
M:NVH)%=W)E=T#,^YV')\\_X)Z_&WX]_\$N?VC?BQ\,_%_P"R9\4OB1XL^)'B
M;6="TJX\/VM];:)HM[K&MF^L-3O-8&DWFEW=@D&PSJER@(D*B5'7*_4__!5/
MPCX_\4_\%7_V(/%>G> ?&%WI]UX^^"6MZK=Z9X=UC4]+T0O<^&[K48;_ %6S
MLY;.W73I'DBFDGFC5?*=FVJK$>=3I45DSIPA4CBECL-'%JU6,H_OFH)<RY(R
M4;VY%=:.6MC]7S3..()_2#AG&.QV58O@RIX<<6XW@FM&KD5?#XK_ (0LOK9C
M*;P<OK^(P]?$QIQC',Y2A4BJD,)^ZYSP'_@H1^RY^V'_ ,$V=6^"G[3E]^V+
M\0_B=XW^(/B^:;Q9I%SJ6HV'AO1-:L1I^IZG9:?I*:M-I^IZ?<RWKVD;O9PH
MD8\Q8A@"OV(_X*%?$SQY\8_^">7[,7Q4O/V@X/V;Y?&9T7Q7\2]:TN>TBUS6
M=&OO#]R+S2O#%@;O3IK^]CNWBNUM[!UE*(2 %!(\_P#^#E#POXJ\3? OX )X
M7\+^)/%$ME\0_$$MY!X;T/4]=N+:*2RT)8Y)X-+M;J6*-V5@KNJJ2K8/!Q\-
M_P#!4[]FKX\_$?\ 8'_8#\=>"_!_B;Q-X6^'?PW\&P^,_"-K9WAU+1[RSBN;
MJYO)_#IA>_:ZNK=UL& LQ,-S*V51@/0Q$'@JN<T,/"O4HK#8:HJ3JU9>_.5-
M3J<UW-[R<^62;5U=+;\PX9QV'\1<G^CWQ+Q1F'#N5\0U>,^+<LKYTLFR+#Q6
M7X'#XYY=E<L Z%++;-TZ-+ ?6L/*G3JQI5%"K6O[7\F/B1\<?AI^SY>Z#X[_
M &-?^"C/[2_QU^*>E:O:MJ?AWXF^$->\,^&M-LS(9;^[A;4/$VIV6J_9YPJ1
MV\EL$FC?@@5^[7_!9SXM7?QT_P""1'P4^*>I.)-5\32>$FUF8*(Q<:O9M8V^
MHW0C556,7-T))MBC"ER!QP/RD_;&^--S^U)^RYX/\ _ K_@FIJ/P!TCX<:GH
M-[XW^(T'P[M_^$_\3:QI%BT,D%K?Z7X:L-?DT34D,ES>65P;Q)+DJ3(BJD:_
MH?\ \% ? WCF]_X(<?L_:/8>"?%U_K5IJVFM=Z%I_AO6+S6[59M3MF1KC2+>
MSDOX5VY9VDMU" $O@#->?1<U0SBG3GST)9=&I'V<,3"DZBG&,N2.)G4J75VI
M2O:35HI)'ZCQ!1P57B7P%SK-,$\NXDP?BIB<JQ57-LQX1QV=K*W@W6P\<QQ7
M".!RW*Z="HZ=/$87"NBZN%A5_?5JE2JSTK]I_P 5>)?"'_! KX5ZKX6\1:[X
M8U&/P_X/D_M/P[JU]HNI*L#Z))LCOM.GMKJ-6Y5U24!T+(V5)%?'O@?]BO\
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M6P*>*K=].U6P\*0ZK+J3Z:/M<&G3ZAJ4E[<F47%O!EMY39@$C"/O1H\KQ?\
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M=HH2UTVRM+"V15"*EO9P1V\*JJX50L<:@*O  P.!5VBBO%/4V"BBB@ HHHH
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M\8U"XTRSN8;+>BLZ_:'CRBEAP,U]O?\ !:W]DZ?X]_\ !.WP/X_T"PF;XF?
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MVNGZ?:SWVH7]Q#9V-C:QM-=7MW<2+%;VMM"@+S3SRNL<42 L[L%4$FO[/O\
M@BS_ ,$6[7X>6WAK]J_]JKP[%=^.[N&#6/AC\-M6MED@\*VT\:26VO>(K.<
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M?LO?#?Q+\3/BMXP&FZ%9:)X;ETZ&==%O;M8=>DFDU&[M8]C:=),@16);<22
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MY4TI;7OU,70C*O&NW)RA!PC'3E7,[N5K7YNE[VMTNDPHHHKG-@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_P P#_@Y9_Y2W?&/
M_LGGPG_]1E*_T_Z_B8_X+"_\$+OVS/V\?V\OB/\ M'?!?Q#\$=-^'_B'PSX)
M\/Z=;^./&M]HGB);[POI TS4C<Z9!HU['' URA>UF%R3+$PW1H5RWE9QAL1B
M<'&&'HSK3CB:4W"FDY*/)5BY6;6B<DGKU/VKP%XBR3ACCJKF6?YGA,IP,N'\
MQPT<5C*JI4I8BKB\MG3HJ3WG.%*I)1W<82>R9_$ GWA^/\C4U?T@+_P:T?\
M!2'((\8?LQG_ +J5JG\_^$=J4?\ !K1_P4B/_,X?LQ^__%RM4/\ +PX?YU\S
M_9F9_P#0OQ.R?PPV=O\ IYY_UH?VC#QB\,+?\EOD&_\ T&1\O(_F^C[_ (?U
MJ2OZ05_X-:/^"D0SCQA^S'^/Q(U4_P O#GO4H_X-9_\ @I$>OC']F(#O_P 7
M(U;/_J.5G+*LS;O]0Q-G;[,.RT^/S-(^,7A?=?\ &;Y!NO\ F,CY>7G_ %I?
M^;M/O#\?Y&IJ_I!7_@UE_P""D0(/_"9?LQ?^''U?T]O#AJ4?\&L__!2,]/&/
M[,7_ (<?6/Z>&Z%EF9<K7U#$W;_EA_=_O_U\T;Q\8_"^Z_XS?(-[_P"^+I9_
MR_U9]C^;FI(^_P"']:_I$'_!K+_P4C)Q_P )C^S'SZ?$;6?Z^&A_G\ZD7_@U
MD_X*2#C_ (3#]F,D_P#51M9[?]RW_G\*C^R\S_Z ,3_X##R_O^:.B'C+X773
M_P!>,@Z_\QD?+RZW5C^;NID^Z/Q_F:_I"'_!K)_P4E/_ #.'[,?_ (<76OZ>
M&C4J_P#!K+_P4E& ?&'[,F!_U436_P"?_"-'^54\LS)VM@,1HDOAA_\ )^9M
M_P 1E\+?^BXR#_PL7E_=\_ZTO_-U3D^\/Q_D:_I&'_!K)_P4E[^,/V9<>WQ"
MUS_YF>:D7_@UB_X*2]1XP_9EX]?B%KGI_P!BS[U']F9E_P! .([;4^MO^GGF
M:P\9?"VW_)<\/[W_ -\7E_=/YNZ*_I('_!K'_P %)B<?\)?^S)_X<+7?_F9/
M\J=_Q"Q?\%)N_B_]F7_PX6O'_P!U<4?V;F7_ $ XCY*GW7_3SS1O#QF\+$O^
M2YX?U?\ T&+39:^[Y]+G\VM2IT/U_H*_I('_  :P?\%)#G_BL?V9OP^(&O'_
M -UBI%_X-8?^"D@X_P"$P_9GZ\G_ (3_ %_V[?\ "+_UI?V;F/\ T 8G_P !
MAUMVGYHWCXT>%=DO]>N'[_\ 89WM_=_O(_F[3H?K_04^OZ1U_P"#6+_@I(!Q
MXP_9GYY_Y'WQ ?\ W6!2_P#$+)_P4E_Z'#]F?_PO?$/_ ,S%9RRS,VVU@,3K
M;[,.R_O^GWHN/C1X577_ !G?#VZ_YC/-?W/-'\V]/3J?I_45_2./^#6+_@I*
M>3XP_9GQ[>/?$7_S+$4\?\&L?_!2,'(\8?LT_P#A>>(?_F7H669ERM?4,3=N
MZ]V'E_?_ *^9O'QJ\*+I_P"OG#VZ_P"8ST_N>:^]=S^;JBOZ2!_P:Q_\%)3S
M_P )A^S1_P"%WXC_ *>%C2_\0L?_  4D[^,/V:/_  N_$8_]U4U/]EYG_P!
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M 8G_ ,!C_P#)FD/&_P )%K_K_P .6:_Z#?3^X?S=U.O0?0?RK^C_ /XA9_\
M@I&>GC#]FL_]SOXG_P#F3J0?\&M'_!2/ '_"8?LUC _Z'7Q1_3PK_2D\LS*Z
M?U#$Z7^Q'JO\1JO''PCU_P"-@\-ZZ?[[YQ_N>9_.$G0_7^@I]?T>K_P:U_\
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M)?\ 1S>%/_"^7E_TZ\_S[,_G9JQ7]#W_ !##_P#!1?\ Z'#]F_\ \+#Q1_\
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MCQ?^SG_X5WB?_P"9NC^QLV_Z%^)_\ 7_ ,EY_P!69LOI%^!B27_$4N$=$O\
MF82\O^G/]6]+_P ]%3KT'T'\J_H2'_!LI_P43_Z&_P#9R'_<W>)__F;J4?\
M!LO_ ,%$@ /^$O\ V<>/^IO\4?\ S,TO[&S;_H7XK_P!?_)>?Y]F-?2+\"W_
M ,W2X17KF$O_ )3_ %Z'\]-%?T+?\0R__!1+_H;_ -G'_P *_P 4?_,U2_\
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M/J/YU/7]!P_X-F_^"AP(_P"*O_9TZ_\ 0W>)_P#YFJ?_ ,0SO_!0_P#Z&_\
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M'Q*\.7Z-\//#?AJ>YU?P?HCQ>7-%XEGFU"TT^XGUB&3SK:.SGMY[$P.)'4R
M"OZ9E5454151$4*B* JJJ@!550 %50       !BOK.'N''2<<;F-.U5.]##3
M2?LVGI5JK5<Z:O"&JC\4M;)?P]]*GZ7=+/:&*\._";-7/*,12]EQ'QA@9SIO
M,:56*<\IR2M:%2G@Y0?+C\='EJ8AMX6@X4HU9UU       P !@ >@ X I:**
M^W/\W HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M11[1_P M/_P7#_Y'^KORL<B[S_\  Y?Y_P!7?E;C_P"R?%W_ $-5O_X)+?\
M^/4?V3XN_P"AJM__  26_P#\>KL**/:/^6G_ ."X?_(_U=^5CD7>?_@<O\_Z
MN_*W'_V3XN_Z&JW_ /!);_\ QZC^R?%W_0U6_P#X)+?_ ./5V%%'M'_+3_\
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M ./5V%%'M'_+3_\ !</_ )'^KORL<B[S_P# Y?Y_U=^5N/\ [)\7?]#5;_\
M@DM__CU']D^+O^AJM_\ P26__P >KL**/:/^6G_X+A_\C_5WY6.1=Y_^!R_S
M_J[\K<?_ &3XN_Z&JW_\$EO_ /'J/[)\7?\ 0U6__@DM_P#X]7844>T?\M/_
M ,%P_P#D?ZN_*QR+O/\ \#E_G_5WY6X_^R?%W_0U6_\ X)+?_P"/4?V3XN_Z
M&JW_ /!);_\ QZNPHH]H_P"6G_X+A_\ (_U=^5CD7>?_ ('+_/\ J[\K<?\
MV3XN_P"AJM__  26_P#\>H_LGQ=_T-5O_P""2W_^/5V%%'M'_+3_ /!</_D?
MZN_*QR+O/_P.7^?]7?E;C_[)\7?]#5;_ /@DM_\ X]1_9/B[_H:K?_P26_\
M\>KL**/:/^6G_P""X?\ R/\ 5WY6.1=Y_P#@<O\ /^KORMQ_]D^+O^AJM_\
MP26__P >H_LGQ=_T-5O_ ."2W_\ CU=A11[1_P M/_P7#_Y'^KORL<B[S_\
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M_P#X]7844>T?\M/_ ,%P_P#D?ZN_*QR+O/\ \#E_G_5WY6X_^R?%W_0U6_\
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M.1=Y_P#@<O\ /^KORMQ_]D^+O^AJM_\ P26__P >H_LGQ=_T-5O_ ."2W_\
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M*QR+O/\ \#E_G_5WY6X_^R?%W_0U6_\ X)+?_P"/4?V3XN_Z&JW_ /!);_\
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M>KL**/:/^6G_ ."X?_(_U=^5CD7>?_@<O\_ZN_*W'_V3XN_Z&JW_ /!);_\
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M/5V%%'M'_+3_ /!</_D?ZN_*QR+O/_P.7^?]7?E;C_[)\7?]#5;_ /@DM_\
MX]1_9/B[_H:K?_P26_\ \>KL**/:/^6G_P""X?\ R/\ 5WY6.1=Y_P#@<O\
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M>-?CXY_Y!L/]&J5;#Q 3C_A((A_W#8S_ .SUL)U/T_J*G3[P_'^1HYGO:/\
MX!'R\O(+7Y;N6]OBEM[OF8JZ?XBR,>(H1S_T#(^W/]^IAI_B/G/B.(_]PR(?
M^S_YYK<3[P_'^1J:IYGS;0VO\$+WOWY2VDE+?=?:EU4?.YA_V=XE'_,QP_\
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MBZ7XKP,>*[<#_L#Q?_%TO]E>*_\ H:[?_P $T7_Q==0GW1^/\S3J.9]H:?\
M3NGY?W/+\6%EY_>_\SFDTOQ7SCQ5;C@9/]CQ<_AOI_\ 97BO_H:[?_P31?\
MQ==-'W_#^M25DJDKKW:>Z_Y=4_+^[Y?B^XVNFNR^U+JD^_\ 7W6Y7^RO%?\
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M_P!7?E8Y%WG_ .!R_P _ZN_*W'_V3XN_Z&JW_P#!);__ !ZC^R?%W_0U6_\
MX)+?_P"/5V%%'M'_ "T__!</_D?ZN_*QR+O/_P #E_G_ %=^5N/_ +)\7?\
M0U6__@DM_P#X]1_9/B[_ *&JW_\ !);_ /QZNPHH]H_Y:?\ X+A_\C_5WY6.
M1=Y_^!R_S_J[\K<?_9/B[_H:K?\ \$EO_P#'J/[)\7?]#5;_ /@DM_\ X]78
M44>T?\M/_P %P_\ D?ZN_*QR+O/_ ,#E_G_5WY6X_P#LGQ=_T-5O_P""2W_^
M/4?V3XN_Z&JW_P#!);__ !ZNPHH]H_Y:?_@N'_R/]7?E8Y%WG_X'+_/^KORM
MQ_\ 9/B[_H:K?_P26_\ \>H_LGQ=_P!#5;_^"2W_ /CU=A11[1_RT_\ P7#_
M .1_J[\K'(N\_P#P.7^?]7?E;C_[)\7?]#5;_P#@DM__ (]1_9/B[_H:K?\
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MN_*QR+O/_P #E_G_ %=^5N/_ +)\7?\ 0U6__@DM_P#X]1_9/B[_ *&JW_\
M!);_ /QZNPHH]H_Y:?\ X+A_\C_5WY6.1=Y_^!R_S_J[\K<?_9/B[_H:K?\
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M ()+?_X]7844>T?\M/\ \%P_^1_J[\K'(N\__ Y?Y_U=^5N/_LGQ=_T-5O\
M^"2W_P#CU']D^+O^AJM__!);_P#QZNPHH]H_Y:?_ (+A_P#(_P!7?E8Y%WG_
M .!R_P _ZN_*W'_V3XN_Z&JW_P#!);__ !ZC^R?%W_0U6_\ X)+?_P"/5V%%
M'M'_ "T__!</_D?ZN_*QR+O/_P #E_G_ %=^5N/_ +)\7?\ 0U6__@DM_P#X
M]1_9/B[_ *&JW_\ !);_ /QZNPHH]H_Y:?\ X+A_\C_5WY6.1=Y_^!R_S_J[
M\K<?_9/B[_H:K?\ \$EO_P#'J/[)\7?]#5;_ /@DM_\ X]7844>T?\M/_P %
MP_\ D?ZN_*QR+O/_ ,#E_G_5WY6X_P#LGQ=_T-5O_P""2W_^/4?V3XN_Z&JW
M_P#!);__ !ZNPHH]H_Y:?_@N'_R/]7?E8Y%WG_X'+_/^KORMQ_\ 9/B[_H:K
M?_P26_\ \>H_LGQ=_P!#5;_^"2W_ /CU=A11[1_RT_\ P7#_ .1_J[\K'(N\
M_P#P.7^?]7?E;C_[)\7?]#5;_P#@DM__ (]1_9/B[_H:K?\ \$EO_P#'J["B
MCVC_ ):?_@N'_P C_5WY6.1=Y_\ @<O\_P"KORMQ_P#9/B[_ *&JW_\ !);_
M /QZC^R?%W_0U6__ ()+?_X]7844>T?\M/\ \%P_^1_J[\K'(N\__ Y?Y_U=
M^5N/_LGQ=_T-5O\ ^"2W_P#CU']D^+O^AJM__!);_P#QZNPHH]H_Y:?_ (+A
M_P#(_P!7?E8Y%WG_ .!R_P _ZN_*W'_V3XN_Z&JW_P#!);__ !ZC^R?%W_0U
M6_\ X)+?_P"/5V%%'M'_ "T__!</_D?ZN_*QR+O/_P #E_G_ %=^5N/_ +)\
M7?\ 0U6__@DM_P#X]1_9/B[_ *&JW_\ !);_ /QZNPHH]H_Y:?\ X+A_\C_5
MWY6.1=Y_^!R_S_J[\K<?_9/B[_H:K?\ \$EO_P#'J/[)\7?]#5;_ /@DM_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;^#L?O=_Q$K_ /!6/_HI_P *3]?@_P"&OZ 5./\ @Y7_ ."LF!_Q<_X5=/\
MHC_AG_"OP/J=>@^@_E6:S','>^.QFB;7^TUNEEUGV1O3\*/#.T?^,#X4WM_R
M),#W_P"O/7KT/WL'_!RS_P %9 ,#XG_"G_PS_AG_  J9?^#EG_@K)@'_ (6A
M\*N?^J/^&?7Z>U?@=4R?='X_S-)9CF%TOKV,U:7^\UO+^_\ U\V=4/";PQO;
M_4+A31=<DP+ZKO1\OS[G[XK_ ,'+'_!6;@CXG_"CVS\'_#7K["I!_P '+7_!
M6;O\3_A1GV^#_AK_  K\$D^Z/Q_F:=2_M',/^@[&?^%-;R_O^7Y]V=$/"7PP
M;UX X3=E_P!"/ >6_P"Y_JY^^"_\'+/_  5G X^)_P *,'GGX/\ AK_"GC_@
MY:_X*S#K\3_A1_X9[PR?YBOP37H/H/Y4M']H8_\ Z#L9T_YB:W2W]_R1T0\(
M_"YJ[\/^$7K_ -"/ =E_TY_J[/WO'_!RW_P5E) _X6=\)_Q^#WAG_"K"?\'+
M/_!6;''Q.^$W7_HCOAH?XU^!2?>'X_R-6TZ'Z_T%3+,,P2NL=C-+?\Q-7R7\
MWE]_R.K_ (A%X6K_ )M]PC_X8L!Y?].?)'[VC_@Y9_X*RC_FIWPF_P##.>&3
M_.GK_P '+/\ P5E)_P"2G?"4\=_@YX9'I[&OP2IZ=3]/ZBH699A:3^O8O2R_
MWBKW_P 7D=$/"'PL]W_C7O"'31Y%@.MO^G/E^+/WO'_!RS_P5D[_ !,^$G_A
MF_#'^ J1/^#EC_@K(<_\7,^$G'_5&O#']0:_!&I(^_X?UJ?[2S#_ *#L7_X4
M5?\ Y,ZX>#_A7J_^(><'WV_Y$.7[:?\ 3G[S]\1_P<J_\%9."/B7\(O7GX->
M&/\ #%/_ .(E?_@K)W^)OPC_ /#,^%Q_C7X++T'T'\J6E_:.8?\ 0=B__"BK
MY?WO+^M+;P\'_"IWOX=\'O;_ )D.7_\ RCR_%G[V+_P<K?\ !6,C ^)?PBX]
M?@SX7_PIX_X.5?\ @K'W^)?PB_#X,>%_Y_\ UJ_!2/O^']:DH_M',/\ H-Q?
M_A15\O[WDC:'@]X4MV?AWP<UO_R(,O\ +_IQUMK\S][$_P"#E7_@K$1_R4KX
M0]>_P8\+D_R'M_GK(/\ @Y1_X*Q$ _\ "R_A!C_LC'A?_ U^"B=#]?Z"K*?=
M'X_S-0\RS"*=L=B_B_Z"*O5)_P W='3'P=\*+V_XAUP;LG_R(,N_NO\ Y\>5
ME_F?O*/^#E'_ (*P]_B5\(?_  S'A?\ P%2K_P ')_\ P5@X/_"R?A 0?7X,
M>%_\*_!>IUZ#Z#^51_:>8WO]>Q?_ (45?P][3Y'33\&O"9\M_#C@QZK_ )I_
M+NZ_Z<?W4?O(/^#E#_@J^2!_PLCX/\G'_)&/"_\ A4H_X.3?^"KW?XD?!\_]
MT7\,=?S_ *"OP87J/J/YU/2_M+,?^@[%Z?\ 415\O[W96.C_ (@SX2K_ )MO
MP7_XCV6]+?\ 3CR6WYG[Q+_P<F_\%72<?\+(^#_/K\%_"Y_G4@_X.2_^"KO?
MXC_![_PRWA?_ !'\J_!M/O#\?Y&IJ/[2S#_H.Q?_ (45?_DCHI^"_A&[7\-N
M"MD_^2=RW^[_ -0_D?O"O_!R5_P5;8X_X6/\'Q_W1?PO4B_\')'_  5<)Q_P
ML?X/8_[(MX8].^"/YU^#J=3]/ZBIT^\/Q_D:3S+,4F_KV+V?_,15[?XCKAX+
M>$5O^3:<$:.W_).9;Y?]0_D?O!_Q$C?\%6O^BC_!_P#\,MX8_P#BJ<O_  <B
M_P#!5DGGXC?!_I_T1?PQ[?[5?A'3TZGZ?U%9O-,R2C_M^+UO_P Q%7I_V\;0
M\%?"%WOX9\$.UO\ FG,L_P#F?R]#]W?^(D/_ (*L?]%&^#__ (9?PS_\51_Q
M$A_\%6/^BC?!_P#\,OX9_P#BJ_">BI_M3,O^@_&?^%%7_P"2\OS[LZ(^"?@^
MTF_#+@?K_P TYEG?_L'/W9'_  <A?\%5R0/^%C?!_P#\,OX8_P#BJD_XB0/^
M"JW_ $4;X0?^&8\,?XU^$B?>'X_R-34_[4S+_H/Q?_A15_\ DC:'@CX/-:^&
M/ ^__1.99Y/_ *!_ZNS]V?\ B(]_X*K_ /11O@]_X9CPU_\ %4O_ !$>_P#!
M5;_HHWP?_P##+^&?_BZ_"VBE_:F9?]!^,_\ "BKY?WO+\7W+7@CX.K_FV' W
MSX;RQ]N^'\OS[G[J#_@X^_X*J?\ 11/@^?\ NC'AK_XNG#_@X[_X*JD9_P"%
MB?![_P ,SX:_^+K\*:F3[H_'^9H_M3,O^@_&?^%%7R_O>7XON;1\#_!RR?\
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MAX(XORN-:OE=7*<#A\KRS-W*,7/+,XHX2G"FU6<$L+C^257!UGKS8>I6@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%FDR0M?TH>']>TKQ1HFE>(M#O(=0TC6K&WU'3KVW=9(KBUN8Q)&Z.A93P=K
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M\[=UVMJ]59#JXG$.6)E1=.-/"N*E&47)U)/XE>Z44M?/1=S]W/VA/VM/@?\
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M)X0^,?@NRU?3_#?C33QJ&FV>NV\-KJL$6XJ4O(()[B*.0,,%4F<#'6OYQ?\
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MQBRP7. ?TA\/:W:>)= T7Q%IXD%CKNE:?K%F)@%E%KJ5K%>6XD4%@LGE3)O
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M:? ;]AOQG\5+/1],CO\ XE:O#-X@@\(^#&,"SS;_ !!9Z5=026T"+<,\]PL
M5(68@<BOU._8?_X*P_!W]KK]F+QW^T#J=D/ %_\ "C3[R_\ B1X5EN&NH]'2
M%)?L)L;VX\A[Y-4N(9;:R9HH?.DV!,[^"KE^+HP]I4I6BIJF[2A*49R:45*,
M9.4>9M)72O=6W04\9AJLN2%2\N5R5XRBFDKNSDDG9;V?1]C]8:*_E.M/^#BG
MXX^.]4UCQ?\ !+_@G_X\^)W[.OA[6I-+\0?%[3&\32Q:$D,JI-_:]M9Z-<6-
MC>11O'+):S7H**Z$G#"OZ2?V=_C1HW[0WP6^'WQGT"RNM-TGQ[H@U>UL+V-H
MKJS*W5Q93V\R/\RM%<VLR?-R5 ) )P(Q&#Q&&476@HJ3LK3A)J5K\LE&3<96
MUM))E4<31KMQIR<FE?6,HIK17BVDI*[M>-UYGM%%%%<IT!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5_F ?\'+/_*6[XQ_]D\^$
M_P#ZC*5_I_U_F ?\'+/_ "EN^,?_ &3SX3_^HRE>)G_^XT_^PNC_ .FZY_0?
MT9_^3CU_^R8S7_U-RD_!M.A^O]!4R=3]/ZBH4Z'Z_P!!4R=3]/ZBOD)_"_E^
M:/\ 02.R]%^1+4Z]!]!_*H*G7H/H/Y5G'[7^%_H=%/:/K^HM3)]T?C_,U#4R
M?='X_P S2CNO5?F=D-WZ?JBPGW1^/\S3J:GW1^/\S3J1T0W?I^J)UZ#Z#^5+
M2+T'T'\J6@ZH;/U_1#D^\/Q_D:MIT/U_H*J)]X?C_(U;3H?K_05,_A?R_-'6
M/IZ=3]/ZBF4].I^G]16:^&7_ &[^9T0^S_V[^A+4D??\/ZU'4D??\/ZU)VPV
M?K^B+:]!]!_*EI%Z#Z#^5+0;T^OR_4DC[_A_6I*CC[_A_6I*#>&[]/U1*G0_
M7^@JRGW1^/\ ,U63H?K_ $%64^Z/Q_F:SGL_\2_])1TQ^+_MU?E$=4Z]!]!_
M*H*G7H/H/Y5F==/:/K^HY>H^H_G4]0+U'U'\ZGH.D<GWA^/\C4U0I]X?C_(U
M-0=5+I_A7Z#TZGZ?U%3I]X?C_(U G4_3^HJ=/O#\?Y&E+9^C_(ZX;/U_1$U/
M3J?I_44RGIU/T_J*R?PQ_P"WOS-Z?7Y?J2T445)U0^%?/\V.3[P_'^1J:H4^
M\/Q_D:FH-X;/U_1%BBBB@L*F3[H_'^9J&ID^Z/Q_F:#>.R]%^0ZBBBIG\+^7
MYHZ([+T7Y#TZGZ?U%2U$G4_3^HJ6G'9>B_(VAL_7]$*O4?4?SJ>H%ZCZC^=3
MU@6%%%%!T$R?='X_S-.IJ?='X_S-.H-X[+T7Y!4D??\ #^M1U)'W_#^M!M#9
M^OZ(F3[P_'^1J:H4^\/Q_D:FI2V?H_R-([KU7YA1111'9>B_(W)UZ#Z#^5+2
M+T'T'\J6E/X7\OS1O'9>B_(*DC[_ (?UJ.I(^_X?UIQV7HOR-(_&O1?^DEB/
MO^']:DJ./O\ A_6I*RG\3^7Y(VCNO5?F?4?[('[7OQB_8H^,N@_&3X/:U+:W
MUA-!!XB\-W,\RZ%XR\/_ &F*XO?#^M01[B;.]:*+S98%CNE\M?+F3FO]&K]@
MO]O+X._M[_!VP^)'PUU&*T\1:?!9VOQ \!W4L2Z]X.UR5'1XKRT6:>1--OYK
M>XGT:Y>1GN+(1M,$F+)7^7E7U)^R%^U]\8OV*OC%H/Q@^#^N7%E>6%Q''XB\
M.22EM%\7:%(\8U+1=3M)!):[KVU1[6'43;R7=@)&EM61QD^]D>>5<KJ^SJ.5
M3!5)7J4]W3D[)U:5]FOM0VFNTM3^7?I*?1JR;QLR>IFV4QPV4^(>589QRK-9
M15.AF]"G'GCDV<RBKRHS;E'!XUJ57 59W?M,,ZE%_P"J917P[^P9^WC\(/V]
M?@UI?Q*^'.HV]EXCM((;3Q[X#N;B(:WX2U^.*);Z)K1Y/MD^AO>--#I.L200
MQWZ0L0BNI6ON*OU.C6I8BE"M1G&I2J14H3B[J2?Z]&GJG=-)H_Q(S_(,YX6S
MG,>'^(,NQ.59SE6)J83'X#%TW3KX>O3=I1DGI*$E:=.K!RIU:<HU*<Y0E&3*
M***U/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM]\0-)\(^(['7)-(@O=-T*VTIO$%CI=S=2020W=K=*(KU(WM7B=F"CD^[?\
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M:N"I..,C@%13GRW>'JQE5YER^[[J?+OS:+2R.'P\\;>!^&LN\$\/FE7-_K'
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M=/GFAT6[2\FM[5 $*RS'?YZ96?(D#,"#7[9?%#_@W>_X)]_%'XFW7Q,N]/\
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MEDYQ2E)JSYDDE*RVZ?DU_P &STTEE^T/^W3HUGXCF\1Z9IGPFT&2PUW$L/\
M;$G_  DUXG]M")W>2&6["*_S.T@*\N3TJ_\ !&_XB^"_AO\ \%<_VU]=^(/C
M'0/!NDW'POUVR_M'Q-K-EHMI=7D?CC0[P6*SZA<6\4]V8HC/':JSS/L#)&2
M:_H[_8I_X)6?LT?L&?$GXN_$SX(3^.CJ7QETRTT;Q!H?B;7+/5/#>DZ78ZBV
MIVUCX=TV#2[)M/MHYW:,1R3W(\DE/>OFS]H__@@%^PE^TO\ %G7/C!XIB^)?
MA#7O$6IQZQJ^D?#[Q-I_AWPY>7Z&)FFETXZ)=L3(8EWCS\$%@ !C&E3,,)5K
MX[GE5C2Q="C352--.<734+WA>*WB[6=O1$0P>(IT<+RJG*IAZM2;ASN,9*;=
MK2Y7:RWTOJT?E/\ \'(6HV&K?M2_\$V]3TR\M=0TZ_7Q7=65]93Q7-I=6\OB
M/P\\<UO<0L\4T3JP*O&[*01S7SY_P6%>U\'_ +>?[$?CWXDVDH^%,O@/X"^1
M=:C"USHTKZ5IVCR:X8+>1#"YMH\->JFXLO$FT'-?TJ_M/?\ !)+]F']JV\_9
MON_'U_\ $;0E_9=TO^R/AS:>#/$=IH]I/:&33YI!K\4^DWIOWFETZ&25HFMM
MS/*2/GX]T_::_8&_9O\ VMOA5X:^$_QE\(+KNG>#--M-,\(>)8S;)XN\-0VU
MI;64LFCZO-;3K:S7UM:PQWK"W99E!PJGD10S'#T8X&+4Y*C3Q-&M:-I*-:?-
M&4-;-I)-J_=:E5<'6J2Q4O<BZLZ%2G=W3=*"4HRTNDVG9V=]+VZ?F5_P6P_:
M5_9-\3?\$S/B=H>B^._AOXJU[Q[X0TJW^#6F:#J&B:EJ.FZB;[1[F&:TT^RE
M>Z\.^7H\-Q9B.6"T*_\ 'IL!38OY+^&O"WB?PS_P;QZA/XDTV]TRW\0^*X-5
M\/1WRO$\^E#1]2MVGBMY51X(VN$< %1N.2.,U^M?P_\ ^#;;_@GKX!\9VGC$
M2_&#Q8;2\CO1X=\8>,M/UCPU,\4@E2*?3?[ @\R$.JDIYJ\#&:_4O]HW]BKX
M*_M*?L]R?LR^)K+5?!WPN%O!:6&G?#ZZMO#]SI-K;Q3Q10:9(]G>06Z*MQ*Q
M_P!'<M(QD8EBQ*AC,'AX8>A1G6JPCBX8FK4J04'%127)""E*[TNW?5W[Z.6&
MQ%:=6K4C3IR="5&$(2<D[N]Y2:6G;MHM4KGY"_\ !(C0M"3_ ((0M>IHFDI>
M:Y\*/C_)KEVEA;)<ZU):7'C"&UEU6X5!+?/;0)'#;FX=Q#%&B1A0#G\T_P#@
MA6/A#;_ ;_@H5#\<;A-*^$-SIWAS2O&%[%:37+:?8W^KZI965Q!;VD<DY:SN
MY8IHA&F(S'EBJ U_4Y^SO^Q-\)?V9_V4+;]COP#?>+KSX6VOA[Q?X:2^\1:O
M!J'BI[#QK)J4NKO)JD5C:P-<*VJ7'V63[&!$!'N5]IW> _LN?\$E?V6_V4?!
M_P ;/ ?@R3QYXN\*_'NUAM/'&D_$/7K/Q!;"&WFNKBW_ ++2'2K 6KP3W32Q
M%_.VO'$<?*=T_7J#68+FJ)8C%4ZU+E6O)&MS/5NT9*&U[ZI(I86JG@M(/V%"
M5.I=W7-*FH[63E&_Q-6;1_+GXT^'/Q5_X)C_  TUCX^_L,_MF_#GXN_LT^+]
M6?5[SX4Z[>:9<K/:W4B3-%KOP[U/7I+G5[YXT6"6[N--,C#RPXPB@_UM?\$T
M?VC/^&J?V,O@S\99/!.G_#V[\2Z%.U]X6T72X=)T*PNK?4;R"5M(M;6&"R2U
MN6C-R5M$,:332!CO+5^<5I_P;5?\$]+/QHGC)+SXSR[-1_M#_A&I_&NGR>%V
M/F^;]D;3#X?&;,GY3%YOW>-W>OW:^'7P[\&?";P1X;^'/P]\/Z=X6\&>$M-C
MTK0-!TJ!+:PT^SC=Y3'!"@"J99Y9KB4@#?-+(YY:IS#%X;$4H1@Y5:ZGS2KR
MI1HR<.6RA-1;522T]^T=GWU>#P]:C4DY*-.ER<JI1J2J)3NFY1<O@C96Y;OI
MJ[:=K1117D'HA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5_F ?\'+/_ "EN^,?_ &3SX3_^HRE?Z?\ 7^8!_P '+/\ REN^,?\
MV3SX3_\ J,I7B9__ +C3_P"PNC_Z;KG]!_1G_P"3CU_^R8S7_P!3<I/P;3H?
MK_05,G4_3^HJ%.A^O]!4R=3]/ZBOD)_"_E^:/]!([+T7Y$M3KT'T'\J@J=>@
M^@_E6<?M?X7^AT4]H^OZBU,GW1^/\S4-3)]T?C_,TH[KU7YG9#=^GZHL)]T?
MC_,TZFI]T?C_ #-.I'1#=^GZHG7H/H/Y4M(O0?0?RI:#JAL_7]$.3[P_'^1J
MVG0_7^@JHGWA^/\ (U;3H?K_ $%3/X7\OS1UCZ>G4_3^HIE/3J?I_45FOAE_
MV[^9T0^S_P!N_H2U)'W_  _K4=21]_P_K4G;#9^OZ(MKT'T'\J6D7H/H/Y4M
M!O3Z_+]22/O^']:DJ./O^']:DH-X;OT_5$J=#]?Z"K*?='X_S-5DZ'Z_T%64
M^Z/Q_F:SGL_\2_\ 24=,?B_[=7Y1'5.O0?0?RJ"IUZ#Z#^59G73VCZ_J.7J/
MJ/YU/4"]1]1_.IZ#I')]X?C_ "-35"GWA^/\C4U!U4NG^%?H/3J?I_45.GWA
M^/\ (U G4_3^HJ=/O#\?Y&E+9^C_ ".N&S]?T1-3TZGZ?U%,IZ=3]/ZBLG\,
M?^WOS-Z?7Y?J2T445)U0^%?/\V.3[P_'^1J:H4^\/Q_D:FH-X;/U_1%BBBB@
ML*F3[H_'^9J&ID^Z/Q_F:#>.R]%^0ZBBBIG\+^7YHZ([+T7Y#TZGZ?U%2U$G
M4_3^HJ6G'9>B_(VAL_7]$*O4?4?SJ>H%ZCZC^=3U@6%%%%!T$R?='X_S-.IJ
M?='X_P S3J#>.R]%^05)'W_#^M1U)'W_  _K0;0V?K^B)D^\/Q_D:FJ%/O#\
M?Y&IJ4MGZ/\ (TCNO5?F%%%%$=EZ+\C<G7H/H/Y4M(O0?0?RI:4_A?R_-&\=
MEZ+\@J2/O^']:CJ2/O\ A_6G'9>B_(TC\:]%_P"DEB/O^']:DJ./O^']:DK*
M?Q/Y?DC:.Z]5^85]5_L>?L>?&#]M?XPZ)\(_A)HES=2W=Q')XD\2O"PT?PGH
MB-&U_JFH7<@2T\ZVM&DN;;3Y)XI[XQ-%;AFSAO['G['OQ@_;9^,>A_"'X1Z-
M/<3W<T,_B7Q--;RMHOA'01,D5[K>J3#8'AL_,C9[:"1KN17!BB8 D?Z-/["/
M["/P>_8-^#^G?#CX;:9#<:_>VUK<>.O&]S%$VN>+=95-\KWEXL44LNG65Q+<
M1:1;RKOM[,HDA9P2/>R+(ZF:554JJ5/!4Y6J5%I*HU9NE2NMVM)3V@GUEH?R
MW])7Z2N3^"F3U,HRB6&S7Q#S7#.65Y7*2JT,GH58\D<XSF,7>-*+3E@\$W&K
MCJD;ODPT9U6?L(?L)_"']@WX.:7\-/AQIUO=:]<00W/CGQO/ G]K^*]=:.-K
MVX>X=#=P:3]J62;3]*>>6*Q$KA"2Q-?;U%%?JE&C2P]*%&C"-.E3BHPA%648
MK;_@MZMZO4_Q)S_/\XXHSC,>(.(,PQ.:YQFN)J8O'X_%U'4KXBO5=Y2E)Z1C
M%6A3IP4:=*G&-.G&,(QBBBBBM#R HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S /\ @Y9_
MY2W?&/\ [)Y\)_\ U&4K_3_K^&O_ (+._P#!$S]N[]N+]O\ ^)7[0WP$T+X7
MW_PVU_POX%T#3+KQ3\1M/\-ZN]_X:T4:=JJ3:3<VLLT4:7:L()2^R:(JZ\Y
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M@<*+6_\ R.L%M9?]/?-'\_:?>'X_R-6TZ'Z_T%?OZ/\ @V,_X*M @_\ "+?
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M'PI?\CO!]H_]//-'X#U.O0?0?RK]\O\ B&:_X*L?]"O\!Q]?B_9?TTPU*/\
M@V<_X*K  ?\ "+_ C@?]%?LO_E;4?V7F7_0%B?\ P5+_ "_KJ=4/&?PE7+?Q
M&X/5GUSS!=[_ //P_ I>H^H_G4]?O@/^#9S_ (*K<'_A&/@..?\ HK]G_P#*
MS^M2C_@V>_X*J=_#/P'_ /#O6G_RK/\ .C^R\R_Z <3K_P!.I>6^GG^#['1_
MQ&GPD_Z.1P=_X?,'Y?\ 3SS_ #['X&)]X?C_ "-35^^ _P"#9_\ X*I@Y_X1
MKX$?^'=M/_E93_\ B&A_X*I]_#/P(_\ #NV@_P#<8:/[+S'_ * <3_X*E_D=
M%/QK\(E:_B3P;M;_ )'F"Z6_Z>'X'IU/T_J*G3[P_'^1K]ZU_P"#:+_@JB#_
M ,BU\".G?XN6G]--J5?^#:3_ (*H@Y/AOX#_ /AW+7_Y6'^E*659E9_[#B7=
M6TI2ZV\O/\'V.J'C;X0)?\G+X,W_ .A[@O+O4/P5IZ=3]/ZBOWL_XAI_^"I_
M_0M_ CW_ .+N6OZ?\2O^?_UZ</\ @VH_X*G Y'AOX$_^';M?_E96;RK,VHKZ
MCBM+_P#+F?6WEY_GV-H>-W@^KW\3."U>W_,]P7_RSS_/H?@M17[V#_@VJ_X*
MF]_#?P)_#XMVG]=,I?\ B&J_X*F?]"W\"O\ P[=I_P#*S_&I_LG,_P#H!Q7_
M (*G_EY_GV9T1\</!VR7_$3>"O\ P_8'O_U]\_\ (_!1/O#\?Y&IJ_><?\&U
M7_!4P'/_  CGP)_\.W:__*NG#_@VL_X*F=_#GP(Q[?%NV_\ E91_9.9_] .*
M_P#!4_\ +S_/LS:'CEX.)6?B=P4KO_H?X'R_Z>GX/45^\W_$-A_P5,_Z%OX$
M_P#AVK7_ .5M'_$-A_P5,_Z%OX$_^':M?_E;2_LK,_\ H Q?_@F?^7]6?E>U
MXY>#;_YN=P2O7/\  ]_^OA^#-3)]T?C_ #-?O'_Q#7_\%2?^A<^!7_AVK7_Y
M64X?\&V/_!4D#'_".? G_P .U;?_ "LI_P!E9G_T 8K_ ,$S_P C:/CIX-62
M_P"(H<$;+?/\"NR_Y^GX.45^\G_$-E_P5*_Z%SX$_P#AV;;_ .5E*/\ @VR_
MX*D]_#GP*_#XM6W]=,J995F;32P&+UM_RXGY>7G^#[&T?';P8LE_Q%#@A:+_
M )J# ]E_T]_KY'X.IU/T_J*EK]WQ_P &VG_!4@'(\.? O_P[-K_\K*=_Q#;?
M\%2/^A<^!7_AV;;_ .5M-93F:27U#%;+_ES+LO+^K,UAX[^"Z5GXH\#ZO_HH
M,#IMO^\/P?7J/J/YU/7[MC_@VV_X*C#!_P"$<^!G'/\ R5FU_P#E;4G_ !#<
M_P#!4;_H6_@9_P"':M?_ )65E_8^:_\ 0!BO_!,O\B_^([^"_P#T=+@?_P 2
M' >7_3WS_!GX045^\/\ Q#<?\%1/^A=^!G_AV;7_ .5E'_$-Q_P5$_Z%WX&?
M^'9M?_E92_L?-/\ H7XO_P $S_R\_P ^S-_^(\^"O_1T^!O_ !(,!Y?]/>E]
M?1GX2)]T?C_,TZOW<'_!MW_P5$ Q_P (Y\##_P!U9M?_ )64[_B&\_X*A]_#
MGP-_\.S:G_W&"C^R,T_Z%^+_ /!,_+R\_P ^S-H^/7@I9?\ &U.!EHM^(<!Y
M?]/?ZL?A#4D??\/ZU^[7_$-Y_P %0_\ H7/@;_X=BU_^5M.7_@V]_P""H:Y_
MXISX&G/_ %5FU_\ E;3_ +'S7_H Q7_@F7^1K#Q\\$TK/Q5X%U?_ $4. TV_
MZ>GX4I]X?C_(U-7[J+_P;?\ _!4$$$^'/@;]/^%L6OTZ_P!F5)_Q#A?\%0?^
MA<^!O_AV+7_Y65+RC-+-?V?B]FOX$_\ +^K>E[CX^^"5T_\ B*O NZ_YJ' >
M7_3WS_!GX3T5^[/_ !#@_P#!4#_H7?@=_P"'7M?_ )6TO_$.#_P4_P#^A>^!
MO_AU[;_Y64+*,U27_"?B^W\"?2WE_5F;+Q_\$7_S=;@1>O$. [_]?3\+%Z#Z
M#^5+7[JC_@W$_P""GX '_"._ W@8_P"2L6W_ ,JZ=_Q#B?\ !3[OX=^!W_AU
M[8_^XP4I91FK32R[&:_].)^3[&R^D!X())?\17X$V2_Y*+ ?_+3\**DC[_A_
M6OW3_P"(<3_@I]_T+WP._P##KVW_ ,K:<O\ P;C?\%/ES_Q3OP..?^JKVW_R
MLIK*,TLE_9V,T27\"?EY?U8N/T@/ _F3_P"(L<!I66_$67_RI?\ /WS_  9^
M&4??\/ZU]6_L>?L>?&/]MGXQ:-\(?A!H<UW<3S6\_B?Q+<0S_P!@^$-#>;RY
MM7UN[A1VMK<E6MXG$;YN9(D*X;-?ISH'_!N!_P %)KK6M*M?$.F_!G2-!N+^
MTAUC4[#XF6FH7MAITD\:7EW:V3:?&MU/!;M++% 77S714W#=D?V8?L)?L(_!
M[]@WX/:9\-?AMIUO>:[<0Q77C?QU<VD::UXMUUHHEN[Z61FFELK*5XD>+2X)
M_L<+KYBQAV)'H99PWC,9B?\ ;*-;"X:FXNHZD7"I5T7[NDGKKM*=K16UW8_&
M_&_Z8' / _"\_P#B'F?Y'QMQ?FD:M#*X97BZ>8Y9D[2BIYGFU6A)P_<\Z>%P
M/.IXNJKRY</3JR#]A']A'X._L&_!S3/AK\-=,BN=<NHK>\\<>.+RWB&N^+M=
M6(I)>7LJ92.*!7^RV\-LL,;011O+&TN2/MZBBOTRC1I8>E"C1A&G2IQ480BK
M**7ZO=MZMW;;;;/\;L^S[..*,XS'/\_S#$YKG&:XFIB\?C\74=2OB*]1W<I-
MZ1A%6A2I04:5&E&%*E"%.$8HHHHK0\@**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>L?_ (_0!Z;17F7_  B7CK_HHTO_ (3UC_\ 'Z/^$2\=?]%&E_\ ">L?_C]
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M_P (EXZ_Z*-+_P"$]8__ !^C_A$O'7_11I?_  GK'_X_0!Z;17F7_")>.O\
MHHTO_A/6/_Q^C_A$O'7_ $4:7_PGK'_X_0!Z;17F7_")>.O^BC2_^$]8_P#Q
M^C_A$O'7_11I?_">L?\ X_0!Z;17F7_")>.O^BC2_P#A/6/_ ,?H_P"$2\=?
M]%&E_P#">L?_ (_0!Z;17F7_  B7CK_HHTO_ (3UC_\ 'Z/^$2\=?]%&E_\
M">L?_C] 'IM%>9?\(EXZ_P"BC2_^$]8__'Z/^$2\=?\ 11I?_">L?_C] 'IM
M%>9?\(EXZ_Z*-+_X3UC_ /'Z/^$2\=?]%&E_\)ZQ_P#C] 'IM%>9?\(EXZ_Z
M*-+_ .$]8_\ Q^C_ (1+QU_T4:7_ ,)ZQ_\ C] 'IM%>9?\ ")>.O^BC2_\
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MU_T4:7_PGK'_ ./T >FT5YE_PB7CK_HHTO\ X3UC_P#'Z/\ A$O'7_11I?\
MPGK'_P"/T >FT5YE_P (EXZ_Z*-+_P"$]8__ !^C_A$O'7_11I?_  GK'_X_
M0!Z;17F7_")>.O\ HHTO_A/6/_Q^C_A$O'7_ $4:7_PGK'_X_0!Z;17F7_")
M>.O^BC2_^$]8_P#Q^C_A$O'7_11I?_">L?\ X_0!Z;17F7_")>.O^BC2_P#A
M/6/_ ,?H_P"$2\=?]%&E_P#">L?_ (_0!Z;17F7_  B7CK_HHTO_ (3UC_\
M'Z/^$2\=?]%&E_\ ">L?_C] 'IM%>9?\(EXZ_P"BC2_^$]8__'Z/^$2\=?\
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MO]9A>]I+2VJ6]_)_U8Q]C/\ N_?_ ,#^K/ROE)U/T_J*EK1_X51KO_0]S_\
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M]%&E_P#">L?_ (_1_P (EXZ_Z*-+_P"$]8__ !^@#TVBO,O^$2\=?]%&E_\
M">L?_C]'_")>.O\ HHTO_A/6/_Q^@#TVBO,O^$2\=?\ 11I?_">L?_C]'_")
M>.O^BC2_^$]8_P#Q^@#TVBO,O^$2\=?]%&E_\)ZQ_P#C]'_")>.O^BC2_P#A
M/6/_ ,?H ]-HKS+_ (1+QU_T4:7_ ,)ZQ_\ C]'_  B7CK_HHTO_ (3UC_\
M'Z /3:*\R_X1+QU_T4:7_P )ZQ_^/T?\(EXZ_P"BC2_^$]8__'Z /3:*\R_X
M1+QU_P!%&E_\)ZQ_^/T?\(EXZ_Z*-+_X3UC_ /'Z /3:*\R_X1+QU_T4:7_P
MGK'_ ./T?\(EXZ_Z*-+_ .$]8_\ Q^@#TVBO,O\ A$O'7_11I?\ PGK'_P"/
MT?\ ")>.O^BC2_\ A/6/_P ?H ]-HKS+_A$O'7_11I?_  GK'_X_1_PB7CK_
M **-+_X3UC_\?H ]-HKS+_A$O'7_ $4:7_PGK'_X_1_PB7CK_HHTO_A/6/\
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M (3UC_\ 'Z /3:*\R_X1+QU_T4:7_P )ZQ_^/T?\(EXZ_P"BC2_^$]8__'Z
M/3:*\R_X1+QU_P!%&E_\)ZQ_^/T?\(EXZ_Z*-+_X3UC_ /'Z /3:*\R_X1+Q
MU_T4:7_PGK'_ ./T?\(EXZ_Z*-+_ .$]8_\ Q^@#TVBO,O\ A$O'7_11I?\
MPGK'_P"/T?\ ")>.O^BC2_\ A/6/_P ?H ]-HKS+_A$O'7_11I?_  GK'_X_
M1_PB7CK_ **-+_X3UC_\?H ]-HKS+_A$O'7_ $4:7_PGK'_X_1_PB7CK_HHT
MO_A/6/\ \?H ]-HKS+_A$O'7_11I?_">L?\ X_1_PB7CK_HHTO\ X3UC_P#'
MZ /3:*\R_P"$2\=?]%&E_P#">L?_ (_1_P (EXZ_Z*-+_P"$]8__ !^@#TVB
MO,O^$2\=?]%&E_\ ">L?_C]'_")>.O\ HHTO_A/6/_Q^@#TVBO,O^$2\=?\
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MB7CK_HHTO_A/6/\ \?H ]-HKS+_A$O'7_11I?_">L?\ X_1_PB7CK_HHTO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%(RR$*>T\0^)?#GA'2;G7O%>OZ)X8T.R4->:SXAU6QT72K13G#7.HZE/;6D
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MDA_X(T_LF_\ !4']H3X&?%3Q+^PE^VMI'[,/P_T3XIC0_%_A#4)]:BN/$7C
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MH1>%+66:YATK1(+68*L;1/'',&8N7D2,_J1\0_\ @US_ &2+#1_M'[-?Q/\
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MI]9#!88^J1^82Q1,?,Q/4YKW#_@W!^-'BC]FS]KOXF?L2?$'4+K3+'Q_X?\
M^$ST/3-2N6BTW3[G1]+%U81Z=;3-Y=K-K<6I)<;8\&X=@QR6)/D7_!Q@2/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_VIVLWA:V-H]K8/;-:LGEFUD@/B40/;M%^[> Q"%TRIC"G;7].6@?!KX/\
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MIT+F72]+EN=3\40ZCJ4L(4QVR3K' MW,24PD(8( M?U@ZQ\"?@AXB\1+XO\
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M="FYM.<E!6<YM))RF[RE96NW;0****YCO"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ?E_T\\G_38?ZD<4?]'*XC_\)<M_^4>7Y]V?RJ_\/9/^"L7_ $91#_X+5_\
MEG1_P]D_X*Q?]&40_P#@M7_Y9U_55]GM_P#GA#_WZ3_XFC[/;_\ /"'_ +])
M_P#$T?ZP91_T2F5=/^7V+\O^GGD_Z;#_ %(XH_Z.5Q'_ .$N6_\ RCR_/NS^
M57_A[)_P5B_Z,HA_\%J__+.C_A[)_P %8O\ HRB'_P %J_\ RSK^JK[/;_\
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M_GA#_P!^D_\ B:/]8,H_Z)3*NG_+[%^7_3SR?]-A_J1Q1_T<KB/_ ,)<M_\
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M;_\ /"'_ +])_P#$T?9[?_GA#_WZ3_XFC_6#*/\ HE,JZ?\ +[%^7_3SR?\
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MM_\ E'E^?=G\JO\ P]D_X*Q?]&40_P#@M7_Y9T?\/9/^"L7_ $91#_X+5_\
MEG7]57V>W_YX0_\ ?I/_ (FC[/;_ //"'_OTG_Q-'^L&4?\ 1*95T_Y?8OR_
MZ>>3_IL/]2.*/^CE<1_^$N6__*/+\^[/Y5?^'LG_  5B_P"C*(?_  6K_P#+
M.C_A[)_P5B_Z,HA_\%J__+.OZJOL]O\ \\(?^_2?_$T?9[?_ )X0_P#?I/\
MXFC_ %@RC_HE,JZ?\OL7Y?\ 3SR?]-A_J1Q1_P!'*XC_ /"7+?\ Y1Y?GW9_
M*K_P]D_X*Q?]&40_^"U?_EG1_P /9/\ @K%_T91#_P""U?\ Y9U_55]GM_\
MGA#_ -^D_P#B:/L]O_SPA_[])_\ $T?ZP91_T2F5=/\ E]B_+_IYY/\ IL/]
M2.*/^CE<1_\ A+EO_P H\OS[L_E5_P"'LG_!6+_HRB'_ ,%J_P#RSH_X>R?\
M%8O^C*(?_!:O_P LZ_JJ^SV__/"'_OTG_P 31]GM_P#GA#_WZ3_XFC_6#*/^
MB4RKI_R^Q?E_T\\G_38?ZD<4?]'*XC_\)<M_^4>7Y]V?RJ_\/9/^"L7_ $91
M#_X+5_\ EG1_P]D_X*Q?]&40_P#@M7_Y9U_55]GM_P#GA#_WZ3_XFC[/;_\
M/"'_ +])_P#$T?ZP91_T2F5=/^7V+\O^GGD_Z;#_ %(XH_Z.5Q'_ .$N6_\
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MOL7Y?]//7\.MP_U'XH_Z.5Q'_P"$N6__ "C^O4_E6_X>R_\ !6+_ *,F@_\
M!;_]]*/^'LO_  5B_P"C)H/_  6__?2OZJ?L]O\ \\(?^_2?_$T?9[?_ )X0
M_P#?I/\ XFG_ *PY1_T2>4]/^7V+\K_\O?7[_N7^H_%'_1RN)/\ PERW_P"4
M?U=^5OY5O^'LO_!6+_HR:#_P6_\ WTH_X>R_\%8O^C)H/_!:/_EI7]5/V>W_
M .>$/_?I/_B:/L]O_P \(?\ OTG_ ,31_K#E'_1)Y3T_Y?8ORO\ \O?7[_N/
M]1^*/^CE<2?^$N6__*/ZN_*W\X.H_P#!3C_@KE;^!/AEJ_A#_@DO\1?BE?\
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M7U?TV8'H/R%&!Z#\A0!_,G_P])_X+5?](3OB[_X<WX6__+ZC_AZ3_P %JO\
MI"=\7?\ PYOPM_\ E]7]-F!Z#\A1@>@_(4 ?S)_\/2?^"U7_ $A.^+O_ (<W
MX6__ "^H_P"'I/\ P6J_Z0G?%W_PYOPM_P#E]7]-F!Z#\A1@>@_(4 ?S)_\
M#TG_ (+5'_G"=\7?_#F_"W_Y?5@O_P %<?\ @L7'))$__!%_XLJ\3M&ZGXE?
M# E74E64XUT\@@C^5?U%8'H/RKYQO3_Q,=2^5/\ C^N?X$_Y[/\ [-;4:<:C
MES-JW+:UNKL]TS*K-PY;6UOOY6_.Y^ 0_P""N7_!8L]/^"+_ ,6?_#E?#'_Y
M>4X?\%</^"QAZ?\ !%_XL_\ AROA@/YZ[7[\(>/NIU_YYI[?[-6$/!^5.O\
M<3V_V:W>&A>RE+:^MN_I_P -YF/MI_W?N_X/]7?E;\ /^'MW_!8W_I"]\6?_
M  Y7PP_^7M._X>V?\%C_ /I"[\6?_#E_##_Y>U_0&AY^ZG3^XGM_LU+G_93_
M +]I_P#$U'L(63O*]WVZ6\O/N-5Y]4G\GY>?]7^1_/R/^"M7_!9 ]/\ @BY\
M6?\ PY?PO_\ E]2_\/:/^"R1Z?\ !%SXM'_NI?PO_P#E]7]!BG@?*G0?P)_\
M34R'@_*G7^XGM_LT>PCWE^'^7K_2U:K2UTCIZKJEW??^NO\ /:/^"L__  62
M/ _X(M_%K_PY?PO_ /E]3O\ A[+_ ,%E/^D+7Q:_\.7\+O\ Y?5_0LAY^ZG3
M^XGM_LU.A^8?*G?_ )9IZ'_9H]A'O+\/\O7^EJ_;2=M%J[=?+S\S^>0?\%8_
M^"RIZ?\ !%GXM_\ AR_A=_\ +ZC_ (>Q?\%EO^D+/Q:_\.9\+O\ Y?5_1&I^
M8?*G_?">G^[4V?\ 93_OVG_Q-3[&/-:[VOT_R_KSMJW5DDW9:-='Y>?FS^=C
M_A[!_P %F/\ I"O\7/\ PY7PN_\ E]2C_@J]_P %FCR/^"*_Q<_\.7\+O_E]
M7]%V?]E/^^$_^)J5#Q]U.O\ SS3V_P!FH]FN[_#_ "*YWV7X_P"9_.;_ ,/7
M?^"S1_YPK?%S_P .7\+O_E_3O^'K?_!9S_I"K\7/_#E_"W_Y?U_1JI^8?*G_
M 'PGI_NU-G_93_OVG_Q-'LUWE^'^7]7?E8YWV7X_YG\XG_#UK_@LZ>G_  14
M^+A_[J9\+OZ:\:7_ (>L_P#!9_K_ ,.4_BW_ .'-^%O\O[>S7]'T9Z_*G;_E
MFGO_ +-29_V4_P"_:?\ Q-'LUW?X?Y!SOLOQ_P S^;X?\%5_^"T!Y'_!%/XN
M?^'-^%O_ ,OJ/^'J_P#P6A_Z0I?%S_PYOPM_^7U?TD*>!\J=!_ G_P 32Y_V
M4_[]I_\ $T<B[L.=]D?S<#_@JK_P6B/(_P""*7Q<_P##F_"W_P"7U'_#U3_@
MM%_TA1^+G_AS?A;_ /+ZOZ34/RCY4[_P)Z_[M.S_ +*?]^T_^)I>S\_P_P""
M'.^R_'_,_FP_X>J?\%HO^D*/Q<_\.;\+?_E]1_P]4_X+1?\ 2%'XN?\ AS?A
M;_\ +ZOZ55/RCY4_[]IZ_P"[3L_[*?\ ?M/_ (FCV?G^'_!'[3R_'_@'\U(_
MX*I_\%HST_X(H_%S_P .;\+/_E_2_P##U+_@M)_TA1^+G_ASOA9_\OZ_I9C/
M7Y4[?\LT]_\ 9J3/^RG_ '[3_P")J$KM+NP<VGLMD_O5S^:+_AZE_P %I/\
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M'\S'_#TS_@M1_P!(3_B[_P"'-^%O_P OJ/\ AZ9_P6H_Z0G_ !=_\.;\+?\
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M /+.OZJOL]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\ B:[_ /6#*/\ HE,JZ?\
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M $2F5=/^7V+\O^GGD_Z;#_4CBC_HY7$?_A+EO_RCR_/NS^57_A[)_P %8O\
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M\K_\O?7[_N/]1^*/^CE<2?\ A+EO_P H_J[\K?RK?\/9?^"L7_1DT'_@M_\
MOI1_P]E_X*Q?]&30?^"W_P"^E?U4_9[?_GA#_P!^D_\ B:/L]O\ \\(?^_2?
M_$T?ZPY1_P!$GE/3_E]B_*__ "]]?O\ N/\ 4?BC_HY7$G_A+EO_ ,H_J[\K
M?RK?\/9?^"L7_1DT'_@M_P#OI1_P]E_X*Q?]&30?^"W_ .^E?U4_9[?_ )X0
M_P#?I/\ XFC[/;_\\(?^_2?_ !-'^L.4?]$GE/3_ )?8ORO_ ,O?7[_N/]1^
M*/\ HY7$G_A+EO\ \H_J[\K?RK?\/9?^"L7_ $9-!_X+?_OI1_P]E_X*Q?\
M1DT'_@M_^^E?U4_9[?\ YX0_]^D_^)H^SV__ #PA_P"_2?\ Q-'^L.4?]$GE
M/3_E]B_*_P#R]]?O^X_U'XH_Z.5Q)_X2Y;_\H_J[\K?RK?\ #V7_ (*Q?]&3
M0?\ @M_^^E'_  ]E_P""L7_1DT'_ (+?_OI7]5/V>W_YX0_]^D_^)H^SV_\
MSPA_[])_\31_K#E'_1)Y3T_Y?8ORO_R]]?O^X_U'XH_Z.5Q)_P"$N6__ "C^
MKORM_*M_P]E_X*Q?]&30?^"W_P"^E'_#V7_@K%_T9-!_X+?_ +Z5_53]GM_^
M>$/_ 'Z3_P")H^SV_P#SPA_[])_\31_K#E'_ $2>4]/^7V+\K_\ +WU^_P"X
M_P!1^*/^CE<2?^$N6_\ RC^KORM_*M_P]E_X*Q?]&30?^"W_ .^E'_#V7_@K
M%_T9-!_X+?\ [Z5_53]GM_\ GA#_ -^D_P#B:/L]O_SPA_[])_\ $T?ZPY1_
MT2>4]/\ E]B_*_\ R]]?O^X_U'XH_P"CE<2?^$N6_P#RC^KORM_*M_P]E_X*
MQ?\ 1DT'_@M_^^E'_#V7_@K%_P!&30?^"W_[Z5_53]GM_P#GA#_WZ3_XFC[/
M;_\ /"'_ +])_P#$T?ZPY1_T2>4]/^7V+\K_ /+WU^_[C_4?BC_HY7$G_A+E
MO_RC^KORM_*M_P /9?\ @K%_T9-!_P""W_[Z4?\ #V7_ (*Q?]&30?\ @M_^
M^E?U4_9[?_GA#_WZ3_XFC[/;_P#/"'_OTG_Q-'^L.4?]$GE/3_E]B_*__+WU
M^_[C_4?BC_HY7$G_ (2Y;_\ */ZN_*W\JW_#V7_@K%_T9-!_X+?_ +Z4?\/9
M?^"L7_1DT'_@M_\ OI7]5/V>W_YX0_\ ?I/_ (FC[/;_ //"'_OTG_Q-'^L.
M4?\ 1)Y3T_Y?8ORO_P O?7[_ +C_ %'XH_Z.5Q)_X2Y;_P#*/ZN_*W\JW_#V
M7_@K%_T9-!_X+?\ [Z4?\/9?^"L7_1DT'_@M_P#OI7]5/V>W_P">$/\ WZ3_
M .)H^SV__/"'_OTG_P 31_K#E'_1)Y3T_P"7V+\K_P#+WU^_[C_4?BC_ *.5
MQ)_X2Y;_ /*/ZN_*W\JW_#V7_@K%_P!&30?^"W_[Z4?\/9?^"L7_ $9-!_X+
M?_OI7]5/V>W_ .>$/_?I/_B:/L]O_P \(?\ OTG_ ,31_K#E'_1)Y3T_Y?8O
MRO\ \O?7[_N/]1^*/^CE<2?^$N6__*/ZN_*W\JW_  ]E_P""L7_1DT'_ (+?
M_OI1_P /9?\ @K%_T9-!_P""W_[Z5_53]GM_^>$/_?I/_B:/L]O_ ,\(?^_2
M?_$T?ZPY1_T2>4]/^7V+\K_\O?7[_N/]1^*/^CE<2?\ A+EO_P H_J[\K?RK
M?\/9?^"L7_1DT'_@M_\ OI1_P]E_X*Q?]&30?^"W_P"^E?U4_9[?_GA#_P!^
MD_\ B:/L]O\ \\(?^_2?_$T?ZPY1_P!$GE/3_E]B_*__ "]]?O\ N/\ 4?BC
M_HY7$G_A+EO_ ,H_J[\K?RK?\/9?^"L7_1DT'_@M_P#OI1_P]E_X*Q?]&30?
M^"W_ .^E?U4_9[?_ )X0_P#?I/\ XFC[/;_\\(?^_2?_ !-'^L.4?]$GE/3_
M )?8ORO_ ,O?7[_N/]1^*/\ HY7$G_A+EO\ \H_J[\K?RK?\/9?^"L7_ $9-
M!_X+?_OI1_P]E_X*Q?\ 1DT'_@M_^^E?U4_9[?\ YX0_]^D_^)H^SV__ #PA
M_P"_2?\ Q-'^L.4?]$GE/3_E]B_*_P#R]]?O^X_U'XH_Z.5Q)_X2Y;_\H_J[
M\K?RK?\ #V7_ (*Q?]&30?\ @M_^^E'_  ]E_P""L7_1DT'_ (+?_OI7]5/V
M>W_YX0_]^D_^)H^SV_\ SPA_[])_\31_K#E'_1)Y3T_Y?8ORO_R]]?O^X_U'
MXH_Z.5Q)_P"$N6__ "C^KORM_*M_P]E_X*Q?]&30?^"W_P"^E'_#V7_@K%_T
M9-!_X+?_ +Z5_53]GM_^>$/_ 'Z3_P")H^SV_P#SPA_[])_\31_K#E'_ $2>
M4]/^7V+\K_\ +WU^_P"X_P!1^*/^CE<2?^$N6_\ RC^KORM_*M_P]E_X*Q?]
M&30?^"W_ .^E'_#V7_@K%_T9-!_X+?\ [Z5_53]GM_\ GA#_ -^D_P#B:/L]
MO_SPA_[])_\ $T?ZPY1_T2>4]/\ E]B_*_\ R]]?O^X_U'XH_P"CE<2?^$N6
M_P#RC^KORM_*M_P]E_X*Q?\ 1DT'_@M_^^E'_#V7_@K%_P!&30?^"W_[Z5_5
M3]GM_P#GA#_WZ3_XFC[/;_\ /"'_ +])_P#$T?ZPY1_T2>4]/^7V+\K_ /+W
MU^_[C_4?BC_HY7$G_A+EO_RC^KORM_*M_P /9?\ @K%_T9-!_P""W_[Z4?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'?&A_E!4P_X.*?\ @DB1_P E\\;^^/@YXSQ^L%1_9>967^P8S=_\PU;KR_W
M_P!8<A_Z'.6?^%V&\O\ IYYH_;U>@^@_E4R=#]?Z"OQ"'_!Q5_P20P,_'SQO
MD#_HCGC/\/\ E@:D7_@XL_X)( $'X^>-AW_Y([XU_P#D?Z4O[+S+_H7XU_\
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M..%_^6G[G1]_P_K4E?A@O_!QQ_P297/_ !?7Q:<_]4H\=C_W$FI!_P '&_\
MP2:(R/CIXL_\-1X[_P#E/6:R'.DU_P )68;K_F$K_P#R /BWA=_\U%DVR_YF
M.%Z)+_G[_5O0_<NID^Z/Q_F:_"__ (B-O^"3?_1=/%G_ (:GQW_\IZD7_@XX
M_P""3:@ _'3Q9^/PI\>#_P!PQH>0YVVVLIS'5MK_ &2OW_P#EQ?PKRI?ZQY*
MFK7OF6%[?]?3]SJ*_#0?\'&__!)QAD?'/Q81_P!DI\>?_*:E_P"(C7_@D[_T
M7/Q9_P"&I\>?_*:C^P,\_P"A1F/_ (25_+^YYCCQCPHDD^),DO\ ]C+"=_\
MK[YH_<].A^O]!3Z_#!?^#C;_ ()/ ?\ )<_%77O\*O'G]-&IX_X.-O\ @D^3
M@?'/Q3_X:KQY_P#*:C^P,\_Z%&8_^$=?_P"0)_UQX3Y[_P"LF26_[&6$[?\
M7W^ON/W,HK\-/^(C3_@E!_T7/Q3_ .&J\>?_ "GI1_P<9_\ !*$]/CEXI/\
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M+=XG_P##6>.__E13_P!6^(/^A+FG_A%B/+_IWY_U9B_UZX,_Z*G(/_#K@_\
MY;YK[S]P:*_#[_B(E_X)6_\ 1;_$X_[I9X[_ *:.:7_B(D_X)6GI\;_$Q_[I
M9X]_^4U'^K?$'_0ES3_PBQ'6UO\ EWY_U9A_KWP7_P!%5D'_ (=<'_\ +C]P
M**_$#_B(C_X)7?\ 1;_$_P#X:OQ[_P#*:E_XB(O^"5Q_YK?XF_\ #6>/!_/1
MZ/\ 5KB%_P#,DS3_ ,(<1Y?]._-"_P!>^"_^BKX?_P##K@O_ )=YK[S]OJ*_
M$'_B(B_X)7?]%O\ $W_AK?'G_P IZ/\ B(B_X)7?]%O\3?\ AK?'?_RGI_ZM
M<0_]"3-?_"'$?_*_/\^S#_7S@K_HJ^'_ /P[8+_Y<?M]17XA_P#$0_\ \$L/
M^BW>)O\ PUOCO_Y3T?\ $0__ ,$L/^BW>)O_  UOCO\ ^4]'^K7$/_0DS7_P
MAQ'_ ,K\_P ^S%_K[P3_ -%9P]_X=L%_\N\U]Y^WE%?B(/\ @X>_X)8'_FMW
MB;_PUOCO^FCFE_XB'?\ @EC_ -%N\3?^&L\>_P#RFH_U9XA_Z$F:_P#A#B>M
MO^G?G_5F'^OO!/\ T5G#W_AVP7_RX_;JBOQ&_P"(AS_@EC_T6_Q+_P"&N\=_
M_*>C_B(<_P""6/\ T6_Q+_X:[QW_ /*>C_5GB+_H1YK_ .$.)\O^G?F@_P!?
M>"?^BLX>_P##M@O_ )<?MS17XC?\1#G_  2Q_P"BW^)?_#7>._\ Y3T?\1#G
M_!+'_HMWB7_PUWCO_P"4]/\ U8XC?_,CS7_PAQ'_ ,K%_K_P1_T5O#W_ (=L
M%Y?]/O-'[<T5^)'_ !$,_P#!+/\ Z+=XE_\ #7>._P#Y3T?\1#/_  2S_P"B
MW>)?_#7>._\ Y3T?ZL<1_P#0CS7_ ,(<1_\ *P_U_P"!_P#HK>'?_#O@O_EW
M]?)G[;T5^)(_X.&/^"6A.!\;?$O_ (:[QW_\IZ7_ (B%_P#@EK_T6WQ+_P"&
MO\=?_*BC_5CB/_H1YM_X08G_ .5^?Y]F'^O_  /_ -%=P[_X=\#_ /+C]M:*
M_$K_ (B%O^"6IZ?&SQ*?^Z7^.O\ Y44X?\'"G_!+8_\ -;?$HQZ_"_QU_P#*
M>C_5?B/?^PLU_P#"#$__ "OS%_Q$#@?_ **[AS_P[X'R_P"GWFOO/VSHK\3?
M^(A/_@EM_P!%M\2?^&O\=?\ RGH_XB$_^"6W_1;?$G_AK_'7_P IZ/\ 5?B/
M_H19K_X0XG_Y7YH7_$0>!O\ HKN'/_#O@?\ Y=Y_GV9^V5%?B=_Q$)?\$M_^
MBV>)?_#7>.__ )3TO_$0C_P2X_Z+9XD_\-AXZ_\ E13_ -5^)'MD6;/_ +D,
M3_\ *P_XB#P+_P!%?PY_X>,#Y?\ 3[S1^V%%?B?_ ,1"/_!+C_HMGB3_ ,-A
MXZ_^5%+_ ,1!_P#P2Y_Z+7XE_P##7^.O_E/1_JMQ)_T(LV_\(,3_ /*P_P"(
MA<"_]%APY_X>,#UM_P!/_/\ JS/VOHK\4/\ B(/_ ."7/_1:_$O_ (:_QU_\
MIZ7_ (B#_P#@ET?^:U^)?Q^&'CD?STBC_5;B3_H0YM_X08G_ .5B_P"(A<"?
M]%APW_X>,#UM_P!/_/\ JS/VNHK\4?\ B(._X)=?]%K\2?\ AL/'/_RHH_XB
M#O\ @EU_T6OQ)_X;#QS_ /*BC_5;B7_H0YM_X08G_P"5A_Q$/@3_ *+#AO7_
M *G. \O^G_FC]KJ*_%/_ (B#/^"7A_YK7XD_\-CXX_\ E31_Q$&?\$O/^BU^
M)/\ PV/CC_Y4T?ZK<2_]"'-O_"#$_P#RL7_$0^ _^BQX:_\ #S@/_E_G^?9G
M[645^*?_ !$&?\$O./\ B]?B3D@?\DQ\<=SCMI'Y^G6OU!_9_P#VA_A#^U!\
M--#^+7P4\7V/C#P7K\3R6MY!NM[^T=)IH6MM7TJ?;?Z3>$PM(MK?PP3-"4F5
M#&ZL>3&9+F^74HUL?EF.P=&4U3C5Q.%K4:;FTY*"G4A&/,TFTKW:3:/2ROBO
MAG.\1+"9/G^3YIBH4G6EA\#F&%Q5:-*+C&51TZ-6<^2,IQ4I6LG))M7/:Z**
M*\P^@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S#_P#@Y1_Y2W?&
M;_LGOPF_]1JO]/"O\P__ (.4?^4MWQF_[)[\)O\ U&J^NX+_ .1K5_[ ZO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%O!E_P"$]<^+?Q3\61/<:;\.O"EU]DU4VSPP36#FY;3]1C:741-_HD*0EI<
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MC_REN^,W_9/?A-_ZC5?Z>%?YA_\ P<H_\I;OC-_V3WX3?^HU7UW!?_(UJ_\
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M^']:U,22IUZ#Z#^505.O0?0?RH.<6E7J/J/YTE*O4?4?SK>.R]%^1G4Z?/\
M0GHHHIF98IR?>'X_R--IR?>'X_R-..Z]5^9SDU%%%;DS^%_+\T%3KT'T'\J@
MJ=>@^@_E08CT^\/Q_D:FJ%/O#\?Y&IJUAL_7]$93W7I^K)(^_P"']:DJ./O^
M']:DJR IZ=3]/ZBF4].I^G]10<Y+4J=#]?Z"HJE3H?K_ $%=!,_A?R_-#Z**
M*#$*E3H?K_05%4J=#]?Z"@!]%%%5#XE\_P F<XY/O#\?Y&IJA3[P_'^1J:K?
MQQ]/\P"I(^_X?UJ.I(^_X?UJGM\X_FB9_"_E^:)****9B%*O4?4?SI*5>H^H
M_G3CNO5?F!/11153W7I^K,I[KT_5A4D??\/ZU'4D??\ #^M:D$E%%% %BBBB
M@QA\2^?Y,<GWA^/\C4U0I]X?C_(U-52^S_A7ZA/XG\OR04444U\$O7_(D***
M*J&S]?T1E/=>GZLL44459 Y/O#\?Y&IJA3[P_'^1J:@B>R]?T85)'W_#^M1U
M)'W_  _K36TO3]49$E%%%5#=^GZH HHHK4YQR?>'X_R-35"GWA^/\C4U !7Z
M0_\ !-__ (*/?%?_ ()]_%:#7M N+GQ'\*/$5S;6OQ%^'-U<O_9^I:>9'7^T
MM++I<?V7JNGO.U^)K"&.:_:!+2Y=H7('YO4]" &)P  ,YZ8YKDQV!PF982M@
ML=0AB,-B(.%6E-733V::LXSB[2A.+4H22E%II,]'*<YS+A_,<+F^48NK@LPP
M-6-7#XBE*THR3M*,EK&I2J1;A5I34J=2$I0G&46T?ZM/[.?[1OPG_:H^%?AS
MXP?!SQ+:^(_"?B*TBF"K+ NJZ+>/&LDNC^(-/BFFETG5[8,K36-T4F6-XY=N
MR12?=*_C$_X-Q_@Y^V%:^//$/Q2\/ZY>>#OV7+R,V?B71_$5I<76E^.=666V
MG/\ PB^ESSVZ6.I&!86'BRV@N8C;PR6)=BVT?V=U_)O%>2X;(,ZQ.787&T\;
M1IM2BXN]6ASW?U?$-)0]O35E+D;333DH2;@O]*_#?BO'\9\)Y=GF9956RK%U
MXNG4C./+0QCII1>.P2E)U5A,0[N"JI.,E.$9581C5F4445\X?>!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXFT+P;I4>D:9-<MJ^B2/<O:PDQB5Y9))#L"(&<A45< >H_\ !PC<PZ?_ ,%
MOV1M1O7^RV%EXV^&%[=7<RLD$-K::YHTUU.9"NQEMX4>24*24526 '-?O5^T
MW_P2.^%'[3W[7?PA_:_\2_%'X@>&_%?P@\4^&?%>F>$]$M=$E\.ZQ>>%[JRN
M;.#4I;N%KY(9FLD24P.'"NY4YQCT_P#X*#?\$S?@5_P42\+^&M'^*-UK/A7Q
M)X.N+N?PQX[\+16C>(-(%^D$=W'"+T&VE66.!4!F1VC#$Q[3BNNGF-"-7+YS
MG4G[+#5*->5I.493?Q7EK/SL]MK['-/ U94\7"*A'VE>G5I)-).,$KK16C=I
MVT_S/R'_ .#E3XP_"[7?V7O@IX7T7QUX>U?Q#X@\=P>)M&TK3+Z*^N;W0;K2
MV2WU,?9C(L-O,ZE8_.*.Q#?(,<_)?_!3/(_X-^OV&<':?^%E?#CGZS?$$?KT
MK]$='_X-JOV1K'X<>)_!>L?%+XM^*?$^MP00Z1\2M>N+&]\2^$C!=P7/F:):
MS22Z6I=(7MBDEOL$4\A SC'VA^T-_P $D_A3^T1^Q#\(?V'==^*'C_P[X+^#
MVNZ!KVC>--&M=$D\4:G=: ^M/!'J$%W VG+'.=;G\TPQAAY4>W&6R4\7@Z$<
M%2IUJDXX?&.M.<J3C>#B_>C%7>C?+RN[=KV2"IAL56>*J2IPA*MAU3A%5%*T
MHRB[.5DM5%N]K:I>9\7^'_ /@;1O^"#^K6.D^$M!TZSO_A?KFN7MO:V,<:76
MLQPZA/'JDYY=[R.95DCE+?(VXH%WON\ _P"#><D?\$TOV@I!RYL/BJQ)^;++
MH.JD'!R.I.1C![YK]VX/V'_ \/[&\_[&?_"6^)7\'3>#[_PA_P ):T-A_P )
M&D%_!<0/?K"$^P&ZB-PTB*8S&64!AC->=_L _P#!-KX;?L!?!#Q-\"O"?CSQ
MA\3/#7BJXUF75+[QK;Z5;7SP:Y%)!>V832(H8?):&62,$C?M8Y.>:YY8RD\-
MBZ?-)SJXV%>":EK33NW=Z)^3:9O'#U%7P\^6/+3PWLI--:2]S2V[6C=UI\V?
M@'_P:Z^(=$T+1OVAWUG6=+TF&*6ZGE.HWMK9L$_MZTPZK<21RN"1@",-N8JH
M!9E!XK]O_P#Y6!/V-#V/QM^&S YX*M<6;*0>F"I!!'!!SWK])A_P;??LLV'Q
MOM?B]X8^,'Q@\(Z+:>)AXCC^%N@S:;:>#W"SBX33)I8V349K)9@' EE=B0,Y
MKZ^^-/\ P2,^$WQJ_;7^#W[;6K_%'X@:+XP^#GB#PQXATCP5IEKHDGA?5KGP
MM':Q64.I3W,+:DL4L=HBS&&4/\S$'.#77+&X-8VMBXU9M5\-5@XNE)<DW"$8
MPOKS7:=Y)**.:.$Q/U6EAY4XIT:].2DJB:G",^:4K:6MT3U?D?@3_P %Q]-T
M_6?^"KO['^C:M9V^HZ3J_P 1_A'IFJZ;=H);34=.O=5\/V]Y8W41P)+:Z@=X
MIHR0'1BI/-?97_!S+X/\*:!^S/\ LU6^B^'='TJ'0OB'K&F:+%I]A!9II6GV
M^D:.D-E9) B)!;1H2J1*-J@G: 2<_I9^UW_P2-^%'[7W[3WPB_:A\6?%'X@>
M%/$OPA\2>%_$NF^&O#MKHDVA:S=>%;NPN[*#4I+^![Q(9GL(UF-NZN%=RN"!
M7KW_  41_P""=WP__P""BWP\\&_#SX@>/?&'P_L_!?B&[\16&I^#8-+N+ZXN
M;R"TMY()UU6*6$0A+1"I10V7;/:L:>.H1GE3<Y*.%C-5[1E[KDK*UOBTZK9.
MQK/"57',$HQ;Q$XRI/F5W%<K:;^SJGHWJ]3^8[_@J1I>A:I_P3X_X);66B7<
MMQ\7Y="\)Q^'O#<DRII]YHB1:K+:W,PEV1B:35%>!GDN$'E@ @ 9KI/'G[-_
M_!7O_@HIK7[/7PV_:4^!?PO^!_PQ^%ESX<?3/'^C:OX>$DN@11V4B7]Y#:>*
M]3O'N#9QPN(K6SC&_>WD&>20MG_\%Y-#\#?!Z/\ 8:_8?DAU,:!X!\#Z/=?\
M+UU<?9]6@\/VFL:MHKZ=<36ICTV&Z5]^I>6D090?]9M/'P5^V-^SM^Q;^RG\
M)_"?Q6_9#_X*+_$'XW?&&\OM(CE\&P^,[35QH=I<6\<U[>3VVG7'F6S6EU^Z
MCM9T?RUC(?>I5F]3#^]0PK@U&I4J8F6'J5,-4K<JJ5&E)2A.$*2<?^?D96^6
MO!6O&K64DW"$,.JL8UH4N9PA!N+C*$G4::^PUZZH_H#_ .#B?09/"'_!,[PG
MX0:[6_'AEO GAY[Y8P%O'T6#1],^U*Q7<JW1M/-5=P^^!C->J_LV^(YKK_@B
M;IVA>$==MY?&@^"<,-GI>CZA9-KJ@V&GR72+:P2O=+_H<5T92T0;RE=21TKV
M;X _ FX_X*2?\$OOAK\/OVR]/OGU?Q1I%C*=4$"Q:S!#HCPGPOK\0D6))+F2
MV2&ZS*K1RG;N#"JO["'_  1)^"?["7Q3UGXI>&/B_P#%3XFW>JZ//HD/A[QW
M)IS>']-LKJ&YMKI+6QL=L!\^UNI;=@\) 0@KA@"/)]M1IX1X6K-JOA<7.M%1
MASPK.\5R\Z:4$VGJT[=%J>@J56>(5>$/W5?#QIN\U&5--)WY;-NRM9+KJ[6U
M_,C_ (->]?\ @QI7PV_:"T[6[WPSI_QK?XI:K<V+ZK)!:^(&\ _8[5'2TN+H
MQG[$-66X:>%7#ESOV; Y'RU\1'\"^+/^#A;PG/\ L\Q:;J.E6OQ$^'MYXJF\
M$PJFEAK./21XENI3;*(&ACO1<M?21_N))2S)\A%?K9\?O^#<7]DCXP>/=:\<
M>!?B+\4OV?DUS4)-1NO#OPMN+6VTI)9R'GBB>]G>[\F64O)L>5MI<C)QFOL[
M]@K_ ())?LT_L":M>^,? ;:YXZ^)M[IUQI$OQ)\9F*3Q(NEWFW[;9J;:0V^V
MZ\N,2R%/-VH5#!7<':>-P<:F)Q=.K6J5<30=/ZO*FXQIRDHI\U1R:E&/*[6U
M5W:]S*.$Q+IX?#RITXPH58S=:,TW-1;>D+)J3O9MOMVU_GI^!_A3POXV_P"#
MDC5M$\6Z!I7B;15C^,&L1Z9K%K'>V U/1]%U6_TC4/L\H,;7.G7D45U:LZLJ
M2HI*L,BM'_@OAH^DV?\ P4H_9?O+/3;.TN[OP]X(CN[FVA6&6Y2/Q1>B-93&
M%#!%157C.% SQ7[U?#K_ ()(?"GX<?M_W/\ P4#T[XH_$#4/'=Q8>*K$> [V
MUT1?",:^+--NM-O95N(H!JADACNFDAS*09%7?D9R[]MS_@DI\+/VW_CO\-?C
MUXQ^*?Q \$Z_\-+72;33]'\+6NB3Z7J<6D:C/J,/VY]2@DN$,LD[))Y)7" ;
M>>:(9AAXXO#U7.?LZ>!5"3Y9Z5+-./+U6UVE9Z=AO"5OJ]6GRQYYXM58KFCK
M!<FK;LD]):>?F?JIH_\ R"=+_P"P=9?^DT5?RF_MH_L'3_$;]M/Q]^U7_P $
M\?VH/ VA_M(^#!IMQ\0_A/>ZA<:;K=E<6=E$8AHTUV+&QCM[N&U:>_C>XE:2
M1UV%2"#_ %>6MNMK:VUJK%EMH(;=6;&YEAC6-6;'&Y@H)QQDG%?AA^V3_P $
M$_V<?VN_B_K_ ,:(_BE\5O@IXI\4K9GQ GPTO+:WM=3GL[9+9;B<7<NX.X5G
M9%P@9V 7;@5Y^7UX4*LY3K2HJ5-PO[)5H23E&\*E.Z<HM7V:::3N=>+HRJTH
M1C351QDI6]HZ<HM+24)V:33WNFFNA\[_ /!%S_@H9XA_:"^.WQU^#WQQ^$O@
M/0/VA] EBT7Q;\5/ FC?9;[QLWABXU.-K/Q?J37=RVH3Z>R7#VL\6V$S32E"
MZRAE_>O]IG_D@'Q<_P"Q(UG_ -$5\I_L#_\ !,+]GO\ X)]Z9KA^&*ZKXG\:
M>)X;6V\2?$+Q2(6\1ZQ!9M(\"7)MV-NK!Y9&>2-5DD+MYC-GC[\\7^%]+\;>
M%]?\):U&9=*\1:5>Z3?(/O>1>0M$SKR/GC+"1,G&Y!GC-3BZN'GB_:8>,HTD
MZ>]U=Q2YG&+;<8Z>[&^B7397AZ=6.'4*S3J-3N[I_$W;F:2YFKZRMKOJS^-O
M_@V1O+*S^+O[1[WM]8V:_:/$!'VR]M;5G UF')B2>6-Y=H!9O*5]B*[MA$8C
MTO\ X.-?VN?A7\7O"?@+]D/X1Z_8?$+XCZSXIB;6;3PX[7YT+5+6]METK3+A
MXXRLL^I2O(L9MGEA7;\\B]_<[C_@UO\ V=VU#4K_ $_]J[]HS1#J.H7U^T.C
M?\(YIJ1&^NYKMH%>R2"22*-IC&GFLQ**N[FON']D/_@A7^Q[^RCXTTGXC2CQ
M%\9O'6@2+<Z'XD^)+17-YIM]&Z217T:6DRQ37$4D:21F=9%#J"P9=RGU*N+R
M_P"N?7U6JU9PC%TZ"I2@N>,%&+E4D[-)W;22VW>S\^GAL8L,L(Z<(0D[3JNI
M&3Y;JZ4(K?3>_P!Q^,W_  5]^&NL_"'_ ()7?\$\O 7B,-'X@TIH)=8MFC:-
MK&_N_#/AJXN-/=6);S;-I1!,<*/-1PH*@,?LC]HC]EGX _M>?\$V/V$/A9\2
M?CAX7^!WQ;_X0KPOJ7P;UCQ2UXFFZYK0T^[C@TK46M()"UB"DT\:>9"1,I);
MH#^M/_!1'_@G3\/O^"B_@+P1X"^('C[QA\/[/P-XAO/$-AJ'@ZWTNXO+J>]A
MLH9;>Y758I8A $LDP8U#?.V>@QY]^T1_P27^ O[2?[,WP=_9N\:^(O%EE!\$
M-+T_2O!7Q%TEK:W\7VT>GVL]JDKA&BLED=9W<A4(5R2F QK"&.I.GA.:K4I5
M88JO6J2IT^;V:J<SBTI>[->]:4=[7ZV-982HJE=J$*E.="E2@IRMS."BFG9W
MB[*Z>U^^Q_/EX1_:N_:P_P""?W[37[-/[+7[<?ACX8?M&_#\>)-'N?A?XJGM
MX?$GB;PJEKJ*VVG>*/!FH1ZC-#I=QIYE$MJ+F%IUD=6$+ $5\H?\%%M"^*_Q
M&_X+*:KI:_%L_L\^+O%^C?#J[\!?$OQ=)=BS\-V6J:/!+X:@6;38Y3$]Q;36
MJ*(%"0&/$PC  ']"W[+7_!O9^RQ^SC\4="^*OB'XC?$_X\:WX5U6UUKPO:_%
M">SNK70M2LI!+:7%H]I)YQ$,@W"*1C"Q/S(<#'U]^WG_ ,$I/V:OV^SI>L_$
M*WU/P;\0-&M38Z=\1?""0Q^(X+,11006X^T/]F9;6*)4MR8\QK@+C:*Z(YA@
MJ6)A.-VI4*E*M6C1Y8\\Y1DIQP\G))6C::7Q.SMHT\G@L3.C*,K)QK0J4Z4J
MG-)0C&SBZT4G_@;^%76ES^<;]IO_ ()/_M3:K=?#?QO^VK_P5M^"'C#2="\5
M^%_^$1O?'[^,]:N5N#K&GI:6>AQV%JTRRWS-%9VTVQ[<23(7E";B/3?^"F'[
M4?[1S?MQ?L__ +$GP%\2Z+\*?B-I>@Z+\/K#X^R":Q\4QZGNEFCO+?6VDQ!X
M;:%A.(98A(+AMY?/!_07X%_\&X7[*/PF\:Z%XO\ &GQ6^,7QSA\/ZG::O9>'
M?B+J43Z1]NT^XCN["5DL+F-P;6ZAAGC X+Q*&!&17U1^W_\ \$;?V=?V_O%V
MB_$3Q5XD\7_"WXB:1IL6D/XT\ "R76+_ $^!V:*&=[[='&Z91?/@5)B(U^?)
M;*^OX7V]%5:OMZ=.G649+"PI4J4Y\O(U1C9S2L^=2NGIRK5A]4Q"IU'3I^RG
M.=)RB\1.I.I"FVVG4EI![<K6JU\C^1G]N[X._M+?L^_ME?LO:3^TO^V1I7[7
M?Q0EU[2M6AUG2KW4;N]^&D<6JV<D6BZE/?QQXGU,2QWEN+<$".(F1$.W=^[_
M /P4;_89\'_M?_%?X+^+_@I^TAX.^&/[;_@CX=?#+Q#_ ,(=XGO+JUN-5M;?
M0--OM OK>?RH;5+HK \L)EO2%<"1P,[1WND_\&T_[+NCW'@#5;?XW_&>?Q)X
M'UZQUV?Q+J!T;4=4\3/871N(K35I+X7 C@9=L!-KL81J,<U]:_MQ?\$7?@#^
MV_JOA;Q3XA\?_$3X8>.O#/AC0/"7_":> +BWM]9U32O#FGP:9IR7GGR+"K);
M0[3Y2#[[8[&G4S##RGA'#$2@Z-.M"=2.&C&#<Y1<5*@O==*233C%\R=GH[L4
M,'64<1S48R56=.4:<J\G)<J=W[9MRYUI:3TZ+1(_+C]@/]O[X[7_ .W5<_L;
M?MD?#/X>^+/CS'IWC/POX/\ CKHFFQ7GCV#4-!\-:S.PU+Q%'>75M)I-S#;2
M0V:01K(D]P[A\%0/QF_9(^#/[2OQJ_;Y^-_A+X3?M;:?^Q_\>H[[6[J;Q1XH
MNM6M=6\2L-41$\.VMQ8PR,;R:(I=QI*1OCAV1+)*R1M_7K^P5_P1J_9L_8.\
M7WOQ&\/:UXK^+'Q(FMOLNF^.?B(;>;7-%1Q(D[6,MG($:6XAED@DDG60F.1Q
M]XAEX/\ ;0_X(4_LJ?MA?$K4_BVGB#QI\$O'OB%GN?%&O?#%[:VNO$&IN0#J
M=VUW)^XN?*6.(K:^5$50-L#$FE#,,%3K5XTTZ=.M0ITW5]CS056#;DUAYN25
M.5[<G1JZWN.6#Q,Z5)S]^=.K.7L_:N,W3DHI)UHV]]--\W9]7=/\F_A?_P $
MP?C#\,?V^_@C\4OVHO\ @I3\%?BM\8O^$HT?7H/#ES'XPOOB'XRM-(U&S$EA
M#=_9/L=N\BK%;(E^( ?,1L%#N/\ 8Q7XL?L4?\$.?V8OV-?B!I_Q2C\5^/\
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M_D:FJ%/O#\?Y&IJ")[+U_1A4D??\/ZU'4D??\/ZTUM+T_5&1)11150W?I^J
M****U.<<GWA^/\C4U0I]X?C_ "-3$XY-  3@$GH.37[@_P#!(_\ X)(>,OVW
MO&%G\4/B?9:EX6_9P\+ZDC7^H/&]K?>/=0LY [Z%H32QR 102BW?4IKFW^SS
M6,[QP2ESFC_@D?\ \$C_ !A^V_XOT[XI_%"QU'PS^S=X:U&*>[OYK=X;CXA7
MEI*7.AZ&98S#=:89[=['7;A)8IK:*9?(8NPK^_#P%X"\'_##PAH'@+P%H-AX
M9\)>&-,M-(T/1=-A$5K96%E"D%O$O5Y&6*-5::5GED(W2.S<U^4<?<>QRF-7
M)\GJQEF<TX8G$P:E' 1:UA!IM/%-=-516K]^RC_2?@QX+U.)*F'XHXIP\Z>0
M4YQJY?E]6+A/.9PDG&K5B[2CEL6M=GBY+E@_8J;F> ? 7@_X7^#_  _X!\ ^
M']-\+>$/"VG0:5H6@Z1;I:Z?IUC;C"0P0H JC)9F/)9F))YKKZ**_GB<Y5)2
MG.4ISG)RG.3<I2E)WE*4G=MMMMMN[>K/[BITZ=&G"E2A"E2I0C3ITZ<5"G3I
MP2C"$(12C&$8I1C&*2BDDDD@HHHJ2PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *))X6_K9_RK[)<84D_]RJWM_P _*?=>?J?E_P#Q"C$_]#7#_P#@NK_\K/\
M);%]9'I=VW_?^+_XJI$OK(9S=VW;_EO%_P#%5_K3+^PS^Q 3S^QU^S3TS_R2
M3PM_+[)BI1^PS^Q .G['/[-/_AI/"_\ 2TH7&=!12^I5MU_R\AT:;^Z_]=)?
MA/B6K?VMAU?_ *=5?+^YZ_TM?\E?[?8_\_EM_P!_X_\ XJK'V^Q_Y_+;_O\
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M!G[$?_1H_P"SE_X9[P-_\I:/^(DX3_H68C_P=2_^1)7@-F#U6>X.S_Z<5_\
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M*/\ HTW]G?\ \-!X%_\ E)6G_$5,'_T*<3_X/I>7]WU_ E_1VS)JW^L6!_\
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MY2_VZS_Y^K?_ +_1_P#Q5'VZS_Y^K?\ [_1__%5_JT?\,+_L7_\ 1J?[/?\
MX:/P-_\ *2C_ (87_8O_ .C4_P!GO_PT?@;_ .4E/_B+>!_Z$^+_ /"FC_\
M($+Z,V:IW7$^7_/!XG_,_P IE;ZRW#_2[?\ [_1^G^]4OV^Q_P"?RV_[_P ?
M_P 57^K#_P ,+_L7_P#1J?[/?_AH_ W_ ,I*/^&%_P!B_P#Z-3_9[_\ #1^!
MO_E)5/Q<P#M?)\9HDO\ >*/_ ,B)_1FS9N_^LV7:_P#4)B?+S9_E/?;[(]+N
MV/\ VVC_ /BJ7[;9_P#/U;\?]-H__BJ_U8/^&%_V,/\ HU/]GO\ \-'X&_\
ME)2_\,,_L8_]&J?L^?\ AH_ _P#\I*/^(N8"S7]CXS5W_P!XH^7]WR%_Q+-F
MW_13Y=_X28E]O->?X=]/\I[[=9_\_5O_ -_H_P#XJE^V6?\ S]6W_?\ B_\
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MZ*G+?_"/%>7GZ_AYG^5I]LM/^?F#GG_6H?\ V:C[9:?\_,'_ ']3_&O]4O\
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MIF.#HTJ^)P<97KT:-;^%4G&VD9Z6U>Z;2NK^B4445RGH!1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^;[[_D):E_U_
M7/\ Z.>OI"OF^^_Y"6I?]?US_P"CGKJPN\_^W/\ THYZ_P!C_M[_ -M&)T/U
M_H*L)T/U_H*KIT/U_H*L)T/U_H*[/M_]N_J<Y,G4_3^HJ6HDZGZ?U%2UET7J
M_P H@3KT'T'\JF3H?K_05"O0?0?RJ9.A^O\ 04AK:7I^J)DZGZ?U%3I]X?C_
M "-0)U/T_J*G3[P_'^1H&OL_XG_[:6$^\/Q_D:FJ%/O#\?Y&IJG[?_;OZERV
MEZK\HEBI4Z'Z_P!!452IT/U_H*Q+)4^\/Q_D:FJ%/O#\?Y&IJ )(^_X?UJ2H
MX^_X?UJ2@"=>@^@_E2TB]!]!_*EH F3[H_'^9IU-3[H_'^9IU $R?='X_P S
M3J:GW1^/\S3J )(^_P"']:DJ./O^']:DK".Z]5^8WO\ */Y(*F3[H_'^9J&I
MD^Z/Q_F:);OU?YER^"/R_)CJ***14/A7S_-DJ=#]?Z"GTQ.A^O\ 04^@G_EY
M_7\H4444&@5.O0?0?RJ"IUZ#Z#^5!$MX>OZH6BBB@L**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /YHO^#H-G_P"&-O@E"'<17/[1>A07$08B.>)_"WB+,<R?=DCR VQP5W*#
MC(%?GS_P1L^*.O?L,_MBZ?\  #Q?)-IGP7_:;\.V&L> K^\NC;VFJ^*XK33+
M&T73[:3$1"WUW=6\H@)!;).'X7]!?^#H/_DSOX&?]G(:!_ZB_B*O#/VP?V9]
M2\;_ /!+3]DS]J[X9VGV7XS_ ++>GV'BW2M5M;9Y;AO#-KJ=_K.KL_D*)=\$
MMA;LLID "LHQD9/ZSDM7#RX1RS+,798;.<=F6 <WHJ.(FU4PE>__ $[Q%.FF
M];1DW9V/YIXLPV,I^)?$'$.6\[Q_"F49%G4:,-\7@*2C1S3!^?ML%6K2C&WO
M5*<8W5SF/^"A449_X+P_ 60QH9%T+P!MD**74'2[$':Q&X9&0<'D<5_2?^U'
M^VE^SI^QQX7@\5_'GQ_8^%K.[=EL]-M_+U+Q!>!%+-+:Z'!,M_-#@$"58MC,
M&522K;?Y#_$_[0VB_M5?\%0_V*?C%I,CR-K?@7X6Z-X@::=)YW\4:1H6C6WB
M*24K@IYFH/*P20>8O(<LP+'A/^"JVK_'3XX_\%?;+P#X$\,Z!\1_&_A]X_#?
MPO\ AOX\33SX'U5=*EU&5!J5EKUU9Z1(L]J)B\T]Q%'<NBHKF0C=5?AZ.9U>
M',!CZKPM++^':M;&/GA3DOJ]90E3]I43A37-?GJRC)4XIR:9&$XYGD&%XXSG
M)<-',<1GG'6'PN5_NZM>F_K^$A5A6="BXU<1)0_AX>G*$JM22CS1U/Z>OV<_
M^"TO_!/[]J+QU9?#GX8_%;4(?%&I3K:Z?;>,O#EWX/M;VY=MB6]M>:O-%#+,
M[?<1220">@S7MW[6'_!1O]E[]BWQK\*/ /QV\2>(](\0_&G[8? D>@^%=1\1
MV=ZEA>65A<27U[89AT^,7-_;*C3$B1'+J=JG'\CO[0/_  3]_P""NOQQUKP3
MXIU3]B3]FWX$ZEX#O-.DT?6?@A+\*OA*IN;:?S$O-3N;;Q.PO;LHT@:3>LC*
M#M4E<'ZD_P"#@:UU'3/C5_P2\L->=%UBP\&W=IK#-<13J-2M+WP=#J+&Y1VB
MF4722DW".T<@_>!RK GSUPKD%;-LJPV%Q_M\/C:.8O$X?#9AA<96PU3!X5UZ
M4GB*-)0Y*KLN65&+]V:4GNO<EXC<9X3AKB/'YADOU3&93BLDCE^.QV39AEF%
MQ]#,\?2PN(A]1Q.)E4]KAH\_O4\5*+]I3DXJUG_3S^TK^VK\!OV3?@I:?M ?
M&36]:TOX<7T.CW%K>Z-X?OM<U.6/7%MFT\KI5I_I.76[A,@_Y9[CN^Z:\X\6
M_P#!2K]E7P3^S#X3_:]U_P 3^)(/@IXT%I_86KP>$]3N-9E-XD4D(N-!C_TV
MV8),C2"09C&XMC::_)__ (+P7-FO_!+'X?0M=V:SW&A_#LVMNUU +BY1;#P^
MS/;0F3S+A$7YG>)755Y8@<U\+?M+''_!O]\ 2.")+8Y]QHMK@_H*X<LX9R_&
M8'*L15GB54QO$%3+*W+4A&*PT*<I)TTZ4G&K=?&W*+U]WJO9XAX^SK*\VXCP
M6&IX"5'*>":/$&&=6A4G-X^I6I0<:KCB(*6'49O]TE"=TG[2V_[\^'/^"QW[
M!WB[XR_"SX#>&OB;JFM_$3XQ:OINA>"[#3O#5[=V$NJ:LY2RM=5U*&1X-)DD
M8?,+K:5[C/%>A?M8?\%0?V-?V+M4CT'XY?$W^SO$!"&XT#PUILOBC6M/$JJ\
M7]I:=ITIN;'S4821^?&A=,L.!7P9_P $2OV&/V9M/_8J_9G_ &BK_P"&'AKQ
M%\8_%]I%\3O^$ZUW3+*_U[0?$5AJ>LZ)9MH&H20?:=-AA@M!,(XI2#.V_/&#
M^-/_  2Q^&'P_P#VS?\ @I[^T7XH_:DT[3_B=K6@^+?B+!I>A^,A;ZAIVJPZ
M)K5_::6MWI.IB;^T(]/MK>&.*/:RB,;<!,XN&0\/U,5G4HRS/ZCP[1FL;%SH
M?6<9BOK%6C'ZLU3<*-&/LY*7M%.3=I72;MA4XRXVHY=PG2JT^'UG/'.+I2RJ
M:IXSZAE>7O!X;%3>-BZJJXK%26(@X1I2A!>]%W<5?^E?]E__ (*^_L*?M=^+
MH? _PA^*5U_PDMUYHLM/\9:'<^#FOY(D9VAL6U>6,7,S!<)%'EG8J%&6&??/
MVL/VY_V;/V*_#UGXC^/OCI/#<.H9-CI6G6CZSX@NXAN'VBWT6UD%[+;ED=!,
MB%#(C(#D$5_)W_P7"^ 'P:_9B_:__9B\6_L\^']'^%_B+Q'XQ\*+J^A^!(K/
M0[*P%OJFFM#-:Z1I:0_8O[3,CI<!8U2Z0^4BE,+7/?M:S?\ #5G_  6/_9D^
M&O[0^H31^!-3BT?PYJ]KJB26>GVVF6\>IWT;BUO=L<7VN\5(9)6 5_-()RS$
M]5'A'*,6\OS'#UL=2RG$Y;CLPKX>JZ4\=#ZARJ=*E4A!0G[1R?+/V>G+HI<R
MMYN+\3>)\KAG>1XW"Y/B.)<!GV3Y+@L;06(I9156<N3I8C$4:E5UJ?L(Q7/#
MVRYG-MN"@^;N?^"X/_!0G]EG]NK]F#P#J/[/'CJX\13>'OB#I2ZKI.LZ5-X?
MUNWB9+R7SQI5[(;QK= P$DPC$:,R MEN/Z9?V/OB/X(^$W[!GP@\>?$/Q'I?
MA3PIH7P[T2XU'6-7NX+*TB']FV_EPK+<21(]S<,/*MH%;S)Y2L: L17\Y?\
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MMX[BPU.Y\:2>)!?VU_<P*CWANH(KC+OYT:9KZE^,'[.G[0GP)_X(:^)/AO\
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M-1U/2];FGLAJUC/%+#?6:LS":WD4"9#Y9(5B:_1G_@M=\4OV9?V8[/\ 9W^
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M /CM')'_ )^0Z=)>7]WS?W,.:7\DOOCY>?G^'K;LZ*XS^Q_%7_0P6W_@&_\
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M[82?_%"GRQO;G7K:7^7]?DT_AT>]^G]WS_X;YHZI/O#_ #V-38/I7*KINNY
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MW,.:7\DOOCY>?G^'K;LZ*XS^Q_%7_0P6W_@&_P#\=H_L?Q5_T,%M_P" ;_\
MQVCDC_S\ATZ2\O[OF_N8<TOY)??'R\_/\/6W9T5QG]C^*O\ H8+;_P  W_\
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M[X^7GY_AZV[.BN,_L?Q5_P!#!;?^ ;__ !VC^Q_%7_0P6W_@&_\ \=HY(_\
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M]\9? 5Y?-X>\6>(8-0_LN[TS5X[6VU'3]7?1[:XU&:-+6"1;01IA7F97;RP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?-]]_R$M2_Z_KG_ -'/7TA7S???\A+4O^OZY_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[_\ 1Z7_ (.0_P#@DM@#_A;WQ3SP/^2+^*_\_P JG7_@Y"_X)+ <_%[XI_\
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M,/\ P?2\N^'?;^M;Y_\ $:.*NF%R;_PEQ#[?]1?E^+/](5?^#E#_ ().C/\
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M<9\_^9CU_ _T-?\ B(J_X)>?]%2\?_\ AI_&'_R)1_Q$5?\ !+S_ **EX_\
M_#3^,/\ Y$K_ #RJ*<?"KAIJ_MLUW_Z"L/Y?]0?J9R^D?QY%V^I\.O2_^XXQ
M=O\ J8^3^_R/]#;_ (B*?^"7O_14?B!_X:;QC_\ (E'_ !$4_P#!+W_HJ/Q
M_P##3>,?_D2O\]&BJ_XA1PUUKYM_X58=?^ZC%_Q,CQ[_ - ?#O\ X08SR_ZF
M/]7]#_0N_P"(BC_@E[_T5'X@?^&F\8__ ")3O^(B?_@E[_T5+Q]_X:?QC_\
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M_#WXI>,]8@U7XF1K?Z7\0!%;V]H\.J6^I7T%E-):VJ10P?;;&W2=42-0&\P
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ME'_E+=\9O^R>_";_ -1JO]/"O\P__@Y1_P"4MWQF_P"R>_";_P!1JOKN"_\
MD:U?^P.K_P"G*)^<>*/_ "3=/_L8X?\ ],XD_!^ID^Z/Q_F:AJ9/NC\?YFOU
M6&[]/U1_-PZI(^_X?UJ.I(^_X?UJH_ O5?\ I1,_A?R_-$E6*KU8JS$****<
M=UZK\S&?Q/Y?DB5.A^O]!3Z8G0_7^@I]:KXI?]N_D26*<GWA^/\ (TVG)]X?
MC_(U1SDU%%%5]C_M[]")[+U_1BKU'U'\ZGJ!>H^H_G4]:QV7HOR,B5.A^O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_C:WN)(=6@M=0N+C2(-.DOHY6N+F\L'M7E&HF?S&=PRA3DGYM^"O_!</XG?
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MYI(8=(L+^37++6+737L[B-PB7/V5)%+ %\"OJ#_@EA^U!^U5^R1_P49\5?\
M!/;]HSXC^*OBCX<GEDTPWWC'4+[7?$,&O7AMSX6U6WU+5;F\O+:PO+.Y-U<6
M,;!&695:3<BM7Y^?\$A_^"A7Q#_8!\.?&+Q8O[/_ (M^-'P;U[Q1JUOK%]X&
MB@?7]%\9>;YL4<ID6>5M.2RB226..V.YFXD!/'W3_P $NOA/\?OV[O\ @IWX
MK_X*&_$GP-KW@GX>J%U%+K6;";3KF?4M'CL[?PMI$=M=)#, EE:+;SL(?*!B
M8J0H53KBH27]H>WIT(X/V+=%I4E+ZPU%QMR^_P [UNG9+1I:-&&&DI?4W2G5
MEB?:+VMW-Q]E:SWM'DLK*W]Z^J1\F^._A_\ '_XE_P#!<?QQX _9E\7V_@/X
MOZW-X\L[#QC<!"F@^&DLM13QAJ$2R3VVZY@T5IYK9(YUF:2,"'Y\5Z1X^N_V
MVO\ @D3_ ,% ?@[X.U_]JKQU^T7H7CZ+1M6U1?%NKZS-HFH6NOZA<Z7/I46@
M:MJM_!8M9NLDRW2#Y@JH@! ->^_LR:%XB7_@Y'U/5[CP[K\&EG0_C/*^JS:)
MJL6DC[5X8U?R0-4DM%L"TK$+&HN,NQ 4$D S?\%\-#UZ]_X**_LLW]AX?U_4
MK%-$\&1R7FF:'JNI6D4B>)[YW6:YL;2>&$HI#-YKIM4@G (IQJ<^(P^%G&G*
MC/+8RFI0BY2=G;WVN9*.KBDTD^9Z]*5/EH5JT95(U(XWEBU*223<')\JT;=[
M-M/1)='?TK_@N=\;_C-X%_X*%_L Z!X ^+'Q'\">&_$_P\75/$/AOPAXQUSP
M_H6NW<GCN^@\W6=+TR\M[34F%MMM\W4<A,*K'G8 *] _X+2?MZ_'[POXQ_9Q
M_8<_9U\0W?A;QC\9[?P=I7BCQ?;226VM_P!M>(8-(30K/3=522&ZM!=_;V:[
MN(9SNE8-*3L6O _^"]&@>(-2_P""B_\ P3HNM,\/Z_JEI!\,8;>XN],T35-0
MM+6<^/;V017=U96D\%J^SY\7$D9"_,>.:W/^"XG[,?QX\,?&G]E?]N_X5>$-
M3\;:%\,X/ _B#Q)9V%G)=3^'->\(VNA2Z+#<V49:ZN8-1-G(["" [#%(D@4X
M+<^&A1:RI5%3N\/B7#GLE*LIOV7-LF[[<W5)*YK5E5_VYP<W^]H<[CS<RIM1
M]HXVV5NRM:Y]'_LW?\$OO^"F?[*7Q;^$?Q0TO]LGQ3\==(U.Y63XL> ?'>N7
MTNG>&K2X@@-Q!ISZ[KU[;ZN\+37,*26L".'@615PR$_TVW7_ ![7'_7";_T6
MU?S2?L[?\%Q/CO\ M??$OX4?"#X,?LC>._#.OWMS;1?%'Q9X\TR6'PY%;P1P
M-J5YH<3+I\MK&RI=R0)/+.ZC8"#C%?TN7"EX)U499H9%4#J248 ?B3BO)S#Z
MUSP^MQI1J\LK*FJ<9.-]'-4_=MTA=)V6NIZ6$]ARS^KRJ2AS+6;FTGRK2#GK
MM;FMI?[C^%K]F7_E8)\>_P#8_P!E_P"X^O[<_B;'K$WPX\?1>'M1MM(U^3P;
MXF71=6O)H[:TTS53HUZ-/U"ZN)GCBM[:SNO*N)YY9$CBBC:21U52P_@3\>?&
MS6/V(?\ @LO\9OCGXT^#/Q,\=:5X6\=6LTV@>$M#U)KN_1;6PNE>SU0Z=<:9
M(K( H*2N-QP2""!^[OA#_@K/<_\ !4#P'\=OV9?@E^SI\>?@S\0M:^#GC^^T
M7Q%XV2WLM.U)[+P]=.WA^">&TM=EYKBS"PA5YA&6E(<E>OHYAA:U9X.M&*]C
M#"X=5*KE#E@K1NVG)-I)W=MUL<6#KTJ:Q%*4FJLJ]5Q@E)2EV2=G%-^;\['X
M0?&?7_#VG^)/&EW\<_\ @M'\7OA]\5M-U#5TM/AY\//"WCSQ%X6O=1L#(]KI
MEMXB\->*!HR6]U=*+87:(8@CB7!4<_HK_P $L?B_^T9_P4B_9)_:0_8]\3?M
M*>*O!7BK0-+N]1\%_&C38M2N/&.DZ$;C3]-M&N;Z+5+35+QI':1KEVOUE$4\
MA5)74(_Y2?L:?%+X:_LL^#OBG\ ?CS_P3GUK]H+]I?Q!/JVC>&_$?BKP19Z[
MHOA34-ES;3+/<ZIITFZ2T:02I=Z=>1N9[:(Q3>66#_J5_P &VO@_QGX=^.W[
M65EXK\%ZOX.U$>"IK&?2[S1;_2[&ROI/$NG2C3K"2YMX[:=(8G3:+::5-HR&
M(!QWXQ*GA:[23GAY4:E"I*.%Y6U**YZ4*<.94];/VKDGLV];\F&;G7HQNU&K
M[2%6"E7YE[J]VI*<FG/1M.'+;OL?E1_P3M_8,^+'[4G[57Q;^"O@+]K+QU\!
MO%/@/3O$-QJGQ.\*1ZL^N^+4TK5+>QN+>[%GK6EW CU*25;FZ^TWK@!6RLLF
MU&_2?_@K=_P45^)'A#X]>#?V%_#G[0WB#X.?"GX4?#_P3H'Q0^.6DZ3J=_XN
M\1:W)X:T^TOM;$&GWT.KQ7"W5G<SS)%>2F:1V;S&9F=_F+]GG]H+XD?\$F_^
M"A'[0&O?%+]FSXJ?$75_&D/B;0/#6@^#+!V:;4->U:VU#2[^74VM;C3CIWDQ
MJEP@N%F'FAE8,IQ[9_P4]_9J^)/P?_;4\"_\% 8?V=W^-O[/_P 4?!7@+Q3X
MJ^'WBC2HO%::3>W'A_3K_P 2Z!K.EQ8:2_AGO)K;32L CMG =MZ$$NHU5QM*
M5?DG1>&YL)_!7/7<:?/9M.\E?W%.\$[V6C0H+DPLX4N>-15U'$+][>-+FER\
MR6B6W,X-2:6K/B/P1^WWJ_[%GQK^%7B7]F7_ (*+?$7]M31-8\0:5I7CK0?B
MGX:\5^'+#3;'6;F#3[F&WM?&.M:A%>RJ+J1(Y8$#JX61,%0:_5G_ (+R_M/_
M !V^'_QZ_8U\;? CXA^,O!MUK_P]T;Q3I_AO2=?U/3] U35-7UK4H(X]?TBW
MN(++5HHHK@1E;V)U<0QMC"J!Y3X;_;1^ G[1OB+P5X,_8V_X(L> ;'X@:AXH
M\/C4]7^+'PD\-OH>FV,>JV<FJZAIR6]KHAAGL+-;J[M99IG9)H8F5"5(;T+_
M (.&_"VLS_M4_L;P>'O"VL76G6/A;1-/BBT'0=2OK#31!XKU#9:!M/L[B"UC
MAA"A$D= L8':L[PECL)[7#^SJ>RQ'/[5T'.I%03C[2-!1@K7:B^5-J_5,M<Z
MPN(<*W/'GH.'LU6C&$G)*7)*JW)W2N[/33I8^\OV6OV$_P!MGX!^!OC;^T;\
M8/VSM;\7^-/BM^SIX[.G>#_$>I7<7@SX4^.M;T:"3POJ]I=7^N3:1Y6G*?M$
MTT<5DD$I:-I 1N/\Y7Q-\6>%O#]AKGB'Q]_P6I^-MM^T!IBSS-\)/"GA+XAW
M/A+4==T]6:UT^S\5:3XG;0A9ZA=IY/GQ1M (G#'*]?[(_P#@HS\+_BE\6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIN)@8Q@8QC&.,=,8Z8QVJG_9NG"7SQI]D)\[O.^RP>;N/5O,\O?D^N<U=HH
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MYD)/4ES'N)/<YYJ:&SM+=G>WM;>!Y/\ 6/##'$S\Y^=D52W('WB:L447??\
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M$NZ\BW4D??\ #^M4?MUG_P _5O\ ]_H__BJDCOK/G_2K?M_RVC]_]JM>:/\
M,OO1C[*K_P ^ZG_@$O\ +S7WEZIUZ#Z#^59WVZS_ .?JW_[_ $?_ ,54PO[+
M _TJ#H/^6J?XT77=?>8>RJ_\^JG_ (!+_(N4J]1]1_.J?V^R_P"?J#_OZO\
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M7V7D6Z*J?;[+_GZ@_P"_B_XTHO;,]+J#_OZG^--? _7_ "(]G/\ DG_X"_\
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M=W4JN=1MHHHHKY4_1@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^:/^#?3_ +!M3)^QY^Q[@G_ADS]F_.<?\D?\'=./^H;7T$O0?0?RJ9.A^O\
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M_P"5=2)^QM^QV1G_ (9-_9P'/_1'O!7H/72C7T34J=#]?Z"LOK&(_P"@BO\
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MZ-2_9T_\,YX$_P#E)7TBGW1^/\S3J/K.)_Z"*_\ X.J>7][R0?4,!_T X/\
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M/_DB?[-R[GM_9^"MV^J4.R_Z=^2/FG_AC#]D#_HUG]GG_P ,Y\/_ /Y04?\
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M_P!&N?L]_P#AG?A]_P#,_1_PQC^R%_T:Y^SW_P"&=^'W_P S]?2U%'US%_\
M05B?_!]7_P"2\E]P?V7EG_0NP/\ X28?_P"5^2^X^:O^&,OV0_\ HUW]GS_P
MSOP__P#F?H_X8R_9#_Z-=_9\_P##._#_ /\ F?KZ5HH^N8O_ *"L3_X/J_\
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MMP'_ (1X?_Y6?-O_  QM^R-_T:_^S[_X9[X?_P#S/T?\,;?LC?\ 1K_[/O\
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M/_\ X9_P!_\ *"OI"BG]=QG_ $%XK_PHJ_\ R?DON#^R<J_Z%F7_ /A%AO\
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M_P#?U_\ XW1[*?9?^!+R\_/^KJYSQ\_N_K^D_*_9T5QG_"0ZU_T 7_[^O_\
M&Z/^$AUK_H O_P!_7_\ C='LI]E_X$O+S\_ZNKG/'S^[^OZ3\K]G17&?\)#K
M7_0!?_OZ_P#\;H_X2'6O^@"__?U__C='LI]E_P"!+R\_/^KJYSQ\_N_K^D_*
M_9T5QG_"0ZU_T 7_ ._K_P#QNC_A(=:_Z +_ /?U_P#XW1[*?9?^!+R\_/\
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M>RGV7_@2\O/S_JZN<\?/[OZ_I/ROV=%<9_PD.M?] %_^_K__ !NC_A(=:_Z
M+_\ ?U__ (W1[*?9?^!+R\_/^KJYSQ\_N_K^D_*_9T5QG_"0ZU_T 7_[^O\
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M ($O+S\_ZNKG/'S^[^OZ3\K]G17&?\)#K7_0!?\ [^O_ /&Z/^$AUK_H O\
M]_7_ /C='LI]E_X$O+S\_P"KJYSQ\_N_K^D_*_9T5QG_  D.M?\ 0!?_ +^O
M_P#&Z/\ A(=:_P"@"_\ W]?_ .-T>RGV7_@2\O/S_JZN<\?/[OZ_I/ROV=%<
M9_PD.M?] %_^_K__ !NC_A(=:_Z +_\ ?U__ (W1[*?9?^!+R\_/^KJYSQ\_
MN_K^D_*_9T5QG_"0ZU_T 7_[^O\ _&Z/^$AUK_H O_W]?_XW1[*?9?\ @2\O
M/S_JZN<\?/[OZ_I/ROV=%<9_PD.M?] %_P#OZ_\ \;H_X2'6O^@"_P#W]?\
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M $!S_P!_)/\ XFIY)<U]-K?%&][KI?S1;DFI6[KITT1UM2IT/U_H*Y0:SJA
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M[O?XX^7GY_U=7F4DW'?1]GY=D_Q[,[2BN,_X2'6O^@"__?U__C='_"0ZU_T
M7_[^O_\ &Z7LI]E_X$O+S\_ZNKUSQ\_N_K^D_*_9T5QG_"0ZU_T 7_[^O_\
M&Z/^$AUK_H O_P!_7_\ C='LI]E_X$O+S\_ZNKG/'S^[^OZ3\K]G17&?\)#K
M7_0!?_OZ_P#\;H_X2'6O^@"__?U__C='LI]E_P"!+R\_/^KJYSQ\_N_K^D_*
M_9T5QG_"0ZU_T 7_ ._K_P#QNC_A(=:_Z +_ /?U_P#XW1[*?9?^!+R\_/\
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M>RGV7_@2\O/S_JZN<\?/[OZ_I/ROV=%<9_PD.M?] %_^_K__ !NC_A(=:_Z
M+_\ ?U__ (W1[*?9?^!+R\_/^KJYSQ\_N_K^D_*_9T5QG_"0ZU_T 7_[^O\
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M ($O+S\_ZNKG/'S^[^OZ3\K]G17&?\)#K7_0!?\ [^O_ /&Z/^$AUK_H O\
M]_7_ /C='LI]E_X$O+S\_P"KJYSQ\_N_K^D_*_9T5QG_  D.M?\ 0!?_ +^O
M_P#&Z/\ A(=:_P"@"_\ W]?_ .-T>RGV7_@2\O/S_JZN<\?/[OZ_I/ROV=%<
M9_PD.M?] %_^_K__ !NC_A(=:_Z +_\ ?U__ (W1[*?9?^!+R\_/^KJYSQ\_
MN_K^D_*_9T5QG_"0ZU_T 7_[^O\ _&Z/^$AUK_H O_W]?_XW1[*?9?\ @2\O
M/S_JZN<\?/[OZ_I/ROV=%<9_PD.M?] %_P#OZ_\ \;H_X2'6O^@"_P#W]?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBU/E.,<[J\/Y7#,*-&G7G]:IT.2KSN/+4A4FW[DZ;NG327O6LWI>S7]P"?\
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M8]=_<P_E_P!._7\"/^)E,_\ ^B?R?_P/&^5_^8GU_#Y?ZEW_  \]_P"">?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?LT_\$_AI&E_$RYUCQ=X[UB,W-M\.O!*VUWXL2Q:%9K>_FM;J2&%+>[4O]G
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MGO/#?A/Q'K]I!<;O(FN='T>\U&"*?85?R9);9$EV,K;"VT@X-?BA_P $AO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG&!7\M:_LQO^U_\ \%*?VT/@M"#+J%K\(_BY\1?"]B@Q)?>,O">G*_A^VB=
M)UDFNKD1HL399FX!.*^R?^"!'CSQO^R;^WG\9OV,?C-#'X9UK6[2_L=0T!;M
M)H8OBDVH6=VL5NX\M+HSZ:DB(R+\L<F54X KK?\ @F*-O_!P/\=E)Y7X9_%-
M3@]2MUI0(_ @\>H]JZ%!X3$YI5HM<LL(L31E'6-I24_=>S7-?;HU8P<EB:.
MA46JK.A43WO%1CJG;6UGJM[W/L?]AW]JG5OCS_P22_:(^$'C^_DG^,G[,?A3
MQ'X \<Z;,VZ32M)LH+S1O#ENY<B;?&FFW$1\U QV#DE6KN_^#8RQMM4_X)R^
M/--O(HY[34/VAOBI974,J)+'+;W6E>&X)HWCD5D='C=E9'5E8$A@02*^!?\
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M;PQZU^;O_!N9\9_@Y\/?V./&FE>/?BU\,_!.JS_$LW$6E>+O'7ACPUJ3V_\
M85BBW"66M:G93R0,ZNBRQHZ;D=201BO9HIO)<0DFW]<CHDV_AH=CS9M+,Z;;
M27U:6K=OM/N?</\ P5E_X*B>/_\ @G3J/P3L_!7PG\)_$N+XI76HP:I)XDUW
M5M&DTB.QO;.U5[)=-C<7#.ERSD38 9% X)KW/]MK]N[Q3^RK_P $\;O]M3P_
MX!T+Q;XD@\(?#3Q)'X'U;4[^PT5Y_'DVB17%J^I6B-?+%8#57,+A2TAB42#Y
MC7X7?\'+?BOPWXGTG]D;X@^%=;TKQ9X%:Z\320^+_"VH67B'PU<FWUG3HI8K
M36])GNM-NIEFBDA,4-R[":-XB ZL!ZA_P5D_:^_9N\5?\$9?#?PA\+_%GPGX
MD^(_CWX;_!>RT'PEH.K6&JZQ#=>%/^$6OM=BUJSL[F6;139P6=RNV]5)))D"
M(C#>RW2P5*=/*I*BY.KB)0Q+7/[T%4BFI6?N\L>9.W*TB*F)G&ICE[5)4Z*E
M13<5:3AIRW^)M^NMK;Z_;5U_P5P^(%O_ ,$O;S]O<?![PBWC2VNH;1/AX=?U
M<>&F=A8/*SZOY?\ :2HD=W(5(CY9%R.37Q/J?_!P=^T?XT^&-AX[_9Q_85UG
MXN#POH[ZA\:==@_X2=OA_P"!IXF,LQM/$.GB22>RALGAFDGO(XV5V9<8&:^8
M]5!/_!N5K ').K<?4VFC\5]=?\$9OVO_ -COX=?\$U-9\+_$7QGX$TK6_!6B
M:I%\2_!FKW6DZ'KOBH26ET[6MK;W$\5YXE>YLYUM1+%%.ZB4Q!6"LHU>&PU*
MC7K+!_6)4\=.C&"E425.T4D^5ZI=+V?-)-RM=/-5Z]2I3IO$^QC+"JHYN,&^
M=.]TY*R;6^ZY4[*[N?HM_P $]?\ @JYX1_;N^ _Q2\<V'A6'PC\6_@YHM]J'
MC/X?RW$YTUKE-+U'4['^R+RX<W]Y8E;%8=0G:)'MI)D"AMWR\%_P2J_X*K>/
M_P#@H1\6OVGOAMXS^$GA+X<6WP#N-$BTG4O#>O:OK$_B&/5M2U.Q9M0BU*)(
M[1HDL%D5;<L"TC \*#7X>?\ ! [PYK'B?XH?\% /B)X4TN^'P^ET+XGPZ=]F
MBF-G+'XCL]=F\-V-NJ#9=3QVI2&&-,NA7:J@\5T7_!OI\:?A1\%_VLOV_K'X
MM>/O"_PYF\1WFDII$GC+6;#P_:W,_AG6=?N=:L_M.ISVT27UI#*C?9&832MF
M*-&F,<;K$8'#PCF:I4[RI1PTZ,4Y2G3]I.'M(JSN[1<OB3:C]XZ.*K3>!=2:
M2J2K1J/W4I\B:C)NRM=VT5DWZV/V T3_ (*X_$'5O^"I6H_\$_W^#OA&+P=9
M>*M3\-I\14U_6&\1.NGV]Q<&Y?23'_9R[DAY ?:,GZUX?^T__P %T/BMH/[3
M'C+]F#]AW]E#4/VK?'7P_:4^)+>R;7?-GM;5(&OM3T6+0_-:\TVSDF$%Q<.L
M8CG_ '9&>:_+;]G?XM>!OC;_ ,'"%U\1?AGK*Z]X0UGXH>(Y],UA(S'!?6W]
MF7SR3VQ#.LT#1))LE1BKCIUKV;]IC]F']G[QI^T%\9?VNOV!/VVO#_P(^-WA
M"ZOKGQQ\./%6KVG@2:_U6Q1'NK+2;_6];L+B_L;M[<,VE06[Q7+N"ZR,@9K6
M$PE*M256A:^"I2:E[5TOK$Y6O7Y'SP3UCHXJ_;0EXC$3I3=.K>V)J1O%T_:.
ME%)VI<RY96O?6[:[G] W_!.+]N_Q'^VWX+\:7/C_ .$.L?!3XE_#C4[#2/&O
M@C5H+Z$Z??:@+TQ1PG43]J?9]AE63>J[6P.]=Y_P4L /[$/[0 /(/@Y\_P#@
M;:U^8/\ P09_;Y^+7[6]A\>/ ?QFT'PU>^,/A1J^C6,WQ,\(^'-+TBU\9"?^
MT49]9N=&MTANKBV\A5M+Z[N9Y;P.\D;?O&%?I]_P4KX_8B^/^?\ H3G_ /2V
MUKS*M+V&8QI\BI\M>BU",G.*4G"7NR>K3O=7U2=GJCMIU/:X)U.=SO3FN9Q4
M&VKIWBKJZ:LVM&]5I8_@X_9O^$/Q"\'_ +&VG_\ !1?X6-++XW_9L_:VE\.:
MM<0;HVT7P#8>'H[Z?4)A I\R%;W4?*+W"%-T@!;.!7[9?\%^_C3X:_:,_P""
M9W[-7QP\'WO]H^'?B#K'AS4;2]^7$UY:R366K %&92(M3BN8P0>0H) .0/1O
M^#=/X5>%?CA_P3;_ &JOA-XWL8]2\+>.OCQXXT+5K210RR07/ASP\R, P8!H
MYTBD! S\N 1G-?S^?M>^+/&OP4_9Q^*__!/GXKMJ$/B/X)_'+2]1^'&G7$<J
MVMCX$NY-5UJ=;4MB)%;[?:.RHJAB<]0:^A3^L9@XW_>X'%)K;FEAJJ5UTO[.
MIJWVFV[MGCO]S@;WM#%X;7RKTY73[?O(73ZMKLF?VU_%']NCX6_L%_L"_ 'X
MI_$5+S5KZ\^"OP@TOPIX4TF,7&K>(-6N/ GAR"*."W\V*1K2WFF@-]+$2\$,
MF\*3@'\F;G_@O5^W7X9TJ#XL_$'_ ()L>(/"W[-+7-M<3_%Z8>+ULDT"[GBC
MM]12695L3)*DJF-2_EL[*N[!S7S7_P %^/#WB:\_9#_X)@^)X?MMIX!\/?"_
M0K?QKK,'F-;:0VK?#GX>0:1<3Q*5CFG\Z.=K2-G1WE0K&=QR/&/!O_!,KX*_
M$[]F;0_B'XI_X+4ZUIGPTU#PA::WKOPNU^[L[V#06^RI<RZ$GP_U#XA+>WLE
MBVR*WB31!OD3**JH67BP^%P2P\*^(BIRK5ZL9-PKU'%1J.*A!4/AG9<UZET[
M['77KXIUI4J+<8TJ5.24948<SE"+<I.JFY03?*^2UK.[/Z-OVC/^"J>@>"/V
M M+_ &X_@)X5TSXCZ;K8M5L?#'BN^N=%-I<36\T\]GJSZ8UQ/:W,(A)" G=&
MZ-W('YFZ]_P<'?M'>*_ <'CG]G']A76OBUH?AK1EU/XJ^+0/$X\"^$B+9;NX
M>VUW3A+YUG:0B9KB:Y1#&8FR, UY!^T#\,/A/\*_^"$,.C_!'XO:E\</AWJ_
MBL:IH_C[5?"4G@BYOU72;NS9!X?EN;M[:/,3.K><0P88!YKZ"_X),?M>_L@^
M!?\ @D%%X!\:>/O .B^-? ?P_P#B!9?$WP;JMUI.C^(O$-WJU_XDOM/@@M;B
M6*[\3R7>DW=K:)+&EQ+$/]&V*B)NSCAL+2H2JQPDL4XXV="*DZL9*#VYXKE:
M<;62:C[S7,^CIUZ]2LJ;Q$:%\+&J^54Y+F5F^23NO>NVVG+W59'W[^Q)_P %
M,_ W_!1S]E/XZ:YIVA_\(?\ $KP'\//%L/Q!\&PM+/8:0NK>&M=_L>YL;RYE
M:ZN(+Y+.Y93-#'@1AE9@Y"?RQ_\ !*_]N'XD?LA_$K]HG3O@C^S[XJ_:/^+7
MC_SK/1_!'AVPU&ZCAM[#5_[2%W>2Z46NXHFCBF$A$9'[O@@U]@?\$ ]$U#7/
M%O\ P4F^)_AFUNM-^&%]X'\3?V=M$UKI^H6VHZ3XLFTBPBB51!>/I<*$O&V1
M9,H!"R,BMZQ_P;0Z=ILWQV_:ZU&73[&;4;33(!::C+:P27UJLOB<0RI;7;(9
MX$DBD>.18G4/&S(V5)!WE2H8..:P5+VE**PT_92E)6<^67)*2M*T92UM:5DE
M=.YDJE;$2R^3GR5&Z\7445JHN*YE%WC=I>E]=C]%/^":O_!:S5?VQ/CEXB_9
ML^/GP7M?@%\8=+LI[VPT.WO-5N[6::":&#^Q;^35_+N+;6Y3(TD5DL1W1@-N
M'./$_P!H/_@OYXN^ W[6OQ>_9IG_ &=K'Q<OA%K'1OAU<>&]1UK4/%7C'Q;J
MUAYFEZ9?Z.@2"UM9]2*VKRVCO*(F#*I<XKX6^$UO;P?\'+'QX@@@AA@B^(FF
M-'##$D<4;OHFB.[)&BA$9Y&=W90"SLS$EF)//?#S2-)UK_@XP\;6VLZ=8ZK;
M6\C7\%OJ%M#=PQ7UI;63VUU''.KJEQ ^6BE4!T;E6!K/ZI@U6G-T+TWET,4J
M/M)I0J/DDU&5^:UG;WK[O3:U?6<2Z<(JK[ZQLL.ZG+&\HJZO)6M>^NEMDGW/
MM?\ :N_;Z\8?%'_@FCXR^,O[;_\ P3R\-'7=&\9_V=9? ?XDZSXT\-Z3J&G#
M6K2RLM:EU2V:#78'GBVW2K PB9HPN2A:N3_:6_;%^*^F_P#!'SX8R?LR_L<0
M:+\+OBMX(M/#?CJ#P#JWBR]T7X!>&I+:'48]6M=;$G]H210WMM;:?%=:G<J2
M9SN8L5KZ\_X.2%0?\$]O$K!5#G7-)!?: Y4:GIY"ENI4$L0.@))[FO,O@T7_
M .(>CQ6(]Q;_ (45" $SN.Z^T$. !SRN0P[C(.14471>'PM=44E+,N14O:U7
M2A%J-K)SM>+?,I?$VK-N.A=3VBKUZ3JMN.";=3DI\\FM7=\MTI*Z:325[I)Z
MGYU?\$(/VROVSO!NH^$?@3X+_9>\7?&7X%?$#XR:+8_$;]H.^O\ Q;J\'PML
M=0MY8;R2ZNI9;JQ2*T@C^U!+N:-!EF<$'C[?\%_M'_ .#_@N1X@^#.A_L5?"
MS3OB(ME=6P_:3MO%OBY_'-\;BRA#QR>&'G/AF..?>$,T</F;,.#O))B_X-M/
MC%\+/"O[-'CGP5XF^(_@[0_%_B;XUV6C^&O".K>)-*LO$6MZC?:2R00Z/H=Q
M=IJ%_P">Z&/S;6WDC\R(QNROL#?&7@%9E_X.0-;2,;;@0A(U) Q,+*T55.<8
M(<8.>F*WK*%3&YDO9>SY,+4?-"=6'M9>X^>:YU%V3Y>6W)I=QOJ9TY3AA\"_
M:<_/B*:M*-.7LU9KEBW%M7M>[?,KZ-'Z>?MC_P#!;WQ_\,_VE]5_95_8W_9F
MO_VI/BGX?\^UUC1K7^VH[E]5TXW']L6.EP:*TTER=,2VD><NJ,L:[V5<[1]N
M?\$V_P#@H/XU_;0T[QUX>^+_ ,#M;^ /Q?\ AW>/!XD\#ZI;ZC'%! DEM;M)
M')JA%VT@N;E4*M&J[03G(P?Q5_;$_98_9K^,W[57Q6^/_P"QU^VEH?[.G[3W
MPLUKQ0GQ \*^+-3M?!,>K>)=+:]75!I&MZQK&E^>+^[6>,K:Q.MQ&X1F=&Q7
MTU_P0B_X*!?&W]I_QO\ &?X(?'33/"/B+Q5\*O#L>J1_%KPOH.CZ<^O6B:Y8
MZ.NC:GJ^DP'^WKL-.VH/?W-Y-/,-I8$*&KDK8:@\![2C07/2I4Y5I5'4IUX3
MDU=N,E[.=-W7+R6>N[N;4Z];ZTH5:K<9SG&FH*G*E*,4M+Q:G":=[\R^1_2S
M1117AGK!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^8?_P '*/\ REN^
M,W_9/?A-_P"HU7^GA7^8?_P<H_\ *6[XS?\ 9/?A-_ZC5?7<%_\ (UJ_]@=7
M_P!.43\X\4?^2;I_]C'#_P#IG$GX1Q]_P_K4E1Q]_P /ZU)7ZO':/I+\T?S<
M6*G7H/H/Y5!4Z]!]!_*JCLO1?D<XM3)]T?C_ #-0U,GW1^/\S6D=E_C7Y'.3
M1]_P_K5B/O\ A_6J\??\/ZU8C[_A_6M3&?Q/Y?DB2E7J/J/YTE*O4?4?SK2/
MQ?\ ;J_*)SS^)_+\D64^\/Q_D:FJ%/O#\?Y&IJUCNO5?F83W7I^K+%%%%:0V
M?K^B.:?Q/Y?DB=>@^@_E5A>@^@_E5=>@^@_E5A>@^@_E5G//XG\OR0M6*KU8
MK>.R]%^1SS^)_+\D21]_P_K4Z=3]/ZBH(^_X?UJ=.I^G]151W7JOS.>?Q/Y?
MDB6E7J/J/YTE*O4?4?SK<YY_$_E^2)ZL57JQ6E/K\OU,:G3Y_H6****T.>IT
M^?Z$Z]!]!_*K"]!]!_*JZ]!]!_*K"]!]!_*M8[1])?FCGJ=/G^@M*O4?4?SI
M*5>H^H_G5F9/1115PW?I^J,9_$_E^2)D^Z/Q_F:=34^Z/Q_F:=5Q^U_B?Z$D
MZ]!]!_*EI%Z#Z#^5+3CLO1?D<X5.O0?0?RJ"IUZ#Z#^54MI>GZHF?POY?FA:
ME3H?K_05%4J=#]?Z"M(;/U_1&(^IUZ#Z#^505.O0?0?RJS.IT^?Z"U8JO5BG
MT7J_RB3+[/\ A7ZA1115KXH?X5^3,Y_"_E^:'IU/T_J*EJ).I^G]14M:&),G
MW1^/\S3J:GW1^/\ ,TZG'=>J_,QG\3^7Y(L44454-WZ?JB0J2/O^']:CJ2/O
M^']:U.<DKTOX-^(_BAX3^*'@C7?@M>:[9_%2R\1Z5)X(;PV)9-7G\0+=(VFV
MUO:Q'%\9KI8E^QS))!<$".2-U)%<5H&@ZWXJUO2_#?AK2;_7=?UJ\AT_2='T
MJUFO=1U"\G;;%;VEI;I)//*W)V1HS8!., D?W1?\$<O^"..A_LNZ)H_[0?[0
MFCZ?KWQZUVPAN] \/W<<%_I?PYTZ[C$J(J/YMM>:Y<(+2\6[>W@N](G#VZ$2
M!BOS'%7$N7<.9=.MC5"O5KQG3PV =G+%R:M*,HM-*A%/]].2Y5%\JYIRC%_H
M/ASP%GO'>>T<+E4JN#PV#JT<1F&<I3C3RVG&:E&5.<7%SQD^5_5:,)*<IKGD
MX4X3G']E?V1=>^//B;]GKX::U^TIH&C^&_B]>^'=.D\2Z?H]Q/.LC?8K;R;[
M5(IX+;[!KE[F2?5]-AC^SV-XTD,!** /I.BBOY,Q%55Z]:M&E3H1JU9U%1I)
MJE24Y.2ITTVVH0ORQ3;LDC_2[!8>6$PF%PL\17Q<L/AZ5"6*Q,HRQ&(E2A&#
MK5Y0C",JM1KGFXQBG)MV"BBBL3I"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\\?VL/^"8_[-'[9
M_P 6_AQ\9/C6?B%>>(_A?IL6E^'=(\/^+ETCPI<00ZI<:M'+K&B/I=XM_<_:
MKEU:;[1"3 J18PN3^@6GV-OIEA8Z;:*4M=/L[:QMD8Y9;>TA2WA4D  E8XU!
M( R1G Z5<HKIK8S%5Z.'P]:O5J4,)&4<-2G)N%&,Y<TU3CM'FEK*VKLK[(X,
M-E>78/%8[&X7!X>AB\RG3J8_$TJ:C6Q<Z47"E*O-:S=.#<8WV3=MV?F7XD_X
M),_LH>)/VLK?]LZ2/XCZ/\8K:>QND30/&2Z9X1:XL5"K-)H":3(SO<\M>?Z<
M!.Y+$*37-_M<?\$:/V)/VT/B#_PL[XL>&?&&D^+IMAU*^^'WB6#PHFM2J[.]
MQK$:Z1?&]N)G8M-,SJSGG(/-?JQ1793SS.*52A6IYEBX5<-06&H5(UIQE2PZ
MM:C%IW]FK*T7=*R/+K<(\,8C#XO"U\BRVMA\=C/[0Q=&IA:<H5\=K_M4TT_W
MVK7.K.S:V;/R,TS_ ((C?L&:#XJ^#GC+PUX,\5^%]<^"=[9:CX;F\/\ B2WT
MV+7+^PEEEAO/&<<6CY\07+&9HY97>V9XE2/(5>?K?]K7]A[]GW]M7X>6?PW^
M./AN\U+2M,>%M)UC0[V+2O$^D"%=OEZ;K+VEY):QRD(TR)%B1XT;C;S]>45%
M3.,UJUL/B:F88N>(PKD\-6E7FZE%SDYR]G-N\>:3;=G9^AI1X6X<P^$QN!H9
M)EM'!9C&$<=A:>$I1H8J-.$:=-5J2BH3Y(1C&+:NK)IWU/S:_9)_X)1_L@?L
M9^$_BEX)^%GA?Q#KOA_XS66G:=\0;/XD:W;>,!K=EI+7;Z?!()-*LHPEK)>S
M20AHW\N4B5"KJ#7R5XS_ .#=/_@F_P"-?%5UXLNO#OQ4T2>ZG-PVC^&O'T&D
M>'X"9#(8[;3$\/RK!#D[?+23&SY:_=JBMJ?$.>4J];$T\UQL*^)Y'7JQKS4Z
MKIQC"#F[^\X0C&,6]5%**T5CFK\$\(XG"83 5^'<IJX/ ^T^IX>>#I.GAE6G
M*I55)6O%5*DYSFKVE*4I23;;/G']F?\ 9/\ @9^R/X&'P_\ @=X,LO"VC221
MW&I78CMY-9UN[BC\I+S6=1AM[9K^Z6(",2O&#M !X Q\\_LJ?\$O_P!F+]CG
MXK_$+XR_!Y/B /&/Q+U+6=5\1_\ "4^+EUS2DN=>N[J]OQIM@-+LS9QM/=RF
M-3-,47:I9@HK]%**Y/[2Q]L6GC,0_KZBL;>I)O%*#;@JS;;GRMNUWI?L>C_8
M.2IY8UEF"C_8KF\I4:$(K+W4C&,WA5%)4G.,(J3BM>57U/SI^ __  2\_9A_
M9T_:/^(O[4OP[3X@_P#"T/BAKNO>(O$O]N^+AJGAQ=2\27-Y=:FVF:.-,MS9
MQ/-?3F*,W4QC4HN]@@IGQ9_X)<?LO_&?]JGP7^V'XR3X@GXN^!/LYT6/2O%R
MV/A*5K9[EXFU#0?[+F-TV;N7>1>Q;P$# [!7Z,T5K_;&:>W>)^OXGV\L-]3E
M5]K+G>%Y>3V#?_/OETY?U,5PQP\L+' K)\ L'#'?VG##JA%4HYAS^T^MJ&RK
M<_O<WRVT/@3]MG_@FY^SE^WWIWA+2OCU_P )Z;3P7C^QD\%^*E\-LP$K38O2
M=-U 7(W,1C;'@8P00#6%^U#_ ,$N_P!F']KJT^ %E\6E^(7D_LV:=;:7\-_^
M$7\7C1'^QVMKHUFB:^QTN[_M5FAT*P$C 6VYA,>!*0OZ,44J.;YGAXX6-#'8
MFE'!.L\(H5&EAWB(\E=TOY?:Q]V=MT/$\-9!C)YA/%91@:\\U6%CF4JM",GC
M5@IQJ818B_\ $6'G&,J5_A:5CY!_:0_8B^"7[4W[/EO^S1\4$\6+\-[6PTG3
M;=O#>OKH_B&*WT46JV6W5FL;L>9BSA$S&U(E&\%0&XM?#/\ 8N^#/PG_ &8_
M^&2_":^*E^%/_".2^%F;4-=%WXG;3)BI=FUL64(-W\H G^R# _@KZTHK)9AC
M50CAEBJRH0Q'UN-'G?LXXG3]^H[>TT7O;G0\ERF6+GCWE^%>,JX'^S*F)=*/
MM9X!_P#,)*6[H?W'IT/A?]B__@GA^SM^PCX3^)?@KX)VOBZ]T#XL^(H/$WC&
MV^('B"'Q:;N_@L9].6&#?IMC'%8O:W$B2VTL4XD)!9N"#\=>-/\ @@)_P3O\
M=?%6]^+>K^$/'MMK&H:W)K]WX<TKQA;V/@J6]FNVO)T/AX:')']EGF9O.@^T
M$.A*LV<$?M;1733SS.*.(Q&*I9EC*>)Q:C'$UH5IQJ5E"*C#VDD_>Y8I*+W2
M5DT>?7X/X7Q6"P66XC(<KKX'+93E@,+5PE.='"2J3=2HZ$9)\G/.4I32TDVW
M),_.'X%?\$K/V1_V</CM<?M!_"3P[XF\->,I]%&@C2(=?B'@VWLA'<Q%[;P]
M#IL"17+1W4JM-]J.0%&W@YF^#?\ P2Z_9@^!G[47CO\ :Z\$1_$'_A;'Q#:Y
M?74UCQ:FH^%8GNYH)YFTW0QI<#6C;[>/9F]EV+N50-QK]&**B><9K4=9U,PQ
M4WB,/'"5W*M*3JX:#O&C-MMRA%W:3[ONS6EPMP[06&C0R7+Z,<'C:F986-/#
M0A'#XZJDJF*I1BE&%:22O)+HM+I6_.;XW_\ !+G]F']H#]ICX<_M8>/1\1%^
M*OPO\0Z#XG\-G0O%ZZ7X;DU/PW<VMUIO]J:,=*N&O+<2V</GQ+=PF5 R%U#&
MO6_VM/V&/V<?VUO#5CX;^/'@I-;.E>?_ &/X@TR2WT[Q/HXN0BW*Z9K,EG=R
MVJSJBI($C^91M/& /KZBH6:9BI82<<;B8SP$/9X.4:LHRPU.]W"DTTXQ;W2W
MV>AM+AW(IT\RHSRK SI9Q55?-*<Z$)PQU:/PU,1&2:J3C:ZDU=/WEKJ?B!\*
M_P#@WP_X)R?"?Q;8^,=,\'_$#Q5?:?=0WEOIWCOQE!XDT0SV\JS0F33I="MU
M<)*J.N9 047GBOVST_3['2;&TTS3+2WL-/L+>*UL[.UB6&WMK>% D4,,2 *B
M(H   ]SDDFKE%&.S3,<RE"6/QN(Q<J::INO5E4Y%*U^5-VC>RO9:VU#*.'LC
MR"%6GDN58'+(5W&598/#PHNJXIJ/M)17-+E3?*FVE=V2N%%%%<![(4444 %%
M%% !1110 4444 %%%% 'YS_M8_\ !+O]F7]L_P"+'PV^,?QKE^)-YXF^%6I:
M=JOA33O#_C,Z-X:CNM-FM9XQ?:.=,NUNHKA[2+[8@GB\]=P)7.1^AMA86FEV
M5IIUA;QVME8V\5K:6T*A(H((4$<44:* %5$4  #  JW16DJM2<80G.4H4TU3
MBW=03W45LKVU(C3A&4Y1BE*HTYR2UDTK)M];+1=C\S-=_P""3?[*&N_MF:'^
MW;)'\1].^.FA^+;;QJK:1XR%CX/U36[6U-G&^M>'5TI_[0MS;D(\+7R%MJ_.
M-H%;_P '_P#@E_\ LP_ _P#:W\8?MI^!H?'T7QE\;:1K.B:RNI^+!?>$$L=>
M:!]0^P>'AID/V69FMT,<GVU]AW$JQ.:_12BK>*Q#CRNM4<?9*C9R=O9+54_\
M/D0J%%/F5*"E[1U;\JO[1VO._P#,[+4^0?VROV'O@+^W;\-H/A?\>M(UF]T.
MROAJ.EZGX9U5-#\1Z1<EX&G;2]7-G>O:"[6WABNPD)\Z) C'%>(?#C_@E-^S
M#\*/V/\ XC?L1^"-0^+.D?!SXHZ[JGB+Q/>Q^/F_X3L:AJ[Z5)>C3O%":5&U
MG;2'1[0"'[%+M7S1N/F?+^EM%*.(KPA&E&K.-.,U4C!2?*IQ:DII;*2:3OW'
M*C2E-SE3@YRBX.32NX-6<6^J:/C?]B[]A/X ?L%_#[5?AO\  +2=<M-&US5E
MUO6=2\4ZM'KWB'5=16 6RSWVK"RLI+@B( ?-%DGDD\8^?OBW_P $@OV1?C%^
MU)H_[8&LI\3?"_QCT?7/#7B!+GP'XV'ACP_?W_A;[/\ 81JFCP:1/]LM[DVR
M'483=)]K+2?-'NP/U)HIK$XB-2=55JBJ5$XSFI/FFG:ZD^J=EH^R!T*+A&FZ
M<.2#3A&RY8M;-+I:Y^>_[:'_  3#_9*_;R.FWGQW\':F_B#3(%M(O%W@[4K?
MPWXKN+&-=D%C>:P-.O9KBTM@7-O 558C(^WAL#S_ /8\_P""/'[$?[$/BEO&
MWP@\%:]JOBN, Z;KWQ$UNW\7:CH<H;)N=$N)-*LGT^Y*EHS+&2WENR#&<U^I
M%%-8K$JDZ"KU51:LZ?.^6W:U]O+83P]!U/:NE!U/Y^5<WWGQI^V'^P3^S;^W
M-X7L/#'Q\\'RZLVDATTCQ)HES!I/BS2;:1GDFL]/UM[.\FMK.>9_.E@2/:\J
MJ_!'/R-^R_\ \$,OV OV3O'UG\2/A_X*\6^)_$>FR"XTP_$SQ+;^,K#3;U"'
M@O[&TFT>S$%[:RJLUM.LFZ*50XR17["44HXK$PINC"O5C2=[TXSDHN^^B?7K
MW"6'H2FJLJ4)5%:TW%.6FVOE96/@/]MK_@FM^S#^W]8^'K+]H+1_$]XWA9YW
MT6^\*Z]'H&H6AN(Q%*%NFT^^;#1C;A57@GKFO&/V5/\ @BM^P9^R#XHB\9?#
MCX?:UXF\1V<HGTS4OB=K-KXSFT>Y'W;K2C/I-F;2X3D+(I;"DJ00:_6.BG'%
M8F-)T8UZL:3_ .7:FU'5WVOW!X>A*I[5TJ;J:>^XIRTT6OD(JJBJB@*J@*JJ
M %55&  !P    !P!Q2T45SFP4444 %%%% 'B_P"T/\!/A]^T_P#!KQW\"/BG
M;:C>> ?B+I<6C^)+?2;T:=J,EG#?6NHQ_9+UH+@6\JW5E XD\F3 4C'.1^)T
MW_!LA_P3.N&WSP_'Z5N<%_BRI(!);:,^&^%&< =A@5_0S1711Q>)H1<:->I2
MBWS-0DXIRLE=VZV27R,:F'H5FI5:5.I)*R<HIM*][7>MK]#\VK7_ ()2?LA0
M_L<^$_V&[SPUXDUKX*>!IM2N?"L^MZ[!J/CC1KK5M6O=9O+FR\42:8KP3->W
MTK*\5F@V1P*RL85:OFKX>_\ !OG_ ,$XOAUH7BO0M/\ !'CG7_\ A+;1K.YU
MCQ9XNM]<UW24=94>70=2ET.)],N&$S9E1)#\J<?+S^W5%..,Q<5-1Q%:*G-U
M)VG)<TV^9R>N[:NWU8GAL/+EO1IOEBH1O!>[%*RBM-$EHOEV/YP?^"KG[,?P
MP_8[_P""0'Q ^"/PC/B!/ _A_P JYM)/%6L_VWK!E:2Q@+W6IFVLQ)^[C0 F
M%/F&<G/'R!_P3(_X(]?L4_MU?L.?!?XG?&?PWXNM?&<%I(DVN> /$L/A:?5P
ME[=.LNK3)I>H2:C(>(R[NFV.-$&1T_JO^+OP8^%GQ[\#ZM\-?C'X'T+XA^!-
M<C6+5_"_B.W>ZTN_C5UD5+B*.2)V =$88=>5%+\(O@S\+/@)X'TGX:_!SP/H
M7P\\":%&T6D>%_#EN]KI=A&SO(R6\4DDKJ"[NW+MRQKJAF-2&%=*$ZL<1+$.
MM*M&5KQE#E:;3NVWJ]+?,PE@H2Q"J2C3E15'V:IN-[----*UDDEO>^KT/.?V
M8?V2_@?^R#\.H_AC\$/"4/A[P\7274+BX\BYUC6YHQ(L4^MZA';6W]H31)+*
MD;R0C:DC@#YC7YZ?&_\ X(*_\$]_CY\5]4^,/B_P?XYTCQ'K>JRZWJ^E^#_%
ML'A_POJ6J7%PUU=WEYHL>BW"337DS%KIVG)ES\QK]GJ*XX8G$4ZDJL*U2-2?
MQS4VI2UOJ[Z_IT.F5"C.$82I0E"/PQ<4U'T5M/D?F#\,/^"0O[%_P:^//P\_
M:(^&GA/Q+X1\=?#30H="T"PTC7X;/PG=11"Z4ZAK.A0Z6BZCJTT=W+'-?&YB
M:2,(A3"#/CO[1?\ P04_X)]?M-?$[6?BSXZ\+?$#0?%.OWGV[5(O /C&'POH
M]Q=$*&F;3X]$NQO;;EB9B26;UK]H**I8S%QFJD<164U'D4E.7-R7YN6]]KN_
MJ2\+AW'D=&DX\W-R\D;<UDKVMO9)?(^7OV4_V.O@+^QCX /P[^!'A&/P[I-Q
M+%-JNIW;07?B+7IK<2+:RZYJT5M:OJ,EHDTL=LTD0\I)'51\QKUGXN_"OPI\
M;?ASXJ^%OCB.^E\+>,=-DTK6$TVZ%E?&UD96)M;LQ3>1*K*K))Y;[2,XKTBB
ML95)RG[24Y2J.2DYR;<G):IW>MU96-5""@J:C%02Y5%)<MNUMK'Q?^Q!^P=\
M"O\ @G[\-O$?PK^ (\9#PMXI\8WWCG53XV\1_P#"3:FVNZA:VMG<&"]^PV'E
M6GDV<(2 Q,48,=YW8'SS^V;_ ,$;OV+_ -NOXAVGQ1^-6C^/;'QA;Z>=.NK_
M , >+D\*+K,($212:TBZ3?-J$]O#!'!!+)(OEP*(P"*_5:BM(XG$1JNO&M4C
M6E?FJJ34W=).\MWLON1#H4735)TX.G&UH-+E5MK+R/G;X@?LK_!/XJ? O2?V
M=?B)X0M/&'PST/PQX>\*:;I^O1V^H7UM9>%],M=)T:\2\GMW U6UM[."07JP
MJ3<J9O+!P!^3-C_P;=_\$T['Q6OBW_A'OBU>72W9N_[+O_B'%<Z"[%]_DOIC
M>'U1K?/RF(OC;\N>:_>^BG3Q6)HJ2I5ZM-3;<E";2;>[=NKZL4\/0J.+J4J<
MW%)1<HIM);6OV/Y]O^"VWPM\ _!#_@E[??#3X:>'M-\(^"/"M[:6.CZ+IL$-
MI9VL,>GWWS,D*11M*YY>0J"QP.  !\2?\$S?^"-?[$7[</\ P3Q_9:^,/QC\
M->,+7Q]=:7XNFU77O GB>+PQ-KTD/C/6+.V.M,NEWS:A]EMK&&&W+NICC+IR
MNW']27Q?^"?PG^/W@Z[^'WQF\":!\1?!5^XDO/#GB2V>ZTVX<*R!I(HY8F)"
MNR\..":M_"7X0_#/X$> =!^%OP?\&:+\/OAYX7BN(/#_ (2\/6[VVCZ3%=74
MU]<QV<#R2NBS7=Q-.X,C9DD8C&<5U0S"=/!JC3G5A7^L.LZL963C*+BXMI\S
M;;3=U;2][G/+!PGB75J1ISI>Q5.-.2O9QE%II-<J22:5G?4\D^ W['?P'_9K
M^#-]\"OA)X37PYX*U72]6TG5ID:V;Q!JL.LVD]E>W&HZQ%:0275V8;B4Q321
M;8Y&+B,L6W>/_L9?\$U/V;/V$?$7Q$\4? M/'JZI\3@!XE/C'Q7_ ,)';A5O
MEU!4TV'^SK'[$BW"C"AI!LROO7Z!45Q>WK-5(NK-JLTZJ<G^\:=TY=[/:YU*
MC23@U3BG25J=DER)I)J/:Z27R/SAT;_@EI^R]H7[9WB7]NZP'Q%7XY^+-5@U
MC5Q)XQW^#'O;>VMK6,P>'!IB^5'Y5I$&0WS;FW'(S@-T+_@EC^RWX>_;)U?]
MN?3X_B'_ ,+NUNW>WO(Y_& E\%*CPQ0,\'AK^S%\J7;"C!_MS8?+8Y(/Z045
M7UK$:_OJFM-47[S_ (2M:G_@5E[NV@O84=/W<-)^T6B_B?S_ .+S/E']L;]C
M3X.?MS?!_4O@A\<%\4_\(7JEU:W=Q)X/UW_A'=;26TGBN(_(U/['>F)6DA02
M*(3N3*Y&:U_@_P#LE_!KX*_L\Z7^S!X;T:^UOX3:7X>_X1C^RO&-Y'X@O=1T
MKRU0)JMW);6Z7LPV1R>:UNG[R-'VY45]+T5'M:OLU2]I+V<9^T4+OE4[6YDO
MYK==RO9T^=U.2/.X\KE97<?Y6^WD?C)\(O\ @@[^P+\$_P!H'PO^TGX)T+XE
M)\0?!GBB#QAX9M-4\<1W_A72-;MKA[F">TT+^Q(5BCBED?9&ERI53@/WKW_3
MO^"6O[+VE_MGW_[=]HGQ#'QRU&)HITD\8!_!2EXDA,L7AK^S!Y<VU%82?;CB
M3+8[5^CE%:2Q>*FVY5ZLFZ;I-N;;=-N[A_AOK;N1'#4(I*-&G%*:J)**5II6
M4O6VES\=_P!J+_@AC^P1^UO\2=0^*_Q+\+^.M'\7ZO>S:CJ]SX!\70^%K75;
MZXD::>[O[>/1KPW$\LKF221Y=S-SFOL[]D7]AW]G;]B/P9<^"O@-X/\ [&MK
M^<SZGKVK26VI^*M5RL(6#4-<2SM)[BV1H%E6$H$\TF1MS!-GUU12GB<1.FJ,
MZU25**2C3<VXI+;2]M.@1P]"$W4C2A&H[MS44I.^^H4445@;!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7^8?_P<H_\ *6[XS?\ 9/?A-_ZC5?Z>%?YA
M_P#P<HD?\/;OC-S_ ,T]^$W_ *C5?7<%_P#(UJ_]@=7_ -.43\X\4?\ DFZ?
M_8QP_P#Z9Q)^$<??\/ZU)4:$<\^G]:DK]7CM'TE^:/YN+%3KT'T'\JKY'J/S
MJ<$8'(Z#O51V7HOR.<=4R?='X_S-0U,I&T<^O\ZTCLO\:_(YR:/O^']:L1]_
MP_K5="!G)]/ZU/&1SR.W?ZUJ8S^)_P!=$2TJ]1]1_.FY!Z$&G#J/J/YUI'XO
M^W5^2.>?Q/Y?D64^\/Q_D:FJ%/O#\?Y&I<CID9],UK'=>J_,PGNO3]66:*,C
MU_R>GYT5I#9^OZ(YI_$_E^2)UZ#Z#^56%Z#Z#^55QT'T'\JL+T'T%6<\_B?R
M_)"U8JO5BMX[+T7Y'//XG\OR1)'W_#^M3IU/T_J*@C[_ (?UJ=/O'Z?X54=U
MZK\SGE\3^7Y(EI5ZCZC^=)2CJ/J/YUN<\_B?R_(GJQ5>K%:4^OR_4QJ=/G^A
M8HI,CU%+6ASU.GS_ $)UZ#Z#^56%Z#Z#^55U^Z/H*L+T'T%:QVCZ2_-?Y,YZ
MG3Y_H+2KU'U'\Z2E'4?4?SJS,GHHHJX;_+_(QG\3^7Y(F3[H_'^9IU-3[H_'
M^=.JX_:_Q,DG7H/H/Y4M(O0?04M-;+T1SA4Z]!]!_*H*G7H/H/Y52VEZ?JB9
M_"_E^:%J5.A^O]!452IT/U_PK2&S]?T1B/J=>@^@_E4%3KT'T%69U.GS_06K
M%5ZGR/4?F*?1>K_*),OL_P"%"T4F1ZC\Z6K7Q1_P_H_\T9S^%_UU0].I^G]1
M4M1)U/T_J*EK0Q)D^Z/Q_F:=3$(VCD?Y-/IQW7JOS,9_$_E^2+%%)D>H_,49
M'J/S%5#?Y?Y$77="UM>'M!UKQ1K6F^'/#NF7FLZ[K-Y;V&F:9I]O+=7=W=7,
MJPQ1Q0PH\C9=P68+M1 SL0JDB/0=!UOQ5K>E>&O#>EWFM:_KE_:Z7I&DV$+3
MWE_J%[,EO:VT,:\EYII$C4L54%@695R1_=1_P1O_ ."-^B?LM:-HW[0W[0FB
MVFL_'_6;*&^\.^'[^#S;?X7VEU"KQJL4T:O'XK,4UQ9ZFPDN+1(_+$/S@LOS
MW$_%& X8P+Q.):JXFHI1P>#C)*IB*J77=PHPNG4J-62TBI3<8O[CP]\/<X\0
M<XA@,!%X? 4)0GFF:5(2E0P6';U2V57%5$I*AAU*+G).4G"G&<XO_P"".7_!
M''1?V6]$T;]H/]H;1K'6OC]K-I!?>'_#U[%!>67PQMI-DL2JCBX@?Q1'(AD3
M5K.=!#;7#0>6'R5_HGHZ=**_EK.<YQ^>XZKF&8574K5':,5=4J--/W:-&#;4
M*<.BNVW>4FY-M_Z+<+<+9/P=D^&R3),,J&%H13J5'9U\77:2JXK%5$DZM>JU
M>3TC%6A3C&$8Q11117E'T84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"GM/^2:R'_PT8#M_V#^1^0?_  X<_P""5 _YM2T'_P +#X@'^?BBE_X<._\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN.O_B!
MX+TN[EL=0\1Z;:7<.!+!+*PDC)Z!@$(&?K53_A9_P_\ ^AKTG_O\_P#\;H [
MRBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\
MA9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\
M_H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^
M_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\
M&Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_
MP_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:
M])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_
M /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [
MRBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\
MA9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\
M_H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^
M_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\
M&Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_
MP_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:
M])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_
M /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [
MRBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\
MA9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\
M_H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^
M_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\
M&Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_
MP_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:
M])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_
M /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [
MRBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\
MA9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\
M_H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^
M_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\
M&Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_
MP_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:
M])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_
M /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [
MRBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\
MA9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\
M_H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^
M_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\
M&Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_
MP_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:
M])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_
M /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [
MRBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\
MA9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\
M_H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^
M_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\
M&Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_
MP_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:
M])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_
M /QN@#O**X/_ (6?\/\ _H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [
MRBN#_P"%G_#_ /Z&O2?^_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\
MA9_P_P#^AKTG_O\ /_\ &Z/^%G_#_P#Z&O2?^_S_ /QN@#O**X/_ (6?\/\
M_H:])_[_ #__ !NC_A9_P_\ ^AKTG_O\_P#\;H [RBN#_P"%G_#_ /Z&O2?^
M_P __P ;H_X6?\/_ /H:])_[_/\ _&Z .\HK@_\ A9_P_P#^AKTG_O\ /_\
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M[FIUZ#Z#^5>?_P#"S?A__P!#9I7_ '\D_P#C=2#XG_#\ ?\ %5Z3T'_+9_\
MXW03)-N+[/7[T=[17!_\+/\ A_\ ]#7I/_?Y_P#XW1_PL_X?_P#0UZ3_ -_G
M_P#C=!1WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!W
ME%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +
M/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T-
M>D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^
M-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\
MA_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I
M/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#X
MW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'
M_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_
M /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]
M_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\
M+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\
M]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y
M_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!W
ME%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +
M/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T-
M>D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^
M-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\
MA_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I
M/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#X
MW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'
M_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_
M /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]
M_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\
M+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\
M]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y
M_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!W
ME%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +
M/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T-
M>D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^
M-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\
MA_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I
M/_?Y_P#XW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#X
MW0!WE%<'_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'
M_P +/^'_ /T->D_]_G_^-T?\+/\ A_\ ]#7I/_?Y_P#XW0!WE%<'_P +/^'_
M /T->D_]_G_^-UMZ)XL\-^(Y+B+0]8L]3DM422X2U=G,*2$JC/E5P&(('T-
M'0T444 %%%% !1110 4444 %%%% !1110 4444 4I--TZ9S)+864LC?>>2U@
M=V^K-&6/XFF?V3I7_0,T_P#\ K;_ .-UH44 9_\ 9.E?] S3_P#P"MO_ (W1
M_9.E?] S3_\ P"MO_C=:%% &?_9.E?\ 0,T__P  K;_XW1_9.E?] S3_ /P"
MMO\ XW6A10!G_P!DZ5_T#-/_ / *V_\ C=']DZ5_T#-/_P# *V_^-UH44 9_
M]DZ5_P! S3__  "MO_C=']DZ5_T#-/\ _ *V_P#C=:%% &?_ &3I7_0,T_\
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MH44 9_\ 9.E?] S3_P#P"MO_ (W1_9.E?] S3_\ P"MO_C=:%% &?_9.E?\
M0,T__P  K;_XW1_9.E?] S3_ /P"MO\ XW6A10!G_P!DZ5_T#-/_ / *V_\
MC=']DZ5_T#-/_P# *V_^-UH44 9_]DZ5_P! S3__  "MO_C=']DZ5_T#-/\
M_ *V_P#C=:%% &?_ &3I7_0,T_\ \ K;_P"-T?V3I7_0,T__ , K;_XW6A10
M!G_V3I7_ $#-/_\  *V_^-T?V3I7_0,T_P#\ K;_ .-UH44 9_\ 9.E?] S3
M_P#P"MO_ (W1_9.E?] S3_\ P"MO_C=:%% &?_9.E?\ 0,T__P  K;_XW1_9
M.E?] S3_ /P"MO\ XW6A10!G_P!DZ5_T#-/_ / *V_\ C=']DZ5_T#-/_P#
M*V_^-UH44 9_]DZ5_P! S3__  "MO_C=']DZ5_T#-/\ _ *V_P#C=:%% &?_
M &3I7_0,T_\ \ K;_P"-T?V3I7_0,T__ , K;_XW6A10!G_V3I7_ $#-/_\
M *V_^-T?V3I7_0,T_P#\ K;_ .-UH44 9_\ 9.E?] S3_P#P"MO_ (W1_9.E
M?] S3_\ P"MO_C=:%% &?_9.E?\ 0,T__P  K;_XW1_9.E?] S3_ /P"MO\
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M , K;_XW6A10!G_V3I7_ $#-/_\  *V_^-T?V3I7_0,T_P#\ K;_ .-UH44
M9_\ 9.E?] S3_P#P"MO_ (W1_9.E?] S3_\ P"MO_C=:%% &?_9.E?\ 0,T_
M_P  K;_XW1_9.E?] S3_ /P"MO\ XW6A10!G_P!DZ5_T#-/_ / *V_\ C=']
MDZ5_T#-/_P# *V_^-UH44 9_]DZ5_P! S3__  "MO_C=']DZ5_T#-/\ _ *V
M_P#C=:%% &?_ &3I7_0,T_\ \ K;_P"-T?V3I7_0,T__ , K;_XW6A10!G_V
M3I7_ $#-/_\  *V_^-T?V3I7_0,T_P#\ K;_ .-UH44 9_\ 9.E?] S3_P#P
M"MO_ (W1_9.E?] S3_\ P"MO_C=:%% &?_9.E?\ 0,T__P  K;_XW1_9.E?]
M S3_ /P"MO\ XW6A10!G_P!DZ5_T#-/_ / *V_\ C=']DZ5_T#-/_P# *V_^
M-UH44 9_]DZ5_P! S3__  "MO_C=']DZ5_T#-/\ _ *V_P#C=:%% &?_ &3I
M7_0,T_\ \ K;_P"-T?V3I7_0,T__ , K;_XW6A10!G_V3I7_ $#-/_\  *V_
M^-T?V3I7_0,T_P#\ K;_ .-UH44 9_\ 9.E?] S3_P#P"MO_ (W1_9.E?] S
M3_\ P"MO_C=:%% &?_9.E?\ 0,T__P  K;_XW1_9.E?] S3_ /P"MO\ XW6A
M10!G_P!DZ5_T#-/_ / *V_\ C=']DZ5_T#-/_P# *V_^-UH44 9_]DZ5_P!
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M;_XW6A10!G_V3I7_ $#-/_\  *V_^-T?V3I7_0,T_P#\ K;_ .-UH44 9_\
M9.E?] S3_P#P"MO_ (W1_9.E?] S3_\ P"MO_C=:%% &?_9.E?\ 0,T__P
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MT#-/_P# *V_^-T?V3I7_ $#-/_\  *V_^-UH44 9_P#9.E?] S3_ /P"MO\
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M -DZ5_T#-/\ _ *V_P#C=']DZ5_T#-/_ / *V_\ C=:%% &?_9.E?] S3_\
MP"MO_C=']DZ5_P! S3__  "MO_C=:%% &?\ V3I7_0,T_P#\ K;_ .-T?V3I
M7_0,T_\ \ K;_P"-UH44 9_]DZ5_T#-/_P# *V_^-T?V3I7_ $#-/_\  *V_
M^-UH44 9_P#9.E?] S3_ /P"MO\ XW1_9.E?] S3_P#P"MO_ (W6A10!G_V3
MI7_0,T__ , K;_XW1_9.E?\ 0,T__P  K;_XW6A10!G_ -DZ5_T#-/\ _ *V
M_P#C=']DZ5_T#-/_ / *V_\ C=:%% &?_9.E?] S3_\ P"MO_C=']DZ5_P!
MS3__  "MO_C=:%% &?\ V3I7_0,T_P#\ K;_ .-T?V3I7_0,T_\ \ K;_P"-
MUH44 9_]DZ5_T#-/_P# *V_^-T?V3I7_ $#-/_\  *V_^-UH44 9_P#9.E?]
M S3_ /P"MO\ XW1_9.E?] S3_P#P"MO_ (W6A10!G_V3I7_0,T__ , K;_XW
M1_9.E?\ 0,T__P  K;_XW6A10!G_ -DZ5_T#-/\ _ *V_P#C=']DZ5_T#-/_
M / *V_\ C=:%% &?_9.E?] S3_\ P"MO_C=']DZ5_P! S3__  "MO_C=:%%
M&?\ V3I7_0,T_P#\ K;_ .-T?V3I7_0,T_\ \ K;_P"-UH44 9_]DZ5_T#-/
M_P# *V_^-T?V3I7_ $#-/_\  *V_^-UH44 9_P#9.E?] S3_ /P"MO\ XW1_
M9.E?] S3_P#P"MO_ (W6A10!G_V3I7_0,T__ , K;_XW1_9.E?\ 0,T__P
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MQVJS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img136305557_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img136305557_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "W >8# 2(  A$! Q$!_\0
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MD@$[1Q[UYUX1\3^9;BSEB-L0O[M6/)&/U-7/$&LPZ3"MS<L(X <EB<#&/\:
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M92.3D'W_ $IH#KK-VEMT9N2<_P ZL52TAMVGQ'.<YYSGN:NTQ!1110 4444
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M"5HR V2"N3Z'-5O"MK)9:#:MJ4<<FIQ1!)I0JEF;&.O7DUS%K^T%X=C\4?\
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MIEI&H59;1IS*,Y.YPS<\Y]:ZS4_@YX\AL%DO8;/5[E&^9&VY$8QCYAAL_C0
MSPW\8/"OB&=QXIT#^Q!<.0]XZB2-7!QM8@9 _/%>@Z=\(= O5M]6T:9;F%V$
MA>%A(C@9QG^5?*WQ;\$:]%?175SX6>2%8BP6U9P%/1L <9K"\,>//$?@^3[;
MH>NZIIQM(@5LIHS(L@[KQQGUS0![?^U+\+]4@T&W\0>&+9G90([U;>+]YM(.
M& ^O!_"OE6.*^UK3IDU*5[*[7C,J'(8'H<]^]?9'P9_:_P!,\9F+0_%NF26N
MH2H(A="$^5.^<8QV)%>E:K\+? GCB&2S;1+-E\SS /*VL'/H>O/Y4 ?$7PV\
M*Z/;>/;!%LKK6;'[7;2:EJRQMY5FJ-N89 P!P,GM7U5XKN'\;^*/[=TZYV>&
M=,@,5K/'&&6[G?J5'=0,#/J:I>)/!=CX2GOX[/0YK;3C!O"P32+;.1_ST5>O
MXUMZ;XKEA\.6$.E:%#+=OB-5M<O!'QU_*@#TKPO"$T*U5S()VB4L'&%W#KC\
MZZ2VB,K8WR!U. 4Y(KYDN/'/B;P_XB5[IKJRED)5K65&DB<@YXYZ9!Z5J:SX
MJU_7&+ZIXI_L6W>+?$+!A&02>ASDD^U 'T>+BTMU:*;4+=+W.<22 $-CN*^:
M_BOX5UO7-0>YMM3CN[@3#S$,R% IYPJY[>@KEO#M_I>GZS>M/KEW.TA!\R1L
MNW^\<=3Z5NWUC:P6+2P:9J%_:@D0Q2.X9R<?-P,CO@4 :>G>%/$5AIS2V6H7
M+V\T05[;RGCW8Y]<9[5CQ_"3QIX]:SAOH[JVCC9BTA81HD9_@"_Q''K72_#'
M_A)K+68I)+:\@LID^:"0-^[]&)/7ITKZ,TR6YCTR)KQ3YFT$[ !G\* .>\)Z
M!HGPG\,HDUQ]GAA0(9G.3DCICJ3[5RFI?%[3+W4-0L]+M[C5KNT($D$(*8],
MEN!]*Z_Q3HEGXMA2TU*V\VU27<H#%6!'<$>A-<'H'PB'P_UF_P!1M_M6IVNI
M,&F+ONE1N<9]1VXH \UU[XS:SX5UJ+7+S1?(TE;I()K>>-4:&)CC>'!.YMV,
M@CITKU_5/C$EII GL[>.X8H'W"557GOGT YK@_%/P+N?B'J#3M?R:3I>_>UE
M. YF;'WCGH!V%:=O\!;6QL8[2TM]P1 K7,-R1Y@/!WH<C\L4 <;/^U#KMIK,
M\=U#IFJ6NS(@@;RYQC^ZVXAL]L"O,/&OQ"T[6]8E73+JY\(7LN9);'41^Y?<
M.2' (7KT->J^)_V--+UA_M6G:K<Z5=IPD@C5PO';-<[;_L1E+.>*Z\5W5[<.
M,B66$;<^XS0!Y-HVF?$OPY$;O2=1?4K?S"W_ !+KA7W'))!P>XYJS;?M$?$;
M3=3>R2[-NWF LTP+^7CJI7'YUZ#XE^#7Q#\'V-M:Z'#!JL,/"&(B-@-O/&>3
M^-<)>(][=16OC'1+JRUI %6Z*O&P_P"V@ZG'KD4 ?0'@?QCHOQCLK4:I9S:9
MK\:AF:,%=X!ZQMW4GG&<BNPU'P(JQR6]R[:E:'#-%-@GZY]:\*\,Z-HECJ^E
M7<NI:U]GMCM6.3RV0J.,\8/6N[\9?%K4_ .O0SB8:IH;LJI%)@,&P,KGL<=J
M *%Q\(;32];BUO0'@@E!VR6<T>UBO7I[=*[SPM\3K_2-4@CN%$"."D^!N!8'
MA@.PK>\.:]X:^,&BR2V\C+.A*,N#%+&X]NOX]*X_5/AZ^E,XCU"9;N(DQ32\
MJXYP#[C- 'I>E_$+2_%>HM:1:@+6X7E4D&S?],_>'TKL["4NX2:-BO&T'Z"O
MG'PAH4FO3R:C&J"XMI'1G![CT'<'VKU70_%>IZ?-'"UH7A5<O([GGGT_'K0!
M],^"QCP[;CGAFZ\]S6]7(?"W6H?$'@^VO(D" RRH5!!P5<J?Y5U] !1110 4
M444 %%%% '"_&L9^%GB0<G-OT S_ !"OCJ(+'&I9$W$=#[^M?9/QEP?AAXA#
M#(^SG(_X$*^/HPKQ* @R$P"PX-=E!:-GQ^=O][#T-[P]$LEW"N%'S8R.IKV:
M^FBT7X<W<< #3[F94P ,?7ZFO$M*G6&2&7!9U<=_?^5=UXD\3V=[X5EL);Q+
M2YW!H<O@L><CG\..]566BU./ S45+N?.<$E[9)J-M-&R3RWDCR_-GDD8(-7F
MU*./1;NW=I"[*$QC!()Z9_"KNJ6MMI>J/#',L^?F/F#YF/J>V>*P-5U*)X7!
MA'F[U,:>N#R:.:/PGE-25Y%"]NQ'</%$P.[Y<^A%>0_&J]N;GQ9X?2%)9(+&
M%PTDAP#(W3GKBO4])M4U_4&DDFQ#"7W,<8!SVXKC]9M+7QS\1XM-TZ=;BRT^
M16O'1.FT#:H/NW7Z4ZB]I%1OK>Y>$E[.;G;2UOZ_(]5\,Z8=(\+:=;D 3>6I
MD;OO(!;GUR2:]#^#H/\ PLSPUP"!>H,^O-<YY44<42$Y'4 #IWKLOA%$I^(7
MAYT3*I=IECP.O\ZW:M%MCHRO7@EW7YG<_&>26'XMVLNG2FVOA(BR[E^66,Q-
MD9^N.*\6_P""C/A""/X)>&?%\ULD.I:=J:6[A0 )8I4.0WKR :]:_:*U*;3_
M !AJ,]J^VY@-NZ C(;C'/YG\*^)/VW?C!<^+/"^G>&;[5)[Z_BE2X:V16V0[
M=P);C'0C%>%B'!QC!K<_6<)SQJ<\7L?)>M6\3XEC2-!OVCR^-V1UQVK.@B$E
MO. Q\Q2#M!QD=ZMP6UQ/IZO"-X/R,B\GUZ=JH*,)O(![8/6I@K1Y;['HUW>:
MJ<MN9?U8?&Y5B4RG&>3S6B-.EO)R(R$C4!B$;/)[BLE9&CPV,_[U;5A>K,K!
MW1%9@Q4+R,"BI=*\2L+R3?)-_H=%X0DN]*GU0^?"T9MI!Y<L@7>P7H >_IVS
M7VI^SO!J&G_"B&ZU*"Z:6^9EEBG7/S(2#ANXQC'I@U\Z_LN?"Q_C5\0AH)L/
M*M'B827LT188[#G@<^E?;NE?"37O@9\-+/PWK,W]IV\.KN;&^B9BRV[)PKYY
MZCCGH:\RC"4L4I./S^1Z&,KP>$]E&=[=+^?]6^9Z2WQV\46]C#% T"BWC"J[
MP@^>3C9[ J,CCKWKS3Q/XNOO%&H7&HZAHY:^D(W2I(%C<XP"%_"G3WD3>8C(
M<Q E.?FVDX_ @_G5'4=2\JRW%E#XPL0&6/\ GK7U,$EJ?#R;>A[+^RS?W,_B
M/7&FT[[-FSCPN\$_?-%0?LF7!N?$>NR22JQ-G'U.<?.>**YYZR9<;V.N^(P2
M7Q/?*1N^=0<'GH*X]HU"&+9E2!C/)Z=JL?%KQ7=:!XXU??:.]JKJ?,V\8V#I
M[5Y>OQDB+!X[>260C_5^7SGT^N:R-CT1=,M7*N80K*/EP/F'XUSNK:9J<$+F
MR!+%B41R%4^^?6J_AGXR:3KNKKI,B/:7Q&2DF,*>A!YZUW%W;++("9 <G SR
M/I]: /-K/6O%]T%MHK9XF VS29XQ_LU>T>RU-[P"^O'R3AD9^N#_ "KL)-.E
MN8OW%TUL4(<NG!//3Z'I55?#[RM)=22GS!EE.,?7\* (+C0(]37RKJ..XMR?
MF609^E<3\0?A;;2:$S:5X:LKB\12,@;"J^Q'.37I^C&X\U5F97 &?,VX!_R*
MX[Q?\>](\'WYTTZ<UW<N<*@8)D_Y% 'RO=?$B/X:WDUG#X>OK9T(#+M"H#_?
M!=>O7FO2?!'[0=H-2M(I[*%TG7?]I$R[XR.QQ^0XKV#PE\4/!OQ0S8W5M:V]
M\X(>RO3&^?Q/7/IBJFO?LP^![I6N=-L/[*N02%EM.!ZG(.1C/I2 JZ;\7O#^
MN;8KP2VRS-Y82X VD'OZ8-==H%EX6MK98].N[:+>V!$DB@AL=@/?TKR.?X(>
M+K'57BBOK'4;)% C%RK+P<]<#^59</[+^OO>-?#4+:QE1_,1H9'W>XY'?I3
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M*+L>;2ISIUX*::U7YG7?M)GR_&-\RJ=YA3#J.?NYYKRGXY?LMKXG^'=_XO\
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M^UO.GHGK:^VMRL;C8+W9*[M:_?2USRK6[?Q#/XGNT$2KI[JWV28Y;:><$]\
MY!'7%)H6E:I%IL#:N;>75MY6Y-FC)$=I.&4-D@8QD$]:[ 6T&G:;/I\MVUU,
MKD"9F*E"3E?SS^E4'FG@L;2"Z4K)&Q,C@_>)R0#Z\<U]I3C9:GQ$VF]#V#]F
MN!(=<U<942_9(PRC_?/:BG_LX303ZOJTZR*TDELA8 \CYJ*YZK7.RX?"?/WQ
M2_:6U'PG^T'XP\+W6G+>6,5XB6YDRAVF)"<-C&,DUZ/X6\5Z9XPTJ2>PF_>
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MMNW6Y#^7P< /_=ST!]LUT@NHY8U 96 &-RD'/O1L!RDNG-JE\D\DS"53A"O
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MBI*+::&HC*$@@GGBI/[+.W 8=,9]J**+ 5I= :1@PD4D=B.M26^C&(-AUY[
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EOX)U#PEJ=_)=&,0RQ*L;!]Q."<\=NU%%%85:LG-LWITH\J/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img136305557_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img136305557_2.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &@ B0# 2(  A$! Q$!_\0
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M^5*TL:;M\B+M 9MS*-JG@$Y/ )X!/!-'U?#_ //BC_X*A_\ (A[:M_S]J_\
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M];2K*$Z+-=6?_"8VNG7-M<>+?#FB6]O<R:;X5GF@L7U.:WN[B1DMC%)\D?\
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M^@K>0R6D'BCP3XE\0WUSJ'AKQ#ITV"=.\2^'[N2QU"QNE)A:97($L"D?I?\
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M\LN>C5<FYT>32%*$4TE-TTTYQ3::BDD?3?[#']J^-/A]\7O'O[/W_!//PO\
MM%?M/:Y\5]2UG6/B-\7-*T23]E+X$_#;5YI;^'PMX2T[Q%K^AZ-%XNEN9_)C
M@U&XNI[;2418$98\'Z'_ &OOAWH/[*OB?_@GQ^UO-^RK^SCX$^+GQZNO$W@+
MXV_ /3X=/^(?[/\ 'XJT7Q9I%GI_Q*\&V6C:S=:7IFO7.GS&^C@L-1GBTW46
M3S5,T+AODWX%_'7]D#XJ?\$^=!_8F_:(^.7Q2_96\1?#CX[^)OC)HWCWP'\/
MM;^)/@_XH6/BBR2VFT?QGX=\.WEKJ3:YH\:&'1[J[8V%LQCE#*AE0R?MF?M,
M_L9:_P#LM?L(_!;]D[6/BGJTG[)?Q-\;ZCK>E_%70Y-.USQ-I&KZI8^('\:C
M5K;SM&A;Q3K5M<RVOARWN'N-!LKJ"VN5+6[,[<*DL4E[.LHNM5A4]VORNA[&
M:@W6=3V3A*2@XPC!.#6LE*_.*<%1?OP;5.G..M)-554@Y)4U'VG-%<W-*4K3
M5[1:MR_H9^V[XG\)?'+_ (+R_ K]G?Q[\%?@Y=^#-+^,_P (K/Q/JUOX15/%
M'Q2TCQ1X%LY[C0OB9J4MS+%XCT?3?EBTFS:VA6VACC1S(%Y^3_AU\!?V>/AA
MX]_X*P_MD_%#X1Z!\1_AU^Q=\>=<^'GP/^ 5YY]A\-M2^(7C#QU?:5X/M?%.
MG6,D<]YX.\+6?V:2/0XY([>8+LE9D"BMCXW?M=_L2>*O^"G/[,'_  44\$?&
M/QO?:=>_$/X8>)?CM\)]7^%7B"PU7X067@?PE!H]_>:;X@W/8^.C?WL92"PT
M**:6%%,IE=755\2^&O[;?[.UW\5/^"COP@^.,/C6\_9$_;R^)WB;QA8^._!N
ME>=XX^&^OV'C"\\0?#OXBP^%-0:&7488H98!JVA,8M06-!&%+!DK.G2KQHTH
M0A7C".$PT*L$JD).4<0OK,(7L^>5/FLX_%&W(VFF5*=)U)RE.E*4L17G"5X2
MC:5']Q*5KKD4N6Z:=FGS*ZD=_I.I_";_ (*9_LL_M>>*=7_9U^$'P#_:<_9
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MI+=7GU7P)K=^L,7B;PO=L':"Y@9KK39A)INI*MS!YLWW#_PT9\"/^BM> _\
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MX7_^2*/[<R[_ )_3_P#!53_Y'^K/RN?V7C/^?<?_  9#_,_C%HK^SK_B%Z^
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M375M9JL%OJ5Q#/J,:(I%T64&OWR_XA>O@!_T=-\7O_"2\+__ "11_P 0O7P
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MY_9>,_Y]Q_\ !D/\S^,6BO[.O^(7KX ?]'3?%[_PDO"__P D4?\ $+U\ /\
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MLK2W2."UM;:%%BA@A1(XT4 #KFR3GT& %  "JJJ JJJJ JHJ@*BJ JJ J@
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M:)=/8Q7#B*:^BM ZJ;H0JK @L%R,^V;2(WE8JD494/+(ZQ1(7.%#2R,J*6)
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MQ!"2;=CD':QQ01A'D8JD48!DED=8XHP2 #)+(5C0$D %F ).* $HI[1NC!7
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M4,TN,^5"'*F:3 ),<89P!G&*:002"""#@@C!!]"#R#2&)1110 4444 %%%%
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M"M+I6KK>:7<JI6>T<'(^6/B#X-^!?P!_X)M?LR?#R/Q?\>OA]H'QE;X)3O\
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M88[3Q))?I/8WEO;ZC!,H0UTNJZ+)\'/V O\ @F-^SS\%?$'BCX2Z+^W/XL^
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MI.C1W_QF^+OC6VUOPS+IUGIU]<7%IH6D7.K1V5Y>7,LD=G.\:H?N#PQ^P)X
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MDJHR2237P_\ "7]AKPI\*/%G[2J+\1O%_C7X#_M.:SXR\4^*?V:_%ECHUSX
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MTPJUO92BK.5X3ERJUWRU*,%JVDG>KHGH];M65_Z3C!,&1#%(K2$+&&1E+EB
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M&[OEBB;Q5\0KN[OM6U#4M4LHX!)IFG:5+8V-K=SSRRF>/:B_:A)/7L
M!@*H& JJ  J@ *    ,4E35Q=2JZMU#EJ5*E11<(3=-U&G)4YRBY1NDD^5QO
M:Z2;N73P\(*G9RYJ<(0NI2CSJ"]USC&24K=.9.U[7:"BBBN4W"BBB@ HHHH
M**** "BBB@ HHHH XWQ7_P A&#_L'VG\I**/%?\ R$8/^P?:?RDHK>.R]%^0
M'94445@ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?6OI"[U*YC=K&*])_=1QSR)E&:3RE\Q<@Y:-0 @3'4$8YP/R_A[P\X@XUS?
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M_89< 9#'P_CQ!0S6IC.(Y8Q4*V C.%'#8.#=G>#ISJ5Y*/+)M3A92LXJVO\
MHOR_\'4'_!)B$D-XB^/A(Y(7X/W9('')!U8'OZ>M6[#_ (.E?^"36HS+!!XH
M^.R.W0S?"*[1!]6&JD =1G/4&O\ ,?U741+*%11$8U*.^\@OP1G+$=AZCKR#
MUJ+PY?/+?"W5I@JN,NA)VAC@,.2#R3D>@SQG(_JSC'Z,W@)P_P /9KC\/B^-
M8X_"X!8C"2JYWA*U!XA<DYJK1CDT)RI1IJI>TXVLFWW_ )VSG'YME\:\J%3"
M5%0E5^*A)W5.UM/:ZM]=4M_E_J*+_P '+G_!+DV46H-XE^-D=I/,8(I9?A3=
M(&9>KY.J8\O_ &P2,<XZ9^@/A?\ \%QOV OC#X>\0>)? WBGXAWVG^&-/N=4
MU:*Z\#RVM]%9VL3S3/';&_<RGRXV*@, 6PN<G-?YCWA[X0_&OXQQ:9X0\"6%
MU=S>2%MU:2.&UP[;?.DF8@1+@@LQ8A1R:^OOAKH'[0W[!?PP^)&N^+M)T^5/
M&=A=>#/*O;IIUM)KJ"1#>6?E,$G)#L%!8JP^8#Y2#_BWQMXDX_"8_.,FX2XI
MX/\ ]8(YQ6PW#^29E3>)Q>88)8OV=.$X0QN'G&NL.I3E44.24HM\BC[I_,GB
M#XV<98'*E@>"N)/#_P#U]Q6:Y?ALIX9S2C/%5<?AL1CZ5'$1G3AF6&J49K"K
M$3A5YK*I"W+)KE?]NU]_P=(_\$GM/>[2X\3?'8M922Q3B/X17;G="Q239C5N
M0&4@$@9Z^H'!3?\ !VS_ ,$>X9&C;Q+^T,S*<$I\&+MESZ9_MD8^OIS7^;B=
M,UVXAO->U1'9-4N[N1K=24W1EW>0Y7.T?-PI&<<#IS\L:L&&IWC;#'&;F8HA
MZI'O.U<D9X' /?!)[U^I\/YMB<REB*>(J8:K.A&GS2PRM!5&DJD/BDVHSYDG
MHFN_3^EN%\ZQ>;?688JKA:T\-"BISPL7&FJLDE5CK*7,HSYDFM++:Y_JAZ?_
M ,'9/_!(#4IHH(/%/Q^26:5(D6;X.W:?,Y"J6_XFYPN2,MC K]Q_@7^U7\(?
MVBOAQX=^*OPTO->N?"/BFQ@U'29-8T=]+U VUP@DB-Q9/+*87*$$KO;&>M?X
M@'AV>&'6])-Q*8+8ZC9BXN 21# UP@FDVY ;9'N.#QP!Z5_J\_\ !*CX\_#G
M4OV9OA/X)TK6M/:QL?"&@6VB:DTT$0OUATV".3S!&Q03^>'5AG(88/-?PU^T
M-^DOXN_1GX'X0XD\(\IR/,L7FN;8C#YU_K!D>,SG"4,%A\-2J/V2PF89<Z-:
M=2K>+E5JOV=.<O9\L7)?TWX8^%]+COA/CK/5A<PQ6*X4Q/#O+#+\327L\#F2
MS-8[$8C!RH5<15C3EA<*H5(.$:/-4YN?F5OU*_:A_;L^"/[(G@\>.?BMIWQ)
MU#0#'-*6\!^#+GQ7>*L S*&M;>XA?>HYVC)(Z5^/T_\ P=>?\$C+6>6UNM?_
M &AK:X@D,4T$_P &+V*:&525:.6-]6#QNI&"K $=^:_5_P",W@W1?B!\.?$>
MC:O96VHJ-(OI[)YHHY5BF%J[+(H<,NPA1OP>5Z'-?Y6O_!4GP-X;\ _M.>.=
M!\,:79:3]I;[9>BUC$,4EY-(SS2H%'RJ[$LB@<8.<=]/V;'TX*7TL<;G'!OB
M?PS"'&>5TOK*QG"LZF3Y;6IN<(QI/!XJ>:3A._-!R^L/WO*5E[7%GA+D</"#
M$<?<+XC'8?.^$^(,!D_%N79GBJ.)PN98'/5CJN69ID\88;#UL+6P?U*6&QF"
MJ3Q*Q/,L31G14)TW_H V?_!U%_P27OR!;>)/CTVX AF^$-T!ST!_XF_I5R?_
M (.E?^"3UMGS?$7QYXP?E^$5T< XZ_\ $VXZ]_;%?Y??A?3K^..&1=1BB+D
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M>F:_E?UW6;V,PPED$;(2D9"M*NX9&UN<( #R#]X#(/-?TY?\&BDES)_P4_\
M$[3<A_V:?B<<DY/%[X>Q^/J./IZ?B?BWXV?VAX"^)_#&5JKB:>:\-YGA,9C:
M2]KAUA9TH<T)5(.47&;47"3=NR[?#9/@E'&8&LE""C7C4C&^KE?7335*Z;MT
MOIU_TM:***_Q;/T@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH XWQ7_P A&#_L'VG\I**/%?\
MR$8/^P?:?RDHK>.R]%^0'94445@ 4444 ?PO_P#!Z?I6HWNE?L"WE@A<V<_Q
MF$A52Q02Q^'CN(P>"L;+QDY(..,U_!9<Z3>S0/*&,AMXPTIDR"@QDC)R" >
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M]8W6I*R:E<V5WI=K<6D^I(X#KJ$MO)&]Z' ;[29-PS6O7F'H!1110!QOBO\
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M%W-<7=U?ZIJ4\MU<SW$\CEBJ*5C1$7O@"2  220  ,DD\  #DDGH*^(/B/\
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M*2+I]PTS?TFEW**A=BBDE4+$JI;&XA<X!.!D@<U(+BX$AE$THE(P9!(P<@#
M!;.2  !C..*SAB^73V::M03O+7]Q0J44T[-*3]ISIM/EE%:-7+>'3^W9WJM>
M[_S]JPJM/75+DY79IM-ZH_E=UW2VTO\ 9T_X+6Z]I/@CX_Z'X,\4:!^SSX@^
M'MY^T!9^*6\>>.M!LAI5JVJQ:SXO#7=\EY>Q-!9:;?7S:CI<<MM#J<-H9E6O
MT)\8^/\ 5/VR_P!IK]@S2_A'\+OBUH$7[+GB[5OB]\:?&GQ.^'_B#X=:1X)@
M7X;GPYI?PXM=8U^RBMO$>J^,M6NHX+Z/PM+J^GQ:=$U[)<L@PWZ;_M!_!OP]
M^TE\&/'WP.\<:IK>G^%?B)I5OI&L7^B7$<>L6EO;ZOIVLK+I\MRDL$<SW.FP
MHYDC8&)Y  &P1ZS;JUM96.GK+*]OI]G:64"R.6_=V=M%:H[#.WS'2(/(0!EV
M8]ZUGC8RBI>S?M;U$KS;C&,L-0PW,W9.<FJ<G9\MI6;NKIQ'#--QYO<]QMJ*
M3E*->I7LM7RI.45=W;5[6>J_G;T#4?&/@3QYX/\ "'[-O@7]I_X;?$K4?CS8
MW/Q-_81^*/@2Z^)_[)6BZ!JWCJ6_\?>/_"OQ,U_PS'H'A717TV27QQX:UGPS
MXE$]EJUPEM!H"7!DQS/BWX1>*/@G\>_VU?"WQ>^+?[>/PV\._M!_&'Q/\1_A
MG#^R_P""++Q]\/\ XU^$O'7AZTTF?0=1OXO!7BB71?'EG)'+X>O['Q1JFCZ6
M+(VES!.D'F2)_2F;BX,?DF:4Q8QY9D8I@'(&W., \XQUHCN)XE*Q32QJW54D
M90>V2%(&<=Z7UZS;]E%*4;2=TYMJ49I\\H2NHN-ESJ<^5M.HWRN)]45E>H_=
MDG%6:@ERN+]V,U9R3;?*XQ32:@E=/\"?B=\.? 7P(U+X&VEQX<_;:_9TN_ W
M[-/@GP-\,/VL_@S97/Q)\=>)K*SDGNY_@)\>OASX5\->)-$DUGPM<-;W.GSZ
MA:2:3<RW%U:Z?JNG+'FOTZ_86U+XSZQ^RS\,M5_:!\':=X%^*E\FO3ZWHFG^
M%],\$2W6G-KM]_PCWB36_!^C$Z9X;\3>)M%^QZSX@TJTPEMJ5W,&59"ZK]=Q
MSS1$F*62,M]XH[+N^N",_C49)8EF)))R22223U))Y)/J:QJXCVM.,'!<RES.
M;DY2M[VD6US13YFY)RE%R2<8P6AM"C[.;DI/ELTH))+7EUE;1M<MDU&+L[2<
MG9B4445S&P4444 %%%% !1110 4444 %%%% '&^*_P#D(P?]@^T_E)11XK_Y
M",'_ &#[3^4E%;QV7HOR [*BBBL "BBB@#^8_P#X./M9M-%T;]F&6Y\1S:";
ML_$.T58;CR?MJ.FE^8C@$,X3 ^4<X8_A^!OP"_:H^''A;2;CPGJ[WUQJUU<V
MMMINMV]T(_L4<3$2B2(G=.;ARNQV(,17=SD5^ZW_  <P^$CXG\*_LN21:<VH
M7EC>^/TLU169XY;F'31\N P!)4$9'.#[5_+K\)_V+?C7K,&K^-K+X<>(]2TC
M2$5KUKA);>.%KDXCO8BP4E(@?,^7( ^8U_FG])G)^ \VXRXRCQ;G=/++5LC5
M.%3%X/ .IBEDN5QPT*=6K4I3J*3G3YHU9.$G)T[<F_\ H_X+<+Y+P[X,<'\?
MSRS"U\RSG^VZ.(Q,\?6BX4\-G^9X+#UJN$C:*E3^J\L(P3YTHR=W.Q^^EGKF
M@_$/2/"DUN$@L[:(P:K?7K+-=32,5DA+$OA8GB^]V&0>":\7^-WPGC\2:/KM
MS#K=F]G!:RQ6.GK*-MP[  Q! Q&/*!)! &,#O7!:3\'_ !;8? W1IK/Q5-:W
MEE.T&HV\RR)-&N (5DN(N)I0XV*,[MH^;GKP,GB_QEX<L(= U#3[R:8/=0W5
M[<;I&NYO*)B$2KO.%0J1C!X^8BO\Y<DX?>%S2IB^&.(,-7CEF:XO#1PDJ;4U
M2IXCVTZWM,1RIN:2BO8\S5.5-)V?,>5C/I+<&8_"<9X# 1KY97I<_"6<87%\
MKH82I27^UU^6,I5.252<5S4HM\ME;=&-^SSX6TG2Y]:ME$^BQ6L/V2[B,GD)
M>(Q\N2SM%'-S),/F$>UE(R2>!7%_'K7O@/X"U>RO];TA[F^LQ->V=[-LDN9)
M,[19RQL/W$4;$8W= #M%>H^&+6^>]T;47A:U21A=W,T2,98KJ!@Z*R8Y#Y(8
MJ"2,JV<5\2?MX_#/QGXY\:?VG:6\MU%JD<#O-86,MK8Q_P"CJ@C6)$V[Q@-(
MP^\YSSDY_9N$,-A>(?$BG'.<]Q.68/'8*K+$U,/C94).=",:,Z+K1MS^T3J2
M]^::@^14Y<RFORGBSCK&Y3PI%UZ.4>RSFE#"8/&0RVDZ-'!1A%X9.C)WQ:Q$
M8N6(Q$U"<)J#C#W%;\UOV[/%GA?XKZ=::WHTP?4R\B0V\-TKI9Z9$ %M9(@%
M42&0&5<9^4XSBOR/TVXM-)U,G4EDC2(DYC1OG89(0A>2I(Y.?7L:_6WQI^SO
MJWA?0+B^UNRN5<QL8C<[D78!EY,2 '@#DGKVYZ_FWXT\#7$^LS&#RS"[.(RH
M!^Z<#.!DC/0\' ZU_JCX,YCP]@^'5P[EF83QF58+GIT<3*JG))M-TX3O)/D5
MU=MN_,]VS^6<KIXG/)?VCE^$G%4JM/#^U4'R8K%4N=2DNDI1E;VC=TF[7TTR
M]6^(%IJ]FME;P21A6Y=WD=BF/NX?(5,CY0#QT[9$>EW>C21V]MJZN]H9@9Q&
M 7V8R?+R"-^<8!QUXZY/*#P;J5M=!3'(<$[^#@8/L",8![^F>XJZ-,N[BXC@
MA@E=HV7*HC$,RD'!P.Y[@#@#FOU]X3*Z=%4L)7<*7O574C5M*+LO>YV[IMNZ
MZ+1GEY]AL=F&+C#%8>K&O"IRU<1&$HR4HI-)->[[JN[MK?5GVEX%T[PU/X8L
MM1L--C,%I>*K/,JR70@:3&6VK\I*G:.""?7'/VAH7PZ^'MY9>']9TNQNX'O9
MG@OD"+;SFZC0%6@F)"NGF8W#&!G!(YSXC^RA\/-5\3PO8:K9/::<]Q;O,[6Y
M\KY<, Q*@% N2P'< ]J^\_#OA:P\8:Q:?"SP_+Y#V.HW5O9ZB8XE^RQRX:1Y
M'4AB7=2(B,D!@.QK^-_$GBFG@<VS# T<QQ<5E]:OB\PQ-+$RJ4:&7UJ4FYU^
M5-S<*G+)1C)2W:5[1?R.1>)M3PW>:5<-2FGAJSJU<QQB6/HSG3DI4VJ4[JE=
MKV35-R2MS*]VCY\\4? *V\?K=-H,L,&J:=IES>W+7\B" K$C+-;M,>&N&R!'
MLW$D\' R/-?AG^Q_=>+PFC:YI:W]G<^>"ZVQ,]NWF%8VC+!0VP\-(V!M..>M
M?TD_ G]BW2_!?AJ27Q]I?GV\ND^?I5\8+>Z34YKH!$@N&:0LTK3,&V("ZKDL
M!72^(/ _@_P,NH^$/#?@BW@\5&Q'V?4[)9=D\UQB1H$3:0S0@X;9D*W'4&OY
M;G]++$8&>8<-<,5L3F#H5::PF9JI2ITJ$(O][B%6G.,U3H2K4Y3@N:=*_+)/
M5K^ML;G>=^*66\+^*&7<&?6,EQKR^A5JQH3IX9UL3AYX&IBJG.J:C3Q>*I5*
M=.K-1A&5I5'%2C,_EC_:1_9"M_A2EJNASK?Q1Z<\U]#/;I%';J@)6WA<?ZR8
MXW,02,#)QS7PC#X-T#6M%NKU95MIK.9K?[/.5CD>=U8NPXW&*/;A<@>W<5^]
MO[9?B:Q\,W":=K^EN9+M;I9-)E!?RYXX7A-R+IP'VG)8VBG[PP"17X6W^GV[
M:\;#3I9([:\NY)V5T"$*Y9@%B!RI7)4 ]<CGT_NCP1XQXBXFX0H8W.L97EC.
M2.)I9DN1T\52C.HZR?(W&33BHQE'1Q?NSD^9GXWQYC\%E&>U>&L'DF.RN5##
M4Z&:3QU*I2JX?,X2BL51P\*B4Y4Z3:O-7A-S3IRE';F-#T6>S#:?;W,%K+Y<
MDRW-T083 !T4YYR1D $\YZ9YLWEQ<^(-*.EO;27%]%',UM<Q,%A5578RB,D
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MP4H1DX7BI2C&[LC_ $::***^?/BPHHHH **** "BBB@ HHHH **** "BBB@
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M4-+*YR-IS@=*S?AG\4;'4)=+-QX;-O#;V\]M>W9N)C/JE[&24O#N.(B&P/)
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M]H^*[6ZLM/;;-%I4^G2&298-T<2,PD=QF23;$NQ@!M/4^_X23:SHWPX^.?\
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M+4-$\06!/V36?#VJVX>VU71M0BFM+NV8JR!PCK_J1_\ !+'_ (*L_#W_ (*
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M_$L%O');>%M7-M+!C,ZK/"&W@8(\HC8N<Y4?3/E7QE_X)E?M=^$UFN_A_;^
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MH6DA=$\07LMO8Z?<1O!>-%%*BI=8D'[RWFWY1TR,=37ZE?L"?\$<OA%XUL/
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M@2Y62XC\BUN;"-YDW$.-I!_RXOA7\0+RXT[^S=0N1<%9E\H3;6.Y@ "7/S*
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M0Q"*[,0%CC>5V)^58HT,KR$C(V+&K.6&1M&1D5\L:1^W+^QGKWB;PQX-T?\
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M-].^#6LZC<Z1HGQ$N]<6'0-<U6TN9[.YT[0RT7VW5[R&YMIXWAT^TN'VQ/*
M80)">RJO:E4UER?!+X_Y-OC_ +OQ>0>TIZ^_#2/,_>CI'^9Z_#JM=CZ'HK@/
M"7Q7^%WCSX?0?%GP7\1/!OB7X7W.G7FK)\0-+UZQE\*1:=IR.^I75[J[RQVV
MGKIJQO\ VC'?M;S6)1ENHXF&*\B^'G[:7[)7Q?U?3?#7PI_:'^&'C_Q-KMWK
MNF:!H'AW7?M>JZOJ7A[3'U;4X;*R>&*:>"ULE%TUZB_8IX,M;7$I! 7LZGO>
MY/W/C]V5H?XG;W=GO;9]F-S@N6\XKFUC>27,M-8ZZ[K:^Z[GTY17YQ_LV_M<
M_$;XW?"C]E_X@^)-8^"'@36OC'\8OBWX#\2^%=43Q+#J?BS1O .L>+-+TO2O
MA'#%-=1#QD;?0;75M9;79O[/:P74#;A)/*4?2_B3]K;]EWP?\4[+X(>*OC]\
M+_#_ ,7-1N;2RM/ 6I^)K2#6OM^H#-AIMVW-AI^IWH*BUTV_O+:]G+QK' 6D
M0-4J%6,G#D<I1Y[J"E*RA)PE+1?"FOB5XVU;1$:U.45+F45+EY>9J-^>,91M
M=[M26F][Z=3Z%HKY&T7]H#Q?J7[=/C_]EZ?2?#\?@7PE^SMX*^+]AK<45X/%
M$_B+Q+XCU'1K[3KN9K@V#:1#;6<<ELD=JERL[.7E92 /KFIG"4'%2M[T(S5G
M?W9Q4HW[.SU1<9*=VK^[*47=6UB[/Y7V?4****@H**** "BBB@#C?%?_ "$8
M/^P?:?RDHH\5_P#(1@_[!]I_*2BMX[+T7Y =E1116 !1110!_#5_P>@W#0V?
M[ "*"S3W/QFC1!D[I#%X>"?(#EB'*X&.OKTK^(/0+Q[?;:SQRP21G9+',IC?
M=GG*G!QDX'&#CK7]L_\ P>H74EC#_P $][R)2SVUS\9I4Q_>!\,@?3!(YZG\
M*_ATOO%&K>)]336-0$$,JP06J_9H1"AB@7:C.BC#R$#YW/+'!.3U_NWZ%?BC
MQGP%XAY)B\ORN>:\.87 8O#XUJK4C4PD*^.EB*JI1DW2C&HY2=1J+W:;4I77
MS>>4)XB,Z$G1IX>K33E5=O:>W@TX1Y4N:49)15[Z==+6]:G*Q1B1"#O&>._L
M,DGG/0CH?0\,C:YD *2I$=K,&<D*<#.WIR2.@'7WXKGK/4%GBB21\[=O<<G@
M=".F?0#C@5Z+I\3Q*K-&@#Q@J'C# JP'(W  8X(Q@\?45_T?<*9E@/%&EB99
M'FSPF%Q6 P\8X3#356LJ^+BHUI580?-1C"3DG*I&*W>J5S\WJTJN#J<LZ;<H
MRUET2O%+E>TM^E_ELJT5JR0Q#[4EP]TFZ;RA*GE'HT+<#/!!;&5P1D'FMFR@
M2&(HI P 22N,XXX[]R1Z]^>D@C12H55QR<>_4GKW/)QZ'KS3BRHV.07VA0!U
M.<8_&OUKP\\).%?"O!UL7@8QGC(TJLL3F%2$55E&I)U*UYN\I.4I2LVTME;1
M6ZEB\56Y*-62<)S2<?>^*RY6UK'^5::Z/R#<L;%ACZC//OUQCM@8ZG\<?4+G
M:_DL&03D-ZK@'&2 .3^([5HZFTUM'EK9MH*[BP* ;_N<_>R<9Z<UR\LLTTJ&
M1 (T^YDDYYZ'..AST&#]:^9XJXZH\6XK#9'D.7U\7@*&8T(YGF-2E"6$A3YT
MJL5*[YFXN24H.2N[MG?4H3RJG*=3$4U4J0YJ-.E*\O>2[:)='JMGH[F[IUMY
M08@_>YSCOP>AQ[?D16A-M"-NXX)[\]R,>^<_X54AE^52&4  9Z\9QP..OMT'
MO45SJ";B&4.@5@_O@8./J.?3M7TO'7&6!\.>#'#*<*\1BX81TL!@J47+GE.#
M=XJ-]'*5FT[0[(C)LM69U^?$5'&$9.I.3=E*2:;C=[;;[;JY6MKV>,S"!U3=
MG)(ZKUV]\8]>N?IBK>EWKK,^<G>2'SP&/)!'M]>V/7-4;AH&ABFMR!NRK(!@
MJ1P<G/WL9)SP<]C68MT\!)4@MGIC.<?3 Z9SGDX(%?YR<*T<=EO%F!\3<YRN
MO@,75Q6+K3@JT93G"O4E*2CAXOG]Y725KMO1.Z1^G8;'QEAYY?1KVIN*CRJ+
MLK)12YKVWZIO3O9)>A2A)<-G+$?7CMGGZ8SUSC&>*\T\1SBV>990X1<DE"-P
M'&2.>WT&,8],=1;ZJS6SR2E8WC4D1Y_UFWMDY_48QD]0*\QU^_EU"1RPV^9N
M4J">><'GOG SD<GU[>]X_?27X8XTX.S'AKP^J5I<5^TGAJE.>%Q%.-"4L.Z%
M2<Y584X^TA)Z1YE+1/16-:7#-;+_ &>/S&I%8:<54I/FB^?5..D9-\KT;T5U
MWN=[\*+73=5\6Z+IMMJ:06M_>6JWUQ>R+$L:L^V9%# !]N<8R!QGG-?TG^!?
M'WP[\#_#NVTRSN='T^/0K:"*#5G@AD%[.T2+<1HB%C(91N(RHW8SVS7\G=W;
M7.G2I<6%T1):B&=9HI6CDAF<AA&H^5F*$X8C(/3K7K-O\7?&NH6\-M+JMU'!
M%!'$8%N)VB8QIM$H0OQ(1U.,YZGG-?\ ,-X^?0'\3/'KQ$P5''YS4P.&6+K8
MW-<2X*5-3E4C>;?.XU'[)2IJ,E.'+*3Y;V:_J;P)\?.#?"?#<0XG%\/QSK/,
MQHT:.5XB<U3IX;V<?X<HNFW*#FU-N.[7+=6/ZZOAO^V9\(/#&A>([;7=5T;4
MH[G3H[/3K$VX@NDGD1E,B%0=B*6#$+G.,=:_F:_X*'?$,^)?B3<Z3I]XE[I
MEDU&WE1MRJ+F1FCA0_PK&K 8!Y/7BO X?'WB2W=+D:E/(ZXVM*\DF&'W6P6
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MZ#\-/A?J?_!!C1]8U#P)X.NM1O?C5HVH7>M2:%IW]KSZC?\ [5,.C7E^^KK
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M)R2Z1NK6LTK-;.P4445SFP4444 %%%% !1110 4444 %%%% !1110!QOBO\
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MRU.6*J)SQ$;03_=Q;2?(VMFW?2UFEK9VMT-72G:\NH[<E8VD?:">!C'//]W
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MTZ(W8K/4[4_8KF/<^U )(SOC8,HP5D'!X[>H[59CTW<'\V>.WVDC,@9LL%.
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MFZ]V4[./-S7M&6J3C=6YC]T@2,X)&1@X.,CT/J*,G&,G'IDX_+I7XQQ_'O\
M;)^"7@S]C#]I+XP?'/P-\6?A5^T/XH^#7@'XO_"[3OA)I/@H^!)?C1IMI%X?
M\7_#[Q/IUW/K-_=:1KMW:1:UI>LI):7MO<W$]G]F6&.,<CXM_:^_:<M_CO\
M$_P'KWQ\^'G[-7Q3\-?&27PO\&?V8_C3\)SIWPH^-7PHM]3M(=(\20?M%7<&
MR;Q'X\T9KS4--.F:E:PZ/JIL]&EL+B1G8"P523?+.E**4KRBZC2<9*,DU[/G
M7*VG*3BJ<8M2<TFFQXF"M>%1-N.C4$[2CS)WY^77914G-R32BVC]R:7)XY/'
M3D\?3T_"OP\_:*_X*&:K9_M0?&WX!0_M0^#OV.M'^ WACP:++5]5^#^I_&37
M?BS\3_%6A/K]UI]T(M(U+3_#_P /?#RFUTV>6W^SZYJDUQ+<6TR1HI&/KW_!
M0/X\>,/@[^QS\3M6\1W'[,'PE^+WAKQZOQV_:-\.?!+6/BQIWA+XD^#=5ET7
M0/#]GX5U.PNIO"'A#QT+2Z\067B37M+EQ9O%IT9CGRP:P-=J$G:*FHM752]I
M4W5C:T&JCE!-J-)U)*5H249-(/K=*\TKOD;3LX;J<:<K^_>"C*2NZB@FKM-I
M'[N%F.<LQR<G)/)'0GW]Z\-\5K\!?VBT^*W[//BPZ!\1F\&R^&;;XL?#^X?4
M(KKPU>:S;IXB\(7%W<VYLYK/49(8HM7T>_TV\-Q93Q1S)+%,@%<=^Q_X^^)'
MQ)^">G>*?B9X[^$OQ5U&?7O$%MX9^*?P8ND?PG\0_!%K= >&O$NHZ1&SIX6\
M77-HQB\3^&8V\O2]0B:)4B)*#\__ -I_]K;X[?";0?\ @JUX@^'&K^$-)\2_
MLYZ_^RS8?"#4+SP5HMR+)OB1INA)XA7Q?.L2W?B^*XDU":.UEU626XTBU<Q:
M<4VJ*SI4)RJRIQDE4A*"C)2<4IRKTJ47?EYM)5$]HRCOO'E=5*T8PC.46X3C
M-RBXIOEC2G4::<DMHO\ F3V6CYC]%O@K^R?\!?V?M;\0>*OAGX.O[?QGXIT^
MUT?7_'7B_P 6^)_B#XVO]"L)6FL/#P\4>,=3U75;70+*9C-;Z/:3PV2S'SFC
M:3YJ^B)[B&VMYKBZN8+2SM89;FYN;NXBM;2UMX4,DUQ<W%Q)';V\$2*SRS32
M)&B@LS "OS4\+_$#]JCX4?M:?LS_  O^,'QI\+_&;P-^U-\-?BAKEUH>G?#'
M1O <GPM\9?#?PUH_B>.7PEJ^F7-QJ&O>&M7BU.;39K3Q$TE]"T$5VDO[QD3/
M_P""I][?ZK\.OV8O@S)=WEEX&_:+_;#^$GPF^+/V*XELI-8^'<HU/Q%J?A:>
M]@EAFM]/\27>D6FG:G'%(IO;!Y[)R4G(+=*=2M2C.JJGM8J2JIRE[D7*,OC4
M97A[.2479.R2=FF)580I5)0IN/LWRNG:,??DH2C=Q<DE)3BW+5J[NKIH^X?A
MO^T)\!OC'J6MZ'\)/C9\+/B;K'AJ1DU_1_ WCC0O$6I:05=HF>[L+"[DN%B6
M1'C:>*.6)64AY%&">S\7^._ _P /K'3=3\>^,?#7@K3=9U[2O"VCW_BG6+/1
M;/5?$VNW M-%\/6%Q>R11W.L:M<L(-/L(R9[J7Y(U)K\OOC?+_P3X^&_[47[
M.G@"_P#AYXS^!OQH^&GQ-\(Z5\(_'?PC^#.L^#/ VMZCXQL)M-T[X7>(/B1H
MFBP>%/$GAOQ)9G[/J_A_4+J:>&YM?,5X;F%R?"/^"G-]\+OVDOVCM+_9(^)'
MQ<\$_"OPC\#?@7XJ_: N+SQ-XSTCPJ;K]HSQ!(MC\ 8-->_NH'N;GPJ^GW?B
M&:),B.SN@Z@3/"QN&&C4J4DO;0ISIRJR<Z=Y1A%VYHV:4U)N*3M&SDHM.R<I
ME7E"$V_92J1FJ:49VBY.SM*]W!KWKW;NHW6]E^\;*RLRL"K*2K*1@JP."".Q
M!!!'K25\N?L4_M Z;^U%^RO\%_C78WD-W?\ B3PE:Z5XN$,B2"U\=^%&;PWX
MPM\H[@Q/K.G7%W:2;CY]E=6]P"1*#7U'7).$J<Y0DK2A)QDNSBVFOO1T1DIQ
MC.+O&45*+[J2NG]S"BBBI*"BBB@ HHHH **** "BBB@ HHHH XWQ7_R$8/\
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M?R>:K8);.1?3213&XD82X+;U;Y@..<MQQV-?U)_\&AU_)+_P5!\3V99V2/\
M9G^)K@,"!Q>^'=I/H2#Z_P L5_"&;^*U?AOPM\<?!KQ%X?J8;B*>59S_ &,\
M3S4:M+,,5#FAB(4*D4Y0II2DIPW4]+6U_8,'AI5\7@,50G+DI3I*J[2Y9TXQ
M2]V6SOL^JZVZ_P"E]1117^:)]L*IVL#@'!!P1D'!Z$>AZ&ORR^+G_!/_ .,_
MQ-T[XC_!P?M9W-S^RM\8?%&J>*/&/@3XC?#JU^)'Q;\(1Z[J-KJFM>$_A/\
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M1KY?!U7[*IBHQ5/36#>J>FLKI6[JV^A_I*4445_SW'Z8%%%% !1110 4444
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MM3,F=Y)QD@GCKC/'?M^F*Q]3T&&:/)PS]CP?P_/KSSGOU'T-)^S?^T-:C*?
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M:;119/= .RO_ #QM?_ 2U_\ C-)E?^>-M_X"VW_QJDHI679?< [<O_/&U_\
M .U_^,T;E_YXVO\ X!VO_P 9IM%%EV7]?\,ON =E?^>-K_X"6O\ \9I/D_YX
MVW_@+;?_ !JDHHLNR^X!VY?^>-K_ . =K_\ &:3*_P#/&V_\!;;_ .-4E%%E
MV7W .RH_Y8VOXVEL?YQ494_\L;7_ ,!+4?RAIM%%EV7W +\G_/&V_P# 6V_^
M-4N5_P">5O\ ^ MOVZ?\LNU-HHLNR_K_ (9?< N5/6&V/_;K;?\ QJC*?\\;
M;_P%MO\ XU244679?< N5/\ RQMO_ 2V'\HJ/D_YXVW_ ("VW_QJDHHLNR^X
M!<J/^6-M_P" EL?YQ4NY?^>-KSQ_QZ6H_P#:--HHLNR^[^NR =N7_GC:\?\
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=52\,,DBA@')4LJD!@""1UP0>]%;Q:LM5LOT _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img136305557_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img136305557_3.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &? F0# 2(  A$! Q$!_\0
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MSA*ARSE&\9WY9-7UCO9H^\O^'H?_  4,_P"CQ/CW_P"%_JW_ ,<H_P"'H?\
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M3;O;38I3KM)JI5:?,])R;M%7DVD[I):MO2UWT9]/_P##T/\ X*&?]'B?'O\
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MG.::]4W<^^/^'H?_  4,_P"CQ/CW_P"%_JW_ ,<H_P"'H?\ P4,_Z/$^/?\
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M*CHZAD974]&4A@?Q&15?5L-_T#T/_!5/_P"1\E]PO;5?^?M3_P #E_F?>O\
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M $#T/_!5/_Y'R7W![:K_ ,_:G_@<O\S[W_X>A_\ !0S_ */$^/?_ (7^K?\
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M@ HHHH **** "BBB@#Q?]I#_ )-Z^.O_ &1_XD_^H=K-?Y-!Z_@O\A7^LO\
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M)!'.ZN0\T;OQNP/-?C%X]_X)4_M+_%74_P!JWQA^TA^UQ\&=:^(E^OC3XO\
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MK7P-\0>"F_X1!I?A1()F\6VGCV*Y\N:WNY;2")-.BMF>2WO-S.DL+J>Z\?\
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M7^*GAC1=-U/4H/#C:]9PRQ:QID,SQ&Z*290;2WB'[-?[37[-7Q(_9 7]A?\
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M>74Y[2_^(<U_=ZCK5_XDTBQ-KJ-_,L9>ZFD*1)"P5>2_9:^)7P._X**_#O\
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M[=R[_G[4_P#!-3_Y'S_/LP_LO&?R0_\ !D?+_-_=YG\3]%?VP?\ $,%^R/\
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MBO?$GB?5-I@L[*T1RT5MO-W?3;+>UB=WR/ZRS_P; _LD$$#]HW]I($C .SP
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M=4VFK735TFKIJZ:NFK]&M4]FMA)IWLT[-IV=[-;I^:ZH****0PHHHH ****
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M_E^2/<[C_CWG_P"N,O\ Z U<)<_Z^3ZC_P!!%=W<?\>\_P#UQE_] :N$N?\
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M)&B>#/@/_P $,O!VI?"WP1XWN?B0OB32]'\7^(UO_P#A(?A9>:7X<U2Z;7_
MOV1TM5U34(9'L;P:@DL/V;#1J)0#7N?[97[57_!0G]E#0[GQ<OAW]CKQC#XP
M\?VO@+X$?#&PN_B?<?%CXIZ]KNHBV\/>&]/TZW5;!M9CLV^WZ_=QLNF:7;0S
MW$TJ1!=W'_"_]C[]H;P_X/\ ^"-&DZSX%BL[[]E#4O%D_P ?8AKVE3#P1#J7
MAR\T^R:)XY2NN>?=RQP_\2OS?+W%V&T53T[1_P!L?4_VV?'G[5'QV_8>^(_Q
M0M/AVVI^ _V/_!OA;XE_#$>$OAKX*=GBU?XDS1:UJL$LGQ,\>84RWK6P?1=*
M*6<,BLS,ER]A.LYWP]2,?;SE"=6%ZDGBZKIP@Y5$H<\7&4G&R]G[Z3E*/,DJ
MD::C^^IR?LDI1A*T$J%%2E*T&Y.+YE&,D[S]UM14N7WKXS_MJ?'3PMX_^$'[
M+G@3P[\!O#W[4GB7X/Z?\8/C9XB^,/C6YT'X)?"33)'@T^?0])FCF@UGQ9X@
MU379)[32+.!S%!86=Q>WC[,5S?A'_@J+;:-^SI^U3\0_C5X'\.'XP_L@>+-,
M^'WC;PC\(O%$7B?P)\2_%'C!+(?#:]^'?B.5Y)8M%\6W&HV=M>C4-]SHTPNE
MDW!% \L_:J_9'\5_$/\ :<^&W[:/B+]BW2/VF_!GB_X(:=\-?C1^S9XG\1>'
MA\4/A3K>D:D^K:%XJ\&7%S>P>%_$]Y;1W-SI&N6-OJ$!N%9'M)@,2#0U#]AW
MQ-\9_P!C#]I?X7^"_P!DWX4_L-^)_'_B;PEXO^#/A#3=>@UK5_$5[\-[^S\1
M^&9_C/<Z09]+TB[U35;)M.2#2Y[O^S;&Y)G9Y(R3$88)TZ#G&"4G1]K*-2%X
MS=5*M&ZJNHXJ%XI*ERJ*C44WK*3<L3SU.5RT53DC*,GS15/]VTO9*"DYV;;J
M7;<H.*T4?G_]KKQ/^W%XC\2_\$V[[]JSX=_ 7PWX8\3?MQ_"7Q1X>/PD\1>(
M]2UWP3K%UX;UZXM/!GBVU\06Z6^JW)TZY=I=<TEU2&\M)(98VBEA<_T,^-_%
M6A>!/#/C'QSXHNS8>&?!>A:]XK\07H3S&M=&T&SN=2U"6.,$&206]NXB0'+2
M,HZ9K\2/C+I7[>G[7&O?L0Z9XD_8NOO@[IG[._[2?PY^)_QF\4Z_\4?"&K6V
MHR^&M&O]"U*]^'>G:;(;G5O#6VZ?4Y;N\,-X%>"SM[=Y$E<_LU\6_ 6F?%OX
M:?$[X7:M=2V6E?$OP5XL\$WE_"GF2V5OXFTJ[TS[:D9QYAM6N5G,9(W*A7()
MK#$N+6$C+V,%'VBJ1H3C4C",JL7=.,ZBYG!-K5WLK]36@I*5=KVDK^SY958N
M,I-4UO>,7H]'IIM<_(T?MZ_MQGX#C]O)?V=/@_)^QP+5_&[?#A/%7B$?M*I\
M#4U$V<GQ.DF,/_"(C58=.5O$TOAE1L71 29C,IKV?XM?MH_'N_\ VHO@Y^SC
M^RK\,_AKX^LOCG^R-<_M+>'OB#\1M?U;0=)\&6\GB?3M+T_5O$MMI:37&J>'
M)=)U&!8]+TI/[6FUFX@#21V23,/E^/P3_P %#(OV(F_X)N+^S%8#Q6_@*X_9
MW/[4H\?>'6^!S?!*Z:30Y_B NF&0>+(_%S>#Y&M8_"1TUF75,7/VORAY9^MO
M!/[+?CWX<?M[_L^>/=#T;[?\"O@]_P $XKG]F)_&\NH6<=Q)XYTKQSX<N](T
MQ]&9_P"T&_M#0M)FU!KU(S:Q'$#L)"!6THX6#E)PP]U]9]E"-7GC.G&$?82J
M6J-\]V^5-QG.S4XZ)/*+KOE2E6L_8^U<H*,HS<G[51O!)1M:]DXQT<9)NYW/
M[$_[37Q@^,WB']H[X+?M%^"_!/A#X[_LP^.M"\,^++GX:WVHWW@/Q?X=\8Z1
M_;GA+Q3H:ZN%U&P>]M1+%=V%P/W,D8VXR13OVOOVI/B?\+?B!\#/V</V<? W
MA3QW^TA^T--XFU#PTWQ#U*_TKX<> O G@JWCG\4^-O%L^E1R:I>^2\L-EI6E
M6*B2[NI 9&$8IG[-_P %?B5X!_;._P""@_Q9\6>'TTSP#\<=:^!=Y\+];&HV
M=TWB.W\&^"[G2/$;O80.UUIOV#4)$@"WJH;C.^+*\UP_[9GPA^.NE_M%_LP?
MMI?L^?#VV^-'B#X%:5X_^'GQ&^#:Z]8^&?$7BKX;?$*"WDN-8\$ZMJF-,D\1
MZ%J%K'*-,O7B2]MCY<<@D8;<4J,L4K*DH2HQG&#E:E[>6&C/DE+F7+%5VXN+
MDDFN25E<UO55!W<^:-5Q<N6]1T56Y7-147>7LM;J+;^))L^3OV<-?^.EE_P5
M9_:UUG]H'PU\.](^*OA?]@OX9RR-\--4U/4_ WB?3]'UKQ-J&E:UI[:O!#K&
MEQ7\L;V]WI-YYDEJT3M!,\3QM6E\-_\ @H3^W#XI_8)^)'_!0;QI\%/@)X.^
M&/AW]G#Q3\3/AYX3MO$GB75O$_C?QMX=U1[.VU;4T1%CT/X?:Q#!<_9+'SGU
MZ/RXY;C;YJ@^C? [X7?M4^/OVX?VFOVIOBS^S_)\$/ _Q3_9&\.?!_X;Z!JO
MC?P_XF\3R:MH%UK\D5IXKBT9C;Z3K%Z-2CF:"!I[.UA>*)[IYED-:_PS_8[^
M+VH_\$5]-_8>\7Z99>#/C?J?[+7BGX6:CI%YJ=K?Z?HWB_4M1U>]L+.XU>Q:
M2SEMY1+:H]U SQ1^>"Q^1L=%26'<H>TC0;OE].2C-RC3IJE/ZPH<LVFHM1C)
M^]RZ)--HQ@JUFH.LERXN<7*/*YS]I'V3ES13NU)M+W6]WLSZ _:-_:O\8_!C
MX/?LH?$?0O"_AO5]4_:!^*GP#\ ^(]/U6?4([#0M.^+>G6E[K5]HKVQ$TMYI
M<EPR::EYF)T53<$G)KY^^(_[:G[4WC']J#]H/]GG]E3PG^S7;ZA^S/%X8M]6
M\/?M!^--:\/>/?C?KWBC01XCM;/X9Z5I1B%MX=CM=ND?\) Z72'6Y%A<+'G;
MX-\1="_;X_:4\"?L6_"K4OV*K[X4:1^SQ\9?@+XE^,'B_P 5?$_PE>'5+?X6
MQVVD7UY\.-*TR:274]">*W_M:>_U![>X:U*6MK;/.6:N[_:]^$OQ2^(OQ8^,
M-C\8/^"=OA[]K'2-4C)_97^//P6\2Z)\-?B-X,CN]/>.V\.?$[Q3=:II7B/P
M[>>'-8/VS3O&6ERZA;06H7R].:5]JJG2H4W&,U0E-QJ_\OJ<TOWM+DDU[:$)
M_NW)<KJPDHR<U>4='*I6E=Q=:,4Z6GLZD7+]W+G2?LYRC[_+=J$ES+E=DVSW
M_P"./[=7Q!^'_P //V7]#T#X2:#X*_:E_:L_M*WT7X9_'/Q7;>$_"'P='A33
MFU'Q[XB^)6NQ2I)-HVAQQM'HEII[K>^(+BXLX( 79TKGO@U^W9\3;[5_VG?@
MQ\;=)^"=W\=?@)\"]5_:!\'>)/@CXNN/%/PH^*O@"VT[4MEV5DGGU;P]JNA^
M(;*'2?$6F3N"T-Y;W-@6C<.WS!\7/V OV@?$/P8_8!\?_%?X>>#_ -M'XX_L
MO^%_$7@WX^_"3QQXFBBA^*/@SQDLSA?#OBG5&2SN_''P\;^SOL.HZB5@UZ>R
MD:9BLI)]V^!O[/+?\(W^U!J'P]_X)V^!_P!CBU\:? 'QC\-?AU=7?B#1IOC)
M\0=<\2:)?QW>CZ_INB75_H?AOPB^J1Z8+-KG4I;J:[B2ZE"6YVJN3"*DTO9S
M?--2DIQ3C-8AQCR\]95'3='EY4J4E*$G4<N:,N1J6)=1-\\5:-HN#LXNE%OF
M2IN'.JCDF^>-FHQ4;/WO'=/_ ."BW[<NE_LU_L_?MT_$#X$_ '1_V8?B)%\+
M'\?^$]&\6>)[WXO:;H7Q'U.ST4^/]"FEA708M-M[Z]BU&P\/73R7YTC"WLAN
M=RK^ZTE[9VUG+JSLTFG6VFRZTS$;7ET^"P;4SP<[7DM4Z'(5FP<XK\7OB%^R
M1^T#KO\ P1@^"G[)>E^!HKKX_>$?AG^S[X>\0^"#KNEQQ6.K>!_$&C7WBBU&
MN/+_ &7.--M;.XD$L4K1W.S;"69@*_9:'3Q=Z'!HMY^Z%WX;@T*\.0WD&YT1
M-*NR".&\EI)""#M;9P<'-<^*]BU%TXTX6KXBFU2;=Z472=*33E)N_--1G]M)
M[\NFN'=5.TW.2=&C.\U9^TDI>T2=HKI&\?LOHKZ_SQ^'53XH_P#!(;_@I9^U
M_P")9&U+QK^USX3_ &D?&\NLWJ&:YL/AEX5&I^#OA=X2LVEW/!I6B:#I\SFS
MA9;22_N[BX6(.[,WMOAK]KG]M#]GOX;_ +&'C_XL_!;X-:5^RK\2H?@%\%;G
M2=)\6:SJGQS\"KXR\):)H7@WQIK\\<$7A2\35-0BMI+G1-/W_P!GV-];Q2RO
M=I*PX_X _#+QKXJ_X)0_ML?L >#=)_MCXY? Z']HG]G+1_"-U>P:;<:NGB>]
MU#Q#\*M3-S?>5!96'BW0]8CN+>]G;[(DL<\?G,8R*^J_VN?V<OC'\4/V-/V5
MOA/X'\*1ZQX^^&WQ'_8\U_QIH;:OI]FNDZ3\*Y/##^.[D7]S(EK=G11IUWMB
MMV9[TQ?Z*&W+GLG.ESRI5/9N,L;45IMIT\/*C1C1G"TDHKV:ARRLU[MD[-I\
M\(U'",X>TC)8:FVXJ_-652;J1E=/F?,Y.44T_>=^ENK_ &D_CU^V/X5^)WB_
MPK\'?!G[-_PU^''@+0+'4+?XJ_M4^/YO#5A\9_$UW9R7]SX5^&FE:3>P7-GI
MNB)'_9VN>(=4#&'5)8XK:)XPY'PE^T_^TS8_MB?L-_\ !/?X_P /AC_A#[SQ
M?_P4 _9XL]>\+?;$U6TT3Q/X9\>ZUX>URWTO4U&W4=(DO].FN](OOOS:?<6[
M.?,W5WWQM^ 'QOL?VSOVC/B9XQ_8BTK]NWPQ\6K#P5:?LT^+O$7CGP]:>%?@
M5;Z3X=DTSQ#X.\2>%_%,CP^'=&O=<9_$-]XBT2PN;[5BL<1(G92GE_@3]A_]
MJO3/^"?/['7P'UOX6:;I7Q3^#/[>GA#XM^.O#6F>)M&ET72OAGH_Q)UOQ/J'
MB30]0$H@NM+L],U2%;#3%VZB\,(C$(<8HIQPU.-"?-24XSH/FC.";C.E-UE.
M/M9S?+-1C)SC3M.ZA%1E8*DJTY58\M5Q<:ONN$FDXU::@XM4XI\T+M*,IW6L
MGS':W/Q@U?\ 9Z_:Z_X+:?'+PYI&E:WKWPL^!WP9\<:7I.LFXCTO4[[P]X1U
M2^M[/4I+/%V+29XPDI@/FA3E,&MKQW_P4$_;V^#OPD^!'[5GQ&_9V^ NL_ ?
MXT7_ ,,O#*_#+P3XY\0'XQ:/KOQ:M+>W\%ZA-KVIVR^%S;7^OW-O#>6:(Z:9
MITV997N87-;?QG_9#_:$\6^./^"PFL^'_ T-]IW[4WP!\&>"/@3<?V]I<!\:
M^)](\):EI>H:<\<LBMHH@OKB&$7.I^5#(K^8A*J:] _:>_9@^.'Q%_X)]?LH
M? [P=X.CU7XH?#/QY^R!K7C7PXVM:;:)I&F?"W6=(N_'5PNI7$JV5X=%M[2=
MQ%;NTEZ4VVP8L*.;"N5#G]A/GEAJ524Y?!26%HQEK&<>1QGS+FT:DFKIIH.6
MO&-3D=6'*JTX*,;J4WB)N.CB^:\;/E6\7>VS75>#OVI/VPOAQ^UA\$OV??VN
M/AM\#K'PW^TYI/C2;X8^)O@KKOB6_O?!/BOP98IK%YX/\9)XAB2'65FTJ0A=
M7TP(C7EO-L7R=HK@_P!I+]L[]M/X2?\ "ZOB7I'PP_9F^'OP@^"TVM7.@^ ?
MCS\3)]$^.OQ_\,>$XGN->\5^!]-TN\&G^'['6XH+D> [2^BFN]9DCC-VB+*H
M/T5^TU\%/B7\0_VSOV /BSX0\/+JO@#X(>+/BUJ?Q-UMM2L[-O#MEXG\&2:1
MH<Z6-PZW6I&[U!A"8[-'>$?/* E?E+X\_9 _:<ET[]LGX=>*_P!@[PO^TW\=
M?CCXP^+VI?"W]LSQK\1/#=SX6TKX<^,4NX_!&E7%EKQGUWP9J?PZT^:+2M#\
M-Z':06UQ=QQW*W"1"1VSH+#5)4YS5"/-3C[2FY**3]O.,FE.K!0?LHQ<M934
M9*4(W;DJJNO!3C&55KVDE"=KNWL:<DGR4I-_O')1TC&Z<92LE%_>/QJ_;U^-
M\NH?L!Z-^RC\'O!?CG6_VZ_ WQ'\4Z9IWQ1U_4- B\ _\(KX(\/^+++4]4OM
M+21;G2=$_MBZ?Q';Q0O>ZA;VD4.EJ)921\M^+/VDK#]E#_@I+\2OB]^U1>>'
M%\=VW_!,?X5:%?\ AOX9I=7:?$#XHZM\<M1MM*\"?"VPOP-4U6[UW49(;?38
M)E+PQ2-=7.R*-VKZ!^%G[,/Q[T?QW_P1P\1Z]X$_LRQ_95^#?QT\)?'MI==T
MJ>;P3KWBWX6^'O"OAJU5()6.N#5M7TVYB$VE^;';1A)9RJL*QOVE?^";-C^U
M[^WU\0?B/\7O!]Q#\(Q^Q;X;\!_"'XN:7KJ6GB#X>?M#:;\0[[5[;Q!X>TVU
MG34(]7\.Z3+:ZE:W]Q&UC(IEM482R$BJ;PE.?))P5)X>LJLZ<U*K)_6Y1C"[
ME;6E&#2BDW#WUS73%-8B<7)*3J*M2Y(R5H1_V:$I2MRWLJLI)\SLG>-T?I#^
MS5XD^/WC/X3:)XP_:3\$>$?AE\1_%$UQK<7PW\(WM_J8\$>%[XK/X>T'Q3J=
M\[B]\:6]BZ-XC:PQIUO>,;:VW>4['Y4_:6_:I_:5\&_MB_"3]D+]G3X8_"WQ
MAK'Q8_9]\:_%Z3QA\3?$&LZ)I?@:\\)^,+?P\]_JD&DQRS:QH0M)D0:98HNI
M7&JW5MB5+..<CW7]C6]_:=B^#UOX,_:W\-VMG\7/AMJMWX)?XA:3JFGZEH/Q
MI\,Z.1;^'/B=80V;FXTF_P!=TY(6UW2M0BAG@U-9I$!CE&/S\_:P\8_%#P%_
MP6 _97\3_"GX42_&C5;+]AGXQKXC\"Z?XBT[PUXCNO"4OQ4TQ=1U#PG=ZPT>
ME7OB"PNA8R0:3?S6T-_;-<Q)<13>6:YZ-.,L36BXT9\M.O."4[T+Q@Y0:GSK
MW59-<T_*>MT;5)RC0I/FJQ;G1C)N*]JE*<5.Z46N;5WY8M=8Z69]2_LS?M8?
M&OQ1XX_:)_9Y_:5^%GAG1OVDOV>?#NC>/+/3?@_J5[J7@_XU_#[Q78WEUX6U
MGP,^O"*[L-6N;^S.AZGI]\WE66H7-MR$+@?+GB#_ (*%?M8_!?4/A9\0?VC?
MAU^S'X;^&7Q,^*?@[X<>(/@1X.^*$VK_ +4OP<MOB)KD&@>%M6\1:;]KET3Q
M!J6E7=W:S>-=*LH8XM*A>86\A>%@/0/A7\$/VIOB[\2OVU/VJ_'W@_\ X9G^
M(OQF^!=G^S]^S1X(U#Q!8:YXL\%>'-"TW5+FW\:>-]2T5YM/TW7==\375I<Q
M65G+,^C16[,)'8*U?F?JO[%?[3GB+]GWX(_!_P *_P#!-+PUX(^,WPK^*'P9
M\8?'+]H[Q)\2O"&M>*?B=>> _&FFZUXF\0> /$%Q+<^(]?NO&2V\^JZU-K=[
M:);6\\NGK!+,L/E]-.GA95)\ZPZC^Y51>TBHTW.E>JZ<Y5HKEC4=KP562G[J
M:@O?QG4KJ$.7VS:]JX2Y&W.,9I4U4C&FWS..OO>SBXWD_>^'[:TSQ5^V^O\
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M%+2KC7?AU\2_#\_ACQAH]M?W.F7&H:/<SV]Q+;PZA:,MS9R-+:PL)X&$BA2
M<,:]+HIIN+4HMJ46FFG9IIW33Z-/5,32:::33333V:>C3\FBCI>FV>C:7I>B
MZ=&8=.T72].T?3H6=I&AT_2K*#3[*)I&):1H[6WB1I&)9V4NQR35ZBBD,7).
M,DG'3V^E )'0D=N#CCTI**  $CD'!]11110 4N3ZG\S244  )'(.#ZBCKUHH
MH 4DG&23C@9/0>@I*** %R<8R<>F>/RI*** "@$CD'!]1110 =>M%%% "DDX
MR2<<#)Z#T% )&<$C/7!(S]<=:2B@ I223DDD^IY-)10 9/7//K1110!Y/%\%
M/ -K\:[K]H'3;/4-(^(^K>"5\ >*+C2M0EL]$\:Z#:W27FB3>+M%B M-8UKP
MS()X_#^LS#[=8VMY=6OF/"ZJOK%%%-R<K7;=DHJ[O9+9+R71=%HA))7LDKMM
MVTNWN_5]>[U%R1D D ]1GK]?6DHHI#"BBB@ I<G&,G'7&>,^N*2B@ HHHH *
M\BU/X%_#36/CKX4_:2O]%N9?B_X)^'&O_"?P[XA34KJ.UL_ WB;6;;7]8TR3
M25865Q/<:I:03I?2H;B%5,2,%8UZ[13C*4;N+<;IQ=FU>,E:2=MTT[-;-":4
MK72=FFKJ]FG=->:>J8$D\DY/J:7)XY/'3GI]/2DHI#%!(S@D9&#@XR/0^HI*
M** "E)).223ZGDTE% !3@S!@P)#*00<\@@Y!!]CTIM% 'Y__ !'_ ."8/[&W
MQ4\;^)/'/BSP'XM6;QOKT7B?Q]X/T'XF^-] ^&WC[7XY$EDU/Q?X"T[5HM U
M::]>-#J2/;1PZE@B[CDR<^M_&O\ 8R_9^_:$?X5VWQ/\,ZSJ'A?X.36,W@WX
M=:'XHUCPQ\-9AI5Q:7.CVWB?P7HT]MH_B:QT::RMFTRQU2&:UMA$JB,@DGZE
MHK;ZQ7?)^^J?NTU#WY7A=6?+KI=:76MDNR,_8TK27LX6D[R7+'WG>]WIKKKK
MUOW#@!5551$5(T1%")''&H2..-%PJ1QHJHB* JHH4  "CITHHK$T DGDG)]3
M1110 4I).,DG'3))Q],]*2B@ KA?B;\._#WQ;^'_ (K^&?BV768_"WC72Y-#
M\1+H&K76A:K=:/<.AOM.AU:Q9+NT@U*!7LKXV[I)+93SPAU$A-=U133:::;3
M3336Z:U37FF)I---73333V:>C3]3"\+^&/#W@GPUX?\ !OA'1['P]X5\*:-I
M_A[PYH.F0K;Z?I&BZ5;):6&GVD* *D-O!&J@_>=MTCEG=F.[112;;;;=V]6W
MNWW8]M@HHHH **** "BBB@ HHHH **** ..\6?\ (2@_[!UG_P"@O11XL_Y"
M4'_8.L__ $%Z*WCLO1?D8S^)_+\D>YW'_'O/_P!<9?\ T!JX2Y_U\GU'_H(K
MN[C_ (]Y_P#KC+_Z U<)<_Z^3ZC_ -!%8&Q!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QWBS_D)
M0?\ 8.L__07HH\6?\A*#_L'6?_H+T5O'9>B_(QG\3^7Y(]SN/^/>?_KC+_Z
MU<)<_P"OD^H_]!%=W<?\>\__ %QE_P#0&KA+G_7R?4?^@BL#8@HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QWBS_D)0?]@ZS_\
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M>YTU)E.W>I96C'\()7)&[CWR*]'O;)/#GB+2M:@<O8:YYIO+,\*ERC$Y0*<
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MGW\YN;B33;BULB0"D2R(P*97[Q"D=20 #CK7YT>(+.33]9O["<,);6>:,#@
M 2'MR,=#_P#7YK]'=%.EV=U+I-M?*UPL1:6&3Y9HY>0X!;^''!SV[=:^#_B<
M+5_'6LBT=9(5N6C+CYMTH/S].H!&/Z<U_2/[73AO)LV\,_#OB7VF%><Y1QE7
MRS#T7.$JL\-F>6<^.]E"2AR1PE;!T)UIM*5/V[E*-JC:TRB-*G*@E54ZKI2H
M5U[5UHITYIKFE*\KKF:M))Z7ULK>=K(\8!_VOF!Z$>O'/^'45<BN?ESO("D$
M  D@C[N#C.,GZ_7.:)8%0MN&X!"65<_+SP<]^1R??\ZT<.#EMH.U6PQ.0K9
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M/+SD_+A2P^[@D#CH*\<U&X=WN1O5OD=F*\*=JDX )SD@# )QSC%8<T[NN[+
MGN3QC..@)QBI$82Q-D-C:X))Y.U3DYZG/4\#H<@U\MXK>-.=>+_B#Q)QGBE#
M!YAQ2J6*Q,*2Y:-/$T\$L/+E@DK1KR3JXAV=Y;7O<K!Y9' J:=1SZ-:M65G=
M.][NUW=ORTV_VX_^"??_ "85^Q;_ -FQ?!S\CX,TLBOKJOD7_@GV,?L%_L6C
M.?\ C&+X.?\ J&:77UU7\]5M*M5;6J3T[>\STX[+T7Y!11168PHHHH ****
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M6MWV/5J5U)-Q?,O=LUK=MK1ROMVTU=EV/]L7_@GV2?V"OV+<]?\ AF+X.?\
MJ&:77UU7R+_P3\Q_PP7^Q=@Y'_#,?P<P>O'_  AFEXKZZK\CK?QJVM_WM35:
MI^^];G4MEZ(****R&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=155J-HIS3>FGDV@_$GPU=BXO]9NPNL0VL%I/'=P^8(6B(64P@KD8VD@$#!
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M?!NJ?&JZU>W^V>#-%FN?A@]G\-]>\<PO'+9Q^'M.\82V4KWNI(=.M)C'-.5
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MH;]HGQQX0^*?P5\!_$+5?@I\.=,^,OP"_;E\$&3P/\1_A_8^#KV\T*T^"WQ
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M8O\ ;?$4L3KKAM8UATG1;=9Y]5F=ANA12U>'>,/VGM#_ &DOBE_P2?\ BO\
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MB]5>UN\;_LUK7PB^$?B7Q#>>+O$GPI^&OB+Q9J&BR^&]0\4:[X(\.:KXAO\
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M^^I/F;;=]4T-X6#2CS25E42MRJWM)PG>W+;W7!<JM:U[IF7IVHWVNZ%9ZO\
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M&ZACEM]$O3<WD^L.L]W<F'>JC@)/@1^TR_[($_[,ES^SSX]A\8?";]O'P?\
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MQW]O/!J,GFS3>9)OD+AB'927)S@=\#/'7\N:ZOX;_"SXG_&[QGIGP_\ A#X
M\8?$KQQKDJPZ9X4\$:#J?B77KYGD2(R+I^DVUS.L"22HLUS*J6\ <--+&OS5
MO&%&G1Y8S3E9:*[UTO:Z2>RUWT=DKGK91PM@\H]C5IS;K)*4DDDDU'EL[-VW
M;:W;UE=JYP<\JO;P(K$^667GKSD\CZGZ?SK8\(^#O%OC_P 1Z3X/\#>&=>\8
M^*]>O(=/T3PWX9TF^US7-5O;AUCAM=/TO38+F\NII'955(87/.3@9-?V)?\
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MQ4KSM%P^KI-\BG*-_:I*_O2YE>[3;?T91117"=@4444 %%%% !1110 4444
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MO"^BZAXGL=$WZEK][ID331VV@VK@7\L&U2/+BPV+@8 'K7O_ ,9OV!?B#9_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-*EB\RQ;FZN88KFE?%8=3JXBI&A3HJ&&DJE6=2I4I*I*4IRJ3E_:%_P:R_\
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M(_)LRJ4UC9UJ4Z4=)23:C&U^1RM97=Y=%9K>U]#P#QEX+7Q<;TPQI'#;PR9
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M[C;#9OBL55IXO))JKEL)2FJ4:CIRA[J3BDU"=5/G4TFVM&DUX!K^AR64LUU
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M;_\ 4+TNOKROD/\ X)\C'[!/[%F?^C8?@W_ZA>EU]>4 %%%% !1110 4444
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MV)QL,1A84IRY:%7#4Z6'CB)5*5:I*7+%N,OU"_8T^'W_  34_;-_;0^,_P
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% ''>+/\ D)0?]@ZS_P#07HH\6?\ (2@_[!UG_P"@
MO16\=EZ+\C&?Q/Y?DCW.X_X]Y_\ KC+_ .@-7"7/^OD^H_\ 017=W'_'O/\
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M=5NCBX_X'K<3936Q<:F'69X:,:WM*\H0>+MJJ4:<F_>I/W+QYFU[S2LD?IC
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MY5'4CK7M?A3X=M=6EM:ZV"X>,/;"W&9X]V<J00"[)QNSCIZ#GZ(N? FJ2S>
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MMSD/*\K*'YX7VZ5X^+XPQCBU2P->4I))58)JG!W2O[&R3O;=ZIM75T>#Q/\
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M $2>Z>2,7#Y9GY;'7''<9].,;Q#XZU;7K:VNY[N5=2D#9N&EVK&PSLRN[D@
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MCA:E:6'4N6?L^:$&O.>38!^T_=U5[5PE-K$8B[<&G&W[S3X4M+::;'\-</\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M''>+/^0E!_V#K/\ ]!>BCQ9_R$H/^P=9_P#H+T5O'9>B_(QG\3^7Y(]SN/\
MCWG_ .N,O_H#5PES_KY/J/\ T$5W=Q_Q[S_]<9?_ $!JX2Y_U\GU'_H(K V(
M**** "BBB@ HHHH **** "BBB@ HHHH **** *M];&]L;ZR$TEM]MLKNS^TP
M[?.MQ=6\D!GAW KYL0D\R/<"N]0&!&17SG#^RUX#@N#<)J_B!@-!\(Z!%:R/
M:-96\?A:_BO[K48+81>7'JGB@6UG9:W=#YOL5JD-MY:O)N^EJ* /F_4?V:?#
M^K6MQ8ZEXU\87=CIUQ<7?PYLW.FI;_#&[N-9CU\WNBHEMC6;R/48HTBN-<^T
MNFG Z=CR6)I/^&:?#]SIWB"VUKQCXIUW5/%5EJ5GKVOWD6F0W]Z=<UW3M=UV
MX2*V@CM[<ZH^EVFGR01((8;!!'$ R@U](T4 ?.OC;]FOPAXWO9M5N]4O+35I
M/$U]XA6[GT;0->MX[?4]+M-'O-%CTS7+.[L5A%E90"QU+RO[1L)@98)?X3IV
MOP#T*P\;:;XIT_Q+KUGH.F>(]+\91?#^&WTM?#DGB[2=#7P_:ZY)<+;+J"$6
M"(WV"&2.R2[4W$<2LS"O=Z* /!YO@!X<G^('B/XCR^(-??7/$:>*DD@(L_L=
M@/%7AJT\*2&TQ$)6.E:9:,=.\UF FN[@RAEV@<UXQ_9;\,>,/L3OXP\4:1-I
MVC^$?#]HMO!I6H:8VB^$M/N["+3M1T;4;>;3]5M]0:\EOY8[Z*5+34EAO+1%
MDB4U].T4 ?%MW^S/XK@\4>%/#WASQ+#I'P7TV#P0WC"Q>[AEU7QE_P (,]U+
MI^FW>CIIJ"Q:YEN%6>^L-4ALFMXHQ)IK2HKU[1\(_@7X4^#-QJ\OAB99DOD>
MTTT2:%H.GWFD:4U[/J"Z=-JVF6<&HZ^Z7=P[F_UF>>X=5C5\E=Q]JHH \<\+
M_!/PSX7M]/M$O]5U6VLO#GC7PY-%?F!#J$/C_6;G6?$5]<R6Z(Z7D\ER;2,Q
M%8UMHHB5+KFL#PW^SQH6A:_X2\3ZCXL\2>*=9\#?9+/PK/K$6FQ1:3X=TJQO
M[/1/#L5O9P1QM#IKZA+?2:B1]OU&\AMWO)&6, ?05% 'COAWX*^'_#W]GE-8
MUV]DT[P)X@\ P7,LT5M=K8^)M7;6=6U:&YM526VUF6Y*+'<0,JQ+%&Z#>,UR
MUI^SCHYNH=5\0^._&?BKQ(FIZ'=7'B34)+"SU*YTKPOIFK:9X:T%%L((H;2#
M2_[9N=0?4+=5U'4-32*[NY7D45]%T4 ?*/AG]DOPWX3BU"\TGQSXEA\7S:KH
M&L:/XWCTCPY!JVAWOARVOK*RD:TBLEL=<>\M-2O8]6FUA+B;4)KA[J63SCD>
MH^$_AGK/A70?&/ARU\>:N+77Q*VA:JEK;2:YH&I:A;LVN^)I9[A9+?4->U?5
MI9M28O$+*U M[:"!8X17KM% 'S3IG[.4VF>'M$T>+XI^)%U;PKK5WKOA3Q99
M>&O"VG:QI5]K-A=:;XGGU".&T>U\17GB6UNYOMVH:NLUW!<;)[5XRB@>EVOP
MJ\-V:>#+6"74%TSP3X;\1>&M/T\RH1>P>*=/&G:MJ%_=;1<'4I(3+(MQ$R_O
M[B20C(6O2Z* /(/A;\'=.^%S3/;^)M>\3R1Z!I7@[1&UJ/3X!H'@W0YI9])T
M"W33H(%OY;>25FN-9O\ S=2O2J>?(<'/K]%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 <=XL_P"0E!_V#K/_ -!>BCQ9_P A*#_L'6?_
M *"]%;QV7HOR,9_$_E^2/<[C_CWG_P"N,O\ Z U<)<_Z^3ZC_P!!%=W<?ZB?
M_KC+_P"@-7 7$T9FD(;N.S?W1[5@;#**C\V/^]^C?X4>;'_>_1O\* )**C\V
M/^]^C?X4>;'_ 'OT;_"@"2BH_-C_ +WZ-_A1YL?][]&_PH DHJ/S8_[WZ-_A
M1YL?][]&_P * )**C\V/^]^C?X4>;'_>_1O\* )**C\V/^]^C?X4>;'_ 'OT
M;_"@"2BH_-C_ +WZ-_A1YL?][]&_PH DHJ/S8_[WZ-_A1YL?][]&_P * )**
MC\V/^]^C?X4>;'_>_1O\* )**C\V/^]^C?X4>;'_ 'OT;_"@"2BH_-C_ +WZ
M-_A1YL?][]&_PH DHJ/S8_[WZ-_A1YL?][]&_P * )**C\V/^]^C?X4>;'_>
M_1O\* )**C\V/^]^C?X4>;'_ 'OT;_"@"2BH_-C_ +WZ-_A1YL?][]&_PH D
MHJ/S8_[WZ-_A1YL?][]&_P * )**C\V/^]^C?X4>;'_>_1O\* )**C\V/^]^
MC?X4>;'_ 'OT;_"@"2BH_-C_ +WZ-_A1YL?][]&_PH DHJ/S8_[WZ-_A1YL?
M][]&_P * )**C\V/^]^C?X4>;'_>_1O\* )**C\V/^]^C?X4>;'_ 'OT;_"@
M"2BH_-C_ +WZ-_A1YL?][]&_PH DHJ/S8_[WZ-_A1YL?][]&_P * )**C\V/
M^]^C?X4>;'_>_1O\* )**C\V/^]^C?X4>;'_ 'OT;_"@"2BH_-C_ +WZ-_A1
MYL?][]&_PH DHJ/S8_[WZ-_A1YL?][]&_P * )**C\V/^]^C?X4>;'_>_1O\
M* )**C\V/^]^C?X4>;'_ 'OT;_"@"2BH_-C_ +WZ-_A1YL?][]&_PH DHJ/S
M8_[WZ-_A1YL?][]&_P * )**C\V/^]^C?X4>;'_>_1O\* )**C\V/^]^C?X4
M>;'_ 'OT;_"@"2BH_-C_ +WZ-_A1YL?][]&_PH DHJ/S8_[WZ-_A1YL?][]&
M_P * )**C\V/^]^C?X4>;'_>_1O\* .2\6?\A*#_ +!UG_Z"]%7?$.FWU_>P
KS6D FB%C:QEO-BCPZH2R[9'5N RG.,'/!X-%;)JRU6RZHRDGS/1_=Y'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img136305557_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img136305557_4.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 7Q#1$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***KW-W;6B>9=3QP1\_/*P1>.O)X
M[T 6**Y2Y\=>#;,D77B?1+<CJ)M0MX\?7<XQ^-9__"T/AUG'_":^&L^G]KV>
M?R\VJ49/:,GZ)L7-'NOO1W=%<;!\1/ ERVVW\7>'YF/&V/4[5S^0D)K?M=9T
MF]Q]DU&TN<]/)G23/TVDTK-;I_<%UW7WFG1112&%%%% !12,P52S$!5!))Z
M#J3["L6X\2Z!:$BZUC3K<C((ENHD((Z@[F&* NEN[&W17/V?BOPUJ$PM['7=
M+NYR<"*WO(99"?3:KDYKH!GG..O&/3W]Z NGL[A1110 4444 %%%% !1110
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MZ=$1GS+N=($_[ZD('ZT :=%<*WQ/^':'#^-?#2X_O:M9C^<M:VG>,?"FK_\
M(+\0Z1J'_7I?6\__ * YI\LDKM-+O9V^\7-%[23^:_KJOO.DHI%97 92&4]"
M#D'Z$4M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%?G1^VK^V1??LS6-Q=6EJMP8;=YAN56^['OQ@CGI^73/-?S=^.?\ @YG\
M5^%_%-QH2:%$RPW+0[OLT62 ^W.=N/\ /UKNP^78K%1YJ,$XVO=RM^G]>IR5
ML;AZ$N6I)IZZ6]/EU[W\C^UNBOYVOV+O^"Q.M_M*WVE6MUIL<'V^6&,D1(A
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?#\,BD@HUU$",=<C?Q^-7&G.7PPE+TBW^A+G!.SG%/SDE^;/IFBOEV+]L_\
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M?VW_ /@K;\,?AQ:7FAZ1J<<%S )H0R7*^89!N4L<$9.X#H!T&.^?Y<OVB/\
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M1B5=1P",X'3D]??GYJC0G6JJE'XKZ^B:3:^_3N>Y5K0I4_:2VM=>=U='F/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5X1^T%\0!\.O U]K98IMMYP""1R$XY![YQ7N]?GO_P %'=>A\/\
MP+U&\G?8OEW0SG'(C'?VYK6A!3K4X/:4TF9U9.-.<EHTKW^9_!O_ ,%<?BMK
M'Q'^,5WJ%OJ$OV9;J;<@E8@CS3P><=!CWXQU-?)/[-7PNG^)OB?0X(XS*R7-
MOYF%W$X=2<\$\_YQS6I^V3XAA\2>,-4NK>0.JW,V#G=_RT/UXR/TY]!]O?\
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MX=UF_MQ<RS%!;W,RXW$@8VL/PP<U],_\%QOB_P"+]=\4R6]_=3R1K-(@!>3
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M43:\@PMU>F4#M\S9S_+_ #U_=K_@I?\ \$YKOX2:DT_A;06M+:$L[&&$JNT
ML<A5 &.V?7\:_!'7[.71[V'2KD%;B&81NI&"&#8.>ISQ_P#JK?!O#S@JM!6Y
MUJD]MOU(KQJPE[.J[\NSMH]%MIT_/Y'](_\ P2/_ .0QX:_Z^K/^:U_=3X8_
MY%[1?^P=:_\ HI:_A6_X)'_\ACPU_P!?5G_-:_NI\,?\B]HO_8.M?_12U\KG
M?^\1_P"WORIGN95_!?K^D3=HHHKQ3U3DO&/BZP\':1=:I?<K#;RRHN<!F16(
M!/7&0,@8)' (/-?YWW_!:#XZ:MXL_:!U:.SOYH[&2[G4PK*P3!FQ]W..G]?2
MO[JOVRO$L?AOX<W=S(^P-:7'.<= U?YR7_!1[68O$'Q>U*^C8N/M<QW!L]9,
M_P#Z_P Z^BR"DG6=1WO9I=M&G_PWGZ'BYO-JFH)];Z;[+INSY7^'G@FZ\9>.
M_#BP1LXGO[/S"HR&#3)NSCUS7^CO_P $TOV8_!GA/X%>#_$.HZ#92W]Q8P%#
M+;1[F98XV)+%=V 2"><\CGDU_#A_P3Z\':?XG\7Z/)>PK*T-Y;E=P!^[(A'7
M/3IG\*_T:?V6+*/3O@KX2LH@%C@M%5 !C'[J+M^%=&?UY6A2BVK2;=NNW7Y^
M3TZF>44HN52HTGII\G;;8]X32=,C1$CT^S1$&U52WB50!QC 49_'-<=XR^&O
MA#QCI-]8:KH6GW#7%M,B.;:+<':-@G&W!RV,\9]Z]!I"<8X)R?RKY9-IW3::
MZIZGNM)]%V/\WS_@L/\ LYZQX6^/NNWGA_P]<-817<[*EM:OLV^<Y&!&F,8_
MKBOR;^%GC'X@>$OB=X7BM/#FJ011:I9!REM<*,">,<@*,<#_ .OBO]3[XG_L
M:? KXO:C-JOC;PK;ZG>7!+22O'"6)8Y/+Q,>YZ^O4UX=%_P2N_8\BOX=23X=
M6:W<$BRQR"*U^5T.X'_49R",YSFOIJ&>TH4(TJE&<FH<MTU9]_U[_A8\*KE-
M2=5U(5%&\E*VO=.WRU_X)T/_  3J^(TWC?\ 9V\&6]];RV]]8:3;.PE#!F5X
MXU<'=SE6"D=<@L<\5_))_P '%WC?QCHGQWDT[1]+OKVUEEE!^SQ32(07Q_ "
M,8_G^-?W)_#_ .&/A+X9:7#H_A+3DT^Q@B6&.) H C7&!P%':O!?C7^P_P#L
M^_'_ %G^WOB5X1M]:U')/G21PL<DYSF2)SU_#VKRL'C*6'QDL3*FY0?-:.G,
MKM/S7X_\#T,3A:E?#1HJ:C)*-WK9VM=?UMT/\L#P-X$\:?$'Q)H!/AK48B]W
M;M(WV69<AI%)R2H]NI[U_I*_\$H/@MX<\)_LT>&+K4/#UH-7-O:HTMQ:KYJ_
MN 6(+*&)!4 9)QD]R#7LFA?\$S/V3O#LT-QI?@"T@D@96C(BMA@KR.D K[8\
M'>#="\"Z+;Z!X=M5L]-M@!# H4!0!M'"A1T'I75F6:PQM.-.G"<.65VVUKMV
M?]6,,#@)X6<ISE&;:MHMGIMZ6?R9?U;3=,DT>_MKBSMFM/L<X>,PIM"^4W0;
M>"..?P/'%?QL?\%E?"?A#3M*\07>F6UG#=F6X;,21JX)W=P,]3U_,\\_UW?%
MWXC^'?AUX,U[5=;OX+9TTF^,$+NJL[M;R*I.3\H4G<"<Y('&#FO\[O\ X*3_
M +55W\0?B?XKT"+4FGTXZC=1Q1K(67:9&  ^8C&/3@G]9R6C.IB.>-[0:;[/
M5#S.I3A2479R=TEU6UK^35UL?E?\%P\OQ(LDC&93J2!?4_O>,=^W^%?W_P#_
M  2,L]1M](LFNDD5#90D%@0,>3QR1VS^/MS7\.7[''P1\4>._CCX9N+*TFFT
MZ?5[=I"L;%"IE7/8CI[U_I3_ +'WP3L_AG\._#4ZVBV]U+I=H7PH5B3 H)QC
M..W7^5>GGU:,8*GO*2:]-4]=?+RZZ,X<IIRE.4VK*+[[ZK57Z7OIV_'[/HHH
MKY(^B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?BYXP/KJ=\?SD:O"O^"9O_)W_@S_ +#EO_Z/CKW3_@H'_P E:\7_ /82O?\
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M-T5@<>O;KV./>OZQ/V(_@7K'['W[/-[8>+WQ<Z9IXN)4;AE%O%D%@<D G!Y
M#=!ZUPYSBL-B*,8T:L9S<H^ZGYK9;]CJRRA6HU&ZE-P2B]7Y6O\ A^/I<]"^
M/'@?X4Z#:7VK>(KO3+1RLL^V[>!"&;)P=_4C(Y/Z<U_/C\=/V]O!_P !?%-X
MWA>/2[R*SE?RFA:W<,48XZ'V!X_4<U\J?\%=?V_/%'B:[U?0/ _B&[LIK:ZN
M8F6WN67(61@>%([?@.V:_G<^'EY\2OCWXJM_#-UJ=WJ&H7]R(B9)7D9C(^WI
MN)_B]ZO+\L_<JKB)^ZUK%]%IN_2VED_F+%X^U1TZ*7-?XE;5Z:+?;_ADM3^C
M>_\ ^#B[XG^&Y19^'M -S;PN!LAACDC?:<#*@E3GI7S=^U'_ ,%Q?BU^TSX'
M?P;K?A&33K*2-U++:1PQY=0K-M15&XC@MQD#)S7T%^R%_P $7?&'B[3K75->
MT9;A+A8YB]S;Y&TX<DEL=CR?0<^M>H_MR_\ !+JQ^!/PNDU]-#L86C@D;SX(
M4P2B9;YER#@YSCIBM(O*85X0A2C*HI*TD_M)I;+NM'U^1#682I2E*<E%K56U
M:TT\OQV^[^4OQWK$OB4WUW.GE/,S2$8[DYZ#_/\ 3][O^"#?CV[\#>,9!;,Q
M\VX4'!/\6T?A^O7\_P (?B7IRZ1<W]NJA CNF !CAC^/J?ZU^T'_  1456\8
MJ6 )^T1]?]X5ZF.498*HOLN,5^*77[O+HCAPC:Q5-];V\_B5_P ^I_H$>'[J
MV\<^%()=2A66*]MPLJD $[XP"W3 ;G/(SGK7\/'_  <.?!EO"OQ#@FT6S+V\
MS&7='&<;)$+9.T=3QG/0D^^/[>?A2 /!FE@#'[J,?^0TK\#?^"SWP17X@Q7>
MM26)NOLEI*P<QE]H2(XP<>@P.PZ^U?)936]CC8MOW7=-7\TE_E_P;'T&.INK
MA7HKVB]KZ:/UV1_%;^RSXV;X<^*=(N99OLS_ &F ,&;80?,&>X/Y=<>N*_T,
M_P!D_P")$&I?L+W_ (M^U*[0:"TGF!\X(MF(^;/7'\Z_S6/B=#>^'/'[:98%
M[=K/4RA5<KMV2^V.F.G]!7]@'[)/[6^G^&?^">&L^$+W4%_M*3P^T(5I1OW?
M9'4#&<Y'OV'XU[^;X?VT*,X[RJ0O_AO'\CR,NKJE.I%Z)0E:]][+3[M^J_/\
M,O\ @HU\9#\2O&.O6(NA.;6_O8U7>'SMFD'3)';'XX[5YW_P2B^&^H^/OVA-
M&T:YLI#:/?1?,4.W'GJ >F/?C]:^,O'WB6^\3?%?6C<S-+%>ZS=E QR"LMTY
M&,G'?\>/>OZA/^",O[/%O8^-_#7B^335 D>WF,OE<$;U;.[&._?OU]NG$RCA
M,"X=73LNEG9>>MOD<]&+Q&)B[_;N]GI=+73?2_KN?UG?#KX=V?PA^#MS8V2A
M)X]#,\FT;=A,"X7H#GG)]/KG'\4/_!7_ ,=:EK^HZ[837$K1K>7*A2QQMWM@
M<^F/3VP*_NW\?JJ>!_$:J/E32)U4#^ZJJ !^ &*_@-_X*NE3KVOX0J?MESSC
M_;:OG\F]_$N<M9.2NWZQZ]=&_7U/9S*\:$8IV2CJN]K+^OR[?A)X&U(^%[Y-
M6 #M%/YF&Y&5;=SGCG!']:_:S]E+_@MOX@_9/L/[.L-)MKA#&(F#) RL N""
MK<$$#D'@],5^,WPQ\*W7Q&U^W\)V'_'U=W'DH>IW,P7I[%O\*_7SX8_\$&?C
M3\9K"#4]*ADFCN8TE7;&S<.N[CG\?7/?O7TN,^I./+BW%1W][Y??Z=KGB8=8
MI-2PR;:T=NGE\OOTU/NR'_@Z)\91W#SOX>L9(Y 0L36]JR+VRJ$;5([8'N*_
M)+]M3_@H_J'[:?B.7Q%JUK;VDDA8D9C'WN1PIX[CG^M?:LG_  ;5?'^)RAL9
MLC_IBW]<U/#_ ,&W/[1$/RQ0W40/]V)@!7%1EDN'FJE*=.,TK)WZ::/6_P!]
M_3>W34CFE6/+4A.4>J:WVU_K37;8_GTNM8BMO$GA^>&\CB+W\&=L@!_UR^A'
M&!ZY]S7^F)_P2@_XG_[$/ANV:3SC<Z6D(8'=EFLB5 ]R<"OY.K[_ (-L?VD9
M-2T>[4W;)9W44S@1N2 D@8YP>G'I_P#7_LZ_X)Z_ 'Q#^S=^SSX>^&GB4.-2
MTN.W63>"&_=P>6<Y]P,UQ9UC,-7P]*-&K&<XU+M+HK?\-Y;'5E>'K4JU1U:;
M@G"R;M9ZK3S_ *Z(_D5_X+F?!;QBOB9KG1]&O+N#SI&>6.W=PH+/DDA3@8]2
M, >U?@A\&?B3J7P%UVTU>6 1WEM*CO#)A7#(W(*M@Y!]?\:_U!?VE/V3O!'Q
MZ\/ZC;7^DV$NISV\R1//!&?WCHP#*Q'!W$'''MFOY"/VP?\ @@U\4M/U_6/%
MVBQ@Z--///!%;IE%0L6P AQC! /0>N,9K7+,SP\J,</6:@TDKN_O/3UT\^GX
MD8[ UE4]M2BY:W=GJM5K]ZTZ[:=#N_V1O^"[&O>#M*L/#%U#!]D'E1E)_*>,
M8 4':QQG&<-C/)Y K]AO#7[??@/]I6QL['Q1J.DV\5PJ K+-;HBB3J I8!1R
M2,8 ZU_&;XO_ & ?BK\+4N;DVEXC6A8[HXY ?D)YZ9[?F>QKYGU/Q_\ &OX;
MW9MK'4M9T\VTA4%))HP-C8!'3IC_ /7S714RS"8AN>'E&$GK=;[>7];]C"&.
MQ%)*-52E'16>^EOOLNJM^9_HCZ-^Q)^S1\5K./5;7Q%H4]_= 2>1%=6KL';G
M[N_=DG^Z"1W&:^H_A)^QQX.^$^PZ') %!5E\M" 0"",8 &2.X[=*_P ^7]DK
M_@HE\:?A;XSTS5_%OC76)-%MKB'S8)[V4IL##@ACT &3^?I7]UO_  3U_;B\
M/_M3>$;>6SO1<306T:L[2!B9-H&<D\ D8/UKQ<?@L9A8W=256EZ:+;IKY:>N
MYZ>#Q.'Q#5J?LZG1-V;O:^GZ_KJ?IK9VPM+:*W4Y$2A0?I_G^E6J,@]#FBO$
M/5V"OS__ ."DL<TO[-?B9( QD\NYP%SG_4#TYK] *^0OVV=+75_@AKUH\?FA
MHKCY<9_Y8]<?_6K;#NU>D_\ IY'\_P ^WF9UE>G-=T?YDW[1L%U!XCUT70=6
M-S<8WY_YZ-TR>_:ON'_@C\R+\6;8OT-W%W_V_P!<UX9^WWX>C\/^,M2BB@\@
M/<3DKMQGYFZ_YZ?E7>_\$M?$,7AOXE65Q-(L8>YB.6;'\0'7..O^?3[RH^;!
M3:6\%97\XVM;9>6OS/D8QY<3&+>TM[=[/_)?>?Z/_P !2I\"6!7IY5O_ .@-
MBO;*^:_V6-9BUSX8:;?0R+(K16XRIR!F)C@^_'^>WTI7P%56J23[GUU)6A'T
M7Y6_0**1F55+,0JJ"6).  .22?0"OR<_:Y_X*U? []D7Q+_PC/C<PR7F\IG[
M08^1UX#?Y_.JI4:M>?)2@YRM>RWMW'4J0I1YJDE&/=Z+>WZGZR45_/IIW_!P
ME^R[J4]G!!%$S7CHB!;MB<N0 .O7GT%?L)\+OVA_#'Q6^$B_%K05VZ,]I]J
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MI>^NY^!/[71#?$'4]IR/MLA_#S#C/^?RK]Y?^"(4UK"UN9W"#SXLY)'\:_\
MUZ_GR^,NN1^//$EWJML0T<T[2#'/#,6X_/(/Z5]]_L.?M:Z-^SG:M_:<PB*
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M_)W_ (,_[#EO_P"CXZ]R_P""@;I_PMOQ?EU_Y"5[U8=?,;WKPO\ X)F.A_;
M\&893_Q/+?HP_P">\?O7UD?]QG_V#K_TB)\_4_WN'_7Q?^VG^I1ID9F\ V$0
M&3+X1MHP/4OHZ*!^9K^&3_@KK\"=9T/Q9XK\8W5A+%:275U,)S&P0J7=L@D8
MZ'KGMUK^ZKPLH?PKX>4]&T#2E/T;3X ?T-?EG_P4^_9'L?CC\'M7MM+LT^VR
MV\^]TB4R!O+/=5R>H(_Q!S\;EV)6'Q*YOAG*S?97U/I<90]OAVNL8W7F[+R/
M\X'X)Z[#HGQ>T;Q&DB[-,U:"9G)P%\J96Y^F.>WIUK_0_P#^"<7[>/@[QYX&
M\/\ @S6-8T]'L]/MK>)Q,HDBD2-4P1QD<8(/IP<\C^!3]HK]G/Q=^S?XKO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3!P1\I.&)SSWSSC-?R7_ +2W_!$WXU:EK>H#P)X<N4L&EE,(@MI0N"S8.47
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M:UB4*D2#"J%&!^G_ -:M' '0 45Y%6M.M)SG)MO\#T:=*%**C"*2796/EO\
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MKPSW%PI^S2@U:R;O?_A_RZ'FRRC#2ES7DM;VZ'\CWP1_X(ZW>A_#G5;/7O#
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M']M-Z?J/\:Q:* -K^VF]/U'^-']M-Z?J/\:Q:* -K^VF]/U'^-']M-Z?J/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M']M-Z?J/\:Q:* -K^VF]/U'^-']M-Z?J/\:Q:* -K^VF]/U'^-']M-Z?J/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,+6?N#ZC^E<VO0?0?RKI-9^X/J/Z5S:]!]!_*@!:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***7!/0$T )12X/H?R-)@CJ,4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !4MO\ \?"?5?\ V:HJEM_^/A/JO_LU
M '<1_<7Z4^F1_<7Z4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N;UK[W_ ?Z"NDKF]:^]_P'^@H PEZ#Z#^5+2+T'T'\J6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** $/5?K_0UVEA_Q[I]!_6N+/5?K_0UVEA_Q[I]!_6@"
M[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 86L_<'U']*YM>@^@_E72:
MS]P?4?TKFUZ#Z#^5 "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !112X)Z G\* $HI<'T/Y&DH **** "BBB@ HHHH **** "E +$ =
M32HI=@JC)-/O+S3='L9[S4;A($A5F9G(  49)R>_7KT]!0!<CLWQN.T#U)QG
M_P"M[=/<\U3NM7T_3LK<R0 CKF1>/PZ_A^'/%?EA^UQ_P41\#?!72;_^SO$N
MGF\MEE'E?:X@VY01C;NSP>.GX5_-7\=O^"ZWQ:&J7<7@VWN-4A$CK&]H3,"
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MB@ HHHH **** "N;UK[W_ ?Z"NDKF]:^]_P'^@H PEZ#Z#^5+2+T'T'\J6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $/5?K_ $-=I8?\>Z?0?UKBSU7Z_P!#7:6'
M_'NGT']: +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A:S]P?4?TKF
MUZ#Z#^5=)K/W!]1_2N;7H/H/Y4 +1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !112JI8@#DF@!*>D9?N!UZ^W^?\BKJ6QC4R2)\JC))QTQ^G?VZ>^?
M,/&WQK^'W@.UEEUW4K:T\A6+F26,8QDGJ?3_ /52;2W:7J.*<MDW\OQ\OG8]
M*6U!Y:5!]2!C]>?T%3+%"GWKF$8Z L.,?4_KGO7Y4?%;_@IM\"/"OVF&'QAI
MT<T>]0HN8L[AG_:SG(&#WS7YV^.O^"NWA5;B9=$\76\B!FV[+D$$9XZ/Z<#J
M/Y5485:C_=TIS_PIM=-=$_Z\]#*KB<%A_P#><;AL/;=5:D86V>KEIW^Y=S^F
MPBV;@74)_P"!J?RYZU&;17Y29&^A'/U]_3 ]N:_EO\,_\%>=(%W'_:7BN%8M
MX+;KD#"@@'.6].1Z^QK[R^$O_!57X*:VUO#J?C/3O-?8,/<QG).!C!;UR/4<
M_@YTZU-7G1J17=Q?E_G^7?2:&*R_$/EPV/PE:3UY:=6,GK;:S?W>7JE^R[VS
M)GD$#^?I_G^=5B,<&O$OAY^U!\*?B'%!_8FM65V\ZKM\N:)B2PXQANG3]:][
M4)J$8FLEW1L P*D$8('IUS[9Z].U0FFKHW<7'=-+H^C[6?6Y1HI[HR$AA@CB
MF4Q!1110 444Y!N8#WH U[6W%L%NI?N!2Q)Z8 !_SS_3/XG?\%//VZ]&^!'A
MW6=+2_6WNIK*Y6/RY51M_E,!C!SD'_/6OV+^*.N#PUX&O]2#^68+8D-G&/W3
M$X-?YZ?_  6Z^.]_XI^)MGH*7LCQ75Y]F=5D.,/)Y9& <]"1_P#6H _-K6?%
M?QV_;V^.NI>$O!^NZO+;7VINL<:32NFR65E  &1CW_\ U5_2'^Q%_P $,/'E
MCX?L;[XBZ:NHRR+%/(]["7)# $_?P.<COZ5P/_!"G]C7PXOC;P[X_N]/1I[L
M6UT998P02S!\DL/?U[U_<!(UOH=G;6UI;QI!&GEQ1* BJ(U4#A0 21U/4F@#
M\#[[_@COX&?1S:P>#]*6Z$10.+*,-N"X!!VYZ^_Z<'\GOVC_ /@A5\64N-0U
MKP/;/IT7F-)#]EB:/ RS#;MZ'I_];O\ V?G7[C=CR(\9_P!K&/KG_P"O4QU!
M=1B>UN((O+E&UMWS*0>O#9&>OK^= '\LG_!.;]E#XW?L\W4%AXRU#4)52XC&
M)FD("K(,\$GL.!ZY]J_J1\.(]SX5L8WR9OLR;LGG> #DGOQG^7:N<N?AWX>D
MG6Y2&W67<&&Q%&&SD9X^N?Z9KK[5X-#LY!=,(;:"+<&;A=J@G&3@=.* .$^)
MOCO3?AYX*OM6O)XHS:P2.2S!<;5)SR?IW],]Z_B&_P""O7[86M?$UM3T'P?J
M=SO#7%N5MI6/\3IR$;C]/;-?L1_P5&_;8M/#%CXB\%Z+K"+=R07$,<*3?,6(
M*@!5;)[?X=J_!#]D#]G'Q+^U-XB\3ZMXHL+B^MHI;FXC>6-I%VY9P1N&.AH
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MR@).^1!T'/<'M[>]> ZU^V;\(]+E>&7Q#8H4)&#/&,<\\9_^OSSVJE%OR^3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH PM9^X/J/Z5S:]!]!_*NDUG[@^H_I7-KT'T'\J %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BB@<L%[MTH 4 G@ GZ5=D:QL+3[;=W"0(@+%G8+@
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MJW$4%S86UY:X<3QQRAE((=74-G/3@DC@X]ZQB"#@\$=1[U\H?L2_M'Z7\>/
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MBBNO^"XUS=:3]ACBU,3R1!-P:?.XKCV)Y]P>:^*?%?[5?QD_:6\12Z?X;O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/>OY.OVRH_-^(%@;TOM&I(3NSQB<8^]Q[U_7+KUFFL>';C3^IFB=,=^5./\
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M&&;<4.,X!)]/7J.:_@G\6V_Q%_8B_:!L?L.F:DFGZ=K"S%EBF2,+%-DY(4*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDKKWM/7J]^HTW%IK=.Z^1_+G_P $POVEQH5I<>'_ !'?LMQ).+=%GDP>9-H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@S[_ /Z_PYK_ %,G%PC2I)_PXQ3>]_=2>U_QVW;[?$F=1114@%%%% "F6?\
MAD8#V.#_ )_QI/.N?^>LG_?9_P#BJ** '"6?^*1B/=B3^'6FGGKS]>:** %#
M,O*DCZ&G>?<=I#_WTW^-,HH ?Y]Q_P ]#_WTU'GW'_/0_P#?34RB@!_G3'[T
MA/XD_P Z:22<DY-)10 4444 %%%% !1110 4444 (>J_7^AKM+#_ (]T^@_K
M7%GJOU_H:[2P_P"/=/H/ZT 7:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O5
MO^/8_P# OY"N2'3\6_F:ZW5O^/8_\"_D*Y(=/Q;^9H 6BBB@ HHHH ?&YC=7
M'8Y_S^->0_&/X0V/Q2\,:P+HKYJ6=R8U89+,D+-@>^,?6O6ZE$SB"6 ,1'*"
MK+V(88.?J/SZ'BNC"8S$Y?BJ&-P51T<30J0G"I'=)2BVOG;RVW.?%X3#X_#5
ML'BZ:JT*T)1G"6SYE:_K;9]'9]S^"K]JKX8>*/A+\=]9OK'2[H65MJ4C+.D+
MA=JRDYW8 ]N/8GW_ %<_8;_X*$M\-?"XTS5IHHS&J1LES(HSC'57;) X[=>>
MM?KI^U3^QYX4^+&A7\VFZ+:R:W<QR'SO)4R&1E(SD+DDD\<Y/IQ7\_7Q&_X)
M+?M#OJ=R_A%+NVMGE9E6&.55V[N/NX'3MCOQWK_0/*/$3PU\7^#<!D/'&,P>
M2XK T</AY5\?5476=",8N:UNE)IM(_A;-> ?$/PKXLQF=\&83%YOA<;6K5XT
M<'3<E35:5_9O1W<4[/RTZGUS^V%_P4L?Q3X9FL]'NHM\J.BK;3+QN!P $;CD
M]NG<5^''PHTWXC?'#X^:7>-<ZHME=ZFC%E:<H%:4'J"5(QZ=#V'2OO'PQ_P2
M-_:1GN[?_A)$O;BW612XECF*D C)P3@<?CDGZU^TG[)O[ VG_"M--OM>T:!=
M2M3&YE: ;PRCDDE<]??W/6O4_P!=O"7P?X5S' \'8_+,ZS#&8:O0A5PLH5)0
M=6+49>\I/1VZW^=CSEP=XH^*W$N7XSBS!9AE&!PE?#UITL1&5.,E2E%RBN7E
M2ND^VWD?9?[)WP?N?A?X7T=[FXDGDFM;<OYA8M\R(3][^=7_ -N-E'PLOR2
M/LLQY_W37U':P065E:6L*A5MTC0    ( .@[<=J\(_:?\"ZE\3_ 5UH.CAFN
M98)$ 4%FRR\=.O7'\^1S_!^6YW/,>.<OSO,ZL::GF4:M>K))1ITE44E)V6BC
M&Z;VO8_M;,<FA@>#L=D^74I3E#+Y4J%)-RE.HX0NEW<FG_3/X;/BM-$/CG8
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M8#3/#RX79N@!].J?_7!_ 9P1FOQ:^(A-W^TW*&Y!U5LCD_\ +QD_A[=B>?\
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M25S>M?>_X#_04 82]!]!_*EI%Z#Z#^5+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!-%$'5V_NC/^?\ ./Z_(W[5G[0!^ W@34O%*%0;
M*WDER2!]Q&;/7V_PK[ M_P#53?0_R'^-?B'_ ,%C+^\MOV?/%36;,DGV*X (
M)!SY3XZ>GK]<T+=+N[!T;[*Y^5GC/_@O9XLM]9O+'2K1[H6]P\/[KY_NN5&,
M'I[_ $JI#_P72^)$D"R_V+=<@'F-OY_C7XA_L0_!F?XJ:[KLVJVJWA%_-CS4
M,G6<XSG/;\<8ZU^UUE^P]H[:1&XT.VSY8_Y8]>!QT_SUK]>X?\(L5G^78?,8
M8A4X8A*45RO;2_E_GVUU_F?C/Z2N5\'9]B\AKX"56I@Y^S<U-)-Z=+7U]2:+
M_@O#X]M;G==:7<11*069U8!1GN3U_$^O3%?K;^PG_P %,)OVFKM;*Y9 X*J5
MW D'@= 3_A7\[?[2/[)-IX7\":YJEGI,$,L%I*Z.D6"&4$YR .N.WUZ@5+_P
M10O=:TSXF:I9W$KB.'4)(U7<V %EQP#P..G _P /GN-.!*_!OLO;5U5]K'F4
M4FOY>CT]+?CT^]\,?%G!>)RQ#PV&>'^K2C!IR4D[V>FW=6OH?WHV,0OM/%\#
MD,@;(]QG^OIV JK3_ TIG\(6DC<LUL,GZ1J1^6?Z=*C'5OK_ $%? Q?,D^ZN
M?KDH\K<>VF@M%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !112@9./6@!*ECB=SPK8[\>]7[;3V
MD <LJK_M$#\?P'7G'7Z'A_'_ ,4?#WPUTVYO-5NK5!#$SDM(@/"D]R/3TY^M
M ':WL^DZ19F[O[I+<(NYFD8*!@9SEB/?^O'-?)7Q)_:P\"^"KY;%?$.GB1FV
MA#=P@D] ,%\]>PQCL>E?BU^W;_P6!\#^%K+6?#&B:D4U",2PI]FG (<!U&-N
M3U_'U&<5_/9I?CO]HK]KKX@V>I>"-9UMM/.H1LP62=DV&4?W2.,']?>@#^^3
MX6_&>P^)%U%'9W<,Z2A2ICD5P0<=-K'U'3_]7T)>6QM7"<\C//X?X_I7Y,?\
M$\O@3\4/A[H&@ZEXVFNI66U@,S3^9DL "<[SGG\Z_7/5IXIGCV'.U<$^Y.>F
M>PR#UYH QZ*** %4LCJX8C!''^?\^];T=Y9W\)MKRW2960H5D1'5@005(<<<
M=Q]:P*0[E^YP<]L#_/:@#\Z_VO\ _@G)X/\ V@-+U>\MXK6UO;F"9L1QJL@W
M G@A?F^@)X^E?RD_M#_\$^/'/[*>N7NK^&(]4OT6>294@CN)% 5F; "J<^G&
M?RK^]ZUU&; CN')BQM(./NXQC.#^1..M<CXO^$7PP^(5M-#XDT'3M2$R,"\Z
M1EU+ \X92#US@<GU%<N/R_+\VP\\)F>&AB:$X\KC*,=%MO:_X_(J$Y0DI1;3
M74_@'^&7[??Q:^'6HV_A_5= U**&V<1&6>WF4 (<')=1V'<Y[_3]2_A3_P %
M!E\06]N-8GAM78*&$TJ(<G YW$>_OSCJ3G]-_P!IG_@EEX)\:1ZA<^!O"UC;
MW4OFM$\%J@.3D@C8F0<G^OJ*_#[XK?\ !'K]I33+RXG\+I>VL"N[1K#',H !
M.W[OIQ[<<U_/O%?T:^&,\G4Q&5NAE\YMODMS.[:?DENM>YZM#.*U*/+-2G;2
MZ?IK^/X,_4?1OVJ_"%] LDVMZ<I*ACFZA7J/]\^W''/'UYOQQ^V1X7\-:?/=
MV6L6,LD2,P1+J)F)P<8&_/X=\C':OP[U+_@F]^V=I<K0QZAK*[3MPOVD# X'
M1@.GO_6M/PY_P2^_;(\2W4<-]>:Q-!(R@JXN2,9YR">GKCCD=:_+J?T2Z_UI
M.KFU%T%)7CR-)Q;6C\NIVO/5RZ4W?3M>^FKTL^M^Y>_:C_;S\:>/-4&AZ!9W
M%W%=.UL6ME,G#GRQ]S/K^?-?17_!-_\ 8MU_XE_$73/&WB+3;J*.]FBN7-S
MX7YW#'EEQQGG^=?9O[)O_!(#Q3H%Y8ZC\2]&6]:*2*1VN;9F.%;))+AATS_+
MZ?TA_"GX.> ?A3X:T^PT;2+*RO+6W1&DCB1)!(B@ *  >H!)/7..U?TOX?\
MA?D/A_A%#"4:57%RBHSKP2W5G?5/\'I>Z/'Q6,JXJ3<FU&^US;^&WP]T[X5:
M!;:18+&%$"(P0  ,@4$8&,\XY'!)XKH)&WR._P#>8G\SFI;R[ENG!+95<A1Q
MP,Y&>W/>J]?H[;DVV[M]3C"BBBD 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (>J_7^AKM+#_CW3Z#^M<6>J_7^AKM+#_CW3Z#^M
M %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#156Q9FL;-F.6:UMV8GJ6,*$D_4U:KS#O"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M61;=MP([$9Z=OI7\5_\ P59.WXQ>(VZ_Z;,<?25A7]OEBJ)I5VD2A(ECG$:
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M5_\ C]?_ '(__01697Y,?T6%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !115JWMS,Z@G:K'&>GXY_P ]O>@!
ML%O),?E4L!R<>F:QO&WCGPO\/-#FUC6[R&S2VB=W>614 VC.22>GH#ZU!X^\
M>Z'\-=&O-1U"_MXO+MW<"61%.0I(ZGVX'7VK^1[_ (*:_P#!4Z74[CQ#\,O"
ML\TEU,TUI$]I(Y.6+H-OED^WO0!ZK_P4W_X*F2:/->>%?AKK\-X]V)K7R[2X
MWMN<,BJ A)SD_KU%?B-^RU^RS\7_ -L/XP1:UX\T?5VT'5+Y+DW,D,S1,DDN
M<@M@8QVZ5W?[#/\ P3W^*'[9'C6/Q?KT^H26<5^ET4O#(ZLGG"0C$H.05[GL
M.IK^Y[]F/]ESP3\ _A_HVD/H6GC5=.M889;H6T0E+H@!.Y5#9R.YZY- '!?L
M0?L?>%_V:_!5AINFQ%94MX6V,NT[P@Y.3G /U!/ QUI?V[W8^!KB,9Q]BE.1
MVRK9Z=?QZ?C7V]'?Q7%Y;I;#9&"%P!M!&.FT<8QQ@=LY'>OB_P#;BM3/X(NL
M#/\ H4O_ * ?\_UJ*GP_./\ Z4CIPEO;I=>65O*Z>OX,_A7\9G_C)Z09X_M1
M\YQT\[/Y=:_>3X0X_L&WQ_S[)_Z!_/KFOP?^(R&T_:=E9N -4;.1@?Z_GZ8Z
MGW]J_=/X)3BYT"W(.<6ZCZ?(,_AC../UK^IO"22>3SZOF7KLKO?[O5]3_ W]
MH71G2\2,'4G?E=*H[^M1??Y*W;8[:[_X^I/]_P#K3*?><7<@_P!L_HP_QIE?
MJBWEZ_HC^"G\%-_W5^2"BBBF2%%%% !1110 4444 %.3[P_'^1IM.3[P_'^1
MH FU#_D"7_\ U[S?^@O7X3?M%I_Q5%YZ_;6/_CXX].O]>:_=757\O1-0]K>8
M9_X Q&/S_P#UU^$GQ_N1-XPO(\Y/V\\?]M#^7_U^M?$^(4N7A_$=;TI?E'^N
M_P KV_I_Z'=&57Q?RF*O=8_"WLF]IQ[?T]C^FC_@C,''PWASTVIG_OD?I["O
MWFU08LUXP=QS]:_#7_@C59-_PK&%]N (T/M]T8/;GI^=?N/J;9M\9Y#'^?;Z
M?IFOXZCJY/35NUO6_P!VJ/\ I'K1<:>'@[KDA&^]V^6&_7?OZLYE?NC_ #WI
MU'2BK,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J6W_X
M^$^J_P#LU15+;_\ 'PGU7_V:@#N(_N+]*?3(_N+]*?0 4444 %%%% !1110
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MQ]N?TH _1O\ :6_;3^&WPAT34@?$5C:WUM#*5C:X16WJ#VW#GIQ7\CO[:?\
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M@O[\?S1%3X)>A_GM?\%44F\9_&NQTN\O+F."XU)(W"NP&'E /&X=OZ5^F/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH R]6_P"/8_\  OY"N2'3\6_F:ZW5O^/8_P#
MOY"N2'3\6_F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#HK+_D%W?\ USG_ /1%?P__ /!5K_DL7B7VO)?_ $:]?W 67_(+N_\ KG/_
M .B*_A__ ."K7_)8?$W_ %^2_P#HUZWP/_(SRS_L+I_^E1.7-/\ D1YY_P!B
M^K^3.R_X)K_\@.^'^_\ S_\ KU^I>DDB_P!1QZ-_Z"W\NM?EI_P37_Y =]_P
M/^8K]2])_P"/_4?H_P#Z ]?Z"\-_\B+"_P#7F/Y(_P 8>.O^2KSO_K\__3A_
M._\ MR@'X\J3Q_I;#ZXE _6OZ'_^"-O^I7_KWB_]%K7\[_[<Q'_"^%]KUB?I
MYW_UJ_H@_P""-O\ J5_Z]XO_ $6M?R;XS_\ )1T_^OE3\X'^CGT8&WP3*ZVI
M4;?<O^ ?OKJ__'Z_^Y'_ .@BLRM/5_\ C]?_ '(__01697Y)'9>B_(_HP***
M*8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%3PPO*PPI*@C)QG'U]O\ ]5 #K:VDN7VH.@SSP,#_ #_G%<I\1OB5X?\
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MH **** "BBB@ HHHH NV_P#J9OH?Y"OP]_X+%?\ ) /%'_7I/_Z*DK]PK?\
MU,WT/\A7X>_\%BO^2 >*/^O2?_T5)2^W#U?Z%+X9?]N_F?S%?\$P/^0KKO\
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M#^X:O\6?^)BT4459F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M0]5^O]#7:6'_ ![I]!_6N+/5?K_0UVEA_P >Z?0?UH NT444 %%%% !1110
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M_P!<Y_\ T17\/_\ P5:_Y+#XF_Z_)?\ T:]?W 67_(+N_P#KG/\ ^B*_A_\
M^"K7_)8?$W_7Y+_Z->M\#_R,\L_["Z?_ *5$Y<T_Y$6>?]B^K^3.R_X)K_\
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M@?\ (5UW_K^E_P#2EJ_HYL/^0*G_ %R'\C7]U^&'_))9=_U[7XR3/\DO'O\
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M-?T2?\$W/^"2-SX5LM"\4?%+0[?4+N(PW%Q+>V^]V)V.23)DD\=.,]J^V/V
MO^"6'PS^!VB:-XKN-,CBUF6UMIKA9H$W^<44L#D!L[LYS],CI7[.H]OX?M8=
M,T^");>",)&$ 4+P.2J\$XX_  YZ4 9?AOPAX-^'VFPZ?X:TJQTJ*"%846TC
M57<*NW,F#M_# ] #R:=/=W,\A+2,8R>%SQCZ?2HI)6N&+/G.>WXG'3W_ )4T
M# P.U "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A
MZK]?Z&NTL/\ CW3Z#^M<6>J_7^AKM+#_ (]T^@_K0!=HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY
MPO\ @X\MX;C]EZT$T:R!;>[*AAD [YC_ # K^CVOYRO^#C3G]F"U_P"O:[_1
MIC7W?AG_ ,ESP[_V'P_)GQGB%_R1N??]@4O_ $J)_!7^SM\:_&7P:\96.NZ7
MJMU9Z99Z@LLL4,KHFU7SD ' X'.!W&>:_NR_X);_ /!4KPO\2]*L/#NOZLL\
MXAAM6$]QE@X54RNXYW @8ZC(QZBO\_#3K<7%K/$V1F5AD>Y?\.G/^%>^_ WX
M[^,/@)XET^]\+W5Q%']JA>?;(RC:'4L1@XX SG&.N,9(/]I\=< 9?QCE]2G*
MG&&/A!^PKZ1;:MI)I7]-3^3.$^-L;PMFKJTI-X651.MAHJ\/9J"YJD4Y6N[-
MRBEJVY+71_ZZFBZQ8Z_IEKJNG2K-:7<8DB=6##![$CC(!!^A![UJU_-M_P $
MP_\ @IUI'Q"T/P[X4\5^(+<W3PV\4L,UPN\/A5(PQZ@]Q@C//.:_HUTC6=-U
MVRBU#2KN*\M9E5TDB8,,,-P!QD X]"1Z$U_"/$?#F8<-9C6P&.HS@X3DJ=1Q
M:C.*;LTVDKM:^:U1_9'#W$& XBP%+&X*K&?/"+G"ZYH2:3DFDWHF[&I1117S
MY[P4444 %%%% !1110 4444 %>#?M&_\DSUC_KE+_P"BS7O->#?M&_\ ),]8
M_P"N4O\ Z+-73_B4_P#''_TI$5/@EZ'^>U_P5%1[WXJ)86GRWL]_Y<++]X,T
M@"D>^<'\>O2M3]F[]@O]L_XK:=I<WPV\3ZW8PW-O&\ MI9UPC_= V,,?AQC'
M:JO_  4CX^/VDGN-6B^G^M!_I7]27_!(S5Y(O#/AF,0Q,KZ=;1L2HW8:,*2I
MP<, 3@^O-?7XC$U,-@:,H1A)N.TTFOL]SYNC1A6Q4XS<DDX_"VM-.WZ?Y'X@
M:Q_P1\_X*=W]E)8W?CKQ5)#-'C8]Q=$%3V(,GH?>OM[]A#_@C5\7_ ^MC4?C
M_#-KZB=9<ZG$TW1MQQYF[GW_ ")%?UQT5X53-\54A*G:E!2W<(<K^]/M_6K/
M7AEM"$U.\Y-=)2NOQ/'_ (7_  7\"?#'1+#3O#^@6-E+;PHAEBA5&5D &%V@
M8Z<DY)/I7K^>2,'COV-+7&?$37Y?"W@?Q1XB@;;-H^D75]&WHT*@@_A7F7E.
M6K;E)[MWU;[G>DHK16271+9'&?&WXU^%_@?X7;Q1XGGACM5\PB.241LPC )(
MYR022.G4'TK\</B!_P %_?V9? &KS:1?63SS12-&6CNF(RIP?N@]Z_GP_P""
MC7_!3'XS?%SQUJ_POT:\NKJWM-4GT\Q6\LC$1K-LQM&>W;J/QK[=_P""?/\
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MY[''M]ZZC?+=&,091$&,9Q[8P!@>@QV%6;VYCLQ]@M%2*!$5%C0 *HQ]T8Y
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M49OD6+ISHU:>.Q,H1FG%\BJ-*R>ZL8M% Z#/7O174>4%%%% !1110 444=*
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M5?\ V:HJEM_^/A/JO_LU '<1_<7Z4^F1_<7Z4^@ HHHH **** "BBB@ HHI
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M_P#7O_[22D'5OK_05_-=/X(^A_;]3XY>HM%%%60%%%% !1110 4444 %%%%
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M#U619EW_ -VG_D'^M7#G_0ZR_7;_ &B'EY^?]69^OE%?D)_P^Q_8H_Z')/\
MP,M?\*7_ (?8?L4_]#E'_P"!MI_A3_U.XI_Z$.9_^$T_\A?ZU\-_]#K+_P#P
MH@?KU17Y#?\ #Z[]BK_H<4_\#+7_  I1_P %KOV*B?\ D<HQ];VU_P *:X,X
MJ>V09G_X2S\O+S0O];.&O^AWEW_A3#_,_7BBOR)_X?5_L5_]#E'_ .!MK_\
M$TH_X+4_L6'IXQC]/^/VU_PI_P"IG%?_ $3^:?\ A+/_ "\_S[,7^MW#/_0\
MR[YXF'6WGYH_76OYS?\ @XQ4G]F"U."1]FNP3V^_+G]*^P8O^"TW[%;R(C>,
MXT5F +_;+1MH/?'RYQZ9'UK\8_\ @MI_P46_9U_:+^ ,?@?X8^(8=9U!4N'\
MSS(3)OF7 0+&[X52 ?O')R3C.*^T\/.%.)<'QGD&(Q.29C0H4L;3G5JU<-.%
M.G"SO*4FK)*ZW??LSY'COB?A[%<(YY0P^<X"M6J8.4:5*G7A*<YMQ:C&*=VV
MO^"?Q:Z. (9<?\]F_F?\:U_+#9.T%NS$#CCUQ].E4]+@:&*57')D+#(['/\
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MTIRCN[.Q_G8?LU?M+7WP%^//B"VDN7LXX[V: *93&%VN5 QN R!^A]LU]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-XJLY;_3[Z]%Y']KC,B%9)-X(W@@]>.. /7J ?J-_P $>/\ @G/:7GAWP_\
M%/Q/9,NIP2079%U$=V<!S]\=<X]/2OZMYFATG3+2QM$2-+>"&WC2,!51(4"X
M  X)*Y.!DG).2:\]^$GPVT3X/>$+3PSIL$%LD,$8VP*JJ3&FW VG'7]!],])
M)))([%SN&21GGOQ[<#V^E $9)D;S&)R3D_@?7_/UIU%% !1110 4444 %'I[
M'/\ /_&BB@#H+65+Z,6<HW(8V4@C/\)!_3W]_>OP"_X*M?LP+XPL=2UNRL#*
M;>VN9@T<1;I&QSE0>_UX]2>?WGLY_L\PD/3_ #Q^/O7&?%KP%I?Q"\%ZS;7%
MM'/++9W$:;D5B=T9!'(/=ACZU+NFI1=I1:DFM]'<JFJ<HU,/5C>C6IRA--73
MYUROOTWOVVL?YU?[-OC'5/A+\>+W3]4=[.TM;]HAYQV* LI&.< 8Z]/>OZ+_
M  AXCLO'^BPZM:S+<+]G4[D8-_"#R0?<?X'I7X^_\%*/V8=:^#?B?6O&6E64
MELKZA/,'@B*?*'+=5ZCOGIUXS7?_ + '[24#^%+;PWK5R?MTC) !.^7S]W/)
MZ$G\Z_I?PMXJIXS"+*L342G%7BY2=WRI))7?IU2N['^'OT]_ #%\-\15./,C
MPLIX.NXQK>QA[J<WSSDW%)7W6O9GZA.K+(ZD< D#\#_D=,<4E;U]9)]CAOXW
M1UN0)%"'/#C<.GM^GZX//<8/IZ5^QVL[/U^3UT?;73R/\W*=2-6"E'I[K6S4
MHZ--=[K7]-@HHHH+"BBB@ IRC<P7U.*83@9ZUHVEMN*S,0$5@23TXYZ^W/T[
M<\T+5VZZ?B*3Y8N3V5_FUTL3)<0Z1;7$]PXB41LV6X'"]>HQ].YZ5^)W[9'Q
MIEU35]4\*:;<B5IF>)(XWR6R2IP <CJ,< ]N.*_0/]JWXT6'@'PY(([A%D:)
MDPCX8L%((P/4]>O?Z5^-WP8^'_B+]H7]H/3+B.*XN;"]U-,Y5GC*F9>_(Q@]
M>,\YYK\W\1>)J639;/"TYKVU6+A9/7WHI+1=NB37S/[2^A=X&9AXF<<X7.\7
MA)O*LOJ4L3SSA>FW0G!R5VK7LG_F?L'_ ,$:OV6)?&FI2ZUK^GN-DXG1IHB.
MCA@<E3CCDGH<<5_8/HFD6WA?PY;Z';A56TMQ"BK@#E0,C'L._7O7Q]^Q5^S=
M:? KP;I[FTBMI[O3X<D1A&S)$IR>,\DGD]_H:^OM2F:2[?:V8S@#KC &.W'(
MZ=>E?R<YSJU)UZC;J5&VV]6TW==_+[O0_P"@^GAL/E^#PN68%1AA,'2IPI1B
MK134(QDTDE;;R* !&<G//'?BEHHI@%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !4MO\ \?"?5?\ V:HJEM_^/A/JO_LU '<1_<7Z
M4^F1_<7Z4^@ HHHH **** "BBB@ KYX_:I^*U]\%/@9XY^).FJ7O/#>FR7<*
MCJ66.5^.O=!7T/7Q-_P4017_ &1OBXKJ&4Z%/D$9!_T>XZUWY73A6S+ 4:L5
M.G5Q>'ISB]I0E5C&2?JFT<695)T<OQM6G+EJ4\+7G"2^S*-.3B_DT?QE>(/^
M#HKX\Z9XU\1:#%I<K6NEZC>6D) CY%O.\8.&8'!V#&3SR<8I%_X.C?CQCG2I
MORB_+[_]*_F%\;Z;:#XI>-@+:+!UW5?X> /MDQ_+O]:JBPM!@"WC)_W>3^5?
MVE0\-^#JE.G)Y%A&W"/V9M_#%W;YM?-Z?<S^4L5Q[Q!2G&,<WS)-TX3DE5HM
M<\E&4N5.E=0O=13NTM+O5G]0X_X.B_CL?^85-^"Q'_V<4]?^#HGX['_F%3?3
M;$"?I\Y_E7\O:V%H!S;Q9_W<T\6%H3Q;Q9_W:[(^&?!6G_"#A&[+[,[K;6_-
MOW]3BEXA\1J__"QF7_@RCY?].;+9_?<_J&7_ (.A?CNW_,*F ^D7_P 53_\
MB*#^.W_0*G_\@_\ Q5?R^BPM!C%O'GIG;R:D_L^V_P">$7Y=/\^V:WAX8\$M
MJ^0X3O9J7D_YNEMCG?B-Q)?_ )'.9_*I0\K_ /+E7Z_\,V?U +_P=!?'8_\
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ML=;^,&OQ7UPB%-5G W,!R)B>G?G/M^1S^D?[6_P]N_&?PK\1Z?:(3-=6,Z*
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M  &NMMM#FECJU]73MTO2I>2_D^^Q@)IVIG!_M:[.>@\Z3\^O\_K5I=.U(?\
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MT5D]?Z_3_AS@E4O>W7K_ ,  ,D ?_J%.DCWQO&O!==N>_P!>.<_Y%2 8&/\
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M%KH\#JTEY K!@0)+F%"3GIAF!Y/7OZ8/-? /_!1K0%\1_!F[M])U5+>_6"Y
M6WN4#E"N5;Y&W9)+ ?[OTKS<XQU3+LKQN.H4U6K8:C*K3I.W+.4;6BW>^M]+
M>I]EX=<,X'C/COACA7-<=++,KSS,Z&!QN/IZU<+3JRLZL([/EMJWIKJ=W?\
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MY8_KT/X7Q]1*JM=?9TUZ>ZOQ_I@J<<C\/2G@ =!UIZJ3ST%2I'S_ )X_^O\
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MD>H_,49!Z$'\:W!%X>)P-1M"?07UL3^0;-*]CI[(3;7*2'J%25),Y''W"?\
M/Z@&'13ID>)RNQL>N#T_I^O]:;0 4444 %%%% !1110 4444 %%%% !5ZRMV
MDEB++E"P_KD^G'O_ $JK%$TK;5!/<X&??^E<[\2_'&F?#GP/J7B"[NHH7L+:
M2?:[A3F-&)R"00!CBDVEJP/GK]L/]I7PQ\ ?!>KW6HZE!82/83%2\JH=WE-C
MN._3U_&O\R#_ (*,_MP>+/VC/VA]>\#:-JDVHZ3?:G) L<4K2(R-.RXV@D8P
M<=OTQ7ZZ?\%Q/^"E5YXX_M#PIH.I2!HI;BU(MYR#@.Z<A&'7MW]J_GQ_8-^
M&M_%WX[Z+XMU9)KI;K4XYF:96<$-,IY+ Y'Y]<<\U[.0Y1B,WS+"8>$'RU*\
M(RT^RVEV[]^G9:GR_%O$F#X=R7,L75JQ56CA:LXIM6YHJZ2??7_@:G]*_P#P
M1R_9Z?P3X8FU#5+)H);J,7&77;DL0X.2,'ZCN<=*_<G4+@6[RVJ$!48KCI@
M\>W/?\L<8KSKX+?#VT^&/A33+2VM5B+64(;8@7GRP.<=.1WZ_P ^OOF>:YED
M*D!F)YSQVYSS_7G'M7]Z<.94LFRC!X"*25*E%:6WM=[=KI??UN?Y"<8Y]5XI
MXHS3-YRYHXBJW!MWMRR2T>K_ $9%>:7!KMDUA<JKQ3 HP(SD,,'&3^O^.:_%
M3]O_ /9;$LEMKGAS3V:6UD6Z9H(QD,CF3.4!QT_ECC@?MG9W,-O(OG2*B@C)
M+ $8]OYCW_/-\:^$-'\;:)?VVR&[=K>15R%D*DH1QU[G^G%7Q!DF$S_+:V"Q
M,(/G@U%M)NZ6EK^>GS'PGQ1C^$<[P>:8.K5I^QJ1E)1;47[R3NUIMUUW]#\O
M/^"5/[>GB+X>?$OP_P#"7Q5JSVVE6EQ#:207$S!0HD2/&&;'0$'IDYSV%?VV
MZ)XFT'Q]H]IJ6@7L-[!-&D^Z-E;RPZ E6/(^\0 <X]1SBO\ .*_:-^#&O?L]
M_$?4/BGI7GPI;7IN%6(.@ $A?C;[#MZ]P:_I-_X(U?M]V_Q)\)#1?$^H+'.H
M2U6.[G"N2&"K@.<Y! P!7\*<6\.8GAC-J^$K4Y1H5*DYTIM.RA>T5M9=%;_@
M'^M/AUQM@./>&\+F&&JQEB:-&E3KPC).3J*,7-N^M[W?^1_1%(ABD:-AAD)!
M!&,8_P#UTRM658+^Q&KVT@DCN%$R%<E2C=,>H_/KQ60I)&2,'/3_ "37S9]R
M.HHHH **** "BBB@ HHHH ***<J.QPJL>F, G/7_ #[T (!D@#J3@>Y-<AXW
M^)/A#X4Z8VM>.+^'3=."EC<3E J@#.?G.TXYZGCVKTBSLK?Y7N) C!@0KD)D
M@]/F..O;G/&*_*3_ (+#:#-KO[.EW;:/JQLM26*Z"B&Y"2E2NY6PC!N26 XZ
M#'2O'XAS*MD^29EFF'HK$8C!8:=>E0D[1J2A]EN]U>_3[S]'\'^"<M\2/%'@
MG@3.<RED^4\3YUALKQV94DI5\'2KRLZU.#33Y+:W5M=3Z07_ (*"_LM,6"_$
M'3,H2K#=:\$=O];4T7[?O[+\\B11^/\ 3&>1@JKFVY8]!_K:_P XGQ$WB_PW
MJ5S87VN:MYB32*7CU2]"R%6/S%1,,,>I'(&< FLFU\5^)[6X@N(?$&LK+#(C
MQEM3O64%6!&5:8J5SU!&/QK^6W])3/H3<*G#^ C*,K37M*BDK/56:WWZVV^?
M^\M+]B7X48K#QQ.#\7^*ZU*M252A4C@<%*E44HIP?/&H_<;ZI-I/:^B_U ?#
M/Q9\"^/+6*\\,:C;WMO, T<D3H0X/.<*2,$<\9]17;8X#=B,C_/ZU_)O_P $
MKOVO;O4M6\.^ M6U5YW+00LTTY9B<JN<L3W/8C]*_K2Q;OIUA- X<2PQ,&#!
MMX:)6)XZ8)(]NG7K_1G!/%M'C'*(YG24(32A&M3@](5))-Q5]6D[Z[Z=MO\
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M** $/5?K_0UVEA_Q[I]!_6N+/5?K_0UVEA_Q[I]!_6@"[1110 4444 %%%%
M!1110 4444 %%%% !7,^-/\ D3_%7_8NZU_Z;KBNFKF?&G_(G^*O^Q=UK_TW
M7%73_B4_\<?_ $I$5/X=3_!+_P!)9_DX_P#!2\$_MB_$7C/_ !.[H$=^+B7/
M\Z^,U7L/K_G_ #^M?:G_  4N7/[8GQ$..FMW7/M]HE_^O7QBJXXZY/I^E?Z(
MY!"^397T7U#"[=_84].V_P!_3K;^%.(:ELRQ:77%8MV_[F:EU>WW^ENXH '
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Y7^-7[(?PI^.PNAXUL3<_:T=)<0QR A^N=[#/'8UXI\&O^"9?[.7P/
MUF;6_!NC""]FD,KL;.W3+DYZHY[_ .?3]$Z*V6(K1A[-5)J#5G%/2R\OZZ=D
M9NC2;YG"+EWMK]YF:3I-KHUG'96:A88P%50 H 48' ]JTZ**Q- HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C
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M2/\ P(;_ !H_X3;X<_\ 0>TC_P "&_QHYH_S1^]?UU7WA==U]Z'9'O\ D?\
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M 213GG_./P-?W(?#'PK:>#O &BZ$D2136-E# ZJH!#QHHQTS@ '/7]*_-_\
MX)6_L^Q_!3X>I:7.G"&6:V5E,T05LE%(P& R0>Q)P>WK^JUP1YTH4 *9&(
M Z]L=J_N[PCX/H\,\.8?$RI\N.S"C%XKFBDU))-6NK[6O^=S_E!_:'_2.S/Q
MR\9\WR6AC95>$^$<QJT\B=.I)QJTI-*7.DW'II;2]].I"23UI***_5C^ @HH
MHH **** "BBB@ HHHH **** %1FB.Z/@_7_'-;&ZTU6T;3M3"2V\RE)(W VN
MNTC:<@\<]\XX^M8U-V_-NR1_];WH%KHT[-.Z?SOZ_<T?G#^VA_P3T^&GQNT6
M\N-,\-6,^I-#(XVPH["4@D'<J9)W<YSD>U?R!_M)?\$S_P!IOX0>+]1UCP99
M:A8:%:W$LD"V\<RHL:L6&-N .  ,8YST[?Z&-KJOV9?+:/>&QWP>XZG/'L?Y
M5R/C[X9^&_BAI$VG:M8VFR>-D9VB4N0P(R=JY)Y/TSR<\UMAL3B,'55;"U9T
M9Q::Y)<J;335[=--OR/.SG)<DXDP53+L^R["YAAJL73OB:,:TH*22;CSJ5G;
MMJ_35?YU'@;XX_$SX-.+#XA7^I;[=@C"8RC&P[3G=G&.F/P/.*^H-$_X*(^"
M;2*..]OI?,P VY^_X]P>_OQ7]+_QI_X(O?!;XK275[+-;Q7,N]E1863YCD@9
MP%Z^IQ[5^:WC3_@@/X!L[N8V(D90[XV1DY&3Z'IP/K_/]!RSQ1S[ 4XTJL:=
M515N:=Y2:5NM]_1KKY'\?<:_0+\(.+<75QV$GB\%6K2<YTJ$84:<6VFE&,4D
ME>Z^_P!%^;>I?\%%_ $L3""]DW%3T<')[>OX\U\]>-_VL]<^(>ZS\&W][YEQ
MN2,1ESR_  V_[WOCMTK]B/#W_!!#P5=7<:7(F$9< DQ, !GK][BOO/X/?\$*
M_@UX.>UU"\FB$D120*\1=B5P3P,]3Z^G)K7'>*^?8JG*%&%.',K)I-.SMVVT
MOOMHMCS>%/V??A'P]BZ6+Q^(QN)=.49*G4Y:D&TTTFK/Y^5_,_E:^&?[$W[5
MWQ_\30W4PU6\T6]G1PDBSLAB=NAZCI^%?U,_L!?\$J?#7PYTFPU+XE^&;9]6
MB$,HEN+9=V]2&SF1=V<X/]<'G]?_ (2?LW>!_@O8VT&AV=I*MFBHC- JGY>A
M^93Z?YYKW&XUL8,<<..,$E@>.G   QU_^M7YYC<=C<RJNMC*]2I*3NXN;E%7
M[)MI>7;T/[(X9X3X8X*P%/+>&LJP>#I4H1BJ]+#QHUWRI*[<4G=VUUU_$R=%
M\/>'_!>E0Z;X>@AM8[9%BC2)5'R*" "%' Z<<BDFGDN'\R8[F_#C'3'I^'2H
MB2[F0D_-SCZ_T]O7FBN8]YMR;;;;?5[A1110(**** "BBB@ HIP1CT4TOEO_
M '30 RBE((Z@_P"?>DH **** "BBEVGT/Y4 )1110 4444 %%%% !1110 44
M44 %2V__ !\)]5_]FJ*I;?\ X^$^J_\ LU '<1_<7Z4^F1_<7Z4^@ HHHH *
M*** "BBB@ KXJ_X*%?\ )I7Q9_[ DO\ Z)GK[5KXK_X*$_\ )I?Q9_[ <W_H
MBXKT\E_Y&^5_]A^$_P#3\#SLW_Y%68_]@6)_],S/\FOQNN/BAXUR.NNZIQCI
M_I<V*HJI)'''\_85J^-US\4/&V>AUW5.?3%W-^5544*!QS_+_P"OZ_\ ZZ_T
M;PL+4*5_^?<-O\*U^2T/X+Q\U[9/_IU3T\^57_X+_P" "H .0,^G84\#T'Y4
MH!/05*JX^O<UVP@K:K3HOU_K?<\R4KZM_P# ]!%7'4<^_:I=C>G\J>B9(SU_
ME[G_ #^O2QL7W_Q_S[8KIC!6U^2[+S_K\=N>=37K;LOUU&1QXP2..O/?_P"M
M_GG-3JN>!T_E0JYX'3^56D3&#V[>_N?\_I73"%NG:R[?\$PE+J_DOT7G_6B0
MWR_]D?I_6I57'U[FGX/H?RJ15QR>O8>G^?\ /MO&#;U7X[O[_P!3"4F_)?UN
M"+CD]>WM3Z>J;O7VQUJ5(QGO[D]O_KUTQA9ZV\O+^O3[NN$I[VT7?K_7X_,2
M./N?Q/I[#W]_\FR!V H Z #Z5,JA?ZUO&%M7\EV_K\/7;FE*_IT7^8P(<\\#
M\*EHJ14SR?P'K_G]?IUU2NTDO\K?Y&4I6T6[_ :%8\X_E4L:'_$^@]*F"#N3
MGV__ %4X# P.U:J*6N[,F^[^\  .E+14@08&<Y_S[5K&%]7HNAE*5]MOS_K^
MO)@!/2IU7L!_]?ZT@&.!4ZJ!]<<__6K6,=DOZ]?U,I2LO/H0O")5*2#*'J"?
MT_S[UU?@CQ]XJ^&^NV&H>%;V>P$5Q#+)Y+LNX(X)R5(/08S^)]^= R<?Y%#O
M&BM&6 =U(7)(.2#CG&/\*MT(582I580JPJ)QE3FN:$D]^:+33^[I]RA6J4YQ
MJ4Y.$XN\91E*+4K64DXR3NNC^3NM#^R+_@E__P %3-,G3P]X+\8:\T\\<=O!
M-'-< Y;"(0=S?YZ5_53X)\>^'_'VEPZMH%Q]HMI8DE/*G:' P,J<-C(YP/I7
M^7!^Q?X(^(5S\5-,U#P]9:C,GVJ$CR(Y&5P95P  .0!^F?Q_T2?^">EGXIL_
MA?%'XHMKFVN19P!5N%=6/,?]\9SC.?\ ZU?PYX]\"Y)D.+_M7+*T(5<0U*MA
M8SAI.I+5\L>U]+):63/[+\$^,LXSC#O*\?%UJ&'7+1Q;A/WE&$;+F>_9[JZ;
M6A^A5%%%?S.?T0%%%% !1110 5S>M?>_X#_05TE<WK7WO^ _T% &$O0?0?RK
M2C0V4/V^8JL$?SL6.!@#)Z\<]/PJ"RC1RWF' 5-V?3 /7],U\$?MD_M6:;\)
M/!>NV=EJ,*:E!9SF*+S5$C.JD  9SUXX&?3-'5)7;;LDM6V^R#5M))MR:22U
M;;V1Z=\=_P!N'X4?!>RN$UW4(5GV.HW3QX# $<#Z@]>GYU^*'QA_X*5#Q-J%
MTW@K6YT@D=Q"(IAC&3C!5O3^5?CYXN^*_P 1OVL_&VJ:7J*W[6<5],L;(9&!
M02MM( QQ@CW_ *_8'PN_8OLX=,MIKYI_/"JQ$BMDD@$\'G\N]?HW#7AKF>?T
MXXFO&5'#RVNW&5M+M)KL_P!?7]:X/\(<WXHHT\9B(3H8:6L;-PD[-;I]-&^O
M7OKWNG?MU_$VUO%GN]?OS '#$&5\;0<\_/[?Y.:^Y?@5_P %0_"VC7EM#XQU
MEG!*(XFF')R ?O'].W!KY.G_ &0-,NK8H(W(*X)"GIC!.<C/J<9QS7R_\5?V
M/+;187O;)[E9(BTF$#<$<]CQ]"!U'3!%?29GX-5\/1G5PE63G&-TIS=GLUOO
MK_5F?69M]'_%X:A.K@JM2=2$;I3FVKI)ZVW>BZOO8_KI^$W[3'P[^,VEPW?A
MV[@E-PBA,2QO\S 8VC[W?C!X^E>QW-C+;+Y[$%'P1@YX/([]<8_6OXH?V;_V
ML?%GP#^(ND>$)Y[F+2HKR**229V5 BN%ZMQ@#J">N?<U_7+\#?VD/ 'Q3\,:
M:TFN:>]Y]D@:0-<(1O\ +4D,0P/!R >>E?D&.P&*RS$SPN+BHU(2Y5V=EKKU
M\KZZGX1F>58[)L95P6/IJ%6G-Q35[2MO9M:^MSVL,#Z_D?Z9I<CW_(_X4LWC
M/X=V[%)M=T=&7J#<GCVZU!_PG?PU_P"AAT;_ ,"6_P :X[KNCS[KNOO1-D>_
MY'_"C(]_R/\ A4/_  G?PU_Z&'1O_ EO\:/^$[^&O_0PZ-_X$M_C1==U_7_#
MK[PYH_S+[U_75?>39'O^1_PHR/?\C_A4/_"=_#7_ *&'1O\ P);_ !H_X3OX
M:_\ 0PZ-_P"!+?XT77=?U_PZ^\7-'^:/WK^NJ^\FR/?\C_A1D>_Y'_"H?^$[
M^&O_ $,.C?\ @2W^-'_"=_#7_H8=&_\  EO\:+KNOZ_X=?>/FC_,OO7]=439
M'O\ D?\ "@,"P7GDXSC_ ":A_P"$[^&O_0PZ-_X$M_C4R^-OAT4,JZ_HY5,$
MD7)..X.,_P _QIW7?^OZ:!-/9I^C3-J&>VTJ&6ZO&2.-8F?+D#[H)/)]0,>W
M8=J_F9_X*X?M^:;X'L_$7@#2M8$-[=6MS;11PS #<RL@  8=SQ[XZU^EG_!1
M']LSPE\%_A=>ZAX<\16,VI);3IM@N$&&VG 49SD#') YS7\%G[4_Q+\4?M*^
M+K[QO=O<SV\-S*Y=6=X@H8G);H!@\?7TZ^GDV5U\WQL:%&+E"%JDVD[*,6G+
M6W17OY6[GA\29[A>'<LGC,14BIU&Z-*#:YG4GI#1]V]_EN?EQ\7[3QA\1OB)
M<ZEXADGO++4-3DFA\PO("LTQ(P"2.X/]:_I-_P""9/[,%MI&C>'O%(TY$5%A
MF$ABQ@[4;KCM^&,\>WY4_"_X:1?$G6]-L;6$7,UK/$L@1=[ HZYR!R",?SS7
M]:O[,G@JP^&GP4T];R)+9X+%22ZA"-L0/?!Z\?3'([?T?X=<,X59E4Q$H/ZM
M1IPE3J**TJQ<>:[T5E*^G0_AKQRX_P 6\DHX%56L=C<1.C5IIV_<5/AM%ZW:
M?H_1W7T+K7B;1M&M+."XEA3RXE0J64<*F.<\=OI7.6_B71=<)AL9(7DP2-K*
M3P/8YSZ?Y-?SW?\ !17_ (*"7'PA\3QZ9H^I(!YA0JLX!!&1CKG\@/P.:Z/_
M ()O_MGZQ\;?&MK8:A=&2*<1Y+/N&"QY/7(/Z^O:OT^''&5+._[ IS;Q"J>S
M>S5YVZ_EUUT3OI^#1\)<]I<)_P"MDXVPGL98B[=FXW3=U;L^NO3H?JU\>/&D
MW@/0-3U9Y6ACMH9)2P)& H))S^A_+UKP_P#8Q_:TT7XE>(M5T6YU%)VAFEAV
MO*IY!VXP3Z@D<<C')X%>S?MN>$QJ'PB\0SVP)=]*G;* YSY9/&/S)YZ>M?R+
M_!S]HC6/V=?B[J"O=2V\=SK$B'S'*#:UR5_B/<?3GVKR.+.):W#^>99[25L!
M73]LU?9V2OMKKO\ \$^DX!X'PW'/"&>*A%/-,/R+#)+6Z2<NET]&VU>]MKZG
M]A'[67P,TKXJ>"M12ULXKE[B!W&U V25)!X!/N?PK^>G1/$OCO\ 9"^,^AZ?
MIMQ=:5I!UBW,\<321QM$)PS9Z \9[8],]*_H^_93^-'A[XQ_"G2;Z34+:ZOK
MNS3='YJNQ+1KD8/7DD>_X5\+?MT_LJVGBA;[Q?;6A6ZLH)KF Q1\EHU++C&<
M<]/ZUQ\?<*X3C'(GC,-!.O&C"K2J0LY3I\JGNMY+:2>J=[[H[?!;Q%S'PSXN
M>39E.I3P<<3+"U:55R4?:<ZAS*,NBUL_78_I[_88_:U\'?'7X:^%=%MK^*YU
MZ/2K:.X'G(SLYC&X,N22V[)SP<GO@5]QZG:BVD4IRCKD #D8XP1T^G//Z5_
M)_P2X_:\\3_ OXX2:#XIO)M.TBQOEMHFNY&BC\N.0J,%\#@?KQ[5_=/\)_CU
M\/?BKX5L]>M]=TIW>"-I<W"8^9021M.,YR2, ^F<9K^-*^'JX+$5<)B(RA4H
MSE#WDU=1LD]>^^GX/?\ U$PF+PN:8+#YG@IQJ8?$4J<^:,E)*4XQDUIYO\ST
M'<,XYSZ8.?Y49'O^1_PI&\:_#I20VNZ0""0<W##D'!].])_PF_PY/37M(/\
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MGB%PW@*>)XJX=H4L.E&G>I+!J3G5FY1BY.T(M7V5KL_L%:U8RSH.?*!;(Z8
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MK2Q1&0]#@#)^GK]/?^?-<SXJ\?>%?!6G7%YK.H06@@1F<RR+&!M!)R21COU
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MOO\ \OZ]!%CXZ ^O3],U*J8Z@>PXIX ' I:U22V1DW97?0*4*3T%"C)]N]3
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M:'>?97NK=I)3 Y0*S*2<D>@_F>#BO[J_V4_V0/"7[/.@:0^E,?[1-G;O,@3
M1C$OREB>OJ #C.,YS7\E_2&XAX5JX>&6P5.MG,8S7M:,(R<9)KXYJ[5M=7K^
M%_ZB\"<BXDI8C^T7[2CE+5/FIU*DTJB2MS1A+2\NR22:;TZ?;%%%%?QH?UJ%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=A?%MW;V#^58-)(RPPMM3.[C(4@="?\ (K"B^+WC"&R2Q2]<6Z($5?,; 4#
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MA(UWI]KXLL[2\421HJW$>?,&0!@/US0!^[$VI:19_P"MU2T4CJ&EC'3ZGMW
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M/[#7TMDM[F?2X9I790K%C;JS$G /<XQCVK\AOV\OCRGC/Q'K/@*WO!+)+))
M(%D!)RS(5V@Y/3CBOUF$(<)<*RA*<(XC$0FX2;7,ZE5*25][K:RVO='\\X+!
M8SQ=\6,%@\-&53"0Q6&P[@DW!*G.%-MI725E=M6>Y_-Q^V7?^*_V@/%U[K.G
M2W,D%E<2N?F=AM0L2>XZ=,_D ,C[D_X(XZ]<^'OBK8Z/=RD36TL,3J20Q*M@
M\$YX^GM[U]1?"G]FKPW'\._%VL^(+&-;DV-[/&TJ@D'RW93R.?UKX2_8+UV#
MP[^U[K.F6D@2V@UEXHU4@ *)\#'/Y]AV&:_"LNHU<%Q1D^;UZRE7S#%ISCS-
MM<LE:ZO;^M^I_I7XW>%&%X(\&(8&G&"J/+I*4(:M-PB]O._7MJ?VR_&R*'Q!
M\&=3+KYF_29 00&SF$\^_P"/\LU_"9^VS\.=1C\>W=[I):V,.IS2$I\N<7#,
M<8],=>G4\DU_=NV-?^"EV1^\+:41ZYS#_P#6(_IQ7\;?_!0HV_A#Q?(+K;$D
M^HR [AC(:X8<'CGD>H[FOU/Q5P\,7EU#%5%:$81?/M9WBUKNE=][+T/\_?HW
MXVM@<\S+!T[.;KSC[.7O72B[IQ]%\]-[W/J?_@F7^T_K'@>Z\/\ AS6;^X:W
M@,,3"25]F 5&,%@,8]N?RS_5;;ZEH7QI\&D6_DS_ &BS*L!M;):,]1SUSC&1
MW]./XP_AQ9:!H7PGL?&>A%5U<1)*LD9^;< &[?-Z9(]N*_:S_@FY^UW;'34T
M/Q?JBK=2O'!#'/*-QW-L& QS]/H0,CFKX#SV6$IX7*,=6C*->@IT*DY-P4'%
M)0;;>K32:>FMK7M;/QEX4H9I7QO$^205/%Y?BI4L10IM*K*I&=YS4(ZV33L^
MGEN>!?MX_L[:W\,WO/%'A.)["X$\EP9K1#$YP2V=R8.2/?\ IGQ7]FO_ (*N
M>)?@_9VWPXUO6K[[;O6VS)<R9!4[?[X]>^,YZ5_25\;OA-HGQA\%SW5S;175
MM=6CR1-M5MP:,D$<'Z\=?KS7\:/[:7[)NI_#GXNW7B/3-.G@TNTNWG,L:,(P
MHDR3D*!C&?RQWKP./_#[!XK.,)F,::6$Q->E2Q$J;248RE'VC;B[*R;;ONE=
MG[']%SQ=P^+J4>#N)*[]FI*%.56?+:;:@E>3N[-K\>Z/WIF_X*,^)KFT@O(-
M<O9!.@D 6Y<_>Y[/SUX_(UF_\/&_%8)!UC4,CUGE_H]?E9^RCJ?A3QS =-U:
M82R6<8B*NPX9%"X.3QR"/K7V#?\ PO\ !<<[R+&GE @YR.F<]LCOT&/I7[ID
M7T0^%>(LIPN<9?C*<Z&)A%I+$.34DESWLWHM5K]S/].\/X99;BL/2Q.'KP=*
MK&,XR=2ZM)1=KKR_KM])?\/'/%7_ $&+_P#[_P O_P 71_P\<\5?]!B__P"_
M\O\ \77R\/AYX(;HJ?F#_+-+_P *[\$?W4_/_P"M7J+Z%62?]!,.G_+Y^7_!
M_'?[5KPNP?\ S_I]/MO^[Y>;^]?+Z@_X>.>*O^@Q?_\ ?^7_ .+H_P"'CGBK
M_H,7_P#W_E_^+KY?_P"%=^"/[J?G_P#6H_X5WX(_NI^?_P!:G_Q)5DG_ $$T
M^G_+]^7_  ?QW^TUX6X/3]_2Z?;?]W_-_?\ =]0?\/'/%7_08OQ_VWE_JYJ6
M/_@H_P"*D(/]KW^ <G_2)/Y!B>?QQ7RU_P *[\$?W4_/_P"M0?AUX'/&U/S_
M /K4G]"G)&O]YA_X/?E_P;_GU9_Q"W!_\_Z?3[;_ +O=>?X_=Z+\6_V]_&_B
MVP-E8ZSJ*&5#&0MQ-R&R.?G_ ,<?E7Q9X:\$>)?'WC2'Q3KDLUY%+/YK_:"7
M)!;=@EL\<]2<<] .OTC#\-? 9D5GCCPK9R<=?7+?KQ_6O6=!C\)Z';I!:-"F
MP< ;<\#IP>">I[<=:_3/"[Z+O#/ F=K.*KI8B<%%PC.:J6E%Q=[3O9Z>2Z7/
M9R'@/ 9/BEB.>G.2Y6DY*2O=-:._]::WL:.F:#I&D6MO'!:10L(T#%4 R0!G
M\ >HQ_*LWQ3XTTGP39O?7)B=0NXID9&,] #DYQCZCOBL[QA\2?#.CZ;=>9=1
M)<+$YC!8$[MIQQG/Y9]J_/"^UWQQ\7_%<^@:)Y]Y:O<F.-8][#86P.!D9([8
M[_2OW7Q \2,FX$RMSJ3ISQ-2G*.%PU&4')2BE9.">W2UO-ZV1];F.8QPSC2P
MMJN)JM1I0I6ERRLK)Q5]&]=?5VN>S^-_VH=$U59]-M[!I'EW1@JK'))QVXY]
M.W%?+6LWYOKAKI;.2)9W+ E&  8YST[9S^ P*_6;]GO]@6/6+"UO?%FC2?:7
MVR,98SG& QQN7MD<\U[!\:?V&]+TO0VET#21O@BW-LBY 5<]D]O_ ->:_P H
M_I?8?.O'O@W$XVM@H2QF4X>4<I4<.E6A3?O2ORKF;LM7?OU6G]O?07\3^*_"
MGQ(RV.;8ET>&L^Q4:F94I7@DG:,$V[15KK1V[6/PAKVGX$>.M5\&?$GPG>6E
MY+;VW]LV2SHKE4V><I).,>F#GC)SZYX_XA^&)_"7B6\T>XB:*2!W!0C&,.1Z
M#_..?3C[2YELKF"[A;;+;S)+&0<$.A#*?;D=:_PNJTL3DN:3H5>:EBLOQ?)4
M2NG&I0J+FCWWC9I^C/\ I"Q5#+^+N&J]%PIXC+\]RJK""JQC.$J6-PTHPDT[
MJ\>=237571_<A\2?V[]&\(?LJ^'DM=1C34/["@21DE42%O('WB&W YSU. 3C
MCDU_'Y^U%\5Y?B[\0[SQ)+.UP7EG.]F+'YWSU)(]>A[]ZYK7_P!H'X@^)/#T
M/AG4=1DDTR"(11Q>=(0$ P!M/' KQ&21I&+L2222<G/)Z_K7W''/B'C>,*>#
MPTW.&%PN'H4_9RTO.E&,>:RTU:W]3^1OHK?0ZX8^CEB^),ZP\:%?/L^S;,\8
M\72M/DPN/K.JJ/,U=<J=N5:+9=&/MXS+/!$J[FDFCC51U8NZJ%&.>2<<5_3U
M_P $G?V/9[?7/#OQ&OM/S:R&WN#OB[$JW5A@]1U/O[U^*?['7[/US\;O&-E#
M;V3W@LK^$R*J%@NV12"0 <\=QT_&O[XOV0?@SI/PV^$>B:>UFD%Y;V<2L-@!
M0K".N0.I '/<\XQ@_<>!W!+SC-?[8QE)/"X-1K8:36DJT)[:JSMVOW/Y;_:G
M?2AI^&WA^O#CAW'-9[Q'*M@,YHTY+VE+ 8JBE%N,7S1O=R4G;=)>?U8UO9VE
ME8Q6D4<2QPHJA%"X01J/FXR3G/;N156G%B0J]E& /IZ>@]A3:_M9VTMHDDON
M21_S P4DFYRE.4I2DY2?-)\TG+5]7=L****"PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *>BEG5?5@/S/XT
MRMJQ@7[-).X'[OYL^N.1^G'/^% ')^.O$]EX$T.XU6]FCB1+=WRY4=%)ZD^H
M_P >*_C@_P""KW_!5J'PMK>M^ - U*5+RX%Q;1?9IV#;SE%QY;]1^/K]?VO_
M ."LO[24_P +OA5J4FGW_P!GE6WFCRLFTY"'W'\SSVK^ F#2]9_:R_:IT1M7
M6;4;*^U^**7)9U*27 R#G(Z>H]?7D ].^!O[-W[2G[<?C*YGTC7M>CM;RY::
M,-<7!7;*^X=201@C_/-?MS\./^" ?[0<NA0/?ZQ?23&%69I&D).Y0><C.?\
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M^/%*B  '\0/ZG_/I]*F"D\@5T1C?961A*?:WK_7]=ABKCZ]S4ZKCDCGM[?\
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MK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#QOXY?%[2?@CX%U#QQK$:R65BLC2*Q."43>>A!_6OQML_^"[WP
M6O/'=IX'32[<7EW?1V*-YLI/F22",?\ +7&<G.#^7K]Z_P#!2B!+C]FCQ/')
MG:8KGH<'_45_GV:!X>L?^&E]!DS+N'B:V8?.<<7:_CSQ7N99@</B:-2=92<H
MWY>5^FC777KTN>7CL56H5*<*;5IM+5+NM/\ @^?J?Z<?@#Q?:^//".B>++)0
MMKK5G'=PJ"2 DBA@ 3D]_6NP+*.I ^I _G7@/[+D:Q? CX=1KG:N@6@&>O\
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MR!9=H(/EY&2K<\$#!.<<&MT.AZ.I^C _R-?Q_?\ !2?_ (*$?%_]F*WU;1/
M6KW=E::=<26\"P/(H"1Y5<!"., #U]J;_P $N_\ @I/\;/CY)8#Q;K5Y=^;>
M11N)GE;(9L'[S<<=>F/3K6+RNO[#ZPG'DNK*SO9ZFBQU/VBHM2<UH[;:67XW
M/[!:*PO#-W)?Z!I-Y*29+FRBE<GJ68'-;M>8]&UV.Y.Z3[I/[PHHHH&%%%%
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MS2EHKMJ[UZV\E_:GT+O"G&<.<.T.(U0=+,,3%R]I*'O-74H[J_9]._0^'O\
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M1@ZE)S4IIQBHZV;W:3]&]]S\L1XW\9<YTJ]//>*08_09I?\ A-_&/_0)O/\
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MK'.<9ZGJ2<8' Q7]8W[.7[$>K?%;X4W'Q0\1:6UVL4;73S7$19MH1G)+,/\
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MFGKK<0(_T2?_ +X8#\<)_GZ5JJ4G9O3R?7;TWO\ EN8NCB'?]W*SZ:>7G?\
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M*J(H5<*H R0.3C).2<FH=.TVQTFTBL=-M8K.TA 6*"%=J(  .!SS@?C5ZO\
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MDBVAVV\R%>0#P<D_YZ?6NF?MK0>#;;4/#'B6]G)M87M%CFD.%*(T> "<=O\
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M)7ANX;G=*FX_>#'D@_\ UOT'Y(:9X,N/B?\ %FX\)V$)FC34=BQJ"RX\T@'
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M;S_OW)1_PF_C'_H$WG_?N2OZ4/\ AB7P=_T!=/\ ^_<='_#$O@[_ * NG_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*MW<_9HRX 8\]>WH3[5\O?'7X!^'_C#X6U*#4+:&2>Z@E0DJK/EU/3C)Y_\
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M: /ZVOVI?&/[(?Q6\*:NDOBWPSYJV=P(PES;DD^4VW&#W)'>OXF_BWI_P_\
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MG_&GC_@WH_90'9/PL\?TK^@FBFO$[CQ;<39G_P"#5T_[=%_Q#G@C_HG,N_\
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MFK*6'C5A:,G[L4FO>U>MO+7NSTO4I4O[6S>R/FJ(4W%/F ^4'Z=/ZCBL)P5
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MUVS\ 7>KR[\C3I)\D'M$6ZD?G]3]#_-G^TQ9ZA\/_'5Y8SSN5M]4=,;CCY)
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MO>6)?("O_K(B2.,\Y8X]P2<'%?R^?M5?!/6O@'XVU3XC>'[&:*>*\>=72-E
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MWXQ^@S6N+*"50\=S&P//RL#QV^G^<D=P9DT5;EM3'G#;O\_KW]/U%52".O\
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MP%AF_P"NQZ_4UL>_8=3Z5EZ0G[J;D8\TYSQW:M(&>2ZALX(7F:=E10BDDF3
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M=)?+;Z;<2/!(N]4(C8L.=Q Z#//&1VYK_0O*C:5'RC;M&.,#&!CTQVK\$/\
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M*UK^_P _X*0?\FU^)_\ KG<?^D[5_ 'H'_)R>A?]C);_ /I6M5DO^[UO)O\
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M%+1%GD;_ )9#8!AB>PQ7]1OQ5^%_A3]IOX8W/A+Q$SQZ/JD3;VB D^:6+:Q
M++\N.V2>HR<\?Y]__!.3Q')X8^-&KQ6+"&)]9F4>7\H(^TL!]W'^>M?Z#7[.
M&HOJGPNT*[D8NTD$1))R?]6O?@_G6F;T8T*ZJ4H^S>C35MVD_P /3K]\Y;5=
M:C[*I[]N9._5*UOT7_#G\S'[:/\ P1+^!_PR\->(/%VBWC23+:W5_&""IW*K
M2#*LQP<KCI@X],$_S=_L_?L^>'_B5\;M3^'FI2%=/LM2DLU;U1)"H.<CT_I7
M]YW_  4@GF_X5WXF7S7VC2[Q0NXX"B!P !GH!T%?Q2_L>LR_M4Z\02#_ &[/
MR"0?]?\ _7KT,NQ->IA*\JE64I1BG%MZKWDNV_Z''C:%*&(I1A!)2G:26S5T
MOZTMY;G]$'P:_P"#?7]F[XA^!+36?$-_*CWT2$"*-I#N*AF)"N !DCJ<\\9Y
M-?KE^Q%_P3<^$_[#R72?#NZEN!=*ZMYD;)@."">6/.#7NG[(TLC_  QT]7D=
M@+>W(#,2 =G8'I7U57@XG&XJHYTIUIRIWLXO9[/;Y'KT,+AX1IU(4HJ:BGS6
MUOW_ *_1,_*#_@L1 ;G]D[78A*\1)OOF0D,/]%7N"*_B'_8XT1XOCQH[_;[I
ML>((,@R,0?\ 2!ZM@_C_ /J_N _X*_?\FIZW];[_ -)5K^)[]CW_ )+II/\
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MG5IJ32YW!-VMOK;0V?V:?A)KW[4GC"'QQXMM9-0EBU-9DEF0MQYN1RP.!T(
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M%_2UQJPW!.#PZE9SQ$UVOS15O-Z/37SZ'2_\%,=5L-/\%ZAI\9C$DNE7$:J
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M7L?U2_\ !.SPEX=^,O[%'ACPQ?Q0737.AHC1LJL23;HN,$'CG)X[C\/Y8/\
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MMGC\OQ'YU1-M*.J_K7XO?L[_ /!3W2/']I8+XCU:SL)9TC\Q9[F.,J3C.0S
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M:@'G//\ CQQUH YB/[O'K_04^FJ"!SZYIU !4UL["=5&<9'?\?3CO4-2V_\
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MRJHS@G_/^?\ Z]8>SA_*C-J*M>*WMLN_];=C1@T+2ROG&.(JA))V)T49.[C
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M2G:_*KV_JQ^6/_!2?_@JUHWAK5AX5^#?BC?J14VD7V6=0\L^T(K$1N<;GR0
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MXG]!/_!(-1_8/A0XY-G;G\?\C^G2OZ&?BQ_R3[Q-_P!@Z;_T$U_/1_P2#_Y
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MM*F_;(:'1=AC;59% CQC_CX''R^_'],5^^G_  1.TBXL+&WDF5@&LHL;N.L
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M_A5(T#LA?3&Y4D'_ %)]/IC_ ":_S\_C7=)J7[;$MQ>G<#K>27]/M9/?/O\
MAQU%?Z,_C'X?Z=\2? 1TF^+(]QICK XZ!S$RJK#C )&"><9K_.D_X*%>%]9^
M#7[9FK20V<@L+76)#]H*$)@73#._@#@ X''],,A<6ZU.]IN#UO:Z=O\ +?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^"7/[9Z_'[X2:SJFNZM'+J&DZ?*T(:0LV^&,D#YB,'"CM^9K\^\2O".'#6
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M;&)CM#A[GD'OG+?X4 ?T%/8,"<.I^AS_ %Z=N]0-;LO4C\/_ *Y%?F[\/?\
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M HHHH **** "OX__ /@OE^S]XH^,7QH\(0Z+!--%+<V<3>6A9<,BH<X!'?\
M/'KQ_8!7SQ\4?V;_  /\5M>L?$'B*WCEO+"2.6$M"KG='C'+=.GI[U]UX=<6
MK@KB6AGK@Y^QP^(I12CS>]5BHQ=NR9\5Q]PO+B_AZMDT9J#JXC#U7)RY6HTI
M\SL^C[/RT/QR_P""7W_!-/3/A9X=\+^,/%^A6[[["WG G@57=PH;&6&2V<#@
M'!R:_H'T_3K'2K6.RTZUAL[6(!8X($"1H  . /8#KD\=:@T32;70M)T_1[)
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M7;^1$M[>,N^\A<#:3R<@#@?AQGIBKUC;+LGDE'RQQEB>.@!/<>G/U':OQO\
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MG#1>8<OUX ;G^5?%\>Y+G/$&0XG*\EJ4Z5;$TI4IRJ2Y%[RLK/=7ZZ]_._\
M37T2_$SPU\(O%G(^.?$W XS'Y9DF8X?&X:A@Z"Q$Y.E*,I*5-I\VVS7EU;/\
MY&]U"]U&9[B^N9KJ:1F=Y)G+L6;DGG@9]  /05K>%O#NH>)];L-)T^WEGEN;
MF&-O+1F"(TBAB2!P2,@#J3SC ./[H4_X(7?LP()!]E@Q(Q)_T+UYYS'[\_SK
MN?!7_!&G]G;P1?07^EVMMYT$@D3-H5^92&'.S'4=\9K^6J/T>>-)5H/$U<O5
M)SBZLHU^:;C>/-O:[:>Y_O-F?[8[Z,='+,5')<#Q=/'1H3A@:5;*%0PZJ.G:
MFY<DFHPC)KW4K-6U2=CR'_@F%^RA'X8^''AWQ=/IRQ7B6T$IE,6'R(T;))&>
MHSG^6*_<)IY'MX(G;=Y:*#Q@DJH&3],<9]37)^ O".G?#/PY;^%=(BC6RM%6
M.+:H 7:FT<# Z>H[^E=.$=\E5)SSQSWK^N^&LBP_#V483+J$5&=*C3A7<=IU
M812<K]6WUN[G_.MXW>*N;>,GB+Q#QIFM>=:ACLSQ=?*55;YZ&"KU74I4O>;M
M:+2LK6V2&8'I6%X\T+_A,O"E]X;"AQ?V[02(1D.NPJH(SV&?SZ&M\HZ]5(^M
M/AE\B02XW;0<CGD$$$>V03SQZ]J]R<(U(3I3OR58N$TMW"7Q+YH_*\/B*N$Q
M6%Q^%DEBL#7IXK"SNK0KT91G3E\I136JV3/XL_\ @K9^QY=_#*[FU[3]**&>
M9[DF&(C<2YDP=J]^XZX^M?SX.CQLR.K(ZDAE8%64CJ"#@@^Q%?Z:GQ__ &9/
M!7[2EE%9>+[>!H(T6,>9&)"%  '&UB> !W[8[X^#=1_X(?\ [+>I.US+9Q?:
M&W-G[%'MWDY'/7KU)'8C':OY5XZ\"<YS;/<1F'#TL)3P==IJG7J*FU+>326V
MKZI7WT/]^?HI_M6_#;@#PIR;A#QBI\0XSB;*8SISQ>5X1XNG*DDE3C*4I7=H
MQ7VKIMZ,_A>^%GBB_P#"?CWPQK%E<2Q&UU>S:14=@&B\U0V0#T4?-D<@*>V:
M_P! 3_@GQ^TO:_%'P!X8\,V]^)+RUT^TB<,X8AA$BG.23DXYQS7\^W[>G_!+
M?2_@AJ-QJOPZT=Y+6TB>=)8(, *BEU.54$9 &#P>G>O+?^":'[6$_P "?BD=
M)\=ZH-*L[2Y6 "[E,:@1MMQ\Y'8=/7KT(KZCPK\-.,.!\=B:N8U<+]3Q/L^>
M%&K[1M0=VTFTDWUT\]3\(^GS]-WZ.7TI>%,CP'!V!SY\29']9GAL7F. CAE&
M==1Y:<I)R<HP:>K:>MK*R1_<M<S3V[J))LQ,.<*@;' (^[GOZUS&L^%O _B5
M676M-LKW<,,MR@.?7/!]>>GX5XI\+_VF_AI\6[.TGT76[&\DN(TVB&5&!9@,
MXP>YZ8Z=.!7NEQIY$:7$8.R0!@?4'D'KZ<XZ'.<>O]"'^/$4U%)W7DW=^6O7
M0\$\;?LB? #QG8SQS>"-"^U2*VV2.WB<LS>HVDCZYQ[&ORH^/O\ P2HTWQ U
MV_@7PW9V;2!S";>W"X)!V_= [_C7[F6]PUHP88R/7\_0^W/3\ZUEUU\X,*L1
MUY8'W]A^7I04?Q3?%3_@D3^U+HT]Q=>'9]0MH59VC$(F7"@DC&#QC@=_7K7S
M1-^R;^V'\*9S<ZCK.MB&V;+#S+@ !>O\6.@]>_I7]_/VFVU*)K>X@C9'!!64
MAUP?8KP>W'N*\B\9_ 'P/XYBFAU*TMRLP8-LAC;ALC/3'0_I[YH _BA\-?M2
M?%CX12)#XDU75W^SD!]TLO.SKG.?3_ZV37U-X&_X*[V&AM!!JU[?,R%5;>[<
MD=0<]LY_QK][O&W_  2J_9_\<--)J5J%>7<3MM4QEN^<Y'//0_I7R#\0?^"'
MWP+$,MUI$"NY#%0D*@YZ@$$#G/\ 6@#S;X;?\%D?AU>B"WN;A][;5.]QWQSR
M!^/3\.#7W3X$_P""CWPZ\5+#Y5U%^\"_>D4GG&._X?IZU^,/Q*_X)0KX+-Q-
MX7TN]D>'<8O*B/)7)'3W''?^OPSXX^!G[37PWDE'A7PYKKI Q$9CBFZ+G'W1
M_C[#I0!_9)H'[4_@K6D0Q7EK\X! ,B9Y]<M_GMWKU'3OB[X:U+9Y=W:?/C'[
MQ#U_'_\ 57\$DGQB_;B\(2>6OAWQ"BQ' S'<#@=L8]O0_7M7>^%OVX_VP-#F
MC&KZ=K,"QD!C()P !U[=!R._>@#^].UUS3=04-%<VQ##LZ_4?Q=:TA!%+RL\
M//\ M#/?D<_Y^E?QX?#C_@II\6+ 0+X@O9[9E"B3S9'&".N<GC%?9WA#_@J9
M;@0C5_$=O%P-^^XP0>_4\<_E0!_1^=-+9*RQGZ$=^F1GD^N*B.G2C^-#].?Z
MU^-/A#_@IS\-[WRUO/%^GACM#;KI>/7^+U_+K]?I'PU^WW\(=4V;_%FFMNQG
M_2%Y_P#'O\\]: /T"-C(.X_$<?GDU7:%EZD?Y_\ K>U?-.F?M=?"34@HA\2:
M>^[& +A#^. W/^3]?1=)^.7P]U<CR-6M9 V,8E0\G\?\?ISB@#TTH1SU^E-J
MA:>-/"EXH:&ZA;.,8=>_XG_)Z5J1:MH4W*S(V>F&7^O^?KV (J*T5GTM_N,I
MS[C_ ![=_2G>5;O_ *L \X[?ATX[\F@#,HK6%F#TC)_*HWL9/X8S^7]?\":
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M)Q75ALRH2P[PN-C*5-62Y%K9=_N5O^ 85L%5C6]OAFE/KS;:V7]?>V>/Z?\
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MX[Z?*YYC\1_^#AG]F"[\!Z]:^%$O4\276G3P6C&X#K%)(FT-&HB5M_. 6<@
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M"WN%N$)LXWPZN&').>OTYZU]X?![]G3P7\&-,LM+\,Q[(+&&.&']V$PD8
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M^X5(<X..N#CZ]JX*GB5Q95R)<.5,?&IE<?9VHSI*4DZ5N3WV[Z?F82XES:>
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MD;9O,Q\KDD$=,$]NW/!K^*7_ ()W?M>:]\#?'N@_#'Q+JD]I NH16TEO*[*
MJNJ='([<=./>O[2?"?C'1/B%X;T_4-$NXK@7-K;SN%93Y9,8+9()XR<CO@B@
MHD#,.5)7\2/SP13UGN0?]<X'8!F'_P"K\SZ4LT+02&)^&7CC_/'\JBH TX;X
M=+@O*.X9B<_@<\<]Z6:/PQ=Y^U:99S$]?.M(I<YZY+*2?R^E9=-V+Z?J?\:
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YO6OO?\
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M-W>\O>>V[2N_3_@'^@TI7FDOA@U&"72*=EWZ?+L?Q_\ _!?#Q;LM--@$F<W
M7 ;G_6D<#H.N/H>M<!_P3D\.^=\/M!UDIC,2N6Q_LJ1STZ\X[^G'/G'_  7%
MU]M>U'3[:-]^R_P0#UQ<$'&#QTZ_3CG%?6'_  3NTA++]GS0KIT <60.[C/^
MK7\>?<]R*_H7P'PD:N88VK-.T,-S)^=TDUUOY+\[G\8?2\QZHY%EN&C*TIXO
ME<;:^\NR?9?H?(/_  48\1;?&6BV0;[\L28R>AP/KZ9//L">GW-_P33^'7VV
MXM]0-O\ ZRP5]VWKE6/7ZD$?CSWK\N?^"A.K?:/BUX<M=V=]_;J%SG_EHO3W
M_P#K<"OZ)O\ @F-X#">#M(U P?ZS1X6#;>#F+MQ]/_K<BOEO&;%>WSR%%:^Q
MK6MOIHO-^7RWV/OOHM8!X+@[V]K?6,,E>V^J_)ZZ?\ _FT_X*36+Z!^W'HQ"
M[435$)QG'$Z=^G/(&37[?_"G4EUSX6VL2D.5T2)2!_UZ+D]<<?\ ULYK\G_^
M"M_AHV7[7EMJ@C*B&_+[]O83)SV('O\ 2OT(_8_U\:_X/>S\P2&+3$7&XMC%
ML!R/_P!0K]%\#,>HY?F6&;UFTDF_[J5MM+6Z'XC]+O *&8Y'CE&RA&[=MWSQ
MW>WZ]^K/QT\:V9\,_M-7FJE?+V:H&W=./M!)] 3P#WZ\]J_LX_X)B^+!XG^'
M+2B0R>7:1CKD#[H]>_T_*OX_/VLM+.@_%'5=35=FV^W;L;>1(3U[^W\Z_IV_
MX(D^*/[=^%M^KR!W%NH7G)^5@>F>/E!^@K\>\4,(\+Q5+2RJJ=1K7K+=?UMZ
MG],_1_QGU_PYI5'+F]E["FDW>R48[:]U_P .?MSJ-E!J":E;S()%:%TP0.Z8
MXSQW_3\_X]/^"O7[*4EMK7B/XFV%B%:S6XNA(D?S?*Q?(8#/09)].WI_8=._
MEW5P>@8[?8Y7]>>N/KVKX&_;Q^"&G?$GX*^)[=+1+B\N=/N5'R!F),3]."<\
M_P"<5\'"I.C6I5X.TJ4U.-KIW6NOEIY'Z]5H4\3AZV$J)2IXBG*E)2U5I*S^
M?;TL?R)_\$G?CI/?:YKOA_6;EE6UFEMU6:3C"-Y8&'/;' QW'O7W)^W]\(K/
MQ_\ #O5+NVM4F\^%W#*@8$&-NX'/4^I_$\?B=J=AJ_['OQ8NC,)-+AU+6' S
MN0,KW)QUVC&.>_KZU_1Y\.=6TWXT? 33KJ1H[N:\TU6).')9H0,\D^OO^ K^
MQ.!<UP_%/"CP%=JIB)T)4ZJ>ONO1:.[3M>VB?Z_YA>,7#>*\.?$NGGN!A*A@
MWBZ52E**<8MIQD[-))]]_P #^/MOA2G@Z^O=-\A8;F:=U0E K;BV !P#^/7]
M*^T_V6?B7KO[-VO6^N:O<7#V5W*AC221]@5CV!( Z]N?TJ?]K[X=ZAX-^-.E
M)% T.FG4HVG 4JGE^;EL\!<8Y[YS7KGQA^%4'Q1^&GA^V^'EL)M9M+2W>X%L
M 7#J@9BPCYSU_#T/7^?*]?&^'_&E6=)SIX5XI<L=4G&\7ML_O[']LX3#95XS
M^%V&H5U3KXWZA:I4]UN$N1:MZN+;7SW/W[^%_C71/V@/AQ%K#-#*MU:@-$2&
MR3&.QYYR?Y<\U^&W_!0']EG4XO$=KXH\.Q/9IITXNF-NACR(6:0GY .#CGID
M]:U?V,?VEKWX.>(]'^$GBZ_>VOQ.EL]M.Q'0A,$.P/)R.A_$$5^X/Q1\%>'?
MBEX'DN(X8+F2ZT]F4@(S,9(3_O8/S<?7-?U IY;QWP]R5%"HZ]&+:BH_N:G*
MFXMK6/,]==G=/=6_SUA+//!CCWEBJM&C2Q;C2DTXQG1YTFU>R:MU\EN?!'_!
M)3_@H/<Z7XYT3X.Z_?2QIIS06+-<2L%S&PC_ (VQSS].GI7]DMCJ&G^+M.M-
M2TVYBGBDMUD#1L&&7 ; *D]R<?Y-?YKOQ;^''C#]F'XH7WQ!T&"XTY(]2,RS
MQ!D 59-V<KM]\G./3MC^MS_@D-^W5HGQ/^%]MHOC371)K;+;Q0M-,ID\P *%
MP[Y(;[N,@YP><8/\=<3</U^&\UKX.K"4*4ISG3FTU'E;]U7:71^FY_J-P+QG
MEW'/#N$S/!UH2KQI4H5J:DG-U'&//)I=+Z]T[+N?MFV5D:,CE21^7K_G^=+6
MO=V\<\ U*!E:&<"5"O(*/RK<<888/&??TK(KPCZP*>LDB_==U^C$?UIE% FD
M]TGZJY-]HG_Y[2?]]G_&D,\QZRR'_@1_QJ*BG=]W_7_#+[A<D/Y(_P#@*_R\
MD2(C2MMY)Z^O3GKS]:\G\<?%73/ UTEK>W,4!8X&]@A/_?1'J<<]SC/2O7H+
MF"Q=IKIQ'&(V.\]!CD]<=LCTYZ\5_,K_ ,%A?VL+KX=^*%MO#>I-"X+*%AD(
M)?!VC"D9); &/7C/%?)\9\2T>%,CK9M5:_=5(14;^])-J]EY/\&?O_T9_!/,
M_'_Q3R[P]R^E*V.PU>L\1R-TJ;I*-N:25EN[>:>VE_Z%_"?Q.T;Q<Z16-]!/
M(^/DC=&;G''#$_A@'Z=*],="A&<C(R,C'X_0]J_DI_X)'_MA>+_B1\7XM$\2
MZI-+;">-#%/*<*&8$##.1T/;U_"OZX;N:&Z\B6W9&5H0V5QC#8*@D=P/R[5A
MP-Q9A^,<D6:T(N"5:5%PD[RO!)/^NAZ?TJ/H^YO]&OQ.?A_FM6&)E++J.84\
M323]DX5E>,5)JS:5M4];JQ35W7[K,O\ NL1_(U=LKZ6"4-)([I_=+%ACTP<C
MITZ8/?FJ%%?9'\W.,7JTF^[29R7Q>^%^A?%+P?JEC=V,$]Q=6LL2-)&CD%D*
M@#<I]1T_Q%?Q2?\ !33_ ()[^-OAMJ&J>+_!XNK4M=7%ROV)7C.-Y<#]T >A
MZ<=J_N2AO9X<1*Q$9Z^G\\?G^7.:XKQS\%/AY\6-/FLO%^E0ZG'*A1E9(R5W
M#&2'1LC/;CIR?0$HQ6JC%/NDE^A_ %^PU^VW\0/@+XPT;PQXJ?5&2UO8HI'N
MGGV[5D"G)D..W?\ E7]QO[*/[4GAWX^^&K Q7MN+A+2(LAEC#,WE@[<YSUR!
MGI[5^*7_  4"_P""6OAS1=.UWQ;\,?#:1744<T]M+;0A6#@,P(\M 0<\G\?Q
M_(S]DS]IOXF_LC>.&T;X@ZE>Z=9&_$$*3O(BB-9MH WE1C Z8]\4%']Z%_9+
M&[/$=R=1C!QD9QD>W4Y]_:LJOFG]F']JWP-\;/!>D/8ZG#<ZE=6T9(\U"79D
M4<C<3D'H1^N>/JJ]T^2+:X"[6 Z9X]CQZ4 9@+#H2/H2/Y$4@><=)6'T8BCO
MCN.U% $Z75RN/W\OO\[8/Z_K_P#JJ_!?1@C[0&E&.=Q+=>O4GZ_YYR:* -F5
MO#UQG[186\N>OF6L3_GD?TK+G\,> =2!6Y\.:+.&R")=,AYS[B////<5!M7T
M_G3U)0@KQCI0!Y?XM_9J^%_B=)&C\*:/$T@/2QMP,D=B8^F>>>WN*^0/B!_P
M3I\(^*$F%AI6F6QDW8*V]NF,Y_V,\Y]*_1I=2NXEVHQQ],]/Q/\ +Z5(FL7P
M(!*GUR@_K_C_ $H _G^\<_\ !&"^\023OIVH6UJ)"Q7RWC3&>1T(Z?Y]*^5/
M%W_!!KXBSB:6P\23J,$KY5R>,Y_NMW]..W-?U:KK-Q_$L>?=3C]"/\*L+JTC
M=?+4>H4G^I'H?I0)I/='\3OBO_@BW\9O![231^)]2=8\MA;F;H,GLWU_0UX-
MK7['7QK^'3NIUC69O(/::Y)^7Z-ZU_>;>Z-HNM*RZC'#+O'(9%YSP>2._P"(
M'K7G&L?L_P#PJUTLVH:-:S&3).?)YSUSE?\ ]5)7Z_UI_GZ>@S^%>#5/B_X&
M),TNMS>0?[]U_ <GO^E=+IW[=_Q'\ ,JW&G:S-Y) .4N3G;Q[^AY_ U_:!J'
M[%G[/>J!A=>%+.0OPW_'N<Y]O*KS+7?^":O[+VN*YE\'6BN^>3!;L.1Z[ ?T
M.1QZ4))-OJP/Y</#7_!83Q5IGEQ7&B:I\I .Z*X/3Z@]?\YKWG0O^"SVIXC$
MVD7R?=SNCF'YY^F.WOVK]E_%?_!)C]GN42OIGA2RW?,5VPQ9S[ 1\?A^/K7R
M_P"+?^"3O@A/._LGPO"",^7LB7\.D>/R]^E,#YX\-?\ !8_[4\:S6$R9(!W*
MXQG'K]>3^O-?27A3_@K)I5ZL?G($W8R&8#T]3_7/3VKY-\8?\$L/$EL93H?A
MV52-VS9&V?;&U/;\^.]?+?BW_@FO^T59-)_86BWZ 9V;$F&/3H@_GC/>@#]T
M-%_X*:>&[Q4WSPKOQUD08_,XY_\ K]:]>T/]OSPKJFP-?6J[L#F:/J?JWX^_
MO7\K.K?L#_MJV,CFQTW5U52=NU;KIGCH, ]_ZUS4O[)_[=FB*2MMK:;.!Q=#
M 'O@>E ']EVA?M>^$-1,8.J60W[>LT7<\\9_SQ73>,?CKX5O-"DG@UFSW&$L
M L\6?NDCHWX?X=OXDW^%_P"WKHKC:==4(<?\O?;_ #Z$^N.*Z33;C]M_3\PZ
MW<:T+94PP<W>-HZ]3T/8^W3I0!^K?[5G_!26T^"?BN14O?-A@E9BRRY&$;_9
M;  X].:L_LY?\%Q?"'C74H='N[ZWB9"D9,LZCGH>K<8Z?_7K^8;]LL^/9M$U
M>[\6&Y?44MYSF4ONW!6R?F.1SU]_QK^:F;X\_%/P)XOU.70M=N].>"]E5$W3
M#*JQP01(O<]L]".YH _V>?A9^VCX#^(-K;.FO:>IG5" ;B'/S#_>Z\G/?FOJ
MK3?%WAO6(4DMM7M)3(H8;)HC]X=L$]N@X_'BO\=#]GC_ (*=_M)^&=4LH9_%
M&K&UAEC&Y9KC8R@C&#N';KZ=!7].O[&?_!6?QAJ<FE6GB;Q->.SF!6\R23^+
M:#]Z3ZGW_&@#^\5V@<EH9DD!Z;2"/H,?3\/2HZ_/;]EK]IC3?BCIVG%;\W$M
MQ%$Q+').X ]R<?\ ZQTK]%;>-9C$RX(90??&/Y?F?7O0!;L85^SW,S\"-&;G
MMA2<_I^?Y5^,O_!2/]K:'X<> ]?L;2X\NXMX9HQY;X;.QP!D$=\9_7!K]D/$
M,KV.AZF\)VL+:4Y'KY;'V_SZ5_%]_P %2_%VJZEXC\2:7<2R/;-<RKL+$+M+
M./7'0C/KTK#%U_JV"Q6+U?L:,JD?5)-?U?OOL.*O*,;VYFE][/S,TCX=_$']
MMCQT=1LM5OQ:QZ@"R^?*4VF;;T+$8QCCW'?)K]Z?@A_P3,A\*>%--O-:6WNY
MOLL0?SHTD<D("V2P)SGJ#T!XZ\^(?\$?_A[H$^@ZEJ#V\7GH6E#,JDAE;(QD
M=0>GMUYZ?MKJOB/5[(R:?#*5MH7*(J\  <8[\8_P-?Y<^+OB5Q'GG%68Y=0Q
MLZ&%P=5J--2E%VNEIRORZ6_,^TR_!TZ="$G%.32=_1)_JK_\.?DM\?\ _@F9
M_P )%X9U'4=#6&SD^SN4,,<:,"%8C&P YYQU^E?AM/X9^(/[&_CZUENM5OWM
MWU) %$TH4*)L 8#$?=)_ =.M?V9C6]3U#3&L[B7=#(-I5AG@J0?7ZX/IS7X4
M?\%'_AOX?N9;:\EMX3,LHDR H.XMNST'\6>A[\>W=X,^)G$61\2X/ XC&3KX
M.M5C&=-N4G9M):MOO?<68X.E5HRDHI225GHNWZKOL?NO_P $[?VK[7XE_#+P
M]I-S.)+R>U@5O,<ERQC0$_,<\Y^N">E?J7J%L(5A<?\ +10?H<9Q]>F?6OY
MO^"57C/5;/XG:#X<AED73XYX8Q&&;8%\Q1TR ?K@?A7]A>JC-I:D]0!]?]6#
MU_#FO]/:5:.(PN$Q237UBA3JM/>\U'?[]CXMIIR3^R[?@CG:***H HHHH **
M** "BBB@ HHHH 0]5^O]#7:6'_'NGT']:XL]5^O]#7:6'_'NGT']: +M%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO7X!U[)\ O&R_#WXJ>%O%4DGEPZ;>QRS'.!L5T;GD="O7ZU_&7"G$6-R'/\
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MUMM8LL6KP3"8",!>5.[@+P>1GOZYYK]:_P#@C+\9]6U'QMI?A:XN)9;>V%O
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M_"TFX?=//&"Q&._;CZ9]J_+S_@IYI6/"FNWR1D')8-C!Z,>V.OXCC\:^M/\
M@WP\2_9?"]];RO@M,% /_73'3W&>@'8@=:\SQIH*GQ#1JJ-G&DXR=G:]U?\
M'MIIHSZ?Z*F8/%<"UL-)W<:T$DWK[L(NW5_=Z:-NW]<%^,K)*/XG)^N?\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *,?_JHHH B:"%OO0Q-_O1H?YBGJB+]U57_=
M4#^0%.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ I4B0OYA )!Z$9_'\?_K4E% &TFKR0H$$4;;1QU&!^'?\S2'79CTA1?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[]O_ *U &=14DD;1L00?Q';N>G;K_6HZ "BBB@ HHHH **** "BBB@ HHHH
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MP+@1'@;>!@<=OZ=>>W3/50N<=_\ /]:4 @ $Y-+4)6_K?S?F 4444P"BBB@
MHHHH **** "BBB@!#U7Z_P!#7:6'_'NGT']:XL]5^O\ 0UVEA_Q[I]!_6@"[
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!EZM_P >Q_X%_(5R0X!^K?S-=;JW
M_'L?^!?R%<I"IDDV#J6/Z]/U_G0!<M+5KA'F&-D0+-GN "2,>O!_+\:_/_\
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MS^.3]U_ _P"#^A?#CP)HEO;V=NL]O9V\9S&@8E4 R3C.?7/\Z]BFU)%<A8$
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M%;B%I)EC\I9 &!!8+C'KQCMTK]R?VU?^"F>A^*_A'H>G^%]<!U)]+MTN_*G
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MT89PQ!QC=G!SGI^#)8Q%*8V!&W.0<]1Z_P"?ZT 0T4Y@ <CIZ]OS_P \TV@
MHHHH **** "BBEP3T!- "45,L$C?PM^ Z_Y_&I5M)#U1_J00/P__ %_TH J4
M5>-F^,^6WMP1G\<U7:"1?X&Q[CI]: (:*4J1U!'UI* "BBB@ HHHH **** "
MBBB@ 3Y#E>#^-:EOJ=RA5"Z[.@W*#CVS6710!T,L&EWP!N_+<C^\JYS]0#S^
M'3\Z4+I]BN;/RT8=-J@X)[=!UQS^M<X1GN1],?X4 8[D_7'^%*RWLK[WLM^Y
M3G-KE<I./:[M]US2GU*YERN\;?90,_E_G^=9I +%C]X]32T4R0HHHH ****
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MAVO=BXJSO*S.4HK0;2M12+SGLYUB_P">A7Y?SSQ6?TK^'JM"M0ER5Z-6C/\
MEJTYTY?^ S2?X'_15@,SRW-*3KY9F&!S&C%\LJV Q>'QE)2_E=3#U*D$_)NX
M44HQSG/3CZUZ#H7PH^(_B>U%[X?\&ZYJUH1D7%E:&6,@]]VX4J5&K6ER4:52
MK*U^6E"525N_+!-V\[%8W,<ORVC]8S''8/+Z#DHJMC<30PM%R>T?:5YTX<SZ
M+FN^QZ1^SQ\<?%'P>\7:5<:#?36<5SJ-NLYBD*?ZR55YP1P<@9[$_4U_H1_L
M.?$I?B#\!O#FK:A=)/J%Q80O*S.&:0F <$DDYR<_KZ5_G7Q_ SXR0S1/'\/?
M$Z31R(\;BP)*.C!E8'<0"K $9].AK^E'_@E7^T%^T)9:SX>^&OBGPUJ]CHD'
MD6[27-O+&BH"J$DLH& N/Z=Z_H'P.XFQ609U/+<PHYA]5Q\8T<-!X>M[*G6E
M))MWBE!;:^NO;_(/]J=X(9!XM^&.%XUX0S3A%9_PIB*^9YUB(9KE_P!?QF74
M*%XPA[.M*I7E&THJG>]^6R/ZJR" #ZTE79T06=BXP'D@C9QW),:L2>.Q)'Z=
M<U2K^U&K?<G]ZN?\QE.?/%NUK2E'_P !DXW_  "BBBD6%*K%&#KPP.0>^1TI
M** -NTO%NHI+>_8-%(I0AP.01@@Y!//TXXK\Z/VT/V$O 'QE\'ZS?:;X?MKG
MQ!=0S%)%AC,AD*L0P(4DY+>W(]<"OOLC..<8.?K_ )_QK<L-3V!8)%W+G&>F
M,\<Y'/TH _SZ/C5^SG^T3^R/XZ.H^'(]2TG2(K[SW,"S(GDQR[S]W:/NBOVN
M_8 _X*C:#/\ V+X'\;ZZTFKVZ0V]RES-SYH(5@=[9)SD'K7[H_M)_LH>"OV@
M="OHM3M;:.[DM)EC81+EV,;#.Y1PQ/;UX!YK^//]L#]@7Q;^RQXJU7Q]X!LM
M2N)(;R6>-;:&8KM1BXP5![=.W;Z@']P'@GQYX=^)6DPZGH4\$T4D(?*.&QN
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0S3'PLL[S"SMB9^\U[>UW;6UO*QDZ1X4\+>$H1;^$]+M-*AQAH[.)8DP><#
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MM%"[Z+>S_#S5]S^@K_@F/\6KV#]DG289;ERXTU5)WMG_ (]P/4_Y'-?S\?\
M!6W6[OQ5\7O#2O*71M6M@P8D\&<<'J>>W''.>N*_<'_@F/X&U6\_9+TFX2"1
MHVT]6W!6Q_Q[CK@=2,G_ .N,5^%'_!5&#_A'_C!X86[_ '>=6M1\PZ?OUSG.
M<?KSSBOXOX9C2>=X:-6SI^TC:_PZ3C;5Z)?GMH?ZC<=U:]+A+&5*%_;_ %>?
M,HZRNX*_GI][_ _:3]D3PAI^B_ SPIJ,,")<-IENQ=5"MGRUZ$8[X/\ .O>K
MVZDN9 78M@<9)Z<8_E7DW[*VJP:C^S]X3BA968Z5!T()YB7'?KT[#CO7J$Z&
M%RK\$\\_X=:_T%RR/+EN%22450H\EK?"Z5-WT[ML_P 9LTE4J9OFDZS;JO'X
MF[E\2_>._6Z[:D=7K)0TBCN0?S!_S[51J_8.JRKGL#_G_/I[UVQW7JOS.&6D
M7N]'MN?*7[4WB:XT7P?KT44K)NL;L84XZ1./U/?C&>37\Z_['VGIX]_:BU:V
MU "YC.JN<2#?_P MB0,$G'3K],^M?T&_M<Z3-J'A'7'A0L!8W1X!YS"Q]0/\
M/IBOY^/V#[AM _:LU5[SY$&JN/GXR?/;OGW_ %Z\U^-\4RJ5.+,FHUK^P^M*
MW,WRM>[=:O9/H^W=G]'>&L80X"XNK4++$QRYR5E[Z=E:S6M[?/3KN_ZP/!ND
M6WA#0X-.LT6W0VZ81 %&0H'0<<#(Z?KQ3G9F=F8Y)8G/XU>L;A=8L;>ZML/$
M+=/F4@C[H!Z=_P /<]0#GDC<P[@G(^AP:_8HQIQITXTTN6,4E:VR2MMOV^1_
M.CE*=6M.;;JSDY5;WNGS=;Z[_@%*"001U%)13$;ME*6CG60\&(C!/!^4C!_S
MS[=:_$_]N_P'91OK7B*&"-;F)))1*$&X,#G(8#/8'D].O)S7[66"-*D^WG"$
M_H?\/SK\?OV]?$=G%HNOZ89%%R\$JJF1NW'('''?CWR,]17R/',(3X>Q:JI6
M5*HKR5[>[H]=O+T9][X7UL10XSRIX5R4Y8O#*2BVGRNI!-.UM+:ZZ=S['_X(
M!_$"_>T\9PWUQ)(EK#=J@9R=H1>, ].G8<=NE?,__!7WXDWGB[Q#XH\-B=VB
M-Y+'Y98E0-SC&TG!^O?I7L7_  ;[^';ZYB\>.\;E98KXID$<%3C'IGZ_GTKY
M@_X*N^&+[PUX_P#%.KWD<D5L+]VW,"%^\YR.V>/\CBOX5RZ%'^VZ%-M.B\6U
M+72W/'S2]/UZ_P"N^=SKKA;%U$_]I_L^+5EK=4HM:+7_ "\CT_\ X)-^"++2
M?A[J$TT"&8Y<-M&<Y)S^.><?_K_3K4KB4W-Q#O/EK(P"YX'/].E?G?\ \$I]
M?L]:^&]^UK(L@5"#M(['IQGTZY_ 5^A6I(5O[DGO(WZG/6O[XX948Y/@H4[>
MRAAJ7);;7FU]9:7?DEV/\;N,ZE>MQ?GD\4W*M]9DFI/KWUOKY*WSN4JEB +=
M,\K[]3452Q, 1GLP/ZC_  KZ ^<[GF?QJUF;0_"]Q<1R%"+=R2"5XVGN#GUS
M^5?RQ_'2:?QA^TQH3W#F6-M9B!#'.1YP'Y8]>W'J:_J)^/\ 8R:CX1N(H06?
M[/)P,]E]N?7\.U?RX?%'?H7[2^@17(*'^VH>'[?O_?\ Q'KTK\J\192G/!0J
M-^Q>(P]^BOSPOVON?T#X*4Z:IYK6@E]9C@,8H]9<OLGLO+\^M]#^JCX#^&K'
MPW\./#5Q:PK%+)IEF6* *3F%"<X'KCZ]^]>F7L[SSL[L6STR>W/^?:N2^$5[
M%J7PP\+B$AB-+LQA3G_EE'Z<GW[?F:Z>X'ERE&.",=<]_P#/?^AK].P4:<<%
MAXTDE%4J>L5I9PCNTN^WI<_!L;4JSS+'3JMNI]9KKWM7;VC6]_+].A%3E9E^
MZ2,^E-HK<Y[)Z-)^35T_EU(CX4\(ZQ,DNL:7:7DK')::)')XP1D@_E]:_/K]
MM_X3>$)M*AET'2+2SD10SF&%5Z')Y&,\8S[]\5^C5DF^1!UYQ^9(_G[CC-?$
M7[:6N6F@Z.OVQEC\U,+N8?0=3GZ@?0YZU\UQ#E.2U\#BZV+RK+:TI4Y\]6M@
ML/4DY67O.I*FY\VFK<MF]+L^XX-XLXXP.?95A\IXXXQR^C3JPC1P. X@S##X
M2$%**Y(8>E64%&VT5&R1^('C>YT/2/#\FD_9HQ=JK+OV*&R!C/?\^O\ .OD5
M_OM_O-_,U]0?$G2+O4H9]8@5VMFW,' .W!!/7IW'/L?Q^7W^^W^\W\S7^'?T
MHZ.$H<?1IX.A0P])8>I[E"G&G#^)&SM!)>G;IH?][?[#G,LXS/Z,N>5\ZS;,
M\WQ2XEI_O\TQE;&5X)X:3<%4KRG-1V;5]QM?W3?\$9?A/\+O$?[,FG:EK?A'
M1]7U=H[0/)?6:3'RGC.]LD EBVU1D\!C@;L$?PLU_>[_ ,$1O^38K#_KVL_Y
MI7@?1ZI4:O&U6%:C2K0>75K1JPC.*?,K-*2:NO0_2/VQ&.S#+_HQY;7RW,<=
MEM?_ %URR+K8#%5L)5G!PE>G*I0G";@^L>9)GZ:O^S]\#M[;O /A@-N;(^Q)
M\ISR!\IZ'CJ?J:U=*^$7PI\-S"]T'PIHVG7J<QS6EJB.&!R#NV#CUY'/%=K-
M_K9?^NC_ /H1J.O[96#P,9*4,#A(23NI1P]*,D]+--1335MTT]=['_,#/B/B
MC$T72Q'%/$6(HU()5*%?.,=5I5(M*\)PG6E&47;5--.[NA=SD!6.57 09S@#
MZ]*2BBMSR4DMDEZ:!1110,**** "D.<''7L?I2T4 7+2]GB95>1_*S\RYSD9
MY_3(]^F*XGXH_"/P/\5M!NM+U;1[&^EEB<*9+=&;+*?O!E()!Y[^]=55B"\D
MM#NCQR<8/Z^W3/:@#^4']O+_ ()4>,['6=2\>?#ZW?2[&S\R[5+*+R@ I+C'
ME@=,5\&_LV_ME>-_V2O%O]D>.KS4YX+2X^S 7$LVP")O+[D\<9]*_NYUG1M*
M\:Z)<Z/K4,4MM=H8Y4*AOE92&P&]<_R]:_ _]O[_ ()J?"_5=.OO$'AS28WU
M K+<MY42!@YW.<[02"&/3)]/2@#UKP/_ ,%+O"'C/X>0ZT+N&)Y;=6P\H#YV
M9[G)[?2NI^%W[>/A?6M8M]..I6Y>YG2-09D/WW QC.3U_&OXG/VGO''Q2_9O
MEU#0;$7MEHE@\B#YI%540D#T'"C_  KXD^$'_!3+Q!H_Q)T2*YUYTBBU&W$V
MZ<@ +*H;/S<#@^N/2@#_ %I=#NK;7_#5EK%O(LB7=LLZ,A!!!'3([]"?PJJ0
M0<$8-?DS_P $U_V\O!WQH^'_ (7T&77+:[O6L+5'C,Z,^XH!C!8GKZ^M?L%J
M%JLXCGM%#1M'O+)C:1USQT!&/_K4 85%!X)7N.HHH * ,\"E )( ZFM*&#R5
M>6<?*JECVP ,G\/\CK0!'!:;\,[JJ@\Y( _7'3\*Y?Q;X_T3P19RW%[?6J>6
MA8AW0'(&3W'H?_U@5\R?M(_M<_#[X.Z!J1O]8M+.\M(9&(::-2I53TY!X[^A
MK^3?]LO_ (*B>.O'6HW^D_"W79;[,LL.RTE=NY7'RN1U(!]/3 K2C0KXJHJ6
M'ISJSDTER+FW:V2O??4XLSS7+,DP=3'YOC</@L-2CSRG7J*FN5*[UE;\]]%<
M_HN^./\ P4Y\#?#O[9;M=6\CP;P=DJDX&<_=Y[=,>O6ORW^('_!;WPG97<T=
MNTAPS#Y9&['U'?MWK^>#1-*_:@^,FMK>>(+#6)M/NY-SNPG*E7.<G(((_P \
MC%?9O@C]A--<MXYO$^F7 FD +F1<88X)SD?_ *L<5^A91X9YUF48U:D?91ER
MZ5(N+L[-6Z?Y^5V?QSXB_3D\+^"*]7!X6N\PK4G*+EA:M.K'F6C^&3WML^[/
MO6/_ (+E>'Q.,_:""1R9'QU^GU/7I[5[_P##?_@MKX0U&ZMXIF9=S+G?(PXR
M.N['KUSV_&OS=E_X)V^!1"6&G-NQD<#.0/3/'O\ 7' KP[Q]^Q'J7ARWGG\)
M:5=&>,,T7EJV<@$KC /?\.>!S7LXKP@S6G3<J4X2DHWLFV]H_GT^=^I^:Y#^
MT8X!Q^.IT,=A<72IU)J//-1A&";2NWMI?7TU>I_77\#_ /@HSX&^):6T4=W;
M(TH0#=*N?FP.YYX..O<8K]&/#_B72?%>GQ7MG>VT@F56 1TS\P!'0GGGK7^:
M7/K7[57P4U>&72;+6+>RMI068"<*$1@<] , #\1Z]OV8_8:_X*G^)=+U;2O#
M_P 2?$!M3$8H9TN9F&"I56!#L!ZCD=.PS7YSFO#^:9/-PQ5"HHQ=N?D:C9):
MIM;]?3TN?VCP%XO\"^).%IU\AS?!3JU81?U;ZS3E63?+:+C&3=[_ #?XG]G)
MTHJ5EWJ4/?/&,_RS[>WM7S/^T%^T5X=^".B7=YJ-U;J4A<C,BJ00N>N>O;_(
MKC?#O[;'PI\1?#"ZU^QUZSEN8-.=\K<1$;]A.>&)!!!';\#7\GW_  4N_;'\
M<?$[5;KP_P"!=0GO4:]EMREK(S?(9"H'R$YX//'ISCBOG,;C<-EV$JXW%U(T
MJ%*+E)S?+HE?=GZ=&G/F4$KMV4=-[_Y*VMD>E?M>?\%:4\5>)-2\&^&KFY6>
M>66WC>WE?@[BH.5..O8<U^=2?#_]H?X^W$NH:-K^M01W#&11Y\^"')VX&[WQ
MD<?R'UE^P_\ \$_;?XI_V1X[^(VD3//-(EQ<2W$;'[VUF)+K[^_J>.G]!7AK
M]G#X6_#;3[.#P];VBND2;P$3((4#G:/4=\?C7\4^)7TE,5ALPJY;PUO1G*$J
MG+SQYHNVCC?MV_-'TF#R>#A&==;I.WGIKK_7Y/\ E-NOV2?VG? 42ZO=^)=;
M>.(B0A;B?)"X)'WNF.HX/K7J'PD_;M\;?L\>(K+1_%U_JEP+::-96FEE*X1E
M!R3D?S!YSCFOZA+GX;>#_$L3V.JQ6Y@9=OS(I'(QW'_UO0C-?G#^U?\ \$Y_
MA?XFT#6/$.AZ;'+J2P32PF%%)\S;N4C ]1U'/7J:^5X.^DUGV%Q]*CQ U5P]
M2I&+=.GI%2:6[V25_DNAK7R:E.+=%6:77?2VCTO?IUO\]?T9_8?_ ."COA+X
MZ6UCI8NH5G6&)"995W$E1G.X]<GOG\Z_7>)(=5M!J5K*CQ.@==A!!7;G@C(_
MSGUS_G'>$O$GQ3_9!^(2BU6]TW3AJ&Q"_FHOE+-M'/ QM'N.PZFO[3_^"??[
M6^C?%KX9:%::IJ<5QK5U;0JT;2AGWE%4\$Y!R>_]!7]W<-\0Y=Q3E=#-<NJQ
MJ1JP3E",E*4=$W=)V6]_\[GS-:E*C4=.>C3^\_0X')(P1@XI:U=1LQ L<B@;
M7ZX]<9Q_G\,=*RJ]PR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#U7Z
M_P!#7:6'_'NGT']:XL]5^O\ 0UVEA_Q[I]!_6@"[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!EZM_P >Q_X%_(5RUJYBF$GH_P#(Y_PQ74ZM_P >Y'U_4?\
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MRN\2O!WB/A+/,7]3PM;%8"I5DZ'LZ4N51>N]FM-/O];_ *C_ &-L'AOJ0?\
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M[/\ M_?';3?@]X %QI5[%<7<T3Q&&*56<'&,%5R<\],<^F<5^/W[%/P(U_\
M:&_:1\,_%F?3KKR1K4%P9/(D*X,ZR9W!2,>^?S[?!_CO]L6[_:$\=3:%>:E-
M?:8FHG9%)(701F4?PYP!CKZ^HK^JO_@F-\>_V;/@W\.-+7Q'!IL.M6\4$A>0
MP*X=8U)///7GKCWZU_*?BIQM1S^M#+<!6Y\+1<7S74N:4;<TKI6N^R76_2Q_
MH3]'7PBGP5@?[:S:4)9EB8---6E&$TFDT[_#>R[]FS^CF3X4Z??_  63PY-;
MC[6/"Y1-R G>MB5"D$9R0,C\!CO7^?M^U7\'O$/[/7[7GB/XD)IUU'9Q:W-,
ML@AE5-HN7;K@+C;[XK^VN+_@IY^SP8!&=4@W;1&$6[A$8& H7:0<C'&-P&.*
M_$S_ (*G?%_]G?XI_#?6=5\*VVFOKUS%-*)8O),A<J6!RO).X\X/'?UK\IRW
M&RRO,,)CZ<U&6'K1J.SU?+9]?QO9WUUZ_P!%YYE6%X@R7,<HQ52'L\9AY4(N
M3O;G5K;=FM=-'?H+^QO\;-*^-/A%+N^O88;BWA2,1/(JMN VD8)'/H,#GMT%
M?5=]I<,<DC0/O3<<%3N'4]Q^'0G/8"OXR?@Q^VQ=? 3Q6-%DU.:TLGOP/*64
MJIC\PYXZ8P>^!UQ[_P! ?PJ_X*/_  SU[P_IWVR^CDN7@B,A:5"260;LG(ZD
MY_SS_:G"'B!DV=X&@\1CZ5#$*E",X59QBN=6O+^9-IV=[[:+0_RN\2/!SB+A
M+.\9' X:KC,!4JR=!T(-Q4;W6MMF_P =NI^D!M&VYPWY'/7'N/RJY96AD98W
MRJ,P!R"."1Z@?GV]*^0(_P!NKX5R$!;NV&1P#*H_F<8_S[5B>(_V^?A9I.FW
M,PO;<2)%(RD2H2"H)'))_GSP*^TEGV2TXN<LSPB26_M8OHMEO?7;S2;6I^;0
MX4XEJR5..48MSFTD_9O1NUGMT>_Z6L<G_P %2_AGHNJ? RZGCN81<^3(^P,N
M[(C)R>0?ZY'7D5^$7[#G[2$WP=\66/@<L1!<:G' SDX4 RE223[']?8UZE^U
MW_P42TCXIQZAX2T_5GFA+RQ+$)05P<J!A>O&!@<GUK\R?#\\FG7Q\80AE:VE
M^UK*"0P*MOW X'L,YZ=/;^=.,^.<MP/$V%QV Q$*]2G[.C4KPDE>/-%2ND[+
M3_/U_LWPE\(,[S/P_P ?D^?S=*G6G6Q-"A6@TXU'#]W\6MTWMWN?WB^$KS1O
M%'@S1]3M[Z&66[M()F19 S R(K8PIX()[X[=B*2?3Q$Y5=S =\$C]/\ /N:_
MF:_9&_X*86&DWL.@>(M:9H+(I (Y9QM41X7 !/L.W0?G^QFA?\% /A3J-BD[
MWL#,47GS$)Z?CCUZ]\Y[U^WY'QGD6;86G6CF%"$Y1BY0G4BG%V5XJVR6MKW=
MK+L?RIQ1X8<5\,YIB,'+ XC$TXU9^SJ4Z;Y7%RM%+1KR_P"'T^TOL9]#^35K
MZ7HD%[(5N)/*51G+<=!DXS]._3Z]/C2/]NGX5R*6%Y;#!_YZJ#CZ$_7FO!OC
M9_P4M^&/@S1)I[/48HI61T5HYDSNQ[=\G_/)KU<3Q%DF'HSJ2S3"+EBVG[5.
MSTZ6UZ_AIV\/"\&\4XVO3PU'*<6JE62C%^R>C=M=OG=;WOMH?0G[9GQ^T?X=
M?"SQ1X9M+^WEO6TZ>)(UF3S"VPKA5#9Y/H,YR*_&S_@E?\,==_:%^-NL7.J6
M-P+:/5YY8WEB?:1YQ<$$\8[^GYUX%)KWQ-_;1^,>G-X5O[B\\.:C?I')%YCO
M&T<DH!! 8C!'H,GL.M?VA_\ !,[_ ()\V?P"T+3?%&HZ;9VMY>6D$\K+&HED
MD:)"V !DDDGG/&.:_E7Q2XWIY]B(Y?@I?[-1YX5I1=X57=/FT[V;U[]S_0;Z
M//@_7X'P-3.LUIWQ^,]G7@IQY9TW9:-/U6W6_4_4;X"^#X_ 'P_T[PVJ;#:0
M0C  4<1[?_U#]!7\CO\ P<)G/Q<T4>ET?_1,G\J_M"2P$,C-$P6(QA1'C&""
M#U'!& .H_ES_ !@_\'"T13XMZ(21\USNX/K#)C\?6OXX\=$EX>XY+IB<*OES
MQ2_(_P!POV4DIR^F-PNY)J+X?X@Y7W;P]-M=W:WWV/YMJ^J/V+/^3D?AM_V&
M(?\ T;%7RO7U1^Q9_P G(_#;_L,0_P#HV*OX?R+_ )'64_\ 8QP?_J13/^I;
MQ6_Y-EX@?]D=Q%_ZJL4?Z3W@O_DGGA?_ + >E_\ HI:TJS?!?_)//"W_ & ]
M*_\ 12UI5_J#3_@X?_L'H?\ IN)_PF8O_D99O_V-LP_]2)!1115&(4444 %%
M%% $\2;UDYQ@'^7_ -?_ /57RC^T1XEU3POX=U"_LX9KDQ0R,(T#-G"L0 !G
M_..*^J Q&<'&>M5KWPUX=\1PM::W:Q7,$BE720 @@CH<@@<9_P B@#^ _P#X
M*??M2>.+A-:TR#P9?3K(MU$)18RMC(=0P)C/\Z_BA^+B^*YO&NJZ_J6G7]@;
MB\::%FBEC6([RW P-IR><C!'!XXK_9\^//\ P3Q^ WQ7TN^+>$=,FO9XI I:
MWB<[W4XP0G.2<]/_ *_\I_[??_!!#6=9BUB_\"^$TAB)GDA^SVC< ABN-J^G
M0_4^] 'XB?\ !&S]N;4/AEXL\*>&M0U1X8VO[.)UDN-H WJ.C,!C')_K7^GI
M^SY\8-"^+GP\\/W5G>PSW,VFVAE\N57+#RT89"D\]O<?G7^1+XV_83^.O[)_
MQ0AU.YL]1LH-+OA,6CBEC 6&0'/0#MC\NHZ?V4_\$1OV[KNZN=.\*^+-3N96
MM(X+8QW,IX**JD8;Z<X_+T /[#+VW-K/Y2C*\$'IP<G_ .O_ /7-5:U=+U6P
M\5:3%K%@P:&:%70@@Y&TN>1^GMC)XJC;6SS2@C.T$9]/_P!7Z9H L6=J)F/F
M?*H!;)X& ,]_\^W6OGK]H7]H'PW\'/!^J:G+JEJEQ96\L@B>:-6RB$C@L#U]
M^>.:Z_X[?%[0_A!X6NM6U*XA@"VLA!+JO*H3GD@^V/UQU_A__P""D/[=WBKX
MH?$34?!/@O6[IX-0GEM8XH)F*'?(5 PAZ@''3Z<\'7#X>MBZ\,/0A*=2<E'W
M5=J[2_7^M;>?F^;Y?D&68G-\UQ%/"X3"T9UI3JR4(OV:4FN9M=+E_P#;^_X*
MG>*_B7K5]X6\,+=3*US+:[[-G?@R,@/[LGJ.O7'KS7Q1\%_V$O''[0FJVGCC
M6]7U"!+^1;AX)Y9PH#,&P5<@=&_#'X5])?L1?L:WVN:PWB7XHZ7]NAO&6ZB>
M[C9O]9^\!!D'(Y&3S_A^XVC>&_"G@+34TSPY;Q60@1418E10, =,#V]^G7H*
M_HW@CPSPN%HTL?G%.-2I)*2I2TDGHUHUK\MS_%GZ4GTXL\SO-,;PAX<XFMA,
M)1G*C5QU*2G2J0OR22E':S6NM_U^0_A'^Q+HGPFLK=;U+>_8*A+2HDAW 9Y+
M GKZ^WK7U%8>'?"FFQB :'9': ,_9XO3V4_K_B:OW&LZG<L1+,[*,A<YX'M5
M/S'/+'D\GH>?RK]AH4</AH*GAJ$*<(Z)."TV\E_G\C_-W,\RSS/,1/&YWFF)
MQ>)JR<YS5>JDY.SUBI+Y?DE8GN-(\*W*[/[#L1D$<VT9ZCW3V_2O%/B#^S3X
M<^)-I<0P65I:-(CJ&2*-""ZGH0H_/].E>R!V'?\ E4\>HWMN1Y$C*,C.W/\
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MGT]<>O\ =?\ L,_M8>&?C?\ #32;DZC'/?S00C<TJLSDIC:P)R>O/O7\RX_
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M*U&?MEN>O_+5/7H1D?3]:\Z\??\ !0[X8:'IDT\%] CB)B")8\Y /3GUQ^7
M-?3U,]R6E"4IYGA5RJ]U5B^W2VNM^OZGQE+A#BFO4A2IY1BU*;23]F]+M+:W
M?[[]MOKWXU^.M%\"> ]<N1?P"YM[*=TC,J[BR(3P"<YR/KQUXK^;7SM>_:\^
M*LGAR*QN9[>QU=E1UBDD5E6?((*@@C ZY[=^_EW[37_!0UO'OC,Z'HNL3-I]
M[,T#Q++E"LC;=I /0CV[GCFOUI_X),^+_@MX'\1P^*O'=K8E[KRYWEG\K)9O
MF)RXYR?S]Z_F_P 5O$##YC2>49=652G*].K.$DXRUTO;==MO4_N'Z.G@MB<A
MKQXGSQQAB+QKX>E5CRU(WM=:KY/ST\C^HW_@GW\"HOA[^S5I'A.]M#%*=/CB
M DB*L6-O@9# 9&0,^FX#L*_F7_X+A?LU:S_PG.G>(=-TZYDCL+I;HM%!(P B
M<OR54CC&?Z@\'^E]/^"E7[-WAZ&'3;._MH+2WB58XX;B&-%P /N@8[<YYXQG
M S7PS^UW^U_^S%\9O"NL?:ETV\O?L5PENTC0.^\Q.%))ZDG')Y)SQGFOP##S
MGA:M&M3DN>G*+T=[V<6WNM?GT/[(QF'I8^CB,-5<94J\)QLW>W/'E5[:+1Z]
M?F?BS_P3X_:82_DT7X7ZQ(+06,4-HXF;9@J0G(8@]5QZ]??/[0^(-*T^0Q36
M5RDZM&&S&P8<@'C:2/KVZ\9Z_P 7_P 3/CA;?!?XSZMXH\-7/V#2UU*5X# ^
MQ1&)"0!C Z<^@_+/Z\_LJ_\ !3OP9X@T"WC\1ZJ+BY"K&3-,I(. /XCZCDXY
M[9[?V#X?^(679K@L-AL=CJ="M0I^SY*DTE-*,8KF6ZLUHUW>^Q_F/XS^"6=9
M!G^*S/):,\9@<3.=:4*$)2Y9U)<SNTWKO?36Q^S0M&W;<-QD=#CCZ#^1_2K-
MM9L)02&^N"/8XX_GBOD9?VZ?A4T"3"\M_G ./-0X'KC(_G5:Z_;S^%-K$TAN
M[<84\^:GUSW_  _3KBOU%YWDR7-_:.$MH_XR:Z;Z-VWO<_"O]5N)9:1R?%Z^
M[_#>^G==]/G]WT=\6/!NE:SX%UXWEQ%&QL+H .5')B88^;GT/(QZ=L_R/^._
M$T?P!^-FK^(-.<2DZM*?W9R1^^))^7M@]>/IUK]0/VH_^"F7A"WL;W2=&U81
MBYBEC"QS+CYE(QA3ZD#V ZU^#NM>,#\6_%UYJ$DAN8I[AK@;CN^\Q;MQ^6.>
M,\<_A_B9QADU.KA:F!KTJV*PM1RC.G--IW5NVW?=VWV;_JGP%\,>),33S&EF
MO/@\NQ]&-.=*O!Q4H67NZK\MO4_L/_8-^-NE_&#X707^H7T,%VT,:B.250_*
M?W6.>I_H.E?6FH:1# S2P2>:KLV"I+#!)YR,CW/)YX^G\8OP:_;1O/V??%>G
M>&6U2:ST])XUDA20JFT$#IG&,=1Z'';G^@GX1?\ !1WX:>)-'L5O-1BDF\B(
MN7F3=DH,YR>N>>>?6OM^"^.\HS?+\/\ 6,=2H8F%&$*T*M2*O-*[DNL6[V=V
MT]---?R;Q.\&^(N%.(<PJ8#"U<9@,3B)SI>QIOEC#2RND]/3<_1P6A/8_B#G
M\A5F#3Q(ZA\J-PR2& Q_G_)KY(?]NCX5 X%Y;]./WJ<]?3C_ .O7,^(?V_/A
M9I^G7,R7D"LB,RD2H#P"1SGV[>O-?;SSS)81<I9GA$DFV_:KI;;:^M^O8_,J
M?"?$U248+*,7>323]F]W:VZ7_#NWI]J^*M>T7P3I-S>7-_#$?L[G:\BC)"G@
M GKQT(.?Y?S)_M)?%#6?BO\ M#+X'TJVFO++4-0%MYD*/*F'E5>J@CH<@?UJ
MK^V+_P %)K3Q##+I?A?69%8S-$5BFY(+ ?PGD <<@?X>D_\ !/3Q?\-=8\5:
M'\0OB##:W4\%Y!<RW%R49N'5RV7'MG)QP.17X+XI>(F%K8*>5Y7B(5IRDHSG
M!QDI1DK-:=//?N]$?U[]'SP/QU#,:?$?$$?9J"4J-"M%QFIQY91>MO)6T_,_
MJ=_X(_\ [,$WP6\*7&IW=H\)UBQ65_,B9/\ 71*V/F4=<_TKY=_X+=?LS7&L
M_#KQ)XBTNPDFFF$LZM#"Q+?NW;(*J>OJ*_2;P3_P4@_9E\.^&-(TO3+VSMOL
MUK!%+'#<6\2Y1%4EL*23[$X'89)KS?\ :(_;A_9O^*W@>[\/W=Q8WT<L$OR3
MS03$%DP1G XST&*_F6FI4IQK1DHU(S]HG=7NVGM>_7_.^E_[QJQIXF$\/4E&
M-*=.-*2;6J44O2SZ7_S1_)[_ ,$V_C==_!0S^"M<5[0W=Z+<BY!C)#2;?XR/
MTQ7]',$6E:[X?L];M+V*9[R%9]J.K$&0!OX2<?0CCC SR/Y(_P!O'XD^%_ ?
MQ6CU?X=^78Z?#>^>?LA55PLF_/R87\#SWY/7ZW_9#_X*?^')H;#0?$6L-+]F
MAAB9)IA@%5 /#$]QW''Z5_5OAMXAX.O@<+EN/Q5/#RPT8P<JCBO:+MK=VUT>
MC[6/\Y_'GP0S3 YWBN(<B@\11Q=2=:K2HP<FMK*ZTOJ]UKK>Q_0#)9LC%?F/
MOM/3\J<+-MZY#=1Q@_UY_+\:^1+7]O#X57<2SK>6^TH"?WJ=2,D\8Z8[C-.F
M_;M^%21._P!LMQM&>)4_^*/],]N]?M*SO)FDUF6$LU?^+';37;56;UMV\S^:
M/]5.)FTGE&,4KV?[MOJDNG]:(^O-:\,V&LZ=-!>3)$GD-GS"!C@^N/Q!/7IS
M7\GW_!0[1+3P#\>[/7-/G21;*^$_[M@1\DN>W3I^ASTK]2_V@_\ @I=X"T/0
MKH:5J:13!'1=DJ@@X('(.?0=>N1WK^?7XU_&U?CUXEDU>*Z:[#S-@LV\\MQC
MZ\ D>OTQ^0^)W%>1?48TZ.)I8C$4ZT*D7":=N5I]VW9]=[_<?T;X">&_%5;.
M:F(Q<*N!P-;#5:$XUH-1?M%9VO9.Z[W\[G])/_!./]IJT^*=CI_AG4KE+9;*
MU@@4R2!<F.,#O_D9Z],?JUX@T:S%RTMI.LR;0VZ,[@?RR/<^G<GH/X@_A3^T
M5<_LX7MGJ2WDEBLCQY*.4RN0.1D9Y^GH37[W_L[?\%-/ /B;P[9'6=36:ZDC
M0,99D)SCW.?P[=\=:]+@+C_+<TP%"GC,=3H5H1<.2I.*37NJ+:U::M96W7GH
M?->,/@MGW#7$&)QF4X>IC,!6M)1H0;Y9RM*;OKN]&N^GF?K,+1CG@_DW]#_.
MI([$LV"&'O@CC/<_ECV]3Q7R4W[=/PJ"(WVRW^8 _P"MC[@'L1].2?YUEZE^
MWQ\*;&%Y3=P#:A/^L3KSQU[BOTMYWDL5S2S+"62N_P!\MO=\K]>GEYGXM'A;
MB:5N7)\6FWI^[>CT_I_GV^VM1.EZ!H\NK7-W'%]G0R$.ZKR!GJWT[G\*_GE_
MX*3_ +14^N:EI6B>'F^VL;R.!OLS>80/."X(0DCWK<_:0_X*/Z%XF^W^#_">
MKE+V\1X+=8IA]]SM7&T^I&/?&<8Q5/\ 8(_8@^)/[3WCF/7/%<)U33VO4NH?
MM >0!&D$BX+9_A_H?05^->)/B+@Z&7U\LRVO&O4KIQ]K3DFH[:>[TZ7ZWU;/
MZ7\"O W.,=G6$S_/:$Z&%PTXU%2K0<>9:6W5G;KZ_,]^L?V6+J]_8M@^*%_9
MO%<2:4URQDC*MDVXD[@G/(YR?S-?A-<+LN)U_NS2K_WR[#^E?W^?MG_!W0O@
MU^P)JGA"WM(()],T8P/Y:*%#K:'<JX&>#C/O[<G^ B__ ./Z]_Z^[G_T<]?Y
M#?26DZG%V7U9.\JN7N<GWDYQO_7_  Y_VT_L2Z<:'T?N-<)"#A'"\9^RBFFD
MH_5I.-K_ -VS=]5MT94K^]W_ ((C?\FQ6'_7M9_S2OX(J_O=_P""(W_)L5A_
MU[6?\TKR_H[_ /)<5/\ L75O_2D?;?MD_P#E%[+O^RVRS_TAGZ_S?ZV7_KH_
M_H1J.I)O];+_ -='_P#0C4=?VZ?\N</@C_AC^2"BBB@H**** "BBB@ HHHH
M**** )VW)!O5B" > >>F?Z=?IZ<_!_[5/Q)OO"VA:CY6F2:@6@E 7RFE_A.
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MW>IV]M#=6\4L3F95VJ0I!#D<8SZB@#^Z&YME"_:(F#I(20PP003D'(^O7O\
MK5#G'3GTS_6N,^$WC*W\7^%-)!?S+G[+!YA8Y)8H-QY]SS_]>O2HK,M>F/&
M,GGV^OH/3^N"">B?4BMH$$9GF(1$.2Q[#GDYZ?\ ZO6OB/\ ;%_:QT'X%^%+
MV\34K<3K;RJ5$R!@0IXZ^OO^(YS[?^T'\8-'^%G@K6Y[NYB@F@L[AU)<*0R1
ML<\GV/IV^@_A1_X* ?M=>,OC[XMU;P7X1U:ZN"FH30>7#*S#87V]%)XQ^'('
ML-L+A:V-Q%/#8>+G4J24?=3=KM=NW4\O/<]RWA?)\7GF;UZ>'PN$I2JR]I)1
M4DE?=M>GD_0X']L;]L?QM^TE\3;SPIHDU]]BU.ZDMA-;O*4Q(^S.Z,XQALY'
MOS7MG[)/_!/"]M;B+Q/XBO);K[64NBETS/R^U\$2$^N/U]:[?]AC]DFWET*P
M\6>.-*6;4T=+AIKB/+Y^]DE@3G\<9]1FOU[N)=/T:PMK+0ML(@18RL8 X4 8
MX^G/3/7Z_P!1\"\!8+*,)2QV/I1J8J<8SC%Q]Z+:3?NOMY:[K<_P:^E7]+?B
M;Q"X@Q_"O"6-JX/(L/6JX:M4IR;IUHQ=E)2AJDTNZ??L9'A?P_X7\!:;%I*:
M-92/;HJ>9]GBR<#'!VY]\?KUK7GU[392!#8Q1 = D:K]<8 _SR#7.2337!WS
MDLYZDD\^]0[$'10*_4.>7+%04(Q25DHI671:+^ON/X1^JPG.5;$U*U;$3;E4
MJ2JSES2=FVN:3Z_U<Z#^U;4\^0GO\H[^O-7(-=TF,@3V$$P P0T2L3U[D>_!
M^E<KM'H/RINQ#U4&CGJ*S3C==UI^7K^ 2PF&FFI*I;I:3B^G9]_4K^.O /A?
MXCZ=<VO]DV<4DT;('%O$I^9<#G /&?7L<]!7XL_M$_L#ZMX.O;_QIH-]/"=\
MERD5LSC !WXQ&>,\=A_*OVTBN;BW=/)8JH()Q_G^>?UK7OK33/%=D^GZNJ7$
M;Q%2L@# Y!'?/?/7GCGH,^7FN3X#/,//#XVC&4I)QC.R5I-+K9::[^O='W7A
M]XD\7>%><X;..&\SQ-*A1K4ZE;#*I.?/"#B^6S;2OYK[MU_(_K/[>7Q*^ KS
M_#.X?4Y(KDM9F1WGP%)V9RQP..<\=O7-?HS_ ,$[_ 4?[1_BI-7URX$[7,RW
M1CG(?!D(DQ\^?7_ZPI/VX?V']!US4K[Q5H^APG[.LLXE2'D$988('3 '(/Z5
MY3_P3W^,5K^SUX]>PUB<VD4=R(%5R$'RML ^;\>/?%?YT_2NX+XER+AO'?V'
M&M+"SI2<G1@VHQTWDK]--TS_ *%OHF?2.R+QKR'"4,=B:5'B'#4:5.M1JU%[
M6M5:5[0O?IM;[D?V"^"/#FD_#/PG'X9L;*%/(MT421H@YV <8 YX."!QU^N+
M)-//*S-*Q&25!8G ST[_ *?I5'X9^/M.^*7A*#Q!831SQS6\;!@RL2"N<\'G
MUSU/YBM*2 PN0<\D\G\_\_2O\@XQJ0JUHXCF6)YW[;F;<N?3FO=O6Z[MVMZO
M^XI1<6XM?#HGT:26OGZ]=R(F7&%D8'U!(P?PZ_C73V=Y#=6?]G74:SK*"K!Q
MN!R,<@Y]_4?GFN:JQ9N4NHV/0,,'\\G_ #_^MU(*47?=:IK=-==UM9=;Z?(F
M]C\H?^"B'[-5GXHTU=3TRRC@DA#3EXHE4[A\^<J,^X[=.,\5\2?\$_/CUK'P
MF^.>B^";V\FCMK2^B@99)&5-JS(IX8XS@=#C@=QU_H/^+_AJW\6>';V*6,2%
M;9\$J& ^0^WKC&#CJ>>:_ET^*&@W/PL^/%UXBM4:V6VU(N)%RO28G.0?Z9//
MX_UK]&;CRO@LPED6*JRE0G%4Z4)2;2E-I:7?76]O^"?/YSA5**JQ7O)W>EEI
M:VW7I]Q_H&>!O%VG^/\ P[I][:RHY>TADD*L&&XQ@9X]>^.Y-7IT\J9X_P"Z
MQ'Y8X_6OR_\ ^"5GQAG^)G@-Q<W9N'M[157<^[&Q5X'/&<<#]*_4G48R+R=\
M'!8\]NG^?U-?WU4CRS:6UDUK?=)_JSY<HT445 !1110 4444 %%%% !1110
M4444 %%%% "'JOU_H:[2P_X]T^@_K7%GJOU_H:[2P_X]T^@_K0!=HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC=58-[_Y[<<=EXY^%_BF;PO%H-OIMP\=O"(EQ$W0#&1P23_GZ?T'?\*@T89
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M'76[?4(_,0JV]9._?GL2>WOG'4?T?CX->!9(P9=#L7FQRYMHR<XP<G;G]?\
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M8A_]&Q5\KU]4?L6?\G(_#;_L,0_^C8J_C_(O^1UE/_8QP?\ ZD4S_K5\5O\
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MYO*')QG'8>G..U=1=Q?9[AHL8P3CZ8R#^(]_>OYY_P#@C3^UM'XMTN70M=U
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M]HQU^5OQ7<^"DK2E'M_P?\AH.?S(_(XHIJG(S[XIU= @HHHH **** "BBB@
MHHHH **** "BBB@!#U7Z_P!#7:6'_'NGT']:XL]5^O\ 0UVEA_Q[I]!_6@"[
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 86L_<'U']*YM>@^@_E72:S
M]P?4?TKFUZ#Z#^5 $UMS=0C_ &T_5Q7SY^V+>+9_#FYD<X'V>;G./7^G\C7T
M':_\?<'^^G_H8KY<_;ES_P *PN=IP?L\_P#7_/MFM:/\6'K^C.C"NV(I=N;]
M&?Q#_M1^($E^-SJC@YU!\=_^6N,\GC'^>E?9OP<OISIEN<\>1'C/H4&?\XX]
M\FOSG_:/,A^.9^8D'46'.3P)N1_/\*_0_P"#2L-)M#M/%O%SCJ=@_3C_ .O7
M\C^-"3SE;;RM?KK']'UOWNC_ #C^D^HOB>#LG[U1J_?F77UO_P ,>IWU]/\
M:G.<\^F<\_KZ^^>:A-[.>I4_5?\ Z]1WV_[4_P ISG^Z>>W\N?U]*AP?0_D:
M_&5LO1'\S1A!QA>,;\J_%*^NC>MOP+ NY@<[A^73Z4[[;/\ WA^7_P!>JN#Z
M'\C1@^A_(T<J[+^K?Y?U=E<E/LOZM;\U^!9%Y..A'Y?_ %Z7[;<?WA^7_P!>
MJN#Z'\C1@^A_(T));+^OZ0O9T_Y8_P!6_P"!^!:^VW']X?E_]>D^V3GJ5/\
MP&JV#Z'\C1@^A_(T679?=_79?<'LZ?2,?ZM_P/P)VO)P,Y'7L,?K_GG%7K34
M+C'7N/Y@9^I]3GVQ640W8'/N#_A5RV#@$[3C('0D 9YY^N>M'+'LON)J1@H_
M#%ZZ:V[/?Y+[T?'W[:U_.W@252?X&SVS\OX^_?G-? O[,]Y,-6M2#_R]I]/O
MX^GKU]_K7WA^VJK?\(+,=IQL;M_L]^_Y^M? _P"S/N&J6JX/_'VN>,_\M/\
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ME/ID?W%^E/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M -]K7X,:3^V/XON;2&TCGD)B15($C'H,']3W]3[U>?\ :R\:;C^\E'_ V_\
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M?IWXKGF!4D'J#BN)^ WBO_A+_!UG>LXD(M(5SDL/F0 ]_P#/;I7;S$BYE4]
M[#'L#Q^-?A<7S13[H_U;K4_959T]7RNUWH]D]5\_^&&T4451F%%%% !1110
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M *Z/_P"A&HZDF_ULO_71_P#T(U'7]NG_ "YP^"/^&/Y(****"@HHHH ****
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M,W>>(G4<F]6_?;UZWU_KH4444CH"BBB@ HHHH *:_P!T_A_,4ZFO]T_A_,4
M0^OUX_(5=AD,1X/4 9^G\O\ ]=9Y8AL=N!^?^'^?:SNX7W_S^AK&2:=^[=OO
M"U]+7OT/.?CKX>36/ E\ICWEH&'3/53R1C\!['Z5_.KXVAN/!?Q2TGR<PJ=4
M@)QE>//7^7T[\9Q7].'C6U%]X4G@(#%X7'3_ &<?D,'ZX]\U_.[^U?X=;3/B
M%IERJ;=E]&_"D 8E!ST].W^%?C?COD5+/. LTISIJ;5"=DU=Z0TLM?\ *[]+
M?W'] 7C6IPUXJ8'"NM[.EB*TTXMM+WFDK+;7T[M=3^I/]DGQA'KOPA\-VAEW
MR'3K<$9!)^11TYZ'N?PZ\?0^IQ>1(%QC(./<<?TXS7Y>?\$]O&YU+1-!T@R[
MO+M8%*[LXPH'3/4]O_K5^J_B6$+>PH!]Y1^N/UQQ^72O^=SB#!RR[B'-,&UR
MJ&+Q%EIHE.UOZ_S/^D=M5:6%Q$7=5\/3J][\\8OOY^8W1P!:W)(Z1G\@/_U_
MY%?B[_P4 \41Q:-K5JLG(+KMS[./PYSW_2OV5O;I-)TF]FD.T+;R-SU^X>F?
M?_/K_-G^VSX[/B+Q7J^A6\WFL]TZ",-NZL1@ 9'Y_7%?6>%64U<WXQP$(1YH
MPQ-&4MG9.<+WTT]?2YPXZ<88>;D]T^MEHUO_ %Y=3ZU_X))>$G\2W37OE%]E
MTC[B,XQ*#D8/U_R:_KYT.T-CX1LK8C!CMD4CGC ''Z?Y-?SS_P#!$GX7&'PS
M=WU];E2%\T%EQP&#$\Y[=_RZYK^B:\E$,+V:X"1G:![   ?C^7YXK_67#T/J
MF#PN$5OW-.*LME>,=O\ ANEKGPC:DW+O;[NAB#G]?T.**/\ /YT5H(**** "
MBBB@ HHHH **** "BBB@ HHHH 0]5^O]#7:6'_'NGT']:XL]5^O]#7:6'_'N
MGT']: +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR/0#D&OYY_#'PINI/&%]"[Y19G&W"X^\>V#^'KR>E?U5_P#!2K5[V6W8N_\
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M8A7YH=UHW%][=[?/8Y7_ ()^>$%TC]I'2%=5)2\3T/25>.QZ>_0=.!7Z)?\
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MW_Y!,_\ N/7\X'_!7](9?!FI!T#<3]5!QPWMC]?3WK^C^W_Y!%Q_N/7\W_\
MP5[_ .1.U+Z3?UJ:R_V:N_[C_-?YF>*;6 Q;7_/MG\8USX=TNY\8AGM(23>G
MEHUY^<]B",]?Y\@U]/OX2T9;"U_T&WYC0X\I<'Y>F<<X_"OG621E\8* >/MA
M^N!(>,U]3R2O]@MN?^6:?APHXS]:_D+B6I5_MO&)5)I>WFOB>ZEIZ+\/P/\
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M!A*$N1IT]8MQ>RTTZ?U=ZGTE_P (GHW]DV9^PVX)BCY\I?0=..A^HSCM6?\
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M?*?26_Y*C)_^Q7_[? _[1?V)J2\!..DO^BT7_J/4*E?WN_\ !$;_ )-BL/\
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MMY'0D\8Y^I],5_4%X^UFQ\.:(-5OGCC6WM/,9BP& J!LYSC^=?\ .5XQ8/\
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MTSS!?]?*7XRBS^A/_@EG_K='_P"O.'^M>:_\%6_^1RN/^N;_ ,C7I7_!+/\
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M?RK:C^^OUK%\6?\ 'JW^XW\J);+_ !0_]*1E+9?XH?\ I<2;]A/_ ).4TO\
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M_P""-$^?AK$HZ[$'Y*/UZ9]O8<_N[JBXM0<YRQ_4YK^/(Z.:6RD[?>_\D?\
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MWZ./^Z5/^O4O_2H'Y-_\%8_^0WI__7PG_H3U\D?#7'_")Z=_UP7\\ "OK?\
MX*Q_\AO3_P#KX3_T)Z^2/AM_R*6G?]<$_P#9:^0\5?\ D9T_^OO_ ,K/RWZ0
M?_([H?\ 7]?G [9^H^G]32Q]_P /ZTC]1]/ZFEC[_A_6OS0_!CC_ !U_R KG
M_=/\FKU[]B;_ )&W3O\ L(6W_HU*\A\=?\@*Y_W3_)J]>_8F_P"1MT[_ +"%
MM_Z-2OT#PV_Y'='Y_P#I43]L\#/^2EH?]?/_ )$_H]_;1_Y--L_^P0?_ $GK
M^/35_P#D<W_Z_#_Z&:_L+_;1_P"33;/_ +!!_P#2>OX]-7_Y'-_^OP_^AFOT
MKQ3_ .1=3_[<_-'[;](/_DGX>L/R1]5)_P @JT_ZXI_Z#5&KR?\ (*M/^N*?
M^@U1K^<H;/U_1'\0T?@7JRT/^/27_KF__LU?/^O?\A./_KX3_P!#KZ '_'I+
M_P!<W_\ 9J^?]>_Y"<?_ %\)_P"AUZN1_P#(VPO_ %\A_P"E0/HN$_\ DI,N
M_P"PFG^4#^D+]@G_ )(]'_U[I_Z!7Y9?\%5/]?;?]?(_]&U^IO[!/_)'H_\
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M_P#8!_\ ;,U_!Y?_ /']>_\ 7W<_^CGK^\/]H;_E&Q+_ -@'_P!LS7\'E_\
M\?U[_P!?=S_Z.>OE?I+?\E1D_P#V*W_Z7 _[2/V)W_)A>.O^RT7_ *CU"I7]
M[O\ P1&_Y-BL/^O:S_FE?P15_>[_ ,$1O^38K#_KVL_YI7D?1W_Y+BI_V+JW
M_I2/MOVR?_*+V7?]EMEG_I#/U_F_ULO_ %T?_P!"-1U)-_K9?^NC_P#H1J.O
M[=/^7.'P1_PQ_)!11104%%%% !1110 4444 %%%% !1110 4444 *!D@>O\
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M]/<5_2_^R;_P1S^,EUJ6C:[X^MIM0MD-O+,+N-WR@VDY+>W'(./Y_P"2V?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7A5)/-*C5_L-_)Q_KUN?T/\ 1UDO[>JOI[GX.+_3^F?I;_P4I_X]F_Z\G_\
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MS_G-?='_  55.?$?ACVCA'Y0&OT_C]W\'*MK_P"\X1?^30_KN?\ 1;^Q%?\
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M'^@KI*YO6OO?\!_H* ,)>@^@_E2TB]!]!_*EH *:_P!T_A_,4ZFO]T_A_,4
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ME4N+7=@9N<=>WFD'C.<9Y[_F>/ZDS?3AB+[8>-U\H[?\$_T$XG_Y("BU_P!
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MF7JGQ?:A<'_3H\X]I1]?;V_6OZ6/VC)B/V1$8_\ 0+Q_Y+'@<?K^M?U7P?\
M\DO2M_S[?RT7]>O0_P!$/#%/_42+[X>I:^FZ5M-[::['\G>K _\ "42X[7?_
M +.<'_/K7T3 I&DVO'_+->F<<K7S?J5U$?%,P9T4B]YR1QB3(X^O7V'<U]+V
MSVQTBU)F4#RD/WAZ#K^E?SCQ0_\ A<Q>_P#%[-]5V1_#/B _^,OS/1_[Q+H_
M3M8SMIQG!_S[=:O0@_993_LO^H'/Z57-S:*"OVB/G_:7GGZ^WI]15Z)[8VDY
M$Z']VW<'MG&>GT/MQWKP9R5FK2Z='ON?)RE97M+=='W3/F/Q.#_:HXSBY&?K
MO_6OZ6_^":P(^#[9_P"> _\ 18']*_F@\57<*:J=KJ<7([C^\,Y^G4__ *Z_
MI;_X)IR^;\'I& Z6ZX_[]#'%?O7A(_<J->=KWZ<GDC^Q_HX23A4E9_!+=6V4
M;_?:Z_X<_/'_ (*N@_93_P!?$A_#SB*_/7X- CPA;CV'Z!<_R-?H'_P5>G5+
M3!.!]H<=1_ST;\LG^>37Y_?!>6"3PC;[I57CID=,#\N!TSZ=Z^7\59)9A%N]
MU-+9[>ZO3HNI^>_2(FGF\4DW^]@]$^C7_#]/SMZ4X.<]L?XTL0;/ [?YZ_C_
M )Q5B1K48_?H./4?_6&/UXIL$ELS',Z=/4#/?&>?2OS"^E[-Z;6:[?Y^?S/Y
MZYK=)-V_E>NVV_?6U[?=?D?%X)TJZ)_YYD_D#G]35K]E,$>.K#(_YB$?_HT"
MH?&<MNFD7>)5;]T<<@\X(['_ .MW^L7[*=XK^/+%00<7\?I_SU''!&>1V^E?
M>>'+OG5)I?;[-*SY7V\M/RZK]E\$IWXFH*S3]KM9^7]=K=3^TK]H;_E&Q+_V
M ?\ VS-?P>7_ /Q_7O\ U]W/_HYZ_O!_:$;=_P $UY#C&= _]LS_ )_QK^#Z
M_P#^/Z]_Z^[G_P!'/7RWTEO^2HR?_L5_^WP/^TK]B=_R87CK_LM%_P"H]0J5
M_>[_ ,$1O^38K#_KVL_YI7\$5?WN_P#!$;_DV*P_Z]K/^:5Y'T=_^2XJ?]BZ
MM_Z4C[;]LG_RB]EW_9;99_Z0S]?YO];+_P!='_\ 0C4=23?ZV7_KH_\ Z$:C
MK^W3_ESA\$?\,?R04444%!1110 4444 %%%% !1110 4444 %%%% "J<$&H/
MB#$)O .J+U_T-O?LW^1VJ4_U'ZD5/XN3S?!5^AYS9MQUS][_ #_A2EL_1_D5
M2_BP?]^"_%/[]3^%3_@KO:M;>)H6P1G46[XX\X_Y_$5[7^PM=K)\/M#C!^8P
M)W&3\JYX_F1_2N6_X+$Z$[:U'(J$ 7K-G'_37=SQQCU^M8_["^L>7H&B:>6P
M0B#&>I^4>_\ 4<U^Z>#E7DK5*;6\$N_\NW36U]]_O/\ *7]I1EDJF69?BHQ=
MHXF[LGLH+6_]?D?J+KXV>23W"Y_[Y(_^M^%8B]!]!_*M[Q(I5;?/=$/Z9/\
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M3KWK_4)^,O@D_%+PE<^&9&9EN(7C*L>"74KG!/).>IR>G6OYOOVDO^"!%_\
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MFFOK\^Q_1E12*=RJWJ ?S&:6O%/3"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX)\WWBZTLK[4;:Z3S45F+Q2=P.,X[Y_G]:[?XR?\$W9]"TRYU'3K>YD,$#R
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MN%25X-.UU9I--?CMTZKRZLI\!LLRK,J>9TZM1RI.+2;6R:DOTM;J^FY^KW[
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M8Z1?V37A6X\N**1-Y?D   DYR<8ZY]<5ZN=9)A<^I*ABVXQ5M5:^EM.VNO\
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MROOTYS^M?T?_ +1O["O[.L?P4\83V7@ZQM+[3]#N)+>[V0DRR"/ P!$,%OO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YO6OO?\  ?Z"NDKF]:^]_P !_H* ,)>@^@_E2TB]!]!_*EH
M***1B0"1UH O6MN69)2.%8<GV/KU_P#U_C7QY^VW\:4^&W@*\N(+HVTGV68;
ME?:<[6[^WTXK[8LE5=.FD.,A6.>F-OO_ /6]J_ G_@K=XPNK+P->Q12NHVS+
M@-_LD=!^>/TYH _E(_:7^)/BOXS?M'1VG]J75UI]UJ9C:)I6>,JTV""IXY!_
MSS7[)?L^_"G0OAMH%AJ$]C#'/=6L+LXC4,SNBDDG'7/?.2:_&;X2Z!'K_P 7
M-.U:X7?(-35MS -_RU!Z_P _?I7] ^IJ(?#&C1Q@#;:P ;>. B\<=#_B: &R
M:RIU%W61A;$X"9^7'8 8 [X'M^ODOQB\":'XP\+ZI<&TCEN3:S;'* L&*'VZ
MYZ<\?A76H25!/7\^_K6M<*)/#]Y&>=T3CGG(((Z>V* /P!T37/%/P"^)K:I8
M7]S80-JAV^5(T8"^=P!@@8Q_+\#_ '3_ /!.?XZ+XU_9XTO6-8O6N;I+2&3S
M)9-S%E@Z$DDD$G)'7CVK^*/]K+P]'#J*7"IM/VW=E1C_ ):9_#ZY^E?OU_P3
MF^(][H?[/UCIT<[JBVB+C<1TA ]?R_I0!YS_ ,%D/VG=7T><Z5I>K3P"[:2$
MK%,5R'W)@@'KS@?RYK\3OV1?A-J/BOXE6OC3Q"KWMK=SK<,TX+@[I-_);KP?
MY5[]_P %7O$,^O>+=%661G#WL6>20<RC@^H/I_ABOHS]D[PM::=\.="U..-1
M*;2-L[1G[JGK_/\ S@ ^R+X:5X<AMK;28UMHQ$H(B 7)P/3'Y^_?)JK;36&L
M17,6HJ+A7C8 . W4?0_YZ^E86J3&[=6<Y(&!WP/\^A^N:98'RMVTGGC],\^U
M 'Y>?M>?"9+ :KXDT&W%K<(6ECFB7:X()8$%<8SUR.,U]>?\$>/VC?$?@O5O
M[(UW6+EU>[2!$EF8X!E50/F)X';MZ]:G_:,TB/4/!.IET5MT#Y)&3]UN>G_Z
M_7BO@[]EK49O"?CZR6U8Q@ZI#]WY1C[0OI_(\?6@#^W[]J3XNCP]\!V\5VEV
M87N=.:;S$<*Q+0Y)SUYQZ^IK^!7]K;XC^+_B_P#M"6UNFJW=Q8W&J^5)'YK.
MC*TV"#SC&.W?I7]5G[9'Q(OF_9#T[,S?-I"@DM@\P+UY_+IU^E?RM^ -!A\3
M?%&RU:=/,D35%;<PS_RUSGI^/Y&@#]>OV=?A/HGP[\-:7J]S8Q)<W-G;R/)Y
M8#%VB4DDXR23GFO>KC6P^H&2.5A;9P$!PN.G ^G;G\<XJ%E$/@S18$  2TMU
MPN. $7KC_P#5^5<O'G:,_P">G]<]* .:^+7@?0O&7AW4I6M(I;@6LVQF0%@Q
MC8 YQU)QSZ8Q7XBZ1-XJ^!7Q6FUNQOKFQMAJ9*>6[(-GF @ C'0=Z_?G:KZ+
M>HP&#$^<_P"Z1C\?\YK\</VJ="BBNY)T0*WVPME0,YWY'/KG\J /[(_^":OQ
MP;QQ\!+75]8OGNIHK6%]\LFXEDB)Y).<''/?\AG\CO\ @L?^T[J>B6[Z=I>J
MS0?:))8L13%<AF9<<')X/?\ 6M3_ ()L_$V[\._ 3[!'<,@%NH +$?\ +-AC
M&3Q7Y0_\%5?%%SXEUC3Q+*[@WP[D]9\\^W/3'^( /G#]ESX2:GXW^(EAX[UT
M/>6MS<K.[3 OD&0.<EL\8)Y_#%?NK<C2?#EI9P:3$ML%A56$0" D*.PZ\C_(
MKXG_ &/?#UM:?#+1KU(U$OV=&S@;LE5/)XKZQU*5KDJ'/*X_E_\ 6]NGI0!T
M-I=6.KK/%J*^>C1GB3##H?7C/4_GGD5^4_[7GPH@MI-4\2:';BVFB626.2)=
MC @E@00,^W^2*_373AY3,0>V,GC^O>O!OVAM(AU#P7JI= 2UO)VYY4Y]/\XR
M: .;_P""/'[2/B'P7XGFTS7=8N7B^U"%$EF8JH\Q5  )[8/KQ7]5O[27QHAT
M3X!W'B^TNO)>;3VE,B/@EO()SD8Q[]\FOX6OV9=5D\&>/T-L[1;M27.UB,9G
M&>GM7])7[37Q+O;S]CF(>>Q+:5CACG_CV]1_GG\: /Y?OVQ/BQXL^,7QPM8H
M=4N[BSEU58I(_-9D*M-@@@'D8Z]/0]>?UG_9T^%FA>!O"FC:Y<6,274]G [R
M^6 Y9D!R6QG]>_XU^/?@+0$\2?$:"_NE\QTU1&!89Y\[/<?YZU^_MC"D'@'1
M[=  ([.%0%XZ(O''IC'\J+=?U?Y; 7KC75DOU>.1A;C@H" "./P_EG\*\L^+
M7@W0_&FA7[M:QRS);3;79%9@?+;\>IR?7%=!$,)SUS]?\_A6W!$LNE7J,,AH
MI!^AXH _ /2[GQ5\#_C#/KMC?7-C:0ZD"@C=D4 2$@#IV/ S^%?V_?\ !,?X
MZS?$7X(#6-5OGNY;>TC;?+(7.4C!QDD]3^F>G6OXZ?VK-"AM;V[NE0*WVMGR
MHQ_%U_\ U=?Y_N'_ ,$J_B-=Z)\";NRBG8*;?;]XY^YCIG_]?'L* (O^"QO[
M2^JZ5IEQ8Z5JL]N9)98<1S%01O*XP,^W^<FOP@_9D^$NI^/_ !QIWCK6P][!
M+="9WF&_<"X?DG/J>3_.OK#_ (*M>(+G79DWNSAKUSC<>\Q_F/KQFNY_8KT.
M.'X7Z9>>6OF")6)VY.=@/7GZ?_6H ^Z9UT?0-.L(-*A2V*0QJ_E +DA!G@#O
MC_.:KVMQ8ZR9(=07SXV1AMD&X?K_ )["N?O9FN0JN<[1@>F!C_ZW]*332(92
M1Z?YZYH _-#]L'X10QW.H^(M#MA;RP1R2I)$@5E8'(((Q@^N.?YU[7_P2!_:
M6\1^!/'LVE^(-8N7MTNA"D<LS%0%;:  Q QQ]<]J]8^/>E1:EX1U9I$#;K63
M)(!/W3WY.1]<C!K\N/V?[V3P9\3HWM&:+S-4&=I*Y_?XZY'XT ?VN?\ !1[6
M[7Q9^Q1XDUV J\5_I;7*,,'!:T;=T/'S9QC' 'TK_.VO_P#C^O?^ONY_]'/7
M]]/[2FI'5_\ @FM)>2L7D?0"26.2?]#)_KT]^F*_@6O_ /C^O?\ K[N?_1SU
M_&WTDXI<493;1?V8U;TG'_,_Z4OV)E253P'X_<FVUQO&+;ZVPDHWZ]M>[*E?
MWN_\$1O^38K#_KVL_P":5_!%7][O_!$;_DV*P_Z]K/\ FE>7]'?_ )+BI_V+
MJW_I2/N/VR?_ "B]EW_9;99_Z0S]?YO];+_UT?\ ]"-1U)-_K9?^NC_^A&HZ
M_MT_Y<X?!'_#'\D%%%%!04444 %%%% !1110 4444 %%%% !1110 5K:9(#-
M$F>^,<^GM_G'XUDU:LG\NYB8\ $<_P"?3&?0T":O;R=_N/@3_@H'X&3Q'X1O
M'6#S"MG(V0,D$QD^GOU_/UK^(RXAE\$?M.SNX:**'4VY/RCBX/!Z8Z>OX=*_
MT+/CAX2@\7^%-3A,8EQ9S #&XD^4<<?IC_"OX6_VZ_AI=?#KXN:WXB2V:!(;
MZ1RX4J /-<_3MP3Z\5]!PKF#R_.\-5;Y8NK3N]MG'=W_ $/R#Q^X2CQCX89[
M@%#VE6&7XIP5KN\J;LK;_P!?)_KG\,=<C\6Z';SQN'\NW4'#;L84=^W/<^O>
MMRX(2YDCX^4D'KU'O[_UKXY_8%^(L/BOPM<K+.)'C0I][=R..Y'OSV[]*^S+
M^$_;9Y #M+G!_'V^G//OQ7]H87$+%8/#8F#NJL4V]]DOEY;=WYG_ #'9YE57
MA_B/.,CQ,73E@*\X*+33OSOHVN^GYE:BBBN@X HHHH **** "BBB@ JU;1&0
MD@9(_I_GD?CVJJ>AQU[5L:2@V2L_158Y],#.,\>GT_*A)MI+K?\ 3^OD9U9J
MG3E-O9K3KJTOU/#?V@O$D>D> ]1'F;62!\_-@<*>GKTQUZFOPW\/:7<_$#XM
MZ))$K3HFL6V2N6QBX7D]L_\ Z^>*_1G]LKQ^EGX?U?3TG =49 -W^\,8SGW]
M_P ,5Y[_ ,$SO@W<?%+Q5%JKVK7/V>_CDW;"V,3*V<X.,8SSGUZ\C\+\7\WC
M##1P,9^]**T371KL[[]_P/\ 5C]G%X<SQ6<SXKQ&'_<X>K.U2<-%SQ36KTUO
M?K^:7]B?[&'@N+PW\#O"<C1".8Z7!C"X;Y84))[\9SZ_ES],:C-YTH/4 ?7I
M_A_3/K7/?#+1F\-_#C1])V>6;.Q2()C&/DC7I^!K2+ER23T)'_ZJ_GF"]U=V
MDWZM'^R-:7-4GM:,G&-NB3LOO6NHE%%%49#-4A.IZ'>:/U-Y&\(!Z?O 5Z>F
M#_DU_)[_ ,%F/V,=0\.^$=3\:V]B9/M#7%RKQ1Y)R&8\J/\ /(X.:_K(C<QN
MCCJC!A]0<UXO^T+\&?#O[0/A.;POXGMH9K/R)$5'0-RX).-WN3_+'-=>"Q+P
MM>%3[/,G-=UIUW6R.;%4%7I2A;WK/E>VKL?YG7[+GQPUCX"?%'2]6U'[7!I^
MG:FCRHQ=%V1R G/  QCVZ9]J_L\^!O\ P7$^$-YX/TG3+UK=KFPLH(79Y!NS
M'$H;J<]5)P<XSQUK\W?VS/\ @D9!9WVIS> ?#LLVYII(FMK?JV21]Q3@]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2_%S1]2\EGCE=&W%20<L#GI[_3Z4 ?3O_!2J.\6]B,F_ M#U_P"N8]?IWS^
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M+K7]K?\ P3;^!,?A;X5^%?$$EL(IC86[EB@4Y**V,D9]_P 3GM7\KW_!.'X
M:G\<_&J:O)9O=);Z@DNYHRP 6=7!R1@<@]#C [G%?W8?!WPG'X#^&6B:"L2P
MM96(5U V_,(U51CVQQQGFOXOXGS.6;YUB:_,Y4U*\'>ZNFEI_5VK][O_ *;/
M C@6EX=>&6193&DJ&,EAXK$IKEE:4(R]Y636G>W<[?7'#M&JG.T<\]R0?PXK
M%ISS-,Q+$G'K^--KPS]65[:[]0HHHH&%%%% !3E2UD^6Z@6:,]58!@1]#QWI
MM% #GT3P3/S<^'=/E;NTEE%*2?\ @0[_ $J'_A&/AYG/_"*Z/GU_LJVS^>VI
M**$VNK^_T7Z"LNR^X<NC^#[89LM L8'&"K0VD4)!![;1V_SZ4-L'$:[$'11T
M'I@=J;11YMMOS?\ 7884444 &3V/U]Z=_9OANZ'_ !,])M;QCU,UO'+GZAAS
MCZTVBC7HVO3U3_3^M !=!\$6^6M/#FFP2==T-A!"<_51052/Y;8"&,<!%&T
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M&?2@#H;;G2K@#^X?\?UZ5_.K_P %>+&=O!=ZR@D'SNQ]#^GX]:_HCLYE^S-
M>K\8]SQ_D\_AS7X\?\%1_A;>>(_A_>26]N9#Y,K?*I8_=;T_SU]Z /Y!O@-<
M0P_$&PAD*JYU!1@]0?,X_P .,_ED5^[FKX7P[I+9R#;0XQZ;!_C7\Z-GJLWP
M^^/NGZ3=,\(35@I5@5'$V.?J/;MVK^AC2]7@\2>%-&-LZL19VY(4Y.?+7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP'K@\<?_ %A@U^.EU^VK<_'3QI)IWVV5K6>[!"22,4VLV,8)/0'T_E7],/\
MP3A_:'^''P:\-V$^NQV+7,0BF+R>7NRN#U)]>?K0!_8W^RG\*K+X:_#C2H$M
M_*FETZVC=2FUMJQ+OX/<X .?4BOP@_X*V?LE2Z]!XF\?V.F2R7!6:972$MG
M=QRH['U)]^U?1J?\%E?ACINFV^GVUU9H($$6%E0848&!AL_EW(]*\U^-_P#P
M4_\ A!\6_A]>^'I/[/ENKNVDCRQC;+,C =2?4_XT ?S&?LX_$G4?A=XCN])U
MHO9*+PQ*)CY>1YNW^+'I7[>>$?%WA_Q1X>M;I+R*66:)6(5P>JYY&<^OMVK^
M:#]NGXJ:5X9\5R:SX=EB@A-R\V+9@G&\O_#CTX/->4?!?_@JK9>$7M](U&ZE
M?[-&J-NE8C*\'C=_3_&@#^M'5-8T#PYI4NI37,<;VZ&3YG4?='(.3_G-?B3^
MV[\9[SXAZA8Z+X>E:]VW*0E;=O,/$NW!"G/Z]>G6OA+XO_\ !7?2->L+K0]/
MG=);B%HD*R,,,P(SP?4\?6N>_8]^+-K\0O&::KXAG2YMS=B=5NF#@ L'P-Y.
M.O&* /ZIO^".W[*-Q?:KX8\8ZQILT;;%N)))(6 4 )(6R1SQDY^O7I7EG_!P
M;H%GH/Q(\*6UHNU1Y7;&0;=B..W^/>ONC]DS_@H+\(/@IX0TW3IET^.2VM%C
M;#(ASL (R&4CH.A'OFOQK_X*[?M6Z!^T[X]TG5]!EBD@LY?^63!@%6-D &">
M!D"OR#QW_P"3=8S;_>\/;O?VD?P_6Q_HS^R?_P"4SN';-I_ZM9QS*VCC]6G9
M)[WYG?6R5EJV['XQU]5?L5*6_:3^&H'?6(>G_76*OE6OI3]D;68- ^/_ ,/]
M6N76.&TU6*1W8@*H$L1R2>.WM]:_AO(O^1UE/_8QP?\ ZD4S_J@\5O\ DV7B
M!_V1W$7_ *JL4?Z7/@J!S\/O"R;&W#0M+) '/^HC/]<_TK5^RR_\\Y/R_P#K
M5\>^$_VP/A[;> ?#&=6L!=)I-A!)FXBP/+@1/NEA@_+CGOS[U<_X;+\"?]!?
M3_\ P(A_^*K_ % IIJCA[_\ 0/1?R=.+7YG_  EXN4)9EF[@VTLWS&,KI+WX
MXF<9)6Z73L][;GUM]EE_YYR?E_\ 6H^RR_\ /.3\O_K5\D_\-E^!/^@OI_\
MX$0__%4?\-E^!/\ H+Z?_P"!$/\ \55F1];?99?^><GY?_6H^RR_\\Y/R_\
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M!G3_ /O]%_\ '* /IW[,_P#<?\O_ *U'V9_[C_E_]:OF+_AK?P/_ -!G3_\
MO]%_\<H_X:W\#_\ 09T__O\ 1?\ QR@#Z=^S/_<?\O\ ZU'V9_[C_E_]:OF+
M_AK?P/\ ]!G3_P#O]%_\<H_X:W\#_P#09T__ +_1?_'* /IW[,_]Q_R_^M1]
MF?\ N/\ E_\ 6KYB_P"&M_ __09T_P#[_1?_ !RC_AK?P/\ ]!G3_P#O]%_\
M<H ^G?LS_P!Q_P O_K4?9G_N/^7_ -:OF+_AK?P/_P!!G3_^_P!%_P#'*/\
MAK?P/_T&=/\ ^_T7_P <H ^G?LS_ -Q_R_\ K4?9G_N/^7_UJ^8O^&MO _\
MT&=/_P"_T7_QRE_X:V\#?]!K3O\ O]'_ /%T ?3GV9_[C_E_]:C[,_\ <?\
M+_ZU?,?_  UMX&_Z#6G?]_H__BZ/^&MO W_0:T[_ +_1_P#Q= 'TY]F?^X_Y
M?_6H^S/_ ''_ "_^M7S'_P -;>!O^@UIW_?Z/_XNC_AK;P-_T&M._P"_T?\
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MP9X'C&]@V2RD9Y8^_OG\* /Y^]&U?7_@3\?&TJ_AGL=+LM0*%Y5:- JS8Y)
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M%K<+&Y 9M[HP!SD^OKQZU_)Q\0_VH=1\"^.=4U[2;F>WMI;R62-8'90%+EL
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MM+8SDG\:_C'_ &-/VE=,LO%&C^*/%*BZCM[N*>0W)WY56#'EL]\U_6=\-O\
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M;QOIL>JV=PDZM"K;HV##.T'L>_3K]<XJ5K>V5F!S@$C\CCV_G^%?S ?LE_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^V3*Q9['7<YR<BXZ^PQ_45:MX_VS[5ALL=<('3/VDCW['_.:_M4_X4/X-_Z
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M_OY>5_6$/V"O"!_YAUH/K!%_\35.]_84\)6JAAIMFW_;"(Y^F%_.F2?RD_\
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M_P % _\ GX\0?]_;K_"C_AO+_@H'_P _'B#_ +^W7^%?U,?\,+>%O^@99_\
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M(&?YU#/\>_VT;F![5UUHQ2 J1FYQ@\'L>WJ?PZ5_76?V&/"Y/_(-M/Q@C/\
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MB#_ON\_QH_X>"?\ !0G_ )[^(/\ ON\_QK^K#_AWWX0_Y\+/_OS'_P#$T?\
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MJ_\ P\-_X*"_\_>O_P#?RZ_PH_X>&_\ !07_ )^]?_[^77^%?U4?\.[O"/\
MSX67_?J/_"C_ (=W>$?^?"R_[]1_X4 ?RK_\/#?^"@O_ #]Z_P#]_+K_  KW
M+]C+]OC]NSQ#^U5\.=&U[4M?ETN]\16,.H6DL=XD44#3H"YF9VCD#= NQ2 2
M2<C%?T;?\.[O"/\ SX67_?J/_"N^^ G_  3_ /"?ASXU>&->ALK-9;34[:92
ML,0;*2*1C"Y!X_+VH _LP^"M[>ZE\)OA]?ZCN^WW?A;2I[O=][SW@4OG.#G/
MK7I]<EX#LDT[P9X9L$ "6FCV4"@< ".( 8KK: "BBB@ HHHH **** "BBB@
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M!XYR@![_ ,L]*_M>_P"$=\)_] *R_P# >+_XBD/AWPK@[=#L@<?\^\?\]O\
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M^)%9?>;_ )=XO4_[%-_X1WPG_P! *R_\!XO_ (BO[:/^7F'PQ_PK\D?Q#_\
M#'W[0W_0&UG_ +YF_P#B*/\ AC[]H;_H#:S_ -\S?_$5_;Q_PCOA/_H!67_@
M/%_\11_PCOA/_H!67_@/%_\ $4%'\0__  Q]^T-_T!M9_P"^9O\ XBC_ (8^
M_:&_Z VL_P#?,W_Q%?V\?\([X3_Z 5E_X#Q?_$4?\([X3_Z 5E_X#Q?_ !%
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MXT76/^^9_P!>,8]?Y>G]LO\ 97A7_H V7_@/%_\ $4ATGPH1C^P++_P'B_\
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M+K'Y7'^%'_#+W[3/_0%UC\KC_"O[>/\ A$_"7_0 L?\ P'B_PH_X1/PE_P!
M"Q_\!XO\* /XA_\ AE[]IG_H"ZQ^5Q_A1_PR]^TS_P! 76/RN/\ "O[>/^$3
M\)?] "Q_\!XO\*/^$3\)?] "Q_\  >+_  H _AHNOV7/VF_^$F\,.-&UD1QZ
MC;-)\MQ@*)U)S\OISC]><5_J+?\ !';P[X@\,?L9^!]+\2Q2PZI#;V8F2;=O
MRMJ <[N>OZY':OQRE\)>$?[1TT_V#8Y%Q&0?L\/!#C_9SWS7])'[)UM:VGPD
MT:&TA2"%8X<(BA5'[H=AQQ[<4 ?35%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_C0!-_;&H_\ /5O^^A76_"35K]_B?H2M.Y!OH00?]\#V^GU_*N,\E?\ .?\
M&NP^$D*CXGZ&?2]@_P#0U]\_CGZ#- ']/OA(D^&=#).2=-MLGU_=BNAKG?"/
M_(LZ'_V#;;_T6*Z*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU'Z_X5<\L?W3^M'EC^Z?UH I[#ZC]?\ "C8?4?K_ (5<\L?W3^M'EC^Z?UH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\<?^"CJ[M3LN_RQ\?\!_\
MU_CC%?L=7X]?\%%5#:G99'9/_0!0!^7UG&?LT6/[HZYS_GM^%6=A]1^O^%6K
M2-?L\7^[VQZ_C_\ JJQL'J?T_P * ,W8?4?K_A1L/J/U_P *TM@]3^G^%&P>
MI_3_  H S=A]1^O^%&P^H_7_  K2V#U/Z?X4;!ZG]/\ "@#-V'U'Z_X4;#ZC
M]?\ "M+8/4_I_A1L'J?T_P * ,W8?4?K_A1L/J/U_P *TM@]3^G^%&P>I_3_
M  H S=A]1^O^%&P^H_7_  K2V#U/Z?X4;!ZG]/\ "@#-V'U'Z_X4;#ZC]?\
M"M+8/4_I_A1L'J?T_P * ,W8?4?K_A1L/J/U_P *TM@]3^G^%&P>I_3_  H
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M@#.\D>WYFCR1[?F:T=C>GZC_ !HV-Z?J/\: ,[R1[?F:/)'M^9K1V-Z?J/\
M&C8WI^H_QH SO)'M^9H\D>WYFM'8WI^H_P :-C>GZC_&@#.\D>WYFCR1[?F:
MT=C>GZC_ !HV-Z?J/\: ,[R1[?F:/)'M^9K1V-Z?J/\ &C8WI^H_QH SO)'M
M^9H\D>WYFM'8WI^H_P :-C>GZC_&@#.\D>WYFCR1[?F:T=C>GZC_ !HV-Z?J
M/\: ,[R1[?F:/)'M^9K1V-Z?J/\ &C8WI^H_QH SO)'M^9H\D>WYFM'8WI^H
M_P :-C>GZC_&@#.\D>WYFCR1[?F:T=C>GZC_ !HV-Z?J/\: ,[R1[?F:/)'M
M^9K1V-Z?J/\ &C8WI^H_QH SO)'M^9H\D>WYFM'8WI^H_P :-C>GZC_&@#.\
MD>WYFCR1[?F:T=C>GZC_ !HV-Z?J/\: ,[R1[?F:/)'M^9K1V-Z?J/\ &C8W
MI^H_QH SO)'M^9H\D>WYFM'8WI^H_P :-C>GZC_&@#.\D>WYFCR1[?F:T=C>
MGZC_ !HV-Z?J/\: ,[R1[?F:/)'M^9K1V-Z?J/\ &C8WI^H_QH SO)'M^9H\
MD>WYFM'8WI^H_P :-C>GZC_&@#.\D>WYFCR1[?F:T=C>GZC_ !HV-Z?J/\:
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M]]K_ $XK#^SGT'Y#_&NI^%4!'Q)T3CI>P],_\]!QS^?KZ4 ?TE^%>/#>B?\
M8.MO_18K?K \+?\ (N:+_P!@ZV_]%BM^@ HHHH **** "BBB@ HHHH ****
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M0!F^1[_K_P#6H\CW_7_ZU:6QO3]1_C1L;T_4?XT 9OD>_P"O_P!:CR/?]?\
MZU:6QO3]1_C1L;T_4?XT 8,D'^GZ?W_?Q^O]\>@'^?U_H=_9:&WX5:0/1(O_
M $4*_GSD0_VAIYQ@^?'Z<_./\\U_0A^R]_R2S2/]R+_T70!]%T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'YN?M_C.@6 QG]T/SS7Y)V$?^C)P>IX';
M^?7^>:_7']OH9T&R_P"N0_+)K\G-/C_T9.>Y_GS0 GE>S?E_]:CRO9OR_P#K
M5>\OW_3_ .O1Y?O^G_UZ */E>S?E_P#6H\KV;\O_ *U7O+]_T_\ KT>7[_I_
M]>@"CY7LWY?_ %J/*]F_+_ZU7O+]_P!/_KT>7[_I_P#7H H^5[-^7_UJ/*]F
M_+_ZU7O+]_T_^O1Y?O\ I_\ 7H H^5[-^7_UJ/*]F_+_ .M5[R_?]/\ Z]'E
M^_Z?_7H H^5[-^7_ -:CRO9OR_\ K5>\OW_3_P"O1Y?O^G_UZ */E>S?E_\
M6H\KV;\O_K5>\OW_ $_^O1Y?O^G_ ->@"CY7LWY?_6H\KV;\O_K5>\OW_3_Z
M]'E^_P"G_P!>@"CY7LWY?_6H\KV;\O\ ZU7O+]_T_P#KT>7[_I_]>@"CY7LW
MY?\ UJ/*]F_+_P"M5[R_?]/_ *]'E^_Z?_7H H^5[-^7_P!:CRO9OR_^M5[R
M_?\ 3_Z]'E^_Z?\ UZ */E>S?E_]:CRO9OR_^M5[R_?]/_KT>7[_ *?_ %Z
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M_6H\KV;\O_K5>\OW_3_Z]'E^_P"G_P!>@"32XO\ 2EX/W6Z\=NW3_.*_"?\
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MO*'M_P!\C_&CRA[?]\C_ !H S<'T/Y&C!]#^1K2\H>W_ 'R/\:/*'M_WR/\
M&@#-P?0_D:,'T/Y&M+RA[?\ ?(_QH\H>W_?(_P : ,W!]#^1KJOA8I_X61HI
MQ_R_0?\ H:_YY[5C^4/;_OD?XUU/POC ^(NB\?\ +[#]/OK^G\\4 ?T7>%_^
M1=T;_L'V_P#Z *WJP?"__(NZ-_V#[?\ ] %;U !1110 4444 %%%% !1110
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MHT4 9WDGW_,4>2??\Q6C10!G>2??\Q1Y)]_S%:-% &=Y)]_S%'DGW_,5HT4
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MZY']/\,U0>,;L$<Y[=^>G]/\BM]NA^AK+D^^WUH I^6/[I_6CRQ_=/ZU9HH
MK>6/[I_6CRQ_=/ZU9HH K>6/[I_6CRQ_=/ZU9HH K>6/[I_6CRQ_=/ZU9HH
MK>6/[I_6CRQ_=/ZU9HH K>6/[I_6CRQ_=/ZU9HH K>6/[I_6CRQ_=/ZU9HH
MK>6/[I_6CRQ_=/ZU9HH K>6/[I_6CRQ_=/ZU9HH K>6/[I_6CRQ_=/ZU9HH
MK>6/[I_6CRQ_=/ZU9HH K>6/[I_6CRQ_=/ZU9HH K>6/[I_6CRQ_=/ZU9HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_6HV?[/_ ([_ /6JQ11KY?=_P?7^EJ:^7W?\'U_I:U]G^S_X[_\ 6HV?[/\
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M_P#K5+H2G_A#=!/_ $Y6W_HM1_0?G3Z_U!@FJ.&U_P"8;#]/^G4.UK?U\_\
MA'K?\C'.O^QWFO3_ *C*GZ?Y^17V?[/_ ([_ /6IK1D] 0?H<?RJU15:_P!+
M_@^O];K7^E_P?7^MZ?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%
M7** *?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?
M\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%
M7** *?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?
M\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%
M7** *?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%7** *?E/Z?H?
M\*/*?T_0_P"%7** *?E/Z?H?\*/*?T_0_P"%7** *^S_ &?THV?[/_CO_P!:
MK%%&O]+_ (/K_2U-?Z7_  ?7^EK7V?[/_CO_ -:C9_L_^.__ %JL44M?+[O^
M#Z_TM5KY?=_P?7^EK7V?[/\ X[_]:C9_L_\ CO\ ]:K%%&OE]W_!]?Z6IKY?
M=_P?7^EK7V?[/_CO_P!:C9_L_P#CO_UJL44:^7W?\'U_I:FOE]W_  ?7^EK7
MV?[/_CO_ -:C9_L_^.__ %JL44:^7W?\'U_I:FOE]W_!]?Z6M?9_L_\ CO\
M]:C9_L_^._\ UJL44:^7W?\ !]?Z6IKY?=_P?7^EK7V?[/\ X[_]:C9_L_\
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M;%]/U/\ C1O3^\O_ 'T/\:-Z?WE_[Z'^- !L7T_4_P"-&Q?3]3_C1O3^\O\
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MBF$@'!(!]"0#^M ";%]/U/\ C1L7T_4_XU(J._W%+?09J3[//_SQD_[X/^%
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M]<Z /H*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\)_\50!^'_V@_P#/!_\ O@T?:#_SP?\ [X-?N!_PR9\-?^?8?]^$_P#BJ/\
MADSX:_\ /L/^_"?_ !5 'X?_ &@_\\'_ .^#1]H/_/!_^^#7[@?\,F?#7_GV
M'_?A/_BJ/^&3/AK_ ,^P_P"_"?\ Q5 'X?\ V@_\\'_[X-'V@_\ /!_^^#7[
M@?\ #)GPU_Y]A_WX3_XJC_ADSX:_\^P_[\)_\50!^'_V@_\ /!_^^#1]H/\
MSP?_ +X-?N!_PR9\-?\ GV'_ 'X3_P"*H_X9,^&O_/L/^_"?_%4 ?A_]H/\
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M_M!_YX/_ -\&C[0?^>#_ /?!K]P/^&3/AK_S[#_OPG_Q5'_#)GPU_P"?8?\
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MPU_Y]A_WX3_XJ@#\/_M!_P">#_\ ?!H^T'_G@_\ WP:_<#_ADSX:_P#/L/\
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MHH _&O\ X8@\;_W9/^^3_C1_PQ!XW_NR?]\G_&OV4HH _&O_ (8@\;_W9/\
MOD_XT?\ #$'C?^[)_P!\G_&OV4HH _&O_AB#QO\ W9/^^3_C1_PQ!XW_ +LG
M_?)_QK]E** /QK_X8@\;_P!V3_OD_P"-'_#$'C?^[)_WR?\ &OV4HH _&O\
MX8@\;_W9/^^3_C1_PQ!XW_NR?]\G_&OV4HH _&O_ (8@\;_W9/\ OD_XT?\
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MJ?\ 8;\9Q2%!ND .-R*2#^(X'YGUJ/\ X8?\:=DD_P"^:^KOV0OVS/AM\?\
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M-7J\H] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_"IF?_(RS#_L.Q?_ *D5 HHHK4X0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#\W/^"J?_ ":3XV_ZX3_^D[U_
MG*W_ /Q_7O\ U]W/_HYZ_P!&K_@JG_R:3XV_ZX3_ /I.]?YRM_\ \?U[_P!?
M=S_Z.>OXQ^D=_P E-E/_ &+9?^G(G_2_^Q;_ .3'>('_ &6\?_4)%2O[^O\
M@B)_R:EIO^[9_P#HMJ_@%K^_K_@B)_R:EIO^[9_^BVKS_H\_\EKB/^Q77_\
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M[)72L]WV;_X/]@7[%7QCC^*7@;3G6X$[6UA$&(?=@K$H(ZG_ #BON.OY^O\
M@A[XEU;7O ^I#4I7D\JU8)O8M@   <],5_0+7D8RFJ6(J06R>GS['?A9^THP
MEY6^Y+7Y[A1117,= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5_&#_P<1?\ )6/#W_72+_TG
M:O[/J_C!_P"#B+_DK'A[_KI%_P"D[5^.>.O_ ";['_\ 83A/_3A_I/\ LHO^
M4ON%?^Q!Q!_ZC4S^:6OK']B'_DYGX9?]AF'_ -&PU\G5]8_L0_\ )S/PR_[#
M,/\ Z-AK^'\B_P"1UE/_ &,<'_ZD4S_J2\5O^39>('_9'<1?^JK%'^E]X'_Y
M$WPM_P!@#2O_ $BAKJ:Y;P/_ ,B;X6_[ &E?^D4-=37^GU#^!1_Z]4__ $B)
M_P *F:?\C+,?^P[%_P#J14"BBBM3A"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /S<_P""J?\ R:3XV_ZX3_\
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MZ+"R*02TA_AP>IZC S^O+?\ !!_7-:T*:\MK:>:YA:[*_>9AM\T=#D\#V_\
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M/B7AVJ;HPY5>*E/6U[*ZT[;O3NS^OO\ 8>^).G>!O!,=KJ3PQ176GHKM.RJ
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M?_D3?"W_ & -*_\ 2*&NIKEO _\ R)OA;_L :5_Z10UU-?Z?4/X%'_KU3_\
M2(G_  J9I_R,LQ_[#L7_ .I%0****U.$**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;B(@@@$,DB^G0Y!K^)+X<_!GQ[^R]^T[=W]E:ZC+IMEJV(XD28P[4G)&  %
MQZ<<'%?UP_LV?%'4/B9X0@O]0M9;:6"VB4K(I4Y 4'AN<\X[>OI6F94(1J*M
M2:<*BYGKJG*VGRN9X*K)P]E45IP]WY+2_P!_GOMUMQ'QC_8<^"GQO29/&6E+
M.)BQ?;:PL26.3]YQGOUKX]N?^"(G[&=U.T\GAZ3>S%CBQM>IY_YZ^OZ<5^Q=
M%<<,5B*:M3K3BET3LO\ A_/<Z98>A)\TJ4)/>[5W^/H?G3\+?^"8W[-OPCN8
M+KPMH@BEMY$DC+6D"X*'*_=D/?VK]!=,TNUTK3;;2K2-4M+6 6\2!0 (P",%
M1QT.#6C145*M6J[U)RFULY.Y<*<*?P14;]E8^2?B]^QE\'OC3+--XPTM)WG#
M!R+:)R=V<\LX]>/3Z\U\6ZI_P1'_ &-=6NFN[KP_(97<N<65MC).?^>OJ:_8
MBBM(8K$4URPK5(QM:REI;T(E0HS=YTX2?FK_ -;??KN?F7\//^"4O[+WPTNX
M+SP]H1CFMV5XRUG;J 5((Z2'TYK[^\%^ M!\"6*V&AVZPP*@C $:IA5Q@?*3
MV%=M16=2M5JZU*DI_P")W+A2IT_@A&/316\@HHHK,LX[QEX'T/QSIS:9KEND
M]NZ,A#1JYVL#D#=]<U^=?Q!_X))?LK?$G4Y]5\0Z$9+JX=GD*V5N1EB2<;I!
MCDU^HM%:TZU6E_#J2A_A=B)TJ=32<(R7FKGY :/_ ,$4?V.=%O8KZS\/.)HI
M!(N;&UQD'(_Y:_K7WK\'/V8_AK\$!$/!>GI;&%!&C>1'&P4# P59L8Z]SGG-
M?15%.IB*]5<M2K.<>TG=$PH4J;O"G&+[I6*E[9P:A:SV=P@:&=3&ZL 00?8]
M17Q/\8?^"?\ \!OC:TC^,='6=I2Q8I:PL?FS_><>OIS7W'140J3IOFA.4'WB
M[%SA":M.*DNS/QYM/^")/[&ME?KJ$7AZ3SU<2#-C:XR#G_GIZU]T?!C]DSX5
M? N"&W\%::END!4H3;Q(<IC;G:S>G\Z^GJ*TGB<147+.K.<>TI77W$0H4:;O
M"G"+76*L_P"M#YQ_:,_9?^&G[3OAN'PM\2K'[;ID 8(GDQR\.2Q&V1E'4U\W
M_!__ ()>_LT_!36+76_!NB?9[VSF$\+?8X(\."#G*2'N*_1ZBIC7K0CR1J3C
M![Q3=M?(<J-*4N>4(N>GO-:Z;:_(SYK"VFTZ32'4FVDLFL&7 Y@: P$8_P"N
M9QCIVK\X-5_X)5_LPZQ\0;OXDW>A[O$5Y=&[EF^Q6YS*SER=YDW'D]37Z7T4
MH5:E*_LYRAS*SY7:Z\^XY4Z<[<\(RMM=)V]#S;X;_"_PS\+=(&C^&8#!9JBI
MLV*GRIC' )';UQ7G/[1'[+_PT_:;T"#P[\2+#[;I\",D:^3'*0K,S'AV48RQ
M/6OH^BDJDXS4XRDIIW4DW>_J/EBX\O*N6UK6TMZ'Y;?"'_@D;^RG\%O&=IXY
M\'Z!]GUJRG%Q#(;&WCPX8,/F64GJ!V_"OU%B18HTA082)$C08P-J*%4#Z  >
MU244ZE:K6:=6<IM:)R=[>@H4X4TU3BH)N[25KON<?XV\$Z)X^T6;0M>@6>QF
MW;D9%?[PVG 8CJ!^/%?G5\0_^"2/[*OQ*O9;[Q#H1DGF9F<K9V[<L23UE'//
M7BOU%HITZU6E_#J3A_A;0ITJ=3XX1EZJY^0WAW_@BO\ L>>&;R.^T[P_(LT3
MAU+65MU!R.1+GKWK[BT']E7X7^'O"\?A+3[ )I4<7DJGD1@[-NWIN(Z>]?2]
M%.>(KU+<]6<K6M>3=K6_R0HT*4+J%.,;[V5OR/S.\7?\$J/V7_&GBBQ\6ZQH
M?F:KI]PEU!)]CMVQ+&P=3N:0$8('2OT)\&^$]*\#>&])\*Z+&8],TBV2UM$V
MA=D4:A0, D#H.A/-=114SK5:BBJDY34?A4G>WIV*C3A!MPBHN6[2M<R]9TFT
MUW3KG2[Y-]M=(8Y5*Y!4@C&#P>#_ (U^?7Q9_P""87[-?QCNFO/%NAB>5Y&D
M)%G;N=S'<>6<=\GI7Z,T44ZM2D[TYR@^\78)TX5%:<(R79JY^=7PC_X)D?LW
M_!G5;?5_".CM#=6Q!CW6L"*,'(X5ST./7I73?&W_ ()Y? 'X]2)+XXT=;AT3
MRP5M('XV[?XW&#BON^BJ^L5W-3]K/G2:4N9W2>^I/L:7*X>SCRNUXVTTV/RG
M^'__  1]_9-^&^I2:IX>T)XKF7.XM9VZCUZK+GJ<^GM5OQ!_P2)_91\2:^OB
M/4= +:BK!@XLK8\@YZF3/6OU-HJ_K>)O?V]2[5F^9WMMN)8>@E;V4+)W2Y59
M,^;O@_\ LM_#+X)Z?-IO@VP%O;31F)PT,:90KMQ\K-GCUX_IXS\8?^"='[/G
MQLN;NZ\8:.)I;UF:9EM(')+9SRSCJ#CD5][T5G&O6C-SC4DIO>5]2G2IN/(X
M)Q71[?U_74_&FR_X(;_L76%\+^'P]+YX?S,FQML;LY_YZGO^=?;_ ,%/V,/@
M[\!Y(I?!&EI;O"%"%K:),!<8^ZS>@_\ K5];T5<\5B:B<9UJDD]TY;DQP]&#
M4H4H1:V:5FBEJ%A;ZE9S6-RBO!,FQT*@C&,#C@<>E?#OQ?\ ^">7P!^-<LDW
MC#1UF>0L6V6D#?>SG[SCU_2ON^BLH5*E-WISE!]XNW]>I<H0FK3BI+L]5]W]
M7/QTB_X(A_L9PW8O$\/2"4/O&+&V SG/_/7UKZW^$G[!_P #O@TUL?">E>6+
M9E:,-;PQ\H>.49OSQZ]:^U*P/%&JOHF@ZEJL:EWLK=YE0#)8J.F._P#C6LL3
MB*B495JDD]+.3_J_GN9K#T(:QI0C;JHGQY^V/^TSH/[.7@2X6:]@TZ2XTZ6"
M LRJR*\;(%4Y!&0<''7)'0XK^&W0_"7B?]I?]O>'QG!!-J.C7^O"4SJK21%3
M= YS@C&#Q]>O-?L[_P %1/$WC[]HS4+?PQIECJ$$4%YY!>*.90R";!)*C!XZ
MYX[CTK[:_P""9_\ P3JT[P-X0\.?$#Q#'&-3'ES+]ICS,\@"2'[R[N,]^!GK
MT%>QAI4L!A)59/\ ?5HN%EK;MM?RUZ'FUXSQF(C3BK4Z34D]K[:?UII=6/UB
M_9H^$]O\-/!6DP16ZV[RZ?!N4+M.3$F<@ >_7_ #Z;J.&)((HH8P%2*-(T X
M 5%"@#\!4E>#.3G)R>[=W^1Z\(J$5%;))?<DOT"BBBI*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OXP?^#B+_DK'A[_ *Z1?^D[5_9]7\8/_!Q%_P E8\/?]=(O_2=J_'/'
M7_DWV/\ ^PG"?^G#_2?]E%_RE]PK_P!B#B#_ -1J9_-+7UC^Q#_R<S\,O^PS
M#_Z-AKY.KZQ_8A_Y.9^&7_89A_\ 1L-?P_D7_(ZRG_L8X/\ ]2*9_P!27BM_
MR;+Q _[([B+_ -56*/\ 2^\#_P#(F^%O^P!I7_I%#74URW@?_D3?"W_8 TK_
M -(H:ZFO]/J'\"C_ ->J?_I$3_A4S3_D99C_ -AV+_\ 4BH%%%%:G"%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?FY_P53_Y-)\;?]<)__2=Z_P Y6_\ ^/Z]_P"ONY_]'/7^C5_P53_Y-)\;
M?]<)_P#TG>O\Y6__ ./Z]_Z^[G_T<]?QC]([_DILI_[%LO\ TY$_Z7_V+?\
MR8[Q _[+>/\ ZA(J5_?U_P $1/\ DU+3?]VS_P#1;5_ +7]_7_!$3_DU+3?]
MVS_]%M7G_1Y_Y+7$?]BNO_Z5$^Q_;%_\HR95_P!EQE?_ *1(_9ZBBBO[>/\
MEO"BBB@ I",@J1D,"#]",8_'FEHH \9U?X ?"K7-2DU?4_"]I<W\KF1YW6/<
MSDDDG]WG.3ZUZ#X;\(Z!X2M?L>@V$=C;X \N,#& <CH!72T53E)JSDVNU].G
M^1*C%.Z23[I=PHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JO=VD%];RVMS&)()E*2(>C*>H-6** /$]0_9X^$NJ77VV^\*6
M<UQO\SS&5,[\YW<QGG->K:)HFF^'M.@TK2;9;2QMAB&!  J# '& !T [=JUJ
M*IRE)).3:6R;;2TM^0E&*U22]%8****D84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
MQ@_\'$7_ "5CP]_UTB_])VK^SZOXP?\ @XB_Y*QX>_ZZ1?\ I.U?CGCK_P F
M^Q__ &$X3_TX?Z3_ +*+_E+[A7_L0<0?^HU,_FEKZQ_8A_Y.9^&7_89A_P#1
ML-?)U?6/[$/_ "<S\,O^PS#_ .C8:_A_(O\ D=93_P!C'!_^I%,_ZDO%;_DV
M7B!_V1W$7_JJQ1_I?>!_^1-\+?\ 8 TK_P!(H:ZFN6\#_P#(F^%O^P!I7_I%
M#74U_I]0_@4?^O5/_P!(B?\ "IFG_(RS'_L.Q?\ ZD5 HHHK4X0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_R:3XV_ZX3_ /I.]?YRM_\ \?U[_P!?=S_Z.>O]&K_@JG_R:3XV_P"N$_\
MZ3O7^<K?_P#']>_]?=S_ .CGK^,?I'?\E-E/_8ME_P"G(G_2_P#L6_\ DQWB
M!_V6\?\ U"14K^_K_@B)_P FI:;_ +MG_P"BVK^ 6O[^O^"(G_)J6F_[MG_Z
M+:O/^CS_ ,EKB/\ L5U__2HGV/[8O_E&3*O^RXRO_P!(D?L]1117]O'_ "WA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q@_\
M'$7_ "5CP]_UTB_])VK^SZOXP?\ @XB_Y*QX>_ZZ1?\ I.U?CGCK_P F^Q__
M &$X3_TX?Z3_ +*+_E+[A7_L0<0?^HU,_FEKZQ_8A_Y.9^&7_89A_P#1L-?)
MU?6/[$/_ "<S\,O^PS#_ .C8:_A_(O\ D=93_P!C'!_^I%,_ZDO%;_DV7B!_
MV1W$7_JJQ1_I?>!_^1-\+?\ 8 TK_P!(H:ZFN6\#_P#(F^%O^P!I7_I%#74U
M_I]0_@4?^O5/_P!(B?\ "IFG_(RS'_L.Q?\ ZD5 HHHK4X0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\W/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_U"14K^_K_@B)_R:EIO^[9_^BVK^ 6O[^O^"(G_ ":EIO\ NV?_ *+:O/\
MH\_\EKB/^Q77_P#2HGV/[8O_ )1DRK_LN,K_ /2)'[/4445_;Q_RWA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q@_P#!Q%_R
M5CP]_P!=(O\ TG:O[/J_C!_X.(O^2L>'O^ND7_I.U?CGCK_R;['_ /83A/\
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M_P#']>_]?=S_ .CGK^,?I'?\E-E/_8ME_P"G(G_2_P#L6_\ DQWB!_V6\?\
MU"14K^_K_@B)_P FI:;_ +MG_P"BVK^ 6O[^O^"(G_)J6F_[MG_Z+:O/^CS_
M ,EKB/\ L5U__2HGV/[8O_E&3*O^RXRO_P!(D?L]1117]O'_ "WA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q@_\'$7_ "5C
MP]_UTB_])VK^SZOXP?\ @XB_Y*QX>_ZZ1?\ I.U?CGCK_P F^Q__ &$X3_TX
M?Z3_ +*+_E+[A7_L0<0?^HU,_FEKZQ_8A_Y.9^&7_89A_P#1L-?)U?6/[$/_
M "<S\,O^PS#_ .C8:_A_(O\ D=93_P!C'!_^I%,_ZDO%;_DV7B!_V1W$7_JJ
MQ1_I?>!_^1-\+?\ 8 TK_P!(H:ZFN6\#_P#(F^%O^P!I7_I%#74U_I]0_@4?
M^O5/_P!(B?\ "IFG_(RS'_L.Q?\ ZD5 HHHK4X0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEKB/^Q77_P#2HGV/[8O_ )1DRK_LN,K_ /2)'[/4445_;Q_RWA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\W/\ @JG_ ,FD^-O^
MN$__ *3O7^<K?_\ ']>_]?=S_P"CGK_1J_X*I_\ )I/C;_KA/_Z3O7^<K?\
M_']>_P#7W<_^CGK^,?I'?\E-E/\ V+9?^G(G_2_^Q;_Y,=X@?]EO'_U"14K^
M_K_@B)_R:EIO^[9_^BVK^ 6O[^O^"(G_ ":EIO\ NV?_ *+:O/\ H\_\EKB/
M^Q77_P#2HGV/[8O_ )1DRK_LN,K_ /2)'[/4445_;Q_RWA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q@_P#!Q%_R5CP]_P!=
M(O\ TG:O[/J_C _X.(S_ ,78\.CUDC_])FK\<\=?^3?8_P#["<)_Z</])_V4
M7_*7W"O_ &(.(/\ U&IG\TU?6/[$/_)S/PR_[#,/_HV&ODZOK#]B(@?M,?#+
M/_09A_\ 1L5?P_D7_(ZRG_L8X/\ ]2*9_P!27BM_R;+Q _[([B+_ -56*/\
M2_\  _\ R)OA;_L :5_Z10UU-<MX'_Y$WPM_V -*_P#2*&NIK_3ZA_ H_P#7
MJG_Z1$_X5,T_Y&68_P#8=B__ %(J!1116IPA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YN?\%4_^32?&W_7"
M?_TG>O\ .5O_ /C^O?\ K[N?_1SU_HU?\%4_^32?&WO!/_Z3.:_SE;__ (_K
MW_K[N?\ T<]?QC]([_DILI_[%LO_ $Y$_P"E_P#8M_\ )CO$#_LMX_\ J$BI
M7]_7_!$3_DU+3?\ =L__ $6U?P"U_?U_P1$Y_92TS_=L_P#T6U>?]'G_ )+7
M$?\ 8KK_ /I43[']L7_RC)E7_9<97_Z1(_9ZBBBO[>/^6\**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^-/_@X=TJ]G^)>AWT5
MM))! \3/(JLP4&(J3P" !D9]L^E?V65^-O\ P4L_8LU/]HRPO-5T[3A=RV]K
M(4<1ER&6,^@/3C\L'L*_-O%?(\9Q#P=CLNP,)5,1*I2JQC&+DVJ4G)JR/[7_
M &?WBGP]X/\ TD^%>,.*,32PF4T\)C\OKUZU14H0>.C3I1;E+335G^?S7V#^
MPIIES?\ [2WPZ>"%Y([;5H'D95)";IH0N3TR0&_KP:]>\6?\$U_CQ8^+=0TG
M3-'=[9;R18V:VF)C4N>/E(R #D#C K]<?^">G_!,_P =>!_%>@>*_$VE.)K6
MZAN'ED@92"'#'DC&./\  9P#_&?"W!'$6)X@P%.>68JE##8ZC4K5)TVHI4:T
M9/7L[;]C_I8\>OI1^#61^$'%6+H<<9!C\5G?#.8X3+\#AL=2GB)SS# 5:4.:
M"=XN/M5H]6]M-_ZX?!2E?!_AA2,%=!TL$>F+.&NGK+T2U-EH^EVA&#;6%K 1
MTP8H43'X8Q6I7^B-)<M*G%[QIP3^44C_ (VL=4C6QN,JQ^&KBL14C_AG6G)?
M@PHHHK0Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#\YO^"H]G-??LH>-(($:21H9\*H)/_'N_I^6?_UC_.4U
MNTN+'5]2MKF)X98[VZ4HZE3CSG((SV((/XX/.:_U"_VC?AM)\5OAGJ_A&*$3
MO>QR@(5W9S&5Z<]<]<'Z5_%?^V9_P2\^*6@>,KF\\,:.Z+//*^P6TA1P[$]%
MP>>,')P0>H&#_+'C]PIFV:8[ 9O@,+5Q-+#X;ZO45*+D[RDGTZ[?(_WN_9%>
M/WA]P'PMQ9X=\69[E^28_.,]EFV#JX[$1HPE"GAU3L^9Z1=VKVT=F_/\-(HI
M)Y8X8E+R2NL:(HR69B H 'J37^@)_P $4["?3_V6--@N$:-_+LCAAM/$1SQ^
M/ZU_+U^SW_P2W^,^N^*M/NO$.D.+:.:-Q&+:4(!O!));<">.O;MCDG^TC]B3
MX.77P6^$]GX6N[?[-+'' &3;LY1,'@\\'BO-\!>%<XR[/L1FV.P5?"T98.I0
MA[:#BWS-.^NNK_(^U_:T^/GAQQCX391X?<)\2Y7GV9T^(L%FF)_L_$PKQITZ
M2Y7&\7TOJ^]UJD?9M%%%?UR?\[@4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHJ&19V_U4R1C_ &H?,_7S$_E0_2_I;]6AI)NS:CYN]O\
MR5-_@345!$EPI_>S1R#T6 QG\_-?^53TEKT:];?HV#23LI*2[KFM_P"3*+_
M****8@HHHH **** "BBFL&(^1@I]2NX?EN7^= ?A_7D.HJJ([O/-S$1Z?9B/
MU\\U94$#YB&/J!M'X#)Q^9I)M]&O6WZ-E226THR_PJ6G_@48_A<6BBBF2%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMVNWL%%%%:G$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=VZ<I**\W9%4L;A:S4:=:+D]%&5X-M]$IJ/,_*-S]+Z***X3J"BBB@ HHHH
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M)7LKZ-Q2V\^_9GZTT445PG4%%%% !1110 4444 %%%% !1110 4444 %%%%
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M7UV=_P#(MK?XJ/\ Z=@>!E?^^4_\-3_TAG]6E?Y+'Q\_Y+I\:?\ LK/Q&_\
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MCQ5_ZG$M>ED?_(QI?X*O_IN1QYI_N=3_ !4__2T?RS5_IF?\$;/^48O['O\
MV3.Z_P#4P\35_F9U_IF?\$;/^48O['O_ &3.Z_\ 4P\35[/$7^Z4/^PA?^FZ
MAYN3_P"\5/\ KR__ $N!^FE%%%?'GT045\6_M _\%%?V(/V6[J\TOXY?M+?#
M+P=XAT^3RM0\'6>JW'C/Q[I[G&!?^ ? EGXF\9V2MGY9+K0HHVP^UR$?;\03
M_P#!PE_P2WAU%;&/XT^,;JV.<ZQ!\&?BHNG+@X!:*Z\+6VK\CYAMTMCCJ >*
MZ88/%U8\U/#5YQZ2C2FXOT:C9_)LQEB,/!\LZU*,NJ=2*:]5>Z/VQHK\]/@A
M_P %7?\ @G?^T/J-OHGPR_:K^&LVOW=Q%9V/A_QO+K7PHUW4[Z9E2*QT;2_B
MGI'@V[UV[D=PL<&B1Z@\I#>5O"L1^A=95*56D^6K3J4Y?RU(2@_NDDS2$X5%
M>$XS7>$E)?>FT%%%%9E!1110!^3_ /P6P_9S^(/[3?\ P3R^+_@;X5^'M0\7
M?$#PWJ7@[XD>'O">D6]Q>:UXC3P9K]M=Z]I>B:?:13W6JZW)X7N-;GTC1[6&
M6\U?48+;3+&*6]NK>-O\W#5]'U;P_J=]HNO:7J.B:SIES-9:EI.KV-SINIZ?
M>6[M%<6E]87D4-U:7,$JM'-!<11RQ.K(Z*P('^N_JVKZ5H&EZCKFNZGI^BZ+
MH]C=:GJVL:M>VVFZ7I>FV,+W-[J&HZA>2PVEC8V=O')/=7=S-%!;PQO++(B*
MS#\^?$7_  5#_P""9-KJL<&N?M=?LYZGJ.FW#1VUW;>*=(\3PVLZ%@9++6-*
MAU2Q5,YVW-K>&%P<I*P.3[F5YE6PM*=&&$GB8<[G>FY)P<HQ33Y:=1-/E35[
M-:ZM:+R\=@J5>I&I*O&A+EY?>46I)-NZO.&JN[[WTV/YA?\ @VM_93^+NJ?M
M5:S^U%J_@OQ)H'P>\#?"_P 5Z!HWC+5],U/2=%\8>,O&%SIVCV^B^&;NZMH;
M3Q+'I>CV^OW^NS:=-=6^B7$6C17YAN=3L%?^Y"O%/@K^TC\ /VCM)U#7/@+\
M9?AM\7=-TB2WAUJ7P!XOT7Q)/H4]XLKV<&O6.FW<U_HD]VD$TEK#JMM9RW,<
M4DD*.B,P]KK@S#%5,7B95:M-T9*,8*F[WA&*NDW)1;;;<K\JWVL=>$H0P]&,
M(3]HFW)S5K2;TNK-I*R2W>VX45\B_&/]OG]BW]G[Q/=>"/C)^TY\&_ /C33T
MADU+P?K'C72I/%6DI<V\-W:G5_#NGS7NL:2;RTN(+NS74K.U:[M9H[FV66%U
M<[WP-_;2_9._:7U6_P! ^ O[0GPJ^*7B+2[%]4O_  UX5\6Z;>>);;2HY88)
M=5?P[++!K1TN"XN;:WN-12Q:R@N+FW@FG26>)'YG1K*'M'2J*G9/G=.7)9[/
MFMRV?1WL;>TI\W)[2'/>W+S1YK]N6][_ "/IRBN&^(OQ/^&_P@\+7WCCXK>/
MO!WPV\&Z;@7_ (H\=>)-(\*Z#;.R.\<,FJZW>65F+B98W\BV$QN+AE*01R/\
MM?E'XN_X+[_\$MO"FIOI47[0.J^*YX+I[2[N?"/PH^*FI:9;/&[(\J:I>>$-
M-T_4K4%=R76BW&IP3H5>!Y5.:JEA\17O[&C5JI;NG3E)+U:32^;%.M2I?Q*M
M.%]E.<8M^B;3?R/V5HK\Z?@'_P %9_\ @GC^TKKMGX4^%O[3O@B3Q=J-U;V&
MF^%?'%IXC^%NN:OJ5VRI:Z9H%K\2=%\*Q^)=1N'=4@LO#D^K7$LA,<:,ZLH_
M1:IJ4JM*7+5ISIR_EJ0E!_=))CA4A47-3G&<>\9*2]+IO7R"OY6/^#J#_DA?
M[*'_ &5GQW_ZA]A7]4]?RL?\'4'_ "0O]E#_ +*SX[_]0^PKMRG_ )&.%_QR
M_P#3<SES'_<J_I#_ -.0/XIJ_P! S_@VX_Y1MV?_ &73XJ?^BO#%?Y^=?Z!G
M_!MQ_P HV[/_ ++I\5/_ $5X8KZ3/_\ <%_U_I_^DS/'RG_>G_UZG^<3]]**
M_-KX\?\ !7G_ ()T?LY:W=^%OB-^T[X,N_%=C+<6U]X;^'ECXC^*NI:=?6CF
M.YTW6)?AQHWB;2_#^IV\@,<VG^(-1TN[BD5HWB5U8#Q?P3_P7O\ ^"7'C74K
M/26_:%O?"%[?W"VULWC;X7_$_0]-$C$A6O->C\)WV@:7;D#<UWJVJ6-K&,>;
M-&Q"GY..#Q<H\\<+B)1M=25&HTUW34=5YK0]]XG#J7(Z])2VLZD$T^SUT?D]
M3]C:*X[P#\1/ /Q5\*:5XZ^&/C;PG\0_!6N1O-H_BWP3XATKQ1X<U..-VBE-
MCK.BW=[I]R8)D>&=(KAG@G1X9E25&0=C7.TTVFFFG9IJS3[-/5,V335T[IZI
MK9KN?(W[>_P5\1?M%?L8?M+_  5\'P0W7C#X@?"+Q=I/A&SN+A;2"_\ %=O8
M-JGAK3YKI_W=M'J&MV%C9/<2XAA6<R3$1*YK_+B\:^!?&OPV\2ZIX,^(?A#Q
M-X$\7Z'<O9ZSX7\8:%J?AOQ#I5TGWK?4-'UBUL]0LY1D'9/;H2I# %2"?]=5
MF5%9W8*J@LS,0JJJC)9B<   $DD@ #)K\_\ Q[_P4L_X)N>'M4N?#GC?]K3]
MG.\U'1[UH+JP3QEH'BY-/U&WDV2PR/HO]M6MO>6DR&.XC\U9[2>-HIQ%+&RK
M[&59A6PD:M*GA9XF,Y*?+!R4H2MRMWC3J74DDK-+5;]#S<?@Z>(<)RK1HRBG
M&\K.,E>]M91LTV]4WO:Q_%A_P0E_93^+OQF_;T^"7Q6T;P7XD3X2?!3Q!J/C
MWQQ\1I=,U.S\)V-SHNA:@N@^'+?Q ;9=,OO$6M>(+[1X(_#T%VU_+HYU74Y+
M?^SM/O)%_P!%"OG#X&_M>?LL_M(SWVF_ +X^_"?XJ:GH]G]MU'P_X*\9:)JG
MB'3-,26*V&H7OAJ*Z77++3!/+#;)?SZ='9&:1(%F,C!*^CZYLRQE7&8A3JT7
M0<(*$:;YG)*[E>3E&+;;D]>6*M96TN]L%AX8>DXPJ*KS3<G-6LW9*R2<K))=
MV[M^27^>Q_P<9?\ *3/QE_V2;X2?^F">OPFK]V?^#C+_ )29^,O^R3?"3_TP
M3U^$U?:9?_N.$_[!Z7_I"/G,9_O6(_Z^S_,_UC/V7O\ DV?]G;_LA?PD_P#4
M \/U[I7S=\!?%'AGP3^R1\#?%GC/Q%H7A'PMH'[/_P *-1UWQ+XGU?3]!\/Z
M+I\'@#P]YU_JVLZK<6FG:=9PY'FW5Y<PP1Y&]QD5\+?$?_@NU_P2_P#AMJ][
MH5Q^T=#XSU33Y#'<#X<> _B!XTTAF!(_T+Q7I?AH^$-4C.,B;2]?O8<8_>9(
M!^#5"O7J5%1HU:MIRO[.$IV]Y[N*:7SL?4NK2I0A[2I"G>*MSRC&^BVNU?Y'
MZ]45^6'PB_X+6?\ !,OXSZYI_ACPW^U#X9\.>(=3(2VL/B;X<\;?"ZQ\URJQ
MV[^*O'7AO0_!0NII&6*"U7Q*\]Q*1'#'(S*&_4:RO;/4K.TU'3KNVO\ 3[^V
M@O+&^LIXKJSO+2YB6:VNK2Y@>2"XMKB%TE@GA=XI8G62-F1@3G4HUJ+2K4JE
M)O95(2@WZ<R5_D7"I3J*].I":ZN$HRMZV;M\RS7\]G_!QO\ LP_%+X__ +(7
MP^\7_";P=KOCW6?@C\4CXF\3>'/#&FZAK?B$>!O$7AS4M$UG6].T33+:[OM3
MCT35H_#]SJJVT#OI^B2:EK,YCT_3;V6/^A.N6\:^.?!7PV\+ZOXW^(GB_P ,
M> _!GA^V%YKOBWQEKVE^&?#6C6ID2%;C5=<UJZLM,L(6FEBA22ZN8D>:2.)2
M7=5-X6M/#XBE6A%2E3FFHN_O7]UQTUO)-I-:IN]F37I1K4:E*;Y8RC9RT]VV
MJEKIHTGKV/\ (MDAFAF>WFAEBGCD,4D$D;I-'*K;6C>)@'616!4HRA@W!&>*
M_LK_ .#8_P#94^+GP^B_: _:0^(7@SQ'X*\(?$#P]X,\!_#-_$NF:EHD_C2U
MM=0O_$GB3Q)I.GZC;6KW_ART/_"/6.E^(H5FT_4;V?6+/3[B233=05/VRO/^
M"IO_  3$CUJ.YN?VN/V>Y]:@#0PZK'KUE?2Q*"%98M:M[.>)(S@8*7@C=0&4
ME0#7VI\*OC+\)/CIX5C\<?!CXF>!?BKX/ENI;$>)/A_XIT;Q9H\6H01Q2W&F
MW-[HEY>0V>IVT<\+76FW30WUJ)8_M%O'O7/MYAFN(KX:5%X*IAXU.52J3<VF
ME)2Y8WI02;<5JV]+I*^J\S"8"C2KQJ+$PK.%VH045JXVN[5)O1/:RUL[]#TJ
MOY.?^"Z7_!6']LS]D+]I[PI\ _V;/''A[X8^&_\ A4'ACQ]J_B!? O@_QEXH
MUG6_$OB/QAIL]M+-X]T;Q/HEAI%C8>';!;*WT_0[>_\ M4^HW%UJES'-9VVG
M_P!*WQC_ &F?V=OV>3H2_'?XY?"CX/2>)Q?'PW!\2/'OAGP=<Z\FF?9QJ4NC
MVVNZE97&HP:>UW9I?3VD4L-I)>6D=Q)&]U LG\&W_!P1\:?A%\>/VZ]#\;?!
M7XE^!_BMX/@^ 'P_T*;Q/\/_ !+I/BO0HM:L/%'Q!N;W2GU/1KJ[M%U"TM[^
MRGN+4RB:**[MW= LJ$\V38:-7%Q=:A[2E[.HU[2GS4W)62^).+:UT=S?,JSI
MX=JG5Y*G/!/DGRS2=WT?,KJS]/(X+0/^"^/_  54T34[;4+G]I:U\1VL-PDU
MQHNO_!SX'OIFH(K!FM;F32?ASI&KP6\@&QSIFJZ?.JDB*>(X(_T%/V=OB/JG
MQB_9^^!?Q<UNQL=,UKXI_!SX9?$?5]-TOSQIFGZIXX\%:)XFU"QT[[5+/=?8
M;2[U.:"T^TSS3_9XX_.EDDW.?\F&O])/]CK_ (*'?L(>$OV1OV6/"GBC]L+]
MF_P]XF\,?LX_ _P]XBT#6/C!X&T_5]#UW1?AEX8TW5]'U6PNM:CN;'4=,U"V
MN+*^L[B..>VN8)89461&4>AGN#IQAAWAL-&,G.:E["DHWC:-N94XJ^NS:TV1
MQY7B)RG55:NW%1BX^UJ7L[M/E<WVM=+0_6VBO!?@]^U/^S5^T)?:SI?P*^/G
MPA^+^J>'K2"_UW3/AS\0O"WB_4M'L+J8V]M?ZCI^AZG>7=I8SW -O%>3PI;/
M<?N5E,I"5[U7S$HR@^6491DK74DXO576CL]5JO(]Q2C)7BU)=TTU]ZT"BBOB
M?X\_\%'?V&/V9KJ\TWXT_M/?"OPKKVG3O;:CX2T[6I?&_CC3IXW,;QZCX%\
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M,>*O_4XEK^6:OZF?^#IS_DX?]EO_ +(QXJ_]3B6OY9J^_P I_P"1=A?\$O\
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M?Y,U?ZS/[1__ ";Q\>?^R,?%'_U!]=K_ "9J^GX;_AXK_'2_])F>)G/QT/\
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M#^97Q(_X+9_\$O\ X7:K=:'K?[5WA/Q!JEID-'\./#'Q!^*&ES%6*E;;Q1X
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M<,;RRND442-)))(RI''&BEG=W8A41%!9F8A54$D@"@#X+_X*)_\ !0#X6_\
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M*!ZE^WU^RI'K/Q NK27XZ_!_5K?P!\6Y+2VCLH_$,DEF;SPC\0([&W M;/\
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M/G_)=/C3_P!E9^(W_J8:S7T'#?\ $Q7^"E_Z5,\C.=L/ZU?RIGUG_P $F_\
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MJ87$T5S5</6IQ_FG3G&/_@35OQ)A7HU':G5IS?:,XR?W)W/>Z***P-0HHHH
M*_B8_P"#IS_DX?\ 9;_[(QXJ_P#4XEK^V>OXF/\ @Z<_Y.'_ &6_^R,>*O\
MU.):]?(_^1C2_P %7_TW(\_-/]SJ?XJ?_I:/Y9J_TS/^"-G_ "C%_8]_[)G=
M?^IAXFK_ #,Z_P!,3_@CQ>6FG_\ !+K]D>_O[JWL;&Q^%>HWE[>WD\5M:6=I
M;>*_%,US=75S,R0V]O;PH\L\\KI%%$C22,J*2/9XB_W6A_V$+_TW4/-R?_>*
MG_7E_P#I<#]/**_*GXN?\%LO^"9?P:UFZ\.Z]^T]X;\5ZY:;Q-:?"SP_XO\
MBEIX>-BCQ+XJ\$:#K/@QIE<%&@'B/SD8'>B@$US_ ,.?^"Z__!+SXD:IIVAV
MW[2EKX.U;5)TM[:'XC> OB-X*TN)WX#ZCXMU;PJG@K2(!_'<ZKXDL[=,Y:4
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M3>&I2<5%+VLD[.3:34$UJDD_>L]6^5Z)W**_17_@FM_P3H^)W_!1CXWM\/\
MPK=OX2^&W@Z*PUOXP_%":R%]:>#/#]]-<QZ?8:=9O+;QZKXO\3RV-[9^&M(,
M\2/]DU+5KUX]+T>_<?WQ?LR_\$LOV%OV4O#>G:-\._@!X&U[7[6R@MM2^)'Q
M,T+2?B%\1==N(PK7%_=^(?$5A=)I+7LZK<7&F>%;+P]H"2)$+;2+=(843TL=
MFV'P,O9M2JUK)NG!I**>W/)WY6UJDE*5K-I)IOBPN JXI<Z:A3NTIRN[M;J,
M5J[=7=*^E[Z'^8117^L-X]_98_9F^*6CSZ!\1_V?/@MXWTB>,QM9>)_ACX,U
MB.+Y#&DMH]YHTLUE<PJ<VUW9R075JX62VFBD56'\Z7[>?_!M?\,?%^DZQX__
M &$]:F^&WC>'S[]_@IXWUV]U;X<^(5 :5K#PCXKU3[=XD\&:K*WF"UA\0ZCX
MB\.7,SVUEY_A.PCEOEY</G^&JS4*U.>';=E-R4Z:?]Z247'U<>5;MI&U;*:]
M.+E3E&LEO%)QG\HMM/KIS7[)MV/5_P#@V<_:%^(WQ6_9:^+OPI\>^)M4\4Z=
M\!_'_AS3?A_<ZU=RW]]H/@OQEX?NKFV\(6UW.[SMH>B:IX>U2YT6TF:0:9;Z
MK)IEF\>EVFGV5E_23=75K8VMS?7US;V=E9V\UU>7EU-';VMK:V\;37%S<W$S
M)%!;P1(\LTTKK'%&K.[*JDC\!?\ @W]_8:_:"_8P^#'Q[?\ :-\#O\./&'Q-
M^)6@G1_"EUK/A[7-17PYX(T&ZLXM;N;KPQJVMZ9%;ZIJVOZM;6$#7YNI(=+:
M_,"V5]83W/Z(?\%0[S4K#_@G7^VE<:5-/!=_\,Y_$^!I;=V2465YX:O;35%#
M)\P1],GO(YL$9A:0$@$FOG\<J5;,ZL:,H>SJUJ<5.#3A>:@IR36C7.Y-VT;O
MKU/8PKG3P5-U%+GA3DW&5U*T7)Q3NKKW5%*ZT5M#\7?^"CG_  <8> /A>=>^
M$G["T6C_ !3^($)N=,U7XZZM;_;?A;X5N5+6\S>!=,<QO\1]7M7$K6VM7/V?
MP)#-':7=H?'&G7$]M'_&U\6OC!\4?CQX\USXG_&/QWXE^(_C[Q'/Y^K^*/%6
MISZGJ,X4MY%G;F4B#3M+L48P:9H^FPVFDZ5:+'9Z;96MI%'"F9\//AO\0/BW
MXPT;X?\ PO\ !?B?X@^-_$-R+31/"G@_1-0\0:]J4W5_LVFZ9!<7+10(&FNK
M@QK;VENDEQ<RPP1R2+^Q'QL_X(A?'']EK]A/XF_M?_M(^+=%\&^,/#$OP\M_
M#/P/\.FV\3:I!_PFGQ \+^$KNY\>^+K2[.@Z;>:?8ZU=7%OH?A<^)(YI_LLM
MWXALW@N=+E^KH4<!EGLZ2E&-:M*%-2DU*O5E.2BM$KJ',U>RC".[UU?@5:F*
MQO/4:DZ=-2DU'2E325WOHY675N3Z:61^(5?U-_\ !K'_ ,G"?M2_]D:\)?\
MJ;K7\LE?U-_\&L?_ "<)^U+_ -D:\)?^INM/-_\ D6XK_##_ -.TQ9?_ +Y0
M_P 4O_2)']LM%%%? GU@445\S_'_ /;*_97_ &6;>";]H+X\?#?X77-W ;JQ
MT/Q#X@MW\6:E:J&+76E^#=,%_P"*]4M5*[&N=/T:Y@61HXFD$DD:M483G)1A
M&4Y/:,8N4GZ))MBE*,4Y2DHQ6[DTDO5NR1],45^)^J?\'"7_  2WT^\%K:_&
MGQAK</FF,ZAI?P:^*4=FJ@D><5UCPOI-ZT1QN&RS>4@C]UG('N7PG_X+-?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M73;B6XT_P3)>6MU::7X,T_4#:ZS8,^I>+Y-1FO+/1?#WXI5]R?L#?L"?&O\
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M>DDNB=NA_DL?'S_DNGQI_P"RL_$;_P!3#6:^L_\ @DW_ ,I)/V,O^RZ>$?\
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MUC&+@[?:BG-2<?.UVM4GI>XY3B904[TXR:O[.3DI+R;46E+ROIU:=TOXX_\
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MI)I6KHZD@@[71F1UZ,K,I!!(KXZ^/W_)=_C7_P!E;^)'_J8ZS7V'_P $AO\
ME)=^QO\ ]EBTK_TV:K7Z-6_W*K_V"S_],L^-H_[Q2_Z_0_\ 2T?Z<5?Q,?\
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M_P"4F?C+_LDWPD_],$]?A-7U&7_[CA/^P>E_Z0CQ,9_O6(_Z^S_,^XOVM?\
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M_P#@H9^SSI7QA\(VL'AGQAI-W_PC/Q7^&[ZBNH7_ (#\96\2S- EPT5M-?\
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M#W_!N_\ MA?&GP'^VK\/?V6/^$UUO5/@;\:M.^(=K>> M7OI]0T#PUXH\,^
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M:Q(89KB:*WMXI)[B>1(8((8VEFFFE8)%%%$@9Y))'942-%+.Q"J"2!7]W_\
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M6,6[['I83 5L+B>=SC*ER23:NF[VLG%WZZZ-K3>^A]MT445\\>N%>,?M'_\
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M.D+B-S&H:0(QC5CM5G"DHK-S@%L G' .:_R J_TU_P#@D5^TQJG[5W_!/[X
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MD=F=W8LQ))-15_H-_LJ_\&\G["/P%L]*U7XL:/K'[4'Q"M$BFO-7^(\TVD^
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M^)/[4_A']E;1KZ>/P;^SKX9T_7/$UC'.5MM3^*7Q*T?3_$+7-S#&YAN5\/\
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M+<3+$46JCO4I-1<NLHM7C)_WM&GWM=N[84445XYZ(5_$Q_P=.?\ )P_[+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !44\$-S#-;7,,5Q;W$4D$\$\:2PSPRH8Y89HI R212(S))&ZLCHQ5@02
M*EHH _G5_;H_X-UOV9_VA9]7\>_LSZE!^S%\4+U[B]N?#]AITNJ_!7Q)?2EI
M&$WA*"6*^\!S3R;(Q=^"YQH%E"))%\#WMU*TU?R0?MA_\$S?VQ_V&[R:;XY?
M"F_7P.;P6>G?%KP5*_B[X7:H\D@AM0?$UA!')X=NKZ0LMAI'C33O#&NW@222
M#2GB4O7^H36?JVDZ5KVF:AHFNZ9I^M:-JUG<:?JND:M96VHZ9J=A=Q-#=6.H
M6%Y%-:7EG<PN\5Q;7,4D,T3-'(C(Q!]C"9UB\-:%1_6*2LN6HWSQ7:-35[;*
M:FELK'G8C+*%:\H+V,WU@ER-^<-%_P" N.NKN?Y!];_A7Q5XE\#>)="\9>#=
M>U;POXK\,:K8ZYX=\1Z%?W&F:SHFL:;<)=6&I:9J%I)%<V=Y:7$:303PR(Z.
MH(/45_0;_P %]/\ @F-\,?V-/&/@7X__  "LU\,_"GXW^(]?T/7OAM%@:/\
M#_Q]:64>N0KX- 7=:^$O$^G#5KNW\/.S0^%[[2+FUTF5=#O],TG0_P"=.OL,
M-B*>+H0K4[N%1/W9)733<91DM5=--/5I[IM,^=K4IX>K*E.W-!K6+T::3C)/
M31II]&MG9IH_TW/^"47[;DG[>O['/@CXO:\;2/XG^&[^^^&?QCM;&W2TL_\
MA87A>TTZYN-8LK6/$=O9^+/#^K:!XL2VMT2TTZYUJ[T>V+IIA8_'G_!Q[_RC
M4U[_ ++/\*/_ $MU>O@/_@U0U[4KCPS^VWX7EFG;2-)UWX Z]8P%I#;0ZEXA
MT_XO:=JLR(1Y23W5KX8T9)6C)DDCM(1*%6*'=]^?\''O_*-37O\ LL_PH_\
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M8L9V+,/V<_AB@+')"1>'+..-?HD:*BCLJ@=J_P O.O\ 4)_X):?\HYOV+/\
MLW;X:?\ J/VM>MQ'_N^'_P"OTO\ TAGGY/\ QJO_ %Z_]OB?R=_\'//C?4-:
M_;D^%?@@W1?1O _[.'AJ\MK+.5M]<\6^/?B#=:Q==2 ]YI>E>&8F& =MC&23
MD8_FZK^@S_@Y:T>33/\ @HOI5ZY?;XA_9S^&6L0[B<".#Q)\0M (CSP$\W0Y
M20.-Y<]2:_GSKU,L26 PEMO8Q?S=W+\6SBQS;Q=>_P#S\:^222_ _P!,K_@C
M=\,M,^%?_!-']DO1].MH8)/$_P -8?B;JL\:;9;_ %/XH:IJ/CN2YNI"-\TT
M5IKMGI\;N3Y=G8VMM$1!!$J_IM7YW_\ !);Q5%XR_P"";/[&>KPSQW"6?P/\
M+^%3)$ZR*LO@0W7@B> LA($EM/X>DMID)W1S1/&X5U8#]$*^$Q3;Q6)<OB=>
MM>_?VDKGU-!)4**6WLJ=O3D1X=^TU\.='^+_ .SI\=?A=KVG1:KI7C[X2?$'
MPM<V,JD^:VL>%M4M+62%E^>&[M;N2"[L;F$K/:WD$%S;NDT4;K_DX5_KF?$G
MQ58>!?AWX^\;ZK(L.E^#?!?BGQ5J4S[=D5AX>T.^U>\D?>0NU+>SD9MQ"X!R
M0,U_D9U]'PVWR8M?94J+7:[512\ME&_R\CQ\Y2YL.^K51/O9.%OQ;_$_5;_@
MB-XFN/"O_!4?]DR]@N9+==2\5>,?#-T$;"7-OXI^&'C?0#;3+G;)&\VH0NJN
M#MGCAE0"6*-E_P!*JO\ --_X(G>'[CQ)_P %1OV1[&WCFD-GXR\5^()C"')C
MM_#'PS\;^(II)"GW80FF%9"Q"%6V-G?@_P"EE7)Q%;ZY1[_5HW]/:U;?J;Y/
M?ZO4[>V?W\E._P"A_DL?'S_DNGQI_P"RL_$;_P!3#6:^L_\ @DW_ ,I)/V,O
M^RZ>$?\ T;/7R9\?/^2Z?&G_ +*S\1O_ %,-9KZS_P""3?\ RDD_8R_[+IX1
M_P#1L]?3UO\ <JO_ &"S_P#3+/#H_P"\4O\ K]#_ -+1_IZ5_EK?\%(_&M_\
M0/V__P!LSQ-J-T;QY/VE/C!HEC.QW$Z%X2\;:QX2\-1 Y/RVWA[0]+ME .T+
M$ OR@5_J4U_E/_MO:1)X?_;0_:[T*8L9=&_:>^/FE2,Y+,S:?\5?%=J79CRQ
M?RMVXYW9W9.<U\YPXE[?$OJJ4$O1SN_Q2/9SEOV=%='.3?JHJWYL\.^'WBU_
M 'C[P1X[CTFPUY_!7B_PUXM30]5,XTO67\.:U9:PNDZD;62&Y%AJ)LQ9WAMI
MHIQ;S2&&1)-K#^E7_B*6_:B_Z-L^ ?\ X,OB'_\ -%7\V/PT\%3?$GXC> /A
MU;ZKI^A7'C[QMX5\%0:YJPG.EZ--XIUVPT.+5=2%K'-='3].>_6[O!;12SFW
MAD$,;R;5/])?_$+5^U-_T<C\ /\ P!^(O_S,U[>/_LWFIK'\G-:7LN?VFUUS
M6Y--U&]]=CS,+]=M/ZKSVNN?EY-^E^;Y_CYC_P#B*6_:B_Z-L^ ?_@R^(?\
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M^_Y+O\:_^RM_$C_U,=9K[#_X)#?\I+OV-_\ LL6E?^FS5:^//C]_R7?XU_\
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M9T*].G#F<N5*JUS.R;]Z+>MEU,JF%Q]:7/4I3G*R5WR)V6RT:[_G?9GZ)_\
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MOSP\%SR6WC'PG<0L4FM_$NA3Q..J21:I:R1L/=64$?2OTK_X+:?\I2?VNO\
ML</!W_JJ_ =?F?X2_P"1J\,_]C!HW_IQMJ_1L([X+#-[O"T6_P#P5$^.K_[S
M6_Z_U/\ TY(_UX*_E8_X.H/^2%_LH?\ 96?'?_J'V%?U3U_*Q_P=0?\ )"_V
M4/\ LK/CO_U#["OBLI_Y&.%_QR_]-S/I,Q_W*OZ0_P#3D#^*:O[^?^#:W1='
ML/\ @G7<ZO9:7IUIJNN_'?XCOK6I6UG;PW^KMIUCX7LM/.I7D<:W%[]AM +:
MS%S)(+: F.$(K,#_  #5_H&?\&W'_*-NS_[+I\5/_17ABOI,_P#]P]:]._W3
M/'RG_>G_ ->I_G$_?2OY<_\ @Z8T*RN/V:/V9?$TD,;:AI'QTUO0K6X(_>Q6
M7B/P!JVH7\*'M'//X6TUY!W:WB/:OZC*_F/_ .#I#_DT/]GS_LY"'_U6/CVO
MFLJ=LQPO_7QK[X23_ ]G,/\ <Z_^&/\ Z7$_AOK^^;_@V:GEF_X)X>*8Y&RM
MK^TU\28(1_<B;P1\*[DK^,UQ*W;[WXG^!FO[X/\ @V5_Y1Y^,?\ LZ#XC_\
MJ _"6OIL^_W!_P#7ZG_[<>+E7^]K_KW/]#]N?VC_ /DWCX\_]D8^*/\ Z@^N
MU_DS5_K,_M'_ /)O'QY_[(Q\4?\ U!]=K_)FKDX;_AXK_'2_])F=&<_'0_PU
M/SB?N9_P;K_\I.OAW_V3/XO_ /J'W-?Z&E?YY?\ P;K_ /*3KX=_]DS^+_\
MZA]S7^AI7!Q!_OT?^P>G_P"EU#JRC_=9?]?I_P#I%,_SV/\ @XR_Y29^,O\
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M $MO^"@/C*^^'W[#'[8/C+2KM[#6-!_9J^--UHM]&<26>MR?#W7[71KJ,_\
M/2WU.>TEC'=T4=Z_RNZ_U"/^"IFE3:Q_P3F_;3M("ZO#^SO\2M58H2&\G0M
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M'_U!]=KV>O&/VC_^3>/CS_V1CXH_^H/KM73_ (E/_''_ -*1,_@E_AE^3/\
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MHY$/9E!K[O\ ^"I_BZP\<?\ !1?]LG7],N8;RQ'QY\;Z#!=6\PN+><>$+_\
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M1^]BLO$?@#5M0OX4/:.>?PMIKR#NUO$>U?U&5_,?_P '2'_)H?[/G_9R$/\
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M_P ^&O\ 0>_X-QO^4:/AK_LL7Q9_].>G5])G_P#N"_Z_T_\ TF9X^4_[T_\
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M98T"_P":-7^F9_P1L_Y1B_L>_P#9,[K_ -3#Q-7L\1?[I1_["%_Z;J'FY/\
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M7JGCZ26:+S;*3QYXGCG\'> K";@A+J%+_P 2^+=-D)7R[SP=&XR5"G\!J_T
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M4?GQ)_[.Q^(?_JJ_@C7\&%?WG_\ !L1_RC\^)/\ V=C\0_\ U5?P1KZ?/O\
MD7R_Z^TOS9XF5?[VO^O<_P!#^C&OY)?^#J[_ )$W]BC_ +&;X[_^FKX4U_6U
M7\DO_!U=_P B;^Q1_P!C-\=__35\*:^;R;_D98;UJ_\ IFH>QF7^Y5O^X?\
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MZ\FB(%U\1?B/<6<L[:?.04D.@^"-'UN#6(EQ)"/%^B.7$<Y23^X&ODC]A_\
M8^^''[#/[.7@?]G[X<1K=1:% VK>,_%<MLEMJ7C[X@ZM!;?\)1XRU1%:1HY-
M1GMH+/2[*2>Y.C>'=.T708KF>WTN&5OK>OC,QQ2QF+J5HW]GI"G?1\D-$[=.
M9WG;IS6Z'TF#H?5\/"F_C=Y3Z^_+=76_*DHWZVN?Y+'Q\_Y+I\:?^RL_$;_U
M,-9KZS_X)-_\I)/V,O\ LNGA'_T;/7R9\?/^2Z?&G_LK/Q&_]3#6:^L_^"3?
M_*23]C+_ ++IX1_]&SU]Q6_W*K_V"S_],L^7H_[Q2_Z_0_\ 2T?Z>E?YP?\
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M6IJ2>Z?.KI^9_IQ5_$Q_P=.?\G#_ ++?_9&/%7_J<2U_;/7\3'_!TY_R</\
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MDM[6^\3:O=ZJ^G6/FDO'INEI<IIVF6_"6VGVMM;QJD<2J/+R2QR22< 9)).
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METBX#Z9ING:7/%F[^&FF:I"L_BO6[I1IOB)K-O"&E)J2W/B*[\/_ -[0
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M_P"30_V?/^SD(?\ U6/CVOZ<*_F/_P"#I#_DT/\ 9\_[.0A_]5CX]KYK*O\
MD887_KX__2)'LYA_N=?_  Q_]+B?PWU_?!_P;*_\H\_&/_9T'Q'_ /4!^$M?
MP/U_?!_P;*_\H\_&/_9T'Q'_ /4!^$M?39]_N#_Z_4__ &X\7*O][7_7N?Z'
M]$%%%%?$GTP5S_BWPKX?\=>%?$W@CQ9I=MK?A7QCX>UKPKXFT:\4O::OX?\
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MA6UTSPG\2M&TY;C7+W2/#UM%#I_A_P 3^'K#5]2M],6STK5]&D@L6UROZHO
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M_P"JK\!U^9_A+_D:O#/_ &,&C?\ IQMJ_3#_ (+:?\I2?VNO^QP\'?\ JJ_
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MFO!I3C"<9R@JBB[\DFU%M;<UMUY;/9W5T_\ 4FT;]OO_ ()T^'=(TOP_X?\
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M3;R(*9;34-/N([NSN8PZNAD@N(8Y4#JRED&Y6&0?]$S_ (+4_P#!,^X_;^^
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MX-PY=0;4["']@ 7,\HF,6N:%X8AT]7R"%72?$NGII5O%TS EE%!C(:/&X5_
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M)\5Z=93^#M7N;"RAN+Z>QTSQ!=WPL;:ZO5MFM;6XFC^RJ_SB?^"!NE:IJ/\
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M2;G%/1\O+%)_-IM=U9]0HHHKQ#TPHHHH **** "BBB@ HHHH **** "BBB@
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M3I3C4IR<)P=XRB[-/NOZU6C-IPC.+A.*E&2LXO5->9_,<O\ P:W?LB"YWO\
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MV:_K[F?S'0_\&M_[(BW.^?\ :$_:/DL\C]Q#+\,8;G;GD?:G\!7$62. ?L>
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MG\??BY\(!<2O+)I'BO1_#WQ;T*S5L[+?2D6?X?>((8$&WG5O$FMW#$-NN/F
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MM>$%&+MTNG;H52PN'HN].E&,NDM927I*3E)?)A7\[OQI_P"#:_\ 8O\ BO\
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M8S$KEK8BI.+WA=1@_6$%&+\KK0VI87#T6G3HPBUM*W-)?]O2O+\0KP']H_\
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MU:-W96T3:6C-987#SC&$J,'&%^5)62O:]K6WLK][*]S\\/\ @GM_P32^!/\
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M)+Y*R"BBBH*"OS _X*&?\$H/V>?^"CM[X!U_XL>)?B7X(\7_  WTW5=%\/\
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M4Y.4Y2E*3O*4FY2;>[;=VV^[9V1BHI1BE&*5DDK))=$D%%%<A\0?'7AGX7^
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MIZ7]?F:]%<MH7C'0_$<CQ:7=)</'G<%96QCK]TDUOW=W#90M/.P6-026)P
M,]>E39WM9W[===AW5KW5BU17R#\5?VXOV?O@U/);^.?%D&F21YWJTD((V]?O
M2+TYKA?AE_P4F_98^+>KG1/!?CB#4M0#;/*1X#\V<8^25N<_G6BH5G'F5*;B
MOM<KM]Y'MJ2ERNI%2?1M)_<??%%>>6OQ/\)7BJ\&H1LK*&4[TY!Z?Q5U>EZ[
MIVK@FRF64 $Y!!Z?0GZUFTUNFO5,M-/9HV****0PHHHH **** "BLK6M8L=
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MFU]QWM%%%9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPKXJ%.<>:+3;7I8Y<95E2H2G%J,DU9WMU_+O]UM;KPW7/^#C7XX+K<^F>'_
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M[HYV4]3[5Z]+ X*6'KN#A6E12]]/T]>_7\3SYXK%*M0C+FIQJ-7BUK;32_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA@58KMQSGH0..#7Z0Z9_P<-^';WQ*^B6WPWFEM$)CB=+2Z50%)5<%"HP
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MR:YNJNW%;7^6J/P=_P""F/[4&H_M:ZU_PK'1+W[<-+U)[7[-:-OV!)L$;4.
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M.NT%@3G@$#(..![D_P @'Q>_X([?'KX#ZY<^-K;QCK)L+&4W ABO9_+V*V_
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MT>>^M/[0BNDC>(NOF;Q+@C!Z$GC_ /6*_K%$L1B$X=?),8E$I(">45W[RQP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\?CR.XS7)A6O[(JZKF]M>S:N]5K9[[?D=%=7S*GH[*FEMINOEU/:_P#@X ^
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MC\N*N&55*>(5:4X>QYURM3C>UU;3TL]A2Q\)T?9Q4W4Y4G=.UUOVO;TZ&?\
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M##&1SUX*]^]<[SJ<I.4L+AW+I)QU2Z='M^IJLKBE95ZT5;6*>FMK[-=ON/\
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M'HTB!B/P)K3KB.E:I/N>4?%#XN>%?ACH>HZCKFH16TUM:S211NRIEUC8@Y+
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MMD"6]K"D$* 8"QH,* !Z"OXE1_P7Y_;*BCCBA^$NM0I%&J!1H\F  !SC[/\
M7\ZS[?\ X+__ +:DOB31-+;X6:\+:_O((9W_ +(EPJ22JC$_N,# )SR/;%8U
M\LS#$3=2;IZZI>T344DM$M=OZW-J6.P=&*C'GZ)ODE=MVU?W]>VNM[?U(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.<Y?%*4O63?YL2A".T8KT216N;2WO(6M[F)986!5D894J1@@^V*\8\0?LV_
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M[DY+%NN2>3[UZ[134I*Z3:3W2;5_432>Z3MM=)V*]M:V]G$L-M$D,2@ (@P
M!T_*IR P*L 0000>A!ZBEHI#/.?%7PD^'/C:)H/%7A/2=;B?.Y+ZW$JMGKD'
MKGO7%Z3^S!\!="E$^D_#+PQ8RJP=7@L45@PYW ^N>?K7O5%4IS2LIR2[*32^
MY,GDA>_+&ZV=E<Q])T#1]#B$.DV$%C$%"A($"J%'  %;%%%24%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4QXTE5HY422-AAD=0RL.X8'((/H1_P#7
M?10!D1:!H<$AEAT?3(I6)+21V5LCDGJ2RQ@DGZUJHB1J%1511T50%'Y"G44"
MLNR"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>annx-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-03T13:13:35.9717+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://annexonbio.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:annx="http://annexonbio.com/20241231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage" id="Role_DocumentCoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" id="StatementConsolidatedStatementsOfStockholdersEquity1">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" id="DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure">
        <link:definition>995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance Disclosure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>995465 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>995495 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995505 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquity" id="Role_DisclosureStockholderSEquity">
        <link:definition>995515 - Disclosure - Stockholder's Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlan" id="Role_DisclosureEquityIncentivePlan">
        <link:definition>995525 - Disclosure - Equity Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995535 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare1" id="DisclosureNetLossPerShare1">
        <link:definition>995545 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995555 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995565 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>995575 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>995585 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995595 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>995605 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995615 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityTables" id="Role_DisclosureStockholderSEquityTables">
        <link:definition>995625 - Disclosure - Stockholder's Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" id="Role_DisclosureEquityIncentivePlanTables">
        <link:definition>995635 - Disclosure - Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995645 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995655 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995665 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail" id="Role_DisclosureOrganizationAdditionalInformationDetail">
        <link:definition>995675 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995685 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
        <link:definition>995695 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail">
        <link:definition>995705 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995725 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>995735 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" id="Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail">
        <link:definition>995745 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>995755 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail2" id="Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail2">
        <link:definition>995765 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail" id="DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail">
        <link:definition>995775 - Disclosure - Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995785 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" id="Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail">
        <link:definition>995795 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail">
        <link:definition>995805 - Disclosure - Commitments and Contingencies - Future Undiscounted Lease Payments Under Non-cancellable Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" id="Role_DisclosureStockholderSEquityAdditionalInformationDetail">
        <link:definition>995815 - Disclosure - Stockholder's Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails" id="DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails">
        <link:definition>995825 - Disclosure - Stockholders' Equity - Summary of Warrants Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" id="Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>995835 - Disclosure - Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail" id="Role_DisclosureEquityIncentivePlanAdditionalInformationDetail">
        <link:definition>995845 - Disclosure - Equity Incentive Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail" id="Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail">
        <link:definition>995855 - Disclosure - Equity Incentive Plan - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail" id="Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail">
        <link:definition>995865 - Disclosure - Equity Incentive Plan - Summary of RSU Activity under Equity Incentive Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail" id="Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail">
        <link:definition>995875 - Disclosure - Equity Incentive Plan - Summary of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel" id="DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel">
        <link:definition>995885 - Disclosure - Equity Incentive Plan - Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail">
        <link:definition>995895 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail">
        <link:definition>995905 - Disclosure - Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>995915 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995925 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail">
        <link:definition>995935 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" id="DisclosureNetLossPerShareAdditionalInformationDetail">
        <link:definition>995945 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" id="DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail">
        <link:definition>995955 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>995965 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails" id="DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails">
        <link:definition>995975 - Disclosure - Segment Reporting - Schedule of Operations for Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>995985 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage" xlink:href="annx-20241231.xsd#Role_DocumentCoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" xlink:href="annx-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="annx-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" xlink:href="annx-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="annx-20241231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail" xlink:href="annx-20241231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="annx-20241231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" xlink:href="annx-20241231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="annx-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" xlink:href="annx-20241231.xsd#Role_DisclosureStockholderSEquityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails" xlink:href="annx-20241231.xsd#DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:href="annx-20241231.xsd#Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail" xlink:href="annx-20241231.xsd#Role_DisclosureEquityIncentivePlanAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail" xlink:href="annx-20241231.xsd#Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel" xlink:href="annx-20241231.xsd#DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="annx-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:href="annx-20241231.xsd#DisclosureNetLossPerShareAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" xlink:href="annx-20241231.xsd#DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails" xlink:href="annx-20241231.xsd#DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="annx-20241231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="annx-20241231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="annx-20241231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="annx-20241231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="annx-20241231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="annx-20241231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="annx-20241231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganization" xlink:href="annx-20241231.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:href="annx-20241231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="annx-20241231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="annx-20241231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="annx-20241231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquity" xlink:href="annx-20241231.xsd#Role_DisclosureStockholderSEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlan" xlink:href="annx-20241231.xsd#Role_DisclosureEquityIncentivePlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="annx-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare1" xlink:href="annx-20241231.xsd#DisclosureNetLossPerShare1" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:href="annx-20241231.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="annx-20241231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="annx-20241231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="annx-20241231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="annx-20241231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="annx-20241231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="annx-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityTables" xlink:href="annx-20241231.xsd#Role_DisclosureStockholderSEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" xlink:href="annx-20241231.xsd#Role_DisclosureEquityIncentivePlanTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="annx-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="annx-20241231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="annx-20241231.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail" xlink:href="annx-20241231.xsd#Role_DisclosureOrganizationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="annx-20241231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="annx-20241231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="annx-20241231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:href="annx-20241231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:href="annx-20241231.xsd#DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" xlink:href="annx-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail" xlink:href="annx-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail" xlink:href="annx-20241231.xsd#Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail" xlink:href="annx-20241231.xsd#Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:href="annx-20241231.xsd#Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail" xlink:href="annx-20241231.xsd#Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="annx-20241231.xsd#Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:href="annx-20241231.xsd#Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="annx-20241231.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail2" xlink:href="annx-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ComputerEquipmentAndSoftwareMember" xlink:label="annx_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" xlink:label="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingLeaseExpirationMonthAndYear" xlink:label="annx_LesseeOperatingLeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesTable" xlink:label="us-gaap_GainContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_UnvestedRestrictedStockUnitsOutstandingMember" xlink:label="annx_UnvestedRestrictedStockUnitsOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:label="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfGrossProceedsOfCommonStockToBePaid" xlink:label="annx_PercentageOfGrossProceedsOfCommonStockToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_WeightedAveragePricePerShare" xlink:label="annx_WeightedAveragePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingSubleaseCommencementYearAndMonth" xlink:label="annx_LesseeOperatingSubleaseCommencementYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingSubleaseExpirationYearAndMonth" xlink:label="annx_LesseeOperatingSubleaseExpirationYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxTable" xlink:label="annx_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxLineItems" xlink:label="annx_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_RestrictedStockVestedDuringPeriodShares" xlink:label="annx_RestrictedStockVestedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IssuanceOfStockAndPrefundedWarrantsValue" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrepaidAndOtherAssetsCurrent" xlink:label="annx_PrepaidAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DisclosureOfBalanceSheetComponentsAbstract" xlink:label="annx_DisclosureOfBalanceSheetComponentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="annx_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxRateReconciliationSection162MCompensation" xlink:label="annx_IncomeTaxRateReconciliationSection162MCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfPreFundedWarrantsShares" xlink:label="annx_ExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedCompensationCurrent" xlink:label="annx_AccruedCompensationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AggregateSubleasePaymentReceivable" xlink:label="annx_AggregateSubleasePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightExcercised" xlink:label="annx_ClassOfWarrantOrRightExcercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoFourAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InterestAndOtherNonOperatingIncomeExpense" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:label="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets" xlink:label="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromIssuanceOfCommonStockGross" xlink:label="annx_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfCommonWarrants" xlink:label="annx_ExerciseOfCommonWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty" xlink:label="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="annx_PrepaidResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember" xlink:label="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" xlink:label="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="annx_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfPreFundedWarrantsValue" xlink:label="annx_ExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantsAndCommonWarrantsMember" xlink:label="annx_PrefundedWarrantsAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockSalesAgreementExpirationDate" xlink:label="annx_CommonStockSalesAgreementExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear" xlink:label="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PersonnelExpensesMember" xlink:label="annx_PersonnelExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate" xlink:label="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ShortTermInvestmentsPolicyTextBlock" xlink:label="annx_ShortTermInvestmentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesLineItems" xlink:label="us-gaap_GainContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IssuanceOfStockAndPrefundedWarrantsShares" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonSharesExchangeValue" xlink:label="annx_CommonSharesExchangeValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased" xlink:label="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoOneAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InvestmentExpectedMaturityPeriod" xlink:label="annx_InvestmentExpectedMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants" xlink:label="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember" xlink:label="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses" xlink:label="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonWarrantsMember" xlink:label="annx_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DouglasLoveMember" xlink:label="annx_DouglasLoveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CowenSalesAgentMember" xlink:label="annx_CowenSalesAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightIssued" xlink:label="annx_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis" xlink:label="us-gaap_SubsegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_WarrantsPolicyTextBlock" xlink:label="annx_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BrisbaneCaliforniaMember" xlink:label="annx_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" xlink:label="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedAndOtherLiabilitiesCurrent" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonWarrantAndPreFundedWarrantsMember" xlink:label="annx_CommonWarrantAndPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain" xlink:label="us-gaap_SubsegmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember" xlink:label="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ReserveForTwoThousandTwentyIncentivePlanMember" xlink:label="annx_ReserveForTwoThousandTwentyIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockAndPrefundedWarrantsMember" xlink:label="annx_CommonStockAndPrefundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BalanceSheetComponentsDisclosureTextBlock" xlink:label="annx_BalanceSheetComponentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" xlink:label="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OfferingPricePerShare" xlink:label="annx_OfferingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOtherIntangibleAssets" xlink:label="annx_DeferredTaxAssetsOtherIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LaboratoryEquipmentMember" xlink:label="annx_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PreFundedWarrantsMember" xlink:label="annx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProgramExpensesMember" xlink:label="annx_ProgramExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedConstructionCostsCurrent" xlink:label="annx_AccruedConstructionCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InvestmentMaturityPeriod" xlink:label="annx_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsLeaseLiabilities" xlink:label="annx_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" xlink:label="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" xlink:label="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_EmployeeStockPurchasePlanMember" xlink:label="annx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="annx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability" xlink:label="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_SalesAgreementWithCowenAndCompanyLLCMember" xlink:label="annx_SalesAgreementWithCowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_EmploymentInducementIncentivePlanMember" xlink:label="annx_EmploymentInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Weighted Average Exercise Price Of Warrant Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right weighted average exercise price of warrant exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax provision at U.S. statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Warrants Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Pre Funded Warrants Net Of Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock pre funded warrants net of commissions .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock and pre-funded warrants, net of commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- average exercise price per share, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share purchases funded through payroll deductions maximum percentage of employee's eligible compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_UnvestedRestrictedStockUnitsOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Units Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_UnvestedRestrictedStockUnitsOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_UnvestedRestrictedStockUnitsOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due After Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases future minimum payments due after year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfGrossProceedsOfCommonStockToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of gross proceeds of common stock to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfGrossProceedsOfCommonStockToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Gross Proceeds Of Common Stock To Be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfGrossProceedsOfCommonStockToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of gross proceeds of common stock to be paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_WeightedAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_WeightedAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_WeightedAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Subject to Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholder's Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due, Next 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five And Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due year five and thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants or Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Stock options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingSubleaseCommencementYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease starting year and month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingSubleaseCommencementYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease Commencement Year and Month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingSubleaseCommencementYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease commencement year and month.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingSubleaseExpirationYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease expiration year and month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingSubleaseExpirationYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee operating sublease expiration year and month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LesseeOperatingSubleaseExpirationYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease expiration year and month.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock per Employee Stock Purchase Plan purchase, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">(Decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_RestrictedStockVestedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Vested During Period Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_RestrictedStockVestedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock vested during period shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_RestrictedStockVestedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock vested in the period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Holding Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Stock and Prefunded Warrants Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of stock and prefunded warrants value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants, net of issuance costs, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrepaidAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid And Other Assets Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrepaidAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid and other assets current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrepaidAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DisclosureOfBalanceSheetComponentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Balance Sheet Components [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DisclosureOfBalanceSheetComponentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Balance Sheet Components [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock reserved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxRateReconciliationSection162MCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 162(m) compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxRateReconciliationSection162MCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Rate Reconciliation Section 162(m) Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncomeTaxRateReconciliationSection162MCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax rate reconciliation section 162(m) compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Pre-funded Warrants Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of pre-funded warrants shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value Per Share, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option grants description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options to Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedCompensationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedCompensationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Compensation Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedCompensationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued compensation, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized gain (loss) on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AggregateSubleasePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate sublease payment receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AggregateSubleasePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Sublease Payment Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AggregateSubleasePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate sublease payment receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightExcercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightExcercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Excercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightExcercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right excercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 ATM Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Two Four At The Market Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two zero two four at the market program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Non Operating Income Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and other non operating income (expense).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included in Other Non-current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in other non-current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock, gross.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Vested and Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, capitalized research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiry period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of common warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock including related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From The Issuance Of Common Stock Including Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from the issuance of common stock including related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">prepaid research and development costs, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock per Employee Stock Purchase Plan purchase, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options reserved for two thousand twenty incentive award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Reserved for Two Thousand Twenty Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Reserved for 2020 Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- average exercise price per share, Stock options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remains available for offer and sales of shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remained Available For Offer And Sales Of Shares Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remained available for offer and sales of shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Pre-funded Warrants Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of pre-funded warrants value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrefundedWarrantsAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants and Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrefundedWarrantsAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prefunded Warrants and Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrefundedWarrantsAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prefunded warrants and common warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockSalesAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock sales agreement expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockSalesAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Sales Agreement Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockSalesAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock sales agreement expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value Per Share, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">End of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Credit Carryforwards Expiration Beginning Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal carryforward losses expiration beginning year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets credit carryforwards expiration beginning year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PersonnelExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PersonnelExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PersonnelExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Stock Issued Under Sales Agreement After Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock issued under sales agreement after expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock sold after expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Lease Payments and Related Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options available for future grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock reserved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value Per Share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost expected period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingency, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Stock and Prefunded Warrants Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of stock and prefunded warrants shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonSharesExchangeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common shares exchange value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonSharesExchangeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Shares Exchange Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonSharesExchangeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional stock issued during period common shares purchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Stock Issued During Period Common Shares Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional common shares purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted/Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of common stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, interest or penalty accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, pre-funded warrants and common warrants, net of issuance costs, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of issuance costs, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Undiscounted Lease Payments Under Non-cancellable Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right, Weighted-Average Exercise Price of Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of Warrant or right, weighted-average exercise price of warrant issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 ATM Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Two One At The Market Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two zero two one at the market program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InvestmentExpectedMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment expected maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InvestmentExpectedMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Expected Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InvestmentExpectedMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment expected maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the issuance of common stock, pre-funded warrants and common warrants - related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from related parties for the issuance of common stock, Pre-funded warrants and common warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Related Parties For The Issuance of Common Stock Prefunded Warrants and Common warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock, pre-funded warrants and common warrants - related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Employment Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Reserved For Two Thousand Twenty Two Employment Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock reserved for two thousand twenty two employment inducement award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeasePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeasePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss position for more than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity under Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOLs do not expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reductions based on tax positions related to prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State carryforward losses expiration beginning year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Expiration Beginning Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, operating loss carryforwards, expiration beginning year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued and current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">underwriting commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Commissions and Discounts and Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting commissions and discounts and offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from the computation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash And Cash Equivalents And Restricted Cash Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash and cash equivalents and restricted cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DouglasLoveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Douglas Love [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DouglasLoveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Douglas Love.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, ASU adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability for Uncertainty in Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CowenSalesAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cowen sales agent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CowenSalesAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cowen Sales Agent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CowenSalesAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cowen as sales agent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Holding Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsegments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Useful Lives of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Useful Lives Of Property And Equipment Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of useful lives of property and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingency Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants were recorded at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, pre-funded warrants and common warrants, net of issuance cost, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brisbane, California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brisbane California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brisbane, California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyPendingClaimsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency pending claims</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyPendingClaimsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Pending Claims, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful lives of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the issuance of common stock, including to related parties, of zero and $17,995 for the years ended December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- average exercise price per share, Stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of taxable income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use Percentage Of Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards, limitations on use, percentage of taxable income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other liabilities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonWarrantAndPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrant and Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonWarrantAndPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Warrant and Pre-funded Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonWarrantAndPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Warrant and Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsegmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsegments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Stock Options And Nonstatutory Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive stock options and nonstatutory stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ReserveForTwoThousandTwentyIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserve for 2020 Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ReserveForTwoThousandTwentyIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve For Two Thousand Twenty Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ReserveForTwoThousandTwentyIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reserve for two thousand twenty incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockAndPrefundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock and Prefunded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockAndPrefundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock and prefunded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CommonStockAndPrefundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Prefunded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued for exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares For Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares for exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- average remaining contractual term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BalanceSheetComponentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BalanceSheetComponentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Components Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_BalanceSheetComponentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Balance sheet components disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, ASU, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Incremental Borrowing Rate Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease weighted average incremental borrowing rate percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain/loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOLs with annual limitation utilization that do not expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Annual Limitation Utilization Not Subject To Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards annual limitation utilization not subject to expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_OfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOtherIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOtherIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsOtherIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, other intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Minimum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award minimum employee subscription rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share purchases funded through payroll deductions minimum percentage of employee's eligible compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrefundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prefunded Warrant Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrefundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prefunded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrefundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PrefundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Loss Before Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of Common stock at end of each offering period at price equal to percentage of fair market value of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from Employee Stock Purchase Plan purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- average exercise price per share, Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in the carrying amount of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">pre-funded warrants Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">pre-funded warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProgramExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Program Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProgramExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Program Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_ProgramExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Program Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedConstructionCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued construction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedConstructionCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Construction Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_AccruedConstructionCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued construction costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stocks, Including Additional Paid in Capital, Net of Discount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOLs subject to expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2024 and 2023; 109,381,556 and 78,369,099 shares issued and outstanding as of December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 5)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operations for Reportable Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Of Common Stock Outstanding On Last Day Of Immediately Preceding Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of capital stock outstanding on last day of preceding year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Number Of Shares Of Capital Stock Outstanding On Last Day Of Preceding Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of number of shares of capital stock outstanding on last day of preceding year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discount on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- average exercise price per share, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- average exercise price per share, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Reserved for Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In The Measurement Of Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_SalesAgreementWithCowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement with Cowen and Company LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_SalesAgreementWithCowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement With Cowen And Company L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_SalesAgreementWithCowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement with Cowen and Company LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, ASU, Immaterial effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_EmploymentInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Two Employment Inducement Award Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_EmploymentInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Employment Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="annx_EmploymentInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Employment Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" xlink:to="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ComputerEquipmentAndSoftwareMember" xlink:to="annx_ComputerEquipmentAndSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" xlink:to="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_LesseeOperatingLeaseExpirationMonthAndYear" xlink:to="annx_LesseeOperatingLeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingenciesTable" xlink:to="us-gaap_GainContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_UnvestedRestrictedStockUnitsOutstandingMember" xlink:to="annx_UnvestedRestrictedStockUnitsOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:to="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PercentageOfGrossProceedsOfCommonStockToBePaid" xlink:to="annx_PercentageOfGrossProceedsOfCommonStockToBePaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_WeightedAveragePricePerShare" xlink:to="annx_WeightedAveragePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:to="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_LesseeOperatingSubleaseCommencementYearAndMonth" xlink:to="annx_LesseeOperatingSubleaseCommencementYearAndMonth_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_LesseeOperatingSubleaseExpirationYearAndMonth" xlink:to="annx_LesseeOperatingSubleaseExpirationYearAndMonth_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_IncomeTaxTable" xlink:to="annx_IncomeTaxTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_IncomeTaxLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_RestrictedStockVestedDuringPeriodShares" xlink:to="annx_RestrictedStockVestedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_IssuanceOfStockAndPrefundedWarrantsValue" xlink:to="annx_IssuanceOfStockAndPrefundedWarrantsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PrepaidAndOtherAssetsCurrent" xlink:to="annx_PrepaidAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DisclosureOfBalanceSheetComponentsAbstract" xlink:to="annx_DisclosureOfBalanceSheetComponentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="annx_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_IncomeTaxRateReconciliationSection162MCompensation" xlink:to="annx_IncomeTaxRateReconciliationSection162MCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ExerciseOfPreFundedWarrantsShares" xlink:to="annx_ExerciseOfPreFundedWarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_AccruedCompensationCurrent" xlink:to="annx_AccruedCompensationCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_AggregateSubleasePaymentReceivable" xlink:to="annx_AggregateSubleasePaymentReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ClassOfWarrantOrRightExcercised" xlink:to="annx_ClassOfWarrantOrRightExcercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_TwoZeroTwoFourAtTheMarketProgramMember" xlink:to="annx_TwoZeroTwoFourAtTheMarketProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_InterestAndOtherNonOperatingIncomeExpense" xlink:to="annx_InterestAndOtherNonOperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:to="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndemnificationGuaranteeMember" xlink:to="us-gaap_IndemnificationGuaranteeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets" xlink:to="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ProceedsFromIssuanceOfCommonStockGross" xlink:to="annx_ProceedsFromIssuanceOfCommonStockGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBondSecuritiesMember" xlink:to="us-gaap_USTreasuryBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ExerciseOfCommonWarrants" xlink:to="annx_ExerciseOfCommonWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty" xlink:to="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="annx_PrepaidResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember" xlink:to="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" xlink:to="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="annx_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ExerciseOfPreFundedWarrantsValue" xlink:to="annx_ExerciseOfPreFundedWarrantsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PrefundedWarrantsAndCommonWarrantsMember" xlink:to="annx_PrefundedWarrantsAndCommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_CommonStockSalesAgreementExpirationDate" xlink:to="annx_CommonStockSalesAgreementExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear" xlink:to="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PersonnelExpensesMember" xlink:to="annx_PersonnelExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate" xlink:to="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ShortTermInvestmentsPolicyTextBlock" xlink:to="annx_ShortTermInvestmentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_GainContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_IssuanceOfStockAndPrefundedWarrantsShares" xlink:to="annx_IssuanceOfStockAndPrefundedWarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_CommonSharesExchangeValue" xlink:to="annx_CommonSharesExchangeValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased" xlink:to="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" xlink:to="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_TwoZeroTwoOneAtTheMarketProgramMember" xlink:to="annx_TwoZeroTwoOneAtTheMarketProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_InvestmentExpectedMaturityPeriod" xlink:to="annx_InvestmentExpectedMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants" xlink:to="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember" xlink:to="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeasePayment" xlink:to="us-gaap_VariableLeasePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear" xlink:to="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses" xlink:to="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_CommonWarrantsMember" xlink:to="annx_CommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DouglasLoveMember" xlink:to="annx_DouglasLoveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_CowenSalesAgentMember" xlink:to="annx_CowenSalesAgentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ClassOfWarrantOrRightIssued" xlink:to="annx_ClassOfWarrantOrRightIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_WarrantsPolicyTextBlock" xlink:to="annx_WarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_BrisbaneCaliforniaMember" xlink:to="annx_BrisbaneCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyPendingClaimsNumber" xlink:to="us-gaap_LossContingencyPendingClaimsNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" xlink:to="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_AccruedAndOtherLiabilitiesCurrent" xlink:to="annx_AccruedAndOtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_CommonWarrantAndPreFundedWarrantsMember" xlink:to="annx_CommonWarrantAndPreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="us-gaap_SubsegmentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember" xlink:to="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ReserveForTwoThousandTwentyIncentivePlanMember" xlink:to="annx_ReserveForTwoThousandTwentyIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_CommonStockAndPrefundedWarrantsMember" xlink:to="annx_CommonStockAndPrefundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:to="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_BalanceSheetComponentsDisclosureTextBlock" xlink:to="annx_BalanceSheetComponentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" xlink:to="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInvestments" xlink:to="us-gaap_DeferredTaxAssetsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" xlink:to="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_OfferingPricePerShare" xlink:to="annx_OfferingPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DeferredTaxAssetsOtherIntangibleAssets" xlink:to="annx_DeferredTaxAssetsOtherIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:to="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PrefundedWarrantMember" xlink:to="annx_PrefundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_LaboratoryEquipmentMember" xlink:to="annx_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PreFundedWarrantsMember" xlink:to="annx_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_ProgramExpensesMember" xlink:to="annx_ProgramExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_AccruedConstructionCostsCurrent" xlink:to="annx_AccruedConstructionCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_InvestmentMaturityPeriod" xlink:to="annx_InvestmentMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_DeferredTaxAssetsLeaseLiabilities" xlink:to="annx_DeferredTaxAssetsLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" xlink:to="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" xlink:to="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_EmployeeStockPurchasePlanMember" xlink:to="annx_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="annx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability" xlink:to="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_SalesAgreementWithCowenAndCompanyLLCMember" xlink:to="annx_SalesAgreementWithCowenAndCompanyLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="annx_EmploymentInducementIncentivePlanMember" xlink:to="annx_EmploymentInducementIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentAnnualReport" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="annx_PrefundedWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentTransitionReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_Security12bTitle" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_SecurityExchangeName" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFileNumber" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine2" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine3" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressCityOrTown" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CityAreaCode" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_LocalPhoneNumber" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntitySmallBusiness" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityShellCompany" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityPublicFloat" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorFirmId" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="us-gaap_StatementTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedAndOtherLiabilitiesCurrent" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="annx_AccruedAndOtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InterestAndOtherNonOperatingIncomeExpense" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="annx_InterestAndOtherNonOperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PreFundedWarrantsMember" xlink:label="annx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantsAndCommonWarrantsMember" xlink:label="annx_PrefundedWarrantsAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfPreFundedWarrantsValue" xlink:label="annx_ExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfPreFundedWarrantsShares" xlink:label="annx_ExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfCommonWarrants" xlink:label="annx_ExerciseOfCommonWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IssuanceOfStockAndPrefundedWarrantsValue" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IssuanceOfStockAndPrefundedWarrantsShares" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_RestrictedStockVestedDuringPeriodShares" xlink:label="annx_RestrictedStockVestedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_18"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="annx_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="annx_PrefundedWarrantsAndCommonWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_ExerciseOfPreFundedWarrantsValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_ExerciseOfPreFundedWarrantsShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_ExerciseOfCommonWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_IssuanceOfStockAndPrefundedWarrantsValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_IssuanceOfStockAndPrefundedWarrantsShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_RestrictedStockVestedDuringPeriodShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockAndPrefundedWarrantsMember" xlink:label="annx_CommonStockAndPrefundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants" xlink:label="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="annx_CommonStockAndPrefundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability" xlink:label="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets" xlink:label="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" xlink:label="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="annx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="annx_IncreaseDecreaseInOperatingLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty" xlink:label="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DouglasLoveMember" xlink:label="annx_DouglasLoveMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="annx_DouglasLoveMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DisclosureOfBalanceSheetComponentsAbstract" xlink:label="annx_DisclosureOfBalanceSheetComponentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BalanceSheetComponentsDisclosureTextBlock" xlink:label="annx_BalanceSheetComponentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_DisclosureOfBalanceSheetComponentsAbstract" xlink:to="annx_BalanceSheetComponentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ShortTermInvestmentsPolicyTextBlock" xlink:label="annx_ShortTermInvestmentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_WarrantsPolicyTextBlock" xlink:label="annx_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="annx_ShortTermInvestmentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="annx_WarrantsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DisclosureOfBalanceSheetComponentsAbstract" xlink:label="annx_DisclosureOfBalanceSheetComponentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_DisclosureOfBalanceSheetComponentsAbstract" xlink:to="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_DisclosureOfBalanceSheetComponentsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_DisclosureOfBalanceSheetComponentsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:label="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LaboratoryEquipmentMember" xlink:label="annx_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="annx_LaboratoryEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InvestmentMaturityPeriod" xlink:label="annx_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InvestmentExpectedMaturityPeriod" xlink:label="annx_InvestmentExpectedMaturityPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="annx_InvestmentMaturityPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="annx_InvestmentExpectedMaturityPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="annx_PrepaidResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrepaidAndOtherAssetsCurrent" xlink:label="annx_PrepaidAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="annx_PrepaidResearchAndDevelopmentCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="annx_PrepaidAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LaboratoryEquipmentMember" xlink:label="annx_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ComputerEquipmentAndSoftwareMember" xlink:label="annx_ComputerEquipmentAndSoftwareMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="annx_LaboratoryEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="annx_ComputerEquipmentAndSoftwareMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="annx_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedCompensationCurrent" xlink:label="annx_AccruedCompensationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedConstructionCostsCurrent" xlink:label="annx_AccruedConstructionCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedAndOtherLiabilitiesCurrent" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="annx_AccruedResearchAndDevelopmentExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="annx_AccruedCompensationCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="annx_AccruedConstructionCostsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="annx_AccruedAndOtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesTable" xlink:label="us-gaap_GainContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesLineItems" xlink:label="us-gaap_GainContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BrisbaneCaliforniaMember" xlink:label="annx_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingLeaseExpirationMonthAndYear" xlink:label="annx_LesseeOperatingLeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingSubleaseCommencementYearAndMonth" xlink:label="annx_LesseeOperatingSubleaseCommencementYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingSubleaseExpirationYearAndMonth" xlink:label="annx_LesseeOperatingSubleaseExpirationYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AggregateSubleasePaymentReceivable" xlink:label="annx_AggregateSubleasePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" xlink:label="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="annx_BrisbaneCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_GainContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_LesseeOperatingLeaseExpirationMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesTable" xlink:to="us-gaap_GainContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_LesseeOperatingSubleaseCommencementYearAndMonth" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_LesseeOperatingSubleaseExpirationYearAndMonth" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_AggregateSubleasePaymentReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_SubleaseIncome" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_VariableLeasePayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:label="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoOneAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CowenSalesAgentMember" xlink:label="annx_CowenSalesAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoFourAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_SalesAgreementWithCowenAndCompanyLLCMember" xlink:label="annx_SalesAgreementWithCowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OfferingPricePerShare" xlink:label="annx_OfferingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses" xlink:label="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased" xlink:label="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonSharesExchangeValue" xlink:label="annx_CommonSharesExchangeValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfGrossProceedsOfCommonStockToBePaid" xlink:label="annx_PercentageOfGrossProceedsOfCommonStockToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromIssuanceOfCommonStockGross" xlink:label="annx_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" xlink:label="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockSalesAgreementExpirationDate" xlink:label="annx_CommonStockSalesAgreementExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate" xlink:label="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_WeightedAveragePricePerShare" xlink:label="annx_WeightedAveragePricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoOneAtTheMarketProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PrefundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="annx_CowenSalesAgentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoFourAtTheMarketProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="annx_SalesAgreementWithCowenAndCompanyLLCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_OfferingPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_StatementScenarioAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_CommonSharesExchangeValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_PercentageOfGrossProceedsOfCommonStockToBePaid" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_ProceedsFromIssuanceOfCommonStockGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_CommonStockSalesAgreementExpirationDate" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_WeightedAveragePricePerShare" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightIssued" xlink:label="annx_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonWarrantAndPreFundedWarrantsMember" xlink:label="annx_CommonWarrantAndPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightExcercised" xlink:label="annx_ClassOfWarrantOrRightExcercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PrefundedWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="annx_ClassOfWarrantOrRightIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_CommonWarrantAndPreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="annx_ClassOfWarrantOrRightExcercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoOneAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PreFundedWarrantsMember" xlink:label="annx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoFourAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonWarrantsMember" xlink:label="annx_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember" xlink:label="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_UnvestedRestrictedStockUnitsOutstandingMember" xlink:label="annx_UnvestedRestrictedStockUnitsOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_EmployeeStockPurchasePlanMember" xlink:label="annx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember" xlink:label="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ReserveForTwoThousandTwentyIncentivePlanMember" xlink:label="annx_ReserveForTwoThousandTwentyIncentivePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoOneAtTheMarketProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoFourAtTheMarketProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_CommonWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_UnvestedRestrictedStockUnitsOutstandingMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_EmployeeStockPurchasePlanMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_ReserveForTwoThousandTwentyIncentivePlanMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" xlink:label="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_EmploymentInducementIncentivePlanMember" xlink:label="annx_EmploymentInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember" xlink:label="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_EmployeeStockPurchasePlanMember" xlink:label="annx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" xlink:label="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_EmploymentInducementIncentivePlanMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_EmployeeStockPurchasePlanMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxRateReconciliationSection162MCompensation" xlink:label="annx_IncomeTaxRateReconciliationSection162MCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="annx_IncomeTaxRateReconciliationSection162MCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOtherIntangibleAssets" xlink:label="annx_DeferredTaxAssetsOtherIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsLeaseLiabilities" xlink:label="annx_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="annx_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="annx_DeferredTaxAssetsOtherIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="annx_DeferredTaxAssetsLeaseLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="annx_DeferredTaxLiabilitiesRightOfUseAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxTable" xlink:label="annx_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxLineItems" xlink:label="annx_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" xlink:label="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear" xlink:label="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="annx_IncomeTaxTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxTable" xlink:to="annx_IncomeTaxLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_OpenTaxYear" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PrefundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis" xlink:label="us-gaap_SubsegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain" xlink:label="us-gaap_SubsegmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProgramExpensesMember" xlink:label="annx_ProgramExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PersonnelExpensesMember" xlink:label="annx_PersonnelExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InterestAndOtherNonOperatingIncomeExpense" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="annx_ProgramExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SubsegmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="annx_PersonnelExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Depreciation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="annx_InterestAndOtherNonOperatingIncomeExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoOneAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CowenSalesAgentMember" xlink:label="annx_CowenSalesAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoFourAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_SalesAgreementWithCowenAndCompanyLLCMember" xlink:label="annx_SalesAgreementWithCowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoOneAtTheMarketProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="annx_CowenSalesAgentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoFourAtTheMarketProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PrefundedWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="annx_SalesAgreementWithCowenAndCompanyLLCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="annx_PrefundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PreFundedWarrantsMember" xlink:label="annx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantsAndCommonWarrantsMember" xlink:label="annx_PrefundedWarrantsAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfPreFundedWarrantsValue" xlink:label="annx_ExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfPreFundedWarrantsShares" xlink:label="annx_ExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ExerciseOfCommonWarrants" xlink:label="annx_ExerciseOfCommonWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IssuanceOfStockAndPrefundedWarrantsValue" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IssuanceOfStockAndPrefundedWarrantsShares" xlink:label="annx_IssuanceOfStockAndPrefundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_RestrictedStockVestedDuringPeriodShares" xlink:label="annx_RestrictedStockVestedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="annx_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="annx_PrefundedWarrantsAndCommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_ExerciseOfPreFundedWarrantsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_ExerciseOfPreFundedWarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_ExerciseOfCommonWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_IssuanceOfStockAndPrefundedWarrantsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_IssuanceOfStockAndPrefundedWarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_RestrictedStockVestedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockAndPrefundedWarrantsMember" xlink:label="annx_CommonStockAndPrefundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants" xlink:label="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="annx_CommonStockAndPrefundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DouglasLoveMember" xlink:label="annx_DouglasLoveMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="annx_DouglasLoveMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LaboratoryEquipmentMember" xlink:label="annx_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="annx_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LaboratoryEquipmentMember" xlink:label="annx_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ComputerEquipmentAndSoftwareMember" xlink:label="annx_ComputerEquipmentAndSoftwareMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="annx_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="annx_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesLineItems" xlink:label="us-gaap_GainContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesTable" xlink:label="us-gaap_GainContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_BrisbaneCaliforniaMember" xlink:label="annx_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingLeaseExpirationMonthAndYear" xlink:label="annx_LesseeOperatingLeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingSubleaseCommencementYearAndMonth" xlink:label="annx_LesseeOperatingSubleaseCommencementYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingSubleaseExpirationYearAndMonth" xlink:label="annx_LesseeOperatingSubleaseExpirationYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AggregateSubleasePaymentReceivable" xlink:label="annx_AggregateSubleasePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" xlink:label="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_GainContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_GainContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="annx_BrisbaneCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_GainContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_LesseeOperatingLeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_LesseeOperatingSubleaseCommencementYearAndMonth" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_LesseeOperatingSubleaseExpirationYearAndMonth" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_AggregateSubleasePaymentReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_VariableLeasePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoOneAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CowenSalesAgentMember" xlink:label="annx_CowenSalesAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoFourAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_SalesAgreementWithCowenAndCompanyLLCMember" xlink:label="annx_SalesAgreementWithCowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OfferingPricePerShare" xlink:label="annx_OfferingPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses" xlink:label="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased" xlink:label="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonSharesExchangeValue" xlink:label="annx_CommonSharesExchangeValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfGrossProceedsOfCommonStockToBePaid" xlink:label="annx_PercentageOfGrossProceedsOfCommonStockToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromIssuanceOfCommonStockGross" xlink:label="annx_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" xlink:label="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockSalesAgreementExpirationDate" xlink:label="annx_CommonStockSalesAgreementExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate" xlink:label="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_WeightedAveragePricePerShare" xlink:label="annx_WeightedAveragePricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoOneAtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PrefundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="annx_CowenSalesAgentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoFourAtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="annx_SalesAgreementWithCowenAndCompanyLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_OfferingPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_CommonSharesExchangeValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_PercentageOfGrossProceedsOfCommonStockToBePaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_ProceedsFromIssuanceOfCommonStockGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_CommonStockSalesAgreementExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="annx_WeightedAveragePricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightIssued" xlink:label="annx_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonWarrantAndPreFundedWarrantsMember" xlink:label="annx_CommonWarrantAndPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightExcercised" xlink:label="annx_ClassOfWarrantOrRightExcercised"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" xlink:label="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PrefundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="annx_ClassOfWarrantOrRightIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_CommonWarrantAndPreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="annx_ClassOfWarrantOrRightExcercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoOneAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PreFundedWarrantsMember" xlink:label="annx_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember" xlink:label="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoFourAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonWarrantsMember" xlink:label="annx_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_UnvestedRestrictedStockUnitsOutstandingMember" xlink:label="annx_UnvestedRestrictedStockUnitsOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_EmployeeStockPurchasePlanMember" xlink:label="annx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember" xlink:label="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ReserveForTwoThousandTwentyIncentivePlanMember" xlink:label="annx_ReserveForTwoThousandTwentyIncentivePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoOneAtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoFourAtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_CommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_UnvestedRestrictedStockUnitsOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_ReserveForTwoThousandTwentyIncentivePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" xlink:label="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_EmploymentInducementIncentivePlanMember" xlink:label="annx_EmploymentInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember" xlink:label="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_EmployeeStockPurchasePlanMember" xlink:label="annx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" xlink:label="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_EmploymentInducementIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="annx_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxLineItems" xlink:label="annx_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxTable" xlink:label="annx_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" xlink:label="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear" xlink:label="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear" xlink:label="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_IncomeTaxTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="annx_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="annx_IncomeTaxTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="annx_IncomeTaxLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PrefundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis" xlink:label="us-gaap_SubsegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain" xlink:label="us-gaap_SubsegmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain" xlink:label="us-gaap_SubsegmentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProgramExpensesMember" xlink:label="annx_ProgramExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PersonnelExpensesMember" xlink:label="annx_PersonnelExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InterestAndOtherNonOperatingIncomeExpense" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="annx_ProgramExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SubsegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="annx_PersonnelExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="annx_InterestAndOtherNonOperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoOneAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoOneAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_CowenSalesAgentMember" xlink:label="annx_CowenSalesAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_TwoZeroTwoFourAtTheMarketProgramMember" xlink:label="annx_TwoZeroTwoFourAtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrefundedWarrantMember" xlink:label="annx_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_SalesAgreementWithCowenAndCompanyLLCMember" xlink:label="annx_SalesAgreementWithCowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoOneAtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="annx_CowenSalesAgentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="annx_TwoZeroTwoFourAtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="annx_PrefundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="annx_SalesAgreementWithCowenAndCompanyLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="annx_AccruedAndOtherLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedAndOtherLiabilitiesCurrent" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="annx_InterestAndOtherNonOperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InterestAndOtherNonOperatingIncomeExpense" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="annx_IncreaseDecreaseInOperatingLeaseLiabilities" order="11" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="13" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" xlink:label="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="annx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_Cash" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCash" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="annx_PrepaidResearchAndDevelopmentCostsCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="annx_PrepaidAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="annx_PrepaidResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_PrepaidAndOtherAssetsCurrent" xlink:label="annx_PrepaidAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="annx_AccruedAndOtherLiabilitiesCurrent" xlink:to="annx_AccruedResearchAndDevelopmentExpensesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="annx_AccruedAndOtherLiabilitiesCurrent" xlink:to="annx_AccruedCompensationCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="annx_AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="annx_AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedAndOtherLiabilitiesCurrent" xlink:label="annx_AccruedAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="annx_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_AccruedCompensationCurrent" xlink:label="annx_AccruedCompensationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:label="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="annx_IncomeTaxRateReconciliationSection162MCompensation" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_IncomeTaxRateReconciliationSection162MCompensation" xlink:label="annx_IncomeTaxRateReconciliationSection162MCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="annx_DeferredTaxLiabilitiesRightOfUseAssets" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="annx_DeferredTaxAssetsOtherIntangibleAssets" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="annx_DeferredTaxAssetsLeaseLiabilities" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInvestments" order="8" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="annx_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsOtherIntangibleAssets" xlink:label="annx_DeferredTaxAssetsOtherIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_DeferredTaxAssetsLeaseLiabilities" xlink:label="annx_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="annx_InterestAndOtherNonOperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_Depreciation" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="annx-20241231.xsd#annx_InterestAndOtherNonOperatingIncomeExpense" xlink:label="annx_InterestAndOtherNonOperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="annx_EmploymentInducementIncentivePlanMember" name="EmploymentInducementIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_WeightedAveragePricePerShare" name="WeightedAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="annx_ClassOfWarrantOrRightExcercised" name="ClassOfWarrantOrRightExcercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_InvestmentMaturityPeriod" name="InvestmentMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_PercentageOfGrossProceedsOfCommonStockToBePaid" name="PercentageOfGrossProceedsOfCommonStockToBePaid" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_ShortTermInvestmentsPolicyTextBlock" name="ShortTermInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_CommonStockAndPrefundedWarrantsMember" name="CommonStockAndPrefundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_PrefundedWarrantMember" name="PrefundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_AccruedCompensationCurrent" name="AccruedCompensationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants" name="ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_PersonnelExpensesMember" name="PersonnelExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_DisclosureOfBalanceSheetComponentsAbstract" name="DisclosureOfBalanceSheetComponentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_BalanceSheetComponentsDisclosureTextBlock" name="BalanceSheetComponentsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_AggregateSubleasePaymentReceivable" name="AggregateSubleasePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_DouglasLoveMember" name="DouglasLoveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_InvestmentExpectedMaturityPeriod" name="InvestmentExpectedMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_AccruedAndOtherLiabilitiesCurrent" name="AccruedAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_ReserveForTwoThousandTwentyIncentivePlanMember" name="ReserveForTwoThousandTwentyIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_CommonStockSalesAgreementExpirationDate" name="CommonStockSalesAgreementExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate" name="NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_LesseeOperatingSubleaseCommencementYearAndMonth" name="LesseeOperatingSubleaseCommencementYearAndMonth" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear" name="DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" name="PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_SalesAgreementWithCowenAndCompanyLLCMember" name="SalesAgreementWithCowenAndCompanyLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" name="SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember" name="StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_OfferingPricePerShare" name="OfferingPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" name="OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="annx_RestrictedStockVestedDuringPeriodShares" name="RestrictedStockVestedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember" name="IncentiveStockOptionsAndNonstatutoryStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_CowenSalesAgentMember" name="CowenSalesAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased" name="AdditionalStockIssuedDuringPeriodCommonSharesPurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_PrefundedWarrantsAndCommonWarrantsMember" name="PrefundedWarrantsAndCommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_InterestAndOtherNonOperatingIncomeExpense" name="InterestAndOtherNonOperatingIncomeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_BasisOfPresentationAndSignificantAccountingPoliciesTable" name="BasisOfPresentationAndSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" name="BasisOfPresentationAndSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_CommonWarrantsMember" name="CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember" name="CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses" name="UnderwritingCommissionsAndDiscountsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_UnvestedRestrictedStockUnitsOutstandingMember" name="UnvestedRestrictedStockUnitsOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_ExerciseOfPreFundedWarrantsValue" name="ExerciseOfPreFundedWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear" name="DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_ExerciseOfCommonWarrants" name="ExerciseOfCommonWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_PrepaidAndOtherAssetsCurrent" name="PrepaidAndOtherAssetsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants" name="StockIssuedDuringPeriodSharesForExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_TwoZeroTwoFourAtTheMarketProgramMember" name="TwoZeroTwoFourAtTheMarketProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_CommonSharesExchangeValue" name="CommonSharesExchangeValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" name="OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_LesseeOperatingSubleaseExpirationYearAndMonth" name="LesseeOperatingSubleaseExpirationYearAndMonth" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_BrisbaneCaliforniaMember" name="BrisbaneCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" name="DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_ProgramExpensesMember" name="ProgramExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability" name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_ExerciseOfPreFundedWarrantsShares" name="ExerciseOfPreFundedWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty" name="ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_IssuanceOfStockAndPrefundedWarrantsValue" name="IssuanceOfStockAndPrefundedWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_AccruedConstructionCostsCurrent" name="AccruedConstructionCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_IncomeTaxRateReconciliationSection162MCompensation" name="IncomeTaxRateReconciliationSection162MCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_DeferredTaxAssetsOtherIntangibleAssets" name="DeferredTaxAssetsOtherIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" name="ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets" name="DeferredOfferingCostsIncludedInOtherNonCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_CommonWarrantAndPreFundedWarrantsMember" name="CommonWarrantAndPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="annx_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="annx_LesseeOperatingLeaseExpirationMonthAndYear" name="LesseeOperatingLeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" name="PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_IssuanceOfStockAndPrefundedWarrantsShares" name="IssuanceOfStockAndPrefundedWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" name="OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" name="RemainedAvailableForOfferAndSalesOfSharesOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="annx_TwoZeroTwoOneAtTheMarketProgramMember" name="TwoZeroTwoOneAtTheMarketProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955061056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANNEXON, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001528115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-5414423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1400 Sierra Point Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">822-5500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 477.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,709,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=annx_PrefundedWarrantMember', window );">Prefunded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,543,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=annx_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=annx_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889956819648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,498<span></span>
</td>
<td class="nump">$ 225,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">262,519<span></span>
</td>
<td class="nump">34,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,444<span></span>
</td>
<td class="nump">4,144<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">316,461<span></span>
</td>
<td class="nump">263,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">12,638<span></span>
</td>
<td class="nump">14,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">16,705<span></span>
</td>
<td class="nump">18,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">3,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">350,071<span></span>
</td>
<td class="nump">297,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,426<span></span>
</td>
<td class="nump">5,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">17,568<span></span>
</td>
<td class="nump">10,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,512<span></span>
</td>
<td class="nump">17,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">26,454<span></span>
</td>
<td class="nump">29,190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">56,966<span></span>
</td>
<td class="nump">47,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2024 and 2023; 109,381,556 and 78,369,099 shares issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,003,685<span></span>
</td>
<td class="nump">823,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(710,699)<span></span>
</td>
<td class="num">(572,499)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">293,105<span></span>
</td>
<td class="nump">250,556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 350,071<span></span>
</td>
<td class="nump">$ 297,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957524192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">109,381,556<span></span>
</td>
<td class="nump">78,369,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">109,381,556<span></span>
</td>
<td class="nump">78,369,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955046944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 119,448<span></span>
</td>
<td class="nump">$ 113,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">34,625<span></span>
</td>
<td class="nump">29,967<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">154,073<span></span>
</td>
<td class="nump">143,723<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(154,073)<span></span>
</td>
<td class="num">(143,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_InterestAndOtherNonOperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">15,873<span></span>
</td>
<td class="nump">9,486<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (138,200)<span></span>
</td>
<td class="num">$ (134,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (1.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (1.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share, basic</a></td>
<td class="nump">137,404,145<span></span>
</td>
<td class="nump">75,673,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share, diluted</a></td>
<td class="nump">137,404,145<span></span>
</td>
<td class="nump">75,673,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_InterestAndOtherNonOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and other non operating income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_InterestAndOtherNonOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889954051648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (138,200)<span></span>
</td>
<td class="num">$ (134,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (138,138)<span></span>
</td>
<td class="num">$ (133,917)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889954262704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Related Party [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Related Party [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Related Party [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Values at Dec. 31, 2022</a></td>
<td class="nump">$ 231,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 669,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (372)<span></span>
</td>
<td class="num">$ (438,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,722,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, Value</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ExerciseOfPreFundedWarrantsValue', window );">Exercise of pre-funded warrants, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ExerciseOfPreFundedWarrantsShares', window );">Exercise of pre-funded warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,646,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IssuanceOfStockAndPrefundedWarrantsValue', window );">Issuance of common stock and pre-funded warrants, net of issuance costs, Value</a></td>
<td class="nump">117,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IssuanceOfStockAndPrefundedWarrantsShares', window );">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock per Employee Stock Purchase Plan purchase, Value</a></td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock per Employee Stock Purchase Plan purchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_RestrictedStockVestedDuringPeriodShares', window );">Restricted stock vested in the period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation, Value</a></td>
<td class="nump">18,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, Value</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(134,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Values at Dec. 31, 2023</a></td>
<td class="nump">250,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">823,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(572,499)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,369,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, Value</a></td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">382,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ExerciseOfPreFundedWarrantsValue', window );">Exercise of pre-funded warrants, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ExerciseOfPreFundedWarrantsShares', window );">Exercise of pre-funded warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,947,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ExerciseOfCommonWarrants', window );">Exercise of common warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs, Value</a></td>
<td class="nump">$ 42,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,326,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IssuanceOfStockAndPrefundedWarrantsValue', window );">Issuance of common stock and pre-funded warrants, net of issuance costs, Value</a></td>
<td class="nump">116,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IssuanceOfStockAndPrefundedWarrantsShares', window );">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,001,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock per Employee Stock Purchase Plan purchase, Value</a></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock per Employee Stock Purchase Plan purchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_RestrictedStockVestedDuringPeriodShares', window );">Restricted stock vested in the period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation, Value</a></td>
<td class="nump">19,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, Value</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(138,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,200)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Values at Dec. 31, 2024</a></td>
<td class="nump">$ 293,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,003,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (710,699)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,381,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ExerciseOfCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of common warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ExerciseOfCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ExerciseOfPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ExerciseOfPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ExerciseOfPreFundedWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ExerciseOfPreFundedWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_IssuanceOfStockAndPrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock and prefunded warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_IssuanceOfStockAndPrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_IssuanceOfStockAndPrefundedWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock and prefunded warrants value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_IssuanceOfStockAndPrefundedWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_RestrictedStockVestedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock vested during period shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_RestrictedStockVestedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957768176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 1,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=annx_CommonStockAndPrefundedWarrantsMember', window );">Common Stock and Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 8,183<span></span>
</td>
<td class="nump">$ 8,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=annx_CommonStockAndPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=annx_CommonStockAndPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889953741168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (138,200)<span></span>
</td>
<td class="num">$ (134,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">2,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on available-for-sale securities</a></td>
<td class="num">(9,054)<span></span>
</td>
<td class="num">(2,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,433<span></span>
</td>
<td class="nump">18,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of right-of-use assets</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(300)<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(3,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,936<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">7,292<span></span>
</td>
<td class="num">(3,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(2,383)<span></span>
</td>
<td class="num">(1,503)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(118,006)<span></span>
</td>
<td class="num">(121,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(583,932)<span></span>
</td>
<td class="num">(108,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of available-for-sale securities</a></td>
<td class="nump">365,150<span></span>
</td>
<td class="nump">178,984<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(218,797)<span></span>
</td>
<td class="nump">70,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan purchases</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, including to related parties, of zero and $17,995 for the years ended December 31, 2024 and 2023, respectively</a></td>
<td class="nump">44,371<span></span>
</td>
<td class="nump">17,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions', window );">Proceeds from the issuance of common stock and pre-funded warrants, net of commissions</a></td>
<td class="nump">117,500<span></span>
</td>
<td class="nump">117,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of financing costs</a></td>
<td class="num">(2,259)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">161,206<span></span>
</td>
<td class="nump">135,524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">(Decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(175,597)<span></span>
</td>
<td class="nump">85,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">226,142<span></span>
</td>
<td class="nump">141,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">50,530<span></span>
</td>
<td class="nump">226,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability', window );">Cash paid for amounts included in the measurement of lease liability</a></td>
<td class="nump">4,893<span></span>
</td>
<td class="nump">4,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred offering costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets', window );">Deferred offering costs included in other non-current assets</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock pre funded warrants net of commissions .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889953386784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Financing Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty', window );">Proceeds from the issuance of common stock including related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the issuance of common stock including related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955478240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (138,200)<span></span>
</td>
<td class="num">$ (134,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889953666048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Arrangements of Section 16 Reporting Persons.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Company&#8217;s last fiscal quarter, the Company&#8217;s directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company&#8217;s securities set forth in the table below.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:28%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:11%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:11%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:8%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:7%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:7%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:9%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:10%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Types of Trading Arrangement</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Position</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Termination Date</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule <br/>10b5-1*</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Rule 10b5-1**</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shares of Common Stock to be Sold</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shares of Common Stock to be Purchased</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Douglas Love</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/16/2024</span></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,994</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/22/2025</span></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">__________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#242424;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#242424;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** &#8220;Non-Rule 10b5-1 trading arrangement&#8221; as defined in Item 408(a) of Regulation S-K under the Exchange Act.</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=annx_DouglasLoveMember', window );">Douglas Love [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Douglas Love<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">12/16/2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">1/22/2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">37,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=annx_DouglasLoveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=annx_DouglasLoveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955451504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented a risk-based approach designed to identify, assess and manage cybersecurity threats that could materially affect our business and information systems. We attempt to identify and assess risks from cybersecurity threats by evaluating our threat environment using various methods including, for example: maintaining manual and automated tools, subscribing to reports and services that identify cybersecurity threats, evaluating threats reported to us, and completing third-party cybersecurity threat assessments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use cybersecurity consultants and penetration testing firms in an effort to identify, assess, and manage material risks from cybersecurity threats. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers in various elements to our business operations such as data hosting providers. To help manage cybersecurity risks associated with our use of third-party service providers, we primarily </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with industry-preferred service providers, and we also contractually require service providers with access to personal, confidential, or proprietary information to maintain data security controls and practices.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity risks and the failure to maintain the security, confidentiality, integrity, or availability of our information technology systems or data, and those maintained on our behalf, could lead to adverse consequences that materially adversely affect our business, including, without limitation, regulatory investigations or actions, a material interruption to our operations, including clinical trials, damage to our reputation and/or subject us to costs, loss of customers or sales, fines and penalties or lawsuits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses our cybersecurity risk management as part of its general oversight function.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for advising on our cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span></span></p></div><div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CFO has supervisory responsibility over IT and cybersecurity functions.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our management is responsible for helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security-related reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.</span></span></span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a cybersecurity policy, reviewed with our audit committee, which is designed to address cybersecurity risks to us (including by escalating certain cybersecurity incidents to members of management and the board of the audit committee, in each case depending on the circumstances). We also maintain incident response procedures designed to assist us in responding to cybersecurity incidents.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CFO has supervisory responsibility over IT and cybersecurity functions.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our management is responsible for helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security-related reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.</span></span></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses our cybersecurity risk management as part of its general oversight function.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for advising on our cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses our cybersecurity risk management as part of its general oversight function.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CFO has supervisory responsibility over IT and cybersecurity functions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our management is responsible for helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security-related reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.</span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CFO has supervisory responsibility over IT and cybersecurity functions.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our management is responsible for helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security-related reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.</span></span></span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a cybersecurity policy, reviewed with our audit committee, which is designed to address cybersecurity risks to us (including by escalating certain cybersecurity incidents to members of management and the board of the audit committee, in each case depending on the circumstances). We also maintain incident response procedures designed to assist us in responding to cybersecurity incidents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for advising on our cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890047656656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annexon, Inc., or the Company, is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for people living with devasting inflammatory-related diseases. The Company is located in Brisbane, California and was incorporated in Delaware in March 2011.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s wholly-owned subsidiary, Annexon Biosciences Australia Pty Ltd, or the Subsidiary, is a proprietary limited company incorporated in 2016 and domiciled in Australia.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, the Company has been involved primarily in performing research and development activities, conducting clinical trials, hiring personnel, and raising capital to support and expand these activities. The Company has experienced losses and negative cash flows from operations since its inception and, as of December 31, 2024, had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">710.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash and cash equivalents and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically funded its operations through the issuance of shares of its common stock and warrants. Based on projected activities, management projects that existing cash and cash equivalents and short-term investments will enable the Company to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements. The Company&#8217;s future viability beyond that point is dependent on its ability to achieve development milestones and obtain additional funding. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years. There are uncertainties associated with the Company&#8217;s ability to (1) obtain additional equity or debt financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs and its business could be materially harmed.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957483040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. Management evaluates its estimates, including but not limited to the fair value of investments, operating lease right-of-use assets and liabilities, valuation of deferred tax assets and uncertain tax positions (including valuation allowance), clinical trial accruals and stock-based compensation. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the operations of Annexon, Inc. and its wholly owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s chief operating decision maker ("CODM") is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">considers</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds and short-term government bonds, are stated at fair value.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash as of December 31, 2024 relates to the letters of credit established for the Company&#8217;s office lease.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,651</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,488</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,847</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,622</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,498</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,110</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,032</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,032</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,530</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226,142</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short-Term Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security&#8217;s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of investments sold is based on the specific-identification method. Interest on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available-for-sale debt</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities is included in interest and other income (expense), net.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation begins at the time the asset is placed in service. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized.</span></p></div><div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The useful lives of the property and equipment are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:39.588%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:58.352%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment and furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8f39b772-731f-41b9-9d02-0d66e7276fae;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Shorter of remaining lease term or estimated useful life</span></span></span></p></td>
         </tr>
        </table></div></div><div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. When indications of impairment are present and the estimated undiscounted future cash flows from the use of these assets is less than the assets&#8217; carrying value, the related assets will be written down to fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairments of the Company&#8217;s long-lived assets for the periods presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. The Company includes operating leases in operating lease right of use, or ROU, assets, current and noncurrent operating lease liabilities in the Company&#8217;s consolidated balance sheets. The ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company measures the ROU assets based on the associated lease liabilities adjusted for any lease incentives such as tenant improvement allowances. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the commencement date. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Lease expense for lease payments is recognized on a straight-line basis, net of sublease income, over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a practical expedient, the Company elected, for all facility leases, not to separate non-lease components from lease components and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred taxes to the amounts expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merit, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liabilities</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company&#8217;s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company&#8217;s product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company&#8217;s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company&#8217;s behalf; (iii) contract manufacturing costs to produce clinical trial materials </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and commercial materials to support future biologics license applications ("BLA") to the FDA,</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation), (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf. The Company also estimates manufacturing costs based on services performed pursuant to contracts with contract manufacturing organizations that develop and manufacture product on the Company&#8217;s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company&#8217;s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employees on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation costs are based on the fair value of the underlying RSUs and options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period.</span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Determining the appropriate fair value model and related assumptions requires judgment, including estimating expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share because the effects of potentially dilutive securities are antidilutive.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company&#8217;s cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Management </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting: Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annual and interim requirements under ASU 2023-07 on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2025, respectively. The adoption of ASU 2023-07 did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company's consolidated financial statements. See Note 10</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes: Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890048401840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1 Inputs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2 Inputs: </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than quoted prices included in Level 1 inputs that are observable for the asset or </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3 Inputs: </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On a recurring basis, the Company measures certain financial assets and liabilities at fair value. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.467%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:9.946%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,680</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,680</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,847</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,847</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,424</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,519</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,424</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,519</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309,271</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309,366</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.467%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:9.946%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,933</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,933</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,622</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,622</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,596</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,606</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,596</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,606</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,218</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,228</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the investments held as of December 31, 2024 had original maturities of less than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, all of the investments are scheduled to mature in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any credit losses. The Company determined that the decline in fair value of debt securities was not due to credit-related factors, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for expected credit losses was recorded as of December 31, 2024. There were nominal unrealized losses as of December 31, 2024, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrealized losses have been in the loss position for more than 12 months. However, the Company is planning to hold these securities until maturity and expects to recover the amortized cost basis.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the Company recognized no material realized gains or losses on financial instruments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957524192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DisclosureOfBalanceSheetComponentsAbstract', window );"><strong>Disclosure Of Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_BalanceSheetComponentsDisclosureTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheet Components</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,640</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,617</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid and other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">823</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,444</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,254</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,838</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,832</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">692</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">692</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,817</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,802</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,179</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,638</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,773</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total depreciation expense recognized for the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued and Other Current Liabilities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,992</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,833</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,607</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">602</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">501</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued and current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_BalanceSheetComponentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet components disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_BalanceSheetComponentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DisclosureOfBalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Balance Sheet Components [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DisclosureOfBalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957371872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases its offices and laboratory in Brisbane, California, or the Brisbane Lease, under a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">noncancelable lease agreement that ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> renewable option. In November 2021, the Company subleased unoccupied space for two years from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for aggregate sublease payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The sublease income, while it reduces the rent expense, is not considered in the value of the right-of-use assets or lease liabilities. The Company&#8217;s sublease income was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the operating lease right-of-use assets were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">16.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and lease liabilities were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">29.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the consolidated balance sheet. The weighted average remaining lease term is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average incremental borrowing rate used to measure the operating lease liability is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease cost for the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Variable lease payments for the years ended December 31, 2024 and 2023 were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments and related lease liabilities as of December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;box-sizing:content-box;"></td>
        <td style="width:2.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,065</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,242</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,425</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,615</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,985</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,332</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,360</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,972</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantees and Indemnifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t paid any claims or been required to defend any action related to its indemnification obligations. As of December 31, 2024, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957352992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder's Equity</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders' Equity </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Financing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 2024, the Company raised net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting underwriting discounts and offering expenses through the sale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,001,120</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and pre-funded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.249</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which equals the per share offering price for the shares of common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each pre-funded warrant. The pre-funded warrants are immediately exercisable, subject to certain beneficial ownership limitations. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#8217; equity within additional paid-in capital.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Financing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Company raised net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting underwriting discounts and offering expenses through the sale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,035,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.880</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and pre-funded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">18,379,861</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.879</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which equals the per share offering price for the shares of common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each pre-funded warrant. An entity related to one of the Company&#8217;s directors participated in the public offering and purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for an aggregate price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#8217; equity within additional paid-in capital. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,243,400</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">965,427</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the cashless and cash exercise of these pre-funded warrants in February 2024 and April 2024, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Financing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, the Company raised net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting fees and expenses through the sale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,013,834</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, pre-funded warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,696,206</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock and accompanying common warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock. The offering price per share and accompanying common warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.87125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the offering price per pre-funded warrant and accompanying common warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.87025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which equals the per share offering price for the shares of common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each such pre-funded warrant. The pre-funded warrants remain exercisable until exercised in full. The common warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.806875</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Both the pre-funded and common warrants are immediately exercisable, subject to beneficial ownership limitations. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#8217; equity within additional paid-in capital. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,582,557</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the cashless exercise of the pre-funded warrants in March 2023. The Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,901</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,739,096</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the cashless exercise of the common warrants and pre-funded warrants in June 2024 and November 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Funded and Common Warrants</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes warrant activity during the years ended December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.9%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Common Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,696,206</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,379,861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,583,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,492,923</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">322,893</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,949,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.216</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,104,615</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,543,577</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 At-the-Market ("ATM") Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into a sales agreement with TD Cowen, as sales agent, or 2024 ATM program, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. TD Cowen </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is entitled to compensation up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross proceeds for the common stock sold through the 2024 ATM program. During the year ended December 31, 2024, t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting commissions paid to TD Cowen. As of December 31, 2024, approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million remained available for the offer and sales of shares of common stock under the 2024 ATM program.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 ATM Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2021, the Company entered into a sales agreement with TD Cowen as sales agent, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under an at-the-market offering program, or 2021 ATM program. TD Cowen is entitled to compensation up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross proceeds for the common stock sold through the 2021 ATM program. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,576,067</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,646,458</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, respectively, under the 2021 ATM program for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting commissions paid to TD Cowen and other financing costs. The Form S-3 registration statement, which registered the 2021 ATM Program, expired on August 15, 2024. As a result, no further shares of common stock may be sold under the 2021 ATM Program.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the Company&#8217;s common stock have one vote for each share of common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common stockholders are entitled to dividends when, as, and if declared by the board of directors. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends had been declared by the board of directors.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock for issuance as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.089%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.676%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.676%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,594,720</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,208,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options reserved for 2020 Incentive Award Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,109,758</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,988,340</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">770,028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">495,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2021 ATM program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,619,471</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2024 ATM program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,250,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,983,924</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,338,381</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2022 Employment Inducement <br/>&#160;&#160;&#160;&#160;Award Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,359,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">758,084</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for pre-funded warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,543,577</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,493,510</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for common warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,104,615</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,715,852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,329,843</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957101152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plan</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Incentive Plan</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2020, the Company&#8217;s board of directors and stockholders adopted and approved the 2020 Incentive Award Plan, or the 2020 Plan, and the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may not grant any additional awards under the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of common stock reserved for issuance under the 2020 Plan automatically increase on the first day of January, in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of the Company&#8217;s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company&#8217;s board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards granted under the 2020 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. For the Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period but may be granted with different vesting terms.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2024 and 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,109,758</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,988,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the 2020 Plan, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Employment Inducement Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, the Company&#8217;s board of directors adopted the Annexon, Inc. 2022 Employment Inducement Award Plan, or the Inducement Plan, and together with the 2011 Plan and the 2020 Plan, the Plans. The Inducement Plan was adopted by the Company&#8217;s board of directors without stockholder approval pursuant to Nasdaq Marketplace Rule 5635(c)(4), or Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan may only be granted to newly hired employees as an inducement material to the employees entering into employment with the Company. Awards granted under the Inducement Plan expire no later than ten years from the date of grant. An aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,850,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved for issuance under the Inducement Plan. As of December 31, 2024 and 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,359,230</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">758,084</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the Inducement Plan, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents stock option activity under the Plans for the period:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.420000000000002%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,208,970</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.53</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,930</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,749,824</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.73</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">382,122</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.22</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">981,952</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.55</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,594,720</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.29</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.94</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,059</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,813,637</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.06</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.58</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,194</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The intrinsic value is the difference between the fair value of the Company&#8217;s common stock at the time of exercise and the exercise price of the stock option.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted to employees during the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.56</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the total unrecognized stock-based compensation cost related to outstanding unvested stock options was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which the Company expects to recognize over an estimated weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are share awards that entitle the holder to receive freely tradeable shares of the Company&#8217;s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder&#8217;s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a three-year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company&#8217;s common stock on the grant date.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of RSU activity under the equity incentive plan and related information is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.383%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.923%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">495,579</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.69</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">602,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.13</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197,177</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.85</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,974</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.29</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">770,028</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.28</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, unrecognized stock-based compensation expense related to outstanding unvested RSUs was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.9</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ESPP enables eligible employees to purchase shares of the Company&#8217;s common stock at the end of each offering period at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Share purchases are funded through payroll deductions of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of an employee&#8217;s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP increase automatically on the first</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">day </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of each fiscal year, by a number equal to, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or such number of shares determined by the Company&#8217;s board of directors. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,983,924</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future purchase. The ESPP generally provides for six-month consecutive offering periods beginning on May 15</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and November 15</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of each year. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. As such, stock-based compensation expense has been recorded for the years ended December 31, 2024 and 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock-based compensation expense related to the ESPP for the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total stock-based compensation expense recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.6%;box-sizing:content-box;"></td>
        <td style="width:2.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,878</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,763</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,305</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,433</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,183</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the value of stock option awards for stock-based compensation purposes, the Company uses the Black-Scholes option pricing model and the assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The fair value of each share of underlying common stock is based on the closing price of the Company&#8217;s common stock as reported on the date of grant on the Nasdaq Global Select Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company continues using the simplified method as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Beginning in 2024, the expected volatility was estimated based on a weighted volatility using both the Company&#8217;s trading history for its common stock and the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. Prior to 2024, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.16%;box-sizing:content-box;"></td>
        <td style="width:3.24%;box-sizing:content-box;"></td>
        <td style="width:27.68%;box-sizing:content-box;"></td>
        <td style="width:3.24%;box-sizing:content-box;"></td>
        <td style="width:27.68%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.90</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.20</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.40</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.48</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.65</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.47</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.85</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957514064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For financial reporting purposes, loss before provision for income taxes, includes the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.74%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,193</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,233</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,237</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each of the years ended December 31, 2024 and 2023, the Company incurred insignificant amounts for an income tax provision. The U.S. federal and California deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax provision at U.S. statutory rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,022</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,190</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,548</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,343</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,526</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,883</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,184</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,066</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,594</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Tax Assets and Liabilities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,198</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,996</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,070</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other intangibles</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,116</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,074</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,599</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,185</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,568</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,087</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,610</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,937</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,506</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,958</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,939</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,979</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,567</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,469</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,771</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,510</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,796</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,979</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,567</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2024, the Company completed a research credit study for the years ended December 31, 2020 through 2023. This resulted in true ups to the credit carryovers, which also impacted the Section 174 capitalized research expenses and net operating losses deferred tax assets disclosed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state net operating loss, or NOL, carryforwards available to offset future taxable income. Under the Tax Cuts and Jobs Act of 2017, or the Tax Act, federal NOLs generated after December 31, 2017 will be carried forward indefinitely with the yearly NOL utilization limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of taxable income. The Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">324.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of such federal NOLs that do not expire. If not utilized, the federal carryforward losses generated prior to 2018 and the state carryforward losses will expire in various amounts beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state credit carryforwards available to offset future taxable income. If not utilized, these credit carryforwards will expire in various amounts for federal purposes beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The state credits do not expire.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not some portion or all of the deferred tax assets will not be realized. Management believes that, based on available evidence, both positive and negative, it is more likely than not that the deferred tax assets will not be utilized; therefore, a full valuation allowance has been recorded. The Company&#8217;s valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively. The changes in the 2024 valuation allowance were primarily due to the addition of capitalized research and development costs, current year loss carryforwards and research and development credits. The changes in the 2023 valuation allowance were primarily due to the addition of capitalized research and development costs, current year loss carryforwards and research and development credits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of the net operating loss carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2024. Federal net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and state and local net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are not expected to expire unutilized as a result of ownership changes identified through December 31, 2024. The Company has identified $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of federal and state net operating losses, respectively, that will expire unused due to ownership changes,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that will not be able to be utilized due to ownership change limitation; these amounts have been excluded from the deferred tax assets table above. Further ownership changes subsequent to December 31, 2024 may be identified which could result in limitations to the amount of net operating losses and credits which may be utilized prior to expiration.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Uncertain Tax Benefits</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the following activity relating to the gross amount of unrecognized tax benefits (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.248%;box-sizing:content-box;"></td>
        <td style="width:1.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.917%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.917%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,388</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reductions based on tax positions related to prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,787</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,055</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,419</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of these uncertain tax positions will impact the Company&#8217;s effective tax rate if assessed. The Company&#8217;s policy is to classify interest and penalties associated with unrecognized tax benefits as income tax expense. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest or penalty accruals associated with uncertain tax benefits in its consolidated balance sheet and consolidated statement of operations for the years ended December 31, 2024 and 2023. The Company files income tax returns in the United States, various states, and Australia. The Company is not currently under examination by any major tax jurisdictions nor has it been in the past. The tax years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a1b6e2c0-03d3-4a20-b626-abcffa81b2cd;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2011 through 2024</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remain effectively open for examination by the Internal Revenue Service and most state tax authorities because of net operating losses and credit carryovers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next twelve months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957100320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding. The weighted-average number of shares of common stock used in the basic and diluted net loss per share calculation include pre-funded warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,543,577</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,492,923</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for the years ended December 31, 2024 and 2023, respectively, as the pre-funded warrants are exercisable at any time for nominal cash consideration. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.383%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.383%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,594,720</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,208,970</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares subject to Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,922</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">770,028</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">495,579</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,104,615</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,485,285</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,149,257</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957519136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Segment </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is related to the research and development of its product candidates focused on complement-mediated diseases of the body, brain and eye for which there is significant unmet medical need. The accounting policies of the one reportable segment are the same as those described in the summary of significant accounting policies. See Note 2&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The segment is managed on a consolidated basis and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results and allocate resources. In assessing the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. This includes a review of budget versus actual expenses and direct program spend, which includes clinical costs, consultant fees, manufacturing expenses, and other direct external costs.</span></span></p><div style="font-size:12pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the operations for the reportable segment during the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.02%;box-sizing:content-box;"></td>
        <td style="width:2.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - program expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,548</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - personnel</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,893</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative - personnel</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,578</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,896</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,073</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,183</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,073</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,073</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,873</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated segment net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,237</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">__________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Research and development - program expenses include other non-program specific expenses and other research expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Other general and administrative expenses include consulting and professional services fees for legal, accounting, tax, and facilities costs.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889953723296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. Management evaluates its estimates, including but not limited to the fair value of investments, operating lease right-of-use assets and liabilities, valuation of deferred tax assets and uncertain tax positions (including valuation allowance), clinical trial accruals and stock-based compensation. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the operations of Annexon, Inc. and its wholly owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s chief operating decision maker ("CODM") is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">considers</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds and short-term government bonds, are stated at fair value.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash as of December 31, 2024 relates to the letters of credit established for the Company&#8217;s office lease.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,651</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,488</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,847</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,622</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,498</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,110</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,032</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,032</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,530</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226,142</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ShortTermInvestmentsPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short-Term Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security&#8217;s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of investments sold is based on the specific-identification method. Interest on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available-for-sale debt</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities is included in interest and other income (expense), net.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation begins at the time the asset is placed in service. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The useful lives of the property and equipment are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:39.588%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:58.352%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment and furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8f39b772-731f-41b9-9d02-0d66e7276fae;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Shorter of remaining lease term or estimated useful life</span></span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. When indications of impairment are present and the estimated undiscounted future cash flows from the use of these assets is less than the assets&#8217; carrying value, the related assets will be written down to fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairments of the Company&#8217;s long-lived assets for the periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. The Company includes operating leases in operating lease right of use, or ROU, assets, current and noncurrent operating lease liabilities in the Company&#8217;s consolidated balance sheets. The ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company measures the ROU assets based on the associated lease liabilities adjusted for any lease incentives such as tenant improvement allowances. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the commencement date. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Lease expense for lease payments is recognized on a straight-line basis, net of sublease income, over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a practical expedient, the Company elected, for all facility leases, not to separate non-lease components from lease components and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred taxes to the amounts expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merit, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liabilities</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company&#8217;s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company&#8217;s product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company&#8217;s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company&#8217;s behalf; (iii) contract manufacturing costs to produce clinical trial materials </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and commercial materials to support future biologics license applications ("BLA") to the FDA,</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation), (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf. The Company also estimates manufacturing costs based on services performed pursuant to contracts with contract manufacturing organizations that develop and manufacture product on the Company&#8217;s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company&#8217;s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employees on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation costs are based on the fair value of the underlying RSUs and options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Determining the appropriate fair value model and related assumptions requires judgment, including estimating expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share because the effects of potentially dilutive securities are antidilutive.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company&#8217;s cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Management </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted/Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting: Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annual and interim requirements under ASU 2023-07 on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2025, respectively. The adoption of ASU 2023-07 did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company's consolidated financial statements. See Note 10</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes: Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957520384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,651</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,488</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,847</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,622</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,498</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,110</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,032</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,032</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,530</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226,142</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Useful Lives of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The useful lives of the property and equipment are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:39.588%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:58.352%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment and furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8f39b772-731f-41b9-9d02-0d66e7276fae;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Shorter of remaining lease term or estimated useful life</span></span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash and cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889956869472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.467%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:9.946%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,680</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,680</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,847</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,847</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,424</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,519</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,424</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,519</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309,271</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309,366</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.467%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:9.946%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.946999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,933</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,933</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,622</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,622</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,596</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,606</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,596</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,606</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,218</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,228</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890040918992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DisclosureOfBalanceSheetComponentsAbstract', window );"><strong>Disclosure Of Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,640</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,617</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid and other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">823</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,444</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,254</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,838</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,832</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">692</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">692</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,817</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,802</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,179</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,638</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,773</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,992</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,833</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,607</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">602</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">501</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued and current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DisclosureOfBalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Balance Sheet Components [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DisclosureOfBalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890134298208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments and Related Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments and related lease liabilities as of December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;box-sizing:content-box;"></td>
        <td style="width:2.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,065</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,242</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,425</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,615</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,985</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,332</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,360</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,972</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890049732320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes warrant activity during the years ended December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.9%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Common Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,696,206</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,379,861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,583,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,492,923</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">322,893</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,949,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.216</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,104,615</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,543,577</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock for issuance as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.089%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.676%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.676%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,594,720</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,208,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options reserved for 2020 Incentive Award Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,109,758</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,988,340</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">770,028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">495,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2021 ATM program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,619,471</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2024 ATM program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,250,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,983,924</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,338,381</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for 2022 Employment Inducement <br/>&#160;&#160;&#160;&#160;Award Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,359,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">758,084</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for pre-funded warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,543,577</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,493,510</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved for common warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,104,615</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,715,852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,329,843</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955941760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents stock option activity under the Plans for the period:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.420000000000002%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,208,970</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.53</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,930</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,749,824</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.73</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">382,122</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.22</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">981,952</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.55</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,594,720</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.29</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.94</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,059</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,813,637</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.06</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.58</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,194</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity under Equity Incentive Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of RSU activity under the equity incentive plan and related information is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.383%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.923%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">495,579</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.69</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">602,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.13</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197,177</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.85</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,974</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.29</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">770,028</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.28</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total stock-based compensation expense recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.6%;box-sizing:content-box;"></td>
        <td style="width:2.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,878</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,763</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,305</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,433</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,183</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.16%;box-sizing:content-box;"></td>
        <td style="width:3.24%;box-sizing:content-box;"></td>
        <td style="width:27.68%;box-sizing:content-box;"></td>
        <td style="width:3.24%;box-sizing:content-box;"></td>
        <td style="width:27.68%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.90</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.20</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.40</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.48</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.65</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.47</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.85</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957058336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of Loss Before Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For financial reporting purposes, loss before provision for income taxes, includes the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.74%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,193</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,233</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,237</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax provision at U.S. statutory rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,022</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,190</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,548</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,343</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,526</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,883</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,184</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,066</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,594</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,198</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,996</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,070</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other intangibles</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,116</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,074</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,599</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,185</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,568</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,087</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,610</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,937</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,506</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,958</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,939</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,979</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,567</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,469</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,771</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,510</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,796</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,979</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,567</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the following activity relating to the gross amount of unrecognized tax benefits (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.248%;box-sizing:content-box;"></td>
        <td style="width:1.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.917%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.917%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,388</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reductions based on tax positions related to prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,787</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,055</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,419</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890040845424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.383%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.383%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,594,720</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,208,970</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares subject to Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,922</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">770,028</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">495,579</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,104,615</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427,508</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,485,285</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,149,257</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955675744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operations for Reportable Segment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the operations for the reportable segment during the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.02%;box-sizing:content-box;"></td>
        <td style="width:2.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - program expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,548</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - personnel</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,893</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative - personnel</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,578</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,896</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,073</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,183</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,073</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,073</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,873</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated segment net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,237</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">__________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Research and development - program expenses include other non-program specific expenses and other research expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Other general and administrative expenses include consulting and professional services fees for legal, accounting, tax, and facilities costs.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957484064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 710,699<span></span>
</td>
<td class="nump">$ 572,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short-term investments</a></td>
<td class="nump">$ 312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890047549776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairments of long-lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member', window );">ASU 2023-07 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, ASU adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, ASU, adoption date</a></td>
<td class="text">Jan.  01,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, ASU, Immaterial effect</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955477632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,651<span></span>
</td>
<td class="nump">$ 8,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">46,847<span></span>
</td>
<td class="nump">216,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">49,498<span></span>
</td>
<td class="nump">225,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 50,530<span></span>
</td>
<td class="nump">$ 226,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955966592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889954406720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 309,271<span></span>
</td>
<td class="nump">$ 251,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">309,366<span></span>
</td>
<td class="nump">251,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">46,847<span></span>
</td>
<td class="nump">216,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">46,847<span></span>
</td>
<td class="nump">216,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Cash and Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">31,680<span></span>
</td>
<td class="nump">143,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">31,680<span></span>
</td>
<td class="nump">143,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Cash and Cash Equivalents [Member] | Government Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">15,167<span></span>
</td>
<td class="nump">72,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">15,167<span></span>
</td>
<td class="nump">72,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">262,424<span></span>
</td>
<td class="nump">34,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">262,519<span></span>
</td>
<td class="nump">34,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-Term Investments [Member] | Government Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">262,424<span></span>
</td>
<td class="nump">34,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 262,519<span></span>
</td>
<td class="nump">$ 34,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955670496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_InvestmentMaturityPeriod', window );">Investment maturity period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized loss position for more than 12 months</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_InvestmentExpectedMaturityPeriod', window );">Investment expected maturity period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_InvestmentExpectedMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment expected maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_InvestmentExpectedMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_InvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_InvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889953579472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="nump">$ 2,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_PrepaidAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,444<span></span>
</td>
<td class="nump">$ 4,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_PrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid and other assets current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_PrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_PrepaidResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>prepaid research and development costs, current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_PrepaidResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955599872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 19,817<span></span>
</td>
<td class="nump">$ 19,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(7,179)<span></span>
</td>
<td class="num">(5,029)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">12,638<span></span>
</td>
<td class="nump">14,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">17,254<span></span>
</td>
<td class="nump">17,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=annx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955047936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890041041040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 10,992<span></span>
</td>
<td class="nump">$ 4,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">5,833<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued and current liabilities</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_AccruedAndOtherLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 17,568<span></span>
</td>
<td class="nump">$ 10,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation, current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses, current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889949441328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Claim</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_AggregateSubleasePaymentReceivable', window );">Aggregate sublease payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,705,000<span></span>
</td>
<td class="nump">18,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency pending claims | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=annx_BrisbaneCaliforniaMember', window );">Brisbane, California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_LesseeOperatingLeaseExpirationMonthAndYear', window );">Operating lease, expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2031-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_LesseeOperatingSubleaseCommencementYearAndMonth', window );">Sublease starting year and month</a></td>
<td class="text">2021-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_LesseeOperatingSubleaseExpirationYearAndMonth', window );">Sublease expiration year and month</a></td>
<td class="text">2023-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_AggregateSubleasePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate sublease payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_AggregateSubleasePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_LesseeOperatingLeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_LesseeOperatingLeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_LesseeOperatingSubleaseCommencementYearAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease commencement year and month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_LesseeOperatingSubleaseCommencementYearAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_LesseeOperatingSubleaseExpirationYearAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease expiration year and month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_LesseeOperatingSubleaseExpirationYearAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average incremental borrowing rate percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=annx_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=annx_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889953343392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 5,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">5,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">5,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">5,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter', window );">2029 and thereafter</a></td>
<td class="nump">16,985<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">38,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(9,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 28,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889949970144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the Company&#8217;s common stock have one vote for each share of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,369,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,381,556<span></span>
</td>
<td class="nump">78,369,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,371<span></span>
</td>
<td class="nump">$ 17,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,379,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,379,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_OfferingPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.87025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember', window );">Pre-funded Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,696,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants or Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_OfferingPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.87125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.806875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants or Common Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,427,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,326,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants', window );">Common stock shares issued for exercise of warrants</a></td>
<td class="nump">2,739,096<span></span>
</td>
<td class="nump">19,901<span></span>
</td>
<td class="nump">965,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,013,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriting agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,001,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_CommonSharesExchangeValue', window );">Exchange value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriting agreement [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=annx_SalesAgreementWithCowenAndCompanyLLCMember', window );">Sales Agreement with Cowen and Company LLC [Member] | 2021 ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_PercentageOfGrossProceedsOfCommonStockToBePaid', window );">Percentage of gross proceeds of common stock to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,646,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,576,067<span></span>
</td>
<td class="nump">2,646,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,400<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=annx_SalesAgreementWithCowenAndCompanyLLCMember', window );">Sales Agreement with Cowen and Company LLC [Member] | 2024 ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock', window );">Remains available for offer and sales of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=annx_SalesAgreementWithCowenAndCompanyLLCMember', window );">Sales Agreement with Cowen and Company LLC [Member] | 2024 ATM Program [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_PercentageOfGrossProceedsOfCommonStockToBePaid', window );">Percentage of gross proceeds of common stock to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=annx_SalesAgreementWithCowenAndCompanyLLCMember', window );">Sales Agreement with Cowen and Company LLC [Member] | 2024 ATM Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_CommonSharesExchangeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares exchange value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_CommonSharesExchangeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_OfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_OfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_PercentageOfGrossProceedsOfCommonStockToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds of common stock to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_PercentageOfGrossProceedsOfCommonStockToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remained available for offer and sales of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=annx_SalesAgreementWithCowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=annx_SalesAgreementWithCowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoOneAtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoOneAtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoFourAtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoFourAtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889950268736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Warrants Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Number of Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning Balance</a></td>
<td class="nump">8,427,508<span></span>
</td>
<td class="nump">8,427,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ClassOfWarrantOrRightExcercised', window );">Exercised</a></td>
<td class="num">(322,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">8,104,615<span></span>
</td>
<td class="nump">8,427,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember', window );">Number of Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning Balance</a></td>
<td class="nump">40,492,923<span></span>
</td>
<td class="nump">24,696,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ClassOfWarrantOrRightIssued', window );">Issued</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">18,379,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ClassOfWarrantOrRightExcercised', window );">Exercised</a></td>
<td class="num">(8,949,346)<span></span>
</td>
<td class="num">(2,583,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">38,543,577<span></span>
</td>
<td class="nump">40,492,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=annx_CommonWarrantAndPreFundedWarrantsMember', window );">Common Warrant and Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued', window );">Weighted-Average Exercise Price, Issued</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">$ 0.216<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ClassOfWarrantOrRightExcercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right excercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ClassOfWarrantOrRightExcercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right weighted average exercise price of warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or right, weighted-average exercise price of warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=annx_CommonWarrantAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=annx_CommonWarrantAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957837024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock reserved</a></td>
<td class="nump">14,594,720<span></span>
</td>
<td class="nump">9,208,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved</a></td>
<td class="nump">2,109,758<span></span>
</td>
<td class="nump">1,988,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">93,715,852<span></span>
</td>
<td class="nump">65,329,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock reserved</a></td>
<td class="nump">14,594,720<span></span>
</td>
<td class="nump">9,208,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember', window );">Stock Options Reserved for 2020 Incentive Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved</a></td>
<td class="nump">2,109,758<span></span>
</td>
<td class="nump">1,988,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=annx_UnvestedRestrictedStockUnitsOutstandingMember', window );">Unvested Restricted Stock Units Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">770,028<span></span>
</td>
<td class="nump">495,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=annx_EmployeeStockPurchasePlanMember', window );">Common Stock Reserved for Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">1,983,924<span></span>
</td>
<td class="nump">1,338,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember', window );">2022 Employment Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">3,359,230<span></span>
</td>
<td class="nump">758,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=annx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">38,543,577<span></span>
</td>
<td class="nump">40,493,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=annx_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">8,104,615<span></span>
</td>
<td class="nump">8,427,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoOneAtTheMarketProgramMember', window );">2021 ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoFourAtTheMarketProgramMember', window );">2024 ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">24,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=annx_UnvestedRestrictedStockUnitsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=annx_UnvestedRestrictedStockUnitsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=annx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=annx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=annx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=annx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=annx_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=annx_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoOneAtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoOneAtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoFourAtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=annx_TwoZeroTwoFourAtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955019712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear', window );">Percentage of number of shares of capital stock outstanding on last day of preceding year</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock option grants description</a></td>
<td class="text">Awards granted under the 2020 Plan expire no later than ten years from the date of grant. For the Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than 100% of the estimated fair value on the date of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiry period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">2,109,758<span></span>
</td>
<td class="nump">1,988,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, Stock options granted</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost expected period for recognition</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock for future issuance</a></td>
<td class="nump">93,715,852<span></span>
</td>
<td class="nump">65,329,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,433<span></span>
</td>
<td class="nump">$ 18,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, Stock options granted</a></td>
<td class="nump">$ 4.56<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=annx_EmploymentInducementIncentivePlanMember', window );">2022 Employment Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">3,359,230<span></span>
</td>
<td class="nump">758,084<span></span>
</td>
<td class="nump">7,850,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember', window );">Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase of Common stock at end of each offering period at price equal to percentage of fair market value of shares</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="nump">$ 33,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost expected period for recognition</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=annx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase of Common stock at end of each offering period at price equal to percentage of fair market value of shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Share purchases funded through payroll deductions minimum percentage of employee's eligible compensation</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Share purchases funded through payroll deductions maximum percentage of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock for future issuance</a></td>
<td class="nump">1,983,924<span></span>
</td>
<td class="nump">1,338,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear', window );">Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of number of shares of capital stock outstanding on last day of preceding year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award minimum employee subscription rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=annx_EmploymentInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=annx_EmploymentInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=annx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=annx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955157008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Beginning balance</a></td>
<td class="nump">9,208,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Stock options granted</a></td>
<td class="nump">6,749,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Stock options exercised</a></td>
<td class="num">(382,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Stock options forfeited</a></td>
<td class="num">(981,952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Ending balance</a></td>
<td class="nump">14,594,720<span></span>
</td>
<td class="nump">9,208,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Vested and Exercisable</a></td>
<td class="nump">6,813,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, Beginning balance</a></td>
<td class="nump">$ 10.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, Stock options granted</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, Stock options exercised</a></td>
<td class="nump">3.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, Stock options forfeited</a></td>
<td class="nump">11.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, Ending balance</a></td>
<td class="nump">8.29<span></span>
</td>
<td class="nump">$ 10.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, Exercisable</a></td>
<td class="nump">$ 11.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- average remaining contractual term</a></td>
<td class="text">7 years 11 months 8 days<span></span>
</td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- average remaining contractual term, Exercisable</a></td>
<td class="text">6 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 4,059<span></span>
</td>
<td class="nump">$ 2,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">$ 2,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955676560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Summary of RSU Activity under Equity Incentive Plan (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested as of December 31, 2023 | shares</a></td>
<td class="nump">495,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">602,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(197,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Cancelled | shares</a></td>
<td class="num">(130,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested as of December 31, 2024 | shares</a></td>
<td class="nump">770,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2023 | $ / shares</a></td>
<td class="nump">$ 5.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="nump">5.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="nump">5.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Cancelled | $ / shares</a></td>
<td class="nump">5.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2024 | $ / shares</a></td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955029568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Summary of Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,433<span></span>
</td>
<td class="nump">$ 18,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">9,670<span></span>
</td>
<td class="nump">8,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,763<span></span>
</td>
<td class="nump">$ 9,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957823024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">95.90%<span></span>
</td>
<td class="nump">81.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">99.80%<span></span>
</td>
<td class="nump">82.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">3.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.65%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890040921296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (138,193)<span></span>
</td>
<td class="num">$ (134,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (138,200)<span></span>
</td>
<td class="num">$ (134,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955802192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax provision at U.S. statutory rate</a></td>
<td class="num">$ (29,022)<span></span>
</td>
<td class="num">$ (28,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(9,526)<span></span>
</td>
<td class="num">(3,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">35,184<span></span>
</td>
<td class="nump">29,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IncomeTaxRateReconciliationSection162MCompensation', window );">Section 162(m) compensation</a></td>
<td class="nump">1,773<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_IncomeTaxRateReconciliationSection162MCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax rate reconciliation section 162(m) compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_IncomeTaxRateReconciliationSection162MCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955363120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 94,198<span></span>
</td>
<td class="nump">$ 70,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">29,095<span></span>
</td>
<td class="nump">16,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DeferredTaxAssetsOtherIntangibleAssets', window );">Other intangibles</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">5,599<span></span>
</td>
<td class="nump">5,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">49,837<span></span>
</td>
<td class="nump">36,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">6,087<span></span>
</td>
<td class="nump">6,610<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">185,937<span></span>
</td>
<td class="nump">136,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(180,958)<span></span>
</td>
<td class="num">(130,939)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">4,979<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(1,469)<span></span>
</td>
<td class="num">(1,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(3,510)<span></span>
</td>
<td class="num">(3,796)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(4,979)<span></span>
</td>
<td class="num">(5,567)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DeferredTaxAssetsOtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DeferredTaxAssetsOtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955447392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 367,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">$ 223,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome', window );">Percentage of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear', window );">State carryforward losses expiration beginning year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 30,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest or penalty accruals</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year examination</a></td>
<td class="text">2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration', window );">NOLs with annual limitation utilization that do not expire</a></td>
<td class="nump">$ 324,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 33,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear', window );">Federal carryforward losses expiration beginning year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs do not expire</a></td>
<td class="nump">$ 367,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">NOLs subject to expire</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Federal credits</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs do not expire</a></td>
<td class="nump">189,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">NOLs subject to expire</a></td>
<td class="nump">$ 34,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets credit carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards annual limitation utilization not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, operating loss carryforwards, expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards, limitations on use, percentage of taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889956886224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 3,970<span></span>
</td>
<td class="nump">$ 2,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior year</a></td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions based on tax positions related to prior year</a></td>
<td class="num">(1,726)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 8,419<span></span>
</td>
<td class="nump">$ 3,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889955388032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail) - Pre-funded Warrants [Member] - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">18,379,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">38,543,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,492,923<span></span>
</td>
<td class="nump">24,696,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,696,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember', window );">Maximum [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercised</a></td>
<td class="nump">38,543,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,492,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=annx_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890048217152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">23,485,285<span></span>
</td>
<td class="nump">18,149,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Shares Subject to Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">15,922<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">14,594,720<span></span>
</td>
<td class="nump">9,208,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">770,028<span></span>
</td>
<td class="nump">495,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">8,104,615<span></span>
</td>
<td class="nump">8,427,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45890040763696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">The segment is managed on a consolidated basis and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results and allocate resources. In assessing the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. This includes a review of budget versus actual expenses and direct program spend, which includes clinical costs, consultant fees, manufacturing expenses, and other direct external costs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45889957804176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Operations for Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 119,448<span></span>
</td>
<td class="nump">$ 113,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">34,625<span></span>
</td>
<td class="nump">29,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,433<span></span>
</td>
<td class="nump">18,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">154,073<span></span>
</td>
<td class="nump">143,723<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(154,073)<span></span>
</td>
<td class="num">(143,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_InterestAndOtherNonOperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">15,873<span></span>
</td>
<td class="nump">9,486<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(138,200)<span></span>
</td>
<td class="num">(134,237)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative expenses</a></td>
<td class="nump">22,073<span></span>
</td>
<td class="nump">16,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">2,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,433<span></span>
</td>
<td class="nump">18,183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">154,073<span></span>
</td>
<td class="nump">143,723<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(154,073)<span></span>
</td>
<td class="num">(143,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_annx_InterestAndOtherNonOperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">15,873<span></span>
</td>
<td class="nump">9,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Program Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">79,548<span></span>
</td>
<td class="nump">76,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Personnel Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24,291<span></span>
</td>
<td class="nump">23,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="nump">$ 6,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_annx_InterestAndOtherNonOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and other non operating income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">annx_InterestAndOtherNonOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>annx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=annx_ProgramExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=annx_ProgramExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=annx_PersonnelExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=annx_PersonnelExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MQO#= U6[#<$VV2-&"R8$"[.7:TH\RM,=Y.=+QL1^(_V"XK&VF_\ 4$L#!!0
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M:;!R-LT"[S90-@#G-U*:QXXMG_UMF?X!4$L#!!0    ( $B!8UIL,4IGF@,
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M,!#^*Z<PH4V"I4V[EHTT4MLQP<-0M3)X0#RXR:6QYMC!=MKMWW-VTM!!._'
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M9.]\?!& ;N9.<["J\JV[4I8&@=\6-*I1.P>ZSY6RNX-+T W_Y!=02P,$%
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M-*V#W6.Q(TPB"EM-Z8VF>N9%ZPIMH'AE!VO#E1Y3NRRTD8(P"?I\R[DZ!*9
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M!LF9%T%EK&1 (40.LF"<F%3HG'#" 0Q2!,GVA<JX&RMU*.SU7*-6UY: &\,
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M[+!!1F]$:ZMCB7[9J)"JH>W** R"Z/SNS+-1D0LJ=&"T6!C1+P^12J#&Y4E
M6UIZ'3)E>4@WRFCXL5J1L@5M5<!^[GSM?"_\#H:WRK,\?U0^+\&KZ?3(_+/O
M7L^FK]X&VI;.F-V9VUKHAB8+NM"84\,>1UIJ%T @FR._ZT8H9.#Z-N[H0RSV
M^-X=:":(:^]JKSEB!5A46D+K4?TZ7D1WD9(I7 4D3;NZ=S:B#_I+ ^OP>0==
MR2OG6JH]/"PNE< B8[;8WSBS@1F$@*FKC?A$9;S,<ZF#D#@!D[SR!F.Z3K5,
M\U)'-,P0X=JBR5/=>L)0]%H9[)4ZD0(F@P-09I@L>:5#$E>UCB+M &F-3&/:
MYOM:_A!RX -/QW67)" (T@GF!4@0P(VD;WFM9)S#?BAIA:,%E/.N(IQ6/K$_
M4&@!BN$!)-%%?(FVF#1<9>SWTP:IJ (2B"=OJJ9C)*]0AR@*W].KZ63T"E/8
MF,Y6ZW[_P*C-1AF@UT892N1[%ME74@<.L4I;R=9\.AM->EO_SKO4&/U>@$;%
M5HU,UY3*07ZQ]*Y9EZGN.H1&2;JP'=# G+R( IA6(5A8RS]W;>*]0A@C6J+5
M"L(F&/H73DF\'!:]4A8C(7&A$Q"?*J(FNNWA_Y7]%BD36Y5A-!Q2%@R1/ ^S
MA NIO^VKWI,I+:()&C2V%[>>6]LR=1"@P1")%+<,YE/5'E")'>*O0%T3. >0
MM3Q<:8L%L!IH02B9/#TJ5DWRO=$JTT::,>.=2WR&]]II0(;6+UC"%/R L:35
M2R-5E9<:S7;4<2 #4'*VR]9E$9<J4@4R1<$1EN #4$889?O2"!:I,DZZ%)@U
M+,^@?.._M6..X4/>F'N1 D+$]*$=YD2+!U*7F=H /2\Q"E_05<$!/&%1&O7Q
M!&X' #R?OCB1H103^XBCX"SV%0$/@* PJ6.@>%^I#>9F8I$[/MB>SUZ 8! '
M"@D68U0F,U;25VO/W#,18<IDC;S6.=7*1XLIU@ZPY_,7F%AYSNT(EO)U57\
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MY^EF'BAU?75];=XVE_^KZLY[9U[]<GBK_!R5PTZ9P;77.1FVJM-@^Q#=,MV
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MU1Z'P<A 07=1RU)_CYW+NI:Y_KD2'-A""_!\(8%Z[04IZ#_07_T;4$L#!!0
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M.>QY(-6KK._Z(B=D>'AJ]%"ES^[1C(3ZDZ)# R*^>:4+[/"3&72.LKZWMG-
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M7VJ$1]6T3&ZA8*+H!+-H7*GS B39"V??DKWQ]JLME/R5EQ3/]VU:M(2S\9<
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MI,]LO(#&%V]6X=*W,!ZOD&&YQ#L[6%) >6GP8&I?R$'W7\#\/U!+ P04
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M(G[8->( KR^)@#SIC23;UM'8/.9[@SA.6TD*!4>FI%(OL>[]:.^7RX558TK
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M!X$_)>[<R1S8DXTQWWGQ1[6(4B:$"DO/"((^CWB/2C$0T?BQQXR.)EGQ='Y
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MS/5_"PJS0/LSSM5N8A)T?T+SOP%02P,$%     @ 2(%C6JI03['I P  6 H
M !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULK59M;]LV$/[N7T%HP9
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M^#&9(O87H6E-VC>SO2*Q&\>Q'0,<+V0Y&;*<O#W+> Q+_=WB/WSKF.7ODC]
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MM,LIS\TOM93<T2D["TP5<*F5XVJ%*N=HX>B)+03:XVGLJ);/B/,6]Z+!33_
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MDY/3402FF3Z-XW05.GZA'<V/8)8TL-'X -I?:NTVCB_0_0+F?P%02P,$%
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M&I\K:Q=$:280L]LJ2:1QS+OG)Z7IL\)8"Z*6ECX2U>VL \%X=>'\L6IF*(#
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M[8O "@17 -TEXE!3'F K*N1>6*, ;]YSX$PK6C#.#$-H(35VVK?>D/#HI6]
MU:Z?60.DZQ[]<75LF5==IWB!=_WV,U4UPQ/ H4+3Z&(^]8GJ>E@W,;)U?6,K
M#78A-]QAVP=E ;A?26F&B74P_B.Q_A=02P,$%     @ 2(%C6I84:3AL @
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MH6U_;]9V0(-V ?9\I10^.&X&#"._^ -02P,$%     @ 2(%C6@P@1ML* P
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M$*9 SZ\X5R\=<W'4_PGCOU!+ P04    " !(@6-:N&^&L/ "  "T"0  &0
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M*F=\_85M?2+9//E(]<2D9%%R."-X3+@V4/<GC,F7$_W=*_O.V?\?4$L#!!0
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M'Q;T0*%V!K2_5LH>)BY ^^2E?P%02P,$%     @ 2(%C6G1-\"BP @  9@<
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M]0Y?S[&O$XJ(KQ3VHG&-="DKQG[HP7TTLQS-"&((I88@ZFL'<XACC:1X_*Q
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M967&+DJ;8,Y70NA]8"_H!GG^!U!+ P04    " !(@6-: 0K>$=8"   ("
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M<=[<.\U$LLJT[CF3ZB(PPUQ=U<!U@'J_8$QN)OHVZ"[_Y"]02P,$%     @
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M4WTD8L4RJ;.WU$CO9J2MJ2CV)Q4'BF_R#3@+KA1/\X]K2F(JS 7Z_TO.U?'
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M:&9@4[5J;8XP\Z\\*J%7B=:I9,J+@BA]S$HBS#(TY4P1M@:6$I#H$MU6JA*
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M9H->7W&NWB>FQ[=7=/('4$L#!!0    ( $B!8UIDI^+CX X  #O9   9
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M]H$I _E^3JG8#52 ^N>#R7]02P,$%     @ 2(%C6GP&#$CX!   Y!X  !D
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M0&Q4O%K3<C9W0VA=[JUQ@8:<"^Q;$M]W'-33;C_.#3W/#T](M[4N<)1W&?@
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MJXKX?DMU?R+9MMJ5?&)2LJPZW% 24UX&J/LKQN3;2;G1V6QLS_\'4$L#!!0
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MI@%<7PFA]S_,#:KO:!;_ U!+ P04    " !(@6-:SL:3)H $  "X$P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6RUF%]SVC@0P+^*QM>Y:6<2;-GX
M7PZ8@22=ZT/O,N72/MS<@[ 7XXEM44E \NU/LAT#-BB!-#R ++2K_>U*ZY4&
M&\H>^ ) H,<\*_C06 BQO#)-'BT@)[Q'EU#(?^:4Y43(1Y:8?,F Q*50GIFV
M97EF3M+"& W*OCLV&M"5R-("[ACBJSPG[&D"&=T,#6P\=WQ+DX50'>9HL"0)
M3$'<+^^8?#(;+7&:0\%36B &\Z$QQE?7.%0"Y8CO*6SX3ALIE!FE#^KA2SPT
M+&419! )I8+(GS5<0Y8I3=*.G[52HYE3">ZVG[5_+N$ES(QPN*;9CS06BZ$1
M&"B&.5EEXAO=_ DUD*OT133CY3?:U&,M T4K+FA>"TL+\K2H?LEC[8@= =L]
M(F#7 O9K!9Q:P"E!*\M*K!LBR&C Z 8Q-5IJ4XW2-Z6TI$D+%<:I8/+?5,J)
MT>W/52J>T)<B@D(Y%-UEI$"7:%J%%=$YF@H:/:"_EZ7;Q\KM2N+C#0B29I_D
MV/OI#?KXX1/Z@$S$%X0!1VF![HM4\ O9*=O_+.B*DR+F U-(H]749E0;.*D,
MM(\8B&WTE19BP=%M$4.\K\"4M VR_8P\L;4:;R#J(0=?(-NR^P<,NGZ]N*,Q
MQVDBX)3ZO"/ZILICEQ.Y%&-T1Y[D%A%HS!@I$BC;_XYG7#"YW/\[Y+Q*MW-8
MM\H!5WQ)(A@:<I-S8&LP1K__ACWKCT/@OTC9GAOZC1OZ.NVCOU;Y#)A:;]42
MND 32-*B2(M$[E.Y*",XQ%\I=4NE*F6M1Z%M!:%O#<SU+IIV\C/1W ;-/1&M
MVE*TW%(<)3+8HKVT*SRW@^?Y_3!0ZW8/3VO F7A>@^>]"0\>@44I/PSH=0 O
MG<#&MMT"U)IP)J#? /IO I0OTSFD1R+H=P'# (=N&U!KPIF 00,8G @H<^T+
M&R_H<.&^&_9]N[WSN@/;.W3/YK"Q.3S1YN_ 90R0?,V@VVK)D5EVT/:PNZL"
M['B.WS)=:\&9,<'6]LUL:0E_E"4(Q)>(K(')FJK926C)TDA^2_X2_I6YLIXO
MW(V9U7-PBUIOUKG8.P4)_F78K\ZC]9S8VV%W>[[31M>:=BZZO46WWPE=FV/K
M6??@G5XGQ>J-.Q=^6P9A;7GQ!GAM_JUGW8/'N.>Z;?KW*'[PMOK!^O+G%/J7
MDW,]V1YTT+.#</?3=D#_A>RP3[8M?K"^^CF)3)^WZYG"_5!:7IOD/:HAO"V'
ML+X>Z@(S4 =J%;-('F54+;\B&1+ \H.4>O4^>@+".,(8Y=7!*$ Q>3ITM+I^
MI2KO61.V#JC:=\.V:,+ZJND4-[P<>?U<7AO$#H_[Y#TJ+;PMM;"^UAHG"8.$
M")#G8L'2@J<16I-L=1B[TN7O+/B^Y79V;G>4'3I'ZBN\+;"POL(Z:NG+T0J[
M!N&P?6;13W]J(,R=.Y <6%)>#7&YTE:%J.X&FM[F^FE<7KJT^B?J6JJ\6]FJ
MJ>ZTOA(FJRR.,IA+E5;/EWF&5==$U8.@R_*F94:%H'G97 ")@:D!\O\YI>+Y
M04W07-:-_@=02P,$%     @ 2(%C6F-<J"U# P  % L  !D   !X;"]W;W)K
M<VAE971S+W-H965T-3 N>&ULM99?;YLP$,"_BL6F:9/6\B] TB5(2;MN?=@4
M-6KW,.W!@4N""G9FFZ25]N%W-I1D*B&KU+Z ;7QWOSON[!MNN;B3*P!%[HN<
MR9&U4FI]9MLR64%!Y2E? \,O"RX*JG JEK9<"Z"I$2IRVW.<T"YHQJQX:-:F
M(A[R4N49@ZD@LBP**AXFD//MR'*MQX7K;+E2>L&.AVNZA!FHF_54X,QNM*19
M 4QFG!$!BY$U=L\FKJ\%S([;#+9R;TRT*W/.[_3D*AU9CB:"'!*E55!\;> <
M\EQK0H[?M5*KL:D%]\>/VB^-\^C,G$HXY_F/+%6KD=6W2 H+6N;JFF^_0NU0
MH/4E/)?F2;;U7L<B22D5+VIA)"@R5KWI?1V(/0'?.R#@U0*>X:X,&<H+JF@\
M%'Q+A-Z-VO3 N&JD$2YC^J_,E,"O&<JI^//O,E,/Y(HEP'1\R#2GC)R06?67
M"%^0Z]D-&>O@Z8TE2T&0=JGW%Z!HEG\8V@K)M'X[J2DF%85W@,+UR#?.U$J2
MSZ@__5>!C2XU?GF/?DV\3HT7D)P2W_U(/,?KD;?$)G)%!<CZU6'!;R+G&POA
M 0LSK>AD@AF1DBE]P$Q59"P$94LPXY_CN50"L^Y76SPJW7Z[;EV*9W)-$QA9
M6&L2Q :L^-T;-W0^=9#W&O)>E_;X>UG,\2?BKS4^R(_DAFU *G2$2KV,P0.S
MI0Z@3_ZTQJURI3(6&&/Z$-C$O4$01(.AO6F!#!K(X)F07S"VFK&+)7C"$CI>
MZ#CM+&'#$CZ3Y;8*5Q=*^ 3EQ!U$;A2ULT0-2_1,EG.*99CG1W"B%AS?&42]
M=IQ^@]-_V5SJ=5+VGU!&D>-X_7;(00,YZ(3\8<YF2$_&&Q!XUU2I1/# !'))
M,T%N:5[B(8:4QHM=KOU'8>S.EC:'*K#!GD/!:7B@-%QG=V@[K^30,=[:L!O^
M0^SZ!XCWKAGWA8F;$CL"[+8!]X,#P-X.V'MAX/TZ/,+LM3%[A])B=R.YG=?&
MZ^5Y[[A+?DNB/ZE;>Z]1*4 L33LF2<)+IJJ>I5EM6KYQU>CLME?]XC<JEAF3
M)(<%BCJG$1X:HFK!JHGB:]/VS+G")LH,5]BV@M ;\/N"<_4XT0::1CC^"U!+
M P04    " !(@6-:**O),S0#  #6"P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U,2YX;6S%5EUOVC 4_2M7V32UTMI\08 .(O'1;956"95U>YCV8)(+B9K8
MU#;0_OO93IH&EJ)58NH+V,Z]Q^<<WSBWOV7\3B2($A[RC(J!E4BYNK!M$268
M$W'.5DC5DP7C.9%JRI>V6'$DL4G*,]MSG,#.24JML&_6ICSLL[7,4HI3#F*=
MYX0_CC!CVX'E6D\+-^DRD7K!#OLKLL09RMO5E*N97:'$:8Y4I(P"Q\7 &KH7
M8]?1"2;B1XI;41N#EC)G[$Y/KN*!Y6A&F&$D-011?QL<8Y9I),7CO@2UJCUU
M8GW\A/[9B%=BYD3@F&4_TU@F ZMK08P+LL[D#=M^Q5)06^-%+!/F%[9EK&-!
MM!:2Y66R8I"GM/@G#Z41M00W>"'!*Q.\_836"PE^F> ;H04S(VM") G[G&V!
MZVB%I@?&&Y.MU*14'^-,<O4T57DRO+Q?I_(1KFB$5!L*TXQ0.(-9<:S %C"3
M++H[&RFO8ABS7!60(.8(+A_T&.%D@I*DV:E*NYU-X.3]*;R'E,+WA*T%H;'H
MVU)1U1O:44EK5-#R7J#E>G#-J$P$7-(8XUT 6VFLA'I/0D?>0<0)1N?@NQ_!
M<[Q6 Z'QOZ?[!^CXE>^^P0M>P)LEA",TF#KDG- EJC=%PN@1ZG%3\FB6AUO"
M8_CU34'"E<1<_&XRN-C?;]Y?WPX78D4B'%CJ]1?(-VB%']ZY@?.IR9PC@>U8
MU:JL:AU"#[\S23(0I@KGQHBH;A@65=AD08';,;CZ/MN$;J_EJ^/;U+4U1'7=
M[G/4#NEV1;I]D/2-LH'P* %5_S#!C;HO5^;P?EUC/D?>>&0'(5][9$<"VU$?
M5.J#-Z[NX)A6'0ELQZI.957G/U5W@=NNU6TOZ#A[Q?UW4+?;Z3;7=K>BW#U(
M^0M2Y(JT+NUAK#Y*J9"<F*_'H>H^"/K:(SL2V([^7J6_]\;5W3NF54<"V['*
M=9[["^<_U7<)7+^8>YU@__9NBO*=]EZ%V[4.*4>^-(VC4%365!8]1+5:-:=#
MTY+MK8]TTVHZKV>8HN.])GR94@$9+A2D<]Y1+QTOFLAB(MG*]&%S)E579X:)
M:KR1ZP#U?,&8?)KH#:I6/OP#4$L#!!0    ( $B!8UIT&\HQJP,  &4.   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;,57:V_B.!3]*U=9:34K39L'
M[RX@%<K,5-IJ45%G/XSV@YM<B(5C,[:!\N_'=D* *D3M#-+T0[&=>T_..7[$
MM[\5<JE21 TO&>-JX*5:KVY\7\4I9D1=BQ5R\V0N9$:TZ<J%KU822>*2,N9'
M0=#V,T*Y-^R[L:D<]L5:,\IQ*D&MLXS(W0B9V Z\T-L//-)%JNV /^ROR )G
MJ)]64VEZ?HF2T RYHH*#Q/G NPUOQF'#)KB(KQ2WZJ@-5LJS$$O;N4\&7F 9
M(<-86PAB?C8X1L8LDN'QO0#URG?:Q./V'OV3$V_$/!.%8\'^HXE.!U[7@P3G
M9,WTH]A^P4)0R^+%@BGW'[9%;.!!O%9:9$6R89!1GO^2E\*(HX2P<R8A*A*B
MMR8TB@3GG)\S<[+NB";#OA1;D#;:H-F&\\9E&S64VVF<:6F>4I.GAY/O:ZIW
M<,]CY-90F#+"X0IF^;2"F,,G0B5\)6R-MC<A<0HS+>(E_+MR,W&OU!H3F"A-
MC:VF9<9TBF#XN(S/DG -3XKRA1L?,1(OKV9Q*ABJ/<A4TM@&/(@$&7RX0TTH
M^ZOO:Z/1,O7C0L\HUQ.=T1-&!H+K5,&$)YB< OC&G-*A:._0**I%O,/X&AKA
M1XB"J%E!:/SV]$8-G48Y80V'USZ#-TN)-!Z:E9O 6&1F.ROB'+R5QN<%FBVF
M8;2#X[@IV;GAVRV1"7S[QT#"O<9,_5]E</[^1O7[[;%RHU8DQH%GS@V%<H/>
M\,\_PG;P=Y4Y%P([L:I96M6L0Q].7E;FL##Z-X(9CYA9Z!_A@7*:K;,JX3E:
M&#@X>_YMAL%UK]7K^YMC295AW= <G(>_L,PY8=XJF;=^@CEY.<>\5<F\UWW%
MO#*L:U=U%=EV2;9=2_:1JN757"("Y1K--&J09NO76MVN8A(TFJ\9GXOK5%/N
ME)0[/TGYO,>=2BK-=NL5Y3-QW58UY6Y)N5M+N3 3OCU@]HRR<N?6(KQWYUX(
M[$1LKQ3;^\V'7.^25ET([,2J,#A\P8.W'19F)6?P@7+8(9&J^N-9#]7*4Z$-
MF?N(5HG])8A3B4>7E+!^\>?;LG;QUT.\=THOA78J.#H(CG[S!B@(7,JN"Z&=
MVG6X$X6U]XCW;8%ZJ':Q?J,>)&17O0-^ 2$7Z!]=V#.4"U?'*(C%FNO\9EJ.
MEK72K:L07HV/; WE"H$#3%Z /1"YH%P!P[F!#*X[YN,O\YHF[VBQ<F7!L]"F
MR'#-U-2!*&V >3X70N\[]@5E93G\ 5!+ P04    " !(@6-:>E:$D*$"  #\
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6RM55UOTS 4_2M6F-"0
MV/+5IF.TD=86Q"0F3?N !\2#F]PVUA([V$X[_CW7=IJU559XX*7QQSW'Y]SZ
M7H\W0CZI D"3YZKD:N(56M>7OJ^R BJJSD4-''>60E94XU2N?%5+H+D%5:4?
M!4'B5Y1Q+QW;M5N9CD6C2\;A5A+55!65OZ=0BLW$"[WMPAU;%=HL^.FXIBNX
M!_U8WTJ<^1U+SBK@B@E.)"PGWE5X.4M,O WXQF"C=L;$.%D(\60FU_G$"XP@
M*"'3AH'B9PTS*$M#A#)^M9Q>=Z0![HZW[)^M=_2RH IFHOS.<EU,O N/Y+"D
M3:GOQ.8+M'Z&AB\3I;*_9-/&!A[)&J5%U8)10<6X^]+G-@\[@#!Y!1"U@.@0
M,'@%$+> V!IURJRM.=4T'4NQ(=)$(YL9V-Q8-+IAW/R+]UKB+D.<3J]Y)BH@
M#_09%#DC,U'5@@/7BH@E^2J4(E/ NP)D+_!T#IJR\ATB'N_GY/3D'3DAC).'
M0C2*\ER-?8WBS!%^U@J9.B'1*T+"B-P(K@M%/O$<\GT"'UUUUJ*MM6ETE'$.
MV3F)P_<D"J)!CZ#9O\/C(W+B+M.QY4O^FFDR9RHKA6HPK3^N%DI+O,P_^U+F
M&.-^1E/@EZJF&4P\K& %<@U>^O9-F 0?^^S^)[(]\X/._. 8>SI'ZTJSK,^D
M0XXLTC2==7H6QA?A!TSZ>E=_;]P@BE_B]J0-.VG#H]*P&V"M\SYE#CC</7%T
M(*HG9-"O)^GT)$?UV*);N*)C[LYH4W1] I/>U&$'/U#9&X>I&QU(]7<:205R
M9?NK(IEHN':%UZUV+?S*=JZ#]2FV=M>)7VC<NW!#Y8IQ14I8(F5P/L+<2==K
MW42+VK:KA=#8_.RPP.<)I G _:40>CLQ!W0/7OH'4$L#!!0    ( $B!8UKW
M?H)W<0,  /,)   9    >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;*U636_;
M.!#]*X2V6"1 8WU:EK.V@,3>HCT4#>RF>RCVP$ACBX@D:DG*3O]]AY2B^$-6
M]]"+35(SC^\-AS.<[;EXEAF (B]%7LJYE2E5W=JV3#(HJ!SQ"DK\LN&BH JG
M8FO+2@!-C5.1VY[CA'9!66G%,[/V(.(9KU7.2G@01-9%0<6/>\CY?FZYUNO"
MBFTSI1?L>%;1+:Q!/58/ F=VAY*R DK)>$D$;.;6G7N[<!WM8"R^,=C+@S'1
M4IXX?]:33^G<<C0CR"%1&H+BWPX6D.<:"7G\UX):W9[:\7#\BO[!B$<Q3U3"
M@N?_L%1E<RNR2 H;6N=JQ?<?H14TUG@)SZ7Y)?O6UK%(4DO%B]89&12L;/[I
M2QN( P<WO.#@M0[>J4-PP<%O'7PCM&%F9"VIHO%,\#T1VAK1],#$QGBC&E;J
M8UPK@5\9^JGX4YGP LA7^@*2W) 5)+Q,6,ZH"3+?D#<#LN!%52M("57D Z0@
M:$[6BJI:<?&#K*A"",7)@^ [9HX9LXP<;7"U!$59?HT[/:Z7Y.K=-7E'6$F^
M9KR6M$SES%8H2E.SDU; ?2/ NR# ]<AG7JI,DK_+%-)C !NCT87$>PW)O3>(
MN(1D1'SW/?$<+^@AM/C_[OX ';\[(=_@A;\\(;)D,LFYK 60[W=/4@F\!/_V
MA:Q!]/L1=66XE15-8&[AU9<@=F#%?_[AALY??7)_$]B1^* 3'PRAQUIUU>43
MYMWC:#TBLDLZ@4G7%X &=6)0=27;Q3?>U/&\F;T[E-9G%KE3IS,[(CWN2(\'
M2:\53YYO='%)"9X=5EQIKE,?T09I?,# '0?1"<T>(S_P^TF&'<EPD.0*SXJ*
M)"-X[;#N[;"@5UB>%5$8\D1 RE3O;0S/N-Q,QUYXPKC'RH^B"Y0G'>7)(.5%
M1LLMZ'JQHWG=5"B:8R.B9=*;!9,S%O[8C8(3KN=6F"IAV,\UZKA&PSG0MBDW
M]*Z*ZU^F071^PI.)?T*TQV@\#?IY3CN>TT&>7U0&HH_1]&RSX)3/N<GDPLUQ
MG;=VY SR.6X>K*E]2C>/WM;@G%U@YX3DH$E#TCYHGP6(K7E52#RSNE1-V^A6
MNY?+G>G7)^OW^D5CVO(;3/,<^DS%EI62Y+!!2&<TP:B)YH713!2O3)-^X@I;
MOAEF^"H#H0WP^X9S]3K1&W3OO/@G4$L#!!0    ( $B!8UI$*UM*^0,  +X-
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;*V7WV_;-A#'_Q5"*X86
MJ"/1LGYEMH'41M$"W18DZ?8P[(&6SS812O1(VD[WU^\H*;)CT4H>]F*+TO=.
MGSN2=]3X(-6CW@ 8\E2(4D^\C3';:]_7^08*IJ_D%DI\LI*J8 :':NWKK0*V
MK(P*X0^#(/8+QDMO.J[NW:KI6.Z,X"7<*J)W1<'4CT\@Y&'B4>_YQAU?;XR]
MX4_'6[:&>S#?M[<*1W[K9<D+*#67)5&PFG@W]'I&8VM0*?[@<- GU\2&LI#R
MT0Z^+B=>8(E 0&ZL"X9_>YB!$-83<OS3./7:=UK#T^MG[Y^KX#&8!=,PD^)/
MOC2;B9=Z9 DKMA/F3AZ^0!-09/WE4NCJEQP:;>"1?*>-+!IC)"AX6?^SIR81
M)P9T=,%@V!@,WVH0-@9A%6A-5H4U9X9-QTH>B+)J]&8OJMQ4UA@-+^TTWAN%
M3SG:F>G7,I<%D ?V!)H,R!Q6H!0L[0URHS4835BY)-\X6W#!#4?5^SD8QL4'
ME'^_GY/W[SZ0=X27Y&$C=QK%>NP;)+/^_;RA^%13#"]0S"&_(B']2(;!<.0P
MG[W=/'QI[F,^VJ0,VZ0,*W_QJTDA<ZYS(?5. ?GK9J&-PG7WMRO VF/H]F@W
MX[7>LAPF'NXV#6H/WO3GGV@<_.(*]W]R]B+XL T^[/,^_0UK!U8)Q0POUP1C
MUR1G2OW DG%@RCV[M<>D\F@+QWZ:C6B6COW]:51=51)D6=RJ7N".6MQ1+^X=
M)H"I?%,MTR7LL3!ML<P8DN,RYL:)6WN,3D"&69!%9[A=%68X"=RX48L;]>+^
M;C:@<+<85J[Y0H"3+^J\^9RMJPC=7''+%?=RW>2YVC%1[_9F43G9XFY6*(W/
M\!RB(!FY"9.6,.DEO#<R?QS8DKTDN#VQCVEF.X$+,NDF,,JR,TB'B*:1&S)M
M(=->R!G;<L,$_Q?J++I6I@LX[;",LC1,SHB[JC".XM2-G+7(62_R-\"4$G$L
M\"Z^K//F.$C/\1RBF%[8+S0X-JB@E^]!8D+)6ME"M'QN3P9+,ZO:D[/9!-WU
MET99)Y\N'68TN%"2Z$E3I:_D5.MKLF=BQ^K#BL#C$BMS<-+2#L6 IEB/SNNG
M4Q@&69A=X#WV.]K;49H<.[+[D93@7+"-PY<K-CG?8@Y5%,7)!=QCAZ+]+>HS
M?T+*GOD/'8D:Q1TZERQ)Z 6\8T>BK[0D>W0<R-5@AQNKA[+;8 9A=+)A&DJ7
M++G4-NFQ$='^3G1Q7[U2"FBW]PQ<4^^0]<S]L4_1_D9ECR=O+0-QY\#126Z?
MI";T3P[7]LOF5Z;6O-1$P IM@JL$0U3UQT(],');G;<7TN#IO;K<X <6*"O
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M2<R5>L(<6G*5:-<DE,B] MF6FX=1U.WU0OLW;#VL,_3&T)!AIV+8\3*\,]Q
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M#S03:QE$)B-H IB2CYH49T?*K=.)> ?1%1K8OR/'<MR6@*;_WWW0$<Z@KM%
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M-7\5T84 WB^M]?M)*#!^9_-_ 5!+ P04    " !(@6-: <--A]<$  #;%@
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MMRUJI<Y\V96^-+S8[+K;[!@\^0502P,$%     @ 2(%C6O5)DLP! @  7B0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( $B!8UI#O:U+[0   "L"   1
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M965T,BYX;6Q02P$"% ,4    " !(@6-:9GIX$Y("   Y!P  &
M    @($9%@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M2(%C6FPQ2F>: P    P  !@              ("!X1@  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $B!8UI/%D?O! ,  ,H(   8
M          " @;$<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " !(@6-:7K7JN70)  #I8   &               @('K'P  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 2(%C6F9BM.'  @  6 @
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $B!8UJD[_3_L @  &\H   9
M      " @6X^  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ 2(%C6N-4]=[#!0  %0T  !D              ("!54<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !(@6-:V[KZY5<7  "610
M&0              @(%/30  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( $B!8UJ6]85WG@8  %(1   9              " @=UD  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 2(%C6D:%"$P!
M!   V0D  !D              ("!LFL  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " !(@6-:6YWCOY$%   >#0  &0
M@('J;P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( $B!
M8UJ\[8!K@@D  *P?   9              " @;)U  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ 2(%C6L2[?O"0#0  K28  !D
M         ("!:W\  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " !(@6-:!CZ_7W8+   Y(   &0              @($RC0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $B!8UJRE#^;_P,  !,)
M   9              " @=^8  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ 2(%C6I?' _)%!0  $0P  !D              ("!%9T
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !(@6-:ASX$
MTF@8  "]30  &0              @(&1H@  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( $B!8UI4MCTEGP,  %<(   9
M  " @3"[  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M2(%C6@WT&/N; P  %0D  !D              ("!!K\  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " !(@6-:JE!/L>D#  !8"@  &0
M            @('8P@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( $B!8UJZ+W=%PP(   X&   9              " @?C&  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 2(%C6B8,&-U1!
M6 H  !D              ("!\LD  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " !(@6-:U $&-RP%  "D#   &0              @(%Z
MS@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $B!8UIA
M*-07MP4  *T.   9              " @=W3  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ 2(%C6KN <WDE P  HP8  !D
M     ("!R]D  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M" !(@6-:G]+-G+D#  !4"   &0              @($GW0  >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $B!8UJ6%&DX; (  /X%   9
M              " @1?A  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!
M A0#%     @ 2(%C6@P@1ML* P  )0D  !D              ("!NN,  'AL
M+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !(@6-:?HOXA=4"
M   S"   &0              @('[Y@  >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;%!+ 0(4 Q0    ( $B!8UJX;X:P\ (  +0)   9              "
M@0?J  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 2(%C
M6C;0R%#\!   \QP  !D              ("!+NT  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " !(@6-:1QRTQ;,"  #^!@  &0
M        @(%A\@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( $B!8UIT3? HL (  &8'   9              " @4OU  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 2(%C6@EOZTZS P  D1$
M !D              ("!,O@  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " !(@6-:YW(L6W4"  #4!0  &0              @($<_
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $B!8UH!"MX1
MU@(   @(   9              " @<C^  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ 2(%C6J8P.1/4!0  ,28  !D
M ("!U0$! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !(
M@6-:IK0G9,X"  "N!P  &0              @('@!P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( $B!8UIDI^+CX X  #O9   9
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M970T.2YX;6Q02P$"% ,4    " !(@6-:8URH+4,#   4"P  &0
M    @(%\, $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M $B!8UHHJ\DS- ,  -8+   9              " @?8S 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ 2(%C6G0;RC&K P  90X  !D
M             ("!83<! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " !(@6-:>E:$D*$"  #\!@  &0              @(%#.P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( $B!8UKW?H)W<0,
M /,)   9              " @1L^ 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ 2(%C6D0K6TKY P  O@T  !D              ("!
MPT$! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !(@6-:
M(K"(:-L$  "8%P  &0              @('S10$ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( $B!8UH:@WN0] (  )L(   9
M      " @05+ 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ 2(%C6A P@59W P  F!0  !D              ("!,$X! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !(@6-:'=($;PL$   /$P
M&0              @('>40$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( $B!8UK(/TP04@,  ','   9              " @2!6 0!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ 2(%C6@'#38?7
M!   VQ8  !D              ("!J5D! 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    " !(@6-:D_ E%VP#  ##%P  #0
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:+GAM;%!+!08     10!% -H2  !>; $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>156</ContextCount>
  <ElementCount>343</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquity</Role>
      <ShortName>Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlan</Role>
      <ShortName>Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare1</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Stockholder's Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityTables</Role>
      <ShortName>Stockholder's Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables</Role>
      <ShortName>Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlan</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Summary of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Stockholder's Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholder's Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Stockholders' Equity - Summary of Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Warrants Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Equity Incentive Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail</Role>
      <ShortName>Equity Incentive Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Equity Incentive Plan - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Equity Incentive Plan - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Equity Incentive Plan - Summary of RSU Activity under Equity Incentive Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail</Role>
      <ShortName>Equity Incentive Plan - Summary of RSU Activity under Equity Incentive Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Equity Incentive Plan - Summary of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail</Role>
      <ShortName>Equity Incentive Plan - Summary of Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Equity Incentive Plan - Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel</Role>
      <ShortName>Equity Incentive Plan - Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="annx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Segment Reporting - Schedule of Operations for Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails</Role>
      <ShortName>Segment Reporting - Schedule of Operations for Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="annx-20241231.htm">annx-20241231.htm</File>
    <File>annx-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img136305557_0.jpg</File>
    <File>img136305557_1.jpg</File>
    <File>img136305557_2.jpg</File>
    <File>img136305557_3.jpg</File>
    <File>img136305557_4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="531">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "annx-20241231.htm": {
   "nsprefix": "annx",
   "nsuri": "http://annexonbio.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "annx-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "annx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 290,
   "keyCustom": 53,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 20,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://fasb.org/us-gaap/2024": 4
   },
   "contextCount": 156,
   "entityCount": 1,
   "segmentCount": 57,
   "elementCount": 651,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 531,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 7
   },
   "report": {
    "R1": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:EarningsPerShareBasic",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_a2b98230-0f7a-4d29-8918-901b611f045a",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a2b98230-0f7a-4d29-8918-901b611f045a",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_f5167882-1b9d-47e5-a675-47eb50fb2f3b",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5167882-1b9d-47e5-a675-47eb50fb2f3b",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure",
     "longName": "995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance Disclosure",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganization",
     "longName": "995465 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "longName": "995495 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:BalanceSheetComponentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:BalanceSheetComponentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995505 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquity",
     "longName": "995515 - Disclosure - Stockholder's Equity",
     "shortName": "Stockholder's Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlan",
     "longName": "995525 - Disclosure - Equity Incentive Plan",
     "shortName": "Equity Incentive Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995535 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare1",
     "longName": "995545 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995555 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "longName": "995575 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
     "longName": "995585 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995595 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "longName": "995605 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "995615 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityTables",
     "longName": "995625 - Disclosure - Stockholder's Equity (Tables)",
     "shortName": "Stockholder's Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables",
     "longName": "995635 - Disclosure - Equity Incentive Plan (Tables)",
     "shortName": "Equity Incentive Plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995645 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995655 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995665 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail",
     "longName": "995675 - Disclosure - Organization - Additional Information (Detail)",
     "shortName": "Organization - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995685 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
     "longName": "995695 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:Cash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:Cash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail",
     "longName": "995705 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Detail)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_c060d1ca-b9cb-4849-9fbb-3cadae61b6dd",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "annx:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c060d1ca-b9cb-4849-9fbb-3cadae61b6dd",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "annx:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "longName": "995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "longName": "995725 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:InvestmentMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:InvestmentMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "longName": "995735 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "annx:PrepaidResearchAndDevelopmentCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "annx:PrepaidResearchAndDevelopmentCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail",
     "longName": "995745 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail)",
     "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail",
     "longName": "995755 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail",
     "longName": "995775 - Disclosure - Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Detail)",
     "shortName": "Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "annx:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "annx:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "annx:BalanceSheetComponentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995785 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_e30eb803-2850-45ea-964d-0c167ebab98b",
      "name": "annx:AggregateSubleasePaymentReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e30eb803-2850-45ea-964d-0c167ebab98b",
      "name": "annx:AggregateSubleasePaymentReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail",
     "longName": "995795 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)",
     "shortName": "Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
     "longName": "995815 - Disclosure - Stockholder's Equity - Additional Information (Detail)",
     "shortName": "Stockholder's Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_262315fc-5a70-4273-9329-a8573c6e8ac6",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_262315fc-5a70-4273-9329-a8573c6e8ac6",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails",
     "longName": "995825 - Disclosure - Stockholders' Equity - Summary of Warrants Activity (Details)",
     "shortName": "Stockholders' Equity - Summary of Warrants Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_ae76d731-12db-4f4c-9bcd-ade6fdbeaa43",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ec22ff7d-ccec-45fd-a10c-766baaf42b25",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
     "longName": "995835 - Disclosure - Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail)",
     "shortName": "Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29782950-7a96-4afe-b123-68b6a1a44a9d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "annx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
     "longName": "995845 - Disclosure - Equity Incentive Plan - Additional Information (Detail)",
     "shortName": "Equity Incentive Plan - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "annx:PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail",
     "longName": "995855 - Disclosure - Equity Incentive Plan - Summary of Stock Option Activity (Detail)",
     "shortName": "Equity Incentive Plan - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_5c8914a1-6122-42c7-8190-e7a265b496b4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail",
     "longName": "995865 - Disclosure - Equity Incentive Plan - Summary of RSU Activity under Equity Incentive Plan (Detail)",
     "shortName": "Equity Incentive Plan - Summary of RSU Activity under Equity Incentive Plan (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_5c8914a1-6122-42c7-8190-e7a265b496b4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c8914a1-6122-42c7-8190-e7a265b496b4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail",
     "longName": "995875 - Disclosure - Equity Incentive Plan - Summary of Stock-Based Compensation Expense (Detail)",
     "shortName": "Equity Incentive Plan - Summary of Stock-Based Compensation Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07dde65d-d011-4647-84a8-b3adc4b0a081",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel",
     "longName": "995885 - Disclosure - Equity Incentive Plan - Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)",
     "shortName": "Equity Incentive Plan - Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail",
     "longName": "995895 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)",
     "shortName": "Income Taxes - Components of Loss Before Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail",
     "longName": "995905 - Disclosure - Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes (Detail)",
     "shortName": "Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail",
     "longName": "995915 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995925 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail",
     "longName": "995935 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Detail)",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_5c8914a1-6122-42c7-8190-e7a265b496b4",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a2b98230-0f7a-4d29-8918-901b611f045a",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
     "longName": "995945 - Disclosure - Net Loss Per Share - Additional Information (Detail)",
     "shortName": "Net Loss Per Share - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_8472ac84-55e5-434a-90d4-c7f9d7aa4437",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_634f5a22-da7a-4c41-b9ae-27784aa5495b",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail",
     "longName": "995955 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail)",
     "shortName": "Net Loss Per Share - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "995965 - Disclosure - Segment Reporting - Additional Information (Details)",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
     "longName": "995975 - Disclosure - Segment Reporting - Schedule of Operations for Reportable Segment (Details)",
     "shortName": "Segment Reporting - Schedule of Operations for Reportable Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_59694837-0d85-444e-93f3-2dab4c74940e",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "annx-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2023-07 [Member]",
        "label": "Accounting Standards Update 2023-07 [Member]",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r843"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of discount on available-for-sale securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "annx_AccruedAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued And Other Liabilities Current",
        "documentation": "Accrued and other liabilities current.",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "annx_AccruedCompensationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "AccruedCompensationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Compensation Current",
        "documentation": "Accrued compensation, current"
       }
      }
     },
     "auth_ref": []
    },
    "annx_AccruedConstructionCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "AccruedConstructionCostsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued construction costs",
        "label": "Accrued Construction Costs Current",
        "documentation": "Accrued construction costs current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional services",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "annx_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expenses Current",
        "documentation": "Accrued research and development expenses, current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r132",
      "r643"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r68",
      "r139",
      "r638",
      "r664",
      "r668"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r16",
      "r477",
      "r480",
      "r549",
      "r659",
      "r660",
      "r996",
      "r997",
      "r998",
      "r1005",
      "r1006",
      "r1007",
      "r1009"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Additional Paid in Capital, Total",
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r843",
      "r1107"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r1005",
      "r1006",
      "r1007",
      "r1009",
      "r1047",
      "r1109"
     ]
    },
    "annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "AdditionalStockIssuedDuringPeriodCommonSharesPurchased",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional stock issued during period common shares purchased.",
        "label": "Additional Stock Issued During Period Common Shares Purchased",
        "terseLabel": "Additional common shares purchased"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update",
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r175",
      "r176",
      "r177",
      "r178",
      "r189",
      "r241",
      "r242",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r306",
      "r307",
      "r310",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r519",
      "r520",
      "r531",
      "r532",
      "r533",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r591",
      "r592",
      "r593",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants were recorded at fair value",
        "label": "Adjustments to Additional Paid in Capital, Fair Value",
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation, Value",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r365"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "annx_AggregateSubleasePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "AggregateSubleasePaymentReceivable",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate sublease payment receivable",
        "label": "Aggregate Sublease Payment Receivable",
        "documentation": "Aggregate sublease payment receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r909",
      "r942"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r902",
      "r912",
      "r945"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r937",
      "r946",
      "r950",
      "r958"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r406"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for doubtful accounts",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r244",
      "r291",
      "r294",
      "r295",
      "r1074"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities excluded from the computation of diluted net loss per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r102",
      "r134",
      "r163",
      "r204",
      "r212",
      "r228",
      "r232",
      "r278",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r467",
      "r469",
      "r521",
      "r633",
      "r723",
      "r809",
      "r810",
      "r843",
      "r866",
      "r1034",
      "r1035",
      "r1061"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r142",
      "r163",
      "r278",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r467",
      "r469",
      "r521",
      "r843",
      "r1034",
      "r1035",
      "r1061"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Holding Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Holding Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r299",
      "r632"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "terseLabel": "Aggregate Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r299",
      "r497",
      "r625",
      "r831",
      "r835",
      "r1018",
      "r1051",
      "r1052",
      "r1053"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r299"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "annx_BalanceSheetComponentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "BalanceSheetComponentsDisclosureTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Balance Sheet Components Disclosure [Text Block]",
        "documentation": "Balance sheet components disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "annx_BasisOfPresentationAndSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis Of Presentation And Significant Accounting Policies [Line Items]",
        "label": "Basis Of Presentation And Significant Accounting Policies [Line Items]",
        "documentation": "Basis of presentation and significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "annx_BasisOfPresentationAndSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis Of Presentation And Significant Accounting Policies [Table]",
        "label": "Basis Of Presentation And Significant Accounting Policies [Table]",
        "documentation": "Basis of presentation and significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "annx_BrisbaneCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "BrisbaneCaliforniaMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Brisbane, California [Member]",
        "label": "Brisbane California [Member]",
        "documentation": "Brisbane, California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r76",
      "r77"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r636",
      "r689",
      "r717",
      "r843",
      "r866",
      "r992"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r130",
      "r795"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r93"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "terseLabel": "Cash and cash equivalents and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r73",
      "r161"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Ending Balance",
        "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Beginning Balance",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r73",
      "r161"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r73"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1072"
     ]
    },
    "annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liability",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liability",
        "documentation": "Cash paid for amounts included in the measurement of lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, ASU adopted",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r126",
      "r174",
      "r241",
      "r279",
      "r280",
      "r281",
      "r287",
      "r288",
      "r306",
      "r310",
      "r441",
      "r449",
      "r450",
      "r458",
      "r459",
      "r461",
      "r472",
      "r473",
      "r485",
      "r486",
      "r519",
      "r520",
      "r532",
      "r544",
      "r545",
      "r591",
      "r592",
      "r657",
      "r658"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, ASU, adoption date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r126",
      "r241",
      "r279",
      "r280",
      "r281",
      "r287",
      "r288",
      "r289",
      "r306",
      "r310",
      "r441",
      "r449",
      "r450",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r471",
      "r472",
      "r473",
      "r474",
      "r485",
      "r486",
      "r487",
      "r490",
      "r519",
      "r520",
      "r532",
      "r544",
      "r545",
      "r591",
      "r592",
      "r657",
      "r658",
      "r984"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, ASU, Immaterial effect",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r188",
      "r284"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r135",
      "r136",
      "r137",
      "r163",
      "r193",
      "r194",
      "r196",
      "r198",
      "r206",
      "r207",
      "r278",
      "r321",
      "r324",
      "r325",
      "r326",
      "r330",
      "r331",
      "r336",
      "r337",
      "r340",
      "r343",
      "r350",
      "r521",
      "r672",
      "r673",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r690",
      "r709",
      "r732",
      "r750",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r981",
      "r1002",
      "r1010"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r206",
      "r336",
      "r337",
      "r338",
      "r340",
      "r343",
      "r348",
      "r350",
      "r672",
      "r673",
      "r674",
      "r675",
      "r821",
      "r981",
      "r1002"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "annx_ClassOfWarrantOrRightExcercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ClassOfWarrantOrRightExcercised",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "label": "Class Of Warrant Or Right Excercised",
        "documentation": "Class of warrant or right excercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Purchase price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "annx_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued",
        "label": "Class Of Warrant Or Right Issued",
        "documentation": "Class of warrant or right issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants exercised",
        "verboseLabel": "Purchase of shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Weighted Average Exercise Price Of Warrant Exercised",
        "documentation": "Class of warrant or right weighted average exercise price of warrant exercised.",
        "terseLabel": "Weighted-Average Exercise Price, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "annx_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right, Weighted-Average Exercise Price of Warrant Issued",
        "documentation": "Class of Warrant or right, weighted-average exercise price of warrant issued.",
        "terseLabel": "Weighted-Average Exercise Price, Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper [Member]",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r320",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 5)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r96",
      "r635",
      "r708"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r312",
      "r313",
      "r779",
      "r1027",
      "r1029"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r780"
     ]
    },
    "annx_CommonSharesExchangeValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "CommonSharesExchangeValue",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares exchange value.",
        "label": "Common Shares Exchange Value",
        "terseLabel": "Exchange value"
       }
      }
     },
     "auth_ref": []
    },
    "annx_CommonStockAndPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "CommonStockAndPrefundedWarrantsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock and Prefunded Warrants [Member]",
        "documentation": "Common stock and prefunded warrants.",
        "terseLabel": "Common Stock and Prefunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock for future issuance",
        "terseLabel": "Common stock reserved",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, dividends declared",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stocks, Including Additional Paid in Capital, Net of Discount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r858",
      "r860",
      "r861",
      "r862",
      "r863",
      "r1005",
      "r1006",
      "r1009",
      "r1047",
      "r1105",
      "r1109"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value per share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "annx_CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Employment Inducement Award Plan [Member]",
        "label": "Common Stock Reserved For Two Thousand Twenty Two Employment Inducement Award Plan [Member]",
        "documentation": "Common stock reserved for two thousand twenty two employment inducement award plan."
       }
      }
     },
     "auth_ref": []
    },
    "annx_CommonStockSalesAgreementExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "CommonStockSalesAgreementExpirationDate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock sales agreement expiration date",
        "label": "Common Stock Sales Agreement Expiration Date",
        "documentation": "Common stock sales agreement expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r709"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r709",
      "r729",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2024 and 2023; 109,381,556 and 78,369,099 shares issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r637",
      "r843"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "annx_CommonWarrantAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "CommonWarrantAndPreFundedWarrantsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrant and Pre-funded Warrants [Member]",
        "documentation": "Common Warrant and Pre-funded Warrants.",
        "terseLabel": "Common Warrant and Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "annx_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Warrants Member",
        "label": "Common Warrants Member",
        "terseLabel": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r147",
      "r149",
      "r155",
      "r627",
      "r649",
      "r650"
     ]
    },
    "annx_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment and Software [Member]",
        "label": "Computer Equipment And Software [Member]",
        "documentation": "Computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r112"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r100",
      "r170",
      "r204",
      "r213",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r809",
      "r810",
      "r1034",
      "r1035"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r100",
      "r170",
      "r204",
      "r213",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r809",
      "r810",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r800"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Bonds [Member]",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt [Member]",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r825",
      "r831",
      "r844",
      "r855",
      "r1102"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r332",
      "r338",
      "r553",
      "r573",
      "r631",
      "r797",
      "r799"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "annx_CowenSalesAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "CowenSalesAgentMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cowen sales agent",
        "label": "Cowen Sales Agent [Member]",
        "documentation": "Cowen as sales agent."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r973"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r964"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r965"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r965"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r967"
     ]
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs included in accounts payable and accrued liabilities",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit losses",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r299",
      "r304",
      "r305"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss position for more than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r301",
      "r816"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "negatedTotalLabel": "Total gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r95",
      "r431"
     ]
    },
    "annx_DeferredOfferingCostsIncludedInOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DeferredOfferingCostsIncludedInOtherNonCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs Included in Other Non-current Assets",
        "documentation": "Deferred offering costs included in other non-current assets.",
        "terseLabel": "Deferred offering costs included in other non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "annx_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, capitalized research and development.",
        "label": "Deferred Tax Assets, Capitalized Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "auth_ref": []
    },
    "annx_DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Credit Carryforwards Expiration Beginning Year",
        "terseLabel": "Federal carryforward losses expiration beginning year",
        "documentation": "Deferred tax assets credit carryforwards expiration beginning year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain/loss on investments",
        "label": "Deferred Tax Assets, Investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "annx_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets Lease Liabilities",
        "documentation": "Deferred tax assets, lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "annx_DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOLs with annual limitation utilization that do not expire",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Annual Limitation Utilization Not Subject To Expiration",
        "documentation": "Deferred tax assets operating loss carryforwards annual limitation utilization not subject to expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "annx_DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State carryforward losses expiration beginning year",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Expiration Beginning Year",
        "documentation": "Deferred tax assets, operating loss carryforwards, expiration beginning year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOLs do not expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOLs subject to expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "annx_DeferredTaxAssetsOtherIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DeferredTaxAssetsOtherIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangibles",
        "label": "Deferred Tax Assets Other Intangible Assets",
        "documentation": "Deferred tax assets, other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "terseLabel": "Federal credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "terseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accruals and reserves",
        "label": "Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "annx_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "documentation": "Deferred tax liabilities right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r33"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r204",
      "r214",
      "r232",
      "r809",
      "r810"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r1017",
      "r1106"
     ]
    },
    "annx_DisclosureOfBalanceSheetComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DisclosureOfBalanceSheetComponentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Balance Sheet Components [Abstract]",
        "documentation": "Disclosure Of Balance Sheet Components [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plan",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r367",
      "r398",
      "r399",
      "r401",
      "r827"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895",
      "r938"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "annx_DouglasLoveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "DouglasLoveMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Douglas Love [Member]",
        "documentation": "Douglas Love."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year [Member]",
        "label": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r191",
      "r193",
      "r196",
      "r197",
      "r198",
      "r203",
      "r456",
      "r465",
      "r494",
      "r495",
      "r628",
      "r651",
      "r801"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r193",
      "r196",
      "r197",
      "r198",
      "r203",
      "r456",
      "r465",
      "r494",
      "r495",
      "r628",
      "r651",
      "r801"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r200"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r199",
      "r201",
      "r202"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation cost expected period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares Subject to Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employees [Member]",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options to Purchase Common Stock [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "annx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan.",
        "verboseLabel": "Common Stock Reserved for Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "annx_EmploymentInducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "EmploymentInducementIncentivePlanMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Two Employment Inducement Award Plan.",
        "label": "Two Thousand Twenty Two Employment Inducement Award Plan [Member]",
        "terseLabel": "2022 Employment Inducement Award Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Three",
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r123",
      "r151",
      "r152",
      "r153",
      "r171",
      "r172",
      "r173",
      "r176",
      "r183",
      "r185",
      "r187",
      "r205",
      "r283",
      "r290",
      "r307",
      "r352",
      "r439",
      "r440",
      "r452",
      "r453",
      "r454",
      "r457",
      "r464",
      "r465",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r493",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r534",
      "r549",
      "r647",
      "r659",
      "r660",
      "r661",
      "r678",
      "r750"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r909",
      "r942"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r896",
      "r906",
      "r939"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "annx_ExerciseOfCommonWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ExerciseOfCommonWarrants",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Of Common Warrants",
        "documentation": "Exercise of common warrants.",
        "terseLabel": "Exercise of common warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "annx_ExerciseOfPreFundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ExerciseOfPreFundedWarrantsShares",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants, Shares",
        "label": "Exercise Of Pre-funded Warrants Shares",
        "documentation": "Exercise of pre-funded warrants shares."
       }
      }
     },
     "auth_ref": []
    },
    "annx_ExerciseOfPreFundedWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ExerciseOfPreFundedWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants, Value",
        "label": "Exercise Of Pre-funded Warrants Value",
        "documentation": "Exercise of pre-funded warrants value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r511",
      "r831"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r511",
      "r831"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r512",
      "r833"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r512",
      "r833"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r510",
      "r511",
      "r513",
      "r560",
      "r561",
      "r562",
      "r819",
      "r820",
      "r823",
      "r824",
      "r825",
      "r831",
      "r835"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r624",
      "r831",
      "r836"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r354",
      "r359",
      "r498",
      "r511",
      "r560",
      "r823",
      "r824",
      "r825",
      "r831"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r354",
      "r359",
      "r498",
      "r499",
      "r511",
      "r561",
      "r819",
      "r820",
      "r823",
      "r824",
      "r825",
      "r831"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r510",
      "r511",
      "r513",
      "r560",
      "r561",
      "r562",
      "r819",
      "r820",
      "r823",
      "r824",
      "r825",
      "r831",
      "r835"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r300",
      "r302",
      "r303",
      "r334",
      "r348",
      "r483",
      "r518",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r648",
      "r816",
      "r831",
      "r833",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r844",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1048",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainContingenciesLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain Contingencies [Line Items]",
        "label": "Gain Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_GainContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainContingenciesTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain Contingencies [Table]",
        "label": "Gain Contingencies [Table]",
        "documentation": "Disclosure of information about existing condition, situation, or set of circumstances involving uncertainty as to possible gain that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r734"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairments of long-lived assets",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r79",
      "r832"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r81"
     ]
    },
    "annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "IncentiveStockOptionsAndNonstatutoryStockOptionsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs [Member]",
        "label": "Incentive Stock Options And Nonstatutory Stock Options [Member]",
        "documentation": "Incentive stock options and nonstatutory stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r415"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r98",
      "r101",
      "r629",
      "r645",
      "r803",
      "r809",
      "r1011",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r415"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r311",
      "r503",
      "r507",
      "r512",
      "r654",
      "r656",
      "r735",
      "r792",
      "r834",
      "r1076"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r503",
      "r507",
      "r512",
      "r654",
      "r656",
      "r735",
      "r792",
      "r834",
      "r1076"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r416",
      "r417",
      "r424",
      "r436",
      "r830",
      "r1045"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r416",
      "r417",
      "r424",
      "r436",
      "r830",
      "r1045"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r410",
      "r416",
      "r420",
      "r421",
      "r422",
      "r428",
      "r435",
      "r444",
      "r446",
      "r447",
      "r448",
      "r677",
      "r830"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r119",
      "r186",
      "r187",
      "r204",
      "r215",
      "r232",
      "r414",
      "r416",
      "r445",
      "r652",
      "r830"
     ]
    },
    "annx_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "documentation": "Income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r412",
      "r413",
      "r428",
      "r429",
      "r434",
      "r438",
      "r671"
     ]
    },
    "annx_IncomeTaxRateReconciliationSection162MCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "IncomeTaxRateReconciliationSection162MCompensation",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 162(m) compensation",
        "label": "Income Tax Rate Reconciliation Section 162(m) Compensation",
        "documentation": "Income tax rate reconciliation section 162(m) compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r830",
      "r1040"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax provision at U.S. statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r830"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r1040",
      "r1042"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount, Total",
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxComputedAtFederalStatutoryRatesToProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r1040",
      "r1042"
     ]
    },
    "annx_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "documentation": "Income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "annx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "documentation": "Increase decrease in operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "terseLabel": "Other non-current assets",
        "negatedLabel": "Other non-current assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndemnificationGuaranteeMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnification Agreement [Member]",
        "label": "Indemnification Agreement [Member]",
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r937",
      "r946",
      "r950",
      "r958"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r962"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r962"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r962"
     ]
    },
    "annx_InterestAndOtherNonOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "InterestAndOtherNonOperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income, net",
        "label": "Interest And Other Non Operating Income Expense",
        "documentation": "Interest and other non operating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "annx_InvestmentExpectedMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "InvestmentExpectedMaturityPeriod",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment expected maturity period.",
        "label": "Investment Expected Maturity Period",
        "terseLabel": "Investment expected maturity period"
       }
      }
     },
     "auth_ref": []
    },
    "annx_InvestmentMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "InvestmentMaturityPeriod",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment maturity period",
        "label": "Investment Maturity Period",
        "documentation": "Investment maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r693",
      "r694",
      "r696",
      "r698",
      "r756",
      "r758",
      "r760",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r858"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r693",
      "r694",
      "r696",
      "r698",
      "r756",
      "r758",
      "r760",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r858"
     ]
    },
    "annx_IssuanceOfStockAndPrefundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "IssuanceOfStockAndPrefundedWarrantsShares",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs, Shares",
        "label": "Issuance of Stock and Prefunded Warrants Shares",
        "documentation": "Issuance of stock and prefunded warrants shares."
       }
      }
     },
     "auth_ref": []
    },
    "annx_IssuanceOfStockAndPrefundedWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "IssuanceOfStockAndPrefundedWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Stock and Prefunded Warrants Value",
        "documentation": "Issuance of stock and prefunded warrants value.",
        "terseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs, Value"
       }
      }
     },
     "auth_ref": []
    },
    "annx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year [Member]",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r543"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "annx_LesseeOperatingLeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "LesseeOperatingLeaseExpirationMonthAndYear",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, expiration month and year.",
        "label": "Lessee Operating Lease Expiration Month And Year",
        "terseLabel": "Operating lease, expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Minimum Lease Payments and Related Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Year Five And Thereafter",
        "documentation": "Lessee operating lease liability payments due year five and thereafter.",
        "terseLabel": "2029 and thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "annx_LesseeOperatingSubleaseCommencementYearAndMonth": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "LesseeOperatingSubleaseCommencementYearAndMonth",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease starting year and month",
        "label": "Lessee, Operating Sublease Commencement Year and Month",
        "documentation": "Lessee operating sublease commencement year and month."
       }
      }
     },
     "auth_ref": []
    },
    "annx_LesseeOperatingSubleaseExpirationYearAndMonth": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "LesseeOperatingSubleaseExpirationYearAndMonth",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease expiration year and month",
        "label": "Lessee operating sublease expiration year and month",
        "documentation": "Lessee operating sublease expiration year and month."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r60",
      "r163",
      "r278",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r468",
      "r469",
      "r470",
      "r521",
      "r707",
      "r802",
      "r866",
      "r1034",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r97",
      "r640",
      "r843",
      "r1003",
      "r1024",
      "r1056"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r129",
      "r163",
      "r278",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r468",
      "r469",
      "r470",
      "r521",
      "r843",
      "r1034",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax position",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Nature",
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r319",
      "r407",
      "r669",
      "r818",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "terseLabel": "Loss contingency accrual",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r982"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Nature",
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r319",
      "r407",
      "r669",
      "r818",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency pending claims",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r361",
      "r407",
      "r501",
      "r589",
      "r653",
      "r655",
      "r669",
      "r699",
      "r700",
      "r757",
      "r759",
      "r761",
      "r762",
      "r766",
      "r790",
      "r791",
      "r815",
      "r821",
      "r826",
      "r835",
      "r836",
      "r840",
      "r841",
      "r853",
      "r1036",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r361",
      "r407",
      "r501",
      "r589",
      "r653",
      "r655",
      "r669",
      "r699",
      "r700",
      "r757",
      "r759",
      "r761",
      "r762",
      "r766",
      "r790",
      "r791",
      "r815",
      "r821",
      "r826",
      "r835",
      "r836",
      "r840",
      "r853",
      "r1036",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r75",
      "r99",
      "r127",
      "r145",
      "r148",
      "r153",
      "r163",
      "r175",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r195",
      "r278",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r456",
      "r465",
      "r495",
      "r521",
      "r646",
      "r731",
      "r748",
      "r749",
      "r864",
      "r1034"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted/Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r937",
      "r946"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "annx_NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "NumberOfCommonStockIssuedUnderSalesAgreementAfterExpirationDate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Common Stock Issued Under Sales Agreement After Expiration Date",
        "documentation": "Number of common stock issued under sales agreement after expiration date.",
        "terseLabel": "Number of common stock sold after expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r1012"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r814",
      "r1012"
     ]
    },
    "annx_OfferingPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "OfferingPricePerShare",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering price per share.",
        "label": "Offering Price Per Share",
        "terseLabel": "Offering price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open tax year examination",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r803",
      "r1011",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r842"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in the carrying amount of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average incremental borrowing rate",
        "label": "Operating Lease Weighted Average Incremental Borrowing Rate Percent",
        "documentation": "Operating lease weighted average incremental borrowing rate percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r842"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Operating Leases, Future Minimum Payments Due",
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r106"
     ]
    },
    "annx_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 and thereafter",
        "label": "Operating Leases Future Minimum Payments Due After Year Four",
        "documentation": "Operating leases future minimum payments due after year four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r106"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r106"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r106"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureUndiscountedLeasePaymentsUnderNonCancellableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r106"
     ]
    },
    "annx_OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of taxable income",
        "label": "Operating Loss Carryforwards Limitations On Use Percentage Of Taxable Income",
        "documentation": "Operating loss carryforwards, limitations on use, percentage of taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r809",
      "r810"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued and current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r843"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r647"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Other comprehensive income, Value",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r13",
      "r146",
      "r149",
      "r154",
      "r183",
      "r523",
      "r524",
      "r529",
      "r626",
      "r647",
      "r996",
      "r997"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized loss on available-for-sale securities",
        "label": "Unrealized gain (loss) on available-for-sale securities",
        "terseLabel": "Unrealized gain on available-for-sale securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r277"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other general and administrative expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1108"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1025"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r718",
      "r810",
      "r1073"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r901",
      "r911",
      "r944"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting agreement [Member]",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of financing costs",
        "label": "Payments of Financing Costs",
        "totalLabel": "Payments of Financing Costs, Total",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of common stock issuance costs",
        "verboseLabel": "Payment of issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of available-for-sale securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r157",
      "r245"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "annx_PercentageOfGrossProceedsOfCommonStockToBePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PercentageOfGrossProceedsOfCommonStockToBePaid",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of gross proceeds of common stock to be paid",
        "label": "Percentage Of Gross Proceeds Of Common Stock To Be Paid",
        "documentation": "Percentage of gross proceeds of common stock to be paid."
       }
      }
     },
     "auth_ref": []
    },
    "annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of number of shares of capital stock outstanding on last day of preceding year",
        "label": "Percentage Of Number Of Shares Of Capital Stock Outstanding On Last Day Of Preceding Year",
        "documentation": "Percentage of number of shares of capital stock outstanding on last day of preceding year."
       }
      }
     },
     "auth_ref": []
    },
    "annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year",
        "label": "Percentage Of Shares Of Common Stock Outstanding On Last Day Of Immediately Preceding Fiscal Year",
        "documentation": "Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "annx_PersonnelExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PersonnelExpensesMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Expenses [Member]",
        "documentation": "Personnel Expenses",
        "terseLabel": "Personnel Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "annx_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "pre-funded warrants Member.",
        "label": "pre-funded warrants Member",
        "terseLabel": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r709"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r709",
      "r729",
      "r1109",
      "r1110"
     ]
    },
    "annx_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded Warrant Member",
        "label": "Prefunded Warrant [Member]",
        "terseLabel": "Pre-funded Warrants [Member]",
        "verboseLabel": "Number of Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "annx_PrefundedWarrantsAndCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PrefundedWarrantsAndCommonWarrantsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants and Common Warrants [Member]",
        "label": "Prefunded Warrants and Common Warrants [Member]",
        "documentation": "Prefunded warrants and common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "annx_PrepaidAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PrepaidAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid And Other Assets Current",
        "documentation": "Prepaid and other assets current.",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r817",
      "r1025"
     ]
    },
    "annx_PrepaidResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "PrepaidResearchAndDevelopmentCostsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development costs",
        "label": "Prepaid Research And Development Costs Current",
        "documentation": "prepaid research and development costs, current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from sale of common stock",
        "verboseLabel": "Proceeds from the issuance of common stock, including to related parties, of zero and $17,995 for the years ended December 31, 2024 and 2023, respectively",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "annx_ProceedsFromIssuanceOfCommonStockGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from sale of common stock",
        "label": "Proceeds from Issuance of Common Stock, Gross",
        "documentation": "Proceeds from issuance of common stock, gross."
       }
      }
     },
     "auth_ref": []
    },
    "annx_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Common Stock Pre Funded Warrants Net Of Commissions",
        "documentation": "Proceeds from issuance of common stock pre funded warrants net of commissions .",
        "terseLabel": "Proceeds from the issuance of common stock and pre-funded warrants, net of commissions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of available-for-sale securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r1019"
     ]
    },
    "annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from the issuance of common stock, pre-funded warrants and common warrants - related party",
        "documentation": "Proceeds from related parties for the issuance of common stock, Pre-funded warrants and common warrants.",
        "label": "Proceeds from Related Parties For The Issuance of Common Stock Prefunded Warrants and Common warrants",
        "terseLabel": "Proceeds from the issuance of common stock, pre-funded warrants and common warrants - related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from Employee Stock Purchase Plan purchases",
        "terseLabel": "Proceeds from employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "annx_ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock including related party",
        "label": "Proceeds From The Issuance Of Common Stock Including Related Party",
        "documentation": "Proceeds from the issuance of common stock including related party."
       }
      }
     },
     "auth_ref": []
    },
    "annx_ProgramExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ProgramExpensesMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Program Expenses [Member]",
        "documentation": "Program Expenses",
        "terseLabel": "Program Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Total property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r131",
      "r644"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r543",
      "r630",
      "r644",
      "r843"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r113",
      "r116",
      "r642"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives of property and equipment",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r353",
      "r361",
      "r393",
      "r394",
      "r395",
      "r407",
      "r501",
      "r563",
      "r572",
      "r589",
      "r653",
      "r655",
      "r669",
      "r699",
      "r700",
      "r757",
      "r759",
      "r761",
      "r762",
      "r766",
      "r790",
      "r791",
      "r815",
      "r821",
      "r826",
      "r835",
      "r836",
      "r840",
      "r841",
      "r853",
      "r858",
      "r1028",
      "r1036",
      "r1052",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r353",
      "r361",
      "r393",
      "r394",
      "r395",
      "r407",
      "r501",
      "r563",
      "r572",
      "r589",
      "r653",
      "r655",
      "r669",
      "r699",
      "r700",
      "r757",
      "r759",
      "r761",
      "r762",
      "r766",
      "r790",
      "r791",
      "r815",
      "r821",
      "r826",
      "r835",
      "r836",
      "r840",
      "r841",
      "r853",
      "r858",
      "r1028",
      "r1036",
      "r1052",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r896",
      "r906",
      "r939"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r360",
      "r550",
      "r551",
      "r634",
      "r641",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r728",
      "r730",
      "r755"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r550",
      "r551",
      "r552",
      "r553",
      "r634",
      "r641",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r728",
      "r730",
      "r755"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r360",
      "r550",
      "r551",
      "r634",
      "r641",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r728",
      "r730",
      "r755",
      "r1060"
     ]
    },
    "annx_RemainedAvailableForOfferAndSalesOfSharesOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "RemainedAvailableForOfferAndSalesOfSharesOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remains available for offer and sales of shares of common stock",
        "label": "Remained Available For Offer And Sales Of Shares Of Common Stock",
        "documentation": "Remained available for offer and sales of shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r332",
      "r338",
      "r553",
      "r573",
      "r631",
      "r798",
      "r799"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r792",
      "r809",
      "r1069"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "annx_ReserveForTwoThousandTwentyIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ReserveForTwoThousandTwentyIncentivePlanMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for 2020 Incentive Plan [Member]",
        "label": "Reserve For Two Thousand Twenty Incentive Plan [Member]",
        "documentation": "Reserve for two thousand twenty incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r897",
      "r907",
      "r940"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r898",
      "r908",
      "r941"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r905",
      "r915",
      "r948"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1001",
      "r1070",
      "r1072"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r993",
      "r1001"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "annx_RestrictedStockVestedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "RestrictedStockVestedDuringPeriodShares",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Vested During Period Shares",
        "documentation": "Restricted stock vested during period shares.",
        "terseLabel": "Restricted stock vested in the period, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r88",
      "r639",
      "r663",
      "r668",
      "r676",
      "r710",
      "r843"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r171",
      "r172",
      "r173",
      "r176",
      "r183",
      "r185",
      "r187",
      "r283",
      "r290",
      "r307",
      "r439",
      "r440",
      "r452",
      "r453",
      "r454",
      "r457",
      "r464",
      "r465",
      "r475",
      "r478",
      "r479",
      "r482",
      "r493",
      "r532",
      "r534",
      "r659",
      "r661",
      "r678",
      "r1109"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "annx_SalesAgreementWithCowenAndCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "SalesAgreementWithCowenAndCompanyLLCMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement with Cowen and Company LLC [Member]",
        "label": "Sales Agreement With Cowen And Company L L C [Member]",
        "documentation": "Sales agreement with Cowen and Company LLC."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario Forecast [Member]",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r362",
      "r1008"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r362",
      "r982",
      "r1008"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash",
        "label": "Schedule Of Cash And Cash Equivalents And Restricted Cash Table [Text Block]",
        "documentation": "Schedule of cash and cash equivalents and restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table Table [Text Block]",
        "documentation": "Schedule of common stock reserved for future issuance table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Income Tax Computed at Federal Statutory Rates to Provision for Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r830",
      "r1040"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Undiscounted Lease Payments Under Non-cancellable Operating Leases",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Loss Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of RSU Activity under Equity Incentive Plan",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r543"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operations for Reportable Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r89"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Each Stock Option Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r84",
      "r86",
      "r87",
      "r88",
      "r135",
      "r136",
      "r137",
      "r206",
      "r336",
      "r337",
      "r338",
      "r340",
      "r343",
      "r348",
      "r350",
      "r672",
      "r673",
      "r674",
      "r675",
      "r821",
      "r981",
      "r1002"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Warrants Activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r829"
     ]
    },
    "annx_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Useful Lives of Property and Equipment",
        "label": "Schedule Of Useful Lives Of Property And Equipment Table [Text Block]",
        "documentation": "Schedule of useful lives of property and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r692",
      "r695",
      "r697",
      "r758",
      "r760",
      "r764",
      "r767",
      "r778",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r793",
      "r822",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r854",
      "r858",
      "r1037",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r204",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r216",
      "r217",
      "r218",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r240",
      "r804",
      "r807",
      "r808",
      "r809",
      "r811",
      "r813",
      "r814"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r218",
      "r232"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r235",
      "r238",
      "r805",
      "r806",
      "r812"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option grants description",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Cancelled",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Cancelled",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Unvested as of December 31, 2024",
        "periodStartLabel": "Number of Shares, Unvested as of December 31, 2023",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2024",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2023",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfRSUActivityUnderEquityIncentivePlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Share purchases funded through payroll deductions maximum percentage of employee's eligible compensation",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Employee Subscription Rate",
        "documentation": "Share based compensation arrangement by share based payment award minimum employee subscription rate.",
        "terseLabel": "Share purchases funded through payroll deductions minimum percentage of employee's eligible compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options available for future grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock reserved",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, Vested and Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average exercise price per share, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, Stock options forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock reserved",
        "periodStartLabel": "Number of shares, Beginning balance",
        "periodEndLabel": "Number of shares, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted- average exercise price per share, Beginning balance",
        "periodEndLabel": "Weighted- average exercise price per share, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average exercise price per share, Stock options exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- average exercise price per share, Stock options forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average exercise price per share, Stock options granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r371",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option expiry period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfFairValueOfEachStockOptionIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average remaining contractual term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease), Total",
        "terseLabel": "Additional shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)",
        "documentation": "Number of increase (decrease) of non-vested options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of Common stock at end of each offering period at price equal to percentage of fair market value of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Shares",
        "periodEndLabel": "Ending Balance, Shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771",
      "r794"
     ]
    },
    "annx_ShortTermInvestmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "ShortTermInvestmentsPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments",
        "label": "Short Term Investments Policy [Text Block]",
        "documentation": "Short-term investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r135",
      "r136",
      "r137",
      "r163",
      "r193",
      "r194",
      "r196",
      "r198",
      "r206",
      "r207",
      "r278",
      "r321",
      "r324",
      "r325",
      "r326",
      "r330",
      "r331",
      "r336",
      "r337",
      "r340",
      "r343",
      "r350",
      "r521",
      "r672",
      "r673",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r690",
      "r709",
      "r732",
      "r750",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r981",
      "r1002",
      "r1010"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r65",
      "r66",
      "r123",
      "r151",
      "r152",
      "r153",
      "r171",
      "r172",
      "r173",
      "r176",
      "r183",
      "r185",
      "r187",
      "r205",
      "r283",
      "r290",
      "r307",
      "r352",
      "r439",
      "r440",
      "r452",
      "r453",
      "r454",
      "r457",
      "r464",
      "r465",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r493",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r534",
      "r549",
      "r647",
      "r659",
      "r660",
      "r661",
      "r678",
      "r750"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r692",
      "r695",
      "r697",
      "r758",
      "r760",
      "r764",
      "r767",
      "r778",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r793",
      "r822",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r854",
      "r858",
      "r1037",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r205",
      "r534",
      "r590",
      "r670",
      "r690",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r719",
      "r720",
      "r721",
      "r722",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730",
      "r733",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r750",
      "r859"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r362",
      "r982",
      "r983",
      "r1008"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r205",
      "r243",
      "r534",
      "r590",
      "r670",
      "r690",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r719",
      "r720",
      "r721",
      "r722",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730",
      "r733",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r750",
      "r859"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r900",
      "r910",
      "r943"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock per Employee Stock Purchase Plan purchase, Shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r88"
     ]
    },
    "annx_StockIssuedDuringPeriodSharesForExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesForExerciseOfWarrants",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares issued for exercise of warrants",
        "label": "Stock Issued During Period Shares For Exercise Of Warrants",
        "documentation": "Stock issued during period shares for exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, pre-funded warrants and common warrants, net of issuance cost, Shares",
        "label": "Sale of shares",
        "verboseLabel": "Issuance of common stock, net of issuance costs, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r88",
      "r672",
      "r750",
      "r773"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetail",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options, Shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r88",
      "r377"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock per Employee Stock Purchase Plan purchase, Value",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, pre-funded warrants and common warrants, net of issuance costs, Value",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance costs, Value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r88",
      "r678",
      "r750",
      "r773",
      "r865"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options, Value",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r65",
      "r66",
      "r88"
     ]
    },
    "annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options reserved for two thousand twenty incentive award plan.",
        "label": "Stock Options Reserved for Two Thousand Twenty Incentive Award Plan [Member]",
        "terseLabel": "Stock Options Reserved for 2020 Incentive Award Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://annexonbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning Balance, Values",
        "periodEndLabel": "Ending Balance, Values",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r78",
      "r711",
      "r729",
      "r751",
      "r752",
      "r843",
      "r866",
      "r1003",
      "r1024",
      "r1056",
      "r1109"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholder's Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r162",
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r352",
      "r484",
      "r753",
      "r754",
      "r777"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease Income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r842"
     ]
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfOperationsForReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r555"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r555"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r555"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r555"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r555"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r556"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlanAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets",
        "label": "Summary Of Prepaid Expenses And Other Current Assets [Text Block]",
        "documentation": "Summary of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period",
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1017",
      "r1059"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DocumentCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r334",
      "r348",
      "r483",
      "r518",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r648",
      "r831",
      "r833",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r844",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1048",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "annx_TwoZeroTwoFourAtTheMarketProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "TwoZeroTwoFourAtTheMarketProgramMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 ATM Program [Member]",
        "label": "Two Zero Two Four At The Market Program [Member]",
        "documentation": "Two zero two four at the market program."
       }
      }
     },
     "auth_ref": []
    },
    "annx_TwoZeroTwoOneAtTheMarketProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "TwoZeroTwoOneAtTheMarketProgramMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 ATM Program [Member]",
        "label": "Two Zero Two One At The Market Program [Member]",
        "documentation": "Two zero two one at the market program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update",
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r175",
      "r176",
      "r177",
      "r178",
      "r189",
      "r241",
      "r242",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r306",
      "r307",
      "r310",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r519",
      "r520",
      "r531",
      "r532",
      "r533",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r591",
      "r592",
      "r593",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_USTreasuryBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryBondSecuritiesMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Bonds [Member]",
        "label": "US Treasury Bond Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "annx_UnderwritingCommissionsAndDiscountsAndOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "UnderwritingCommissionsAndDiscountsAndOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "underwriting commissions",
        "label": "Underwriting Commissions and Discounts and Offering Expenses",
        "documentation": "Underwriting commissions and discounts and offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r425",
      "r829"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions based on tax positions related to prior year",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r829"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "terseLabel": "Unrecognized tax benefits, interest or penalty accruals",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r829"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r829"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to prior year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r829"
     ]
    },
    "annx_UnvestedRestrictedStockUnitsOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "UnvestedRestrictedStockUnitsOutstandingMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Restricted Stock Units Outstanding [Member]",
        "label": "Unvested Restricted Stock Units Outstanding [Member]",
        "documentation": "Unvested restricted stock units outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r110",
      "r111",
      "r114",
      "r115"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_VariableLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease payments",
        "label": "Variable Lease, Payment",
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsActivityDetails",
      "http://annexonbio.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Warrants [Member]",
        "verboseLabel": "Warrants or Common Warrants [Member]",
        "label": "Number of Common Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrant expiration date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1052",
      "r1053"
     ]
    },
    "annx_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants.",
        "label": "Warrants Policy [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r198"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r198"
     ]
    },
    "annx_WeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://annexonbio.com/20241231",
     "localname": "WeightedAveragePricePerShare",
     "presentation": [
      "http://annexonbio.com/20241231/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average price per share",
        "label": "Weighted Average Price Per Share",
        "documentation": "Weighted average price per share."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481418/840-10-55-40"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-2"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0000950170-25-030849-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-030849-xbrl.zip
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M/@LBX@4>(#WF!D0)%7NQ$GXDW+X1PR8DQU/=O=!A(O*([RM@9=<#2&U+CP@
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M:2NA1])88#F&@0O81@04CW!6A-NA2W@,PS@*$SN3WA+"BOJ,SGY5UQ5H@&3
M"9RJ)]=M3P4A2%R,RL>@NST74_[=2! 91"QR FK'_>O.]C*J\>Y+(DME</<B
MD<A+/)#@Q$X"#Y@Z$"3R$;I1+[9CFTK8UGZ22+\:73_PD>R/! 7BA(LD=@
M.))XF.?(5 !PS_6<",C&M9W^0H'>',6T1H^08DIX 0T(]RB81KZ3$)8H04(G
MB!/E1%[,>R?@>YJH_T@<Q3V/^6#1*FD<OS&)0\\GG@JB4,74E:*W/3<>NPJY
M%]L7.X$;)40EV+M<1"'A/A/$CR3E<4RE'P[1E-MZ3=<G%87C) DH)R% %GI^
M FJ*VB 5@X SEG@.=WJ':?I2?;:A'9&VPL.=B RYCR6=DG!!/2+<*$B$H"J1
MO6W@.*0'7^L1MJ-;BEU]Z9K$K@P#YD42,Q]MXDG7)J!$%?P(;,95$LN@MW[&
MOG69[(,6E2%+!(M)X(L8&W^@3RE(B%0\]+W($6'86P=_GZ-<&Y+E26Q[KA\1
MG]D@RV,W(K&G)"!8VZ=11%V7]2X#;]G)_Y6=[T[K45'"U):WZ1U\6]6IT$*W
MG#U+;DNHXP<QY43&W"6>:X<D"C&ZYMI4!D[HA:RW?4"NR6E]^ ;7:\QJ33P:
M>M)G1'(/S[CV/,)#Q4@$FLR-?=NE_<5'5SM6\$&+AD9S-_I3\J G/@W"* +Q
MR6,)]KGR"0M"[+RKN&]CQ,/M793^<>H= '1%01PZ)   !J:P[X)8"3R"6;V>
M;7N.J_KKBNJ!*7PQP'?;EGCN^EKB)8+"_[R0)*[R3'U1% <1B*)(^A+4OM^_
MEGBK<KS2_ &Z%CY.#!;X* ++AY-$) XZ?'T2,Q^L:<4#%H+Y8T>]5=Z'2N/?
M+VC)?@7M7#&A8Z^_S;K?7'0F+KY96P2GA]S^&*0$!.,J&9&$N:#0&!!5[$<>
MB6DBI1-( /.]RR8=@L,/BG[L0*H@\!!-H&$.VTAX(@*P]SSF\L@)77\PS'L3
M#+1#Q_9M%1"9> &>DA,2+D-!%,4,+EA?.^IM=/9C455[\#8I,%,N4@5*X3.K
MIR6PV.+C"[H!3 LUSF%@DZGW^Y2AR:>>3+:D'4I@+U#>TJ:4> $ KPC$,.$N
MD\+C-K.CWI73WRE;$I.JL H$Y.\[K/(H=%[K<\Z5M$-@O0#,1<4B#.<FBC :
M)22TN<TY9=2VGW@;E">NT"(W=GB,C2A#[/SM"A(+&A/;%[%4-GP5#/':.[#8
M;:L!]*5.O!86B^-$'X8121X"B\4 1[ <RF>^[=JQ@[Z&OF[AKOS'M*DY^U"4
MG]49H ]$LZ#>@)%R^-6XRBYCE.8JH(%<LE)6WR82%A#Q@QT^&>;CL1_ZL4?"
M@.K  ?:(PH073W#?DR(*W-XZ.7O8$>.1K,;$#3BE0!8"VSB%W"%Q $]73H"-
M\6C@QCVU&ON5+VKTY@-EBSX.J5 W$L*1D@".38#?/1](1<5$1324/O5L:?>V
MJ+G/UF,/<"[UP#B)(J KQP$I(!@E'$]E]7@4<#MVP\!YJ@D8CR'*'Z?+-PU\
M)IBM"!<R)HB;,/>4DYBJ$%@TE*'H+1A^]$#^9B 2#9E48<Q([&(<& ]YBW@,
M]F-H2S^P?2?N7X>W'SI#Y:-BE1H5F=P'@5F<JMNHW-XXVFA$N>N$@D3"DZ#8
MA"1Q[&!_-YM%@O%$]=?*OZ7T>\"#$M>Y,:"57 <L0E<(,.]%J A3B4\ :]A4
M\,"G86]3D_J6%[BA'0)$Z"=A1"17V"<8@4,H(Q+;/!%4)@&7O?5Y]ES K5,-
MB80IZ6)'"LQUD2(F@.L28*LH8)Z?/,1148_V\HZ3<!#N$1$1YC<R(-'8 SGO
M1@Q$BZM<W^LMB3Y(O?M+*O!Q7(=R%E#B!R&>$HE:'@L@[4#:B9MX//9[JU$>
MA!B>LZ_+"1R7^HD@/@MM+'=U 9<[,6&1'[HB4!$3&\^'>AJFI!/ZU*$>R$QA
M8Z,!)R(\"F(22SM.) LX<YZJJ^<Y=2:[<$K*O;0D( & ;(S01-M @2 QLZ7N
M!<^B4+H^[:VEVL=(VF/HMCB,G-BW2<AB[-:4*,(IR,\@X@&CS/-8W'^FO;JY
M]8.TY=D0!.7,=QT5$N5YJ'BD3V)*!1%)()03!$$4]K;3SF,7L/:!L807A:YB
M)+ 5R$818(]R9L.?P@\]/U N[^WV/:%&26MT2SA"<4$E6GH,*\8Q\ST0E 2A
M#;9NZ(-L[*TKO,^AJ@V)1^4X-J<QH;X?85NK$""Y4,3C/(F4@VT8>E??CQ!O
MOE._*XS^3D:I6#H2Y;<RK3C+U1[+TJ0 :XP]F1U)I.MPUR>"<H 2$:.$,160
M, 2<J&*;*M;;U-,;6T;?'@<.-L=&I;1K4ZY<P0EE"0<JLQ,2X8EBL1O8KJ),
M>:QW-D=?^/YB']_;PB*ZOCZ^KA-&OHA=$ T8G7$31IB#/@/N>%S&4>3T%Q;=
MAF&73F[<S>4#A-%ZX"1SO<!WJ,V);7, NS20));8#B!B41QS$/]N;]WEMX1.
MAZIF::YDZR%]*EK9]4+IV"''TGZL](==B9U(DM"-G21T)0WBWC'<0VJI'IB*
M;A K&44A"3WLT"IC#MK,]M!>9"P(A!^+WD'9_A;^K_'D!3<*8A& GK)C/"?'
MHY)$CA> ;*,4=!CE3M3;P$_G1);=JE+&1[8LTCZ!G)N9$@[446O+=EW'83!T
M;9.Y$=FS"HN3\!_4 *<L4T\H2N\R2D,E09[':'0Y(B%<*IOXD1>%W/9MA_>6
M1'OHOUVGH2(#[F"+7![B(87*Q:BQPE-<P$CFRN9 ![W?F?ZDQ^JPU:T+C8)U
MF2O*Y4&4",*"!-"3C_E^L-XD\!(6QRKT^]QD[N;>N@>GJMS-LD*7(SU(>&1M
ML4?/!>F&:-8'F 2@"3M01Y%'9)*X#%L?R\TWY7D^H&F-<L_S7!%1Z8!)'P++
M)+X"C111/*_:L2GWDI#USN#HLRVXQJY]GA_[B? 38OO8'(#+A$0J!NP V^4Y
M@!2B:.CM\[BVH.>SQ!5^"$9Z#-R#KC&NCU!*9"#!&K3CI'?NS0?J[?,T76->
M*/T@0G^UM $&.DX,XA"X3U)?4!M0>@_/UNAK.GHOMC-)?,#N1/D1%N<HCT1)
M8A/A<R9#QA(9/U5/YV7_]9.I^? BD7C8?S90,05;*V:$B3@FCJL8BP6/57^M
MX"M.4'C"F4M>'#HL=#W";2FP@ ULX 2>+FG@L"!4E :]S2F[_5F-'QDO2E87
MY6Q^S=/9(!;&%(!YZ&(!CJT<$L513((@BA.N@M!S>VO5/ON3IG]D):[R\'X[
M^EHJ5DW+V6]%+A?I^T]&KC/A1GA^AW Q,A)'@(L3"IH_YI'GAF"WR-X:^;VQ
M)?M@U3 EF2\"8B<VIM8%/F&>C]553#IA&(/UV=O4H&=40?-(F\]#SIV($5]P
MV/PX9(0'H0W@+ PEBR,JGGQ3Z,<HR%TG'N"A 'GJ$1$"%/"2Q"'<CUSB!+Y-
MDRAD/GWJF:\/<U;2VB+/GG2]1')%8ML)B!=2F\2.K4C@V4)@=T'1W[:0/8P[
MK!&2^%ZH&'4$%H,"KWB*DHAR"<+-]I20CIV$O95F=RI>_S %18;=5^'"#^DY
M_O9DHN*^[_C<IC%1'N@=SW,3$B6!(%SX4:PBX*UH,' >R\#I$94P)_*53WP7
M>Q$B4_/$<TED>U1(*5ROOUZC(7G\AW8<(UV^*[".&^U)SR.Q[R5@3R:(<6CB
M/%E[\G&Z3]+;-G]=HPO>CX/8B]R0V#("M@453&(W ;0J&?=$"+MJ;[S[Y-.P
MO'P>^:X'B\0]J0@8X: &@PCF AHQ8A&W;:^WCMB^H,@>)"'Y(HJIQR@)*-@8
MGB-"@)RQ353(P$+C7ASPGG7B6:?(3@+J43<@H1V$6)7I8$,)3ICGV *6.>DA
M#?]PSL*MN6-5!M$\6ZA;J@O@_7.!RU]/,531_>I9.IL"P/8 ZQPB&39W%YYN
M2JJ($X:1QYCOQ7YO-?Q0A/A4+(? MSW7!74J;.X1S\989P2DEL1V[$J'>:J_
M60!-LG6SEP?E87HRJB]E !AUJ^O7DH>L7WLDJ1'0,)8 )),0>VT$?D!BY00D
M<IAPI0K"F/5.R5RG"KYI8US)55W:#J8U$KY,\Y,GPVZ<^S9G MM$ HZ5"GMI
MN#;Q'>FKF$64L["OV_/$#KQ[2;E<@8A<.W C -()IL-2#H:2%Q$W=)V )[$(
MW=[Y?QZM-/*1MBAQ*)>V3V+TX:+52F(><N+'=B %DS(2O=NBV[8GUQP)*A;/
MS<K^<UJFE4S%4\KS"A(_@95SP2[%VK,0C#0>JIBP,(E=SZ6.;_?V+)?;'71U
MD*L[GW-U*Q;>[/F5O?&WA@&(USB11 ;(OCZVA DYP"S'CR)E.S3P>E=PT+O\
MG0UM31Q$#+-E R?4IW?X)%)@-_M@TG _\;%A9U^WYIG7](;<IQ'S$-_B<2IQ
MZ!(L1"> 33PW$!ZE=F^Y9I"K5U((P*=H710B8Z9DF!"PC!0R+W;1P=IB+[+]
M &M*XMXF(=S"L?^E!):ML>K1U$%N&-H^5+OD*9C?>@._'4^FY2)&-=8INNK7
MYAGP:_N ]IOV;WS"BJ?M92P=7WJ<\>;@5W=\'+H)T&, ;U8!+X_AI01[5V09
M*RN=TS@?2J:G0!+=1WP&::RSXB_.)JT*SZ'ASK>C=]=-Y]+]^.$[E1=CD/DK
M'MML&<ZJNNZY2X]XLSS[ZU?#//N*S;IYX!5/;$Z76[UAS9=WW;*C=Y<>=\L5
MAS_2\QUXBV):"E69/T>*2<U:L$:__IME_0+_6E4]RT!<3,#L J1#ZF*R8V_[
M:?[V7R3-I3K?(>Y;6&,R4NA2W*'PS:2HM#L!GI\QC$V\Y<4YJ=)_P0-V>%'"
M( 0^>0N3G[3/3X!K\!*U0^U)_7;,RA-XJ![MK?XN8>,TF^U\!=E269_5F758
MC%G>7LB+NB[&<"VR'F%9>I+O9"JI<8P*Y'P[S-D(J)S )T+M3$I%SDHV>7MA
M[.N&T]]]5QKU[>0 #?6[GZ6R'NTD:4TT\^<X[+__B0;VVU_>X.BPI)/.LLY?
MNED+?$NZ[4]J2Q93GJFWW<6F[8P>?7&<S:W-TJILX&TQ1J;*B^\KBJPH=_YD
MZ_^]O?KMSPQI\R*3W:WPUK8>WS[O?WW_SCKZNOOU_5&[++V<J35L6KL41^_W
MOAWN?]U_?V3M?GYGO?_;WG_L?O[]O;5W\.G3_M'1_L'G82<WN9/K$]5_@,4(
M%]5%OF6]V][;MAS;]^(-[-[ZIGSE[C6[@.)]QW6W7=?]::Y.FJU9IT:9:W/S
MMU9B^K3=]LI2+T0[DQMIHO<JZ*89/#07!&M;D0\'AY^L541_A]'@W0!'PC :
MT:=" ]4/QS$-!7,32A(1A<3C#B/<LVU"0U<ZPG?0;?S*:@RG0Y7<.N'/RAG:
MLE*E.^\*H7U"Z(OHZQ)3F_QU3G)+"_7K?:3-NJ<Y")>G)UQ6X?G[T7VTMN5X
MC1X_ZR!7/Z]?IZYOEA>IOF9@BJVB?#:MBY8V<:+X9-@+O)QD;%9,FTO,(-2V
MM^V?VNL%.E0FE=JIU(25K%;+I*SO>X7#P_AE._AI6J4\S=)ZMM/>WUP$5\DY
M=>OAO)^ZQG;S=L;:?G/%+7%PTSV_O*G+BY-J[7TDX3-X.<)+Q;[OZ)\$/UB]
ME9?GO>192/.WIZJLL4UZ0]CP\449@U<]@N^@^Z@_'ZF30EG?]JVCV1A(\L];
M%<LK4H$L3Z[2@DX8<1;1B/B1Q/HD.\+SMVT2*(=1&7EA:'OKTH*[>3YEV:&:
M%&7]RDJ*<LSJO[Q*X?TJ)8"'BHPS3**&35Z7T+BE9(Q#+WA[@Q+4WI):/EU2
MV>PB[G[^_&WWHW7X_LO!X5?KR[?#HV^[G[]:7P\LL$F_@N%I4=<Z.+2H_UK^
M;!U\L+[^QWNK8Z[.3=7=O:_X-8U=;ZV2^<[R=K[;K:2!?U&>/E54OCY#[T-1
M6O5(64E: :%;,\5*2V%JYDU0_:8I7"&D>.(D+@JI*,#.9=+AA(52D#@.N2T=
M*@)O;5#]BPZ<O#?AE"4IM2/A$S*&449X&Y%L1O#5B<I7">5[O7'D4<IM#QL7
MX9E"3"G"L(K43AAGP!I^P.+[OO'>M"SAA3_H3?P[O,AM7_K2^_:&,-\I8:)]
M&!A;NTFS\>EO;8A_8B":V*$>H2)2!(Q<1F+%*,&S^WQ)I>N[P;KX9T%.'^"3
MJJ^4@GD2-RG\*W' BU< !X>]YJ/!:GI^5M.:W1#WM9LD]922/B=Q M+48XXB
MD<,YH:$?4I\S/Y1\;=Y#3-;7P>N>VDY>'VVGOOBM;K6,7P]W/Q_M:S-IK1:4
M]0%NP.LZ WQY?[A_\,[Z<'CP";<#!G@$.TL3PF!KW;Q26 275IBX9GU(08L!
M:R' W0Q0%$HYW'-M$O(X(9X3Z/.?T/:P7>XHG@AZ;V_0>YT,A^]B7J6O"V_;
ME+@P>>>.>/")QR/N%-]97W3B\2/_G;>ZZ;6NX!XEN RE#(APL-LP]QF)I$A(
M$-(X<!SF.?Z]W12&>P[525K56 6+J<5KY: ;7_Y.+L'W?SOXO&7M?][;7IM5
M]5P3/EZ_/V>BUEMM%8FUV&*+558U40*SG:65YE9:5];>B)7P-AL(7@T)(8.,
M[&,JYM,TXGW[[E;\S?>LT8J_O.=W--(,]:RRT]J/S%K"LM/-![Z6&?:*F"?E
M=J!$#/!..L0#DYUPQ_=(1*GDMN<DWOUCGD9/8^%M.<'F_"DVL@#ZTF5!Y6RO
MD.JR&8_-<=2D+$[Q.>OSLM_2=9ZQ,X8%'YNPY)\>D<1!J)BG(N)$PB->!/80
MY](F5'AQ&+)8>O?WF1LB^<K.]YMJ)J$)9;UVT>W<X2'Q/>IYCGN'_;]&"H5/
M40B%_02:MT./6KI816D5]4B5UC\Z5?P )[O;]\S>/.W*6+T Y0G+TW_IOW_N
M@]QZRJO[>G_[</MHVVH. 2J?,2$M"V'K<[&]DGI^T$.Y,6_%C_KZ'.K:"1,!
M82%V1!"Q)#'G@MC<"4+?B4+FANM1<+M2EJJJFG\^IKFB?37"J6?;UE&JRI)9
M7XH4C.\OK/Q^QF9#.L&"<KPXB1RN$N)'CC[PU@-H%"NBJ&)^Z/N2BWLGIUQ%
M.4Y?*>>W3)Y8>P.9+,@D\!,_C"B>?8>]TD(PLV(GH<1)[$ F29@D<F,"QNTK
MF1Q-86C+L>V^^D/7(!ZH<OS8D\2+\<00(1F)I92$.JYO>S:+_5"L==_WX->#
M\FMQUMN\M-\ C'.6WV1<]W+N&],B4:P"//K/D7@25R@CPOQ($,=G-'&5%$'@
MKI5,M(5T4'XIBU.P&1[._;+VB#"P+TP]3]E3)*=-49/K><(-\!AQ28F'O>"8
M[U$BN><&7AS&W*%KI:8O!9!+]M_I1+OR>KK8\ :VWU=-TYM5>MUL*8;=)B7(
MAG3",DN=*Z%/RH./P2B$9\,WV12-?NM?Z01H2:J?AT5L%W$1K_SW/T4.#=]6
M5JTR-1G!35:N/9I;G15DI6)Z"7>LUYN1"-*7*J%!2!S! 8O02&'2LR2<!4X2
M2.X'87+O%'J4!_ F?98!@7\3UNSEM'_>D*)@H4-9Y',"! %;'$62,"4"DB@;
M;-> !2JX-SK5?52_(.7W.\4IPBZ+_IUMD2<>O1\JKJ]Y^_65+B\.F+5*K1M4
MJ:0UF9;5%)-:ZL*"*[2GE3JO^<^H?+&F;%?4.T.>PY/+<W"=;=>Y>ZH#O?LM
M3O@@P[C1=A#=(P\CZDT$]&KYN3I<%?43L-XNCSZM,YT^IY@860(/&-E8!/#*
M=;7^E.C_V>ZCK/#5:_JC/0(?9-6>(S66#%__AICI4WY#4S#UNMI<G'W@LH'+
MKE_*STW&M!;YZER,L.&W!;@2!H)/%N#SCCE,#ZW!'Z=3R$U1H AIY\HV!<*)
MPLA)B.NA,>U+!T\?$R1R_"1A+G>C^QO3C1TQHP[7VOT':>O6Q59 .+H1^)8%
M2-DZQ?.LK?\%6-JFU@1;E8\>(4GR"J;56_-215R?^2+Q&?.$8H0))R2>"A/"
M@D00E[E2P(] 1NR^?-& "Z.!-\D4NY\__VT@^!=*\'=S'NG]N0,^'JD;O+S7
M<IGK>[9+W80D+E/ ,1P[ KF4""&C",_#%%RM2_N\;W"%KK>[%#E&U'&OH/$M
M@4XEV3\WU:OSKIMGJ%VK2LN<GM*';,G^^?/F;ZMGB<<3Y/5.L!T$X4_7N,CI
MR_,!GRSY@%<*AKZTY?Q<+')Y^CB_*RL%7R -[N<24[J5Q6>6&"F05F/L_)H:
M4NN4V::5Q:PSE67D>UZ<P;05J^#!$KZHIAB]9I4E59+FI@KW<)HIR[/]EF@[
MM [TNVW]'7ZYOU"^L S7MJJYBZ!:ZMK2@UVZ"0?\8+"7VXGK^!'Q;<F)%_LQ
MX1+/55:*4I%$;G3_-GHF*^@/H)N_(MD<-52SKXFF'RSPN=@8:-@L ?2&5X)!
MJ_^81,V+&E3_/Z<I*G[0]PGVL"EU&ZMJ-1!PL8;+]#A:P(%!G/9!G+I!Y-J1
M<,'"<L#@<BB(QD1X1 H_M!.:>-2^MUO#B-/_*K)I7K-2]PDJ?[2+Y"!&>\8C
M@QB]68R>C92NX%V6I3O6:_JS-0((BA)46BS+YF*T*U^Y:BZ AUXC4CM@M?5L
MH)C%KW7;. G?YB?Z4E@#H73.)G4LW0BXLE[#\Q+X?S45(ZL:%=B*QC)'3L(]
MK+ZH",Y8=5D+Z)N;=_@9T'4NK=>.>4>N%.S.E/\#W@"OUY?"33B+YCG8&+'2
MD]"39%5MQ;8EV:S:WHSP4XX ]*]<$@@[!$&F*(FQP(4E7B0B'HI(W-O;9(1?
MTYC9-'M$%V_-ZA_NI+MFHOV[J@8AN"XAV(>E^EST>[6\067\H,K0DA2$Z#BM
M:Q"[*@-A6A8YQAJRF:5.53FS]M'GSX0N<WC':F9Z3%Y0*(MG= %[U_\!@TXS
M4S9_1+Y:K]$1&KYU7&=[[B !6P#TS 1[EFU:NYCYSI6&JG[>D$JP/25=+Y1$
MN'@N0> JPF5""5,QCZE$3+RFAG^=?<)M:C1$/XAR4 F#2AA4PM-0"=K'G<&+
M*8L) 2H!<\&EEI+HX,Y7?FK!!,C*+ZHQZ!(8I6RA*@B[,:S); LM#G@<P'1<
MQ!/KI"S.ZE'[]388($K/33O4=6]S77Z'M6.._?:J&>JOZ=OVLALON'I^[85H
M=3077S'7]LK6Y4\=3IS6CNH:3]L7J/)I)O+3:-L-?N#H ;IM_T#^OQ]L4_<'
MLO-_;#3'!CSR8._F;-\\UK6-'+?OF(&XV8S#=:6(WD=VWDHB?EPM/![R+(+U
M)2IM?+56=N%_WNNR:4CR0I:QA^3U5%9E=Q!./:2>7JS+@PFG:Z"'LTW]/D$/
MIP?[<D]ZA6'PF[^\<EX-*S2LT+!"ZUZA]15R/9'"K2M/M9M#H:M.TU4NB]S0
M)BID,?$BYA+&8DF2,!+<]R+AJC7U9=3)&WN <DZ*<K8B:UY?I/&/:"[:< +]
M*C]6#XZN>S*X]<6A^4WGP+R(11Q(ZX=7Y>@J!_:P6H]-0P^HR&\MBJ[0^#2P
M@R@$%>]RQHGG.@[A(4^(#)434,_V;7KOPVJ-QM?T^MNT2G-55<L'R2?IN9*D
M+J<;K>"^*&+O=8K)8 <_!48<5F58E6%5AE495F58E7MXB>YZ<.(0;1_LMGZL
MRD8MD:>[+ .Q/.E5>;\Z'6]8J\>FH(=R?"SZT=S#]6$S$;DR2(BC(D$\E<2$
M><(A7BP=+XYL/^3^>EP?+;W^KLEUSU#K*A=(PK)J\SX0[T=\("N[]-PIJ?IY
M]"[?3ZY)7L9C+&Y9 (\5.+KN1DE="5\7UK0RB<_PW@K65%IX9:4SH-L:%ZQ]
MP;&R&0Y^EL+0,*R5PXL4Z H^32L=O,I9+E*68:HCGBJ-%U<URR4K967A.4:I
MO*K;CON:_;PRAWG(_'\Z1'KG8K"F=+B))F"+5$Q_9W6M\.@K) R@D;2NX$$Y
M.]$EMO/#7%A5J:K"CUJZ44FB=$52WIR=@W>F6*B4 U'B/,LBLPI0-1U:700R
MIK!9Y9PB/=OK' )PQ$H\+JTB!^>9FNG*Y-?4M[YM'VWO;5NA$^") 3_CB^/5
M2ZVE> :RO\,125J.3=48;,:$X47 1+JEC]0S9E.9ULV\[EHG]B,:R1$L\5W7
M)CR.$^)1BD5C$25!'(745BI.DGL?++XODG(7WZLH=Q>[^R%C)Y>C\+PH,LZR
MK*AY<;Y.RMX0X]_NC)*7* \2JUJ4]0.EW_7<C2L56U>D+%A9'Y=GRO"+RZU?
M]$E/IE.6N:TIWD\R7=,/'XFB+%5[0+G6MV6)Y?P%<NII6DRK;-8RZJI1'X)9
M@?1D8@/C44<I@(\\!,:3G @'1(QM<R:C>S>0>E>(*;[0AS0_JL?U>UR%O?G:
M7&+:-:#(@5W[P*[7\QHB/LU6!0!&PQD+AFG9N\."6L7-JZ!1QXM"EWB#*L]F
M56HT=(Y=7D%E$\X00R+*5'EE=#]68L-7NG7(?/0N4\^QP,6C\<JJ6])= N(]
M11DPGT*#:[LRJ*D0]^QM:K\C% 31 #V?#>VN*CJM1BK+6A/*>KVBE^*5A94_
M#]V_UE/!O5[=Z 8V];W )TPI!W0C<PD/DHB ^G.EFW A6;2FK!*DG0UY5!ZR
MY]6@"Z^JA]+:Z3^GN;*<:,MR;,?;TF* G9P B$5),]8MIIOS&*Y63=T3'"P@
M&ZW-=/TZ:*JL1SR:PDNM LZOC68N#&P665%IOP[+%/IT0-GB/4UG%  !57NE
M:0YN_9X58,P!Q-<PV_3EQDN6UO9GW3*%329E<9X"+RD VO_K?AU2UNK ;,3-
M!]WQ!";?-."R ]_E+"$1\UPPG$'R1)Z(B.U[86)3&474NRAOF,-H$+@QB6+$
M[TG(212$$0D]9;N.")B0SF5Y\T5[$3YD!:M?6=,\-4_[=OSMZ-TKJQ(,EP9L
M=*D$K%Y6_>45\9?%4CX=$UG4I+GBU:]>&&X[K0!HWZM7_5'@_@SFM&U]Z-&L
M /0":)P !-:L BLO=)^A!FE>+1T:WK@D #37;5EGRAHQ@*\,K,NQ:KH*84N]
M8EIK%ZKF.?,,1-I7/4>="S6I3;.BY1'U840PD6):KH#+6Y9,$<H7@)S1!4?M
MG] K!6_#L-=1A=)K5&02+MVVONK>2>VK SO(0K6-58TUS8 4X3Y8Q<:+AZ^C
M9<2$E7-OP&+B>L(:XFNXUBSQQ?X5+UDAX<D4YM#J#C7=4NMT:8CINSXH7DX9
M&$*- /:U_.V]P)4J@LG&/I%,<0!X 0A/+!0*_80E$4U4J"ZUMY(NBY4C!7%#
M+@#@.2$PC!-CO,T#@"^I=.T5'0_U^NGE.])K?;!8PR4);':B*WKW/W^X0?92
M.]X*X?^1$_19 C>,WE#=G,<;1UK_J85ZCE0,C( @B0/BA6#-,1K:Q'$"P>)
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MEB#ZL/$85IYOM11@1(X\Q4KT54 +#+7"E F ]!$@+)-IELVTS9 IL  ODMI
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MA_@@X* XG,9N!\4[Z(F@Z?IS2=+^?<EE&946:7 '9\XNE57#_!+:W$0"4V7
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MA:RJ9G"6!JEF?$1'^O7\U7Y;6U+,##B'K(IGVNW,K?84=@"#+PI@<+0#&.P
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M-;ZMMM1 BF.0%0YX'WR<>P^;8$80<';8L'UR]!"=3.RZLT.=@0^*%%?3K>D
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MJ'S[.PWR#4'.R$_?',MD@J*;/?X'=V]GR?Q>93X0L_Q#CN1?IA[@-Q;\/G%
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M>Z7N1?]Q>'( A<=<ZY>DMQO#OI,514-@$U*;LG(; 9HR,@%A8I$FG;SW\")
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M_S"C=AH@D_,YCCP;^FHU5200;JWEU81!7$7H^J> 1:PR;Q>SKT>FN]S7C8Z
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MD%^!!T,^S;V#9$IGFEE,5XW@&)>KOAET?9D)9*7BTG%#+KA>0S-N%@P-LS.
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M&L<,**EQI5J%LL/LP_J/"_*]@L,/#S3[>)G4 N'7MG0,F$W;Z+^X!*[!!A6
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MX>&L8& ^T]N$\R<,N*(G>Q?@4,"\J+5A0JVL/!P\=]R+\;MNH71W)W]W\O^
MDW_\&T]^B4V<2N%A_^P#URPQ0W^ZY>R.!$4I23F$'1A-P 9\&"OVYNC,GPU7
MV*E'W5ZQ,M",V>">K@9.K)WK>5;-:38O]758%<B%7E2"D9=F]@^YTJ[DLE>%
M"F>9\Y D4KXUQE0.-WW,NM=/LID!ML9@IW3B\L8: LG%ZN]_*4BX3[ZW 7M
MF!:@AX!O"A)<PU@"#G9$KO@E)M"MFQ:^6T#YW-T)#/5(HU-BA(+F6[&T#Y5#
M!-D0F(KLLZ8:8UNZ3I)W0ZW#\3?+P::Q]MR,QMQ%T'H=I4O#C0N(/%[146<_
M6,P_W 0=U"/;(9+7#J\:7G&#N&,OW8BE"H".+C$!DKZ"YD,V'$?<9QQV#I%6
MX3/R,L3@DB0AJVBEE(A=B 6#Y 7K%#_07F5)WTFZY"@SDR"3!=.LA$M97HH[
MC$OU(EV187;SEPW#(OA=-JD&RF><AF8568RRE0=9WZQH0>>K2T_CRN U =[K
MVWGR F"86RFTN>4#1$8;!N5X7'V:VV#Z+*"SQOX)L2]5#K87W!R%]J'/. 15
M!_W)F )/ADP,0TCF51S3YZQ(7EG:XBJ3RO_F,BMF9('/-B<L;SC6?RFZ1@C_
MMS['>&HR\XWL[^TF;?ST?2J;IEU(*I]S>[.VN*EDW\[E@&#!=7T^-"398D:U
M#D)F #(T&H3']'-*8J$-@U,:!GD)C"#(GBCLFM-OMC&0'!/._.$#"WF$AJH0
MP:+CK7I!Y6CP?!8,EB.6F2O(*B8MQ(E2#W[EE.ER ,0_\)EATK#,YAPFPPO3
MQ44^;Y%=M/D,,/NNQ[S!7F"-SR45S.LEB#6.H'L-)E$X2>0/ECUM /Z.@C(J
MB&3#J'K:[+[XWY?,-B"A#-CE*1&UO!YKKK7/$A%9Y)V(O)4?!+ XW@ !@KB_
MO*A<8T!0P/J?%B2%2YEHI<D-%R%<*S<JY"96DMB/8%&R1YH8[=K=DW0\L&/7
MUM8CC>A[:?PTR"SK8;?"K+2 :)U9&KS NH1K7D1].@&$";@L7>#Q@ I>IV@^
MCH?92UTP1.(?#OOX_]E[UR:WK61;\*\PSMR>Z8Y 54NR9;M;,1]D26YK[G';
M5W(?GYDO-T 2)&&!  T056+_^LE<F;D?>)1*LJM4)>V($Z=EB02!C=RY\[%R
M+4, 6%EH5;:K?L_WS*3"@X.W;H+KH<T,N+J@"NA6.[W7*/?I0D "F?2/[6%'
M-_Y<X%P!R#H<IY4G+8HW#)T@/W+6X%MGP:7\!DYA\Q#T&,\V.]+7@?T.%CUD
M^>6#MXL-//+0#O:A,)"R"TV]"D+Q -<#EXX@J5NH+LD&:%O97#[?V_!6MTEK
MQF&$ VL<DP%X4NPQ+&4_I,@8=EI%"\D!?@BX:4-4 ,VQ"5?!0"XVR#.=$@"5
M3TO:"=Y1%NIU@",!+",2$Q<(%:NS*"Q[,M4(R=C9^V/\:9 3+G[DPSEZ%4[%
M7%93584VBEP^#CA2MXW@2/ ;B*@ _ =:R+_]SLTW%( K'W>6,/-$EKZUJ:EW
M^UG&.Y4CHW+H*?,)98,XW]A8NO+M!_R:#J7Y"SD?(W5L.CRE8^GJ._D1,V[Z
MRAUMN@-01Q-VT;)$KHRMSRADX*&SQ6735WQ%#!K7QZ@H5N[Q*4'@*)A1#SF&
MW@W/.(']J"X4ZU'DVYK%OM ";V%[>H>&J72%A0XV2KYI%[Q=G.'1.KG(#8MF
MR2+_PH;?>W#OW&%^JV<T'8;?^;"K4\WG28OF&DV5M[B(;)V[!'G]>>C@:AN"
M=0YM.L4U^%U4/.(W&0<K8XXW]F3 9^L%^!_CC)TY*BF;Y^WZX&]/;&C\& R_
MRWN\8HS]>KGUW>,_'Y\UO^--8':_\)/[1Q=;!90&3EU"SJQ 5&;M9$'PQWSU
MAL.:=D$I^UK\N^VK+H*3.(*"#V,7B(\^A#WT-78)_(0"L9L@LPH+SWXC"CZ5
MZ1Z :6WJR'WJIG<#7OZG2REE+!G<R)N=I6^8-76M+E""TO%M9) RP^QXS;VZ
M5M5JAM^G=T9G2OX&Z)9BA9DB3G>VM)IA$I?DP>\U8N510JQ\,HB5SSZ'^E;U
M-^":!.CM(W"?*B'6]$A=9=H)CYTAJ\XE0-K358S!D>0]-'X&P'\=MLACWZYI
M]#0@?[I%H)6/D.\'9;$Q<P]%)V/IA)!C1\] WV"P1PL2S?'#:K[A<B C%K&B
M7%Q[6/ZN]Q%6_B+.<#S,7P>C >$CC3A\[I9\9BI]#"KA)I,*:S HPZ"4H?P&
MIM9MY%A=A%T(H 5:)IB@S(HW]!50@;]J8@"6#RV5P*A$E<T(M.+.=TE&B*WN
MVA__61R/,@64<Q@FE8]7!0RWT'\%C\+P&S915'37(OJ!L3NF'TX^5FVYE)Z!
M3_9FZ(!X[\[>G7TN]$]QE5.( O+U2?),3V*&!;0T&T-C2+Z@6;QS0K$6YZY.
MJTH'Q:0@(,\@!7W33"[HSDN5HG.W\YV66!285OI!Q+ L\_/H1?$G9A^;5Y3[
MRDJ;XV5HG?\+##$+9C.MZF:OIFJ.@@[_JZ,<5*\>%^M1$. ;LP[LW*T-T18:
MNR]RW11N7?3 H27>([\XYF\D$V%.BM&+K /40_@BPQ+\AU44PI5?4_B&$U:K
MAB&X(MKS$>UOV-=R(_=\_+'M";E>R9O1A/F"6_,2OC%HP-Z'? $2GWYWV9>$
M=YO2>#)(['_N6ND 8U07<G3X+LU-1>XA8F@SI=H8K1E[DVU+!LOO4J8*[6/F
M>/6?I<H'0@E(,0?.S-6(Z6?SLI).B27&M?I]<6DH]W0ZKUD*Z<+.W<Q MVT8
MX(2;T$5YH04K//<5#PJ^\/5*OKT?2L="^!K0!68,HJ^]>O'#:^#W5!H3H!8!
MN8V 'N2<T.<7'E1!V#[%%=!Z,OOL]/K2<*UY<B;7.5=>0D\EIA5*S#4.IUWR
MQ;Z@)>/^@<+HBAK[T@WZ\#A0?E$$-10_M8I5M0MT7+# C:B?*V4K\:O(]*3G
M JVU<_$]6:IMS\.V3*1TZNA:TL'<][7].P\S"R>E G:[(#+TOV'CJG0P4<P@
M1!KAE) B8C('N_0CDX$ZN"P48S;WGA&GJ3JK_[MZ<V@GO)CK-K^,7J0_,3>C
M^)6WI-<@#L[_*+[70WB?E[4V"]G;H<M/+VE/IK.BP]9+TKN?YH'^G4H-RK5Q
M-DP4N<Q1AH&YX>@&SC/LTPZ=IP%*E<E.\-I^('Q8D9MM,#N5 XV,]!5D;O-C
MU[N?FXV;W(SU !]Q!&1P^L'N1T*1@$FR0"_>'LB#\"9_/J#'4;C23]**3Q"E
MH3)X-'@?RS=O-+0?E@@</Q-6-*Z[TW'  YO'N-DYPWHZH:LN\])<V#<,A$6"
MYXO75HK R2Q2MWQ)KR\NU1(*M+>86.$C_SLFZ/FYS5=OHFZD]$1/(QPZ&GT!
M/0K8\S;%&<]WTPUB#&5R $<@K"%*L0C.77!-KD$TU-=T].B!QQR3A<$R.?.9
M')S]#HEE\""C=8O/'ZO[TT/X#'J0"'AF=#0D%JQXQ<\F(/F0]L.A=X/"E@ +
M) 5R_66S),^7X8>*[ ''4(?A/4Y"'_)M6R@Y*KK05WU+W\2XWN9N!GQ3#A4Z
MQ/H<P#]8GWP*Z-$U_:&I)YY!LL<N)O,.;HE#ML':A^\SQ,^,=YL[G*5G?YKN
MV,N>],3@O&I=H>UZ&\LVQ)U /N1FARDT!/F&[?\A3N1],  ^VI>.T]&X2-QL
MRCR@=[*I[UIL<TW]W]'3S\9-?>\+IG<G93RC9)5W^.1K&BZ<;"1#CN&F#2<0
ML$4+F27?S,,'\8NYYDM)6>KPV)OB0OX#3H%PRB0ZAK[E5AE]O>DIEZ.XFQ[M
M%!U(G&UI$",ER4$<(Z; GF1\ZPSS!%<JI6;O_"%D#'XXU$^%V7:<* 5.;,R\
MTB1!>A/+TL%\**$)\P?)H^2T;MI03UXJ1?[(#&&9X78&4M^1*1[Q3)QZP'V-
M.PC#$;AZ+51+/B<,?\AY 3?2VBR!Z5@KHT,9\, $+T6RIVAAC7\Y*&7&A[:"
M0<'$VT4LX I^/NHX*]K_W$56+\T&P'DQ$BP_#TM?E'ND/RC;A[+!&1F6U;R%
M;TE(/@-#DVKKE*'--HC"0J%2G!JPMJ.-X<(*AAV0]7PWGI]*^(%[A1_X(N$'
M$G[@4SGX7]:N:Y!-*B)H.3@ZNWU2Z]/7<X'*#_+/<0PQB" 6$Q%$%X40W;5O
M0;*1H9B6.[-'BD [J$T8TSJ^VO4MG4K\W'9**I*;4_:\:[C\RU4V([JCET.Q
M0: O8;/9R&A\*!%=3'C)*2;.N40KQVJ)I(*Y'5L.MEMAF*!3<%FN%9RQ9P93
M(#6N=4O1DUWGJH[A</@P&;?0Y'B3A+/I:\T@^:) =+9YJ]?@9"&O;,9>,N:P
M)H"H7$:3'.ZDXGA@, KCXA N\'?1='*S"=ITEHKYV7PWXZ(9;#CZI=II LV8
MLJ& 5'2H?JU(^6C.#);-B[#!@_CYVW\7DT;G*D#ZFL*9(UUN=$3]IK3GT[YQ
M^'QYO"RS^R)2V9*UV#<:"-'C%#KX)<FR]"&4VT2H<_.5FTP(BLE!@[[*^YJ^
M&H=(<3G=]0"F6V!-V,SR@T62Q4\^5+G)A!GV;<X%F2RJ66S(OKKP74;UB^A%
M>D$;IBLE1UJA45-SQUGZ"8B2[6-\Y>"=R_/.O<KABJ2T<S ^.UF+S,9E@DD+
M8&_RSNQNW:  01NSWA910:&+@1N,$4;_="X7"#^LX+3SQ8N+ AFDM^1XDB1*
M_%R#12O%<96RXIT(X/%ZH@14-PM*,)GMAXO!7>Q8Y;?TEU<.D#"\5B $XLI>
MEMVT@Z8SD-:T6#LZ'\B8UVD4_!VV' P,+IX'!LA6^N(M98B4R)))IWY+M&K_
M<D(>X?H]71WCO8&"J7UD4"7*)[0>)TI7+1@V)VI4&?!5M8Q]YM-E+!,,&S,2
MT:;><'(OT=NC!P\R2D=QEEV4ZUZF=?$H TTQ!(@3U]LB''[/R]GL3E!,KAL?
M'@HQV.HX"(A738<32IV<(7]T L*/CP..X9=VXN<-IL*HK M0.6'*N:,X<.:&
MI?_!-."#=W<>&4+XJHT'0]%8// E71GMO S1MA0V1K5ZV% W=WFQ-P21_)0Z
MJN1*XSA9BOY(_T:)NE:&T UT+2V9_951*C&U506HF\S'4%CA99O.IVS9D75@
MM.8D"E9K'NAG^$H)EZ[^6 ZG/I;/B5@0QOW%"#LA;:E5Q,.:@A)#;$TEPK#6
M73YK0('>#&)T5)^[H!WV74"H?66#,T!FE?*3B$!'QAK QV"ME5('ROW9OQ;^
M[+$0GS+/>@ D->DK#]P_:3883ID.&.5[VO41NCTBMX RBO,;2(Z*O:;#V%NN
M!\H?G%T(SC'KQ8F29/IY>ACN=LXQ ?B*=LX[Y5*S%0^E[Q'](+2,22?$PX>O
M-E@WS0-LK9CD(E@^%C83%H/A,19>8I?+WN;;4A]<2BD@&,V+\V+./#:"_#V&
M1$L3OV2<^_SWTD'G-&]$1_T.:W,)ZV4>TB&<SSZ4\UC:(?1+!)*+8 AB76XV
M!7#/H\/ZG6:0+:)/3'T_^H')KN13#&GR5<2L0WSAW(X&O7W^=K'B!$_AOX;"
M<(I@ 567M RXKZJ3*M!L\"P7P\9R.!FC+?7DC4>=R0 ,$+XH+]8G?;XY&W7,
M#ZZH( 8#\@8MI"W;)E];T!5 94?.6']L/7%\#\HV4[=3A$A&3E!F@B,M>%8<
MGP5^QQ+$,9(C%'B-* :XDZ8%'F:F+&P G%D0Q"%QV+ML+@J/6BEXUP0H^J C
MV9GCZL+#)^PSJH,U[^K6?,K-#CSL,1H!\SMF= V(C4ADZG&N5WE*^^(UO>1L
MII!RX'=1OS)RU,WTO H"SI3VQEZ-PJLQ B":JD0!QP#:R"+:KE?&A3"4=,1D
M!IIA/<P<WL8$<LNZ%_#TUK+,4$#6A7333 91VA!2=G&RUZ[/F.,87X[$>ISR
M'L_Z\^@2$.PH/4&-1S^:N;W9<1774M 0F*YZ;GR]8]G9)UP)>U1TEJ3/]P?V
M[$6E_-?-N:4@;EPK\]EE-%SA>B,VML0-^Y(K>,/%A_>;$;9WTD<,B%&)3WTY
MV01%5N<DRFP8PW4QI-L6-=LBW]E9JZ6$A!6:&/1/W OAWXT)?;8B^"V?=KS#
M^]@IF@JCQ3]0=D(NO'(3 F-#E-=-WKJNF[Y>Q>-C@16.+WV7T>8)L'&O !M?
M)L#&IP?8^!RB!/.NDGA.\!VXIBWKFS*IO'I0E/:X/%BIHL6J9W<>L;F)?P=D
M0B5TFQZG/IWI/&)XB@^4\\6S^ R=)G3&$8#Y,A3!$' P4AFLS*):B0A! <D.
MEAB@!? S6<BI'IRJOETGM5_1+2RY \P/Q,4*.7PMU.GB0:YH]ET#I+;U0'4^
M;2F;+XU5#32AO-)2\)5E]I'.[%I"EG%N+26+NBP4\"E-.I!64O@"IENZ=A71
MGO*W4 "W24.#+?(Q3P;&<4Y=N)FQIG6@;WHC>0" L,<VXBW%-TCM3@;IIDTM
MF ',<80C>PHGE-VW4A%CAD5L&@@Q,0 Y0VAL#.':O_X#!R#/%_\IU86R0POG
M)"9#.Z'I.]K*?2W#L^[2UA&S #HH#$>BVV!WK3DC7Y4'%'$,-"1DN*B8KV0.
M&-><88')%@KK0*VTD14[7;E:YD-XO'%1"K.8<'H-TP 7U<M8$L)_'98(IN>?
MR/YW&*1@3M+!0YH /F5_)U4*]H[!=3&Z_ 0O++IH-)-KL[IQ#A+]K2)D9 ):
MDX?SQ8_XH.]-0<,8*XV&''#94^G>YR&_>0LA:-(%&CG!V)CKP/DH446\\^.\
M/O-S=^9 O32)N34G#2V7U=DE<WE<H>Q\5/DY"& E0_\8ALY@$CI\?LE%R%KH
M:^0 ZZU/6_"QLI))D4H^D$PSF>9-FZ:+3;AI#2\\C%:2%28KO/E(8--W_OA6
M(GJ#GEB-(*(W9R!(?SB$!#<6O,< %7RP@PRF@& IZF]6#B<U9)])]I[L_<;M
MW?6XBO+?G+XVTL6O';C%-H0T34Q=@1/#%KCSXJW\R8^Q)+--9GOCP0(7#0
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MYPP#WSM)239;B:?E(UAK,E$)>E_QM QKK,A_XOL ZY$'M_. K_#TV=-LH;3
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MP11'8.7:M*E#,-*A9]*1SH.I@AJ>KW'4"#"D3H7R$88[P8>(;B)&C^B6'TL
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MB*^,H1O*HR2<B)6Q,?:48E6S3)(\%J=1%N4'1Q#D9',LE@Y-X@MX=\&J$E/
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MIDG0M$=N>X_0$QU['%]%S9526+_3'[L%29MDG\D^?P_/>Z11[2BS*6824'A
MPQ&ZX ON1@CT'A^7>NEOK(<@$P3V2Y/X=%1+'1FK=%S\O19MVBEII]S\3HG$
MXVU2E(V; O\>\P>J5I.%"C;Q]/+5VC<P_&!*-9EU,NN;/P#>0_'F7236L60-
MCWRIG,W-$ELGDTXF'9JTC36N5FS/"LFOZ<\KC2#8+R,I1*<:X47PV:;B&GSR
MOLE4;S\]E$$AC!<)1Y[$QM>20'T'*19W>@K;#:.H/E)KU8J),=C)%X$MJN@K
MW2H_N/*HQQI[XC_&$#(+XG"^Q"ZD?!Z,#*]3])XVVBUO-,QU"$ELL[F>OFHL
MW1H#T&8Y'$%A*;,%W%9.9I[,_,;-G&?4VWQKB@CE?MFWG8![+:Z1^HG-XEQ1
M08_J\3&+JT98Z[;?:BXLOEWAL+%*"'\UF7XR_5OP\*[K),P15[CT@7D/2I51
MKWK!>PH=HT3W-K?X#$E:]?M>H'1,%%BLI$VOE"W2;U<$B73Q^>04]/"(SKFO
MM:V>>V*-YKW !X.) L&16UE[&JX ^F2PB0"Y+G\2(N40LK4O<EZ/30_$L-&5
M=#L\&7^F9:R6<L4=\N[H?HYY4>J 8L!B:&,M+%JRUST#X>\'#<?G:^QE!S")
M6>>DR8JI8XS5VSM>=P[1#8RL%H5,+80H*>F:2UJ%3-"-;6)$I3LJ4X69WD9S
M-S%8C+J*D0L+83-G[P%(:^H6IG^,ATWQ%9 &-11(YYUH^?(6$9X?1PX@<YQ(
M+LO-^!N3GU:*I?>Z*QDD.[3E*H#M["GO% (@AT-<"4-_"(H_7[P&$;Q^4JYA
MGY3O"8H(TVLF<8 !R3W?+"34BHNRZ3M&CH(CJSJASPLR$_<.BAR6U2VV?:F3
M0]&:W8\M_\G!,*\W-%=V;[K%*R^#QT"X;W6N^F-A&F_J17X\N.)'@M,Z?B[R
MZKLBOV#V/NE5@U]!TON 6RBB@@B+ @:'GIYUOH)NR6@[/ B1CHJ"J1?8D6R%
M/]95^X+?3X#:^QU)_*)'2=UX*H0)76:4AAE6+UC[*QA^KVLW,@YKU>;-@"C"
MEW('@VI*:NFJN7S\\<TI986G/HX()C,9R_/<F)Z$\8:WEJ/9\\0K$BL(@U 1
M\A$I'X];KS,LX21-T??-)88<[O*1G4;G[M7HW!=I=.YS&IW[=(ZP;<F)$?PX
M_"6*;]<BF2P]NZ(;_499[E+/!)ZZ4Z9[)3RUU&M=4'(G(@QK95+>%,=3QJ0Z
M)?Z72]6KDW%1%CRPD:^ -,PGY"'B\7\E7O:GSB0W/L8#=2J=)\Z5T0K5\)G3
M",>@<K).'F_(KA<1V70$(/,D*DP1/'^A^Y%,?J[UHU]V9<4ATJY<EA:_6*.]
MTF:-\$Z!9 5$3/12841K85>.>.+XI><\4O'LX6_A9<%(6C=<$I_^O.0;Q5MR
MZ/0H,G1E=LR4CQ3J?,>[YVW.-^;8O2@:6$E-_ I;5VY6NG0'VDM/^,8JL>4$
M2:2[0:D>LU]!--JTGCJHZ86:?%GX3Z&NQG0>)X$E*'<7 KV3$\N+/RXCL?2%
M+OC&@ '">S99PSH_]D9#7G8S2RKD.(*RN!YJ W1ZSIU)T4M(M]4L)A:W[-18
MW@JS4O0&\>;"(-Z]IF79H,C6GJU;/)S=MZMOTSW4'9<YA()B]JTD1I3!GGXY
M2'ADIZ#ZNV0*H"(N*<S2T87 X@!&K-!BR=N<!<79T#"?FT$8SVDDC0CRR7?T
M^R7S0FZFY#U%GZ:JFLLT\YBZS)]+EWG(W",R#5P&";D0]6 S$H<)Q8= ]S@!
M@Y+=WK;=.MX2-*2YC59N%:FVJ.GRC.SAZ*#25C7,]>4_GV>+HH81AQ%-E*]T
M_7)/F1U]UJ%.E< MN%S"?":;OY71ED(R:%#<A(7B:X7F(2QH.2"P6'04^'!L
MU,KX) 0B0/4[0^TN/'9!A!5SL_4'K88'*!!-->@E<OGZ)%04$HBE_9/VS\V3
M8NT*I"E*Q^K"FN7)DZ%^QQ(G;-K/^<1XNJ9K.?+73!GMF2P*?^Z$47Z2WW=;
MU$"GA@RC >76G#ZX;5\5Y1*>;2-\#*@\T?3YT"[2.]1ETVY,N_'F=Z-F$/4J
M5/C@NL\Z4BT"4'M(,)RC""?#;R%YBI:7QE>9WPNZ^8V@]ZHM[8<DT@9)&^2V
M4YRHJ*IB163='9>R@J+[^QERU&QR726 D7V"#[4D%*GK8L.TOJQL417I@$G[
MYR[O'SD,"@J0F%:45;Y:KQP&^)%QM;@Y(!#E.;"_B\FP/R!46@C==UL6T,(=
M3@<-]H -;AL"RC!1F<*'TS9(V^"V)D6Y<A",B=8%E[@XJ!*8.B:V_>@HN.52
M6)3L^>[9<[[:E<6%,0R85*0I_'"-JVA=<1:J/$7="068:QS/5*$6<NTBNK+4
MVTHOCN)85)FNB[LARTJ+S:ISSA_*@8QQFT1K#9*Q^'N;'U=]9PB%#Z2#)6W$
MCWJP.$G!S4 >$9O@<D?'R&7A=HMHNSJBNT6^IFW!^4Q<#AOC 'C#%%=E\>_<
M+;3W>"_3_VVYPL>5:G3]=7A\7+>#:IX %C*'5AHY!KW%R@E6QIR#JEYK. @1
M@1)O<I2?-I0V[FKX9<[L5LIFLOK'#S^E S;MZUNO.T3=4(/PY-'^1%%B>S*F
M2UJZ32P?"<',#]RYU^4CB2;@@<%SD6T64T=D&$,Q74QR.<M>\(6UB$Z .JLU
M)T _TC+'3RDLS-)"R*M&-$[A!D*6.*_.F79KVJVWOELM@@T0X#:'[.KM3!\0
MT*JX4SCF5]$<T ?*A_R$&#G\BEZ[V_'1)APM,C!E0]RC$#5MBK0I;HD%NB93
M+(N@P71D76,9XV@7ZP:BPJSN27]U';-,<V=W?^[LRS1W]LG,G:43(9T(-X V
M6%(HLSMU%!WE-2O"^;#&Z95J+U4;GLQH("T@#*<$LW<?F-,,R+K\#((Y D1R
ME:8W)BSK^$[=,9:"J;1U;B>88J G?;#6<9QP_P@#$[B4C)QAL)O(F"G!EB(
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MS4)4]B3D(@2MV_P$?JHAW_HKY1[=VDBS0!\)O**0+'+$#A8Z.MRYL";UGRL
M\25E ^6QUUU![K>DE[%L\G8M9>>7K[Z5/TQ,2!VC:EUP)0JG<4Q,#P.&@X:,
M7\>+S.SO>!MMJV8YWJ,9UP\EFF>7_X]O7^,)_O$TF]EO4'A!1D5)CVS.JMCF
M5?P2^1K!JVXVL\NU:ALN5"WJ?K]DW,$F?AE#1Q"A^P<&0O_&0QAF%?]R,AZ*
M^[_ZM5NA3>IEPP?/F1ATR#-(;N38T&85^K;BR$6'6@H0,F,@#C+P0S6.?'BK
MV.9DZ+/MR0<47$;@5-(- 5WD;=GTW> K.A_'S^J$A#)T[]Q!SU]F.%-3(_ 4
M-L5M 56=W_JB.RJ+T*CN$%4KJLH+()DHBC TR,@JY:2U.P;&CD-@Z.W <XQ?
MR_3PAKQ*&*/M1ZE<,@)^' XAAZVW0<&"/-[9^++\MW19'GOA,17<7U^_J14(
M%M1UG(=Q=D6[$[8*8MB.6PP/OWYRE3_@FT?EEEG.@>#G[]9K=@A\B^LRW]:4
M,#!3+BUL41N)K2O:Y^R1L5/I9=#_3C^\KYUA5!,=@;>'HF;YFP%OM.?8Z':E
MG/1XEXL_^_TV^(HPZ_S6YP!J4UXCI6,FNSV3MTFND<G7N0PQ73R6XD[4E,Z#
M10GMVT6@ W/ZB\Q*-=S%L\I309;5[,N5+@O?VD4NHU[B+=_+UE)8,-OYF*DM
M3F)_AVS/DI,@G.3W4A1O/J@ -CGF=:V#H*S#6-5JM-XVY'B]9&*="@I@DI:5
MO LN2H5&^)(DXEITTE!YQOZ6:J[02$.7AQ>CK"3U0LR+FG1>6Y BI&NT%B74
MO:]:#GX%H^7 3X_KR!]PI0X))F>CV#+7?<L3+SEH5TW*8_%:BJC:XN<K:Z'7
M.R4DU>7@%/=T$E=(X431\ID)FM*\/0T6>!ARXJ&'@X+T^1R"=IJ79P$Q^6I7
M4 9#/B\;%KYMC+WAU1@M3V!"6GH^M!S6;HUDCSZX[&VX<ZX(K&^=KLB$K_30
M30V^\'S9F-AVBUG,F@G)@V!$2L=X]G50HP]3M8%U;IIV\NVHUBHV<EPV"(*<
MJQ]!1]?0$FJ#>35UVG./@U9&\$ \D^F?)#)3#H0PS\-&H9Z#IVXW+05TB'M!
M7>6%$R^+@7K@_&WD[:B5Y2HJH0WS>H0G6ZB-2&=S'T29>#+=$>$EX'YAG%$(
MB&; 9:'!BV%@AM^?+^7PI?>LN4);>1@,2\(N#9/9P5,-!Y?L^;8H<[JM_CNG
M %.AZ(87)##XZY\:5S2%O$UC +58G)I^L*/'\:#I?\Y/[C%K#J>1)P]XT6TL
MMT7QQ,J[&X]_D5J0^O,0KGN1EQ5V2EY1OE;#:#MI^KF'UMJI;B1GXQO$NNO2
MYNCA#$3W_= <'.60RW=D,1;+MLD!TV&V%*A+(#WKX((Q9NCS;+JUHI)<%V,E
M$,?KHG9G+T%W=%+$G-^ME9$O<QC"X+Q8!B< $R$5+3W8/HR-Z KD3FH*L,L#
MLHN)PM[0RS2MO$A7,@FN=Z#,XLP7F2U)B,Y@&%I91Q<=))8S&18_F.GI*#VA
MOZLP#VE:E?L8K!?M@V,7+:A7+#%!15XA7.P5#_._H&OWOAO]0PG%*?[/UV@#
M;Z4X]>K%#Z\A>HCA4CAZMW#@?CA-[CETV:=F57W8YA<S8I$,\42V).!Y9 L.
M7'0@[N@I!^;)*R;(".Z'<T^4 Q'^AI(2CFV!NEIR!8(!80'_]!2%F3HH0QUJ
MC.&81EN?"4Q^VX=<4@F\%%72U3&$7"2Z@'L=2CQS+UT=.Z7,4G<23HHU6"*8
MI$5&ZD]%;DF)F([FYT=D>?27Q8#LPA&J1(07?=Z2!1=!WC"T/@LO?.&1Z5J4
M\SDP73#M=)31K7NFH VP0#-)BF]?X5"H69!#O.]0!,LG4B*=\?/3S*!8Q@!X
MG&_9W64GF\ S]PH\\W4"SWQ.X)E/YW2Q4/^$!HAO[J(Q)?*8$^G)LMA"DI:[
M;Q)I[]GMMY%W_X%R1N[L9J[V*=4DO0RN05^@?%;3C)Q%VD/Y]*[OA*FM74CW
M3[H<XPXM99@N"8 HDT]:AW?/A^4TPE[/U\RQM@VAGM:JG\):GR^>3?S0LG"0
MH/ 9UCJ<P)W'0B0')XAPO':5/AIZ+_DGKMV>!K72H%9H6\%02M=S?T J0B%.
M_MB\+?GVMB<?Y7%?O[QHI(%*?SRVC5"!!J5XZ>T[Y6OEL2WKWK$_)B:=9/ ?
M@X3A?8=>N+P&N*$""Q1CP670;:V5.;'&/.Q])?-.YGW;YAW4PUP_;VS4.HPD
M50RT^PWHE8PT&>DM,(KGJQU\*3M5A3%$-!X<RRL/\Z%M,.3%Y3@@WO(QEA&:
MR8*CD6]ZR)^D"4%K!TS:*.[5Q;:QZ,20;HRV"#M6W'4#5M0#O=Q-!+^=MDW:
M-C?/,\*U>7HP9-$4H;=]>33LS;%59]_17PK<R[9(65]PZKT%""09:C+4FR?M
M<Z''RU??!J"KXX(=?^ WDS4F:[QYM[FWDKR (.CM'IJ6SWG1TZ&K 4%N_G+7
M,&(F1C?8\)D4%OVXQT1=$:T$FYN)&VP\AB&T!#P^\UM?TJ[@G[;L,T0NAI]/
MVR1MDQO?)C5]1Z%7&P:*U=O.Z"5%(J2O R9)R()P_C@8*F(%%09>44B?K#99
M[2T0C1DRS*Q6AL*@Q"MYXUQ!+@2*03"^7Y]2-I<L]]:*($$"YPF%?&SA,CGC
MPA/ES]:0K=H@3E6[9+"W8K"[_$(*#"BE=1X[:3/"F+4Y]JV,W0 W#7FRO<2X
M#'@XZP_)5I.MWKR@\D1]F)E!2FEU"_U=- :/L82V.8#!L>E5=#EYUV2QMQ3(
MKM>49W6!AQWQ*>EL#J.XUC*N*=H /3,L)7--YGJ[YHK(-40-^=!UROT^80^;
M+#-9YJTU'R) FQ*F"H?'Y) :HE8>4*2\ZGK2;T:CZWG(<?VR2%3D[Q[G>DM[
MN@3TQ-,=*%L@1CBY*-X516W<@7+DB;9'Q.V23;ZM,4J@BUB A&((M,KX@:&0
MI\T53] +1BHZ5PETNJ9 @A,GY_M9.%\=/K?-LRF*]3)?O1%'.0.N5.4VC%-W
MRH^U;]:T/!'*<A)3*36'F.U,J&K"$6X@DP%5YE%HZ:\IS;8;PQA-OV$.PP#,
MQ3I%U6G[W%[9PL4<L[15O,V4BLRW0&#C 4FZ3L5'I/WK8E6NBVP1,N-T$8]#
MSU"Z@ )PGB.5SV+5"5FW_3;F7FV;;9OO4S,E;9S;0?7[]-,U3!Q5R&8B>+]Z
M;RV9SZ1E_42PL3!1D>,4R19%W395!3N7(>AN>I"-H:=TP$Q>Q?B8K%\NN[.%
M;,C12_6,V%*9E'-7;C%L+:H-PRNG+9>VW*TH\X:I+VCC\I4[37BJTO$DG$RO
M8Y+#+G,?]BPZU@\URDYCI5.N'L\8QDD9<^OUBA>?S_K#,PT\=^^E\WZ%OYB:
MU$T2E&DSWFK>I41Y$=I[L0?M-^@],9DY,?!]?3/G0]38G"> C\Q*C#U5>DKU
MV0V?.[@.TK:97\2-]S7XQK#?IV7M^UIH>9CL:Z!P#[QF]%,<*D3'+K.=B=XL
M7:7IA%B,_(N?1MD5><4/PP2]:3NG[7PKX:QPH8^&I-\=MFX9<S$9<5['=A,=
MSMVGP_DFT>%\,G0XZ=A(Q\8?>6Q8OC1_3+BPR81XNUC@T7*DWYT6Z7E4UD%*
MA@JE)7<IEDJ;XA9PUH,B]X708!6+D>@/'6L+'H.)_@$C7VC]"C)PNM4+B03H
MT 1?#;E'NV$HQC^8S#^9_TT#M>;4 $(QX*%/+REQ8!H1VB6G!089<Z SR'XI
M2&QZH\#9+Y;]T7.&=_VR.1S+O?+V]PD%<Y4LC6H?A'3FUVNYR>D=J!7-2H&?
M&@@#-5T@@B9RY)545(O]H4)#HYS08KB69LIU @U'_5>.Y)\CSL)&/MIY)70D
M#]+8Y+]K:JZP-FO(8K,64_#O5TF1FJ)HPN$DK_]9>/VR9@K.OC:^:,BCI7 [
M6=Z-6U[ R?KA,LWLS]G_J]S$Q'=3;RU9]*T"RJ>,D/ZV8\)_+[HFZIP A2#T
M23XW6>C'M- ;4'U*%ITL^B-:-& %-Z,T%H(9ELU;%B;6?TDVGVS^-B+G#U:@
M2\.5R49OPT8%2<8(*LW9R/Z:"P98RR2DS<LI"]Y5Z5^J#<\M\G?,#O@VYWHK
M"I<2A#F]8F:O#^46G_[SOQ\\>(Q0#P3(CG(E1,+CV/S'MZ^A"L:1'CW"(0>)
MP$:5%XNS;__SZ6)?R&O"%^BGLL618?"FJ@(]R;+M&%18;?@G'CUX]/A\\2/E
M\1BSHO5YPXHO)461>2?J9".1&"=I=K6DO3O8\P6D4I?-F<* 697\IQU=?_%P
M:?-:' J0:\R7Y.!V_.\_/L,MZ_I@:!2W?L8[:A%2T[2\-!FFV9TDLES^"QMA
MW\F8&'Y%KWA)EQ3]#"Z07Q850Y@KU*;7@>RP5$(V><<[ CS3$,ZQ>OJFKU?J
MZ-MBQ8H^IP6/P?:=/33?V*M?7BA#F6BXT>WP=?=L!K*.+#U'C[BE#<=RXE+F
M7[!0XCIOURBVK_C%(ZPZLE[<5"H@HT(YQGG.,-/#UL>02HB]XPY@&K:J].F7
M__5R2_]$O[>E]U@;,85&5W2'FU(D%NQ+= LPQ9]5B\'ZI* #-Y0F&1 _-(RJ
M[$)8=Z QHLM?_MLF=Z6EX%Z>=1KX0%W\ZYQ^TS^K__V&==)I,U0G/X=XO&P\
M"%W&IZIJ;'Y?3.DWK<DITDO0Z0RW$GP5TV 7OHYER;HJY2IH,K/BBBDD,1M(
M50PLT:$J[.[>L8[%:%_&2RDX5]P!O2<9A21'$,V,V3PG3UUO^DZF(_%6R83-
MK)?OW\N*G!>9!,O)LY-I\.(BF4*Y)YG@%DE8+T(8BX"&+*JTHKR?S9LP:EG&
MM47BL5!['PV#A_/=3M-C8+TF0NVTG8,E7)Y,&3'S$M+L7IT>,^Q"PST\GW,(
M]%P',A^WMF1&.X-S>AL)5V+RR3[XP9+8^(BP0-X:!*B]#*U9W68\.XQ-!JS]
M2)J,+(/G*]5 7K[ZUMJ@C),ZEL=>LE/NP.,-PW)L],LAU=T)ZJ[TG#?Y:W$T
M/S1TE#8XW+]MR/D#GO+\]0_?9K!1?TD,TSA3G1+Q#">USQ>O(2P]D*^>G"H8
M+<FZ+\0+^S&]C4P+A6EW(#5M_@-8Z,'R0BN"O/8[!PUL*L)=P.B^\*LA/^C$
MS\3\H)[*YCV63)T4/YJ*I0[9J"/:Z2SDO=!30Q7\^(!0>HQP""(+ERP\=^AP
MH;.1+%E"\[X3S\Y'>L93$O56!I>V'''4T"ZJ["&<'O>:WF:)"\+[^\I)Q4/]
M?/]V0E(4(R,6C:E\%1-+>C^$MS]71_==W[(I9[;UR@EURK)V;.6NZY$INHV;
MS3##1N9M1?9X'B"2&;5T%P8)F+*1X$7&U:O<H4_FQ;40!'6%?EL3!\E6O'"E
M3.WZP'?Z<:3Z BA)2'#MB )C]ADG#+.2_22S0HBTNZ*]*%>*FJ5/]Q2IWN4-
MD*9 [M44R-_2%,@G,P5RC8?^A Z:%=U.L^]4=*O.MXA-_!$PB#N6/=D'Q1WD
MF9H5R'@DYIL0;>Q6.PK\[$2JX*P/34479A>.!)QNH]E3RHV3(@4D=]E.?J(4
MAN'R PTK!QR:8MS@0Q=P^PX5#FX'<N!<=OQ%T:#EDSM7/O7>2/SH)@%JYO\U
M,3@K>ZSR;F>2+4<)1L@>)7TN.7*H:TTDE(& \S8]_,\7+PWE*KZ/?G]7'G3@
MH#XYT>GHJKZV03D(;@+Y%47@/==1FGI3E2M!T*(^1XLCE -3>8C@8*62ZHI"
M&\K3:JX#1+>%QT:1/T=^P:6<G52@6WK77M]4*LTE]('U ]LV*,"AYJ3BPEP-
ME1_U NA3%*%6VOJMYW?=U%I%Y2]25AR6]X;YX+$KJHU]_=>B.5#22[:XSB+*
M/[^HPBNFI9&V^#5. Z->A2LE.6:Q\\53J^A,7$-^RI$*:IG V5E8?[%Y$JO5
M-DX3?1PK)T=UEQV5H/D#2DM?D911;LM>LK!*(O^]@1<8#MN=QJ-V5R52^BMJ
M6DXS\QK3>;N\W?-&L9IS0(%IVW<!8^8BA$JKG#QR?^+"ER6=NP$,5+&<%%(R
M6>9:H9OD%VMWYDN1U"^:+9AMD D_']4\ 6_.0+5$V>=E/?W,$3T9W*]UT<(R
ML7<?P_5P6KF.5R:OM,XZ6BIQ$FZ9FI5L\I4NO(U>5B<=/$-EA_\+;A>_O.2:
M#=U5%OAJSLQUQ8(ABJ!0Q5=S;W^PQGO_YJSV)N?!*N\[882KBIR+]]QQ$K_E
M+1B/OE<_%>?C4^\'Q5(N?>UE5$.OK*ZW5GL.3ZN@I3EMLCA*:1OR#:"'-F_<
M:(MUCL-1BF5TBG*!C>MJ,8<KW5Y?7Y1\+F5_T-+;]GK'BR[6]\.Q7^'%O_EH
M7OQ2\LME4ZW?>SGP4W\OCW0CJ_=W]+X'4'(KC<V<?D+*2^RTPOK2A /+XK^,
MW!*;J92.7:LH<*2H-5_R .L?;$D?82W_F"CB=]1S[E@0H<38-C"L0WA&0*NY
MBU361XW4@(!LF7=EY^G'I+5<GR9/:O*-JBDLD2KL<'(6L&I6U@@7,Y^C_B]H
M:<MWJ%:YY(%S>M\T7I["!&'8BV"6@F(MO67C?,.9<6BQ/ATG)YTD^@=0+@JP
M95MRGU;:#^B4ZSI=?81-M)CHKLO6-Y!HN;CMQ8N?J4:X3CON!$PZB!ZN7C8/
MU-EQ\YMY\&RE)!PD?U,BTUD8ORLC&,9DZI%'XOQ1,1XQ8^545"7+Q01?A61:
MRO$EJQ9\/[Q=OP@27HQ[>FGF,F$C/PML)/8JN5"400"^L*UXDCY1OJV;SM!1
M] Q(7YC=+F3MHVV=T.;)6F_%6MW9@#-;3BJ<\&_U@%FLR)@Y?R$_3YF0(!D5
M_HM3,)EJ,M7;<:RHQVP6H=EZ*&=,])W7>75"$!S4J?GY'W[]A$L#Y9Z9KBAL
M.31ETJE.-GQK[K9MWI9[;6.$Z5&DDI:,,1GC+1BCE]5Q+C+97K*]6Y$-B&76
M6 5]C/ -^_U6?HGJ/>B7TT57QKO@BR#)D),AWXH3+=Z6,HN[;-8XU:<F?0"%
M4) ZFD/6!I/"'H:L^ L#SK)DQ,F(;]R(+95JBTW1MNB$<P=J)=)CAQVE4:LR
M3\:8C/$VF'K+[HV.\1I07R?D%%3BQ+%4O#%NX020-#]0- #KJY*'Z^6KG)".
M0:^DN_1;G[?,U%NG0"*9_2TP]/IH>"^#>[XX8/-5U4GUCP5% G(%-\">K#19
MZ<U;Z45>5GG8) @GV0_*0[ O(JXQ[H?GAU()TJ4]/L+"&*V$=<0$Z"#^^4/;
M8VE^Z<[/+WWY(,TO?3+S2^FD22?-'RN"S5FG]NP$6:LAD?T=YF(.BKPU/8+%
MH>&+E)@A4[4"UP8<X\$E\!=M&[2V;12&+R>GE1Y[51&>94%Z49^@&,)%G&!H
M>5GX(]&.MY"&4^%UP;%6;Y,B2-I?'Z,"KU2;,O.FZKM6%N)A.=YTB:MM%A >
M#EC,S:IHJT**P)-1,+S$!$+7$?,:%C3?FR<J^B./-C)(DQW@W&203-"5G=Y$
MJ6.*%<_]T8>%(T%QJ/CLZ:#%/Y>#>A?8"'=-@8$1X;Z.@*N!W&P#2B2/>U70
M:33!TQUY*(0^&7\NUR;0@.J&\<&8_E ""'V>IAW.N;A;,CCUZ!>".[&'T4,B
M2G/"S"98],Y\>ME:TG*^^%:O$RO10XUMPZ>+>^%Q:XM>3,68 ,PJ%I$H#Y9W
MFNW"YBEA#A.3E&HXT17\<BTP[:,$4M.6,$0DLPEZ.YB;OV4^=!Z+G+BC\\5S
M-]TU 4F6:5L;S[39+M6MP+Q/[F:CCH+AQG!8:\QW[I WP8MAEAD.@@9D6'']
MT$O1S$YE!9X3(8:N6SC#,3_ =)>AT&G69[! 3Y5N";8"(YQ5HL;69P<5U#D"
M46IN6A<M$/G-)K,!RIG1-3'175X=U<5,S0EE8V8W^?#$0%TF'L:N%DR)NF 9
M$\RV^T(6[;K8"@<#(H'?>DPPID&C^QVSC W;+/9=YGVUS<H!V'=B3I-T:!AH
M.A9MVQ]"&X:UC\ZX>CT:W,]E\-,1N9-E@@M^835$N^+5(Z8Q@1L? WEK)]N0
M4B0BP/NED.C&8TW<,6'+J77ZT0%DI!(:R>FDO[]0YBX$3^-HX*++9CH*%?2T
MLC$5ULM-K%\?O<R\Y?%!1X)PC6.+(Y/,\UDZWD(-0J9Y"\%?JJJQ.7IUCO-7
M7A7S$>K[G600G HP]*OO^][T9U"F6XAXX0JEYHGKD^%<9Q;9C=7Q_S#QKY$D
M!VG^^>)G:]&<&<M'O*\\K:1&&+X?#UB4C5LC,O5!Z9C'3*;3A3\T.%XFGB]@
M%G'NWQZO*NU'5E5>[H=QM01(T1.$ XL>FP4>W55#Q\B_Y7V#Y$<\B*.H!BLX
MV@7,>$#/C]TE9R8_CU"-,S@62A#Z2=HM'=.M5,IH./-V.%/AS@'HCR54]K=M
ME,3S1#+\I?[ 4Y7U:9HR]<HSG-?-,2/B_I4 TE9%8U?'?127KJ(5?E>@$+Q/
MM9VR_K5OU0GFQ]W=8"*X%Y%O*F+0VRSREJ=C)\H84-\T:L7<\M8@971H#7[W
M]L]T<+E=0[N[Z92L='[KZ+@P.?(VLU+IH6^[7BA,:\K'*W$W.1/9<DBQ*Y<E
M/$I_8"+R?$]Q0E70)7SY%^53/))X2OA6VC.[R_R4Z50(,X _>_B;DJ#[8S:[
MBD1%PYX1<:L>W)<['.)YU>=*!5_Q63$IQ'2^\!R<$R] /6W,W[TNY,R4/%0]
M7(PG=)$[UB)_<X7C9#98CK)X@/CL1+; 'K=L[@E-Q6>[@=]Q(!F363>AP^&(
MWBT/Z!8<JK2>&B#,"W R!J8^G2:@"J2WD46<S^Z4HYWVSD0S.N(B=:;^B,U@
M/N;8I"GSU+WY++HW,QE.0,1N]1[:S]QP6+?YI=OLG1S3X>YD0GB6E<EK1(XB
M1N)T1$H$^77/O Y@48XEU1+T+)G\C9O\I6.&?%]]D5:TTUPZKP6)9+7):C^2
MU5(@EH,%R((TKF-!C0'A^V4>!T_<'S0VY$(O846?9,7)BF\>]AL(,X3JJ:9"
MQ6HF(O(6,^<ZJ@;+Y$.#EX]:4 '"/"'@+%QK/?RX%N$.=)_2YVJ+9I.L/UG_
MQPRVU:E+:5XW"5N]DR9F/CH1(<K$I:.>A,5X\&0) 9UE\Q;__?")*0T+AS=4
MYG+?24"0#AT@-V!:%2U?^#E7:+[WDB,_"3%>J]IA*K'"^7_%#8^@V<=5[;YV
MB$3^2:U3F^BQ_ZPI$7'>OY=B7K[D.:Q@HR94_J>!RG^84/D)E9^.PG047BN=
M*5TG)5^\>O'#:Z0SW-WE!M$/;AAL\8^>"\5T9%2ETX<5J2ZK1T65Y,V@S!2F
M/9EH9?K#2W3'^"N!]I8RQ+;H1?W5G61J_*+QU:$5!3KPODNSOFD7W<HN<K3>
M%,Z)P,FNJ-; 7BBTEB49K)F2\OUDH!_'S9LX,92>:QE[LO: 0V+%:J:KEF'9
M0.G0_S^F2FNRV=NPV;!<),:+B8"*$U\W]4+)01JP2_9X6P-V;7'H52U-6K,L
M$IO&Z&8AZ2%$48%3\:R.":CEJUU97#@ 9>G*5E)[7BCLF>=RYFO0#AF30;Y=
M9[P$"1.KQ%5-)SE*@%5Q<E@Z#Z>35+C=Z\ IY_&2!K0< &_+]Y(]4M4C$3I*
M>D9IQNE*Y">_SGUF=6E:@3-VI5:6%ALH*L1UK7(98A\:MK]QDY08.62X9ETW
M/?8?V6B_I)-T-Z&Q">2D-#[S3NP:%]?#VP\;PLS:*![-Z:<%X\AJ"QM7!^ F
MTIIR>I,U&P"DS7;U=YT\WP8Q*_]ZFFRZW\?(=T,S WX81KAB"JVR6Y%#5SW3
M*\Q>QNHFK'XHTZ@[8#R!(S\@WQQ8K]6^Q$@'CIW_44=:1_C\ZVP7#%%@HF2?
MORE0X]H+2T:VX+%C:=_0?]#=KIR^DHQ:F:P0YLGYU+231@CU!3[,O^H@HP9*
MQJR&8DS7,M E4Q?-X="TQ[[6B=E-;P<'%^GDOPP:C3$:X4IEQ+2]MT[U=+$]
M%T]#3#;_P,P+M!/-?!*%8W0?N%]696%Q*'Z=.H05G']NJEK?;B:(-_Z*$B*X
M15(Q8:XRYKXI+A/?BN)P%V9W&+32\9A8M"6C:-W*\<K$J[(^MT?\^1HVBA>O
MZE'O[R_C(>S8,^HP?F"-?E'$N2,)&]S/)?[NHFSZCKZA[Y.?*7J/[W/V=#LK
MGUV4Q:4I@:_R7MG"6"1K<.?1[/KY8MI'8.6&_B'8^-&4D-K&8)N+ON\ @F8&
M:#00,J'UG@[!7?3=GF%BMMY4XU1OG:]KGYIQ(38@:J^8H=C+XGC)MOHAKA-F
M[5^(#OWYB+HZ2<TS#%73[- ].7)M8$5F!T*4?HB>V I1>^:.#,G3@'?8MH5Q
MH_!A,W%D%8,#*QLZ8G]"M3IDJX+E0$%S8.;*E:U+#F&,SHU5IY@D@CZ;*]L$
M^^*9='+;YOO,<]-?N"G-=GIN\%T)Z2+@@3%)9LRYUI@<%IWAH7BR3.%Z< 9W
M&78-.S)N'XRB'WHO+'",8:K@7N9DI\N.-24%Y'7)'HK^XG@Z\"?XH'I+AM#Q
MY$9P!Q(@G)H^&"IQ+]Z_[DMUCGZ$B2^]\UGF0/(T8/\/'Q<38#*5IMPN^JAT
MM,GTXV!Q_._Q#1T#Q\\W&8@60WRUV!>1M^(!E_C1AN3N&E:LBU79C<PUP\G%
M;4PO]1H]YLSKF325T&-B[GLB)LK,-8=^F0%%X>$U")2B(*E4]!^',@)%VKQC
MMWNL5,9K&[QR$9/V>[<M\M6.2R\SK%2&W*;WEVF8ZG=5D5U#V#S<TY_8F9.J
M&+) +UCAM=21=TPWP^_K-IR:<A3KFB1+(0L]P88V.<>2C58<!>FW;!O*;-8%
M##IDR \Y"LDS-P=!R?&T'&WINF!T*^^[370P<); _Y+J#O<["'(&>*TJK:9[
M1F,AR)0)6^PR=9=#<QD0$%S+Y(5 'VJ] S>HV&TQ[9'I:LPB[E^AVK@VG8)>
M'R*BZ!1N#"-.BP@Q?IP?H];A9O^TU<F>EU)BRMMFY(F#,VA:ASEH 7IY8@HC
M5M)$N,N>/F%G[Q5V]E'"SGXRV-F;-=P[=G[Y,.8 )2#AHVJ+<K_LVTX GDLP
M=M+ITNJYI%$0>J9(1]X9#KW'>35HS(:G%Q]. :- 4IQ/0)//%&@2U89#?G$.
MP"3O#;%1/$MJ45FX/]?%'A7:,&K3[V@!&X1=]$>IC;O?2>B^9.2WH_X](:LX
MR*_R3OD !30]R][_!'9>O,VY%Y.-2G=/__G?#QY\G86I#2<G/$6W:LNEU&=#
M?FDY,)'3(9L:$$:7P4BK$VSB>__'TR=I\Z3-<PN;9TAIOF*.KWRKR!JC*8R#
M/11^C;51!FJJ7')M"0&E.8%-%D[=Y"?F%W?<F+,ED"FEC'2:I UQ\WP&'AX:
M%; R13ZR^?(>050U*&L-=&0PSXWI,3V7"B$D3KI\R: _1NH>AO2<+]-7T=2"
M4@%+8.20*I*XY"1,C[-ADC#O<M0_5<A-EITL^^;'*,A *:0WF:UE"0*+(# ?
MAN+*&'V9M^NP<?Z.0#S9=[+OC^.YH0KB^<$E'!>N+T^9/!- C[MO$9=Z,N!D
MP#=OP$"6+?9T<TZ,,4 OL:?5#C+TM@+]Q$TLCQAVN/,J,3$DX[T%X]5(N:/_
M[;B')+IX"E$SX/Y[^6241+BVPGH@+L0(%5X"I$)4A514W$51XX.&[U@WG2+K
MZ#$3UV[:%K?44FHZ1,;>AATX>\+J![*Y>76DW\GC2DBGD[5AB;%BZ2$]#.J3
MCA3%:>LA/PWY( =]8<4NV; 2JI,H[@AFNBS"0N5Q5]++Y<^>M%*9S4&8TEY+
M>^U6]IK.DMNP-7W @: Q#.3WG&JP )>=ATB+N/$5[3_?]$KFG,SY5FA8>' 1
M,0PD: H>.)2V4TCPENPQV>.-VR-4,')'5^5H;97J5K285$[PS.6CCK_7M.',
M_2:;339[*SXT#()#3.6U>I1,27,L>38*8Y'H^T1!A'0MFRK)MR2;OJ66>WW"
MJ(ORQB+Y,WW.(T@J0!V;;#'9XJWX5X?4, \+J6**6C&=[N3QR*M&%,3TM:9-
M84 RTUM171$"#NFP< (E>@O12<[C$_E%([J,PT^&0V\^@DT$F,E\;Z.W<@UE
M\<2$.;UVOQ1<7 =1AO#3,]6$JP5^Z.B4S;#+D.^8*E/F9F>*X<*AP>/P_(/+
MTY6@WOG1^G"6?H*L<VHN7DDUK\^BF7@;[A-OPR_%@#GNQ_:PHSM_WO;;!6L.
M;VOI*W$M!I,9CV>&*;Y]#8O]_KG5=/Y5ERP,_/KH.K/\1?X<?>!%S]";B,4.
M$JA7_?R*DQ7Z[NRV _.>0MK[6M"4CL=$*.S\)84WLW$$MC*!3Q'IID2.WC6K
M$G+AZ+S-W%?(OJ(;JG@+9I4+\K3&?.(ERCD1LWZ#LAG*0R#X5=K8MJ"_"FA<
M$\/#^YGJI/V]A_V:J4Y^QMFNY]R3_Z8[@=H*T]@LGC+9U@E,/2]^>$K>NSKN
MFGZ[F[)U,X&AN7=,"<<5)#H\-$62)NK4>6-,D%SM=^P6(Y,_IT59%_)DX>H]
M72F7(Q<)P-"H7^+*P)H_0?>Q+.G%;\M5A+ZOH^O0J5=BR)&)C>B7U@&&>='R
M> I%2ZR"ILR-_S][[]HCN7%D#?^5P@,8V 4XO3,C6_):G\:Z>(776@F6!'UF
M5;&ZZ&&1M;QTJ_SKWXP3EXSDI;I'UJ5[AL!BK>FJ(I/)S,BXG#A'V;/VQ0'9
M8&3&%!9R;LY"-H8>X^(> P^W>OWR91:6WNQ[SEB^;>8:M]#$><0EB/R25>5:
ML&'5C?!<P* 0EF0GM.+<F!G+]4_YY%MY+)X5C\5'*X_%RF/Q'$_I/6&*FK.B
M3W%X(/Z!8X/&1X*<@K\</L^<";Y9/-M/X6E5 :WHZ!?;XM PF>NI[#EO:$=5
M%Z+>L+&9N+#R4IY__?L;_"^UXV",XR_\[^=O0/&( _X'/AW#44XI@5>??-IM
M/@N14KA?P7I1,EQQ $+T]*TD?'"MS[[Y^MLL'$ YE8>6GHS 5F%60MPNU!Z8
M1W4]4C( .DGMB%5795_FMW78BJPX2HH-.#K;4:]%F))#\:(_XCA4P=/=L6UJ
MH9/<%\@3Y)A+.Z0E[J._460,?BT<I0<FGMR\XA,UQ(%$":6O]8L?B,M669>)
MX#/QU#J>%7D*>\A?[-FRX&FUPGV</!?Y5_P)4QKR\[O')09L[DVG7%[P\NF>
M=PCMX>$,P;2^I7@8+X27LG0G8CW9\TL #3DG:IPOI?@B^Q;?BN1T91WNP0\4
MKC"WF9PGYK([8)L8NRT&K*4<P*D(C[('Z>J#DTFK%CD,5LW5WQ8_E5TOU#,G
M\75M1XX4.B228G)E(JU0=0K*7@C8EJ?Z>20,/M1DV%>S3O:2$:.UU--68-[4
MBTB7B=Y)W$4FQQS9Z;4[# 8AQ/@U=S"@EZP;$^*2PTT+,?^),E/A!_FMY!B<
M'0\Q0[&YSTO*7 4K=.@E\J$@Y[HQYB4.IM]@%,H]'NN2[&^Z%R4*8J*UX6LA
MS.=(!X2V^TC_*RL_W']=\T]\S2?*/[F968FL.R&X;X/IH]7D.7*%"MIT5R,1
M4$DJ#9VND\ER<QQ!LHT0/OLE.I=;*BA7[&-W)*XY]\P4$-Q@[/8%LEY(5IG6
M M:TCI[_,A.I,ZT$G?$E'R6$+JPWER(G('<8'?&)AW,+N"^BK2C;W7#JD%Y.
M--B[8W./8_C@*/T'7)?!BG=%@CE/DG!N%I)SC]@R!CKNB!Z#SVC- :K0;#R!
M]<+_-^2\N44%0-[.-(%PL_E"[ENX&G5+4="\$XN7 5$#3D=:AW=84?=&'1W6
M>/AK(Y@BY(62U937?C&A>*!)##=<R]?X'EKN2>1T:$49BO)@"Z5"+L18N)5D
MZFB>-0L .]-^3Z(G3GNBD!)^XB7_8N<"<J Q]\,$W<Z>X]EZ77OTI6GZ-3Q"
M5?$ZN^(YZ6S?;+X_AC4C:]N$EI&*I>%VY4]R,YG&I6?=A15,LX13('AA55/?
MAKD./I3/%O.J95^2=H/+)CE#$!<LB7<(.)V7-&US]2&1PRYJ9=6?3L5ZWCSE
M\T:YB\DJ<+%BT2]QBC_;PIU"L<[A\#.I';GXCGRQ&\Y8[(=";2!)AZ'4 J=L
M7 IQ0<F9^-O#_ R]WU+!V3))BN+JHZ6;M74'K9,'Q+[PW]0),!01[XV^V*7[
MA]5@%(5!UK/@*DS4S2&[T-'-/ M2>@[&.&6#]X3$V23QW;ERK]I8NFPW;#LR
MJ)Z8[-JI&X]:9ZR9K7_OK;38;[FWGJ'@:^93E(\DDHI@0Y(?Z'4@;(\\.9#J
M> NS?,K_R2?]G.([^*>6DS)U4<+'"':L)2F*20(#6C]-PK!-FD1$A8)/#G-E
MAIJ" 7.V)A_3@C;?7P_@Z0V,49'7Y[]-];Y6J'_C"O6;S5\I8=T?6Q30OA?N
M'+_^8EP5#8[/*UTE0HMZ.%61<__6YI!W[!ZY'-S<ZIU97)E$AIM]4W2X;#CS
M6WC2V+>4-"J/3;.?=)=-J.*UC#>UZ*M8P?,^\']T5>#\X?4]ZH-)6G]'\F2L
MT#8@JZ+9N\FEG$3"'(CBS6;K1Z1L5>$42>JT$XO<BS*19F_#5JCD7L$\AX-X
M6VHL@69FK]2 \X-/8W=)2O'$ K(F;,,7)CGLV6AU+%]GLQ1V[QX=<N+_^)-U
M\EA<#S\U-?@'4&F@B!8YG_*$$YTM!,6L2)%*OE8HCRB&<8_JSVJ7+PTS=F["
MS+DPV=_(D1EP_UYPI\)\D+<28I(*RE1Q$42[Q:(-2TBQJ'_H LAPYYGWSZPA
M5",5H@95 AIJ"TY%GT[=%H1HY-B<P]PUK:;/)(,7=N&QJ,Z0CD*"37+A)XI4
MBQBGYV&I'+PDEK?*8<N&:(C((4XH-W(VW8C)K2?G7.4[[C8+Z]?<'W@[3:7L
M#F'I?XX5"!UH*R$]9FK<$92$_6'MW984L'%Y0[(;<GJ@(;]!IY$=* >J3$G]
MB6M:7?=\4'4?:@#WN;.PL(U+!I0,G[BJE!]N"R]*1WGAS9O=K@%Y#]7*7/1$
M+9$$VX0I6>0_.15%S_ZR92'&>9S%\8T00*H9!G<FV+X"JDLCU38HW(YA1BR-
M5U]813X3QSSX,F>ITCWJP)N)!<U3BQ*IL[Z:N6(S;IIOU)?H3Q1D"\^_'KZ)
M[JAPN_H%87[VR.QQ$Q4NZJ1;T:BB[IZD&E7"+E[/9?_#!#WE_;QBA9X55NB/
M*U;H0\(*O4?G9JRR%>\DWZ8*WU=<57^6:;%C1_P7DS2[3]';Z:DQ!->D^7[J
MYS;3:R&-):4#^H$[)_R1@K!><K>2+',X[Z?P1M9TU(/IJ"^#P['Y/H1!;Q>2
M4/3*O_W'5U]_,??Y%U\_F235FJ%:,U1+\_&]+&4"+.@J75CXKK,B..3:1V%_
M_01_?9-9.B#L@.2RTZTR^]M,<_S<_I,EK10+0YO=B,O9-,@WSR2VRAE$X@AX
M>"TWE2:D9G-,+K_$!U"$%8$[?M]2*]Y0GXK>6(;KHM@KH7;9^78*GW1!-N)\
MKKC -C]/5/I.TC2Y_^(T##O. K=P9A]:KG;Y5%$723T%A4(9$7=$AMCRM FA
ME-<V]68-;[]!DZ1/CZ ^#M2O5MT\R$4J^-<R,)3JO/J@BZF<-&V3.0R*^AP:
M5?+7^3F[0N9# G[W+%#4TZMN\XX4WQG8S.X(D93VZ0.FCR^)8'V)9(7+/2I[
M':E[#S)P?,?22CJ0Y8%%1PK9 )8R0,OHM:?!Z3*#+;&A4+V4&T^W59%-,H7G
M$&A(KQP(2Z"#VS(.9 C?F7D$+H/+F*9#XB6N%DTTI&,&)KP_9* )$<Z9#88A
M8F?YG;)FOM)S@LUKV7&Z)DS:*7C;0TWOV7D\-*%%?00^18L3O"^Z(F]WQXW8
MQA'H_63]=#%;[2QEFMR?$RCC=37,F-00_MX6*"JX'/S4OG(JN.6N BZ1<XP!
MR(.K/\=:>2= (N>(Z<R .;+3IRP8MT2@_Q(DP_%Q9:[VDX0[Y_KWX2&:VZ&(
M=I7F&(DZ7:TBP7;N*3&>%N,A(\7<@&=Z1*(+'!2FU;$5#M?L"C>@<)B%MV3I
M]+"%>"0Y 6##/@R[F'>8'N[K#OL5P$&: \X]DF=Z:A& U!]6_#)]'RB<IP6.
M ZNDTZND-HFP@N@^GDX W:W2V*"A<'RAQ>G&'ZNTTB9>6/=+YW*9NYO;3#0(
MHR>(:=I,10:!&.(D]=Z[3'ITTZ[:M_G]DE?)7:[R,GSE,.ULB7D%,7EL$E&A
M!30)\,^YJI;8"SFS'IS)?3.;>)[C?TB#5+$<-YNO074^4_N*=M>ZKMUX9MUK
M?)N8*L0$,>IK$A>^0W[A]]O+OT,@^GG9M<.97VS<C8Y"^Y;JS#7[Q;0/2\'&
M!E\Q/''RUH?^2.XN?0/ -ZP_[:Q _@EM$X2SJIIM6!ZL(PB\6;@'Q12TPX^E
M-HV78?,I-W(3_MY"HAHO&$FQ<]5<-F^+"[(4X7P[EF<W<FX-JXL*37'XVWW9
M%=J$A%X\Q!'[<"![ 5SLEFV!.K^<G00N4+A>PEL27M">C0GEY"I""X9;XMPA
M$$%5*7">GZTN;G.!$);!F BQR7;HZ-C[]ZJN:Q;C=S\[R7XZV4W=3'WC2O#_
M92=*@15HJTY1H:YO+=_<Y6U9\-6FJN=^;VZ'/1Q,2H7(CE.Z_:[/^X%V:.9V
M*P=!YR:\\! \!O?OUF6QK>MTM/N$TQ\;D+:=[3!NA>(X#;YO?E&GVB*IS&U-
M;$"G"1HWI]#]7!E(N&DP/J<0O0:?N*;\3+T3MHDW(G/JP)Z)5>.SH@K3/4CO
M@JCX"M(>M6IV$$;GM9MIG5Y*GBY:2#P9?3/&'.. @]SL.[:6'%K_4P2).7@(
MCZL@9W9(I*F'<D-'H(DIQU(-)0<-0QV6=G"?$>'>;!XTZ]Z6LU^3B_]VS:Q;
M@J*KFOM8B8C]I ?7XSPYW(5MAMX-ASIN+V"]Q^O,S*G.P!6"*+.C0"&9UHIU
M]U0Y8G8(MF@7$?IH;KZ[\;>DB*([#@2JO*_M![*<"(<DS$!C'[7T74?FV&+5
M'3F-?AC:"J4CPDO@_=)K*4YTDA5R]2X8Q?AY7"8WF^_$-]9DCSADU/CA,EUT
MFZNO<8UYQ@UXTG,'_WGO5P*M BR"9K<;6FZO#_ZXN Z&OEOT9T*$4'.C@WH=
MSA_FG;BPU:2;H$9?$H?(I7Z9 (X<6B"XXBW597/7?,K%OA7W\:QP'W]:<1\K
M[N-9VO=XAH).@T,QEXF-T5@_[\$_9*S):^/PSV%MQ7,3ZDK[G4/9IK$A_(3<
MFE[5Q1$$-G#=<['BBIQ8IE7EXU-Z9'PY%UEIR>/Q5U+&A\X3Q'@<0@@Z.H;B
M3$@JM*JDCO:[N=5(J7$$%5-V\"5Y0&MNX'G;H+@<)TMM&7CVP&ISB]C\S'T(
MSII1 '1O]Z;T5;C5MT>"W[S: CXQXCH)HXGPBK_F]6V5[XONR'>$C=+RL+_6
M1U<O8Y4<5)" V0B^=2EB@O$FMH>^/08;?#Z3I0/+*D(<"CR=1YRKVZTCT+I7
MBN?8A\WVYNO/Y=92F?4TQ(>P-(:]SY2/7Y"?O(47HOEM%X?]<VC+CD+R$5SK
MW6T#R)PL/Z#19P0-9AM!7@C6CY^.8FRD(-=X;[07T\T!+$5\^?H^QHL@(4$C
M@@9JA]) OVO"FV0<!; ITZ;X>?90UDZN1)9"BY;.[(>]V_K=RUT"80J_^M_/
M8QG)@)Z^Y=N#-T0UDT=(R41Y2#PVM\T--8;![%G\]TE>8;KL'>,IK>L1(XF4
MML^H*>]$]M8_F"3S./UC,\ZL9.6M"1\1DU_PUBC7S@WVIC>'0I@.UK56A"DO
M]\:GAC:MPI"/83I>D/5Q871:JLI&[?"XJK*%U/YGG-2RQ%5\)811D%G#6'(E
MVJ/!*H!X?BCF;>)MGML2V" BWF&[+A-HU'S./-64$%/3JL9*'-DI03:M&&=8
MQJM*T#!=VO+)YITRPM;-%P= E1!T%,&TPN3>$K33?AV70GB0OWWV;>9%@D9.
ME%*]+<^C<2*/1W=U?KF@NB^*D[Q2]YF]R3&/X#@C/;IC^A0Q1>\H@#I(=!UF
MN'XT[T?\>9+U;<+V *&@3L*IZ*5P.G-@;)L]G15X(UI -\OCAS9*:^NEG(D;
M):+=_J\:&EF5WQL$2W_N3SK'9^PO:TL$YV];:+FC%K(DK)=90  ]\N..RXLJ
M'XR\Z,53?'9C7#_(@=ET8>&[C"[V; FB#8UL89B(2CFO'>$)J<VRM2A/DV;#
MM\P)70D$*1R,=-IUP\ETC8J*4O=8YN9P:B@)/U*X\8U /@YDJ9M7 +%2TQ!P
M!57MDW,/K;1%SB_X,*J=)@3J2S.^>B^C*F-CH+;'N*QE/;]/,YWP6H2&&=TY
M[5J?Q,:9F3#J9";!+-XV?&AU86GMF)WT'S]^$>LA1176'M.>2IZ<3G4B6Y0=
M1]1D$4]9$6(.I8Y#V9YX*S';0"%F+(*2,J/:<>3UY-1+;@:'QA0W/G> 30[/
M&:?MOM XR'Y%CRIA!-._T;92NV#I)&4-\)9?_4*&L1<_O0C_-70<WV .-G7>
M#U1_.H:IUED@X21^\5_][9OO;C;?$N=C1RC(N"3H$RH[=(B\5&J)BKUT!H?C
MA<Z:3H4&+$0+ Z*J,Z'+4[ON!&)H=L+3<755XQ$R.\PI$"MNNX;4W\70EJW.
M &(Z=J8A#"B]($[@A?X9YY0\U%MV)R+%8.1D+FMR(B/<'DR:L"]Q[K\+0P[K
M+ARF;[HRKQ/]S#P,AY!@=>+.=B8R3\L)\QIV]UNA_]$M*&.5E?77OX< \W_"
MX7U']$<>Y06[CP[G2.,OTC[II3T+FX,_TW,=RHH7!@&-G92)]L50\?HP=.R>
M'8BJ((3I3!^U5Q;K,@+8F(\NGBPS>0DG88%% JHGX!E22'3.#-?^3(H'" X?
M+"R:2!^6:(J4\W/2%41?HA;HNM,\!Y]>2,AQ$6UZAB3IAC!48<\B-DT-AMT,
M>@8?6E"P432I.SU.!;@.5PC/9YAX0O4UQ/$M<]OF6(V@2-13+YV)V2?[V0^V
M'H=7V%/O"^]M)EDB.:MR6>P1)*VYHME6FVGV"#N2%D.PMPPG;K!,P@;D)B%R
MV!6&"$9,$?R9 4AVE@RJ& >:]M-%OYU>/C#1J2\JF3':6?5M(\0TNX&K"Q&N
MW8:SEY#C2WB S8_@-7&07SWB#-UMTW@-0<JF3<HK( ._R/WEMG@.=T8++)[3
M)0S&,#;Q45B O<."G$;P+YIAAZ%B'T+LJAY?[K;Z"ZQ@QO YN%(:2X[3B7D[
MYE*_SUM@CZ.3JXMHO#O7$O>S*G%_O):X/Z@2]P=5$)7$Q95P7D-Y]2?G(/VS
MU--(A+!7[@\H&/3+C%*8O]KT9Z/D!MB]E61XV@>Z4#H#(O4J2' MJ#YKO^^-
M.WSGR)MF%VK:D+)5]R0X6D@2SP ZX;%8S)G4]"R?ASZV(G$'$%%,![6]+-7Y
M;"<$]ZFVE$JR+:1T.2)78(QX)X*N\=?*QL[;!W)^G*X4!$3"!"]I;8^S%F.0
M>9K[S#2#D+ NJFINZZ&+L,XU=T[=62PD>Y4U&F1Y[H?CK#)L@4=1SMS9=6[P
M':;)WO2J92VF9M8YCPDB;4="X@EGJU,UN#X7W/;T0R8O9'8I<5())FOA!25A
M15=07JF?(\*81A3U$")*%1X*:^7"C>2S8<;<"J-FMH?66%G?-179]9A,"&\J
M2BU(*L[3*DJ.(1B:H[:>X_F9[MI(\K^J><[LGARP3W<6'07'X22**%8Z\AS;
M;5&>MI2/XHX)OFG9S_)QD\*2<5KSS;F'#S*9N[S3=@DK"9_;4C+<R=ZG.B 0
M\Z[.9D]GO.5,+#EWWBY;-RK:RLB635%BO>3;&5H?>4NBCZK"*Y35-5H>R5'M
M[DBO71!KVM3DD&I)U'>9VBRU=LR!P?(4BTN?QLHIJ[BJ1S<8Q\JI)9'X4A1X
M-3:OJI@0F]E(4JSV$:H2!;INV(GN>12?@Y3#G"N#+%@TM"$PH#8R0:=5.EQW
M;<U,F(;$K^K;K!Q/OS7'TYQ!ZYR2S[U/EJ>:+=3[/A+*Y6I..+&+1(V@:YK:
M\I1A7>W*,S5!K6[P\W:#Z<#^5JHRW[(JA8)QWE"Z;(^"ZF>4Q(+LLN3SPGIJ
MJ)9/QOIK]*>]_BC;O'[YZJ6B%YC,9=A"26=##-(%0S/^:AU=W^+(^\PM,KKM
M5W4=EB;^^8:SYZ]?OOSO3,M\?_WVLZ^L5+ #;1&Y/<$B;@D\S?^T\R+OC_<Y
M]Y5-Q70<!B9\J, ',O$MGP#<V(@9D.(1N?XO1*63:A00YM@5,Q?WXM4R9L[P
M1[TWG ;NSKJ)'13/*',44$&A1SA!2[+JP6)SXV%4#I)TI*L2Q3':$1,V/?//
MV(.D9*\CHH'4E[@^WE.^]XH=+E[B0;]ZK4/6="E&VZ@?_=@1WVP^5^J/X"&]
M>OV"KNJ4OA+I,<TMH*!:L^\1-F$\*G.U=.&"="PZ3I[I8!RT2UP^6NDX>:D$
M=+!RM%[1;'-3JX/41_8@0P11FQCM]90<'V4>RR^'V?V_(9?XZ3[$#"^$%)PV
MU]@W1A 6B>!Q3[#.A#!L **$>WA[T&-8C577[[/P 3[4JM7W6NG(-R$,?"N&
M[!HG8XQ/F%)[*BTFV%"L8O8W:5,K>:FNZZM[S=51B-;%?6"542,250FG\%"W
MQ!?'OG:>8ABIJ3M+JC,)7M5HRQ:>67N&1WNX4R11ND,)F:).<W",<;CH;HV)
MPTO$"$""]V$7:?,-PS$C?,H="@@( =Y5Z)3K)<)WDGD$4YIT_W#\Q(1O(F3@
M:L[4 7XKA'E?AU"U,4Q!6-5:B<)-O5%7YCJ3AXK%LFW8 ?V0$(!&=O>9.0:M
M!9V^JK3A3MA@DBS4UZFT.^CA2&3F<Z=VR;'JI>@9&R;8,QKHOCB3GPM^NBBL
MP&8>J@K"06"1G] B1$^ #X:H&O8\[. :"UF;3$M!+7((9;M_P?J-A+:I2L)@
M(^UF"<E%_EI!Q\2P*;DJA_!L7_C7A8->Z-VPTZ'[I9;77$/RNJNF4UO0%7&$
MZNB&D_@0\YX^=^& CDLI#,Y4"*OB9I!:OJM"BXYHR1"L2&[(YKZ_"/L'8TM*
MR*%Z2AH8<R>ON59+WO,P,>PKX>W"H>/Z7&VOR.?:5+8=RDJ $EB8DNT\M'GP
M1P?9?>$0SL^:RY*D&\/ETVWJ=]12KQN[)[HH.\<&XG;IPH_IM*&\KZ3;%=QF
M=WM,+MHFHB*R,<WMT@,1YDM0K=J?X!Y[]*C7G3@<;&X\#ER;8*,W7?B3D!R&
M*].=:-3*JL52OB%RR!&^11WB1QK(,=1_ ID9V2,G[3MJ$/!]*X]NF 9R2=:;
MJB+QR]>!BU='*P"KAE\.8[L8B =18'(6@-0*H>["G.!*P=S711O=QJJ,#2II
M*ODI>PLKFNA9H8D^6=%$'Q*:Z/UQ%M)FMK<U9;;R;K/[V]??<L'NRO$C-*\1
MFLF<B'8>&;V%5%8!W<>IA::-<):8\DD\;:G'9-<O>\O)P>/:L9:Q%@LM,:G>
MM38>QMB!O/KT:'&'\\%<&'?\+GD"HSRM FY1(42;*Y^*UDGA6AD>.OP%;VRY
M1@T)Y)J9_2%";&FB176&PASE]9MTNSVZU^T0#$TGH9&;HK*V4;W3; GO%BKK
M[G(C+Z:@Q;0KC%XO]I9)79D>0>4_03<8QQ/??<')>GJ"$"U)'?EN[)S$4:0E
MWEE:F5'%UZ U4HJ>JY0#VJ:=Y$MKZ"D[*Q]\BO='Z_"I+KY^.T >8TE@EX$)
M8=6%;=2T'N1X#7DOP<M\DB/866+K[)A^5]IP9!B[8UB W%9.JHMYK5WZ_O.K
M0$O%_BA-XL@@D96'56>0 Z&7Q,9OB),^3S0=9OW_+)X*""V)*CM&B<E/,I8Z
M$27;W?B"J,70%V+ARWU\LWD3^3^GDS!CL)0&=&%B.@DU2/%W;]$E-0!)=I@2
MH]+P'6Y1506QL))5;G9<!V7AXM';8N[SYE[T?1$._43G\Y50[\! H\AGO)J.
M)VXZ?+:& 7 CA\#HQ5KJO)2E"$]AQW!6*<.,SM>X<R2-D.Q7!.;2/DD!=B.N
MT"WZP(LD5S&J5@I_R$P340Y7D!LM/1^"&,)Y@)OF3(M>%%_1"3KRFM"[YQ0U
M%,J&9.?([:%[!+?EU&FC5<?[L$FV^OQH#+S@;0_&%]XB,QD7;4%9"B,8X78L
M;E_EVIFQMFZ1NJCRBSZA)$_&J:JY%)4.K2^8>=0JP#VS4,P""%?OX5F: &P>
M+92%LR&_+1@@G!ZQ#K"0%#"NI"'#45<1,\[M"%N&_ EC@[AMGQJ6.<:RUE]W
M&Y;>T2K)%35!<:VWQ#*D096[E[7@VOV 2R4F,_)FXAU!L)B'V(0O4K2G1W(H
MBA\.,:>4*3I65AD7HE7YO3%H(S:=ZH3Z\E3R0A1+W[2Q**1_LT[,Z/LHI["T
MKLY/$/4;WLJ;^!GO&V\ ]5594Y*=!:F0J *%G^ 0F7<B&/V#=IY@.7M5"C.V
M>A>4$6RQ$(.)>O<.:?%'1%*8LD@?P4]UL_DFC9[@\BJQIK>70+Y'HB%VC"-P
M8;'<Q8N#0'&VD ']G:T_8@D9+!,.-YBLZ(7]1)@*IJ9*CB4C6C$O+_/KJXF5
M0H%4E"$P+Y1OBJ!3=?!FZ47O2SH^27.%9VN;UV_I,KO@%\N/.(%'J =]R[M@
MV9I3)+!*TOS)06F)<;Z68Y2V(62;JKBE_TFOT1;GH5>\-?]ZS* $T9?\)/)5
M )YS)<D=?S]K4Z4+B!)#'!L!)C8)Q\MV'(X_HES2.(4/D*BMA^=3/CQ3".2C
MWK DBEQ=W7NR:D,\@P;)-WN8D.9J]L6)%22OK6=K"'A+2TIS3L84D5I(*C;N
M%.\W2E-UQ<2\.A,Z.2/2X])B=V>L?"0J53]Y:M_>,]<O-0,]'2GLQ>&\0'US
MYCFWNI7]C:5[Z?J,8OZ(.%#C_YX] !LSZ7'PA<9B)C#WQ>XH1X?)FMP?FU@O
MC_7H=-31[-^$Q5K"7-[3(=L^,& F77)Y\JB[Z;4HHUQR$Q4'%A;(5(G(X3XL
M=9\.@\_KU/<X#X2=5EJ>).&2BGV\0P:W]C 5\=TH.92 6D;8E5$:6[8F?#7%
MLHQ<H>B3+BE)ZUY&",9<$.SWV2>YJ54ITT_<.$+I,GN0<.",/M*[HAX*AY)&
M/]EB7Z@\D<",GL?9LB+6YA%KEG:=8E$<\\D<)"7Q7X7U6PHP73&ZN&1F4O,1
MP@3*Z?12J-(:T4".X\ ;9ZZ7[G%X-!QWG+PD[&^1[ZDNO1#</538^.43$BO&
M['<W%4G!8P%MQJ>T 7=PZ/'^>&3#L)2-']<):J5KD-!:2^EE1$/[]Q$-K7#3
MIJ2N3]DHK\"@9P4,^O,*#%J!0<_1PJ>*QM\?HZ#!0ZPF*>V&B^M&OLC8[ IB
M4^G\LLVIJ5$8I_]F EDM@[0%=?AHOX_C$IT444K'X2&$"5%569OV] + F" ^
MT1(T-1;M(7<MLI=#JRU]=AEF!1=LBDCT22 #-("PWDNJT55PRNXM9V1!,D"9
M!7JB<J)'@$J=.IY*M$\E?&G Z;(%/OTL8H?L0%3OD]]5XFE& M_/_O%-EWGJ
MT'!NOM"<X?SY3=<,;]1]:\(Q6B_%:41]7[22K&V87M8Q%7*F/]8G6+0O*N5Y
MS2?6/^'R*3'D*V-MVM"5_"BJG2@B*[RS:D!R5TNP_(.!,P9@H$4.X/OCV%G'
MRKX_AE!01T*S?X *1;$;? +T<7.*;UZ=US/XOI/$3MM4<P!Y:5]Q5Y<^M([X
M=<%):KS,S%"35Q>1D:#-@@>>Q">TX,G_ VVCE[?,J!M."6VIE- :%\\IG#53
M>+OUOJ"[.%F98]"<\S$]JCP_$6=)6BB/B'[=LF R;[CR+$L2!82T5N:@@)-G
M=EOC\:_RZFO,^)8GCJ70<%P*](X-%Z_W\  @!WVWV)(!*E>4&TKT *KI$%J?
M*J]5W:QOPM+@->%4 D@?P)T(0C4NBS9,'Q<8A".&;$HDKVDEW3I8GTCBV,OS
M2X+P>61)/M0,_-?C0MH#QM"4A;&AV=<,;_M8GN47Q@"@B;XB)@--;8/M!C?T
MXJAC#A7.P5WB3;8)1?#D3-*B%[!B"YK-CNKVF+>GY-:4A%>_V2"TZ2RXVU_I
M4$I@?S(Z":R=-Z&*V$M9'UQI6\DF[C)?J+Q>INQ\G;)SA4KZ@,>QF!:B#&]9
M"W$!'97QK,8+'7 ]+6.@MH(&W[T6Q*4<4TE;.OM91G2@0CKAM4JR2?!V;7,J
MN]B=/NG$S/='J=>*E8<9TY;+8+0U_.?RI[5*2SL3H0\F6&%7JB=IX*1<SRDV
M5YY)%@*=GJ4K4EN!-U-%#YH,.AEA^:,E?62ZQ(]R*YWC>YICR7Z[][27.F[!
M/>\.#+D B[^2Y/-UB$,>MG%3)PVH6CIP!\<<Z,HA-3)7!3?77)OQHE4(5Q&G
M[@IDU1+]M'.+O;:.=;V^""VYQ.F^FN7?C4H*S^-H6A/XQHLK]:\THPX>N3WB
MO@MCBXU30$D6C:L??_/DA],"SV@5!9.I:\OL+H>31_A +&%"ZXRHO8QBWBU>
MKD&M#%[/W56R\")/"]<2M1P<]3UCN [-;NC4@U;MSWWJJ"2PT#$65(5'9HD3
MT"M05(76[-U"O- 92PE\V16V)2;[@6JHE(TY-%791("9,7;M]T!P(6?-^'>4
MONF>+RB9P2Q@0]^4I]-0<VZE+H9PD4+,+YVDHB9#(5H$XRZ,N0C/CS+R,O[C
M1+BJ,X+DO;6@D6[./F,1T[;/-&$AEY/(71,*V[(!"$2$#DSP)QB7?*K)ZG"7
M.K@H];'\M-[AS4^7)L2YYV.P$165Z-$Y7A7A%"S9?WGS]^_X%/L?@O#5MWU3
M&V.57!'?^Y_//]T<5;@FRFC0VA(PV<P@.0J>$;3C6Q8BP3*#"6??@7K-X"??
M.0D_/=TGNK'"5L,WO38_R!7H99SC0AXF=V/0Q3%?YCOI"PW/NJ1;RW7\D]V)
MO=(6-"#P#J=CHF_$51S7*\1I8E8!DQU+9^Z<V9S+,^LVQ4TT.5;\SE>-C,B1
MIB7?2UE4^]E,F^-,ZH:RU^Z^&34:%C>M%8:;K$7TV2F1W5^>L@ODRF5A"*<7
M5=GU+\3D81@A//I_HS(,%2!P*GWRA[1"-CJ39HMA*-Y\BM/G!=VQ^XO*<4W.
MJ?@,<K.G='#]\>:3/[W^^/7''W_R^M6KC_[\,IS0]TV[YZK37]X6Q3F,M++Y
MD0H5ING*O%!]Y<^O7W]L!197JN+[OGKY\@^CJSZ5T]NE&Q(Y1!?QR:'7%O45
MIK-F2QK"??%I7*QI87!=M.NB_:46[5Q,'.4_!,VSHSJ'<HNZE(7"K@GT*F )
M/OZ4YBX<M!14=.M27I?RK[Z4YWH'E:GH2.@?5:JF7 ]%]1"#8(9;MW;'JIA,
M><AQ $0"2G0X,EQ;<FG&DNO)+F,U@_'AL]BZ75L"3KOND'6'_&X[1((B@.X9
MG,S**4*UAAC)959'C(,)FIMRIRZ_^RFBOW5IKTO[]UW:)OV:=V#.YJ2$)S<_
M'R]=&99W*F\< O2%Q?O!UW5_++A9 MHYPO6D-*6@2DU5.[7MU%6-$LBZ9A(]
MS^0#>?1\?R>419>8#;KZF_"=%IF6<4=2)!@9=>'X/*;U)E\?ENO?8$O8=<6)
M'MGUMSC0B4NB/I-,R0HL?OK XO]>@<4?$K#X/3I7Q/C'BE+3CFSJR"Q?L\8J
M*I;V-,X>/-EF<N>96M;#E5WG**<2I1*+"D1Q108\)V3 CP7+:"7MT4XO N)Z
MFZ*^*]NFUGII&'"YYVYB4SZ 0J1AR#<L2^2Q/ _X$USVO3*4S,E/J$;F(.VG
MC"@ &Y'[L8K,%771MZ8RT5GYU.>UD3])F11N(=S4ICC:FFG$C>IL!C,TZ7<N
M^F(%,#QOVTV ]S.EU\*MAIY9S;=ED_X):R+\U38&=4'LAXZ%1*6\+JJ**(=:
M0NY?G(/&OJ)V /C_*#C:'N.B>$_*4LD&!:"&D  D6UJ<PH@ 7*]]B97Z#,(8
M>A#-A] F/V/$X1#Y7U5.9=TIA;4K$Y- Z5U D4E.G!M5)M2#460R[+%CD5?]
M<4<7-&R$QX]*Q;GI8B1%WW6Z)ALU3_Z)><<[Z139GK&-X^>\*9N S,1>@(UU
M$P/H4KXO3N$S:9\IH"N7]J2<)&QC<P7#HJ8DP??IJ..<>7*(#/WTP/C)MY9H
M)+(X$+ _NN@O_5H*G&2(; _Q(EI8Z( 8^/RG#RX1W9+B:1,95:V0C!ND3*OW
MT"QJERO>=&I>;S;?B>20RI3)*S#X=+[9MDT>[DG'# PZ+J9W:@Z'@B8JC+PB
M>=,-1VK)G&(,54.^?-&>C$)H%IE-)!<LDQK3*6.>D6.Y%>73Z<&CF(5P !7A
M,JVN)J,QM%[Z?]/*,*4($*WA@D"G@-$KSC)G0'<DH50#/[07S>-@14X$BF[=
MUAH=D^&]R%<(YY.WU>4%*%?=*S( .@YVJ2/,'>D KT>+2#4'R6%$:5RR$E.D
M,;]1)+HZ2LZ6W;'8QR%HMXX_WC$B.8L-FPU@[ZX=2J,99*X4^E=DBG9.#5NX
M.N?1.!*59"Q3O/V&E->3]!OME;+3Q7&85>KHH)Y'_XO&%7+AQT>"PY2QB$C&
M@'-'7Y*EG3[/PCG_4#./GVG3GH?2T]&A'/ 'K5:/(1GD?M[E904?-!RE57-?
MJ"R2<1SA]W86%92S0[-!&W[> R@&Z45:+(>RHHTDXMUD03*'WAJ+127@_DZ+
MZEJ5'.N)JNP,),4C#O$JM9\SM+?@?W(<,UW: N@.(7-(M"L.CA5S1*/#\2JG
M([/R3:P(9I+; K[\_$VV^>+K-XY$;HD.)-&M[,0FB[NGYYZ[\IA*Q+U$_D+3
MGNE7.FHOOV>$/-2X? ##4,1Z7B%0Y@,.CIV?[WB:C&.FQ.*9#VK2WL+/*R+T
MXMRES(],K43?'T-'4_Y:QBM^D@F+$49[W\RL0WK<O[WQD6(S\I?I&WHU3TB$
M^[LL"/<O\\H,+S5O)]U7B$F[0E1+I7T44L+[#0I.+S_]J\#>@2=Y_:F3$<87
M7GW*IWYPV-_4-?E>_T"#-[GO7U*[TZN7+_Z_FS6%\7!LYEH:IHC.*T193H]1
MXC,%G8\%*+GY&B=ME?3_HXL:D0[% <PW9CLC4GO!*N:4$FF+\K0-6YJ=""$"
MXW[3$D'?.?C<.S@R7\:>+MOW4?U"+RE<GW*C]/+++4*3W".3]9W*B9:#VE!$
M:K;5.-80WK8'^H?6],?S=DQHBXE_P>\XKCCN5DR68KH"@[>2[)TT*\ $MAJX
M?PV2!R$NY'^4>V($+^]H-8VWV8C/01@(S_D%AS7E,;I.^D. ZJ;<G^'=.3+1
M\RB'D#PE%KM=6S)I+5-.\+FI(WS$7IJP^6J_DT.3*/W?U9ESH7,WF49G@AXS
M04U[&X*C?\G31)[DO!:T@'9]N'%?*1DO>DR6&/@9QLE<V20JM';1\,DN)P5$
M20L<@UF(3FYS"&MU(BQ!*9PP#?NPL$.X!;=T,,G[;@@1'"L5"RF^QO;2O<!]
M'6)Y[8&N=%UNB9!BLA8SQ]9"4Y-.0O@*_K?%%7P^62<--C\RA>Z:%_(;P?#9
MDH:>SU#;.KM@CMBUB7;[72<C<^F>Q[S57_PE8N_A38[YEKN"E)IFUY7H1^ -
ME7U75 <5.+"(BI5CFUVQIS.V5,[KY)>B1^E?B\99V50/V^9L,_2E^A_(8@J.
M!.*2RL5S9>M+,NB'&J0?W_5L9.A/7_R W$O5%??,Z*G8$PO_KJS/IGW*\?^*
MQ'A.2(P_O5R1&!\2$N/]\68IZV,B,U)X<GU-HL.+#D!OD_%5/MQV5)V(%E=.
M/(V&]FRA2^6<2 3ZU@SL4UX:WT_C""'*"#^ES">7;4$=PY55^"U4R:5Z*3SV
MGU' 28+JCOPPU/RDWG"9"V_8(SP,3)JN^-2'HHE8@&;/F'*_)6,X0E1P+!CM
M$?S,N[RB'_E2*!ZE"ZN:?@ZE3*AA466P[ICUA4K+Z$:WO7&S^0I>E+*[2'/\
M](GP0*H?M9BF[)@_@(JMN;(3@N^.<]L0,I6'=FZQJ<ET2@<W'KK<*_'[J;>&
M'#M.,?ITN?TQC#=\G\NBY#2+:RUE'2L=S@6,FNP)/S/&>S\IODZ/N>'43"1[
MZ^:0Q[P0KQ%02W',K:*PR47?Y*YY*W3XR<H)AW;/?&4YLN\Q[4QVSE)=LA<.
MJ$#=X[-(Y4\9))^HS2WSQ0L"2:Z&ZA:<'<8#,7=FV'T"4^80.]R'7?Y@3FL-
M6YG$37WG13W:P]C/YCZF:,KI[7;^W[2X:+#"O\>#7E+1?>>(V=+Z\[Q#^:8+
M2ZFCNC]5%#Q\8/GA9T0I5F6TYW8,B4B7KVP-M7!P]!?&*'"-C<MIVI)PY0 (
MZR#LR[GR'51-9N/-\;'CR1 TZ41W2E)3^E7-F=&59S-[3MJ5R3QK\("UO>?R
MW!=,WZ7\"^/$/-D:2?/PN:JGF9A&*4<R:>GU84S/>@3_.=7K]F2KYL)R&#PZ
M*G0^-/]HN;>9R3$DKA+:+;XU+0;@-C//*5"910^!<T:T7#U%3I+,$FM=UG7X
MF'E&BCO.QPA!(!]&)= C!Q%&N_ ,Q_,V3>R2.T(:0,>&)E&Y3>4R/B5R)J;A
M8)M 44I$-F'7A)_Q/\?/) 6;'?DZXQHA'_%7_9]5)?+YV<+_#0LHV$ JAV(O
M7(2WY7%I<[@@G2"<9A;4W(Z&J>#^K^S1-PK+"5E.@E$D,&*4X]G%)4>=_F-&
MAMENH^:.74A5P"TM-XK]0=/3#:=(TP8:1?TRQ[2\.3T)N08)(T13Y%@< .LW
M?UG2M N>"[EIQ,C+CZ:96*@(T<:LFW&CW&-RQ^;/0O].!&6[GF$GX/@43B6-
MJ<NVZTW6>P18:8>JF!#UNF)^>FM&K(?7Q9S0]""DC$3&=4>,1N1L03.)?#7H
M:@@$7'F?^"%Q%5U780+G!T%&DCOM5^/SE(W/-T,/,H49YX@@3&VMI-%.Z)W>
M;=27%GY\YD/L)=Q,/0**FY3-V_L-4G>?L$PG:ZYP3DN"_R:C@"<)&T9"@[(O
MA:TG+,\O!L+YNMN1O0NO8*1C(%7"/6]-I>)C 34<WAT*&H*:T*B6?C!T^>T5
M P*G\\2ZWR&<;4NM<%@MR#C_8]38%GY"[_+V8ED8XT,_%;0)R^Z$? %C.H+K
MJV]*:J3=I:-&^9O--\*Z+&.@YO[@S$5 :[C/H?Q)'#5BVW!Q[F2 VS G(M\@
MEIG'Q)<3:%V?U+%LWD?KP/-VJ$G1Z8U+(H*TP#*?Y <\J/X=$@1O=B(Y(2:0
MER&5OA?WPC1G<*4()=G2X/:!@@%3TVJM;^I>:X2\Y3#'.HT]S&1)/EG@)\KF
MCJE?[>T3MK=.JMI9->'[FT @P(W\*)>.?0YN&:!=D)\YXT5+T <NS)",5&1N
M84N*G0@_YU1<F,YCZM1P8C$$=BR_,-X/"]%WQIH1^<@EO%A>"/>08C6S$*CS
MI-B!:]OYQT*XRT?ZS88V$Q/>,1E*70N2T?%!5M?\P$A"3I5UD'W>!P=+@/*&
MC:/IS<;GE1,<T78AAK<5-4LH)#//?J/9S8H@]%S-4QO)0?X^6&D,P9].DY<<
MGE9.Z5$;0H(!FLLL($D_M+=J^AE D,"1#+2=A0.TTXJ1]&^-W/\DZ4!XB,TV
M;ULH<=-HN5^C:)E]7F::6C<NDM&):9RG;-K6XOZS*NZ_6HO['U)Q_\-"C"<J
MG@APZD9: _V),\^Q$ M>_(M$T5L*,A0F((FBI#QC3:>9DH]$>UP!)A7=QZ"V
MC>D)BFL+?L]\8!?&9_ZSWF>%:[\77O2B2FWN&[3;^27OA ,?5<%\MV7'JS],
M5PB5RVKOVF71>(0109$GA+/;@7MLV)-$(V5TL<($O(AZ]NDFI$N^G>L<G8B9
M.5TA\O83Y$6Z35/1C'T#LHD&)N)J%QFUF!8@C)UVAF$RG',>NT9F7HT\@3VR
MM6^+/WI6:4@_>>G$3%XI$KCS>NTF!B\9V8B50*1#11I+0B/(4#L:X@J4_GV_
M>.SSLK?,_2-^J%2G_C>P,YF&8-(@EC0%0G*RK.^:ZHZ3QUA]D;4@+#!I8IO,
M^UA\RP'DCR#5X:9A7*A$4W5Y1W,;.XBI_R[$;0/:>LWFNE0&W[0J\CV (:,@
MKV\%?-WK(94R+8S:D-V)P!N'4!L%%3A)0@$9$G*?PX^HN7GF>GV1GT*(4E],
M4HK*@"3[LX N8 @"LJ&5[N!XN<E[3I8D2[WD^SL:3V5 ZE3RR#5RB1R#%:Y_
MY$VZ.S8-(Z%B\W@QN^<I)X:ENL0(X'O*DW%+QC <NB4'><TF'VYY$N3,=Q>;
M/K?\GDNMFZHL!IV\Q_YTP2&)REQ<<?=FKTE(3*FTU'F1JE\(QN('-E48&JL(
M+8+384D9)CGK^LC$SSM94VL/,8V6>VT?Y8+9WIP9AT\E$O!*1;2&I-Z7Y">:
MKGLNQ>4U,C#/"0>>ZLFI2AHGPK !9,LF)X1S%]S!9TTO0O]CQ\QMV]SWQ]7+
M?MY>]AO4J#X/[AW84CYZE6U>OWS]1]'LW6]>O7RY(1/Z LZ2*03CS$H6F2^J
M.<VTZ/9FL;Q(_V 8H"_=1787K_LMQS^6JRM/3F5RLSB$L=;.2"[Z41'!0X:<
M&R0=D0K*,^K%9'90(HC(=^HJQ)"&*F&DHSG;+8?SBX$,P!.EHY&MAQ&8M*5S
MF5BMFA^-OQM5M@1-886U50#(9U-7#O+WEH/<&9*Q^*K;.ZO2P[H4?_6E>"4T
M$4T[;=Y21RWAA5M(I'ZZKMQUY?[**S?2,0OIG&:.LB1MQ&FDX&]P(!K#27,@
M?4**LP;F.ZTF>%W(OZ4W8%F_L3"OBU<,ON/=[#!:TM3)6P;P-4,OU%I$2<DT
MI,TVK("(N4D2.*OZSKK6?R/IRQB:2]=G&D_'>%S+4RZN52PG6?HS]H /;2-R
MZ!?6XGE_4BQ?'?QT0I_.LM[3.D>,V9GTE$M6@CBU3)ZD@ZG/&94W)6R2!$%\
MF5(;C*F6M/BC;+*)68M\<E,];??;N2+-)$>QYFH?7!SWA4D_YSU.#D?CN^F*
MNFPFB2;2?G<=,"[O1"]I*XR-"CD^Y5 QI&B#X8=:J,KQ"O]-N8LUB_N[FQC:
M^A)4RLXUJG[=N'H([!-2-UYO2?GWU/3"PQ9>:U@CL00\6H.61<E3U0Q;C$@2
M4S5-KL0CHY\/9S#34<JYTQAWLM 3]FCW#;E5UPM2MH*P^\& #^CQ]Z)CKG0M
MG09<" 88F34X^I1^<Z8VK,&WZKQGUHK2H(+')-8)56>5U]3E-<XV&9'#XRD^
M'TQ&/^4D[@??#Q#;A&^'O,W#GT>J>_01%"*(#P$X^91M9\S%Z//[9NLEP^^T
MC*9VGC6BBZ0+?TQ4!ZJ6,,HN2G, %D_UGY%K&,P'[<3P+:I"<!WB0 ]$U[C+
M=]8!+[NN[-KAW"?#'CL(*\+Z62&L7Z\(Z_</8?VAVNG/1@SKT?.)Z+1_0^ D
M7(G0-ITI(+FF(V7FB:(EWFDA_HDS@#C,0]*]#496@%X1J2&571AYSFM!4.4R
MK=4?Q_*M$7S7"9I38T5S7L;),::7$A_(>S.NVF[(MA%$:2;,P5Q3^YL-90;T
MY:2K@?'51\BLHXAI50B[ ,(0NQCX"Q+1EOLH/Q][<8D3S=)US-Y1"+A^6Q0U
M9T_"5:DE&I0F/?/DC;X;WMQ0W7)WG&E6Q5;8ICYP'CUEZ,_\E4JT,I.2CZ3,
MR5&^K^4CTTIJAOX\],_#_5M#?@OYU8.O2O7JJOR^&TKI#M\"#!C6^6U.K!";
M(:Y7 >L1?US.*TBOH>@6ZTP6:V"MGHL!AV!2:/G].A'&FB'XW7>E:M 1.U5-
M\'(!E'MBM;@:71NOZ9=9%%MTJHUWA0XN*F'FHN!E2I1T5SX]I@K>$1.=*JDX
M8UW@[/'TI_=%U(0E UZ0'@U:G^FL_>? QK<D8/* UEZZ$&SQ/74>##7M/)PR
M>Q:F,UY5?M21;IW'A4O_"2/-DQZ$.)DAG"E/EK^M!H+%NW,FS..^H/!,X97^
M3NZ3?4$0W2R\F$,4U+C/6VSC/:&&T38N[U;]%!Y-%H[^V[ LR4_(-L*RX%XW
M^2HM^BA(\@\@Y#[X#9_QR#EZ@VX0'>+!#VE[HUTG7D7MHF",0B^]USF3LO&;
MYO@W 3[0L[&7$6)4XO-0<[<TA8\T@I"">A?[-P?N X5FGN:$#O#:[H6K@DF)
M/&QZL81BR,:;S3] W /B3ME884QD]VFY4RH*5<.AIU;K;'X1F9;1"MU;"Y@?
M1 $S<E+OBY-TY3W:<UGA).L*_?5Q4>QF$.GM0.%9",IPQ*R+;UU\O_KBH[3]
MOLWOA14U56UE5I@R#+-?3>&Z&G\+M%''PF3BWS.M&C,]DX=^NQK&=2G^1GYC
M2050B?1B/ 8ATT\^[6)-DP]M"=+6I;DNS=^@!20F+T[ABR@1Y$3XQD#AR=D-
MM(J(@:PK=%VAO_H*=50O+,VA0/;,T0D0%4?'9-GL@6*=5CE1^TXRI>%G!"Y#
MR5&Y7NF"ZW)>E_.OOIP5)2@4&&OSQ;KN?I-UQV2Q*>1^Q#[@LI@/4 [\HAT6
M[Q%R9XY12-6G4(H1L7E'5S4M,D7](8*8).@3B*XQS)GHYKWV#$M24,TKUJ^:
M7M =RY6LJPC@QRX(7_GD(AWXQ8_E5H$I@F^F]I"$3P]-:U?G  ^H1$<C"//-
MYDW5'T%8A(J<S>[N&*^08>QX7J\Z.0-NB/3O7-?:Y/27MM_\<]C?JL9Q5_1]
M9;K"]'I $,^7%@4T44G*6 :Y$24T[6 Q6)0^HL)M ,G:%#_M7%4.)<,N$H.-
MI:D8DQO_;@I'*),"!727MV4SD'K+KAHZHRW9$U]W3S*"*47?"(FTM'90^Q!6
MN\A7%X>E6"]\PEHM>!'*IX\8@T%B.LU@];YM^E*%/G,_VY@BFIQ"$&&Z\C%%
M6L1NHP2>>Q.3.9^0$M(P,RG9ICLW\[OU,-0<&-'C,$$8/\_-QK.M.]#T,D.I
MK-8YN;$>L =CWF>M12PA-Q93)H@[?XC%:R',8DK%/<M11OUUDZ^"\(*CE[M"
MOI@QT*YG6G(/SIMY!*9[ LC TY[/TR-^2I)?!>8N+L*)!04!S9R):#PK6JI9
M,.)H6P%JSPF@]@9R)LI ""B'IZ7S:L-%I.U+=M\\Z:C2<>Y&?(G<GC#N+S1,
MSR,IFU:(VO-VXGY$.WT\U'I>73B2Z$2<KLK;MM U&98+\[WRTNN*XNVU-7Q8
M:L+"660.7'6Q;SK\<P8'D!MHKFE*H-T-+E2=('T. GJFCZ8^8$L+L5.(@T*C
MNB@QHVR9K#V1L(6.GW,$HW-CQB.5'9J)<S+<MJU5E6D)W+??DR"%X^_(1)@.
MB+HN>\JF?NTN>E;=11^MW47O7W?1AW"4->=C,*?5J=RACV>GB7-%C5:D7Y:I
MY"4Y.%0?;VGQWA938DOVFO*1H:>HMBY:BZM#R$8 7%F'VHUI+)O_A2;EFA7B
MD^:9'&=+^$GL=C:ZR++CH.FG$.S]JQB=F2'$K89BG+4 0&^9_Y@?A@:-4%G;
M5IG4&V^3^U#E\=)#4D]'_PW/AXV);2<4V%-"=.H=3WJ&]/@37=Z4DGK)[S!_
M TAWCP7>C7K)O.A[O%K3)@'L%8>%)9_H&/_)N.N=@&H8HX7PV6;?[ 9V5$KZ
MA?5L6>P+E_I(*/3Z5G[.Y?%QQU;*@0T^$B%">MP$<8>^1(.']&M.'7 YOC U
M 3>H0WX7+B%!ZK VOS]I4_A]9%8P0[&\S!WW#(F=W96DF,O>LRX\,)A$0M_)
M-;&G/DL7VDARLZ96!4K-05+!FR3-G;#6 JW$%62_%JH^B$)5LH/X-/4'6ACT
MKF5^$S0CL< W#H_1YHP\WK$M%ON:]+ OF_%IL9;_U]7]6Z]N=2;.0]L-Q:2W
M_1VI>>"H5'2VT#4]%S[D64G=,B$4:F=N$*Y\V^;!2]JBSX52ZRF.FZMCQ'*?
MB+.7;?2@@Z.Y&[R6:?@PWX6(0ZA<X(")6WH7]6>$D*A<8,)<^%4(&^[RLM)\
M;?@6U6@$Z<->'7G6N!PU-*+IGBLWU%QJM#7AVMN2=:W97@"TV7?.C-"$H7FT
MTY&P7';3ELRCN=J/U7[\YO:#.<0FL;HJ7R4RW[HU$ E..C1XZU-?+E4[1A^'
M?;8-UH8<Y3E]LS;XRKG8%,3V$-.=H1S3U$..+Q"WA(JO$UW:]-(8Z[CI>]UJ
MZU;[C;?:3C2JC#P0G>,XGC+6=.,JX50F+8LG' X6Y3KE1'[%I "U_8O5MN(A
MWPED=6TG7;? [[L%L#*=\F3"$3'5V9,4*0$XG':<K6KU?<D'+7L/;'&!6V->
M'"@RX"N+RF@73HV./;J298P2!G2FW(P)FG6_K/OEU^^ 58K)6V(N4<0=Z=7&
MO3!.$DJ>&3]3&M@0/0E3F"4HPK+FDP'5[74UKZOY]\I5*/.<57'@_2B'#H+W
MBK(0 \<4)*Q\T0T@68JA*ZY\E_T=(ZQSU'0,"KW/+[QI;DO"I+0EB]6JU 54
M3"E,KY-.7W6^:)_]LVB"<[8'AHM&<1<6(8*-GS4H5F@FR=R!T9B&NS:TXKI?
MU_WZ&[09=^>A%][E'-MB6_3W1!@YJ.+DY. !/YD@RX2,G%/J7B7:B!ZSAS.(
M[T#F9W#M"+D7*(+;MI2J:+=EW\[DYF8YH)/<_[KQUHWW&QZ4J/(*$$:W$36"
MY- P.21_ YX](5)#4JQ@6BE'B[O+SP3JQ='"A8+#T"*S_9C-2-N7*E[ECGL)
M5JJJ==,\K4VCWJ5HT.^:%_1?\VZ8M8.E.3790@B:1M .#9S"/CAEH@C(!:!=
M6$H,G>+H2_N !(Z5Q&Z^$6"TTPIM.)L9[[J3UIWT>_A]6/%A4YP%:40K.FRJ
MHNV.Y5F%:>9WF*QR8@VGPX;R&).T!<,EUL[U=7G_U@>%<"8)DI;!I-:]Z-!X
M6OLW;<'.(S<1:)R"3P10,LO-1!>).-#E1.'>ELTN7+?B^G])_EO%>H,%%5,?
MT0Z_-O3QF_RACI#9VZK9&D/QKFV*\+6&@.KH>Z+XC^J]5$PN^?5=:=93$(=7
MC[1?<M$9H!7$IK8@UCZ]YXWH_<:K3H50JALZ(DHH!9!]6X3C+EU"TAHJ2X]7
MW$5=0O=)7$5L7,(6_]OXDQV=LVR!Y%=89[>B9&(K6,2F<'\XETBX<$AH167?
ML8K/,P(MM>&XW-PU!(^0CF?N>Y!P$!=H@PWJXS#?;#KJHRXD75DU-<E_V-[:
M!Q^ M+V\ZC5UFA,JFK?*,T$9KUUS3[]K[H]KU]S:-?<<#Y9]<6[9(&:PC8+&
MC66=;5Z_5?4+Y="1M%I9'QC.1D4BL[M%?5>V3<V]4.'@D);I@MCG-BWWH^V+
M+=^' '+]16SZYE -%*!)X]Z>W$_N):O*\+V]RF;(0>"QL)G)-)-&!LLWL0R$
MWE _95Z]II4S220T5!\*4AT#,/.[(]7[M&.++E+GX3Q!CK+/NS[$D$>=$99E
M[H0*^H2&,T"&LWA,NM.3[A;\(<'NAZEIFS!1R.OGN[==ZA;&0Q4EA*$]-64U
M0]]#U#<%HX*EDZ89.8SQ'+P/)@4EPQ&W_\^0046JERE6]*0?<4JT.47I,SE>
M\+2(BN6L\AA=693'WF#,7'X%0C(\A3HU2]/E-%0(KRW-=!') WVOEM]W26WT
M$'P+/M4EC8AD0<0K P3'Q20N_X0%=4)39".5I5/^%HF[_!*Y#S#!8YJJCF5L
M)'<=OE;<-MQ^26-_0$3ZX8 @FP\'5$8>.9-(B22*,4212@RH/41S=&QT\C#)
M$S5N0>C&)IVJPKK_=0-@78V<RVLQ3GDZY[OK0J5KD#E5F!*JC 2%R5K/]\?F
MQ-VU:.TC]>=K&K5%^.WQ_X9@&%Q*04U>6/O!Y&&/Z YWW03HO%#KK%^EXX02
MV!>(,L>41+X/1C\LD.KBJ9R0S28.+.;OTHNL<>OS=B^^02JU/5-&JZ#NTGUX
M]RTM)%Y'6&3!&IN8'C7J-SLE1:.5_5UXBB^)_*KL=LWFKV$5O0E'N3:0'O/.
MZ7&&A1PNJ7&A7]$JJ>Q.ZONRVA]"J,22F?N&$9H@Z8N_C-1;-YLOXO6R^.LK
MFT5L' \GGB#8/M$8^_#XMS'X:_?V4]XSQ&(W64ODF]Q3CG< 747L]P*&LMG!
M)]]S@= (*,VP#O#"<9A3,XSO,0U;TT-9_!;-!("2GW+*K.Q:.>V#W]^2 SS
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M?4^5C9SL=X)741.EU^$4&D,C8FDB(L%=J<'OA&F&)G8?CG(M8],M?S90$8]
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M'Q$-8_JZV8H<&V$&4$"O&8PS/X5E-]<+MWPAK5-/8$%6/#2@N,TD7WJUP<_
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M9Z#E-AHA4(6Y"Y>@T\*JCJ[$,,?G?AYZ;O5J660@Q7[2<ZJ0_+9PS5/:Q>C
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M*^?@E$!+O4H$)N5V8,Z>[WF3+/4QXI8 -(8KWP[A_U/MC5E.B,?I@5'HYND
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MU,]A?71$Y7O+Y*5YO[ NF%_)S;VR>*K6?40VV)>L+;VJ8E;N<8"%&2DS:WQ
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MZ?**W+VSMZ=E:GTOQP?71=)!C*<79YCS3L?@?1*ES0%]OGIG9QOX:> _]*!
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MP3[3]Q)>-T/8X/C9F,7DR+?HWG?C943;?(#QT@6EZRA/5A!#QL_YY9$K":K
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M+*? 5]MU3YQ9>M%\4U53IE:A8/!SNXKQU(M4^CQ-!9:;F .BIP\EXU.5I1:
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MVH(Q/C:YP?=2\'6NJB)C$ECZS#A;<_<K^W*XE1Z/W$I?#;?2:$M&6_)16^P
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MQLEYT-LDL==,%SCYBT_C6$Y=^9O#"Q6+H72ZN"C<K2)G7H89:754C_DTDYP
MSB$T?E&[6-RJ*&!313=U.T)4!=-C'/%]\3QV_!FV:N@^-2P?\AAS-9MX*0N@
M*3+?-"DH]9I\:-)9MS1C?A>FN>=+T=)06MJ3Z1T)QJG I[9>33^D_L_[>_O[
M!S@[<IM'6HO'+3YP,3!G@'C8391F0[_ W:583[LRB%'4.,I^]\ V&"2JOR)#
MPRBRP7NG9<N2-_".P[J[:WZQ$," O3B_*I$PNR,_2QD_T. ['1 ]Q5!\/O'O
MA1.1DE-TK_1Y&0ZYHV193[*T,)[(<@<5DZ2PU61'X:JNVLLK&4*/IZS!NYY8
M4=4@Q)TK:_G+%##\'DST= R9-GTKSDB/@"*HV^1YA8U,X2<.+K]W$]/I[!)(
M$6,1;WJ*60D>3\\24U^FI<Z@P9CQ:MXJ[KFJDWBB,X-G7'T)/+>P*"[8QUM'
MO2+*'.I1]6N2I$:2V=BB7-9K7K;-XB5?Z1+H#$6^0WD%-GLF"J\:':I#DH2G
MMB'J'<W OLVF:J4YQKE"E$2)WY$K \1\@,XW C6)K*;NZ.BPW,-A,2(A4PR1
MUA$/VQI)M-\9R%H!.F658OH6[+3>HNAO5Y^[5.>6(N<D8.VZ!D+ZJR%\M;-*
M2\^6L8KT'?V*4R+_N+AUS5W0\]9)C8#8WGC1,HI63LB;@9,MH"7#/K9KITLO
M1+52!)E*YZ*FM8*E'GVU+=0R:P:.HK2QA?_+C?J=5-:@Y9ST.\(G6\I#+=$=
MK[G?@%NM$%&VI32KK#"!O&0)79*\77.SGBR=T4]08E5XS="*34Y;DY*ZAK1>
M:JC;D\70=]%GOLC<;!U-S9E@!:1EX:>)5%=]KZ=CE.@^/_' = _L=3[-@;RY
M$C+Y0;^2O'E:W;B2-_2I HQ__/$IVYQ??I _\M;8=\%)-@+W1N#>QWE[9_LC
M<.]; NY]/38LIB*20%A-@]HPP)GN\%$6/-6:=.HE>B.X@/\^7[9+\:VE[=1"
MY8-]"I9]?X>T/^"[ZRD9D:DZ=]'WJLLZ7>KG_/(XN"+?/I-PXCT/MJ!@\<_D
M>_AKW\[ E/JF(+ $R\\43%P(,OVU[^,AP[1,#O:G_]C.:?QW2[<D$W4X">D:
MY#C$JO]W2]& -V"H)K@L<J7T87SL'9CDASW1!Y514#*+3YI0N#$OJO/:X)J$
M:7PDQ=>N7N=X '8-;G.=[_:L(G_-7"L=WTIOJN\?JS,=&F>#/ST&?'?HG#?&
MNMGM$@]R<G= 9$/,C7DY5+E"TEJT#I>\BC'/O-W'*RFU ;92UO@ZR"K+YU)W
MXE1'R8>"6[?QB>T>__N_M)BOS=N'K6]:E1#CD-U>LC,[WM4SM\A/EUZO(=U^
M/CEZ?# Y.3G5A))>)JOH"I$Z2XX>3TZ.CR8G9V<[]-9O2##0%C^>'.P?3TX/
M3G[;57M*>"]Y6287[24)6W)P&/5&H@$PDT 39D;:6:7 %I4VS>*]F9(9VW(-
M)L)KE1OXHVZ9),'2ILH]\!-9/C0U<CYR@K*!B_7_-D/ A.$8[&6T*]SL:$)G
M ?^_TT!\; WB"9JX +82*=?VM\9IT"A%YPJE6,.L@*3I/G(\FH1[Y "C5+DI
M\A+>H*="(B>*C#Y)^H9<3I+X3#-T5C[BC/$Z?<_4%?FL76^UC(Q6H+OMO\;]
MQPVIN$/>T:/'1^;_O3#@Q&OIP$Z>*CO,P?GC4Z$\0 4 ?J4>(7R '&1I_)2\
MO??U+RO6'4:9&.H>@G3S3(FA/1]-K*4UDU.  8R!=(J?[,?EZE65HP(MA$'?
MS3;"O?"(^UY)2:$HLMY$A999X.SIF#ZN79.:K(I"4ENU<].-2XT,3WGOPX,%
M>$I7?'%7O#Q=TEV2S-OW\\L?FTG,KQ.^WQ/K[]@I39EBR7&R#-^*AJ7R%^:D
MH6@=CYA)9;%H: V\K*I9VW7)N@%_6/'!V3XO<,41M10D>/3LOZ >UM8;DH;
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MI3W]Z/>-9_ S)K!)L*_R66[#1CO&0.23(J";&K.O2BO*F!^UJ)A,;> [@KI
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M>$Z;@V/BHQ%R=[N4/BW2?-GH8/O,+24O:8XXM%_8Z'A$;-S4Q>'I=9H77&I
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M'$O+U) ?*$!L5P@.7$ 7 NO(5WE@KP(&8D8J2>Z&[A,'4"DMTV<-E&IX*]V
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M6FO%:2FN^9R;(>T;M\2E:BTT8%B(S7>7#E,D=?J=I0XER>0]YTZ8+XZ;&:3
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M0RQT/Z4U*=G#_8,#10+8-)^HH:8PHJ@U3^$AM[Y*!,UB0R(,6291":TTX01
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M]_;M4B.'0^>D/@U0W= !22= VR*_%:+-W]@T]EJ.ZA_51?,;5SWVU6S3@0[
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MRU@NI$PC420(KI/2&K;2HN*B5%QTH\U0#U3886/8@ZTO2I%N L-A<AB!X2'
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M7Y[C8MYA2U48FV".9I$O1K)-"T.8:AGPAL8S ?UB&##S5P]H3M-_O;PS>P]
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M"5,F/,X;08L0:%P6;5J[R"C'*8'VP;U7>6:H/8/;D:CD%5P PBE5 :R*IZI
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M&!]>O..LA)%@]_.5P)58%O$ZSQ&9P3URK) B!X;O!@8WL!G\!@2!86=WR@_
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M$V%1P1,H2^4\:^ -Y'F>"5FO6DC^^N'=@65KI_N^NUZ-=V4J @[*9105\UP
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MI[.C0IL5A9T94>:JM3LXK6J1'4M-W7#/F''NUZ2"$0(^YRD3Z:A_%]TZ+9'
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M==>T_<CPC'@77MMQ -^R55=W">^/Z;[1]MNQW;<O)<?:PMA$AN=5TPZJ$.4
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M'NHZ8;2G#:[#N5Z?>*UD146;6@/7NNO;S!V=^P9[6'H3ZIV@"CY6\#0)C<
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MIL06N2>A,A)4IM"D=)FU65FHLGA0PH":S;Z\ZK'AG7]?NY\C,/Q7APL?NDR
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M=1W/P^GYZ?QB.K]T+HD2E/1E_TEHF)%<]$T 4-6BJD55.SY5:[2A0I2">%^
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MSZJVS>UIL@KEM84Q8/^U: EGU3&6.0R^J8N+4$H]#U]'RG2U>9W?$/=;PR_
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MMGY?1ZO8&KS?8E313PB&_(I_6JN\_[3?=KSZJ,/:A#5 UW&3-&3(XX[D#65
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M714".Z&B%0)K.*!B8,7 8X<#G/7&$<*!J&1!Z)(@R1*#**5(F3/A##]$..#
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M2>FWZ=R-!^%6!91*Z=UEITXL+/54=J]5RZKA6 W'YS4<C<F>!<:!"JI!*.;
M)*M AN1R3)KPN)5HY *Q5D@.)'!:MN5$<)H&X)+KK 0EBK..K"0QJH:*L6I!
M]G6J5B:H3%"9H(917[.25@RL&%@QL&+@:U;2BH$5 RL&/D=$P"O#B14&G$\.
MA% $O+826-::9Z,D-5M+2?N("!QX*:E& CJ\EE3KXC]E'O]Z-IW- 2'I?#":
M?$S-_+Q6QS]V9<57N.3SNG6G5C*ME4R[*J<ZX:HBU0E7)UR=<'U3I"JG.N'J
MA*L3KA;'OV>Z;ZT@4Q=<7F.B;ZT@TV>EJZM\=97O>5?Y>+:4.!M!"II A"#
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MVKMQB<4/FK.4YDLS>KER5[*_/Z+</A3+_=R-)M?X/4^S\V+ 'RC\X'#8LPI
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MXZO>+JO6(:VHOB":TBMGK9P;)3.O*O%]<^N"'9+!S<F^J;G_>[#4W2LNV&C
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MIHT,EH-SP>$YN12!%:6F !,^6F.8SU\'_G6:T2K+:'?QFAWL<)023:]O2K^
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MF"3^LA6>G[I9+()8LOITMK* UI=NY8?6R459?;@H:%Y"MTO3J5GX)LQ&%RV
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MTM0+&[:*^"<II%9< P\*C[1E9R;1'+PEC+.4LV=Y;[2_)/EU':;-0DU_*>T
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M._GU5]E>#?RG$%W4/()F+(#PAH)UW$)*(@0G529J:X^MSY2'E#VZB)2#4"J
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MLM&<O?!-P^1B F<E]P9^@B'SFXF5)@$#?[#BJZF+AW0SV?<+_\>VA[G'G9X
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M$U0 XGNKD2Z)LT%H1P+OG /^-(@O7Q3BEX0S[ *XZ3IBQ$4)Z&U%0*)47(;
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M1!V^HV[6NFX,2H;LYR(\+P:RE8S!>D80"]0@'H)"*A*#C+?<""$,WH3L/09
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MHSD_'X^^ ; UGLX16"$,\:+57C8F! +)*)'BI49>>T=+%XEEF_FK>UBA>20
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MH#4+P7A7^K2450):>XY4] PQZ[7QA%FZ60'M-(EE5! )*0_G8(!L(Z-%Q,E
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MM\K (*B])GMWY XJ@0I2VJ=MLGN&V;,PN+,MZL'TWQ8I#C   S   S   S
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M(U)DIE!#R"R P#\S*IT1QVLH&_ OA9=?_)*5AQ;W0WY\@!(#FKHN6KZZS<C
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M/< N2(H$21).<_),L''&KW5#)WH"G?J9GR]@\(JQ0A]?#KBDNGA(@#(Q2,\
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M0V>\SD04*?Z7)O_IB;>33MU&?S M+-NU.-S!FW<14@J^.T@5!UP&:<?N\G8
MV:,5I\NW:4$8JZ[,E(W\:Y51?SIL&CI5#74FW+,P6J*&*\NW6))\7A>X"2G$
M=6<0V?@KBM$XPL[638&5/0 L-) 6"E @0/B$JT=J1@?.?".E2 E#=H6R$'%/
MQU9D<+*-/)]OG&=4@[UP=M$@.E_= "J@W%][\<O/PT?'MQ0[.SQG<F951\3H
M">=1F)7Y1<WL;80B7[JX9'>]'D QC5J5@^OO56I$@ES?NY9H(-:/KR?VPV?:
MS5B@)+U!GALKB*6\#Z8>YFKXX%LU#V^@$I[?#6(O6\I'(U0KXH?"%!N9GU1H
ME[@0GVW!8RCL>*C/I2(3570G!'=V2>*2MV\B>I.6SIER'56%E+X)49B+^;*T
MTA 48J@*KE5P<S,[GIP$MQK*#HFDX2T7D-S;N+I_0E=!2'6M2!J=O_+3,PA=
MSW?"'<8^0X T;\FEP"#D6MX)6NK;"\,G">,B#S@ !6X=PQ"^!JD4:C$"%5W4
M:$J&19)Q*6DEE37!+)8>BKZU?45BC">PJ@KC.KNDSE8$=@Z;/HM*D)ZUSFG-
M1AG8Z0^<'>"8,RKEI5[T=@R)#_5&LH=ZA&+^ZO.C._*6>#!^Z@3O]O@8XFD#
MID-!E#Q+-<4R>O,D9#. VSL%V*R'-ZQ2DWY3KOK -3-?\ZOAD;=ZXJ!@CSJ<
MP=O?K. &>!H\T["CJ0EI6/0/EQ2 YQJ3Q*3F+Y\TT18[*Z H0^>,I8(J&F^2
M<76O;UCQ'K7N9#A)Q9;::AIV*F( 4CK]YY;W>/[,_]-UKTG($:1G%:@00B(S
ML9:W&I,:?CCVW?07QI/"%I!UJ^@*)OP#AL' %(NY[Q"W.2/YZ,UD8$0\ G:\
MS)?I%F+$I, Y8U9>40,7BU,,_>N>"/,2F')H23EZ/EGB#"PS<<*JV)2:$OA]
M\.1A)P3P\4B!5H!?9MDI99_&A"% 5E*KY &('@0G:O>5M!(4D1EZK Z#"7,!
MEG)B*<H>-'%QX6 L> %CI5'E#-VX(OSOTA?G44<M6K]ASZI?XJB.#YU5N39U
M-T3W8U1L S4!^YH5;]S#GOJHF]^FBT+\BM4;3(.X"*-KR;YQ9 G#MJ"?=@<,
M7'M@2#8S]Q*#76':E\4P7,&NJ,$@(RR'S> ;B-]4K%4)L_Q]CI^H9-9688GC
M9\=CCJAZ#GFV9_0AOA/0$1Z-CI=\FK8,7 D(/PEE_QP&M>:@RJHP./-WL5/5
M6<293 B3OP8,52[HX6VR+]]QZ(LDG?%=2PWFB!,^@N',B#$$DA,5C&*FK.]\
M(-;2]>7]JQ?THR1:586##1[_WAL?+,N"(F@K,$;Y1F7>/;\1W(14U-92*4==
MTN-,UZLXAQ#"0W61I#59,$4.Q&G60F9P'&F.-YKC%\4QFKB'/8N&8KF1<UVR
M?93A>T9\443:4PVAR&LTL(==@"&+0,ET+&8W:! 5>WF<B;DDDNS!\).%<I9\
M)7&U,M-(AM<.NV[[9"P%39[CRDZT,)BTSZ2 CWU_Z[!;N@G"3KPH>D00)(+B
MU#E@8PP>L*A. S\*F.?B^D8[:"=$F10YA3EH U<F 0.;KV0)N;LGRN_,P7H3
M^)C7WDT5,8H3S%>J2AW!/DC2B2WU9#AV,QO>9-CNRQ^M:E*+6V"Q-;>+Q:Q/
M]W22CZQ2!ZN,ZE8,<I,4OQDTX;J(@L<W3YDWZFSCIR"$:]W7*!LV[JH<W,S
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M8+5GARTA.0-V9$X$'^:_0<P8UC.V%L$QOES5XC*"F4K,WHD,9<5L/1QHE*_
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M87CWPJ\!V_(#)=Q=>(QOLCWX2C1%(DA.G@<VVO"/^;IS8>U=,.>Q4P"8(D2
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M["*!CV H= 8LPN(E6#P%VXB_B(L7_LKM^(D&V$'/%$VT(.I>L 33H<(I3 1
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MI!,P;[EK[13*&M5D+]*0;?1SN"RR!MS-B.B$_";_M>C62D<W $I9-P1_%<'
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M,J/O( <\95FX5)RU&!CUDCX&]]W_PM6*U/WNRO,I0M1VJGG'J::OC>0W("S
M;X>O+MD;4VQ4?L <<^9!9<X@[*[B*TJ#*_;=A\TLC]@TK4!FBL-N''Z(]!$1
MK@@2I'A8G+"1F6CM[U6:J,AZ-A/QT-G:O>YC%EUO)?2O1Z#^M4A%G]"=PQ(2
M[5T"\1VGA/O+UR359QH^!,71FS)J:'"?)F?1BS#S+U+Z"8 2>H^^M_*6G*<D
MM UU('X<]J*X8K^P"LR>\?)B]$V,N#K5^UL2".LH"ZMY)L,%Y."[4P8>.W9
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MT16NPTCKN(OY>L+BN/<;&^6P!N61U;(W,. 'K+H[Z:C[]/EAX<7[ASJD<%6
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MXO8X>*;&#11G.EMVA/<\P4@KM#:9^5,ZN<VH#-E[EG&%E2F57C8S<^V2\8P
M1CBN"$O0+@U0$?[7N;-\2HE/Y?&=1[&W1K\W_PY<Z6=@*.<MT)!'[B-07N'[
M$^8L?S_BK 9PTDHBD(\*#WP)7&H/4UG"YW5+64DRU14Y:_?QGA@Q)WX*W%1#
M75_ZBY< S!Z=%'2PL!X\0[D56(/B/0,8;S"I@XD4>QS>2?X0R\P(P'=Z=CP&
M>Q3@U#J,R@J P38"P":' 5P35(50@&^?/G_A3SQ%\Q"*H79;V$D/A$%UK8WL
M TV@:RB)B+C1GS[S/Z#/MRT9N7)@$"09Q8SH<1QQL1S!2&8D&0LQA BCT<A\
M,Y";&!'!4A,PIL$O347("L50"I'\-6I;#[L(;T+B<I3"<$3ZH>&OQ#9$D;HK
MRVJ"$E.#;T#"!SHTHPO.0K3B SGVW3L:/J/6,%]=>)#<X4%0EL9.AVMA5/Q3
MI_NG)IB"GK=U_RR<Z:NNN31EJ]MNM@R_V'NNQ]5.V'=DRDS71% @I3-D#H8#
M5C!X2Y7<KVD,F60W8?#LN=0]V=U'4&Y 9 _PE^T8(F+$F=4#6H0F2QQ-=W"X
MB.%9E/,'4"Z8EJ>Z@N"';Z$WKH1]1Q+FDQXMPK@F"2&P59Y"NEP0>O_"2V7W
MBT1"??#3KW]&6(X':QM\8@.X#K![ZM[R__)CEG_"C>#>]^)(KIC=(%?^V[M[
MM21W9(O0=:/@<EN518$%2?=*DF[E9HP=)T*R;RLR8DO./-A<?#>ZH:+\QQE=
M,OY/IW2QTU3V@ZNZ(*ZD?8C\L11K=X(U37T&D6;":LB_M<1F+HH\,1KP"U8J
MNOLZB+F"\0^ZC!?!^>O&"SM7_KB>7_$)#8@?8$Z@-[S^;IU=?=$M"*,W["9P
MF<V$TO/^B1P P,HG0["8-2YB>T7.4[909Y_YXX4%.FUJ(C*$.4&M[N5(2\*V
MAW?I],D#RP[?@/.V4A:B!KF=;XXA6AKYL;AE\ 9!4M]-Z 6A3)!R7G71AOXA
MW%7W1'<O$OAP "K''@'>U1C>E)Q*PO/=[5+XK1[0XP5>&"Z"C:Z=H=(2^5ZV
M04'MJ#.8C0[#7_?8[)/=54<Z@7VZDSX+&QQ9&KV@X9=&XJ@3_KX''5?U!J51
M?O95'GW&44>2N+._O3WY9"*DSXH 90,M*/0:+-,Z0NE*&CPV.KD:Z2RE)!&(
M+_QL,E!?M\0T7= =C%,*U(@M[#%.3"XHOS8Z#/#)XFT<\(LE#"O"HN=@#8F4
M[\7F(6U3:@7WR:8)91:ODVV@FSIJGJV1FZSIHPF\GD;7$^!ZGS]^_N'CG[H;
MQX[O[@G0.OKX)VON]4&8DE-:A4=HFT]1@DO4\,D# [=UL8N26X(J*8('/BRV
M4B$?R)LC>4-,BSR&LX7K$ZK*2F6^].6:BFZ<79MZFF;(N2).OE7DOX,H"-4#
MD5U8BCKOG]4\\&D$D:1 Z^"887M-V: :*19M>8'0"/\1RPY&H+2 Z_E,%GJ!
MSW-^J$/NCTQZ[^2MW!H](K*,[/(-L*FO]0:'1F\"0T#U)\H<RAX5G,!;D$+F
MRG%?,M\BR3XEC4!)0U9H'@[]*BF(=NRZ_)E(_G/E^?1SM\)HDM),?2! $Z+1
M#H*7@@)UUADJ*'D H3"]H8NF8N&3/G )%J&,'BJ?K)C%4:!3;U0:)(1,]P*;
M*FV@Y["G#@AYWAL3;)SQUP2$R$@O,R"DBQ8*T2"(/+TQHD%6J@\C .9PV64)
MIQ5Q+[HC(^YER"5ZN5R%QUO7BX/P.(YI)$[?-N6J4\ZETXM;(LD2@RX!PH?!
M#AN1DU3)I=26?AW$W9V;!7C80->B$6D/>S:Z*OCQ=A4L'=;=YX'%."OLUF^%
M\W+_1IUO7\@)#GSL>'#3&U<678]MP?2;1-N?OR[9EF^.X!,4EG-\Z^:K<R<$
M1X(.=Q$X8IVL GP 1VH$)-)#X)<),88$ 769C 1,UMB(_PYK2N1-V KU'D5H
M+)&7%E?2.3E/B>LT+2HU C.,R X$G%%R9A'PFPAZ?*&BJ\>/]5-GXW$E! ?T
MD$4)NP54@LB+J0BFIT+QNA7.;'B@<SF1XYO+TUEQ+F8""H9EV86]!UQ"IT$4
M$V,0E@QS4Q,CZT^"7YOHTH<B5P:.1%3$TNAYX#*+:%5"0*#YZ@8 MZ35!ZZQ
M'N=MY2T!F",I#@49VWR3N6J;S&'RC/U"'6&S9W(,E_BD;V*X;53O5C(^K(N&
MO4NEWA@II,,/LHTI'5"2(D,Z3B*=C1S P 644W#O?6+AZ3P]073R7,A5?*"C
M+P@NURS8\@WK8 ]IOY>!>AWAK(Q@%D_$=<16(TZ[,9,XW%1$BJ1'OI44OQMT
M;24Q.25ETGPCZ0-^ZS'EQ8C-R0<V05^SHK)J?BH?!!YX2P)B&=G,A23PF,Q5
M93W.RX*(V"4;8<ICB"=SE)A+:%E67Q"_#!,QP>_#'IIGP?:1.=%5\$P[G362
M#@%"=C!S.X\\&]5I<#"HRW01.H!+>;=;/P2=C'B2$!&4)CMD9G.TY=;B+F>W
M0&F,4L9B:L6MV9V//))H#B-47G"'CZKMB9D$"#8-\7HX?,AW0C2>@2\E]!ZV
M,1Z($/CLV(@4S)G?.T.VBO<$44N)FX^2/PR&JKP%5G!+T?F!6#J/U%_N,);3
M81VK &??'.'M2'HALAO;L,D#,FON>>7L6D=,'H3C5#@..O(,7AW1Q4$RQJKG
M;S1PY),=8$AT19T! *RC*^\9MQG_T8/]'_>: ^2+U;!D"9>F$/AHOHTCR#?@
MJZ=_8"^#^*$Q9Z[%!(WL</EIH.P>)DME*N\X-:,$&"O?-C3,"^PC$J&XNPLN
M7QCJ#;"IS&75[MDQ )F+H')N[^[;65729;/O:W!Q;-GS>V4Q4Z;QS?#%*EGZ
MEM.-OK/&66*M+555%EUSH$S3M>I%UJLX-NM5R#3;@^69:0]4>4V.H7ELDS_<
MA=G6R<-VIOKT"79\G00'7GI55:0T__;8#39Q1[ N[!82Y$SWO.IY1B#?V!'=
MO"$)L"SS9N2&P7QY<C+D[6#7Y+<XW%*R<E@T_")122>[BR"\YXLSC!W/-Z%@
M>DCJU713*#"'RIFZ@RKRZ&O7'?"_.9\FCL3@6=DUVQYXT,/8B_B6GWS)#^ -
M%X'7@W.V<A<DNG>XUQK?&P.PYYX]#5ZH#T"VT?$C'T0?L2.<((F (G$>!YSC
M_H;/S)$C,8+4;%4A[8&%7 05L.)$YCP,YEV-PC@!Q?N%!H^ALWGRE@[K:J8S
M:1W$X%E^W);,;]D"!9GR!4N^.K:(+X:NE'31@A/*MVL(5.H&<8:4S1($?PV8
MJS(\AO<.VI5 BSH-QA!(3E976%7Q <<!9^30TA(%C:F*ZBXVQ&A\7:QN%*&;
MT?P=HMBO@_AO-+[5\'IF#:2N]4 TOF!4$B+._X@&M]E/4E3-S%HS R(Y5<!]
M)C(0 $-U1W4F A_3T"DQXL0KLM6*.E6=,CZ1PJ&,/.7@F"<.CKFJ[7!8[&05
M$.6W>4G\-B&RY0W*ED;\!-U>U3SKMA$)/5W3FO;(6?&@1R\P*FJ5=:FUD5"Q
MI%+="D#6&R>,=QTMN^+01TIV[A3*J=BQ>&7FI594AXV-[6GL4OC:O:I> %L7
MZY[8*'(56_*EHGYRU4>ZFS[D9*6<*WM5BWKA)756!V.P4:QU&JK>R:ZX)BF4
M!\4((*,.*1B@P-'T:\ W)C38 <BIK$;8"75)$B;/FO),53G\>B54H*N;0TSY
MH1]V575QC5JOQF!G1,L]&2_BU@XN_$R&!U<[5EL&44A1XDS+^=%ZSPT2W1+L
M%_[63L64J^UMR(!EV)]GV#=]JFEOZFAY/P-+I"+C9RLDP]3"V)@+@ZKN[1A&
M[Y;4=T(OZ*(#2Q*6%.!!=E15SN>V*Y::I$-V'F6#7R<G)PJ+9XJ6].W 4'72
M@+H[?UVBR_C:67>+,U$..$60 ,6I<\#&&#SL5+=TLQ558X\?0XI+YQ1,@33<
MP,45NF]7F#7M'4PH'BY'K(09:U4(<RDW_,,I_]N+4TA:79**"A-QL(H$]I.%
M[+*" #04V\8"574QEDC6?NY4/QRQ%G,X.$*^@GQKC<2=2WE+4/3HP!C4O3$A
M9R;!OQL:/;LV]0023[IO[--+J6G/%ZMAR=HVGT[M\FATP@^M>!L"F(*1\=4Y
M&RJ3Y"7Z.%SF6"5?MFY/ZN)G6B"[3E7: GDP+)383^U$QC2 OOOBA+\O O@O
M[135><,O62LH$N$JOV=$7BA?<A#+$+JB\M8*+ES/0T+;V6)=3JO1#631)QT1
MZ EB/V5?YF730CDE%6US1C=<_@(XB']F5*87':^#,)9UR$M/D:YY8V;4CSD0
M*),IAX+6*',P,Y+)&9BE+9FVD\7'E:695CB,-*TG*XXET!3PZR"BM ,$:UM\
MA?&.5S2*?H:$#BU&UQC,FY-!KJ)<[ZMG:)%I6VQ2K3GJQ1=EF%"_4 ?HXF%X
M4/RP'"L&5:M%K>&]HC3!I ?09)U9(HW7T=F60DG9Q5-(6V-;8#\I*'KH:J;+
M!_)ERM69!XIJS PK[!+L\. E8"[>SQ\__\E*"-@_MY!Y\]PU2R.A19"8O=38
M/IA(^2=L<P(V\2_.*P0$=!^])#3]03.[XVU:&:N[]9-EBF.90'G_]__\\^=/
M?_I_+<'E]<VKVJ$+JW]9,_'BOBMP1""& 4U_7=Z8Y*!A6 @ XZ&/@M71EO]A
M!ZJM5]YRIFQY?MXJOB *V8H-^&Z[X4HG!H$P@)"]8,'+I;\*PK7PTW>L5F10
M%Q"Z0)\8'5@L6S00J^ESR>#7U5J@AM!= ?=>TN?/@V?@9&K'G(FB-UUXO,[5
MRYFI6CH'PHU<G$55;<X.BA'S8*O@QI)M ?<P.+PNUU '4-SDNFM+FBPQZ=I3
M1OKCBDV#H40UZ%61FO"X\TK1X+'S6 8"U;E? SCA\63OYL 2E25059V19Z0J
M%*%#X8:E&+D3C B"0O.Q9_<QC4WZR[]Z7!T+ET^[[CY]PQBDJ:(B?GW\ZT$S
MF3=VY?BSYN,783EM(65R>]E2$+)TG^@T>&5*EG%) T/"U%37O<0\:0O5=75'
M%JKK#L]S80'E;[>*6;.4LJ<9'[Z4,D;>RVCYBR"D?%A]&.Q4_+TB:<7XU0\?
M:LNS-?(4:+](*3_;A@ W)IRZH-M'U_0%?^JD4@ %Q)"#^VE*O=@4A&-@_1?Q
ME/IN)BKRKC U'2D!K(0LZ6BGJD'O E*F"T<DPD0'S$H:VK1\MHLF,;(UBR9<
MR<)YE96Y]N:U"DCYP4YL0J^<Y/"3#XL)^1:EL&@@?%K1&S2!KD6IR<[0K!TJ
M< X+X&E5(NQ=&*7IE=.K0MHY1P__\ZO03<6)]:G+.R0I$4'J+7.ME(SN28CX
M#[$C.4C4.^=K,]Y=>(R&IP!('(2=\/,%.8+TB"(X\?&S$89>F[/1T5-7 [4]
MN),.ID::,2Z\:.DPB-#AFL]9QV1G29,(HB(2B9,E9P-GY/;%"QN/C9P]49B;
M^*(S#.G2QNC._5M(NX6K"W_@.@"]3_R)Q]Y5'U@XZ7QK*HNTFJ$.:C1D[A,]
M'GS*'!$1)[%-$)I199BSV<Z4_)PR^06F_)SQY5>Z[?6($56,?3(CUR-FXO6#
MY%6YN8\)<%<9KGGO0P0%)HJ[YZ]+_J@ V.PC]OQRO0'/./$@"YT.CX0Z+*/[
M1^>:71+1Y\#PI=5:=Q?C>1,D5S2NRWQA2^$0/3&:JS65Q_(]#$X*KCQ-9FNR
MMT )/VP42KOT8WX\1MZR<T',X\?'$'<MV* $33MYCY.11G\7Y+F"Y3'&-B-Z
M=,/F5 I[4^A%#XY/3QWFK8+0___9>]/FQG$L4?2O,/K=B-<3X>JNS)I>ZMYW
M/\A;CF><EL-6=D?/?*B@)<AB%T6JN=BI^O4/!PL)D@ ([I#HZ.A*6<)V#H"#
MLQ_/[6Y0XV->./FHXR1([0L:OPC(R<)1UO))-F9P!9Z8<'>%+T8,=F)\Z"^/
MXB]=0^@+V7A/%R2_"$TFW>3 $47T*"'VM+3/ROT.>>2#->;.:!W'9(>B["M,
M2UN)SJ)WZ':+P'4 "<6$2%8RIS@QII(PM2/,324\GMU^).9I4+R(@04PX"D#
MX_>\O\.K7I_0JP?*Q"#IFJ6.*6#S 0?/4M<'!/X4B\_<F5)XXI;;)W0(HP2,
M6L\L-7RGD  R*IBVHFQ<A^6</QV(_#(P^9 .'W/<S#['1T38U2O?]?8Q75CG
M=$5K(:W/@8[OK,D$IP><+\ EC'SAL+$=.C@6*LGP@TM/6>+>6CDJ5@E2O=:(
M)5,X>O$I=BZ/A88%^6G\2K(CH\XO82W<.B9"9ZR5.L?"6CF.J!<].#BCDAN5
M11*=#!C\;:W$0HV2AB'G$&[V*'K%*_@2A>_)#LZ0&_1A)N?C.G1@AXU\(@#Y
M4\+"S]K7,$!'FK3K-@TV/02HD1$=.J1#QAS-1;@?8/S)X?@[@O ?M%F\H<A]
M19RGHPZH@MX.#(_K3G5@V$0_N'0FYM[K,+=[HE9/B<TDD(2YOL#T)XT+OX@&
MATWBY$POG:>H++T\>;A%74@;X$=2>RB<;[%,'X$)+WY"<>K#\;R-POUCY(41
M=?@2"U%WLCNP!(2Q0ZU,8;'(=NQP+5D20A'V,'*.R!V<K9X"*^RB*/V7P8)
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M0I^_Y5T\8&*'#GA!@_['\^/O#9K"2TQ!\LBHY3P3PXNASSOD^_VE@B;#C9<
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M>!>\H3AI5Z59,$O)0WAHT!N9ZP>8S!%F&RG;PH#@ER*8"*PDVR$J!3'%! '
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M"" _AX0.6:A6=N'044>/KNI)20G<N.L37OS5]8(_DAIC83"F3K)/T+@E2!8
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M!P:0[:-1O-(8F:X?(W0KQOVW=%TM16$?\GC_=Q[O3P<>-K5<3]"P35)#<0I
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M"0'GR^$JC#FHKU(>./+534BR4!HRW<WKGH_I[-F@+%?T28#B5Z#@X[%P\I.
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M,GI.7];\+]&2$49M'[J6@UM!^);;+69+,NI<I>+:AE: 4"JG (Z_N5@O*:Z
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M<)"[BLA[Z@"(4A,KEMWZ5@IN5+W>=F%<*Q"$7S-\])(C.*1 UM@L]2"^6C+
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MK !O^-SZM)9[KRK'AG.?!J+CYM572K'/_.4G131;(;SG-4Q/TY[0GJ3V$5,
M$BL<OI&0"C#FF9L*G$2%DK4;QHIS5Y1(]%9R55LK  $/N^56.*PJSSQI0RM
M8.[RY'"H=?755E8LOFW> NN3%8CQ<%K#CY)1;]+9BKV4;(=N"S7-;0&G6"E*
MR&ZE@$?9W@J >$#]*ERL_Y5Z$2JGL,UU]> V(V5 FPUA!]@%35.3$&RSGI8
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M'^PXOH0!S$1F4I'S%05KD*9#WUL?M6'1YKVM +8H4:H*Z%5;37^K,$6,PR!
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MH8\5@,F#!:BG'LD.LX9L66^09"J(U74:6@QC!?@RV_;3\S>U6EC;P0J0<I9
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M*XHBUN*/EAR2[(54\\B51E8LO>@G))=1Q!96++JUT8YF1<E3<U+;[VKG!HQ
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M8*W=AOI^TYVSS<:CW"Y45KH+6 E,U7E2M)YL^4\(7U1OC1E<X)-J-T+9?#(
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M3YQXZT4 ,CGR7IORB^U&M0 =-]LM@H<M7_43)A%/:!T&:\_WR+%LB(L60UJ
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MAQB1G"]21G@(36RYO9U,B46@QV.@1[^RQN9"S"E'*<K,TPR'0N#E*5YA!I0
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MZDG=IUEXP%QZ'6_V %O'UEMB*'M+PWB'_NDF\OQ?4G^//ID6$W%.+_KM2Q*
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M0C]*SU=;J?9XR1@5YQ,:R^ELDLR+;!:47@!"B8^T8_*5]?;\$Y:@<IQSG#V
M $>HXIC6'+T 1(M.-\DS3#["%$U"I'L5K.P1K-"FVH=Z_N<RI/@&Q& ;9OV#
MK>>S?;%JOV$;JA"'0'28^UGX'E41V'05#;LFY% DN;9MJ,$L 3&_,$NKE LY
M\"GS;0/Q=H^U[L?XKF3T: #2KD&68D6[>!RC*/GFQ;[D[9!9>"Q2T$/P^=N*
M_1-H\;_\W+IO[5V] A__[[N_?/^E27T=T,:N8MOADN(:YW]"SS\G"EYJ"?.
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MW"$ZGQ1][+=!"R3&2;.<[BT,4/#D" I*Y[H.')P]]U;C8H]6AG[^#GY[QLH
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M2;OI;OWZ",(NOZC]YSZ6+PDO:PX%&8"A%T6GU78+< S>&KZ0=DU(D3@]A;^
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M>@(?(.(8T 0GFP>NR0?Z.^6:G>36N!Q0S=O:'N,/4'C:!^R\E(&6;/H6%QE
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M>^*9+QF#U6X^A5ECX^AO]:;17WY^S=!;2X1YD.R@=]R'OD>K L<?:]#(E:8
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M8'#+05W;,?=7T=8KD5OZMV^J$)MX->V[;-IGFY=%C:2JC:)JFE_<X%AEC"2
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MSBNCHN&%"RI2])H?#AX\5?7'&"!?JQ8Q%[Y6+=)6M<C5<.%Y@$/7.#F <T7
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M\$-^I>K&$,OZEK-X'WVP>=&INIY#0M-YG/DM%\GO.*YL:-.-D<I;P97E!.*
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M;@4", #!X??W>%X:(A#NX_Q0%A5["M/,7*CC6XJDB^@IW(([D/HP)-A:;S<
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M;]_0%<8SFD92VT$4.^,7G(<<@Z#J"=$X\SNP#?W0*9C%E#K&2]1E4_+PSI1
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MZ%(=R3%X(:^Y%%+"#^Q%WJ"7!GC;#, ) 0,6V"06;W3AOA&3 .XM9ST"SH_
M)+BK5=P MV#NTP$FZS@!<L&V)T-,EE&L9$UDM'T];-J"KBL$32-P2RM /Y":
M$+?88AF1X.0VCBS2#CH;:ZDZ4FX0YE2>;=)2448_4AYCQ,/QM7"J-<@L>,&L
MOHT9!Y2".3"#GX0V8AS0"D8@ACPM@O-6^"7I:4NVZ@*2R. Z[=BS;0=OP(HH
MMXCMP#89_11X&^LX '*#AT\$NE[)?K ;#'H:U/5"BC6 <5RU+_B/6L=R>;\H
MD;WQ/D%:!QBLMW669&. /?)[HY<P^O="2\G1P=0%,'J;O__,H(=>RC#VX.D1
MK9SB^G5H)OHH^L+N$2DT$*14W^R(S]VA/Z19Z+ND -B/U;)SM/4Q9S-@LE_T
M3]L774)C?>]4H>F\HDMH.%\455BH%G3G.>O6(SS_A-^Y/"-E; #B(EZ$.XWG
MZ-A.N']'NDE(R7X<EX" MOCY0YLJXU-N0 RV(8?)HJ%M=#!6Z*.DGH]PX]YC
M-@5'B!LBVLS]+'R/0+D*O9(WSCATR:(U'3?X&D$0A*2$&0F<<JJUZ'0$W)*&
M/X]Q5? 9#2@R]G!9K *2*$J^M>HY.&"X$D!,5;"W9@MMS+P"'__ON[]\_X7:
M<?1/EH9NJJ.-*N6T^"<D2&'9BM;0ST*9E0DW583HCS:_?34/'1]H)=^P#56R
M[YT,BB37M@TUM.=.!GS*?-M E'K09&"765A]57KI5ZIO]ANQBFV'RWB19(Z1
MOH0[ZF"/_-JU3>U1[GH;;>R2D93?FT+&N:.K5?L_'Q>E700#WL;(X5H##J&B
M?90"1^Y<Y0D6! *PUHX8-(.4BMXF\)L' [<1('[1Z1=E?$4-:V\\>8#IU[W3
M;,JID*+1MYQC77#IV$?<^;,(W;KO/>N30X<_[;7K=!K#B( ?I$0J24;S(GHD
MF<T(85-%EPV4SP 621_C#.D76*WLL $'XN>F70<)"G# \J@4%TUE#.&C-,BD
M M9[!RIPCKTNM]XQS(HBV/1L9VI%SB5AH-^*K@3XKTLX=>;(5D/A$N*_66J%
M%A2*>WVZ^;/L 4<"!BLVSA-2& !0IQ@'1-A6,'0X0JO8 "Z%30R1G.'B?E**
MOAA$G!44&YM%M=2^@5EPICW'(NP2T&GS5P_6D(HI!N+ *C: *ZE&2G!$@>7T
M73NN5LB]=KR9-AR8E,XG3*8:#VL.X$<H>6-1(_\IW50NH,P)4/SP*KKA$.D.
M/CS)'C)MZ5IBY-:<8IL_M7:EOH(=WN(+..+RQ_&N;OQ=1PT_)+#X'2=_EQ,*
MQVIJ@V<5*51UY#--<SX+B\UAEA>7[.V]JEE' Y!;Y<X]4 5/L\8(K1.GC1 R
M*;4,2"D2,ZHBBU^3N(.2[HG:6B=4BGA_0*\N]"(LG@2', [3#,_Y6":PY&!%
M(;;=P2,$<;/>OC,-P(0@HXN)8P.BYQ%LJ!RH(\FTQYC/5![<,&VD^6UW28>U
MZ?,XD^W0>>(#=?O\.<H#/H5?QKZ:(3[9V $,/@C4(QB:9;;@[CB8A*8:5 N;
M;QE##6P,,;91UM-$W3)CL+#.6OZ*__..5BG^^?_\'NWG'][Q&,;;!/]3^0]Q
MG&1D!?)O^)] !##K^*\P*"_L_>$8):3LPF,<Y#XH_N2C_R(:P#Z9+^#PCFNX
MQ=X!85!X>('P((._Q7]*_Q$D!R^,<<#S!OW]-_^5YN]I%F8YWMT/,,F/__P-
M/H#P'Z6<0/Z,.$>8!)MBJ1R6>(W#HC+:/W^305SRQGO'-.MGY=]_SP;V)R(B
M@&#U@4A^!YYAZ(-G ,F95!#RQW3!.I:_3  LC-/,P[8F-EQ;+TJY@-U&7IJN
MMS]Y$**EUI#X/7![$>B'*39>%+ -#BO *_:88KA2S2<V"%EMV/GB9;@A]^F9
M?*("B?U[$Y9J*Z:A07O#=P71U7I+_(3/,/$!"-"AX**!2?R:)?XOF^0&/'OA
M&4;9610BQ?-- _^Z3V"V ?#0,-8])U'HGS;@,[M!S/F7"F*AH5TPL^HGTX V
M#@4]J\_HE<FQ";&\=FF;HPH.MI*?=G?;AHSUJY6@\-I(%.#P1C1Y#3I-D)75
M0'0_">7<]Z+%T3]_XQ.G*?_("M:!BU:4#0B>/8@=  \)W.S!8YKF>*T6:^E1
M)2EKBG^N_J$^<TW+*\:P^#WOHC@ [P,8!C!-XAA$E:[9N16LGZV\%K7O8KVE
M-]):E6M5\,G,:(D;&2PSX@R"2]]P#5+OH9*88.USM=KM(-BAJ_J:HP7J:L1U
MP^<S"Q08:<U%'>:%=TF^0Q+Q4_(!VG>4\H.5M[.6CC S\1&S'1*26>-L%)8%
M>F>U7F;>0'<>Z#*"!#^7WY+-/LE3+PXVW]"8$T<OEYUE)3DW1()7+P+I"G$;
M4%)M6"Q_1PI+]"1G_O 6<:-_,4W87W-\""T1",M%("#EW]NPD$*8=/@G+V.?
MMM]I"U ],QA"$!?6)EP4%-UTTKJCPH3TM";D._P3^7?3T$L$WM9'>0-V81RC
M,1B,\P.F8*4>CDRCIVD&J6B?&-^P':0(PB*78)UGF#L'N!A?_.2EV9UW6F^1
MDN&#H(,GI4O::G9I,8*?PFQ_FZ"'H="QCEY\>GJZ;3\F,C.L?$C.S7W1"1V]
ML(I 3#M-?LM(Q9[Q:>1L:P7\,8&/##XB,-,646M042]N-HD22$OY*> *4"O,
M,/NRU_1UK+Q$ZRTZ>\3<J%X2QH\:W"-*;D"[ZGC'Q8/.!9+Q7G230)A\0^-P
MF:+R<3B#/&D-]8^#"K\1(M<,G2""@Q#QC^BO(+C+R<F23Q6/84/+$!MNGV19
MA]J^I6";1T_H'J:8Q1?99\W$LPW^1/]5&+^ M0]#X<T%H+#"YHB98YL.P^G+
M&68E_SJSVR9_1L?T-<$7IR@FV/RI#?/8V5:B@HAOI50'NFX:QH]6 K(*@K"(
MZFNHNTT&5.K"A.54E'HV@XV=;1\WDVO8WK*2"<ZQ18H3\6@->8_X;DGV>"NO
M@$1X7L7)A"<X9+N_\=*0/+^(G..L2BI[#7=QN U]G$KNDP:+^&[CP($0I)NF
M*V/\_!%.JR#[Q_Z$);[\G8C"^MQ7TD ]A3$H*UF.1DQC#>L\>CQ.X-"M%\CY
M8VCL_8&VL/9A!?TL<C=,W T-NV@>5844%%+W@.P^>B%K97@Z1#WC _H'6NPF
MPZ2A>%$KKQ0U&+*CUM]_%J&1Q,QQ'EO]*S^N4G8I6VTGQ)OT#8:8XV.Z"-.T
MU(7NRB;&Q#):&H3J1(P"-6-G6R.*#'*I)^\]@3BL_'0V +0O$V> E1?CC40+
M$$VA:>UYB\,L;3A"VD!*3K(2\.HR$NGGH:4CX)HK9]EQ>)PUU"L0!-,S\?<+
MK\AZ&V66L,[-6)\N/<21_;M]=H(>??948?K/5E[/TAU7Z;$EJ;6-'/PQSDB^
M)1AT6PVNC<* 6V2",TB@ITJM,*7NR-";4SVDC$0DHF?93O9LMD8@^3 D=MJ7
M1OR,OO7M=/8PC)Z%N1.)]S5CZ[*\,3/M8X9(6_DW@ GZ'VXJO,HV>_#%@[^
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M8_'(6Y. :&K3%;GKH6 F[S9GTB3JKBC9(%#:YC0NC-N=K,I)R%PF+AV!O6_
MM"60CV#JM5PV06S)T=604PDSA>5#G>45 V'1K0AU#]@*'A/#6,&1H-H7H8$"
M+@(K]"S#^33)RGGJAMSL&KK&;-9U?O$VY\Q^+[B:[IAAO&A*FYU3KX<T=0;
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M-QQ\8 $>9933.L7TSQBV') JK5-,#SC%]/P8?]?RS7?GQ_HG,?\/4$L#!!0
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MCZ'+C8BQ3A]$QV GS<UYXXX;/CODP(FVR#(>@;C5,$5*; EX$<663NRK(.]
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MP2*:>=TY2;N69,)Z_3OK,I)J3%3*67T90,C#@/S*F&CT45]E,-CN;](R:;E
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M'O.43$#?:4S%5!DV@J: J^E/3I?Y45;L#.A^:VL;#7$AOEN'R&?C2PJ?_D#
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M^O.P3.<__]M/?YXTT_SG_P]02P,$%     @ 2(%C6N&*Q>M: P   0T   \
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M,[%C!]->1M*9N\"L[^"%QEU]/@!02P,$%     @ 2(%C6G"]#WE,"0  Q$@
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MFEK[] VBM[^T]MW7B_X/4$L#!!0    ( $B!8UIJA#8T6@D  -I(   /
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M$X1NR.6(CZV+J%J']&6BUS^T#MTWC?X/4$L#!!0    ( $B!8UH56Q ZA08
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M>5AOY ENJ\A<T%N=9*_/LP7--XSFM5=+<\IASPNPIJKJP3 _#UHU7;,8P%1
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MWN!2[ZND=0'4"Q=Y%S7>MQFOJK:;OV;T_E+KNV9[ 50!5%&/N!>V(D,6?"Z
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MN/W:]-<5\P9371]D8_]B7,AIV"!BUSHIN3/3'2'&5"\*]J5W$K$R(M*FQ9H
MR?36;=4BT?]LAKW3SC'^8%N:%#6JVI<JQ=$-]T !4$@V4)ZX3%6AR;I0?A)'
M\"T]#E_&GH:_R/_N$"1Z>[@RX;@[/RU\RCC=4-6!NT2M5T:1=$*6WRQ-$Q//
M>3SLP6W^W-;^F+Q,#_<QUHE%>/W$[$9MM:^52(E)H:]'*N5,=@U+:71UG/$I
MIW&1&0N=R8)6<)"6L$CX".20$^WPX,1,>'+^JM@E,?51G$J45TDE0E&?U:O(
MXZG@?6B8Y(UQ.L735!VJSB=O=#2:MQURKG^#H8Q;=1(9L58=4>$Q6C(:%A)2
M/C%)@'2^]/I#X7GCZG'.K:(X>]^,Y78?/VQWG\!VPJ5Z;\+RY(E9R9,];1]Z
M&64(0]\Z;4C5T\MBT3)%$G1M%L"NV2!IS?=LT#==6A$;],$I%RY!BV'I\_BQ
MFE/1>Q?&1J?),#9H5[.'E]6YT09G7MT6V95NA6]>0&13!>K8H('PFCG6MB6K
M?H@-&EQT8X/">/=V;=@@PQQGH%?W/Q PUP/];=WR[7K5OMGX6!^3?D#Z0'\@
M9(2>2JYC\2P#%?D<Z4@+GN6-RCHUW'AHG!;8OB>42=0],7V;$E_J6:3TMM#!
M(/#!3A65(/G5S(C<E=<N^0 <+&IGV%YU/OR,WE@1EY')AYHZQQ)[I_ W/T:*
M"1A3*Y%R#SFJ"6&-H9&#OX%WP]$DP:3G="7D#9H?N9L8_V(VZ0/#>M3F#[)K
MM [TP]1TD-*.]<6\,GOCXA[7??$.09DN-;%7[T>K'4K5L7F#FL!_2NT TZ27
M6J&'&1=IVT]F8J9/!*TV@\GI/WQIO+:UHQ5M ^$XI7#*5%^@JXN">NG*<:-P
MU;@YMS<F @FBN9?"I7G-FU56KWH5NVAY7#+IO?@XR2D!U22G>B=OR=3'S..R
MK_7"FT8!NJ;_.M)=+V27@F-QXNCZC/W,% 8?_4[0^L[L\#0GY*R'O77R>X<?
MD+,UC93[-O9?=X1&X021^RD^#BW@=(1R9MF*0=3^<IEC8=7X>S":9 3)@8[^
M@5*@0+_4>1]<=CI#?DE]7&T_UJIH8]:_Q7RP3OIXG/"#_]OR#G$/(57U"K[!
M)UGC-I+M'\T55*R%E>NM$)0Q:;;$U^:GF2KNU!D/>X39J)I8)F7DY.5ZWK:O
M3<UUA/7:RX]"E!G\M BR]AQO3.,AVH[A<>0OQV+)J/>(NXLPEP\KKQP[[BFI
MV.7=F&\8^N@E>:OJ\V9_=U\7K^#>W R4IOZ"Q75Y#F K[BB-BD\TV&RZ)QQF
M8C36DJ5$42O!!!6<382JR:S[+PQ*14\]<98;R"O_X+ERY>QB].=BU9/- 0C+
MEQ[RS1:)%<FXH!UKMW/ZE08R0UC-+A%#?<7/JY[!'MG?^UH\Y+?05&\@VRQ9
M8]!*WK:$:/ A)$\>S;@Y2XNFZZ_ \/2D"%L,JX@:V]T_H5MD7R&DGLIO\.%Z
M5DC22>&>YRF6+SO!MDA] .""T#/OT-SUW,3L2)3$"&N_R;L@;?V&L<K(BCX1
MQ(D5#MC0K/LZ3YZ-B&3]I:]\1VX0K)36WKEFW*2,:YA89IU_\V#8/B:QSM*P
MC5J19/+D8@=/Y)O;<_JYT0T+76LU@3^'/F:"G<G-T=FFE74CZY[%_G7&Z?35
M;V&5F7'%^@Y%1>&OVE\U<2WDO?[NJ7<ZT: $5= "]!<XL^8\,[7>G.X0E-O2
M>)P63/[9#.$>8007T2P[GJ84Y""-1 ['>.W8.-E$Q&<J< 8JEITJGJNI?ZYD
M]?K>X\=' @KLX\3@" N![_.YAV0E%J36$AT:/.<_?KPN.US0T\D)2]8T3E:_
M7^U=!I5U^T!,=HV63=*6BI,T:>&ITCM6<R;^R%_;!?(6^Z-EWOUMO:X%OV?=
MJHCK9_)NON.M;01(0F<LXP(;5)9PEPW*+ZJEV3<NTR+8(*G+Y!96EVX$*^WC
MZJQ'<_@(='6-#9))NS4%W5[/9KT*C98I^=K\]Z*C]QRH)LPDB#** !?>R@Z%
M'[HS )U5&BG9^-B>2PRNBX.V/'5I"'LS-FA<.#WA,&GL)17-*5[%>3!!A18G
M4"JX5UF";JH&D\U)HL8-(Y!O9+"5@ZC[QZP60TI6.23WT:OV^VZDL^G7GC_(
M_#)Q^NYFSQ?!'IM38>]532N?^B\.>EQ*SLR*8JQYPGB=BF\7#&80TTW-XP8]
MQFPV'F2_IX'U4'%( %Y#;5"CV17>+_%NRL)!QC?)J2\ZUCH+O[OA^1F7*6"+
M81U=8AZ^>E!)M3]-+2U%6%;K]O+C/A^W'3\'[CB*@DN6GN4,O@R[%D5QIG8P
MWQ7C'Z!?ICH)?**]#L'2<!;Q<^U:<5-O9\=+ZH6]O +>JRYD9I+&TLY;>#K'
MCQ LCIP]YL$JO3H"KPS[@)$KT?Z@UY&I">F%; 8[6(0DPWV"-5$40E:V:$,)
M."NK&@+/:1 GNC;C!!A2M+8YV'.4O.<EV&D:-U%RK)GI4U&44CN01]'++SH6
M"W2,G3@1W;87T["3T3/MQ0.)$_M.X@:5"<JL(QBZ)ZL;OQ^'=D-'O4*JU)+%
M4IT]"Q!J$&'*X=R"H-3KGVJKZ3<#GV;&$EP:*BZT_VE(T'Z+C'KK_$9<*Q3&
M?_588J:MWFAUF<D$P6ET88.BW!!X9+!(4EW$-S$?9XY!P9PFH#7?&<DYC67,
M!#;H'IS 2UVD+'0 )?#,Z52$>5UI62+=FJ)6.R8$.39P];SAF?R2XJ:CJZ[!
M ?R[59_JT0UQ9U[X1.^E4X$&%GJ918"60IN_H2XRX-4TGR*:V/2MP0I$'0ZT
MNK,W.9F56S+5@EU^='MBTGT495=7GZ5Q[F%RHCXA]H:&1=O=]]8JDO89'IUY
M!35*#Q;*J@,'Z2_=1I+5K546E_,FTF#)]F-C77L3GEXHRP%XS30/,!U-\=)D
MU-N4@9&:]OJ=!W3_%HF_ W)ZD&&.62;LQ&S7Z?HVM]A4&=<Y>#J-*G*YE6P?
MF7W-\Y7/1*YYOKUG4;Z0A61-0#]A.\#C'$3IL,:3R*<U9*OI*.3=V2?U\%SC
M&<][2W9#Z+*SP^";/@&JDY@W_8XA&-&'^J=5T!H:XI=AI\)*++]9X$P#5'?$
MY?&!Z+H"RY8QK-B3P8R[V 9)EY(27.;65DA"W ]<->!<@+RFDA3I(0B(Y"#:
M=9+_>M9$TZ!]$Q%](BA_<_4FN3<N(,1KS-HZL#:YH:$O.>#)05]#3\[8^F;U
M<<Z3.&=F*7H&B%&5S9HJF=DHRW@P5,]31#LF&A/L>*T5S+L=8N!0-BA5GZ7M
MH#>25S>TUMA&+8H2DD=?1#_]QKUJ:ENL@I [46)B[2EITNFGKFA1'3C :5:\
M7%N8,:GZ>*EKU\*ACO1^-Q@87:^\,M<3 /U?RZ8?0!AI1J;W&C",NJ0V0?=\
M[7>)C1',U]#Y5?0#-HBNT BPGZ'$T0!\F VKH0^@+,X);;P4((F,#13I5]&=
M(;0)X%\M.^![KU=4YU57IRND&:G3<7BJE4X &U0@ENMTS32;_(N[0/>,.+V8
M\$6 Y-B&_@V=9#F_2&R!LKN>"44S0Y@I0.0CP55])#39N1DOUBC@Q !_(@O'
MSJ;-78&?#,):#@6\G:W.,G:_G]+;9]@0K\I_?87SC=>/&CGZDU_73H],TA&L
MOU*R^$90,C^FN$95>$_1L%?) 1%12)ZB%9'V,,QJH\0P_\W!.V,X)17Z-:QD
MS]"L<;OCZS,C-P[H%)UY&7!&,A)#XO=YM'C[>W> UTJ?24]C2>2\E6X<[,&@
M![)QU70T<&VC<2([1<!F"H@8CL$?2(UE/D="R=VM>#$EEMCW9;Q0X[B.G XO
MSA%A<U$U/EL(^ZBV.%#-.G1:J/RL?A1&/U7FY,R<$1O$XGQ--W:?+IVL)O7H
M+K5$T,X%Y+<58HHAYVO0(IB\%IG[ XWM9T_PSEWQ-Z)D'+;PO/=I76"QZ$IS
M,3-3$V[82_+%CDRJ;DH.%&)DM/PL7CY9$M5N5X.]W;7#HB__)$33C:DRS.=H
M-_C$3KO]="AKOUV0[RF&9IY)T:J8. 5#6D^>15SD_X/_9HA^5^_>E2)'Q69#
M3[>SVD0[B0>W],4CF #9O0\'4*PTH3WDV@RTW?&R26H[5<U>=[NR[^729X!A
M^^KZCGBMW>W?P(82C"=>BYXWX8P2T<QTUDG#.,44_I![%?#FR:3VQX SJM4]
M(41J@*:@DV&PVNXMTOK/Q_@0UB*R6P\UC!0"T@.8^YNNHK20FF0VJ)4-XG5'
M'T5*OJ=EFU:/^,?)=[#.CZ@H\YFX!'#!#I;9&F"^%U^][E,YG^PLK>'\ J[^
MJU>&V@(]1) -\LB.A):VQV""C($T/0D1<:\6Z8N4HCPN>(()LOAI5%43WFMR
M[?KP8.^3;6[KSV]/: J->Y\+#7UTS%CT)6I 04]Z+2G9V##XM6D/7H)@LN/"
M=*J=;Q")(:B\#\(_J?1/S:SU0OD-P.M9,@#%\4'/O&?QD<<BD5:%"'CY6IIK
MN+\CS&G8N9+26#%F8;NLECCM6%+8\ZZ-'T8-DG!+M!,_UOU)C6H%#4NM5<*X
MX*:"[GKFX4=)JF_K(55:3].CO+?=/L:EV;O_N#!V8O+V<\'"9R+6_J#[(P-M
M=RFGIYHKY#8GTE]/I]#AI:HRHQAOA*G_;J.8"X(4_-01_K4[!^^%$D(W-4+)
MYM 8*"]2FP(V'F0)T8Q-*9#7GB7N+#'*6%2 KG!;"G7'AS.G>K@B;W!=J(LL
M#Z(87_K@=>"TS4("B9.NB[1FIJ+D@I)FEMJAQWIF 4?2/)9+%N^>GOYFWWJ#
M_W'NN\FOKRM9Z0VM5^?U7_0<_4Q,5K 6J5@P3?8(D!:MT3]ADI>9/A2LNZ8Y
M4&(J%R!KRI=<XR)3D3DR@IL/P@B8.QZ^\A\NSGU39X@ WW(^F[2/#7*LP#,U
M;]M0RO_EX>1,]%^U^!(H4Y,?K\@&!6.7E9F2V:,C N;P(R$W_A[??B\ XW=]
M@<H"T&:>AG8#T\]4HIE:\+&]N']]?.#1$KU=G%7?\0O@$S+07*DT# !SV4>!
M.76[HR][;)HALO#0N_X0W7V<65DQ\*2$IC]!U[M][M/E(-]MR/C)6KETY.[S
MF'<'[W\2W(%'U%^A0X"ON8#B9(U-J=*JZ8^52:J%#-//E.3VMS/T!*%Q&M::
M/+E>*M0@E#Q#4F\9=9*E'.H)RQ.VC]5R9!"YKWA[@M-U0 :?4)* '$Z\%_J;
M,U67]H1NYY9=X=JF#8[0RFZ-JGBB<\K]2=ZJUNLQ\7(R<S*Y^<N>53+AVOE)
MX]/GE.P/>;:U/CL*7MH@DJ:BB+!HO%"]^>RL8&\J,0$<U'U[P-M"*G;*G=!8
M$.CG_$CHCX]9R$NYI$?%ZG>?G8W>W9V1COYZ,6.SP.A%T&.2H7VUQ'F22*+-
M[1*/V9# ;V+%/C[OPUI\97H+K5(I(E1D[]B;\VL3IJMO/:JFEG;FR 9?$'0K
M0'6QBFSN)LI+5J<A1;O%7F^ANK5$V[IJ"#KK%)*_>O-S.&'H5OHM,K/^GJM>
M:8)(6#[U\_CSMZ'J?X')UC#1)CH'NDF1(4T_1ZMN0UUFOJMWI@CU3C0_9H.$
M&'J(#TTN/MYHQ4Z3!QNWTY9NE=>.O"&IU1H.NWS^7.5=(7ZD27H6)HIN^@.
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MX8[@L.E?^Y.F@&K!G_&?)NS,NK;W\06!B5G9KCS#<%Z=2RS)(:0T]66\=LK
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M6EF7\32].82=MZ+"^<'BNU65Y+R4_B;7_(ER!\+UTBM"%L<+>T_]];UUC!)
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MYV+"M/+/;58*EJJKO,NT7$_8!2_* W67QL2S03]"/:9I)_&,!(-_5@R-M1)
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M4IVN/Y7IG%ZF&5<Y1<JN;N2?52CBNM\60:I,8(H]I2F+T%8>P'R(8RL;A8T
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M.1#5!V%@^?.3>1ADB0;/9TF^ ,$#%9C_!> !26K'(L!:HR4.+&9S$.M!PEC
M%@E6,ME5Z']NJWXU#35"MPP2R2]@ZY&P?41ZW>#>T6"%8$&+GEV-.8"FA!2.
M]J+I%#0@,[HC%E?($LH#*[*I,N@_-T'^Y\^O:M^Z-_.\'HL#Q-,XDRX&BB/-
M  -$@;P4LC!R9% 9HG=1,[N0(Z#J'KB@^^L<T10'*I'EV/\7;5_9^K'_P#*,
M,D>B6V"W]+'W0)OV_;6&9>H@6!SAH.PHON!DO9-W(9O^QG_5^,??R/V-W/^.
MR&'I% P@T[<C=A<+PJ2TYSBA_]P$N2OR;R*GBVZ)AY%S8.N!&V@0H\J]N/<7
M3?O6$?\:MKU7'( AYX$S.&8MZ,U!D/K </:7K=?8^M'_"KI"I@X84$)!E$C>
M>RBE[ 6HOVC[ VH(\O\W<G\C]_]'Y+!_.\Z_0\Y?(!?Z7T *=%4%43MH ';G
MAEM:O+1Q.[#"I4_T/@W-=T_HYHTSW 6T _=,3GADCE05F@\%RF:516\VA)T*
MO58]&-$X:;L+@2T43OZKD>D7P1J#ETC^\_)-5N_>^])>T5H1S%"F E@*/)!$
M-YV!RVW<CN&% Q8HXRW6:M56U8I_A_]<Q'C7Z/*:^@:#90= D?_:K)I3P)6
MM=X#1&;LMHXV?$M2WWAI%V*N  ="P+)NFY76M%=>07<AXKA%&:)&1*UK]NH:
MJUYR\ORS;6+Y+F2$%/JO1VG)9['O/=?T\5/?XF2'%&Q5'P +K/2A(K!-"QS<
M]086\)I>WX4\GFG-(ZV/Y+S+"6.!I:(J8FYVV*<1 XI(970%B,0&_>NQVKC^
M1Z<"NQ#9B0EP>E)]2:#$/E>?!2'E 6W^)HUU_..'74@1K14]8&E<D9/S*QB
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M_QJ;/E" HGL"1/?7.J$I;F#*X6CY%VW7.'ZXA!O\^8\3Z_\+>/#/!EGLZB!
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MO+H(:M4'/Y#(V+^@/H/MV0!]V;\;H"(7RSJ)7^\S=D4!I)<#$$9/VY;M@+\
M!JJU4%-+*!?"S_BO$=9_3$Y8^ M?^-O:IGSKZ%J:\1(A,H6@_/=MC VUT(B/
M,?:8[B9/Y652))!;V0ZXMVO, =2G%43WQ[($,^ 8/9K__V@$)&6)0)<Q9$M
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MC\1#C?[^G@^.K%(&]'P*5)FG; B/7[,.^I=Q "V. G^HA.<@&8!*F5H@NI!
M\B'75()ST-U&.# ?11%#@C+SQ@94@@0\O!ZLMLX<?C^&FA+@X_8A<#D'8>*(
M&L6Q0*;K3P+;R?M-?Q;NL*?P2QQE28 N$\.60,^RN<FP!AH4>0I)02,9VK@^
M$#_^_6%KTMD6]]<$_PO30*\UVACK:X"Y/M!K#J*CBX.(@"@B;)$4[%\B^!2
M\ MJ)(U[W?A: /_'1JA:&YI:@%SF61K)_[+PSX7T+U6"@W#PQBWQ -7U87KU
M%AC9F4A%5P&$IJ]$H2@QTH#+(.SW[_!+Z._LP])O >0*?EQBOX5< .WXK''
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M'7R1G9:&5%XEO&\&Q'?PELP9''L];AK@1("[8\X?MUKA=1L94Z>S#=+D5ES
M.]4ZT!2UZF=,@:QMCCYPP.RZBZN_3TD8B1T1]U=3.8B_,+:'!^V67R 0T:!9
MAL@2W/,KDPQ L;6MQ)$TTI(?$0']]!G(A3:6( F.$1D1@,5U?E9:G_VX<\=:
MHI].PD$O:!S$!1P[%?0J;=$X>/TQD.]GH-=/0.YQ12?4ULOP1]'Q,6&D)2PU
M"=X^CF.U0ME)+.U)F!>(1L/(-7_]1+T>5Q7&!E>+_<C!3Y6ISWE39"RZB^V;
M@U"FG7/:01FF/@$!OO+'/#V\=K25&>&33SQ4$2]\LSX..U'.QIW3LNF+8=[D
M.CHG?R2TP^_*JS&3H^5N%]/Z?W3O'/[6[_=$V[):^YA4A$VJU=AC4<==FRPV
M;[K?\*0Y;^1-3UDEWIK60>L-FL-?86@&M_[X)4%3*_@WZCUWC>:^TI%KML?,
M6O1;#**<9'-L/\GI%]](]L?-3&_^;=NQ#>LV:VZ0.+;AZK$]6Q6A?3B*/HJN
M:'&6$(JZA.T?J/LD/&X^,$7DU3TP@SFDM_6S^8/10@H^RF=W[.,ZSY'06V2J
M6AXDU7ND13BJ=IUZ#./[PQ,).VQ2I1Z>L)6,5>./E;S]<6K:^.WA1TU-)\\=
MVQ""]4QRU@AL$Q WD'#,L'CFD18_Y\L+%'5LLYLBQ@F^2B\@HX3I.O5^KT5&
M4Q23OQ'BOW7M1<W.+BI==T]$K;<P.=.=\:#V4]E7X^D;"DJN.49=YOJ^N*<;
MA<Q__^]'5+75DZ73-FS$)\*X"ZT(Z(Q[1%=D" =11*J#-K'VTS&4\CH2Z'X!
MXPE/#>_!U2>S2\(SJ=KELU]F#AGI/LM[^7C/S-GZF^^V/VG*E$^_\(/W]8&;
MYT.;R69^3XWDX\8C[HD/=91[*F8(4TV<? ;9(K4X/HW:^E.-!YLU]'CNUXT>
MKMC2.#H1W=#^X72T9B\^+,- .*^8=[1 V,5=2(1H?CS#[ABN5T?X&Y%'5](-
M)Z(K'*A#3\IL\]#!1[/VD$D['CLS1]Z5]J@\,V&6_V9R1,%V$"U=J!#[H?'3
M;Z&Z"8Z/8^,ORI8W&!GI?L_#+YZBBYN)O1,0?%!SP:TI49+/[K5$I9R"<:K[
MD02M1[%38QKOB2I"YEC-0%_V:\BYK2]BK%8-APQ6IJ/)/HU1F8G*?/6C;H0+
MGNXGI1^*6K3-)F*.15UK%E-_8KFQ\8J;V56\B%9<M(;"6<O8**NAA(G]L>5N
M"I7V!>^PB=\TJY02U\M_N'A=V\=)W7!C$MECS-O'2L,XW]!D:RC>NEC?+$7&
MXLK!P$=1> 4#14*&ZZL6$=L.EG[&=SLX/( _*\/#WR<Q/W-ZYT1T)>U9]D"C
MK].M7YRL#PX.F(BW)UI)B^_X9;1HNN3K>(H3K[%@U L-HX:KR=[Q3CN[,F2+
M4IQV)KME=IJJ7DU_J\HV&#O9KNIIT=,09#:)[OSQ>J1S[AT[?<%F[ZT=FTN$
M'1<.WSZL'RP*51\DCF0CB]3G<IC'63?H5E0T&7V_0I@,A?KW%.-=^Q/#7OHE
M-EL<^KZB_JC_9:%:@8]J?*^(W)4HL>H-MJ2H=<4M]B(&]R_K;'EXME-8KB$V
M2EJV9$-*:6;1PQC">- 5_6K1E>V@S13V5K-'\Q[("[GZ]8"UKQ:]24BA,RN&
M<$ 7.?W5/];*^[#/;UT9I@&Y_:6J(LQ/^D(8HX5?](5._S\[5(<DK7V=3NB[
M^-[<DAW!Z^PLM=$*D7CA=\0.,X75=6Q0<4;(N'XT&36'IEJ2,=70?>SF"BL*
MCHQZB")OIPI$!![S&LTIOA'1>3;L%+%K8T-JGKU;GF#U7K6L](_/-ND//':T
M<=@3>"EKRQ;%&GF+;[$11N6*9Y,\I\J>8.HZ:@T.Y_9;W'0HN.9K/*^?'SLT
M6X;K90N#:K<Q6':**%8E2.<;)88]\-S=>'9W0>]LQ-NRV??61E:V)NORM"UR
M%TZ>5K^>#%L278ETC0!:'%V=:4\?(*?%44+(5I,?VM;YM9ETJ.:[F(?4+?B-
M;MT ?;SR/;D7XRCK*/O0]D F4_E13F$;3_+!KP<,Y'WV&L@U)5=T969X>CH%
M#3'V6M>;O]AEEID<;1!O9X8IJUSZ[E+*OMV.E0H\P<X: ^+D(AM-2Z'[[DS*
M7R7Q[:6'D&?L^Z2>F<8&M&Q4]0@XNN@F;_I6])*-4J+FSM^%:8\?>2R&T38
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MUETV_7&FKO0BZPGP^>Z-1DBHEM'E(Q7$00C,'#M-3VI;N!3_UQ^K[4^/D$6
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M);]$?5RG)Z)AN"EGU(WLT8Z7K3<UP&82*:>]!AII!+H.,-*<_4QW0Z ZO2"
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M:BQ3E9FS'5S]&_X>>G;Y@,;+26<^HBK QXX!#18T7F0_G9^2%0$NAKK?I]S
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MI9YFHF.SE08V]LZ,JZ(Q=%E4!J++9)GQGDR#':4QH!'++RYHBK?@W]0[1['
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MO[>+?@#3Q<>CYVZ'%@R912UR7G_(VO;$O]=?3.4H"^6I_,I5\Q/E[7)-Y#&
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MTOH/&E\ZL'R+R)$F3K/ZN*>'E3?J#(T[74(_X@Y:+I_X@KZ[POONBMJ"V)W
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MCP#S7?)@117OQT^ZTH/0TP14&NDS%988K.?60BX#]G";MW3M<,]A8XJ2U<#
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M%S9F4VXY@;'] *#$^R456(E?[(^ 9JCB,(EJ3F:HN*!R-T3/T "^@)X ./]
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M;%?4)-&I0-K:LWZR[8#$5K^BL8V\$3ANH=Q"TPNC3"U)WRI=$T<E>W^K MO
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M<_J'D1QN\Q]QE +2,N&(OQ3*<K1\"$S\U)]4ANYM! 2R-(FG:1QY'*P$R@M
MZWWCRH$Y;@?OPG8;:0DHT FU,SH'P7\<H7"*>\U&-9,7F^=^F\,:P:/7FQN%
M\82&O_8.R^04SYX]YA\F(W+'V.S!O&SY*MYFWF\S^EKBEFX\A!9L*P'F)2#K
M+97OI%+KQV.9I^GINL5X!>MA,I?F;F=OOKH]]_O]28948NB>A'[O-U%'SJ?X
M7.KH2&_G_CAIPKN1W+Y!0<N=_VK9[JOE^W9'&JS/C-07OO&)]BDHLN'F:DM=
M\U6;CF5/\YO;V7EXAS<$2D06Z4BXILJ"SVU$CZVV.6:W?=,A 98=B)C\^)Z\
M:+H383WRB90/W;U .GB_/-E/DIZ:5O,^3ROB "6'2@I]U>]S+OCHVX("7L>X
ML+"BA9+"4_9>(8&XGY>G>*\PU<E8#<4[6%ZIMY\5G6H+CAE,4&M*A-@81<V'
MT-'*$$M2J*:@7?J!NU6OU,)\#%?K2K?IS>W=-J@;_"(F0[+.9%]MFG;+N92P
MCX>5!*Y[0CEZ,I&?HJJBJLKZ8K8<^WG"K*%YW[Y$RH-;/)<=YQ:J%Z^^I?QO
M7H'ZO_9:,VW!QJS!.S':J4/CK*?0<S;FXP$_P_-I!5,23.P\N2,[Z_(Y-L9L
M*/Z$^I=KB99R"UK04=+KUO!G#M@<[P\LJ7+S^=9"I8*;LZUY!7EVSCX=/4HM
M];%YJX4G7R3J<&'XU*)KE&A#\!;\_(8VO"NQ/4Z>YT.8L-]QNO,K'A$?U4\Y
M!Y'M)7EYB>T>4H61?:'2 \I8!X)*Q:%>]2UG"2'=N8*P0.U\ >MFJ> (-C=X
M8C5SJY\9/07JL9;[*54NU!:8QQR^MZG:V_T/&W-$'FL2;!*JDKI#2#G4!'.J
MT>;EN\7WK1'63\[1MN8;'_"SX=*+\6E*.*9M.IYRX@1O=)B7:VMK34D3_O5E
ME2T*E?7)4ZLNDU:VUKJ?-BD3,4PT__K.J=3Q1NW>=T_V.#RAMK\24XF06G^$
ME\M]P5[)Y.=\S+-M5S^>?("EN@_D9Q+RI<83KMEOD$NORVS/;#H8,M_.75QH
ME&-A]YOY]'=2[IUS B'M@=$GH;)SB(*?-=TD,^!#7/5-=>?>>AYG+/65WYK?
M3IWR"31K''>="[_RV496QC-,V/?11/91;\&]>F/71-*Y?G<]N#/[8W=[QGPQ
M6,>7(^U=_*P7> ?<RE'\FH#5/BN-OBDE_ _6WCNHJ>YM%XX5!1%!>HL*2 >E
M2XL-$# @76I$1 @1(M*"A$217A]!0 %!FG20WHD0BHJ = @U04!ZHA*VD(03
M?-[S?>_OS#DS9^;[_M@,#+-75M:Z[G+MO:[[5L-;U"/87B?AAR0V$W+U<J=U
MRK[O:!9,C(V;-]VM,_QE_)CWLC5D_OM$?#(EB^KY0J\V7'W((-SF1F4<SSG[
M.(A9(E3FLQC1FK<Q>A;4(J7?OJ#ZG43/^_"GS?7$:+[!V<@..:U7#C)0BU=(
MLVL$0Z=^^3*_VO6!*4!Z44-4CBS4\<A+5GI >9.3Z*24Q?,-;YW[QG7BE+YW
M:)%YO)7-60YX1)E=LDRR6&2H./T5?#C)2-49XT)EQOV0(,PTMAK2#M6BCE'
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MHU@6!'/9ML/TIA*PO(/F]1?+#6?'@^R6MY?)IE @*I<F119-I3S<'38'$@H
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MUUL3(\_"O%39VAIKZ&^59 &]!6?#SW*J1JJ%!=(ZEMSO7Z5[SFZ5E^DIDP8
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MR8=6GU[,)<UQK#*$JIG1Z=;=B4F[R>ZFT;>O+_:[/WR[I/^3(.GO:B8@2>(
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MGS5<XHN7;!ENH5\>*Q%I/>S"UDK%^49WHQM:ZGQ_%.DL:Y@728A,.TM6N5%
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MICNPVSU)-J[4S#U8K_E7DQY?^_O9G[+?9!_X3*_Y# CK*L4%>S5#G!U9)5H
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MW:FZMN';[EN_U:\Q=UNUPW.I$10'V?C/ ^@F*0Z&411PE>2UB-BT2\A.%Q5
MM7C\<#P'PP==X& $P_"=-7L]4O>@PHQN2J2:L4?XK^^^PEFV&0V?FO,<^AU;
MA4KE)>4BKW^^IJ= GC#+X.<WO^/0<$YE2\ZSQ/A>7;M>):?IY6+!9Z_.%6U^
MTI&E=\/#7:P/=KCB6#T8BWW_5A1Y%ER,;E*!DY\&;S\&9ASQA1W,LD;\AG%4
MJOU;A )<X<;<1!KF8'Z%,X+O!KZ5PFVV=[>Y7';O2OBXIZ=1_W7O'EOS<\=>
MVTS93/&#24L*=F3Y1KQ+'6N*E_N=<92A^P5-8:XZ2JDRU\:'/[8[&AJD:/%I
M:_:K3CMO,870GENJ]\X'P[\?I#K\$O_(M,\RY\*<W&'# W?.#R0^./<I\\M"
M2&)U=YE>"?/^E>+/D4:M=YMEM^D>*NCSVM,QZ3K=Q=Y!?LW!]$ZB?#W,T!%Q
M1-2T ?_<I)A121M-8LP8,!:)@:&FV\?+!G<GO=GR*5C_5.KRX/9XS[2R]ALV
MY@U;G"5_J=MBX>E/4 PFH9ODX*MT8OS@;D;N5#E+%*Y?N J[T03T)@2%X=83
M)">MT>3'XYVJ6K?RU*,?C]LP]5>OU4C42*0Y!R=XVZY;2]'&#]\9$B\A$D'!
MB(/M^_:F/?GZ(4,>]F&FTD?TNKVRBRD=@:J,MB:S3N^==U*LGA6>#[UTOOYE
MW9FU],HG+MW[VM]8-IHY?=OBGQ.2*^]O4/)E:POS[DL+^TD7_\1"=>'\J"BI
M_* &/5$EL:Q#ZDF&YC>SR97QEROP.91($L-ZJ)="7YQ.HP^!6:M"M@$+VPUN
MZD&.T])-G2H[ F!DQ]YB6F1EN'7'T&FB16A3L&[V_8'S*9_2#_@N)Q-:R5-#
MS)D%ERH0I1UAAC"!1OA863>X":[4B$/\W?+1]R\I6[0MH/Q)^RC2I@+U1T\,
MABMCWEQW5W\B?=<UV,2&NE/E8^G\&"(BC/*'/T1;H&W""WZP$"/4C)U5HVEO
MM&#L7[OL]?9[IOOR;><R_3BO WUHZ$W+-^?2IJ)6)[7Z#8MB,JZ\VO:N5,+6
M0]0B0R+=73[I\8?\P;RV[!$^KU+O_XV\]PYJ:GW;A;-51$2D]Q*W-*6*-*5E
M*RH" M*E1D"$$ $+)5*2K33I&VE*BP@8>J2W0*2+"$@7D)(@2"<!#0M2. %_
M[YRSWWGGS/??]\U\?\!,DF&MY[Z?>]TE/-=UW2^;<.X:J3"/ETN5'PTSQVK!
MVBXZV']9>&1J:1OXR$0O'MT\8DOD7%-EAN C,F9=NCS$ 'A*_D&Y2TY?FR?#
M"3OMLUPT@_36H.\B[1JYN4#0F'Q3TJG&LM2XQ:=N.9S2 D?QGS^Z0$69#P-[
M'=7CVZJ$5 .@SJQ+S4 )69FP&8FMN>D;XBN.C7M3$=-NE&;=,++X<KA]QZ;"
M/E]%;?/\J[-=[ *@1R][*RRREK>N&)WD:+ N$%*'1*7Y>/&TU"XD-S=EZ/B(
MWU!=3+;TEK<L7$!,+G=>_Z3HY+SL4$37'[H7-$Z M&(!!??Q=44J'^,+7H3!
M23LVCK.C7J5Q#8;0;2F(]][V\&G'Z94 +?WLBXRQP5_:J54)BWM;2_H>8A7M
M]X3OR#>UT]H9;5#2[<0I]CG4>B)Y@#C>/CLQ0,2OGY^'BB'LMV^-XSV6:(;S
MH?9FD;5/$+$F+>@.0XQ44&E:M(MTX_)6=:.?W)_U?CPW.B[,)%B_*!'33XX_
M3YA,E%I@Z9/]M/;]!_^)K1YU\QG.>U,7BUZ9A^6YGV^KF=6Q*A/"P">N-VB_
MR[(I'@\"?^U>QS"WPH[.;&1=\#'HDT@NFMD@+I@(Y@^Q:W (E65PE<FUFU</
MACFU>LJ,W\.-/+A7^R(S//V"P<,NA?>.<^ A,"<\($?ZBQJ4&T:\XE:^;(^L
MN"_SA[M 8VJI;1KQ.LOSGH5;F1]<C]X[8J!.8Z;P5D<(#/Q,CQ](9>[:3S)X
MG8/*O@01U).F60[GCU=/)7+3],G09S5FX5KQ.25YPJ4MK7GZ(D#DG7*L@$V4
M[37A.F[ODY]9E]'K#<R5WP TJ4=H?(!)V:K]J8S9A!9IP-<(!0I1'L0$1[M>
M84X@%R97+#M;MKIZW;\%9(2.I'WVE7I^&R2?S-OZR>J]5[Q(0@W**W\W]]R(
MWP]XZPV3+A7CF2?F&^4U<D(IQ:Y.]N\I?LV9,0LI[BR7KA=HC&;E3U::- <X
M*(_9R^\>".K$0&#08]\\G26!3:8]:^2H-G1XT!JI!MTA;K33R>8=^N[SAX*-
MM+I&\9H:RE)B1G%RA'QR$_\>@7J%Z0LS'=DYY:\R[90%0)Y0HAP3=+K&P_M)
M <+7:C3SZKV,.UA[N*)-\)W-^\,;A)=]SR+FE5P1"T?AY4]RG&(Q<D96Z9OO
MBMK,LR]?[Z.GG^OI4@Y^-UK:&ZG*J:XIC)_NSC&ZG74O;_J&N07<NG(%63P(
M_119P1SA1$/,R++/%&@PDBA%E(SN--8%WV*.,T0;[*F9,V%M>J?<C@QH[(.X
M[)9M;QMZ'U%LU]EA!UE%O'KV$3NR^17%.-E."J0TTE_A JE_K03H?Q!D%D$U
M:N\^*%J"/XU0GC<XQ)>^)M-%F?\8_'U4Z<^TR9Z,<R'+&L?Z&2<;D$IQN@5&
M-C$9[];/&9EG99A;Q-U;D+@_9&NT8S/-HG-?I+3A3XNMA<>V<6\SC#;Z#67=
MF]$&7^DN;_$IJV; )<Q\8L(O$S=F73Z&GT,S=(!LJA80;)]L3&;M7%?!F2C8
M\^C+Y<].4L:"U#OCX[^;XQ[WP-67SI6'9UW +LM2 H'!/.276986<(C'%X7R
MZFG9[L8SH^L/E-T\RTL_33O:F?E>A'PNX^\K[=E^;'7D+]DC_]6JQ"175A-D
M"N!;/<P@L1D;,DPUX+W1] @C*Y/ZB[G606?%_/SR=<3TTYS!ZWRVY[_\W[1Z
M_Z7;R[@+)CT>H!4TS8/IR0/A^Z"]N (4AOX_"KD[RZ 8\V:,MB7F.-OXXR=X
M$,TPU451952A=)-/9JW5A^S/A]SMA;_Y=2P/>=A;KAXJ83-?2U;^A"8I_HNV
MW -<PQ#<$^>C)&)7%'_#@T;4_X/P,SJ0;,_^9WH/6?C^WV3028?RX]'_(I ^
M77B@OGWY$%50 CMDQ([^/[$U#,$MVN"87LXA@,K]M]A:!N!^P)/M<4UO@-ZT
MQS-R>,S5X+<4N>R# W%QQ7_!%D6'5[?HAI*'-/!YOZE[. @'XNB'_-)RGWZO
MV_HW,;W-;RAC?S"$K$R7%E<!\.NCN]?\_V7^??_A23U\X<)O 8HC!]KF*T&G
MD_Z;'#FKM1*: 'USJ$%NM7SXV5__!W2S0!&=1TNH/S#?Q.R0O_OB;RM[:"H'
M-.&J0:%(:)$BG[F%OSX!"NE+^&_T]IH'>O;78PZHX]\=@JB\1'ZC,=_,:"M?
MWSW]-D;.@X1/7TQX<2#9_MMSBM<.[Y"6=: FKW%P@:M8\U_@?DRAX($RN^48
M2P2?^94O_XW$.^Q0])W_-S34_+>[CW\YT%I__6]Z_D.3X@^9\LVO\QTJN3_^
MEW9[RN%VX@ZU['\?"B]<.83U'"Y(+;&K69#Q\LZ_*<//T\P6=B4]#XC#0PVH
M9Y#C>"&\:V)<(V>76=CD2&W=&.\5UA<XS2<ZO;F(WO9]$"R&N-.^-\*](=/_
MZVUL7QI+PG)(S=:B*9PN@K^+G^J=VUS?) 6T$PW:G6[(FW'#2':3M+](XB,5
M2LUSZX^M_!!810'8=Q,-!CPX^B<\/2F'^/'&\+%7E;:[3VU'T)6"ZZ'D6(H<
MT/F&=A> E#O:.=]Q- "_P%V6*JB&"GI:Z+A9#/IK&QY+:\)ZFZ^[C)C@T@..
MW$@;3>HR:T[ZD?JXL:4_+_46OZ%S@>[T96U9FU0*?%T?5CXTPG#:,PH5J?05
MO1CTNM923,.2*&$=^>A3E=UUR]S,+Q@)Q/>)SV^Q<JH^YJWS]JF.+';3U%NJ
M1=?W0<7N_*3--6$J@G:&WHSD@*%X6L16-"C.DM7/1<TD@-.+Q#_+ &-HPKFT
M/9GJIWH3>I$[\6I:IA527-W(?RI.E!? -^3HIO%>=V)NE]UX5&24;Y5[J:E(
M=N\G;"5[V#"/=G-@Z]2/B*JL[B@@3*ECP:[?.KHHO'M.Q6]:"PCZ.5T@+)N?
M*PT;+F&5\X=]4C_??SOEWN&YY(?_;Y]'/F!4WQUBCF/Q*,]VT@_*'=*/UM#3
MBW8A^N3D3H%)I9J"#VOE#.[Z.ES$CY?2^Z#$5U"KA!-Q=R[=FT&P@G-F_V <
M/S@\P)!@?&H$K\V2, 36#_+*?^_]>.ZOR],_[CRB)]%-S-9OEU"OJZ]O#H6:
MMXRX-&H&VF3D#W:J+^"S67#1[#Y<7;Q[@@<' 5Z!JW;6R\C!!'27<IS6;$?$
M:(O <@6L$1R)NTS4=M)N$PE_N)(N4ND(#[JV9ST_\VUW1UDX2>GN<9:;%%I3
MXE):IHMOP3)%Q/UM:LUPZ?H#Q91_C*8F/J21BLZ ;L:H'_O[>-!)DI>[=85=
MI#RO S>4TV08H\_YR[XB_(>AU$IQ77CSA+'GKT!?8\F])W)D;!0@W[;!,;<A
M1D"*$;.&<KQ?/U+F+]?X6#)/$KJU/A(AEE-^N_#^'0C,@?VYM8N"U?##N'G3
M+-<1C#)Q'\0XP4*6[097):YCR6$4/2#/VY<PP$7[*X;A,,O9IV-AMQRT#VI?
MU;6!9X9*+ A['W'Z9J+ )5UKL:-RXEK\0A*:*H+XT08YC9K#H6M29Q-_T;5;
M:^WKNCFCS;]Z24@VAAD,+YR%C]N^I-Y.FYP4DA+B_F9X)OKKNHUL&)T=$<5@
MDZ2JKL[6<N#7RTY7D;693SU_V;O*>B?E=H9,U3!-;$?@+FN&B23UK$-D\!"[
M,[KNF2K/P_QQ6>K= RV=@],@4P9$[1!+( H^CSX!U"Z_-''=)+0TN1'J?^VV
M5_4^*BUM-*%.#SS\; _3Z5!X>$/%T?Q3E<BE$%TMKWB#OS_+0CE$4NTI7Y\^
MP$BS6[Y,?NS5IUU==@^]A)@5TU$<0&!CJQ[T_'AM(]H)9K_($"*NF3HDMS7?
M2H^YX'^N\566Q.G:BYP76T=RH]H)(SEG4]+?+Z8LK%_.HP&HUBLM%VCJ!^6;
MY0T]2YTSTEE^&.?R#C#K#-*,K&DV,TQ2\OM8DUAG&$@)-@;NI4U25'U:.TB7
MKS[6>LXZ@B<]#NU.W@>=>JHPE%(;*6[J<=]MX09R(L_GG^2M2+F\G%*^TP%Q
M2 RSK)/T(5\#V_64 95Y7[9E"372NP:2[>V*4;_7:N*/N_HA_"LV/+?(4,0H
MJM+I5V:479P%SM?37BW^H<9W>C35A3F*@/9!WIM1 >#3##7/O;#)90Y>SQ9)
M$KVO!4V,%W8#Z=C[8'0+B%/=V@J^6B].4^(YA4H8G[I'VA;?EZQ)0D7M4[V\
M>)/?->AF93D\:JR3#/.&M_1WH\VZ-CDJ$RZ2]"]\$N1Q!5#M"1)]]8'J10D?
M7 H7GT1JKG[U0DRJP5QEKV+55(SYEJZ^]9L; ^?XGUW<!PG@Y\HESE< KYFM
M7CB)$4L:Z!(QBR\@1;7CG]7-<JDQMSJAVS'YYO,=DR]EU>_(+ GI3_RE>/0#
MX7YOY4?BUYUE[Y^\K+?._&L4/0_O[LW+8!M\"ZMCZ +^A"8\^Y(F!<WME^UF
M/NB72=>W-CE[:?-^J,;6(GO9PV]_?XG.C711Y<IL>9"(A=SC!*32US*IPH F
M<?R9#@L&4=(U(P%,N+^#S7(I(F57QI#GM&IR$L9],5<#8&G<Q9,]3Q7^>1GG
MENR6:W,;_ATL@FJM!Y/,9H41Y3\ZSZ[.@R-MB/,#4$Z$0U<0,ITPY;(HK)/I
MK;/$*T3X_JY=/B2+Q_3$\,IKYKRZ?>)V6S^.%,ONP*&UM1 EA98B.$RTW",.
MISCRSUYL+I/L2A1#J+\B17H3TCPZ'#W^_G@AZY&2ZL=ZS-%VA-V\JF9"JXO;
MJ[NJ8LE4&WD.+:'"<<SSCE)WZS6WJ#*M$+)?XF<H<&:Z5$]Q'_0\DS$"Y=,#
MPRI1;>AZX"G16]1DI+1L<OQFE VZ<U+]F\U5EBM\JKV^8N,G&DX-+K2E7E9%
MM?X!^;X/@L"Q5(D6.=2*?O'X+UFJ(O(C^ C>#7M$\V_D"<35X?;)T)'!:;A6
M9O?15>29YAB5D\ZKFE]:62<W;,Y(SBZ\D0-)_FW0/UL)H?%,40+I<4A%VDV@
MCU1B"\2CB-CHO?*Z4CB%H4CF?U>2[^ $WPG4K.M]9W^EP,[06S#;7S8%J]/)
M=T[A:U%NBJLGKJC.U(PCNM-51:?22P41<3S/1/WIN?JI@D:86U4T+8@@(5DP
M[_AG5-]#/Z IK%XY'+BAOG2U15+0+ (3&^'H[&N3;7U*VO&:?!>V:=T*^VE=
M.V]WEND<"YB6:1[S,<ZG8WUJQ)7-1I2J!^)F!3?4>C-[[_C(#ON@:M3;*;'"
M]RPH50M<NTFI#XJS2/(0QDG>7$]--,D)_?>88(9,LK]+J>/RN$A??&<\KC:H
MIGNRYH\?*S8;D=H-%7Q0W&L[?, KR+GNGTY49KO4J@CQ\)UHHKP",JE6 "?3
M&X%D02+VA?H^B <1V0TE\V?O1'K7<')_FW'R.FH\[#+D_:XVZG-SRM5*I_Z/
ML2)I=Y^_)@<SV-RH6B$P>AF.G>J.P-H \;YDR(<CWV!:SDE$46VS$TZB'@V(
M*8NA_"&/AGJI:4.\.^T*I>NF-,O5'C)J@M1>/T@I4=N;PFV"7=:M6I1LGSX.
MS6Z4";(@SS^'$&7FZXN%LC8N7_=EV0>-!''<=1>[]N372X/C;PL5S#9(:$?;
M.P40?_R#HEE+LBSCM&]-U1!.DJJ%"#.KJJD=K7YQMWK8]^PS 6-ME2)5]IM"
MH,&I(R4O4L*%Q!XYFS"]39@H],23;@Z&B@6>1\UE7GEZZF.E_N-T/6$@P.=L
MA@S+O9C;:U(W6.P,6<^,_X12_9A.4T<>8?Z^PLP.GK,BOU OM)PPSR<<C"6.
MDUG*7VRSO,:P!_GX]5V[I5E[(?<"[F@.'$TOW@?-I4&JL.LH&%7;CF8VRI!<
M)B,_-X;6OB;1<>>)VKI*QDT.#KH"G:PO[$-EMM<WOBS9(%W"[3<4(:2>:F=5
MN2Z;'*^YHDOSDG];6:(59R1*W6U?/Z:VK(0T;7M65UX*T2'7/0/@2B0SS@SK
M/D;%!T0BKRS:*,%Y-5C+T3)YK'6!NW5@E1N!IA0G6 ]1O)ZG8#8U-G>9A9#E
M]9>?VF! 2C#,I7+0K^12->H$(&<B(>\@=";1\*6#"??]9)-K?]4F7NPYEYI[
MTO$FH=XM)XHB3!J/G&*<""W[H"9^]E+-9OA>?']CQ9VI;GK58YM93:V<$?"#
M^K;";8]OP&VV#_Q[S5039#O^!,IK8*(?/)%(9&:#V#6=H[X8F,@#P1GAT;+J
M3>YNW[>Q5[S:;^>T;7&J=&9=#9GD_T=0]*\'[&AVE"N>.;2>V >Y%]!?ZJB@
MB,M($6RD-*G$2RL'RS(0\_U]IL\NVMI8R$4S_-P1WXJ_578X[5>>A@:^LN[8
M&J98].J5\']N:"X?JRG-\^;#UHR6X=N'R&91N80 L[9$[@R%'ZSSIX!QKA:L
M;!2CPR?USDB"Y%0P4&//@Q[]YKNN;#GI](UQP&$;'9B^,TLRG07DE%*.?M,O
M6)DY4S&T?B8ZYUJ,V1_PM3,Q:J?Z[=YS<P?1BFL.B+,:46(,+IH\";T.A9,E
MB9R1.MQ/,' MB3(=/9G1!S^C7O::F008#WN(?Q\T#GWTH/2M@_'-=_6GIXZY
M,RRI9"HW\Q*7D4>0K2V<0,&<;WB=LRI9(HR,ZJA Y'620JZ-KM&N#3M?=WN$
M"4V;ZAE^(&G,YEU^S\Y[(<'UQREH(40 F&)PD.C/:$_(KE1B)QW3D7WQA_FX
M]#A61S0/D='6^V';R2Q@//U"2S0]5C(3'BV<YAD_J! >_R%K7%RAZD*[OER)
M$9^<;:MEAT6)D;^[D'WUXDB>^?795$.-LL&":61T-M!)@ K,XQ[T5&5!>19"
M+A,%X&T-8V99[@VZIYRUU!&HHVD6'2XJPNXA3B<&T^2YPPISG>^\OJ&267*I
M-D46F&<6STHR.I(AB6J%0;S,7DB<'K&U(27&M_Q),R8K1ZJ;BUYMS(DNYG"&
MLX]&]R ZR.)30FG.D=60N>Q&TZ025*L?!"8PZM>L;:45@"F:A?6A8!P3[UN,
MJ5+&4ZH7ZR8VDMC/#DB(R?/W<Z#T(57[(!I/&,6&_AJI^PWY!<JF@+,C;'(/
MY"K]G2.<:%,EP5Y3<V?C+:RL&E']M2!AY>;&=]N4F0MWBU+F,\$LJ+DT:!7F
M0^)D$Y%S/6R.#B7JCG?,OEA<J,E6=6 FR\WP,I$5^-/OWLI&B89U];638Q\E
M.4,O_#5TU[V'63O<8-W'WQ4VF']>=5U]W%=/E4N#M1II^NR=:[88V_DR_$(G
MD$05?T$^^=1Q>^4.\@P)'H7@E+R3=4HRVJ[<W(:KZ-2#I7&KY2&$IZR"B?9P
MD>:EKHS8FXQ@_!PF8*SB@*4-Y=;@5OO\LH^>&DTJ.-I"VDX6L5F=&K]X5U7R
M+2FBTDKLU$DR%%#R#??O,V.<;"5\)T,2_97#]4Z046%Z IX,/N#5^QDG_3<K
M)%C/\9)@S-1DK[?R:P^U04-_1=R2VU>1&X[W\1AT K,;- 9/S%+"Z84MPLBQ
M%O6Q%JF)$"/ FFC&">2U4_3 9/'4Q(B-&C#'-_OI.S(E[_KRG<R>^ S97ZMC
MXU]HZA%..EK<P+^*KN5<XZ9>9GR3$!NN5HYG\&J.-RKGJ$'X/=>]W8GQ_#ZI
M @MJTQ9P!^R?'C='I3XK&,6=.N5:\OUKQLBV$&-9:S="P8EE0*KX*M="BMRE
M@G.:??)V=7X9L'4QY9]AA--BGVF2G5I/:X)TU F1OA^RC.W3CG+JF-K%?:[X
MJ>+W:-=)[-Z*RQ,A0HY 3(K\#;45\VQ[GZP65EH9#<6LQTZ F3')($HGD,J<
MF5MA93C4G**RQ:"2CN9Q/&8%S.OS)F-EHT_1TH@TC8__%7JU#4;[6/;]7DWX
ME#S?*_D_$_#O$R?:VS("G[6PA"B1TI*(O,0^97U2&MK#A:COH93EG^D[8\R_
M\]7C?L9XGYW!QCW7WCA>:!+J)&IN&@_([K3A!>\ #=XMLL"* _M'W[>#(2AB
MB7CP%=CZ F_;O?<BBD7N"=:&7&PWA/F^$_%^U=,:[3>&UWZ6R0VQ<VB:UL8,
M=7V:5.%O+JL^(1DCY.;,SPT"(:5>&I9_P_QAR6Y18__*Z\Y3J_ S*2IWXJP6
M/DWY^,L;?=)^W&GP&OY4W6T;*HHS[07&%0C?DN7G3^W$/MPUU53I-BUW:\4I
MMR).*8\MNRP/8I[W5IZ4F"G_<VL\39D[NM,HPMG+)T$B9>0;UOPZ_SJZO_5_
M('-BW3XXXO,G\DNZWE%Z"DV>"EFR?($SIUX!<F:ZS02V4ELT9H1'U'J+UI/,
MP[K%=W%<3\-!"^)_G-%"]V$G-N?J:&+\I'T0Y<Z0WDF:.*!+A>B3!#MGA)/-
M*X9_]>*C3(C&ZY(= 5S"2KXSF[<C*;H6E#%VNT>!K),=);S/TEGP;_%3K PV
M%ZHN<@HJJ"<4X@IT$L$Q;&4TF5&U=8=V$<%(G!GL'>"TH;9;)CM1"$M>UDQ\
MQ#\UT:',K716]?RCU.GNY=.9&#N82&A:.L:A&^:"F=+W\/ ^&1[#'NQWAQBC
M+B;W]ASH-(A_51]LS!F>>S55Q!HSH%73W'S92*7([PT!UK5^W7<0<P^+12M(
M&WV-J?&R*C+2J< 83YC<,&6W>T+%&L@O(UMLH!UXFN@VF;=KMG)VO9V<1U$#
MNKU"9$M7TVR7"Q&/'0H7!&;Y3N=Z7*HQN%KAB&OT^IA4?3<BX4KU/_7E>0RV
M& UFX'[8!XFGY-@2T)UJDB-E8RDG:"<N2[S%OU%\PF 3IEY<A=9N1%.#WU61
M(09 7Q[0-M6U#6N$1*^MZ_"7K6K41GY2*5O"W'Q)I(R^:<-=96AX%P?&V>J3
MH ==WV4:&[TBQ(/J#2A; ;&RG8EBGI.+4<4P>^R+,B6<H+<'D?79YI398-[0
MFQRV6(>\&^NA9RSNI$J-_7IR2M$@IC!E]);-<34,/Z>_K4VC_6Q:[Y.3=[1(
M%*Z0<J$0*XS PJ:64I]G:K(I8P62O0^:VFZW9!K$-,K'+&ZR)=G[Z1MD'[X6
MU6[&HU$E7FJAF)9+/C[>'E2S5G3QPY$+B<ZC;BI/8ZZF<?SS!!J :JW)D1FD
M<1SP<P.91"SWS-3RI'*4GA[-9M1?N_>UQ;DSM=5#.JK:Z4F?BM/;NH5<-6\N
MA:7Q4\6I/L@V\%&(+SHR#7T*J3D%KX!-NN^.^#FAVM(I>[;1U<;1(M^FQ94M
MZBM;'-R;C3U=FHX<WW;]*S^&-!!Q0.XXP S:?=":.UF>(D&"Q"$O+*/8D>=7
M]^I>T*X3U<BA;X PW]#2EI<[%<M!>YX]+&7,(N5F7QC_<_>F38J@][S/D^[;
M9<_B3Y8_*O\1%6]W;ON\Y=MO5IM^W^B9AIBFZ-*'-3#7!1NQ\I@(#U,E&R__
MIPX1M>8_8@-MZE2_,9S4$B.=M9CI;(LQO0\"X]P$<HM@T!,Z1PG-/L.$\MPG
M.LR;#2HK*#\H*]-1EU2)M][<.#;>_C#B2 O%I"%H;YMQ@IUJB\B; W>C8B D
M4]^XNI>P?[ZN!M%GVXT5S7,F%;FK14M&<%5QO1$7$1F+!"7OI&O()WQG#-L3
MEV8I8O1G>L=0K1"&^"KD-)+U"I%M3>=ZJ5)3^6J+$KYFE&98XB7OHY@&7S>:
MZ?I@_")*LL<QQ_2ARC:^$P](HM?JR'!*U> ^Z$%1S4!,"PM0E;\Z(TQF;R=1
M.S4DP*3^HF "JHJ>H6AYB]'9D$8<HTV5>#U2_ :%*0$JST%#[]PBRT0 PQOF
MK<47(OD+G:U6+(V&O9;+ \E>%,:V:N3I&DT#;D%AU]"\5+_O(QYL2\3LLHV"
MC:5R.O<FOFZVPS?*'K(V2.YNFQSO !]=:I%))LQ4J.F)C^G8Y<(:U\C3=_IK
MRXXG/0T5R#W7<%EC0?'C*_E7O=[J .\^Z'@[L/VAA1>0)B>;D<WB:6!"F;$Y
M$%\8#[E%9HWV\Q:U:.'1?6U053'BJUCNDT3Y!WO,1VA."?Y+GC+.W"XPX^,^
MJ"ZJ.Q,_*3DO^()Q$8:\C"-AHFA@Q;KG(1ZPMYZ2QJ2A;S+HL\O;2^G]2M,^
MX'6>S.>57/77NR%:@!F#HX#^' <F#G B>DW(Z>N\>B6$,M,IZ^&A;:),MG2>
MXZ1194<=5S>A,"Y)P+Q!OTA24E(]5:3^Q)R7"\:Y,AMF62)_V^3J0_M./=13
M#8:BF@,TN,1,4,%1OBM>4\3H4?RJ7?_%1SL9WW?LC2CC#B5K T/HZ'V0(/ZN
MLAC-!Q6&%W,#),M#'$@)KY9]O<G!;2T"C<DFPTKA@@.^!? 9E??!5C7U\!<>
MG@H;8Y?=0]<*6B5W)9AVSR',*(85]!+\_6Q5BG18FS%9:1_443<8\M<P4D Z
M;RG _M.,Y_)<M)_?EV&JEGS5PYUX^>5;Y',. ?=Y-H[NI="K47-)Z$K9]>$B
MS[U]4.<Z9X>66<S/^+.*O R>S:->-D&L+WZ)7I*,%!*U' &;X.!%Q)@3>89V
M1X_=QEP2VL9.2#).!%-/([MGU-Z3]T%A.KI$M 20=_.17FPAS7J4.?\)&.8Y
MYTG],[O\=>A!2&POC/M>W:L-E<:2<]_>1(5UNES(JAE]8%DD\AAJ^\CYDV7*
M4Z>%/A_CEGL-2AGV2SHFIVY(9B1CKEYX$M?<F$R).8_)=W18K%SPS>ASLI-]
MLCO"=$$+0K4#Q9QU'G!^U:0\!]+=2ARF5L"L2!!"NU-K8:_?S1O59CYE1E2N
M-C[+Y>LM$IBS';Q;>F7V^1,H!D5ZR+GN3>+LG*T0#,.=GT.]:!$BUS:1;3OL
M'Y$6,PEESKTV+9']VZ8IG4^+)N^8Z4P^VK:[J[$3S5=RSM_?Z4W=1N*Z.U6<
MQD&O;A%%1T+%<!<R%I-]=<:#E$J\O^MC$3X4PMF8Q9TK^ SVB(K&AD@A0L85
M]LWHJTD?)+=%YZ)HHDW,#$L'),GLQD 4S(.L2F092PU*)R&"B08Q"CH&A&B9
M^,])NWNN2VGNHZ(L?V4_M'Y*+$_39K\TM^(J[CG6^F3+$G.BWMK4L/5);8/B
MO>SAB9UK9NPO8CNNIE>E*I@I+IR_]"G3Q@(FO0D+J'%0JE.!W$=-BK;C2<8#
M@*3R!S!/B+=!'=DC*N1H\5>$1]M+ P5;I"3Y?D4Y(NS.%S7?5.%28G/"(L=.
ME6P2SWLETSE1,H;"!0@7HEK-]D%>XOH4,KT!J433_M(BM&R_U$A"MZ.Y0OXB
M]6>&%O45?,-3]-(EHD.+._62W=[J<+46&:N_95:$N^5?S!WV,NCUJ+EL_!&4
M;V)DBQ!@2P[:[LH!D\;#U9TTK0?-VJ?O3[6/CZT7Y%V'W;^/-AUQTY 7/79!
M07[K+:B=?]=%F2;RB^D\X'5=[[S9Y/7,=RC"/5C)GG(DB'Z>4/'JTG"'J;_7
M8">QV,I?KBNQQF_9U/9AP6:GS,:FHGUMYIFRJ(Z&P7"7D_5!7._RV*R^_\BR
M<!P5E&^T&7RPM^E!/PF [4A*580I2=+\'5)M%<%$T?;&^_36QIS4XB4;2=.$
M2Y&OO37B=3M39#Y)\HA>\_?DZA+FXQ]P@HHPVF;?;[8I [*SK>?UCM#X1D(\
MBA$7S82!V&Y%__DR+\5@1\97\H4*D7#7/5'Y8P(WU0#D &O2J\K=P&\J%&M$
M#1_?]Z)/EL]]TQXG*N0WU4]/[#KMY:2(?3O[@U^XNB%/\/-;JJR[7],$"Y_Y
M;;M=9M%D0='S\^BO42Z0N!FEBN9@7T%X$#LBL)5"^GPW9_MV<U-5S-ZE O&3
ML)??JI3))=[B\-WGS"?'C:9Z0/<<(@X<"7&GG@J1!Y1F3S TX;PA5^O&6\Z:
MS+TC2Y0I=K^^-_17X_2OM%SXNZC:$/L>T0XE[@4+X6_@50/*^@'L+.0@$X4!
MDJU($-!'!+_($(RB\1*?AEA["+9O<DT!2&^;+0>K:K@N;,-O^KJOVEQ225EC
M_K6;QKY+\LNS82@VFBQ)F1#X',F-$!"-19T 6*^%_?7%I2E)IL%82"K->GLA
MX9SY]XLFDJH*-]D@ <U&0I-W'O 6B%BM6I<XY%3#AQ\7]/!3J\ND^Z1&1W_:
M!JD^+Q<I>&!;G6HXC#GI6+U@Y*6ZF&P:-%&=,;A3^0L2#OW:Y$S/VP?-Y:!)
MMIPG)Y C&<<CYJ#@$)?1J' <-'^IKM%[)VRCO.7<K)UC=XF=(XPG6Q;D%/K&
M25]>L>B?J!"!Z9\[-+Z!CB!-IAOGYB"12#FRR<I2BVCL!\CQO&0'G(1IEHBQ
MG>0QIY[*(TD5QP-Y^".0L)/E-QDQS#P%!:1FUP:I<-I=P)N,)_H4D27;<RX!
M;A<=/7<D0&3QG#!XT0!'9W-G=>.:Y;+FUJQN46V"=H#A&Y7.ALO]7J@I90;;
M9:H<XUN08)@?/I:2HU0QAN-]^Q6!,B5WA_T*U@5WI6?<SX2Q9)>*Y%1IO [R
MJ6WGE+J*5JOD_OLOY\[7+AC[^* 8\RQ2<KLK_R6[*S-*/.^RLL?B[7<,"X9^
MR'\8CY=+N3M_KIW7M)GU,EP:'*,*"RZK"Y[L*ZN!Y/@"EY7G-UOQ,1+GZ=DA
M[*15(FL4SIMHQ@%@KI,%ZC@C_45UX6850SX;C+YC0UY!?CL:]^^_*M:M>"1W
M-$T(6X"?PY7]R0P7/>3GPH+/WF3?.6KCD2G.]%P@7[)>^)A!_;JKWNV.(T?%
MZ+A9DL\.C7<!*0P#<ZRKS;X8XX79KXD0R+\PT7X_@6>%-4T./:<SB^!];[6^
MP>"*C;T4%\^HST]%47W=RYK=G%^Q<X'K[%3="60?E-</WNQ!H*2[NWGGW_+X
M&YYA,I,)5R](JW()E:ZNN%(RU?D(DAY(N3\YU,#6Y_%K35IY;6G('W-*_&G_
MXRP^]W,]W3,Q%O#FO. 2GPU/4GT,VM&?_Y(QKQ%W3%RF8=>>QBBETF<L:-EM
M*Y"PF>"'$D:U"OD@)6AZY+'X,IH^>HXS8<.A+4>"K!L_'IU\8ZAZW<C$2[19
MKG_#Z>K,]-T4846/9RQM1AHEQUWU+C"KJ"=2/>0/$F<K.!IY@IP8&\(_YQMC
MH]79N5'-.(\?PJD'/\K-Q 1KZQ=Y54W$)L,J7I?J5Z<!"W^ P,Q>Z&LRX\0@
M51K9RM F&W1 PG? W#A#+%!U'4^BO,5SXPS<B<8GJKTM)LK4.;3&QG0E.MUJ
M<'_O!G+?=+>S8KEK>P9 =\\"FF@&&YV\TRV2F("MWGPQ>]K7WX&:;;1C"$")
M<,Y3GD^<IC\.#4C::<0&300^V%9I/3KTLF/.\1$"9E5>2)3K:BP3,<Y0-6FX
M:K5+7UK-6QR=KJ[6IPC5*.BZGS0M$/%)?K>XZ^C-EX_YM/;3UUO9IPX:K<<U
M2@.3JQBG98#0>?#$!KO)DU8]/@!=ZH74&,6I/'B_;,@]K&[L,5HN,GA*4*!R
M0$%%<>::Q>7;8$GOP"!;6FD/&<KH.@"4K:@2)AG)^R!7/""3OE9#99V$HI\C
M^1J3.X*RWR[O,"Z1K2B-=7%*/[_[ISZ0&25452EZR4"U/5+1%Y*;LFR%O9EU
MI8B>Y8WW$0^F4$W<B.;,O";?I\'LD(Q\>>PUGXW-&U=65M1ZJIFM)3U$-U1$
M(?V/*W1^E Q@,59I;TSE"\54)CB2_ JDG_8[#KY,&4*N! 3,3$+KTTY7QFOL
MBLVHN'I)K0N5.]L*U379!SB@^X\%F2:5H5J[]J9S:@J6)SM?@FL*WF'@'.O%
MTU/V-RAUQJ<^?512S-^=2P&1(9_S16:849+@UZ>"?X"><"94K_(^01&5(RF"
M.\<G)=4I.3HF]YYW;5QMPE2Q2\4H?I?1T8ZOO\^Z)U;+?/+,&7UC^-KIV?4?
M$ECR.=I=7"T<YG>?+/V:=#:JSN&)0A"8<K/>KK;PX8_;$%ROFY@U>@K"8',X
M^-YI'\3-$*.9 ?C2$,-AG#ZIUV+PE\EQ\'%$PO"-X7*/0677EBH3BYEY0WSP
M*QQ@^=DJ[6SO/\)/,OY\Y3(?TV;M@Y$6$\G5-K"V3)N47\&.WC%CM2.0^=8E
M@EZEVTC\2I=5<RZ?FM 5WNW>![%*(MS:TR#OT]O9O2%7A_Q6H9PA%H/C5VK>
M5]15U0X2$_7Q;,>SCW'G!]2N@(Z<L[9=L!SA0?(P[7NV$MA81Q/-IJIX"0X+
M^RP"!:0.PW-S=<GEB$4A:A9_@KIXL.W/0:HWHQUR N]K%F$/;>.,"\+$JV%/
MP43H^!?KY3J<90Y+&250!_L^F(BQ_R.70DF'5^]<!U]<4?IC^EG8=[#  9<*
MO@K=Q2PE'_9![^MBU%'1 GA6VA]EGHV4Z")/AF1U%3ESUM/6OF8!/:7^6NWU
M^F)TP9@2;L'AF-+;,\)&/!,N%2/GO[1>S<O,/@7':O8&6P9/S*S/K&,OKA*\
M1HIB4OB>>A%2SWFEX[(";08]?VW5U.J=!#0)V%-3S*F>W=_AIL[EW%98*&F@
MPW:GM@*65C$UX\4]:?A(G#YB]$P69_QB/EOV']72P?P8_;_ABWA P^'&()1B
M!$R7ZB6_JZWRQR)*3!M'^_)EK>J'7X(LNH+[6D+2/.UB_NI;*'*]&I?%V <!
M<(H*8$[PG;@/G1 UPY&M\*<*2*,[$9.45:OG4+[0J-O,V,&(9$Q(G26;]W9K
M?J64_JVB/U3/^17.8)L@:3/8F ,]O@-]4H]])4=G% <AQIM9C*K+#XC#:R<7
MW\N.<KOE: ?W>FN:W9R+M[V0^^R3AN']/@\%=]G(KB'<[BHQUU[$DR#L-#UK
M /?L31!YBXTH\MP:?+/</V M?T5>WJMY?&<7W;=#XXKO2CX\-%M+4WS7R9\3
MX4MJM\?5#<_%NT4*[X,(VH.2BF*P&B[^@#EE"U-X'W[N[WT0;PN8ID*OP7ME
MFKU@*'ZAL:GO@Z(9LM/VD%A_43/.*<-3>M(C[(L_K#+&I%+'.8Y)XWK&7Z76
M8Y<M*9;,.+-E].,K]D'KG&0SRBO O2S$:*3E3(CCEPWF#.0 %0!>#EN3Z,T1
M8V6PTAYZ*J8]?Z(7KCE92CRYZ7^!6]"DX<^H_MEJ#QJ7/(6'GL]0G EQ(:NC
M.Z"LJT'96UY:Y5$D:D?:X=#NEZ_V$@KKRW,V5,D.4YM=E@R^^4-2?50'R5-V
MRTI6KJ+@1;M+$?5F>X9Y-G_9W/?R3%^',MQGR; .RTCQ3LLGN<[5NV*3%O$W
MRF#GEN_5UKF1#-KV07PX5G(BXS0W:1^4H"<*)R'0;8^=G9?^6;4IOE[0E9?G
M8.*-$J_.S):-.6_*@\C.2[WI=TE]"CF]YY-9BFK]@#]6/>UF6C'ZLS=E^/I8
M=I'#]:=NCR63K5^JZ%9_&C223+*Y]@T#+W[?RD__XX"1\[DBHPM\HD6/=HF>
MVR(*DU BH6*0PLO0B0Q(5+63ZZ?QUKVX1!?QN+UW=?GE*>[-HTKA5Q>)"[Y_
M\C@)I-]E]5P_)!HY#[F_#XJ%UAJ$X;TW>5;!/&^ BKE7N;&WAM3P/':3@,R/
MCX)_@F\/0@TSB$1]2A'[Q=GNE[S/:HL6+UG;\(05YYXZ]KZGOAP%@]^@!-1&
MUZ(?A1HU8:25/?H4[LE7Y^\^Y8T-:-P*TG7"#;1! 2V+KDXUY8FQFVME;FGG
M'BB>3?KS.F+]>(T?2['&Q=K5B"-_;G&4=/-OXVEB;&^ -#-^Y@IU:KP];%I(
M/]I[-\-:Q(;5-@7;*;%-$+9/D^ (6XN1EKX_+'T#O>5C"Q6';F)P72ZNTQ#,
M[-04@RWJ\!_,UZJ9F0\V*_HK\<6DCO.)-&&U:)T_B/(FQV$ZL:^5DI0E?AB-
MA'^\EU0G5^S^\ ^A'HIO(J0"\H%STG*N/X($(6Z&NY#-(FBJ;Y?V9)X5.4M7
MMYP=.CNHH/B3JMTK;NH0N*6<(>^9GV$=Y=;?XI%VPM$]ZK/GETCGC*P<B3L1
MUN=*NM13+!YZ3YK83:LEVSKYP!Q8+$K)09UR,ZW#WLW+:I.I-8;K_E@KE&3.
M ?V!W7*+ CWGYX P[0[SU<QU;(A(9AO%_KLS/UD%3_9.2_+6?3DMG2]Q++W;
M5BMFP/5(-^51?N=90YX%_EL/9D<-:+SZA+IP/0%D)_@/'55F)!)M:8JS1]%'
MEG9F^('G:O+X4YU$$X'%"9-W>:>?A4K5V=^R+$YWN)Q5?2WK%[:?DPW56@,A
MF2F?! ITS*0'NGQY(IH=NKZ$F,S#.8S;AYZ=^6?2$!-_1'PL/E$Q=_N&FW3@
MZ1IJYQSD*,*2D!X6HLZ\XX=)Q?0H'3"!X^S 5=)&!.;:^SO+]M;AKO(.VG=L
MV<54SK05"HF7*" U^)>OILB/EJ8::!1$Y5WEWK&WMW0<RFRI]);W:WC'RR%G
M+7W9/$)C[FT6W+I$MG@V>T)1S<87JX'9%F3NZ$U43Q--3)R9B%R7626F-G>Q
MDO1F43#)Q^"9418W<3-"BBN(FQB<\XO.BIR!DLP@SV9)MS>C&!* /[GI-KDE
M*1^ =VCD2 UC:2QE4YY:W9-K':V*[YH:AFND@\_K+,)<N,_?/ZD?9ZM.]F6P
MI5,A-'=ZG!_^JT>G%K9#WC=<Q&0C# 4O@DF<J:DF)]63UN=G[PBK1PTMUMT=
MOMD5<J?HG[M',!F-0BM\2W?/]PQD<L921A5%"TR79Y3VFB4R+L)=X*;E2H\6
M:AY<+##=&L\9=-ZJC379H',.0+XFMC/ 5<SMEUPM\LCUI!25(,"=FEK5 7NA
M.,-B)Z5,MXO?5N1>Z(UK?3[6*S7U,87MN*@4PXP9ZR+5B=QP-.D6&#B7EDI@
M?UJN8Q[*&?UVR+561OOU?<.?$^)N23<(+[A[NF]SH)@!QHYWXXP L^'OR]"3
M:9>?$DO0D0-OO41X9[PF2P61,G GHR'MRPM:+^WTV1JXN[!B^'MM'S7Y'Y 7
M4.^Q-%Z#.58:[TXK0Y,$:5TW[IXY^P6'*II9":)!N/U7S;AU7D*+#1[YLCLL
M!WD5E)P]QEUY^>1GS2>&;DO%B(Z&!;FOC>K+,J59L('71=K4LOS4FO7"4)N\
M''YJD45[?^J-G&*+&'M8>5W@U@J2"]5:BQ:%>&"CH*S[(!C^-.T*V>,9C7N^
M/B3 W\355V!%RS39OQ@(:C?-$#=75%8_?T8S8-"9Q>YGH532AHSYN;K4Y!V4
M,JKU8H@+:;,;37JH_$+'DE1LHN5[=$6/&]A2:ZC./#;LM[L8=;W)N*=L_?8Q
M>85N5,YKNRVI4Q_"H+50/LC<]"8@.]L)CJZ#\BK]/$0!9.R8AYK.MTEPD-4C
MX^=Z?*0S![(T$OR,HU2^&3D;IGS+7I?,BB/_[&Y5!J2@:_%4;>3HI,>Z/RGL
M)AD2%N*=CS@)C:+H<0S5.&C[1G'#=H).(E#FHP91></7]D%3&?DGE)4W;^36
MPBDP6BJKNZ^EZ#-?41N>\I7Y"UM14KG\)Y]\-U]H3'YL4CML>"Y_#/?QDY"C
MQ9T[1FHI%T;SE#S[&DQUQGW&#-4:G>K>C7EL+U//'9PE[ #S1MXP2V HR/%.
MZK];;>74?R[*>NG2:LS6/F@"TI5S#&#6%I9%^AL?O.=4KR+/]FWR8A[&,V,\
MGE_J.2>O3NW+UB)QV]M3?"=KW[P9M3<7095<O.>-7:[Z "89H2>Z"0/K25CD
MU)Y !5D&&HO\<^17L_VVR8B.(0P2YH8;GV^*V2VK]A]RJX\.<#8Z>WR7PA6>
MUGT)6EM'X]ZDZ-(;<>:L\2WGEW*D2-UQ-B.3LT FH:O C5#F9F\I;[RXLF,!
M2U\/O/2M:/&?4@NU4W;/7/'5#X<RXYJ+,99_&+-?[I+/R2*4/(I%_O1=Q-:'
M&N'N9GSW/T_\X:SR.*0JKL'"9.I&Z4P)QNETW7SB>CQ5%1$$GCRY3;A?1!HG
M*J^+D]HI_D 86==MT(\NV1$H$A6EH_BF\ZE,<C"Q3$NT*3C6\/6:*]H@TWQ*
MP6BP6O;3!/0C:FV\ /D%7[</^IMQF19$1M'X?.8I6J3NR&'+T<T6$<03IZ8O
M:NL!'%Z*-Y:KY7W9EEMD!L=6OI;>:'OD[>''.LFEIBV:N&I&.<C_-Y ?(14"
M:&(O.-*>E1FCFO$T2!'"LJ,1T^%M.MX1E%-$:';]\W31VV^.W9BOF^];7B@$
M<E5RK11?Z@R))W("FJP,-C(1')V.YF'6]8B:N^,9N(PF0-6$C$3#YU[D&(<]
MI-Q>RKOB6GL,+?]14_$%TF1ZY4)]J8#H5)MJV6:PLH>SU?F19'-GFO7YAALG
MS0C>/=@/C4"(-<K]_(W,.HBNT&C6V4QXFNDC(PNO@==2*:6UR[O,)N_X@(ET
M^CHGU6]I#"F9V1%T_S4I\\K+=J>.]_N@!X;[(#9U(LK[1/;,3?>F$]AM[9LG
MM[[_+&&.A+Y [!P^DMG2VD*FH$Y V+SXT=9&D^XV>D OU:!CLB\M%N;_%)R@
MIMWJ6K4B*$ V"W!],2!>7/69>E3JWM_P/6UZ#&HN%5UEL"9,EB5N=@P\YP66
M5J#"?KTFHATBX.B:7EW+]B#3=+?"6HRW&V%:@T.IIYKJ^2,@SD!J1[)'6G=U
M<6 2PCC!0F5##NV#!/P'XB3.QQ*AX>J;W%Z/5D5:DI@]XR0J*N3R4V2D#*Q@
M."$ZH..CJ]/\0"O+WR W$:O/%U+A\PT+-FH5?N>&K25-+G<.WVXF(,J(ZQZ^
MUZY=0,3X/<059Q6[K(QD1FG'W7LW7:9D"U?\V5(&3F%:_5@@SZ4$.8(GF32;
MW<+5C*BM_B([C:;^2B$[3CHY]!(AG#I/'+Y='> ;U'HO1VXZ?^P)5 _5ZN(\
MWKH/JD.O&<S/1FN\3(RX"'#.*2?Y%[:-:ZEA"V"3.AF$YS/7+C34)G($%=57
MDF6^/($.8==UF0Y_27^%\IH:F&C9[!YGSI[5TO1T/_Q:8I1&SBFR^+M$F&YN
MLEG&%6RG7G*0[PS,;^E>ZENX]^>MEWI(W6%*!OT9GAE6DU,$V\@67IH[Z?EJ
M8V"8VI2):IN$=-R4;"Q.G:.FH":ETG,/-S9<5CH^-O:^.ZAM.LV=]20FB4]5
M3%=HSG7D>^%PQV"9YZ21.J9/6-]!XZ5)R8Y]JBVK?7Z%Q<[9E?X(H\! DZ'G
M%G'5C288#X]091_T:RC)@7/2EF)"UJ3QJA(#HMX"FP1\3,VF!*!O5 >HO_/4
MBHPN\M+R>>M;'?SJ?O7P6D$P]O1ND(ZF@.OEN]7R^R")S#],8G>5"5AV!+H=
M0O*5R(5$JTU-7YSMT),/LR;]#/Q$UMF[/?A+/B!'_JFUQ(E)@AC(RN>R9-SX
M*K2=.;9I,!O*U3FP\"2BPY@<UADYM*4]2)@50O2:C>FHJW:>23V+-F%\"/L<
MKE5T?A%[5!@[@I_4I,@!\E0CY,!CY.<6F<K1$'%2O4,KS 43HM=82Z+W)\-]
M^<C7C[^6G)BYXA-3Q\,<?0P>#ZDD1;MV%+I=0"!<ELRSO=XG* EEU,A=N=)Y
M7;KGQ'FC3>.Z4"?JTD)DATVV?8VD:58VFWGXG[)2&YM/#0LP/I.*%@V[[,R-
M?O&E6HJ94+AJ5CPSC)SAS($1TE/N5!!1Z;AJ8>^(:!.U\W>(N**X/?574KN/
MCWB'RHUHH=NG4<PD-!?A1N# ?_ %SEE!Q'QXC0#])QC$$R-RQ)I-LF,MV@U5
MLI)F8\OE,&D@M5"ZL1#C&0Y[\?FI:R$'RA)=A5\S(:53/.@IBG@W/&@6T;A-
M\,9&X:"$_!:R /9X+A'SGER:D=+8U%-\W0U^U%'>*QWLGKQV]]JQX%1*]LQ1
MJA*J51KECI\P8(:XJ [K7(_.4^+F25IP3>1PMXA9AV[00(= F^C3\G+%?5#E
MD+C<!WL<[[1:A>!V+>Z16 C&CQX49O=\L3!-DM^T1LD:*P5_HNM0?2^W9K/X
M9D%$<0[[38C+5:L5I^DG1AD)8Z;F^([13(.M'_-F41!^U-RK?1"'>F(B_OW
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M CL$,OW?A_+!6F@H3&\!]"6>*-PY$K,B%92+ 2+DWL$U8T#_@RCT1?/M$&
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M@2X+2K8<C B&FE!!EY8#5Q"J!'8L[$7>6 ZAL!7U8HXGPG;D8U6PMPP+0I&
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MK?=71'A03([N5TD\Q<"'S.%XW&8']..41CPT>1O>]-M\Z3_\EED2<ZLB=GU
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ML3&C=W"+8S@X!=>S.1.-.)5'0JKKEZ#.-FG6(>RXG@#4WDS'(5(MT))>\N@
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M%Q7__0QPI@#XF?-W/XL_!OZEHLNF_W[)>M[\?Y\E_MU4<^B/$:K^GR/40J0
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MPN$F*#=( [KEH*'T^./S]-TX6*J<M9T*^EDRL_>[TUK"<>@=&S+Z,QU:PJ<
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MM[CNDV+JA53AZ++[CH>:.N\MS^IW]W*5DLLY=JGWQ-;=EONW>9\VEF<$+M0
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M&Q5W)^D+O+#85X>IP!DB^^%X&A2-X]/ ,G5J#@L==MS&?!?F0A?[B3[SH6_
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M! /19ENK  R< PT8B/>] "X4> 5LWU60]&!ZUIL;$RI0AOGZ,"\#(6)#H+#
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MEEN?@ 8V3-/8FBNJN/\?!4R"CMI2Y(503O(#,\#("1*,$))2!*+L.#!C%,E
MU">C:.$%:Z58,#&U'XJ\1H 5_C3J-_ "&(*3C>FY,5B]X:TT&5/F49M;VR>$
M<Q)S.&@AU<-F#-#YL0NPKH3%?1[;!@PT11Z6H2FS=DKJ @6VA=AH^YDY[ W6
MV5!%8),#/7\?$L,IP6E/$OR[]5>,-K%3\G\L;Q94V0EA\/_X:2 /1E;" AJ&
M01R5.1(R8_L0,#"%\=)A]S;S W;O!)HB9B]3BB@PR@^YQ06C 2D;%O:Q"UL*
MMW)&O#31JW5$X"O\=R]KBYCFQ5P<P[2O_XC]Y^!4ZX \%19<5P[4"8"W:>Q,
M8:$F0F'092"VE% #,&RQ(^' 0]>,=NVS.EJ\^78\ \&<>/<E@LY7?&L9*G:"
M(XX?)\7;.[!3YRA4D>ZEGPS$T.U_T!#.&7L)R+7!;;4/9K+LU'^RC$!J0!7&
MT?EQ"YO;O(65#6;NB=\[.P#'225?)C58&X\#C<6WQM9,I\9 W8B@ZG[LQ)C1
M2MI_HJ\UD]Z_<M2"]>OP@GST:&"F%^7<"3.-Y6_5_^_TLJOM/HLY)4RB2.EQ
M21NZ@+;&0%6M>'NME0;LD,3F0=\>6D[MT+\;<=)B(G9UE85.-R(7K#.'*/+3
MHPDSO8#S&$TQC4E'%J:#+DRB\Q<LP.P.2V#2R<JN1G_V:2W$6#0:P]&3-8HL
M8TV@\_#Y0IS$P&HZK/*Y1R@]=YG M-QG!N-4S1RZ?/M,!#KTMS6;_%\EQ1R&
M!,!9P84[SA!W%W.4(: M.#(+E3@10!W8&'[%K>#_9!^<8,,<T?\;$YG$Y^FF
MA(DP@J/\EA)Z %9\=G%F8*JOAW(@_/SJ37])^*\=*!$A= %-Q%$)YH__NQ'4
MKQ5Q2 R 53<=)P?KO8919PYD@?T#WG7^-#K+K6R@X2"F&;OF.E:\#*?N_WB4
MSI\]4(PM)0B&#=UMV(B+Y@OPA9J;@0D##OFE+0A&R@CT-]1,3CM BN.9FIX'
M_;%3+I1VH\W-X#2@[QT#,?">ZH2CT6!7#)C2W.@P"R?"48Y&6TJ>_YR*P PJ
M3DTOP,Y,&T_5A#_/_!=VG':BW[L&<_ [,W<8AS7@<'DJT&6:"/^.L#2M<Z7,
M=LB@@7Z2@[KU9@O@P<P =2*$\>>0/+V<AG8@ZQ,3W[SW<Z.XDWKIU1OE28<Z
MW'S(!XGBNMH1Z;Q4C7@7%>.(B:J^A9,OK#LXHQS/\M"KX7,>A/[A@F <6)*V
M=TX-N;GS0<%;FO@$QWZ0XZ\>FN0X]N#MM,.D;PD"%[- H*'2*2TNPZ5+(T:Z
MR0EG=7%/5HF[2'7TL\9(N]=/6T]6I\XWY;ZJWG--T_@Q_E&3A1[2%F_S1D<[
MA:"><50+LXX_?E;]HK7HKY>U<:&8&-7 \K,-CA4)*@W.? ]XJ.B%84WA4@EB
M7K.Q][N(-SH?>-RD2L8_Y0Z><C_?MD;;,RZ_CW::%!8\;K3SMAH01I.>P*OU
MZW<KQIP9E'9S>^AVV63W+2OCW>6'91R6Y&ZR*S5F9;T<^)D\/Y-.$'B1=5;O
M_@O<V=8VDX1[+[+$?255'@QY+)8_Z)R+_->7K-[;7[*&F!TW/*1W*D2$.X/Y
M!6N3:+RNV/7_1[YBE>[0E*0Y@:8D5$,><1F&E4.!DJ2Q!@[O,MT"OP:KDB[%
MLFJ_4?,RVZI6D:=?NYJ71$8J<@MW(7K1(6."M1R!?M^7 @U(SD3+X-J3(.;;
MA*Q<:=Q>MP<V2UC/^R>*6W;W*YOH\NO-Q+9%GS^NNRNR_Z<E!65%40IZDB1=
ML#"]X%\V14FM3NWO'NY?.5O[*=CJY1.__#/-J@^U0BAKM46S6;[&5Z<I'UC=
M.EO;/7"Y7?;21/2@^KA*<.V)66!?M3GY_F=[)(C%-QT8U'FTCN9TH6 D?CA4
MQ#@]T3<XZ6(Q=S-112?F^3XG)Y$GTH.YSGI92JQF.%6IY]/9TZQ:9L&#=^_I
MZLEO9OC\MI/1%B[)K8\)4,)=P!45[#=W,#%S'82^Y3N<G/U1;!3O>J:X)I_;
M6.O\QS\Z'-!LT# ,]5<]'Q-(1H1=,\*:X)C39,Q%';)PJ?L[%PJTY[O[^N(E
MN^'-(;&TT6F3'A-IIQ5T8.W]0P_>6\CL"=(EI1!]PS7/T-1)N,8Q5MDM/]]F
MM7.)Y5DG<1YER4]LT.>%&G5][\1__?@MYYBUX^':_MT>JAT^1GLB<:%9,6_V
M/Z^W3)WM^C#IZB-N^,TKNK)B#)T\HM"9E3S56WS T%R?3SO;,3A#KU:<A<^^
MAE^)$&KB5?8\+;%W*45O#HK0XK:4G-G#;?S7__CBT3']L4;G-2#T*;FU!ZGK
M=R\L^0CI04OF87W-S6V\%555GUY_N?RV_(E*HO71T$L6-_[:W?^")D%_5[N7
MY@,-H/9"TGX"Q.NDM?HA.TUV\IZP3_2$LP^>:@$4R9M4]=><SZ3'ETS4^;L5
M<]NX\OA]Q/12(G-,3B6$"+Y)QRE^NO%K+3+!\N'13JYPG$VB<%; J0([@^_O
MU#[&N+8E5X](F<2_T=J3/WQBT^)#2Y&Q%L_K?Q-,8/EDP9 OY2+H."D.^I/9
M*''@^?$QP1:-(]U^IHV:RETE(SYR<AY[\-6RN.%KF?.B_:+G^7F&NP\]NI5[
M*G7H:DAV=Y5Q5()^E>XYC=87&3S^>J=M[0W$,/WN2!-CXXN*EJ>:O'9'*'(U
M"7[O$-@;:Y7U%_E+]!D^(3YK*T&>8['L@2T%F"%4D4HH=$*EWH@3TX7=5X*.
MR'D_X,(Q;J?37'FN(*+?],>3%+:]W3<K;-_Y/!"ZPLD]<LSA<0=GR._!$#'E
MEX/1UY+M1A**5G^*231_,XDV?6!H(%W;MNCV*^BBEH-;K3AI(TR1;9D;#+?N
M*?$\Z))XQC4@K/R]G99[]L L^9)S_ IQ29M3Q^-9L(C>5^YCLJF6L7X/*?GT
ME$!;4EXC4K!:@5PU459%>EB?Q*N<)@:^S )Q5ZI(F' ?9[%,2XNMQ'+N#A<W
MF<-HZ\P<T4<9URX)[.D_$?*KX&B;WIR*L?M]_8F8[I$UV]I'4]P+4]R#]W1+
ML%(C@U2Y@IM!.[3\>>LYX@A[4+?9D<9DECKY2$U6,"O=A3</YQJ >^)#%0IH
MJZ<3N62S?E#.M#TW[.(\%O-4W=#M-=EW$4U5\F,C:K\F/6S&"F+X_1R)B<6^
MV5:S]HB^:O-L*S 76K7F%)(:[+^<[%.5Z/Z7 6>IU@6GP\>O/9&DJJ5^$TR8
MCO0PGDHZHV\Q[.X=WUL6G":8>XT\%2!Y7\YBM%5]8*P5>[[+WI&L/VE4[_E$
M3518%*PA<]6CV=<$7M]\,F9!#BMU3K?J4-2+D3$>MM<5]"#G/R_.C3=32ZCC
M:0X4H^<1;A'B5)+4@+JX6!2[ICC:^M>(C9]"4X#])Z^]JIHW+>Y_F8^E>5W
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ME9R$[7L"E]U< C#O7__[4PNNBC.G#^*VKR;<YJ>BB #5Q>&?IE;NOPOS.52
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M-#K>M<)2U#A]7"=Y!,^IO^_%L5Z(=E)M4W+B4>P+3TKRRVG"6GY3B-9K7=7
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MX<.5UN<(BV-?;6+GM#F\>GT2+S._C W,M3XY(;#?*=*M<6*WG9* G<J&,ZG
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M]:3=9[L@7^7R?,G5?]W;O^_\OUKI?I?4KZ1)N!0"T30TGLK6^J];^[=]/]$
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M_X0JV0<R/- [J-K)\5^=LT"[9&IM+7GR9W<;[?(<WA/?39FAC ;L,8U"$YG
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M6H67U$GH P*MSQ&'"G%1#(UR=TGO295-.M@!M5\*C^]4_]FG7XR[G6YI^69
M\KCZR?U<D-Z6"COJ';C=37H]C1UEF!IN5B.I$G?^**OH&T-6.[TI5^S44>J1
M#?H5EFUFB2S)YVT>2?3[5J9>8';B%')'-'Q+U-W%UY0[Z)M@>'C+_<OKC?TI
M]GWZJ71D-PRCM59'YA!J87RI/K?[.Z$GD+"K>S_6L+- "2O=VG2Y6,NL8-7#
MW2,AWZ31Q-#8K2^K;M2_0SM19744_@T1A)V*QA+T>\)&UX(])L>N@O3,?D2Y
M:>^0+6[%U], _:+U!8M\\>6O(R[%!?/L=W]EO&SJC/I\+.9X_2\J+""=1F0@
MCG5%A* 9BFMY\6+(XRACDE3V::8O*@+#X-">P<)'C4=5F@6 G<5/I$Q<?:K]
MRJ]+=(Q/&,6V#<*[4?KO.CD"6V\6GU*V9,@C?&^Z?YGT_(RG092+HTQ^*\MV
MJ67%];A94STO9^VF;L[@>\FVQFZDGRYP^:B3^,79<XERW!$%'S[.->;A2MER
M36*;!G;F"UQ$6782*Q%Q3*R0;D<!9TP40"= P*[P[CN;H32(R,#R)3^I*3!*
M<#ATCO1TNO/"V5'+&P7F/^V]]@JS3/3_2'PP:)GU.F#NB,0V-.5A20*3K8A0
M..&.:S"R]%(246AZ'-WL>C2[S-%:HCZP6:-A)T[#YG168[?\XX>#0U=L),XE
MCI@]9.=5\R?I6QCCR*N%3=>-FUKEE1ZTW<_O;[R;K97@R<%=X/;RP;2D@Y:^
MPX:NKDY5?F<PH>GEA])O;$HJ"D^[KK3;<N[]B.PY%XH);>C($C7W=#).J<OR
M2U7PF$WV6+@IDQ%_5N,K\$%OF8A#CBAN_T%BWE<@-5GVHC1QKD'63 #C$M=<
M2.*6C)7ZPE:QJ>'&YLS _8#-/_BQT8C-4!N_>2I,<OPS^0$E#S$5A&5=Q=IW
M(;??4%Y28?8^@-TD'REX54>="MNWMC+@=KZT-_,RJ<_>3K4/PZM&:=V/R/3@
M>:O[ZX@$LJ^+K2FP9T.)48XCNFDHH#@ZX9[-!8,HA7)IOM&L EU98:/(_ ZE
M]3A]QXYM<RN^5H>&9\?=$VS?JBN>-C%[G,QI/Y/@\,#I/O&3W,M,>M9<#0YU
MMV*Z?04WP]BD>ERVH$<R^(@*LX.2X06@->:,_W<^'DHZ8BH=49X*>1.'IEN\
M-IKVUCF[JU#/.<]R(98ABF<QUZ)/_(FX)#YZ5JJL8.75PQ#Z0WMR(/U;*/90
M UCGGE ^%M(N01NGFTK(Q+<%>11:,9XV-;>8)RL^=;#Q5)[)R93:EHV:R*1@
M6,M.HJ9RKI[23S3Q&Z$,9U0CV>ST>$.^L5\Z4QR4J:1,;S1O$,R>QI=1H27=
MI$X?FVO0F:94OR/N0AET55'A<4MY@G+1%C]F_NEQ&YL>;V2S:0O.Z1$;L=QU
MV=VPK3NSV==1+JDL23F]1U'*WQ34KI>"T'H$X>PZ*C>][H@NEUHIS27?(ZUE
M*]>_G7Y'A;%:^H2O36\G3&?'7/E229R_ZXC7U[1Y<4.TL??9_<ZH9GJ*Y\'7
MN[X00E;.[3.06+;U2(4E+?!PI2/3XY<F;Q&'@WOQ%E)G'+Q*7=B[_!X/7[PU
M('4_9N6U#,+!R;;QT"4U_Q)]/9:6>T."4S]+6?/]5,\2S62#F[XWM3$99W,;
M1@FKBZ8F-73@UL0FEB]#^\LYLF\8=RRTN7;I" ]6)A'!'=[:PWWS2OQ H5&S
M4<JXRZ/B>YJZ2J_TW6<TUE]/PTD7O<EL[[[4\T1,GWB)G<I\C@P&#ZTDMNH=
M<Y"KEXC&*?-YW,ZNJ#KK\^2V?E88\SW_OM* B+^^7'Q#(Q<G,Y+T]YDA TG5
M<_AW/9^,)%OA8W@6@;,KLE8L1I_KPV=Q2RT;]OUCEH[5K],X!9",MSY,J1^J
M=@HHX3B4 !0ODC#;4Y27X"EP CA5!'*3K2H_O["O?N<$Y6_V=USU^=,4J^*)
M >NQB]JG3(_=?SV@ZM;%:%8Y_G,X^R_<3S7+?LGBY([XRV:HQ^X^,7E_?OCQ
M/,&Q]6JDD\FVS+3HRG4Y09'K6I(F-?:$J\"I#_+^O-V$%+E3:H^'S\4/=!"0
M8]?3Y'A5F8+R#>(+[G^8O%=LD';V:I#B3?T8<5LNU,0O#_ >,&T,-%C7P\"6
M>AY*[B::)+P=EDOF^UY[E;TBG2S3+\N=,!B,/JPI_OQ83>?TVH?.IU() H"M
MQ>ZEF M99@VG@#^HL(?S0I"M9H"&ZQ5Z1_S[M7USR!J$RL]NU7+-XZ("T181
M>25S<7?X?=_,OL8G%+T/0=Z>/O;JM7.D\",H'1 >MS44:N][#B.<8F+JA0A%
M5]9<CRZ:[*&>'_VPUC/R[<SBS%GEMS&_0L_2"5W"HJ@P*#)'RJ;EEO,)5:HD
M-8)KDQ?(34@+Y[MQRF+"=VP_"N,+>,I@!*(D!J9SI'>#Y2,2(@\-]W>3(D3V
MBNP2AS)#N_!OBAYQP(,Z+B0H\0J,>2PJ"X:G8!RNJ[4^[]!4)C.R3+D(@-]3
M>?89PAK<6NX$W[.VB9U5TC8-S4Q^D,VI]D!8?37M<*J*J;"PEJS(J'1@+*H7
M=$/Q0B'P&#+#1Y0*81DXB6*BPHZ=ZZN5()QZ5NDZE2JZT5*JQQ>GD&5H\<='
M'R\S_9E@^<$OG\T^1C2,GO:/(F% .F3Q* 0TN5K3?5:4"BFE.B0*9?QHQ[1>
MB13BGH=T^$@*]W4_VG];9NG2 (?>^;-G;@AD?V@^E( 9&16;)2J9OL/EJC]-
M8T_)P^7C$>X!37>W/R7K$@JM^G(YS#6KB%6^-8L]M5]([DW7_<2-N8PV1+^W
MV ZNO[.Y:NDEM3CBSR\J^^&'8&BQ_/1]X2R,EDA61IR6B%1'S ^&;3I2R/XE
M_\:]W.7/>."<CT9SVM5!&3T6AQ@<_%1;86[(Q22+&(/HD4%/,0N_6VV')W)3
M=#X]$F[A2&";@A.T$21!N>:U'W&6%,PD7B@:A/NL-2'+DW^8.53RT44@PS=T
M^]A0VJX%-XI271I'F:[-]EB99>P+I?V%3TB93G#:,0^?20/>&@4[T!F'2+J:
MIUWD=KRK:^Q@;)PNZC)978Y+S:PV4>92.O?J>V'3X/V;58A3]YVFUDL>JVFJ
MLTK+\'&5B[74FZ\:90W.EKRK7@;$S.?(9V*VJTE,1(L6ZZN0QYZ!/RH!&/DZ
MKK#SK:0,Y0$>&6)8V6_W-CM&^\7\*._*VXHJ@7A&AK//4+ 3\W9DEAJ0KIA8
MN/V(U("CPD85MY,I69[8&"P7RG1JI)9.8F[,-9>PJ2#1G6];I./VP?':-5,&
M8+M3P/CUW=S8;TQ*P\M=;+T1N!0\;W!^<+-Q4Y=)-I=L*0-=2/25"N'1[X7A
M1I1RW*YQ?V*E_)5)1A^D2-OWMBDWTJ@>0UA^1..?:7;1:?=>-@]@91^K($5[
M3NLZ)5M6Y@QPNXC  ^ ?],AGO?%"R^A]=Y09)4_)%FH:AL.4X/BOM4B^U]-K
MC&.D8,29$:!1TV/G3.I-G9L=IY5K7WS1_'6'/.? 7X,EB:Z1S]KI4^H]F6!D
M-=)](H,>R948^(5#1/)= >F%=?M[2[_XL?JW2@LY]ZR0$MVIXBI^-<*B@D9"
MHO<T5K+9WN$LQV<]GGI:,[=^3]<[3=<:)7OB9@H/V_6^F5_)\18&U;55=7V/
MB%-\YRP1$=-)@85*N=R1A3'%6CX%?<4\5N:EQ:(#I3P=Q2+J6?S3[0(9&-;/
M%GJ[9TDU4'!!?7! B'\O']_W51 !_E1A(17CL?16]\9(]VOUA")<R%)9]B8&
M+0(FE02-]V-6V5^[&E>9E\?X ]J2*6Z4/&#J316ZO(?,@I\>7@:*26.Z?;5(
MPN"F\E-UHG+!!!/33Y_</R+,PK^-MPY]=#RA^<IQ_5G'*X:X#S:36]OA8\PM
M;[OYS<YI%=,C1SZ%A#>T,06EWV1UK+"S-WSY8&IPC;WH9]:.]W4W:RY"R?%S
MM1="6G&(*C?IS@U-_%/Q1U=*Q)C./=5(+G[^,9\K/V^TZ&%6_/F,OG#M73(%
MJDEO@2I@>2>#_ =!KPT]BE<EI1):-Z:%8D >LC3I:487[N(T^I0U:5@-K0<.
MU%4.;/I>9U=TJ@J>*BXJNWWX^MWE/S &D'74@88K_N) @_(64U05FL7_O ]3
M:Q/.>2CU4G0:?:#URP7"CXGQGZ_S@,>CYL&O8Z>-N/WP3]+<VRFE&:4M[I?L
M(G)C,DW,[/N_U84,I6LPW(Q\2-CP%.D03;G8+G1MQD![(F^R=F0PR8V#:>9-
M9!);2+!*-NHO&W8+0[8WN%*#;!Y/X;O%=-6#0BLBK0GR-Z.N^\;;L+6S I>Q
M!$,$Z8)4R]KH_O:;(97KJ%.D0D+/%RZ-2!F?D"@9-%<3[M& )],93?_^B?&;
M'KP*LZ/:UR5>BG&F&;_1>@F/7X67P3_*+5M,2XWT;\L1T,OIF!N9I/#6X48%
M=##9/6^!<#MQ0C3.[!/6=RDL:D#_IU:QJX^$S0;^J,89[B??+%9%1=U1:LGX
M)V2^>\@S:1R'1)\TY=V\G)>MQ9@JI/"Z/'<9-QIR=<<J>5#,*=%-[O3,N2$G
M]-0'R>O13^D'B&7Y)I[V'9S)KPM#HT197%(%S=UU<T5W$O"$]EQRP0300 \X
MPU\@695L<3T_F+8'*T@7IC&<B][/@U9R*E1JV$LN5']*]MF<Y5(/\OUSR$M,
MT<+\PK%$6/KXFR/(3 1!CXET"=/2,Y*$"XD&[)E&];;#A^N5R8^)$Q'W,QR?
MIV/KWMW4]A69_70OEO=F8S>^V^Y3DOP?C#>$ IB6H]CJI<++(KVX<KB939D$
MS>.%AS$\?%R<U9OO<7CZ3WG]QKG<C7*6HR,\S^Q"E*3B\/,V!'F4!Q\+LRE;
M8$//U3;C3K<WX07ZJ5 J,:C],##GT"7R1,7:SND:-$:CIG<TIN7(;*8@W5_[
M-Z#*=*/^BG_/\YW@>A&R' '3" ^<.!]H.J0D@7,"SFH6+Q(F+!UBG=H=*&]M
MW'/+AR__*/?J\N;/^W:_HR"94D0P#?1P/>(CUV1]LD\B78>[<8\1/;VBPG)*
M*Z!)KUQ;'B]=(,IF_RJ$VVW_33WNFYZ%FJLALT&VJ,S#X;+W6>F<+5)A$[HZ
M*)UZC*&P?BY]@FB+RO,22>?*M8ZBV/IVR5#0NQQJUR_VM#$=AE0UP5%J5-C(
M!B3;:<Q+KIUF890^'AW"Y(!3!%BM2*@?$;[C+!K[;"';/(#]YUN?F7]:BG-'
MV(;0*S*-*()TTD1@VQ>*I_<H/<HGV<DP)),G)GA"AH")E#E]L6'/&!MJVGK-
MFT\PL<_L$39YL4/BPONJ:\L?3TJ>(YC:*R53B!F5B??#XBUMA2O$%1K;U]57
M8[TU:Y!O@6O;5\P4F&-C(^.,4ST^IR9H.(T\CONXXX7@Q4X5TTZ#6<*0A+U?
MU%Z0:NIA\7&:WFE%'K)&RH74WL-QRC(MU]1=-8T>&M/OW_+N72F1/9>I;29@
M<8/KOO4C4U=QF%+2M@JD]"-P$/%1BLR"Q-LMOYUFBIBD;VN+"4V3(7J'H<2(
MQX<F6]Q)8JKEQ%O/CQ656K<.B97XY3_>[/QA.3:F]-#RO8'_$X3/?'ZT'#,7
M<].&6E_0[<%(VY,=?9&?8VM,W>O6.#SZ'8<>YP9E+';4)><+*[AHZ?A^U+R6
M^'-(J\>/J56*)"!%/EN]!M(-3DWR3J#4B')!X'G4?2)8);&=C<.>:LJ7?)>[
M8'KHTN?>S=DA">>*0\[*>PQ5]XRQ/E<_K9Y'Y>+@)/Z=-G0(0#"P0FP/4.+K
MQ<E2)&!*#,N\P!421F;&60#0?.VJES'1Z8J(WJ0HE_LI;_9<M7SK8GW$_4KZ
M%:$TP]DC>YH9R6TX8_/!E(%<:\948^'<<S?;!3L_?M14'W-R'D$8IB\O&.@[
MRCS,ULF7%10LWDTLH;AB#7=W(0N&00#B1-W;5T,][Z7"'*%V4PJWC=Y'D('*
MJLHJ[""&'9Q491DI?#RXK!Z2:V4M6>C5]W6X3ZO>,EL_(,#,]"W8"2?<@D>%
M[6O-(RJ8R*SP[=@*2G;]>1_Q)JE@N+:?N9/3Y_/>ET>7"DL<3"R*,L[6YB6&
MEPB=?,(A#\;G%43;A$<)JNDJ%3 FHP64BQSJKE\T^;EXK:]]62B@J3HZ,[ F
M.0_?)7A"UDFGD5RB-5;N+P TZ -3K]DGJYC"E!B(:!J57;$*$_@=8+H0/7R+
M>&?A*6/4,YXK82L5I^\N)":91R9GQR0<J\CJ?9$QHE5O=@3)C(*FP !6<!#-
MJG*-K$2"YKYCK!1,,<+>F7O:LRMU[F5Y%Z.SE_:/Z%3!VLIJYR_#'KZ*R.7V
MJ*++$Z(L5[\P#DT\ ?*UA'/?X/(-HH1U12]'9M(IN"7<5K=H9>.QQ-7&57V%
MM._.S!>NJ4S)R!:DDQ_MOJN7,#JN3UJ UCH*K?X8:EG24:J$'1RPG+E_8PE9
M%M/B&C*JC W>['SG-%8#G"H)RAFI*(ES9<M)S9VPS$KL6(WZ=.6*\\53)S%=
M"$;:31<JS D;#<VL*#G<&DD8O?+V1!OF]#S72P[@/F&FNXY2Z'XL\^V%"HD2
M^\1MX9)I$XV39A<>VQUBVG)5$WT6+)H@JWLV8$97^EVVSF"D]:(LCV7?I/:6
M37Y NH'+$P-OAPZ>#:-?@Q5N6"G=K[.UO--,C*03C7OP0)10]NC\!"]A-=4Y
M>T'!.<6)K:XBN^B!_*#^']SHXYH6YY[=&P][)+!9KF^I<T (-39>O[RH*?BP
M*#%,(G;Y?W0S\W_UAVW#;X?\LD)J#_Q,A?7V(&^;=NU,KI\=P"[MS5%A&LJ>
M][W1%.A/V3Q;8!NEC@JKC#R@C3,[^&GZ7_[MY8?=]]ZZWG[PDHS!@.;!L6M.
MDA&#H/[AWY1Q[;3#Q_),:0QSA@='M+TZH"V[XHG06Q3U.#A*[;UN[@)%3?>
MN>R[[#;03(5M]S7^_<**D<@!F9R.X385MC(Y\-E9RGCW5JG!P9EO&7\?NV:6
MJ/5OM&=WCQX0I6GJM]$XV01AOP\Z,U>CJ63P_6C[C@:>W*60?$#.UY_W?SN
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MKC6;:\!138M-I%NB53_>W"&7%,2J?X_W_W-F\O_E'S9R )0-K(&IO,G*X0#
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M$9KJVA6]]J/+[5940EI:/;DZ[G4QH+,S3S=RH$FA;GV)-P9?JR3)Z.N)_A1
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M.2D\Q+&*M_O@)T^?>JFC^OV.E9&7"[,;!OVVW5Y'?E\^9OP%VM([LI]L\5<
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M#8>?,D%OS@+<TW)>W!&17*F'6-P&IN_X;TAO72?;8[+^O58RSAZ5KR *#,\
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M9G![]K'5K $\SMEAL"S_^8_T7R7B]=:9SR0-/LP/5,<%:7:Y<EB)E;_0A5C
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M;9DPHLNB*?M$,G+^37@IV"$;"3RDYX&BY7=8"WZX02M@%8E=@P+*K<>L4R:
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ME*TWNT#8_24YN(SH3T6,?T21]&]"+A0\S$A%D"9F;]N212&E<E^&1'\$B;X
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MG)5X)[MC\9Q1!M_IU]GM_(FGXSR3PUPSDWWAN<8&6H]$WK!Z*_V?>Z'9P1Z
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M! 2I78W##E&*BWYFU8.>+^G22G3W'V.S%>?".7QD$SK,!]BE@B\+O,/&UYI
MJ-Y-'6P$2I$MA*$-4##.&]\DPD66F'X!\IE1^9>M!OTO35K?E1I/Z%%WT1.Q
M^*XI7]LPUM1FG,[&?K+^ &0.$^H\'L$#::P44]K:%,U&.)\]P7V,2B.ZA?G+
MY2A>Y>]35+>:%S@O@#8X8[OZ_O:(\OF+@DI07-D]V;LVJ@ERO*=IE[_/_HY*
M5C<RK2YV&3&3C4P='IMMJ[@5? \H^9$;DZ=F>6__]> &T3JA*B[=%TWVC[#Q
M.?A=>',T8JZS7#1VZV>6<T]<RI14=:1%IH63]$J+G%$SGHSAMS<3$3'3.!$O
M5(6#3U\4:]7F"&S2FGKX EUPQ(ABD&U@8#2=H=@;5V4U=6%,;HV'8@R)L^Q_
MC=RUB'@'=L#+" LMN)+$4#6[?#-OK\9O,IUU)S\-CY4IGIU)\&T.KCS.;[_6
M);Q+9,7@V1^/I)>6J5++=#[E!L*GNJZ@>CC5J\$WI!D;A5;A])<C,6'7=;(N
MK5RA0+%]V>'TF$5 [8W UGMNTY^.V\8@V"'U9=_\C"-910_MZ#EBJ(-6H!]7
MJ+X:MJKH&_7BT(?;"F+')S@.&W-R[K 18QV:3-):9\+H?'[X09&+Y,(2$F:B
M*[)6D%1R!1JH*5G5+QR?[LSO>__)</-2JAM?<Y[;IP3OJ9H$X9=?[YAD>EX0
M4T-P_7P;[!1CLI7=1_J^$%;OA-IUO<"W=-KBQ<3>G@\_LEZZQR2G9.R95MJ3
M'NM:X/[#O7D(SNW^1)BF2S,ZVW8!SX:GWA@Y%-)X9[Z[T=:I/^?TNF'$0X.4
M8T=ZLF^5\@D]RL\RT-.2W'*;P%)E-Q:52:VM(GLK&)6X._!#8">*4\T]]U+6
MK(;\6>_WA4M3U<,G7(0#'EH,_]CQ2_M,\KT3MU?A:E#Z<T-$D"P2363"N&=
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M\7.*Z9/0Q5):LK=]T'77E.,ZERY?FH'"'=$-1D6-MRXZT"[X/Z2Z90UY&[5
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MG2F0>)DL^FK(_,\"WKLZ):(IF1.G>[&6;"(W;D@&I]JQZTO/K7[X.9)SL;Q
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MA)<JK2%*PKJ$1!X;BR]*"?D[KMJ)RNA+OVE@?_7N%=<?:VY49>2$:1#Z M
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MSS4C>*S)'.P1](F9T2@BA6:$W3G)'4VOWZ] 96<<AO_1I] E -DN[7H)FMW
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M#JSB#M&<M7&#7EM.RR)([>[5_%M8+Q&U9>]A_KJLK&IME>5*B7L.'4_T?^-
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M/%*=U!E-]B!%U>3YAC>O%],V<,3+0L%%FR:)&?H4-4?#\I2R$*VRW8ABW?*
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M</]9B()XB*E-8HZJF&55WZ6<'$;P+.N7#A!M#>(OF;!8[1[?*PR?B48 N="
M*EK;:02.7+C?"P;?9,(84LV>3%@59J!N"#4[#6?"OJ'/0.!<H4]QF&A."#P?
M!$PW!CG!XXEN:[-6$<W)H?[,!8B-&+(V>E.^4)0)X\0<A\2ZB;/JW>D\AZ'6
MNS!AZBI-!IL1S8^ WB[QK=NH60(<^!8N\3]@_]4.P>:%8%^'T&\5=QBQP4:I
M/%J:P8;%@L(LLI*8L S=;AQ"V'>5";L2B+.VV2YU&?3&KOU^UV\0F[]J)6ZI
M+$,:;E;E [ZXI 0>^PW%R&2$(,A7D32Q 7;&7;N(\Q>8,%$<&I?S4D,%:-@+
MC,<^1]/NC4*;#2>  %;44=B=VHT9=!M%2)K9D,H&544E,&$YJ=<,@GU=EOZZ
MAQV4:@"6T6*!ZEC&87.0XW($>DA)8QK,<4- 9%/EC$.V+ZM<0I1XAW',:D76
M!B#7[V('FW<V6@.ZO1($N<B&!1DCN_EH,@C,)P]N\6Y(@$)D)"/C\^.V2=9R
MW(L;CYUD8\(.IJ0#1.<)DN\ZY&E$)8+"4A S,! S]+N1Y#(*JS:W?/SFYDX]
MRG>W.A\4WA\\W^M&G==/!GH)8HA9W$$FK/M*#$#,AZ!]@7\RA9C,"32<T0<F
M>%=5D;.>$(Q5RHE<)+$1.F#JR&XJ'((DPHF$^*&-PNZT-+^EI=)9E$BML*U&
M+56ESH&ICTZJ\A/#F;#/EZ/G<3^,G\YC&+3%0&A%-@6S$@]6G800H #F,'(C
M.]=\9W%FB"+)7X3@R+5+ ;^#J:?Y-Y>,=W*KQOQ3LA>2?^AT&5#G#70M0>M'
MLC,E68T!YS($JCQ.U6-6SGZD,F%8]DD)QD5[D$.;"=/,2 .(]A1V)BS)#SKD
M/F.%!,^&L%$-O^'();2GK+-Q8%VW6E=I><7#UUAZ:C.DC@395UHO? U;4,$E
M"(;\.+1,!Y\OGT2./P?(.H'7MN+*$/H!-A38)M#W#=(V,A%'$T=N"24\A\2$
M;H:#3E)K4ZP4,[Y-9.5*UZ:P'8:&"F/"INI1_4/(V9 #_@8;IUF _[P,?$=&
M;[!Z54!Z_,P$OE$N#7WAA+]DWZ"E0]*#'KSG'20]HV](,G9'>FN;ZQJ(X:'I
M+:X+!@S9%F"YAPGK Z&UD&Y_ F*H)ELV884K4 U-.['.X,GTW(I;13#.J0 L
M,G4@ G!DG9A=3%BP,9D).P%\':5 8DX*V_+:27\SH -7('WK=(0(H6%E-_TG
M7R:RDY,>Z@:?/V2-(Z,3UU%K$'#H.2&X\7C4JE,2.PAYYI#D<C- 8>C6/?D0
MMB8L;+<YJP=Q5FNS(16R#',*+'%#YZ*$>#";C-[B82 A- (@Z_J:D3BR Q,Z
MQ<5C5IVJX:  XC"PD<OJ/7,8:)!B9^"+GM)H.-(N,/ L=C ),C(W+Q V1>QP
MM <0![J!W%K(DOR!@P-$#/2$'X#X.N(O ID$IXG;;PD509@$^: A&_DN"\%*
M9!5_,$.7<D#0S'U9'(6H]TW';#9A@&T<&QGFB5M7EE&]=\#L!R%;/",05<'W
M:_Y&\P^@Z24+2\*J$QXB?0RBX0=+4)">[7D/D6[^#?A;4 K\FPL:B#FN -P/
M+\@:$9OXIY@P@X"_<'WU<'\RE@NZE"SS-Z[1*#()11,/V1*JW\$5!Z'*ZJ$&
M-)Q#_NROA9X2Y+9- '90AT6\Q]+?Q#_:6;7FD-9T2S7A:+;MN(TWC B(3( F
M_A(B\R?;#&D)@=[".P)$Z&BOR\V$*182F;"VEC$DLJM%87-* [D6#CT@;<PE
MJQ#:CH[4)U0RZB#Z[S)A1KZ7P5!]R*-NDK%BPKYNS@=J 4UAD .OGC./)4)D
M>NQ@Q<)5 &B01OX<\$0PI.I/ "O&J"(^0[#8'K(6ESNJ@:]-@CT#3%AB_374
MK-8^"-FS31@(V5K<+.(S(H8-W'\+8F"9,-!T#I*+&8W.$@N2V((CZZ(V%2(A
M'3U @"R,(:IP%0+ZD'V+:\6-<?$N S>S% -?0SQ'_HPE=C'.3Q$8'5,;Z_:3
MB8R+.) #VD<T2]\"1,L) NCX$\+Q"(0C$P8A"6=(!3S>7OD5W6HDU1.6]J]+
MF+#J*-EV,'5#M@HUBX3<Y&[Q)H!VKST -WOL,R(5R88;CR.\5YJ?HK#IT3+(
MSZE^9$(0XV&FA@=7<J%N'BWVMF*XCV#LA19[K+-0?%A'Z?';!+N5.P_$0KL_
M.FUQI8>-M]@\?#4;5J0D&-K2'V$B:LQKD?7HW6E\6,HM'9VS%?,I1<.CJ9U6
M<5./-([>*7E3PY9P9]JP/^7@/H%@GKC9JE:9S-QO01=U7.4B;N/=G<XJW7L6
M=J;(^-M_5)+EO\60BL+1GH[7R2Q:BJ@W^[EDC5SD:3A7(!:1^O2)VK[ <F-0
M &ABPC:%5C%T!JO#\I/+7Z18%A0#F28PN$X"9,*0V^V:?\W[->_7O%_S?LW[
M->_7O%_S?LW[_WK>1CT=5+-(W )N0\?E::S)O[\+N[N6TO8<SX3=\*(<>BXU
M=OO\^Y67DK;N^[<&U;BNMBGT!SM>&LTBNX&BJ=6!BQA6S;64\ZRW1Y*-V^^0
MH@R$?578,(>_<P$SE95;YW-[VU2Y8,])TBH>J=<)#&=\]49&1Z"MJZ5K#1:I
ML/[J%M5OKO3RGME 3)])>1LVBB$$5Q7MW;0I(#"<LIFP%W,-N%6Y&2;L#?2]
MI+JDWW43NGB.CJR:-V<YML82K/8955,4PO/?D*2,WN"+]!XJA).II.]ZPY^'
M [1SO+K&$IFP2'^CZL7Z5?F45+1I-KK:_MZ_O+0KDE9Y/%[ A'UJSW&76X=\
MGHG;?7,3A+W[CE)DD@FTK%4FK,C3R@?E)V0PVLTP'\ZIR<7_W>3DH2Z%K>$$
MQ'P.Q60F[+$N$]::AZ+=5&5'KER8P:WW96RT&'MU^.>[#P=62FKC+;Q0=,<1
MD^V7J442D#/\%/?3H1>YE O0^G4PAQF'T!M"\IVXL<1A\+69N=7@&A/&5;_<
M.;03,\L/0;T,W+L'0=.1[Z+/NH$*QD!C,UEBZY R:FL=<H^%TN>JV2IVFKZ0
M>$E*3UH]2(6RE91V"*M<)HQ<S("<'W4SB!N/]:!+[ZH7<5B:UWI45RD=5_1S
M<?M%@>YM(X86^3@[P]0"=97A 5!8Y("[(3<R'R*N'I+(A(F5#XC+?N&CO=/T
MI"J(%CU^[B -JW.$"7-%@0KZD%)%CR,@O</2%Z'O&H/ W*;S$J=J%R2Z$-2C
MT9R='].1!$E:3[S1M+SM>:C-J7][H\Y<-?V;R->_?WEY ,,3 +N $7"TPD6A
M@$U; VAVXK;N=DB!=(C[D6927K-ACG6Q0Y[+6FX[KY44&H#&=AH D6T7#Y'=
MP9*/*>TUF>[ A(55:B\QW#<QF[;JHYNXK[D2[2*7 [6\-!Y K"I510#?AC.9
M,(([$T;)0Q+M E0A'E1J0SR88O$@#-V(*\KQVWZE_/B!(T6)2(4S3),,IT$_
MW2T;/B:,=@L'A];8_1[<TB2&X?H,F)I>^[[H4'0,%'!CK<IC\ECZAL3.,OWG
MA;??%IVVHXWF&":LL>-_8 ^(00_V.D'#D!F[F#!^Z]AO0#ODAD]X\HH-A\^O
MT;O'NF\C&.<@'D.^N<(,<GT#PF(402X%$4S8MT$6,=.LZ7P^<:S7"IQ((A.V
M=<C/8 L$0"6M?W<C[->T7]-^3?LU[=>T_X.G6?I)A*LHD2[)G/JV%GY%7]=$
M6X:G?^CKV9.2$1NF'^_N1ZC_+G+H?Q$%Y\OL]9QY\UDZ**Y$:>R1])\^;OGR
MMFB2(V9(V7R+31XZENZN8&UK:1HP:"^[-X-:/=@+[;\'AJ']O'LK-@OX=@':
MZ#]*N8%*%GPW]@%4?6@G_+T#.JG""G'0[O8+S"\PO\#\ O,+S"\PO\#\ O/_
M&HP2_=@U)NRM63(3]D01QW J>_?V(&'>!0$^M7 #8?CMMP'%9<#F7D<<C<V9
M"6O-UPF#=8"MW9"SSY_-A(T?PC)A0AGT8UK_3Z#T(/\%2!;8U@/\%,P!QODK
MH:^%0F?8+M,1VA!<ZQ0(KAF!X82>?RP!/O7S 7=9 I2\[O2GM[Q1@XSS](BE
M?_P#6;R*V=P[0Z#M=6$]2S-LGSU@,X-<Y>S%[3#&< N=R81]D]7?X8R"A?R-
M?3Y4U5B(,W67=SC3C_B^:;"U>W5IA[^F&1!__VN W'/\;X()I"Z.ZMFO<]!T
M=]8U$^"?VC,0Q+<+\T\-TOHWVN-@^/M1)NR?FNCY"\PO,+_ _ +S"\S_+F"\
M5 2\O;.2\ /XD:I=7P]K<#Q0WB>7GL#V_E*;4ZD&C,_PU_@U?HU?XY\#8 []
M7U!+ P04    " !(@6-:';P60']Q   Z<@  $@   &EM9S$S-C,P-34U-U\Q
M+FIP9YRZ951<0=?GVT"@(3@$]^#N[I"@P0DNP4*@<7<-#HT%" 0-'J2#-.[6
M$ ($#Q"TD>#=:..3YUWOS-R[UGR8>_>I_:GJU*I?[3JU_WNM\_3[:0- I*&B
MK@) 0T,#O/OW )Y6 ,H #'3T_[1_]NQ?P\3&Q'SV#/,Y$(B%C?<<#P_W.2XN
M/@$)$3X!,0$N+A$Y$3'I"S(R,CQ""DKR%Y0D+\A>_&<2-(Q_[SS#Q,'$Q'F!
MCXO_XO^S/?4!B+$!K6B[&&@O >C$:!C$:$]#  8   T3[;\,\-^&AOYOC5A
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M![!A8QI%DJJ-2SUU8.()FY)RE,(H4WBYYWMD\GO%=C\2@3Z[L[)H_3$'O#\
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M8?K"^;=WSW\BC8?H2 =X&@Z,G\]\_S&0WWXO/Q(ATSGP!&C*F/@VL R]K4_
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MKG*?P@V+T]8^@2QP:57[FL@/='L"R1!3B)"^>$Y5^_YSV:[ N-6XY)#O/@V
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MA*O<S&5(E+">6.%(K1*QXD<7#=EQ0LN)33/I!04,64H@!)N.W# 1IVCK%N?
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MG4!2R?TF6Q#L,*I<,5Y772C&=&JIMHGGM5W;58*?SV(Q&-["S/JWN$HF,,7
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MLFPEHFC\IP'I9;"KC^U:DT)!2]J70PH%C__N@O9PXA7P(^ 8J"=F%C?4-SL
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MEZ^$[K>,>?O]^T)DB$=A#>-9J*RJC[;,3',F:383RL?BIPX\)M?!D]&B*#E
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MT#S;)TJZ#YETGNWI@!Q!2= _5U$&8EQ5@(I9:!+Q.,WM70T-'_MK!7YHN3X
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M$%:N^K HXWKA@0UJADGC<$S+O*S%ZZ:'9:HW-YE0]R%;RV6E-4XB9XPL"O7
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MV3)1BN90Y4';;B-JCMY7"LQ%].ATM>9AP\MN=1X>%T?'R;+*=QFYN?VAN4-
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M#AD"'=JC>FUG5P2_? MT8^X,<[H7!N+=81E1=!-@#45KNUFTBY,0E><X=R"
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M=/>N\-VO'MQOR)53O[('^\4"T_8^N?CUR*X'8D?95'(N(CE7=\V*)<G1X>?
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MRH4/#GZ9_@"6V@(A":*X$\ ZUP@'FL89,PZ8]](:ITJ9=D;=]_H>-MLI]6P
M2M9I;A/*T^D1GMFV0W==3/50=;@/")%0A"GAK2W4@.<$>+)("UN@GI%'A4K0
M74 &]PJ/P-)=W0)5\&Q3YS6K:7%4L41%),^9T2DB'XLV9T0%GA"^]O%F^QXU
MW9,R()D$"YPF6XR#WL:F6UL@0%V,)_''*H>3 "RRQWNHM 3\6>L#Q'[X(7=L
MC]O'<*[N[HNY%=7%*VPWM_E9Y.:G:]-R1TO0ML@2R5D(WM?RE;F8<']A3;HC
M,:'@K YZ8+1<7=W8PD.S0+F$&K*8CM0,=49M) 7'>"Y67CA3U#X$1KL<6FQ
M-C.UQ_[<S9CV))RK/EPGJAQB0IKWL[QFNG'N6/"(_L>:-UDNU_32=QR[N> O
ME%RXYU[A;H(IK0G1&TSBN?(KSO$;MT"WUP@,_^ZF*3!].AIV(RT^]^>VF!0L
M?OPE,_F+< #G,[&F7STG1NG2[FA/"8)X;,:5>2CHW-6^+'[;5\:7@4D%-_JO
M'5HH DX4S.>P_UUONAOBS'4CIHA11@[A#.(&/Z]\],1)D2=_JS2-_=ZG$\:-
M&DJ:5=?YA6Z]GB$XM&;_!67XRMJ@ ^G\^TA(M\^8NK7UP*"4TM#0!><?&8F9
MXS'*)"ET.9KB$'@_R"C]2T9PL,U8]->OE7(>5)>DK[D1&/I<I:H4]^NU_TZ9
M[R_^Y'>%0G_\6\3RTA^APQ072XWE=SU5+S5ZEO?MPAOPMH>)L-#?;V?*^<N>
M7MV+YF+P$X[X#Q[3;W3%!*/3N77%3 78%8#F5S= @M.KT_9]!Q\FCJ4(DNAF
MCF%RS20D)N!66[I^4Z+;E<;X,<+VL&\KJ"QD-VM=(!+*@O71FH3<SW/EL;P
MF# 924N=<L"V>["L'O&<%X80$GUWV2#/\A;>R4@?J?;"@+ K'Y/RQCA3'S).
M[;O*BG!-";B*:T2Y7RC!?V@LW3=0Y_(W\YN4FM6SLA_YS1IG\YK+[1ULG(]'
MJAF,V.O8X6RM9)O+J*XN$9_YK0'EYXXPGTIUK9P^'4U[=&YO*K;,K>S.^Z?M
M57S&B_<R?,8.(3;I:RC=:GO)YNGS*\@WU/%B^(^P%M4^FHA@M$BR#BJ'"VSC
M5_-DZI#@?0+E3\L"V=>3M9!(5HK!&O@RYL#RT^7FZO 2]Z7G%W!FIR]6*P<_
MN[GYC5X4+]##TVB-NFOA3#,XIP3XQI)\ V[0I0R;+QB]&8DG[S+@ZAY 6CFP
MXI[N*:W!F0-/,5'$>7)2DX+_U=>'"+X^?^_=&6.@+4S]=(ZR'"MF"RY1<HD?
MOM+UI]?-TI.(0>C6Y;80'7__'QE''0LRD0/#(QE9-H: E)5.%'50^VYK0%83
M#&537U!34[;PX/RNZ(\+R3]GIYLT^Y6Q/Y7"WKV;KVE5++US!&PC\-,'S^9P
M8@'7;41H8ADED+8];G\?3%YP"C\S#^$7%C'U-W?-Z[/[XWBG:>(&40K^O8IB
MK)1,B6UMR8V,;QQ88.%C,8>?NOMX67"PBUP3E2B9U0+V>)^/,+\>?Q!W"K!F
M%LV.,]/>%*7(P9+U=9/!K&G$?AX2*=8#5@BX9[M2* U$T]/DT%U'1YFC-1 +
ML^;2,G2A0@1:]75N'QV;KW5U,6<R&364JSLS6./KI^->91B:8U K6KVA[C[H
M$#S&OIUZ.K_<3FV(EG+R!Q/+#3Q6&_%E')U+M3"M7L%\ETO<>YZ:N&#2G:CV
M?.?_U0X:]1$V#D4+WG**!FW4V A>S+4MT,O[Q(WTQ'E378N_.V8<+*0>[/Z_
M<CC_WW;(R^(;==XSCAI4@ZGI89H>6,SGE%PX^RYYN".UYO## =(08<>_ZX+"
MTW;S#O$?0<6MV:&7)X)@-\A4!8$)RH2'EVEMB6:H5".PRRPLBC) *O@EGXP=
M4#*)V?"V*C";'> #PIMY%FC[)ALDY8#RE[)Q:^Z@U+'"2G)<V?0';MF$??[)
M\?1VZS[45.J5/(_(K+.PK+:&+R0)P?N<KF/\5H$D_M,04]/3VY1>]!9\%'<L
M[\V!LB%MSJM@YH&((?<T1)*G9(WTDT\JQ2U1JLT1!?F7E*^\AIHNP#_!KK+\
M5UNYOH(/&+:I_00&AB(?Y86Q4]*2G'I:Q#V $[#D)Q!IZOVOV4%4N^L\" +W
ML\?@==?;?4]OD2V^5[R2NNHKI3*TV\XBI-_",J02[NF],>AXKQ/C'Y9%_#3^
M-61QLK6EFAN<[#==%7-?.[SRKQ]3%U"=[I-7$.+HL!%O=*DR5H OUQ*_;6_V
M,@#5"H#9*P IG@$BV:)O706RXQTPAJ>=Y]LQA.<\TLBHQ>2V26%>%!H[3HV+
MLLZ]JF&E\ISP5K]+:POD+Y@_P[/F5UX#BIBP6>)"W5/62B]>BPS@<H_Z[&<'
M%=#7K'JB7<?"O&%7#,FLV$_(/]F<3:/X$S>[XDQ=T-4SY<_R\9T.'EJWCFNJ
M]WLOKB[]G'%VSKS[U[C5V?E#*=ZSN390>+-I._)4%T>@GER8']Y91=%?+'QP
M>M;IYS03L6I0R?/B)^%%\0-7<#8O/V($D@C>GLZB?B<L/FK6[ Y.9B)L=N4_
MQFCZLG'-R&.+:"LAL_=%UT['$8QNB;W$A?'S,-#3N'!^FN"T)] UW<.AU4^G
M0OR8HNMB=N5#]V$IOFQ$]'CWZ"</A/*H59GUM65,X=W2@EL7CHD0=1'.#NY5
MOYUKM0N0NA&FTX]B75NHB=8$'7;#!,D7CH@,MS;SZ:)X3?P_O+U75%-=]/8;
M7U! !*1W4.E=>B>6%S @O=>H2)?> @2B4J5*5UI4>A=(Z$6Z]-YK$HHT2:@!
M0OAXSS@7WSC?N?B?F[/'6#=[C-WG?-;SVVOO-2^.@[;;K> LT-M7*1Y$2JC"
MC>;=]L*4 6FU+[4);OA]7-"H<9A&9B>0K .7I6M%&7)G9_XOGYNI!PWCD6/K
MIS5MK'^^%VTFKA^X!E="P+$OG=K7<I^C"[-E(43.1?Q]@JD:6X.2<SH-70^:
MI"3QWM5/Z\!W25>?K4+J'WYY85Z\ 'M97%@MF]K8>'**V 6G [OSLYT'ENK.
MC%PS4"%&/X/OFFYLC#_SW1^6^.BF*+)R@4"VSFHD#DO$ JNY>R=Q*:C5?<9+
MT=#Q!;(.<&P3S:\*FALNCX3Z8>?5>/#RO43R,;[:EHD3'7EMMV>]NUT7IU]+
MK(8#:!-0%0<\R8+NS+YN?,9X]AL1W)LF<A'XKQJ(M 0S/*Z4\!9Q58?48W A
M\N$*^B+7QE2,\G:X%+'6N4PXD^DAN:/^PJ5/$GSR3:H%F58=KU\SR(FU3@W
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M(R:W"!(WP+-]89H77!#ZJSZ=W'I^%/?EA8DV UT?"M,0QW6W=[!7]X4"1I;
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M&DJPF!:1LGGP3I!F#%2ZS#E3>Y"IHL0YB)A2/.=L^*1@2T?W<.30-?A.Q*U
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MIZ 8>81KWC^0 4#_ 5@)J!X**CVR9G9NCYO?RUCL.U(;U8@WLD_GS^+\M6T
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M?4X'? 8P6@,37:IV.EM3+]V)%TEMDG]VKZTDQ86 <F.#*M>5X@G/XI] >9J
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MV79$7++#511H$@OC- /\Z6^=,"6')^50\'_-G0N'5?ICGSZ*2R=X/TA+(@=
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M6%"X"V01(-R-$-PW?8 $<%C3=4";XV"?9JK*$5Q@*SMEZL73[>_XD8RE9BF
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M).I2LP"IF&\G4S1K4G0T2F@Q7VMMFV_Y$C_Q,Y9]PL_2(W;NODU\LU,OT__
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M[W_:!T,FHY!@%+ '?G?1:AFBCXKN';^W;+ED;_=W&>+9G<_]YV /+O><SCW
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M<BXZ/\@HF4P2G1"57ZPY7[H4'Z(DRO\CA7KR5D#H@GWCJ_A<SCIX_V@W9'=
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M$#:>6AAW8^4^IU$(ZJ-/]RYR\1*6ZW(QU;OW2/ 1*K<N2L14^,VW=8B%EO"
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MGZ"%%.-?$<EUX,\X7Q'I6E-]SK!NE%LZ.HQ.-S$8[;;/UI5P89,]Q%:UV_+
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MBCVRYJ?NS4U6VMP]V4P$!?0EVZ^0!7ZH3/DVKJ9WLJ5MISB^G8W$^L>YJ.4
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M(Y"H[(=;+Z&QWF9KW37 <4;WS%$4J=!G,*OW!'8[1RKI5PI"13 J%+@8#;E
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M71'A"$IR0<;1]'4N2(CMR 4EV'U><#?X^>!V.V[Z?$YED'#>HN+[E6 [ OX
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MI(-%II:\>JQJ?*-3S</RJ5TYVNT#X,1\Q%/^5_3/80@$_L_KD="]7)#[^F0
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MP]GDZH'Y"Y]*%A_:U'FN82>F(C.R'W>78=?^^#AKGL]TFMI*]DJSJ,CWX*2
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M$M"R"VG8Y0[%25X<%7>@ITKNI3IIR2%G): ]8^5ZSI)__;739>.L$"31(:/
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MUT2_DPE)OI>MZW"N@JR=VK/5E)3RE;L1MUZG/0!MW>:OR7>#(W&FB?' ;O\
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M+"^;EAEH!-L(O>9?,&_M5=WB3\@CF*G"!L>#@BS; G4Z6O-//%OBB.;C44:
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M)V<AB.')R<U"@;TLQUQ#F_FK!R/G?EZ!OO:3B&'-\=>T-$/C+4=7>U]:0O'
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M(E.&::NZ/-C(RNTAH3XOU^>EY+.EIA]LE]M,O39[H;=OY<:MVD%,'UW!.:(
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M;HCU,^/F;D 6.(_1*5\Y,HYH:IKE[%5U>OE1SXOK[2MI4$RU4#_IT%>'JVK
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M#[RT:B6)%]A+7-HV+T[!-AT; V(?&YTP9_@(+8 :9U_E_Y>YSFUD$^,V$"<
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M7(V7H(AC^U,)?(GM]>=Y&>8M*C8YC[UA-[E_'-#:R(>+*'Z2]6GQ26Q@,]A
M#K5GWH3Z$W59H7_*?QV_\I^ 1/7^GK.K&X"IPTTZXQ' U2ZZ>>SR:_G ?=.
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M63%<W^>$S87@O;W40KCSWD]GSCK#8[, ]CT)T8Y2]JYL@O+77$_;[K.H.&)
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M>[^F(SG\H_Q_ROGN@['N;!'\I.,8L@E17)V 3/'O9QCT96-P,S3_0I2FTPZ
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MTOTE2];BE(GA]'IDD@R!-B@<<C@>&0H<NKLL>1Z6AU"]ZXME8O8SN,N'Z)D
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M:5^^_>[BZ^L]5U_^>3]0IK3N5UJ!6L@YU5XD%6GRW !2J'B1@?2@QP2CK@#
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M16]&+"&H2=,(\LV6;\R-2>M57\;Z7:7<B!A&DN-<Q*OXH]JS@G!\*@LSNN
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M5A;FBXO+8WX!?J)&<\W-DVIR V/])WPZYLL]%!T-FJ)5=0-4SE-JK#S/,IZ
MCL ;G#B&5&0>#/\0@]%&>B3B!,LM8#W*71Q__DLTH[5_".^10\(1VQ^^O1&L
M"J5UMD%N\PMUZ&)H7W6T%?3KK>=ELV-_-_YTC-204S8U_8H3"A%)VL'#U"_
M'V -\T,*2[9#;2I]P,4KA'9BEP#VTJ(=WC"-D]@  ]?W [K<1O]Z:83P5RE/
MJ-63P$+*G>'B9B%MD>_BRI)-HRY!-X![6[>:3Y3]$]8%:8RCRD2VQ#X(8];:
MN0C"BH2.>M9+!R7OYHM@"T3-64_JHW0:T/GYFVVC+F1M5"%?N[WDQ6 ]:K"-
MZ&[T2UCDOZ0>6 0-B%3T&(3U7CX8VI XV"_9E>?"%E>Y$+N7B&.3D C9/LWV
MO"D1& R51#Y:OGR+6SG/B>_<$6_2FFA3R)O <L)P].48QR&O77F%6X45@S,
M?S0C27+S[[[716FYBW^*.3_L>IWDAO1@U&2>B)(5=4C(X.8_<W'S_T=$H^/^
M]"G=+6OAQ:Z_=6]$K*,]5/IVT(Z1_%VT4#',V3_]I[>!CI$NE!4_:269T@OB
MTD"NFEB 72YLMF'<G*T8?WCA[M8VI?FRK)?P$,X2UJ/4O;$/QG(1'H9S=&_
M%O$G@@NG&R7%]Y8\IT-!8+'+@03G7B._]//UF!1%CZ#BSM5V/KU%K/*T\N.:
M<]I+QM&D;:#IW'DM^5YFVWJT7XB^U5P3]]J^[NQYSE6GOD%WZZ>,%.2E3E?&
MN_;R31O3[7P(F[>: \=[A>IN+%<MCGGUR@D_5>=2 +P!V(X] "X2(D)6?Z&5
MD/N,/V65,*-F4]WOF%P48M@^_LE__"YZU2H0)V++CGL3F^P2 >WC/ E >3 '
M3B.-8\5@C-!7&,=HG!>*-/3(_-"C_[_*[I/"+&?=M_V#.+MFQ63B<D:C^(8\
MLD3N63R[_X+*N_$_>TI?!<-ZY&&;O0HV$U?BH'#8OXA=O_,M:-1_]ZEZ>!VG
M<+ 02GH#V*,MGI]/ ^@J4?W_L3M#_W&LF>L_2G8;81:#!7\.PBC_AJI>RB1A
M+POP+:.W("3FF:FPO_DOZ?J><8#7#8#E] 8P3P\[>U!#L7,-+="]O2/VQT)8
M+->7N_]M0 0,#[1)5, :W[J>P5N$!F$X^P-)ULS^#MZ?/LRS%D8%Q8!W3&*X
M:C0 1!S=$UW=OS5N'R# 4Z\?"-\&NEY=#)OC\I7XS/S?BRG=V,X4BXEL(S4K
M(_6CY7:VFO-ZRYCXIV3N)H.R)SZ9?'K;.6I2ZL-6FFRY><MJ+E\,MXQ8@[E(
MRKH%1/(7"=LEGB2-9A=:-:!/?[05Q)[+2+YMS#>_L]6TM1$SEM?H#F"!]O@K
M#]0_0#[W"=<WIE0A5*X1:!9(I*!Z5CQFNB3&F*).)(I<]O?(<FIJFQFE3.A[
MRV58&U<=^34R0LJ@4I_2B,JF4&OBTH\-%5S=KE]*LZHFV@I6P0EB(<B)N'P)
M]%!?-P'DN!R;.9 YUZ:5Y?"\PL.]^ 3YJA]Q1_"4XE5B:9C+(IXO=#A?&JN"
M#-'_824NGF$E-EF[.>UQUE)CY.7H14$$^F7G\*KHL7 5X ^9BARX[P9 &1BP
M 8[=F?6-&XT3I(&8?:38I;W0"_TW2]V3[V)ZAY3I_5W#GA'4UF#@'WD9J&8S
MAG\1PUS3*M]:AHUO+JQPD6C(.A?QX4&J<N2_FJ+1TT*U>Q'*$8((8R<DL[M"
M(B(?I L>F"WP3$<X:@EX#W!L28^[*:SPZ*0]:XIW-E/%Y3Q'RDL,>;D;:W#T
M3F4^LJV/:9-LM3\/J3J%V%CS\)3PD(F63Z??/RA4]MWA26>KYEW/1$2?<2>6
M^Q4-T>?O$5F1O'ZYRD9/49&_I\I&GOMAK>GI;[\Q^0-1]JJ=1]1(&^^*'_&Y
MGOV4R4.$3/JV+A^0]PHT(?G;D%DD=][$4X\UFL$@MM,)V4T6EWV%NSB9MAD!
MQ.SY11!;P0CL::IW.MW/P96W\?'YN1OS*XB5/</B,</?1>BSBM$EB *$'2()
MI[NJ9IOGSP[07+G28D/R!+%0Y/-TE$T;0I2++>3L:1\:QK=RJOM6^$B:>5IM
M:;KG=.8E":"U>Y) V+U_XA\D7A45R/OZQT?2<>Z@<@F&%*>9&/Z%O[Y.<OUF
MZ$&Y#^0;(#B(%+=[$40>/CB[!\!;$LZN :<S52=MK_AT>ZC<\_6+7.@--FR]
MR_BDZ%>GVE%N 6YT*1";_FB[NQMA#D:;#WLV4T3B \[%]F1W)-*)WG+9<FH3
MC2\5/SJ-YYC2R-?1W_+(&#D4KTJ?4D@-A ^Q<%3&]2.\<9I,]1%2WI.!P>1%
M16DU%2\G+]SG(1!>7DNV+<>3T]"1 J";JW7@KY3&EE>/'O<EY<AW7$XP:WJ9
MW0 .RA&@!B)7=X?&?$Z85#'A=KP@ 1LJGL1K@OZ\%EY=HI$N7LNDL15F^'.Y
M/:CG'D (+DEW )S+N%2),OQ>H)ZH89?WUC/^,"[+0S'TB*M'M@].VG$Q,=<1
MVU"KKF90?DBID0?.INFP2YM=\H>H3QSR'M5 E<%(.!T"HU.%S0B,T5SMRVXO
M6Z[W,B[W^Y5CK&$X-0S*D.!&=D>^_7,+V:)+8IW'^1C>[M2G]^#C[]^_8#WZ
MSLJY,I^TBE/#*,%C_#3UI+27SIV6EG89GAF\"#SYG;M!3=^+VM^_!/=[/%AI
MFAW(:FY*-  +[,Z]EO<-9_]\VBAT""\M#<:"!_&T;<W=N:^9KO,M[NF]),X/
MM1[F3(Z'AW:V%&:^W9\IOP5+5NFVF<R&HAU>;_8Q 4-N^<IL;US2GL"]B?K<
MDX*Y.I%BX^?]KX2'C#,H\GBF*T6O_\YX7:27.HEN<5OQ"'5.M^[B@=BO[UP*
M![X,06QEP6ZTWEJ3@I_'NX7N72[TGW/>"ZB95L*\9JB&)[B?:^KZ[A]J:Z;,
M#>JRG&X/POR8A&V]I0   W1POA>8>_?3GG@#B$M47>.^_@\2[/"]6K;-<S:?
M7:M4Q)6<NFI"5 8GA,-4ZZ#];C\307Q-"!4J.?;T^PIGQLPO&H[&::NIL*V/
MUESC9-Y:\0B/2.UTM>*1^?Y#WTZFY:<CW(@ZPSD!JI#J8 %U4>ZQV02&Y'*N
M$6C7IEW.=NRE0XI>W);J/U[$K1(MH(0*H+=&(9_XJW_AF;O0%U_])[^VSOJ.
MJ0I/W!]>"AA$U/N< D+/0]*ON' A\[+6&Y8B&T/Q.$-9A8<H3&1,0%F@V$(<
MMVWG# 5C&IRIBG1+?5#\AQ1;*I@$2.R2$??,:I?"TDS3@81>D6,H.9!>YCL1
M*N7AA+4NI!G\N$,.XB>>5-*5Y6[&F=9S!T*/^%N](%W.]6?A26KR>VW)VC.-
MR*TST_(?K82/O** B.>?[?LL%!7)S0G[_HH[#E @#T8%:]4C'16E!JV=;3UG
M3E8,_ACUGM@4\E"EJU-9L.JIX94&.[A[5^P_C#\/72:-^(4)/) 7(<B9+8WJ
MM_'\'"_.4,.0[BKW7QU?.UB-/ N-<A+,GN<B:.E:P8?K6)[;^70#0',BM ?;
MD^[@R%*F]="ET;+LA=A(.OX:?1T8\;Z@<Q*;9@BC$(0Y*_Y[!JC]4Z' "P)T
MH=Y4C>CH,%\)UU3_JU;%DTJ*P.$#H=SY.7EQC&#23GUWQWP^?OMH;V=< BXP
M9?GVBPJ+W<>?.ER]7R3I_DC/CQK/>P24#;,V.)@J:ME-9!?9^I"?;=Y'<2:/
MP?([9))16 _^2(V$(6VQ(#^S!:B\+;=!WAMW&N$;@&-E='K03#G#9/&HYJ A
MC]J)A-2(<>IU0$\HTWB+?EA]?)(X\M&*2NSH=]%RFU,^\YS*SS:MQ5 C9JV:
M9T5.^M^^1J:4&_GQ&!15J.OE5FB!EVAQ#+?"X9XC.FE F^&/ EHW:6D6R@WJ
M\R#8]X;UB>&>8ZR^?FVXE4[C63SEV)S*/W"XFPC6L9?VRQ BSGSYM:5C__>\
MEQ3FFLS0&\ 9+*[?"I1O$$8:H)(-(5M Q.G7IQB[:\TD< H, =!?\DEAX7O8
M'</)XFG^,VVFP-ZIM3G)C[H+V#BS.@UZVD\9R69KO1EE\3Z@E/+&E!?4H5<H
MT" QXT+-64$\F.I;ML+Z2Q_:?D&:XG[^E#N)"#]K'LE[&X7AP]N=U[#:D]W+
MAO.?!MXI\5]0'#FSID[IAR'G_@J-VECI??PCQAO ??GK@F[(GVX'("GT;1=6
MXXH=IX*F247!HB0*B)X4],IS8F8_1OO":)U"13&SQ7TN\RE_0ED;6E2F&MO'
M>'XL6BYHR-*RO*/$\5I96>[1&DO,7QK3SL-31WT"@H)DX1+&QB*M*2YQ.3%9
MV_E!10Y!]NE+:LQQ,C1L\^8H4 R(O.M)9RKT!>8R >K%D=&@4@*/E]6OP::?
M;;;8NWRLDYZ]WFTT720O,?>A2T_6B.1YB"P3?\3U[?W_VQ26I_%$M\*.@_R*
M!K;X'7?[9C."&K6UO)L*6,X)W&>5 ],;@$,?VN,&H-,IT-7Q_VB]_U,CDQDH
M.*$(Q_?,P?X13ZK\QX_8\,31R5#E6S8:/5%I_9_7U]O;_R=]:O2@_W]=WH>1
MPM#!AZVIB*@#)9^6.V[(]6BAM!YVW+4PY:=@TBZPG$^!\PU WNA5RS"AP@;P
MO/:,[1;9YF";*?B!@@NIP)T;@&8<>*=;4 D'.Z/Z<O<A='NYXVG/X$LI2=FW
MWO*=#US^25TG9FZL]X$7])$<>1C.OG^JLZ$<H]\L(2Q/4P^F76A^[Q[CTVGR
M?[V9VW[CSE,<HAEZ#\J'-KP!] -I3+!@[1/6C'/<L'N-O<D3.!S^0,URRQWP
MQ/=(Q&H6Z4'I'$HRK]_C@PT+L7TYM9&_]/!M:_*!=3I>14C9HD3B+O4,02[Y
M0"@$J4VFG> 9%$!F[2/KH"]I\_4SRDN2Y]S)()\EOEJK0$Z")C7]NH@IS5[;
MJ'$>XT$O*1S*]M:[!MB+H1%DRV/R9XQN8&CAGOUJO+?HY[!KO:H. S7F&JSP
M'=,O+5F,8^<+_ZBAY/0-T99]JQ"1/1!&,&C1[(3N-[5JT9NWD7L^EZV$8GT:
MA<ZTS:\66(?\^]7WP@.R>%$/RR<5$^D2<VV[@LQ7'0PZ D[]^6@Y3+[]S2IF
MC!S;W/&2ZLV0BZ'_4?M%GF'W,AO_];HPA+*/]_/K)T\2GP<N+&N3$+*A6G>6
M]] F;[0(",-[QWVJF00H)%7GT[;DG7VGME-2.W?'O?2W-,O5M0X+],VJW1F'
MGS>4FV4(![J*2?NZS(7IQY</RM8\TL)LJO-KK#;6<E:^6</:HGLE,Y8-9JLW
M-2+>VJK= ?/M;/,!&.-LB7?_9E\9]_[SZXQ[D>!V\;&5F^Y5"\>3ECL2)"2/
MB5CA4CU5@L _/M^&G)D%'@/%MSWX37CB:0!D400$S'^1G;%#5Z)W'BM_4O&@
M:XKG3GRQ_/TJUUM9:O_G[E([I"+=+MU1.L:,>R:UH-UOI);7;,IMURYE:N0G
MWA+5)32XX[>O6VU5=(B>3C=MD5*O-M7ZG;;%".?(K3KF6/9>:7V:,2<CHZJN
M25*SP2;(R,>HA=BY,^\$8%X)SCYP+<J&";R+GD),WM,M"O?F$+YS,JCZ8X>5
M*6"[)>YUW8<W&;^_![$[D=@O_S)ENCY(O129WNJY=VI)G5@LGBX;0"&LS>9:
MU\'S_+E//-F+P2!W_ IJJESK>5&A%@_EJCK/5'.<<I.:>?MLI_9 W5&UJF$>
M@[J?K9*2OJYWH[F;@5NI@.^RR^@D,Z^S4<84?W?JO4B2UJQG3R9:[+\\C6(,
M J #97?$)E8ZC ,T?>D&ZI?TN>@2>OB@U8DM;T>>$]&Q^<EF%YC/W0":V5-.
MN/@/UA[$"-A85A"-4Z=++J@.GHBTLUVB*/5GJHO">$'B<XIB@\,"3U8B'QMS
M<#YYW']&OP,O>69@L/N2ZVKN>JN@D^.\H[W)T=WE^.NV_<*;U\Q,BNWI*YO9
M[FJG7#T^,I+[?N]DO/]:_O5O+S$?#1!II*5LKQM4I+O\_M1.V-O$D5E+ZGPL
MD#!&GO'-9:JP],@EIX_\ZK+]Q.C=#_FM@P<LGB$N>QYG,9K;@Z2/XPYTOX)6
M!T%U]][B%H]W+8J:Z_FVD:K#)JJ)S[UID*YOGW-6"C(ERFD&-7'/%M-+[D\6
MP]*/&K4=W]5V@^<#W\5@LOS4W44J"GDMVU*C&C8#4I/XFIVU#L4JZIM6\>P8
MSO"MZ9'K;_SU0WG?GQVR1T$3M52/AW2$--&YU24KQ)'-@<5JA8P/^5OLO$Z]
M<B^N W?VCBD#>5 Z3K7]RB\,\U5-FSL<R[V#1L*G:^F&X )=A%$':(M1(E[1
MCSPEU/ :]>^2PX#\TEHX![S/UI#.:EP$X@+R*ZEV^E,SI:$AY@*V!,XX><WP
MVM<76S4&56IYN0U+J9D*AKIUV:6E-&5O!ZPN'.)DD&KWVW(J;7G7OI!7<MFK
MOGCZ*NPAB63/'IFGS_3WJ6./DKKVYH8&B<>COLA#<H,@IPJI3RT_GS#EM8Q+
M;G_'R14K4KQ@3M-^]-XVE<7L/=E+G\FZI,Q(N0;+@7@UN^F.^YNQ2(Z$BSJ=
M>O&7-IW1*$)"R0DY7NF%D?2T5&]='WT8J&-*37QYSFCNL+VHC?7$=:18+"'/
M6;^8F9UM*=XM5(77U'+-DCI[;?XW&D@?R ^U\'@C5.2YW,?QXK[ADE#"<O"F
M+6&#WV5MEJPVFLBZV=1M[:GO[HYZ1SD/BCMRZ%X\)I<,-_\GZ4*D[ZGYMWVJ
M26H1E<>+PE+#%B2/49*<K3O90S,=G#0U74J=C6./2GK$UTP$O%N?2'@-:1?[
MS S,9_(+0L0TS72\<E.,==N,G,<UVRN/,H7GAJ8\)V*R$E6X$#-[7&-7DZ5F
MNMO;:6#1-!!O0LTJRN%Z)V1B"/88*Z+W>PO"'A5,*'2'QFXY42)CT^[MIF<P
M.I@AGQF]UH#,29_V=3%N:^/;2E2O(A^,6$G^\0.0FNNSGWU-CE'H,Y=RR)]\
M*C0X+)&W76,A'1[S.#E]POOA! (LRA$#0Z.,VV<.?@T[\JPHSWMQ>[!)/W_:
MLJ<L]/.GG,^8,V:66S^)1S\[S3:(=]>W:&O*C.-X\KCX\%JD;^V9M0^46MJW
M.,KD7T%[4I-NZFR/@=4)7-2@M9"7([LI^=2]N&@% O=96E->LW/]^4MY19H"
MJ-UQAXXS>TB2@-'[I93LV4'P!A/,BK<5P[XUWA LL!-SN&:R^:DCVI#=T(9&
M]T>/WW[BM<]RG-T/=JV7/R= 0O0LV#\A0H=6-=3J32 W,T_=B+1T>4/Q]7:@
MEUQN]O8[<X/%?RP,C7LZQ0P=-1UBN>5%*'9>\VR-@'=%S=HJ7\*>O9!Y#KR5
M#_OZIH8O?]*S?,RED,'+!H?ZE=K:\I\-NU'Y6(P)KL0"3&J["3B9WP_+HVH;
M%J&B[>B=CU#CFL#NES-?:=>8WL&(;,;!!2:I.G5I5BNR7V5;GGZ/1/-^\9Y2
MKY#>Q*!\^ 3 P]KD9@7P6FD#--8,FM(_EV?V/4Q':\KKHT6E84"CTW2ES**H
MMT-6%Y#;P#:N7S>PRA J1R)^-^WK>=MTK54Z&T*S*5 OOMBJ0=-;I]2H<$I@
M[8X2E3%D[S_:X!WN_L\KA.DG(!SE#OX-ZP7?#:#!&BMQ RBSR@1;_<>JX_^)
M$3+_1T._PO]5O9D/V?_I9J7':6_]95TY4D"MP?ZA!/'O9WLM;@"UJ7L*9^26
MJ_]SS40"F_\0H5$PK)SNZW4BF*T79?^)"18^2+GZB@TL3R?(9\4(66(Z?CPJ
M*ORZWA:23!\\__> AK-\7#JT8(/W^I'"QKDI@^!'6-VW07+Y>120GGV:SXD]
M7\9-=MB#*>7PE('++D5%==35V+M'D4+[[[X156C#6/2_OB\;^]T5[ZAUU:P[
MTQGY5&0@\Q?X5;C6S'5J4?5XR;HXLZT4!FP6Z*B)-/]Q;25F*Q9^0<579S6E
MI]=_[;C//W([P]_^$;#RT^W4Y#2?]>4M:-JE;5BP..3=>;$,=KE+[Q/><R^,
MUWWO\%CTCV!)FTN>>A#'E<9/GV?/NG0VWB8L<@:4RR]N\@9/:W0Q!,TR+%F7
MTKIX>9?Y-Q:_7ZA2GF.5?:_&K#K@5#;I]]6P3+GI+W?3P]/YM.F/3E)F1\):
M%VY%A?Y5C=EGN_KEVI0LZH9_KPL:=4HJC.-WQ\D^EK*/<8WP=QFL]S;6N[GL
MTKA5[8G[V]/WPQ]KLB67_'WT]5&/*N%"(A"Z>79-CN:,*FQNCJ"_BQ2CZ2^9
MYZ%6)1U:=U<AR/W$NS7Q(1]8H#]O=7J08FF^./C5P//'3V_+"?J'QO%^/U'9
MUW?0X\ENUNYF@=N0CA^5C%Z; M[UW+LGY#]WPX>@E]OY(_&[UKO#:CRB1=^J
MG0/4VC0LJ5AR:RO]_9MN!S$F/([[=[IL<X11^16#KE=\+NM]KC7?OWJS@W,:
MYIHRZ_K54V/%$=55OS-%M,:8QUJD[.G^QI7OW".'LY;M&R'RM]'+'03W_E9R
M)ZB2/_R<'/9RL^SOA-SN^/>0KP[3N@X0<B,;G0ACW9FO4O=O '%,CO*SFD4S
MUBO-OZN;V2C4OC,]5ETATP*\U4(<)_)FIX1]-/@ZIF?DE7HE.Z=FKOS7K&W?
M0_%O^J!DUGA534K.QY!<1G_U'+WX)N, =[/:F*4)?;='*U;'M[P6P;\@^Q%A
MUT+0[!7)O_=RXHVN8XCG%$B>W2C)6WFY>_ZQ)%^I3$X-X4E5M*-VMF0^8]EJ
MN*A7I6#Z4]F,<2V1^5+)BXK+E\CL!Z9"C-)'C]12J(\Y9J66[FR _MQ9SGAN
M7):65WUO6FLI6#2G?5ZK6!'X**!2BWLV=#\_TRO5:G^RE'K9=ZG-2")AH#$@
MX*%=3[8(Z\\=7VXNQG15T*J[T#+=F6A&K>OAEDA0<;'IME.R3D/Y'R*Z'GH4
MLXH%PX^4=WIV9%=/WK2K_R@YZ3AZ&O5*995I)^F;V1IKRY5P5=W(CQA%-_MA
M%%'N^Z ]H$7LDT(N@WIGS=*]N?;C[6:MG]O%X;GLG R>SGJ:WLUK,9:FEAXA
M9NU:5ZS?,L2"/(YMC2/9L^EL7GA&V#T)2GP>1,_)FL^K9Y^H0?2CV31[( .8
M[$U2&WX1,:ZFBWOM)Y\[QV>6]GL<;6'^MYHM&CV03MYPYT.'SX'/GE?/OCNI
MLD&'ZH[70[)1L2H"F9&$'B*9^M+RG20O"^HG*T?'!]=SLVMSB8DC_][-!:\.
MNTZ.6HE!)$>\LDMN(<@5V;G#G%K?-3YJ97"U0O+"_,?T3W:AX2V+K_NRI#WQ
M7#UZ#U[8 *V/-:H7%U=#LOG9GR6\A9]^K?>]O@&0UL$5B,>]1>(W+LO>]!QM
MO3-<LD].^ 4'?%1-%/](N*4#9(R2#35ZTA(U8<2U3<T64@;,PS[I9?)\.Z[*
MFCJ?;(+TK$OY^/7>['+]U+QN\U602_7:%=/O:DFU)F[K/YUO:^W'_'[-3C=X
M:>1HN(7&5W-$_X/J#3^'I[S<TKXP&;P!R*TJG]\G@\YP$L83S!CNTTTL<K0$
M+G+&X-8;F$3H_BX0TML\(/!Z'RB;G6'T3K/>_,O)K]<[ 9\-?GI/Q:<$O-T@
M6.:,U1CDTGMG]*DL5DJQ3&88SU4,L*7?O.QA^6)D$:MKD)>+JC1C2\\<=>BX
M.$CMHX[.9Q_*4G>GB'-;TYJ#:&2Q+5TV7>JU&;<%B#7&4&]'$G_^D&+[R8'1
M-EKB5^GV7V_AX.#09P,#::->?-^\1'4L'JK!$6'M][>HWE;L' ?[Y,Z:MR_D
M\>=++NW:QDIQG.!-WWYZ_\;K,<".((5,5:J'L.0ZL9@@"S_*9V7ZGNK]DU,S
M/6_HH)REZOZT@H5!AX*H7?&]V=J:Y@#U?Z;KYOS\J[D4Y=%?+;W5=77BL]/X
MQ_B?"ACEZ*9G>VNN#O]IFO3*3HHXFY^IZ5=6VW8\,9 6(:WY4*R?WZG5-Z$]
M,8(#HX^U9T6'S_;?/<&LJ#SW$W(3VC@\9;.1XC$^W5T&J:JXNI]3I1";O^^Q
MR3>-X=P&V-T5CQ=_2)"!^C"@B6066-MVXCO(JOK68GN1^<@DTY[T4S^ ==SX
M%/5]H_)5T:[D-#93H-;PH5(-Q#)(3K ]5=/DS+N+?\B^I0#RZ+S\BDB]<*M
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MW[9AWY5"F?N2+[+8J\638\EK"TI^YM<+R%=\3+9_+""L2(-[SE2[Y6/<ON^
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M:5_ !9OM.0NSMY_2O2;RPVIP3DWF"ML5[I!T"_6<V\9R+[#KQ+/^L'3[(MQ
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MS5+E<K81HXT%X_FX0$<"B<6W^GF9E@8WC*%EZH'\.UF'%&GFY!^??8@H7A'
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MRHD.?3 ACL1,L=[FU_G_# +(AZ#VA:_L:75TY2ELZ**["60%(K40O+3*Z7;
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M1FY# SG76JJ:%1/']N!CNTFM-[^[IT+TU:/E#!_CB7&0:^8G&;CO7(D\?J_
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MHQO5<LM+^.<D\\S"I7=CRT;W.5X\IU!D#J3:2!0[Y:@NVQ>BWFF&5WJ/<QR
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M&?_1VNQJ,J$C82;KQUDYKMIU;#=5%=W*K7:LCR%3B'H(^C[?C'TWZCI1?";
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ML.Z-2)K._.^0)G+ %X_%Q0?>P@:-CXZ^[@7DB-\\/1R&X0F(;W\FUW7]15>
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MPTW8(RQ/L]@4_2)5.\#Y>;XL_/:UWFJOWW>YWZSRA/;N'JX .WGI@FSHM<]
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M:=G- EQ@BLQE0\3,'HT-5+_1-[F4>#KIE9'%!S:#WW$4O/KKTL6ZA64AD_7
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M18Q8&7WELHHT&5I4,CW; -3:OB,3!PJ[I;'/ NB&P0K<Z.?_?4V[N'8G"NK
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MJUXGV[F/!7FK5J<?3BF&K3/<(RIN_/O5-L"D2/;E9)S]?!-;R4\A5CW8 ;_
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M4U9,Y7V49TRL\);2/_KKPQ'I)WJ;_K[:P*YF6^K$WP;V$U#Y$%=:.P434-*
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M.1 N7&1\O]5_(K.IH&8_3'8'A<#6_<%):3Z['S7B=*C+]HUHKYI==R:B43-
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M_2Q X1*2D!3&^XEI0Q]@3[/G.>^K:65CX&KEG@2L/U07LNP_M+\!HH[L"K$
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M%$NL'L P):2[D%8N&N"VR1G2/.\3UPQJ=%#I/7S"KJ^6*<GYGO.;31HP"O\
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MJ_^H<;A(I30@(A4'OX49JV4WLY&3"PHD*B"0FUI++^\.U]<7S7C)[8.ZB[O
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MK#'4:_C@H<W.BO.=Z X+Y,=9WVH)*<NV_@M)!3P;&9YP,A>N]_=^K-="/H>
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M+?6TFRI_%W]#R^L;0VVTH3FZ>+5/()]\KT=.!R59LW*65><7RU/&@3L<J*:
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M_:U4;S 2H\N[KF"+)@3'H'5BX0B=S$<.M^6O=]YQ#(?Z[7Q?Q=I4%5[E%TT
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M*4($2RYTLTX6MZ-)[-6(:YZ>!DP_#E6WQ_<$WGB\M@[]]HBF:RV";ISKD*P
MV_]FZO*R'-7]_$.TKG%RJLUD.P8S1=S^OA/6:YFL_W8, B[F[ST0P;)1 :GT
M0*<4V@XY'M]CU>T3)7)-P0'XY@ONL5.MPJB_2,YLASVO/1!*LOUU%B+67892
M_"9'>BE-@0H0P![!_I10&,2P'L9CLI]E7<447S$;8EAYW@8R6JDX1?:%4/R(
MB"B%+870V<#@Y$2EM.83R1./P,)D<'N+F(N7P^JZ7J9O/9D5A'4'(\!=\C=\
M0?2A2@U\1DWLGLLB-C/3;6L^"(,9A9]A[:L7.G)7A9NO< .2.G+S,./U$$7^
M'\*[P1U\4S*0\ZZLE5E6=<_D<VXF>#[R:8*&8DJ6'Y"O"O<B+P5&7!8K/?IR
MYZ*@0\/J?;4-804/D#4Y)"\%W18K/1CX@=6XGGZ4,RO-=?S[M_7 4?/$+'W7
MD,V9 )ENTX1-S;MB?4/IY.3-I;W)VO)QR2H)"<FVWU'W[IVTR^6YD]L#]U G
MZ51 1 LA1&>J37FUS"U9;B*+"Q_T,N!OS^'<J,_F7A9YB( ^?10(Z@QFFV@@
M_OP"3%ZF\>+3F1NG.<A&?QI7\1D_227@<%!CP@'.#$1O9:6Z7OS5%WM1_<\M
MIEO6:[39F!+K=PC9(UN6M>:$!VFY(7>?]=A5OD^=]=(W]DHQ=_8/!HU_35>J
M4,VK'3/^HB/94E\+FD*LFY-8/58QO=!W2ZR%>D%[$F\+)V-VVN([0+-!Z!*#
MX.,M,;($Y*7'K-,C0A$6\W"LRD^DRB_N;65O=>;SO*!$=;H_PHK$@UPQPNPX
MQ$Y'1;B8"NA^EOYZ9I8V($_L)9W'EVRTRGX8\7@D[,RQG9\B?SV2HB&%U6'#
MCM;*G9V">#L0J5$T0G,)K--))5/P7S F%9U.7+$PU[LB8\9BA@06YZVUY ^V
M 8UA)&CJ3SM,K%&*P9C'OCX8$K(#<6TI^C97]S;/[]UN)\*(PG-<\;UV900\
MU->B6ESP9F/KEWAB=>35O_$A3CSX?M)W>H".+?!O"I$'DBMVI)7E'RSC"8V+
M:+J3L_I!NHR@;-% ZZ/G[-G$@Q%YR,EW!@JW5_,K78/2]73<^,_K,O"@S\MS
MXG=)+0P/(0 (UMHPPC(WD[VU$N%TNP"$%/Y\;5^>-7LYY'AOYZHO!/L(,JNM
M@65+2ERY:FB4=+G,P^WKM8&;&CG3?9?/0?JW0;^A)#8-O$0C802+-F%OL+<H
MC C2SN!\/?\,K7 ^S]"V((M"3[+RP''@;Y/SWX)[BEUT2C9GNX<M[#,%+E^?
M4;SU*)SN*2X+0 68+US$2S$33'0ZZL5NVUI8#4?=$Q!2Q)1HY(8Y,Z9YEKPQ
M+%'DSZ>TNYYDD",@RS7^?++8Q>@5.(NME85J3DXA2UCQJL*HL9#Q)7];=!ZE
M'=S5<QI 4FRJ/[7#R24_X+3[1ESBZ@NFXZ4"$%F T[2O5II2GE\?)>3T,N99
M^VY!>C@133CV))VX5PE/&"]=*<24"  QL@2_4QTJH,NL#;C\SNOBI^\S-AT#
M<N_=[4-7=#IG$4V(L@U7S-*, (7AP2H0"F)>>BR7$I93 E!@-"T+]=32DC[,
M9]KT'ZF<N@6YHS8,?R M ' 0SB:">9M@HQYSD?A5K'PG\LK6,XB[E<6B;$5_
M)#*1/N4E;7AG9&NC+6*J!3(KA8>FK AW+GB O%G^('6SEB\J6XE=YK$[R#N8
M,#_IA70]AB\7=D@0J #<#4S/,Y#U7!=CN43M]9SN78X+C)Z=#BA50CY3*="9
M?Y8.;;B;@?M@@@7%_(%/'NKK&05^>\+G;%20;-_F-G_/E'('_HT*( A"22PF
MNMBI#\ZK2W%\O*=R!5PQ1WS[-'!/.S3WN&!*@L,AK'^/(,3Q3N7JBLD*+ XL
M,ND[\Q?BY2=J:T@KMU.0L^B0@IJ#JXY S'HH#'I8>%>67WI:\>+&1\%G@J^T
M54NY-#L5S/JTFY JP<_HMOY^^F89J-<S%2R9PJ+MYG!NKK/T*^ YP)..J[,O
MQ+ZFV"GS>.CXE H@XDC5&V('D$XX]AG3Y<!MHQ<21U^XGE8!'C?'=> Z.1G#
MB.9+E,NH6SAP:E9.:\7[#<[[UTS7:">#,:J)  \C S_1)\<"^]O_-N'@OXMI
M_'\N7,&-I!!^ L<^VP!CW@?( QOW2BJ #T&Y0(KVUBA971K^=>Y_7%EZGE>;
M5VUCRT[CACYCK$\F6L&1\''8BQ7H\*=G 0JPSW!G2$(MZ2ZVX_O'P=L/9D:;
M)2+3$V/YLA/\-^<J QPSW<44AN_-N#.(OLC6?Z'%'&:2;=KA#]9K5:@5[[F:
M9N?%%7/?0"%41>BN3H#N9BA^WWU7-0\#WSTSFA=HL,AWE7X>E]X0L[JJK()^
M@;?L^ ,'?:_F%B3P(\9/UG$9N_*G>F?[SKBY&1O[_NC3VW'Y]%M9;P$OT&G"
MC813\QS2VZDCJ01X'6-II9=*]Y[IR^H7-2O%[O>8U%O/4[+MJ  -R ^F'=;E
M)6;"(U6]7O\-GL?)\IGL+R)":"?VE1SH)GRI ,TRQU":98X+CC.YSADO#U20
MW+$]YI5Z'#$Q0M_KO_*]Z=*5*"QJB,5*/!U*4O%<)?5(#M4RS+C;1,!L$T4_
M/WV,'9HQ2C'R2;6TGB^36X398I:+\TX?@R<6:=-G3WL[!%!JP[P6I('7I_EK
M^XCS=MZ*7<@RV5/ETVMG1N_12YQ620'!L->R!UDV/W!=T% >V91&5S8?U'FT
MV87@UZ=,4P%80REZY,K=+SUR>C+EUQ,B1,"AT6]#\U_Y($+W#=E(:((5WI^P
M@$W!1XS##J48MX7UZR8BXU@6C=A_WU/YV$[7X8,J<HT85I'"P:,.=!"7TUX%
M%7-?CJN,37!>P:I,WNTY]G+5KJCTA9W,J9A=[H72*12(?^C]8S%E%=>[LFG^
MI0QT(TUQD,';S%OWMX>Y6]T!99[DA#OH!C&IR+N6NQP\9K%Z_D4H0_ ZTS8E
M<,/ %7>*3SY#,)4DN0@Q,EW/[/M88VBHBT.:]NA]I:1L]#Y)RR->@B)",L4F
MY12YWG#_RC[':6=GGT()C-I\1_$,*S]XL)I!8EW=NKP-9]UJ.*X62_]<5W;3
M*+M:46%S/*DCC9 7H\9%<(WJ:VES_#P8N.57C#V\5__5+$WG>^Z.M<>>F'O%
M8HL GI^Y30MWF37RV8IXQW7L<Y$N>S'[,H,<2T]/Z[$/OXMSB(>GI!Y3<@=%
M)#!O53.ZX<.JWGI-[A''$ =31*7PTXM_F3S.?.9A[>GU0'0O16+,=RC1_Z]5
MI$2=9)^61')_,YU@4@@.U-<'6PX!T9! ORO$U\3+( P'5(#-0P$8@>QZ>I[\
MKF:1Z]<T8[I_[REX-YCRG"@_IG=SI:T\TCM^AMTJNF>L,CKUJZ7,W7&8T-_"
M=9&?MOI6A^8!0"!1%=.FGHGS=]96&I96B$^M-C(I4CHHTY*8J><<J"M8'W\^
M3=;*O>FN4M=Y_@J+IR(2=E2N5ZC;H_;6H:1L^Q#&2O[:(;H!OTRZ7.;:1USD
MWK8*\ 5)/^\P[4>JZO#";U!>J]V'=#FHB06&@%K&V^Z*-^JP#?7F/DU8X'^S
MF9)PQ6%?EI2RLA?%X[1JHY2FX!W-.9Y/SM%MZMLT:=$YN"O[.K=E=PNYI::"
MLXHBJ>:(.!UMG5KB3*+%99Y;MC7JO;A[YXPN3<4>E?K&:9/JH;A^BF_LD]2[
M'G)JRJ%+R)*3GV?.^NJ9DM21PEKBQ4:"9_<71R84DT'2II%+7B0B[G U<\60
M(&[^$W0M]"WV^)U]LK/,KIY18WUJK'WKJ]2[="ES:H1EU.+01N-JE.V#C%/1
MBGL*+M-MFKJ!T2*BO@(CQJ)Z!J]2QL-"H>]CQ_1ZRL(,]H?+AKCC"J(+&#Y;
M/'(O"M*ZYRX98.2V+6%\(G;VGA/DJDTF GB!R)/K:5^6MQNF2)=7R& (@3A1
M-Z<W8 C*<CP/10JK'16!1L<_E)C5<X7ZBHXFG/J,A]8TIN&!(24*DR6Z%;PK
MECE*/\:0Z86F::2=(P:1;Y]>_F<=V(\UR)0^+G_PZ5@;;@/';%L 6![RZOM:
M!K+CS8VE.TW]!7'AU=5X!.9A3E[KY*%57A80^PP9/[#B$=UR>-EGO<Z_5FJI
M3YH[B;!%5P)QH0B0]*ZB?L+C/RZ2CN^R5R3F6E^Q9B1!8;S!/C\AFF=FQPS^
M(<_I5YMA88_?P=L<N?+E0T^%H\UQX?W;<*8SG'^)_\96!C%M0LN$=R7%Y^IT
M;R&F3,5O[>A($?8K5&:0 L\U3BT8SC]LZ2B#I1WM;:^3((=S:$07A</AQZ%K
MB&C3]V>Z8W651M[M]?LG^%_D:H+%UZ[\4+%?*Z:FZ<J<IHGY=E%<G B/4(=S
M,)5<KWF$@BH5@%Q!%DO_=)W+JWYSS3G\P@N'2W15D[3;OR &/B_>MVH!D=M'
MLF0O"0$#AKM:UQ(L=]]4RO]M!9TY&V73(M%ZK\#OR=YE<;T3E<-S;M^3C=M)
M>^ LZ+?XN]S_.,T;^*A[S_D#<YGX;;,=DH*V%^$/@.YS8IEN\H"?<HI$ ),M
MTPGO]F'NX%/KF\+KYYTV__$>VZ?F2'@=M*<0EQL=(.AU4I4^QL8@_VKGK2\7
M)CP$D]NN,KP:A>/ROYTMFQ+O+%FU7;0W!P<]V E5&'FS9NV:BJ[6%V7X9IP2
MXM-4%-#08G-X"OT)FH8__U%+0#E?3X@37;@I])Y.S2F4"+;VWR7?<:GI*'!R
M$I2L^K809/+IF*Y8*PR)2O AI=G8!!8LQ_9QY[R:&W%U\@A^DMES.YHE9<B.
M9@_I40SQA;^&S)YVY4K_>LEW"[53T/3D-X.>Y]<:A3[Z41_$0^40:/KR_#C3
MHW1A\=Z!9Q7; U4!_5EF>B&V9/GV=L,E</+\A>S7A.&,)&]=EI'[D^DO-PVW
MJM/O>.8\*7&ZX;P_IZ_DUWPLF>EZ+ZT[FXU.F"?LGY!31RBYPD\O$,SI*H>Z
M?^O.F)WZS6251C3=)V)P",JA/#2,X%0P9ST/>R]^_;IW(O[]J &C]($#%'<(
M0_#/-N++(1R+6WSLV 62>?4\U^W$FQ\5W&:>/;3&*&[NC82Q^V7;_5 0+9][
MY">F98J^I*_3*.3X#;Z]^970&$WA\9)GQ=F"+-:;*NYPT-C&B#8(L#XJXGQT
M?9T#"-8=^"G5VH[$4 'HT7:Y-!ST:?/8T+?B>E;Y=(.+DNJ* N_&WXW70_(Y
M2,SFZ(I% 4+ ,OSJ2+#-5/>47.*2L+*IK_!\ !U_(H3+$K)37Q&X;09AWLYZ
MB_M<*/]D_]%T=^-GQB>;X^=#S/> )!;M5:M090*L*%"_*K3T;7$,#;?BLW/]
MUP$/*.<=9N&I327"O2^WD7*5= R!S6HO9LH%CR?]&\.DOE(!ZKFT!&B*$Y<9
M1P_IXAW.!">F7T6[Z_1EQ>O7LXP_+*A1 8DS9,1V=?H+J\9A>#J3(06^7P6&
M;5CV\MT=JY2R=_2<VA9@Z[J0:9K2)2!XB.'/,?YXX=.X2@2X'8)DPY45IU@]
M(#XR2A46&;#H6XJ''^V?-,2+%-_\%B]"<X_N(=V*WK]3@?"_JQ#^OTMA'*F9
MC6BW'[):D+]_Z2B?7D7CZVQ@B<9$996#A9[58#SGQ;4^[:^[E" 8>HG" #U5
M !'DG^&8$F6^<$0G6[RVL$^(N#<FW47+G^1)UPZQGPU#?80QG]:<8PPY)TTQ
M=,^-Z! EUU,!KW.X5ZF GD2S^=G"1@[V_;5+/7*ZK-DT2!!BK!866Y388]:%
MBL\1Q?K.)K<<UQUM'6_)S%NZ^O[MT-X_4_SSW>2BOFAGKQ4J@'FI9EY'H5$S
M]RG?JUG O#I>K4E@DTRK8K25)6,Y?R61;2S.*#4RS>NCMBHCY 9% _(&%$NY
M3TY5D[34_C:S,.=,!<S&"5:5;KQCM^O%)$GO(6SUP61P'Q50+QF'D^\F\L?Z
M\9HMZDW41@M&#18_7 :H6V-@:O44Y\"]E73Y:)^MDPX.)JE2^ZW! L\/+O?,
M%@<'B4<-C6H(\3ZM>I$N>)@@'-9_&C&*'DIC-SEM6X[<7,HK.?G3IG?F3?1I
M5W-C@WC2F:WG9=LB;O=7S,7S,/<%YU6I;F]<-3>$#K-8).+8KO!X,WI[/D&?
M0&[Z5'K83N^(M69?FZ><9R9#;I"8Z#]41I\!_J@O)99?C,W<)8_URZR(3J6K
MA5G!)>/?#H')P%E:O#AA"(OJRX+&DX2NKJ=EF]_78[4JC)>+%;2K4G8J4=B-
M1Y/$3C5"7V$U4[/,VLM=8C9I$FD'1&XF*>?EDV*8/+;G>A<!ORBW+=2^?+>R
MVOG,]MK1>J5I[6,8%0 R =T-3*'0?\*F]!X74P(:M%]+A;-RK>5J;P#[X&Y#
M;5:#U2^47AB(=HZ5*4DGO#1+NZ"4J)&1?N#<;CF%_'7 !U(8&4R8-32#%6];
M@57-<Y!_]'KEE_@IBDC>]$^E6RG:XOD.OB6B(^%JX5X)#DETLL2XTVO@KES!
ML:-*[I]@I?&GXQKB/OKBN.JW:RS>,YO$W'G4MG8X%? 2&4,%7+F3A-'7L["4
M*'QU!VR[P.23&Y6R(;:IS&7WRPUE4-/X[K;F)0:1#85MZ$%*Y[8MB)D .VJ[
MLM_!W?V[>T54RRA-4\?X^XI@:AIZ';,O4_!N/:O,S,#8S%G>MR',//W+\4Z0
M4Q\\MH,WHS/9TMFL6O"C,Y([2O,\6W@9SY5<2!%$FE5HJ=L#:MY"4JY\Y)(0
MD% L+2V00F!L1]!%@B;QM>>V;K"7UI#F*O\<G_9W.JC@<H$,%"?@6RJ 4;LP
M,,,$'NW_ ^X_G\^$1MHV8^"&NL=J4!7U]X--'4E\SU^C/\!T65O=!G2=X;8-
M+4</1LKNKLR-+Q@>@(!24AK$V3.0ZAYJ\&55N[NP/7=M7L;_!V!X+DG]69BA
MX?@F*,#VL?$?AR3Y'R3YD(,I."-\^8.:5%H'>V5ALOM5'N<8Q>5WJ#/8(GXT
M MY:NO6F;57ME!TY@0&.%X.SS8DA9F,NA6"N0A3E'&P1T2>187(CQ:?\KFTO
M1(7L_*8BO#6LY,WBG=KD'HLXR5N!PV^3 >:?(B?XAV@;#<2P:/S1V=S,"0_0
MCL6P"H)/-]['9>RGLOI]*S&%3Y%L-[]C;A+!S6RGWI$.[A<;=_V>L=DGW^SA
M''V(1 G0X=:(N9W\?W[CG"CTTJ>O2)*XBP4!RPKU;DJ_K'7MV'_/B] W[="Z
M*UUA.LC:/X7,F% 8A#VN_7!SZ/W2-9.("E,*7@O@I[10 4^I@&L$X9X.\5A'
M?-ZKWJ07/5P.>:"4S3D<3!0RD]=IZ.T.J=VE=5^ WO)"J9#J:"@A5, 9\E_.
M!#7R]]JX]*%[D96V5EPFHZR50^>*8I;5^S=SX>]A6U84>L29F?J#4J.SGG8%
M2_[N#7"]HF4A&!WI 6#1>8E"-;*=PE;.](8+FPW9L S[***@]C2H?S,!9K2W
MV'(YY]7MS]_>2W&K7[E$.PT H'F"^1;"@8*0Y:_\YT(M<%(K?^$K>0P: D*+
M.:HMVM?L[_].H[T\EVV.Q:'Y";=*$ LFB!N++3)Z-4X=S;E<:LB[7<X6$VNP
MLGX!*J 2M%DWZU;\W2O@NO?%+4$ 1KA)!9)799^R@HA>%VS(<4R9.-%!4I3/
M&!!I@Y8TXPLCW 'MSBPOJ*E*]7#<6"@JO%PCLJH7_>P[ .V,,)#>/:P8VB,(
M&Y*N&_Q]- XB1/]@E \KA[F?P5VB/7RL@,*6$0W9X':D L .5,"J,U,/$P.?
MP9=_QB940%P^T_(X7H$<306X(>D(5:/;/P."YRP1GM%1WS"<5^A/$;30(;X8
M>#UR1NHQ2D4,NSAD@-/K][O>&&<]E-/[/;SGCR*F9*I]1(V/X#[L$=$]<FG#
M3,;DZ!2>MV),SA(#+G1^CYL6IH46 ?25RQ^X;391+(!HHNG_(^1T*1B&(M[8
M%?\_2URCV/_-\+\K7O_OD/M''@0\$"NU)I;,"V2GO&Y9^+?)6/]:\^;< I04
MIGE$23N1I0(N*#<UQ_:,G;#<?[UHO?*>PHZ$E*!!%0W:'-+\$$K]/RK5]50F
M9->D9YS[L1.]A^1N?JZ<7##M-!5PM'TH15]TB1"9K%N08/=]^^Z,IBOOW"\"
M\+J HJ>D=UF9KBU2DS]N1J*5R#^(["R,W\;'0G??WSE3TL^CRYPXA2-D(TR6
M_)TRX*7NNL+]N-;P+GB$[_E%FA/S1H,@!8$Q>#PPLO$'(0 ?8U*6)_6Z+!*^
MSG5 /CGB1[9#7$#54R6NJTP7YZR=1Z$LEHCFM'>TT;SMN).S35(.SKA6=G0E
M_7L"I6I_Y[:).=YZ<3>M\C6IJC48(DUF7]=WJ(UW?_9\2OG:.IVCD:;K'>*,
MV!+D@/C][^S0LP"HZ7N;QSH77M'$J-Y3!SC!&FD3IFA)\@20.-PEHYNHMQ"V
MIUCQ:ZBU2L--0'$/N5^>*XSCRU@NY7^&>A4O]GQH[S7 +G@MZ;,*G_K1Q0YW
M.+D-Z-0N97;CZM+[BH*)RR=@PQR/Y)D^:90B"9Z!NV.1BN-SH!.'7OAB7]8G
M7[J_Y];_K>+/^DYZG-@!R+"7TC-<JQ()6.%!<Z6_Q,BER2:E71II0$F)E;N[
MPF*6I(!% EA8I+WCBSK7Q\],K_ZX"7CED+_,]-1K#R1.F9UEBMU5N[ZDYU9B
MU>6%#\*W25\X>>0U=Q.CMO1(;$.*CJ2/+>E]E02YLJ#MQ;UCYW S@O$>V*2Q
MY&C9/ 8\MPSK;ET._F!12P6$9ATUF7&2@)RO3*63?_Z&7>F&UGVU+9R8++H^
M@1;V"P@IP<P?!&:]X-%FP+!ARR^;I?Y@>ZZ4*D!GX/);U\A9YL3#%P5Y0,@E
M5/C@!GNJ+L*N<1T>O*/4D]]"NH#/Y",/\8B[Q8^T^3Y2 8;CBD0J0'")#;+6
M_ (R;2M%YJG_IXAAUQG'67M:0P7\L(80;T$J(=YA0O"U!>QDW1DVB46+!@ 3
M.J#\^[9.9,B<T%*A9,.AVJ5_BJ.$.D[Z#GDPOY$[KGW\3=%AMN9^ N_0-K3?
M=P_T(:\:N7/T/30 ]Q05P!Q6KX\5; DJN/CVX-.\P\1R .PW%4 08T3N(EF8
M<TY2>"%M,Y2.A594_MEDKGS%9I=_EVO%0^J#1NT.&B 5B_X8!85Y.@&Z3[]0
M$,;78\M2!5,/WGN'/B!N%T7_\5W.T1:M0P?9N+K9+!P98-@AZ=J);0'=KX+J
M?;$NQ0)IIFGY!;H!SVK]6^L+%F;X,DZU*%VX0+WE*/-TLVN6"]H.32T/WR^_
M/Y@^Q_0+<[9 :B &DI!P%-Q%ZO+,XO<!4=>I0:Y4Z1,GZP/D5P0$Q3^WM/L;
M XU"?7"Y-D?.>NLVUTC#S>W5)[?,N !D0HOR+F%1?%R+]R KMR+Y"<R(;8J7
M11BOPKC*:A+S*N:+/1O$.6*DN-$G<6-@OUD^3*YA5@9?#5;%INOU9)MTY\WX
M\O)9VS[GEBF@<ZF;G-5%N<)"*GV=CN.P<_S8[Z'\27G39OS$J^YG=-46?)V@
MP@B?#H90(AB!S#9%[4VB7&E>J&2Z<=A)/Q%U,A=/!4"&X3LO/U !XQ64HRX@
MGN?"<:"X//+XWGV1RF/7)Y3C#$(+U'TY%PX*]LATWN0@DPRQ%5+\?T"0([*4
M1GEZV*T[[?P9&;"%/R^-;)@RSI?OB[*.JOFA86>OBH=AH#F\U_LAEZKZ* 31
M^ -S_6_NZ&JM57$[Y%'1?\+Y"DLGK?X-X@_T=K9)&PA"_I3O8APS#1Z09'H*
MWL%D)WDE^&V?M S0MR9 ZA349NBP&%D,B._(JY!@^.QCQ\B4#\\A%9#^RH\*
M4-UZM<OAL6V\J:E;89J&T@_>:QP"MT@\1Z(-*0RQZ(%Z#VY"K*[%3.3\T]8
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MPO[PMZI-W?:<SPE$D?A\G4O-X</0=\>Q[!_)ZZGMA<]GDPTI#(<;ALL>!*F
M#U*DH!*"DTEM\K2UM39K4)[DK]'KRRRJ(4<\"0&45* C<O8N6&4#;_YE,C<D
ML-"N@O[")ZM\X>Q<M?8+D#S8KBQ6%[V"0&R_++$H^M837'C>N*FW)U<MDNB/
M.#IC5>==)OVX1Y1F%_%F7FQU-R_:>[(+8@[X<\!N/ZWEU3@0&A>,70H+U]D$
M*]KG():SF+\=_%X_^8"#0E]6-EKN&44U<_\9\]^=J0^H[S G8UIB^S,+#A';
M9VQ<\?M127FX%(A_/H$B!!FH&#Q)^1OQOYQU(/KFEO,:,^S\\3]T%I=_4?2!
M-PW"^V(P)+?];I\KIV)3ID/G6G4GKW(N%4"&=#?&U9.!7<%"^*+2>?4;<QJ"
M%383GN]?' GDJC(JH98]=E7_I;"G%_;4JN,7ZS/#NKD%E?,:2FO7Y@(!N4WH
M)=1U&C+-M,V,?A#3S!^=BT?K3U3)T+/?='>XDF'U[-78YRM7&^6\P\&EA@=]
MD%$U)W(DW(6;?Y9;JVZJ;M,Q73CY_F6YO?9^M66(BGDS93Z%&P*85U 8*9R/
M3!JA E"E95CX"\I];2TV8<N[6Y5277*0J_"Z"P<N\#J_^0L?Z":R[0ZR1[7Y
M\X^)YCL>.ZUV,D@F28[7&S2'6WED3PA--G,6R9+P7G]I5U[$77W22B"%"I#B
M L8VV@>=&?)CD^6T&JM \-*;/K=?V7Y]72=>L_#2T-O%Z<^-]5V'*Q9/)2"5
MAMA8?+P#Q@IZ[[.!_\K.ZVR/;RZ0HHQBA$<I+VJ_L3SO=RQAPG0;23CUH?PF
MOS!Q/4IK:X<\AN0.Z?IF')^9SL+>,^!D_Z]\_1&H]I.>YIV4I0.FUC\II-Y_
M6EU#I"CM>O1V)^*&)T3< $G9KW1SH(>6$GR#1:\CUV-_6LER<#$._*1\]<V%
MT4C(1R:B2L\9ZG_9O#VJ"OPJ2Q##N<^=*J]>G=_>IP)Z._,TC@_Z+B%.-K-1
M>PVEE]\$4 %'>\"M"A\",R@*6,=P2044(@P@M[]7.$P1X+WO10F2Q8(%C9X'
M@NLG9XN4G6>D#L;W ZK)+P_%AX7?X2#BZRGQ94G=)9@];2(5(,&T+4^YA*O\
M H]<<O(?< TDYJ)=^3#0#!(.5#6;#9&!;F'V!X P$ 9IV,M$$- _D._A3)6^
MJ<VG#5KA(@.!/6RGG\I*[[D?"?/G!5,>%J>:Q&\@B8J] Q.IKA#DM!;H1-R/
MY$X%K"3YQXM4,MK]1Q*!_G]<-8E5\YJ?/V4#>:8'"A2X '@RKXZ&<'597^^G
MB"FW6)#0P,VPWM=(D <6]D.""IC4/P3V0Q+!9URNRT%J3P+NA&23_7)?!R\6
M?DF0Y\0P*3<7;OVK4:_UAZ]'3?.)!1I(D'+Z(''T98A7]/??Z/:>GE-8WM]F
MHP2^,P.@6\9$XM!;??Q1'#[=:!T>E C/0X/>0ZJ9NC(IHJXM.[.5WQ>9(7(J
M$_?]LM&*2 \$YS:H?@KT Y\T^]A=1OGMB0/EQ=&RUSCI"(9J@G2+FT$R7AYP
MVK,IV+.DFHO-Z9U \MS\*$YH8&&5>=<,7NH6+#S-\K/BJ;RL3$JP;_W1T9T/
ME,L]Z#FK')2E3:_1W0N9D^%&N6M')$/84_-MCQWA,^-S[PL^J]5*+/WA\O>T
M>7JZ=[]8*6RD7<H8L$:_))I$7^62'OSTVM"%PJJD3W8QSPR\ =M)2[;YIG"L
MYN4%UZ>$S.\6\[JK"G[T L_GIVD<$0"LPF8G%<"4BS8X#^OJ&)HS?QY6$91J
M['H2K*HJ03@\7;H2:M$5F%W-=#4F$%*N>\]Y0$=Y9K/1SW4#$BPG?7E7!43[
ML9];8-Z)2/0_]WV<=/5N7C=[LKSX5(_PYHU/)TY$WU*$V=DV40?1<@RG_*T"
M-XOL-_+-OI&X;O0_&IO]KTC^*_14.$M1DK!/]QFUV#/?K<-_I!/_#M^]!N3O
M],/P@F-C<53 3WZF4-EQ=P]9JW+3:[VC>D_"L87' N/C>94 _\;:327-S%9X
MBY[GA^8L+8:+%WW2!9:(N)'0-)PP_@=6*@*6_C-4HR2.JR%*WC/"\.$]D&K(
M%8?J3= '4*,'B9VND\)>,Q4J_<U%4_92[X^2F1) +,V$@[LA"#'AQ$;".X.5
MR=_@KK#W<L$9$;(Y;G4'I5K#[#HS<ES:QT_0=$?'^4Q[*2L>?2%,<1Q&VDX!
M5S9%C(L5V;KH>.6JCWB!9- C6RMN<WJD@ J%'TTT7T.06(>6#7\RQ;9<C"P+
MG'4MLW"S>R!#>:T'H!\]R(4HD7TF2^*=H"]')[O4UC#%(5<B45D Q#_YBJ8U
M2DWV][3Y,:33J<. ] #L%]<AWTP+!K9/S)/OSK/=0O $\%MV%BIG_/7TF:,E
MX?.91N&S5 "%?F"9"IBEU9O<DUBMKV]OCGC=Z_6]7_Y<X"VP1[XPM AR%U@'
M)+&B$<":W.:0<H*]JC&9/>B.:81RW/4+K]\"OOML]D%$*<>5?EP_!)J\[?O&
M&-7^2B<L4QZC*[W5I B:V)Y5MKI?A!3U\?I;]^])*6G9Z-&.<CU1]7DW<,0V
M!!W:)\TQJ=QQBHFY$X4>1(L@-!OP</2^*&NJ8!'[N(WA,O]*QNXQSG5EJL!C
MA6S^<.);S$ROEL7NGV?G>'@RC*8#%/<.R7J$,U1[X2+HFM5<HGV@FTU$#*ON
M>V]/Q7EM.%QARP"B3P4XYQ&$,B)"G?F^^BQ[7'XQMZ#WI\[PPG?:E.1+TYET
MPD1B/$GMGXXSYX/)13)#0W$DR8R&'V*M6C\0]\-IE,%[)7SS/B!DF_FAZTK"
MOI\TE]77C%&W#CT?Y8:\9*O*D-S**ZOU(OLCNOYCFT17 N4*6?LWW 5^"?2P
M1K]R<U W1K$E.AAZC&SD\4&@ON 0NY]6(%>=#Q9F7-GO#[ \.*]7FAG7U7>1
M1.'=EYZ%,QY)$>X<[^84#?Y"E+J*U>UVDPNO,-)IT9; CRJ!C) N*?A;*,N"
M]M6C/]4R+/<CJB2?] 7U"Y=4*:SYP8;*R"S;9&>EYGH.=1U;E41A]BGH4-GL
MP>10D7R8LBW1Y;!V&[R^-PO%'^!*H++J7S?8 SB\;)2MV!M,A!E#JX\?;)\<
M@#0A7?)4@/T"9!74:_.@;_'VN/NW)/R;*NOYSA5PP)4@1P07Y@0U Z_Q(+'0
M_E2ZL)Y4@)/2LIJ*?U+HW]SP6L%L0+#IY3AP:)-\BW27H+C,'ZUV8WQ'QNWV
MX.#^U )S89*@SOGW^8!\0'"XCJI/TB19:H4*B#YABB5H7A&Z\=S+.SYANTMB
M,N?($!MLNX'#O1AL*I._,^%1/P*/66+RW8NVO-#PR:XZ^MKM>P\!5]ZI<W(B
M%=8\=59;Z+E#DZB 17O(@ZST_;]6)><;GGM?]^H<U0KQ62Q';>PVR\VUAAG<
M^Q9_]S\<:/\OZV:%0,E^L6'HMGFTL\J9EAFGL*)E*",4X-CZFZ9:$VP._L6/
M-3.<V<,'3E@]Q26.578W/[HP[Y4=&=G#5,*V_T^M=D^/G3B&F ,A3RVMN>E1
MB"!0=SN&CD.A3(/)V"A$I@X"S5)<C^_I:AJL8[4JI@*6(88:QZ/Q% B4Q"-[
M>BM<Q^HC7>4L!->"SXOFQUKNS7Q8G?KJ4?+&G,\:Q2*H\\=6"^SD5I!8 '=O
MWQRB28C_D\[W32_ PQ (W%87?WU#7\CR:GO:&1@$#QM9(R-)SXL)XSTM 7$R
MF<:NO+K,,E+<L<\NT3F_[+IY#1QEKF_M9E%W;/F@2+F\,K?T?XK#G6%S_-DG
M8E)%_=N;-S6NEE5Y105D5'M+_(*APO+@H-*D'A,'P<K445^Y]X;F@71W9>51
M6V^>79(/:-20Q/, !UWUZ(;$+'*V$?PJ%C<Y3!X7F]=EKMH_K;JORSR7Y'H0
M0*%G/=4)]<8=?PB5\D SL;I81IDL]-54_AR&-3^-Z[J"F<#_#/;=GYGH:G.J
MT[F#$JHZ/("#MJN[5+QCA+=&K[:KKC=46AU,YLU-WPS7OID0N765S>QG9L7;
MF22+2K>9N*T7W5$I1[(N;3UM_]41S?^Z".D_0K_R9<#.7^#T7C^0# D>L[&B
M_>*+K.ZD/$_4=!)]EM)6$!"R^/=TJ5G76'=@<P/>/Z/4H4T**6DPT-[__L F
M$[Z>ZHSZ^VX)E11"";7_;O38^9&RU$^\'ORCSY!-P+@C1=WXYZVX'C<SQ&LN
M-C8V-^$"H3=_&[6ZMYILX$[0#4:Z1LZ*DY('+/ZWG6H2(.JH#A^DZE8[&W/)
MI8:QVC!WHA6RO^2NJM0)4V);P]7P:<4>;[7/"-VI#\^[GKFA>=ZE*:#5SGQF
M;G.%R]W!;&&<5):;_PXIJA#];:XA=FBI83VI<I4_&A7L'NN$;\V(\#[OW/&T
MQDZD4Y@VP5L1^1:US^IZJA#JPU]O&.M7NY+XU/G9-E9/D IXG3'TXF>G8/K<
M.X1:CO9M>+..Q%L/NHS2SHQ[N0Q/OG;A>\Y)CY6>T4P.+/:)9&Q,7;5_6T7W
MS_-=M3UT<^$^2"K %NZ#;>P;-H_ATG).7=E74LP:N4>H4-DVS?ZV27;A27*U
M08<<3I- O5 ZS\7;?S)MG4&*E1DJ+1TWZD3&(S* DR5<I0,-%8637U#8ZC,"
M<Z>>8+7RP2KZKI?'2I-]IE6,!?M"XSEEYMR<CC22^3]WU@V6$FP%W.&;M3QA
M0B]!<^OQWYS-G5FBXARRM<+M1$^$ 8S3G*OP]_P$T1ED'Q,+D]X W.(S"NTK
MVC(SQ=AJ7=5@OZT J]F:Q*P;GK9-P3\1.]3R:E;FI^(#$L6+QMSVA R2(SRJ
MVAK'FS?RL/I7U=&_9 ',$.@/%=KQ3XC;<-/#'"/*4MB^%,-"K.+YE'&26H[K
MO@^%_HP2W930WJ "1N'&A]"32R[ OU2 T&TX/#"8N>S32M#D7FR"U?[OHI+<
M$L((PC-R-7M;CT)>))._@3*6)B@!$(_+!?*(R4&1BSM)N<E.1$@B1 ..U?IY
M^1SZ:\0#*N C2I:T UZX9(CH-"214Q"G:%)NYK(/Z+<VB;GQ/6O>B5WL0>(9
MK37?AR0,SFOJV5Q?2X9G>SC.46@HT##.M*;;SF)2#KI# =B^!<J>9&M>1PN<
M!(:??J("-F[7BAF>K2T4105X \GGS1S!3R&:_Z&C^/])GI>'^#PH%7:I[@L&
M*U(!JNT;-#^L!J1/3'_P9 >_KFYS0^==)JG\^C,EV]K_=FQ6."#HE2GMFU$=
MX9)\M7HZ:%O(5Y+L;Y@L[R/*HI3DPCS]*TU%AB=;84V\8>4G?/\TECE3 9.B
MB;\J&MBA[MH1H8D1V4)#9X&4=,E(CW3#QG9 ,(QT?8G"D'D'*HN)!M_8QBZJ
M3F>AANJ:%N>R[XN&1V6O4=HUP0+@(5 -\B<5,,>$/F^)@LJ$V=3Q&I](Z@]_
M'/X_B'OOJ*;"+EW\*"@B" (B("4H(+V#=&*C"TB3)D1%1$"Z"%(2!!6E2E<$
M@@(B4J+T'CH( E)#;Z$CD%!#RLF-WUVWS)V9W_IFULSZ_7&RDI-DG?VV9S_/
M?O?99T#!0,:7Z9X3?ZUU (F9=CTM4 P^+J <WT[<([Y,]8'E#1BU"A6*9@@+
ML4>\LZ[YHYX.KJ ?0<?]FJ$ "%F=N+%J%SCR=,/F?NJJ_4T1F3?'-%)NN C5
M;"1=Y>/Z<XT$"80=N..L7G_\TG;'LNI5I<*F1@N+B8DWZS!'4Z<=;+)AC'!A
M03XC-,HB85)B? V#7R-@)@=FVWV>>Z:V/KSWJHGW&O=:N4^,SXM)-?Z-!5H;
MHH;[YZ*+:*9^,J("V9!=BIM$"%25"JSIK[783^9A4N_LU :!S#1!]PB!%<WE
MP9+,=C.>[I8=^:-F3%^J@LU5G622*/B"3%Q&,X!"%\LI^<Z/YLZ8E26\ -'(
M+^I(A!MEB""B6O-;NDNMO38^OTN1X*2*W4>M>S$*9YEJHSX$_2DY)#7 +,AG
M*)^>NABUQ? ;S*8,?MW>, L%#:<K-=S1!&(2A0ILW,J?\0D0I )/P!AHQP?8
M-^FE#:(009PV9H?6B^%18E_T_V\69)&TS=IY=,%#31M'1B1D,U:P'AV'40%,
M_2R1"3.OLGD>B;=T#*)4Q(/:JGL;E.>H:0<K<@/'[8.J]RX@T.:T^[<([+QH
M)RE!)496J,]TLA]R\!N$4> 5>.V+1FF1>'XO0U@RHH0*2$X2$:L!NE8AL.X'
M*/_XEIF?#?D"LT-C8#IT+J:YLS70;\C-!3R"Y']'S7C<?M ;V#SEMX]JA1&$
MK)(0+3]>'<R=^DT*'8B8S$)FPK'K'A]#7-YU'AT0X1]0V*_KBWLC=?:C5. 9
M#4MS@P9\\B,C:A=?>C5,+KVF!&RO]SG#:<"AM3;\]'-1VS_C^R3L$02"Z;>_
M]<<X_T\V3)C&&W"!(K[7]8_7_YI\C__KL%8I#MTFL.YQ#OZO=^>.O?R?B2\Z
MJ]H11^;_5.3GQ"1B7S&4=8>3@*#II[< &<#?";:E>9+/N="A?=04T__Z^N_3
MW-ZJ$HXM?-IP426'%$ [TB8C44<P'&0L?0=60/Y%DR0R$V>L[[9$@$C9VQHF
M>LL^:T>'X+LGRE? CAM+J"D )^>=(PHU2P>?(.;>NZA7UL3Y(&077: 8[7T*
M[QBBBQ.Z\0[41=>2%0U#+J84V'YM5FK@\UBK@_Z$"*P-P45<TMWW7];.!FXT
MUI'CXZ#N%(-%@NV"U5@$Y?B< (,_]%?\HN2<%T'H]RS>W4XT@E*@8G+R5F?5
M!LP7CKD1T,K*'F_/V)F/2^I?5IPM#M&@*;U@<S3G?LY&0>\>%;CKUQ=Z!FZ,
MW4A*9:3I'IFL>)/"I97)9PC]T+-.]&7*O)*CKRA/BO:#*DH:[0_ C7I ?JY'
MG@J84 &2@1B__0;EA&CK]A$[C71O3-%0/"_O'^<0RD,$H56$MQ4H3+$I-].Q
M_<]%0CC=9F9[O;DW&6IHID)3@*L)FB]/F/MUTJUM3U2PCI6/I6/-+HF-,)T/
M80&T?$,U]@_W5\C&"[&LS1,>O?M;.1Y<XUC74XGZF"UQT7!?=4AVGR0N^&"3
M!N$_5B&GG\9:F ZNQ*T'WOPM5O5.T1.(>],YB1P,@^K29+/7I.E\50L_ASE#
MVYTK5:._N^]<J=;Q6&?U:,W*L-[1(+G2,/DV*!=B/.))UL(U[JQ8&W@Z5TTZ
M"2<N,94B &CK/BH^) #OM8#>Q&"3W+-[BB8FW-(>'?NQ905\P&=A 0@>-84D
MB':2V9P<<;&C2"R4/^';C6>7ZAZB==ZSRDEF'&7O]J-A=@ YGY*"F$-2 0XJ
MX"[+Z5I+!=JE6:V-/$P6U#P?5K\V?_'063AQC+_/;W(/K*8"#V<)(ITMD'&L
MX7>D:5G8]/L'"<-->:WS]LN:V*SZE5T4&N0+D<=!6V99QQ\3'2._V!J[L^?T
M<"9K.W'>/MEQZNI:1CB+J2AW2??A;<5YC_$<G3E G[_NF<![_NIV0$%,NMQ=
M9/ /-E;PQ?7+30P P"" C%]K9S=0$[V<) 7'2P4G&H!/_\\@FL9.*)Q.2MBX
M]3GL2I)]X+#D=5XZ.OJ(HSV:;] <[@!Y";\L[&]VSX4+7^Q@S7;&QL!#"Y%Y
M]'$OXS^U\SZA#_A;;>*KRD?ES$^/--ZP?0)3_$QQ7R(_<2:.]O6+AT.?9:&W
MD+N$8>TG#;FJF\-4P(XY$5+_!\$.+;;(F"A+(C5-?K27SRPXCI/OX6,. D[*
M=S#D.9EJW/T1@ U0Y0L@?Q/J=X276X:% 7+BC_]CZ7AG]V&H/>4)&T1G;2C#
M?HG4O_B8S51N]J_S6/XK#LX%2/F9Q50(BW_PF[<L/XS"534[@D+=)S>:T8]G
MCRX'=5)\TZB 3GIMT' X2$8HZ9B&.T8>;2*:+<V]>,CN/P:W966<PK'F^E.2
MW[F?7]7TY$?GP=_3YC,4,1>'IF_46E7GWXZ2673R<6+>/=_#=VYJC+=4?X\O
M*R/#9=<)/*W7V3DMR>=T)YI[DS0 &Z("9/;KKGJ1FK)O^1#9$RS<<5?B5)7W
M VM'OLZ)J2L^G94UOK(T2X[/;#7/M^"RF- QLFGPWT1T1;8A<)XK?SYI)ZD_
M'IQFPC.*7:YB*^SB$A2WM4\,\NR 5Y"/X-.P[XUH$M-&:FU^*Z_#S79WW\O3
M%[JY'OIZTK_3[^3;$QA3A:Z:P5)IFM\<\E(;0HB8"ZZ+[F%R];PWM/PH4=_L
MK0_'65^]N_>2IF+V+]=GG'=Y:_6YT#+%QB 7JY)_L[*2*) J>4QGT#/YG"B_
M1539X.QB@Q9K*Y(@PD#F-.H$+^%E(^%L@;.W$YE49Y@,G&J2%X$>GB-[[D[$
M4!82<_#QVYC;Z#M'F[OM/B?:#"24/'F7_)D5XUZZ,&@1K8\RR")&_9'0RI!*
MNR<=H[RAWI^E1'NLS'RO C*SM'[#4$!X>Z-H UXT;/-R??7S&0U578=HQ.FX
MW"0[%VZWIRL7AC]_NI!@[F/O>&=SXN#HB:[]F^2%-4N/;@4?XX,[!G D3BJT
M0D?YPVWG#Y9!/TY#%:Y^BR]P'<A$(1[&KA[>%B?'A&%>![5/2$0>E-"FQ#5)
M5C)S%17 IDA9CRI6CGE)/_+::O=ACCT22B+>YG*@ JBUSR,,\:W%ETW5N.D:
M@ZC *QVIW[IQ@[WG'G\SJD^\)%&B)O7KZFT&<_WC89J8=@0/_ )!T##$;*%8
M0__LRB^2Y;>//ADKP@)M(Z8GR$\)UGC&S! (]HRL_4-AN?(/#YOY_,*#\?NH
MI1R026\!>=95GE!-,.U(U"LW6OJH,5>]1(!)[VBI:NFYX5D)@BK19-NB=;LN
M?'ZLZ'NFG\=#&\G?)U>8$<6( NQWY?6B6H5FH_/?ZCIF5F3]X9BADM&1!E8U
MK%V['FM7PT:)^UJH"L8$/9I_4)\H',5_REGK5/XH2PHB)R^9T:O09BI;A[):
M7^71]O4/)/Z>;FBHI)O:@V3/*/TEV+;N.G;77.>YWF>$#!+G:TI.8CV-P%RD
M CFQ\ >(Y@O011\<B@*_03LAA!I"$]1$08/(5S0W3@4&.M#RB+F82<2\ N[+
MP83V.)<HA;"Q_IT*[(@@#J@ .!'(B5YTW<TGJ"J2&O]FK_'*$O<J:7\4O[-Q
M96)K<*:CJ]??BYW7WCM6:D"7[]0[9Z/O#/D/_MYJ70NCT!=!<0JS5"#.NGO\
M $1_B7_^.#$T[8AK]:M33=7']R47DX,ZI6A4+/M'@=_04($:]SEF.XGZM&<_
M7'IKJN+Y0W[FW H-D/NLT6. &'&P[Z&Y_Y6W5&#OO-*Q!U''&-[Y:NDH?;]M
M=/8;].T;NEGA.>;@WW1?OWE\75M_5K&?7I5SMXEU\>Z%\I)$L<?C#J:ZNLSY
MJ]<$P9-A_#J<YY)T3F^EV\P+E.J_@5X1O$U?;F796/INTZC'VNFW2-LMA.#B
M2-'*&D8K%CAGZ25Q,V_YZ5L]O/XZ3;&&RM/M?\NW'&)PT&T*]=SL!(>SF8:M
M6#<=%,'P.Q "#ZT]G1)M 7=*J<"WFO!;>SO+L31*'?(C6Z:."L"&;NZ9N] O
MWD,$"T%BK8))W'W"#>4Q1*U?$HC+WH^/3W.>\]-1V JW68;9Y.K!2&L&G-(T
M$+7*K2]_N6!?^#@^-ZDM<N?1R3"I@=N=?EZRQ(+Y)+"F._X???CU_]>BI/_$
M02?[_U9==R_^?R-2@-T_X<G4)66/3DS3$(DFE_=T$*PT.+5"'4DYBAS4TW!#
MMP'A?1ZVPT3K[Q(_&LF+ B%48*X0MF,38DP;@D3:*4PQ#KJCV /](X,$4SC2
ME*A @L!S*O" B$[2D"5<1I/#MB-)5(!&L5&P@B"#2U3 K#,'L2I-KL4LY9,Y
M8.#5@%D<=%ER7]: UB+*WQ@&D0Y#9&I%[%QJH=GU'M2G MR!&Z!A_3:(AE)4
M$30F6R7&@.U.ZB3:LY:(T.VC5A'@J4DP#[$Q(TLY7T'>!J?:$"T$F/NHZ-H*
M8K^02%-\X5>H0 &,>!A-\X_%B,L$FCTB_%#BD<7N"S NE)LWA$.RN,"L:@H]
M!_G_#$T8\*=])L>O-GV.$@_[CTD84V99269QB5,_.WSV:8"P?YNNN#BW)O2K
M.O-N4],_;DOH#M$EI,Q3@=>.W.@1Y8]O/'HSV&_U"GU[QV8@FG%65\N'> &-
MG>4+1,PW1FJC"F#7W"Z]F/KPT)+'JH_Q$1"PY7Y$3VOH%T2S:44.:AW)&L(5
MB!E89_)YC'Z8]DOM7?F],S&A@4W9S/T$"17RN?7=]C//YZ&O9BXF&FUKV].P
M_H%-YK)6=>S1GB;"D( ^8*"$@Q+P(1A;.?0-DNVI>Z^>3D-CU/)"\/NEI_(:
M13$&_H(Q$,?@_6\PG F,($H%HJ'NK&\[V^#JY<.7RNKKC4;<J[_LC!DNF# 5
MT/NM^VVW(_P19<@_A_.(\<FF*X[G!HNEN<>OL?.^6;B^TG.5^Z2$FC!=]3/*
MU4L4)/H1ZC45*%N)E)(BB^8UY_<?B)U?&E2ZU?6 -_G><1OVY]B,@Y_: \$(
MI1VE>^"*YCV?CN#=]*@=\DQF]A-+5>!9\QIFML*2GR$(^''OD^=<)WD/4H)
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M)#_$'X'GCN$"_ES["SX$'9Q?"Q&>4Q+H.*T\=IX'"'2RI0\[*6.;TW5:[VZ
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M)YG/F215$?L[^E:M?2O'&T7O#JT_N>+.\NS>^D++S=L)[0@5-,[,E.;[FZA
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M!]OBI-2+4-Z)GRR1?PL9$, ZS5SS6&6:6ALV@(/&,_[+M[;,SA[>N\5,KC+
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M_T.AT _4A?X/MJ+829+0MF%[T+5JX.MW"84?H''0M[(D>9JO&#&31I$>8/_
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M^M;!,D VKB>#5$!XK EL)FQBZ0O>]9>!!^(N5.?TO"1!0G[';/^F?"Q:XS4
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M<TX@_0WZ2."(G WQISS@@9(#X)0PUQ,OVD">4=J ?&J S5\HPK9^8ZV4=?<
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MNL3T=N 7Z+<"%="KL$GQ 7<LDM@G\F$X4.>Q1<>EWPDJT $M%<R)_PJB[MM
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M#4?H[:%<@1CS4SE"CPE!%[=R;##)O[,KX3%[ \,??:9?4[&5:WM\ ?&#"K@
MB1_H(=Y1JBD=\$0X&O_FDL>&]S',0=]O@A,06*.$F4A+@OQ*B&NWI6ER:C_Q
MPP%#V$W8;>]Y\\*]["S(H#]-K#'L"M,3C% =@9-]IV]C/],IKQT<^_1M:).V
MB>#V!;&"V/8[):R&HEVV=XW\@XN$4A8+3,IWH)$( RA *EB^TU3A0+"]'Z+T
M5ZILQ^YO@?RPHCQ;RK$EWG&+M>1._$]/1GHL:/5M#UM*<\@KF/U'BKR6U6>A
M9Y$J"G-*0:&P<F;5;N:"O- >5V40. FIA;)123CPSGHR&98<&%3V9B(W5\^_
M 7DX??M']*7_6 7><7\X)U:^ZI\/G(K+JUVIDJ)C?R]TB,YNF2,K^PQ>,G=O
M"+V9M!:3- ->1^JR"G<J:=1T'C/=-.25LWK??K0E=?@WT'S%?_<++M_&V'Q2
M131_+LKR-21185&X4B<3X*T4Z\GLK@ ? <W6H34BWP4K7H]?YM",2KI >-GV
M1)!^XFA[<1,<MWA>#4B(P4>0OQ\.?%JI__VK>6)<T0S2GYZ&$.12A0PKKB/D
M<9Q11:]FWF"KUYMKGM=;J(9L_*RV:1!"_J&,$3DAW%\AZ3T*UGN<'[[U5Q*3
M*U0.(C;K'GIZF[L@*Z'KH327WL:#<(@*=B[2+7,E!L4E18WF?XJ/Y^)+44 G
M!O)Y@:?5HGY:0< =J43^>E,K7:^+8DM,)I=C@YC(0<B>Q0KSG7EGK'A;0]"W
M)V4%C>/+?=<^O.ECR<R6Z1-)6MQPW=[5>9VXBZ^U5Z OOW=>V:MW$YD'%5$<
M*M-&%J**#&M1D]7S2*ADXP@-\HF0-VK@\/:UK^Q<=O?>%K4GORQCFQ#DOI]H
MANK]3L?=-ZSBOY+Z?Z(^R?_IDSGP;) ++!JY>$[M/ 2SHI^1MZ<BG]_G?S$^
M+U41'-\\8CYRA),GL:FS4P&O/&*BM[CU(]34N1G( N@R_[6WRU;2K88E[$J^
M7I! GYC99RG/N[6)^:-=Z299? A>L\S?+L;MR$RAEC^Y^OJ2JZ,D!T@XA2F:
M<) /079:7K:T+G/-VY)/_?Q9<-5J"!?^\86GW^57!WW=HIP4IC@"+OYM$>(V
M0A)!%C^)P+5\<U(3A4Q?<OKE.V].@-#O)@$'$%/%,9?4WTF@1<@+!FO@61,5
M^:6MY,V^U>>:<X+XUXL=G'XG-0>!(7\H1EU>>U>-,NWY%J7UQC^LIEA*^/1I
M&JWIITQ(^K+]'1O;,X,^0U.88@@[T'5V^:4*(#G3&$EABOHOG\??/( 5#$%3
MH)*N=DX,<CA'\MQX5T2.BE47[-BU4HT;:P;#AG]P']@9VG;S&$1 C:-M;^!X
M$*0[K\$$Z80TLF+E#/D85.A !83GA"K7D=KSZ3<YJ0!V RK@TW>*,G1$#$H*
MIP*ZS/>)=R3.2WD(!#IZW/I)&:8]S.QKH3:@X5I7",2^3:)D54$?[V)K<-)@
M99]%B.M,HP*^##GN%SWJIP+VU\!PDHSC$0"!?<O98T\%W$NG%/23ZNV,)4E\
M9-QD!17 \IL*N(V@R?21UXBO;..[#+<6)$\Q\-\4&$;FTB7CL050?UU"!(F9
M!GWF6+?-L1 )\IXP^7EWJ)"7ZDY5Z8 !,>#1 "7+ Y$Z[PXU0.!8%WOTB38]
MY -NFKE%W*:-+CM422#CWQ7:Z#C!?Z2G+1-.[+CQ/?3_CD@:Y<-<.J&Y/0G'
M@33AT&QPPMO1_O=<@T'D+X^6I'%7,ER8:/6(8<6 C2:E!?\,4@%SE@+@PW_Y
MSLU!!>^I  9ETML>)9/%3-K@'.\?T9K+"E4"GD0\53T _D=S@=.6S"=V M!Y
M*N!6YATW@S,+__(DPZVTVEO.CI&4PUVV;2WR'#SV J"IO9C06U[F3_>D:V'[
M^Y'Z5JAC^<W<D&:#S5YHVQ"4+XH*^&R]!$5)0[4H*?]2R P!^1)([>O=2E^
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MJBR>?QJPG!,J*#3Y\FIX)$?P@+1!SQ,=I'4SV[#AZ'J\:F!H5J#Q__QX$!4
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M\P(SZH+A)>(UO8%PV-/2O@M/S 3[?A6B?M2Y5[<>.]?JS%V@P,*Y< =RF?+
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MU/M]N?EM;7TY:DJ:;22K(Z_P;BH+,=H7?__.F([NLR\#,->HY"N:?+9\5@"
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M'2ASS\1&H\)^B=F[AM$Q0U2800^#@V-*;N'ED^C(*I] $H85S]BY6%^?D!W
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M(-(MY]@=<?G3'QY_/\IC\RZ-[3(OT7/^921EIIAF'808( AU:F#TLC6I%O]
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MP 0\7&&W:;.FCD #""7G^!A3(/MCW"$,U# H<O0;"Y'W'G%98IY,%;Q?D,"
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M34T,'/.;<Z^B!<T<')F;3#-7#OK"@E)[":_W3Q$(DW> %R&GV#4L):X[KS,
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MJ@X#P/6"P$X/;\JDL^G_I_E@_NNP$K2<-@$F^'W5Z /OHLFR_U>GP2![[C
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M3GMB%1CO,73K>UUIS+<QI_OI!0/2TN*\H9<G;<V<X6@L;#KZP;AIZ)WYCOQ
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M_0I/]:PKHH>%9\E0H4X!5XO&.KM<._LMN["2F(Z15 O="Y8K:<8C_8KNO_W
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MP[I88&)-AO1*G?F]=7]NIE?WSI<!S<V9\]CC7@41P;3*PR-D8V+$0BI-"+'
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MT/IU[!&N?/DR;5U>;<8MA <MF35W]4U&H4,%/&]_&H\J]NON;1=+KN^EHG.
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MN^T>(P$C9>CX5T7!I"=S<QMY$7O;H&;=T.\[$O@8-:/DLK6;KSE]N+(G3#A
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MOO!FXG80]^>7PF>C0Z7UZV?>C4QS5,M0T_I&-*D5'.H#/F8&4!@MXE^Z:*0
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MJK01="+<,;[XH?I]&PP+SW:#GJ??$KNL)"#_]M/APXQYDTE'W^H.!/XLF0G
M?^:; ]&W816_F0 N)@ -V>G_M^66">B9W%Q$$>\D/[R#^=M=CM[L9&0.DP,-
MJW5FG!E3J43D3]A"4 UF5S$.?!C*!+1B1G=VFE*9  %30<0FQKR2VN&$\M^
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M+;M;$%I!T.\)29X"/5X8<[Y0U9O@4SFHL-:T1V[%(*5U>,/.4TJ1KSGY$NO
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MJ\;&#A0]F(@ <@'1"!J@MA)V$7+)S7FBKUH\Z'KF>0''C+?K$5#P9"GT/ W
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M[PO'Q?A19@?")!)=J#A( S#X^0<ZFR=,1?2F 7WGM;4IH:B%%C@YVHL&V)K
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MI8)1X'XOP@W1'162'EFI=N83P;%H4[5HT5:6.L16U7HU3O 9$0*T)J]3/M
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MSX>0;NQQ3 ?I.P30[NT:#)@#/,C!Y5JC=N4X*- %F&I- VAY$:Z#^AZ!NFB
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M-:@4GPPT.WQP//K^Q%OP*X5><P:?L#J6(JV<43VU@08 $84^(5]B/9[%Y49
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M2Q3;++_: -2K"FHMBC-/Y?[HX=RCQY5^7&H9X)+9'E"H&*Q^B)U"K0S$=W#
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M^@.X 1[9H1+DV+/$# /5MTW+O/:0W;T:F-0RG!YC_Z,I+9#-[U]&I6W*-QK
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MEX'W7;$) .H6S),&> .ZH,T=*N)H?%*_:>VDO<D@[]<M]IU)1$A0X=:)S<D
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M(@\$#P=01W@Y,Z%;-X#%#+/AP8>G8ZP(;04N/),:/5^W)_,1S>A:?Z\14]Q
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M_<?<!B4L]?RL;U,*$4-EQQ>_M3?^JIVI?!1^C=S#L*TS_J)NR$[/K$T.-)X
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ML<HVU&8!FZ"R<<^D!.)6H#ND_2NA5V^5#R$*,.1/RG^*XI*F*M*9TT9;>+[
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M\ZJ 5Y"78#K@/0,ET!]M#M7EJ1EZ6_CZ**H(D0C:-VNCZ^JC==0A^[^Z8U>
MU-N"[#0 4B.<&DNE+XXV7H42\XE.KB;^.!H "\K$_$UI Y*:L#1 2?&_=\8+
ME=PTP&LJ"++]B=PQ-G*(7!^CGI^A^X+N5WM($X0KW1W<$UO</'5-LCF@.S=&
MFR0$?]@?#9>)99>(2W49&8>KY 3*CW\6@OI[GKU^CRDV4B"J:DI'+N'\?;/
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MPO6&M(?9#[M8E>'O F?31AZ%?1D\R=CI3A#_P,SVVL'=MY5/$O1!\^"4HMU
MI"?9C%G$$_ K;<;YOL69Q'=(RWE<9.H5[IH[_OL'*7/Z]X^64&Z@U;<?M;@?
M(9!'F]1[D0WX X+Z'G#[6K')1V*7Q?;UBP).FL/<C_#U&9A?04L=OHFUY#'E
MQ:TAZ4'W"[8_G 5?E(]_/GEP7?3+27UCNV\1R>SW3"*1KV>7NUDLF7RWQP6?
MK];S?A(DU[<HESGA@2DV,FPVRD+4STUKA6.-87FPMVT/JXBMEGD/,;*B;:VY
M^@'[\BZM QHZ8F+\%X_1/EG);@QSSO8S>LDB(_X7C=XP/Y45K@8 \A=._2=1
MK0X0XC6;+=3S6@F'VW=3G&K<9M--82&[5,W)O_\./^E1<E_DS7C-1#C E*?O
MIMUZRO0CB3MP!?^]BR#6#A.5+<8*/"@?<:YVG"TIM;3L;1F8Z]]N; B.B@*>
M"L(:06NE,=V:RG8O<>>MBNZ-=5O$&?-K<>]WCR\4,RN92IA(BFXUS-)ED=F&
M)*A4&A]'O3;RZ?6)4/X@WCMRT2%;1*3#0(N2##,+X$[O[SY/ ZPDB1?$_??!
M\;)6%[@@S+T;^SJ7J0MU:9IHU;/7G6V=]L4BTQPE#F %",2K=9T&'^9GO%KO
M! V1)4]1,:I/X1>>-$=^RW>IC%#WO8+S,JI-L/0HK?"A-K70 -HT@"&,/]"L
MA.GM%)+757*B/$?*68)'0'W8>33;R;(XB]M4P3?=2/F;M>&ARP/[T@2O;Q$>
M-@##BX,6J0OE9R_K6*VQ,JT>U:T8)FT]#\?!A[/5>.?O97!+1!QL0VQ'/?J-
MY])7TKU"VS&S,'#Y('NLIX(%4L^HE$?,_4+:I(*)9VZPQZ>J%G(EK.LI#?#$
M>.9S\63;S4];H:*D!W'<'?@[3Q[-Z$N$@ZKUU#'[->4>F%R3[?X"&,/,W/3W
MWR;LT1=J\_U3%<H^JRZ'\R?0 &:P!!1CI K^T^\OD??.*N@*<\^$GSLY/_,K
M.MP=\RG*_Z0'1P,0A7VW,$L#.T&Q]?$D4_/]R,DW'-]UA'S.?,N8>"F@;G,
M?-/!_+1-I]#Z9S/4UMZ_MV'[IG5NF< 5Q]^&SW9A8A@GLV/C-5>2.9&E&\@2
ML LD.Y<6NFP^>;%Z=!]J\SI;H:%,=%;2R-(FQMBXM2>HV'WOU4*[O3=+G_W5
M*@:%(=?/,S^^Y,M=JTF-<%43^V5SS$Z/M_^%MO<,:[()PP5?! 61(BA-@:B
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M +C\6]?Z#"K:*W$O'N@ .R]/Q@.A<K@ PAER;LN5Z0Z%0)[[UG_2F&X.7^X
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M6M-NP=FV%VHG0X4^_N/X8,GI$%%W]1ST<VLYAL)<006$2(PC5EYD<2JP:7D
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MI7ETPRJDQK)M6B9>D*YI2+36"'%SV)\NGSV![Q<=X^@:/Q6 [/>3BT-%RD@
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M1*37J("H"$B33E!_4H4H"DB-BM*+]!82 0'I @*"0%2:U$B-U-!#42(UTDO
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MT)FG3_!@+F3,XI$[N&T@:;U[[@HC&:ZQIEGY-\O'F@5P[WMSVO -GYD!QS7
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M2<E7D,2K'WM;E5-V54%(B2@)-J).B?B6926+O0W)-C?F5FM+OJJ#OTL<K:Q
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MQ-8EK$6DN$\UJ$N*(31)**JDX 8O=R,YH5L"0*X<M/LUJ=UPKB-X,NGVB40
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M]VO1$_4"D;>1;GDU? 31VK$S_JLXC4.1@V8F%XZL;#;<<BWG>/?@F6WC:L]
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MW29D]EU8AFN'I:SBN@YUHT@R[;>'_[M)FK)9[@O\>-P1ZZ X*H->=="AR<$
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ML;GQ)G]!!UW\57MGKJ,5?TR!>7V:J:G^V?E:6RW*SJ@7T]Q;.E%,_I&8OQ0
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MV*_:AN8F^>I_]+G5-Q)/T6F=53?+TQP_16 MLL8518R,+1]X#<>;MHIXPO;
M[H?_42%W$GP]]#TS?Z90,L\+%*[V:/R0-8:8Y04Q(',LP#28$CRJ>Y7ZO[#W
MGD%-?U'88!05E-X$I$0%I'>03D04! 2D2Y&H- 'IO24J"M*E(RTJ)2 ETE%*
MZ $IH4=Z[RVAA!"2L/S?F7=GWYV=_?3.[)?]<#/Y97Z3<N\YSWF>FW//T2"J
MJIJ_[#D0KT3EY#;[7 M>/^:/(0D2S'&^W: J1I0!=7NZ0>"U-#+B<O]*3]+G
MB9?<@@U4/.LY+S%'_F?*)-NA%AF2Y(A ^IL]24]YPH& H[-@/N>@8;"RNO+N
M!%(>Z8&<-*X0&FMR*W39JI[2DN@WU>$8+"MH</]+[3V]O0^N"XIO?PX1[9U0
MI&4_SC2)?VX@]M=OF<]1K-"M]D_5!-YZFY2Q8!3=,,_8D.OPM6SMET\9=K30
MPN"QN<\SG\#1<(BU''&&_ 7Y9I9J&=J!9M"\]MW3OQCJ9,TUH6RAJTB3EBEM
M(12IC@+V;<5KSTS-O(WC_7B-FN?E.F8S FU+M,1V_8^C<77'H \P-DD_1EY7
MWVQ.CX$RXQ=/YZQ_*J8#+-55[1-JR1UA&KB66)Q->X"=^/!*_*[4*XO/VFWM
MR=E8&Z'(F0?K<7P-ZP1BN6B#Z[CT^-*B16HAGY5G'X?#.: \!+:Y!V2/1"T6
MV__RC7^J<3?G7N&U'#,X^[UTQ&^?&+>Z;L?;6.]Y6 ?;\#WHQPL]VG>Y8"@Y
ME2YI,PD&1Q8*VCXQ^S=G^)R*S42I9X%FV?DMS M$-AMI)J5 O5FS/A@<I[YN
M=AC1\"97: A8D\0)!C^#TB19N&/=K&(2I45$[_8(Y?CXSF/WP:V8W;XSS1=A
MOK@Q3+5M3:ESL##J:P,3K93:%Z\G2CLZO-M$C@L7+*?\N_\L*+ 3RN#NV=KX
MJ*&>INJP@?H!8#"XVYN(.;@4["TQ.][5OV-GM9:L\UI7,#=:+:]#B6^<Y+R,
MYH*^63,[L&5W%!<4AM9TR[J'NOI8@Q3@O5)RE'20 WJXTLOYRA+):"FN=F2)
M!\4ZD&Q9KI\.QWM(1BFJ"4J$9QL(G+@7E2660!U@4Y?/ ?AP0I3;4BP7URW]
M6/^W/)<BJ822,._1P'YH&.P7&,6/.UDTR(B1<F"Q52CCO_I^X1NZY<'*NKJR
M4"$T^XT D^;MB"\Z5YB'(O[%4$HN)&'2.:">X=/"/N,&F$YJ;PP\*W_S;[GP
MX-HEZBOKR"(Y@B7C^[#7!W&;JTHDZ\*,UW>$]')6WY!?^^A:!7I,U'\_AM7:
M;TPR,C?))'ZV%>DX0'G7&47G\P3(?E0N10EVF/H6KTS\S.&G'FB<FD5O#71S
M-5-)4V.NC+J\?2'EIT]OS"D[I\FVS!-?3?]7$Z6Q/I>,K+/X*>%:R"YP5E21
M>!IN:9*K?*]0KV!C0'[4M.C4(2O<U."J+GV'#9-9"@R"M,MK*-YH5==^PP6U
M&O6;Y]HXN77O^Q6?Q_ZL_-%L2N#4#ZU,1K</J,%%,J09:)L!:.%K@,8]UJ#J
MCF?2Z9,.S>#*[@Y!S2_A7=3*O(RW<^P5R#Q=XND'UYEC%HZIB\);X*/8<EJR
MU".<18;WJ[)IS:#J+@'#ZF+[*)-O%4$]Z*?/J+'J9^*0<20KU'$^-GV.;N(E
MLF;8KW2\EG7V^NM$!Y_=P?5+(73'>,3./-Z2_%--$#?:7I>1XF8A%>*^?%G.
M*_YW#Z#D1N=Z,;J8:SF+].'"UE*A;?<'D3_<+J (FM_A7/S7N4$_5M^KZC*5
MM.H7AP58OW,,291 ?:9%TB''J07;+QK=<E7)ZLR*>],GD/SSK17@=D12G/T!
M2OX2^1SP8EK;#.V9$9U@CA(U2XG[;]?6Z65BDW3H,7"P19Q\L?CN0)JP .Q<
MXBOWP$O-;D_4V@]*PJHD?:X/^H2?$K/.6K;:7CP=ZDEHF#U@TJ9!&Z- BP\X
M_4R2/NA\[Q+\7U0P, $DM44O7P+JU#G%=ZG$ %P_%/"B$N97QC?VIJ25!D%H
M#.D].L3OV;4IMX<RD9^,C#2GI^O9D-.5SMFVYX!Y93(4O?H\B+IXX![U-](G
M@)]^V52=[]MP@M8YH"KFB^M-J9/R]\M-WL".'$;KM5_4FC&R.EHQ@(VG4[9?
MZ>'3]6=X_(XRL028ZP F.'=D_62^E^APG5JHYR-/'H$VT4.=0;3!B?<Z_'JA
M74+[.Z6^<\!["O-8KZQ+NAYGLE$*$'IB.9I$VFZC2$$&-)@2.TXL+0(L?FC2
M15QFLYAA.^)$KV[&$+L\)9F8JAK0R'6*ME@&CB\76C&MWJBW5T%S.R>.#V1W
M#EA^ .P4(K$YXX-P=M5+O#I/AL) OO[N7J./Z&[V;T<*,)@;AN#(!A#],*F+
MM98/RE[R_+SR>R),+MPC0XY#0C#UIX9OLF_U/,P.=0\YHCV/]\3>K ZI;[DW
MM(.P57)R^6:I[CN>2E%7I6A4%H7=(1A]^T$/:O\C6!('J/A205%-;N Z/GWP
MC7$1\U]G*N[LQ=UGUK6[U=/I4X8;O%Z&2JM!%X2V'))+$OVOY4$3_:+N#B+R
M^RJGM1"_9(-8I+KW/B4$:C21SL<YVG,SH&YHMUNMAA_^0"7@''!,M(.9?)2\
MG11YJ?7*I=U_21A,+2 ,B.7&<P]!KDQ;D3\0#-U9Y+L/( M4QRA/2FUXZ16D
M(TUL3_Q#W"ZJF*3TPZ8Q6G=6K.JP#31ZM(M:-H]&WWNGL"^!,1OQITD4W%TQ
M[MWGXB3RS2^#>W7^JPB25^)*$<#1U^8,_M MI.-_K?)[.P%%6O EOYE\(2XF
MX#[R0%NY[<K+]2-22U&+"AD!=18#QO%1C>V4O[5/W]N:LP5*6$4[O$+SP4^/
MUJH1VDHYZF_E*;>.9N_/'JV-OK16D"R9A8+Y3\TNEN(ER:\*>\-N(VMU126T
M#Y3*XF)Q7Z W(K[3N4(E /4=L6&--L6>?)8O/K:QV2A2%*WZD%!&\Y*14ZB8
M]QW_]#>*T3G #3AILY2QL[L<\7-CB3C233NJ%ONV(L988,ZW/B$B08DD-JK!
M!FTSDB!=+9PD^'8"/9+7_E[Y )8I$&AZ6>I\^S O&,^3$G,.T%![@05^OI.W
M5)V30F_#KL]A/&A<>.W4?/3%?BCT";'IFK/.I':N]H^%FL8CHZ-S@!S1 0?\
MK 9:1#+,@&W!6JQ:K(KHNXC'/5O:RL>;%PN><T%OYI?[->Y-E/LUWUH3:_=X
MI/HJR8'_)%NFK5?]6@@NJ77]':'\'' 5>"$@<QW]%_<9LC?6FN(Z.*,+6IT7
MO #'*Q3>8"58%7+'&:>%C\+%5]07%ZYV538EK%P?GW&7C=J8L0>.EOL'*2_8
MA9+KHP9\9Q1L)6ZQLZ6ZMA6Z\U$L,+C7J+747*$;!LH*SLX;^'!BHS_(ZB(
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M>UYM<H#LFGLQ^CU[QSS-27G=U+@@U!%K]'&>84=-AD[W4EU][*KY]=Q*=BH
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MV7;!@1<&RQT]'>)])<H&&K1I65Z_78\[!I'?KOV1/O[YREO>6WYM647.U.+
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M+OK0J O)5[TG,"BC) YC-:7_T#&6RRZJ(&A(&;2M/[$VV$1:%J('+ZC'RW-
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M\Q)A@YN.SPPT OA02=#JS@S:;A4:5T;S"*7/#N&I2?^8LG[Q)-JTZ@N=2ET
M0K/A'4 9/>X>_SEEW./HWUI%[S Q(C4\KF_Z/=0UF/Y=B%NJ$ROERP>,JSMA
M>\3SM<,UA!A>:;$M#@_J.,M.+IY2YTFO&WVB^ZCJ=*QD>7DM,>3H[ 4E?O+2
M3/XA-1*U< E+-W$YW5FOEX186<.KXX5*K!Y]_*Q)[^[6'A" .0;BT$N/0_#>
MG75SCW^O1@0&?K;G7]\DB#;_],O.:FA?NXJ,@Q $&+>ERH,HQBN5W1=B6 LS
M+"?=IK>KY!?Z(*6W[?=W;+8N'S9XV9E/A+ NQ@S*3C33W%>>@\6:5+>5_;\
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M,TOFZL[+RB-E*P#7,L[!QR!2IC(0AUBLCQ!+&YZQOB/[YW/-&U:/..^L+I5
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MB<A"W8+F6]I$P;W"A,'ZDJ<N 9P#215Q1FI\5S<E0><N9!E)W0)];_K<_EZ
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MER-4<FVTMJ:N:6/FG)-\DQ)_E;2C['CGJ#N)MUS..20S*Y<QEF*TZ"7*+?4
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MI>T?YRVR?LR]GK.][R$U&=QX1%0"[R_BM6#AY[KK]ZQ"(\^=.3CK]T@7@.Z
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M=%=R7_!RX]Y21\T=(M@)840%@M>J85&/K+6-C<+'+>Z;\9>DX?D,8#"J*$C
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MB^IF3Y<03@?BP:(]D\)<D@6< 0IG@.;GZIY)NE,/GVT3GZYQO(!15LY4QO9
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MSWIMU8%@[DNI0(T0Z&E7ZM$*.>J0S\NT#6>1F-\%&:T:%=8-N/ B\A*?+)T
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MU?RA,!(L=&CW]&O2 Y-^E3K/)051..):_,L53MYIT0]:(V?MM]V@H\17HUM
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M&88KB9[W:B+Z+C!MJ5:9=+5]V6/7*=@'QJ586S27X<U((SOL?*%*;)M G#[
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MX7I>KI?I]MG.:P@24L;*W=_4RB84/B]L[5/A0@--4 @;2M(&-O$]B]PK"_T
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M8$V\H<@"KS>!4Q5:O\5\ARO,E,Q./)\>#+O1_>DJL_3;JM6+*4;TE"9Y0;<
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MB;$GU9!D4S=5<S',#BZ%?(G/!9M@#7O)S80-6GW+'NB=J.FA\^ZS3+X<*W>
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M:K:G;]Y+JL/NXJ/MOXGJT.A  T:Z<)+(;6=;C>:-A=_IF0L_NAJ041A[+Z4
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ME1DI#)/-"&6[BD;I@2B;^JQ,YP^]R$L\3:E06\H4=0H*0>A3QL:@EQ)V^H[
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M90[CM%@[THA@;NDTS9K5X9I9M(+R]=L'7$U4W33G/O$"I0.BHW%3Z8(X2(;
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MC^\J,U,*S8JRB_J=%UK_:UCQR=XK /-'#]B]ET9OG:J^0% 88?R>!M\ZLES
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M?94]V4KI_>.J^WB&D-^ /"*\# ?;MX\%\*CT9&^A=)HB=#R!M![:N1'3B\J
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M_>:=ZF+7[K+KF4YGTF]\$C(%9/]<,+<N\UE5CKE&J9E#0!.^*LY_,@]J'76
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M+5:#0VXH6WT$GB(O@2F33(XN_'%R J0#*(GHGPB#;X"EVV<!#GD4C,\P0XJ
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M3E[6Z.M!OGX9A5KHW'*L#NPTQUF?V[+7TYG%4L]O7#2!,4&23((]>E@E(;^
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MULBU,F_$/;RDS=+>!U!LMZ]RU4\"NY:2%]S.0$4_&G+B#_[68#>7-G\@O>O
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M&B/&40O+4$^N:P5/^"2IC08^R.7HPRI@^H@:^,M=\!N@T-E:O,K@G%S0QWC
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MQLAV9,7D#HAOV4"1EE?JV%OX%5?1L=Q;=?64=%([WB!/G03&(UG"X!G\VVO
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MC:.G]B_F[A*H L9%H#J?=66F#H9LW24\%J+3-<BT_+,ACVH<X[O2+??SIY"
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M7?\^0,TG(GASU5*4517QG/V5Y<Z\S;H]') @H2KIH[9XQW'#+2XM\5TTCI<
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MDPRK=Q[^0%Z*IJA8>*0OQ1Y,N1.9=E"03JGDI0Z1AV25R7?N]IYNZ?;_<\K
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M(DF[[8&^)9/&$B8'JUR+;OS<Q.[L:M +]P&'HF@QYY-]"\;U%FQTM3(]GPL
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M9H:%@'E@$Z(R)@J=-O[OF&4X:Z834E\["_M)#NR.L).P-+:^.6FX(&SPU:Y
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MF[W]1V5ZK,4]94JKTF.!_2YAYVR:W$)HOU63?QSRSY*)$2&@KL[5E6I7<L"
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M%E6-&@E.GZ NECSIPWIJ"HU_'2)(![EX@,W=@SR_7ZM4'<\P][OZ_#3ZZ74
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MH2K9[.L0/HZRG1W&=QEC00T.;9K_1XH*C A%9;,;5)[?HQ'S^95)HCD$OA
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M[_UJ<K[BVV#9:'(2%HPD8?"(%E1<,&M"Z!5WF>J!QO;!:Q9_'@3P@_&B660
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M!V^^IA=,)"*Q6S2VZ6WI.W"H74"'U_$AI59;KHKT%\?FNZ[Y-F\"K:BRK6B
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MP^A3FG"E"8?I 2Q@A*.DH2?/D:)"]A0VU<P00.5B)+Y<*('N7B5T>_:>M91
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MK7MP*>K!INN)QC]>,A%2NA\F@7H-^.0=K\PB15JCKP[NI1E:G3Z']\,//<5
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MB*/A#H2GR@A_^;81P71>[..P6<?O($V3HBDWR16W] :D/X^K X7Z!""O076
MH?E)>#/"V[Y=?G 8A[M2VI&=/6(5OUUCC(.CZY%KYS>Q,PBACN=30,G18HZ@
MUCT >>PU!$!B7SB?]AV9&D 9Z(?K>15!C^>(SX%"RXIE2YV*L,OH'1%XZF$L
MS%P?:/3)F4SLI)05B1WFN]8)5'EI70_WX2OX8S(!1.@YI,@*2'?N6^*(H >5
M6C<@[1]8Q[P$]_?5"^V'094W>3''2S1QGW0B *V)O.)O,P"K'Z;ALN\ JU?*
M#0")/P7(D@FRH!203J*)SDO&-<IP!;#.L/9LX/E<,H=<RT27Y(8R.M5!]14L
MG0)2HNCGB)^/0X0$:?):$<M@U#0>G4[ *>9 +R G&,54H9>1< $11?U"<."Q
M4&3GWX>O^OO\(&012+)O--YV<U<67PX;\:6U"X/TW1E>-.$"\T/'7O+E9L(]
MAMB:H7?(#O+?>JNI%\SDI;5TG47(<^'*XV#ZL1!B8#D7RT!.L(@-.7?HEMFZ
M>8;%NJ9Z%R996*?6C]J7O2X-%6\\ZE\MO.9HL8EMK7?WV8QC_5/RJ#?NME$T
M#QUA9-&%!QB*T;</TSCC 5,=4IV-A0<:986D.@RR1#>XJ6++6N["FFL)J\R\
MMW6?JM[\+0 LYZ:*[,F6^C>>"S]9F#O/\MU9\GE_;5O"C1O7JQ[&Y3I:4-L4
M;87-XL/NO UNQVY71DS86T/T*)T^02NCDD),*Z!8X W5*_;Y4(7*+UD#_7U]
MY'IC+!1=1$)#%L,S=6#Q8GV\Q%*-.#@Y"YTCE5'-FEPS&VOQ3M6/.<[5#@Z-
MBP-O#PW7M.MQ<L-VWGAL>WZIW(YM _%U"P=-4YH"\]Z0VKQP-69? E;NBHM>
M ZGAD<YG"RJ8S9_A_B?7T5K[81#MDTTYB&@BB%^V5(Q(@TN#Q\!DCP&=6HSP
M5<E-J^KWUP#G_]"IYPSB_:U'\I?SRAWQ)?O#4]'B=>+7@<2Z>#>O-FOI2'?N
M'O],J.F3&U6X$>B'95+1S,_6=<\8Q8QGU\53QO)FQ2?L.("JUBE$7HGS#*UE
M97#Q>+"IO\<[8=!(N.O=/A\!U=&Q EL^BO;@<^AA7KC[%L"#\AZCB'=9?_TS
MVOM<U(C6M/R<XI,.K">QX.5LM]%:$S0 RSKA$F#OY/YNMO[&$Z="BGH#_&DE
M*8B3&PB45_# E"S4)5(";=Z-A04:PM_5CIQCB2X![7$; >9MJ5$%Q8XNO:1A
M./,EEY,:9OZA8/Q[P]L>^;HK:AR7_SA!\ZFYAQX\NH>6E1IQ8D)%NL?C_#OH
MIY=W$YJ]KYGA;MIO,&81,8O4E\"[3J*2>(^[*TM.R,7-%6_F>LG*;+0P1C-O
MXYFL7@M.Y($S95:KSRN U+(B4O?C/O)@/DN:SS3M!&H>,XA(<:A+85UZI%]G
M5G'\ ];?+[V*CB8?7';ZM8'B#9>TPU\VH2L#EZF:>;ZY_S3N-K'L$$BA[43A
M J<6Y?)3K>,R>*^N]<BBY_NBZ^10TU1T^N0I!<BE)0"YV$,SZ=VN^$S'8O:0
M8B80(D ?WX8YH?F+P4Q /LM)E4V:&:G]SA@@3(3; =A<C+<>E=V1V@<*_0D3
MJ;&TM[*XG"^NBFW^&R)8_PTP9- \NA0>%%3DT$ I(CB=8M4B^F2A'Q&=KH=3
MEDL@\:B/!'IG/TSX3\ 68$8"@*P+(#Q9I5)\-V0('\.<%@#,M%%A/8C3=K;T
MRX5:^/=Y+)\'/T\-/12SO2MGG5Z^,@&+1_&+LJ.G)5 X((:BM2;4++\0RSL_
M!M$NA--"D_;6WTH0@VU/$9TLU&-?5 A;,6,_")O'5T:/XS<8O'[&)(052L-&
MJ6,ZL!W&M>6!;\ K$0?P6= /EU*%?GI2(P.$(;@X7WH!SU.8PZ8 2J,IPN)!
MXIB[5O<7$P<Y8)H4US']/TJ2S@DI6HMT, "@Y['XR?_<,^,)0>C+O@AW% /J
M8?Z$5"4Q+QP5 M^Q;TJ#&<)W2J#?3?$ CF+SMI_ZS"5SZ?V&H%G]L.L_-02?
M%%F:SV8/< [WB\$GB=^:7P+[ *FTW -NMJON(6LS\D%13N@2UL <#H.WG3PJ
MJF=B6:_QX/KA/2 ,281)0.!2-718*)\ZQ(4[&F^!87[PJ*BP@?@4U)0;@&!\
M HBZ!)'*@A$Z&+M,2D#:&C\9E_8&,+43X([=1-Z/?E 8L$+C,1%52G?AOG[6
M>. B1G\MPK$B?F2@YJ:X@B) ?7\I20-@4_AC3N*Q<) 2HMT?H^]#V&F@%J<*
M?7TO(AW%93AFC?_?.941HR]E B&69[Y.O#MP555VGRTYWO8-7S72+/1!QK=Y
M=E8U289'W-S;IE0:OINM8O/^';*1_=LH!@5"L.X %7FT<,OE?J[.81_+#V?5
M]CW<\?RMQL*Y,9&&:[@#@B1";TE+>M^/%-X=SC">G-<W0IE1G9K7/)(_<MZV
M8^4J5KI_T&EGV1=;5Q<EJC^W&N?@+MB^0!/2N203T>/^+S]E1.>(<:40H3J?
MV!H?,;0P4-TUX&S,NV,:O<7KWE^<')@T!'\Z0_\QD3&+T?+ @4+U?;PWP9J4
MF[?:E9DPR])ROX_+J9I!S HNU['& !*YSZLYKIIEX;+TK8S&? N6>!6H,??0
M4.-X$/8B&:#L1H "Y9";-B2&<^#,=1)(Q6#V. C*!41Q>;F;F%",#,F.@1PB
MS0D=!B>R )9 E01[D$EZ8]'RMP_PK\AS%+RQ6@V@4-I+\O^PDU:/$(&1$%5"
MG@]'PU_N@#;TOIK?6\&_]PD*1TJ3P I+JIVDL;YNRR&7,)OG<C5>@7BV:@<Z
M+:_5-V*C#T)P-C9/J"P($J4RN")"W^4LHL+UF'L- <3,=S1,5LL#?IZ_Q,S]
MLVO-B/+/E%I/%.I2KYQGH3KQ-[L)UX05_B=IG[.!MFJY2U3.FFR;ZG>VSQF^
M=4JQXV3;&7))[C"]+UX\K60O4V"1^O-4#*MG*U[,^]"3O(]&_CJ6&[N<\/=(
MEGJDP_S+CR]=/;[]\I+BZ(D3V:49K-X#?/1N F$O2YQ)P^(8N1,J _4)9EHQ
M+/*0'S [J96&@241R8S!.2Q5>2HG<28Q2W/\L:KE@81=M-'CHCU%6$3!2L\,
MQ:T[U]8ZS-?8:[XC,1_QI?:0&U,%1(#RG1.D""X]2[U<O3+0Z&Z4RGNB:(0Z
M-.HN*XP!('3!1=B(15[W.]&;%\B<RG!>)6:$#Z]* S*P)=[9).=D#Z<LGZZS
MY%57SP#NAV=C><^N<%(DT$VIP4!%O<+<CT\KL<9=!"'X%SWA=CF^O5KO!GYF
MB=TY,\L02EKPQ8;I2?S"SF0><U6I@2578(W=[]\VO\HGT&C+(DPNJ:FF*;>=
MW#2U,M_H;H+*>Z!G\,='2;TP2-I*A3())-/Z\Z1.#)Q1WZ>0'#7-GEO04$1,
M(>=@UQCN2>.GW.\NG=\29L/2]*=W]9$;1WX9?03I^V;4>?]F(R%4_GWETP*&
MVR4B)B<ML[\A11:6"_P>(:VG.#W5I,6O]?3TKM<%='3U[(T"2)'!/PG46K'I
MN4C:Z$$A-U5CM<A>T(>%<L[7;,S4IKVDBA:D(@?]/&?BS*R?9P?XJS"D.!B^
M?(4DG \H@4R(,4S@-!7-\SO\UJA(,_)  ,4*.U?]"KO.<+]QI7=)Y^NT"\89
M:YE+"F<R-_0PZ=JQV",)=,#OT'#54Q;]AP[((+LDX2[-!*7W8BQQ+C*D .&Z
M,">:X6[]X;C:WC8)=/H@,J2].@#7.D(5K,7N'[\T,.1$SN6Q*@.DXCT!.4[\
M0ID&XD=5>NVP'^/Q'[EC\$N:@-QYQ7 E13>B\,&Z98LWW#L5IF*]\+V%GP$+
M\-!J;^"%(G[VZ* NKYESY,/*T,&[P^*" C;5'#DAMX:7<_JU[E5IQQ+H_K!H
M9_QZ7C60HMHU.+H1%I#;(R!\#@>$E9-?17-N:MB/%_F1Q1TQK)&5$FA^=GBO
M#3^ON"J(MJ'29_RF4K6R"+N:U U%$FBX7O"V42_,$7?Y3!MIM43X7_&7@C12
M>/XBYN+[#417+RG7X]Y6Q+= I;WPZB/Z;V8E>T[8Q1]@5;I>7<'O$IWODD.-
M1_J47BZ\WZ.)9)J"XUF#]+X>7)DEC_PCE #K7/0%N#+NQ4_=!J:KVX<<8C4N
M(<P9<G(L.Z'41F/(72B@4=\L[D>G];2F7JZ9Q0BGS\S5.[-4Q8:Y/ZT'Q ,H
M_B;UC\69]&PYT%3\9:6\_C X?$.F>L^EN9K^0=^L02[P!M@\6YIZ/[<D_F;'
M U(TNQ?79IK['VV07OY)F><^VT8**$Z4 SGJ)C$U]P'K#6>0FWQ1G41UL'S+
M089=01?V<-B3)X<D.[A(H)I)U*X<$&E-M(9U@J@+\/.2^T?O3]#8I;]EB9Q6
M?%?EGNT8E>%^MCW+R94F<&/A(>2F>E2G8%K_O7T@'IRE\YQ/%5H'C@6#T5@P
M7 +!H \W: BNY+A4N;]FZLFUTT"(,!DDAWJ0<LQR?V)&]^T9#RI?-K9N:M>1
MBSX=K"V!RBP,Q,Y_]^0Z#ENAI:^R]SP3%3-1 6!^!PB?;0BWW/RV*M]UT3?-
MO*\2R.2@GN9UV@\D9DLX+A_"]3S[+5$S__TJ]<LBJE"N2U0O$ /7=H0AG5,\
M@**;.\8OFCP6)I,.][\E Y7P;AXQ V82%-\)@C36U,Y8KCD^8DWA3-DY?KVK
M'JL106AHG=UWN,HG4NGFM): (+8=E;P9;XHO*9A1V'Q_'\W52ZJQ<?.=X>&!
M>C%2KI.Z0?0,-H/PA?ESQ$:H%^](^@QZJX7!SI!MET,^S"MV"9:]?O>9F5MB
M[)#_H]T*['-6.X=EY8;I77J"O$K4]#B/:A?'LL[*O>'PX;+*I%JLIMG* A$)
MZ=\'D.$:I'X?/+2"SB4_N"V!(ND&R/ BLF@7PL)G2J 4HR\WV*B5MIF3FB;0
MK'8=>3W8.67[8+]^P6DADR^[*\B^V.%(LK?+IWW.S8<;=X6$#%PP#L$# C!D
M#?GYPRB.F!5::1.4XO"UK"V5M<@XS^V(_W,]%%?MP+3@ME< 5 XVLD6[2"^P
M3+OOHD4M/MDO:T"%4JV.)B,EVGAE2<C]GE6:FHN^H)8., <$CI=(UA,>^<1&
M-R!>) Y;OM]+&+,OZ+L$BO=[0Q)/9_\M<NA]R;CS 1X3-1BPYDMKCR#Q.J12
M [!5P9%?Q:\E=H_1.>4ID(0FH/K%\I'BU6.$ADC+DPU$7K20A ?O(8]5/LIK
M_B6] (BPP@ 3NQ^00$N<7+ ]"#X_1#R74N69\'K^,VLQ(%:^.65O5SER HC"
MWYI:2W-%BIOQ/\LE0&: AB;'B#>YX5:-I7"S5)C@64C)/(KT7FQRH/"_!<KQ
M7,;?').,*[-_XZ\%LD( %F&;L&0 &82G"+ CE,C[0,P*QV2R:>)6+WP^(S<9
M>#R8)%"-AT!^Y2/HANU!.L6/WR(N#2<!U%K_ NZ=N+J. )B79 D*A,!R?/K?
M9Y-#ZZ4K@,$G_CDX_I%'QZ!C#)ZV$3X7H(>7\!"U$<:#14QLT%1H-V:A-6A!
MW/O3YPIX(_(BWP 8I/&'06*#8L:0S%\@D\&Y!KL#_2C;0P0!P[%&EUKW 8BV
M.NZ*C_Z4;ZF_MX%_[Q%8<@ YA#2:#U?Y4)\U\$?[0#F4;D9N,!!<W<7=(+4%
M )8QE=S>A8$N#OO9X\$K?BW3IC,T!65JKZ+1GVRVPZB!+(A;UPXBOD=C)N=%
M9B*!8L]&^1OJ>Q?RD]]V3K.O7"XG]TSX8.4\7UW_#BK/ LGQOB?<'3YK2EP0
MI5QM:.?MBYW:ZG)12I5!B[G ;S8/AERRKGENZV$\@2^E8!<LEW:F?JP9TMI@
M1Y+1N>%*)_I:YG?49.\E9K@QXS0<U]5MFMFC6=)56O,CR$!\8I9<F'%%J+O-
M<*Y4$<+/0-FHS<O%(!#!O%E@#6[''DJ?-3PW:P_)]CA@["=]S9L3]^GYW]JH
M\O3;BT?Z'A])MKE^;\AD6W]$A<Q[1]8*1PNS0?D(W41Z;R0+](4\?W=_&E@\
M &7DIGV\_E 66CC6.=QY(3;0@G,*A#X0RA,C*8CA5OG//9?3"D::6/7#/7YG
M3F?GV(9('ZJ']X^HN36UWT,W(R7341!A2=JI(*+*I*<)D(,TJBRMUX+TQV)F
MXD#G@,*L4JD&>$=ZRFF!)9'W"LC GQJ#->C@FRZ!UBPW0TSC:=?Q.RHI<5T
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M>0TEBQ5!AA@U("UF"']ZD?NU7D0%YGV00%GQF(P/\M$+-P5YA?3I@KQQ(@^
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M]^O_+O%?)8#ZCC)3073"H"D::%VO(V2Z6# 6U0]%B?54*"KN;7<38GPDT+-
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MX62P(,M8AM>'3:V?+5+QF-S*]K/B+L*@D^7*"7;0FIB 'Q<IR1OT A<2H1/
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M4XJU[*Y43,[ULEVV4 WH=-LX&H# ,8&Y3;0[+/2?37?))'M4EX2GW=UK6/1
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MB[#2!*V<Q%4I^\@[HKII0&*F1L"E/H$GP:U,3C8A.\[B"PSNXCC<X>A.BI^
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M1&)*2P!=VB<YT[Q/+7EWI;2QZ4WN\X#*[O!3#:?@#Z SZO*>3* :OA=N/V/
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MXWV#'D/Z:C.*I>:P=Z0-1M2JI1_1O;5?#;F,-UX[_3542"A@<K//\E>0'R&
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MI%7EDU2C9-;YW)HXP2ATSJ60<.#1<S5R\0'K@Z$=[U+Y*;VJ:).AL5,0AC.
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M69SS]!^@N'[S-_![J>]?BO]SE_I^\YN_AOD_>GW*]@DFBI>@&$G1ZPK';.6
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M%.O6?P#C^IM_0##1((*BGUX3<M$N/(BY*O[NZ?8!_N*;#Y^)&P%>G]4*JMP
M3S@$TX)$BS[H69\1/NI+XZCWCJ)M+\3MAO;UE!O)M]?I#4$2/*T8>1Q8H-.3
M_IQ]Q?9E(=/KXHE%G;<B$UP3TQ$5(#05X'04 5.C2=:041BT+>*6[)=4 U5A
MD#3*#JVI=PVZ/IS+LB(I.XI<^P5^0FE%./11 3N2V(WYL.68*?,WRPXF&AZ(
M:W5J,G<@6RTH.YP3B1&\U!$;Z7-%Y,'@S$[ROF8T8O*9O<E:;&+4ZZMWEO[
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MD-)RB<^6=S@[=R:GRM;4Q3&C!3TH:1 PPA@C.9V37-;?;4=4GW7"W\J'W2?
MBV?+4G,(6RV3>5G[_KKY&[,B@](0*],AH:KJYF3?CU3 2RWKR08.*H"/V5'+
M0NNY]Y-OFWH5%>G%P#\N5GP\SQ=R_IL2ZF"5"@C1@::UV]VD_>)!^=;,A[.K
M*R(DV#80K)F;9BM+YZ8W W*GE>TP92[* 3-@.UW)OI:JX1<OMC_[Y_I9!T(_
MEE\$ULCT!'_6RW@$GBP<F*BMAT6K6^H=K26-UX^6E.:5K+8L46J43+V;TJ*4
M=O._(U:-T77V[GN!E0?/:%>$Z^#?KXT3[E$N6A!M-WF_[&V[X]SP;W_(1JN
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MS4V3')[<-3<Y17?M+OLYN0,VU=BMQZ[0\ ]XCRQW39.U%3U#\9V1:'QS;]"
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MQ=Y[136UOFV_<5E0$%&Z($0618J *$5I619 0(AT"$)$1 @!(](B!*)(1T1
M0&E1JI00E::T++J"B'0(-4%Z2Q#"%%*^Z7_L,?:[QW@/OG=_^W"?S9$Z\SSW
M?5_7[VF!_:S#H< OK61(<B$V_/?(P[GDK^ZS"ZP,>"*,:1\NBU]V*Q]):\6W
MM>,C,CAI%VHOC0NL.&P6A7F"?9/%A;Q,">] ,EWT9;F0?$_2UA;I%QC\$19<
M2)<IS%U]3RWW!!?25SFR&V*/,^+\NLIIP*^;9M[E0OXMXT*0>.87$).1^B%@
MJ,V1Q<)U6*> @U0D8,'1P=VD0UOP1R3;!MP8/$DLJWS V:)A<"XZ]%4 43?,
M=7UD#VZ?.S4\'QJF#A?3C:2/]\II?W_QQ>[/2'AVP62*:<WTW73B[I&J5-^"
M]+5Z^>6Q95N'!68"F)GVX T^Q#ZUK^G3G!Y7GSE'KO_T?'AZSZ1C&"&?VJMR
M(/%8&9$?9I;H\DKYJ^KR-<<GY#,B.S3X@1?R@_Y&\E7)9QD3<K%T_6,11J_E
M[36J+$X>^WA(\6;T4=OYTH!2ZX\EE@'C0THM-^O6/Z<TK=RG/:/J;5I>J&%]
MM*XE9GU0%?G]FM'+X1,"FV^&G5L]WLN+_<7,H3\OH94):-S?$HC>1<:'J\#1
M_D+"6?!!+7A,)C26=:G ^X'NJW7-24_$P(;OA'#FX='C^AO4!9:8.^=(,$/L
MYL!6 IYB/]Z\6U'H)U+=2&Z#07"F]"""<.HYH["K[;J$R,ZGFO6!=_3'B>9M
M0>D_2LZ;*QN7=W]LILT="XQJNXA8-DLTSEPGJ)7U>-UC7 Q4<W"-S_"T/C)=
M_;EV<X(=G/>>I4/#\P/=5P;TK4 #<7PQ7(4^7.V=40>+;= I<T37B1(]%7#U
MC1<<^M?5JO;VG,X%W4),F O=7O-_BL@(#JH1K=49&=%F!MG;_W*9<G7ID6HD
M%A(;?+7:>WK:OB5?QARXOMFC69'<+G&A7KE$-O,[LZ;>F;@GB?EP)YY% KZ"
M_09&3(07[OB(.DN#AJ1@6G,5&=*93FI5O5%-4 :^7?+:ZY,ISAC #'?BS8KA
M$><O\L;1\UU((9-@7T6-WJ,^Y6*25#Q+3)9S)(KAX/B!SLG9N[%D*#"L]9?H
MX:8SP-5.Y+&MV*_*GQH8,7$L'?>91-C1F7M[;34SC[]%)4ME%-YFW#^UPA?[
MH/IW8Z*Y<^/O0-?01Z_8GL<*NU;ZYAN):S*AS&F\:N]PIHK>]:$MPG$4(JC^
MS7)F4&T>6M2>DIY:CA*KH:2GE:)&WA>VYW!RWCF9:Q5NITT(FAA4#U7U-^NK
MI;3+YA_2U>JIF6_^S]0G#LY8X/#J[1T-_S;BD(GI(%!"J<BHP#7=X)I!G'PQ
MVAJ8[I0(8'Q.G!W$\<U(PH6Q+6WE\5\LIN(.3Z4H7DIL8<'?X9M;D'1SM,K/
MJAI@:);?E><.L62)"SD4KFSD+BXE-3N$4RWR-H*[21-D=]]4Q+IIV#EHZ6L]
M:E\NE+ [A2QXZ</Y=?+..3JNDFAV?CGG>E&CW7K2.*_*Y@;8EJ))G".)#(Q-
M@C%]8<US)HS/)N/V9I/\(D<+,+]#DI$Y#CRE(:-Q*M3BA\:\K>7=52\D)3-@
MA;O2]7E8PO4!T'L2/<T8QYZ4(Z[B"]"9TF]192B)PL26C8@=R\%RA4\?FZIR
M#GO=]RU./RF\;N+68V2F]:[>'JRPH<HO7DINS9MQ(7]3[7,L4(.1>YMFY\'T
MJOTVE!>O\G?OIN,?(9<?F(6STPBQT[NOT%K;!)8@AF-MNG<2/Q9 3^(DYC;=
M^-]X$=F8R)ESX#2#Y:[(B5&%GU+"CRSBE[RX$+B98A[YDN$7Q7+\<6Q"*T>P
M+U!=$%OFTL>Z0)V4&-H(#,.W2>2D)^8MV?N]D*L?K'8Q#D5+2CIV*X8FE-#B
M3"6S[SK,"[1- ZHDEA /U9X8^&8%7PV/:C M0]R?%FN%'P5V:-$92O8>*A@:
M>1_@[$KW63UYO2U<1BY"W,-R>3B'=RC+%F57.LSYGEV,<;5=JYN(&RJ&(])D
MCDUL/L,L!9$V87;O2.W$_9QCA\'<<5JQ.8P)UP,R6B4+-E-<\#,C[9U1<;ZE
M\Q;[F^L6X[4OZBV<.#RXGM6]+Y:M#$CNV81_AU8UO=8NH_/-!K?"$\XAG(V"
M2Q!8]?9,2R)Q\?V-YK\QQ[$/]:(8/#&9)AZV"<X#FK\=/SXFG)\O=?/3=-"Z
M9>#MQT$-9+MS(4^T,&VO'/*M*#D(_[#\BU_97R=VZA3SWFOQ*E9 :="VC6@N
MY'"#1O L,GX*!-=6.,^HKLDC&D$:R+]&3XHA%K[4,SI*Z2"'NA47_#H\_?7Q
MQ*-*$3?!2^)%_S'=8W(5XZLI0Q^T4^I1\O4A\K_TXE4V)3NA=)=>0+[V"6DC
MH(0+0;W2A[\;O=YG(?"$(PDRL5WD,[TQ;)(EW0;K<//9EI./UGALTLZ_S42!
M&!C]%@F07V@CF@T8OV<7;R7Q+F=$'J8"B3.DV*9] W>^VH&:S(#'X<ZXSZR<
MXSN:13K>IO&YP\HIHWC9\;LKIO3.(]_0/=[T6GP,!O8Z:?C!R!QS"Q/J3&D-
M(S(P<Y]W!XS\IX09P5'ZP=0UE?8I'@8LIL&#:O%P"!, %P)L$ .XJ]2U.SU?
MCP07KB",>N:SWCE?LN<S*/S6IW& 1TYB$9T&>C8GHD1H\5C6QGLKI #N'["'
MTSG_XOD:3$H!DTY8]<B_C9)M%)&?NT&U;UMG&U6<!@/"S/H=:AL&M)S##EE8
M5+$MN[ _P52KW\3X+)C$SQ\NL,ZO 53W_,,["54.L2:1AH<Y_7@>CARV<:T"
M(T./B<&A"\QIW65ZB@@:<[.S5>?".#IC./V<4N;N_/<6[%E:6\;Y:P5"96]=
M3'+Z2M^B?]7Y6]7LS%<3?3'^6O:I&<HE%EW,.9LDK3W$#CEYVT78RDGBH @#
MUI8$* FLGJ0GM5%JGQK*<(8)^W$&M)Z_-F<M1QHNXH(+O.N^1Y50;C!W,EVK
MW?(L2FZA$,1L1H-#B <K:(?Y4<D\ 3O^5QWR*;(V9M5S[PHV'7J0)<8N,CR&
MN\)(&]01$W4]_H.%+B"(>)]S^G=')Q65>ZHA=\!I<+:R)G%=7;JEB^I[VB1S
MIE.BDM^%=UE_/=&.#YDSD)E8_PLQ_*OQV1#"\E9IH8[*>)JE_L@:>HIC,AS(
MNH%O'B!L/@"]TS0[.4D$O^RGBO?9_N\>#G&"LIZA\!$D3E9R9R;^\R 7(@)C
MJT*[M?!%GJP3E1RKA#UI+F3L0AT7,MC:-L2Y%\AY3: ;]_XV5E\-!6GY.\@2
M-@)"#I5MR/67L%49_%)=3%8J%])@RX60U,%(?+*+,A)VZ"1<$W9H)U<)L(0=
MF*?9Z>LD3?)S9%5MJSH/-@:>VC6H+^59.H'M[:P+S;Z-!'C^30]78.2DU(2#
M&JJ8[V,X(@/%M/U9%/%',;"!(A^29N'/[A.?^Y=?IGO2\I:ZGSY&J)#XG+U9
M2:]\^T=GW_'$+T4+B-GK#]*'%J13$I4^D8WS/3=].AR?Z4//KE@_JRNV5B+9
MA>8S.^)96X ,*.$N8) &<W[L)C;%T;N990!:FQSL)Y*3%,/"J%73\UT&-XH\
MKI<'^*K3<I-GQAN#UDT>?&C.,WFG7Z"3UJ!R8E?,R;;0_H_!+KR$5[UN)K">
M<J-?*,H(:WG!A2HOOU/TP\I(Y/6?-40\/[D0EF@KTQ]XN@>:T6;])G5 DHJ,
MJ180P_U#GRJ<V8B3EJ;G)F/\'A&QB?HG2>,N*Q37N&**D<%P&?$K-33Q?IBL
M276T<P_2*F+\QH=XY_$R[#AK0BL,:D_G%(?E@:_.ST/K>GP;1J2GEHU.+-7E
M$A[=7Q-I+]R.^GES$G&K6;G*_[*?\,.VY2^+Y8>A*^0R[UW[)X7+NO/U)4N[
M:@GYHY/>(34?RES'476N&46C+3LZ=='Y[US-^0L3$W,:'L(#@_TU;SJW2G:?
MC8W_!C/$&8'M=Q5LO[N4Y0_-%>$CR,K<XG=+M?Q2U9.U\0%)0JUH7=%#YJKN
M9C&V'VR_!TU0IL1OG2HH/P;_G#9O][ZJV%C<E.;V?2'DOFESEX:%(2)0")ZF
M%:I50?1J: CB30M)+E%FO%5S13XR*I$;KVN@EM8W[0RX_XX"\0V-]X EU!6O
MV95S!A'D");I&YPT7:<%C.-%"9UGU6$7;/H#D.+8[@XQW: D3!YP;WV9(@D7
M["Q<9.ZR.?7:.5I#37%^HHDBOZ,7;-X[<'ZJM!OR<OIA$)C7VIF;(X9_L3P
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MI(BFT^'#Y/U54%$OG1$)UT;J-J,CHVPY4[H$I3?NBD(,5<0H%.U:EKC[";]
MHNH>US9]3)/0>R?C%O_)IL1J<R!RV6#M<)?EY)KPV/GLTZ1+QBH-!7E-S#[F
MFLC,]'Z\-VRLE_GJ_= V]#%4@B/)NO6T=<,[]W3"OQRE_NW&JY=UIH)')9W[
M?1=TBY*EP-);$=ZLEN_I*[)4\UF4I%2;Y9D</DBF6\%&>YD:F2.6[+<<7:Q[
M<ZY"4[1>EOK^I6%*[S-6J%;Y8C]B&CXS?7"IC@N)U22JK<H2BZJ)CDMU6M]B
M&4;O-.-O:AE7E88J]K];YD)ZJX]<V@%4>VKJ?=_EF/G%5/E'Q/SZ+ ]E\3)9
M\.IWI*_D"#S=F0PH3'?B)1;QQU@JC'FX -#9+E&='D,EJM-XGC1@9KH-,':#
M%7D?!U9]&TQ*O:ZV#-<ZC/@W^WIB2M$AN!T'(1/^AH?7QTU6Y'6KT#=3$KWM
ME$S+"JT%GZ+KYLU6>KR.EUF6WL^Y;FLZ]LG4K+>R,BC\K9&PO5$4/J6SL_>W
M&D$"OUK.,OXS^N-$VBXF_3>CUUL-.JP;#H 2?LE&_\:"#XR(['K]WPQ6#_23
MOZESCNB ODN._8R\6H<UX4*,>Y%+J@P"6+V:H6,C+=/T3%8@6#EAD1SQ1W=K
MJX9P_C27"_]86&\J-NP,5)FCQV,W B=O7CE:5N@U/$)YEAS!H'R,\+X8?3Y=
M74"\O<LRZN6=+-\]T\64>LR/AK?OJ"N7-%/*@L9-Y;]*.8?(CKPCM>> +N\(
MF!B()<2K 2+8C5FW8BWIYJ6+TSR&9[5?'^I0'A ;9,D6N=ZZ_"+HJX='@)RU
M].G%J] *LB<<4"I>E=VS7^X#_&>"U\[,P 2!BD?N$;W-=<LK9 %]CY*)Z_LV
M V"\.)-^_3,D;%S^65$'.CNZ^*B/\=(_'F?:<P7$+/5_M3I$J@8K6;W+R\CR
M^_A[="L_MK5GLZ-1R3S/[O3XENDD*ZE>,2]^01L6!W*C/\<2RG0&?8\&C<2V
ME"?-99)+"/_=PTU@NX+H&"3VQS4.I!K"SW$A.!)'D0M9.@$;N, Y/ 828CL[
M";_Z>A*_[$;S9FN2OI$!64]6OAC3 /PDST NI"0FKFRKOTE6C+,3SX6\CY_>
M?6@RX,:%3"[B1S*1N]>NQ*O,X9/PM0*K<7OG^%XUZ7/ZH'R&IY9K/IS=Q#K;
M,0QR=IZ[\L3=,R7B]K_-L>FH_: /ERQ/#SFZV.+XWC3=8+1%J$1>XL'+G\QG
M?\^=6<S+POL5%(JKH<PTXB>_%F3TC$%MK9#Q==.L4Z"V'ZCL+W;T:;J$+6N+
MO7MX1/=,<U+"@V;Q,X>,I4_3PY_J&3>RWLD]-*3IB"Q."X"6Z=,TW9P42\FI
M2"SB#%*@,5IZ#0?@L=)'@ PZ%W(C0=Z!K=+&.4L/RJ"JW! ]J2.Q=1O2NR/\
M?A%[ROM6[Y$X<_*'DF)2??'W#G.1Z/O=)XR:$BBM2/D-;U;R[E>CA[E'& M/
MFN2!AZT=L&,X3RH<"IC8.?BJMQOR,D23::1CWN:2/LGE6HV\F^"WU9_XI#@_
MM?S/,]X: 9&AD0L6VIDHHL1_P#-QP,)%K[@4?:\^2MCJ^E_QFYB$:>GP(RP(
M?1=;-AO33HC!'VDPT.L1R2UA\+3O0J-4MU5B3]Q-[S65:%\KJ&L$C*_4A;^6
MFER-ZG.OO1?(\TNV'49'P@'YC.C[Q1\3F/&#^G!_7[WQ[_JJ]%0:F_TN(.S9
M#^_@7)Z!JJQ%6)R:YM[*)WEXII+< 4]O1Q\C7Z\?1+O@8LN'2!WA_M^5EX;S
MX69IJ&9F]JS8CO;K/1FC\%LX,+ B^O'-Y\//>3_PRCW%+L.)4=FN_A)$4ML:
MM -Y9+4M5>I#.Q=R1* -<PR+;NGOZMG\';3[\YOXN],8B^GBD/"W;F6.3LN9
M=MNYQ47>VN]=EW:?$_SYUZ*V<[ZAM:HG<R8KOV("T7Y\!>]O799M/^M#DOSX
M7L';BFA4B$@SLU@MO7(3,_!:A17#^W)99:#D2$6%X#/BRKVU7_JI3! *4K$
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M[V9?M]\,\M 8$-/.9'P7V#V;ZO6AL,]!=$WFN07Y")P+X>'#-ZO=:7*^SM$
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M6BM?: GN##51_9\4&F3YN<SK+6;*Z<7R$QD/2[Y()R-%]/S-,ZCSN*:,()9
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M!Y<'U/SF5]JEZNJ+3?S+?2;X>%_WWQ'99>>&)[@?Z^ TT:_\9[C6VQO:*B*
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M,,Y6YG1"ZK@8 P\F&+2TXU=VWF0!?! -;VM,Q*?E9OLMMM$@$E#F;L.ME/Z
M -(,B<A'4&8(.!94$"BB K@A+'X"PS#"GNW5"DX(MZ]FPF+"IUO$[KL-YQF3
MZTELQ2?-QF&H Z38B@K@@4^X_ 1*PK[.VL?)JJ$8JI:(9[IV7+TX7B4JZ?BY
M2*ELPLJ /9=H<A8AVQ2NTF1N,J[K>[KEX<'S,=KV[Y+4XRTN-\5PYNTM(]6S
MX08J_"-KOQ+3 4$$V\\%I@HP-UC':\OH&*/1+>CYL5F1MI''TG\!"3.[$=6<
MR9#:AOM(=V:_3B^JIUF6^2Q=94WZ=O+;=.<<D=LT(MYR<X-_M$%PN@D@;M?&
M1X_2"AO7=&/#VNCCK6KS(P;&S.P 70&6Y'KH'I8E2SUEU2R33["DSZ7T3K9+
M9.@T9CRK_-;P@8V)G>!#CB$A \&1T;LG^!T(:8@_+-')JY42+65WK2#>$-$M
MHSM*0W/E62MMJ,"S+6//FLU"CQJ\[)=-\ 6;UCIJ0T.M'Q!KGIF<G9O*);$^
M0'RJ28P#>A=#WU06>*"L4$BK(T["4Q7C"M2K]](P9K4[)"7+],*T ND?KM/L
MA*73NF'R#]:J7L*!G?@]T%_^<7DLWVVN**4=(KS6K#C;HL_$=5#.&E;>MP,J
M F=Y@6WAU=3#:@$ZT0S$\2F3&9Z&U8]3^+38ZB)T[O?IJ?,O-^!4KY-34*X
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M>Z3+&_7^Z?UX^9^_M%>H)<87VPK'M)4WJ0R%#*TS:;/RW-J$\,*=*RW2!L!
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M'NA/L=#$X9M3!2DZ\)<W[KU\^?1RXZ]* 1_%[U[;_]OA\Y31%8XYD!;!3N7
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M.JJ58X'W*^L:LZQ]]>9NGA5J!06V?M$1Z?2T7"6P+G\_9R%M#7?C#9Y&@ZA
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M='V=5^]F:YU:?!V:A6^!Y:@_9Z9>45W.>)+@\#2")Y-**!A"XM;Z^(<%<^6
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MK/Q&JTE;7WV7D?SZWH(;L:R39/'FS7UQ8E;(X\CUL:;(-'Q%*-X$%PYAP40
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M)D3SA=B*S]RT;"KDNQ.:30J7<U4;&_=E\W16G+)8Z:I>JN:$^4"^D& "['<
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M,T$%-\]ON83Y*74/W:'#NWKY3!=ODP@4[X-*;NV#K(G ^5UNL0'[ZC[HHX6
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MSHBC'LS.>KCV)=/R0@N\QF<'X2BAH;LZJ(E2HI==-0<RD?]LA@?TS40YS0;
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M)JEP-NAEH7# .1Y4<;7Q'^X5?/:5,?6CE&7WH*S/VQC@:AX[<!\4F\8Y%WF
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M"24ZL2,JND)Y.*.P2LE^$QSPN-;F3=SR]+\3N^$;2NU?[#K.]U"7&UF[[ !
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M]-.C;X&X"VL2<LKCJ!GEI$(4YZLO4O%;"SET3G+7*UD3\:^;59;E@]R7N)\
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MH E$B=GCFT;QAYS<A]C:953\49;Y1.,"\HB[C'2]D[DR;9>GCK"\C25)T+1
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M\#[0!O$?2R8,&@#*\/]8I<'X_]EUZ5P9?/,T^!)Z^1(1Y0F"Q$G2N-2U$@@
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MF#&XW:J*L+VM6&)NF@]K+>##G(E,%KZ=S#VV-A5RV9Y7;2C*.CXN#FE'SKE
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MOG]\YWV%3F(4[F@@^8)VOYI_NU3GQTL+Q0='IL)O_6Z;Z<J'7<_GPS3)+-F
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MG-'40&;G<P70;\ CD%(N:$(P_W GLQ]4$GH_Q;)4-()K5<7X,/HM9"P!7',
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MA\:OSM! [Z[[54;"->$E*MHM;?OM>'E8"XS7K,"M5/(UEC7]A=3SR[#"&#_
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M/TRH0/@GKMF@6XSV=R"/>W-0"R[=[NMW0FHV5=G,OQL9,X97ZVH=(LD>#U5
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M)0YN<-*1U@/RMXP2V$RJT97](L"K&*#(YRM1?(1[D:5$#VZK"1D3'Y+19CE
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M\]W0PT7_@Z+H%1>$:G*URC^6?^([BY&7E"U#Z#M<:H-,W35%:%V-@Q37I1S
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MJ=),0RHWG@>[K_F*4%G5.J8X0?GL>Z"++GS892OHR4HUQKV,D?(,JZ=RW=?
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M(HI"@_)0?-+SJH=SCF(TJ;D?)+:/JWRODYC "RT::C"#8G3,$5+-&3*,E?3
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MD0_,+_\PU2U+S*GK[-88[)V8/&O59),X(#Z0V76JJFM0>Z!P:;!6)P^J<)$
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M-A6=4[?XA3;-+YL-^&>\-$MKJ6L8_S7YH]<%MVHVQ07E\_1@!%D8[4:.<;H
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MZ3/?09$JZ1MH&TQ-&"N7*[1KK&^O-U0W6<:ZAKX*^KQ#70(')SZJO;/S=VH
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M3'2XS&A1XOG70'+KW=46Y:"_!TCVX,- 0#.T?O2B+3JME NRAR20CW D66C
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M/KT 6W63O(7?8EMP\4R0;3*[1_3J$QLH1ZY3;*9(3E_V@/QK>6)!)2?<"@W
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MKX#=+_.NVD4I_*-./C?2T]!PW?:SW> (I*.D,7.KG=;$ #!%EA;G=I:^Z6_
M1+K-'Q0,;_:+543CD_?=S?O$1AFXNH"VV?*3Q47^1M3MRNIO]^P'K:>VU-Y=
M(,RY@,$F5ZWVW(4Z8X-4!(7.[J_:G_FAV"[W.=MB3BXBVU^7>/#(\<.TXM P
MUU;63UOJB<U3SBR5!+@C?/Z8AV8N\+67L383'!M,09S=6.3OTEBX4Q-*AY),
M9Y*2V":HH4OOYW'IS6E$ P?:8+JLZ3W4HL-,V#.RE^=EUSAL<J#:W]A["*>U
MNAKGVCL!E6+92 !26]RZ?KS<]GVD[7OM&INB![N.+WPE)T'XMBWVS!MV'#.-
MPW__WPVM(9+&?(#VI/?'SSK%TLQ3DQLZ$169>>XF?S%;^5LJG\0K1/L7.#Z]
MJI%_X6?M6N8S*1IT=6MFJ?/1(HC)HJ^2@8,&4+UWQ4 ^IE<O =&-X]_X7<<!
M4-RIUM5)&1=RG_OKQ'5]@12V1NP_B58SU^*/C.W<&\=NBIKGDKUSZ[YY6EXZ
MYOE$.2G+GK)M';G:SBL:JJS4256RL>-^[2-?4FXM5;S8',D6E&(X'97A? )E
M&,:(,]]B)9FF)(2@W\)-6ARZ.WD/>'81%MRO+U%<@S2I&P#P"[I- 6(Z+7O!
M,ZAP5E&DS32&WSM 1!>KNUG[4S\'F-T6S!:CL*1N5YOHU-)9C%?38=-O)*'B
M5NC$Z,#/M-K?OQQULD]4JYI^(GB#I3]=<E3Y.W.]/K4G#RAJIGZY04A&U&*H
M%AEE%>5AT=X>L%-31_LW(,N^Z(I%11G6.3W"V5I%+:N%\#CDUUC",Z3QA"Z>
M7\]&\KJ.>I&DDCS.T\:?&:KYA(0"J/TE288R97,PA FF>)=43-Z&QMVTQ:2"
MWQ"KBB8J<]\04^A  HMAP;1B!;+/TP4^265H,E-BQ=&+:X<] <879THG8JU+
M-Z/YOW9,[L>)'6[W.DWE;1 _?VC6K\I^[W\@?"#8'^*CONQ]^#1U-<.B)Z#"
M>^;>D+4U,,K"H ;2N:_S)+V,I(CDE00)-X=@4$&SP']_ I>XI#-WCBB2Q(@_
MJI!I_-8''M+M%0UZ+KA;TP'YS>3BWQTW^2Y<87=?CL6P>%DG$=V&72=^39#L
MDF26?Y+Z(]@PM%[@*I0!EZ4C4CC7-Z.#&LC\7G93>W2D/^W]6K14XIX5OZ[M
MLWKK(E1QYE466EUR=Y=A(HXD-H-,'\-O7N2UP42-\5>1M[+]B>ZRZ$?9^/KV
M?Z=Z2.M6Q46* \[0-Q[K1A+UQ/KVJ -/R-C.0 E3!\?08*+I@@-2%\,@*8M2
MQA)NS/D^U_%4@ :_WR'^.0!W;IU0W%YM6P,Q+36O9RI3W#%3&3.?Q_GK2]$!
MC7>NF$L,]Z1P/?&NHW.8)H VF5/ME*L@F],:Z"^[75_@/U\YFQ\W%^XW69=5
M>WK4M 4]T;DU4]R)6))*D&H$L<5_LJYQAA;%.@3H.W_1=P:.>9(YNLR0]_6=
M)'&I*]#B"XVTHI>M0I@^X3;40CX)?6I=K+XT].\?1^\'1#'['\#)K^NWT/?_
MD&K;L[/LDNZ2MPS?L*S(6K:Q]8G8RFIT;=ES?9DKYOB08GGV8A!5O7[('1NQ
M9U5M9RJ4\@[4*X7-9PM2EFS9EX$D7"+G*CNXC=Z5)A)O:*J;:BA'1B2US1:5
MPS)-9]2;?X;-?_TTNV=[<2W_,*(T@%Y)K>1D&+Z8ORU7-)KSGP\P= )D4[%N
M U :ZGD2R<VQ4[L__0X!Y5_>] "D2;=JS"S'-![AT*TEG\. -"AB*QEKL'I4
M"O3[J;H+##F'.^?9.E]L3BCY!+KH_?(WEN1OWVNN@K816S&LZVSIHR3.:;\2
M'LY99(HL#9[Y'BJV12A)!\  .$%HP7;GD^P-UY:&.!_DNIC_QUS/EI:7_!KW
M)K>NM6">23>!+EDH3#LZ[]._=OSEJ((ONB=?4;:5.^FO4Y9+L-Z)VVG-506<
MU0JMM+R1[=S6N46M0LW[? "M MF7N<B=\NL@\F[SYLPD1HE8N&TR7 3?)6)!
M-J/YIG+$-PO,\FL(8&9#F$.]?T%E?G(LD!PH[C05+$]C9#X1VEL#B%L$7GD0
M$/':?6$P]%#3U,L290F0<<Y9MJD('E%L!X1-_=0F^*]--6F_O6ZO+B1=><:5
M'F.@C?\V"6TR_Z'@PV6^C_!!.K%V ]C,2U6(?"A[AS$;"3FGJEYP#1XFDAUK
M//T0Y-DSQ! ^':6)LSQB'14"?=%)4HWYGXYYDA:;=GJLW)VG2 >]@>H'UE\$
MW:9M4'7?=&KJ-CRD9P$2(+O=P/+6:8![Y(/I?:L6+*:IZ67,8.KPV.3DK<"R
M S&5 .8W9WG-C.BIFBM=/J(N<BJN# OY+4(['D1\,]E[O^Q;C7VZ+%XEX  S
MA9F/=I=GS;FI[$YQSO)QY7KF40%7L99+2M-\,SBJS'ARTO..R"7(^5&2D4Q?
M"?_^Z.^?(; (=YN=!TF6^+ 20:9O'T/DR=<-UY>5D3XA2/G7\$;(6+YNOO/F
M'Q<XE1,/)E'.+V8L;^;J#3!RW(L*FMP+H&';&<H."0\^.J:^=:\OF+)VV(6V
M =\4J7#X0X]>JNV4%;HP]UF6 1%GM#KRG$''/.?":JH2[LD+=V:35JH$X3K-
MKPFU)Q7^-NO-7(LG\?;@3K'YF2ZT@Z75WA'Q# .N!<_%2KV#2?6T1.9G!XA\
M6"N^.A6X-W(B#O'D+SQVLC>HR8,XDM3:EN626G]4/E&-@E(T;^4*>31O*+;W
M6P[)SZ"]LSK;.N&[2IYK]P,GD5?T5'30$?E6+42<>^19VF+F8I/Y)P@AO_MF
MK.'1.[@0TYR<GP 9C[&RO;3>8VURMZTUXV&A'6TP64T2WR=Y>:98]@$.P]9]
M[Q_]*CGJSN:(:M*WZGK8\/VL'&^*8GN-*4:6554W]<.L,=W[K7=.V5Z A3;^
M47$ZQ[-+D^O"]5PX/N9)15?BF KT _)JSV\A*B/RK\F=4KV+PGLJ@,=;V,G7
MOLPX\NF_;V.+P'T%Q-X+\_7&?XNLF/Z2-.$XJH :+LA(U1_R@X%K0LU-"Q@!
MFS(')AX;0\B<Z5N&@3(%G'Y%M)G>@-=)GY1LR&*"$HY]]LE3A,Z8GL]7/8,V
M)>#V6 6(*"K;92'U.;\[DPE@,1QI"7O1F0/C+Z6$.3>/BAVSU$1Z"? D6GYO
MOI]FEX2KBG\'E.Q/B=69G8P%E0Z_$<VEC^_QT108X4P)EA9,;)R$^P1,E+S$
M=%_:M%5;M*)U%>3]V(BT&Y 6*TD.3R%0P'3C1OIO5PF+R1@)!^>BW^OPC<K5
MDA.FH:"!APWZ(+1^&MQY,H&U:VHF\F.Y%<--!%(]E5>,6E%18*PV6B7*3;$L
M=4476+28 :0%(K8@= A9(=U8>@TGV&4<J]]*QR9C2BX'>(A-[*/_@,)%IS!&
MD?=+[+O2[F2ZTYP&VJ%(\=HWQ>+N)AXSWB]NO#3(3;@DMX>;XWHH^^@5PGLG
MPX.7>5 %.Z @^A#B[%LS( ]:1F8Z8/RT"\QFT"V50.9S=]ZQHN'CPS) ]UL_
M1'%FO,X1#K^J]=W#1X"J?Q<@1JM@5FZM6D_""EZ>5^=W=^^OU5X.\@VO.F"-
M^<3WU-2\OV%OOV(S;N%Q@*%VU5KKG[QLYV9N02NA<JG_C[FCEXC 31=Y)IV6
M9C%M^*CEM<O76 =:+?9%EZ+_AWEDKO\%>E!.BC'6Q^MB6.-$!RB8+'$*_SDR
MS=+E7@C3ER[.X7=CFM9LV(_3\AFMS(RE(CGLOV$[R9!S'0"ZSL\S>G<#P;U=
M"DQ;/NGTFN"MI]\2]91-$*#+()]SO:*)F6I7[U*$FB&JY$X9.TN5[_GD4*<>
MSUKC@!PO):/O:%&@R^U^7.$N\"4+R 3H.D%?B"51!Y'= 9?SL\89$:UM'U^_
M:/Q;UH$-;7HIY/>';$/!T\8WI_"F]HN6; VNQ[IQ!='H[RL+FV0\]0R]EFP[
M]]U%RI96_(8DD.CJM.90(KVO7L>Y%L 5YR%]SWM=I[9M'VR7&2&0;2I1OJ(Y
MV;:7)A$C-CE2BV(!D)2W3[>NNL]<7CRHU--HLX?2V *O@#XE7Q48]X[2MM#7
MCMYVG65Z?7*MK_%NB\!01*7LZ1J9X>T:.N(IJA@-<6;9P0.ZRGJV![@W^E"N
MJSRP5.Z;G75PU9^>+\SWCRZ#2O2S:Q3TLW,M.I?U]"P.6^9]W3ROF)I=3)=N
M2;>WB,U]!?IN2TW@WC#SHQ>XQ]:A]^D#K4M%7DL'?42[>G4 1))]J6.R0RZ4
MS'\GX@=\D5QR#N+7AH_'C*P'68U6!U!N-]+E:U8M-<+7KX*'@@^IIDYB^]6V
MQ1D64\7X^(#-)K!%E#;^U7M[I+,AYKKH8'-6Q ]WAQ_.OKN"9*[I[PQM>^?W
M %N69U"%?RTX929S>$SC0H5:GX(^SX2-IQV&@03-)4\$3E#M?4\FO4+Z[2TF
M<AE?I%M-W/[Y*D6$"J+?))]Z(SF8;\F,HQWS]$+XY(JFMS6M:C8)._V1K)M+
MLL_Y#*!YF2&I*PMFH,S#FK+VXI WMW8[K+#A-JGYG#]J:N"Z>L[N\38;SW%O
M-P '>ABFE Q\&/&A9*N6)>0GZ%?2A.Z1$H#)_[C?E#C>)ZGUKQMT\8*AW66;
MIL=TW@Q,:W#'[9A'>,M@F8FRCI8OJO7NA7]-/LY^#-T?O0PJTANK>+MAX_ 6
MDX-44 (ZSP?OZ%.N]"C?2/<2:GZ8936A=EZ#K-!;\AL;3 ,EPZ_&VM"2DCJB
MEFR%'^B\(0//,)%6F%EM(X^ABI?>+[=[=O4\?;&MB7PC!@F.K0U=V):NI@*^
M=IA\YL_V7W_L.87CC!KKX8,!N'^ $G#I6-X67/O'MNP>N R-FCD Y//W5S$P
M13+#ZSMN+T&$7;[^>59: M'OH=RE7-%)^7Z24ZR(HC$_VPAADU#*L80A%4LU
M5.&+G+)%*TR,?T/18Z.SZS&N(44M01L6$?9I]E;##."KDM/<Y/_>63/ 7S<3
M&&A52Q13R?FA?<QSFGTNR6IZYW%O3?:CICJVW0PU;"0_75^>R@=*5?!YW;%L
M(LAAPON!M+\TYG@9?)CBG:6D?^0[Z-NEO@Q^+_)J)MJ3#NKK-!M])<MP/AQJ
M_# 5"Z@B4D&X2;9$.9,KF8JN9]MC.K((1/+1J;)F]+^4$,TG* _[^(6+=B\@
MS!P929]*JDKM:RO>Q+*?-9.I^1:Z2IB5M]]:(969 [CY0<[I#)8&9V%1Q'80
M(L[$DW=Z<<D''E(3;%V4.TP 1.LK.-_I\^Y/1IOU0FDYK*3G\/N7@+P6,W$!
MH.6,]J8%2JV49?H">WN[9(PKY(%,W6,>AM51EK$N4XK"R:4+4H+[@L79>M-R
MLX9R2"861(M+>D$%O%$-VGHXHQ$V?IX)M)Y!;ZO:4U<_).PSZ^R7[:W:K6:<
M3(^^EE5ZT5,S/SQ(3<V729*;:15KRJ".C@2JQ0DG!_,EA1O5EO,Z%!86C)/;
M(C'4F-J%^02X#Z+[-FXI9[$IDWTYB/*I#=]_!"6#XCL@M$V;F3#$>1B2U-5:
M]L#-JGSCX#[$S=]UX0T9<AY6:#6M6MJ94(_RF)VWGB[-B\*S3%'?;PA,N:J<
M=0JX7R/6C%0.EXFQ-*BM*LDM"-3> ]38"#TDV2N'1'1X$ Q^D79]X2^$Y R^
M6C"71]$/&-FX!A>[XLF!'Z3$-R&RUY_!NN9T>XG6%]_ZQ$X\BEB5UC)%W#[F
M^8US!L;'>,(TH/U8\NWE,]@4^"U6B[:,3(S5/56#D*^IZ2QJLM+&1^>52@\$
M[?/?V8TI9*UGJ<#$-E8@36 P./E=YNS:+QQZD'L%C])_G=:67I<5@=G* C4%
M[+A#0O4?!%P&A]4,\-=R@0B+F0_"-\5MH3^ BMB.3'-:.R7S^3XP"7(%+L6T
M(OL^PV0DW:=A,[35@'UBAE-]]6IH+\STM3>! !49F2'D1MXC?G.;MVEIXK51
M,]Z2*::A5>3I,H(_D0O6J *H(S[L\:1_5;:M64$;M,DV]">.N<XUR0BG?_%"
M,,;(=PG?!TPK^4T#O9('C3NE,GJ3#/FGN?2Z:L.#=4F%U)&!C$N:MZQPR=AK
M\E^G1OBRZ0D';+'"][+;VHOS+WMB'O$,X!>;,/T5](8"PZ27 AF1#6/")S3/
M-8+S_S4[6W93B-.[AC83[?*R5AP4E,__T5-D?LSSS.92/CED1*-[B/@E%4',
M6>I:&Y+;-=_U6MIA L"D_:)OEV+_/&ID^Y ->&ZW-M$BNU&"W9%!6F?N =2@
M9(',TO1GKV2S+?,5^)?KSTI-V\[U<DY;<*O#ZM';?8F;?9ILI6D. (:[5Z!2
M*'4I%H8'#5Z\'7KQ/)?^>D0\D<P84O-VMK)U,. @7D,=Y7T7&O/OMYNZ6TY"
M16[C4BZWQH7LQ\//N_K7C\\-B'C8WEE?^I!#I-P1 >MY1,000UM=ZC,"VDZ_
MY[Y*G?YT<N)1KKYR]MW?OV96WN#]/2]5Y<7&6<6R?PR1%"[B_0Z?D#H-OQY[
M@5GH%57-%" ')P:S5<C@0/U#]YMVK).'-2+Z$:6G?9NF5>MEGC.&GV:;2\QT
MF/DI)'U.M%U%V_TJXPBO(;0WMW8<L2R^^E-5M",BL27G "K_DA6D-;"FM /K
MC+GH,_RO_ANX_S;["&#GKJWY[UNMD%+7,(K"J)RX-A$5HSU#199FN!F=I>HW
M4W2%O(G;N3O0JF:<K<<6N_^8YWD<HEL1^.C7XP+JI93,B['7\<;RL,$!R(7F
M(H/;=-X4CNQF@02[Y5"],$Z^7#BWS+]8E(9/U![A Z=-G1S]CGT5$/VBD?!G
MPZ()#TQ\;R-511GS'E18X_JT1L]U-[L]PMFJT4)%MEF]Z)9]:L*M:E./"7#
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M@#W$=4-2$,+PWST6OHUH1PN.5K'M:.J%E[.TGR_:3';<#2L1?9&NF<%_T&?
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M#WWTPL>FU@(-+=%+CHMMNJ#?$D<O!WX(;F6/;9;0H-BMP)A:=_<UA 30[TC
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M8YF9-WBFJH[K8PX,-*!=QXNU.,8U]*2BAO4N>%S!3A(L\*D<^PX\IK!Y)]C
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M!1LTF,5OIX'>[2.ON'+NLIEB?B[8]E3']^_R_B60P,KZR!;SBH!WG:< [E.
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M[]2GTU0F&"7Q82-B5H3XWD6>6FZ*+1FH'Q_6O.PS@OX83W3?/R'2T8;)@#H
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M-05:?&3F6-=-W/2SD.4TD.+M]J/>_ $+Z0VHR4^* (8C6-!+DR.AUEGYDJ>
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MN$87G#M%V#OPRT8/KU?INO*FY]G>@UKVVD<>TN6ZYL7VN<6&U&%]VPK.VJ-
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MTS*-J4>\S":E3\-FVV-M(YF]-P#3DZ;S>I^W/!B2IE(NY1C(=2=4LDA9Z9)
M0> F- '*27..VE- -:1]<S.:+SBD:JXY]\A?7U7[!I[M&'%0\K][1_V?TE,
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ME%OUE[=F*DTDSLR.!-OT!6+61J.[]3,$>%P;)XR]W'/\I@T.]]!@HPIU\U,
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M0PG@5%NAGEGCU%XM&.::M,+@]B);7RSHWG\2/B5I)BJ$"^N<2+8GIE3;HY\
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M=TS) (]%Z'P.ZF9^4/%*32.BN4K(ROCU9C! =>)1SQ!,L.K\"\X:O3M(!K3
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M)[8-:K!]L%^ 6/]?:S.7A=I[W1_#68N@$_! (#+C O([\G+UCL>D^._&H<R
M#+T1&L#ICB_PXA270#GWONE=[+?O1NMJR63 WV/05TA=PF HB9,@B=$L7LQ-
MG4OV3;J?W:=8Y>V5ILM/LZ,VUUHQ&LJHX5SEFY87D@8/(L!\+@8%*]8E#1PV
M#A%[5=%RT5UM!'U\"&FA2PZ7A4GH!U$3@"$RL_WAKYNE7,'7W0%W>.KK39LU
MKT#H3Z'S$23:&G3[.AGP2GAPE;_ZL/K4<&N\S9#YW'8)+,VY;#([O!2P[%>
M."[&B&,SO^-T\-&X_+7L4N^;L&=$N,PD-D+*A+YFNDNC*V"QA1/_&26,4V70
M00]F/2L5[^,MFIL2U>';1M"6TW-D'8U>-:$QLCJMPXT^=NNCHA%RT[4HL#/!
M6AMN$3V<#;KX2NTR!_353<Q37M3F=:6/F>0O'D;_^^#(_&^/ZCX\G7LX)(G$
M:+MJR#XA%A_AX@3C>W3;OUR$IX?ZQ>UK,:&PF4.<&'@_&08BJ/Z,5%_WC!-<
M_/)05-DH)+:BZM?YL.H6S#'">L-Z/YURS5]3<'=AAL50CS%4:K_?310?Q'6I
MU2I@Y$>1<]"6N%:A"@Q S"8#W"8Y)M<$[YHU_E1DDIV<M/[=?'P_J?35W_]>
MI8,GF]CZUCR1,_*^Q#5OO.YTYL+H#JF3.T=[L)/>)A^U>: O-IQ=R!_\S0X$
M-[4\S2<QZ.']0]=11>6?<<[=9Q8*:N=)"X];@C>>QGP\IYUDBKF[C6@9@=<#
M"6R#T]CAKFD"!!,\09(!VKX)8DA.?/\C-%-V2SI,10.@+][EV0/W]O8W31%F
M)0F.53">JZ5]=!#G3_S/YMOM\V%DFA1>@I@4J"FN0RR(%K#?SO:UVWH8M\_"
MH<]O>.W!9NZ]EP#O;G' %E6EQNG.&%7LEPHQ^LRV#W,77H0+V.3WIEO2CI(E
M7[4\?/4'67R@L+6B0A:*"VXAT9ZA5Y'B?:G.]CCGRS^PS6W>_>>/FK-",\4<
M'A<(5VH$G!*8B%FBB&JMNRMN=BD6>I>SJW_=)*2?!F0)#Y,!(@.03V3 OB#8
M-0!MN<;FV)TYV"7<_L+:K%L_AHHQ+I:CCN") Z$5FPJ$&V7A6#<V.1QTB27K
M'M)!29U9?GJW^] Z>\W#^K/#D\R"8D_]3N]R@CS/DH;$DR_;"Q(M![7-GN5%
M\.2_$&_(-UHJY,2KM"(CS6,R0-JJJQB6#72>/+^Q(DP&U/Y_R\>V/,@ +LB:
M:[W^2@&PA_-,2EB!- W]MM4'6VCIS@RE65,(Z$J7-*K:^-(N9=1NR!ELUNWD
MRQ.X"]I"4"80+3&)< E_FX1HAE!W7.O&15C,7>[H8&D]HT_ M:(Z_8:FX%-?
MX3$0G+1S.Z1'5T'WY4L@^IVX: 9D?4?V='_CB0?>X\.LOJ3'A\V1Z=P@@@P9
MP!CVO4;-YX/KZ/?SM>]M1\LW8<<@/[P]A37_U:.UB.2H1\<7KNVO;H<H<;68
M<&J#[]B\;X<TSFNVK1=U@2GW9(_VCY3"F:_)L> <]>_;VQMRW+]YO34UYB\D
MQP]4"T*;JKX ,C0^;7]/3'7O>:['-9+&(IBP"2J HY_,I#FP]#\/8BL#22ZE
M7)V?"-TG5$DJ?GW\0\;*Q^..\4W".BE\&_9GQZ*<4?S[9:ZUVO7EBAT";'O3
M.WW+'@L@9FJXXA_,>^Y6VGJ$<!V/:7@%C_8Y?[=2%:]3H6FI@1BNHHW2<3?%
MXR$O6=ZVK%[E6HB(0#.-G8\^#HOAVA)/$=A*+S< (N/M]"B@B'(,+0J<EHG^
M73 @$:LD:?27GQI&77OPZ/#]R!6X5[0$KG:QNXMKIDE%QLP$VQ# ^,SDO]LT
M&U2B!5L7F0-_;"Z.:ZR96(+9/&1D*^=+?581^;=##<Q+31IK)(96C$O+%H/P
MV!-@/L5]PP@<-/TK@KC\,'1(7TB)=*^Q%K^-Z+4,^['N)QKUXN+?1>M5;W8]
M);X'(G.Y0,UBFW--F/@Y+$-$QU))9O&^2\Y9+G_]($_1G7M#@E+'#=@\S.6S
M 3F<1'J"S*$8N'XIM) 5^2'CC?%:@;>/?+HYKJ@8OX)C0J_VK5#APE"W JMX
MKK7FW)N^F6=3_&!IVK8?=PZ89,HP#9A."^R?Q*LS);SA'+-J4A17;&MJ.K\X
MG Y0NWJQ&3Y5<?[9)-@LO+P%YA 137.LC[>FD#:'%@=IG Q@.HR,0N?*RBI6
M<83=N#JXL_;H'=PH#N'.P]-SL;X)^FV(G<<,]:2_Y5/N.^1>&2\?48*!702X
M+=2X=6YKO_$*1J[#FR!N7<IHQ_?KX_1;VG/.MMZR; ^OOW]AYJ"T4>RK9T24
M^K?@,/9KI#20&@X&QU^ $WRXIA8@G-N+Z\TW1"5]G%6NR^\>[II>>AOZ=Y(I
MT:?DW$51%>Q6A<4?+@[+!V:S]C9Q?.:\-3"H)AY<NQ]%!C@N0G^)$[C4;#I
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M92*,P%!.\,$-?5HT).60 >PJUQ?[B-M/(K::PI7WL_"R.Z"&\FX6VM#)OK;
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MVPRW/W>T9)DS3@C$BII=N4O OVSL10I=@=@,J#AR92GR2C@:C#LB2(TAG6]
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MID)0VF#"J-K=^$"A2#"W5* OAVI]:^-D_MV'7YMN+L#"! (H6HDP%]B%5M,
MH@5EN%UPCZ9'6L9,^PS08Z/6@G0/_W(][5-LO**!K>: /RWU0@"6A/[[(ACE
M3';I@+%>V\.\#B26-9R;JROD.#K^EXFMYQ[)ICBU4Y.Y=9E3+<BX?^;QK7:;
M55FE(&39\!D@E/&IF,P] RWK_/EC4_-<^\T)BM $NC/YB@?E)L%C4>N!68I(
M0ZI)PWV+M%?7J0*2/C*J'ZV@%W5(7&++<\BL!3 /28;[DV>(30;7I@_\\I.5
MVY<8LN' ]:0) G8!1I ";4<1=3Q^0L3N$0*6&+"2M)9]MV<>[7]AI>)KG&,
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M@'5WU%/,] Q=*Z&= V)Q<SB\TSFO%JTV\@AM2K-%Q/G,*# * GX*)R1P.!@
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M__ /__ /__ _T)Q-_S]02P$"% ,4    " !(@6-:SQ@A*D;F P!D+R\ $0
M            @ $     86YN>"TR,#(T,3(S,2YH=&U02P$"% ,4    " !(
M@6-:&""@5:)- 0#/B1, $0              @ %UY@, 86YN>"TR,#(T,3(S
M,2YX<V102P$"% ,4    " !(@6-:ADS6U2$-   9<P  $
M@ %&- 4 86YN>"UE>#$P7S$P+FAT;5!+ 0(4 Q0    ( $B!8UJD6!G;,4\
M #BD @ /              "  95!!0!A;FYX+65X,3E?,2YH=&U02P$"% ,4
M    " !(@6-:X8K%ZUH#   !#0  #P              @ 'SD 4 86YN>"UE
M>#(S7S$N:'1M4$L! A0#%     @ 2(%C6G"]#WE,"0  Q$@   \
M     ( !>I0% &%N;G@M97@S,5\Q+FAT;5!+ 0(4 Q0    ( $B!8UIJA#8T
M6@D  -I(   /              "  ?.=!0!A;FYX+65X,S%?,BYH=&U02P$"
M% ,4    " !(@6-:%5L0.H4&  "40   #P              @ %ZIP4 86YN
M>"UE>#,R7S$N:'1M4$L! A0#%     @ 2(%C6C;8K.S<XP, +#X% !(
M         ( !+*X% &EM9S$S-C,P-34U-U\P+FIP9U!+ 0(4 Q0    ( $B!
M8UH=O!9 ?W$  #IR   2              "  3B2"0!I;6<Q,S8S,#4U-3=?
M,2YJ<&=02P$"% ,4    " !(@6-:^)3VRU>A 0 LLP$ $@
M@ 'G PH :6UG,3,V,S U-34W7S(N:G!G4$L! A0#%     @ 2(%C6AFMZ&@2
MD $ Z:D! !(              ( !;J4+ &EM9S$S-C,P-34U-U\S+FIP9U!+
M 0(4 Q0    ( $B!8UK!B0IQ(5@(  W,"0 2              "  ; U#0!I
G;6<Q,S8S,#4U-3=?-"YJ<&=02P4&      T #0 M P   8X5

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>annx-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:annx="http://annexonbio.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="annx-20241231.xsd" xlink:type="simple"/>
    <context id="C_816a75eb-eeac-444c-b1ad-06f15723b3de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_818dd59d-4920-4aa4-ac11-e7a600a5d4b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">annx:PersonnelExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_83482f61-92c5-4f8a-a1dd-156bef5f21aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_843798ed-5a68-4641-8a36-ece949ec58c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8472ac84-55e5-434a-90d4-c7f9d7aa4437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_855b89a1-84bd-4934-adb2-47fa9352df11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">annx:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8835a1b4-527a-43d8-b69a-a0eca9a1005c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_887b31a4-95c1-40be-a759-5e56b5fa7540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e8bc1e1-c0eb-4e34-a2ff-e496756a8fca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:CommonWarrantAndPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_948f2da9-09b8-4835-b79f-9b108878b9f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_94c78139-5590-4748-8160-840a5d169474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_95063796-51a0-4a4f-80df-7a8de33bf4a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_95335bc0-36c3-45f2-998d-639cb78b1f47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_95493879-152b-4afb-9460-55860ac0385d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_988ddfc5-9dce-4f27-b086-5099244cdafc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9ae8f66d-5240-4728-81a8-25950cb83964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9b5d4612-62c8-4e9e-9732-fb24b3fc9113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a0b71661-aa15-48ab-9fd1-0c1f5bd8eb06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a2a16639-89ee-4f7b-8678-74e032c6acd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_a2b98230-0f7a-4d29-8918-901b611f045a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a4b8204b-10aa-4078-99c0-be6c2915b494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">annx:ProgramExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a59b470f-7ad8-4b6e-a84a-dddba145a948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:UnvestedRestrictedStockUnitsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a6321396-4c80-49a4-a286-91e5bcfaf1eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">annx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a89b88c0-ec52-4b3d-8aa8-2fcdcacd2667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a8a555d1-c90f-4f9c-959d-6220a378be31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a909da49-1edd-4a9f-a0aa-5b1551fca7c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">annx:CommonStockAndPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ab735fa4-b8ce-4204-bd13-e3e5137bced9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_abbf44cf-6ebe-4194-9a41-e2cb42bf1eb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ac099453-0c31-4ead-a71c-3537f6410632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae76d731-12db-4f4c-9bcd-ade6fdbeaa43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b058d9ba-58ce-4e56-a243-4df02901e4e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1f5099c-e23a-49a6-8643-c8f3e583dd88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">annx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b56b58f7-0eb2-431c-93e8-e770362d3636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b57972b4-cb2c-4aba-9af4-d01913068013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b64c79b4-fe65-47cc-bb5d-7ddb0490610e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b7464154-5bfb-48e8-b9ee-4421be6a566c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b856724b-67a4-4bba-a3f2-933d6bdcf267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bbc49f27-1c6e-406e-a095-7623fd68f696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc70ca19-dd4e-484a-9840-e8e349d6ed16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_bd2c86aa-468c-41c3-bcc5-d4bb6af8a626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bf13cefb-5813-466c-a528-52377f64fc89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:CommonStockReservedForTwoThousandTwentyTwoEmploymentInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c060d1ca-b9cb-4849-9fbb-3cadae61b6dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c1fa55bb-8cda-41f2-be10-9c4b61733d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_c86633a7-f190-4e56-90c2-b45ffb2a2fec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_c91f5f8f-b8d5-4019-a7fb-1c7e1652024e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c9766150-3460-412e-b465-7535db7a6402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cc036091-0094-4f93-92df-aa8d88aeaf09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cdc4c27d-b376-4374-8ee1-613abe059850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ce377faf-e56d-4d57-9149-325ff3298695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d1fd9ac5-bc60-4fb7-9382-fc0aedcbb6f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d22db712-c793-4143-97f9-0b1afeba048b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d35db099-094f-4b2e-a082-7d4a3c739571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">annx:DouglasLoveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">annx:DouglasLoveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d39e2be4-3f00-449f-bea4-e4669b559cd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d3a9e2dc-37bc-4427-af29-49d412bd1d30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d579d761-816c-4e55-92d6-ce372f29566a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_db3563d3-30d0-495f-ae87-183cd7735dd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc545e9b-21db-4b67-ad10-065bcc3c2d12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dddec901-694e-4786-914e-180bcc77bb3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_de537ec6-325e-4910-8f4c-21e257afbcae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_df95e66b-dc80-4420-b35b-25735aaee5e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e30eb803-2850-45ea-964d-0c167ebab98b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_e330e31d-eab9-4389-8fa9-bef76e997d23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">annx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e35f510e-8466-4a7b-bbdd-fbb00d74b1e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e4222e01-171b-4f31-917f-bc3457cfb96a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e5457637-3c61-492e-b073-b90232effb2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e671e012-c921-435e-938c-d68a826109d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_e84f496a-0f64-496c-8511-31490901d115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">annx:PersonnelExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e9fbcf92-912d-427d-ae6e-83428851302a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eaec4616-b419-452f-afec-7269fe2849b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eb44a589-ed4e-4789-9745-4e687e913dc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eb92638f-ef52-4c87-b5ac-58d1b991d572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ec22ff7d-ccec-45fd-a10c-766baaf42b25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ed0ef5bd-d7b5-41fd-bc14-c386fcc1efd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_ed76a48d-5680-4d30-a58e-a560abef9d60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ed7afca9-65c9-4663-b96f-deb75482c773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ef904358-5a05-4938-94ed-ed05188133ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f125691b-d9b3-4307-871d-e301d62747a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="C_f4174d5a-db4b-4a44-b7ea-89d6395031d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f5167882-1b9d-47e5-a675-47eb50fb2f3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f9d86972-6bef-4c53-8764-f295400423e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_fc111147-f3e4-414e-8968-b78d5df90526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0428a48b-fcf2-4525-9a5d-beb6a7560084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_06a73ed8-fa35-4a8b-9584-91fdd26d518e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_06de6640-01c9-4281-bfc6-944a3b827353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_072050e6-df46-49a7-bd7c-e1422281108a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_07dde65d-d011-4647-84a8-b3adc4b0a081">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_07f46682-ea8e-47fe-a18f-70b0bb1a100b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoFourAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_08392b92-b47a-463c-9c19-05c9de02b962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_099f9f27-8db7-4796-925e-5a5030924004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0b957594-7615-4933-9789-94cb54dc8638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0f36b114-1cd5-47b2-9612-e2686951639e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">annx:ProgramExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_138cc2dd-081f-4945-96e9-e817d5140d0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_14a08883-0225-4ca1-b9a6-4b86b0937620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_165aca0e-bcd9-4004-974b-91e78177d7c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_17ade79a-934b-4095-8b9f-770d560529d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_181b327c-8c4d-49cd-992f-be0a8cabfe0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1a083296-3cca-4c7e-aef5-14001cb6517c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1cc25f78-dbe3-41a1-b7d8-90bfc1df6bd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_22fb27c8-c805-4aa1-944d-38a2963e3541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2321ba61-567c-412f-bf92-06d0f3f4b95c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_262315fc-5a70-4273-9329-a8573c6e8ac6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_27512148-cc01-4328-b869-9d09fda6ba2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_29782950-7a96-4afe-b123-68b6a1a44a9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2ba532e7-e440-42d5-911c-cf6ce266687f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2c4873ea-60ed-4c68-a1a0-60c57456e3bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2cebc1d1-94ac-454e-86c1-67082e75afe2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2e220b19-1558-4357-a8ce-4bbf8e24c875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">annx:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2fd32b35-c1b6-48a1-aae6-77286e901eaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_301be3cb-1afb-480f-886a-93603e1ae4a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">annx:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_32785c93-aaca-43fa-a248-cb24bd9882bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:CommonWarrantAndPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3465210b-00bd-416d-9ded-e8a899b86e31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_347d207b-e303-43ed-928d-7392f73d169f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_369ed887-7421-4d9b-9304-a1aaa66c59c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_3869c6ca-09db-441d-8246-9d11c931b28c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3a117edd-79b6-42cf-bde0-58487b0502bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3d6b212d-b7a8-4e3f-bfeb-dc2b3be0b024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3e3b68fc-a6f3-457c-8152-64fa99e75d60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_43b053ed-5a1a-4d6e-8884-dff3a7269d3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_443c81d2-cb73-4f5e-bd81-93e201b4f7af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4595fc5f-0546-4bdf-8e9d-71d2422bc886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_45af3c57-9293-4248-ba7b-bfd6daa609f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_47d568cb-1d08-4229-bd46-d15c10848115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_47ff50b0-e58b-40e4-8ff0-c5bad7aafd91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_48cf44ed-6e91-4e9a-ac99-23eaa9cb9ebc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4972a734-b0dc-409d-bf12-d162a67e116d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">annx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_49a7915e-73e3-40e2-8989-6689fbe67430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4ac38cec-c321-4987-9f13-09b843771ddb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4aeda5c6-0f0c-4565-a458-c8ad2779242a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4b7bb28a-5cbc-497a-b670-2377da981ce9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4b7c8434-c7e2-4ff2-b583-26501f87a512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_4d34fdbe-9026-4710-920e-640cc4668c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_547ea12c-5672-44e1-81bd-5c04ecd20f79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5525b019-e48a-443f-8f6c-bc589e834f80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_55a285e5-5315-412c-bf43-8041cddc34bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_571d253c-4271-4944-954f-09fa5121f2db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_59694837-0d85-444e-93f3-2dab4c74940e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5b853485-b4de-4aef-8684-04438a8b004d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5c8914a1-6122-42c7-8190-e7a265b496b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5f614136-7067-4542-9d0b-a420c024f04d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:IncentiveStockOptionsAndNonstatutoryStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_634f5a22-da7a-4c41-b9ae-27784aa5495b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">annx:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_650433ef-c0b4-4034-b841-f9093d2a4e91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">annx:CommonStockAndPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_66179d4e-f740-4656-9e26-82ac3de679ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">annx:UnvestedRestrictedStockUnitsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6bb50bac-b7de-4de8-a130-52d5e9a81ba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6c830638-e7f6-4b1b-b448-37326bf9c73c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6f21bd05-943f-438a-9b7b-5906dcadd8cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6f5f0013-61b6-4736-b7e9-a7f934312508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_766389fd-d63f-45a1-a7be-f2588e021646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7968ae91-6275-4ca5-8e22-5c0bb5f5da6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7b518a40-52a6-4973-869c-448436c41106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">annx:SalesAgreementWithCowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">annx:TwoZeroTwoOneAtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="C_7d9aed7f-6bbe-4caa-a2eb-d48056481199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Claim">
        <measure>annx:Claim</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>annx:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_4daf25ad-1482-4cce-bd6a-2c1b69969a92">0001528115</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_372bda1d-91a3-4095-a2b2-64e8ebd59d19">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_242fa94f-8172-496a-ba18-273e2b04187c">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      id="F_420f1a7b-75ca-4c11-8930-c039b5bd7f95"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      id="F_c0349d88-3f94-454f-954e-b3a1d9c41c2e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_1cc25f78-dbe3-41a1-b7d8-90bfc1df6bd1"
      id="F_8f39b772-731f-41b9-9d02-0d66e7276fae">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:OpenTaxYear
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_a1b6e2c0-03d3-4a20-b626-abcffa81b2cd">2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024</us-gaap:OpenTaxYear>
    <dei:DocumentType
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_917ca3f1-fc87-4b2a-b400-173d2c524312">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_278ba818-58da-4408-bcd0-6e2a1d847704">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_bf2f3818-8608-4d2b-a7dc-997b0d21c642">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_8411b044-b058-4aee-a019-0faba19356a9">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_9aba9214-1c8e-400a-9ea1-26665d1d3536">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_d14eed5b-9f0a-4a2e-82bb-175715ba57db">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_cee2b430-7b9f-426b-930e-a003b2ebfc14">001-39402</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_ecbd7dd6-c2dc-4b5a-8dcf-6719622a4252">ANNEXON, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_21b06ec9-39d2-4175-b254-811db042f404">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_967ea4e8-28c4-489f-bbd0-1c4977a9d436">27-5414423</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_2130fac6-a73f-4c9d-9bbc-0b2675287a37">1400 Sierra Point Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_49f82bef-582a-4d64-bb9e-e1ea5755dbc9">Bldg C</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_65f57819-23de-4775-92f1-2f06dff7ffd7">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_41e2594d-4926-4cda-9ddd-1235040a957c">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_489e615e-2d0c-47d8-a58c-25a1f3edc663">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_4344c36f-8ed1-4013-a541-db4364979b21">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_d5def167-2cbd-418e-9ead-ba62f6db567f">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_a721a85b-18e5-488d-aec6-fe05756a6e6c">822-5500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_8c28782f-34e5-45d2-b84c-825ffa3b386c">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_f5aa4cea-ac27-4e7f-a6fc-3a3dc3a36d8a">ANNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_3540313f-f3ae-44bc-9931-ccd88c0b4cbe">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_ab0f3258-50db-4959-bd40-4ee11cf838a9">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_368308c3-cc2e-421e-9fc4-dc570f1f410a">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_e2cdefe3-6c07-44e1-9926-af48c8b7c8ce">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_04ed347d-c308-463e-bdf1-ae9b91d70f12">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_be3a8370-e7a9-48a3-aa9d-f78cb548c3e7">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_1606879d-3bab-4322-b7bf-d7e26140501b">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_0ac83d6f-2e8c-4ef9-a4c2-49d2498057b5">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_2caf5330-b99f-411e-bd81-698710ee9ff6">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_974df037-12ee-4eb7-93db-c2acc00bad89">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_36015465-aee2-4ea3-b6f8-9693d3fbcda8">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_a2a16639-89ee-4f7b-8678-74e032c6acd2"
      decimals="-5"
      id="F_e0653baf-8a43-4165-84c8-0547f01d8814"
      unitRef="U_USD">477200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_d3a9e2dc-37bc-4427-af29-49d412bd1d30"
      decimals="INF"
      id="F_de820295-daeb-4e6b-8a9d-75faf81fe7e2"
      unitRef="U_shares">109709826</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_f125691b-d9b3-4307-871d-e301d62747a4"
      decimals="INF"
      id="F_142deaa3-6f96-472b-a170-226ca96eca6c"
      unitRef="U_shares">38543577</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_b2f15383-b56d-412e-870f-a423b5450549">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_63c98ab4-c41f-4491-9390-b498a19ca29d">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk management and strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented a risk-based approach designed to identify, assess and manage cybersecurity threats that could materially affect our business and information systems. We attempt to identify and assess risks from cybersecurity threats by evaluating our threat environment using various methods including, for example: maintaining manual and automated tools, subscribing to reports and services that identify cybersecurity threats, evaluating threats reported to us, and completing third-party cybersecurity threat assessments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use cybersecurity consultants and penetration testing firms in an effort to identify, assess, and manage material risks from cybersecurity threats. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use third-party service providers in various elements to our business operations such as data hosting providers. To help manage cybersecurity risks associated with our use of third-party service providers, we primarily &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with industry-preferred service providers, and we also contractually require service providers with access to personal, confidential, or proprietary information to maintain data security controls and practices.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity risks and the failure to maintain the security, confidentiality, integrity, or availability of our information technology systems or data, and those maintained on our behalf, could lead to adverse consequences that materially adversely affect our business, including, without limitation, regulatory investigations or actions, a material interruption to our operations, including clinical trials, damage to our reputation and/or subject us to costs, loss of customers or sales, fines and penalties or lawsuits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses our cybersecurity risk management as part of its general oversight function.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for advising on our cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our CFO has supervisory responsibility over IT and cybersecurity functions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our management is responsible for helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;security-related reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We maintain a cybersecurity policy, reviewed with our audit committee, which is designed to address cybersecurity risks to us (including by escalating certain cybersecurity incidents to members of management and the board of the audit committee, in each case depending on the circumstances). We also maintain incident response procedures designed to assist us in responding to cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_0c186012-1d5c-4bf5-9dfc-68f5950f50e8">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_1f3562d6-fcd2-4e20-b734-1c9b0d15f87d">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_0efb0959-a49c-4d93-a6a1-39fc7bec3193">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses our cybersecurity risk management as part of its general oversight function.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for advising on our cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_0cab033e-5333-417b-8ff1-5a65d953878e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses our cybersecurity risk management as part of its general oversight function.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_7659ed20-33fb-4e4d-bf8a-1c231e89f59f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for advising on our cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_3b27e004-fe63-4fb2-bd07-c1ebfe0302bd">&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our CFO has supervisory responsibility over IT and cybersecurity functions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our management is responsible for helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;security-related reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We maintain a cybersecurity policy, reviewed with our audit committee, which is designed to address cybersecurity risks to us (including by escalating certain cybersecurity incidents to members of management and the board of the audit committee, in each case depending on the circumstances). We also maintain incident response procedures designed to assist us in responding to cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_2d17ab1c-35f5-4e7d-b5e0-57364333bd40">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our CFO has supervisory responsibility over IT and cybersecurity functions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our management is responsible for helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;security-related reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_0c88f3c1-c3fc-442e-b5d1-960416c5a9f6">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_e5bff5fd-a211-4242-a63b-5b9da4eb4e10">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and risk management processes are managed by certain members of our management, including our CFO (who has prior experience in strategic business operations).&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_4df89c7b-5e53-4503-9503-a9a276f5117d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our CFO has supervisory responsibility over IT and cybersecurity functions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our management is responsible for helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into our overall risk management strategy, helping prepare for and respond to cybersecurity incidents, and reviewing security assessments and other &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;security-related reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_1da43bd4-7749-4566-ae65-190ef65c8ffd">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_dfe614b4-8da5-4997-afc9-2faf26ec966e">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_a9474f6a-b3b5-4fc2-8ade-2b0b8bd8246a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our incident response team is responsible for remediating cybersecurity incidents of which they are notified.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <dei:AuditorName
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_dfe4a65f-8a7d-42b8-85c2-967afb64f6b2">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_fcba404b-cd4d-415e-ab79-d3d66dabb3f2">San Francisco, CA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_9c1ad972-277a-48b0-bbf8-64c023fc44df">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_4518111f-f8f4-4913-8b59-8c9d7f1b0ea9"
      unitRef="U_USD">49498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_9e6e48da-feaa-47b0-84d2-d9b86c40469e"
      unitRef="U_USD">225110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_0c355ef8-f9aa-4206-a817-40929e3060ea"
      unitRef="U_USD">262519000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_916bbca5-4892-451e-9791-b406248c171d"
      unitRef="U_USD">34606000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_dc85cebd-e80a-44d5-bb3c-72be16fd7cba"
      unitRef="U_USD">4444000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_85da647f-5d56-419f-9987-5166082aea96"
      unitRef="U_USD">4144000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_90cef349-b80f-4eb3-bd16-4a0fb5bca08b"
      unitRef="U_USD">316461000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_348d7833-db54-49d2-8005-8d29d256a711"
      unitRef="U_USD">263860000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_5e415913-413e-4676-95c4-673e2f704e57"
      unitRef="U_USD">1032000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_c1f5986c-cebe-4696-9f27-8697c50eae93"
      unitRef="U_USD">1032000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_70f8e4f0-4140-4d65-9a32-401744f6edab"
      unitRef="U_USD">12638000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_b393b43d-9102-4420-94f5-34ecb97a1f38"
      unitRef="U_USD">14773000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_ec430792-9758-401c-8b7a-f2ea9dcbd245"
      unitRef="U_USD">16705000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_34fbccc1-e60f-407c-8f14-2d95d2aeabd6"
      unitRef="U_USD">18009000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_7a95dfe3-148b-40bf-b209-46d50190aa45"
      unitRef="U_USD">3235000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_d8e4b440-196f-4ac6-9350-60f95e4f8cc6"
      unitRef="U_USD">350071000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_66a929ab-10e8-483a-ab96-e5e287c4c23b"
      unitRef="U_USD">297674000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_4069588d-ee9d-48ce-97de-6f2a8c83681b"
      unitRef="U_USD">10426000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_b18b60d4-4367-4af6-9a07-a65b8c5cc0fb"
      unitRef="U_USD">5487000</us-gaap:AccountsPayableCurrent>
    <annx:AccruedAndOtherLiabilitiesCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_2bfa1453-2b8f-4a84-8108-c3e5be617ba3"
      unitRef="U_USD">17568000</annx:AccruedAndOtherLiabilitiesCurrent>
    <annx:AccruedAndOtherLiabilitiesCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_4a495236-87e7-4f6a-8871-b4890bdb485c"
      unitRef="U_USD">10276000</annx:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_fe8f0a69-40ec-4975-8eeb-8c88a5aaaac5"
      unitRef="U_USD">2518000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_9a12d50f-4eb6-42c3-b7e2-3d2b91acc935"
      unitRef="U_USD">2165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_9bf73d62-4f0b-48e9-b271-8800e37b3032"
      unitRef="U_USD">30512000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_20151d98-5838-49d1-b168-e2e35c871e34"
      unitRef="U_USD">17928000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_90c92b75-65b9-402a-9659-b470fbfcd3c5"
      unitRef="U_USD">26454000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_a701e07e-2728-4ba0-bc40-e4929dd242a0"
      unitRef="U_USD">29190000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_2a091a83-c75d-4aa9-b203-65db3827a936"
      unitRef="U_USD">56966000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_447172d8-d192-4a89-9176-0f9d9a848917"
      unitRef="U_USD">47118000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_b20f260d-29ba-49d4-8dfc-9bc10920a56f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="INF"
      id="F_29f8024b-a838-4dab-8e8a-eccee524a6b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_cf84dd05-91c3-4c66-858c-87b3ce00ec70"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="INF"
      id="F_de12b456-aee4-400f-a0fc-328dc4ff5265"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_d263248b-5817-4e96-90cf-c9e07326efc2"
      unitRef="U_shares">109381556</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_3f53f4c4-21b9-4dab-8131-9a5fd0afaca5"
      unitRef="U_shares">109381556</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="INF"
      id="F_d277fdee-58bf-4f4f-871d-87789645cd21"
      unitRef="U_shares">78369099</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="INF"
      id="F_b41e11cc-7ea9-45b5-ac37-ea0b2f5ddfe1"
      unitRef="U_shares">78369099</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_9e3c71f7-36d9-4720-9e4a-41075e7cff0e"
      unitRef="U_USD">109000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_724f6880-3376-4737-a1df-c61ec87195cd"
      unitRef="U_USD">78000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_b7805a9b-bf2c-436d-8e2f-6d6fc7d7f03d"
      unitRef="U_USD">1003685000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_7145b1f3-1aa8-4467-bbd2-93baa348c4b5"
      unitRef="U_USD">823029000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_ab658e93-f8a7-4ee8-aa7a-593cad757060"
      unitRef="U_USD">10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_88ddf383-640e-4fb2-9afb-3fdb9cced6f2"
      unitRef="U_USD">-52000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_2f37e577-f4a8-4f82-bea6-59ddd2fce775"
      unitRef="U_USD">-710699000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_9f785006-7ce8-4c4b-873e-e7b832b6dcc5"
      unitRef="U_USD">-572499000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_ae6e805f-bcc5-410f-90bb-8d5ad575d28c"
      unitRef="U_USD">293105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_54287b31-9618-422d-95b5-a083bcb34571"
      unitRef="U_USD">250556000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_6b265ceb-8b49-4251-b779-fc274bc920c5"
      unitRef="U_USD">350071000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_7e6b7cb6-7a98-4b9d-9249-8b8707c76bf3"
      unitRef="U_USD">297674000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_58b01161-448e-42c1-815a-c189b8ae42ce"
      unitRef="U_USD">119448000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_97e0ed74-82fc-4006-ad4e-cdd101e92315"
      unitRef="U_USD">113756000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_2bbb14d9-f10c-40dd-b570-f61837208b5a"
      unitRef="U_USD">34625000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_80954cca-e2df-49bc-96a7-430f0fd32870"
      unitRef="U_USD">29967000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_fa841351-6b7c-40ee-8d64-fb32752a8924"
      unitRef="U_USD">154073000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_6f11c52f-7ca8-4de5-9de4-b00eb1a1b47d"
      unitRef="U_USD">143723000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_85828081-24ba-4302-b720-8ee6ff0ebe3a"
      unitRef="U_USD">-154073000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_44791ccb-1e3e-4a52-af32-c641c0ea8786"
      unitRef="U_USD">-143723000</us-gaap:OperatingIncomeLoss>
    <annx:InterestAndOtherNonOperatingIncomeExpense
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_fe5c2b1d-ce75-4e44-8535-d697e98ae197"
      unitRef="U_USD">15873000</annx:InterestAndOtherNonOperatingIncomeExpense>
    <annx:InterestAndOtherNonOperatingIncomeExpense
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_81bb42c3-761c-44cb-8a5e-7d16772bf48f"
      unitRef="U_USD">9486000</annx:InterestAndOtherNonOperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_fb19144c-1331-454c-81f8-0da2e497492d"
      unitRef="U_USD">-138200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_4df6c280-c61e-46f1-9834-9f3d640c6bf2"
      unitRef="U_USD">-134237000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_5c682e7f-0718-40ed-ab8c-fe430ddc515b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_4dae8709-2629-4e36-98e6-d7f554e4f22f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="2"
      id="F_4a235edc-e255-47fb-ba91-1fc9685bc24e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="2"
      id="F_04ce5345-5701-49c2-b3d6-b4162a731840"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="0"
      id="F_fbff9d8c-fb3c-4c37-aba6-6a14e8491934"
      unitRef="U_shares">137404145</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="0"
      id="F_88ed794c-9e78-4973-a06f-b8ea1e055f66"
      unitRef="U_shares">137404145</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="0"
      id="F_97a6b197-cfbc-406e-a4d1-32e7ba1d6552"
      unitRef="U_shares">75673081</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="0"
      id="F_1a863d14-e9d4-4f84-9b13-db9ba6eab9ad"
      unitRef="U_shares">75673081</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_fedd00d9-0f4a-4643-b401-e8f0bfaa075b"
      unitRef="U_USD">-138200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_28295577-a46b-4b58-b4c0-4768b753b6e5"
      unitRef="U_USD">-134237000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_ca7c3ec3-94e7-4332-9fd5-c721f45fc833"
      unitRef="U_USD">-15000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_b1e3fc18-f245-4757-897e-4962c76e3ab3"
      unitRef="U_USD">5000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_8168b5a5-81d4-456d-980b-dba3c0061399"
      unitRef="U_USD">77000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_671a2327-c74b-4ca6-ba42-4da949cc3918"
      unitRef="U_USD">315000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_dde563aa-a670-423e-9e3b-942c071b35c1"
      unitRef="U_USD">-138138000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_a0172b03-68c7-4e93-87bb-2dc78719a22d"
      unitRef="U_USD">-133917000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_eb92638f-ef52-4c87-b5ac-58d1b991d572"
      decimals="INF"
      id="F_84047048-1844-40ca-b274-68097ee11bb0"
      unitRef="U_shares">47722995</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_eb92638f-ef52-4c87-b5ac-58d1b991d572"
      decimals="-3"
      id="F_6a7625ce-0d6c-4e11-b09e-17060086e542"
      unitRef="U_USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b56b58f7-0eb2-431c-93e8-e770362d3636"
      decimals="-3"
      id="F_51a42454-26b8-4170-9922-303923424fb0"
      unitRef="U_USD">669780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ed7afca9-65c9-4663-b96f-deb75482c773"
      decimals="-3"
      id="F_ceddc67d-36b4-401f-a06f-90466eca3e43"
      unitRef="U_USD">-372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_443c81d2-cb73-4f5e-bd81-93e201b4f7af"
      decimals="-3"
      id="F_06b5cfb1-3392-4de8-a964-246d3e6cce3c"
      unitRef="U_USD">-438262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a2b98230-0f7a-4d29-8918-901b611f045a"
      decimals="-3"
      id="F_082e2eaf-ff31-4e91-a5eb-c25aa497a97b"
      unitRef="U_USD">231194000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2"
      decimals="INF"
      id="F_fd9b692e-a18f-4f5a-b1ad-408d2a36f0ad"
      unitRef="U_shares">76888</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115"
      decimals="-3"
      id="F_d490fc17-ae24-4fb6-9df9-68aab2e3f855"
      unitRef="U_USD">145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_f1f224fa-459c-4e56-97fd-f4005bb5c4fd"
      unitRef="U_USD">145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <annx:ExerciseOfPreFundedWarrantsShares
      contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2"
      decimals="INF"
      id="F_6d53b310-d65f-4245-927b-9e3dd396a96d"
      unitRef="U_shares">2582557</annx:ExerciseOfPreFundedWarrantsShares>
    <annx:ExerciseOfPreFundedWarrantsValue
      contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2"
      decimals="-3"
      id="F_f6191669-909c-4b57-b8ae-f4a730dc5edd"
      unitRef="U_USD">3000</annx:ExerciseOfPreFundedWarrantsValue>
    <annx:ExerciseOfPreFundedWarrantsValue
      contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115"
      decimals="-3"
      id="F_3fa4d670-b80c-45ee-adba-623a4ade529a"
      unitRef="U_USD">-3000</annx:ExerciseOfPreFundedWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_45af3c57-9293-4248-ba7b-bfd6daa609f3"
      decimals="-3"
      id="F_fd9cb68f-8e67-440c-baa6-7cdb59e0adf0"
      unitRef="U_USD">525000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0428a48b-fcf2-4525-9a5d-beb6a7560084"
      decimals="INF"
      id="F_e7130fd2-d01f-4108-9320-71364fcd223d"
      unitRef="U_shares">2646458</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0428a48b-fcf2-4525-9a5d-beb6a7560084"
      decimals="-3"
      id="F_0967a7e8-0191-463a-a3b3-87fc33022ddc"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6bb50bac-b7de-4de8-a130-52d5e9a81ba7"
      decimals="-3"
      id="F_ad3c35e4-0d46-4e41-bdc9-61b7b02bff66"
      unitRef="U_USD">17468000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_45af3c57-9293-4248-ba7b-bfd6daa609f3"
      decimals="-3"
      id="F_316b95c0-f776-4431-be1a-7174e42390f0"
      unitRef="U_USD">17470000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_a909da49-1edd-4a9f-a0aa-5b1551fca7c2"
      decimals="-3"
      id="F_c0afb424-020b-46eb-b81a-816f3b3a31b0"
      unitRef="U_USD">8014000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <annx:IssuanceOfStockAndPrefundedWarrantsShares
      contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2"
      decimals="INF"
      id="F_7155fa5c-e8a7-4b49-ab06-55f846cf828b"
      unitRef="U_shares">25035000</annx:IssuanceOfStockAndPrefundedWarrantsShares>
    <annx:IssuanceOfStockAndPrefundedWarrantsValue
      contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2"
      decimals="-3"
      id="F_91cf04a7-1181-480b-8dcd-6a406f87101a"
      unitRef="U_USD">25000</annx:IssuanceOfStockAndPrefundedWarrantsValue>
    <annx:IssuanceOfStockAndPrefundedWarrantsValue
      contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115"
      decimals="-3"
      id="F_548d87c2-e704-4f2b-ac0e-a748e98aeb88"
      unitRef="U_USD">116977000</annx:IssuanceOfStockAndPrefundedWarrantsValue>
    <annx:IssuanceOfStockAndPrefundedWarrantsValue
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_0edbcede-1b1f-40b9-9952-1571eb206ca0"
      unitRef="U_USD">117002000</annx:IssuanceOfStockAndPrefundedWarrantsValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2"
      decimals="INF"
      id="F_eaca0568-0fbb-4cbc-8e6d-48bd393e98f0"
      unitRef="U_shares">133105</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115"
      decimals="-3"
      id="F_d7d9beb0-abda-4d77-acd7-f12bb3cbbfd5"
      unitRef="U_USD">479000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_826f47ce-bbff-4e17-a400-07940d40acdf"
      unitRef="U_USD">479000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <annx:RestrictedStockVestedDuringPeriodShares
      contextRef="C_d32ab86a-75d5-46ab-b058-0a3179e99cf2"
      decimals="INF"
      id="F_be3cd6ef-6026-4ab2-872e-eb81264bfd10"
      unitRef="U_shares">172096</annx:RestrictedStockVestedDuringPeriodShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_47d568cb-1d08-4229-bd46-d15c10848115"
      decimals="-3"
      id="F_94fd3cf6-23d5-4adc-8c24-925e4baa511f"
      unitRef="U_USD">18183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_ca07eb93-0531-4dd8-9eaa-688cd087fbd2"
      unitRef="U_USD">18183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_df95e66b-dc80-4420-b35b-25735aaee5e0"
      decimals="-3"
      id="F_9e966acc-7bac-4403-b7f9-b3eabd6c97ff"
      unitRef="U_USD">320000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_a791cd42-344a-4f4b-a4c1-2ca97cfc3390"
      unitRef="U_USD">320000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_8835a1b4-527a-43d8-b69a-a0eca9a1005c"
      decimals="-3"
      id="F_34f2c8a7-aa57-447c-ba90-fba8d20e294f"
      unitRef="U_USD">-134237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_35f9a26e-2dff-4c18-87fe-a91f4ae1cf49"
      unitRef="U_USD">-134237000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_db3563d3-30d0-495f-ae87-183cd7735dd2"
      decimals="INF"
      id="F_61226bf8-7617-436a-a4f0-d3c706dc9426"
      unitRef="U_shares">78369099</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_db3563d3-30d0-495f-ae87-183cd7735dd2"
      decimals="-3"
      id="F_66553fba-5dcf-4e08-a72b-82f827322073"
      unitRef="U_USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1a083296-3cca-4c7e-aef5-14001cb6517c"
      decimals="-3"
      id="F_c7f86980-9e5d-4dcc-bfee-f6a428fd43ce"
      unitRef="U_USD">823029000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_06de6640-01c9-4281-bfc6-944a3b827353"
      decimals="-3"
      id="F_537eab8c-ba94-4788-8472-0b152e4a4a30"
      unitRef="U_USD">-52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_766389fd-d63f-45a1-a7be-f2588e021646"
      decimals="-3"
      id="F_8b48b874-8a02-4c10-9bc4-71d89d47c84a"
      unitRef="U_USD">-572499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_e4d74882-cd10-4986-8331-5e169f018bfe"
      unitRef="U_USD">250556000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="INF"
      id="F_d3d08362-0731-43c9-a4e4-6ac156a30149"
      unitRef="U_shares">382122</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60"
      decimals="-3"
      id="F_c45025fb-d14f-44fd-82e5-12ed163f5785"
      unitRef="U_USD">1232000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_ec1d9b0b-f67d-4267-82c3-c6ec0513da40"
      unitRef="U_USD">1232000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <annx:ExerciseOfPreFundedWarrantsShares
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="INF"
      id="F_ddc58398-eb91-48e6-b36a-fe93bcf9fb48"
      unitRef="U_shares">8947923</annx:ExerciseOfPreFundedWarrantsShares>
    <annx:ExerciseOfPreFundedWarrantsValue
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="-3"
      id="F_0418d6c9-79de-4d11-aca6-7f5bf49c8fc6"
      unitRef="U_USD">9000</annx:ExerciseOfPreFundedWarrantsValue>
    <annx:ExerciseOfPreFundedWarrantsValue
      contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60"
      decimals="-3"
      id="F_337106e0-2f77-48c7-9977-27731b4042cb"
      unitRef="U_USD">-9000</annx:ExerciseOfPreFundedWarrantsValue>
    <annx:ExerciseOfCommonWarrants
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="INF"
      id="F_20a49e5b-c627-4903-85f9-b864cbb7c1f3"
      unitRef="U_shares">19901</annx:ExerciseOfCommonWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_efc82fac-a97e-4345-af65-9584f239b523"
      unitRef="U_USD">1528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="INF"
      id="F_2f006f12-05ba-474d-be40-99b77a3182f8"
      unitRef="U_shares">8326067</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="-3"
      id="F_5c178df7-6f68-4b6f-89c1-5e4a059f7f72"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60"
      decimals="-3"
      id="F_5fde75d6-b2dc-44af-93a2-96b2babc462f"
      unitRef="U_USD">42835000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_354e14df-f953-417c-864b-88a8208483c9"
      unitRef="U_USD">42843000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_650433ef-c0b4-4034-b841-f9093d2a4e91"
      decimals="-3"
      id="F_6443b832-16eb-470b-801e-707b46d206c6"
      unitRef="U_USD">8183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <annx:IssuanceOfStockAndPrefundedWarrantsShares
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="INF"
      id="F_4e6e2969-aedb-41ef-ae1a-07cefb2b99e1"
      unitRef="U_shares">13001120</annx:IssuanceOfStockAndPrefundedWarrantsShares>
    <annx:IssuanceOfStockAndPrefundedWarrantsValue
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="-3"
      id="F_1580dea9-2464-4d2f-95e2-ee9bb8f5ad3e"
      unitRef="U_USD">13000</annx:IssuanceOfStockAndPrefundedWarrantsValue>
    <annx:IssuanceOfStockAndPrefundedWarrantsValue
      contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60"
      decimals="-3"
      id="F_de53360f-bae7-45ff-aaac-3fc58ab803c3"
      unitRef="U_USD">116804000</annx:IssuanceOfStockAndPrefundedWarrantsValue>
    <annx:IssuanceOfStockAndPrefundedWarrantsValue
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_dd063fb5-cfba-4b65-9e79-0c08f6f1d779"
      unitRef="U_USD">116817000</annx:IssuanceOfStockAndPrefundedWarrantsValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="INF"
      id="F_535919ca-8928-41ec-ae32-d5d794e24163"
      unitRef="U_shares">138147</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="-3"
      id="F_adb10432-5424-4974-8170-c5e5ccd7634a"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60"
      decimals="-3"
      id="F_0ec9646b-919d-4ba8-bec1-719232ad6712"
      unitRef="U_USD">361000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_3f5eace6-e33e-4188-9666-73b774d5e239"
      unitRef="U_USD">362000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <annx:RestrictedStockVestedDuringPeriodShares
      contextRef="C_286abfca-1f4d-496c-9a0d-7d4aa87d3513"
      decimals="INF"
      id="F_43457a62-2f88-46b8-96ce-7eabf3f560f9"
      unitRef="U_shares">197177</annx:RestrictedStockVestedDuringPeriodShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ed76a48d-5680-4d30-a58e-a560abef9d60"
      decimals="-3"
      id="F_5aef650d-c5ce-4d63-89ee-a31a87800848"
      unitRef="U_USD">19433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_4e5cdfe2-1d71-49ae-a5ed-9dfa1b94e5ca"
      unitRef="U_USD">19433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_138cc2dd-081f-4945-96e9-e817d5140d0d"
      decimals="-3"
      id="F_905fdf24-e0a3-4fdf-8cec-bb93ed473ee6"
      unitRef="U_USD">62000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_9e02211c-93ba-47c2-9dc5-622c9831f4f4"
      unitRef="U_USD">62000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_4ac38cec-c321-4987-9f13-09b843771ddb"
      decimals="-3"
      id="F_2da1fb8c-9e52-45d5-91d3-63060952258b"
      unitRef="U_USD">-138200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_bba45185-87a8-4344-ad41-72f4b0b22c1b"
      unitRef="U_USD">-138200000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_dc545e9b-21db-4b67-ad10-065bcc3c2d12"
      decimals="INF"
      id="F_5ac949bc-b1f5-4826-9d10-1ebbe0687e4d"
      unitRef="U_shares">109381556</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_dc545e9b-21db-4b67-ad10-065bcc3c2d12"
      decimals="-3"
      id="F_c13337e6-ad37-44a9-af62-2f72b7271caf"
      unitRef="U_USD">109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4b7bb28a-5cbc-497a-b670-2377da981ce9"
      decimals="-3"
      id="F_bb1b6031-1581-48ec-81d7-3469cb71dbc7"
      unitRef="U_USD">1003685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2cebc1d1-94ac-454e-86c1-67082e75afe2"
      decimals="-3"
      id="F_4e972a03-c4d8-43d9-a7f7-eb8c135fa5e9"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3465210b-00bd-416d-9ded-e8a899b86e31"
      decimals="-3"
      id="F_e42f340c-7cde-456e-907d-bb404fcc7fc3"
      unitRef="U_USD">-710699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_1051a4b8-8c16-4664-880b-a63f24c422a4"
      unitRef="U_USD">293105000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_9e14311b-82e5-4c37-ad37-59710fa4a55e"
      unitRef="U_USD">-138200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_807d77da-0315-4a68-acb0-681d6c5a3982"
      unitRef="U_USD">-134237000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_f0db5f48-bfac-4495-9dfe-0679882d5be6"
      unitRef="U_USD">2150000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_1cae93b2-1303-46e6-b949-0ec2e2a698ff"
      unitRef="U_USD">2148000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_389b0fc5-c6c9-40de-9820-867b70c7882c"
      unitRef="U_USD">9054000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_e25a8598-9708-4049-a510-10f26e791639"
      unitRef="U_USD">2550000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_f8b64731-0f32-4b2e-8cf9-c6f62aa10a3a"
      unitRef="U_USD">19433000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_c0e95d94-d5b2-47d6-9a17-d9c1c71f2f25"
      unitRef="U_USD">18183000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_a02ee992-0f96-4222-a565-4c9e88af468b"
      unitRef="U_USD">1304000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_aba9a59a-8a9e-4266-b603-7b0dffadbd0d"
      unitRef="U_USD">1119000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_db6b26b7-7b60-4eaf-8265-ac2672b47340"
      unitRef="U_USD">300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_2eeaa69b-cb91-44ed-a66b-e0f3ce210497"
      unitRef="U_USD">-1352000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_cceb94b8-7e42-4fc4-8173-41da5cccc54e"
      unitRef="U_USD">3184000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_ca082264-ab55-469a-bd3f-87ded9787604"
      unitRef="U_USD">4936000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_baced14b-6874-497a-88cd-3badea799190"
      unitRef="U_USD">-2077000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_91419271-d8f0-4156-8868-03ca631b7fdc"
      unitRef="U_USD">7292000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_e9337f4d-72d7-4704-bb5c-32775fc7057f"
      unitRef="U_USD">-3577000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <annx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_d165b461-0686-4833-8d6e-872ed622e098"
      unitRef="U_USD">-2383000</annx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <annx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_b3a8a6d3-a679-4fa6-8714-c3b285a94018"
      unitRef="U_USD">-1503000</annx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_664d879b-9e00-456e-8ed5-80a4757a0ad2"
      unitRef="U_USD">-118006000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_d044746b-7e00-427e-b7d3-e34ece58b7c2"
      unitRef="U_USD">-121142000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_5caccc5c-46ae-45e3-8217-324727de4abb"
      unitRef="U_USD">15000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_73329250-9766-455a-b1cc-aebcc684aca0"
      unitRef="U_USD">193000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_ee873427-eada-4977-b7ac-77c60109f613"
      unitRef="U_USD">583932000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_4582aa62-5358-47df-8c43-52f9384c511c"
      unitRef="U_USD">108088000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_ec9423c6-e1d8-447d-a083-f8ab5af3796d"
      unitRef="U_USD">365150000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_94b98171-9525-4b3f-832b-9ec6ac9f1a1e"
      unitRef="U_USD">178984000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_9547e1e4-9375-4a4f-b30d-15b47f742c0c"
      unitRef="U_USD">-218797000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_f3961dc7-11a2-45ad-9589-8fe879dc8ebf"
      unitRef="U_USD">70703000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_c9376254-f286-413d-bcb0-44ea8058d66a"
      unitRef="U_USD">1232000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_ac1be757-2659-4c78-ab79-4a54b7b7cf3d"
      unitRef="U_USD">90000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_cbc17797-ff69-4b64-86a7-a85e9053856d"
      unitRef="U_USD">362000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_6ce4c2f7-2620-4d09-ae46-91de476c1fe7"
      unitRef="U_USD">479000</us-gaap:ProceedsFromStockPlans>
    <annx:ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_44a3e1da-a4ba-4101-87ec-0e342c455978"
      unitRef="U_USD">0</annx:ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty>
    <annx:ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_2ce2a340-4838-41b2-b3d5-db4c1199e711"
      unitRef="U_USD">17995000</annx:ProceedsFromTheIssuanceOfCommonStockIncludingRelatedParty>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_ef80834f-fb0d-4326-b77f-f229b852bc89"
      unitRef="U_USD">44371000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_442dc7fa-c3ec-4bf0-be1b-92397c8183c2"
      unitRef="U_USD">17995000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <annx:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_01310d58-9f46-4c38-ab8a-d1cf1f6105ff"
      unitRef="U_USD">117500000</annx:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions>
    <annx:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_b6f23df4-cd68-4375-8d0b-80a09b209c9d"
      unitRef="U_USD">117515000</annx:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsNetOfCommissions>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_e253398f-fa68-4043-ab3e-6b70c053ae87"
      unitRef="U_USD">2259000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_75c39459-72e0-4890-b264-42d453a85c5a"
      unitRef="U_USD">555000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_847bde6b-6813-4318-abe4-5340d3960581"
      unitRef="U_USD">161206000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_ec3aa151-1dca-4c64-b3c2-297f2b98e8df"
      unitRef="U_USD">135524000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_531d6b59-25cf-45b9-b782-03ae50293e3c"
      unitRef="U_USD">-175597000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_ff84cf55-8cd5-4676-8785-6715fe2d04c9"
      unitRef="U_USD">85085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_52e7388b-cbc2-4a03-bf72-5c14eb9a2c4d"
      unitRef="U_USD">-15000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_caf14948-80ac-4c70-92a0-778f0f6c4fc0"
      unitRef="U_USD">5000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_b70f1cd3-04d4-443d-8b44-badaec88c40c"
      unitRef="U_USD">226142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a2b98230-0f7a-4d29-8918-901b611f045a"
      decimals="-3"
      id="F_33a121e8-fea1-44f3-a846-793222f71912"
      unitRef="U_USD">141052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_18e29ff1-e7a1-4d55-b9fe-d4a3c0c7f97f"
      unitRef="U_USD">50530000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_3b6d05ab-1261-43fb-afb0-099651ea81df"
      unitRef="U_USD">226142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <annx:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_8336b2cf-bce5-4ea6-ab7e-638fd41694d3"
      unitRef="U_USD">4893000</annx:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability>
    <annx:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_9c4dbc07-38a1-4aa3-a467-46a60ceb17a5"
      unitRef="U_USD">4728000</annx:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_b155cdba-0e26-4443-ba6a-5d7278ccaba6"
      unitRef="U_USD">3000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_c5c7698e-d4ef-455b-a033-c32822993844"
      unitRef="U_USD">483000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <annx:DeferredOfferingCostsIncludedInOtherNonCurrentAssets
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_d6c9c730-e6c2-42b9-8fe9-1acd50728aa2"
      unitRef="U_USD">51000</annx:DeferredOfferingCostsIncludedInOtherNonCurrentAssets>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_856703f5-8725-436b-915c-ddd763f4c335">&lt;p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Annexon, Inc., or the Company, is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for people living with devasting inflammatory-related diseases. The Company is located in Brisbane, California and was incorporated in Delaware in March 2011.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s wholly-owned subsidiary, Annexon Biosciences Australia Pty Ltd, or the Subsidiary, is a proprietary limited company incorporated in 2016 and domiciled in Australia.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since inception, the Company has been involved primarily in performing research and development activities, conducting clinical trials, hiring personnel, and raising capital to support and expand these activities. The Company has experienced losses and negative cash flows from operations since its inception and, as of December 31, 2024, had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;710.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and cash and cash equivalents and short-term investments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;312.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has historically funded its operations through the issuance of shares of its common stock and warrants. Based on projected activities, management projects that existing cash and cash equivalents and short-term investments will enable the Company to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements. The Company&#x2019;s future viability beyond that point is dependent on its ability to achieve development milestones and obtain additional funding. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years. There are uncertainties associated with the Company&#x2019;s ability to (1) obtain additional equity or debt financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs and its business could be materially harmed.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-5"
      id="F_4455e1be-45d3-4e3f-8d28-55da51b89325"
      unitRef="U_USD">-710700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-5"
      id="F_1abe14d3-350d-4f82-a9a8-d67d1bd4bded"
      unitRef="U_USD">312000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_0af2f819-4aa1-48d5-b99b-aaf4a2e4924d">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. Management evaluates its estimates, including but not limited to the fair value of investments, operating lease right-of-use assets and liabilities, valuation of deferred tax assets and uncertain tax positions (including valuation allowance), clinical trial accruals and stock-based compensation. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the operations of Annexon, Inc. and its wholly owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s chief operating decision maker ("CODM") is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#x2019;s resources. Accordingly, the Company has determined that it operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;considers&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds and short-term government bonds, are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash as of December 31, 2024 relates to the letters of credit established for the Company&#x2019;s office lease.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security&#x2019;s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost of investments sold is based on the specific-identification method. Interest on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;available-for-sale debt&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; securities is included in interest and other income (expense), net.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation begins at the time the asset is placed in service. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The useful lives of the property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:39.588%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.352%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment and furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_8f39b772-731f-41b9-9d02-0d66e7276fae;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. When indications of impairment are present and the estimated undiscounted future cash flows from the use of these assets is less than the assets&#x2019; carrying value, the related assets will be written down to fair value. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairments of the Company&#x2019;s long-lived assets for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. The Company includes operating leases in operating lease right of use, or ROU, assets, current and noncurrent operating lease liabilities in the Company&#x2019;s consolidated balance sheets. The ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company measures the ROU assets based on the associated lease liabilities adjusted for any lease incentives such as tenant improvement allowances. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the commencement date. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Lease expense for lease payments is recognized on a straight-line basis, net of sublease income, over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a practical expedient, the Company elected, for all facility leases, not to separate non-lease components from lease components and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred taxes to the amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merit, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company&#x2019;s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company&#x2019;s product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company&#x2019;s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company&#x2019;s behalf; (iii) contract manufacturing costs to produce clinical trial materials &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and commercial materials to support future biologics license applications ("BLA") to the FDA,&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation), (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#x2019;s behalf. The Company also estimates manufacturing costs based on services performed pursuant to contracts with contract manufacturing organizations that develop and manufacture product on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company&#x2019;s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based compensation arrangements with employees and non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employees on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation costs are based on the fair value of the underlying RSUs and options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Determining the appropriate fair value model and related assumptions requires judgment, including estimating expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company&#x2019;s cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Management &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting: Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; annual and interim requirements under ASU 2023-07 on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2025, respectively. The adoption of ASU 2023-07 did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have a material impact on the Company's consolidated financial statements. See Note 10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes: Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_a764e5bc-5ca5-46ca-b7e2-57f870702cd4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. Management evaluates its estimates, including but not limited to the fair value of investments, operating lease right-of-use assets and liabilities, valuation of deferred tax assets and uncertain tax positions (including valuation allowance), clinical trial accruals and stock-based compensation. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_4f4fbd6b-ee69-4251-afa5-57108980c7d6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the operations of Annexon, Inc. and its wholly owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_6adeb2ae-7c35-4d2a-bcd5-38065b3ec71e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s chief operating decision maker ("CODM") is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#x2019;s resources. Accordingly, the Company has determined that it operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_40714774-becc-4926-babb-4bc354af7e2d"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_11a12486-a283-4423-837d-cde06b52eb85">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;considers&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds and short-term government bonds, are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash as of December 31, 2024 relates to the letters of credit established for the Company&#x2019;s office lease.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_caef5fbe-ac32-4ee2-961a-deddad2eb899">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:Cash
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_bad1f977-62c4-4c0c-ba76-0cf77eb18063"
      unitRef="U_USD">2651000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_457ddef2-6b85-42b1-a69b-5ffc5b4051c5"
      unitRef="U_USD">8488000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_4e1d0fea-154f-4db7-93cd-3c29f5a90eef"
      unitRef="U_USD">46847000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_13d57518-8a1c-41df-8acd-2cb13e5582a3"
      unitRef="U_USD">216622000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_008efe2c-d085-4222-912b-4e012b8c535d"
      unitRef="U_USD">49498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_c754fd13-1dbe-47a0-a77a-53d8d1b6d8a1"
      unitRef="U_USD">225110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_ce5b6f1f-dde2-4a11-99a4-d44b97e3c165"
      unitRef="U_USD">1032000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_f4d0a5ac-f8f5-49f7-bb46-089e502c1714"
      unitRef="U_USD">1032000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_8d3bf3af-7edf-4652-8c96-ae99e68e1696"
      unitRef="U_USD">50530000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_cd75b62d-875f-4269-a46b-01a61a2a7bad"
      unitRef="U_USD">226142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <annx:ShortTermInvestmentsPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_0b9351a0-4e2b-41da-a0c3-e3d89b6e6cef">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security&#x2019;s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost of investments sold is based on the specific-identification method. Interest on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;available-for-sale debt&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; securities is included in interest and other income (expense), net.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</annx:ShortTermInvestmentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_d99428cd-0ae7-4c29-a905-57626bcd195c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation begins at the time the asset is placed in service. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The useful lives of the property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:39.588%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.352%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment and furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_8f39b772-731f-41b9-9d02-0d66e7276fae;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <annx:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_1b848835-c3c5-4d46-8ab5-a5138a807d84">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The useful lives of the property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:39.588%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:58.352%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment and furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_8f39b772-731f-41b9-9d02-0d66e7276fae;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</annx:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c060d1ca-b9cb-4849-9fbb-3cadae61b6dd"
      id="F_d0ffe231-adca-44b9-b502-b2db4c2c4c68">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_4972a734-b0dc-409d-bf12-d162a67e116d"
      id="F_2b099106-31f6-4c17-ad8f-cd63068f5d37">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_19509c4d-2f7b-450f-a995-c16c4a346e99">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. When indications of impairment are present and the estimated undiscounted future cash flows from the use of these assets is less than the assets&#x2019; carrying value, the related assets will be written down to fair value. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairments of the Company&#x2019;s long-lived assets for the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_cd43d0b3-e931-4c1c-b938-d1ff65659eff"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_7dfc5ebe-adc4-45fa-8e51-bb9cd393bf73">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. The Company includes operating leases in operating lease right of use, or ROU, assets, current and noncurrent operating lease liabilities in the Company&#x2019;s consolidated balance sheets. The ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company measures the ROU assets based on the associated lease liabilities adjusted for any lease incentives such as tenant improvement allowances. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the commencement date. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. Lease expense for lease payments is recognized on a straight-line basis, net of sublease income, over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a practical expedient, the Company elected, for all facility leases, not to separate non-lease components from lease components and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases).&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_1cf399b9-63d9-46a2-823f-c9fecaa8c8ba">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred taxes to the amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merit, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_bd36dbd7-95e4-493a-9898-2dcffe907de2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <annx:WarrantsPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_e67a10aa-1e0b-4c85-abb7-c40d3b74c950">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company&#x2019;s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.&lt;/span&gt;&lt;/p&gt;</annx:WarrantsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_ba1106f0-839f-456f-b6ba-a3f72d8f7a4f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company&#x2019;s product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company&#x2019;s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company&#x2019;s behalf; (iii) contract manufacturing costs to produce clinical trial materials &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and commercial materials to support future biologics license applications ("BLA") to the FDA,&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation), (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#x2019;s behalf. The Company also estimates manufacturing costs based on services performed pursuant to contracts with contract manufacturing organizations that develop and manufacture product on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company&#x2019;s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_5216a2dd-5141-4cb8-a286-62c55e76c9ad">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based compensation arrangements with employees and non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employees on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation costs are based on the fair value of the underlying RSUs and options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Determining the appropriate fair value model and related assumptions requires judgment, including estimating expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_236bf767-f884-4426-adeb-1db72c1ec220">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_278caac8-5e5e-4bd8-9a13-70bc7aa48f07">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company&#x2019;s cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Management &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_c5f7d80b-71ae-4fd5-8d0d-681e0d937573">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting: Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; annual and interim requirements under ASU 2023-07 on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2025, respectively. The adoption of ASU 2023-07 did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have a material impact on the Company's consolidated financial statements. See Note 10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes: Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_099f9f27-8db7-4796-925e-5a5030924004"
      id="F_e708c463-a6f5-4070-995f-8212ad363af7">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_099f9f27-8db7-4796-925e-5a5030924004"
      id="F_60a9d72b-2d7b-42b4-a665-3b62d3a8d6e5">2024-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_099f9f27-8db7-4796-925e-5a5030924004"
      id="F_12ab1f43-a8b9-4717-8b6c-a73dcd74ff26">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_96820730-adfa-4be2-8877-58be150769d7">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1 Inputs:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2 Inputs: &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other than quoted prices included in Level 1 inputs that are observable for the asset or &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3 Inputs: &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On a recurring basis, the Company measures certain financial assets and liabilities at fair value. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.467%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.946%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;309,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;309,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.467%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.946%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All of the investments held as of December 31, 2024 had original maturities of less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024, all of the investments are scheduled to mature in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any credit losses. The Company determined that the decline in fair value of debt securities was not due to credit-related factors, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowance for expected credit losses was recorded as of December 31, 2024. There were nominal unrealized losses as of December 31, 2024, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unrealized losses have been in the loss position for more than 12 months. However, the Company is planning to hold these securities until maturity and expects to recover the amortized cost basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the Company recognized no material realized gains or losses on financial instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_9979e7c2-98f4-42af-be2a-fa21839f6c39">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.467%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.946%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;309,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;309,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.467%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.946%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.946999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3869c6ca-09db-441d-8246-9d11c931b28c"
      decimals="-3"
      id="F_42c83ace-e63f-443b-bf1a-510865a9a35d"
      unitRef="U_USD">31680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3869c6ca-09db-441d-8246-9d11c931b28c"
      decimals="-3"
      id="F_34450094-d0d5-45e4-962f-4ba2f1f1c62f"
      unitRef="U_USD">31680000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a0b71661-aa15-48ab-9fd1-0c1f5bd8eb06"
      decimals="-3"
      id="F_c23c83d3-20fa-4e77-8062-ebdc3cefa83f"
      unitRef="U_USD">15167000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a0b71661-aa15-48ab-9fd1-0c1f5bd8eb06"
      decimals="-3"
      id="F_a9b8a003-06e9-473b-b2e2-d554ef324a83"
      unitRef="U_USD">15167000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7968ae91-6275-4ca5-8e22-5c0bb5f5da6b"
      decimals="-3"
      id="F_755a1718-5a9e-497f-b134-17f2e3e14bcc"
      unitRef="U_USD">46847000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7968ae91-6275-4ca5-8e22-5c0bb5f5da6b"
      decimals="-3"
      id="F_88203657-07cb-4fef-bae5-5d99d36f1bac"
      unitRef="U_USD">46847000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4"
      decimals="-3"
      id="F_b01bebda-2b23-4951-a063-c53b85b258b7"
      unitRef="U_USD">262424000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4"
      decimals="-3"
      id="F_71d8fb6c-411b-4e15-8783-6b75e8799412"
      unitRef="U_USD">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4"
      decimals="-3"
      id="F_fc889726-87d9-4a1c-917b-7669e9825415"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c0cf97da-af4f-4b5e-970f-6b74d3fb82e4"
      decimals="-3"
      id="F_76392b20-5402-4086-90d6-21dba554e443"
      unitRef="U_USD">262519000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5525b019-e48a-443f-8f6c-bc589e834f80"
      decimals="-3"
      id="F_8f400186-931c-4652-ad83-2ec1e4b40e14"
      unitRef="U_USD">262424000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5525b019-e48a-443f-8f6c-bc589e834f80"
      decimals="-3"
      id="F_b570f87c-26c6-4a14-913d-1b1211eebb35"
      unitRef="U_USD">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5525b019-e48a-443f-8f6c-bc589e834f80"
      decimals="-3"
      id="F_abd226a1-0909-42ad-a2b6-6a905079de7e"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5525b019-e48a-443f-8f6c-bc589e834f80"
      decimals="-3"
      id="F_f1179b7e-140b-4a2d-aaaf-772a0e8d4205"
      unitRef="U_USD">262519000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_9046cd6f-b77a-4417-8c3b-32532b32d67f"
      unitRef="U_USD">309271000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_b130c13f-765c-4d1e-9749-9f85d01e8120"
      unitRef="U_USD">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_30b63b7b-9277-4459-8be7-99dae275cf9f"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_ab8c764c-daad-4283-a17a-755b40de7d22"
      unitRef="U_USD">309366000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9b5d4612-62c8-4e9e-9732-fb24b3fc9113"
      decimals="-3"
      id="F_3f8cb448-4ea6-4fec-8311-9bba12bb2ea5"
      unitRef="U_USD">143933000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9b5d4612-62c8-4e9e-9732-fb24b3fc9113"
      decimals="-3"
      id="F_90aaed36-f359-440c-82d8-1dcbbd51dec6"
      unitRef="U_USD">143933000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bbc49f27-1c6e-406e-a095-7623fd68f696"
      decimals="-3"
      id="F_fc73e361-f6b2-4c76-a2bf-eb9ac45bd1a8"
      unitRef="U_USD">72689000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bbc49f27-1c6e-406e-a095-7623fd68f696"
      decimals="-3"
      id="F_e867adf4-485b-419a-b1ba-0272a48a14be"
      unitRef="U_USD">72689000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ac099453-0c31-4ead-a71c-3537f6410632"
      decimals="-3"
      id="F_88fb2c23-1417-462a-8e96-5ceafde703d6"
      unitRef="U_USD">216622000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ac099453-0c31-4ead-a71c-3537f6410632"
      decimals="-3"
      id="F_b6830948-abea-4460-b795-2f773f86518e"
      unitRef="U_USD">216622000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_49a7915e-73e3-40e2-8989-6689fbe67430"
      decimals="-3"
      id="F_3f910a9d-541e-4cc4-89b4-4c7ddd047bd5"
      unitRef="U_USD">34596000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_49a7915e-73e3-40e2-8989-6689fbe67430"
      decimals="-3"
      id="F_92705a4a-bff4-4ae6-ae88-36cc89674f6a"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_49a7915e-73e3-40e2-8989-6689fbe67430"
      decimals="-3"
      id="F_bbec40c1-1597-472d-ab8e-f4d60657729e"
      unitRef="U_USD">34606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_dddec901-694e-4786-914e-180bcc77bb3d"
      decimals="-3"
      id="F_642a1dd4-0574-4b33-9307-c0adb2c5acfe"
      unitRef="U_USD">34596000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_dddec901-694e-4786-914e-180bcc77bb3d"
      decimals="-3"
      id="F_84490b32-0f95-4cc2-a619-76e2db939a5d"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_dddec901-694e-4786-914e-180bcc77bb3d"
      decimals="-3"
      id="F_7e4e80bd-7ca7-4fc4-b8ef-07bf776c3e03"
      unitRef="U_USD">34606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_8f98e7b2-0e47-4eed-b99e-902af6736f01"
      unitRef="U_USD">251218000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_8fe6858c-4f21-460b-b0c8-e932d696d6c8"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_893d7274-9688-4ce3-bb88-a699d174a7cf"
      unitRef="U_USD">251228000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <annx:InvestmentMaturityPeriod
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_fcded90e-f255-4b5a-8e84-124079da140b">P2Y</annx:InvestmentMaturityPeriod>
    <annx:InvestmentExpectedMaturityPeriod
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_28b74be2-1201-415a-810c-033a93a858ca">P12M</annx:InvestmentExpectedMaturityPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_af02f18a-220e-4c29-9661-3955cd0a4257"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_12f6b07b-6f2e-4dbe-a523-d63f330cb4c9"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_f49c1dbd-2f16-4c34-b8f7-851794a612ca"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <annx:BalanceSheetComponentsDisclosureTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_4a5d719a-931b-4a12-a36d-645da70201d9">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Balance Sheet Components&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total depreciation expense recognized for the years ended December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued and current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</annx:BalanceSheetComponentsDisclosureTextBlock>
    <annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_669d19e4-d08e-4127-849a-0afeb41bb1fb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <annx:PrepaidResearchAndDevelopmentCostsCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_a8d1de93-c956-457a-b49e-68d80c320981"
      unitRef="U_USD">2640000</annx:PrepaidResearchAndDevelopmentCostsCurrent>
    <annx:PrepaidResearchAndDevelopmentCostsCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_14fd8f5d-d586-4c28-aa40-7dc076064cb6"
      unitRef="U_USD">2617000</annx:PrepaidResearchAndDevelopmentCostsCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_4e7a0e2b-cb98-4d8a-bffa-160b56f3da39"
      unitRef="U_USD">700000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_ceff6129-72f7-42b2-9415-913d79168df9"
      unitRef="U_USD">704000</us-gaap:PrepaidInsurance>
    <annx:PrepaidAndOtherAssetsCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_6f2a9b60-ce7a-40b0-a9e8-f03a42184e3c"
      unitRef="U_USD">1104000</annx:PrepaidAndOtherAssetsCurrent>
    <annx:PrepaidAndOtherAssetsCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_bab88fc3-7453-43fe-b2eb-8a2987f745e5"
      unitRef="U_USD">823000</annx:PrepaidAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_2f6fb076-e9ba-47de-90f5-6fee1602a367"
      unitRef="U_USD">4444000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_c171fcab-f698-453c-8aa4-8a42125b41bd"
      unitRef="U_USD">4144000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_3401bfe2-abd4-49e9-b6cb-7ca20541395a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1cc25f78-dbe3-41a1-b7d8-90bfc1df6bd1"
      decimals="-3"
      id="F_50ea9219-e324-4ae9-8a09-43ff05177f65"
      unitRef="U_USD">17254000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_17ade79a-934b-4095-8b9f-770d560529d3"
      decimals="-3"
      id="F_9289f343-a986-4def-9f84-c8fa6c9b6483"
      unitRef="U_USD">17245000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4972a734-b0dc-409d-bf12-d162a67e116d"
      decimals="-3"
      id="F_1b49c089-18e8-4d46-a2fb-75f58f4e4b61"
      unitRef="U_USD">1838000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a6321396-4c80-49a4-a286-91e5bcfaf1eb"
      decimals="-3"
      id="F_0991565d-8a00-4c07-bebc-cccd73829f6f"
      unitRef="U_USD">1832000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_547ea12c-5672-44e1-81bd-5c04ecd20f79"
      decimals="-3"
      id="F_5c8ddd7f-6d22-4dea-a671-0598fb81ff22"
      unitRef="U_USD">692000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_95063796-51a0-4a4f-80df-7a8de33bf4a0"
      decimals="-3"
      id="F_2793356f-3e1a-4818-b40d-b84bbd866cff"
      unitRef="U_USD">692000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e330e31d-eab9-4389-8fa9-bef76e997d23"
      decimals="-3"
      id="F_56fb0ac8-93db-46f7-8920-0202171e8a12"
      unitRef="U_USD">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b1f5099c-e23a-49a6-8643-c8f3e583dd88"
      decimals="-3"
      id="F_d86b57b3-b653-4d92-8739-129c8a7af50f"
      unitRef="U_USD">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_e8d8a669-3b85-4148-818a-05283536b6d0"
      unitRef="U_USD">19817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_402af775-ed30-41ec-b12e-1f20cf823917"
      unitRef="U_USD">19802000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_a098861f-9aa5-4916-9a83-73a8687e4009"
      unitRef="U_USD">7179000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_8fa44d05-5413-4477-a820-d571e69d29ae"
      unitRef="U_USD">5029000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_50b35936-4f04-4b0e-a5e6-a1d1a3bd645c"
      unitRef="U_USD">12638000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_9b65982c-8ecd-434c-93bf-52f3390470f8"
      unitRef="U_USD">14773000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-5"
      id="F_1fe8fe9d-575a-458b-9bd9-f30950571440"
      unitRef="U_USD">2200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-5"
      id="F_8baefc43-4053-4d2d-9899-378226fbade8"
      unitRef="U_USD">2100000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_20cfeb8f-1517-43df-aa1b-a2f0543f309a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued and current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <annx:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_da2d7534-3df0-4be1-8104-65ed86c73e0c"
      unitRef="U_USD">10992000</annx:AccruedResearchAndDevelopmentExpensesCurrent>
    <annx:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_666265a5-205b-4195-ba64-f881a416d797"
      unitRef="U_USD">4027000</annx:AccruedResearchAndDevelopmentExpensesCurrent>
    <annx:AccruedCompensationCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_1fc2871e-2ef0-4612-8540-1cf8c9b33966"
      unitRef="U_USD">5833000</annx:AccruedCompensationCurrent>
    <annx:AccruedCompensationCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_066cd703-d962-49d9-97b9-b99152b5e2a4"
      unitRef="U_USD">5607000</annx:AccruedCompensationCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_50a4be4e-d322-42e9-92d1-67cec7dd34f2"
      unitRef="U_USD">602000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_f233509a-5d6a-462e-9ebd-7dde2d54579c"
      unitRef="U_USD">501000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_2deb1cbc-dc51-4703-bf8b-a613b59c9a9b"
      unitRef="U_USD">141000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_bf7c3cd0-b689-449e-af1c-b67c21524f5c"
      unitRef="U_USD">141000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <annx:AccruedAndOtherLiabilitiesCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_33d4a004-3ca1-4072-8555-17cadee2aae4"
      unitRef="U_USD">17568000</annx:AccruedAndOtherLiabilitiesCurrent>
    <annx:AccruedAndOtherLiabilitiesCurrent
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_5f24ecf8-59b6-410c-92f6-3f50f382fb6c"
      unitRef="U_USD">10276000</annx:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_b9f504da-e84b-4b78-a868-5480fd8d5da2">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases its offices and laboratory in Brisbane, California, or the Brisbane Lease, under a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten-year &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;noncancelable lease agreement that ends in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; renewable option. In November 2021, the Company subleased unoccupied space for two years from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, for aggregate sublease payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The sublease income, while it reduces the rent expense, is not considered in the value of the right-of-use assets or lease liabilities. The Company&#x2019;s sublease income was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the operating lease right-of-use assets were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;16.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and lease liabilities were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;29.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the consolidated balance sheet. The weighted average remaining lease term is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average incremental borrowing rate used to measure the operating lease liability is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost for the years ended December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. Variable lease payments for the years ended December 31, 2024 and 2023 were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments and related lease liabilities as of December 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t paid any claims or been required to defend any action related to its indemnification obligations. As of December 31, 2024, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875"
      id="F_8c8eda20-4b15-4ce7-b31a-d07f18ac46b0">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <annx:LesseeOperatingLeaseExpirationMonthAndYear
      contextRef="C_855b89a1-84bd-4934-adb2-47fa9352df11"
      id="F_4cf3aff0-152e-471b-9049-198750f34bee">2031-10</annx:LesseeOperatingLeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875"
      id="F_d4e5b14c-d9e5-4fe0-aa88-a65ee0b45fd9">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <annx:LesseeOperatingSubleaseCommencementYearAndMonth
      contextRef="C_301be3cb-1afb-480f-886a-93603e1ae4a3"
      id="F_0f7db2ed-f4c9-4afb-9a25-86f54b4e6f30">2021-12</annx:LesseeOperatingSubleaseCommencementYearAndMonth>
    <annx:LesseeOperatingSubleaseExpirationYearAndMonth
      contextRef="C_301be3cb-1afb-480f-886a-93603e1ae4a3"
      id="F_abd40b88-829a-4af5-ac75-1f3fcaaab710">2023-11</annx:LesseeOperatingSubleaseExpirationYearAndMonth>
    <annx:AggregateSubleasePaymentReceivable
      contextRef="C_e30eb803-2850-45ea-964d-0c167ebab98b"
      decimals="-5"
      id="F_f884ac61-bedd-4d02-9bf5-050b0cd4fd2f"
      unitRef="U_USD">3400000</annx:AggregateSubleasePaymentReceivable>
    <us-gaap:SubleaseIncome
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-6"
      id="F_724e5d3a-8cd0-4344-9cfc-ce14a9644e4f"
      unitRef="U_USD">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-5"
      id="F_5a19dac1-3aed-4ade-b184-59dad418bd17"
      unitRef="U_USD">2000000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875"
      decimals="-5"
      id="F_35491445-dc71-453c-82a5-7be13ebee216"
      unitRef="U_USD">16700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875"
      decimals="-5"
      id="F_258bed3f-f088-4bcb-a000-8c1d398fc27d"
      unitRef="U_USD">29000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_2e220b19-1558-4357-a8ce-4bbf8e24c875"
      id="F_aa27df6c-1f0d-4700-b804-2ac3d4485715">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <annx:OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="3"
      id="F_7fd627d1-acf5-472b-b6f3-c76cc59ac40a"
      unitRef="U_pure">0.084</annx:OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-5"
      id="F_f7ac965a-45a9-4266-9f0f-dca757cfa96b"
      unitRef="U_USD">3800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-5"
      id="F_94edd66a-bb7e-4179-9c87-fbd291924ea5"
      unitRef="U_USD">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeasePayment
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-5"
      id="F_a2bbaf05-8c53-463a-bbee-10b88089dde7"
      unitRef="U_USD">2300000</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-5"
      id="F_6ec128c6-0ed4-4529-bba2-e7a85c981609"
      unitRef="U_USD">1500000</us-gaap:VariableLeasePayment>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_3bd54cfe-1b5e-475f-9a04-556ca729ed41">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments and related lease liabilities as of December 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_9c82f908-5810-440b-a9ab-f381575f4022"
      unitRef="U_USD">5065000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_eec894d0-c842-4501-9dcf-e6bf6afc801d"
      unitRef="U_USD">5242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_85cfbf50-1f60-4465-a974-646264838f07"
      unitRef="U_USD">5425000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_e3edeaaa-02d2-4326-9f1b-534c9f839cd6"
      unitRef="U_USD">5615000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <annx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_43fbf499-f4c1-4f9a-90d9-f924724f08f8"
      unitRef="U_USD">16985000</annx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_ba2af39d-255c-40b3-b8a1-3334c64a2e5e"
      unitRef="U_USD">38332000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_49a01ec8-87d2-4cf0-b975-0836379719ac"
      unitRef="U_USD">9360000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_d3876341-3f9e-4602-b840-db23458b8e45"
      unitRef="U_USD">28972000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_0b9e3a29-d057-4f47-831e-82327f8fe72e"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="C_072050e6-df46-49a7-bd7c-e1422281108a"
      decimals="INF"
      id="F_77cfbaf5-5bd9-4385-bf77-14c0e36fab4c"
      unitRef="U_Claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_f7838c5f-dd9b-4b79-998c-d867ec1687c5">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders' Equity &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 2024, the Company raised net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting underwriting discounts and offering expenses through the sale of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,001,120&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.249&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which equals the per share offering price for the shares of common stock less the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exercise price for each pre-funded warrant. The pre-funded warrants are immediately exercisable, subject to certain beneficial ownership limitations. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#x2019; equity within additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2023 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Company raised net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting underwriting discounts and offering expenses through the sale of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,035,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.880&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;18,379,861&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.879&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which equals the per share offering price for the shares of common stock less the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exercise price for each pre-funded warrant. An entity related to one of the Company&#x2019;s directors participated in the public offering and purchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock for an aggregate price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#x2019; equity within additional paid-in capital. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,243,400&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;965,427&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the cashless and cash exercise of these pre-funded warrants in February 2024 and April 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2022 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2022, the Company raised net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting fees and expenses through the sale of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,013,834&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, pre-funded warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,696,206&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock and accompanying common warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock. The offering price per share and accompanying common warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.87125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and the offering price per pre-funded warrant and accompanying common warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.87025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which equals the per share offering price for the shares of common stock less the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exercise price for each such pre-funded warrant. The pre-funded warrants remain exercisable until exercised in full. The common warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.806875&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Both the pre-funded and common warrants are immediately exercisable, subject to beneficial ownership limitations. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders&#x2019; equity within additional paid-in capital. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,582,557&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the cashless exercise of the pre-funded warrants in March 2023. The Company issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,901&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,739,096&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the cashless exercise of the common warrants and pre-funded warrants in June 2024 and November 2024, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Pre-Funded and Common Warrants&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes warrant activity during the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Common Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Pre-funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,696,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,379,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,583,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,492,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;322,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,949,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,104,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,543,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 At-the-Market ("ATM") Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, the Company entered into a sales agreement with TD Cowen, as sales agent, or 2024 ATM program, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. TD Cowen &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is entitled to compensation up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate gross proceeds for the common stock sold through the 2024 ATM program. During the year ended December 31, 2024, t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;he Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting commissions paid to TD Cowen. As of December 31, 2024, approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million remained available for the offer and sales of shares of common stock under the 2024 ATM program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 ATM Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2021, the Company entered into a sales agreement with TD Cowen as sales agent, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under an at-the-market offering program, or 2021 ATM program. TD Cowen is entitled to compensation up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate gross proceeds for the common stock sold through the 2021 ATM program. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024 and 2023, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,576,067&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,646,458&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, respectively, under the 2021 ATM program for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, after deducting commissions paid to TD Cowen and other financing costs. The Form S-3 registration statement, which registered the 2021 ATM Program, expired on August 15, 2024. As a result, no further shares of common stock may be sold under the 2021 ATM Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The holders of the Company&#x2019;s common stock have one vote for each share of common stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common stockholders are entitled to dividends when, as, and if declared by the board of directors. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. As of December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; dividends had been declared by the board of directors.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reserved the following shares of common stock for issuance as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.089%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,594,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,208,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options reserved for 2020 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,109,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,988,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;770,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;495,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for 2021 ATM program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,619,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for 2024 ATM program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,250,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,983,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,338,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for 2022 Employment Inducement &lt;br/&gt;&#160;&#160;&#160;&#160;Award Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,359,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;758,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,543,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,493,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for common warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,104,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,715,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,329,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5b853485-b4de-4aef-8684-04438a8b004d"
      decimals="-5"
      id="F_8778f2e0-8f8d-4041-b46a-8582dbf158ad"
      unitRef="U_USD">116800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_5b853485-b4de-4aef-8684-04438a8b004d"
      decimals="INF"
      id="F_ede82fb0-f560-4c66-86de-721ab7db21b6"
      unitRef="U_shares">13001120</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3e3b68fc-a6f3-457c-8152-64fa99e75d60"
      decimals="3"
      id="F_0781ff8d-8091-4954-9d22-55a4ea89227c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_3e3b68fc-a6f3-457c-8152-64fa99e75d60"
      decimals="2"
      id="F_4d7100d3-222e-4659-b4fe-8c9c1b442cde"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_8472ac84-55e5-434a-90d4-c7f9d7aa4437"
      decimals="INF"
      id="F_af251dc5-3622-4ba1-b418-645f60685d65"
      unitRef="U_shares">7000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <annx:OfferingPricePerShare
      contextRef="C_3d6b212d-b7a8-4e3f-bfeb-dc2b3be0b024"
      decimals="3"
      id="F_08f17ee0-29b6-4c9f-8fad-c20cd199ac75"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.249</annx:OfferingPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_27512148-cc01-4328-b869-9d09fda6ba2d"
      decimals="3"
      id="F_08f5a8c3-3861-4f9f-b6f9-cbe4673abb9f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9ae8f66d-5240-4728-81a8-25950cb83964"
      decimals="-5"
      id="F_b03fa6c0-e7cb-4b11-874b-312acbe577f2"
      unitRef="U_USD">117000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9ae8f66d-5240-4728-81a8-25950cb83964"
      decimals="INF"
      id="F_e30662e8-d606-4331-97e8-dd29770c6ec4"
      unitRef="U_shares">25035000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4d34fdbe-9026-4710-920e-640cc4668c81"
      decimals="3"
      id="F_6dddfe3c-c9ee-4cf9-90bf-55e982833470"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_4d34fdbe-9026-4710-920e-640cc4668c81"
      decimals="3"
      id="F_b7988add-1c84-4e80-bbe1-b42f8d5e0235"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.88</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ab735fa4-b8ce-4204-bd13-e3e5137bced9"
      decimals="INF"
      id="F_f106f6e3-23ac-49da-bcf6-bb6366a04f70"
      unitRef="U_shares">18379861</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <annx:OfferingPricePerShare
      contextRef="C_571d253c-4271-4944-954f-09fa5121f2db"
      decimals="3"
      id="F_15cb8cb4-0d0a-41da-b56f-59e0225a2e34"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.879</annx:OfferingPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_55a285e5-5315-412c-bf43-8041cddc34bc"
      decimals="3"
      id="F_6c6292bb-15cf-453f-a823-64caa984a672"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a89b88c0-ec52-4b3d-8aa8-2fcdcacd2667"
      decimals="INF"
      id="F_b1b5a06d-c99c-4909-a175-2bc2c2ff8885"
      unitRef="U_shares">350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <annx:CommonSharesExchangeValue
      contextRef="C_9ae8f66d-5240-4728-81a8-25950cb83964"
      decimals="-5"
      id="F_5598ac35-ddbb-47b4-9e37-b258a539cdb3"
      unitRef="U_USD">1000000</annx:CommonSharesExchangeValue>
    <annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants
      contextRef="C_08392b92-b47a-463c-9c19-05c9de02b962"
      decimals="INF"
      id="F_e2af01a1-2480-43cd-afe0-5ad3debd9f12"
      unitRef="U_shares">5243400</annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants>
    <annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants
      contextRef="C_c1fa55bb-8cda-41f2-be10-9c4b61733d56"
      decimals="INF"
      id="F_ee576a69-1dae-46a2-a724-59b8a50d1363"
      unitRef="U_shares">965427</annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_262315fc-5a70-4273-9329-a8573c6e8ac6"
      decimals="-5"
      id="F_c59b2e01-741b-4218-b56b-e67e76318ebd"
      unitRef="U_USD">122500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7d9aed7f-6bbe-4caa-a2eb-d48056481199"
      decimals="INF"
      id="F_69bc3e36-3f93-417f-8308-2aafa259e885"
      unitRef="U_shares">9013834</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_de537ec6-325e-4910-8f4c-21e257afbcae"
      decimals="INF"
      id="F_3a5fb63b-f71d-4051-bdc9-3dbe1ccbe9c8"
      unitRef="U_shares">24696206</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d579d761-816c-4e55-92d6-ce372f29566a"
      decimals="INF"
      id="F_f0e4c1a3-8b1c-4dc3-ac17-caf193820d84"
      unitRef="U_shares">8427508</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <annx:OfferingPricePerShare
      contextRef="C_c86633a7-f190-4e56-90c2-b45ffb2a2fec"
      decimals="5"
      id="F_07139a8a-633c-411c-b396-6faaf4bfbbb1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.87125</annx:OfferingPricePerShare>
    <annx:OfferingPricePerShare
      contextRef="C_14a08883-0225-4ca1-b9a6-4b86b0937620"
      decimals="5"
      id="F_7cb9dbc8-7f3f-4154-a2e8-b399f7be0dbe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.87025</annx:OfferingPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_de537ec6-325e-4910-8f4c-21e257afbcae"
      decimals="3"
      id="F_ca69e110-15f7-47ee-8297-d9549a6c35bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_4b7c8434-c7e2-4ff2-b583-26501f87a512"
      decimals="6"
      id="F_f70ce75b-dbc5-4018-8d9e-269ddda41a88"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.806875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_4b7c8434-c7e2-4ff2-b583-26501f87a512"
      id="F_1eaea120-5511-4744-9ee1-3eb47b30f8cd">2025-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants
      contextRef="C_f9d86972-6bef-4c53-8764-f295400423e9"
      decimals="INF"
      id="F_271e8ebd-f596-4992-8ab8-cb33950fad0d"
      unitRef="U_shares">2582557</annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants>
    <annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants
      contextRef="C_cdc4c27d-b376-4374-8ee1-613abe059850"
      decimals="INF"
      id="F_84d16830-04c4-4fe5-8b29-4fbb1e8a931f"
      unitRef="U_shares">19901</annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants>
    <annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants
      contextRef="C_95335bc0-36c3-45f2-998d-639cb78b1f47"
      decimals="INF"
      id="F_3eba047f-2f27-4a7a-a426-edd2b226847e"
      unitRef="U_shares">2739096</annx:StockIssuedDuringPeriodSharesForExerciseOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_d50ea72f-39a7-4652-a5ae-e8056662fdde">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes warrant activity during the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Common Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Pre-funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,696,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,379,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,583,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,492,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;322,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,949,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,104,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,543,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_ec22ff7d-ccec-45fd-a10c-766baaf42b25"
      decimals="0"
      id="F_3f4047f7-b579-4b19-a151-32825834483c"
      unitRef="U_shares">8427508</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b058d9ba-58ce-4e56-a243-4df02901e4e2"
      decimals="0"
      id="F_35a5cdcd-8eef-47e9-b1f2-05c81b8518ba"
      unitRef="U_shares">24696206</us-gaap:ClassOfWarrantOrRightOutstanding>
    <annx:ClassOfWarrantOrRightIssued
      contextRef="C_0b957594-7615-4933-9789-94cb54dc8638"
      decimals="0"
      id="F_6e8db9ee-476d-4111-b2b3-ff7a04f8e4fb"
      unitRef="U_shares">18379861</annx:ClassOfWarrantOrRightIssued>
    <annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued
      contextRef="C_32785c93-aaca-43fa-a248-cb24bd9882bf"
      decimals="3"
      id="F_69152487-6cd2-4315-8d70-9b370620d22f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued>
    <annx:ClassOfWarrantOrRightExcercised
      contextRef="C_0b957594-7615-4933-9789-94cb54dc8638"
      decimals="0"
      id="F_b8172069-daef-44af-81a0-1ee6b1e06dc5"
      unitRef="U_shares">2583144</annx:ClassOfWarrantOrRightExcercised>
    <annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised
      contextRef="C_32785c93-aaca-43fa-a248-cb24bd9882bf"
      decimals="3"
      id="F_f1618251-33c8-4aed-ba07-f6fdd61f71b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_ae76d731-12db-4f4c-9bcd-ade6fdbeaa43"
      decimals="0"
      id="F_83625211-1ff4-47aa-a272-5041c7de599e"
      unitRef="U_shares">8427508</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_ab735fa4-b8ce-4204-bd13-e3e5137bced9"
      decimals="0"
      id="F_f7f524e5-1050-48ee-a924-d18284119416"
      unitRef="U_shares">40492923</us-gaap:ClassOfWarrantOrRightOutstanding>
    <annx:ClassOfWarrantOrRightIssued
      contextRef="C_d39e2be4-3f00-449f-bea4-e4669b559cd6"
      decimals="0"
      id="F_bbf33fa1-182a-44c8-9181-569f942b2614"
      unitRef="U_shares">7000000</annx:ClassOfWarrantOrRightIssued>
    <annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued
      contextRef="C_8e8bc1e1-c0eb-4e34-a2ff-e496756a8fca"
      decimals="3"
      id="F_eaa8c140-eaff-4b37-a21b-89ab330e2967"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantIssued>
    <annx:ClassOfWarrantOrRightExcercised
      contextRef="C_2ba532e7-e440-42d5-911c-cf6ce266687f"
      decimals="0"
      id="F_5c94859f-cbd3-43de-8f12-1632833f91ce"
      unitRef="U_shares">322893</annx:ClassOfWarrantOrRightExcercised>
    <annx:ClassOfWarrantOrRightExcercised
      contextRef="C_d39e2be4-3f00-449f-bea4-e4669b559cd6"
      decimals="0"
      id="F_1bf0637f-528e-4f5d-805b-b7727c4d717c"
      unitRef="U_shares">8949346</annx:ClassOfWarrantOrRightExcercised>
    <annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised
      contextRef="C_8e8bc1e1-c0eb-4e34-a2ff-e496756a8fca"
      decimals="3"
      id="F_08afd25d-e697-487e-b5d2-348cdac66424"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.216</annx:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b64c79b4-fe65-47cc-bb5d-7ddb0490610e"
      decimals="0"
      id="F_46f8bcd8-5780-4812-a59b-e7e8ccb576b9"
      unitRef="U_shares">8104615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_816a75eb-eeac-444c-b1ad-06f15723b3de"
      decimals="0"
      id="F_403399be-b664-4ef7-8f1a-310390095a9a"
      unitRef="U_shares">38543577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_e671e012-c921-435e-938c-d68a826109d9"
      decimals="-5"
      id="F_43617fae-24fe-4bed-a40a-92393d890b9b"
      unitRef="U_USD">100000000</us-gaap:CommonStockValue>
    <annx:PercentageOfGrossProceedsOfCommonStockToBePaid
      contextRef="C_bc70ca19-dd4e-484a-9840-e8e349d6ed16"
      decimals="2"
      id="F_b9464273-3b5e-4cef-bb50-7620a417421e"
      unitRef="U_pure">0.03</annx:PercentageOfGrossProceedsOfCommonStockToBePaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b7464154-5bfb-48e8-b9ee-4421be6a566c"
      decimals="INF"
      id="F_a8e9d654-6f9e-4649-9b29-b79322e8c211"
      unitRef="U_shares">750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b7464154-5bfb-48e8-b9ee-4421be6a566c"
      decimals="-5"
      id="F_321d5b4b-397e-4143-9e5f-8e3e72ebd86f"
      unitRef="U_USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <annx:RemainedAvailableForOfferAndSalesOfSharesOfCommonStock
      contextRef="C_06a73ed8-fa35-4a8b-9584-91fdd26d518e"
      decimals="-5"
      id="F_7d3071fc-ea1f-45ec-ad8c-4f0a9f1522b4"
      unitRef="U_USD">95400000</annx:RemainedAvailableForOfferAndSalesOfSharesOfCommonStock>
    <us-gaap:CommonStockValue
      contextRef="C_7b518a40-52a6-4973-869c-448436c41106"
      decimals="-5"
      id="F_8b5d93f9-38da-4a99-bc51-b06f2fa28ab4"
      unitRef="U_USD">100000000</us-gaap:CommonStockValue>
    <annx:PercentageOfGrossProceedsOfCommonStockToBePaid
      contextRef="C_ed0ef5bd-d7b5-41fd-bc14-c386fcc1efd8"
      decimals="2"
      id="F_fba75845-16e7-4167-8d6d-a12a56644905"
      unitRef="U_pure">0.03</annx:PercentageOfGrossProceedsOfCommonStockToBePaid>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d22db712-c793-4143-97f9-0b1afeba048b"
      decimals="INF"
      id="F_db2b8737-f9b8-433d-b000-eaf171ddafd4"
      unitRef="U_shares">7576067</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6f5f0013-61b6-4736-b7e9-a7f934312508"
      decimals="INF"
      id="F_700e2606-dbba-44e5-ab6f-98acbc0b7a78"
      unitRef="U_shares">2646458</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c9766150-3460-412e-b465-7535db7a6402"
      decimals="-5"
      id="F_1a639960-226a-487e-9381-ad7664e92620"
      unitRef="U_USD">38400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_948f2da9-09b8-4835-b79f-9b108878b9f6"
      decimals="-5"
      id="F_26216e7f-0d31-41f0-bf5a-90c672747337"
      unitRef="U_USD">17500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_6ed4fe06-ebc0-4195-b39a-ac0ab3a27d1b">The holders of the Company&#x2019;s common stock have one vote for each share of common stock.</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_cd7558dc-90c4-422e-9cfe-de8b70f77dc3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <annx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_707dcfe7-db2a-4746-8d97-3a93194a0962">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reserved the following shares of common stock for issuance as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.089%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,594,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,208,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options reserved for 2020 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,109,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,988,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;770,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;495,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for 2021 ATM program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,619,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for 2024 ATM program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,250,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,983,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,338,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for 2022 Employment Inducement &lt;br/&gt;&#160;&#160;&#160;&#160;Award Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,359,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;758,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,543,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,493,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for common warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,104,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,715,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,329,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</annx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_29782950-7a96-4afe-b123-68b6a1a44a9d"
      decimals="INF"
      id="F_d3d4a1f6-6526-451b-abda-2d1b0c1d3f42"
      unitRef="U_shares">14594720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3a117edd-79b6-42cf-bde0-58487b0502bc"
      decimals="INF"
      id="F_541ad21a-c4ef-4ffd-abcf-73d584c9d8a3"
      unitRef="U_shares">9208970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_e5457637-3c61-492e-b073-b90232effb2f"
      decimals="INF"
      id="F_f4e67c84-c864-48e1-90a1-4eba671b49ca"
      unitRef="U_shares">2109758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_2c4873ea-60ed-4c68-a1a0-60c57456e3bf"
      decimals="INF"
      id="F_f67bc5a8-0f89-432e-8231-0857cd1a626a"
      unitRef="U_shares">1988340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_66179d4e-f740-4656-9e26-82ac3de679ad"
      decimals="INF"
      id="F_374bc597-4ee5-4e56-bb5d-e2497cbba19d"
      unitRef="U_shares">770028</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a59b470f-7ad8-4b6e-a84a-dddba145a948"
      decimals="INF"
      id="F_876b7c79-4615-4340-b887-c01cd9a0d9da"
      unitRef="U_shares">495579</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ce377faf-e56d-4d57-9149-325ff3298695"
      decimals="INF"
      id="F_165995a6-bfb1-4969-a62f-f0a077df835f"
      unitRef="U_shares">2619471</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_07f46682-ea8e-47fe-a18f-70b0bb1a100b"
      decimals="INF"
      id="F_ca09e562-3663-4f5f-abe3-e0f8a1ca2a3e"
      unitRef="U_shares">24250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_95493879-152b-4afb-9460-55860ac0385d"
      decimals="INF"
      id="F_8d8e1c1f-e617-4e0e-ad30-8e041a73b880"
      unitRef="U_shares">1983924</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e9fbcf92-912d-427d-ae6e-83428851302a"
      decimals="INF"
      id="F_9d382441-3ddd-402d-86e8-58ee22a2ba6a"
      unitRef="U_shares">1338381</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a8a555d1-c90f-4f9c-959d-6220a378be31"
      decimals="INF"
      id="F_dabd0d83-c474-4843-8875-2631dd78aa4f"
      unitRef="U_shares">3359230</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bf13cefb-5813-466c-a528-52377f64fc89"
      decimals="INF"
      id="F_ecdad73d-722c-4b81-9a39-ee4cca56f06d"
      unitRef="U_shares">758084</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b856724b-67a4-4bba-a3f2-933d6bdcf267"
      decimals="INF"
      id="F_9ad2bade-9bcc-4d5d-9533-c24cd66f302e"
      unitRef="U_shares">38543577</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_181b327c-8c4d-49cd-992f-be0a8cabfe0b"
      decimals="INF"
      id="F_d69f4b98-c3fb-4fd9-91e2-ac7b926157e9"
      unitRef="U_shares">40493510</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d1fd9ac5-bc60-4fb7-9382-fc0aedcbb6f9"
      decimals="INF"
      id="F_915627f1-d9bb-429c-8ecd-f84b5c954409"
      unitRef="U_shares">8104615</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_47ff50b0-e58b-40e4-8ff0-c5bad7aafd91"
      decimals="INF"
      id="F_4700f3ed-4b4d-4f88-b543-33a9fe08c7f5"
      unitRef="U_shares">8427508</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_fd5916c6-5bb3-4109-a594-9479003949b6"
      unitRef="U_shares">93715852</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="INF"
      id="F_62f6c680-a2d8-47db-bc2e-24e49648566d"
      unitRef="U_shares">65329843</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_2eb7e6cb-f1bc-4a0b-bedf-c452e86e0005">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2020, the Company&#x2019;s board of directors and stockholders adopted and approved the 2020 Incentive Award Plan, or the 2020 Plan, and the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may not grant any additional awards under the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The number of shares of common stock reserved for issuance under the 2020 Plan automatically increase on the first day of January, in an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of the Company&#x2019;s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Awards granted under the 2020 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant. For the Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the estimated fair value on the date of grant. Options granted typically vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period but may be granted with different vesting terms.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of December 31, 2024 and 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,109,758&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,988,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for issuance under the 2020 Plan, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2022 Employment Inducement Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2022, the Company&#x2019;s board of directors adopted the Annexon, Inc. 2022 Employment Inducement Award Plan, or the Inducement Plan, and together with the 2011 Plan and the 2020 Plan, the Plans. The Inducement Plan was adopted by the Company&#x2019;s board of directors without stockholder approval pursuant to Nasdaq Marketplace Rule 5635(c)(4), or Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan may only be granted to newly hired employees as an inducement material to the employees entering into employment with the Company. Awards granted under the Inducement Plan expire no later than ten years from the date of grant. An aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,850,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were reserved for issuance under the Inducement Plan. As of December 31, 2024 and 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,359,230&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;758,084&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for issuance under the Inducement Plan, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents stock option activity under the Plans for the period:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.420000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,208,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,749,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;382,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;981,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,594,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and Exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,813,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The intrinsic value is the difference between the fair value of the Company&#x2019;s common stock at the time of exercise and the exercise price of the stock option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value of options granted to employees during the years ended December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the total unrecognized stock-based compensation cost related to outstanding unvested stock options was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which the Company expects to recognize over an estimated weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs are share awards that entitle the holder to receive freely tradeable shares of the Company&#x2019;s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder&#x2019;s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a three-year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company&#x2019;s common stock on the grant date.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of RSU activity under the equity incentive plan and related information is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;495,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;602,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;770,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, unrecognized stock-based compensation expense related to outstanding unvested RSUs was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ESPP enables eligible employees to purchase shares of the Company&#x2019;s common stock at the end of each offering period at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Share purchases are funded through payroll deductions of at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, and up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of an employee&#x2019;s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP increase automatically on the first&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;day &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of each fiscal year, by a number equal to, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or such number of shares determined by the Company&#x2019;s board of directors. As of December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,983,924&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were available for future purchase. The ESPP generally provides for six-month consecutive offering periods beginning on May 15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and November 15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of each year. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. As such, stock-based compensation expense has been recorded for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The stock-based compensation expense related to the ESPP for the years ended December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total stock-based compensation expense recognized was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To determine the value of stock option awards for stock-based compensation purposes, the Company uses the Black-Scholes option pricing model and the assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The fair value of each share of underlying common stock is based on the closing price of the Company&#x2019;s common stock as reported on the date of grant on the Nasdaq Global Select Market.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company continues using the simplified method as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Beginning in 2024, the expected volatility was estimated based on a weighted volatility using both the Company&#x2019;s trading history for its common stock and the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. Prior to 2024, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:27.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:27.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <annx:PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_ed5a5f17-0c97-4f5a-9b60-ca019a3ff9a8"
      unitRef="U_pure">0.04</annx:PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_62afd9af-8d8b-4e4b-b211-51173df8e30c">Awards granted under the 2020 Plan expire no later than ten years from the date of grant. For the Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than 100% of the estimated fair value on the date of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_9975677e-7e6d-4756-9df9-482c883c5ac8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_5f614136-7067-4542-9d0b-a420c024f04d"
      decimals="INF"
      id="F_99b42bd2-e9e2-4b7f-af11-543a7dee1a14"
      unitRef="U_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_62429d6b-626c-4e84-a0f3-c35df3f252f6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_c0f3b5f7-e1d9-4268-9fe1-7bbc706a980e"
      unitRef="U_shares">2109758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="INF"
      id="F_40f5b56c-1f0a-4460-b5b0-cc60f9cbebd6"
      unitRef="U_shares">1988340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_369ed887-7421-4d9b-9304-a1aaa66c59c5"
      decimals="INF"
      id="F_5fc4b36f-2830-45fe-b372-840007070727"
      unitRef="U_shares">7850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f4174d5a-db4b-4a44-b7ea-89d6395031d8"
      decimals="INF"
      id="F_bb3bc31a-c105-478c-aed4-282165de0d47"
      unitRef="U_shares">3359230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_43b053ed-5a1a-4d6e-8884-dff3a7269d3b"
      decimals="INF"
      id="F_6231e5ce-303a-442b-b650-1f081715bb57"
      unitRef="U_shares">758084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_46a7a782-571e-48c7-ad25-6d3313745d19">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents stock option activity under the Plans for the period:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.420000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,208,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,749,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;382,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;981,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,594,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and Exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,813,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="INF"
      id="F_57c16293-9509-44d4-ae70-c15646cf0453"
      unitRef="U_shares">9208970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="2"
      id="F_5516a35f-710f-4d9e-9a87-6190fa9abae4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      id="F_9eae3b20-4e1c-4d6c-8388-42d63d3186e3">P7Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_e2bf9bc6-383a-4344-88f2-1e370b71f520"
      unitRef="U_USD">2930000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_b75a7c72-8845-44e7-adbc-d820ebc04a59"
      unitRef="U_shares">6749824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_7b63e2d9-d4b6-46c7-a819-d9c1716a0a29"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_63f5e3cd-e8ec-47af-a96d-2b41503ac5b0"
      unitRef="U_shares">382122</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_4fb2dbba-8397-47e3-907f-0f09010a129a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_aba2dfdf-f28c-45ce-829e-f66144115671"
      unitRef="U_shares">981952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_815677d4-2619-4564-97f2-e740eb2a9106"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_972ec9f6-4cf3-4164-9211-59053e6a0391"
      unitRef="U_shares">14594720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="2"
      id="F_8c25fdce-2587-4e45-981e-a1ae31e8fd24"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_ee7e4d93-d3a0-40d6-ac38-40017b868ebe">P7Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_bbe07b1c-09ff-466d-955b-609c0da2b626"
      unitRef="U_USD">4059000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_b5a3b86e-1e40-4fa6-bd5d-3f5ec73f6cae"
      unitRef="U_shares">6813637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="2"
      id="F_cae4e647-530c-4258-8d39-de2172ab9f31"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_afd92498-919a-4dff-ac10-116488449467">P6Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_361f464b-85ec-4c0b-8468-a6534488c7b1"
      unitRef="U_USD">2194000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-5"
      id="F_28c7900e-ac53-4c03-873a-79446402d590"
      unitRef="U_USD">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-5"
      id="F_903bcaa6-46e6-475f-87fb-0b3da63cfdef"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_eaec4616-b419-452f-afec-7269fe2849b9"
      decimals="2"
      id="F_1e855fed-6081-4481-bcb8-2acedee0c218"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_c91f5f8f-b8d5-4019-a7fb-1c7e1652024e"
      decimals="2"
      id="F_bcfeee88-8068-4939-bec5-b001e7681cca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_48cf44ed-6e91-4e9a-ac99-23eaa9cb9ebc"
      decimals="-5"
      id="F_520bc201-65d5-4131-bab8-0a0781676de8"
      unitRef="U_USD">33100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_3e68d556-c613-496d-8b12-a19ccabf129f">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_24ad6736-aec7-4411-80fc-ae4b0b7b776c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of RSU activity under the equity incentive plan and related information is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;495,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;602,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;770,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="INF"
      id="F_84e71b0b-326e-445d-9092-101922afe3de"
      unitRef="U_shares">495579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="2"
      id="F_ec20e8fd-e892-4d85-9c3c-d985e9119520"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_fbeb7518-c250-4399-b15a-e1623533a249"
      unitRef="U_shares">602600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_f317410d-eb18-48ff-b362-d49e02e9f0f0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_eb6cd726-088d-488c-b129-7d542ed35539"
      unitRef="U_shares">197177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_42845484-4d24-4193-92cf-3fa8f90da856"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_e7c48261-0ce2-429a-8c7b-852f5d560eec"
      unitRef="U_shares">130974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_adf07d84-6fec-4526-8a6e-52194b2c976f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_b9b370f9-c85d-4eea-8a0f-16e4c5c66690"
      unitRef="U_shares">770028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="2"
      id="F_836c252b-99a8-44d2-8243-d4cc63b16223"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_bd2c86aa-468c-41c3-bcc5-d4bb6af8a626"
      decimals="-5"
      id="F_ed7dc860-25fa-4e3d-b761-05b439950883"
      unitRef="U_USD">2500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_eb44a589-ed4e-4789-9745-4e687e913dc7"
      id="F_f179a85f-b638-4dcb-ad6e-83907e4449ec">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_b57972b4-cb2c-4aba-9af4-d01913068013"
      decimals="2"
      id="F_bd446571-47ee-482a-b30e-3b164b568b6b"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <annx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="C_95493879-152b-4afb-9460-55860ac0385d"
      decimals="INF"
      id="F_e32261bf-1281-4fa9-8f64-be4faad24ada"
      unitRef="U_pure">0.01</annx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_95493879-152b-4afb-9460-55860ac0385d"
      decimals="INF"
      id="F_037b90cd-46d0-40dd-9c43-b967fe9f1415"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <annx:PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear
      contextRef="C_b57972b4-cb2c-4aba-9af4-d01913068013"
      decimals="2"
      id="F_6e09f56c-7df3-4d36-855e-9684ce9dd8a0"
      unitRef="U_pure">0.01</annx:PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_95493879-152b-4afb-9460-55860ac0385d"
      decimals="INF"
      id="F_6cfdb768-fe6c-444d-a683-038b0dba22be"
      unitRef="U_shares">1983924</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b57972b4-cb2c-4aba-9af4-d01913068013"
      decimals="-5"
      id="F_53a33aba-efd8-4177-8dc7-2218a757b2de"
      unitRef="U_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_94c78139-5590-4748-8160-840a5d169474"
      decimals="-5"
      id="F_1586d179-c958-41da-b672-fc054dd7c57f"
      unitRef="U_USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_60ba1df5-df2e-4aa5-a434-47b807da894d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total stock-based compensation expense recognized was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_07dde65d-d011-4647-84a8-b3adc4b0a081"
      decimals="-3"
      id="F_f1a71fce-7093-4de5-bc39-eb8d8fc57855"
      unitRef="U_USD">9670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_887b31a4-95c1-40be-a759-5e56b5fa7540"
      decimals="-3"
      id="F_99da1d17-1e83-4a6f-a15e-b43e077a8266"
      unitRef="U_USD">8878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e35f510e-8466-4a7b-bbdd-fbb00d74b1e0"
      decimals="-3"
      id="F_c5db77ec-765d-4969-b9ec-39dfe43598c0"
      unitRef="U_USD">9763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_988ddfc5-9dce-4f27-b086-5099244cdafc"
      decimals="-3"
      id="F_60b1f1e5-5ad6-42ed-881e-ffbb23e3ef28"
      unitRef="U_USD">9305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_a1d9c964-7aa9-4590-b394-793b65cded93"
      unitRef="U_USD">19433000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_6729ce74-5768-4777-8ac3-2317e4ebb331"
      unitRef="U_USD">18183000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_5b545907-4847-421c-9282-99d49471a3bf">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:27.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:27.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4595fc5f-0546-4bdf-8e9d-71d2422bc886"
      id="F_f5a0fd79-4a5f-4259-a835-f21d7351df9e">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_347d207b-e303-43ed-928d-7392f73d169f"
      id="F_e07240a9-652d-46c9-8ff8-d2efca4d1a2a">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fc111147-f3e4-414e-8968-b78d5df90526"
      id="F_1fc66583-2a6d-458d-924a-119e0dd1b225">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6c830638-e7f6-4b1b-b448-37326bf9c73c"
      id="F_0b82bf72-4f55-42b8-b286-89fe938ec982">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="4"
      id="F_0e96a3ca-f84c-43f6-adf8-3c4fe128ed1a"
      unitRef="U_pure">0.959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="4"
      id="F_223d43f7-7aac-4833-90b6-1d8878932d3d"
      unitRef="U_pure">0.998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="4"
      id="F_66f1457a-d741-4cf2-ad68-a10172747ccc"
      unitRef="U_pure">0.812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="4"
      id="F_26e6da34-3141-44d1-ba5f-37fd63d0e6f6"
      unitRef="U_pure">0.824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="4"
      id="F_df183bd1-2886-4cdb-b689-69fe16124da8"
      unitRef="U_pure">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="4"
      id="F_92198baf-fb62-4e0a-966c-54c0bc3912b3"
      unitRef="U_pure">0.0465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="4"
      id="F_5e11b79d-15f6-426b-bdb9-951cbe69c1e4"
      unitRef="U_pure">0.0347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="4"
      id="F_51430ced-b9f0-465e-9b6e-65847ee4b701"
      unitRef="U_pure">0.0485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_eefc453e-a2a5-4d3e-bb38-8b6e8d61718b">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For financial reporting purposes, loss before provision for income taxes, includes the following components (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For each of the years ended December 31, 2024 and 2023, the Company incurred insignificant amounts for an income tax provision. The U.S. federal and California deferred tax assets generated from the Company&#x2019;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax provision at U.S. statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 162(m) compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2024, the Company completed a research credit study for the years ended December 31, 2020 through 2023. This resulted in true ups to the credit carryovers, which also impacted the Section 174 capitalized research expenses and net operating losses deferred tax assets disclosed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of state net operating loss, or NOL, carryforwards available to offset future taxable income. Under the Tax Cuts and Jobs Act of 2017, or the Tax Act, federal NOLs generated after December 31, 2017 will be carried forward indefinitely with the yearly NOL utilization limited to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of taxable income. The Company has $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;324.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of such federal NOLs that do not expire. If not utilized, the federal carryforward losses generated prior to 2018 and the state carryforward losses will expire in various amounts beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of state credit carryforwards available to offset future taxable income. If not utilized, these credit carryforwards will expire in various amounts for federal purposes beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The state credits do not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not some portion or all of the deferred tax assets will not be realized. Management believes that, based on available evidence, both positive and negative, it is more likely than not that the deferred tax assets will not be utilized; therefore, a full valuation allowance has been recorded. The Company&#x2019;s valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively. The changes in the 2024 valuation allowance were primarily due to the addition of capitalized research and development costs, current year loss carryforwards and research and development credits. The changes in the 2023 valuation allowance were primarily due to the addition of capitalized research and development costs, current year loss carryforwards and research and development credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Utilization of the net operating loss carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2024. Federal net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and state and local net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million are not expected to expire unutilized as a result of ownership changes identified through December 31, 2024. The Company has identified $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of federal and state net operating losses, respectively, that will expire unused due to ownership changes,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;federal credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that will not be able to be utilized due to ownership change limitation; these amounts have been excluded from the deferred tax assets table above. Further ownership changes subsequent to December 31, 2024 may be identified which could result in limitations to the amount of net operating losses and credits which may be utilized prior to expiration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Uncertain Tax Benefits&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the following activity relating to the gross amount of unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.248%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.917%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.917%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reductions based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of these uncertain tax positions will impact the Company&#x2019;s effective tax rate if assessed. The Company&#x2019;s policy is to classify interest and penalties associated with unrecognized tax benefits as income tax expense. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; interest or penalty accruals associated with uncertain tax benefits in its consolidated balance sheet and consolidated statement of operations for the years ended December 31, 2024 and 2023. The Company files income tax returns in the United States, various states, and Australia. The Company is not currently under examination by any major tax jurisdictions nor has it been in the past. The tax years &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a1b6e2c0-03d3-4a20-b626-abcffa81b2cd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2011 through 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; remain effectively open for examination by the Internal Revenue Service and most state tax authorities because of net operating losses and credit carryovers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next twelve months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_f8ce3e1d-23b1-4110-ab58-d50264f8e031">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For financial reporting purposes, loss before provision for income taxes, includes the following components (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_184d5697-65af-44cd-81a0-d7b5fa16218b"
      unitRef="U_USD">138193000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_cd70300e-63b0-47b4-9964-3be9adecd925"
      unitRef="U_USD">134233000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_98e3d094-e825-4132-b209-5a9e30d32388"
      unitRef="U_USD">7000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_1c1edfcb-1d33-48a2-9f4e-97a7f6796be9"
      unitRef="U_USD">4000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_db3107b9-df54-40ff-ad57-6d1997c20962"
      unitRef="U_USD">138200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_58490425-9eaf-4e41-bdf4-48835cad26cc"
      unitRef="U_USD">134237000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_ba6b5d90-7740-4e49-b11f-310ef7aa086c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax provision at U.S. statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 162(m) compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_e60b1d6d-3942-4d01-8437-d28b0eadcb80"
      unitRef="U_USD">-29022000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_9eb93fdf-2b48-48af-b962-91eef7416551"
      unitRef="U_USD">-28190000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_bc5d929c-a828-4074-bcbc-430978d58fa1"
      unitRef="U_USD">1548000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_1359661f-bc45-458e-9674-63fdd7773554"
      unitRef="U_USD">1343000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_8c251414-9ff1-47ff-8649-3704d2dfb1dc"
      unitRef="U_USD">9526000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_f3cc960c-417b-486e-8c6e-26a52eedbee0"
      unitRef="U_USD">3883000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_47beeb48-fe48-4369-a1cb-718fea1eb344"
      unitRef="U_USD">35184000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_87febd31-3e2a-4ee8-8f1a-adb4a666a044"
      unitRef="U_USD">29066000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <annx:IncomeTaxRateReconciliationSection162MCompensation
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_a75bdc29-9d28-49fa-869d-1bd800eb7afb"
      unitRef="U_USD">1773000</annx:IncomeTaxRateReconciliationSection162MCompensation>
    <annx:IncomeTaxRateReconciliationSection162MCompensation
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_4760e463-aab2-4aba-bace-21dda558b5b2"
      unitRef="U_USD">1594000</annx:IncomeTaxRateReconciliationSection162MCompensation>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_0de0b042-99f4-4978-8e30-f0654843d74e"
      unitRef="U_USD">43000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_2afb1629-0528-43ff-9d4f-0a44a5fb98ab"
      unitRef="U_USD">70000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_d9e2c45c-89df-4343-8030-be829b203cb3"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_b5f01c76-1c0d-4c1c-8512-68c80ef04eb4"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_33552ab4-8e22-46ea-adb3-71e18fa2c840">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_6507b4b5-17ae-4792-b36b-d5b7e9bfe5c4"
      unitRef="U_USD">94198000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_64af6d9a-d86a-4ba7-8521-f9dd4a33d418"
      unitRef="U_USD">70996000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_5852b74b-c223-487f-90a4-b41e36c277fe"
      unitRef="U_USD">29095000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_13673311-89b1-4b6e-a915-a64259378b93"
      unitRef="U_USD">16070000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <annx:DeferredTaxAssetsOtherIntangibleAssets
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_e4ec61f7-94ff-4f0e-a494-afa272aa819b"
      unitRef="U_USD">5000</annx:DeferredTaxAssetsOtherIntangibleAssets>
    <annx:DeferredTaxAssetsOtherIntangibleAssets
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_aa318126-a467-4134-b171-b89fb1228196"
      unitRef="U_USD">3000</annx:DeferredTaxAssetsOtherIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_f53ccc89-bd0f-46f0-af0f-f00fe9f7815c"
      unitRef="U_USD">1116000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_7698d990-4fc1-461c-a4b2-db9444ccd06c"
      unitRef="U_USD">1074000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_20e10cef-7a74-4521-ae9a-ded0442168f4"
      unitRef="U_USD">5599000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_fd146a7a-94aa-47b9-b44a-5d92c460884c"
      unitRef="U_USD">5185000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <annx:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_c57c63d8-8800-4fda-8f34-dc71d2f50928"
      unitRef="U_USD">49837000</annx:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <annx:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_58a5d8d6-5230-4d7f-b1cc-5d2d86ae4d4c"
      unitRef="U_USD">36568000</annx:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <annx:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_1e9b79c4-a0f4-4417-ab47-23b46a07c38f"
      unitRef="U_USD">6087000</annx:DeferredTaxAssetsLeaseLiabilities>
    <annx:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_8cee7199-e2ab-4976-ad0a-7a944e17a9be"
      unitRef="U_USD">6610000</annx:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_e1b392f9-cd16-4391-8a5f-0ff945747735"
      unitRef="U_USD">185937000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_e85c47cf-495b-43d0-9cd7-3cd3d3acd6dc"
      unitRef="U_USD">136506000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_53b79aa0-8e8e-4784-a220-1533915aec9d"
      unitRef="U_USD">180958000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_da7fa040-cf99-49e2-9655-70a1127c7abe"
      unitRef="U_USD">130939000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_1b2c7e47-5133-44ac-848b-717017ba6364"
      unitRef="U_USD">4979000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_3c1d060f-5476-47d3-87c9-2464919be6dd"
      unitRef="U_USD">5567000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_ab706a1d-d558-4f69-b083-2bed452a4e47"
      unitRef="U_USD">1469000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_e8da547c-eb50-4e94-b0f3-2705d958f92b"
      unitRef="U_USD">1771000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <annx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_871f6a01-cf6e-4bf6-b97d-f2a2c6fd3422"
      unitRef="U_USD">3510000</annx:DeferredTaxLiabilitiesRightOfUseAssets>
    <annx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_d79fc671-061f-4a78-8097-6e6b8ca03b1d"
      unitRef="U_USD">3796000</annx:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_44930757-2664-431c-ade7-7b67a78dd797"
      unitRef="U_USD">4979000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_5019f6ef-77a3-4f21-b1b0-64e759fa9cd8"
      unitRef="U_USD">5567000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_5a0c781b-2b96-474f-8937-a356d4062e45"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_a8abfbe0-7887-40e4-b485-00f1f03dcf33"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-5"
      id="F_e31f2703-775c-4adb-9c50-3b54ea2dee90"
      unitRef="U_USD">367700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-5"
      id="F_9ea872be-cdbd-4292-8f99-3ecaf127ce56"
      unitRef="U_USD">223800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <annx:OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="2"
      id="F_c032fb2d-1857-47bd-9979-ee3a95e53100"
      unitRef="U_pure">0.80</annx:OperatingLossCarryforwardsLimitationsOnUsePercentageOfTaxableIncome>
    <annx:DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration
      contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2"
      decimals="-5"
      id="F_b64f64b3-8f53-43d8-8c63-559c6fa309d9"
      unitRef="U_USD">324700000</annx:DeferredTaxAssetsOperatingLossCarryforwardsAnnualLimitationUtilizationNotSubjectToExpiration>
    <annx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_a50e3032-53b3-43ad-b979-4980c233f303">2031</annx:DeferredTaxAssetsOperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2"
      decimals="-5"
      id="F_054eb9d7-91e7-4af7-8459-d9dc25cf1b35"
      unitRef="U_USD">33200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6f21bd05-943f-438a-9b7b-5906dcadd8cc"
      decimals="-5"
      id="F_6cf85d0b-8bbe-4cc3-9271-e3f9a43db51f"
      unitRef="U_USD">9300000</us-gaap:TaxCreditCarryforwardAmount>
    <annx:DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear
      contextRef="C_ef904358-5a05-4938-94ed-ed05188133ac"
      id="F_a0db9ebf-a622-4745-8689-1c72299ab13d">2031</annx:DeferredTaxAssetsCreditCarryforwardsExpirationBeginningYear>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-5"
      id="F_32d86d8c-61cb-425c-82ab-01c27857aaa2"
      unitRef="U_USD">50000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-5"
      id="F_ca88f2a1-ed4f-49ab-803c-0b17bbbaae12"
      unitRef="U_USD">30200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2"
      decimals="-5"
      id="F_f0d44401-c7a4-4334-9746-8ae4f97c21c8"
      unitRef="U_USD">367600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_6f21bd05-943f-438a-9b7b-5906dcadd8cc"
      decimals="-5"
      id="F_d36c17c1-9035-48f2-b05f-f6462b1fdbb6"
      unitRef="U_USD">189200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2"
      decimals="-5"
      id="F_08bebdf3-3612-4c63-8f8c-236212486318"
      unitRef="U_USD">100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_6f21bd05-943f-438a-9b7b-5906dcadd8cc"
      decimals="-5"
      id="F_8dbf7ca2-5451-48e6-9cd0-7b3d00883ece"
      unitRef="U_USD">34700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_165aca0e-bcd9-4004-974b-91e78177d7c2"
      decimals="-5"
      id="F_27b93636-62fb-4cab-a669-49bbc8e510c2"
      unitRef="U_USD">4300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_bfc808c5-4a06-4dca-8c22-64d2873a80eb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the following activity relating to the gross amount of unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.248%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.917%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.917%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reductions based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_c45386fb-2adc-40c4-bf22-78a1f24ec182"
      unitRef="U_USD">3970000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a2b98230-0f7a-4d29-8918-901b611f045a"
      decimals="-3"
      id="F_5ff89cfa-f6cd-4a95-bde0-671d2ddbb189"
      unitRef="U_USD">2726000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_e9fc5409-601a-4f47-bdcf-a255ac47b4f4"
      unitRef="U_USD">3388000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_416911e3-0f90-4c83-9280-02eddcd3c43b"
      unitRef="U_USD">189000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_1838ece2-c016-4f20-8139-f61df4d4911b"
      unitRef="U_USD">1726000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_9e55e480-7e17-4302-9a48-d763f9a22101"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_6d2c8613-3829-4630-b675-a3295723c58d"
      unitRef="U_USD">2787000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_b9911901-e233-4ea6-bc01-0170f6b251c7"
      unitRef="U_USD">1055000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="-3"
      id="F_ec5a238e-16fc-46b0-95aa-d99b3351f96c"
      unitRef="U_USD">8419000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_5c8914a1-6122-42c7-8190-e7a265b496b4"
      decimals="-3"
      id="F_26ce22e4-01d0-40ca-9c38-e23f075f00b4"
      unitRef="U_USD">3970000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_d3946e32-8082-47f1-9a50-3777caefd67b"
      unitRef="U_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_1cfaed3a-9675-4dc9-86bf-3c86a45f82e4"
      decimals="INF"
      id="F_d7e38585-dda8-487c-b3c0-f298683d7a3f"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_b059d745-ac6e-4d3e-97a3-064071ce97fc">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.87%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.87%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding. The weighted-average number of shares of common stock used in the basic and diluted net loss per share calculation include pre-funded warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,543,577&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,492,923&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock for the years ended December 31, 2024 and 2023, respectively, as the pre-funded warrants are exercisable at any time for nominal cash consideration. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,594,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,208,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares subject to Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;770,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;495,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,104,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,485,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,149,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_634f5a22-da7a-4c41-b9ae-27784aa5495b"
      decimals="INF"
      id="F_e752d4b7-3952-4201-abce-b760131d3fba"
      unitRef="U_shares">38543577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2fd32b35-c1b6-48a1-aae6-77286e901eaa"
      decimals="INF"
      id="F_d2770691-fbdf-4c39-8d3c-0450b9c18066"
      unitRef="U_shares">40492923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_f977a5ed-c8e9-48a6-87dc-0a47e6fe9ed3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,594,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,208,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares subject to Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;770,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;495,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,104,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,485,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,149,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_abbf44cf-6ebe-4194-9a41-e2cb42bf1eb6"
      decimals="0"
      id="F_8a9e081c-e082-450b-80f1-544a334ec356"
      unitRef="U_shares">14594720</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e4222e01-171b-4f31-917f-bc3457cfb96a"
      decimals="0"
      id="F_87058036-c9c9-49d2-9d0d-5f0836396752"
      unitRef="U_shares">9208970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_eaec4616-b419-452f-afec-7269fe2849b9"
      decimals="0"
      id="F_a4497a16-d182-4cfa-affd-4eb460785893"
      unitRef="U_shares">15922</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c91f5f8f-b8d5-4019-a7fb-1c7e1652024e"
      decimals="0"
      id="F_3eeadc5d-e085-4cd4-8fd3-3bd9ad13b2d3"
      unitRef="U_shares">17200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_22fb27c8-c805-4aa1-944d-38a2963e3541"
      decimals="0"
      id="F_29f9b7dc-6063-4703-8c3c-2d667c213c36"
      unitRef="U_shares">770028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_83482f61-92c5-4f8a-a1dd-156bef5f21aa"
      decimals="0"
      id="F_64a1bf3c-7c3d-431f-9dd0-c5e09cf7bce6"
      unitRef="U_shares">495579</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4aeda5c6-0f0c-4565-a458-c8ad2779242a"
      decimals="0"
      id="F_2c56da0e-8ae7-4d7d-b54e-56e7d9abd92a"
      unitRef="U_shares">8104615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2321ba61-567c-412f-bf92-06d0f3f4b95c"
      decimals="0"
      id="F_37b7b8a1-23d8-4ba8-b83e-133390198523"
      unitRef="U_shares">8427508</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="0"
      id="F_0ed55de9-4172-4f76-9c44-2f97a989092b"
      unitRef="U_shares">23485285</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="0"
      id="F_099ced65-fa87-457e-bbf9-45ac54df834a"
      unitRef="U_shares">18149257</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_c33c0341-0fc4-4155-a252-adec786baba9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Segment &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment, which is related to the research and development of its product candidates focused on complement-mediated diseases of the body, brain and eye for which there is significant unmet medical need. The accounting policies of the one reportable segment are the same as those described in the summary of significant accounting policies. See Note 2&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The segment is managed on a consolidated basis and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results and allocate resources. In assessing the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. This includes a review of budget versus actual expenses and direct program spend, which includes clinical costs, consultant fees, manufacturing expenses, and other direct external costs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the operations for the reportable segment during the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - program expenses&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative - personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consolidated segment net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;__________________&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) Research and development - program expenses include other non-program specific expenses and other research expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) Other general and administrative expenses include consulting and professional services fees for legal, accounting, tax, and facilities costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="INF"
      id="F_f55a3ced-44aa-4317-8e29-a4686abb93ff"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_b240e588-dda8-4aa1-a285-a3d6c41ddb14">The segment is managed on a consolidated basis and the CODM uses total operating expenses and consolidated net loss to assess performance, forecast future financial results and allocate resources. In assessing the Company's financial performance and making strategic decisions, the CODM regularly reviews operating expenses by function. This includes a review of budget versus actual expenses and direct program spend, which includes clinical costs, consultant fees, manufacturing expenses, and other direct external costs.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      id="F_7b0630e8-2cdc-478f-aeb1-1aef19d21081">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the operations for the reportable segment during the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - program expenses&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative - personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consolidated segment net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;__________________&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) Research and development - program expenses include other non-program specific expenses and other research expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) Other general and administrative expenses include consulting and professional services fees for legal, accounting, tax, and facilities costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a4b8204b-10aa-4078-99c0-be6c2915b494"
      decimals="-3"
      id="F_1d8dc279-f592-47a7-9d3f-3471b24e94b3"
      unitRef="U_USD">79548000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0f36b114-1cd5-47b2-9612-e2686951639e"
      decimals="-3"
      id="F_06baf220-5d86-438a-842b-67519b942cb2"
      unitRef="U_USD">76008000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e84f496a-0f64-496c-8511-31490901d115"
      decimals="-3"
      id="F_6e353c3c-0aac-4e98-b4e2-5f2496ca1d11"
      unitRef="U_USD">24291000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_818dd59d-4920-4aa4-ac11-e7a600a5d4b6"
      decimals="-3"
      id="F_368cf87d-e789-43fb-b0c2-4fcb6ddb9e5d"
      unitRef="U_USD">23893000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e84f496a-0f64-496c-8511-31490901d115"
      decimals="-3"
      id="F_f0d4eb41-a228-441f-a76a-da76250cd59e"
      unitRef="U_USD">6578000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_818dd59d-4920-4aa4-ac11-e7a600a5d4b6"
      decimals="-3"
      id="F_9fd28006-7d67-4835-af69-6e2f5942714d"
      unitRef="U_USD">6896000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c"
      decimals="-3"
      id="F_e9f1cc64-e0f8-414e-aa87-16937aa72784"
      unitRef="U_USD">22073000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3"
      decimals="-3"
      id="F_08d24199-1a0e-40eb-8c25-2d52b469f6c6"
      unitRef="U_USD">16595000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:Depreciation
      contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c"
      decimals="-3"
      id="F_a01170ab-a885-4d29-ae7d-a2a723499b07"
      unitRef="U_USD">2150000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3"
      decimals="-3"
      id="F_70ad18eb-394f-4e94-893c-61c6734bfcb6"
      unitRef="U_USD">2148000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c"
      decimals="-3"
      id="F_9a03c8a0-8598-4d6e-ae23-c6775a5fe382"
      unitRef="U_USD">19433000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3"
      decimals="-3"
      id="F_9688f377-de64-4c34-bc95-12cb4d97d537"
      unitRef="U_USD">18183000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingExpenses
      contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c"
      decimals="-3"
      id="F_1c97a8bf-6fa3-4c43-b7b7-a79ec02a24c6"
      unitRef="U_USD">154073000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3"
      decimals="-3"
      id="F_0b3a26b1-5ae0-41bc-8bdd-fb8e9db92fad"
      unitRef="U_USD">143723000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c"
      decimals="-3"
      id="F_92089de2-014e-40f9-94a1-8d6ced78bcba"
      unitRef="U_USD">-154073000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3"
      decimals="-3"
      id="F_60b4fdce-1db2-4fb1-bf97-5aaa9480c3b0"
      unitRef="U_USD">-143723000</us-gaap:OperatingIncomeLoss>
    <annx:InterestAndOtherNonOperatingIncomeExpense
      contextRef="C_d453b9a3-18a8-4fb8-a1ca-74ab6c31899c"
      decimals="-3"
      id="F_cfd19e20-9efa-4921-ac8b-33ff96e6ff50"
      unitRef="U_USD">15873000</annx:InterestAndOtherNonOperatingIncomeExpense>
    <annx:InterestAndOtherNonOperatingIncomeExpense
      contextRef="C_843798ed-5a68-4641-8a36-ece949ec58c3"
      decimals="-3"
      id="F_78cfe5a0-2ada-4929-b7bb-29290a86e060"
      unitRef="U_USD">9486000</annx:InterestAndOtherNonOperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_59694837-0d85-444e-93f3-2dab4c74940e"
      decimals="-3"
      id="F_4238a7fe-3b49-4085-abcb-67dfa42b37dd"
      unitRef="U_USD">-138200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc036091-0094-4f93-92df-aa8d88aeaf09"
      decimals="-3"
      id="F_9bdf7525-4d2f-4c94-ad96-71c8aa5241d6"
      unitRef="U_USD">-134237000</us-gaap:NetIncomeLoss>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_f5167882-1b9d-47e5-a675-47eb50fb2f3b"
      id="F_a853ef61-32f0-436b-8cf5-cd0c40235922">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trading Arrangements of Section 16 Reporting Persons.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the Company&#x2019;s last fiscal quarter, the Company&#x2019;s directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company&#x2019;s securities set forth in the table below.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:28%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:11%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:8%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:7%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:7%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:9%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:11pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Types of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name and Position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Action&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Termination Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Rule &lt;br/&gt;10b5-1*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-Rule 10b5-1**&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total Shares of Common Stock to be Sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total Shares of Common Stock to be Purchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Douglas Love&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Terminate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12/16/2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1/22/2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;__________________&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#242424;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#242424;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;** &#x201c;Non-Rule 10b5-1 trading arrangement&#x201d; as defined in Item 408(a) of Regulation S-K under the Exchange Act.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName
      contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3"
      id="F_864ad0af-0930-487c-98d1-606fc05b21f3">Douglas Love</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3"
      id="F_6c78a090-3bc6-4662-9cc9-b1e8d1119e7d">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrTerminationDate
      contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3"
      id="F_45bfa6a5-a7d3-41bd-8d47-655a8f51d13d">12/16/2024</ecd:TrdArrTerminationDate>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3"
      id="F_5935eb1e-e453-45e6-bdc4-46ae1bca54df">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_d35db099-094f-4b2e-a082-7d4a3c739571"
      decimals="INF"
      id="F_50977837-0d6b-429f-b126-3791826b8fa1"
      unitRef="U_shares">37994</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_d3902bbd-93e9-414e-b3fb-5689c7415ad3"
      id="F_bee34d8b-10cb-4dbe-9528-a1668f83c020">1/22/2025</ecd:TrdArrExpirationDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
